<SEC-DOCUMENT>0001193125-25-197877.txt : 20250908
<SEC-HEADER>0001193125-25-197877.hdr.sgml : 20250908
<ACCEPTANCE-DATETIME>20250908100339
ACCESSION NUMBER:		0001193125-25-197877
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		64
FILED AS OF DATE:		20250908
DATE AS OF CHANGE:		20250908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LB PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001691082
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289812
		FILM NUMBER:		251298829

	BUSINESS ADDRESS:	
		STREET 1:		575 MADISON AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		917-450-6581

	MAIL ADDRESS:	
		STREET 1:		575 MADISON AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LB PHARMACEUTICALS INC.
		DATE OF NAME CHANGE:	20161129
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d12080ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the U.S. Securities and Exchange Commission on September 8, 2025.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-289812 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Amendment No. 1 to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt"><B><FONT STYLE="white-space:nowrap">81-1854347</FONT></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>One
Pennsylvania Plaza, Suite 1025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10119 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (212) 605-0300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Heather Turner </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>One Pennsylvania Plaza, Suite 1025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10119 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel:
(212) 605-0300 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brandon Fenn</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Marc
Recht</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Minkyu Park</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>55 Hudson
Yards</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10001</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gad Soffer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Business Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>One
Pennsylvania Plaza, Suite 1025</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10119</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (212) 605-0300</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William C. Hicks</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>John T. Rudy</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alok A.
Choksi</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Samantha M. Silver</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>One Financial Center</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02111</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (617)
<FONT STYLE="white-space:nowrap">542-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said section 8(a), may determine. </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed.
These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion. Dated September 8, 2025 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>16,666,667 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g65h87.jpg" ALT="LOGO" STYLE="width:2.26833in;height:0.963333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the initial public offering of LB Pharmaceuticals Inc. We are offering 16,666,667 shares of our common stock. The initial public offering price is
expected to be between $14.00 and $16.00 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. We have applied to
list our common stock on the Nasdaq Global Market, or Nasdaq, under the symbol &#8220;LBRX.&#8221; We believe that upon the completion of this offering, we will meet the standards for listing on Nasdaq, and the completion of this offering is
contingent upon such listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; under applicable Securities
and Exchange Commission rules and have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See the section titled &#8220;<A HREF="#toc12080_4">Risk Factors</A>&#8221; beginning on page
13 to read about factors you should consider before buying shares of our common stock. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any
other state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#8220;Underwriting&#8221; for additional information regarding compensation payable to
the underwriters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to 2,500,000 additional shares of common stock from us at the initial
public offering price, less the underwriting discounts and commissions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers
on &#8195;&#8195;&#8195;, 2025 through the book-entry facilities of The Depository Trust Company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:14pt"><B>Leerink Partners</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Piper Sandler</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:14pt"><B>Stifel</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Dated &#8195;&#8195;&#8195;, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_3">Summary Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_11">Management&#8217;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_19">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_23">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc12080_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not, authorized anyone to provide you with information other than in this prospectus or in any free
writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for and cannot provide any assurance as to the reliability of any other information others may give you. We are not, and the underwriters are
not, making an offer to sell shares of our common stock in any jurisdiction where the offer or sale is not permitted. The information in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of
delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained in greater detail elsewhere in this prospectus. This summary is not complete and
does not contain all of the information you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus. You should carefully consider, among other things, the sections
titled Risk Factors,&#8221; &#8220;Special Note Regarding Forward-Looking Statements,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and our financial statements and the related
notes included elsewhere in this prospectus. Unless the context otherwise requires, the terms the &#8220;Company,&#8221; &#8220;LB Pharmaceuticals,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar references in this
prospectus refer to LB Pharmaceuticals Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other
neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> which we believe has the potential to be the first benzamide
antipsychotic drug approved for neuropsychiatric disorders in the United States. <FONT STYLE="white-space:nowrap">LB-102</FONT> is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in
over 50 countries, not including the United States, because the development and regulatory requirements of the U.S. Food and Drug Administration, or FDA, for amisulpride were incompatible with patent coverage on the drug. Amisulpride is a generic
drug that has been extensively used in clinical practice following its initial approval in France in the 1980s, generating at least two&nbsp;million monthly prescriptions in 2023 in a subset of 16 continental European countries. Among these European
prescriptions for amisulpride, our data suggest that approximately 60% are for schizophrenia and schizoaffective disorders, approximately 20% are for mood disorders, approximately 14% are for anxiety, and the remainder are for a variety of other
indications. We developed <FONT STYLE="white-space:nowrap">LB-102</FONT> in order to address the limitations of amisulpride with a differentiated therapeutic profile and strong intellectual property protection. We believe <FONT
STYLE="white-space:nowrap">LB-102&#8217;s</FONT> mechanism of action, data from our recently completed Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia, and the legacy of clinical experience with amisulpride
support the continued development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia and bipolar depression. If successful in treating bipolar depression, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> in the
treatment of major depressive disorder, or MDD. In the future, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of other neuropsychiatric disorders, including schizophrenia with predominantly negative symptoms,
Alzheimer&#8217;s disease-related agitation and psychosis, manic episodes associated with bipolar disorder, and cognitive impairment associated with schizophrenia, or CIAS. We believe that <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved,
can become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> is a Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> oral, small
molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. Schizophrenia is a chronic, severe, complex, and debilitating
psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability. Symptoms are divided into three categories: (i)&nbsp;psychotic or positive symptoms, which include delusions, hallucinations, thought
disorder, and movement disorder; (ii)&nbsp;negative symptoms, which include lack of motivation, interest, or enjoyment in daily activities, withdrawal from social life, and difficulty showing emotions; and (iii)&nbsp;cognitive symptoms, which
encompass problems with attention, concentration, and memory. The disease is associated with increased mortality, with approximately 5% of schizophrenia patients dying by suicide, and average overall life expectancy decreasing by as much as 29 years
compared to the general population. There is currently no cure for schizophrenia, which means the disease must be managed with <FONT STYLE="white-space:nowrap">life-long</FONT> therapy, increasing the importance of therapies that can improve
compliance rates and dosing challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, we announced positive data from our four-week placebo-controlled,
double-blinded, Phase 2 trial in the United States, which assessed the safety and efficacy of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
schizophrenia. Results from the trial demonstrated (i)&nbsp;statistically significant clinical activity at all <FONT STYLE="white-space:nowrap">LB-102</FONT> doses tested; (ii)&nbsp;a significant
average change in overall symptoms (effect size); (iii) a potentially class-leading tolerability profile among D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>/D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> antagonists and
partial agonists; and (iv)&nbsp;a potentially differentiated impact on cognition as measured by CogState Computerized Schizophrenia Battery of Tests. The trial achieved its primary endpoint of change in the Positive and Negative Syndrome Scale, or
PANSS, a <FONT STYLE="white-space:nowrap">30-item</FONT> scale that measures the severity of schizophrenia symptoms, from baseline to Week 4. A statistically significant decrease in symptoms was observed for all three dose cohorts (50 mg, 75 mg, and
100 mg) compared to placebo. Additionally, our Phase 2 trial data showed a statistically significant impact on negative symptoms versus placebo at the 50 mg dose even though the inclusion criteria enriched for patients experiencing predominantly
positive symptoms of schizophrenia. An exploratory <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis of our Phase 2 data on the treatment effect in patients with negative symptoms at baseline (i.e., those patients with a PANSS Negative
Subscore greater than or equal to 24) yielded similar results with a statistically significant impact on negative symptoms versus placebo at the 50 mg dose. <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well tolerated in the clinical
trial, with adverse events being mostly transient and mild to moderate in severity. If replicated in our planned Phase 3 trial, we believe this tolerability profile has the potential to be class-leading among D<SUB
STYLE="font-size:75%; vertical-align:bottom">2</SUB>/D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> antagonists and partial agonists specifically with respect to the rate of sedation and extrapyramidal symptoms, or EPS, a group of
movement disorders including involuntary movements, muscle stiffness, and tremors, that, together with sedation, are quite burdensome to patients and can result in discontinuation of treatments. The impact of
<FONT STYLE="white-space:nowrap">LB-102</FONT> on cognitive function was also evaluated as an exploratory endpoint in this trial. After four weeks of treatment with <FONT STYLE="white-space:nowrap">LB-102,</FONT> a robust, dose-dependent, and
significant treatment effect size was identified in a post-hoc analysis in the completer population for all doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> compared with placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed our Phase 2 acute schizophrenia trial to be potentially registrational by including a large sample size (n=359), robust
statistical analyses, as well as numerous sensitivity analyses. Based on positive <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 feedback from the FDA, as well as historical precedent, we believe that
our Phase 2 acute schizophrenia trial may serve as one of the two pivotal trials required for approval of a new drug application, or NDA, in the United States. As a result, we believe there is a viable path to approval of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in the United States for the treatment of schizophrenia with a single, <FONT STYLE="white-space:nowrap">six-week</FONT> Phase 3 trial alongside other planned
<FONT STYLE="white-space:nowrap">NDA-enabling</FONT> studies. However, there is no guarantee that our Phase 2 trial may serve as one of the two pivotal trials required for FDA approval, and in such case, we may be required to conduct an additional
pivotal trial in acute schizophrenia. The adequacy of our Phase 2 trial to support registration will be a matter of review by the FDA at the time of NDA submission and will depend on the totality of the data included in our submission, including the
results of our planned Phase 3 trial. We are planning to initiate a <FONT STYLE="white-space:nowrap">six-week</FONT> Phase 3 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia patients in the first quarter of 2026, which
we believe, if positive, could be sufficient to support a regulatory application for approval in the United States along with our completed Phase 2 trial and other planned <FONT STYLE="white-space:nowrap">NDA-enabling</FONT> studies. The Phase 3
trial is anticipated to be a <FONT STYLE="white-space:nowrap">three-arm,</FONT> inpatient, double-blinded, placebo-controlled, oral once-daily dose of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute schizophrenia, with a <FONT
STYLE="white-space:nowrap">six-week</FONT> treatment duration. We plan to study the effects of 50 mg <FONT STYLE="white-space:nowrap">LB-102</FONT> or 100 mg <FONT STYLE="white-space:nowrap">LB-102</FONT> versus placebo in this trial, and patients
will be randomized in a 1:1:1 ratio across the three arms of the trial. The sample size will be approximately 400 patients, and we plan to conduct this trial at approximately 25 sites entirely in the United States. The primary endpoint of the trial
is anticipated to be change from baseline in PANSS at Day 42. We expect to disclose topline data from this Phase 3 trial in the second half of 2027 and, if positive, meet with the FDA in the first quarter of 2028 to discuss the potential for
submission of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our clinical development program in schizophrenia, we plan to leverage our expertise in
neuropsychiatry and the unique mechanism of action of <FONT STYLE="white-space:nowrap">LB-102</FONT> to develop our product candidate in other indications, starting with bipolar depression. Most people living with bipolar depression experience
dramatic shifts in mood, energy, and behavior, alternating between manic and depressive states. It is estimated that 2.8%, or approximately seven&nbsp;million Americans, experience bipolar disorder in a year, and approximately 40&nbsp;million people
live with bipolar disorder worldwide. Our initial Phase 2 trial will explore the utility of <FONT STYLE="white-space:nowrap">LB-102</FONT> in </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
controlling the depressive symptoms of the disease. We plan to initiate this potentially registrational Phase 2 trial in bipolar depression in the first quarter of 2026, with topline data
expected in the first quarter of 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> strong antagonism of the D<SUB
STYLE="font-size:75%; vertical-align:bottom">2</SUB>, D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>, and 5HT7 receptors makes it well suited for treating bipolar depression, providing potential to control psychosis and mania through its
effects on D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> and potential for antidepressive and <FONT STYLE="white-space:nowrap">pro-cognitive</FONT> effects through its antagonism of 5HT7 and D<SUB
STYLE="font-size:75%; vertical-align:bottom">3</SUB>. Our Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia demonstrated strong antipsychotic activity and suggests opportunities for potential differentiation in
bipolar depression given the observed tolerability profile (low rates of EPS, sedation, and gastrointestinal side effects) and positive impact on cognition. Amisulpride is approved for the treatment of dysthymia, a form of depression, in certain
countries outside of the United States and has been shown to be as effective as certain approved agents for MDD and dysthymia. We believe that results in dysthymia and MDD provide strong scientific and clinical rationale for development of LB-102 in
the treatment of depressive episodes associated with bipolar disorder or bipolar depression because episodes of major depression, whether unipolar (as in MDD) or bipolar (as in bipolar depression), are typically characterized by a similar imbalance
in the neurotransmitters serotonin, noradrenaline, and dopamine, regardless of the underlying pathophysiology of the disease. There is wide use of amisulpride in bipolar disorder with approximately 3.4% of at least two million monthly prescriptions
written for this indication in a select group of European countries including Germany, France, Italy, Spain, and several others. A non-racemic form of amisulpride also showed antidepressant activity in two independent third-party, placebo-controlled
bipolar depression trials with an approximately 17- to 18-point reduction in Montgomery&#8211;&Aring;sberg Depression Rating Scale, or MADRS, from baseline observed across these studies. Additionally, among the four antipsychotics approved for
schizophrenia and MDD or treatment resistant depression that were also studied in late-stage bipolar depression trials (quetiapine, cariprazine, aripiprazole, and olanzapine), three out of four, or 75%, generated positive data for the treatment of
bipolar depression. Our planned Phase 2 trial for bipolar depression will utilize a fixed-flexible dose of <FONT STYLE="white-space:nowrap">LB-102.</FONT> This trial design allows us to evaluate two doses of
<FONT STYLE="white-space:nowrap">LB-102</FONT> in the trial, thereby increasing the chances for a patient to derive clinical benefit from treatment with <FONT STYLE="white-space:nowrap">LB-102,</FONT> while retaining the advantages of a <FONT
STYLE="white-space:nowrap">two-arm</FONT> trial, which is known to mitigate the risk of a high placebo rate. Additionally, flexible dose trials typically have better signal detection than fixed dose trials for depression, as flexible dose trials
lower the magnitude of symptom reduction with placebo. We believe <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to provide improved tolerability and clinical activity in bipolar depression compared to currently available
treatments worldwide, which are associated with troubling adverse events and insufficient efficacy for certain symptoms, including cognitive impairment associated with the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing a long-acting injectable, or LAI, formulation of <FONT STYLE="white-space:nowrap">LB-102,</FONT> which may improve
compliance, a common issue in patients with schizophrenia and bipolar disorder. We believe an effective LAI form of <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to benefit patients worldwide, as relatively few approved agents are
available as long-acting formulations and there are no benzamide class LAIs currently available or in development worldwide. The American Psychiatric Association recommends injectable formulations in circumstances where doing so will improve
adherence, decrease mortality, reduce hospitalization risk, and decrease treatment discontinuation rates. We have commenced LAI formulation development and expect to continue these efforts in 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. market for branded antipsychotic drugs was approximately $12&nbsp;billion as of 2024. Despite the widespread use of generic
antipsychotic drugs, several of these branded drugs each generate U.S. sales in excess of $1&nbsp;billion annually. Additionally, while available therapeutics to treat schizophrenia and bipolar depression demonstrate clinical benefit, a significant
unmet need remains for a treatment that balances tolerability with clinically meaningful efficacy for the chronic management of symptoms related to both psychosis and mood disorders. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our leadership and advisors are composed of individuals with extensive experience in the discovery, development, and commercialization of
neuropsychiatric therapeutics. <I></I><I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heather Turner, J.D., our Chief Executive Officer, was previously President and Chief
Executive Officer of Carmot Therapeutics Inc., prior to its acquisition by Roche Pharmaceuticals for $3.1&nbsp;billion. Anna Eramo, M.D., our Chief Medical Officer, previously led U.S. clinical and medical affairs at Lundbeck A/S, where her primary
responsibilities extended across its U.S. neurology and psychiatric portfolio of products, including brexpiprazole (which is approved in schizophrenia, MDD, and agitation associated with Alzheimer&#8217;s disease), vortioxetine (which is approved
for MDD), and Abilify Maintena (an LAI form of aripiprazole that is approved for schizophrenia and bipolar 1). Other members of our team held various positions at Celgene Corporation, Genzyme Corporation, and ImmunoGen, Inc., with experience working
on late-stage development and commercial products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chairman of our board of directors, Scott Garland, most recently served as Chief
Executive Officer of PACT&nbsp;Pharma, Inc. Previously, Scott was the Chief Executive Officer of Portola Pharmaceuticals, Inc., which Alexion Pharmaceuticals, Inc. acquired for $1.4&nbsp;billion in 2020. Prior to that, he was President of Relypsa
Inc., which Vifor Pharma AG acquired for $1.5&nbsp;billion in 2016. He is joined on our board of directors by Robert Ruffolo, Ph.D., who previously served as President of Research and Development at Wyeth Pharmaceuticals, Inc., Zachary Prensky, <FONT
STYLE="white-space:nowrap">co-founder</FONT> of LB Pharmaceuticals and former manager of a family office with a heavy focus on investing in the biotechnology and pharmaceutical sectors, and other board representatives from our major investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advised by renowned experts in treating neuropsychiatric diseases. John Kane, M.D., is a Professor of Psychiatry and Molecular Medicine
at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years. Christoph U. Correll, M.D., is a Professor of Psychiatry at the Donald and Barbara Zucker School
of Medicine at Hofstra/Northwell. Maurizio Fava, M.D., is the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Psychiatrist-In-Chief,</FONT></FONT> Department of Psychiatry and Director, Division of Clinical Research at Mass General
Research Institute. Dr.&nbsp;Fava is also the Executive Director of the Clinical Trials Network&nbsp;&amp; Institute, as well as the Associate Dean for Clinical&nbsp;&amp; Translational Research and Slater Family Professor of Psychiatry at Harvard
Medical School. Luca Pani, M.D. is Professor of Clinical Psychiatry at the University of Miami and Pharmacology at the University of Modena &amp; Reggio Emilia, former Italy&#8217;s AIFA Director General and EMA CHMP/SAWP Representative, with
expertise in pre-clinical and clinical CNS drug development strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised over $120&nbsp;million from a
leading syndicate of investors, including Deep Track Capital, Pontifax, TCG Crossover Fund, and Vida Ventures. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk
tolerances and have received their shares in prior offerings at prices lower than the price offered to the public in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of schizophrenia and mood disorders
initially and subsequently for other neuropsychiatric disorders in the United States and internationally. Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Achieve regulatory approval for <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of
schizophrenia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">LB-102</FONT> as a potential treatment across the spectrum of disease
for patients with schizophrenia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand development of <FONT STYLE="white-space:nowrap">LB-102</FONT> into bipolar depression and other psychosis
and mood disorders. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Extend the life-cycle and global reach of <FONT STYLE="white-space:nowrap">LB-102</FONT> by advancing alternate
formulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the commercial opportunity of <FONT STYLE="white-space:nowrap">LB-102.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factor Summary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our
common stock involves significant risks. You should carefully consider the risks described in the section titled &#8220;Risk Factors&#8221; immediately following this prospectus summary and elsewhere in this prospectus before making a decision to
invest in our common stock. If we are unable to successfully address these risks and challenges, our business, financial condition, results of operations, or prospects could be materially and adversely affected. In such case, the trading price of
our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face.<B> </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history and no history of
commercializing products, which may make it difficult to evaluate our approach to the discovery and development of our product candidate and the prospects for our future viability. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred substantial losses since our inception. We anticipate incurring substantial and increasing
losses for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a result of our history of losses and negative cash flows from operations, our consolidated financial
statements contain a statement regarding a substantial doubt about our ability to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional financing in addition to the proceeds of this offering to achieve our
goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated our research and development efforts on the treatment of psychiatric and neurological
conditions, a field that faces certain challenges in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and
results of earlier studies and trials may not be predictive of future trial or real-world results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our
current product candidate or any future product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is
expensive, time-consuming, and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of our product candidate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if our product candidate receives regulatory approval, it may fail to achieve the degree of market
acceptance by physicians, patients, and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The successful commercialization of our product candidate, if approved, will depend in part on the extent to
which governmental authorities and health insurers establish coverage, adequate reimbursement levels, and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidate could limit our ability
to market those products and decrease our ability to generate revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business depends on the success of our product candidate. If we are ultimately unable to successfully
commercialize our product candidate, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on, and intend to continue to rely on, our internal clinical development expertise to conduct our current
and future clinical trials. This model includes internal teams and systems as well as external vendors and CROs to comprise a full clinical trial team. If our clinical trial team does not comply with
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
applicable regulatory requirements, meet expected deadlines, or run trials effectively, our development programs and our ability to seek or obtain regulatory approval for or commercialize our
product candidate may be delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory
requirements or to supply sufficient quantities at acceptable quality levels or prices, within acceptable timeframes, or at all, would materially and adversely affect our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The obligations from our royalty agreements may be a drain on our cash resources or may cause us to incur debt
obligations to satisfy the payment obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Competitive products may reduce or eliminate the commercial opportunity for our product candidate for our current
or future indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective or safer than ours, our ability to develop and successfully commercialize our current products may
be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are dependent on the services of our management and other clinical and scientific personnel, and if we are not
able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain sufficient intellectual property protection for our technologies, and
product candidate and any future product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar
or identical to ours, and our ability to successfully develop and commercialize our product candidate may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patent terms may be inadequate to protect our competitive position on our product candidate for a sufficient
amount of time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information and Trademarks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc was incorporated under the laws of the State of Delaware in September 2015. Our principal executive office is located at
One Pennsylvania Plaza, Suite 1025, New York, NY 10119. Our telephone number is (212) 605-0300. Our website address is https://lbpharma.us. Information contained in, or accessible through, our website does not constitute a part of, and is not
incorporated into, this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The LB Pharmaceuticals logo, the name LB Pharmaceuticals, and other trademarks of LB Pharmaceuticals
Inc appearing in this prospectus are the property of LB Pharmaceuticals Inc. Solely for convenience, trade names, trademarks, and service marks contained in this prospectus may appear without the
&#8220;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&#8221; or &#8220;<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&#8221; symbols. Such references are not intended to indicate, in any way, that the respective owners will
not assert, to the fullest extent possible under applicable law, their rights to those trade names, trademarks, and service marks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of
Being an Emerging Growth Company and a Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the
Jumpstart Our Business Startups Act, or JOBS Act, and we may remain an emerging growth company for up to five years following the completion of this offering. For so long as we remain an emerging growth company, we are permitted and intend to rely
on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404(b)
of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on
executive compensation and any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two&nbsp;years of audited financial statements and have not included all of the executive compensation-related
information that would be </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for
complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to take
advantage of the benefits of this extended transition period and, therefore, we are not subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies; however, we may
adopt certain new or revised accounting standards early. We would cease to be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last day of the fiscal year in which we have $1.235&nbsp;billion or more in annual revenue;
(ii)&nbsp;the date on which we first qualify as a large accelerated filer under the rules of the SEC; (iii)&nbsp;the date on which we have, in any three-year period, issued more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or Exchange Act. We may
continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled
disclosures for so long as the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last
business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year, and the market value of our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>16,666,667 shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 2,500,000 additional shares of our common stock at the initial public offering price less the underwriting discounts and commissions.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Total common stock to be outstanding immediately after this offering </P></TD>
<TD>20,100,137 shares, or 22,600,137 shares if the underwriters exercise their option to purchase additional shares of our common stock in full. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that our net proceeds from this offering will be approximately $228.5 million (or approximately $263.4 million if the underwriters exercise in full their option to purchase additional shares of our common stock), based on the assumed
initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to advance the clinical development of <FONT STYLE="white-space:nowrap">LB-102</FONT> to treat acute
schizophrenia and bipolar depression and utilize the remainder for general corporate purposes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#8220;Use of Proceeds&#8221; for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read and consider the information set forth in the section titled &#8220;Risk Factors,&#8221; together with all of the other information set forth in this prospectus, before deciding whether to invest in our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq trading symbol </P></TD>
<TD>&#8220;LBRX.&#8221; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
3,433,470&nbsp;shares of common stock outstanding as of June&nbsp;30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">427,526 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Stock
Incentive Plan, as amended, or the 2023 Plan, as of June&nbsp;30, 2025, at a weighted-average exercise price of $41.84 per share (which does not take into account the option repricing described below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,943 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Stock
Incentive Plan, or the 2018 Plan, as of June&nbsp;30, 2025, at a weighted-average exercise price of $66.40 per share (which does not take into account the option repricing described below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,397 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Stock
Incentive Plan, or the 2017 Plan, as of June&nbsp;30, 2025, at a weighted-average exercise price of $49.81 per share (which does not take into account the option repricing described below); </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">717 shares of common stock issuable upon the exercise of outstanding stock options granted subsequent to
June&nbsp;30, 2025, at an exercise price equal to the initial public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24,919 Class A common stock warrants to purchase 24,919 shares of our common stock, of which 24,919 Class A
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class A Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31,605 Class B common stock warrants to purchase 31,605 shares of our common stock, of which 31,605 Class B
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class B Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54,813 warrants held by Maxim Partners LLC to purchase 54,813 shares of our common stock of which 54,813 warrants
remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Maxim Warrants;&#8221; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,557 Series B-1 common stock warrants to purchase 2,557 shares of our common stock of which 2,557 Series B-1
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Series B-1 Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,509 New Series B common stock warrants to purchase 3,509 shares of our common stock of which 3,509 New Series B
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $41.84 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;New Series B Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,907,335 shares of common stock reserved for future issuance under our 2025 Equity Incentive Plan, or 2025 Plan,
which became effective upon the execution and delivery of the underwriting agreement for this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price, as
described in the section titled &#8220;Executive Compensation&#8212;2025 Equity Incentive Plan&#8221;), as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully
described in the section titled &#8220;Executive Compensation&#8212;Equity Benefit Plans;&#8221; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">201,000 shares of common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan, or ESPP,
which became effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more
fully described in the section titled &#8220;Executive Compensation&#8212;Equity Benefit Plans.&#8221; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September
2025, our board of directors approved the repricing of stock options previously granted to current executive officers, employees and directors with per-share exercise prices above the initial per share to the public in this offering, or the Option
Repricing. Assuming an initial price per share to the public in this offering of $15.00 per share, which is the midpoint of the price range set forth on the cover page of the prospectus, upon the execution of the underwriting agreement related to
this offering, stock options to purchase approximately 406,998 shares of our common stock will be automatically repriced to an exercise price per share equal to the initial price per share to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 1-for-27.8874 reverse stock split of our common stock effected on September 8, 2025 and the resulting
adjustments to the respective conversion ratios of our Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock, or the Stock Split; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of an aggregate of all 4,251,960 shares of our Series Seed convertible preferred stock,
Series A convertible preferred stock and Series B convertible preferred stock outstanding prior to the Stock Split into an aggregate of 152,390 shares of common stock upon the closing of this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all 73,820,346 shares of our Series C convertible preferred stock outstanding prior
to the Stock Split into 3,029,425 shares of our common stock, including 382,467&nbsp;shares of common stock issuable in respect of anti-dilution adjustments, upon the closing of this offering, based upon an assumed initial public offering price of
$15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus. A&nbsp;$1.00&nbsp;decrease in the initial public offering price would increase the number of shares of our common stock
issuable in respect of our Series C convertible preferred stock by 19,731 shares, and a $1.00&nbsp;increase in the initial public offering price would decrease the number of shares of our common stock issuable in respect of our Series C convertible
preferred stock by 19,254 shares; provided, however, that in no event would the shares of our Series C convertible preferred stock outstanding prior to the Stock Split convert into more than 3,049,156 shares of our common stock upon the closing of
this offering. A 1.0&nbsp;million share increase in the size of this offering would increase the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,261&nbsp;shares, and a 1.0 million share
decrease in the size of this offering would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,795&nbsp;shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated
bylaws immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options or warrants described above subsequent to June&nbsp;30, 2025; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock and no issuance
of additional shares of common stock issuable in respect of anti-dilution adjustments to the Series C convertible preferred stock that may be made upon the underwriters&#8217; exercise of such option. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_3"></A>SUMMARY FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our financial data as of, and for the periods ended on, the dates indicated. We have derived the
summary statements of operations data for the years ended December&nbsp;31, 2024 and 2023 from our audited financial statements included elsewhere in this prospectus. The following summary condensed statements of operations data for the six months
ended June 30, 2025 and 2024, and the summary condensed balance sheet data as of June 30, 2025 have been derived from our unaudited condensed financial statements included elsewhere in this prospectus. Our financial statements appearing elsewhere in
this prospectus have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Our unaudited condensed financial statements were prepared on a basis consistent with our audited consolidated financial statements and
include, in our opinion, all adjustments of a normal and recurring nature that are necessary for the fair statement of the financial information set forth in those statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of results that should be expected in any future period. You should read the following
summary financial data together with our financial statements and related notes included elsewhere in this prospectus and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations.&#8221; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,376</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-operating</FONT> income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(176.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(122.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used in calculating net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro&nbsp;forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.39</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro&nbsp;forma weighted average shares outstanding used in calculating net loss per share, basic
and diluted (unaudited)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,539,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,468,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,540,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,538,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unaudited basic and diluted pro forma net loss per share were computed using the weighted-average shares of
common stock outstanding, including the pro forma effect of the conversion of all outstanding redeemable </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
convertible preferred stock into shares of common stock. Pro forma basic and diluted net loss per share does not include the shares expected to be sold in this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability &#8211; warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma balance sheet data gives effect to (i)&nbsp;the automatic conversion of all of our outstanding
shares of redeemable convertible preferred stock into an aggregate of 3,181,815 shares of common stock immediately upon the closing of this offering and the related reclassification of the carrying value of the redeemable convertible preferred stock
and preferred stock warrant liability to stockholders&#8217; equity upon the closing of this offering and (ii)&nbsp;the filing of our amended and restated certificate of incorporation immediately prior to the closing of this offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in
footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of 16,666,667 shares of common stock in this offering at the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease)
each of our pro forma as adjusted cash and cash equivalents and marketable securities, total assets, working capital, and total stockholders&#8217; (deficit) equity by approximately $15.5 million, assuming that the number of shares offered, as set
forth on the cover of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase
(decrease) each of our pro forma cash and cash equivalents and marketable securities, total assets, working capital, and total stockholders&#8217; (deficit) equity by approximately $14.0 million, assuming the assumed initial public offering price
per share remains the same and after deducting the estimated underwriting discounts and commissions payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This pro forma as adjusted information is illustrative only and will depend on the actual initial public
offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working capital is defined as current assets less current liabilities. See our financial statements and the
related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
together with all of the other information contained in this prospectus, including our financial statements and their related notes included elsewhere in this prospectus and the section titled &#8220;Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations&#8221; before making an investment decision. If any of the following risks actually occurs, our business, prospects, operating results, and financial condition could suffer materially, the trading price
of our common stock could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently
believe to be immaterial also may materially and adversely affect our business, prospects, operating results, and financial condition. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Limited Operating History, Financial Position, and Need for Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage biopharmaceutical company with a
limited operating history and no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of our product candidate and the prospects for our future viability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in 2015 and our operations to date have been
limited to organizing, staffing, and financing our company, conducting research and development activities, conducting clinical trials for our product candidate, and establishing our intellectual property portfolio. If we are successful in achieving
regulatory approval for our product candidate in the future, we will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to the discovery and development of our product candidate is unproven, and we do not know whether we will be able to develop any
product candidate that succeeds in clinical development or products of commercial value. Moreover, as an organization, we have not yet demonstrated an ability to obtain regulatory approvals, manufacture a commercial-scale product or arrange for a
third party to do so on our behalf, conduct sales and marketing activities necessary for successful product commercialization, or generate revenues. We may encounter unforeseen expenses, difficulties, complications, delays, and other known or
unknown factors in achieving our business objectives. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays, and difficulties frequently encountered by companies in clinical development, especially
clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and
commercializing pharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred substantial losses since our inception. We anticipate incurring substantial and
increasing losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain
regulatory approval, and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date. As a result, we are not profitable, have incurred substantial losses in each period
since our inception, and we expect to incur significant losses for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2024 and
2023, and the six months ended June&nbsp;30, 2025, our net losses were approximately $63.1&nbsp;million, $6.3&nbsp;million, and $10.2&nbsp;million, respectively. As of June&nbsp;30, 2025, we had an accumulated deficit of approximately
$114.5&nbsp;million. Substantially all of our losses have resulted from expenses incurred in connection with the development of our pipeline, research and development, clinical trial costs, and from general and administrative costs associated with
our operations. We expect to incur significant losses for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the foreseeable future, and we expect these losses to increase as we continue our development of our product candidate. We anticipate that our expenses will increase substantially if, and as, we:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct further clinical trials for <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with
schizophrenia, initiate clinical development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in bipolar depression and other neuropsychiatric indications, and advance our preclinical programs into the clinic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify additional product candidates and acquire rights from third parties to those product candidates through
licenses or other acquisitions, and conduct development activities, including preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">procure the manufacturing of preclinical, clinical, and commercial supply of our current and future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for our product candidate or any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercialize our current product candidate or any future product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take steps toward our goal of being an integrated biopharmaceutical company capable of supporting commercial
activities, including establishing sales, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire, and retain qualified clinical, scientific, operations, and management personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add and maintain operational, financial, and information management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protect, maintain, enforce, and defend our rights in our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against third-party interference, infringement, and other intellectual property claims, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">address any competing therapies and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays in our preclinical studies or clinical trials and regulatory approval for our product
candidate due to macroeconomic conditions, geopolitical conflicts, or other global events, including any health epidemics and their residual effects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional costs, including legal, accounting, and other expenses, associated with operating as a public
company following the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no product candidates approved for commercial sale and have
not generated any revenue from the sale of products. Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue, if any, unless and until we, either alone or with a
collaborator, are able to obtain regulatory approval for, and successfully commercialize, our product candidate for its initial and potential additional indications, or any other product candidates we may develop in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization will require achievement of many key milestones, including demonstrating each product candidate&#8217;s safety
and efficacy in clinical trials, obtaining regulatory approval for these product candidates, manufacturing, marketing, and selling those products for which we, or any of our future collaborators, may obtain regulatory approval, satisfying any
post-marketing requirements, and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the
timing and amount of revenues, the extent of any further losses, or if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never
generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, our expenses could increase if we are
required by the FDA or any comparable foreign regulatory authority to perform clinical trials in addition to those currently expected, or if there are any delays in completing our clinical trials or in the nonclinical or manufacturing-related
activities associated with the development of our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we succeed in commercializing
<FONT STYLE="white-space:nowrap">LB-102,</FONT> we expect to incur substantial development costs and other expenditures to develop and market additional product candidates. We may also encounter unforeseen expenses,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our
expenses and our ability to generate revenue or raise additional capital. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and our working capital. Our failure to
become and remain profitable may depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings, or continue our operations. If we continue to suffer losses as we have
in the past, you may not receive any return on your investment and may lose your entire investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a result of our history of losses and
negative cash flows from operations, our financial statements contain a statement regarding a substantial doubt about our ability to continue as a going concern. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our history of operating losses and negative cash flows from operations combined with our anticipated use of cash to fund operations raises
substantial doubt about our ability to continue as a going concern as our existing cash and cash equivalents of $14.2&nbsp;million as of June&nbsp;30, 2025 will not be sufficient to meet operating and capital requirements for at least 12&nbsp;months
from the date of issuance of our audited financial statements. Based on our current operating plan, we will need to raise additional financing to continue our products&#8217; development for the foreseeable future, and until we become profitable.
Our future viability as an ongoing business is dependent on our ability to generate cash from our operating activities or to raise additional capital to finance our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital as and when needed, our business, financial condition and results of operations will be
materially and adversely affected, and we may be forced to delay our development efforts, limit our activities and reduce research and development costs. If we are unable to continue as a going concern, we may have to liquidate our assets, and the
values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The inclusion of a going concern explanatory paragraph by our independent registered public accounting
firm, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into licensing and collaboration arrangements or other
contractual relationships with third parties and otherwise execute our development strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional financing in
addition to the proceeds of this offering to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future
commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to
spend substantial amounts of cash to conduct further research and development, preclinical studies, and clinical trials of our current and any future product candidates, to seek regulatory approvals for our product candidate, and to launch and
commercialize any products if we receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, we had $14.2&nbsp;million of cash and cash
equivalents. Based upon our current operating plan, we believe that our existing cash and cash equivalents as of the date of this prospectus will enable us to fund our operating expenses and capital expenditure requirements for at least the next
twelve months. In addition, based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure
requirements through. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will, in any event, require additional capital in order to complete
clinical development of our current program. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our programs and product
candidate are highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and future commercialization activities, if any. Our future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for
our current or future product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of clinical trials required for regulatory approval of our current or future product candidates, which
may differ between the United States and other countries or regions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with acquiring or licensing additional product candidates, technologies, or assets,
including the timing and amount of any milestones, royalties, or other payments due in connection with our acquisitions and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical and commercial supplies and any other activities related thereto of our
current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the
financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any product candidate for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of the product candidate(s) for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses to attract, hire, and retain skilled personnel for us to grow as an organization and achieve our
business objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors for any products that receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to mitigate the impact of adverse macroeconomic conditions or geopolitical events, including any
health epidemics and their residual effects, the ongoing conflicts between Ukraine and Russia and between Israel and Hamas, bank failures, or inflation and increased interest rates, on our preclinical and clinical development or operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require substantial additional capital in addition to the proceeds of this offering to achieve our business objectives. Additional
funds may not be available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Market volatility resulting from adverse
macroeconomic conditions or geopolitical events, including the ongoing war between Ukraine and Russia and the war in the Middle East, bank failures, inflation, increased interest rates, or other factors, may further adversely impact our ability to
access capital as and when needed. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations,
licenses, and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or
other preferences that adversely affect your rights as a holder of our common stock. Any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends, or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to
conduct our operations and execute our business plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through future collaborations, licenses, and other similar
arrangements, we may have to relinquish valuable rights to our future revenue streams or product candidates, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise
additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights
to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated our research and
development efforts on the treatment of psychiatric and neurological conditions, a field that faces certain challenges in drug development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused our research and development efforts on the treatment of psychiatric and neurological conditions. Efforts by biotechnology and
pharmaceutical companies in this field have faced certain challenges in drug development. In particular, clinical trials focused on many neuroscience diseases, such as schizophrenia and bipolar depression, rely on subjective patient-reported
outcomes as key endpoints. This makes these trials more difficult to evaluate than indications with more objective endpoints. Furthermore, these indications are often subject to a higher placebo effect, which may make it more challenging to isolate
the beneficial effects of our product candidate. While a product candidate may show clinical activity or therapeutic benefit, a high placebo effect in a clinical trial will make it difficult to ascertain that benefit or to show a statistically
significant effect of the product candidate as compared to the control arm, which may ultimately cause a clinical trial to fail or otherwise not translate to actual clinical benefit. Moreover, the risk for this higher placebo effect can increase
from successful completion of a Phase 2 trial to a Phase 3 trial, as there is clinical evidence of therapeutic benefit to which patients would already be aware of. There can be no guarantee that we will successfully overcome these challenges in our
ongoing or any future clinical trials of our product candidate or that we will not encounter other challenges in the development of our product candidate. In addition, negative investor perception of our clinical trial results due to a high placebo
effect may adversely affect our stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, certain of our primary or secondary endpoints in our clinical trials, including
our completed Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute schizophrenia, involve subjective assessments by physicians and/or patients, which can increase the uncertainty of clinical trial outcomes. The
primary endpoint of our proposed Phase&nbsp;3 acute schizophrenia trial is to evaluate the efficacy of <FONT STYLE="white-space:nowrap">LB-102</FONT> compared to the placebo, as measured by change from baseline in PANSS total score at six weeks,
which requires patients and raters to undertake a questionnaire regarding symptoms at protocol specified timepoints in the trial. This and other assessments are inherently subjective, which can increase the variability of clinical results across
clinical trials and create a significant degree of uncertainty in determining overall clinical benefit. Accordingly, these subjective assessments can complicate clinical trial design, adversely impact the ability of a study to show a statistically
significant improvement, and generally adversely impact a clinical development program by introducing additional uncertainties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The obligations
from our&nbsp;royalty agreements may be a drain on our cash resources or may cause us to incur debt obligations to satisfy the payment obligations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of our Series C financing, we entered into several amended and restated royalty
participation agreements, or the Amended and Restated Royalty Agreements, with certain of our existing investors, <FONT STYLE="white-space:nowrap">co-founders,</FONT> former and current directors, and former and current executive officers, including
Zachary Prensky, Andrew Vaino, Ph.D., and Marc Panoff, none of whom were new investors of&nbsp;our Series C preferred stock. We received no consideration as part of the Amended and Restated Royalty Agreements. Pursuant to the Amended and Restated
Royalty Agreements, we are obligated to pay royalties to all of the holders in an aggregate amount up to 2.75% of net sales arising from <FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide through December&nbsp;31, 2035. Thereafter, we are
obligated to pay royalties to such holders in an aggregate amount up to 3.25% in perpetuity. Future sales are defined in these agreements as the gross payments received on total commercial sales of <FONT STYLE="white-space:nowrap">LB-102,</FONT>
whether by us or by any licensee of <FONT STYLE="white-space:nowrap">LB-102.</FONT> See the section titled &#8220;Business&#8212;License and Other Agreements&#8221; elsewhere in this prospectus for additional information regarding these agreements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to satisfy our obligations to make these payments, if and when they are triggered,
we may need to issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash and cash equivalents or incur debt obligations to satisfy the payment obligations in cash, which may adversely
affect our financial position. In addition, these obligations may impede our ability to raise money in future public offerings of debt or equity securities, to obtain a third-party line of credit, or to license, sell or otherwise monetize our rights
in <FONT STYLE="white-space:nowrap">LB-102.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Candidate Development and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial or real-world results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidate or any future
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LB-102</FONT> is in clinical development and its risk of failure is high. It
is impossible to predict when or if our product candidate will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize our product candidate, we must demonstrate through lengthy, complex, and expensive clinical
trials that our product candidate is safe and effective in patient populations for the relevant indication(s) for use. Preclinical and clinical testing can take many years to complete, and its outcome is inherently uncertain. There is typically a
high rate of failure of product candidates proceeding through clinical trials, and failure can occur at any time during the preclinical study or clinical trial process, despite promising preclinical or clinical results. The results of preclinical
studies and early clinical trials of our product candidate may not be predictive of the results of later-stage clinical trials, and results in one indication may not be predictive of results to be expected for the same product candidate in another
indication. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. A number of companies in the
biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unfavorable safety profiles, notwithstanding promising results in earlier trials. For example, emraclidine was previously being
developed by Cerevel Therapeutics Holdings, Inc. for the indication of schizophrenia and ceased development due to, among other reasons, not achieving a statistically significant outcome for the primary endpoint in two completed <FONT
STYLE="white-space:nowrap">six-week</FONT> clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates achieved promising
results have nonetheless failed to obtain marketing approval of such product candidates or, upon commercialization, achieve or maintain positive real-world results. We may be unable to establish clinical endpoints that applicable regulatory
authorities would consider clinically meaningful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing any future clinical trials is subject to finalizing the trial protocol and
submitting an IND to the FDA or a similar application to initiate a clinical study to a comparable foreign regulatory authority. Even after we make our submission, the FDA or comparable foreign regulatory authorities could disagree that we have
satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies (including additional carcinogenicity studies in animal models) or amend our protocols or
impose stricter conditions on the commencement of clinical trials, which may lead to delays and increase the costs of our preclinical development programs. The FDA also has the authority to require a panel of experts, referred to as an Advisory
Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of such an Advisory Committee, although not binding on the FDA, could have a significant impact on our ability to obtain approval of our
product candidate in the future. Similar decisions may also be made by foreign regulatory authorities and have a similar impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most
product candidates that commence clinical trials are never approved as commercial products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support the approval of our current or any
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on our clinical trial sites and clinical trial teams to ensure the proper and
timely conduct of our clinical trials, including the participant enrollment process, and we have limited influence </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
over their performance. In addition, we may in the future enter into collaboration agreements pursuant to which our collaborator would be responsible for clinical development. We or our
collaborators may experience delays in initiating or completing clinical trials due to unforeseen events or otherwise, which could delay or prevent our ability to receive marketing approval or commercialize our current and any future product
candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, such as the FDA or comparable foreign regulatory authorities, Institutional Review Boards, or IRBs,
or ethics committees may impose additional requirements before permitting us to initiate a clinical trial, may not authorize us or our investigators to commence or conduct a clinical trial at a prospective trial site, may not allow us to amend trial
protocols, or regulators may disagree as to the design or implementation of our clinical trials and require that we modify or amend our clinical trial protocols, statistical analysis plans, or diversity action plans developed for recruitment in
pivotal clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with contract research
organizations, or CROs, or with individual clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment
of additional patients, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or amendments to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites may deviate from the trial protocol, fail to ensure the integrity of the data being
collected at the site, or drop out of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by any of our third-party contractors to perform in accordance with good clinical practices, or GCP,
requirements or applicable regulatory rules and guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of participants required for clinical trials may be larger than we anticipate, we may experience
difficulty in finding and enrolling sufficient qualified patients for our trials, enrollment in clinical trials may be slower than we anticipate, or participants may drop out or fail to return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients may fail to enroll or remain in our trials at the rate we expect, or fail to return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> including patients failing to remain in our trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing an alternative product for the indications for which we are developing our product candidate,
or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality or quantity of data relating to our product candidate or other materials necessary to conduct our
clinical trials may be inadequate to initiate or complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience difficulties in manufacturing, or fail to manufacture, sufficient quantities of our product
candidate for use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients experiencing severe or serious unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reports from clinical testing conducted by other companies of other therapies in the same class of agents that
could be considered similar to our product candidate may raise safety, tolerability, or efficacy concerns about our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lack adequate funding to initiate or continue one or more of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidate or any of their components being ordered by the FDA or comparable
foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or cross-contaminations of product candidates in the
manufacturing process; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to our manufacturing processes may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical investigators may lose the licenses or permits necessary to perform our clinical trials and may fail to
perform our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs, or other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors being unwilling or unable to satisfy their contractual obligations to us in a timely or
accurate manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors could become debarred or suspended or otherwise penalized by the FDA or other government
or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing
applications; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidate may fail to show appropriate safety, tolerability, or efficacy, may
produce negative or inconclusive results, or may otherwise fail to improve on the existing standard of care, and we may decide, or regulators may require us, to conduct additional clinical trials or we may decide to abandon product development
programs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory
authorities&#8217; legal requirements, regulations, and guidelines, and remain subject to oversight by these governmental agencies as well as ethics committees or IRBs responsible for overseeing the conduct of clinical trials and ensuring the
welfare of patients participating in the research. We could encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, the FDA or comparable foreign regulatory
authorities, or the Data Safety Monitoring Board, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial
protocols, adverse findings from inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to establish or achieve clinically
meaningful trial endpoints, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend
clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial.
Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the factors that cause,
or lead to, a delay in the commencement or completion of, or the termination or suspension of, clinical trials may also ultimately lead to the denial of regulatory approval of our product candidate. Further, the FDA may disagree with our
interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, in the future, conduct preclinical and clinical research in collaboration with other academic, pharmaceutical, and biotechnology
entities in which we combine our development efforts with those of our collaborators. Such collaborations may be subject to additional delays because of the management of the trials, contract negotiations, and the need to obtain agreement from
multiple parties, which may increase our future costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays
in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any
periods during which we may have the exclusive right to commercialize our product candidate and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product
candidate, if approved. Any delays or increase in costs in our clinical development programs may harm our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the marketing approval
process is expensive, time-consuming, and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of our product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate we may develop and the activities associated with their development and commercialization, including their design,
testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, import, export, marketing, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by
comparable foreign regulatory authorities. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product
candidates from regulatory authorities in any jurisdiction and none of the product candidates we may seek to develop in the future may ever obtain regulatory approval. We have no experience in filing and supporting the applications necessary to gain
marketing approvals. Although we believe that we have the capabilities to conduct preclinical studies and clinical trials and complete these applications using our internal resources and the necessary personnel we intend to hire in the future, we
selectively employ and may in the future rely on CRO or consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory
authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. The FDA may also not agree with our determination that our Phase 2 acute schizophrenia trial may serve as one of the two pivotal trials
required for approval of an NDA in the United States. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory
authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our ability to obtain marketing
approval for such product candidates or prevent or limit future commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining marketing approvals, both in the
United States and abroad, is expensive, often takes many years following the commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of
the product candidates involved, as well as the target indications and patient populations. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in
regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial
evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. The FDA and comparable foreign
regulatory authorities have substantial discretion in the approval process and may delay, limit, or deny approval of a product candidate for many reasons, or may decide that our data are insufficient for approval and require additional preclinical,
clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Despite the time and expense invested in clinical
development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are
commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may
involve additional product testing, administrative review periods, and agreements with pricing authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we eventually
complete clinical trials and receive approval of an NDA or comparable foreign marketing application for our product candidate, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional
clinical trials and/or the implementation of REMS, which may be required because the FDA believes it is necessary to ensure safe use of the product after approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to obtain approval of any
product candidates we may develop, the commercial prospects for those product candidates, including for other indications, may be harmed, and our ability to generate revenues will be materially impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidate receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, and others
in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never commercialized a product candidate for any indication. Even if our product candidate is approved by the appropriate regulatory
authorities for marketing and sale, our product candidate may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If our product candidate for which we obtain regulatory approval does not gain an
adequate level of market acceptance, we may not generate sufficient product revenue or become profitable. Further, the number of patients that our product candidate is designed to treat may be smaller than expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of our product candidate, if approved and commercialized, will depend on a number of factors, some of which
are beyond our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and cost-effectiveness of our product candidate, as well as the ease of administration, time burden,
and market acceptance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy, and tolerability of our product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our approach to precision psychiatry by patients, the medical community, and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care for targeted indications and the reluctance of physicians to switch their
patients&#8217; current standard of care; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reluctance of patients to switch from their existing therapy regardless of the safety and efficacy of newer
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our product is approved and the scope of efficacy/safety claims that we may
make for the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our product, and the prevalence and severity of any adverse effects;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any distribution and use restrictions imposed by the FDA as part of a mandatory REMS with respect to such product
candidate or to which we agree under a voluntary risk management plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate coverage and reimbursement by third parties, such as insurance companies and other
healthcare payors, and by government healthcare programs, including Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and strength of our marketing and distribution of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of such product candidate, as well as competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our product candidate for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitiveness of existing approved therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about our product or favorable publicity about competitive products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> is an <I>N</I>-methylated version of amisulpride, a
drug already approved in certain parts of Europe for the treatment of schizophrenia, predominantly negative symptoms of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
schizophrenia and dysthymia. While we are developing <FONT STYLE="white-space:nowrap">LB-102</FONT> for acute schizophrenia initially in the United States and potentially in other jurisdictions
where amisulpride is not approved, we currently plan to develop <FONT STYLE="white-space:nowrap">LB-102</FONT> to treat bipolar depression globally and if there is a recall, safety concern, or adverse regulatory action with respect to amisulpride in
Europe, it could prevent us from achieving or maintaining market acceptance of <FONT STYLE="white-space:nowrap">LB-102</FONT> or otherwise adversely affect our ability to successfully commercialize <FONT STYLE="white-space:nowrap">LB-102.</FONT>
Furthermore, although <FONT STYLE="white-space:nowrap">LB-102</FONT> is structurally similar to amisulpride, which is an approved product in many countries outside of the United States, there can be no assurance that our ongoing and future clinical
trials will show similar results with respect to safety and/or efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our efforts to educate the medical community and third-party
payors about the benefits of our product candidate may require significant resources and may never be successful. Even if our product candidate, if approved, is safe and effective for its approved indications, physicians and patients may not
immediately be receptive to such product candidate and may be slow to adopt it as an accepted treatment for the approved indications. If our current or future product candidates are approved, but do not achieve an adequate level of acceptance among
physicians, patients, and third-party payors, we may not generate meaningful revenue from our product candidate and may never become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the
speed at which we can recruit and enroll patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. We may not be able to initiate or continue clinical trials for our product
candidate if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or comparable foreign regulatory authorities. Patient enrollment is
affected by many factors including the size and nature of the patient population, competing clinical trials in the same or similar indications or at the same trial site, the severity of the disease or condition under investigation, the availability
and efficacy of approved drugs and diagnostics for the disease or condition under investigation, the number and location of clinical sites, the proximity of patients to clinical sites, willingness of patients to participate in a decentralized
clinical trial that may involve remote monitoring technologies, the inclusion and exclusion criteria for the trial, perceived risks and benefits of the product candidate under study, the design of the clinical trial, continued enrollment of
prospective patients by clinical trial sites, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, efforts to facilitate timely
enrollment in clinical trials, patient referral practices of physicians, the ability to monitor patients adequately during and after treatment, competing clinical trials, and clinicians&#8217; and patients&#8217; perceptions as to the potential
advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for, or any product candidates under investigation for, the indications we are investigating.
Clinical trial recruitment and enrollment activities may also be delayed as a result of macro-factors such as public health emergencies or pandemics, natural disasters, acts of terror or war, or staffing shortages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. We may not be able to initiate or
continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding eligible
patients may prove costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, clinical trials in acute schizophrenia and bipolar depression have experienced significant
participant withdrawals or discontinuations. There is no guarantee that our estimated withdrawal rate in any of our clinical trials will be accurate, and if we experience a withdrawal rate larger than expected, this may compromise the quality of our
data. Withdrawal of participants from our clinical trials, including participants in any control groups, may compromise the quality of our data. Even if we are able to enroll a sufficient number of participants in our clinical trials, we may have
difficulty maintaining enrollment of such patients, and delays in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enrollment may result in increased costs or may affect the timing or outcome of our clinical trials. Any of these conditions may negatively impact our ability to complete such trials or include
results from such trials in regulatory submissions, which could adversely affect our ability to advance the development of our product candidate. Additionally, participants with neuropsychiatric disorders, including schizophrenia, constitute a
vulnerable patient population and may withdraw from the clinical trial if they are not experiencing improvement in their underlying disease or condition or if they experience other difficulties or issues relating to their underlying disease or
condition or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, other biopharmaceutical companies targeting these same diseases are recruiting clinical trial patients
from similar patient populations, which may make it more difficult to fully enroll any clinical trials. Our inability to enroll a sufficient number of patients for any of our future clinical trials would result in significant delays or may require
us to abandon one or more clinical trials altogether. In addition, we expect to rely on clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we
will have limited influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that our assumptions used in determining expected
clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our product candidate could be associated with adverse side effects, adverse events, or other safety risks, which could delay or preclude the
candidate&#8217;s approval, cause us to suspend or discontinue clinical trials, cause us to abandon the product candidate, limit the commercial profile of any future approved product, or result in other significant negative consequences that could
severely harm our business, prospects, operating results, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a
high and unacceptable severity and prevalence of side effects or unexpected characteristics related to our product candidate. Undesirable side effects caused by our product candidate could cause us, the IRB, or regulatory authorities to interrupt,
delay, or halt clinical trials or cause the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities, or, if such product candidate is approved, result in a more restrictive label and other post-approval
requirements. Any treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or could result in potential product liability claims. Any of these occurrences may harm our business,
financial condition, and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidate is associated with undesirable side effects or has unexpected
characteristics in clinical trials, we may need to interrupt, delay, or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less
severe, or more acceptable from a risk-benefit perspective. To date, TEAEs from our Phase 1 and Phase 2 trials were generally mild or moderate. TEAEs included events typically associated with dopamine antagonists. In the Phase 2 trial the most
frequently occurring TEAEs were insomnia, headache, anxiety and agitation. Low rates of adverse events associated with EPS and modest increases in QT prolongation were observed. Consistent with other antipsychotics, use of <FONT
STYLE="white-space:nowrap">LB-102</FONT> resulted in elevated serum prolactin levels, but these elevations were associated with very few adverse events associated with that increase. In our Phase 2 acute schizophrenia trial, 10 participants reported
TEAEs leading to withdrawal, including two in each of the placebo and 50 mg cohorts, as well as three in each of the 75 mg and 100 mg cohorts. There were five reported serious adverse events, or SAEs, overall with two SAEs in the placebo cohort
(psychotic disorder and death), one SAE in the 50 mg cohort (suicidal ideation&#8212;deemed possibly related to treatment), one SAE in the 75 mg cohort (dystonia&#8212;deemed possibly related to treatment) and one SAE in the 100 mg cohort (psychotic
disorder&#8212;deemed not related to treatment). The incidence of TEAEs was similar across groups, with most events being mild or moderate. For additional information, see the section titled &#8220;Business&#8212;Our Solution: <FONT
STYLE="white-space:nowrap">LB-102</FONT> for the Treatment of <FONT STYLE="white-space:nowrap">Schizophrenia&#8212;LB-102</FONT> Clinical Data.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients in our ongoing and planned clinical trials may in the future suffer significant
adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Even if such side effects do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may
inhibit market acceptance due to tolerability concerns as compared to other available therapies. Any of these developments could materially harm our business, financial condition, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if our product candidate receives regulatory approval, and we or others later identify undesirable side effects caused by such
product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of treatment with such product candidate
outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring, or distribution systems and processes that are highly
controlled, restrictive, and more costly than what is typical for the industry. Other potentially significant negative consequences associated with post-marketing identification of adverse events or other safety risks include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to suspend marketing of a product, or we may decide to remove such product from the
marketplace; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or modify their approvals of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings or new contraindications on the label, or may limit access
of a product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of a product for patients, or to conduct
post-marketing studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is distributed or administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held
liable for harm caused to subjects or patients; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product may become less competitive, and our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, participants with neuropsychiatric disorders, including schizophrenia and bipolar depression, constitute a vulnerable patient
population, and any adverse side effects or adverse events may be exacerbated in such patient population. Any of these events could diminish the usage or otherwise limit the commercial success of our product candidate and prevent us from achieving
or maintaining market acceptance of our product candidate, if approved by the FDA or other regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a
product candidate and may experience delays or unexpected difficulties in obtaining, or fail to obtain, regulatory approval for our product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never obtained regulatory approval for, or commercialized, a drug product in the United States or elsewhere. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trial results may not support regulatory approval. In addition, our product candidate could fail to receive regulatory approval
for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials, such as our determination that our Phase 2 acute schizophrenia trial may serve as one of the two pivotal trials required for approval of an NDA in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
our product candidate is safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have negative or ambiguous results from our clinical trials, or results may not meet the level of
statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in
the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may not accept clinical data from trials that are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of their own country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by
individuals using drugs similar to our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidate may not be sufficient to the satisfaction of the
FDA or comparable foreign regulatory authorities to support the submission of an NDA, or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose
requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with us regarding the formulation, labeling, and/or release/stability
specifications of our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than those sought by us, and/or
may include significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the
submission; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may find deficiencies in or fail to approve the
manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> is an <I>N</I>-methylated version of amisulpride, a
drug already approved in certain parts of Europe for the treatment of schizophrenia, predominantly negative symptoms of schizophrenia and dysthymia. While we are developing <FONT STYLE="white-space:nowrap">LB-102</FONT> for acute schizophrenia
initially in the United States and potentially in other jurisdictions where amisulpride is not approved, we currently plan to develop <FONT STYLE="white-space:nowrap">LB-102</FONT> to treat bipolar depression globally and if there is a recall,
safety concern, or adverse regulatory action with respect to amisulpride in Europe, it could adversely affect our ability to obtain regulatory approval for <FONT STYLE="white-space:nowrap">LB-102.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the FDA and comparable foreign regulatory authorities may change their approval policies and new regulations may be enacted, which
could delay or prevent our ability to obtain approval. If our product candidate fails to achieve regulatory approval due to the above factors, or otherwise, any such failure would adversely affect our business, results of operations, and financial
condition. In addition, difficulties in obtaining approval of a product candidate in any of the initial indications for which we are developing it could adversely affect our efforts to seek approval from regulatory authorities for other indications.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">&#8220;top-line,&#8221;</FONT> and preliminary data from our clinical trials that we announce or publish
from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or <FONT STYLE="white-space:nowrap">top-line</FONT> data from our preclinical studies
and clinical trials, which are based on preliminary analyses of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular preclinical
study or clinical trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the <FONT
STYLE="white-space:nowrap">top-line</FONT> or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been
received </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and fully evaluated. <FONT STYLE="white-space:nowrap">Top-line</FONT> and preliminary data also remain subject to audit and verification procedures that may result in the final data being
materially different from the <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data we previously published. As a result, <FONT STYLE="white-space:nowrap">top-line</FONT> and preliminary data should be viewed with caution until the
final data are available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim
data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from our
clinical trials continue other treatments for their disease. Adverse differences between interim data and final data could significantly harm our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and could adversely affect the
success of our business. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is
material or otherwise appropriate information to include in our disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the interim,
<FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, our product candidate may be harmed, which could harm our business, financial condition, results of operations, and prospects. Further, disclosure of interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> or preliminary data by us
or by our competitors could result in volatility in the price of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if we fail to
replicate the positive results from our preclinical studies or clinical trials in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for, and commercialize our current or future product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to develop and commercialize our current product candidate for additional indications or fail to discover, develop, and commercialize other
product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of our current product candidate for the treatment of schizophrenia and bipolar depression is
our primary focus, as part of our longer-term growth strategy, we plan to evaluate our current product candidates in other indications (such as MDD, negative symptoms of schizophrenia, bipolar mania, and Alzheimer&#8217;s disease psychosis and
agitation) and develop other product candidates. We intend to evaluate internal opportunities from our current product candidate or other potential product candidates, and also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or
acquire other product candidates as well as commercial products to treat patients suffering from other disorders with significant unmet medical needs and limited treatment options. These other potential product candidates will require additional,
time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials, and approval by the FDA and/or comparable foreign regulatory authorities. All product candidates are prone to the risks of failure that are
inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such
products, if approved, will be manufactured or produced economically, successfully commercialized, or widely accepted in the marketplace, or be more effective than other commercially available alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to identify product candidates require substantial technical, financial, and human resources, whether or not any product
candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential product candidates;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our product candidate(s) obsolete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates that we develop may nevertheless be covered by third parties&#8217; patents or other exclusive
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party
payors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth
and achieving our strategic objectives may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our resources to pursue a particular product candidate or indication and
forgo the opportunity to capitalize on product candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we intend to focus on developing product candidate for specific indications that we
identify as most likely to succeed, in terms of both their potential for regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to
have greater commercial potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or
profitable market opportunities. Our spending on research and development programs and product candidate for specific indications may not yield any commercially viable product candidate. If we do not accurately evaluate the commercial potential or
target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to the product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of <FONT
STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates we may develop in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of such product candidate in other jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek regulatory approval for <FONT STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates we may develop outside the
United States. Foreign regulatory authorities have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining and maintaining regulatory approval of
<FONT STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates we may develop in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. However, a failure or
delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in
foreign jurisdictions also must approve the manufacturing, marketing, and promotion of the product candidate in those jurisdictions. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In
addition, in some jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also
subject to approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in
significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive and maintain applicable marketing approvals, or if regulatory approvals in
international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our product candidate will be harmed, which could adversely affect our business, results of operations, and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidate, if approved, will depend in part on the extent to which governmental
authorities and health insurers establish coverage, adequate reimbursement levels, and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidate could limit our ability to market those
products and decrease our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of coverage and the adequacy of reimbursement by
governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidate, if approved. Our
ability to achieve coverage and acceptable levels of reimbursement for our product by third-party payors will have an effect on our ability to successfully commercialize the product and any future products we may successfully develop. Even if we
obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that
coverage and reimbursement in the United States, the European Union, or the EU, or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may
refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidate as substitutable and only offer to
reimburse patients for the less expensive product. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an
appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products, if approved, and may not be able to obtain a
satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and
reimbursement of newly approved products. Regulatory approvals, pricing, and reimbursement for new drug products vary widely from country to country. In the United States, third-party payors, including private and governmental payors, such as the
Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative drug
therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time-consuming, costly, and uncertain. The Medicare and Medicaid programs increasingly are
used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United
States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and
clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding
reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under currently applicable U.S. law, certain products not usually self-administered (including injectable drugs) may be eligible for coverage
under Medicare through Medicare Part B. Medicare Part B is part of original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain biopharmaceutical products,
that are medically necessary to treat a beneficiary&#8217;s health condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer&#8217;s eligible drugs, the manufacturer is required to participate in other government
healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the U.S.
Department of Health and Human Services, or HHS, as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must
extend discounts to entities that participate in the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject
to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of
pharmaceutical products. In many countries, the prices of medicinal products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor
and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidate, if approved. Accordingly, in markets outside the United States, the
reimbursement for our product candidate may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. See &#8220;&#8212;EU drug marketing and reimbursement regulations may materially
affect our ability to market and receive coverage for our products in the EU member states&#8221; below for further discussion of risks related to foreign marketing and reimbursement regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may
cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection
with the sale of our product candidate, if approved for marketing, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare
costs in general, particularly prescription drugs and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates are developed through <FONT STYLE="white-space:nowrap">pre-clinical</FONT> to late-stage clinical trials towards approval
and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation (including raw materials and starting materials), are altered in an effort to optimize processes and results. Such
changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidate to perform differently and affect the results of planned clinical trials or future clinical trials to be conducted
with the altered materials. Such changes may also require additional testing, notification to the FDA or comparable foreign regulatory authorities or approval from the FDA or comparable foreign regulatory authorities. This could delay completion of
clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate and/or jeopardize our ability to commence product sales and
generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may conduct certain of our clinical trials for our product candidate outside of the United States in the future. However, the
FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently conduct all of our clinical trials in the United States, in the future we may conduct one or more of our clinical trials
for our product candidate outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions imposed by the FDA. For example, to accept data from a clinical trial that was conducted only at sites outside of the United States and not subject to an IND, the FDA requires such
clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection if the FDA deems such inspection necessary. In
cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are
applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the data may be considered valid without the need for
an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other
appropriate means. For studies not subject to an IND, the FDA generally does not review clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design, protocol, and/or
results from a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial were inadequate for the purposes we intend, which could require us to conduct additional clinical trials. Many foreign regulatory authorities have similar requirements
for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance the FDA or
any comparable foreign regulatory authority will accept data from clinical trials conducted outside of the United States or the relevant jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept data from our clinical
trials of our product candidate, it may result in the need for additional clinical trials, which would be costly and time-consuming and could delay or permanently halt our development of our product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Neuroscience drug development is a field that has seen limited success. The ability to successfully develop drugs in this field is difficult and is
subject to a number of unique challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug development in the field of brain diseases, neuropsychiatric disorders and
neurodegenerative diseases in particular, has seen limited success historically. Developing a successful product candidate for treatment of these brain diseases is difficult and subjects us to a number of unique challenges, including obtaining
regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to work
closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation in an effort to obtain regulatory approval for our product candidate; however, the process of developing our product
candidate may be more complex and time-consuming relative to other more well-known approaches to drug development. We cannot be certain that our approach will lead to the development of a product candidate that effectively and safely addresses the
underlying brain diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us
or others may result in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business depends on the success of our product candidate. If we are ultimately unable to successfully commercialize our product candidate, or
experience significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for
commercial sale or for which regulatory approval to market has been sought. We have invested a significant portion of our efforts and financial resources in the development of our product candidate, which is still in clinical development, and expect
that we will continue to invest heavily in such product candidate, as well as in any future product candidates we may develop. Our business and our ability to generate revenue, which we do not expect will occur for many years, if ever, are
substantially dependent on our ability to develop, obtain regulatory approval for, and then successfully commercialize <FONT STYLE="white-space:nowrap">LB-102,</FONT> which may never occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved for marketing by applicable regulatory authorities, our ability to generate
revenue from our product candidate will depend on our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of our future approved product by patients, the medical community, and third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create market demand for our approved product through our own marketing and sales activities, and any other
arrangements to promote the approved product that we may otherwise establish in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive regulatory approval for the targeted patient populations and efficacy/safety claims that are necessary or
desirable for successful marketing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">price our product competitively such that third-party and government reimbursement permits broad product
adoption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture our product candidate through contract development and manufacturing organizations, or CDMOs, in
sufficient quantities and at acceptable quality and manufacturing cost to meet commercial demand at launch and thereafter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and maintain agreements with wholesalers, distributors, pharmacies, and group purchasing organizations
on commercially reasonable terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, and enforce patent and other intellectual property protection and regulatory
exclusivity for our product, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain compliance with applicable laws, regulations, and guidance specific to commercialization including
interactions with health care professionals, patient advocacy groups, and communication of health care economic information to payors and formularies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assure that our product candidate, if approved, will be used as directed and that additional unexpected safety
risks will not arise. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on, and intend to continue to rely on, our internal clinical development expertise to conduct our
current and future clinical trials. This model includes internal teams and systems as well as external vendors and CROs to comprise a full clinical trial team. If our clinical trial team does not comply with applicable regulatory requirements, meet
expected deadlines, or run trials effectively, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product candidate may be delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conduct much of our clinical trial work (e.g., clinical and medical monitoring, data management, and project management) with CROs as well
as utilizing internal personnel to augment and oversee our CROs. Although we believe that our CROs currently have the capabilities to conduct clinical trials in collaboration with our internal staff, we may need to rely on additional third party
CROs to conduct clinical trials if our internal and existing CRO capabilities cannot scale as we work to progress <FONT STYLE="white-space:nowrap">LB-102</FONT> through development, as we potentially expand our product candidate portfolio, or if we
do not have sufficient personnel to support our clinical program. Our failure or the failure of any CROs we may employ to conduct the trials in compliance with FDA regulations could result in a delay or failure in obtaining FDA approval and could
require us to repeat any preclinical studies or clinical trials we or the CRO administered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as part of our engagement with CROs,
we have to negotiate budgets and contracts with them and/or each trial site, which may result in delays to our development timelines and increased costs. If any of our relationships with CROs and/or trial sites terminate, we may not be able to enter
into arrangements with alternative trial sites or do so on commercially reasonable terms. Switching or adding additional trial sites can also involve additional costs and requires time and focus of our clinical trial operations management team. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive products may reduce or eliminate the commercial opportunity for our product candidate for
our current or future indications. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective or safer than ours, our ability to develop and successfully commercialize our current
products may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is characterized by rapid innovation and intense competition.
While we believe that our clinical program provides us with competitive advantages, we face competition from multiple biopharmaceutical and biotechnology companies that are similarly working to develop therapeutics targeting neuropsychiatry and,
central nervous system, or CNS, disorders, as well as from academic institutions, governmental agencies, and public and private research institutions. Many of our potential competitors, either alone or with collaboration partners, have significantly
greater financial resources than we do, as well as equal or greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products, and the commercialization of those products.
Accordingly, our potential competitors may be more successful than we are in achieving regulatory approvals and commercializing their products. We anticipate that we will face intense and increasing competition from existing, approved drugs, as well
as new drugs entering the market and emerging technologies that become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing
<FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of schizophrenia and bipolar depression. While there remains significant unmet need in schizophrenia and bipolar depression, we believe <FONT STYLE="white-space:nowrap">LB-102,</FONT>
if approved, may face competition from product candidates also being developed for treatment of schizophrenia and bipolar depression. See &#8220;Business&#8212;Competition&#8221; for additional information relating to our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors affecting the success of our product candidate that we develop to address schizophrenia, bipolar
depression and other CNS disorders, if approved, are likely to be efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. Our profitability and
financial position will suffer if our product candidate receives regulatory approval but cannot compete effectively in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will
need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of August&nbsp;15, 2025, we had 16 employees. As our development and commercialization plans and strategies develop, and as we transition
into operating as a public company, we expect to expand our employee base for managerial, operational, financial, and other resources. In addition, we have limited experience in manufacturing and commercialization. As our product candidate enters
and advances through clinical trials, we will need to expand our development and regulatory capabilities and contract with other organizations to provide manufacturing and other capabilities for us. In the future, we expect to have to manage
additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting
systems and procedures, which may lead to significant costs and may divert management attention. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover
deficiencies in existing systems and controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to successfully manage our growth and expand our operations could adversely
affect our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on the services of our management and other
clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our continued ability to attract, retain, and motivate highly qualified management, clinical, and scientific
personnel. We are highly dependent upon our Chief Executive Officer, Heather </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Turner, and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development and commercialization of our product
candidate. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as
expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in light of our insourced clinical trial model, we are heavily reliant on the expertise of our clinical trial
team, and the loss of even a small number of those employees could have a significant adverse impact on our ability to conduct our clinical trials in a compliant and timely manner. Additionally, as we expand our clinical trial operations, or if we
experience turnover within our clinical trial team, even if we are able to recruit qualified personnel to support our insourced clinical trial model, the onboarding and integration process takes time and can result in delays to our clinical
development timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to expand and effectively manage our managerial, operational, financial, and other resources in order
to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future
due to the intense competition for qualified personnel among biopharmaceutical, biotechnology, and other businesses, particularly in the greater New York Area. If we are not able to attract and grow our headcount with the appropriate personnel or
integrate, retain, and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital, and our
ability to implement our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the
risk of employee fraud or other illegal activity by our current and any future employees, independent contractors, consultants, commercial partners, CROs, CDMOs, and vendors. Misconduct by these parties could include intentional, reckless, and/or
negligent conduct that fails to comply with FDA or other regulations, provide true, complete and accurate information to the FDA, European Medicines Agency, and other comparable foreign regulatory authorities, comply with manufacturing standards we
may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of our product candidate and begin commercializing the
product in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. In particular, sales, marketing, and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results
of operations, and prospects, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain
approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, integrity oversight and reporting obligations, or reputational harm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business entails a significant risk of product liability and our ability to obtain sufficient
insurance coverage could adversely affect our business, financial condition, results of operations, and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we conduct
clinical trials of our current or future product candidates, we are exposed to significant product liability risks inherent in the development, testing, manufacturing, and marketing of new treatments. Product liability claims could delay or prevent
completion of our development programs. If we succeed in obtaining approval for, and marketing products, such claims or certain adverse event trends could result in an investigation by the FDA, comparable foreign regulatory authorities, or other
regulators into the safety and efficacy of our future approved products, our manufacturing processes and facilities, or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved
indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our future approved products, termination of clinical trial
sites or entire trial programs, withdrawal of clinical trial participants, injury to our reputation and significant negative media attention, significant costs to defend the related litigation, a diversion of management&#8217;s time and our
resources from our business operations, substantial monetary awards to trial participants or patients, loss of revenue, the inability to commercialize any products that we may develop, and a decline in our stock price. We may need to obtain higher
levels of product liability insurance for later stages of clinical development or marketing our product candidate. Any insurance we may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product
liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could adversely affect our business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may
encounter. Some of the policies we currently maintain include property, general liability, clinical trials, and directors&#8217; and officers&#8217; liability insurance. We do not know, however, if we will be able to maintain insurance with adequate
levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse
consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse
consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we and the third parties with whom we work, collect, receive, store, process,
generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share, or collectively, process, personal data and other sensitive information, including proprietary and confidential business information, trade
secrets, intellectual property, information we collect about trial participants in connection with clinical trials, and sensitive third-party information, or collectively, sensitive data. As a result, we and the third parties with whom we work face
a variety of evolving threats that could cause security incidents. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive
data and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer
&#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for
geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon with whom we work may be vulnerable to a heightened risk of these attacks, including
retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the third parties with whom we work are subject to a variety of evolving threats,
including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of
advanced persistent threat intrusions), <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks,
supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by artificial intelligence, or AI, telecommunications failures,
earthquakes, fires, floods, and other similar threats. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, severe ransomware attacks are becoming increasingly prevalent and
can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware
attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not
be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain
access to other networks and systems after a compromise of our networks and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Remote work has increased risks to our information
technology systems and data, as more of our personnel utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit or in public locations. Additionally, future or past business
transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and
technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our reliance on third parties could introduce new cybersecurity risks and vulnerabilities, including supply-chain
attacks, and other threats to our business operations.<B><I> </I></B>We rely on various third parties and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation,
cloud-based infrastructure, data center facilities, encryption and authentication technology, personnel email, and other functions. We also rely on third parties to provide other products, services, parts, or otherwise to operate our business,
including with respect to our cybersecurity infrastructure. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If the
third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if such third parties fail to satisfy their privacy or security-related obligations
to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.<B><I> </I></B>In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217;
infrastructure in our supply chain or that of the third parties with whom we work have not been compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented
security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may
experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized,
unlawful, or accidental acquisition, modification, destruction, loss, alteration, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could
disrupt our ability (and that of third parties with whom we work) to provide our services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may expend significant resources or modify
our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or
industry-standard or reasonable security measures to protect our information technology systems and sensitive data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable data
privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, regulators, and investors, of security incidents, or take other actions, such as providing credit
monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may
experience material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data
(including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability
of data); financial loss; and other similar harms. Security incidents and attendant material consequences may negatively impact our ability to grow and operate our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our
contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage, if any, will be adequate or sufficient to protect us from or to mitigate
liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data
brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data that we possess could be leaked, disclosed, or
revealed as a result of or in connection with our personnel&#8217;s or vendors&#8217; use of generative AI technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified
material weaknesses in our internal control over financial reporting. If we fail to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise fail to maintain effective internal control over
financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, we had limited accounting personnel and other resources to address our internal control over financial reporting.
In connection with the preparation of our financial statements for the year ended December&nbsp;31, 2024, material weaknesses were identified in the design and operating effectiveness of our internal control over financial reporting. A material
weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or
detected on a timely basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our assessment, we did not appropriately design and maintain entity-level controls
impacting the control environment, control activities, information and monitoring activities to prevent or detect material misstatements to the financial statements. These material weaknesses relate to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) an insufficient number of qualified resources to ensure adequate oversight and accountability over the performance of controls, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proper segregation of duties, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controls over the completeness and accuracy of information used in the operation of control activities across
substantially all financial statement areas, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of control evidence, and </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) improper access and a lack of review over user access and user provisioning as it relates to our information technology environment and
general controls over information systems that support the financial reporting process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These material weaknesses could result in a
misstatement of our accounts or disclosures in our annual or interim financial statements that would not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These material weaknesses have not been remediated as of the date of this prospectus. To remediate the material weaknesses, we continue to
hire finance and accounting personnel, as well as improve our financial controls and accounting systems. We continue using services of a third-party firm to assist in the design and implementation of controls. We intend to continue to take further
steps to remediate these material weaknesses through formalizing documentation of policies and procedures and further evolving the accounting processes. The material weaknesses will not be considered remediated until management completes the design
and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective. Although we currently expect to remediate these material
weaknesses by December&nbsp;31, 2025, we cannot assure you that we will be able to successfully do so on this timeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The measures we
have taken to date, and those that we are continuing to design and implement, may not be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. If the steps we take do not correct these
material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our
financial statements would not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to remediate our existing material weaknesses or
identify new material weaknesses in our internal control over financial reporting, if we are unable to comply with the disclosure and attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to
conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to conclude that our internal control over financial reporting is effective when we are no longer an emerging
growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected. As a result, we could also become subject to investigations by Nasdaq, the
SEC or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and financial condition or divert financial and management resources from our regular business activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our projections regarding the market opportunities for our product candidate may not be accurate, and the actual market for our products may be smaller
than we estimate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The precise incidence and prevalence for all the conditions we aim to address with our product candidate are
unknown. Our projections of both the number of people who have these diseases, as well as the subset of people </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with these diseases who have the potential to benefit from treatment with our product candidate, are based on our beliefs and estimates. These estimates have been derived from a variety of
sources, including sales of our competitors, scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect in general, or as to their applicability to our company. Further, new trials may change
the estimated incidence or prevalence of these diseases. The total addressable market of our product candidate, if approved, will ultimately depend upon, among other things, the diagnosis criteria included in the final label for our product
candidate approved for sale for these indications, if any, the ability of our product candidate to improve on the safety, convenience, cost, and efficacy of competing therapies or therapies in development, acceptance by the medical community and
patients, drug pricing, and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product, if approved,
and our product candidate or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be adversely affected by the effects of health pandemics or epidemics, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, which could cause significant disruptions in our operations and those of our current or future CDMOs, CROs, and other third parties upon whom we rely. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health pandemics or epidemics, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, have in the past and could again in the
future result in quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders, remote work policies, or other similar events that may disrupt businesses, delay our research and development programs
and timelines, negatively impact productivity and increase risks associated with cybersecurity, the future magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations. More specifically, these types
of events may negatively impact personnel at third-party manufacturing facilities or the availability or cost of materials, which could disrupt our supply chain. Moreover, our clinical trials may be negatively affected. Clinical site initiation and
patient enrollment may be delayed due to prioritization of hospital resources. Some patients may not be able or willing to comply with trial protocols if quarantines impede patient movement or interrupt healthcare services. Our ability to recruit
and retain patients, principal investigators, and site staff (who as healthcare providers may have heightened exposure) may be hindered, which would adversely affect our trial operations. Disruptions or restrictions on our ability to travel to
monitor data from our trials, or to conduct trials, or the ability of patients enrolled in our trials or staff at trial sites to travel, as well as temporary closures of our trial partners and CDMOs&#8217; facilities, would negatively impact our
trial activities. In addition, we rely on independent clinical investigators, CROs, and other third-party service providers to assist us in managing, monitoring, and otherwise carrying out certain of our preclinical studies and clinical trials,
including the collection of data from our trials, and the effects of health pandemics or epidemics, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may affect their ability to devote sufficient time and resources to our
programs or to travel to sites to perform work for us. Similarly, our trials could be delayed and/or disrupted. As a result, the expected timeline for data readouts, including incompleteness in data collection and analysis and other related
activities, and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory approval for and to commercialize our product candidate, if approved, increase our operating expenses, and adversely
affect our business, financial condition, results of operations, and prospects. In addition, impact on the operations of the FDA or comparable foreign regulatory authorities could negatively affect our planned trials and approval processes. Finally,
economic conditions and business activity may be negatively impacted and may not recover as quickly as anticipated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend,
in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our product candidate in foreign markets, including in the
European Union, United Kingdom and Japan, for which we may rely on collaboration with third parties. We are not permitted to market or promote our product candidate before we receive regulatory approval from the applicable regulatory authority in
that foreign market and may never receive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such regulatory approval for our product candidate. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such
countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing, and distribution of our product candidate, and we cannot predict success in these jurisdictions. If we fail to comply with the
regulatory requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidate will be harmed and our business will be
adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of our product candidate by regulatory authorities in another country may significantly diminish the commercial prospects
of that product candidate and our business, financial condition, results of operations, and prospects could be adversely affected. Moreover, even if we obtain approval of our product candidate and ultimately commercialize our product candidate in
foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting, and legal requirements, and reduced protection of intellectual property rights in
some foreign countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property, Collaborations, and Related Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain sufficient intellectual property protection for our technologies, and product candidate and any future product
candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to
successfully develop and commercialize our product candidate may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, <FONT
STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and confidentiality agreements, to protect the intellectual property related to our technologies, and product candidate and to prevent third parties from copying and surpassing our
achievements, thus eroding our competitive position in our market. We may also rely on protection afforded by <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights and proprietary technology of third parties in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries for
our product candidate and its uses, as well as our ability to operate without infringing, misappropriating, or otherwise violating the proprietary rights of others. We seek to protect our proprietary position by filing patent applications in the
United States and abroad related to our novel discoveries and technologies that are important to our business. Although we own issued patents, our pending and future patent applications may not result in patents being issued. Even if our patent
applications result in issued patents, we cannot assure you that such issued patents will afford sufficient protection of our product candidate or its intended uses against competitors, nor can there be any assurance that the patents issued will not
be infringed, designed around, invalidated by third parties, or that they will effectively prevent others from commercializing competitive technologies, products, or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce, or license all
necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications at a reasonable cost or in a timely manner. We may not be able to obtain or maintain patent applications and patents due to
the subject matter claimed in such patent applications and patents being in disclosures in the public domain. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to
obtain patent protection. Therefore, patents and applications that are relevant to our product candidate may not be prosecuted and enforced in a manner consistent with the best interests of our business. Although we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside
scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Consequently, we may not be able to prevent any third parties from using any of our technologies that are in the public domain to compete with our technologies or product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Composition of matter patents for pharmaceutical product candidates often provide a strong form of intellectual property protection for those
types of products, as such patents provide protection without regard to any method of use or preparation. However, we cannot be certain that the claims in any of our patent applications directed to composition of matter of our product candidate will
be considered patentable by the United States Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United
States or foreign countries. Further, our issued composition of matter patents covering our pharmaceutical product candidate may expire at such a date that our patents may not prevent competitors from developing, making and marketing a product that
is identical to our product candidate after expiration of any applicable regulatory exclusivities. Similarly, patents for pharmaceutical formulations containing pharmaceutical product candidates may provide an additional form of intellectual
property protection, as such patents provide protection without regard to any method of use. However, we cannot be certain that the claims in our pending patent applications directed to pharmaceutical formulations containing our product candidate
will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. In addition, we
cannot be certain that the claims of such patents, if granted, will be sufficiently broad to effectively prevent competitors from working around our claimed inventions by developing alternative compounds and thereby competing with us without
infringing our patent rights. Method of use patents protect the use of a product for the specified method or indication. In the absence of separate composition of matter protection, this type of patent does not prevent a competitor from making and
marketing a product that is identical to our product candidate for an indication that is outside of the methods of use claimed in our patents. Moreover, even if competitor products are not approved for use in our patented indications, and our
competitors do not actively promote their products for indications that are covered by our patents, clinicians may prescribe these competitor products <FONT STYLE="white-space:nowrap">&#8220;off-label.&#8221;</FONT> Although <FONT
STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method of use patents, such infringement is difficult to prevent or prosecute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent
years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. As a result, the issuance, scope, validity,
enforceability, and commercial value of any patent rights are highly uncertain. Our pending and future owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications may not result in patents being issued that protect our
technologies or product candidate, effectively prevent others from commercializing our technologies or product candidate or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all. The coverage
claimed in a patent application can also be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of
the United States, or vice versa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no
assurance that we will be successful in protecting our product candidate by obtaining and defending patents. For example, we may not be aware of all third-party intellectual property rights potentially relating to our product candidate or its
intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is
highly uncertain. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in
some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a
third party can establish that we were not the first to make or the first to file for patent protection of such inventions, our patent applications may not issue as patents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and even if issued, may be challenged and invalidated or rendered unenforceable. As a result, the issuance, inventorship, scope, validity, enforceability, and commercial value of our patent
rights are highly uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and
our pending patent applications may be challenged in patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before
various patent offices or in courts. For example, our pending patent applications may be subject to third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submissions of prior art to the USPTO, and our issued patents may be subject to
post-grant review, proceedings, oppositions, derivations, reexaminations, interferences, <I>inter partes</I> review proceedings, or other similar proceedings, in the United States or elsewhere, challenging our patent rights. Such submissions may
also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one or more of our pending patent applications. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being
narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technologies and product candidates, or limit the duration of the patent protection of
our technologies and product candidate. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could impair our
competitive position and adversely affect our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may also
claim that our patent rights are invalid or unenforceable in a litigation. We can also be accused of infringement by a third party in a litigation. The outcome following legal assertions of invalidity, unenforceability, or infringement is
unpredictable. An adverse result in any legal proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could allow third parties to commercialize our products and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize our technology, products, or product candidate without infringing third-party patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our
rights or permit us to gain or keep any competitive advantage. Any failure to obtain or maintain patent protection with respect to our product candidate or its uses could adversely affect our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidate, or the method of use of our product candidate could be found invalid or unenforceable if
challenged in court or before administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiate legal proceedings against a
third party to enforce a patent covering our product candidate, or our other proprietary technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
<FONT STYLE="white-space:nowrap">non-enablement,</FONT> insufficient written description, or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of
the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In addition to such counterclaims, third parties may raise claims challenging the validity or enforceability of a patent before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, derivation proceedings, and
equivalent proceedings in foreign jurisdictions (<I>e.g.</I>, opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patent rights in such a way that they no longer cover our product
candidate, therapeutic programs, and other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose
at least part, and perhaps all, of the patent protection provided to our product candidate, proprietary technologies, or other components of our therapeutic programs, as applicable. Such a loss of patent protection could have a material adverse
impact on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary
rights to third party patents for our product candidate through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use third-party
intellectual property and proprietary rights. Other pharmaceutical companies and academic institutions may own patents or may have filed, or be planning to file, patent applications potentially relevant to our business. In order to avoid infringing
such patent rights, we may find it necessary or prudent to obtain licenses to such patent rights from such third parties. For example, we may be required by the FDA or comparable foreign regulatory authorities to provide a specific companion
diagnostic test or tests with our product candidate, any of which could require us to obtain rights to use patents or know-how owned or controlled by third parties. In addition, with respect to any patent or other intellectual property rights we may
<FONT STYLE="white-space:nowrap">co-own</FONT> with third parties in the future, we may require licenses to such <FONT STYLE="white-space:nowrap">co-owners&#8217;</FONT> interest to such patent or other intellectual property rights. We may be unable
to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations.
In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights
and may need to seek to develop alternative approaches that do not infringe, misappropriate, or otherwise violate those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such
alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same technologies licensed to us. In
that event, we may be required to expend significant time and resources to develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and
acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property
rights that we may consider necessary or attractive in order to commercialize our product candidate. More established companies may have a competitive advantage over us due to their size, resources, and greater clinical development and
commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and
ultimately acquire the rights to the intellectual property related to the products or product candidate that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to
maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business, financial condition, results of operations, and prospects could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our
existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our
technologies and product candidate in the future. In that event, we may be required to expend significant time and resources to redesign our product candidate, or the methods for manufacturing them, all of which may not be feasible on a technical or
commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidate, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any
assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidate, or future methods or product candidates resulting in either an injunction prohibiting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may form or seek collaborations or strategic alliances, enter into licensing arrangements or other business transactions in the future, and we
may not realize the benefits of such transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into licensing arrangements and strategic transactions to acquire
and advance new assets or product candidates in the future, including strategic partnerships, <FONT STYLE="white-space:nowrap">in-licensing</FONT> of product candidates, strategic collaborations, joint ventures, restructurings, divestitures,
acquisitions of companies, asset purchases, business combinations, and investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future transactions that we enter into may not be
successful. In particular, the success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidate or may elect not to
continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business
combination that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit
sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that causes the delay or termination of the research,
development or commercialization of our future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
product candidate that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with
applicable laws resulting in civil or criminal proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future transactions could increase our
near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses, or acquired
<FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future acquisitions may also require us to obtain additional financing, which may not be
available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt our
existing business and may be a complex, risky, and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional
transactions of the nature described above, any additional transactions that we do complete could adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents are of national or regional effect. Filing, prosecuting, and defending patents on all of our research programs and product candidate in
all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from
practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These competitor products may compete with our product candidate, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign
intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Various companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many countries do not favor the enforcement of patents or other intellectual property protection, particularly
those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various countries outside the United States have compulsory licensing laws under which a patent owner may be compelled to grant licenses to
third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. As a result, a patent owner may have limited remedies in certain circumstances, which could materially diminish the
value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects
may be adversely affected. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. As
such, we do not know the degree of future protection that we will have on our technologies and product candidate. While we will endeavor to try to protect our technologies and product candidate with intellectual property rights such as patents, as
appropriate, the process of obtaining patents is time-consuming, expensive, and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, geopolitical actions in the
United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any future licensors and the maintenance, enforcement, or defense of our issued
patents or those of any future licensors. As a result, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive
advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property
rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make or use product candidates that are similar to ours, but that are not covered by the
claims of our patents or pending patent applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or future collaborators might not have been the first to make the inventions covered by the pending patent
application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or future collaborators might not have been the first to file patent applications covering certain of our or
their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing or otherwise violating our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that noncompliance with the USPTO and foreign governmental patent agencies&#8217; requirements for
a number of procedural, documentary, fee payment, and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications or those that we may own or license in the future will not
lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents, if any arise in the future, that we either own or have exclusively licensed may be revoked,
modified, or held invalid or unenforceable, as a result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may have access to the same intellectual property rights licensed to us in the future on a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot predict the scope of protection of any patent issuing based on our patent applications, including
whether the patent applications that we own, or, in the future, <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued patents with claims that directed to our product candidate or uses thereof in the United States or in other
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the claims of any patent issuing based on our patent applications may not provide protection against competitors
or any competitive advantages, or may be challenged by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if enforced, a court may not hold that our patents, if they issue in the future, are valid, enforceable, and
infringed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which
will be costly whether we win or lose; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our trade secrets or proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> may be unlawfully disclosed,
thereby losing their trade secret or proprietary status; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to adequately protect and police our trademarks and trade secrets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business, including if others obtain patents claiming
subject matter similar to or improving that covered by our patent applications. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval
for our product candidate, the regulatory authorities may also approve generic products that compete directly with our product candidate. Once an NDA is approved, the product covered thereby becomes a &#8220;listed drug&#8221; which can, in turn, be
cited by potential competitors in support of approval of an Abbreviated New Drug Application, or ANDA. The FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, <FONT
STYLE="white-space:nowrap">non-infringing</FONT> versions of a listed drug to facilitate the approval of an ANDA for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product
has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as our product candidate and that the generic product is bioequivalent to our product candidate. These generic equivalents could be
significantly less costly than ours to bring to market and companies that produce generic equivalents may be able to offer their products at lower prices. Accordingly, competition from generic equivalents of our product candidate could materially
adversely impact our ability to successfully commercialize our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these or similar events occur, they could
significantly harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may
incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the pharmaceutical industry expands and more patents are issued, the risk increases that our product candidate may be subject to claims of
infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe, misappropriate, or otherwise violate existing or future third-party patents or other intellectual property
rights. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the
meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims, or the expiration of relevant patents, are complete or thorough, nor can we be
certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidate in any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both
the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain,
patents that will prevent, limit or otherwise interfere with our ability to make, use, and sell our product candidate. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent
applications in the United&nbsp;States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain
United States applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or
unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, product candidate, or the use of our product candidate. As such,
there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that may be infringed by the
manufacture, use, or sale of our technologies or product candidate or will prevent, limit, or otherwise interfere with our ability to make, use, or sell our technologies and product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent, and the patent&#8217;s
prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our product candidate is not covered by a third-party patent or may
incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our
failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide any assurances that third-party patents and other intellectual property rights do not exist which might be enforced against
our current technology, including our product candidate, its respective methods of use, manufacture, and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future
sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be
involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors or other third parties may infringe, misappropriate, or violate our patents, trademarks, or other intellectual property. To counter
infringement, misappropriation, or unauthorized use, we or one of our licensing partners may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific
personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Any claims we assert against perceived infringers
could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In patent litigation in the United States,
defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT
STYLE="white-space:nowrap">non-enablement,</FONT> insufficient written description, or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the
patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk
that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such
patent is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the other party&#8217;s
use of our invention, or decide that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e). An adverse outcome in a litigation or proceeding involving our patents could
limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely
affect our competitive position, and our business, financial condition, results of operations, and prospects. Similarly, if we assert trademark infringement claims, a court may determine that the marks to be asserted are invalid or unenforceable, or
that the party against whom trademark infringement to be asserted has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, misappropriation, or violation, the court may decide not
to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to
file and pursue such infringement, misappropriation, or violation claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention
of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights of
third parties could adversely affect our ability to commercialize our product candidate or any future product candidates, and we, or any future licensors, collaborators or strategic partners may become subject to third party claims or litigation
alleging infringement of patents or misappropriation or violation of our other proprietary rights or seeking to invalidate patents or other proprietary rights. We might be required to litigate or obtain licenses from third parties in order to
develop or market our product candidate or any future product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop, manufacture, market, and sell our product candidate and use our proprietary
technologies without infringing, misappropriating, or otherwise violating the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed, misappropriated, or otherwise violated their
intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time-consuming and, even if resolved in our favor, is likely to divert
significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or
proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the pharmaceutical industry, and we may become party to, or threatened
with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidate. We cannot be certain that our product candidate will not infringe existing or future patents owned by third parties.
Third parties may assert infringement claims against us based on existing or future intellectual property rights, regardless of their merit. We may decide in the future to seek a license to such third-party patents or other intellectual property
rights, but we might not be able to do so on reasonable terms. Proving patent invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption
of validity enjoyed by issued patents. As this burden is a high one, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent or find that our technologies or product candidate does
not infringe any such claims. If we are found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing, or commercializing
the infringing technology or product candidate. Further, we may be required to redesign the technology or product candidate in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner, which may not be commercially feasible.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing, or marketing the infringing product
candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if
we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our technologies or product candidate or force us to cease some of our business operations, which could materially harm our business.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are
developing our product candidate, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture, or methods of use or treatment that cover our current or future product
candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates, could be found to be infringed by our current or future product
candidates. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our current or future product candidates may infringe. Our competitors
in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and
obtain, patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our current or future product candidates. The pharmaceutical industry has produced a considerable number of patents, and it may not always be
clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for
patent infringement, we would need to demonstrate that our current or future product candidates or methods of use either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not
be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there
is no assurance that a court of competent jurisdiction would invalidate the claims of any such United&nbsp;States patent. Even if we are successful in these proceedings, we may incur substantial costs, and the time and attention of our management
and scientific personnel could be diverted in pursuing these proceedings, which could adversely affect our business and operations. Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to challenge the enforceability or validity of claims in a third party&#8217;s United States patent by requesting that the USPTO
review the patent claims in an <I><FONT STYLE="white-space:nowrap">ex-parte</FONT></I> <FONT STYLE="white-space:nowrap">re-exam,</FONT> <I>inter partes</I> review, or post-grant review proceedings. These proceedings are expensive and may consume our
time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial
and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO, or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidate.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to
protect our product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other pharmaceutical companies, our success is heavily dependent on
intellectual property, particularly patents. Obtaining, defending, maintaining, and enforcing patents in the pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws
in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce
and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. For example, patent reform legislation in the United States and other
countries, such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of our future issued patents. The Leahy-Smith Act included a number of significant changes to United States patent law. These changes included provisions that affected the way patent applications are prosecuted, redefined prior art, and
provided more efficient and cost-effective avenues for competitors to challenge the validity of patents. These included allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the
validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <I>inter partes</I> review, and derivation proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States
federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the
claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a
district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our future issued patents, all of which could
adversely affect our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After March 2013, under the Leahy-Smith Act,
the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether
a third-party was the first to invent the claimed invention. Consequently, if a third party that files a patent application in the USPTO before we file an application covering the same invention, the third party could therefore be awarded a patent
covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the
United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&nbsp;file any patent application related to our product candidate and other
proprietary technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed
invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Thus, the changes to the United States patent system by the Leahy-Smith Act introduces
uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, all of which could adversely affect our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by
the United States Congress, the United States courts, the USPTO, and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would
weaken our ability to obtain new patents and patents that we might obtain in the future. For example, recent decisions raise questions regarding the award of patent term adjustment, or PTA, for patents where related patents have issued without PTA.
Thus, it cannot be said with certainty how PTA will or will not be viewed in future and whether patent expiration dates may be impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, changes in patent law and regulations in other countries or jurisdictions or
changes in governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may obtain in the future. For
example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect on June&nbsp;1, 2023, which will significantly impact European patents, including those granted
before the introduction of such a system. Under the unitary patent system, all European patents, including those issued prior to June&nbsp;1, 2023, now by default automatically fall under the jurisdiction of a new European Unified Patent Court, or
the UPC, for litigation involving such patents. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Our European patent applications, if issued, could be challenged in the UPC. During
the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We may decide to opt out our future European patents from the UPC, but doing so may
preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for <FONT STYLE="white-space:nowrap">opt-out</FONT> under the UPC, our future European patents could remain under the
jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain <FONT STYLE="white-space:nowrap">pan-European</FONT> injunction. It is
uncertain how the UPC will impact granted European patents in the pharmaceutical industry. We cannot predict how future decisions by the courts, the United States Congress, or the USPTO may impact the value of our patents. Any similar adverse change
in the patent laws of other jurisdictions could also adversely affect our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may become subject to claims challenging the inventorship or ownership of our or our future licensors&#8217; patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual
property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from
conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third
parties involved in developing our product candidate, or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging
inventorship or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could adversely affect our business. Even if we are successful in defending against such claims, litigation could
result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future licensors may have relied on third-party
consultants or collaborators or on funds from third parties, such as the United States government, such that our licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. If
other third parties have ownership rights or other rights to our future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and
technology. This could adversely affect our competitive position, business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in
executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached,
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could adversely affect our business, financial
condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidate for a
sufficient amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the
natural expiration of a patent is generally 20 years from its earliest United States <FONT STYLE="white-space:nowrap">non-provisional</FONT> or international patent application filing date. Various extensions may be available, but the life of a
patent, and the protection it affords, is limited. Even if patents covering our product candidate are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time
required for the development, testing, and regulatory review of a product candidate, patents protecting such candidate might expire before or shortly after such candidate is commercialized. As a result, our owned patent portfolio may not provide us
with sufficient and continuing rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term
extension for our product candidate, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of
any FDA marketing approval of our product candidate, one or more of our issued United States patents or issued United States patents that we may own in the future may be eligible for limited patent term extension under the Drug Price Competition and
Patent Term Restoration Action of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term
extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for
manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as the EU Regulation (EC) No 469/2009
concerning the Supplementary Protection Certificate for medicinal products. However, we may not be granted any extensions for which we apply because of, for example, failing to exercise due diligence during the testing phase or regulatory review
process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. In addition, to the extent we wish to pursue patent term extension based on a
patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.
If we are unable to obtain patent term extension, or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of
operations, and prospects could be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural,
document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of noncompliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and/or applications will be due to be paid
to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and patent applications. We rely on our outside counsel or third party vendors to pay these fees due to United States and <FONT
STYLE="white-space:nowrap">non-United</FONT> States patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-United</FONT> States government patent agencies require compliance with several procedural, documentary, fee payment, and
other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and
this circumstance could adversely affect our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and
confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our discovery
and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may
be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know-how. If a competitor independently develops a technology that we protect as
a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own <FONT STYLE="white-space:nowrap">know-how,</FONT> and if the
license is not available on commercially viable terms, then we may not be able to launch our product candidate. Additionally, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or
unwilling to protect trade secrets. The laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws within the United States. We may need to share our trade secrets and proprietary know- how
with current or future partners, collaborators, contractors, and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or
controlled by state actors. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. Additionally, although we require all of our employees to assign their
inventions to us, and require all of our employees, consultants, advisors, and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to enter into confidentiality agreements,
we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets. If our trade secrets are not adequately protected, our
business, financial condition, results of operations, and prospects could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks.
During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. In
addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may
be filed against our trademarks, which may not survive such proceedings. Moreover, any name we propose to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to
register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative
body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark
laws, not infringe the existing rights of third parties, and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim
asserted by the owner of a senior trademark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our rights to these trademarks and trade names, which we need
to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered
trademarks or trade names. Over the long term, if we are unable to establish </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our
proprietary rights related to trademarks, trade names, domain name, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition,
results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or
disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants, or advisors have in the past and may in the future be employed at universities or other pharmaceutical
companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work
for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be
necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm our
business and may prevent us from successfully commercializing our technologies or product candidate. In addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire
employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our technologies or product candidate, which could adversely affect our business, financial
condition, results of operations, and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may in the future be subject to claims by former employees, consultants, or other third parties asserting an ownership right
in our patents or patent applications. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part,
which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technologies and product candidate. Such
challenges may also result in our inability to develop, manufacture, or commercialize our technologies and product candidate without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents
and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future technologies and product candidates. Any of the foregoing could adversely affect our business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may develop or license intellectual property for which development was funded or
otherwise assisted by, the U.S. government and/or government agencies, such as the National Institutes of Health, for development of our technology and product candidates. Failure to meet our own obligations to future licensors or upstream
licensors, including such government agencies, may result in the loss of our rights to such intellectual property, which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. government and/or government agencies in the future may provide, funding, facilities, personnel or other assistance in connection with
the development of the intellectual property rights owned by or licensed to us. The U.S. government and/or government agencies may retain rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or
sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for
public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses, could result in the loss of significant rights and
could harm our ability to commercialize licensed products. For example, research resulting in future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology that was funded in part by the U.S. government could result in the government having certain rights, or <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to such patent rights
and technology which may permit the government to disclose our confidential information to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use our licensed technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
have relied and expect to continue to rely on third parties to conduct certain aspects of our clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected
deadlines, or terminate the relationship, our development programs could be delayed, more costly, or unsuccessful, and we may never be able to seek or obtain regulatory approval for or commercialize our product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on our internal, proprietary systems for data collection and our own clinical trial team to conduct our clinical trials in addition to
external vendors and CROs to comprise a full clinical trial team. If our clinical trial team does not comply with applicable regulatory requirements, meet expected deadlines, or run trials effectively, our development programs and our ability to
seek or obtain regulatory approval for or commercialize our product candidate may be delayed. Because we currently rely and intend to continue to rely on these third parties, we will have less control over the timing, quality, and other aspects of
clinical trials than we would have had we conducted them independently. These parties are not, and will not be, our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. Additionally,
such parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs and harm our competitive position. As a result, delays may occur, which could negatively
impact our ability to meet our expected clinical development timelines and harm our business, financial condition, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also
rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our product candidate or commercialization
of any resulting products, producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties
for development activities will reduce our control over these activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable trial protocol and applicable legal, regulatory,
and scientific standards, and our reliance on clinical trial sites and other third parties does not relieve us of these responsibilities. For example, we will remain responsible for ensuring that each of our preclinical studies is conducted in
accordance with good laboratory practices, or GLPs, and clinical trials are conducted in accordance with GCPs. Moreover, the FDA and comparable foreign regulatory authorities require us to comply with GCPs for conducting, recording, and reporting
the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through
periodic inspections (including <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections once an NDA is submitted to the FDA) of trial sponsors, clinical investigators, clinical trial sites, and IRBs. If we, our clinical trial sites, or
other third parties fail to comply with applicable GLP, GCP, or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA
or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications, if ever. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical trials comply with GCPs. Moreover, our business may be significantly impacted if our clinical investigators or other third parties violate federal or state healthcare fraud and abuse or false claims
laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, principal investigators for our clinical trials may be asked
to serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the
interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any
NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if our third party
contractors do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, our clinical trials may need to be repeated, extended,
delayed, or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidate, and we may not be able to, or may be delayed in our efforts to, successfully commercialize our product
candidate(s) or we or they may be subject to regulatory enforcement actions. As a result, our results of operations and the commercial prospects for our product candidate would be harmed, our costs could increase and our ability to generate revenue
could be delayed. To the extent we are unable to successfully identify and manage the performance of third-party service providers in the future, our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third parties terminate, we may not be able to enter into alternative arrangements or do so on
commercially reasonable terms. Switching or adding additional contractors involves additional cost and time and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result,
delays could occur, which could compromise our ability to meet our desired development timelines. Though we work to carefully manage our relationships with our third-party investigators and other third parties, there can be no assurance that we will
not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. In addition, if an agreement with any of our collaborators terminates,
our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidate utilizing the collaborator&#8217;s technology or
intellectual property or require us to stop development of such product candidate completely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third-party manufacturers and suppliers to
supply our product candidate. The loss of our third-party manufacturers or suppliers, or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, within acceptable
timeframes, or at all, would materially and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate facilities for drug
manufacturing, storage, distribution, or quality testing and have no current plans to develop our own clinical or commercial-scale manufacturing capabilities. We currently rely, and expect to continue to rely, on third-party contract developers and
manufacturers to manufacture bulk drug substances, drug products, raw materials, and other components for our product candidate and delivery devices, as well as for commercial manufacture if our product candidate receives regulatory approval.
Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture the product candidate ourselves. There can be no assurance that our clinical development product supplies will not be limited, interrupted,
terminated, or will be of satisfactory quality or be available at acceptable prices. In addition, any replacement of our manufacturer could require significant effort and time because there may be a limited number of qualified replacements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process for our product candidate is subject to the FDA&#8217;s review and, in the future, may be subject to comparable
foreign regulatory authority review. We, our suppliers and our manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with
regulatory standards, such as cGMPs, and to ensure the quality and safety of drug products. Securing marketing approval also requires the submission of detailed information about the product manufacturing process to, and inspection of manufacturing
facilities by, the FDA and, in the future, comparable foreign regulatory authorities. If our CDMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory authorities, they will not be able to secure and/or maintain regulatory approval for the use of their manufacturing facilities to produce our product candidate. Moreover, we do not
conduct the manufacturing process ourselves and are completely dependent on our CDMOs for manufacturing our product candidate in compliance with cGMP and other applicable requirements. In the event that any of our manufacturers fails to comply with
such requirements or to perform its obligations in relation to quality, timing, or otherwise, or if our projected manufacturing capacity or supply of materials becomes limited, interrupted, or more costly than anticipated, we may be forced to enter
into an agreement with another third party, which we may not be able to do timely or on reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the
technical skills or technology required to manufacture our product candidate may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party. These factors would increase our reliance on
such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidate. If we are required to change manufacturers for any reason, we will be required to
verify that the new manufacturer maintains facilities and procedures that comply with applicable quality standards and regulations and guidelines; and we may be required to repeat some of the development program with the new manufacturer. The delays
and costs associated with the verification of a new manufacturer could negatively affect our ability to develop product candidate in a timely manner or within budget, or obtain regulatory approval for or market our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we
have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those
related to quality control and assurance. Any manufacturing facilities used to produce our product candidate will be subject to periodic review and inspection by the FDA and comparable foreign regulatory authorities, including for continued
compliance with cGMP requirements, quality control, quality assurance, and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for our product candidate, or to do so on commercially
reasonable terms, we may not be able to develop and commercialize our product candidate successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs, or maintain a compliance status acceptable to
the FDA or comparable foreign regulatory authorities could adversely affect our business in a number of other ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or complete clinical trials of product candidate in a timely manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of the cooperation of existing or future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands
for our products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails additional risks such as limitations on supply
availability resulting from capacity and scheduling constraints of third parties; the possible breach of manufacturing agreements by third parties because of factors beyond our control; the possible termination or
<FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by the third party, at a time that is costly or inconvenient to us; failure to manufacture our product according to our schedule or at all; and the possible
misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> Additionally, our CDMOs may experience difficulties due to resource constraints or as a result of labor disputes or
unstable political environments. If any of our CDMOs were to encounter any of these difficulties, our ability to provide our product candidate to participants in clinical trials, or to provide product for treatment of patients if approved, would be
jeopardized. Any performance failure on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement, which would
have a material adverse impact on our financial position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any third-party manufacturer of our product candidate is unable to increase the scale
of its production of our product candidate, and/or increase the product yield of its manufacturing, then our costs to manufacture product candidate may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our
products, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the output. The transition to larger scale production could prove difficult. In
addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidate, or if they are unable to produce increased amounts of our product candidate while maintaining
the quality of the product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on limited source suppliers for certain drug substances, drug products, raw materials, components, and other materials used in our product
candidate. If we are unable to source these supplies on a timely basis, we will not be able to complete our clinical trials on time and the development of our product candidate may be delayed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on limited source suppliers for certain drug substances, drug products, raw materials, samples, components, and other materials used
in our product candidate. Currently, there are limited sources of raw materials and starting materials used in the manufacture of <FONT STYLE="white-space:nowrap">LB-102,</FONT> and we rely on a single CDMO for the manufacture of <FONT
STYLE="white-space:nowrap">LB-102</FONT> drug substance. Any change in our relationships with our CDMOs or changes to contractual terms of our agreements with them could adversely affect our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any of the limited source suppliers upon whom we rely could stop producing our supplies, cease operations or be
acquired by, or enter into exclusive arrangements with, our competitors. Establishing additional or replacement suppliers for these supplies, and obtaining regulatory clearance or approvals that may result from adding or replacing suppliers, could
take a substantial amount of time, result in increased costs and impair our ability to produce our products, which would adversely impact our business, financial condition, results of operations, and prospects. Any such interruption or delay may
force us to seek similar supplies from alternative sources, which may not be available at reasonable prices, or at all. Any interruption in the supply of limited source components for our product candidate would adversely affect our ability to meet
scheduled timelines and budget for the development and commercialization of our product candidate, could result in higher expenses and would harm our business. Although we have not experienced any significant disruption as a result of our reliance
on limited suppliers, we have a limited operating history and cannot assure you that we will not experience disruptions in our supply chain in the future as a result of such reliance or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The operations of our suppliers that are located outside of the United States are subject to additional risks that are beyond our control and that could
harm our business, financial condition, results of operations, and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, some of our suppliers are located outside
of the United States. As a result of our global suppliers, we are subject to risks associated with doing business abroad, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">political unrest, terrorism, labor disputes, and economic instability resulting in the disruption of trade from
foreign countries in which our products are manufactured; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition of new laws and regulations, including those relating to labor conditions, quality, and safety
standards, imports, duties, taxes, and other charges on imports, as well as trade restrictions and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
restrictions on currency exchange or the transfer of funds, particularly new or increased tariffs imposed on imports from countries where our suppliers operate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater challenges and increased costs with enforcing and periodically auditing or reviewing our suppliers&#8217;
and manufacturers&#8217; compliance with cGMPs or status acceptable to the FDA or comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights, including trademark protection, in some countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions in operations due to global, regional, or local public health crises or other emergencies or natural
disasters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions or delays in shipments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local economic conditions in countries where our manufacturers or suppliers are located.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other factors beyond our control could interrupt our suppliers&#8217; production, influence the ability of
our suppliers to export our clinical supplies cost-effectively or at all, and inhibit our suppliers&#8217; ability to procure certain materials, any of which could harm our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have conflicts with our current or future licensors or collaborators that could delay or prevent the development or commercialization of our
product candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may have conflicts with our current or future collaborators, such as conflicts concerning the interpretation
of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations, or the ownership of intellectual property developed during our collaboration. Moreover, a
collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products. If any conflicts arise with any of our collaborators, such collaborator
may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidate, and in turn prevent us
from generating revenue: disputes regarding milestone payments or royalties; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional
collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of a product candidate, including providing us with data or materials; unwillingness on the part of a collaborator to keep us informed regarding the
progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by
either party to terminate the agreement. Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our
trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we currently rely on third parties to manufacture our product
candidate and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality
agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior to beginning research or
disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share
trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and
confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage third party collaborators to market and commercialize our product candidate, who may fail to effectively commercialize our product
candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may utilize strategic partners or contract sales forces, where appropriate, to assist in the commercialization of
our product candidate, if approved. We currently possess limited resources and may not be successful in establishing collaborations or <FONT STYLE="white-space:nowrap">co-promotion</FONT> arrangements on acceptable terms, if at all. We also face
competition in our search for collaborators and <FONT STYLE="white-space:nowrap">co-promoters.</FONT> By entering into strategic collaborations or similar arrangements, we will rely on third parties for financial resources and for development,
commercialization, sales and marketing and regulatory expertise. Any collaborators may fail to develop or effectively commercialize our product candidate because they cannot obtain the necessary regulatory approvals, they lack adequate financial or
other resources or they decide to focus on other initiatives. Any failure to enter into collaboration or <FONT STYLE="white-space:nowrap">co-promotion</FONT> arrangements or the failure of our third party collaborators to successfully market and
commercialize our product candidate would diminish our revenues and harm our results of operations. In addition, conflicts may arise with our collaborators, such as conflicts concerning the interpretation of clinical data, the achievement of
milestones, the interpretation of financial provisions or the ownership of intellectual property. If any conflicts arise with our collaborators, they may act in their self-interest, which may be adverse to our best interest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
relationships with healthcare providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties,
contractual damages, reputational harm, and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and
third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Our current and future arrangements with healthcare providers, third-party payors, and customers can expose
us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, and if approved, sell, market, and distribute our products.
In particular, the research of our product candidate, as well as the promotion, sales, and marketing of a future approved product, is subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring, and commission(s), certain customer incentive programs, and other business arrangements generally. Activities subject to these
laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable federal, state, and foreign healthcare laws and regulations laws that may affect our ability to operate now or in the
future include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting,
receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order, or recommendation of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating
the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers,
and formulary managers on the other. The civil monetary penalties statute which imposes penalties against any person or entity who, among other things, is </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that
was not provided as claimed or is false or fraudulent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the federal False Claims Act, or FCA, which prohibit,
among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using, or
causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly and improperly avoiding or decreasing or concealing an obligation to pay
money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government healthcare programs if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In
addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a
&#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the
money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (<I>e.g.</I>, public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a
material fact, or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can
be found guilty of violating the health care fraud statute under HIPAA without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its
implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule,
including health plans, healthcare clearinghouses and certain healthcare providers and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable
health information for or on their behalf, as well as their covered subcontractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act and its implementing regulations, which require some manufacturers of
drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the HHS information related to payments or
other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners (such as physician assistants and nurse
practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and may be broader in scope than their federal equivalents; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers; state laws </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and local
laws that require the registration of pharmaceutical sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products
is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Distribution of prescription drug samples
to licensed prescribers is also highly regulated within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain
and subject to rapid change in the current environment of healthcare reform. Federal, state, and foreign enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led
to a number of investigations, prosecutions, convictions, significant fines and penalties, and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible
investigations by government authorities, can be time- and resource-consuming and may divert our management&#8217;s attention from the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future
statutes, regulations, or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal
and state funded healthcare programs, contractual damages, and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to
resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s
attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future marketed products could adversely affect our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU member
states. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidate in the United States and we may also seek to do so in selected
foreign jurisdictions, including the European Union. If we obtain approval in one or more foreign jurisdictions for our product candidate, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly
those in the European Union, the pricing of medicinal products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidate. In these countries, pricing negotiations with
governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some countries provide that products may be marketed only after a reimbursement decision has been taken by the relevant regulatory
authority. In addition, market acceptance and sales of our product candidate will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidate and may be affected by existing and
future health care reform measures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of
benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to
physicians is governed by the national anti-bribery laws of EU member states and the industry codes of conduct. Infringement of these laws or codes of conduct could result in substantial fines and imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to healthcare professionals, healthcare organizations, students, or patient
organizations in EU member states must increasingly be publicly disclosed. Moreover, agreements with healthcare professionals must be the subject of a prior written agreement between the parties and often must be the subject of prior notification
and/or approval by the healthcare professional&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry
codes, or professional codes of conduct applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, or fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in most foreign countries, including the EU member states, the requirements governing drug pricing and reimbursement vary widely
from country to country. For example, EU member states may restrict the range of medicinal products for which their national health insurance systems provide reimbursement and control the prices of medicinal products for human use. Reference pricing
used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU member states, can further reduce prices. An EU member state may approve a specific price for the
medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies
that compare the cost-effectiveness of our product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement
limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for our product. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend
to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory
levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our product candidate in those countries would be negatively
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, Regulation No.&nbsp;2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was
adopted. This regulation, which will apply from January&nbsp;12, 2025 is intended to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level
for joint clinical assessments in these areas. The regulation foresees a three-year transitional period individual EU member states will continue to be responsible for assessing <FONT STYLE="white-space:nowrap">non-clinical</FONT> (<I>e.g.</I>,
economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. Entry into application of the HTA regulation is anticipated to increase reliance by competent national authorities on reference pricing
mechanisms, the mechanism whereby countries reflect the reimbursement price in other EU member states. This has the potential to result in a decrease in reimbursement price in a number of EU member states to reflect the price fixed in the EU member
state with the lowest reimbursement price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of our product candidate, we will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product
candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidate is approved, it will be subject to extensive and ongoing regulatory requirements for
manufacturing, labeling, packaging, distribution, storage, advertising, promotion, import, export, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy, and other post-market information, including both
federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMPs and similar requirements outside the United States and GCP
requirements for any clinical trials that we conduct post-approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA
and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs or similar regulations. As such, we and our contract manufacturers will be subject to continual review
and periodic, unannounced inspections by the FDA and other regulatory authorities to assess compliance with cGMPs or similar requirements and adherence to commitments made in any NDA, other marketing application, and previous responses to inspection
observations. Accordingly, we and others with which we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our product candidate will require the submission of reports to regulatory authorities and
surveillance to monitor the safety and efficacy of the product candidate, and such approvals may be subject to significant limitations on the approved indicated uses for which the product may be marketed (e.g., use restrictions for specified age
groups, warnings, precautions or contraindications), and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS program as a condition of approval of our product candidate or similar risk
management measures, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician training and communication plans, or additional elements to ensure safe use, such as
restricted distribution methods, patient registries, and other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory
authorities may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our
product candidate, such as adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on that
product, the manufacturing facility or us, including revisions to the approved labeling to add new safety information, contraindications or a &#8220;black box&#8221; warning, imposition of post-market studies or clinical trials to assess new safety
risks, or imposition of distribution restrictions or other restrictions under a REMS. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market, or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters, or holds on clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to
approved applications submitted by us or suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidate and generate revenue and
could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policies of the FDA and
comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidate. We cannot predict the likelihood, nature, or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are
not able to maintain regulatory compliance, we may be subject to enforcement action and our business, results of operations, and financial condition could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and comparable foreign regulatory authorities
strictly regulate marketing, labeling, advertising, and promotion of prescription drugs. These regulations include standards for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising (in the
United States only), industry-sponsored scientific and educational activities, and promotional activities involving the internet, as well as restrictions on promoting approved drugs for unapproved uses or patient populations (known as <FONT
STYLE="white-space:nowrap">&#8220;off-label</FONT> promotion&#8221;). Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. While physicians in the United States may choose, and are
generally permitted, to prescribe drugs for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. However, companies may share truthful and not misleading information that is not inconsistent with
the labeling, and the FDA has recently published a draft guidance with recommendations for how drug manufacturers can share scientifically sound and clinically relevant information on unapproved uses with health care providers so long as such
presentations are not promotional. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have promoted any <FONT STYLE="white-space:nowrap">off-label</FONT> uses of our
future approved products, or to have engaged in the promotion of an unapproved product candidate, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged
improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our future approved products, we could become subject to significant liability, which would
materially adversely affect our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing healthcare legislative and regulatory reform
measures may adversely affect our business, results of operations, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or
the interpretation of existing regulations could impact our business in the future by requiring, for example, changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products;
or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system
that could prevent or delay marketing approval of our product candidate(s), restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or,
collectively, the ACA, includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers. There have been judicial, executive and congressional challenges and amendments to certain aspects of
the ACA. For example, the Inflation Reduction Act of 2022, or IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
&#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost and through a newly
established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the second Trump administration
will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted.
For example, on July&nbsp;4, 2025, the annual reconciliation bill, the &#8220;One Big Beautiful Bill Act,&#8221; or OBBBA, was signed into law which is expected to reduce Medicaid spending and enrollment by implementing work
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. OBBBA also narrows access to ACA marketplace
exchange enrollment and declines to extend the ACA enhanced advanced premium tax credits, set to expire in 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The Budget Control
Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction, which
triggered the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year until 2032 unless Congress takes additional action.
Additionally, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective
January&nbsp;1, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, there has been increasing legislative and enforcement interest in the United States with respect to
specialty drug pricing practices. Specifically, there have been several recent U.S. presidential executive orders, congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of
prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, at the federal level, the IRA, among other things,
(1)&nbsp;directs the HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, or the &#8220;Medicare Drug Price Negotiation Program, and (2)&nbsp;imposes
rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions took effect
progressively starting in fiscal year 2023. On August&nbsp;15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to
legal challenges. On January&nbsp;17, 2025, HHS selected fifteen additional drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation
Program. On February&nbsp;14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare&nbsp;and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and
improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in 2023,
an initiative to control the price of prescription drugs through the use of <FONT STYLE="white-space:nowrap">march-in</FONT> rights under the Bayh-Dole Act&nbsp;was announced. Also in 2023, the National Institute of Standards and Technology
published for comment a Draft Interagency Guidance Framework for Considering the Exercise of <FONT STYLE="white-space:nowrap">March-In</FONT> Rights, which for the first time includes the price of a product as one factor an agency can use when
deciding to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights. While <FONT STYLE="white-space:nowrap">march-in</FONT> rights have not previously been exercised, it is uncertain if that will continue under the new framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. For example, in January 2024, the FDA approved Florida&#8217;s Section&nbsp;804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how
this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such
approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to
predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, particularly in light of the recent U.S. Presidential
and Congressional elections. The current Trump administration is pursuing policies to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduce regulations and expenditures across government including at HHS, the FDA, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, and related agencies. These actions, presently
directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions and proposals include, for example, include (1)&nbsp;directives to
reduce agency workforce and cut programs; (2)&nbsp;rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending; (3)&nbsp;eliminating
the Biden administration&#8217;s executive order that directed HHS to establishing establish an AI task force and developing develop a strategic plan; (4)&nbsp;directing HHS and other agencies to lower prescription drug costs through a variety of
initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (5)&nbsp;imposing tariffs of imported pharmaceutical products; and (6)&nbsp;directing
certain federal agencies to enforce existing law regarding hospital and price plan price transparency and by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, or
Loper Bright, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision
could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation
that could, among others, impact the drug approval process and make changes to modify the Medicare Drug Price Negotiation Program created under the IRA, and expand the orphan drug exclusion in the IRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product and could significantly harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other national and foreign government authorities caused by funding shortages or global health concerns could hinder their
ability to hire, retain, or deploy key leadership and other personnel, or prevent new or modified products from being developed, reviewed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a
variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of
user fees, and other events that may otherwise affect the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in
recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other
national and foreign authorities also may slow the time necessary for review and/or approval by necessary government authorities, which would adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA,
have had to furlough critical FDA employees and stop critical activities, including as a result of current administration budget cutting activities and significant reductions in force across federal agencies, such as FDA and CMS. During the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, moreover, FDA was required to prioritize resources, which resulted in the slowdown of certain operations including manufacturing facility inspections. If a prolonged government shutdown or
slowdown occurs, or if future global health concerns prevent or delay the FDA or other comparable foreign regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the
ability of the FDA or other comparable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations,
industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions;
litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we process sensitive data, and such data processing activities subject us to numerous data privacy and
security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security. Further, our use of AI
and/or machine learning technologies in the future may require additional privacy considerations. Sensitive, proprietary, personal, or confidential data and information could be leaked, disclosed, or revealed as a result of or in connection with our
or our vendors&#8217; use, if any, of AI and/or machine learning technologies. The rapid development of artificial intelligence and/or machine learning technologies tools could render obsolete certain technologies or tools we currently use, or
otherwise provide competitors with a technological edge. New or evolving legislation or regulations might impose restrictions on how AI and/or machine learning technologies can be used and impose various penalties for any noncompliance (such as
disgorgement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws,
including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH,
imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. In addition, other federal and state laws establish and may in the future establish requirements for
protecting the privacy and security of health information that is not protected by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, numerous U.S. states have enacted
comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. These state laws allow for
statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of California residents and requires businesses subject to the CCPA to provide specific disclosures in privacy notices and
respond to requests of such individuals to exercise certain privacy rights. Although there are minimum revenue or personal data processing thresholds for entities to be subject to many of these laws and there are limited exemptions for clinical
trial data under the CCPA and similar U.S. state comprehensive privacy laws, such laws may impact (possibly significantly) our business activities depending on how they are interpreted, should we become subject to the CCPA or other such state
comprehensive privacy laws in the future. In addition, similar laws are being considered in other states, as well as at the international, federal and local levels, and we expect more laws related to personal data to become effective in the future.
These developments may further complicate compliance efforts and increase our legal risk and compliance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States,
an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, Brazil&#8217;s
General Data Protection Law (Lei Geral de Prote&ccedil;&atilde;o de Dados Pessoais, or LGPD) (Law No.&nbsp;13,709/2018), and China&#8217;s Personal Information Protection Law, or PIPL, impose strict requirements for processing personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, under GDPR, companies may face private litigation related to processing of personal data brought by classes of data subjects or
consumer protection organizations authorized at law to represent their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests, temporary or definitive prohibitions on data processing and other corrective actions, or fines of up to the greater of 20&nbsp;million Euros under the EU GDPR / 17.5&nbsp;million
pounds under the UK GDPR, or 4% of their worldwide annual revenue, whichever is higher. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to transfer
personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be
localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or EEA, and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy
laws it generally believes are inadequate. Other jurisdictions may adopt or have already adopted similarly stringent data localization and cross-border data transfer requirements. If there is no lawful manner for us to transfer personal data from
the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations
(including future clinical trials), the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and
penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Regulators in the United States such as the
Department of Justice are also increasingly scrutinizing certain personal data transfers and have enacted cross-border data transfer restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security laws, we are and may become contractually subject to industry standards adopted by industry groups.
We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or
self-regulatory principles, regarding data privacy and security. Regulators are increasingly scrutinizing these statements, and if these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair,
misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obligations related to data privacy and security (and individuals&#8217; data privacy expectations) are quickly changing, becoming
increasingly stringent, and creating uncertainty. Additionally, these obligations are subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these
obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover,
despite our efforts, our personnel or third parties with whom we work (such as contract research organizations and clinical trial sites) may fail (or be perceived to have failed) to comply with such obligations, which could negatively impact our
business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited
to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or
restrictions on processing personal data (including clinical trial data); orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related
claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending
on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations
(including, as relevant, clinical trials); inability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to process sensitive data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry;
adverse publicity; or substantial changes to our business model or operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional laws and regulations governing international operations
could adversely affect our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we further expand our operations outside of
the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, prohibits any U.S.
individual or business from paying, offering, authorizing payment, or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate, and other related parties for the purpose of influencing any act or
decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions
requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for
international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a
recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.
Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations, and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit
our growth potential and increase our research and development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business
practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting
provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and
regulations. We can face serious consequences for violations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to U.S. and foreign anti-corruption, anti-money
laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws. Among other things, Trade Laws prohibit companies and their employees, agents, clinical research organizations,
contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.
Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We
have direct or indirect interactions with officials and employees of government authorities or government-affiliated hospitals, universities, and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to
increase over time. We may engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our
personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities, and any training or compliance programs or other initiatives we undertake to prevent such activities may not be effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and
safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of
hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely
eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability
could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this
insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active and liquid trading market for our common stock may not develop, or we may in the future fail to satisfy the continued listing requirements of
Nasdaq and our stock may be delisted, and you may not be able to resell your shares of common stock at or above the public offering price, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no market for shares of our common stock existed. We have applied to list our common stock on Nasdaq under the symbol
&#8220;LBRX.&#8221; Assuming that our common stock is listed and after the consummation of this offering, an active or liquid trading market for our common stock may never develop or be sustained following this offering. To the extent certain of our
existing stockholders and their affiliated entities participate in this offering, such purchases would reduce the <FONT STYLE="white-space:nowrap">non-affiliated</FONT> public float of our shares, meaning the number of shares of our common stock
that are not held by officers, directors, and affiliated stockholders. A reduction in the public float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock
and depressing the price at which you may be able to sell your shares. Moreover, the initial public offering price for our common stock will be determined through negotiations with the underwriters and may vary from the market price of our common
stock following this offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price, at the time you wish to sell them, or at a price that you consider
reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock in the future and may impair our
ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a
delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken
by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid
price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the listing requirements of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly and annual operating results may fluctuate significantly or may fall below the
expectations of investors or securities analysts or any guidance we may publicly provide, each of which may cause our stock price to fluctuate or decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly and annual fluctuations which may, in turn, cause the price of our common stock to
fluctuate substantially. Our net loss and other operating results will be affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expense related to the ongoing development of
<FONT STYLE="white-space:nowrap">LB-102</FONT> or future development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results and timing of preclinical studies and ongoing and future clinical trials, or the addition or termination
of any such clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of payments we may make or receive under existing license and collaboration arrangements or the
termination or modification thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our execution of any strategic transactions, including acquisitions, collaborations, licenses, or similar
arrangements, and the timing and amount of payments we may make or receive in connection with such transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit or opposition, interference, or cancellation proceeding in which
we may become involved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our product candidate receives regulatory approval in the future, the terms of such approval, and market
acceptance and demand for such products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting our product candidate or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">global or regional public health emergencies, including any health epidemics and their residual effects, natural
disasters, or major catastrophic events; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, the
conflict between Israel and Hamas, high levels of inflation, heightened interest rates, and bank failures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impacts of inflation and rising interest rates on our business and operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors or securities analysts or any forecasts or guidance we
may provide to the market, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. We believe that quarterly or annual
comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
stock price may be volatile, which could result in substantial losses for investors purchasing shares in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market
price of our common stock is likely to be volatile and could fluctuate widely in response to many factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">volatility and instability in the financial and capital markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse macroeconomic conditions or geopolitical events, including any health epidemics and their residual
effects, the conflict between Ukraine and Russia, the conflict between Israel and Hamas, high levels of inflation, heightened interest rates, and bank failures; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to our product candidate, including the results of clinical trials by us or our
collaborators and the timing thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by competitors that impact our competitive outlook; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative developments with respect to our product candidate, or similar products or product candidates with which
we compete; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments with respect to patents or intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of technological innovations, new product candidates, new products or new contracts by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements relating to strategic transactions, including acquisitions, collaborations, licenses, or similar
arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in our operating results due to the level of development expenses and other
factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by equities research analysts and whether our earnings (or losses) meet or exceed
such estimates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts and receipt, or lack of receipt, of funding in
support of conducting our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders, or other stockholders, or issuances by us of shares of our common
stock in connection with strategic transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the
section titled &#8220;Underwriting&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions and trends in the pharmaceutical, biotechnology, and other industries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruitment and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments within, and outside of, the United States, including changes in the structure of health
care payment systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation or arbitration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, political, and market conditions and other factors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any of the risks described in this section titled &#8220;Risk Factors&#8221;.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in
particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad
market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends on our common stock for the foreseeable future, so any returns will be limited to the value of our
stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and
any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our
common stock will depend upon increases in the value for our common stock, which is not certain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able
to exert significant control over matters subject to stockholder approval. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on 3,433,470 shares of our common stock
outstanding as of June 30, 2025, after giving effect to the Stock Split and the conversion of all outstanding shares of our convertible preferred stock into 3,181,815 shares of our common stock, prior to this offering, our executive officers,
directors, holders of 5% or more of our capital stock, and their respective affiliates beneficially owned approximately 43.6% of our voting stock. Immediately following the completion of this offering, our executive officers, directors, holders of
5% or more of our capital stock and their respective affiliates will beneficially hold, in the aggregate, approximately 7.6% of our outstanding common stock (assuming no exercise of the underwriters&#8217; option to purchase additional shares of our
common stock, no exercise of outstanding options, and no purchases of shares in this offering). These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders
would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This level of control may prevent or discourage unsolicited
acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to
investors&#8217; perception that conflicts of interest may exist or arise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will incur
immediate and substantial dilution in the book value of your shares. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price will be substantially
higher than the pro forma as adjusted net tangible book value per share of our common stock after this offering. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the pro forma as adjusted net
tangible book value per share after this offering. As a result, investors purchasing common stock in this offering will incur immediate dilution of $3.12 per share, based on an assumed initial public offering price of $15.00 per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this offering and the assumed initial public offering
price. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they
purchased their shares than the price offered to the public in this offering. To the extent outstanding options or warrants are exercised, there will be further dilution to new investors. As a result of the dilution to investors purchasing shares in
this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering,
see the section titled &#8220;Dilution.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced reporting
requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may
take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (i)&nbsp;not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act, (ii)&nbsp;reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and (iii)&nbsp;exemptions from the requirements of holding
nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In addition, as an emerging growth company, we are only required to provide two years of audited
financial statements and two years of selected financial data in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be an emerging growth company for up to five years following the year in which we
complete this offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the
completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion and (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0&nbsp;million as of the prior June 30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT>
debt during the prior three-year period. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for
our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies also can delay adopting new or
revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption, and, as a result, our operating results and financial statements may not be comparable to the operating
results and financial statements of companies who have adopted the new or revised accounting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also are a &#8220;smaller
reporting company,&#8221; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than
$700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities
that directly or indirectly compete with us. As a result of these relationships, when conflicts arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders, members of our board of directors
that are representatives of the principal stockholders may not be disinterested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the
public market could cause our stock price to fall. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our stockholders sell, or indicate an intention to sell, substantial
amounts of our common stock in the public market after the <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on
3,433,470 shares of common stock outstanding as of June&nbsp;30, 2025, after giving effect to the conversion of all of our outstanding shares of convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering, we
will have outstanding a total of 20,100,137 shares of common stock immediately after this offering. Of these shares, only the shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#8217; option to
purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, our executive officers, and the holders of substantially all of our common stock or securities convertible into, exercisable
for, or exchangeable for our common stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or agreements containing market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to offer, sell, or transfer such
securities for a period of 180 days following the date of this prospectus. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions expire, based upon the number of
shares of common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, outstanding as of June&nbsp;30, 2025, up to an additional 3,433,470 shares of common stock will be eligible for sale in the public market. Approximately 43.6%
of these additional shares are beneficially held by directors, executive officers, and their affiliates and will be subject to certain limitations of Rule 144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity
compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, and Rule 144 and Rule 701 under the
Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, the holders of 3,244,405 shares of our common stock will be entitled to rights with respect to the registration of their
shares under the Securities Act as provided under the terms of our investors&#8217; rights agreement between us and the holders of our convertible preferred stock and our outstanding warrants, as applicable, subject to the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described above. See the section titled &#8220;Description of Capital
Stock&#8212;Registration Rights.&#8221; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule
144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in how we use the net proceeds of this offering and may not use these proceeds effectively, which could affect our results of
operations and cause our stock price to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have considerable discretion in the application of the net proceeds of
this offering, including for any of the purposes described in the section titled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used
appropriately. As a result, investors will be relying upon management&#8217;s judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for
purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our
stockholders to replace or remove our current management and limit the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended
and restated certificate of incorporation, as they will be in effect immediately prior to the closing of this offering, and our amended and restated bylaws, as they will be in effect immediately prior to the closing of this offering, may have the
effect of delaying or preventing a change of control or changes in our board of directors and management. Our amended and restated certificate of incorporation and amended and restated bylaws will include provisions that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated
preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting
and not by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that special meetings of our stockholders can be called only by directors representing a majority of the
total authorized size of our board of directors, the chairperson of our board of directors, or our chief executive officer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including
proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish that our board of directors is divided into three classes, with each class serving three-year staggered
terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit cumulative voting in the election of directors, therefore allowing the holders of a majority of the
shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed for cause only upon the vote of at least 66 2/3% of our outstanding
shares of voting stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of
voting stock to amend our bylaws and certain provisions of our certificate of incorporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our
management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which generally, subject to certain exceptions, prohibits a Delaware
corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Any of
the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers of our company, thereby reducing the likelihood that holders of our common
stock would receive a premium for their shares of our common stock in an acquisition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation that
will become effective immediately prior to the closing of this offering will provide that the Court of Chancery of the State of Delaware and the federal district court for the District of Delaware of the United States will be the exclusive forums
for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering will provide
that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of
incorporation, or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate
of incorporation, or our amended and restated bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal-affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&nbsp;22 of
the Securities Act creates concurrent jurisdiction for federal and state courts over all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Additionally, investors cannot waive compliance with the federal securities
laws and the rules and regulations thereunder. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of
incorporation will further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined
that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will
affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and
enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and the provisions may not be
enforced by a court in those other jurisdictions. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant
additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This exclusive forum provision may result in increased costs to stockholders to bring a claim. Further, this exclusive forum provision may
limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other
employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with
resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. As of December&nbsp;31, 2024, we had federal gross net operating loss, or NOL, carryforwards of $37.2&nbsp;million and state gross NOL carryforwards of $41.9&nbsp;million. The federal NOL carryforwards, if not utilized, will begin to
expire in 2036. The state NOL carryforwards are expected to begin to expire in 2036, although not all states conform to the federal NOL carryforward period and occasionally limit the use of NOLs for a period of time. As of December&nbsp;31, 2024 and
2023, we had federal research and development credits of approximately&nbsp;$2.7&nbsp;million and $0.8&nbsp;million, respectively. The research and development credits, if not utilized, will expire between 2036 through 2042. Certain of these NOL
carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code of 1986, as amended, or the Code, federal NOL carryforwards arising in taxable years beginning after December&nbsp;31, 2017
will not expire and may be carried forward indefinitely, but the deductibility of such federal NOL carryforwards in a taxable year is generally limited to no more than 80% of current year taxable income (with certain adjustments in such year). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a
greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and certain
other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not completed a Section&nbsp;382 study to assess whether one or more ownership
changes have occurred since our formation, due to the complexity and cost associated with such a study. In addition, we also may experience ownership changes in the future including in connection with this offering or as a result of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequent changes in our stock ownership, some of which may be outside of our control. As a result, if we undergo (or already have undergone) an ownership change, and our ability to use our <FONT
STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset our post-change income or taxes is limited, it could harm our future
results of operations by effectively increasing our future tax obligations. Similar provisions of state tax law also may apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which
the use of net operating losses is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. Even if we attain profitability, we may be unable to use all or a material portion of our net operating losses and
other tax attributes, which could adversely affect our future cash flows. As a result of the foregoing, we have a full valuation allowance for deferred tax assets, including our NOL carryforwards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent and future changes to tax laws could materially adversely affect our company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax regimes we are subject to or operate under, including with respect to income and <FONT STYLE="white-space:nowrap">non-income</FONT>
taxes, are unsettled and may be subject to significant change. Changes in tax laws, regulations, or rulings, or changes in interpretations of existing laws and regulations, could materially adversely affect our company. For example, on July&nbsp;4,
2025, the U.S. government passed the OBBBA, which made permanent certain of the tax law changes originally enacted under previous tax reform legislation, in addition to other changes that may impact our tax liability. For example, the OBBBA
reinstated immediate expensing of certain research and experimental expenses incurred in tax years beginning after December 31, 2024 if incurred in the United States (though the requirement to amortize foreign research and experimental expenses over
15 years remains unchanged). In addition, previous tax reform legislation includes provisions that impacts the U.S. federal income taxation of certain corporations, including imposing a 1% excise tax on corporations that repurchase their stock in
certain transactions. Future guidance from the Internal Revenue Service and other tax authorities with respect to this and other legislation may affect us, and certain aspects thereof could be repealed or modified in future legislation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable economic and market conditions may have serious adverse consequences on our business, financial condition, and stock price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global economic and business activities continue to face widespread uncertainties, and global credit and financial markets have experienced
extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, tariffs, rising interest rates, bank failures, labor shortages, declines in
consumer confidence, declines in economic growth, increases in unemployment rates, recession risks, and uncertainty about economic and geopolitical stability (for example, related to the ongoing Russia-Ukraine and Israel-Hamas wars). For example,
there is currently significant uncertainty about the future relationship between the United States and various other countries, including, without limitation, China, Brazil, Mexico, and Canada, with respect to trade policies, treaties, tariffs,
taxes, and other limitations on cross-border operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent of the impact of these conditions on our operational and financial
performance, including our ability to execute our business strategies and initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments which are uncertain and cannot be predicted.
There can be no assurance that further deterioration in economic or market conditions will not occur, or how long these challenges will persist. If the current equity and credit markets further deteriorate, or do not improve, it may make any
necessary debt or equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our business, or if they publish inaccurate or unfavorable research about
our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced in part
by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over the industry or securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
analysts, or the content and opinions included in their reports and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence
coverage of us, or if analysts cease coverage of us, we could lose visibility in the financial markets, and the trading price for our common stock could be impacted negatively. If any of the analysts who cover us publish inaccurate or unfavorable
research or opinions regarding us, our business model, our intellectual property, or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, as a public company, and
particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. The Securities Act, the Exchange Act, Sarbanes-Oxley Act, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and
financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our
legal and financial compliance costs and to make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability
insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could
also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers. The increased costs may require us to reduce costs in other areas of our business.
Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to establish and maintain effective internal control over financial reporting could adversely affect our business and if investors lose
confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently required to comply with the rules of the SEC implementing Section&nbsp;404 of the Sarbanes-Oxley Act and are therefore not
required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC&#8217;s rules implementing Sections 302 and 404
of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting.
Although we will be required to disclose changes made in our internal control over financial reporting on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting until our
second annual report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control
over financial reporting until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. When we lose our status as an &#8220;emerging growth company&#8221; and
reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our
management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need
to upgrade our information technology systems; implement additional financial and management controls, reporting systems, and procedures; and hire additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our
financial reporting and the trading price of our common stock may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a private company, we do not currently have any internal
audit function. To comply with the requirements of being a public company, we have undertaken various actions, and will need to take additional actions, such as implementing numerous internal controls and procedures and hiring additional accounting
or internal audit staff or consultants. Additionally, in connection with the preparation of our financial statements for the year ended December&nbsp;31, 2024, material weaknesses were identified in the design and operating effectiveness of our
internal control over financial reporting. If we are unable to remediate these material weaknesses, or we identify more material weaknesses that we are not able to timely remediate to meet the applicable compliance deadline for the disclosure and
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, or if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting once
we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected, and we could become subject to investigations
by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. In addition, if we fail to remedy any material weakness, our financial statements
could be inaccurate, and we could face restricted access to capital markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all
errors or acts of fraud. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject to the periodic reporting requirements of
the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded,
processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. Any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities that judgments in decision-making can be
faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party
transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our
control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a formal risk management program for identifying and addressing risks to our business in other areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock is likely to be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in
particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies. In the past, companies that have experienced volatility in the market price of their
stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation (including the cost to defend against, and any potential adverse outcome resulting from any such
proceeding) can be expensive, time-consuming, damage our reputation, and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements
other than statements of historical fact contained in this prospectus, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product
candidates and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they
contain words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;shall,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;
&#8220;will,&#8221; or &#8220;would,&#8221; or the negative of these words or other similar terms or expressions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements
involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, potential registrational quality, and results of our research and development
programs, preclinical studies, any clinical trials, Investigational New Drug, or IND, and other regulatory submissions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our approach to reproducibly predict treatment outcomes for
<FONT STYLE="white-space:nowrap">LB-102</FONT> amongst identified patient populations and achieve clinical success; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and costs involved in obtaining and maintaining regulatory approval of <FONT
STYLE="white-space:nowrap">LB-102</FONT> and any future product candidates that we may identify or develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of <FONT
STYLE="white-space:nowrap">LB-102;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to efficiently and cost-effectively conduct our current and future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and commercialization
of <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements,
including our ability to comply with our financial obligations pursuant to the terms of such agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and likelihood of the achievement of milestones pursuant to our existing collaboration and licensing
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for treatment of additional
indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of our third-party service providers, including our suppliers and manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility for <FONT STYLE="white-space:nowrap">LB-102</FONT>
and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of competition with respect to <FONT STYLE="white-space:nowrap">LB-102</FONT> or any of our future
product candidates, as well as innovations by current and future competitors in our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunities and the number of patients for <FONT
STYLE="white-space:nowrap">LB-102</FONT> and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, <FONT STYLE="white-space:nowrap">LB-102,</FONT> and
any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position, including the scope of protection we are able to establish, maintain, defend
and enforce for intellectual property rights covering <FONT STYLE="white-space:nowrap">LB-102</FONT> and any future product candidates we may develop; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and legal developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain employees and collaborators with development, regulatory, and commercialization
expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to comply with the terms of our term loan agreement and our expectations regarding our ability to
access additional tranches thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding future expenses, future revenue, capital requirements, and need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future
operating expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and
assumptions as of the date of this prospectus and are subject to risks and uncertainties. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are
based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We discuss many
of the risks associated with the forward-looking statements in this prospectus in greater detail under the heading &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to
time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus and the documents that we have filed as exhibits to the registration statement, of which this
prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual
results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events, or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates, projections, and other information concerning our industry, our business, and the markets for our product
candidate, including data regarding the estimated size of such markets and the incidence of certain medical conditions. Unless otherwise expressly stated, we obtained the industry, market, and similar data set forth in this prospectus from our
internal estimates and research and from academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this data is
derived. In that regard, when we refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise
expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information that is based on estimates, forecasts, projections, market research, or
similar methodologies is inherently subject to uncertainties and involves a number of assumptions and limitations; as a result, actual events or circumstances may differ materially from events and circumstances that are assumed in this information.
The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk Factors.&#8221; Although we are responsible for all of the disclosure
contained in this prospectus and we believe that the data we use from third parties are reliable, we have not separately verified this data. Further, while we believe that our internal research is reliable, such research has not been verified by any
third party. You are cautioned not to give undue weight to any such information, projections, and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $228.5 million (or approximately $263.4&nbsp;million if the underwriters&#8217;
option to purchase additional shares is exercised in full) from the sale of the shares of common stock offered by us in this offering, based on the assumed initial public offering price of $15.00&nbsp;per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set
forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $15.5 million, assuming the number of shares of common stock offered by us, as set forth on the cover page of this
prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares of common stock offered by us, as set forth on the
cover page of this prospectus, would increase (decrease) our net proceeds from this offering by approximately $14.0 million, assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth
on the cover page of this prospectus, remains the same, and after deducting the underwriting discounts and commissions payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our common
stock and to facilitate our future access to the public equity markets. We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and marketable securities, primarily as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $133.0 million to advance the clinical development of
<FONT STYLE="white-space:nowrap">LB-102</FONT> to treat acute schizophrenia through a Phase 3 trial, the open label safety trial designed to accrue the requisite safety population required to support approval, and other <FONT
STYLE="white-space:nowrap">NDA-enabling</FONT> studies, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $25.0 million to advance the clinical development of <FONT STYLE="white-space:nowrap">LB-102</FONT>
to treat bipolar depression through a Phase 2 trial, and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the net proceeds from this offering to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in
complementary businesses, technologies, products, or assets. However, we have no current plans, commitments, or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash and cash equivalents and marketable securities, together with the
estimated net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through the first quarter of 2028. We have based this estimate on assumptions that may prove to be wrong, and we could
use our available capital resources sooner than we expect. The expected net proceeds from this offering, together with our existing cash and cash equivalents and marketable securities, will not be sufficient for us to fund our product candidate
through regulatory approval and commercialization, and we will need to raise substantial additional capital in order to do so. To obtain the capital necessary to fund our programs through regulatory approval and commercialization, we expect to
finance our cash needs primarily through equity offerings and potentially through debt financings, collaborations, licenses, and development agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As
of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will spend on the uses set forth above. The amounts and
timing of our actual use of the net proceeds will vary depending on numerous factors, including the progress, cost, and results of our preclinical and clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development programs, our ability to obtain additional financing, and other factors described under &#8220;Risk Factors&#8221; in this prospectus, as well as the amount of cash used in our
operations and any unforeseen cash needs. We may find it necessary or advisable to use the net proceeds for other purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying on our
judgment regarding the application of the net proceeds from this offering. In addition, we might decide to postpone or not pursue clinical trials or preclinical activities if the net proceeds from this offering and the other sources of cash are less
than expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we plan to invest the proceeds in short- and intermediate-term,
interest-bearing obligations, investment-grade instruments, certificates of deposit, or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and future earnings,
if any, to support our operations and finance the growth and development of our business. We have no present intention to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will
be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions (including any restrictions in our then-existing debt
arrangements), business prospects, and other factors our board of directors may deem relevant, and subject to the restrictions contained in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and marketable securities and our capitalization as of June&nbsp;30, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to reflect (i)&nbsp;the conversion of all outstanding shares of our redeemable convertible
preferred stock into 3,181,815 shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to stockholders&#8217; equity upon the closing of this offering, and (ii)&nbsp;the filing
of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to reflect (i)&nbsp;the pro forma adjustments set forth above, (ii)&nbsp;our
issuance and sale of 16,666,667 shares of common stock in this offering at the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us, and (iii) our issuance of 382,467 additional shares of common stock issuable upon conversion of our Series C convertible preferred stock due to anti-dilution
adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma and pro forma as adjusted information below is illustrative only, and our cash and cash equivalents and marketable securities
and capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information in conjunction with our audited financial statements and the related notes included elsewhere in this
prospectus and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and other financial information contained in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)<BR>As of June 30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability &#8211; warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed preferred stock, $0.0001 par value; 295,467 shares authorized, issued and outstanding,
actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred stock, $0.0001 par value; 3,655,374 shares authorized, issued and outstanding,
actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B preferred stock, $0.0001 par value; 301,119 shares authorized, issued and outstanding,
actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C preferred stock, $0.0001 par value; 75,000,000 shares authorized, 73,820,346 shares
issued and outstanding, actual; no shares authorized, issued, or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)<BR>As of June 30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value: no shares authorized, issued, or outstanding, actual;
10,000,000 shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 105,000,000 shares authorized, 251,789 shares issued and
outstanding, actual; 500,000,000 shares authorized, 3,433,470 shares issued and outstanding pro forma; 500,000,000&nbsp;shares authorized, 20,100,137&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(103,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of $15.00, the midpoint
of the estimated offering price range set forth on the cover page of this prospectus, would increase or decrease each of the pro forma as adjusted cash and cash equivalents and marketable securities, additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and total capitalization by approximately $15.5 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1.0&nbsp;million in the number
of shares we are offering would increase or decrease each of the pro forma as adjusted cash and cash equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#8217; equity and
total capitalization by approximately $14.0&nbsp;million, assuming an initial public offering price of $15.00, the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts
and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our current certificate of incorporation, the conversion price
of the Series C convertible preferred stock will be adjusted as a result of this offering. The current conversion price is $41.8311. Applying the formula set forth in our amended and restated certificate of incorporation for issuances of our common
stock below the current conversion price and partially waived anti-dilution adjustments by the holders of our Series C convertible preferred stock, the conversion price of the Series C convertible preferred stock will be adjusted to $36.5499 as a
result of this offering, based upon an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. A $1.00 decrease in the initial public offering price would
increase the number of shares of our common stock issuable in respect of our Series&nbsp;C convertible preferred stock by 19,731 shares, and a $1.00 increase in the initial public offering price would decrease the number of shares of our common
stock issuable in respect of our Series C convertible preferred stock by 19,254 shares; provided, however, that in no event would the shares of our Series C convertible preferred stock outstanding prior to the Stock Split convert into more than
3,049,156 shares of our common stock upon the closing of this offering. A 1.0 million share increase in the size of this offering would increase the number of shares of our common stock issuable in respect of our Series C convertible preferred stock
by 4,261&nbsp;shares, and a 1.0 million share decrease in the size of this offering would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,795 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma and pro forma as adjusted information are illustrative only and following the completion of this offering will be adjusted based
on the actual initial public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information in conjunction with our financial statements and the
related notes included elsewhere in this prospectus, the section of this prospectus titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and other financial information contained in this
prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 3,433,470&nbsp;shares of
common stock outstanding as of June&nbsp;30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">427,526 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $41.84 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,943 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $66.40 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,397 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $49.81 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">717 shares of common stock issuable upon the exercise of outstanding stock options granted subsequent to
June&nbsp;30, 2025, at an exercise price equal to the initial public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24,919 Class A common stock warrants to purchase 24,919 shares of our common stock, of which 24,919 Class A
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class A Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31,605 Class B common stock warrants to purchase 31,605 shares of our common stock, of which 31,605 Class B
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class B Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54,813 warrants held by Maxim Partners LLC to purchase 54,813 shares of our common stock of which 54,813 warrants
remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Maxim Warrants;&#8221; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,557 Series B-1 common stock warrants to purchase 2,557 shares of our common stock of which 2,557 Series B-1
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Series B-1 Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,509 New Series&nbsp;B common stock warrants to purchase 3,509 shares of our common stock of which 3,509 New
Series&nbsp;B common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $41.84 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;New Series B
Warrants;&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,907,335 shares of common stock reserved for future issuance under our 2025 Plan, which became effective upon
the execution and delivery of the underwriting agreement for this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price, as described in the section titled
&#8220;Executive Compensation&#8212;2025 Equity Incentive Plan&#8221;), as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in the section titled
&#8220;Executive Compensation&#8212;Equity Benefit Plans;&#8221; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">201,000 shares of common stock reserved for future issuance under our ESPP, which became effective upon the
execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described in the section
titled &#8220;Executive Compensation&#8212;Equity Benefit Plans.&#8221; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of June&nbsp;30, 2025 was $10.4 million, or $41.27 per share of common stock. Our historical net
tangible book value (deficit) per share represents the amount of our total tangible assets less our total liabilities, divided by the total number of shares of common stock outstanding as of June&nbsp;30, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of June&nbsp;30, 2025 was $10.4 million, or $3.03 per share of our common stock. Pro forma net
tangible book value per share represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock and the related
reclassification of the carrying value of the redeemable convertible preferred stock and preferred stock warrant liability to stockholders&#8217; equity upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of 16,666,667 shares of common stock that we are offering and the issuance of 382,467 additional
shares of common stock issuable upon conversion of our Series C convertible preferred stock due to anti-dilution adjustments, each based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set
forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2025 would have been
$238.9 million, or approximately $11.88 per share of common stock. This amount represents an immediate increase (decrease) in pro forma net tangible book value of $(38.24) per share to our existing stockholders and an immediate dilution in pro forma
net tangible book value of approximately $8.85 per share to new investors participating in this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new
investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share
basis to new investors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in historical net tangible book value per share attributable to pro forma
adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors purchasing
shares from us in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual
initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover
page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by approximately $(0.77), and dilution in pro forma net tangible book value per share to new investors by
approximately $0.22, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Each increase of
1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma as adjusted net tangible book value per share after this offering by approximately $0.10 and decrease the
dilution to investors participating in this offering by approximately $(0.10) per share, assuming that the assumed initial public offering price remains the same, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after deducting the estimated underwriting discounts and commissions. Similarly, each decrease of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of
this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by approximately $(0.11) and increase the dilution to investors participating in this offering by approximately $0.10 per share, assuming
that the assumed initial public offering price remains the same, and after deducting the underwriting discounts and commissions payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as
adjusted net tangible book value after the offering would be $12.11 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $0.23 per share, and the dilution per share to new investors
would be $2.89 per share, in each case assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting the
underwriting discounts and commissions payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes on a pro forma as adjusted basis as of June&nbsp;30,
2025, the number of shares of common stock purchased or to be purchased from us, the total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the
price to be paid by new investors in this offering. The calculation below is based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before
deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our existing
stockholders paid. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,433,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,886,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,100,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374,886,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The presentation in this table regarding ownership by existing stockholders does not give effect to any
purchases that existing stockholders may make in this offering. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed
initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors in this offering by $16.7 million,
assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. Similarly, each 1.0&nbsp;million share increase (decrease)
in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all stockholders and the
average price per share paid by all stockholders by $15.00 million, assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same,
and after deducting the underwriting discounts and commissions payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the
underwriters&#8217; option to purchase additional shares of common stock in this offering. If the underwriters were to fully exercise their option to purchase additional shares of common stock from us, the percentage of our common stock held by
existing stockholders after this offering would be reduced to 17% of the total number of shares of our common stock outstanding after this offering, and the percentage of our common stock held by new investors would be increased to 83% of the total
number of shares of our common stock outstanding after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based
on 3,433,470 shares of common stock outstanding as of June&nbsp;30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering and
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">427,526 shares of common stock issuable upon the exercise of outstanding stock options under our 2023 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $41.84 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,943 shares of common stock issuable upon the exercise of outstanding stock options under our 2018 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $66.40 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,397 shares of common stock issuable upon the exercise of outstanding stock options under our 2017 Plan as of
June&nbsp;30, 2025, at a weighted-average exercise price of $49.81 per share (which does not take into account the Option Repricing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">717 shares of common stock issuable upon the exercise of outstanding stock options granted subsequent to
June&nbsp;30, 2025, at an exercise price equal to the initial public offering price per share in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">24,919 Class A common stock warrants to purchase 24,919 shares of our common stock, of which 24,919 Class A
common stock warrants remain to be exercised as of June&nbsp;30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class A Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31,605 Class B common stock warrants to purchase 31,605 shares of our common stock, of which 31,605 Class B
common stock warrants remain to be exercised as of June&nbsp;30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Class B Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">54,813 warrants held by Maxim Partners LLC to purchase 54,813 shares of our common stock of which 54,813 warrants
remain to be exercised as of June&nbsp;30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Maxim Warrants;&#8221; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,557 Series B-1 common stock warrants to purchase 2,557 shares of our common stock of which 2,557 Series B-1
common stock warrants remain to be exercised as of June&nbsp;30, 2025, with an exercise price of $0.28 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;Series B-1 Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,509 New Series B common stock warrants to purchase 3,509 shares of our common stock of which 3,509 New Series B
common stock warrants remain to be exercised as of June 30, 2025, with an exercise price of $41.84 per share, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Warrants&#8212;New Series B Warrants;&#8221;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,907,335 shares of common stock reserved for future issuance under our 2025 Plan, which became effective upon
the execution and delivery of the underwriting agreement for this offering (of which we will grant certain options to purchase shares of common stock at an exercise price equal to the initial public offering price, as described in the section titled
&#8220;Executive Compensation&#8212;2025 Equity Incentive Plan&#8221;), as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in the section titled
&#8220;Executive Compensation&#8212;Equity Benefit Plans;&#8221; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">201,000 shares of common stock reserved for future issuance under our ESPP, which became effective upon the
execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described in the section
titled &#8220;Executive Compensation&#8212;Equity Benefit Plans.&#8221; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_11"></A>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with our financial statements and the related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information
with respect to our current plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk
Factors&#8221; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the
&#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#8220;Special Note
Regarding Forward-Looking Statements.&#8221; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other
neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> which we believe has the potential to be the first benzamide
antipsychotic drug approved for neuropsychiatric disorders in the United States. <FONT STYLE="white-space:nowrap">LB-102</FONT> is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in
over 50 countries, not including the United States, because the development and regulatory requirements of the U.S. Food and Drug Administration, or FDA, for amisulpride were incompatible with patent coverage on the drug. Amisulpride is a generic
drug that has been extensively used in clinical practice following its initial approval in France in the 1980s, generating at least two&nbsp;million monthly prescriptions in 2023 in a subset of 16 continental European countries. Among these European
prescriptions for amisulpride, our data suggest that approximately 60% are for schizophrenia and schizoaffective disorders, approximately 20% are for mood disorders, approximately 14% are for anxiety, and the remainder are for a variety of other
indications. We developed <FONT STYLE="white-space:nowrap">LB-102</FONT> in order to address the limitations of amisulpride with a differentiated therapeutic profile and strong intellectual property protection. We believe <FONT
STYLE="white-space:nowrap">LB-102&#8217;s</FONT> mechanism of action, data from our recently completed Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia, and the legacy of clinical experience with amisulpride
support the continued development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia and bipolar depression. If successful in treating bipolar depression, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> in the
treatment of major depressive disorder, or MDD. In the future, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of other neuropsychiatric disorders, including schizophrenia with predominantly negative symptoms,
Alzheimer&#8217;s disease-related agitation and psychosis, manic episodes associated with bipolar disorder, and cognitive impairment associated with schizophrenia, or CIAS. We believe that <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved,
can become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> is a Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> oral, small
molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. Schizophrenia is a chronic, severe, complex, and debilitating
psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability. Symptoms are divided into three categories: (i)&nbsp;psychotic or positive symptoms, which include delusions, hallucinations, thought
disorder, and movement disorder; (ii)&nbsp;negative symptoms, which include lack of motivation, interest, or enjoyment in daily activities, withdrawal from social life, and difficulty showing emotions; and (iii)&nbsp;cognitive symptoms, which
encompass problems with attention, concentration, and memory. The disease is associated with increased mortality, with approximately 5% of schizophrenia patients dying by suicide, and average overall life expectancy decreasing by as much as 29 years
compared to the general population. There is currently no cure for schizophrenia, which means the disease must be managed with life-long therapy, increasing the importance of therapies that can improve compliance rates and dosing challenges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our clinical development program in schizophrenia, we plan to leverage our
expertise in neuropsychiatry and the unique mechanism of action of LB-102 to develop our candidate in other indications, starting with bipolar depression. Most people living with bipolar depression experience dramatic shifts in mood, energy and
behavior, alternating between manic and depressive states. It is estimated that 2.8%, or approximately seven million Americans, experience bipolar disorder in a year, and approximately 40 million people live with bipolar disorder worldwide. Our
initial Phase 2 trial will explore the utility of LB-102 in controlling the depressive symptoms of the disease. We plan to initiate this potentially registrational Phase 2 trial in bipolar depression in the first quarter of 2026 with topline data
expected in the first quarter of 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe LB-102&#8217;s strong antagonism of the D2, D3, and 5HT7 receptors makes it well suited
for treating bipolar depression, providing potential to control psychosis and mania through its effects on D2 and potential for antidepressive and pro-cognitive effects through its antagonism of 5HT7 and D3. Our Phase 2 trial of LB-102 in acute
schizophrenia demonstrated strong antipsychotic activity and suggests opportunities for potential differentiation in bipolar depression given the observed tolerability profile (low rates of EPS, sedation, and gastrointestinal side effects) and
positive impact on cognition. Amisulpride is approved for the treatment of dysthymia, a form of depression, in certain countries outside of the United States and has been shown to be as effective as certain approved agents for MDD and dysthymia. We
believe that results in dysthymia and MDD provide strong scientific and clinical rationale for development of LB-102 in the treatment of depressive episodes associated with bipolar disorder or bipolar depression because episodes of major depression,
whether unipolar (as in MDD) or bipolar (as in bipolar depression), are typically characterized by a similar imbalance in the neurotransmitters serotonin, noradrenaline, and dopamine regardless of the underlying pathophysiology of the disease. There
is wide use of amisulpride in bipolar disorder with approximately 3.4% of at least 2 million prescriptions written for this indication in a select group of European countries including Germany, France, Italy, Spain, and several others. A non-racemic
form of amisulpride also showed antidepressant activity in two independent third-party, placebo-controlled bipolar depression trials with an approximately 17- to 18-point reduction in Montgomery&#8212;&Aring;sberg Depression Rating Scale, or MADRS,
from baseline observed across these studies. Additionally, among the four antipsychotics approved for schizophrenia and MDD or treatment resistant depression that were also studied in late-stage bipolar depression trials (quetiapine, cariprazine,
aripiprazole, and olanzapine), three out of four, or 75%, generated positive data for the treatment of bipolar depression. Our planned Phase 2 trial for bipolar depression will utilize a fixed-flexible dose of LB-102. This trial design allows us to
evaluate two doses of LB-102 in the trial, thereby increasing the chances for a patient to derive clinical benefit from treatment with LB-102, while retaining the advantages of a two-arm trial, which is known to mitigate the risk of a high placebo
rate. Additionally, flexible dose trials typically have better signal detection than fixed dose trials for depression, as flexible dose trials lower the magnitude of symptom reduction with placebo. We believe LB-102 has the potential to provide
improved tolerability and clinical activity in bipolar depression compared to currently available treatments worldwide, which are associated with troubling adverse events and insufficient efficacy for certain symptoms, including cognitive impairment
associated with the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2015, we have devoted substantially all of our resources to the research and
development of <FONT STYLE="white-space:nowrap">LB-102</FONT> by conducting clinical trials and preclinical studies and recruiting management and technical staff to support these operations. To date, we have funded our operations primarily through
the aggregate gross proceeds of approximately $121.7&nbsp;million from the sales of our redeemable convertible preferred stock, common stock, and convertible notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales and we have incurred recurring losses since our inception. Our net losses were
$10.2&nbsp;million and $43.9&nbsp;million for the six months ended June&nbsp;30, 2025 and 2024, respectively. As of June&nbsp;30, 2025, we had an accumulated deficit of $114.5&nbsp;million. We expect to continue to generate operating losses and
negative operating cash flows for the foreseeable future. We anticipate that our operating expenses and capital expenditures will increase substantially with our ongoing activities, particularly as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to progress the clinical development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute
schizophrenia, bipolar depression and other indications; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance additional product candidates through clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the manufacture of larger quantities of <FONT STYLE="white-space:nowrap">LB-102</FONT> and any additional
product candidates to support future clinical trials or potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing authorizations for <FONT STYLE="white-space:nowrap">LB-102</FONT> and any of our future product
candidates that successfully complete clinical development, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or license other product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments under our current royalty agreements or any future license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, and enforce our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to attract and retain new and existing skilled personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, legal, financial, and management information systems and personnel to support our product
development and clinical execution, as well as to support our transition to a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not generate any
revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to
incur significant expenses related to developing our internal commercialization capability to support product sales, marketing, and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our operating activities as we advance our product candidates through
clinical development, seek regulatory approval, and prepare for and, if any of our product candidates are approved, proceed to commercialization. Until such time, if ever, as we can generate substantial revenue from product sales to support our cost
structure, we expect to finance our operating activities through a combination of public or private sales of equity, government or private party grants, debt financings or other capital sources, including potential collaborations with other
companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable
to obtain funding, we will be forced to delay, reduce, or eliminate some or all of our research and development programs, product portfolio expansion, or commercialization efforts, which could adversely affect our business prospects, or we may be
unable to continue operations. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, we had cash and cash equivalents of $14.2&nbsp;million. Based on our current plans, we believe that our existing
cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements through the first quarter of 2028. See &#8220;&#8212;Liquidity and Capital
Resources.&#8221; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2025, we initiated a reduction in force, or RIF, as part of a strategic realignment to streamline
operations and extend our cash runway. The RIF impacted several positions, including the Chief Financial Officer and Chief Scientific Officer, while prioritizing continuity in key programs and minimizing operational disruptions. This initiative is
intended to enhance our ability to allocate resources efficiently as we focus on advancing LB-102 and other high-priority development programs. We estimate the total cost of the RIF will be approximately $0.7&nbsp;million in one-time restructuring
charges, primarily related to severance and termination benefits, including a reduction in stock-based compensation expenses arising from equity award modifications. We anticipate completing all actions related to the RIF by May 30, 2026. See Note
11 <I>Restructuring</I> in the accompanying unaudited condensed financial statements for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of the Series C financing, we entered into several Amended and Restated Royalty Agreements
with certain of our existing investors, <FONT STYLE="white-space:nowrap">co-founders,</FONT> former and current directors, and former and current executive officers, including Zachary Prensky, Andrew Vaino, Ph.D., and Marc Panoff, none of whom were
new investors of our Series C preferred stock. We received no consideration as part of the Amended and Restated Royalty Agreements. Pursuant to the Amended and Restated Royalty Agreements, we are obligated to pay royalties to all of the holders in
an aggregate amount up to 2.75% of net sales arising from <FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide through December&nbsp;31, 2035. Thereafter, we are obligated to pay royalties to such holders in an aggregate amount up to 3.25% in
perpetuity. Future sales are defined in these agreements as the gross payments received on total commercial sales of <FONT STYLE="white-space:nowrap">LB-102,</FONT> whether by us or by any licensee of <FONT STYLE="white-space:nowrap">LB-102.</FONT>
For additional information, see &#8220;Business&#8212;License and Other Agreements&#8212;Royalty Agreements.&#8221; As of June&nbsp;30, 2025, certain of our former and current officers and their affiliates held 1.13% of the future royalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not recognized any revenues, including revenues from product sales. We do not expect to generate any revenue from
the sale of products in the foreseeable future. If our development efforts for <FONT STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates are successful and result in regulatory approval, or license agreements with third
parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for the development of
<FONT STYLE="white-space:nowrap">LB-102,</FONT> which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits, and stock-based compensation expense for our employees engaged
in research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with the preclinical and clinical development of
<FONT STYLE="white-space:nowrap">LB-102,</FONT> including under agreements with clinical sites and CROs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">formulation costs and chemistry, manufacturing and controls, or CMC, costs including formulation and active
pharmaceutical ingredients, process development, analytical and quality infrastructure <FONT STYLE="white-space:nowrap">build-out,</FONT> and validation support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with consultants engaged in research and development functions; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses related to regulatory affairs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs in the periods in which they are incurred. Costs for certain activities are recognized based on an
evaluation of the progress to completion of specific tasks, using information provided to us by our vendors and analyzing the progress of our clinical trials or other services performed. Significant judgment and estimates are made in determining the
accrued expense balances at the end of any reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We
expect our research and development expenses to increase substantially for the foreseeable future as we advance <FONT STYLE="white-space:nowrap">LB-102</FONT> and any of our future product candidates into and through later stage clinical trials,
pursue regulatory approval of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, build our operational and commercial capabilities for supplying and marketing our products, if approved, and expand our pipeline of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. Furthermore, product
candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. The actual probability
of success for our product candidates may be affected by a variety of factors, including the safety and efficacy of our product candidates, conduct of clinical trials, investment in our clinical programs, competition, manufacturing capability, and
commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion of costs of our research and
development projects or if, when, and to what extent we will generate revenue from the commercialization and sale of <FONT STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates, if approved by the FDA and other applicable
regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future research and development costs may vary significantly based on factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of our clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of any milestone payment due under an existing, or any future, license or collaboration
agreement or asset acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in our clinical trials, and per participant clinical trial costs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and duration of clinical trials required for approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in our clinical trials, and the locations of those sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in adding trial sites and enrolling participants in our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities, including the FDA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hiring and retaining additional personnel such as clinical, quality control, scientific, commercial, and
administrative; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain, and other commercial infrastructure in the
future to commercialize various products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the competitive outlook; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional strategic collaborations or other arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of any of
our product candidates could significantly change the costs and timing associated with the development of that product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also
expect to incur significant manufacturing costs as our CDMOs develop scaled commercial manufacturing processes. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous
factors associated with the successful commercialization of <FONT STYLE="white-space:nowrap">LB-102</FONT> or any future product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with
accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel expenses, including salaries, benefits and stock-based compensation, for personnel in our executive,
finance, corporate and business development, and administrative functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional fees for legal, patent, accounting and audit, information technology, and tax;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consulting services including fees paid to our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other expenses including travel expenses, rent expense, and other operating costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase in the future as we expand our headcount to support our continued
research and development of our product candidates. We also expect to incur increased expenses associated with operating as a public company including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to accounting, audit, legal, compliance, regulatory,
<FONT STYLE="white-space:nowrap">and&nbsp;tax-related&nbsp;services;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with the rules and regulations of the SEC and listing standards applicable to
companies listed on a national securities exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">director and officer insurance costs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investor and public relations costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization
collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing, and distribution activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-operating</FONT> Income (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expense) consists primarily of interest income on our cash and cash equivalents
and marketable securities, interest expense on borrowings under our convertible note agreements, and <FONT STYLE="white-space:nowrap">non-cash</FONT> changes in the fair value of our outstanding preferred stock warrant liability and conversion
feature derivative liability related to our convertible notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2024 and 2023 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&nbsp;31, 2024 and 2023 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;51,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 43,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(64,830</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(11,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>53,454</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-operating income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,204</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,373</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(63,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(56,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(63,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(56,827</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated no revenue during the year ended December&nbsp;31, 2024 or 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our research and development expenses for the periods presented (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Direct research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formulation and CMC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indirect and unallocated expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>51,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,845</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>43,326</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $51.2&nbsp;million for the year ended December&nbsp;31, 2024, compared
to $7.8&nbsp;million for the year ended December&nbsp;31, 2023&nbsp;. The increase of $43.4&nbsp;million was primarily due to: (i)&nbsp;a $37.0&nbsp;million increase in clinical trial expenses related to the conduct of our Phase 2 trial of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in the treatment of patients with acute schizophrenia, the majority of which took place in 2024; (ii) a $2.1&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase in personnel-related expenses related to an increase in headcount; (iii)&nbsp;a $1.8&nbsp;million increase in formulation and CMC expenses due to the
<FONT STYLE="white-space:nowrap">scale-up</FONT> and production of <FONT STYLE="white-space:nowrap">LB-102</FONT> to be used for clinical and preclinical development; and (iv)&nbsp;a $1.6&nbsp;million increase in preclinical research expenses
related to the continued clinical development of <FONT STYLE="white-space:nowrap">LB-102</FONT> for schizophrenia and other indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $13.7&nbsp;million for the year ended December&nbsp;31, 2024,
compared to $3.5&nbsp;million for the year ended December&nbsp;31, 2023. The increase of $10.1&nbsp;million was primarily due to: (i)&nbsp;a $3.2&nbsp;million increase related to the write off of deferred offering costs; (ii)&nbsp;a
$2.3&nbsp;million increase in stock-based compensation primarily related to modifications of outstanding stock options of our former chief executive officer; (iii)&nbsp;a $1.3&nbsp;million increase in personnel-related costs related to increased
headcount (including the hiring of a chief executive officer and chief financial officer) and merit increases; (iv)&nbsp;a $0.8&nbsp;million increase in termination benefits related to the resignation of our former chief executive officer;
(v)&nbsp;a $0.7&nbsp;million increase in consulting expenses primarily related to industry market research; (vi)&nbsp;a $0.6&nbsp;million increase in accounting and audit expenses related to preparation of public company-compliant financial
statements; and (vii) a $0.5&nbsp;million increase in office and rent expense primarily related to relocation of our corporate office in the third quarter of 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-operating</FONT> Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income was $1.7&nbsp;million for the year ended December&nbsp;31, 2024, compared to
$5.1&nbsp;million for the year ended December&nbsp;31, 2023. The decrease of $3.4&nbsp;million was primarily due to: (i)&nbsp;a $17.2&nbsp;million decrease in the gain (loss) on change in fair value of derivative instruments, resulting from a loss
on the change in fair value on warrant liabilities of $0.9&nbsp;million during 2024 and a $16.3&nbsp;million gain on the change in fair value of derivative liabilities during 2023; (ii) a $7.4&nbsp;million loss on extinguishment of debt related to
the conversion of the convertible notes to Series C preferred stock in August 2023; (iii)&nbsp;a $4.8&nbsp;million decrease in interest expense related to the convertible notes converted to Series C preferred stock in August 2023; and (iv)&nbsp;a
$1.5&nbsp;million increase in interest income and realized gain related to the increased investment in marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six
Months Ended June 30, 2025 and 2024 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the six months ended June 30,
2025 and 2024 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)</B><br><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(11,288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(31,920</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-operating income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,753</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,673</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated no revenue during the six months ended June 30, 2025 or 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our research and development expenses for the periods presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)</B><br><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Direct research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formulation and CMC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indirect and unallocated expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>5,842</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>40,131</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>(34,289</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)</B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $5.8 million for the six months ended June 30, 2025, compared to $40.1
million for the six months ended June 30, 2024. The decrease of $34.3 million was primarily due to: (i) a $35.8 million decrease in clinical trial expenses related to the conduct of our Phase 2 trial of LB-102 in the treatment of patients with acute
schizophrenia, the majority of which took place in 2024; and (ii) a $0.6 million decrease in preclinical research expenses related to the completion of preclinical studies in 2024, partially offset by (a) a $0.9 million increase in consulting and
other expenses primarily due to engagement of regulatory and industry experts to analyze Phase 2 clinical trial results and planning for future clinical trials; (b) a $0.8 million increase in formulation and CMC expenses due to the scale-up and
production of LB-102 to be used for clinical and preclinical development, and (c) a $0.5 million increase in personnel-related expenses primarily due to termination benefits related to the RIF in May 2025, as well as the hiring of the Senior Vice
President of Technical Operations in February 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $5.4 million for the six months ended June 30, 2025, compared to $3.1 million for the six months ended
June 30, 2024. The increase of $2.3 million was primarily due to: (i) a $0.6&nbsp;million increase in stock-based compensation primarily related to the grant of 5.1 million stock options to our Chief Executive Officer in November 2024; (ii) a $0.7
million increase in personnel-related costs primarily related to the hiring of our Chief Executive Officer in November 2024 and our Chief Business Officer in February 2025; (iii) a $0.4 million increase in termination benefits related to the RIF in
May 2025; and (iv) a $0.3 million increase in market research expense to assess product marketability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Non-operating Income (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-operating income was $1.1 million for the six months ended June 30, 2025, compared to $(0.6) million for the six months ended June 30,
2024. The increase of $1.7 million was primarily due to: a $2.3 million increase in the gain (loss) on change in fair value of derivative instruments, resulting from a gain on the change in fair value on warrant liabilities of $0.6 million during
2025 and a $1.7 million loss on the change in fair value of derivative liabilities during 2024, partially offset by a $0.6 million decrease in interest income related to the decreased investment in marketable securities and money market funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for
the foreseeable future. To date, we have funded our operations primarily with proceeds from issuances of our redeemable convertible preferred stock, common stock and convertible notes. Through June 30, 2025, our operations have been financed
primarily by gross proceeds of $35.7&nbsp;million from the issuance of convertible notes and $84.8&nbsp;million from the sales of shares of redeemable convertible preferred stock. As of June 30, 2025 and December 31, 2024, we had cash and cash
equivalents and marketable securities of $14.2&nbsp;million and $28.0&nbsp;million, respectively. Until required for use in our business, we typically invest our cash, in accordance with our investment policy, in money market funds and fixed income
securities including U.S. treasury bills and government securities. We attempt to minimize credit risk related to our cash and cash equivalents and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure
as to maturity and investment type. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary use of cash has been to fund operating expenses, which consist of research and
development and general and administrative expenditures. As we progress through the phases of development of <FONT STYLE="white-space:nowrap">LB-102</FONT> and any of our future product candidates, we anticipate that we will incur increasing losses
in future quarters and years compared to historical periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for the years ended December&nbsp;31, 2024 and 2023 and the six months
ended June 30, 2025 and 2024 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Unaudited)<BR>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,350</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the six months ended June 30, 2025 was $13.7 million, consisting of net loss of $10.2 million adjusted
for non-cash items, including $0.6 million related to gain from the change in the fair value of the warrant liabilities, partially offset by a $1.0 million charge for stock-based compensation expense. Additionally, we had outflows of
$4.0&nbsp;million due to a change in our net operating assets and liabilities from the year ended December&nbsp;31, 2024, including a $4.4 million decrease in accounts payable and accrued expense primarily related to timing of payments and clinical
trial expenses, partially offset by a $0.3&nbsp;million decrease in prepaid expenses primarily related to decreased payments to our CRO due to the completion of the Phase 2 acute schizophrenia trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the six months ended June 30, 2024 was $25.4 million, consisting of net loss of $43.9 million partially
offset by non-cash items, including (i) the change in fair value of the warrant liabilities of $1.8 million, (ii) stock-based compensation expense of $0.3 million, and (iii) amortization of premiums on investments of $0.2 million. Additionally, we
had inflows of $16.2 million due to a change in our net operating assets and liabilities from the year ended December 31, 2023, including a $18.2 million increase in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accounts payable and accrued expense primarily related to timing of payments and clinical trial expenses, partially offset by a $1.9 million increase in prepaid expenses primarily related to
advance payments to our CRO for the Phase 2 acute schizophrenia trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December 31,
2024 was $53.1&nbsp;million, consisting of net loss of $&nbsp;63.1&nbsp;million adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> items, including the realized gain on marketable securities of $1.0&nbsp;million, partially offset by <FONT
STYLE="white-space:nowrap">non-cash</FONT> items, including: (i)&nbsp;stock-based compensation expense of $3.1&nbsp;million; (ii)&nbsp;write off of deferred offering costs of $3.2&nbsp;million; (iii)&nbsp;change in fair value of the warrant
derivative liabilities of $0.9&nbsp;million; and (iv)&nbsp;lease expense of $0.3&nbsp;million related to the lease agreement executed in May 2024. Additionally, we had inflows of $3.3 million due to a change in our net operating assets and
liabilities from the year ended December 31, 2023, including a $5.0&nbsp;million increase in accounts payable and accrued expense related to timing of payments, clinical trial expenses and compensation and termination expenses, partially offset by a
$1.7 million increase in prepaid expenses primarily related to advance payments to our CRO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the
year ended December&nbsp;31, 2023 was $12.1&nbsp;million, consisting of net loss of $6.3&nbsp;million and <FONT STYLE="white-space:nowrap">non-cash</FONT> items, including the change in fair value of conversion feature and warrant derivative
liabilities of $16.3 million and realized gain on marketable securities of $0.3 million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> items including: (i)&nbsp;loss on extinguishment of debt of $7.4&nbsp;million related to
the conversion of the convertible notes in August 2023; (ii) amortization of deferred financing fees related to the convertible notes of $3.9&nbsp;million; (iii)&nbsp;amortization of premiums on investments, net of $0.4&nbsp;million; and
(iv)&nbsp;stock-based compensation expense of $0.3&nbsp;million. Additionally, we had outflows of $1.3 million due to a change in our net operating assets and liabilities from the year ended December 31, 2022, including a $2.2&nbsp;million increase
in prepaid expenses primarily related to advance payments to our CRO and a $0.2&nbsp;million increase in accrued interest on marketable securities, partially offset by a $1.1&nbsp;million increase in accounts payable and accrued expenses related to
timing of payments and clinical trial expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities for the six months ended June 30, 2025 was $5.0 million primarily related to proceeds from the sales and
maturities of marketable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities for the six months ended June 30, 2024 was $19.2 million primarily
related to $29.7 million for the purchase of marketable securities to invest our excess cash, partially offset by $10.7 million in maturities of marketable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities for the year ended December 31, 2024 was $23.2&nbsp;million primarily related to proceeds from the sales
and maturities of marketable securities, partially offset by the purchase of marketable securities to invest our excess cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used
in investing activities for the year ended December&nbsp;31, 2023 was $28.0&nbsp;million related to the purchase of marketable securities to invest our excess cash, partially offset by maturities of marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by
financing activities for the six months ended June 30, 2024 was $38.3 million primarily related to the proceeds from the issuance of redeemable convertible Series C preferred stock, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December 31, 2024 was $38.3&nbsp;million primarily related to the proceeds from the
issuance of redeemable convertible Series C preferred stock, net of issuance costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&nbsp;31, 2023 was
$33.7&nbsp;million related to $33.0&nbsp;million in proceeds from the issuance of redeemable convertible Series C preferred stock, net of issuance costs, and $0.6&nbsp;million in proceeds from the issuance of convertible notes, net of issuance
costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase substantially in connection with our ongoing activities, in particular as we continue to advance <FONT
STYLE="white-space:nowrap">LB-102</FONT> and any of our future product candidates through clinical trials. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2025, we had cash and cash equivalents of $14.2&nbsp;million. Based on our current plans, we believe that our existing cash and
cash equivalents and marketable securities, together with the net proceeds from this offering, will be sufficient to meet our anticipated operating and capital expenditure requirements through the first quarter of 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we
currently expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our
future funding requirements will depend on and could increase significantly as a result of many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results, and costs of researching and developing
<FONT STYLE="white-space:nowrap">LB-102</FONT> for our current and future indications, as well as other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining marketing approvals for
<FONT STYLE="white-space:nowrap">LB-102</FONT> for our current and future indications, as well as future product candidates we may develop and pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of future indications and product candidates that we pursue and their development requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if approved, the costs of commercialization activities for <FONT STYLE="white-space:nowrap">LB-102</FONT> for the
treatment of acute schizophrenia, bipolar depression or any other approved indication, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any future collaborators, including the
costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of <FONT
STYLE="white-space:nowrap">LB-102</FONT> for any program or revenues received from any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products,
product candidates, or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our organization to achieve our objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing, and prosecuting patent applications, and maintaining and protecting our
intellectual property rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could
significantly change the costs and timing associated with the development of that product candidate. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements
associated with such operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our
operations through a combination of equity financings, debt financings, collaborations with other companies or other strategic transactions. We do not currently have any committed external source of funds. To the extent that we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making acquisitions or capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or marketing, distribution, or licensing arrangements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or
debt financings or other arrangements when needed, we may be required to delay, limit, reduce, or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our operating plans may change, and we may need additional funds to meet
operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the
development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we entered
into an operating lease agreement for office space in New York, New York. The lease agreement was <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> and could be terminated by either party with three
months&#8217; written notice. We terminated the lease effective as of September&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, we entered into a new lease
agreement for office space in New York, New York totaling approximately 8,900 square feet. The term of this lease commenced on June&nbsp;21, 2024, which is the date we took control over the leased premises. The lease term continues through March
2032. See Note 7 to our audited financial statements for more information regarding such leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs, CDMOs, and other third parties for clinical trials, preclinical research
studies, and testing and manufacturing services. These contracts are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations
of our service providers, up to the date of cancellation. These payments are not included in the preceding table as the amount and timing of such payments are not known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, we entered into a work order with a third-party CRO to provide services with respect to our Phase 2 trial of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia. Minimum advances will be kept by the CRO throughout the duration of the clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations, or cash
flows is disclosed in Note&nbsp;2 of our audited financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets
and liabilities in our financial statements. In accordance with GAAP, we evaluate our estimates and judgments on an ongoing basis, including those related to accrued research and development expenses, preferred stock warrant liabilities, and
stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We define our critical accounting estimates as those that require us to make subjective estimates and judgments about matters that are
uncertain and are likely to have a material impact on our financial condition and results of operations. While our significant accounting policies are more fully described in Note 2 to our audited financial statements appearing elsewhere in this
prospectus, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses as of
each balance sheet date. This process involves reviewing open contracts and purchase orders, including our site contracts for sites that are participating in our ongoing clinical trials, communicating with our personnel to identify services that
have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers
invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm
the accuracy of our estimates with the service providers and make adjustments if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and
development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development
expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our
estimate, we adjust the accrual or prepaid balance accordingly. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the
activity has been performed or when the goods have been received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not expect our
estimates to be materially different from amounts incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or
too low in any particular period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs incurred in obtaining technology licenses through asset acquisitions or <FONT
STYLE="white-space:nowrap">in-licensing</FONT> arrangements are charged to research and development expense if the acquired technology has not reached technological feasibility and has no alternative future use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for our stock-based compensation awards in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards
Codification, or ASC, Topic 718, <I>Compensation&#8212;Stock Compensation</I>, or ASC Topic 718. We have issued stock-based compensation awards including stock options and restricted stock awards and we also account for certain issuances of warrants
in accordance with ASC Topic 718. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure the cost of employee, nonemployee, and director services received in exchange for an award
of equity instruments based on the fair value of the award on the date of grant and recognize the related expense over the period during which the employee, nonemployee or director is required to provide service in exchange for the award on a
straight-line basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair value of each award on the date of grant using the Black-Scholes option-pricing model. This
model requires the use of highly subject assumptions to determine the fair value of each stock-based award, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Fair value of common stock</U>. See &#8220;&#8212;Determination of the Fair Value of Common Stock&#8221;
below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expected term</U>. The expected term represents the period that the stock-based awards are expected to be
outstanding. The expected term for our stock options was calculated based on the weighted-average vesting term of the awards and the contract period, or simplified method. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expected volatility</U>. Since we are not yet a public company and do not have any trading history for our
common stock, the expected volatility was estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies
were chosen based on their size, stage of their life cycle, or area of specialty. We will continue to apply this process until enough historical information regarding the volatility of our stock price becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Risk-free interest rate</U>. The risk-free interest rate is based on a treasury instrument whose term is
consistent with the expected term of the stock options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Expected dividend yield</U>. We have never paid dividends on our common stock and have no plans to pay
dividends on our common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the foregoing
assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of the Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These estimates and
assumptions include a number of objective and subjective factors, including external market conditions, the prices at which we sold shares of our redeemable convertible preferred stock, the superior rights and preferences of securities senior to our
common stock at the time of, and the likelihood of, achieving a liquidity event, such as an IPO or sale of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no
public market for our common stock prior to this offering, the estimated fair value of our common stock underlying our stock-based awards has been determined by our board of directors as of each option grant date with input from management,
considering our most recently available third-party valuations of common stock and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the
most recent valuation through the date of the grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These third-party valuations were performed in accordance with the guidance outlined
in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,<I></I><I>&nbsp;Valuation of Privately-Held-</I><I></I><I></I><I>Company Equity Securities Issued as Compensation</I>, or the Practice Aid. In accordance
with Practice Aid, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently use a hybrid method, which is a hybrid between the option pricing method, or OPM, and the probability-weighted expected return method, or PWERM. The OPM treats common securities and
preferred securities as call options on our total equity value, with exercise prices based on the value thresholds at which the allocation among the various holders of our securities changes. Under this method, the common stock has value only if the
funds available for distribution to members are expected to exceed the value of the preferred security liquidation preference at the time of the liquidity event, such as a strategic sale or a merger. The PWERM employs additional information not used
in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of our company, as well as the probability of remaining a private
company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of our common stock is then applied to arrive at an indication of value for the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We performed common stock valuations, with the assistance of an independent third-party valuation specialist, as of June 30, 2025, March 31,
2025, December&nbsp;31, 2024, September&nbsp;30, 2024, June&nbsp;30, 2024, March&nbsp;31, 2024, December&nbsp;31, 2023 and August&nbsp;29, 2023, which resulted in valuations of our common stock of $28.45, $22.03, $35.14, $31.23, $49.64, $41.83,
$23.15, and $21.19, per share, respectively. In conducting the valuations, the independent third-party valuation specialist considered all objective and subjective factors that it believed to be relevant for each valuation conducted in accordance
with the Practice Aid,&nbsp;including our best estimate of our business condition, prospects, and operating performance at each valuation date. Other significant factors included: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our redeemable convertible preferred stock sold to outside investors in arm&#8217;s length
transactions, and the rights, preferences and privileges of our preferred stock as compared to those of our common stock, including the liquidation preferences of our preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs, including the status of preclinical studies and clinical
trials for <FONT STYLE="white-space:nowrap">LB-102;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of guideline companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations, including cash on hand, and our historical and forecasted performance and operating
results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our common stock and redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the life sciences and biotechnology industry sectors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock and stock options, such as an
IPO or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the state of the IPO market for similarly situated privately held life sciences companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our contemporaneous valuations have not always coincided with the dates of our stock option grants. In determining the exercise
prices of the stock options, our board of directors considered, among other things, the most recent valuation of our common stock and their assessment of additional objective and subjective factors that were relevant as of the grant dates. The
additional factors considered when determining whether any changes in the fair value of our common stock had occurred between the most recent valuation and the grant dates included our stage of research and development, our operating and financial
performance, and current business conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimates of fair value of our common stock are highly complex and subjective. There
are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other
liquidity event, the related valuations associated with these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management&#8217;s best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions, our stock-based compensation expense, net
loss, and net loss per share applicable to common stockholders could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuations after the completion
of this offering, our board of directors will determine the fair value of each share of underlying common stock based on the closing price of our common stock as reported on the Nasdaq Global Market on the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We review the terms of
debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative
financial instrument. Additionally, in connection with the issuance of financing instruments, we may issue freestanding warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in FASB ASC Topic 480, <I>Distinguishing</I> <I>Liabilities from
Equity</I>, or ASC Topic 480, and FASB ASC Topic 815, <I>Derivatives and Hedging</I>, or ASC Topic 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC Topic 480, meet the definition of a
liability pursuant to ASC Topic 480, and whether the warrants meet all of the requirements for equity classification under ASC Topic 815, including whether the warrants are indexed to our own stock and whether the warrant holders could potentially
require &#8220;net cash settlement&#8221; in a circumstance outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and
as of each subsequent quarterly period end date while the warrants are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For warrants that meet all criteria for equity
classification, the warrants are recorded as a component of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, on the statement of stockholders&#8217; deficit at the time of issuance. For warrants that do not meet all the criteria
for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and on each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a <FONT
STYLE="white-space:nowrap">non-cash</FONT> gain or loss in other expense, net, on the statements of operations. The fair value of the warrants was estimated using the Black-Scholes option pricing model, which requires the use of highly subjective
and unobservable assumptions to determine the fair value of the warrants, including the fair value of common stock, expected term, expected volatility, risk-free interest rate and expected dividend yield. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Repricing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September
2025, our board of directors approved the repricing of stock options previously granted to current executive officers, employees and directors with per-share exercise prices above the initial price per share to the public in this offering, or the
Option Repricing. Assuming an initial price per share to the public in this offering of $15.00 per share, which is the midpoint of the price range set forth on the cover page of the prospectus, (i) upon the execution of the underwriting agreement
related to this offering, stock options to purchase approximately 406,998 shares of our common stock will be automatically repriced to an exercise price per share equal to the initial price per share to the public in this offering and (ii) we would
incur additional compensation expense of approximately $1.7&nbsp;million in the aggregate, recognized over the remaining service period of the affected options, or through 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual amount of total additional compensation expense resulting from the Option Repricing will be determined at the pricing of this
offering by comparing the estimated fair market value of the stock options, using the Black-Scholes option-pricing model, immediately before and immediately after the Option Repricing. The estimate of total additional compensation expense set forth
above is subject to the actual initial price per share to the public in this offering as well as other assumptions used by the Black-Scholes option-pricing model, including expected volatility and the risk-free interest rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on the effective date of the registration statement of which this
prospectus forms a part, assuming we issue 16,666,667 shares in connection with this offering at an assumed price of $15.00 per share, we will issue to our current executive officers, employees and directors stock options to purchase an aggregate of
1,618,452&nbsp;shares of our common stock under the 2025 Plan, subject to continued service through such grant date. Based on an assumed exercise price of $15.00 per share, which is the midpoint of the estimated price range set forth on the cover
page of this prospectus, we estimate that the aggregate grant-date fair value of the options to be granted in connection with this offering is $12.7&nbsp;million, which is expected to be recognized as stock-based compensation expense over a period
of four years. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act, and we may remain an emerging growth company for up to five years
following the completion of this offering. For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our
internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports
and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two years
of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the
information you receive from other public companies in which you hold stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would
otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period, and therefore, we are not subject to the same requirements to adopt new or revised accounting standards as other public
companies that are not emerging growth companies; however, we may adopt certain new or revised accounting standards early. We will remain an &#8220;emerging growth company&#8221; until the earliest to occur of: (i)&nbsp;the last day of the fiscal
year in which we have $1.235&nbsp;billion or more in annual revenue; (ii)&nbsp;the date on which we first qualify as a large accelerated filer under the rules of the SEC; (iii)&nbsp;the date on which we have, in any prior three-year period issued
more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the fiscal year following the fifth anniversary of the consummation of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even
after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparation for our initial public offering, we did not appropriately design and maintain entity-level controls impacting the control
environment, risk assessment, control activities, information and communication and monitoring activities to prevent or detect material misstatements to the financial statements. These material weaknesses related to: (i)&nbsp;an insufficient number
of qualified resources to ensure adequate oversight and accountability over the performance of controls, including proper segregation of duties; controls over the completeness and accuracy of information used in the operation of control activities
across substantially all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial statement areas; management review controls at a sufficient level of precision to detect a material misstatement across substantially all financial statement areas that involve complex
and judgmental areas of accounting and disclosure; and retention of control evidence, and (ii&nbsp;)&nbsp;improper access and a lack of review over user access and user provisioning as it relates to our information technology environment and general
controls over information systems that support the financial reporting process. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are in the process of implementing our remediation plans with respect to the material weaknesses. We will continue to increase the number of resources (internal or third-party) dedicated to our accounting and finance team, including personnel with
additional knowledge, experience, and training, to ensure we have adequate staff, to segregate key duties, and to comply with company policies and procedures. We have engaged a third-party provider to assist in designing and implementing internal
control activities, including over information technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of designing and implementing an effective accounting and
financial reporting system is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain an accounting and financial reporting
system that is adequate to satisfy our reporting obligations. As we continue to evaluate and take actions to improve our internal control over financial reporting, we may determine to take additional actions to address control deficiencies or
determine to modify certain of the remediation measures described above. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate the material weaknesses we have
identified or avoid potential future material weaknesses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a smaller reporting company as defined by Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act and are not required to
provide the information required under this item. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product
candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. <FONT STYLE="white-space:nowrap">LB-102</FONT>
is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S. Food and Drug
Administration, or FDA, for amisulpride were incompatible with patent coverage on the drug. Amisulpride is a generic drug that has been extensively used in clinical practice following its initial approval in France in the 1980s, generating at least
two&nbsp;million monthly prescriptions in 2023 in a subset of 16 continental European countries. Among these European prescriptions for amisulpride, our data suggest that approximately 60% are for schizophrenia and schizoaffective disorders,
approximately 20% are for mood disorders, approximately 14% are for anxiety, and the remainder are for a variety of other indications. We developed <FONT STYLE="white-space:nowrap">LB-102</FONT> in order to address the limitations of amisulpride
with a differentiated therapeutic profile and strong intellectual property protection. We believe <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> mechanism of action, data from our recently completed Phase 2 trial of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia, and the legacy of clinical experience with amisulpride support the continued development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia and bipolar depression. If
successful in treating bipolar depression, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> in the treatment of major depressive disorder, or MDD. In the future, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT>
for the treatment of other neuropsychiatric disorders, including schizophrenia with predominantly negative symptoms, Alzheimer&#8217;s disease-related agitation and psychosis, manic episodes associated with bipolar disorder, and cognitive impairment
associated with schizophrenia, or CIAS. We believe that <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved, can become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics
for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, <FONT
STYLE="white-space:nowrap">LB-102,</FONT> is a Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by
hallucinations, delusions, and other positive symptoms. Schizophrenia is a chronic, severe, complex, and debilitating psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability. Symptoms are
divided into three categories: (i)&nbsp;psychotic or positive symptoms, which include delusions, hallucinations, thought disorder, and movement disorder; (ii)&nbsp;negative symptoms, which include lack of motivation, interest, or enjoyment in daily
activities, withdrawal from social life, and difficulty showing emotions; and (iii)&nbsp;cognitive symptoms, which encompass problems with attention, concentration, and memory. The disease is associated with increased mortality, with approximately
5% of schizophrenia patients dying by suicide, and average overall life expectancy decreasing by as much as 29 years compared to the general population. There is currently no cure for schizophrenia, which means the disease must be managed with
life-long therapy, increasing the importance of therapies that can improve compliance rates and dosing challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, we
announced positive data from our four-week placebo-controlled, double-blinded, Phase 2 trial in the United States, which assessed the safety and efficacy of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute schizophrenia. Results
from the trial demonstrated (i)&nbsp;statistically significant clinical activity at all <FONT STYLE="white-space:nowrap">LB-102</FONT> doses tested; (ii)&nbsp;a significant average change in overall symptoms (effect size); (iii) a potentially
class-leading tolerability profile among D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>/D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> antagonists and partial agonists; and (iv)&nbsp;a potentially differentiated impact on
cognition as measured by CogState Computerized Schizophrenia Battery of Tests. The trial achieved its primary endpoint of change in the Positive and Negative Syndrome Scale, or PANSS, a <FONT STYLE="white-space:nowrap">30-item</FONT> scale that
measures the severity of schizophrenia symptoms, from baseline to Week 4. A statistically significant decrease in symptoms was observed for all three dose cohorts (50 mg, 75 mg, and 100 mg) compared to placebo. Additionally, our Phase 2 trial data
showed a statistically significant impact on negative symptoms versus placebo at the 50 mg dose even though the inclusion criteria enriched for patients experiencing predominantly positive symptoms of schizophrenia. An exploratory <FONT
STYLE="white-space:nowrap">post-hoc</FONT> analysis of our Phase 2 data on the treatment effect in patients with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negative symptoms at baseline (i.e., those patients with a PANSS Negative Subscore greater than or equal to 24) yielded similar results with a statistically significant impact on negative
symptoms versus placebo at the 50 mg dose. <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well tolerated in the clinical trial, with adverse events being mostly transient and mild to moderate in severity. If replicated in our planned
Phase 3 trial, we believe this tolerability profile has the potential to be class-leading among D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>/D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> antagonists and partial agonists
specifically with respect to the rate of sedation and extrapyramidal symptoms, or EPS, a group of movement disorders including involuntary movements, muscle stiffness, and tremors, that, together with sedation, are quite burdensome to patients and
can result in discontinuation of treatments. The impact of <FONT STYLE="white-space:nowrap">LB-102</FONT> on cognitive function was also evaluated as an exploratory endpoint in this trial. After four weeks of treatment with <FONT
STYLE="white-space:nowrap">LB-102,</FONT> a robust, dose-dependent, and significant treatment effect size was identified in a post-hoc analysis in the completer population for all doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> compared with
placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed our Phase 2 acute schizophrenia trial to be potentially registrational by including a large sample size (n=359),
robust statistical analyses, as well as numerous sensitivity analyses. Based on positive <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 feedback from the FDA, as well as historical precedent, we
believe that our Phase 2 acute schizophrenia trial may serve as one of the two pivotal trials required for approval of a new drug application, or NDA, in the United States. As a result, we believe there is a viable path to approval of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in the United States for the treatment of schizophrenia with a single, <FONT STYLE="white-space:nowrap">six-week</FONT> Phase 3 trial alongside other planned
<FONT STYLE="white-space:nowrap">NDA-enabling</FONT> studies. However, there is no guarantee that our Phase 2 trial may serve as one of the two pivotal trials required for FDA approval, and in such case, we may be required to conduct an additional
pivotal trial in acute schizophrenia. The adequacy of our Phase 2 trial to support registration will be a matter of review by the FDA at the time of NDA submission and will depend on the totality of the data included in our submission, including the
results of our planned Phase 3 trial. We are planning to initiate a <FONT STYLE="white-space:nowrap">six-week</FONT> Phase 3 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia patients in the first quarter of 2026, which
we believe, if positive, could be sufficient to support a regulatory application for approval in the United States along with our completed Phase 2 trial and other planned <FONT STYLE="white-space:nowrap">NDA-enabling</FONT> studies. The Phase 3
trial is anticipated to be a <FONT STYLE="white-space:nowrap">three-arm,</FONT> inpatient, double-blinded, placebo-controlled, oral once-daily dose of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute schizophrenia, with a <FONT
STYLE="white-space:nowrap">six-week</FONT> treatment duration. We plan to study the effects of 50 mg <FONT STYLE="white-space:nowrap">LB-102</FONT> or 100 mg <FONT STYLE="white-space:nowrap">LB-102</FONT> versus placebo in this trial, and patients
will be randomized in a 1:1:1 ratio across the three arms of the trial. The sample size will be approximately 400 patients, and we plan to conduct this trial at approximately 25 sites entirely in the United States. The primary endpoint of the trial
is anticipated to be change from baseline in PANSS at Day 42. We expect to disclose topline data from this Phase 3 trial in the second half of 2027 and, if positive, meet with the FDA in the first quarter of 2028 to discuss the potential for
submission of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our clinical development program in schizophrenia, we plan to leverage our expertise in
neuropsychiatry and the unique mechanism of action of <FONT STYLE="white-space:nowrap">LB-102</FONT> to develop our product candidate in other indications, starting with bipolar depression. Most people living with bipolar depression experience
dramatic shifts in mood, energy, and behavior, alternating between manic and depressive states. It is estimated that 2.8%, or approximately seven&nbsp;million Americans, experience bipolar disorder in a year, and approximately 40&nbsp;million people
live with bipolar disorder worldwide. Our initial Phase 2 trial will explore the utility of <FONT STYLE="white-space:nowrap">LB-102</FONT> in controlling the depressive symptoms of the disease. We plan to initiate this potentially registrational
Phase 2 trial in bipolar depression in the first quarter of 2026, with topline data expected in the first quarter of 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe <FONT
STYLE="white-space:nowrap">LB-102&#8217;s</FONT> strong antagonism of the D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>, D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>, and 5HT7 receptors makes it well suited for treating
bipolar depression, providing potential to control psychosis and mania through its effects on D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> and potential for antidepressive and <FONT STYLE="white-space:nowrap">pro-cognitive</FONT>
effects through its antagonism of 5HT7 and D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>. Our Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia demonstrated strong antipsychotic activity and suggests
opportunities for potential differentiation in bipolar depression given the observed tolerability profile (low rates of EPS, sedation, and gastrointestinal side effects) and positive impact on cognition. Amisulpride is approved for the treatment of
dysthymia, a form of depression, in certain countries outside of the United States and has been shown to be as effective as certain approved agents for MDD and dysthymia. We believe that results in dysthymia and MDD provide strong scientific and
clinical rationale for development of LB-102 in the treatment of depressive episodes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with bipolar disorder or bipolar depression because episodes of major depression, whether unipolar (as in MDD) or bipolar (as in bipolar depression), are typically characterized by a
similar imbalance in the neurotransmitters serotonin, noradrenaline, and dopamine, regardless of the underlying pathophysiology of the disease. There is wide use of amisulpride in bipolar disorder with approximately 3.4% of at least two million
monthly prescriptions written for this indication in a select group of European countries including Germany, France, Italy, Spain, and several others. A non-racemic form of amisulpride also showed antidepressant activity in two independent
third-party, placebo-controlled bipolar depression trials with an approximately 17- to 18-point reduction in Montgomery&#8211;&Aring;sberg Depression Rating Scale, or MADRS, from baseline observed across these studies. Additionally, among the four
antipsychotics approved for schizophrenia and MDD or treatment resistant depression that were also studied in late-stage bipolar depression trials (quetiapine, cariprazine, aripiprazole, and olanzapine), three out of four, or 75%, generated positive
data for the treatment of bipolar depression. Our planned Phase 2 trial for bipolar depression will utilize a fixed-flexible dose of <FONT STYLE="white-space:nowrap">LB-102.</FONT> This trial design allows us to evaluate two doses of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in the trial, thereby increasing the chances for a patient to derive clinical benefit from treatment with <FONT STYLE="white-space:nowrap">LB-102,</FONT> while retaining the advantages of a <FONT
STYLE="white-space:nowrap">two-arm</FONT> trial, which is known to mitigate the risk of a high placebo rate. Additionally, flexible dose trials typically have better signal detection than fixed dose trials for depression, as flexible dose trials
lower the magnitude of symptom reduction with placebo. We believe <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to provide improved tolerability and clinical activity in bipolar depression compared to currently available
treatments worldwide, which are associated with troubling adverse events and insufficient efficacy for certain symptoms, including cognitive impairment associated with the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing a long-acting injectable, or LAI, formulation of <FONT STYLE="white-space:nowrap">LB-102,</FONT> which may improve
compliance, a common issue in patients with schizophrenia and bipolar disorder. We believe an effective LAI form of <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to benefit patients worldwide, as relatively few approved agents are
available as long-acting formulations and there are no benzamide class LAIs currently available or in development worldwide. The American Psychiatric Association recommends injectable formulations in circumstances where doing so will improve
adherence, decrease mortality, reduce hospitalization risk, and decrease treatment discontinuation rates. We have commenced LAI formulation development and expect to continue these efforts in 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. market for branded antipsychotic drugs was approximately $12&nbsp;billion as of 2024. Despite the widespread use of generic
antipsychotic drugs, several of these branded drugs each generate U.S. sales in excess of $1&nbsp;billion annually. Additionally, while available therapeutics to treat schizophrenia and bipolar depression demonstrate clinical benefit, a significant
unmet need remains for a treatment that balances tolerability with clinically meaningful efficacy for the chronic management of symptoms related to both psychosis and mood disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidate <FONT STYLE="white-space:nowrap">LB-102:</FONT> Leveraging a Proven Mechanism with Efficacious Data to Bolster Development for a
Broad Range of Indications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LB-102</FONT> is a novel, patent-protected benzamide antipsychotic drug
that was designed using amisulpride as a starting point. Amisulpride is one of the most effective and commonly used antipsychotic drugs currently approved outside the United States. Amisulpride was ranked as the second most effective antipsychotic
drug in the 2019 Lancet meta-analysis of clinical trials on antipsychotic drugs. In this meta-analysis, amisulpride was ranked the most effective antipsychotic drug in treating positive symptoms and the third most effective in addressing negative
symptoms of schizophrenia. Despite amisulpride&#8217;s efficacy and tolerability profile, it has not received regulatory approval in the United States for the treatment of any neuropsychiatric disorders, including schizophrenia, because the
development and regulatory requirements of the FDA were incompatible with patent coverage on the drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The modifications we incorporated
into <FONT STYLE="white-space:nowrap">LB-102</FONT> were designed to improve the tolerability and efficacy profile of amisulpride by addressing its shortcomings, such as limited blood-brain barrier, or BBB, permeability and dosing frequency.
Enhanced BBB permeability was expected to improve the potency of the molecule with respect to dopamine receptor binding and enable the use of lower doses compared with amisulpride. The use of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lower doses was hypothesized to improve the tolerability profile. We also aimed to create a new chemical entity with strong composition of matter intellectual property protection. We believe that
the methylation of amisulpride addresses these design goals, and we aimed to demonstrate in our clinical trials that <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> improved BBB penetration would confer benefits over amisulpride and other
antipsychotic drugs, including lower dosing levels, a wider therapeutic window, improved tolerability, and once-daily dosing. Use of lower doses may also improve the feasibility of developing an LAI formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because amisulpride was used as the starting point in the creation of <FONT STYLE="white-space:nowrap">LB-102,</FONT> we have conducted
preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> studies with the compound to determine superiority as well as to assess whether the clinical development path of amisulpride may provide a
risk-mitigated path for our development of <FONT STYLE="white-space:nowrap">LB-102.</FONT> We have not conducted <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trials to date comparing <FONT
STYLE="white-space:nowrap">LB-102</FONT> to amisulpride; however, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical studies that compared amisulpride to
<FONT STYLE="white-space:nowrap">LB-102</FONT> in animal models of schizophrenia demonstrated that <FONT STYLE="white-space:nowrap">LB-102</FONT> had equivalent or better results than similar doses of amisulpride and that <FONT
STYLE="white-space:nowrap">LB-102</FONT> bound similarly to the dopamine D<SUB STYLE="font-size:75%; vertical-align:bottom">2 </SUB>and D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> receptors, with a K<SUB
STYLE="font-size:75%; vertical-align:bottom">i</SUB> (inhibition constant) of 0.82 nM compared to amisulpride&#8217;s reported K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 1.1 nM, and had a similar affinity for the <FONT
STYLE="white-space:nowrap">5-HT7</FONT> receptor with a K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 31 nM compared to amisulpride&#8217;s reported K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 44 nM. Our Phase 1
trials in healthy volunteers showed that <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well-tolerated, and in our Phase 1b imaging trial, we observed that <FONT STYLE="white-space:nowrap">LB-102</FONT> achieved a level of dopamine
receptor occupancy in the brain of approximately 70% (50 mg dose) and approximately 80% (100 mg dose) under steady-state conditions; typically, 60% to 80% dopamine receptor occupancy is the target range for efficacy in treating schizophrenia. The
dopamine receptor occupancy levels seen in the imaging trial at 50 mg of <FONT STYLE="white-space:nowrap">LB-102</FONT> are approximately equivalent to those observed with 300 to 400 mg of amisulpride. By dosing
<FONT STYLE="white-space:nowrap">LB-102</FONT> at a lower level, we are aiming to decrease side effects common to amisulpride and other antipsychotic drugs currently used to treat schizophrenia. We believe that fewer side effects of a drug may lead
to stronger adherence, continued use of the drug, and therefore, better efficacy results and long-term control of the disease. Because each relapse of psychotic symptoms can result in a functional deterioration from which the patient does not fully
recover, long-term control of the disease is a key treatment goal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our current Phase 3 trial is designed to investigate <FONT
STYLE="white-space:nowrap">LB-102</FONT> as a treatment for people experiencing the acute phase, or positive symptoms, of schizophrenia, we believe <FONT STYLE="white-space:nowrap">LB-102</FONT> also has potential to address predominantly negative
symptoms, an indication with significantly fewer treatment options as well as CIAS, an indication for which there are no approved therapies. We believe that our data with <FONT STYLE="white-space:nowrap">LB-102</FONT> as well as data previously
generated with amisulpride support the further investigation of <FONT STYLE="white-space:nowrap">LB-102</FONT> in these settings and that, if positive, such data have the potential to further differentiate
<FONT STYLE="white-space:nowrap">LB-102</FONT> from other drugs available for schizophrenia. Amisulpride demonstrated a statistically significant benefit versus placebo in three independent third-party placebo-controlled trials in patients with
predominantly negative symptoms with treatment durations ranging from six weeks to six months. Additionally, our Phase 2 trial data showed a statistically significant impact on negative symptoms versus placebo at the 50 mg dose even though the
inclusion criteria enriched for patients experiencing predominantly positive symptoms of schizophrenia. An exploratory <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis of our Phase 2 data on the treatment effect in patients with negative
symptoms at baseline (i.e., those patients with a PANSS Negative Subscore greater than or equal to 24) yielded similar results with a statistically significant impact on negative symptoms versus placebo at the 50 mg dose. We find these results
highly encouraging and plan to explore options to advance <FONT STYLE="white-space:nowrap">LB-102</FONT> in this indication. For example, we have developed a synopsis for a Phase 2 trial in patients with predominantly negative symptoms of
schizophrenia and expect to seek regulatory guidance on the design of this trial in 2026 to establish a clinical registration path in this setting. We also expect to generate additional negative symptoms data in our planned Phase 3 trial. We also
plan to further explore the impact of <FONT STYLE="white-space:nowrap">LB-102</FONT> on cognition in patients with schizophrenia both clinically and <FONT STYLE="white-space:nowrap">pre-clinically.</FONT> For example, concurrently with our Phase 3
trial in patients with acute schizophrenia, we expect to initiate an open label trial in patients with stable schizophrenia that will enroll both patients who participated in the Phase 3 trial as well as patients who did not. Although the primary
objective of this trial is to collect the requisite safety data required for an NDA submission, we also expect to collect efficacy data in certain subsets of patients enrolled in this trial. Efficacy measures will include periodic assessments of
cognition as well as open label assessments of improvements in positive and negative symptoms, including in patients with prominent negative symptoms at enrollment in the trial. Although we do not expect data from this open label trial to lead to
product label claims </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without additional randomized clinical trials, we believe these data have the potential to further support the differentiation of <FONT STYLE="white-space:nowrap">LB-102</FONT> and expect these
data to provide publishable valuable insights as we consider further investigating <FONT STYLE="white-space:nowrap">LB-102</FONT> as a potential treatment for CIAS as well as in patients with predominantly negative symptoms of schizophrenia.
Following the potential approval for the treatment of schizophrenia, we may also consider conducting another Phase 3 trial in acute schizophrenia where <FONT STYLE="white-space:nowrap">LB-102</FONT> is used as an adjunctive therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the potential advantages in treating schizophrenia, we believe there is significant potential for
<FONT STYLE="white-space:nowrap">LB-102</FONT> as a treatment for mood disorders and other neuropsychiatric diseases. Based on existing third-party data investigating amisulpride and a <FONT STYLE="white-space:nowrap">non-racemic</FONT> form of the
drug as a treatment for several types of depression, including bipolar depression, and the approval of amisulpride in multiple countries outside of the United States for the treatment of dysthymia, a form of depression, we have identified bipolar
depression as our next development opportunity for <FONT STYLE="white-space:nowrap">LB-102.</FONT> There is wide use of amisulpride in bipolar disorder with approximately 3.4% of at least two million monthly prescriptions written for this indication
in a select group of European countries including Germany, France, Italy, Spain, and several others. A <FONT STYLE="white-space:nowrap">non-racemic</FONT> form of amisulpride showed antidepressant activity in two independent third-party,
placebo-controlled bipolar depression trials with an approximately <FONT STYLE="white-space:nowrap">17-</FONT> to <FONT STYLE="white-space:nowrap">18-point</FONT> reduction in MADRS from baseline observed across these studies. The <FONT
STYLE="white-space:nowrap">non-racemic</FONT> form of amisulpride was also shown to be substantially similar to amisulpride in preclinical models. We also believe that the strength and selectivity of our binding profile for each of the D<SUB
STYLE="font-size:75%; vertical-align:bottom">2</SUB>, D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>, and 5HT7 receptors suggests that <FONT STYLE="white-space:nowrap">LB-102</FONT> is potentially well suited for development in bipolar
depression since D<SUB STYLE="font-size:75%; vertical-align:bottom">2 </SUB>mediates effects on psychosis and mania and 5HT7 and D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> mediate effects on depression and cognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are two types of bipolar disorder, distinguished as bipolar 1 and 2, which are characterized by chronically occurring episodes of mania
or hypomania alternating with depression. A person diagnosed with bipolar 1 disorder experiences a manic episode defined as a distinct period of persistently elevated or irritable mood with increased activity or energy lasting for at least seven
days or requiring hospitalization. The manic episode may be preceded or followed by a hypomanic or major depressive episode. A bipolar 2 disorder diagnosis is based on experiencing a hypomanic episode and major depressive episode without a manic
episode. Manic episodes are markedly more severe than hypomanic episodes. It is estimated that 2.8%, or approximately seven million Americans, experience bipolar disorder in a year. For those living with bipolar disorder, an estimated 82.9% have
serious impairment due to the disease, the highest percent of serious impairment among all mood disorders, indicating there is significant need for new and better treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a 2022 placebo-controlled <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial conducted
by a third party in 341 patients across U.S., European, and Japanese clinical sites, <FONT STYLE="white-space:nowrap">non-racemic</FONT> amisulpride demonstrated meaningful improvement over placebo on the MADRS in treating bipolar depression.
Although the trial did not meet its primary endpoint, which was defined as MADRS delta versus placebo in United States and European patients, the results when analyzed for all patients across all geographies demonstrated a statistically significant
benefit versus placebo in favor of <FONT STYLE="white-space:nowrap">non-racemic</FONT> amisulpride with a 3.4 to <FONT STYLE="white-space:nowrap">3.7-point</FONT> MADRS delta versus placebo and an approximately
<FONT STYLE="white-space:nowrap">18-point</FONT> reduction in MADRS versus baseline in each of the two treatment arms. The mean reduction from baseline in the placebo arm in this trial was 14.3 points. The placebo rate observed in this trial was
higher than the average placebo rate from a recent set of bipolar depression trials which was an approximately <FONT STYLE="white-space:nowrap">12-point</FONT> reduction in MADRS from baseline. We believe that the high placebo rate in this trial was
in part a result of poor trial design and conduct. A Phase 3 trial was subsequently initiated by the same third party with <FONT STYLE="white-space:nowrap">non-racemic</FONT> amisulpride and though the trial was terminated prior to completion,
results from 82 patients enrolled in the trial were reported. These results showed a 4.0 to <FONT STYLE="white-space:nowrap">6.4-point</FONT> MADRS delta versus placebo and an approximately 14 to <FONT STYLE="white-space:nowrap">17-point</FONT>
reduction in MADRS versus baseline in the two treatment arms. Amisulpride and the <FONT STYLE="white-space:nowrap">non-racemic</FONT> form studied in these two trials have been shown to be substantially similar in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. Additionally, amisulpride has been shown to be effective in clinical trials addressing other forms of depression, such as in a 1999 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial conducted by a third party in dysthymia and major depression which showed amisulpride and another study drug each leading to a statistically significant improvement over placebo on the
MADRS. A 2001 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial conducted by a third party also found amisulpride to be as clinically effective as sertraline, a commonly used antidepressant, in
treating dysthymia, and a 2002 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial conducted by a third party found amisulpride to be as clinically effective as paroxetine, another commonly used
antidepressant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is widely recognized that episodes of major depression whether unipolar (as in MDD) or
bipolar (as in bipolar depression) are characterized by a similar imbalance in the neurotransmitters serotonin, noradrenaline, and dopamine, regardless of the underlying pathophysiology of the disease. Among the four antipsychotics approved for
schizophrenia and MDD or treatment resistant depression that were also studied in late-stage bipolar depression trials (quetiapine, cariprazine, aripiprazole, and olanzapine), three out of four, or 75%, generated positive data for the treatment of
bipolar depression. We believe that the approval of amisulpride in the United Kingdom for the treatment of psychosis and mania serves as additional supportive evidence for the broader utility of <FONT STYLE="white-space:nowrap">LB-102</FONT> to
treat neuropsychiatric disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate this potentially registrational Phase 2 trial in bipolar depression in the first
quarter of 2026, upon the clearance of an Investigational New Drug, or IND, application for that indication. We are designing this clinical trial to be of registrational quality and if successful, we expect to ask the FDA if this trial could serve
as one of two adequate well-controlled trials needed to obtain approval of <FONT STYLE="white-space:nowrap">LB-102</FONT> in bipolar depression. Following a successful Phase 2 trial, we may also consider conducting two Phase 3 trials in bipolar
depression, one as a monotherapy and one as an adjunctive therapy in combination with mood stabilizers, a commonly used treatment for bipolar depression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the extensive third-party research that has been conducted on amisulpride and a <FONT STYLE="white-space:nowrap">non-racemic</FONT>
form of the drug and our research indicating a comparable or even improved clinical activity and tolerability profile, including with respect to rates of EPS, sedation and gastrointestinal side effects, of
<FONT STYLE="white-space:nowrap">LB-102,</FONT> we believe there is broad potential for the development of <FONT STYLE="white-space:nowrap">LB-102</FONT> for a variety of psychiatric indications and mood disorders. We believe the extensive body of
research on amisulpride provides a potential road map for future development opportunities for <FONT STYLE="white-space:nowrap">LB-102,</FONT> including the potential for development of <FONT STYLE="white-space:nowrap">LB-102</FONT> in MDD, negative
symptoms of schizophrenia, bipolar mania, and Alzheimer&#8217;s disease psychosis and agitation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our leadership and advisors are composed of individuals with extensive experience in the discovery, development, and commercialization of
neuropsychiatric therapeutics. <I></I><I></I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heather Turner, J.D., our Chief Executive Officer, was previously President and Chief
Executive Officer of Carmot Therapeutics Inc., prior to its acquisition by Roche Pharmaceuticals for $3.1&nbsp;billion. Anna Eramo, M.D., our Chief Medical Officer, previously led U.S. clinical and medical affairs at Lundbeck A/S, where her primary
responsibilities extended across its U.S. neurology and psychiatric portfolio of products, including brexpiprazole (which is approved in schizophrenia, MDD, and agitation associated with Alzheimer&#8217;s disease), vortioxetine (which is approved
for MDD), and Abilify Maintena (an LAI form of aripiprazole that is approved for schizophrenia and bipolar&nbsp;1). Other members of our team held various positions at Celgene Corporation, Genzyme Corporation, and ImmunoGen, Inc., with experience
working on late-stage development and commercial products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chairman of our board of directors, Scott Garland, most recently served as
Chief Executive Officer of PACT Pharma, Inc. Previously, Scott was the Chief Executive Officer of Portola Pharmaceuticals, Inc., which Alexion Pharmaceuticals, Inc. acquired for $1.4&nbsp;billion in 2020. Prior to that, he was President of Relypsa
Inc., which Vifor Pharma AG acquired for $1.5&nbsp;billion in 2016. He is joined on our board of directors by Robert Ruffolo, Ph.D., who previously served as President of Research and Development at Wyeth Pharmaceuticals, Inc., Zachary Prensky, <FONT
STYLE="white-space:nowrap">co-founder</FONT> of LB Pharmaceuticals and former manager of a family office with a heavy focus on investing in the biotechnology and pharmaceutical sectors, and other board representatives from our major investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are advised by renowned experts in treating neuropsychiatric diseases. John Kane, M.D., is a Professor of Psychiatry and Molecular Medicine
at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years. Christoph U. Correll, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
M.D., is a Professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Maurizio Fava, M.D., is the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Psychiatrist-In-Chief,</FONT></FONT> Department of Psychiatry and Director, Division of Clinical Research at Mass General Research Institute. Dr.&nbsp;Fava is also the Executive Director of the Clinical Trials
Network&nbsp;&amp; Institute, as well as the Associate Dean for Clinical&nbsp;&amp; Translational Research and Slater Family Professor of Psychiatry at Harvard Medical School. Luca Pani, M.D. is Professor of Clinical Psychiatry at the University of
Miami and Pharmacology at the University of Modena &amp; Reggio Emilia, former Italy&#8217;s AIFA Director General and EMA CHMP/SAWP Representative, with expertise in pre-clinical and clinical CNS drug development strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have raised over $120&nbsp;million from a leading syndicate of investors, including Deep Track Capital, Pontifax, TCG
Crossover Fund, and Vida Ventures. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and have received their shares in prior offerings at prices lower
than the price offered to the public in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of schizophrenia and mood disorders initially and
subsequently for other neuropsychiatric disorders in the United States and internationally. Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Achieve regulatory approval for <FONT STYLE="white-space:nowrap">LB-102</FONT> for the treatment of
schizophrenia. </B>The regulatory pathway for antipsychotic drug development in schizophrenia is well-established and provides precedent for regulatory approval requirements. Based on recent positive feedback from the FDA, our current strategy is to
utilize our recently completed Phase 2 trial in acute schizophrenia to serve as one of two adequate and well controlled trials required for FDA approval. In this Phase 2 trial, <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well
tolerated and resulted in a statistically significant decrease in symptoms related to schizophrenia as measured by PANSS after four weeks of treatment. These results have informed the design of our Phase 3 trial, which we aim to commence in the
first quarter of 2026. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">LB-102</FONT> as a potential treatment across the spectrum of disease
for patients with schizophrenia. </B>We believe <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to treat a broad range of patients living with schizophrenia by addressing positive symptoms experienced during the acute phase of the
disease, negative symptoms experienced between acute crises, and cognitive symptoms, such as memory deficit, decision making and attention deficit. We plan to initiate a Phase 3 trial for <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients
with acute schizophrenia while developing our clinical development strategy for other unmet needs within schizophrenia. Negative symptoms and cognitive issues are core symptoms of&nbsp;schizophrenia where more than 80% of people with schizophrenia
have cognitive impairment of some kind up to 60% may experience predominantly, clinically relevant negative symptoms that require treatment.&nbsp;Based on our own clinical results and the breadth of third-party data, we believe <FONT
STYLE="white-space:nowrap">LB-102</FONT> has the potential to become a cornerstone therapy for schizophrenia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand development of <FONT STYLE="white-space:nowrap">LB-102</FONT> into bipolar depression and other
psychosis and mood disorders. </B>Based on the extensive body of third-party research that has been conducted on amisulpride and a <FONT STYLE="white-space:nowrap">non-racemic</FONT> form of the drug as well as our data with <FONT
STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia, we believe there is significant opportunity in the clinical development and commercial potential of <FONT STYLE="white-space:nowrap">LB-102</FONT> in other mood disorders and other
psychosis-related indications. We have identified bipolar depression as the next indication for which we intend to develop <FONT STYLE="white-space:nowrap">LB-102.</FONT> If successful in bipolar depression, we may also develop <FONT
STYLE="white-space:nowrap">LB-102</FONT> in MDD. We believe the mechanism of LB-102 as well as preclinical and clinical data for amisulpride and the <FONT STYLE="white-space:nowrap">non-racemic</FONT> version of amisulpride support development of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in bipolar depression and MDD. Our mechanism and clinical trials to date support our belief that <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to benefit people living with other
psychosis-related diseases such as bipolar mania and Alzheimer&#8217;s disease-related psychosis. We continue to assess other mood disorders and neuropsychiatric diseases for potential future development. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Extend the life-cycle and global reach</B><B> of <FONT STYLE="white-space:nowrap">LB-102</FONT></B><B>
by advancing alternate formulations</B><B>.</B> We are investigating alternate LAI formulations of <FONT STYLE="white-space:nowrap">LB-102.</FONT> We believe that such formulations have the potential to provide improved clinical results and
treatment adherence for schizophrenia and bipolar depression patients compared to oral formulations, for which compliance may be lower. We believe that the success of the 50 mg dose in our schizophrenia Phase 2 trial affords the opportunity to
develop an LAI. Additionally, we believe that an LAI formulation of <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved, could have additional advantages, including extending the commercial protection for
<FONT STYLE="white-space:nowrap">LB-102,</FONT> potentially providing a better alternative to the currently limited option set of approved LAI antipsychotic drugs for other neuropsychiatric disorders, such as bipolar disorder or Alzheimer&#8217;s
psychosis, and potentially enhancing <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> competitive positioning outside of the United States. <B></B><B></B><B></B><B></B><B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B>Maximize the commercial opportunity</B><B> of
<FONT STYLE="white-space:nowrap">LB-102</FONT></B><B></B><B>.</B> We currently own global rights to <FONT STYLE="white-space:nowrap">LB-102</FONT> and intend to retain commercialization rights in the United States. If approved for schizophrenia, we
expect to commercialize the oral formulation of <FONT STYLE="white-space:nowrap">LB-102</FONT> in jurisdictions where amisulpride is unavailable as a generic, and we expect to commercialize an LAI form of
<FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide. If approved for bipolar depression, we expect to commercialize both the oral and LAI forms of <FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide. We expect to expand our team and
develop internal resources to support the potential commercialization of <FONT STYLE="white-space:nowrap">LB-102.</FONT> Additionally, we may opportunistically evaluate potential commercial collaborations outside of the United States to maximize the
value of <FONT STYLE="white-space:nowrap">LB-102.</FONT> <B></B> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schizophrenia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Disease Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schizophrenia is a chronic, severe, complex, and debilitating psychiatric disorder that affects approximately 1% of the U.S. population and is
a leading cause of disability. Symptoms of schizophrenia are typically grouped into three categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Psychotic or positive symptoms</U>, such as hallucinations, delusions, thought disorder, and movement
disorder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Negative symptoms</U>, such as loss of motivation, interest, or enjoyment in daily activities, withdrawal from
social life, and difficulty in showing emotions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cognitive symptoms</U>, such as problems in attention, concentration, and memory. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While antipsychotic drugs are commonly used to treat schizophrenia, there is currently no cure for schizophrenia, which means the disease must
be managed with life-long therapy, increasing the importance of therapies that can improve compliance rates and dosing challenges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schizophrenia is typically diagnosed in the late teen years to early thirties and tends to emerge earlier in males than in females. The
estimated average potential life expectancy for individuals living with schizophrenia in the United States is reduced by as much as 29 years in comparison to the general population. This significant reduction is believed to be due to multiple
factors, including a high rate of other comorbidities and an increased risk of accidental death and suicide. An estimated 5% of people with acute schizophrenia die by suicide, which is a rate approximately 350 times higher than the general
population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The progression of schizophrenia usually follows a typical pattern. The prodromal phase refers to the early stage of the
disease where subtle changes in behavior and cognitive function occur but before psychotic symptoms, such as hallucinations or delusions. This is the stage when the first warning signs of the disease can be identified. The prodromal phase ends when
the patient experiences the first active phase which is characterized by positive symptoms, including hallucination, delusions, and disordered thinking. Recent studies have shown that if treated properly early in the course of their illness, most
patients recover from this first episode and have a substantial reduction, or even remission of psychotic symptoms. While in this &#8220;stable&#8221; phase after recovery from an acute episode, it is estimated that 13% to 48% of patients continue
to have residual symptoms. At this point, the patient may experience cycles of active disease, characterized by positive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
symptoms, and periods of stability, potentially with persistent negative symptoms. A meta-study showed that 55% of people with schizophrenia required hospitalization over an average <FONT
STYLE="white-space:nowrap">follow-up</FONT> of seven years after their first episode. With each relapse, the disease worsens, and the patient typically is unable to recover to the same level of health as prior to the active episode. Over years of
experiencing these cycles, most patients deteriorate, experiencing worsening symptoms and health outcomes. A therapy that reduces the number of relapses a patient experiences has the potential to provide a significant and life-long benefit. The
figure below depicts a graphic illustration of these phases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g07t84.jpg" ALT="LOGO" STYLE="width:6.06105in;height:2.89514in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pathophysiology of Schizophrenia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the main hypotheses for the pathophysiology leading to schizophrenia is an imbalance in neurochemical signaling in the brain, including
serotonin, dopamine, and glutamate. Specifically, schizophrenia is associated with an imbalance of dopaminergic pathways at the D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> receptor subtype. Increased dopamine activity in certain parts
of the brain can contribute to positive symptoms of schizophrenia. In contrast, reduced dopamine activity in other parts of the brain may cause negative and cognitive symptoms. Detailed understanding of the specific changes in dopamine signaling
that lead to schizophrenia is limited by the relative inaccessibility of methods to assess signaling pathways in the brain, the heterogeneity of psychological responses, and the lack of highly translatable animal models. Since the 1970s, clinical
trials with haloperidol, risperidone, and olanzapine, among others, have conclusively demonstrated that antagonism of the dopamine D<SUB STYLE="font-size:75%; vertical-align:bottom">2 </SUB>receptor can improve symptoms of schizophrenia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Schizophrenia with Predominantly Negative Symptoms </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative symptoms are a core component of schizophrenia and are distinct from positive symptoms. They account for a large part of the long-term
morbidity and poor functional outcomes. It is estimated that up to 60% of people with schizophrenia may have predominantly negative symptoms that are clinically relevant and require treatment equating to approximately 1.3&nbsp;million people in the
United States. In a meta-analysis for 20 placebo-controlled trials of second generation antipsychotic drugs, 62% of patients were experiencing predominantly negative symptoms and after six weeks of treatment. Negative symptoms are linked to worse
functional outcomes in occupational and academic performance, household integration, social functioning, participation in activities and quality of life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">People living with negative symptoms of schizophrenia are considered to have a higher burden of illness, which may be partially attributed to
the limited number of effective treatment options for this population. To date, there are no FDA approved treatments for predominantly negative symptoms in schizophrenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cognitive Impairment Associated with Schizophrenia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CIAS is a major burden for patients and negatively impacts many aspects of a patient&#8217;s life. Cognitive impairment is a core feature and
leading cause of functional disability in schizophrenia and other neuropsychiatric disorders. Antipsychotic drugs are the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatment for schizophrenia
but typically only address positive symptoms. So far there are no approved pharmacotherapies for the treatment of CIAS. More than 80% of people with schizophrenia have cognitive symptoms of some kind, equating to approximately 1.8&nbsp;million
patients in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Current Treatments for Schizophrenia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antipsychotic drugs are commonly classified as first-or second-generation drugs. First-generation antipsychotic drugs function primarily as
antagonists or partial agonists of dopamine receptors. These drugs, some of which were discovered in the 1950s, primarily address positive symptoms of schizophrenia. Current literature suggests a high correlation between dopamine receptor binding
and clinical potency; typically, 60% to 80% dopamine receptor occupancy is the target range for efficacy in treating schizophrenia. Second-generation antipsychotic drugs are typically dual serotonin and dopamine antagonists. The multimodal mechanism
of action of these drugs allows them to treat symptoms of schizophrenia with a lower incidence of EPS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing antipsychotic drugs fall
short of the ideal profile, as most currently approved medications have significant side effects, primarily address positive symptoms of schizophrenia, and are often not effective in treating negative and cognitive symptoms. Negative symptoms are a
core component of the disease, and it is estimated that up to 60% of patients may experience clinically relevant negative symptoms that require treatment. Negative symptom severity has been linked to worse functional outcomes in areas such as
impaired occupational and academic performance, social functioning, and quality of life. Despite the prevalence and seriousness of this component of schizophrenia, there are few treatment options that effectively address negative symptoms.
Additionally, cognitive impairment affects approximately 80% of schizophrenia patients. There are currently no approved drugs for cognitive impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both first- and second-generation antipsychotic drugs are often associated with sedation, dry mouth, constipation, EPS including akathisia
(inability to remain still), and sexual dysfunction. Some side effects are severe or even life-threatening, such as dystonia, a form of EPS (involuntary muscular contraction), tardive dyskinesia (movement disorder that causes involuntary facial
tics), and weight gain, which can lead to hyperlipidemia (high levels of lipids in the blood) and cardiac arrhythmias (abnormal heart rhythms). The combination of side effect profile, as well as poor efficacy and tolerability, results in
approximately half of all schizophrenia patients not adequately responding to current antipsychotic drugs. High rates of failure in achieving a clinically meaningful response with existing therapeutics, the evolution of patient symptoms over time,
inconvenient dosing regimens and significant side effects cause patients with schizophrenia to switch medications or layer on additional antipsychotic drugs frequently. Aside from suboptimal efficacy and tolerability, some current therapies also
accompany inconvenient administration profiles, such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">twice-a-day</FONT></FONT> dosing or the need to be taken with food. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together, these limitations lead to significant issues with patient adherence. One study showed that
<FONT STYLE="white-space:nowrap">one-third</FONT> of patients admitted to the hospital after their first psychotic episode of schizophrenia were <FONT STYLE="white-space:nowrap">non-adherent</FONT> to their treatment six months after discharge. A
multitude of studies have shown the serious outcomes that accompany <FONT STYLE="white-space:nowrap">non-adherence</FONT> to medication, including impairment, hospitalization, higher risk of suicide, longer time to remission, poorer prognosis, loss
of job, dangerous behavior, arrest, violence, drug and alcohol consumption, psychiatric emergences, poor mental performance, and low satisfaction with life. Interruptions in treatment as short as one to 10 days has been associated with an increased
risk of hospitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nearly 50% of all schizophrenia patients fail to respond adequately to existing therapies, many of which have
limited efficacy against the range of symptoms associated with the disease. Most antipsychotic drugs are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with significant side effects that drive high rates of treatment discontinuation. Approximately 74% of schizophrenia patients discontinue their medications within 18 months of starting
treatment due to their perceived lack of efficacy or burdensome side effects. Since these medications only treat symptoms of schizophrenia and cannot eliminate the underlying pathology, their discontinuation results in symptom recurrence. As a
result of these high rates of discontinuation, there is a significant amount of switching therapeutic treatments. A therapy with sufficient efficacy, tolerability and ease of use which would support a patient&#8217;s efforts to remain compliant
could provide significant benefit over currently available therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the table below, we show the efficacy and side effect profiles
of branded antipsychotic drugs approved for treatment of schizophrenia based on the approved labels. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Drug</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Mechanism of<BR>Action</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Baseline<BR>PANSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Reduction&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PANSS<BR>vs.&nbsp;Baseline</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Placebo-Corrected</FONT><BR>Reduction
in<BR>&#8195;&#8195;PANSS&#8195;&#8195;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Notable&nbsp;Lab</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Findings&nbsp;and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Side&nbsp;Effects</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Recommended<BR>Dosage</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dosing<BR>Frequency</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Caplyta</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dopamine Receptor Antagonist</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">88.1 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">90.0 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">13.2&nbsp;(Trial&nbsp;1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">14.5 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">5.8&nbsp;(Trial&nbsp;1)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">4.2&nbsp;(Trial&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sedation&nbsp;(24%), dry mouth (6%); EPS (6.7%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">42 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Once-daily, with food </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Cobenfy</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">M1/M4 Muscarinic Receptor Agonist</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">98.2 (Trial&nbsp;1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">96.9 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">21.2 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">20.6 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">9.6&nbsp;(Trial&nbsp;1)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">8.4&nbsp;(Trial&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Nausea&nbsp;(19%), dyspepsia (18%), constipation (17%), vomiting (15%), hypertension (11%), EPS (non-akathisia, 2%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Up&nbsp;to&nbsp;125 mg/30&nbsp;mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Twice-daily,</FONT> 1&nbsp;hour before or at least 2 hours after meals </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Rexulti</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dopamine Receptor Partial Agonist</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">94.7 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">95.0 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">19.7 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">20.0 (Trial 2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">7.6&nbsp;(Trial&nbsp;1)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">6.5&nbsp;(Trial&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Akathisia&nbsp;(6%), weight increase (4%), diarrhea (3%), dyspepsia (3%), tremor (3%), blood creatinine phosphokinase increase&nbsp;(2%); sedation (2%)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4 mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Once-daily </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Vraylar</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dopamine Receptor Partial Agonist</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">97.1 &#8211; 96.7 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">96.1 &#8211; 95.7
(Trial 2)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">96.3 (Trial 3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">19.4 &#8211; 22.3 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">20.2 &#8211; 23.0
(Trial 2)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">22.8 &#8211; 25.9 (Trial&nbsp;3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">7.6&nbsp;&#8211;&nbsp;10.4 (Trial 1)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">6.0 &#8211;
8.8 (Trial 2)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">6.8&nbsp;&#8211; 9.9 (Trial&nbsp;3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EPS <FONT STYLE="white-space:nowrap">(15-19%)*,</FONT> akathisia <FONT STYLE="white-space:nowrap">(9-13%)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1.5 - 6&nbsp;mg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Once-daily </TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Note: Characteristics of antipsychotic drugs approved for the treatment of schizophrenia. PANSS is a measure of symptoms in
schizophrenia patients including positive and negative symptoms, and general psychopathology, and reduction in PANSS v. baseline is a measure of efficacy of antipsychotic drugs. The change in PANSS score has been used as the primary endpoint in many
registrational trials of antipsychotic drugs, as it provides a comparative measure against baseline; a higher change from baseline can suggest greater improvement in patient symptoms. As this assessment requires patients or raters to undertake a
questionnaire regarding symptoms at protocol specified timepoints in the trial, it is, however, inherently subjective, which can increase the variability of clinical results across clinical trials and creates a significant degree of uncertainty in
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
determining overall clinical benefit. Caplyta efficacy data is based on four-week data from one Phase 2 trial and one Phase 3 trial (n=335; n=450). Cobenfy data is based on five-week data from
two Phase 3 trials (n=236; n=234). Rexulti data is based on <FONT STYLE="white-space:nowrap">six-week</FONT> data from two Phase 3 trials (n=674 total). Vraylar data is based on <FONT STYLE="white-space:nowrap">six-week</FONT> data from three Phase
3 trials (n=1,655 total). Akathisia is a form of EPS but is reported separately in a number of product labels. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the
fragility of the patient population and high rates of <FONT STYLE="white-space:nowrap">non-adherence,</FONT> tolerability and ease of use is an important factor for schizophrenia medications. Studies have shown that medication-related obesity,
distress related to weight gain, and cognitive impairment are associated with increased rates of nonadherence. Caplyta, Rexulti and Vraylar all contain warnings in their labels regarding metabolic changes, including weight gain. Somnolence, or
sedation, are among the most frequent adverse events observed with Caplyta and Rexulti. Despite the burdensome side effects associated with these antipsychotic drugs, they are still commonly used, with patients frequently switching between different
medications in search of the right balance of tolerability and efficacy. We believe a medication with an improved tolerability profile, increased efficacy, including with respect to negative symptoms or cognition, or both, have the potential to
provide a much-needed alternative to currently available therapies. We also believe a simple administration profile, once-daily dosing with no food effect, would provide a significant advantage as it has the potential to improve patient adherence
and, therefore, improve long-term outcomes. Additionally, an LAI has the potential to further simplify the patient experience and improve medication adherence. Currently, there are no LAIs available for Caplyta, Rexulti or Vraylar although several
are in development. In addition, there are no LAIs among the benzamide class of antipsychotic drugs currently available or in development worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the availability of several generic and branded treatments for schizophrenia, there remains a significant unmet need. Only 20% of
people with schizophrenia report favorable treatment outcomes. The remaining population experiences numerous psychotic episodes, chronic symptoms and a poor response to antipsychotic drugs. Additionally, patients who experience predominantly
negative symptoms and those with treatment-resistant schizophrenia live with a significant disease burden that cannot be sufficiently alleviated with currently available treatments, and there are no approved therapies for cognitive impairment
associated with schizophrenia. We believe a treatment that is effective, tolerable, supports adherence in a fragile population and can address negative and resistant symptoms could become a cornerstone of schizophrenia treatment. We believe <FONT
STYLE="white-space:nowrap">LB-102</FONT> has the potential to meet this profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development of <FONT STYLE="white-space:nowrap">LB-102:</FONT>
Improving upon Amisulpride </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amisulpride Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amisulpride is a dopamine receptor antagonist originally developed in France in the 1980s and is approved in more than 50 countries worldwide
(not including the United States) for the treatment of schizophrenia and, in certain countries outside of the United States, for the treatment of dysthymia, a form of depression, and predominantly negative symptoms of schizophrenia. In 2000, Sanofi
S.A., the manufacturer of Solian, the branded version of amisulpride, announced it would not pursue approval for schizophrenia in the United States because the development and regulatory requirements of the FDA were incompatible with its patent
coverage on the drug. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amisulpride in Schizophrenia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In multiple third-party studies comparing the clinical efficacy of antipsychotic drugs on schizophrenia, amisulpride consistently scored near
the top. For example, a 2019 Lancet meta-analysis of clinical trials, which included over 54,000 subjects and 32 medications, found that amisulpride had the highest efficacy as measured by effect on positive symptoms and was second only to clozapine
at reducing overall symptoms of schizophrenia. This analysis also found that amisulpride was 20% more effective at reducing overall symptoms of schizophrenia compared to risperidone, which is a first-line treatment for schizophrenia in the United
States. A 2020 Lancet Psychiatry report of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> long-term study showed amisulpride to have greater reduction in PANSS
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
score from baseline compared to first-line treatments of aripiprazole and olanzapine. In addition, a 2018 systematic review and meta-analysis across 21 randomized, controlled third-party trials
showed that in their analysis across these trials, amisulpride was the only antipsychotic drug that outperformed placebo in the treatment of patients who suffer from predominantly negative symptoms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart shows the antipsychotic efficacy as measured by overall average change in symptoms from the 2019 Lancet meta-analysis of
clinical trials on antipsychotic drugs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03r84.jpg" ALT="LOGO" STYLE="width:6.32in;height:3.68667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride was ranked as one of the most effective antipsychotic drugs in the 2019 Lancet meta-analysis
of clinical trials on antipsychotic drugs. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart shows the antipsychotic efficacy as measured by average change in
positive symptoms (left) and negative symptoms, a notoriously difficult aspect of the disease to treat, (right) from the 2019 Lancet meta-analysis of clinical trials on antipsychotic drugs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g03r85.jpg" ALT="LOGO" STYLE="width:2.91666in;height:2.04682in;">
 </P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g01p65.jpg" ALT="LOGO" STYLE="width:2.91667in;height:2.04696in;">
 </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride was ranked
the most effective antipsychotic drug in treating positive symptoms and third most effective in addressing negative symptoms of schizophrenia. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2024, Cobenfy was approved for use in schizophrenia. A 2025 third-party study in European
Neuropsychopharmacology highlighted that its overall treatment effect on symptoms was 0.56 using an approach similar to that which was used in the 2019 Lancet meta-analysis. In the table below, we have included the treatment effect of Cobenfy
together with those antipsychotic drugs reviewed in the 2019 Lancet meta-analysis for comparison purposes. This table shows how amisulpride&#8217;s effect size compares with Cobenfy&#8217;s and the other approved schizophrenia drugs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g02p65.jpg" ALT="LOGO" STYLE="width:3.2166in;height:3.15514in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride&#8217;s effect size was greater than that of Cobenfy. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EUFEST, a European clinical trial published in 2005 in which 498 first-episode schizophrenia
patients were randomized to receive haloperidol, amisulpride, olanzapine, quetiapine, or ziprasidone over 12 months, evaluated the primary endpoint of <FONT STYLE="white-space:nowrap">all-cause</FONT> discontinuation rate, which is the number of
patients who stopped taking their medications for any reason. Besides olanzapine, amisulpride had the lowest <FONT STYLE="white-space:nowrap">all-cause</FONT> discontinuation rate over 12&nbsp;months out of all drugs evaluated in this <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> comparison, supporting a favorable tolerability profile. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03r66.jpg" ALT="LOGO" STYLE="width:2.88in;height:3.33667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride had a low discontinuation rate in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> EUFEST trial. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amisulpride has also been shown to have a relatively low rate of EPS (11%), long-term weight
gain, and cardiovascular risk compared with other second-generation antipsychotic drugs. In a 2014 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> meta-analysis conducted by a third party comparing weight
gain among antipsychotics, amisulpride had lower weight gain compared with other antipsychotic drugs across various outcome measures including body weight gain (in kg). The results comparing weight gain for amisulpride with that of other
antipsychotics are highlighted in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g93g01.jpg" ALT="LOGO" STYLE="width:6.25in;height:3.40707in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>FGA = first generation antipsychotics; SGA = second generation antipsychotics; st= number of studies</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride had a lower weight gain compared with other antipsychotic drugs.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in a third-party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial completed in
2002 that compared long-term weight gain of amisulpride over six months to that of olanzapine, amisulpride weight gain exceeded that of olanzapine over the first 30 days of the study, and plateaued at approximately 1 kg, whereas weight gain with
olanzapine continued to increase throughout the <FONT STYLE="white-space:nowrap">six-month</FONT> period reaching a weight gain of approximately 5 kg, as shown in the graph below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g93g02.jpg" ALT="LOGO" STYLE="width:2.69333in;height:2.67667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride had lower weight gain than olanzapine in a third-party <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pharmacovigilance data on amisulpride from the United Kingdom covering 16,000
patient exposure years had 8 incidences of QT prolongation with all 8 events occurring in patients concurrently taking clozapine, a drug known to prolong the QT interval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to market research in 2024, amisulpride continues to be widely used in Europe. Among a select group of European countries including
Germany, France, Italy, Spain, and several others, there were at least two&nbsp;million monthly prescriptions per year for amisulpride. Among these European prescriptions for amisulpride, our data suggest that approximately 60% are for schizophrenia
and schizoaffective disorders (a mental health condition that includes symptoms of both schizophrenia and mood disorders), approximately 20% are for mood disorders, approximately 14% are for anxiety, and the remainder are for a variety of other
indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amisulpride has also been studied for the treatment of predominantly negative symptoms of schizophrenia in three independent
placebo-controlled trials conducted by third parties. A trial conducted in 1995 evaluated two doses of amisulpride, 100 and 300 mg per day, versus placebo for six weeks of treatment. In this trial, the two amisulpride-treated arms showed a reduction
in the Scale for the Assessment of Negative Symptoms, or SANS, of approximately 39 to 45 points compared with a reduction of 22 points in the placebo arm (p = less than 0.02). P refers to &#8220;p-value,&#8221; the conventional method for
determining the statistical significance of a result, which represents the probability that random chance caused the result (e.g., a p-value = 0.01 means that there is a 1% probability that the difference between the control group and the treatment
group is purely due to random chance). Generally, a p-value less than 0.05 is considered statistically significant. The SANS scale is a 25-item scale that assesses negative symptoms across five domains: affective blunting, alogia, avolition-apathy,
anhedonia-asociality, and attentional impairment. A trial conducted in 1999 evaluated two doses of amisulpride,&nbsp;50 and 100 mg per day, versus placebo for 12 weeks of treatment. In this trial, the two amisulpride-treated arms showed a reduction
in SANS of approximately 25 points compared with a reduction of 13 points in the placebo arm (p = 0.0002). A trial conducted in 1997 evaluated 100 mg per day of amisulpride versus placebo for 6 months of treatment. In this trial, the
amisulpride-treated arm showed a reduction in SANS of approximately 34 points compared with a reduction of 17 points in the placebo arm (p = less than 0.0005). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amisulpride in Mood Disorders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amisulpride has been studied extensively in mood disorders. A 2002
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial conducted by a third party found amisulpride to show similar reductions in mean MADRS scores as paroxetine (Paxil), a commonly used antidepressant and
a 2001 head-to-head trial conducted by a third party found amisulpride to show higher reduction in mean MADRS scores compared to sertraline (Zoloft), a commonly used antidepressant, in treating dysthymia, as shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g94g01.jpg" ALT="LOGO" STYLE="width:2.90278in;height:2.36221in;">
 </P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g94g02.jpg" ALT="LOGO" STYLE="width:2.90278in;height:2.36221in;">
 </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride was
demonstrated to be as effective as paroxetine and more effective than sertraline in third-party <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trials</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amisulpride has also been shown to be effective versus placebo, such as in a 1999 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial conducted by a third party in dysthymia and major depression, which showed amisulpride and another study drug each leading to a statistically significant
improvement over placebo on MADRS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g94g03.jpg" ALT="LOGO" STYLE="width:3.1812in;height:2.79017in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Amisulpride had an approximately <FONT STYLE="white-space:nowrap">4.8-point</FONT> MADRS delta versus
placebo in a randomized controlled third-party trial in patients with MDD</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-racemic</FONT>
version of amisulpride was studied in bipolar depression. In a 2022 placebo-controlled <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial conducted by a third party in 341 patients across U.S.,
European, and Japanese clinical sites, <FONT STYLE="white-space:nowrap">non-racemic</FONT> amisulpride demonstrated meaningful improvement over placebo on the MADRS in treating bipolar depression. Although the trial did not meet its primary
endpoint, which was defined as MADRS delta versus placebo in United States and European patients, when results were analyzed for all patients across all geographies, a statistically significant benefit versus placebo in favor of <FONT
STYLE="white-space:nowrap">non-racemic</FONT> amisulpride was noted with a 3.4 to <FONT STYLE="white-space:nowrap">3.7-point</FONT> MADRS delta versus placebo and an approximately <FONT STYLE="white-space:nowrap">18-point</FONT> reduction in MADRS
versus baseline in each of the two treatment arms. The mean reduction from baseline in the placebo arm in this trial was 14.3 points. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g05h01.jpg" ALT="LOGO" STYLE="width:4.81206in;height:2.0922in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">Non-racemic</FONT> amisulpride demonstrated anti-depressant activity in
two independent placebo controlled trials</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placebo rate observed in this trial was higher than the average placebo rate from a
recent set of bipolar depression trials, which was an approximately <FONT STYLE="white-space:nowrap">12-point</FONT> reduction in MADRS from baseline. We believe that the high placebo rate in this trial was in part a result of poor trial design and
conduct. A Phase 3 trial was subsequently initiated by the third party with <FONT STYLE="white-space:nowrap">non-racemic</FONT> amisulpride and though the trial was terminated prior to completion, results from 82 patients enrolled in the trial were
reported. These results showed a 4.0 to <FONT STYLE="white-space:nowrap">6.4-point</FONT> MADRS delta versus placebo and an approximately 14 to <FONT STYLE="white-space:nowrap">17-point</FONT> reduction in MADRS versus baseline in the two treatment
arms. Amisulpride and the <FONT STYLE="white-space:nowrap">non-racemic</FONT> form studied in these two trials have been shown to be substantially similar in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is widely recognized that episodes of major depression whether unipolar (as in MDD) or bipolar (as in bipolar depression) are characterized
by a similar imbalance in the neurotransmitters serotonin, noradrenaline, and dopamine, regardless of the underlying pathophysiology of the disease. Additionally, third party prescription data which we analyzed suggests that in 2023, there were at
least two&nbsp;million monthly prescriptions of amisulpride in a subset of 16 continental European countries with considerable use in depression and approximately 3.4% of prescriptions were written for bipolar disorder despite the absence of an
approval for this indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Amisulpride to be Addressed by <FONT STYLE="white-space:nowrap">LB-102</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While amisulpride is a clinically effective and well-tolerated drug, it has low BBB permeability that limits the amount of drug that can reach
its desired target. As reported in a 2014 third-party study of 30 psychiatric drugs tested in an <I>in vitro</I> assay to estimate BBB permeability, amisulpride was the least effective at crossing a model of the BBB. This low permeability is one of
the main factors that lead to high dosing of amisulpride, compared to other antipsychotic drugs, to achieve clinically meaningful BBB penetration. The recommended dose of amisulpride for acute schizophrenia ranges from 400 mg to 800 mg per day,
which may be increased up to 1,200 mg per day. By comparison, clinically effective doses of other antipsychotic drugs with similar affinities for dopamine receptors are often much lower (e.g., 1.5 mg of Vraylar and 4 mg of Rexulti). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high doses of amisulpride increase systemic exposure to the drug, contribute to some of its side effects, and limit its ability to be
formulated into an LAI &#8211; there are currently no LAIs approved among the benzamide class of antipsychotics. Another drawback of amisulpride is that it is typically dosed twice-daily, which can lead to lower adherence relative to therapies with
less frequent dosing schedules. Lower adherence can, in turn, lead to less efficacy of a drug in treating schizophrenia which can result in relapses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our </B><B><I></I></B><B>Solution: <FONT STYLE="white-space:nowrap">LB-102</FONT> for the Treatment of Schizophrenia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">LB-102</FONT> Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LB-102</FONT> is a patented benzamide designed to improve upon the safety and efficacy of amisulpride. In
creating <FONT STYLE="white-space:nowrap">LB-102,</FONT> we have added a methyl group to the chemical structure of amisulpride with the intention of improving its permeability of BBB while only minimally affecting receptor binding. We believe that
making this chemical change allows <FONT STYLE="white-space:nowrap">LB-102</FONT> to be dosed at lower amounts than amisulpride. By dosing at a lower level, we are aiming to decrease side effects common to amisulpride. This change to the chemical
structure also allows us to differentiate the dosing frequency of <FONT STYLE="white-space:nowrap">LB-102</FONT> from that of amisulpride. We are developing <FONT STYLE="white-space:nowrap">LB-102</FONT> for once-daily dosing, in contrast to the
typical twice-daily dosing of amisulpride. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart shows the molecular structures of amisulpride and <FONT
STYLE="white-space:nowrap">LB-102.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03r70.jpg" ALT="LOGO" STYLE="width:6.02667in;height:1.65333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">LB-102</FONT> is a methylated and patented derivative of amisulpride.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In Vitro Receptor Binding of <FONT STYLE="white-space:nowrap">LB-102</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In vitro</I> binding of <FONT STYLE="white-space:nowrap">LB-102</FONT> to target central nervous system, or CNS, receptors was found to be
similar to that of amisulpride. <FONT STYLE="white-space:nowrap">LB-102</FONT> bound most strongly to the dopamine D<SUB STYLE="font-size:75%; vertical-align:bottom">2 </SUB>and D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB> receptors,
with a K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 0.82 nM (compared to amisulpride&#8217;s reported K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 1.1 nM), and had a similar affinity for the <FONT
STYLE="white-space:nowrap">5-HT7</FONT> receptor with a K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 31 nM (compared to amisulpride&#8217;s reported K<SUB STYLE="font-size:75%; vertical-align:bottom">i</SUB> of 44 nM). Compared to
other commonly prescribed antipsychotic drugs, both <FONT STYLE="white-space:nowrap">LB-102</FONT> and amisulpride have weaker binding to other <FONT STYLE="white-space:nowrap">off-target</FONT> CNS receptors that are commonly associated with
adverse side effects such as anxiety, weight gain, or metabolic syndrome such as 5HT2C. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In Vivo Activity of
<FONT STYLE="white-space:nowrap">LB-102</FONT> is Similar to Amisulpride </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluated <FONT STYLE="white-space:nowrap">LB-102</FONT>
in the Locomotor Activity, or LMA, rat model of hyperactivity, often used to predict clinical activity in treating positive symptoms of schizophrenia. In the LMA, rats dosed with amphetamine alone displayed hypermobility, while rats additionally
dosed with antipsychotic drugs showed more normal, calmer activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">LB-102</FONT> had equivalent or
better results than similar doses of amisulpride in the LMA model of hyperactivity. In our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> preclinical rat model of cognition, the Novel Object Recognition
model, and in a mouse model of stereotypy or excessive repetition, the Apomorphine Induced Climbing model, we observed that the effects of treatment with <FONT STYLE="white-space:nowrap">LB-102</FONT> were statistically indistinguishable from that
of amisulpride. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Brain Penetration and Dopamine Receptor Occupancy of <FONT STYLE="white-space:nowrap">LB-102</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of <FONT STYLE="white-space:nowrap">LB-102</FONT> to cross the BBB was estimated using a standard<I> in vitro</I> membrane
permeability assay. In this assay, the permeability of <FONT STYLE="white-space:nowrap">LB-102</FONT> was approximately <FONT STYLE="white-space:nowrap">200-fold</FONT> greater than that of amisulpride. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An<I> in vivo </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study in mice using positron
emission tomography, or PET, demonstrated that at a dose of 100&nbsp;mg/kg of both <FONT STYLE="white-space:nowrap">LB-102</FONT> and amisulpride, <FONT STYLE="white-space:nowrap">LB-102</FONT> had greater dopamine receptor occupancy in the brain
than amisulpride, as shown below. We believe these results supported dosing <FONT STYLE="white-space:nowrap">LB-102</FONT> at much lower levels than amisulpride to achieve the desired effect on symptoms of schizophrenia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03r72.jpg" ALT="LOGO" STYLE="width:6.22in;height:2.14667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">LB-102</FONT> reduced the binding of a dopamine receptor PET ligand in
the brain by <FONT STYLE="white-space:nowrap">two-fold</FONT> compared to amisulpride. More faint luminescence represents greater dopamine receptor occupancy. %ID/g represents the percent injected dose per gram. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">LB-102</FONT> Clinical Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Completed Phase 1 </I></B><I></I><B><I>Trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in Healthy Volunteers </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a Phase 1, randomized, placebo-controlled, double-blinded clinical trial in the United States to evaluate the safety,
tolerability, and pharmacokinetics of oral administration of <FONT STYLE="white-space:nowrap">LB-102</FONT> in 64 healthy volunteers after submitting an IND in October 2019 and receiving approval to proceed in December 2019. In the single ascending
dose, or SAD, portion of this trial, cohorts of six volunteers received doses ranging from 10 mg up to 200 mg. In the multiple ascending dose, or MAD, portion of this trial, cohorts of six volunteers received doses of 50 mg to 100 mg twice-daily for
one week. In total, 48 volunteers were dosed with <FONT STYLE="white-space:nowrap">LB-102.</FONT> The following chart demonstrates the design of this Phase 1 trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g03a73.jpg" ALT="LOGO" STYLE="width:6.30554in;height:2.32095in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Design of the Phase 1 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in healthy volunteers. BID
= twice a day. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, we announced the clinical results of this Phase 1 trial. The half-life of <FONT
STYLE="white-space:nowrap">LB-102</FONT> was slightly greater than 12 hours, and maximum drug levels were observed approximately three hours after administration. We observed the plasma exposure of 50 mg of
<FONT STYLE="white-space:nowrap">LB-102</FONT> to be 1,648 ng/h/mL. In a previous third-party study of amisulpride, plasma exposure was reported at 667 ng/h/mL. The chart below shows the pharmacokinetic profile of
<FONT STYLE="white-space:nowrap">LB-102</FONT> in healthy volunteers from the SAD portion of this trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g03b73.jpg" ALT="LOGO" STYLE="width:5.28333in;height:4.19333in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Pharmacokinetics of <FONT STYLE="white-space:nowrap">LB-102</FONT> in healthy volunteers. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Analyses of the MAD portion of the trial demonstrated that peak-trough concentrations of <FONT STYLE="white-space:nowrap">LB-102</FONT>
plateaued before dosing on Day 4. <FONT STYLE="white-space:nowrap">LB-102</FONT> accumulated moderately after multiple doses but less than what has been reported for amisulpride. Exposure to <FONT STYLE="white-space:nowrap">LB-102</FONT> increased
in a dose-proportional manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this Phase 1 trial, <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well-tolerated. All
treatment emergent adverse effects, or TEAEs, were either mild or moderate. TEAEs included events typically associated with dopamine antagonists. At doses higher than those studied in our Phase 2 trial and which we plan to evaluate in our planned
Phase 3 trial, moderate dystonia and QT prolongation, which is a measure of delayed repolarization of the Q and the T waves in electrocardiogram were observed. Consistent with other antipsychotic drugs that act as dopamine antagonists, use of <FONT
STYLE="white-space:nowrap">LB-102</FONT> resulted in elevated serum prolactin levels. Subjects with moderate dystonia were treated with either Benadryl or Cogentin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the safety results of this clinical trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g20l82.jpg" ALT="LOGO" STYLE="width:6.32986in;height:2.93826in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>TEAEs observed in the Phase 1 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in healthy adults.
BID = twice a day. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At 50 mg, 75 mg, and 100 mg, the doses being evaluated in our Phase 2 trial, we observed no adverse events
associated with QT prolongation, sedation, weight gain or EPS in our Phase 1 trial. Prolactin elevation, a common laboratory finding of most antipsychotic drugs that act as dopamine antagonists that is believed to be the result of inhibition of
dopamine receptors in the pituitary, was observed at all doses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">QT prolongation refers to the lengthening of the QT interval in an
electrocardiogram, during which interval, the heart recovers from one heartbeat and is preparing for the next heartbeat. The QT interval is a vulnerable phase in the electric cycle of the heart, and prolongation of this interval may lead to serious
side effects. Amisulpride has been associated with QT prolongation. Although the mechanism linking amisulpride to this adverse event is not known, amisulpride is a weak inhibitor of human <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ether-a-go-go-related</FONT></FONT></FONT></FONT> gene (hERG) potassium channels, and it has been shown that QT prolongation is dependent on amisulpride
systemic exposure. At therapeutic doses of amisulpride up to 1,200 mg/day, literature reports of cardiac toxicity due to QT prolongation are extremely rare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Completed Phase 1b PET Imaging </I></B><I></I><B><I>Trial </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a Phase 1b dopamine receptor occupancy trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in the United States using PET
imaging to assess dopamine receptor occupancy in the brains of healthy volunteers. In this trial, the ability of <FONT STYLE="white-space:nowrap">LB-102</FONT> to bind to dopamine receptors was measured directly by displacement of the dopamine
receptor PET ligand <SUP STYLE="font-size:75%; vertical-align:top">11</SUP><FONT STYLE="white-space:nowrap">C-raclopride.</FONT> This trial enrolled four cohorts of healthy volunteers dosing from 50 mg to 100 mg per day. The first three cohorts in
this trial received a single dose of <FONT STYLE="white-space:nowrap">LB-102;</FONT> in the fourth cohort, volunteers were dosed once-daily for four days. Of the four healthy volunteers in the fourth cohort, two received one daily dose of 50 mg, and
two received one daily dose of 100 mg, each over four days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03a75.jpg" ALT="LOGO" STYLE="width:6.30555in;height:1.97929in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Design of the Phase 1b imaging trial of <FONT STYLE="white-space:nowrap">LB-102.</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We announced data from our Phase 1b trial in December 2021. We observed that single doses of <FONT STYLE="white-space:nowrap">LB-102</FONT>
led to a linear, dose-dependent dopamine receptor occupancy that achieved maximal levels at approximately eight hours post-dose and persisted for at least 24 hours, as shown in the figure below. Based on results from our 50 mg single-dose cohort, we
measured dopamine receptor occupancy at 48 hours for the 75 mg single-dose cohort. These results and the previously observed plasma half-life of approximately 12 hours supported our decision to develop <FONT STYLE="white-space:nowrap">LB-102</FONT>
for once-daily dosing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03b75.jpg" ALT="LOGO" STYLE="width:5.62667in;height:3.2in;">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>For cohorts one, two, and three,
single doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> led to dose-dependent dopamine receptor occupancy. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluated
dopamine receptor occupancy under steady-state conditions in our fourth dose cohort. We observed that the receptor occupancy following the Day 4 dose was relatively consistent over 24 hours in all four volunteers. Under steady-state conditions, at
the 50 mg dose of <FONT STYLE="white-space:nowrap">LB-102,</FONT> the average receptor occupancy was approximately 70%, and at the 100 mg dose, it was approximately 80%. Previous reports analyzing receptor occupancy of multiple antipsychotic drugs
have found that occupancies of 60% to 80% correlate with maximum efficacy and tolerability in the treatment of schizophrenia. Receptor occupancy above 80% can be associated with an increased risk of EPS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart depicts the dopamine receptor occupancy in the fourth cohort of our
Phase 1b trial. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03r76.jpg" ALT="LOGO" STYLE="width:6.24in;height:2.64in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dopamine receptor occupancy following repeat dosing of <FONT STYLE="white-space:nowrap">LB-102.</FONT> S1
and S2 indicate Subject #1 and Subject #2, respectively. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dopamine receptor occupancy persisted over 24 hours after the final dose of <FONT
STYLE="white-space:nowrap">LB-102</FONT> was administered under steady-state conditions and yielded a consistent engagement of dopamine receptors not always observed in other antipsychotic drugs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Completed</I></B><I></I><B><I> Phase 2 </I></B><I></I><B><I>Trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in Acute Schizophrenia
Patients </I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a four-week <FONT STYLE="white-space:nowrap">in-patient,</FONT> double-blind, randomized, placebo-controlled Phase 2 trial of <FONT
STYLE="white-space:nowrap">LB-102</FONT> for acute schizophrenia patients with total PANSS scores between 80 and 120, who have shown good response to previous antipsychotic drugs other than clozapine in the prior 12 months. The Phase 2 trial
enrolled 359 participants at 25 clinical trial sites in the United States, who were randomized 3:3:1:3 across four cohorts, three doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> and placebo (n=108). Prior to initiating dosing, patients
underwent a <FONT STYLE="white-space:nowrap">seven-day</FONT> <FONT STYLE="white-space:nowrap">wash-out</FONT> period, a length of time that an enrolled patient may not receive any treatment before they begin the trial. Because we were able to
achieve 70% receptor occupancy under steady-state conditions with a once-daily dose of 50 mg of <FONT STYLE="white-space:nowrap">LB-102,</FONT> we chose to advance this as the lowest dose in our Phase 2 trial (n=107 participants) while exploring the
potential of higher doses at 75 mg (n=108 participants) and 100 mg (n=36 participants). Based on previous results, we believed that there was a potential for the 100 mg dose to result in receptor occupancy above 80%. As a result, we chose to limit
the number of participants enrolled at this dose level while maintaining enough patients to provide insight into the therapeutic potential of this dose. Participants in each cohort received once-daily doses for four weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint of this trial was to evaluate the efficacy of the 50 mg and 75 mg doses of <FONT STYLE="white-space:nowrap">LB-102</FONT>
compared to the placebo, as measured by change from baseline in PANSS total score at four weeks. The secondary endpoints included change from baseline in the Clinical Global Impression-Severity, or <FONT STYLE="white-space:nowrap">CGI-S</FONT>
(which measures the severity of schizophrenia) as measured by clinicians, and change from baseline on the PANSS subscale and Marder factor scores at four weeks. The 100 mg dose cohort was exploratory and was intended to characterize safety at the
higher dose. However, we analyzed the 100 mg cohort with the same statistical rigor, including sensitivity analyses, applied to the 50 and 75 mg cohorts. We also evaluated the safety and pharmacodynamics of
<FONT STYLE="white-space:nowrap">LB-102.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart demonstrates the design of this Phase 2 trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g26j13.jpg" ALT="LOGO" STYLE="width:5.8558in;height:1.28373in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Design of the Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The topline results from the trial were announced in January 2025. Based on the design of this clinical trial, the results discussed below,
and recent positive feedback from FDA as part of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 interaction, we believe this Phase 2 trial may serve as one of two adequate well-controlled clinical
trials of <FONT STYLE="white-space:nowrap">LB-102</FONT> required for approval. However, there is no guarantee that will be the case. In addition to our planned <FONT STYLE="white-space:nowrap">6-week</FONT> Phase 3 trial, which we shared with the
FDA as part of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 interaction, we anticipate the FDA will require 1,500 patient exposures to support an approval in schizophrenia. We expect to accrue
these patient exposures through the registrational trial as well as an open-label trial that we expect to conduct concurrently with the Phase&nbsp;3 trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demographics and Patient Characteristics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 359 participants enrolled in this Phase 2 trial, 81% (n=290) were male and the average age was 39.1 years. Participants were diagnosed
with schizophrenia a minimum of two years prior to enrollment in the trial with an average time since diagnosis of 15.8 years. The baseline PANSS scores were balanced across all four cohorts with mean measurements of 93.8, 93.9, 93.6 and 93.9 for
the placebo, 50 mg, 75 mg and 100 mg cohorts, respectively. Acute schizophrenia is measured as 80 to 120 on the PANSS scale. If a patient drops below 80, they are no longer considered to be in the acute phase of the disease. There were several
psychiatric and neurological disorders diagnosed in greater than 5% of the participant population prior to the trial including insomnia (74.1%), anxiety (58.8%), depression (32.9%), agitation (30.1%), and headache (40.1%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also used the <FONT STYLE="white-space:nowrap">CGI-S</FONT> total score to measure the severity of schizophrenia in participants at
baseline and weekly for the four weeks of the trial. Using the <FONT STYLE="white-space:nowrap">CGI-S,</FONT> the investigator rated the participants&#8217; severity of illness, including behavior, symptoms, and function, over the past week on a
scale of one to seven, with seven being the most severe. All participants were categorized at least as moderately ill, or a 4 on the <FONT STYLE="white-space:nowrap">CGI-S</FONT> scale, with the majority of participants (range of 61.1% to 70.4%
across the four cohorts) categorized as being markedly ill, or a 5 on the <FONT STYLE="white-space:nowrap">CGI-S</FONT> scale, at baseline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g66z54.jpg" ALT="LOGO" STYLE="width:6.14027in;height:3.07013in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">CGI-S</FONT> Scores at baseline. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy Results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Primary Endpoint </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trial achieved the primary endpoint of change from baseline in PANSS total score at four weeks. The least squares mean change from
baseline at Week 4 was a <FONT STYLE="white-space:nowrap">14.3-point</FONT> decrease and <FONT STYLE="white-space:nowrap">14.0-point</FONT> decrease in PANSS score for the 50 mg and 75 mg cohorts, respectively. The exploratory 100 mg cohort showed a
<FONT STYLE="white-space:nowrap">16.1-point</FONT> decrease in PANSS total score at Week 4. The placebo cohort had a <FONT STYLE="white-space:nowrap">9.3-point</FONT> decrease in PANSS total score. We included a number of measures in this Phase 2
trial in order to reduce the risk of an elevated placebo rate including consistent, frequent, and close engagement with clinical sites, the use of a third-party vendor to help identify and exclude professional patients from the trial, and a
centralized review of PANSS ratings to ensure consistency and quality control throughout the trial. When adjusted for placebo-response, the 50 mg cohort achieved a five-point decrease (p=0.0009) and the 75 mg cohort achieved a <FONT
STYLE="white-space:nowrap">4.7-point</FONT> decrease (p=0.0022) in PANSS total score. Despite the highest dose cohort being exploratory and not sized to detect a statistically significant difference, the 100 mg cohort demonstrated a <FONT
STYLE="white-space:nowrap">6.8-point</FONT> decrease (nominal p=0.0017) in PANSS total score when adjusted for placebo, which did achieve statistical significance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g58d74.jpg" ALT="LOGO" STYLE="width:5.50391in;height:2.62926in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Least square (LS) mean change from baseline in PANSS total score. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in PANSS total score was observed as early as the first measurement on Day 8 with improvement seen through Week 4 across all
three dose cohorts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g93j60.jpg" ALT="LOGO" STYLE="width:5.63923in;height:3.06432in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Change in PANSS total score from baseline over time. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Week 4, the 50 mg, 75 mg, and 100 mg groups showed effect sizes of 0.61, 0.41, and 0.83, respectively, as highlighted in the table below.
Effect size is calculated by taking the difference in average observed PANSS change among completers between two groups (an active treatment arm and placebo) and dividing it by a single measure of variability that combines both groups&#8217;
spreads&#8212;also called the observed pooled standard deviation. The observed pooled standard deviation averages how much individual patients&#8217; score changes scatter around their group&#8217;s mean. Clinicians value effect size because it
conveys not just how large the average PANSS improvement is, but also how consistently patients respond. Even if two treatments reduce PANSS by the same amount on average, the one with less scatter (i.e., a lower observed pooled standard deviation)
will have a higher effect size&#8212;and gives a clinician more confidence that a higher proportion of patients will see that same benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><FONT STYLE="white-space:nowrap">Dose&nbsp;of&nbsp;LB-102</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;Size&nbsp;versus&nbsp;Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50&nbsp;mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75&nbsp;mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100&nbsp;mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Effect Size versus Placebo in our Phase 2 trial. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also calculated effect size versus placebo based on all patients with at least one post-baseline PANSS assessment combining both observed
and imputed data and yielding effect sizes of 0.50 at 50 mg, 0.45 at 75 mg, and 0.64 at 100 mg. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Secondary Endpoints </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within this trial, responders were defined as those who had a 20% or greater reduction in PANSS score at Week 4 (floor-adjusted). The three
dose cohorts achieved a responder rate of 31.9% (p=0.0587), 32.1% (p=0.0160), and 43.5% (p=0.0214) for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a responder rate of 18.3% for the placebo cohort. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also assessed response to treatment with <FONT STYLE="white-space:nowrap">LB-102</FONT> using PANSS subscales for positive and negative
symptoms, respectively. Looking specifically at positive symptom response, we observed a <FONT STYLE="white-space:nowrap">4.8-point</FONT> decrease (p=0.0051), <FONT STYLE="white-space:nowrap">4.9-point</FONT> decrease (p=0.0039), and <FONT
STYLE="white-space:nowrap">5.3-point</FONT> decrease (p=0.0120) in the PANSS subscale for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a <FONT STYLE="white-space:nowrap">3.1-point</FONT> decrease in the placebo cohort. When
looking at the negative symptom PANSS subscale, we observed a <FONT STYLE="white-space:nowrap">2.2-point</FONT> decrease (p=0.0116), <FONT STYLE="white-space:nowrap">1.7-point</FONT> decrease (p=0.1633), and
<FONT STYLE="white-space:nowrap">1.8-point</FONT> decrease (p=0.2632) in the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a <FONT STYLE="white-space:nowrap">1.1-point</FONT> decrease in the placebo cohort. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g23m57.jpg" ALT="LOGO" STYLE="width:5.51528in;height:2.49739in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>LS Mean change in PANSS score from baseline to Week 4 in positive subscale. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g15u24.jpg" ALT="LOGO" STYLE="width:5.43059in;height:2.46027in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>LS Mean change in PANSS score from baseline to Week 4 in negative subscale. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also conducted an exploratory <FONT STYLE="white-space:nowrap">post-hoc</FONT> analysis of our Phase 2 data on the treatment effect in
patients with negative symptoms at baseline (i.e., those patients with a PANSS Negative Subscore greater than or equal to 24). In patients with negative symptoms at baseline, the LS Mean change in negative symptom scores at Week 4 was <FONT
STYLE="white-space:nowrap">-1.6</FONT> (placebo), <FONT STYLE="white-space:nowrap">-3.4</FONT> (50 mg, &#916; <FONT STYLE="white-space:nowrap">-1.7,</FONT> p=0.0045 versus placebo; effect size=0.67), <FONT STYLE="white-space:nowrap">-2.6</FONT> (75
mg, &#916; <FONT STYLE="white-space:nowrap">-1.00,</FONT> p=0.1501, effect size=0.34), and <FONT STYLE="white-space:nowrap">-3.3</FONT> (100 mg, &#916; <FONT STYLE="white-space:nowrap">-1.70,</FONT> p=0.0658, effect size=0.60). Across all analyses,
the effect on negative symptoms was seen at the first measurement at week 1 and continued through Week 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using the <FONT
STYLE="white-space:nowrap">CGI-S</FONT> scale, participants in all three dose cohorts demonstrated an improvement in total scores from baseline to Week 4. We observed a <FONT STYLE="white-space:nowrap">0.72-point</FONT> decrease (p=0.0008), <FONT
STYLE="white-space:nowrap">0.67-point</FONT> decrease (0.0048), and <FONT STYLE="white-space:nowrap">0.84-point</FONT> decrease (0.0026) in the 50 mg, 75 mg, and 100 mg dose cohorts compared to a <FONT STYLE="white-space:nowrap">0.39-point</FONT>
decrease in the placebo cohort. With these changes, the majority of participants shifted from markedly ill <FONT STYLE="white-space:nowrap">(CGI-S</FONT> of 5) at baseline to moderately ill <FONT STYLE="white-space:nowrap">(CGI-S</FONT> of 4, range
of 45.8% to 65.2% of participants across all three dose cohorts) or mildly ill <FONT STYLE="white-space:nowrap">(CGI-S</FONT> of 3, range of 17.4% to 25.3% of participants across all three dose cohorts). A small number of participants (0% to 2.2%
across all three dose cohorts) achieved a <FONT STYLE="white-space:nowrap">CGI-S</FONT> score of 2, which is considered borderline mentally ill. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g11v99.jpg" ALT="LOGO" STYLE="width:5.40237in;height:2.43107in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>LS mean change in <FONT STYLE="white-space:nowrap">CGI-S</FONT> total score from baseline to Week 4.
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g75h77.jpg" ALT="LOGO" STYLE="width:4.43004in;height:2.22181in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Shift in <FONT STYLE="white-space:nowrap">CGI-S</FONT> Score from baseline (shadowed colors) to Week 4
(solid colors). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also used the PANSS Marder factor, a way to analyze the PANSS data to identify responses in different dimensions
of schizophrenia, including positive symptoms, disorganized thought, uncontrolled hostility/excitement, negative symptoms and anxiety/depression. PANSS Marder is a way to group the 30 individual items of the PANSS into five broader categories or
dimensions. This factor structure is widely used in clinical trials and research to assess and analyze symptoms of schizophrenia. Statistically significant reductions were seen from baseline to Week 4 for all three dose cohorts for positive
symptoms, disorganized thought and uncontrolled hostility/excitement. Numerical reductions, which did not reach statistical significance, were observed from baseline to Week 4 for all three dose cohorts for negative symptoms and anxiety/depression.
These findings are depicted below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g56v34.jpg" ALT="LOGO" STYLE="width:1.21483in;height:2.16958in;">



<IMG SRC="g12080g16t96.jpg" ALT="LOGO" STYLE="width:1.21141in;height:2.16958in;">



<IMG SRC="g12080g27v96.jpg" ALT="LOGO" STYLE="width:1.21483in;height:2.16958in;">



<IMG SRC="g12080g59s60.jpg" ALT="LOGO" STYLE="width:1.21141in;height:2.16958in;">



<IMG SRC="g12080g42a80.jpg" ALT="LOGO" STYLE="width:1.21483in;height:2.16958in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Change in PANSS Scores from baseline to Week 4 for each of the five Marder factors; * P&lt;0.05, **
P&lt;0.01 versus placebo. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety and Tolerability Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 2 trial, <FONT STYLE="white-space:nowrap">LB-102</FONT> was generally well tolerated. Safety was assessed through TEAEs, and EPS
was assessed through TEAEs as well as the Simpson-Angus Scale, or SAS, the Barnes Akathisia Rating Scale, or BARS, and the Abnormal Involuntary Movement Scale, or AIMS. The majority of TEAEs were mostly transient and mild to moderate in severity.
TEAEs were defined as any adverse event that began on or after the first dose of trial medication, or any <FONT STYLE="white-space:nowrap">pre-existing</FONT> condition that reappeared during the treatment period and up to 14 days following the last
dose. TEAEs were reported in 56% (placebo), 69% (50 mg), 57% (75 mg), and 75% (100 mg) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of participants. The most commonly reported TEAEs were psychiatric neurological conditions that many participants were experiencing at the time of enrollment. Weight increase was the only TEAE to
occur in at least 5% of the total population and at a rate at least twice that observed with placebo <FONT STYLE="white-space:nowrap">(LB-102</FONT> 50 mg at 12.1%; <FONT STYLE="white-space:nowrap">LB-102</FONT> 75 mg at 7.4%; <FONT
STYLE="white-space:nowrap">LB-102</FONT> 100 mg at 8.3%; placebo at 3.7%). This TEAE includes any weight increase without a threshold. Over the course of the trial, we observed approximately 1.6 kg placebo-adjusted weight gain on a last observation
carried forward basis. Despite the weight gain observed in the four-week trial, no clinically meaningful signal in metabolic parameters such as cholesterol, LDL, HDL, triglycerides or fasting glucose were observed. The discontinuation rate reached
18% during the treatment period (four weeks) and 27% when taking into account up to 14 days following the last dose. The most common comorbid medical conditions at baseline were insomnia (74.1%), anxiety (58.8%), headache (40.1%), depression
(32.9%), and agitation (30.1%). Comorbid conditions at study entry enriched the reporting of TEAEs in our trial. Because TEAEs were defined as any adverse event that began on or after the first dose of trial medication, or any <FONT
STYLE="white-space:nowrap">pre-existing</FONT> condition that reappeared during the treatment period and up to 14 days following the last dose, the rates of certain AEs, such as insomnia, appear elevated in both placebo and <FONT
STYLE="white-space:nowrap">LB-102</FONT> patients. Change from baseline to Week 4 in SAS, AIMS, and BARS demonstrated no difference between treatment arms and placebo. The following table summarizes the adverse events from the trial: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Adverse Events</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>50 mg<BR>(N=107)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>75 mg<BR>(N=108)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>100&nbsp;mg<BR>(N=36)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Placebo&nbsp;(N=108)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insomnia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">27&nbsp;(25.2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">23&nbsp;(21.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">14&nbsp;(38.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">24&nbsp;(22.2%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Headache</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12&nbsp;(11.2%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9 (8.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10 (9.3%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anxiety</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10&nbsp;(9.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9&nbsp;(8.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4 (11.1%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9 (8.3%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11&nbsp;(10.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6&nbsp;(5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4 (11.1%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10 (9.3%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weight increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">13&nbsp;(12.1%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8&nbsp;(7.4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 (8.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4 (3.7%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hyperprolactinemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11&nbsp;(10.3%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8&nbsp;(7.4%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6 (16.7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blood creatine phosphokinase increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4&nbsp;(3.7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 (2.8%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alanine aminotransferase increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3&nbsp;(2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.9%)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Somnolence</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4&nbsp;(3.7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Constipation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4&nbsp;(3.7%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>TEAEs reported in 5% or more of patients in any cohort. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ten participants reported TEAEs leading to withdrawal, including two in each of the placebo and 50 mg cohorts as well as three in each of the
75 mg and 100 mg cohorts. There were five reported serious adverse events, or SAEs, overall with two SAEs in the placebo cohort (psychotic disorder and death), one SAE in the 50 mg cohort (suicidal ideation &#8211; deemed possibly related to
treatment), one SAE in the 75 mg cohort (dystonia &#8211; deemed possibly related to treatment) and one SAE in the 100 mg cohort (psychotic disorder &#8211; deemed not related to treatment). The incidence of TEAEs was similar across groups, with
most events being mild or moderate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the frequency of certain adverse events associated with schizophrenia
medications, we identified adverse events of special interest, including EPS, sedation, adverse events associated with a prolactin increase, and QT interval corrected for heart rate, or QTcF, prolongation. These adverse events are depicted in the
tables below. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EPS </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="9"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Number of subjects (% of treatment
group)</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50 mg<BR>(N=107)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75 mg<BR>(N=108)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100&nbsp;mg<BR>(N=36)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N=108)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Dystonia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3&nbsp;(2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Akathisia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (1.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.9%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Extrapyramidal disorder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (1.9%)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total EPS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (1.0%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4 (3.7%)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related to prolactin increase </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="9"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Number of subjects (% of treatment
group)</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50 mg<BR>(N=107)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75 mg<BR>(N=108)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100 mg<BR>(N=36)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N=108)</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Galactorrhea</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2&nbsp;(1.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Breast enlargement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Erectile dysfunction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (2.8%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total related to Prolactin</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (1.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1 (0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sedation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Number of subjects (% of treatment
group)</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Preferred Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50 mg<BR>(N=107)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75 mg<BR>(N=108)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100&nbsp;mg<BR>(N=36)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N=108)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sedation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1&nbsp;(0.9%)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0</TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>QTcF Prolongation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>QTcF from Baseline at Day 28
(ms)</I></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50 mg<BR>(N=107)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>75 mg<BR>(N=108)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>100&nbsp;mg<BR>(N=36)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Placebo<BR>(N=108)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Baseline</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">393.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">394.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">390</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">393.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Day 28</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>4.9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>4.3</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>5.4</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>1.7</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stopping criteria not met at any dose
</B></P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exploratory Endpoints </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also included a measure of cognition as an exploratory endpoint in our Phase 2 trial. This analysis utilized the CogState Computerized
Schizophrenia Battery of Tests, a well validated measure of cognitive ability in subjects with schizophrenia. Patients had one practice session during the screening visit and completed the actual test on the first day of treatment (Day 1), the
baseline assessment, and again on the last day of treatment (Day 28), the final assessment. The CogState battery utilized in our Phase 2 trial consisted of five tests designed to evaluate psychomotor function, memory, attention, working memory, and
executive function. Test completion rate, one measure of quality control, was greater than or equal to 99% for each test across baseline and Day 28 visits. The test performance pass rate, another metric of quality control where data for a complete
test is compared to expected rates of performance, was generally high for each test, with rates ranging from 93.6% to 99.4%. As part of our analysis of this data and consistent with other published literature utilizing the same CogState battery of
tests, we conducted a post-hoc analysis in which we computed a global composite effect size, or overall improvement in cognition, versus placebo after excluding certain outliers that did not meet the test performance pass quality control metric.
After excluding these outliers, the analysis was completed in all patients and did not enrich for patients with higher levels of cognitive impairment at baseline. After 4 weeks of treatment with <FONT STYLE="white-space:nowrap">LB-102,</FONT> a
robust, dose-dependent, and significant treatment effect size was identified in the completer population for all doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> compared with placebo. Results of this analysis are highlighted in the table
below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Dose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;Size&nbsp;versus&nbsp;Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>p-value</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>n</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50 mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.0476</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">84</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75 mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.0027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">74</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 mg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.0018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">20</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the magnitude of cognitive improvement and dose-dependent effect observed in this trial
supports the further evaluation of the potential cognitive impacts of <FONT STYLE="white-space:nowrap">LB-102</FONT> in schizophrenia including in patients who have been stabilized with respect to positive symptoms of the disease. We also expect to
study cognition in other diseases where cognitive impairment is well recognized to be a domain of the disease, including bipolar depression. We are also encouraged by the improvements observed in cognition in this trial and intend to further
investigate the effects of <FONT STYLE="white-space:nowrap">LB-102</FONT> on cognition in both schizophrenia and bipolar depression. Improvements in cognition, if replicated in our subsequent clinical trials, have the potential to further support
the differentiation of <FONT STYLE="white-space:nowrap">LB-102.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Planned Phase 3 Trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in
Acute Schizophrenia and Additional <FONT STYLE="white-space:nowrap">NDA-Enabling</FONT> Studies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning to initiate a <FONT
STYLE="white-space:nowrap">six-week</FONT> Phase 3 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in participants with acute schizophrenia in the first quarter of 2026, which, if positive, may be sufficient to support a regulatory approval
application along with our Phase 2 trial and other planned <FONT STYLE="white-space:nowrap">NDA-enabling</FONT> studies. The Phase 3 trial is anticipated to be a <FONT STYLE="white-space:nowrap">three-arm,</FONT> inpatient, double-blinded,
placebo-controlled, oral once-daily dose of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with acute schizophrenia, with a <FONT STYLE="white-space:nowrap">six-week</FONT> treatment duration. We plan to study the effects of 50 mg <FONT
STYLE="white-space:nowrap">LB-102</FONT> or 100 mg <FONT STYLE="white-space:nowrap">LB-102</FONT> versus placebo in this trial, and patients will be randomized in a 1:1:1 ratio across the three arms of the trial. The sample size will be
approximately 400 patients, and we plan to conduct this trial entirely in the United States at approximately 25 sites, a similar number of sites as were utilized in our Phase 2 acute schizophrenia trial. We expect there to be significant overlap
between the sites utilized in our Phase 2 trial and those we plan to utilize in the Phase 3 trial. The primary endpoint of the trial is anticipated to be change from baseline in PANSS at Day 42. To mitigate the risk of an elevated placebo response
in this trial, we expect to employ the same strategies which proved effective in our Phase 2 acute schizophrenia trial including consistent, frequent, and close engagement with clinical sites, the use of two third-party vendors (including the one
used in our Phase 2 trial) to help identify and exclude professional patients from the trial, and a centralized review of PANSS ratings to ensure consistency and quality control throughout the trial. Secondary endpoints will include <FONT
STYLE="white-space:nowrap">CGI-S,</FONT> PANSS positive and negative subscales, Marder factor scores, the Personal and Social Performance Scale, or PSP, and cognition as well as safety and tolerability. We believe that the <FONT
STYLE="white-space:nowrap">6-week</FONT> duration of this Phase 3 trial has the potential to further improve PANSS reductions observed following treatment with <FONT STYLE="white-space:nowrap">LB-102</FONT> given that in our Phase 2 trial, the PANSS
score in the <FONT STYLE="white-space:nowrap">LB-102</FONT> treated arms declined at a faster rate than placebo through the <FONT STYLE="white-space:nowrap">28-day</FONT> duration of our Phase 2 trial. We expect to report topline data from the trial
in the second half of 2027. Concurrently with the Phase 3 trial we expect to run an outpatient, open label trial to accrue the requisite safety population required to support NDA submission as well as other clinical and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies typically required by FDA at the time of approval. To support approval, the safety population must include at least 1,500 cumulative patient exposures to LB-102, including at least 100 patients
with greater than or equal to one year of exposure and 300 patients with greater than or equal to six months of exposure. As a result, we expect to enroll approximately 900 patients in our planned open label safety trial. If our Phase 3 trial is
positive, we plan to hold a <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting with the FDA in the first quarter of 2028 to seek agreement from FDA on the suitability of our data to support an NDA submission for the treatment of schizophrenia
with potential for submission of such NDA thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bipolar Depression </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview and Disease Background </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">People living with bipolar depression experience extreme shifts in mood, energy, and behavior, alternating between manic and depressive states.
There are two types of bipolar disorder, distinguished as bipolar 1 and 2, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which are characterized by chronically occurring episodes of mania or hypomania alternating with depression. To be diagnosed with bipolar 1 disorder, a person must experience a manic episode
defined as a distinct period of persistently elevated or irritable mood with increased activity or energy lasting for at least seven days or requiring hospitalization. The manic episode may be preceded or followed by a hypomanic or major depressive
episode. A bipolar 2 disorder diagnosis is based on experiencing hypomanic episode and major depressive episode without a manic episode. Manic episodes are markedly more severe than hypomanic episodes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">People experiencing a manic episode may have a highly inflated sense of self-worth or self-esteem, talk quickly and rapidly shift from one
idea to the next, have trouble concentrating, be easily distracted, have a decreased need for sleep, engage in reckless or risk-taking behavior and have a fixed or mistaken grandiose or persecutory belief. During a depressive episode, a person may
experience poor concentration, feelings of excessive guilt or low self-worth, hopelessness about the future, thoughts of dying or suicide, disrupted sleep, changes in appetite or weight and feeling very tired or low in energy. For those living with
bipolar disorder, an estimated 82.9% have serious impairment due to the disease, the highest percent of serious impairment among all mood disorders, indicating there is significant need for new and better treatment options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Current Treatments for Bipolar Depression </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Worldwide, it is estimated that 40&nbsp;million people live with bipolar disorder. In the United States, an estimated 2.8%, or approximately
seven&nbsp;million people, experience bipolar disorder in a given year. Stigma and discrimination against people with bipolar disorder are widespread, which can undermine access to treatment. Although with proper treatment, recovery is possible.
Mood stabilizers and antipsychotic drugs which are the mainstay for treatment of bipolar disorder, have been shown to help manage periods of acute mania as well as depression. Based on third-party market research conducted for us, an important
advantage of certain antipsychotic drugs in the treatment of bipolar depression is the ability to control depressive symptoms while preventing the emergence of mania. Antidepressants, such as selective serotonin reuptake inhibitors, can be effective
in controlling depressive symptoms but also carry a risk of triggering manic events and therefore are typically reserved for later lines of therapy. This market research, together with an advisory board that we held, also highlight unmet needs in
the treatment of bipolar depression. These unmet needs include fewer adverse events, better efficacy, including improvements in cognition and anhedonia, improved compliance to treatment, and a desire for therapies with novel mechanisms of action.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution: <FONT STYLE="white-space:nowrap">LB-102</FONT> for the Treatment of Bipolar Depression </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our clinical development program in schizophrenia, we plan to leverage our expertise in neuropsychiatry and the unique mechanism
of action of <FONT STYLE="white-space:nowrap">LB-102</FONT> for further development in bipolar depression. If successful in bipolar depression, we may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> in MDD. In the future, we may also
develop <FONT STYLE="white-space:nowrap">LB-102</FONT> for other psychiatric disorders, including schizophrenia with predominantly negative symptoms, psychosis and agitation in Alzheimer&#8217;s disease, manic episodes of bipolar disorder, as well
as CIAS. We plan to initiate a registrational-quality randomized Phase 2 trial in this indication in the first quarter of 2026, with topline data expected in the first quarter of 2028. Our initial Phase 2 trial will explore the utility of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in controlling the depressive symptoms of the disease. We may also develop <FONT STYLE="white-space:nowrap">LB-102</FONT> as a potential treatment for the manic episodes of bipolar disorder in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> strong antagonism of the D<SUB
STYLE="font-size:75%; vertical-align:bottom">2</SUB>, D<SUB STYLE="font-size:75%; vertical-align:bottom">3</SUB>, and 5HT7 receptors makes it well suited for treating bipolar depression, providing potential to control psychosis and mania through its
effects on D<SUB STYLE="font-size:75%; vertical-align:bottom">2 </SUB>and potential for antidepressive and <FONT STYLE="white-space:nowrap">pro-cognitive</FONT> effects through its antagonism of 5HT7 and D<SUB
STYLE="font-size:75%; vertical-align:bottom">3</SUB>. Our Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in acute schizophrenia demonstrated strong antipsychotic activity and suggests opportunities for potential differentiation in
bipolar depression given the observed tolerability profile (low rates of EPS, sedation, and gastrointestinal side effects) and positive impact on cognition. Amisulpride is approved for the treatment of dysthymia, a form of depression, in certain
countries outside of the United States and has been shown to be as effective as certain approved agents for MDD and dysthymia. We believe that results in dysthymia and MDD </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide strong scientific and clinical rationale for development of LB-102 in the treatment of depressive episodes associated with bipolar disorder or bipolar depression because episodes of major
depression, whether unipolar (as in MDD) or bipolar (as in bipolar depression), are typically characterized by a similar imbalance in the neurotransmitters serotonin, noradrenaline, and dopamine, regardless of the underlying pathophysiology of the
disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, among the four antipsychotics currently approved for schizophrenia and MDD or treatment resistant depression that
were also studied in late-stage bipolar depression trials (quetiapine, cariprazine, aripiprazole, and olanzapine), three out of four, or 75%, generated positive data for the treatment of bipolar depression. There is also widespread use of
amisulpride in bipolar disorder with approximately 3.4% of at least two million monthly prescriptions in Europe written for this indication. A <FONT STYLE="white-space:nowrap">non-racemic</FONT> form of amisulpride showed strong antidepressant
activity in two independent third-party, placebo-controlled bipolar depression trials with an approximately 17 to <FONT STYLE="white-space:nowrap">18-point</FONT> reduction in MADRS from baseline observed in each trial. The <FONT
STYLE="white-space:nowrap">non-racemic</FONT> form of amisulpride has been shown to be substantially similar to amisulpride in preclinical models. Our planned Phase 2 trial for bipolar depression will utilize a fixed-flexible dose of <FONT
STYLE="white-space:nowrap">LB-102.</FONT> This trial design allows us to evaluate two doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> in the trial, thereby increasing the chances for a patient to derive clinical benefit from treatment with <FONT
STYLE="white-space:nowrap">LB-102,</FONT> while retaining the advantages of a <FONT STYLE="white-space:nowrap">two-arm</FONT> trial, which is known to mitigate the risk of a high placebo rate. Additionally, flexible dose trials typically have better
signal detection than fixed dose trials for depression, as flexible dose trials lower the magnitude of symptom reduction with placebo. We believe <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to provide improved tolerability and
clinical activity in bipolar depression compared to currently available treatments worldwide, which are associated with troubling adverse events and insufficient efficacy for certain symptoms, including cognitive impairment associated with the
disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Planned Phase 2 Trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in Bipolar Depression </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning to initiate a Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> in participants with depressive episodes
associated with bipolar 1 disorder or bipolar depression in the first quarter of 2026, which, if positive, could potentially support a regulatory pathway along with an additional Phase 3 trial for the treatment of bipolar depression as a
monotherapy. We plan to report topline data for this trial in the first quarter of 2028 and, subject to positive results from that trial, meet with the FDA to discuss trial results at an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting thereafter. The Phase 2 trial is designed to be an outpatient, <FONT STYLE="white-space:nowrap">two-arm,</FONT> double-blinded, placebo-controlled, oral, once-daily fixed-flexible dose
of <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients with depressive episodes associated with bipolar 1 disorder, with <FONT STYLE="white-space:nowrap">six-week</FONT> treatment duration. We plan to enroll approximately 320 patients and
conduct this trial entirely in the United States at approximately 30 sites. Patients will be randomized in a 1:1 ratio to <FONT STYLE="white-space:nowrap">LB-102</FONT> or placebo. Across most atypical antipsychotics, bipolar depression doses are
usually approximately 50% lower than schizophrenia doses to keep D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB> receptor occupancy at a level that lowers the potential for EPS yet high enough for antidepressant benefit. This is the
dosing model that was used by Vraylar and Latuda, both of which are approved for schizophrenia and bipolar depression. In contrast, Caplyta, another drug approved for use in both schizophrenia and bipolar depression, utilized the same dose in both
indications, in part because of its low rates of EPS. In selecting doses for our Phase 2 trial, we are blending these two paradigms. We plan to initiate all patients on half the lowest dose used in our acute schizophrenia trial (25 mg). Importantly,
we believe that results of our Phase 2 acute schizophrenia trial, which demonstrated &lt;1% EPS and no sedation even at 50 mg, provide us an opportunity to explore that dose in bipolar depression similar to Caplyta, which used a single dose across
both indications. All patients randomized to receive <FONT STYLE="white-space:nowrap">LB-102</FONT> will begin treatment at 25 mg for the first three weeks of the trial. At the end of Week 3, if a patient has not improved based on a protocol guided
set of specific items in the Clinical Global Impression-Bipolar Illness, or <FONT STYLE="white-space:nowrap">CGI-BP,</FONT> scale and the patient is tolerating the drug, the dose of <FONT STYLE="white-space:nowrap">LB-102</FONT> will be increased in
this patient to 50 mg for the remaining three weeks of the trial, subject to an allowance for up to one dose reduction for safety reasons. This trial design allows us to evaluate two doses of <FONT STYLE="white-space:nowrap">LB-102</FONT> in the
trial, thereby increasing the chances for a patient to derive clinical benefit from treatment with <FONT STYLE="white-space:nowrap">LB-102,</FONT> while retaining the advantages of a <FONT STYLE="white-space:nowrap">two-arm</FONT> trial, which is
known to mitigate the risk of a high placebo rate. The primary endpoint is expected to be <FONT STYLE="white-space:nowrap">MADRS-10</FONT> and will compare all <FONT STYLE="white-space:nowrap">LB-102</FONT> treated patients regardless of the dose
received versus placebo. Secondary endpoints are expected to include <FONT STYLE="white-space:nowrap">MADRS-6,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CGI-BP-S,</FONT></FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cognition, anhedonia, as well as safety and tolerability. We have designed this trial to highlight what we believe will be differentiating attributes of
<FONT STYLE="white-space:nowrap">LB-102</FONT> in bipolar depression. Specifically, we are targeting competitive <FONT STYLE="white-space:nowrap">MADRS-10</FONT> versus other approved agents, improved tolerability as evidenced by lower rates of
sedation and gastrointestinal side effects compared with other approved agents, a rate of EPS consistent with or lower than what we observed in our schizophrenia Phase 2 trial, and the potential to demonstrate improvements in anhedonia and cognition
versus placebo, which we believe could address important unmet needs in this disease. Following a successful Phase 2 trial, we believe that a single additional Phase 3 trial could support an approval for LB-102 as a monotherapy to treat bipolar
depression. We expect an additional Phase 3 trial to be required to support approval as an adjunctive therapy for bipolar depression. Based on historical precedent, we expect to be able to utilize the safety dataset that we generate from our open
label acute schizophrenia trial to support a potential approval for LB-102 in bipolar depression as the doses utilized in our bipolar depression trial will be equivalent to or lower than those utilized in our acute schizophrenia trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Flexible dose trials typically have better signal detection than fixed dose trials for depression. A third-party study from 2003 examined if
the dosing schedule (either a fixed dose or a flexible dose), in an antidepressant clinical trial affects the frequency with which antidepressants show statistical superiority over placebo. In flexible dose trials, 59.6% (34/57) of the
antidepressant treatment arms were statistically significant compared to placebo. In contrast, in the fixed dose trials, only 31.4% (11/35) of the antidepressant treatment arms were statistically significant compared to placebo. These data suggest a
significantly lower magnitude of symptom reduction with placebo in flexible dose trials compared to fixed dose trials. To further reduce the potential for an elevated placebo rate, we expect to employ many of the same strategies which proved
effective in our Phase 2 acute schizophrenia trial including consistent, frequent, and close engagement with clinical sites, the use of two third-party vendors (including the one used in our Phase 2 trial) to help identify and exclude professional
patients from the trial, and a centralized review of MADRS ratings to ensure consistency and quality control throughout the trial. We also expect to utilize remote structured assessments to enhance enrollment precision in our clinical trial, which
has been shown to reduce placebo response rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Development </B><B><I></I></B><B>Opportunities of
<FONT STYLE="white-space:nowrap">LB-102</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Additional Indications for <FONT STYLE="white-space:nowrap">LB-102</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to schizophrenia and bipolar depression, we are exploring the possibility of testing <FONT STYLE="white-space:nowrap">LB-102</FONT>
in other neuropsychiatric disorders, such as major depressive disorder, psychosis and agitation in Alzheimer&#8217;s disease, predominantly negative symptoms of schizophrenia, and CIAS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on existing third-party data investigating amisulpride and a <FONT STYLE="white-space:nowrap">non-racemic</FONT> form of the drug as a
treatment for several types of depression and the approval of amisulpride in multiple countries outside of the United States for the treatment of dysthymia, a form of depression, we are exploring the potential to study
<FONT STYLE="white-space:nowrap">LB-102</FONT> in major depressive disorder. It is estimated that there are approximately 20&nbsp;million people suffering from MDD in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also assessing <FONT STYLE="white-space:nowrap">LB-102</FONT> as a potential treatment for psychosis and agitation in Alzheimer&#8217;s
disease. A third-party clinical trial published in 2018 in The Lancet studying the efficacy of amisulpride in treating elderly patients with very late-onset schizophrenia-like psychosis showed that over 12 weeks, there was a statistically
significant <FONT STYLE="white-space:nowrap">7.7-point</FONT> improvement in the BPRS (Brief Psychiatric Rating Scale, a prior iteration of the PANSS) for amisulpride as compared to placebo. Importantly, amisulpride was well-tolerated in this
vulnerable elderly population, where the average age in this trial was 81. Another third-party clinical trial, published in 2017, explored dose levels of <FONT STYLE="white-space:nowrap">off-label</FONT> use of amisulpride in treating older people
with Alzheimer&#8217;s disease-related psychosis. The clinical trial showed a reduction in symptoms was associated with amisulpride concentration and D<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>/D<SUB
STYLE="font-size:75%; vertical-align:bottom">3</SUB> occupancy. To further investigate the potential of <FONT STYLE="white-space:nowrap">LB-102</FONT> in Alzheimer&#8217;s disease, we will need to conduct a Phase 1 trial to evaluate the safety of <FONT
STYLE="white-space:nowrap">LB-102</FONT> in a healthy elderly population (aged 65 and older). It is estimated that approximately 40% of the approximately seven&nbsp;million Americans with Alzheimer&#8217;s disease experience psychosis or agitation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our current schizophrenia clinical program is designed to investigate <FONT
STYLE="white-space:nowrap">LB-102</FONT> as a treatment for people experiencing the acute phase, or positive symptoms, of schizophrenia, we believe <FONT STYLE="white-space:nowrap">LB-102</FONT> also has potential to address predominantly negative
symptoms based on the results from our Phase 2 trial and clinical experience to date with amisulpride, an indication with significantly fewer treatment options. Amisulpride demonstrated a statistically significant benefit versus placebo in three
independent third-party placebo-controlled trials in patients with predominantly negative symptoms with treatment durations ranging from six weeks to six months. We are also encouraged by the magnitude of the cognitive benefit we have observed to
date in our schizophrenia trials and are also assessing the potential to study <FONT STYLE="white-space:nowrap">LB-102</FONT> as a treatment for cognitive impairment of schizophrenia, an indication for which there are no approved therapies. In both
negative symptoms of schizophrenia and CIAS, we will need to study <FONT STYLE="white-space:nowrap">LB-102</FONT> in patients who have been stabilized with respect to the positive symptoms of their disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential New Formulations of <FONT STYLE="white-space:nowrap">LB-102</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also developing an LAI formulation of <FONT STYLE="white-space:nowrap">LB-102,</FONT> which may improve treatment compliance, a common
issue in patients with schizophrenia and bipolar disorder. <FONT STYLE="white-space:nowrap">LB-102&#8217;s</FONT> consistent dopamine receptor engagement over 24 hours and the lower administered dose may allow
<FONT STYLE="white-space:nowrap">LB-102</FONT> to be administered as an LAI. We believe an effective LAI form of <FONT STYLE="white-space:nowrap">LB-102</FONT> has the potential to benefit patients worldwide, as relatively few approved agents are
available as long-acting formulations. The American Psychiatric Association recommends injectable formulations in circumstances where doing so will improve adherence, decrease mortality, reduce hospitalization risk, and decrease treatment
discontinuation rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe LAI formulations can have additional benefits in treating symptoms of schizophrenia, such as consistent
drug exposure, which is potentially beneficial compared to orally dosed antipsychotic drugs, as it relieves the requirement for patients or their caregivers to rely on often self-enforced daily oral dosing to maintain efficacy. The latest guidance
from the American Psychiatric Association calls for the use of LAI with patients who have a history of poor adherence. Using LAI antipsychotic drugs to treat schizophrenia patients may decrease mortality risk, reduce hospitalization risk, and
decrease rates of treatment discontinuation. We believe such a formulation of <FONT STYLE="white-space:nowrap">LB-102</FONT> would potentially benefit patients both in the United States and globally. We have commenced LAI formulation development and
expect to continue these efforts in 2026. We believe that the success of the 50 mg dose in our Phase 2 acute schizophrenia trial affords the opportunity to develop an LAI. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schizophrenia is one of the top 15 leading causes of disability in the world and affects approximately 3&nbsp;million Americans, or
approximately 1% of the U.S. population. The United States market for branded antipsychotic drugs in 2024 was approximately $12&nbsp;billion, where despite the widespread use of generic drugs, several branded antipsychotic drugs each generate sales
in excess of $1&nbsp;billion per year. The chart below depict the United States market share of branded antipsychotic drugs in the United States for 2024 in terms of revenue. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g24d83.jpg" ALT="LOGO" STYLE="width:3.10712in;height:2.43168in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>United States market for branded antipsychotic drugs &#8211; 2024. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the schizophrenia drugs with greater than $1&nbsp;billion in sales, all have approvals in additional indications beyond schizophrenia,
such as mood disorders. In addition, these drugs generally received their initial approval in schizophrenia prior to their approvals in mood disorders. It is well recognized that in the United States, antipsychotic drugs have higher prices than
antidepressants, such as the selective serotonin reuptake inhibitors. Vraylar, Abilify, Rexulti, and Caplyta are approved in the United States for the treatment of schizophrenia in adults. Beyond schizophrenia, Vraylar, Abilify, and Caplyta are
approved for the treatment of bipolar depression. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The high incidence of schizophrenia, inadequate clinical response, and side effects from
current therapeutics lead to a discontinuation rate of 74% within 18 months of treatment and present a clear market opportunity for more effective schizophrenia drugs that are well-tolerated. Switching treatment is also common in bipolar depression.
For example, market research that we conducted suggests that approximately 61% of bipolar depression patients have switched therapies at least once. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g03l46.jpg" ALT="LOGO" STYLE="width:6.32in;height:2.67747in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Several factors, including new diagnoses, inadequate responses, and high discontinuation rates contribute
to a significant market opportunity for effective schizophrenia drugs. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, data from 2023 show that despite limited
marketing efforts, there were at least two&nbsp;million annual prescriptions for amisulpride in the European Union. We believe that amisulpride&#8217;s continued use as an agent for the treatment of schizophrenia outside of the United States over
the past 25 years supports the significant commercial potential of <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Other
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalty Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2016, we entered into several Royalty Participation Agreements, or the Original Royalty Agreements, with certain of our existing
investors, <FONT STYLE="white-space:nowrap">co-founders,</FONT> former and current directors, and former and current executive officers, including Zachary Prensky, Andrew Vaino, Ph.D., and Marc Panoff, for royalties payable, in the aggregate, of up
to 5.0% of future commercial worldwide sales of <FONT STYLE="white-space:nowrap">LB-102.</FONT> In this transaction, we received $0.2&nbsp;million in cash in exchange for the certificate holders receiving convertible notes with a face value of
$0.2&nbsp;million, shares of our common stock and the future royalties provided for in the Original Royalty Agreements. The future royalty payments provided for in the Original Royalty Agreements had an expiration date of December&nbsp;31, 2037. The
royalties were transferable upon surrender of the royalty certificate accompanied by written and notarized instructions of the transfer, provided that the certificate holder could not transfer to any individual or entity (i)&nbsp;to which it was
unlawful for us to make such payments or (ii)&nbsp;that owned, controlled or possessed voting rights in the aggregate of more than 10% of our common stock. We had the option to purchase all issued and outstanding royalty certificates under the
Original Royalty Agreements by way of a tender offer to all such holders, which would become binding at such time as the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding royalty interests agreed in writing to accept
such tender offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of the Series C financing, we entered into several Amended and
Restated Royalty Agreements to remove the expiration date and modify royalties payable to certificate holders in the aggregate amount of up to 2.75% of net sales of <FONT STYLE="white-space:nowrap">LB-102</FONT> through December&nbsp;31, 2035 and
increasing to up to 3.25% of net sales in 2036 and thereafter. Future sales are defined in these agreements as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the gross payments received on total commercial sales of <FONT STYLE="white-space:nowrap">LB-102,</FONT> whether by us or by any licensee of <FONT STYLE="white-space:nowrap">LB-102.</FONT> None
of the proceeds from the Series C financing were allocated to the certificate holders as the investors in the Series C financing are not parties to the Original Royalty Agreements or the Amended and Restated Royalty Agreements. Each certificate
holder has the same rights and obligations as the other holders except with respect to its individual royalty amount that may come due from us if we generate any revenue from future sales of <FONT STYLE="white-space:nowrap">LB-102.</FONT> The
certificate holders may not transfer rights under the applicable Amended and Restated Royalty Agreement to any individual, entity, corporation, partnership or any other such organization without our written consent, which shall not be unreasonably
withheld. We may purchase all issued and outstanding royalty certificates under the Amended and Restated Royalty Agreements by way of a tender offer to all such holders, which will become binding at such time as the holders of <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding royalty interests thereunder agree in writing to accept such tender offer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business,
including by seeking, maintaining, enforcing and defending patent rights. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United
States related to our proprietary technology, inventions, improvements, and product candidate that are important to the development and implementation of our business. We also rely, in part, on trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology and product candidate, continuing innovation, and <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our
proprietary position in the field of precision psychiatry and neuropsychiatric drug development; however, trade secrets are difficult to protect and provide us with only limited protection. Our commercial success will depend in part on our ability
to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements, to preserve the confidentiality of our trade secrets, and defend and enforce our proprietary rights, including any patents that we own or
may obtain in the future. Intellectual property rights may not address all potential threats to our competitive advantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
July&nbsp;21, 2025, we owned approximately 49 patents and pending patent applications in the United States and foreign jurisdictions, including seven issued U.S. patents and 11 issued foreign patents. The issued patents, or patents that may be
issued from the pending patent applications, are expected to expire between 2037 and 2046, without taking into account potentially available patent term adjustments or extensions in the United States and other countries, and assuming payment of all
appropriate maintenance, renewal, and annuity fees. We expect the patent term adjustment or extension to be up to five years. <FONT STYLE="white-space:nowrap">Forty-one</FONT> of the patents and pending patent applications relate directly to <FONT
STYLE="white-space:nowrap">LB-102.</FONT> Additionally, we own two U.S. patents that are directed to open-ring derivative compounds of <FONT STYLE="white-space:nowrap">LB-102.</FONT> The two U.S. patents claim open-ring derivative compounds of <FONT
STYLE="white-space:nowrap">LB-102</FONT> as compositions of matter and methods of using these derivative compounds in the treatment of schizophrenia and other mental illnesses. In addition, there are two patent applications pending in Hong Kong and
one patent application pending in China, the European patent office, and Taiwan, respectively, that are directed to uses of the <FONT STYLE="white-space:nowrap">R-enantiomer</FONT> of <FONT STYLE="white-space:nowrap">LB-102.</FONT> These patent
applications cover methods of using the <FONT STYLE="white-space:nowrap">R-enantiomer</FONT> of <FONT STYLE="white-space:nowrap">LB-102</FONT> in treating schizophrenia and other mental illnesses, such as depression, bipolar disorder,
Tourette&#8217;s syndrome, schizoaffective disorder, Parkinson&#8217;s psychosis, Alzheimer&#8217;s psychosis, oppositional defiant disorder, personality disorder, childhood schizophrenia, dysthymia, treatment resistant schizophrenia, chronic
fatigue syndrome, and predominantly negative symptoms of schizophrenia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Candidate Patent Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">LB-102</FONT></I><B> </B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;21, 2025, we owned approximately 43 patents and pending patent applications in the United States and foreign jurisdictions
relating to <FONT STYLE="white-space:nowrap">LB-102,</FONT> including five issued U.S. patents and 11 issued foreign patents, seven pending U.S. patent applications, 19 pending foreign applications, and one pending patent cooperation treaty, or PCT,
application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own all of the following patents and pending patent applications directed to <FONT
STYLE="white-space:nowrap">LB-102,</FONT> which are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Indication(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subject&nbsp;Matter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Projected</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expiration</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issued&nbsp;or&nbsp;Pending&nbsp;Patent&nbsp;Applications/<BR>Jurisdiction</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schizophrenia and other mental illnesses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Composition of Matter and method of treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2037</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Respectively, one patent issued in each of the following: Australia, EPO, Indonesia, Japan, Republic of Korea, Malaysia, and Singapore, two patents issued in China and Hong Kong, and five patents issued in the United States; one
patent application pending in each of the following: Australia, Brazil, Malaysia, New Zealand, Singapore, and the United States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Method of Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2042</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Respectively, one patent application pending in each of the following: Australia, Brazil, Canada, China, EPO, Japan, Republic of Korea, Malaysia, New Zealand, Singapore, and the United States; and two patent applications pending in
Hong Kong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Method of Treatment (Poor Cognition)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2044</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">One PCT application pending; and one application pending in Taiwan.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Method of Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2046</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Five provisional applications pending in the United States.</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Projected expiration dates are based on issued patents or patents that may be issued from pending patent
applications, and do not take into account possible patent term adjustments, extensions, or terminal disclaimers and assumes payment of all appropriate maintenance, renewal, and annuity fees. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to <FONT STYLE="white-space:nowrap">LB-102,</FONT> our U.S. and foreign patents and pending patent applications cover claims
directed to composition of matter, and method of treating schizophrenia and other mental illnesses such as depression, bipolar disorder, Tourette&#8217;s syndrome, schizoaffective disorder, Parkinson&#8217;s psychosis, Alzheimer&#8217;s psychosis,
oppositional defiant disorder, personality disorder, childhood schizophrenia, dysthymia, resistant schizophrenia, and chronic fatigue syndrome. The issued patents covering the composition of matter of <FONT STYLE="white-space:nowrap">LB-102</FONT>
and method of treating schizophrenia are expected to expire in 2037, and any patents that may be issued from the pending patent applications are expected to expire between 2037 and 2046, in each case, without taking into account any possible patent
term adjustment or extensions or terminal disclaimers and assuming payment of all appropriate maintenance, renewal, and annuity fees. Our foreign patents and pending patent applications are filed in foreign jurisdictions including Australia, Brazil,
Canada, China, Europe, Hong Kong, Indonesia, Japan, the Republic of Korea, Malaysia, New Zealand, Singapore, and Taiwan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property
Protection </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to assess the extent to which we may seek additional patent protection related to our product candidate.
The term of individual patents depends upon the date of filing of the patent application, date of patent issuance and the legal term of the patents in the countries in which they are obtained. In the United States, the patent term is 20 years from
the earliest date of filing of the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> application to which priority is claimed. Outside of the United States, for patent applications first filed in the United States, the duration of
patents varies in accordance with applicable local law, but typically is also 20 years from the earliest <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In the United States, the patent term may be lengthened by a patent term
adjustment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a patent with an earlier
expiration date. Moreover, in the context of approved products, there may be additional exclusivity for the patents covering such approved products. In the United States, the term of a patent that covers an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the period of the patent term lost during the FDA
regulatory review process. The length of the patent term extension is calculated based on the length of time it takes for regulatory review. There are specific limitations to a patent term extension under the Hatch-Waxman Act. The extension cannot
exceed the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those patents with claims covering the approved drug, a method for using it,
or a method for manufacturing it may be extended. A patent term extension provided for under the Hatch-Waxman Act is available only for the first approved use of the drug, and thus, no extension is available if a product is approved for a subsequent
use. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to
extend the term of a patent that covers an approved drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to pursue, in the normal course of business and when possible,
additional patent protection for future compositions including solid state forms, methods of use, processes, composition, method of use, process, dosing, and formulations of our product candidate(s) we develop and commercialize. We may also pursue
patent protection with respect to manufacturing and other technologies. In order to expand market exclusivity, we intend to strategically obtain or license additional intellectual property related to a current or contemplated product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, we submit patent applications to the USPTO as provisional patent applications. Corresponding
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications must be filed within 12 months of the provisional application filing date. Claims of the corresponding <FONT STYLE="white-space:nowrap">non-provisional</FONT> application
may be entitled to the benefit of the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the later <FONT STYLE="white-space:nowrap">non-provisional</FONT> application filing date.
Provisional applications for patents were designed to provide a lower-cost first patent filing in the United States. This system allows us to obtain an early priority date, add material disclosure to the patent application(s) during the <FONT
STYLE="white-space:nowrap">12-month</FONT> period, obtain a later start to the patent term and to delay prosecution costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PCT system
allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the PCT member states in which national or regional patent applications can later be pursued based on the
international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a <FONT STYLE="white-space:nowrap">non-binding</FONT> patentability opinion which can be used to evaluate the chances of
success for the national or regional applications prior to having to incur the filing fees and prosecution costs. Although a PCT application does not result in the issuance of a patent, it allows the applicant to seek protection in any of the member
states through national/regional-phase applications. At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by
direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Office. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent
applications and enables substantial savings when applications are abandoned within the first two and a half years of filing. We intend to file U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications and PCT applications that claim
the benefit of the priority date of our earlier filed provisional applications, when applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all patent applications, we
determine claiming strategy on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. Advice of counsel, country-specific patent laws, our business model and commercial needs are always considered. We
may file patent applications containing claims for protection of all useful applications of our proprietary product candidate, as well as all new uses we discover for our existing product candidate, assuming these are strategically valuable. We
continuously reassess the number and type of patent applications in our portfolio, as well as the pending and issued patent claims, to help ensure that maximum coverage and value are obtained for our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processes, and compositions, given existing patent office rules and regulations. In addition, claims may be modified during patent prosecution, to the extent allowed, to meet our intellectual
property and business needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be able to obtain, maintain, enforce, and defend all patents and
other intellectual property rights necessary to conduct our business. The patents we currently own, possibly <FONT STYLE="white-space:nowrap">in-license</FONT> in the future, or patents that issue from our owned patent applications, if any, may be
challenged by third parties, may not effectively prevent third parties from commercializing competitive technologies or may not otherwise provide us with a competitive advantage. For more information regarding the risks related to our intellectual
property, see the section titled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property, Collaboration and Related Agreements.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales,
Marketing, and Commercialization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have a commercial organization for the marketing, sales, and distribution of
prescription pharmaceutical products. We intend to build our global commercialization capabilities internally over time, such that we are able to commercialize any product candidate for which we may obtain regulatory approval. We expect to manage
future sales, marketing, and distribution through internal resources and third-party relationships. In addition, we will opportunistically explore commercialization partnerships, particularly with entities that have strong capabilities in
geographies outside of the United States. As our current and future product candidates progress through clinical development and regulatory review, our commercial plans may change. Clinical data, the size of the development programs, the size of our
target markets, the size of the requisite commercial infrastructure, the competitive landscape, and manufacturing needs may all influence our future commercialization strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate,
and currently have no plans to establish, any manufacturing facilities. We have engaged, and expect to continue to rely on, well-established third-party CDMOs to produce and supply our product candidates for use in our preclinical studies and
clinical trials. Because we are responsible for ensuring all aspects of our product candidates&#8217; compliance and quality but rely on third-party contract manufacturers and analytical testing laboratories, we must employ personnel with extensive
technical, manufacturing, analytical, and quality experience to oversee our contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. We believe our current manufacturers have
the scale, systems, and experience to supply our currently planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we intend to rely on third-party CDMOs
for later-stage development and commercial manufacturing, if our product candidates receive marketing approval. As our lead product candidates advance through clinical development, we expect to enter into longer-term commercial supply agreements to
fulfill and secure our production needs. Key starting material is manufactured by a limited number of CDMOs. The final drug substance in manufactured at a single CDMO. In the event it is necessary or advisable to acquire supplies from an alternative
supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. If we need to change manufacturers
during the clinical or development stage for product candidates or after commercialization for our product candidates, if approved, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will
involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To adequately meet our projected commercial manufacturing needs, our CDMOs will need to <FONT STYLE="white-space:nowrap">scale-up</FONT>
production, or we will need to secure additional suppliers. Processes for producing drug substances and drug product for commercial supply must be developed, with the goal of achieving reliable, reproducible, and cost-effective production. We
believe the drug substance and drug product processes for our current product candidates can be appropriately scaled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is characterized by rapid innovation and intense competition. While we believe that our lead product candidate, <FONT
STYLE="white-space:nowrap">LB-102,</FONT> offers a potentially attractive alternative to generic and branded therapeutics treating neuropsychiatric diseases, should it be approved for marketing, today we face competition from multiple
biopharmaceutical and biotechnology companies that are similarly working to develop therapeutics targeting schizophrenia, as well as from academic institutions, governmental agencies, and public and private research institutions. Many of our
potential competitors, either alone or with collaboration partners, have significantly greater financial resources than we do, as well as equal or greater experience in the discovery and development of product candidates, obtaining FDA and other
regulatory approvals of products, and the commercialization of those products. Accordingly, our potential competitors may be more successful than we are in achieving regulatory approvals and commercializing their neuropsychiatric products. We
anticipate that we will face intense and increasing competition from existing, approved drugs, if <FONT STYLE="white-space:nowrap">LB-102</FONT> becomes a commercial product, as well as new drugs entering the market in the future and emerging
technologies that become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the key competitive factors affecting the success of our product candidate, <FONT
STYLE="white-space:nowrap">LB-102,</FONT> that we are developing to address schizophrenia and bipolar depression, if approved, are likely to be efficacy, safety, frequency of dosing, convenience, price, the level of generic competition, and the
availability of reimbursement from government and other third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with schizophrenia have historically been treated
with a variety of antipsychotic drugs and, accordingly, we believe <FONT STYLE="white-space:nowrap">LB-102,</FONT> if approved, would compete with several currently approved therapeutics, including: clozapine (marketed by HLS Therapeutics, Inc.);
quetiapine (marketed by AstraZeneca plc); aripiprazole (marketed by Otsuka Pharmaceutical Co. Ltd.); risperidone (marketed by Janssen Pharmaceuticals, Inc.); olanzapine (marketed by Eli Lilly&nbsp;&amp; Company Ltd.); haloperidol (marketed by
Janssen Pharmaceuticals, Inc.); Latuda (marketed by Sumitomo Pharma America, Inc.); Invega (marketed by Janssen Pharmaceuticals, Inc.); Rexulti (marketed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S); Vraylar (marketed by AbbVie Inc.);
Caplyta (marketed by Janssen Pharmaceuticals, Inc.); iloperidone (marketed by Vanda Pharmaceuticals Inc.); Uzedy (marketed by Teva Pharmaceutical Industries Limited); Lybalvi (marketed by Alkermes, Inc.); and Cobenfy (marketed by Bristol-Myers
Squibb Company, Inc.). We are also aware of several companies developing compounds for the treatment of schizophrenia, including Alto Neuroscience Inc., Minerva Neurosciences, Inc., MapLight Therapeutics, Inc., Reviva Pharmaceuticals Holdings, Inc.,
and Acadia Pharmaceuticals Inc., as well as other earlier stage competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In bipolar depression, we believe <FONT
STYLE="white-space:nowrap">LB-102,</FONT> if approved, would compete with several currently approved therapeutics, including: Vraylar (marketed by AbbVie Inc.); Caplyta (marketed by Janssen Pharmaceuticals, Inc.); olanzapine-fluoxetine combination
(Symbyax, marketed by marketed by Eli Lilly&nbsp;&amp; Company Ltd.); quetiapine (marketed by AstraZeneca plc); Latuda (marketed by Sumitomo Pharma America, Inc.); and seroquel. We are also aware of several companies developing compounds for the
treatment of bipolar depression, including Alto Neuroscience Inc., NRx Pharmaceuticals, Inc., and Xenon Pharmaceuticals Inc., as well as other earlier stage competitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government
authorities in the United States, at the federal, state and, local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage,
record-keeping, promotion, advertising, distribution, marketing, and export and import of human drug products. We, along with any third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval
requirements of the governing regulatory authorities of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals and ensuring compliance with applicable federal,
state, local, and foreign statutes, regulations and requirements both during development and post-approval requires the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938, or the FDCA, and its implementing
regulations. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States. Failure to comply with the applicable U.S. requirements at any time during the product development or approval
process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities. The process required by the FDA before a drug may be marketed in
the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s
GLP regulations and other applicable requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an IRB or ethics committee before each clinical trial may be initiated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with GCPs to evaluate the safety
and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA inspections of the manufacturing facility or facilities at which the drug is
produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with current cGMP regulations to assure that the
facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and a potential inspection of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Studies and IND Application </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a product candidate is identified for development, it enters the preclinical development stage. The preclinical developmental stage
generally involves laboratory evaluations of chemistry, formulation, and stability, as well as studies to evaluate the product candidate&#8217;s toxicity, in an effort to support subsequent clinical testing. Such toxicity studies generally involve
the use of animals, although <I></I><I></I>an NDA applicant may fulfill nonclinical testing requirements by completing various<I></I><I>&nbsp;in vitro</I>&nbsp;assays (e.g., cell-based assays, organ chips, or microphysiological
systems),<I></I><I>&nbsp;in silico</I>&nbsp;studies (i.e., computer modeling), other human or <FONT STYLE="white-space:nowrap">non-human</FONT> biology-based tests (e.g., bioprinting), or<I></I><I>&nbsp;in vivo</I>&nbsp;animal tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate in the United States, the product&#8217;s developer, also referred to as
the IND sponsor, must submit the results of preclinical testing, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational drug
product to humans, and must become effective before human clinical trials may begin. In addition to including the results of these nonclinical studies, the IND will also include a general investigational plan and a study protocol, detailing, among
other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the trial protocol includes an efficacy evaluation. The IND may also include any available human
data or literature to support the use of the product candidate. Additional nonclinical testing may continue even after the IND is submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,
within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the IND on clinical hold. In such case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of
an IND therefore may or may not result in FDA authorization to begin a clinical trial. Clinical holds also may be imposed by the FDA at any time after initiation of clinical trials due to safety concerns about ongoing or proposed clinical trials or <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. A clinical hold may affect one or more specific studies or
all studies conducted under an active IND. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Human Clinical Trials in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical trials must be conducted under the supervision of one or more qualified investigators, generally physicians not employed by or
under the trial sponsor&#8217;s control, in accordance with GCPs, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials
must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, research subject selection and exclusion criteria, and the safety and effectiveness criteria to be evaluated. Each protocol must be
submitted to the FDA as part of the IND, and a separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent material amendments to a protocol. While the IND is
active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA. Sponsors also must submit written IND
safety reports to the FDA and investigators in a timely matter for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or
<I>in vitro</I> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, an IRB must review and approve the protocol before a clinical trial commences and must also approve the information regarding the
trial and the consent form that must be signed by each research subject or the research subject&#8217;s legal representative, monitor the study until completed, and otherwise comply with IRB regulations. Regulatory authorities, the IRB or the
sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. In addition, some clinical
trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move
forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical trial results to public registries, including clinicaltrials.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1: The product candidate is initially introduced into healthy human subjects or patients and tested for
safety, dosage tolerance, absorption, metabolism, excretion, distribution and elimination, and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2: The product candidate is administered to a limited patient population with a specified disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases, and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to
provide substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and
provide an adequate basis for product labeling. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may require, or sponsors may voluntarily pursue, additional clinical
trials after a product is approved to gain more information about the product. These post-marketing clinical trials, sometimes referred to as Phase 4 studies, may be used to gain additional experience from the treatment of patients in the intended
therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A pivotal trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a product candidate&#8217;s
efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal trials are also Phase 3 trials but they may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit,
particularly in situations where there is an unmet medical need. Congress recently amended the FDCA to require sponsors of a Phase 3 trial, or other &#8220;pivotal study&#8221; of a new drug to support marketing authorization, to design and submit a
diversity action plan for such clinical trial. The action plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Sponsors must submit a
diversity action plan to the FDA by the time the sponsor submits the relevant clinical trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. If the FDA objects to a
sponsor&#8217;s diversity action plan or otherwise requires significant changes to be made, it could delay initiation of the relevant clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to
provide advice, and for the sponsor and the FDA to reach alignment on the next phase of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials,
companies usually complete additional nonclinical studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and
purity of the finished drug product. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disclosure of Clinical Trial Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of certain <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, including prescription drugs, are
required to register and disclose certain clinical trial information on a public registry maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation,
study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development
programs. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely
register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the <FONT STYLE="white-space:nowrap">non-compliant</FONT> party from receiving future grant funds from
the federal government. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of the required clinical testing, the results of nonclinical studies and clinical trials, along with detailed
descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission
of an NDA is subject to the payment of a substantial user fee, unless a waiver or exemption applies. An annual program fee is also assessed on sponsors of approved prescription drug products. FDA adjusts these user fees on an annual basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission,
before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the
additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and
whether it is being manufactured in accordance with cGMP requirements to assure and preserve the product&#8217;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act, or PDUFA, policies that are currently in effect, the
FDA has a goal of ten months from the filing date to complete its initial review of a standard application for a drug that is a new molecular entity, and six&nbsp;months from the filing date for an NDA that has been granted priority review. The FDA
does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and the sponsor&#8217;s process to respond to such inquiries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA likely will <FONT STYLE="white-space:nowrap">re-analyze</FONT> the clinical trial data, which could result in extensive discussions
between the FDA and the applicant during the review process. The FDA also may require the development of a risk evaluation and mitigation strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh
its risks and to assure the safe use of the product. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. If
the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS can include medication guides, physician communication plans, and/or elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer an
application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making product approval and risk mitigation decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA&nbsp;will not
approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before
approving an NDA, the FDA may inspect one or more clinical trial sites to assure that the clinical trials were conducted in compliance with GCP regulations and to assure the integrity of the clinical data submitted to the FDA. To ensure cGMP and GCP
compliance by its employees and third-party contractors, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA completes its evaluation of the NDA and any inspections or advisory committee consultations, the agency will issue either an
approval letter or a Complete Response Letter, or CRL, to the NDA applicant. An approval letter authorizes commercial marketing of the drug for specific indications for use. A CRL indicates that the review cycle of the application is complete, and
the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by the FDA. Such deficiencies may be minor, for example, requiring labeling changes, or major, for example, requiring
additional clinical trials or other significant and time-consuming requirements related to nonclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies that the FDA has
identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the agency will issue an approval letter to the applicant. The FDA has committed
to reviewing such resubmissions in response to an issued CRL in either two or six&nbsp;months depending on the type of information included. Even if such additional data and information are submitted, however, the FDA may ultimately decide that the
NDA does not satisfy the regulatory criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials
designed to further assess a drug&#8217;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other
conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescription or dispensing of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric
clinical trials for most drugs; specifically, in relation to applications for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements thereto must contain
a pediatric assessment unless the sponsor has received a deferral or waiver. Sponsors must also submit Pediatric Study Plans, or PSPs, to the agency for review within sixty days of an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must
include an outline of the pediatric trial or trials that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information,
and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric trials along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can
submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials or other clinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric
subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless a waiver or deferral has been granted. The FDA may defer, on its own initiative or upon the sponsor&#8217;s
request, submission of the pediatric assessments for some or all pediatric subpopulations until a specified date after approval. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults
before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a PREA <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to
any sponsor that fails to submit the required assessment, fails to keep a deferral current or fails to submit a request for approval of a pediatric formulation. The agency publicly posts such PREA
<FONT STYLE="white-space:nowrap">non-compliance</FONT> letters and sponsor&#8217;s response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fast Track, Breakthrough Therapy, and Priority Review
Designations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of programs intended to expedite the development or review of a marketing application for an
investigational drug. For example, the Fast Track designation program is intended to expedite or facilitate the process for developing and reviewing product candidates that are intended to treat a serious or life-threatening disease or condition and
demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track
product candidate has opportunities for more frequent interactions with the applicable FDA review team during development and, once an NDA is submitted, the application may be eligible for priority review. An NDA for a Fast Track product candidate
may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the
FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy
designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the
development and review of the product candidate, including involvement of senior managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an NDA may be eligible for
priority review if the product candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to available therapies for such disease or condition. The FDA will attempt to
direct additional resources to the evaluation of a NDA designated for priority review in an effort to facilitate the review. For <FONT STYLE="white-space:nowrap">new-molecular-entity</FONT> NDAs, priority review designation means the FDA&#8217;s
goal is to take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date, as compared to ten months for review of <FONT STYLE="white-space:nowrap">new-molecular-entity</FONT> NDAs under
its current PDUFA review goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track designation, Breakthrough Therapy designation, and priority review do not change the standards
for approval, but they may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated Approval Pathway </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions and
that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval. Such products may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate has an
effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an
effect on IMM or other clinical benefits, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will generally require the sponsor of a
drug receiving accelerated approval to perform adequate and well-controlled confirmatory clinical studies to verify and describe the drug&#8217;s clinical benefit, and may require that such confirmatory trials be underway prior to granting
accelerated approval. Sponsors are also required to send updates to the FDA every 6 months on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NDA sponsors must conduct such post-approval confirmatory studies in a diligent manner, and as a result a product candidate approved on this basis is subject
to rigorous post-marketing compliance requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products receiving accelerated approval may be subject to expedited withdrawal
procedures if the sponsor fails to conduct the required confirmatory studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, all promotional materials for product candidates being considered and
approved under the accelerated approval pathway are subject to prior review by the FDA, which could adversely impact the timing of the commercial launch of the product. Drugs granted accelerated approval must meet the same statutory standards for
safety and effectiveness as those granted traditional approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new drug, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to monitoring and record-keeping, reporting of adverse experiences with the product, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After
approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Certain modifications may require the NDA sponsor to
develop additional data or conduct additional nonclinical studies and clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There also are continuing, annual program fees for any marketed products. Drug manufacturers
and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state
agencies to assess compliance with cGMP requirements and other laws. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and
closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. In addition, changes to the manufacturing process are strictly
regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting
requirements on the NDA applicant and any third-party manufacturers involved in producing the approved drug product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain
compliance with cGMPs and other aspects of quality control and quality assurance. The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the
approved labeling to add new safety information; imposition of requirements for post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS. Other potential
consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials or labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on ongoing or planned clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of prescription drug products following approval. A company can
make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, e.g., unapproved uses or unapproved patient populations. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and
potential civil and criminal penalties. Although physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those
tested by us and approved by the FDA, manufacturers may not market or promote such uses. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The
FDA does not regulate the behavior of physicians in their choice of treatments. Manufacturers may also share truthful and not misleading information about their products that is otherwise consistent with a product&#8217;s <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling, which helps to support well-informed clinical decision-making by physicians and other health care professionals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, national&nbsp;distribution of pharmaceutical products is subject to the Drug
Supply Chain Security Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing and Data Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orange Book Listing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In seeking approval
for a drug through an NDA, applicants are required to list with the FDA each patent with claims covering the applicant&#8217;s product or method of using the product. Upon approval of a drug, each of the patents listed in the application for the
drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of
approval of an ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement
for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, nonclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as generic
equivalents to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i)&nbsp;the required patent information has not been filed;
(ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new
product. The ANDA applicant may also elect to submit a Section VIII statement certifying that its proposed ANDA labeling does not contain (or carves out) any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than certify to a listed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. If the applicant does not challenge the listed patents, the
ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A certification that the
new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant
must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been received by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph
IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement
of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An applicant submitting an NDA under
Section&nbsp;505(b)(2) of the FD&amp;C Act, also called a 505(b)(2) NDA, which permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the
applicant has not obtained a right of reference, is required to certify to the FDA regarding any patents listed in the Orange Book for the approved product it references to the same extent that an ANDA applicant would. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory exclusivity
provisions under the FDCA can delay the submission or the approval of certain marketing applications that seek to reference an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product. The FDCA provides a five-year period of <FONT
STYLE="white-space:nowrap">non-patent</FONT> data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other
new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or file a 505(b)(2) NDA, for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
another version of such drug where the applicant does not own or have a legal right of reference to such data required for approval. However, an application may be submitted after four years if
it contains a Paragraph IV certification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA alternatively provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA,
or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new
indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs
or 505(b)(2) NDAs referencing the approved application for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA that does not
reference the approved application. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. If granted,
pediatric exclusivity provides for the attachment of an additional six months of marketing exclusivity to the term of any existing regulatory exclusivity or listed patents. This is not a patent term extension, but it effectively extends the
regulatory period during which the FDA cannot approve another application. A product candidate may be eligible for this <FONT STYLE="white-space:nowrap">six-month</FONT> period of exclusivity if the NDA sponsor conducts clinical trials in children
and submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the product&#8217;s active moiety in children. The issuance of a Written Request does not require the sponsor to undertake the
described clinical trials. In addition, the clinical trial data do not need to show the product to be effective in the pediatric population studied; rather, the additional protection is granted if the pediatric clinical trial is deemed to have
fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product
candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare
Laws and Compliance Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our current and future operations are subject to regulation by various
federal, state and local authorities in addition to the FDA, including but not limited to, CMS, other divisions of HHS (<I>e.g.</I>, the Office of Inspector General, the Office for Civil Rights), the U.S. DOJ and individual U.S. Attorney offices
within the DOJ, the Federal Trade Commission, or FTC, and state and local governments. For example, our business practices, including our clinical research program and any future sales, marketing and scientific/educational grant programs may be
required to comply with the anti-fraud and abuse laws the false claims laws, transparency requirements, and similar state laws, each as amended, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in
whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. In addition, a person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. The federal Anti-Kickback Statute has been
interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common
activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not
qualify for an exception or safe harbor. Failure to meet all of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the
arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our future practices may not in all cases meet
all of the criteria for protection under a statutory exception or regulatory safe harbor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil monetary penalties statute imposes
penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or
service that was not provided as claimed or is false or fraudulent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal false claims laws, including the FCA, impose significant
penalties and can be enforced by private citizens through civil qui tam actions, prohibit, any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by,
the federal government, including federal healthcare programs such as Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A
claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free
product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for
unapproved, <FONT STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. In addition, a claim that includes items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes
that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the
control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme
or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
HIPAA, as amended by HITECH, imposes certain requirements on covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates and covered subcontractors that receive or obtain
protected health information in connection with providing a service on behalf of a covered entity relating to the privacy, security and transmission of individually identifiable health information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, and its implementing regulations, require that certain
manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report information annually to CMS related to certain
payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners (such as
physician assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Failure to report accurately could result in penalties. In addition, many states also govern the reporting of payments or other transfers of value, many which differ from each other in significant ways,
are often <FONT STYLE="white-space:nowrap">not&nbsp;pre-empted,&nbsp;and</FONT> may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services
reimbursed under Medicaid and other state programs, or, in several states, apply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regardless of the payor. In order to distribute pharmaceutical products commercially in the future, should FDA approval be granted to any of our product candidates, we must comply with state laws
that require the registration of manufacturers and wholesale distributors of drug products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no
place of business within the state. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on
sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and
biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring business
arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or
future governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from
participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts,
contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of <FONT STYLE="white-space:nowrap">non-compliance&nbsp;with</FONT> these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage, Pricing, and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory
approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish
adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the
price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all <FONT
STYLE="white-space:nowrap">of&nbsp;the&nbsp;FDA-approved&nbsp;products&nbsp;for</FONT> a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of
medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in
addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement
rate will be approved. In addition, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Further, obtaining reimbursement for our product may be particularly
difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of physicians. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
realize an appropriate return on our investment in product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under currently applicable U.S. law, certain products not usually
self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and
disabled, and covers outpatient services and supplies, including certain biopharmaceutical products, that are medically necessary to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treat a beneficiary&#8217;s health condition. As a condition of receiving Medicare Part B reimbursement for a manufacturer&#8217;s eligible drugs, the manufacturer is required to participate in
other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement
with HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that
participate in the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the
price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list
systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a
particular product candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicines, but monitor and control company profits. In addition, in some countries, cross-border imports from <FONT
STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any
product candidates for which we receive regulatory approval for commercial sale in any country or region may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. The downward pressure on the rise in
healthcare costs in general and pharmaceutical products in particular has become intense. As a result, in the European Union, increasingly high barriers are being erected to the entry of new products. In the United States, the emphasis on managed
care, the increasing influence of health maintenance organizations, and additional legislative changes has increased and we expect will continue to increase the pressure on product pricing. In addition, coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform in the U.S. and Potential Changes to Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and continue to be, legislative and regulatory changes and proposed changes regarding the healthcare
system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates that obtain marketing approval. The FDA&#8217;s and other regulatory
authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product candidate. Moreover, among policy makers and payors in the United States, there is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. The pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and many foreign jurisdictions have enacted or proposed
legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for
which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes measures that have significantly changed the way healthcare is financed by both
governmental and private insurers. There have been judicial, executive and congressional challenges and amendments to certain aspects of the ACA. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health
insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost and through a newly established manufacturer discount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the second
Trump administration will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since
the ACA was enacted. For example, on July&nbsp;4, 2025, the annual reconciliation bill, OBBBA, was signed into law which is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping
state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. OBBBA also narrows access to ACA marketplace exchange enrollment and declines to extend the ACA enhanced advanced premium tax credits, set to
expire in 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to
recommend Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction, which triggered the legislation&#8217;s automatic reduction to several government programs. This
includes aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year until 2032 unless Congress takes additional action. Additionally, the American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate
cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January&nbsp;1, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. presidential executive orders, congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under
Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, at the federal level, the IRA, among other things, (1)&nbsp;directs HHS to
negotiate the price of certain high-expenditure, single-source drugs covered under the Medicare Drug Price Negotiation Program, and (2)&nbsp;imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace
inflation. These provisions took effect progressively starting in fiscal year 2023. On August&nbsp;15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price
Negotiation Program is currently subject to legal challenges. On January&nbsp;17, 2025, HHS selected fifteen additional drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become
subject to the Medicare Drug Price Negotiation Program. On February&nbsp;14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the
cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in 2023, an initiative to control the price of prescription drugs through the use of <FONT STYLE="white-space:nowrap">march-in</FONT>
rights under the Bayh-Dole Act&nbsp;was announced. Also in 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of
<FONT STYLE="white-space:nowrap">March-In</FONT> Rights, which for the first time includes the price of a product as one factor an agency can use when deciding to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights. While <FONT
STYLE="white-space:nowrap">march-in</FONT> rights have not previously been exercised, it is uncertain if that will continue under the new framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. For example, in January 2024, the FDA approved Florida&#8217;s SIP proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented,
including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when
implemented, may result in lower drug prices for products covered by those programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to predict the future course of federal or state healthcare legislation in the
United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, particularly in light of the recent U.S. Presidential and Congressional elections. The current Trump administration is pursuing
policies to reduce regulations and expenditures across government including at HHS, the FDA, the CMS, and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose
policy changes that create additional uncertainty for our business. These actions and proposals include, for example, include (1)&nbsp;directives to reduce agency workforce and cut programs; (2)&nbsp;rescinding a Biden administration executive order
tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending; (3)&nbsp;eliminating the Biden administration&#8217;s executive order that directed HHS to establishing establish an AI
task force and developing develop a strategic plan; (4)&nbsp;directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing
Most-Favored-Nation pricing for pharmaceutical products; (5)&nbsp;imposing tariffs of imported pharmaceutical products; and (6)&nbsp;directing certain federal agencies to enforce existing law regarding hospital and price plan price transparency and
by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, or Loper Bright, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were
required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies
applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could, among other legislation, impact the drug approval process and make changes to modify the Medicare
Drug Price Negotiation Program created under the IRA, and expand the orphan drug exclusion in the IRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the healthcare
reform measures that have been adopted and may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future
revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from
being able to generate revenue, attain profitability or commercialize our products, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval of a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign
countries prior to the commencement of clinical trials or marketing of the product in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. The approval process varies from
country to country, can involve additional testing beyond that required by FDA, and may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing, promotion, and
reimbursement vary greatly from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of
products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly to the United States, the various phases of <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research in the
European Union, or EU are subject to significant regulatory controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies are performed to demonstrate
the health or environmental safety of new chemical or biological substances. <FONT STYLE="white-space:nowrap">Non-clinical</FONT> studies must be conducted in compliance with the principles of good laboratory practice, GLP, as set forth in Directive
2004/10/EC. These GLP standards reflect the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials of medicinal products in the EU must be conducted in accordance with the Clinical Trials Regulation (EU) No 536/2014, and
national regulations and the International Conference on Harmonization, guidelines on GCPs, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>EU Review and Approval process </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a
centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA
may be granted only to an applicant established in the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single MA by the
European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products,
including for (i)&nbsp;medicinal products derived from biotechnological processes, (ii)&nbsp;products designated as orphan medicinal products, (iii)&nbsp;advanced therapy medicinal products, or ATMPs, and (iv)&nbsp;products with a new active
substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and
products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval. Under the centralized procedure, the EMA&#8217;s Committee for
Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA.
The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each
EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft
assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the
assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads
of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures&#8212;Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this
authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a
medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the
competent authority of another EU Member State. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An MA has, in principle, an initial validity of five years. The MA may be renewed after five
years on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder
must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> data concerning the quality, safety and
efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified
grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual
placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset
clause). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Accelerated and Abbreviated Pathways in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of
expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support
for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if
there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of
product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA
assessment once a dossier has been submitted. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public
health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the
standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The
European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i)&nbsp;the benefit-risk balance of the medicinal product is positive; (ii)&nbsp;it is likely that the
applicant will be able to provide comprehensive data post-authorization; (iii)&nbsp;the medicinal product fulfils an unmet medical need; and (iv)&nbsp;the benefit of the immediate availability to patients of the medicinal product is greater than the
risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed
annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and
approved by the European Commission, the MA will cease to be renewed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An MA may also be granted &#8220;under exceptional
circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced.
These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to
generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does
not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA
will be withdrawn if the risk-benefit ratio is no longer favorable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in
the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of
the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in
adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for
which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study
results are included in the product information, even when negative, the product is eligible for a <FONT STYLE="white-space:nowrap">six-month</FONT> extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of
authorization or, in the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of orphan market exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and Market Exclusivity in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally
entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar
application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful
generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period may, occasionally, be
extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity,
and products may not qualify for data exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April&nbsp;2023, the European Commission issued a proposal to revise and replace
the existing general pharmaceutical legislation, which was supported in large part by the European Parliament in April&nbsp;2024. Additional procedural steps remain in the European legislative process and the proposed legislation is not expected to
be adopted until at least&nbsp;2026. If adopted and implemented as currently proposed, these legislative revisions will significantly change several aspects of drug development and approval in the EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-authorization Requirements in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory
requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA,
the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who
is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new MAAs must include a risk management plan, or RMP, describing the risk management
system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization
measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of
medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States
and can differ from one country to another. Interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations,
industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pricing, Coverage and Reimbursement in the EU </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be
marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory
developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. In addition, the EU provides options for its Member States to restrict the range of products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product, may adopt a system of direct or indirect controls on the
profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In
addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is
the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The
outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or
indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. United States authorities
that enforce the FCPA, including the DOJ, deem most health care professionals and other employees of foreign hospitals, clinics, research facilities and medical schools in countries with public health care or public education systems to be
&#8220;foreign officials&#8221; under the FCPA. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly
reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition
to the foregoing, state, federal, and foreign laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used
in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material
compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal, and foreign laws, regulations and standards govern the collection, use, access to, confidentiality, and security of
health-related and other personal information, including clinical trial data, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including
data breach notification laws, health information privacy and security laws, and consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information. Further, to the
extent we collect personal data from individuals outside of the United States, through clinical trials or otherwise, we could be subject to foreign laws, such as the GDPR, which govern the privacy and security of personal data, including
health-related data. Our use of machine learning may also be subject to evolving laws and regulations, controlling for data bias and anti-discrimination. Privacy and security laws, regulations and other obligations are constantly evolving, may
conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of July 15, 2025, we had 16 total employees. Of our 16 employees, two hold Ph.D. and/or M.D. degrees and eight were engaged in research and development. None of our employees is subject to a collective bargaining agreement. We consider our
relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize that our continued ability to attract, retain, and motivate exceptional
employees is vital to ensuring our long-term competitive advantage. Our employees are critical to our long-term success and are essential to helping us meet our goals. Our human capital resources objectives include, as applicable, identifying,
recruiting, retaining, incentivizing, and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain, and motivate selected employees, consultants, and directors through the
granting of stock-based compensation awards and cash-based performance bonus awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties and Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal office is located at One Pennsylvania Plaza, Suite 1025, New York, NY 10119, where we lease approximately 8,900 square feet of
office space under a lease that will expire in 2032. We believe that our existing facility is adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we
may become involved in legal proceedings arising in the ordinary course of our business. We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results
of operations, financial condition, or cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information about our executive officers, directors, and certain key employees as of June 30, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather Turner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gad Soffer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eramo, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc Panoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, Finance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Silva</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, Technical Operations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Garland<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajul Jain, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebecca Luse<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ran Nussbaum<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zachary Prensky<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P.<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Yu, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rekha Hemrajani<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director Nominee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Kane<SUP STYLE="font-size:75%; vertical-align:top">(2)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director Nominee</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Jain and Dr. Yu will resign from our board of directors effective immediately prior to the execution of the
underwriting agreement related to this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms. Hemrajani and Mr. Kane currently are director nominees and have been appointed as members of our board of
directors effective immediately prior to the execution of the underwriting agreement related to this offering. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive
Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B><I>Heather Turner</I></B><B> </B>has served as our Chief Executive Officer and director since November 2024. Prior to
joining us, Ms.&nbsp;Turner was President and Chief Executive Officer of Carmot Therapeutics Inc. (acquired by Roche) from January 2023 to June 2024 and Chief Operating Officer from September 2022 to December 2022. Prior to Carmot, Ms.&nbsp;Turner
served as Chief General Counsel and Secretary at Lyell Immunopharma, Inc. from April 2019 to May 2022. Prior to Lyell, Ms.&nbsp;Turner served as Executive Vice President, General Counsel and Secretary of Sangamo Therapeutics, Inc., a publicly traded
gene therapy and gene editing company, from February 2018 to March 2019, and served as Executive Vice President, General Counsel and Head of Portfolio Strategy at Atara Biotherapeutics, Inc., a publicly-traded allogeneic cell therapy company, from
July 2015 to February 2018. Prior to that, Ms.&nbsp;Turner served as General Counsel and Secretary at Orexigen Therapeutics, Inc. a publicly-traded company focused on metabolic diseases, from June 2007 to June 2015. Ms.&nbsp;Turner started her
career at Cooley LLP as a corporate securities associate. Ms.&nbsp;Turner received her J.D. from UCLA School of Law and her B.A. in Environmental Studies from the University of California, Santa Barbara. Ms.&nbsp;Turner has served as the chair of
the board of directors of Avalyn Pharma Inc., a clinical-stage biotech company, since November 2024 and as a member of the board of directors of Terns Pharmaceuticals, Inc., a publicly traded clinical-stage biopharmaceutical company, since November
2024. Our board of directors believes that Ms.&nbsp;Turner&#8217;s extensive experience as an executive and director of companies in the biopharmaceutical industry provides her with the qualifications to serve on our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B><I>Gad Soffer</I></B> has served as our Chief Business Officer since February 2025. Mr.
Soffer has also served as a consultant and director of General Metabolics LLC since 2023. From 2021 to 2023, Mr. Soffer created and managed a family investment vehicle that focused on investing in the biotechnology and pharmaceutical sectors. Prior
to that, Mr.&nbsp;Soffer served as Chief Executive Officer of <FONT STYLE="white-space:nowrap">Consonance-HFW</FONT> Acquisition Corp. from November 2020 to June 2021. Prior to that, Mr.&nbsp;Soffer served as Chief Operating Officer at Rheos
Medicines, Inc. from October 2018 to June 2020. Prior to that, he served as Executive Vice President and Chief Strategy Officer at Atara Biotherapeutics, Inc. from October 2016 to September 2018 and served as Chief Operating Officer from March 2013
through October 2016. From August 2008 to March 2013, he held various roles in Business Development and served as Global Project Leader for Abraxane at Celgene Corporation. From June 2000 to June 2001 and from April 2004 to April 2006,
Mr.&nbsp;Soffer was a healthcare consultant with Easton Associates LLC. He received an A.B. from Harvard University, an M.S. from Columbia University and an M.B.A. from Harvard Business School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anna Eramo, M.D.</I></B> has served as our Chief Medical Officer since September 2020. Prior to joining us, Dr.&nbsp;Eramo served various roles with
increased responsibilities at Lundbeck A/S from 2017 to 2020, where she led U.S. clinical and medical affairs with primary responsibilities extending across its entire U.S. neurology and psychiatric portfolio of products, including brexpiprazole,
vortioxetine, and Abilify Maintena. Dr.&nbsp;Eramo holds both an academic degree in Medicine and a specialty degree in Psychiatry and Psychotherapy from the University Medical School of Naples, Italy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marc Panoff</I></B> has served as our Senior Vice President, Finance since June 2024 and previously served as our Chief Financial Officer from March
2016 to May 2024. Immediately prior to joining us, Mr.&nbsp;Panoff served as an independent consultant to several companies. From 2013 to 2015, Mr.&nbsp;Panoff served as Chief Financial Officer at Retrophin, Inc. From 2006 to 2012, Mr.&nbsp;Panoff
served as Chief Financial Officer, Treasurer and Secretary of Neurologix, Inc. From 2004 to 2006, Mr.&nbsp;Panoff served as Chief Financial Officer of Nephros, Inc., a publicly traded medical device developer. Mr.&nbsp;Panoff has served on the board
of directors of Little Bear Pharmaceuticals, Inc. since February 2025. Mr.&nbsp;Panoff received his Bachelor of Science degree in Business Administration from Washington University in St. Louis and his master&#8217;s degree in Business
Administration from Arizona State University. He is also a Certified Public Accountant in New York State (inactive). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B><I>Richard
Silva</I></B><B><I>, Ph.D. </I></B>has served as our Senior Vice President of Technical Operations since February 2025. Prior to joining us, Dr.&nbsp;Silva was Senior Vice President of Pharmaceutical Sciences at Carmot Therapeutics Inc. (acquired by
Roche) from April 2023 to July 2024. Prior to that, Dr.&nbsp;Silva served as Vice President Technical Operations, Development and Manufacturing at Epizyme, Inc. (acquired by Ipsen) from March 2020 to April 2023. Prior to Epizyme, Dr.&nbsp;Silva was
Senior Director at Kaleido Biosciences from March 2019 to February 2020, and prior to that he served as Senior Director of Chemical Process Development at ImmunoGen, Inc. from July 2015 to March 2019. Dr.&nbsp;Silva holds a Ph.D. in Synthetic
Organic Chemistry from Dartmouth College and a B.S. in Chemistry from the University of Massachusetts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Director Nominees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scott Garland </I></B>has served as Chairman of our board of directors since February 2024. Since September 2023, Mr.&nbsp;Garland has been a partner at
Vida Ventures. Mr.&nbsp;Garland was the Chief Executive Officer of PACT Pharma, Inc., an immuno-oncology company focused on developing neoantigen targeted <FONT STYLE="white-space:nowrap">T-cell</FONT> therapies for solid tumors from 2021 to 2023.
Prior to PACT Pharma, Inc., Mr.&nbsp;Garland served as President and Chief Executive Officer of Portola Pharmaceuticals, Inc. from 2018 to 2020, where he led the company through the commercial launch of Andexxa and acquisition by Alexion
Pharmaceuticals, Inc. Before joining Portola Pharmaceuticals, Inc., Mr.&nbsp;Garland was at Relypsa Inc. from 2014 to 2018, where he served as Chief Commercial Officer, and then as President of the U.S. organization after Relypsa Inc.&#8217;s
acquisition by Vifor Pharma AG. Prior to Relypsa Inc., Mr.&nbsp;Garland was Chief Commercial Officer at Exelixis, Inc. from 2011 to 2014. Mr.&nbsp;Garland has held numerous other commercial leadership roles at Genentech, Inc., Amgen Inc.,
Merck&nbsp;&amp; Co., Inc., including leading the commercial franchises for two multi-billion-dollar therapies&#8212;Avastin and Rituxan. He also serves as a board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
member for ALX Oncology Inc., a biopharmaceutical company, since November 2022, and Day One Biopharmaceuticals, Inc., a biopharmaceutical company, since August 2021, and Olema Pharmaceuticals,
Inc., a biopharmaceutical company, since October 2023. Mr.&nbsp;Garland served on the Board of Directors for Karyopharm Therapeutics Inc., a biotechnology company, from 2014 to 2020 and on the Board of Directors of Calithera Biosciences, Inc. from
2020 to 2023. Mr.&nbsp;Garland received a Bachelor of Science degree from California Polytechnic State <FONT STYLE="white-space:nowrap">University-San</FONT> Luis Obispo and a master&#8217;s degree in Business Administration from the Fuqua School of
Business at Duke University. Our board of directors believes that Mr.&nbsp;Garland&#8217;s extensive leadership experience in the healthcare industry and his service as a public company director qualify him to serve on our board of directors. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rajul Jain, M.D.</I></B> has served as a member of our board of directors since September 2023. Since May 2019, Dr.&nbsp;Jain has been a partner at
Vida Ventures, where he currently is a Managing Director. Dr.&nbsp;Jain previously served as Vice President at Kite Pharma, Inc. Previously, Dr.&nbsp;Jain was at Amgen, Inc. where his last role was Global Development Lead. There he oversaw the
development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&amp;D pipeline including regulatory approvals of Xgeva and Prolia. Dr.&nbsp;Jain also serves as a board member of
Capstan Therapeutics, Inc., InduPro, Inc., Locanabio, Inc., A2 Biotherapeutics, Inc., Quanta Therapeutics, Inc., and Third Arc Bio, Inc. Dr.&nbsp;Jain completed his B.A. in Chemistry and Biochemistry at Rice University, and M.D. and Internal
Medicine internship and residency at UT Southwestern Medical School, where he was a Howard Hughes Fellow. He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at M.D. Anderson Cancer Center, where
he was chief fellow. Our board of directors believes that Dr.&nbsp;Jain&#8217;s financial expertise and investment experience in the life sciences industry provides him with the qualifications to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rebecca Luse</I></B> has served as a member of our board of directors since August 2023. Since January 2021, Ms.&nbsp;Luse has served as Principal of
Deep Track Capital. Ms.&nbsp;Luse previously served as Principal of New Leaf Venture Partners. Previously, she worked on the sell side at both Jefferies and Piper Jaffray, covering biotechnology and specialty pharmaceuticals companies. Ms.&nbsp;Luse
started her career as an investment banking analyst in the health care group of Bank of America and as a venture capital associate at Bay City Capital. Rebecca earned a Bachelor of Science in Biochemistry and Mathematics from Indiana University. Our
board of directors believes Ms.&nbsp;Luse&#8217;s financial expertise and investment experience in the life sciences industry provides her with the qualifications to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ran Nussbaum</I></B> has served as a member of our board of directors since August 2023. Since 2004, Mr.&nbsp;Nussbaum has served as a Managing Partner
and the <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Pontifax. He also serves as a board member on many of Pontifax&#8217;s portfolio companies. He currently serves as a director of Keros Therapeutics, Inc. since April 2016, Lutris Pharma
Ltd since May 2016, Kamari Pharma Ltd since April 2021, Indapta Therapeutics Inc. since April 2022, and Graviton Bioscience Corp since December 2022. Mr.&nbsp;Nussbaum previously served as a director of Urogen Pharma Ltd., ArQule, Inc. (acquired by
Merck&nbsp;&amp; Co., Inc.), BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., Prevail Therapeutics Inc., VBI Vaccines Inc. and Kite Pharma, Inc. until its acquisition by Gilead Sciences, Inc. Our board of directors believes
Mr.&nbsp;Nussbaum&#8217;s financial expertise and experience serving on the boards of directors of other public companies qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zachary Prensky </I></B>is our <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> has served as a member of our board of directors since September 2015
and served as our Chief Executive Officer from September 2015 to November 2024. Prior to joining us, Mr.&nbsp;Prensky managed both Little Bear Investments and The Kybartai Trust, a family office with a heavy focus on investing in the biotechnology
and pharmaceutical sectors, from 1998 to 2015. Since February 2025, Mr.&nbsp;Prensky has served as the Chief Executive Officer and member of the board of directors of Little Bear Pharmaceuticals, Inc. Mr.&nbsp;Prensky attended Yeshiva University.
Our board of directors believes that Mr.&nbsp;Prensky&#8217;s experience as our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and former Chief Executive Officer, as well as his expertise in the field of neuroscience, qualify him to serve on our
board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P.</I></B> has served as a member of our board of
directors since July 2019. He served as the President of Research and Development and as the Corporate Senior Vice President of Wyeth Pharmaceuticals, Inc. from 2002 through 2008. In these roles, he managed an R&amp;D organization of 9,000
scientists with an annual budget in excess of $3&nbsp;billion. From 2000 to 2002 he served as an Executive Vice President at Wyeth Pharmaceuticals, Inc., where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth
Pharmaceuticals, Inc., Dr.&nbsp;Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals plc (now GlaxoSmithKline plc) where he was Senior Vice President and Director of Biological Sciences, Worldwide from 1984 to 2000. Before joining SmithKline
Beecham Pharmaceuticals plc, Dr.&nbsp;Ruffolo spent six years at Eli Lilly and Company from 1978 to 1984 where he was Chairman of the Cardiovascular Research Committee. Dr.&nbsp;Ruffolo currently serves on the boards of directors of Elicio
Therapeutics, Inc. and several private companies. He received his B.S. in Pharmacy from The Ohio State University and his Ph.D. in Pharmacology from The Ohio State University. Our board of directors believes that Dr.&nbsp;Ruffolo&#8217;s extensive
leadership experience in the healthcare industry and his service as a public company director qualify him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chen
Yu, M.D.</I></B> has served as a member of our board of directors since December 2023. Dr.&nbsp;Yu is the founder and Managing Partner at TCG Crossover Fund. Prior to founding TCG Crossover Fund, Dr.&nbsp;Yu spent 16 years as a Managing Partner at
Vivo Capital, a life-sciences focused investment fund. Dr.&nbsp;Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the Chief Operating Officer of Sagent Pharmaceuticals, Inc. from
2012 to 2013, and Chief Business Officer of China Kanghui Holdings, from 2010 to 2012. Dr.&nbsp;Yu previously served on the boards of Structure Therapeutics Inc. from 2021 to 2023, Tarsus Pharmaceuticals, Inc. in 2020, Sagent Pharmaceuticals, Inc.
from 2008 to 2013, Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. from 2011 to 2019, and over a dozen private companies. Dr.&nbsp;Yu also serves on the California Leadership Council for The Nature Conservancy and was previously a member of
the Stanford Medical School Alumni Board of Governors. Dr.&nbsp;Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University. Our board of directors believes that
Dr.&nbsp;Yu&#8217;s financial expertise and experience serving on the boards of directors of other companies qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rekha Hemrajani</I></B>&nbsp;will join&nbsp;our board of directors effective immediately prior to the execution of the underwriting agreement related to
this offering. Ms. Hemrajani has served as a member of the board of directors of ALX Oncology Holdings Inc. since April 2020, MaxCyte, Inc. since June 2021, and BioAge Labs since August of 2021. Ms. Hemrajani served as Chief Executive Officer and
Director of Jiya Acquisition Corporation from August 2020 to November 2022. She previously served as President, Chief Executive Officer &amp; Director of Aravive, Inc., a clinical-stage biotechnology company, from January 2020 to April 2020. From
March 2019 to September 2019, Ms. Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March 2016 to March 2019, she served as Chief Operating Officer of RAPT Therapeutics,
Inc., a biotechnology company. From February 2015 to March 2016, Ms. Hemrajani served as Chief Financial Officer and Senior Vice President of Business and Financial Operations at Sagimet Biosciences, Inc., a biotechnology company. From November 2013
to January 2015, Ms. Hemrajani advised privately held companies on strategic corporate development and financing activities at Ravinia Consulting, a consulting firm she founded. She previously served as a director of Adverum Biotechnologies, Inc.,
Aravive, Inc. and Jiya Acquisition Corp. Ms. Hemrajani holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. Our board of directors
believes that Ms. Hemrajani&#8217;s extensive leadership experience in the healthcare industry and her service as a public company director qualify her to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>William Kane</I></B>&nbsp;will join&nbsp;our board of directors effective immediately prior to the execution of the underwriting agreement related to
this offering. Mr. Kane currently serves as President and CEO of Uniquity Bio, Inc. and has previously served as President and Chief Commercial Officer of Anthos Therapeutics, Inc. from October 2024 to April 2025. Previously, he served as the Chief
Commercial Officer of Karuna Therapeutics, Inc. from February 2023 to March 2024. From November 2021 to December 2022, Mr. Kane was an independent consultant. From </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June 2020 to October 2021, Mr. Kane was Executive Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. Prior to that, he served in multiple leadership roles at Allergan plc,
most recently as Senior Vice President, U.S. General Medicine, from January 2017 to May 2020, and prior to that, as Vice President, Internal Medicine Brands, from July 2014 to December 2016 and Vice President, CNS Marketing, from October 2013 to
June 2014. Mr. Kane has also held senior level commercial positions at leading biopharma companies, including Pfizer and Sepracor (now Sumitomo Pharma). Mr. Kane holds a B.A. in Government from Connecticut College and an M.B.A. from the Wharton
School at the University of Pennsylvania. Our board of directors believes that Mr. Kane&#8217;s extensive leadership experience in the healthcare industry qualify him to serve on our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and
affairs are organized under the direction of our board of directors, which currently consists of eight&nbsp;members. Two of our directors, Dr. Jain and Dr. Yu, will resign from our board of directors effective as of immediately prior to the
execution of the underwriting agreement related to this offering, and Ms. Hemrajani and Mr. Kane currently are director nominees and have been appointed as members of our board of directors effective immediately prior to the execution of the
underwriting agreement related to this offering, at which time our board will consist of eight directors. All of our directors currently serve on the board of directors pursuant to the provisions of the voting agreement between us and several of our
stockholders. The voting agreement will terminate upon the completion of this offering, after which there will be no further contractual obligations regarding the election or designation of our directors. Our current directors will continue to serve
as directors until their resignation, removal or successor is duly elected. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated
certificate of incorporation that will become effective immediately prior to the closing of this offering, we will divide our board of directors into three classes, Class&nbsp;I, Class&nbsp;II, and Class&nbsp;III, with members of each class serving
a staggered three-year term. In connection with this offering, our board of directors will be divided into the following three classes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will consist of Zachary Prensky, Rebecca Luse, and Ran Nussbaum, whose terms will expire at
our annual meeting of stockholders to be held in 2026; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will consist of Robert R. Ruffolo, Jr., Scott Garland, and Heather Turner, whose terms will
expire at our annual meeting of stockholders to be held in 2027; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will consist of Rekha Hemrajani and William Kane, whose terms will expire at our annual
meeting of stockholders to be held in 2028. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial
classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. Our amended and restated bylaws that will become
effective immediately prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of a majority of our board of directors. Any additional directorships resulting from an increase in
the number of directors or from the filling of any current vacancies will be distributed between the three classes so that, as nearly as possible, each class will consist <FONT STYLE="white-space:nowrap">of&nbsp;one-third&nbsp;of</FONT> the
directors. This classification of our board of directors may have the effect of delaying or preventing changes in our control or management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director
Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of the independence of our directors and considered whether any director
has a relationship that, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a member of our board. Based upon information requested from and provided by each
director concerning such director&#8217;s background, employment, and affiliations, including family relationships, our board of directors has determined that all of our directors, except </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for Ms.&nbsp;Turner and Mr.&nbsp;Prensky, representing six of our eight directors, are &#8220;independent directors&#8221; as defined under the listing standards of Nasdaq. In making these
determinations, our board of directors considered the current and prior relationships that each director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining their independence,
including the beneficial ownership of our capital stock by <FONT STYLE="white-space:nowrap">each&nbsp;non-employee&nbsp;director</FONT> and the transactions described in the section titled &#8220;Certain Relationships and Related Party
Transactions.&#8221; Our board of directors has determined that Ms.&nbsp;Turner, by virtue of her role as our Chief Executive Officer, and Mr.&nbsp;Prensky, by virtue of his role as our former Chief Executive Officer, are not independent directors
under the current rules and regulations of the SEC and the listing standards of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of
our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a
standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole. Additionally, in connection with this offering, our board of directors will establish various standing committees
of the board of directors that will address risks inherent in their respective areas of oversight, as described below. In particular, our audit committee will monitor our major financial, accounting, legal, compliance, investment, tax,
cybersecurity, and data privacy risks, and the steps our management has taken to identify and control these exposures, including by reviewing and setting guidelines, internal controls, and policies that govern the process by which risk assessment
and management is undertaken. In addition, our compensation committee will oversee the management of risks relating to our employment policies and executive compensation plans and arrangements, and our nominating and corporate governance committee
will oversee the management of our corporate governance practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our board of directors oversees our risk management, management
is responsible for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes. Our board of directors expects management to consider risk and risk management in each business decision, to
proactively develop and monitor risk management strategies and processes for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, and to effectively implement risk management strategies adopted by
our board of directors, as a whole and at the committee level. We believe this division of responsibilities is the most effective approach for addressing the risks we face. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this
offering, our board of directors will establish an audit committee, a compensation committee, and a nominating and corporate governance committee. Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering, our audit committee will consist of Rekha Hemrajani, Robert R. Ruffolo, Jr., and Scott Garland, with Ms. Hemrajani serving as the chair of the audit committee. Our board of directors has determined that each of these
individuals satisfies the requirements for independence under the current rules and regulations of the SEC and the listing standards of Nasdaq. Each member of our audit committee can read and understand fundamental financial statements in accordance
with Nasdaq audit committee requirements. In addition, our board of directors has determined that Ms. Hemrajani and Mr. Garland each qualifies as an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. In arriving at
these determinations, the board has examined each audit committee member&#8217;s scope of experience and the nature of their prior and/or current employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of the audit committee will include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing the selection, engagement, qualifications, independence, and performance of a qualified firm to serve as
the independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing cybersecurity matters and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm that describes its internal
quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving, or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee will operate under a written charter, to be effective immediately prior to the closing of this offering, which satisfies
the applicable rules and regulations of the SEC and the listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our compensation committee will consist of Scott Garland, William Kane, and Rekha Hemrajani, with Mr. Garland
serving as chair of the compensation committee. Our board of directors has determined that each of the members of our compensation committee is independent under the listing standards of Nasdaq and qualifies as
<FONT STYLE="white-space:nowrap">a&nbsp;&#8220;non-employee&nbsp;director&#8221;</FONT> as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3&nbsp;promulgated</FONT> under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of the compensation committee will include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or, as applicable, recommending to our board of directors) the compensation of our Chief
Executive Officer and other executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving, or making recommendations to our board of directors with respect to, incentive
compensation and equity plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, adopting, amending, and terminating the terms of any employment agreements, severance arrangements,
bonus plans, deferred compensation plans, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections, and any other compensatory arrangements for our executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating, and recommending to our board of directors succession plans for our executive officers;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees, including our
overall compensation philosophy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee will operate under a written charter, to be effective
immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our nominating and corporate governance committee will consist of Rebecca Luse, Ran Nussbaum and Zachary
Prensky, with Ms. Luse serving as chair of the nominating and corporate governance committee. Our board of directors has determined that each of Mr. Nussbaum and Ms.&nbsp;Luse is &#8220;independent&#8221; as defined under the applicable listing
standards of Nasdaq and SEC rules and regulations. Mr.&nbsp;Prensky, by virtue of his former position as our former Chief Executive Officer, is not independent under applicable rules and regulations of the SEC and the Nasdaq listing rules. We are
relying on the phase-in exemption provided under Rule 10A-3 of the Exchange Act and the Nasdaq listing rules with respect to the composition of our nominating and corporate governance committee. Mr. Prensky will serve on our nominating and corporate
governance committee under the phase-in exemption referenced above. In accordance with the phase-in exemption, a majority of the members of our nominating and corporate governance committee will satisfy the independence standards under the Exchange
Act and the Nasdaq listing rules within 90 days of the date of effectiveness of the registration statement of which this prospectus forms a part and all members of our nominating and corporate governance committee will satisfy the independence
standards under the Exchange Act and the Nasdaq listing rules within one year from the date of listing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities
of the nominating and corporate governance committee will include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing, and evaluating candidates, including the nomination of incumbent directors for reelection
and nominees recommended by our stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of
the committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting plans or programs for the continuing education of our board of directors and orientation of new
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and
matters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board
of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee will operate under a written charter, to be effective
immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of this offering, we intend to adopt a written code of business conduct and ethics, or the Code of Conduct, that applies
to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. Following this offering, a copy of the Code of
Conduct will be available on the Corporate Governance section of our website, https://lbpharma.us/. We intend to disclose on our website any future amendments of our Code of Conduct or waivers that exempt any of the principal executive officer,
principal financial officer, principal accounting officer or controller, persons performing similar functions or our directors from provisions in the Code of Conduct. Information contained on, or that can be accessed through, our website is not
incorporated by reference into this prospectus. We have included our website in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our current or former executive officers serve as a member of the compensation
committee. None of our officers serve, or have served during the last completed fiscal year, on the board of directors or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our
compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT></B><B><I> </I></B><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have not had a formal compensation policy with respect to service on our board of directors. In 2024, only our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, Mr.&nbsp;Garland and Dr.&nbsp;Ruffolo, Jr., received cash fees and option awards in respect of their board service, as shown in the table below. We did not provide compensation for 2024 to
our investor designee directors. We have reimbursed and will continue to reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending board of directors and committee meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Compensation Table </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information regarding the compensation of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors earned for service on our board of directors during the year ended December&nbsp;31, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:75%; vertical-align:top"> </SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Garland<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">801,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">856,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajul Jain, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebecca Luse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P.<SUP
STYLE="font-size:75%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">459,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Yu, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported in this column represent the aggregate grant date fair value of the stock option awards
granted to Mr.&nbsp;Garland and Dr.&nbsp;Ruffolo, Jr. during 2024 as determined in accordance with FASB ASC Topic 718. Assumptions used in the calculations of these amounts are included in Note&nbsp;10 to our audited financial statements included in
this registration statement. The amounts do not reflect the actual economic value that may be realized by Mr.&nbsp;Garland or Dr.&nbsp;Ruffolo, Jr. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes consulting fees of $3,500 per month paid to Dr. Ruffolo, Jr. for clinical consulting services provided
to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2024
for Mr.&nbsp;Garland was 21,514, none of which were vested. 25% of each of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly
installments thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2024
for Dr.&nbsp;Ruffolo, Jr. was 13,266, 2,510 of which were fully vested. 25% of the option awards vests upon the first anniversary of the grant date, and the remainder vests and becomes exercisable in thirty-six (36) substantially equal monthly
installments thereafter. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Turner, our current Chief Executive Officer, and Mr.&nbsp;Prensky, our former
Chief Executive Officer, each of whom is also a director, did not receive any additional compensation for their respective service as directors in 2024. Ms.&nbsp;Turner and Mr.&nbsp;Prensky&#8217;s compensation as named executive officers in 2024 is
set forth below under &#8220;Executive Compensation&#8212;Summary Compensation Table.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2025, our board of directors approved <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> compensation policy
that we expect will become effective in connection with this offering. Under <FONT STYLE="white-space:nowrap">the&nbsp;non-employee&nbsp;director</FONT> policy, our&nbsp;directors who are not also serving as employees of or consultants to us will be
eligible to receive the compensation summarized below for service on our board of directors and committees of our board of directors from and after the completion of this offering: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Compensation</I>. Under this policy, we will pay each of our non-employee directors cash retainers for service on our board of
directors and committees of our board of directors as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Cash</B><br><B>Retainer<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual retainer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for non-executive chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for audit committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for audit committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for compensation committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for compensation committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for nominating and corporate governance committee chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for nominating and corporate governance committee non-chair member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also reimburse each non-employee director for ordinary, necessary and reasonable
out-of-pocket travel expenses actually incurred by such director in connection with in-person attendance at and participation in meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Compensation</I>. In addition to cash compensation, each non-employee director will be eligible to receive options under our 2025
Plan. All options granted under the policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value of the underlying common stock on the date of grant, and a term of ten years from the date of
grant, subject to earlier termination in connection with a termination of service. Vesting schedules for equity awards will be subject to the non-employee director&#8217;s continuous service with us on each applicable vesting date, provided that
each option will vest in full upon a change in control (as defined in the 2025 Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Initial Award. </I>Each new non-employee
director elected or appointed to our board of directors after the effective date of the policy will automatically be granted an initial, one-time stock option award for 20,000&nbsp;shares. The initial option grant will vest in substantially equal
annual installments over a three-year period such that the option is fully vested on the third anniversary of the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Annual
Awards. </I>On the date of each annual meeting of stockholders of our company after the effective date of the policy, commencing with the 2026 annual meeting of stockholders, each non-employee director that continues to serve on our board of
directors will automatically be granted a stock option award for 10,000 shares. The annual option grant shall be prorated for non-employee directors who have served on our board of directors for less than one year as of such annual meeting. The
annual option grant shall vest on the one-year anniversary of the date of grant, provided that the annual grant will in any case be fully vested on the date of the our next annual stockholder meeting (or the date immediately prior to our next annual
stockholder meeting if the non-employee director&#8217;s service as a director ends at such meeting due to the non-employee director&#8217;s failure to be re-elected or the non-employee director not standing for re-election). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Non-employee director compensation limit</I>. The cash and equity compensation that each non-employee director is eligible to receive under
the policy will be subject to the director compensation limits set forth in the 2025 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director IPO Option Grants and Option Repricing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the date of the pricing of this offering, each of our non-employee directors will receive an option under our 2025 Plan to purchase a number
of shares of our common stock with an aggregate grant date fair value of $1.1&nbsp;million (which, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated price range set forth on the cover page
of this prospectus, will be 140,701 shares of our common stock), which will have an exercise price equal to the initial price per share to the public in this offering, and will vest in three annual installments such that each such option is fully
vested on the third anniversary of the grant date, subject to such non-employee director&#8217;s continuous service with us through each applicable vesting date, provided that each option will vest in full upon a change in control (as defined in the
2025 Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in September 2025, our board of directors approved the repricing of stock options previously granted to current
executive officers, employees and directors with per-share exercise prices above the initial price per share to the public in this offering, including options held by Mr. Garland and Dr. Ruffolo, Jr., which were &#8220;underwater&#8221;, meaning
that the exercise price per share of these options was greater than the current fair market value of our common stock. This Option Repricing is effective on the date of the pricing of this offering and reduced the exercise price per share of such
options to the initial price per share to the public in this offering, the fair market value of our common stock on the date of the Option Repricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2024, consisting of the two individuals who served as our principal
executive officer during the fiscal year ended December&nbsp;31, 2024 and the next two most highly compensated executive officers who were serving in such capacity as of December&nbsp;31, 2024, were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Heather Turner, our Chief Executive Officer and a member of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Zachary Prensky, our former Chief Executive Officer and a member of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roger Sawhney, our former Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anna Eramo, M.D., our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information regarding all of the compensation awarded to or earned by or paid to our named executive officers during the fiscal year ended December&nbsp;31, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather Turner<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,709,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,333<SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">4</SUP><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,792,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zachary Prensky<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,063,546<SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">6</SUP><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,561,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roger Sawhney<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,301,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,833<SUP STYLE="font-size:75%; vertical-align:top"></SUP><SUP STYLE="font-size:75%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">8</SUP><SUP STYLE="font-size:75%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,604,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eramo, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,800</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">891,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported in this column represent 2024 discretionary annual bonuses and, for Dr.&nbsp;Eramo only, an
additional $75,000 discretionary bonus paid in 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported in this column represent the aggregate grant date fair value of the stock options granted to
our named executive officers during 2024 under the 2023 Plan, as calculated in accordance with FASB ASC Topic 718. Assumptions used in the calculations of these amounts are included in Note 10 to our audited financial statements included in this
registration statement. The amounts do not reflect the actual economic value that may be realized by the named executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commenced employment as our Chief Executive Officer in November 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents a housing stipend. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resigned as our Chief Executive Officer in connection with Ms. Turner&#8217;s appointment as Chief Executive
Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown includes $13,800 in Company-paid 401(k) matching contributions and certain benefits in connection
with Mr.&nbsp;Prensky&#8217;s employment termination pursuant to the Prensky Separation Agreement (as defined below), which include the following: (i)&nbsp;eighteen (18) months of base salary ($750,000), (ii) an amount with respect to his 2024
annual bonus ($250,000), and (iii)&nbsp;eighteen (18) months of the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, premiums ($49,746). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commenced employment as our Chief Financial Officer in June 2024 and was subsequently terminated in May 2025.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents Company-paid 401(k) matching contributions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set,
experience, role, and responsibilities. The base salary of our named executive officers is generally determined and approved by our board of directors in connection with the commencement of employment of the named executive officer and may be
adjusted from time to time thereafter as the board of directors determines appropriate. The 2024 annual base salaries for our named executive officers were as follows: (1) $550,000 for Ms.&nbsp;Turner, (2) $500,000 for Mr.&nbsp;Prensky, (3) $410,000
for Mr.&nbsp;Sawhney, and (4) $375,000 for Dr.&nbsp;Eramo. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bonus Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to base salaries, each of our named executive officers is eligible to receive a discretionary annual bonus of up to a percentage of
the executive&#8217;s gross base salary based on individual performance, Company performance or as otherwise determined appropriate, as determined by our board of directors. For the year ended December&nbsp;31, 2024, cash bonus targets were 50% for
Ms.&nbsp;Turner, 40% for Mr.&nbsp;Prensky, 40% for Mr.&nbsp;Sawhney, and 40% for Dr.&nbsp;Eramo. The amount of any discretionary annual bonus is determined after the end of the year for which the bonus relates. The amounts paid to the named
executive officers for the 2024 discretionary annual bonus (other than Ms.&nbsp;Turner and Mr.&nbsp;Prensky) were as follows: (1) $108,397 for Mr.&nbsp;Sawhney, and (2) $187,500 for Dr.&nbsp;Eramo. Mr.&nbsp;Prensky received a $250,000 annual bonus
payment pursuant to the terms of the Prensky Separation Agreement, as described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the annual bonus, in May 2024, our board of directors (following the recommendation of our compensation committee) awarded
Dr.&nbsp;Eramo a discretionary bonus equal to $75,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards are designed to align our named executive officers&#8217; interests with those of our stockholders and to
retain and incentivize our named executive officers over the long term. Our board of directors is responsible for approving equity grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional retention
measure. Our named executive officers generally are awarded an initial <FONT STYLE="white-space:nowrap">new-hire</FONT> grant upon commencement of employment. Additional grants may occur periodically in order to specifically incentivize our named
executive officers with respect to achieving certain corporate goals or to reward our named executive officers for exceptional performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have granted all equity awards pursuant to our 2017 Plan, 2018 Plan, and our 2023 Plan. Following this offering, we
will grant equity incentive awards under the terms of our 2025 Plan. The terms of our equity plans are described below under &#8220;&#8212;Equity Benefit Plans.&#8221; All options are granted with a per share exercise price equal to no less than the
fair market value of a share of our common stock on the date of the grant of such award. Generally, our option awards vest over a four-year period subject to the holder&#8217;s continuous service to us, as further described under
&#8220;&#8212;Outstanding Equity Awards as of December&nbsp;31, 2024&#8221; below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2024, our board of directors granted
Mr.&nbsp;Prensky, Mr.&nbsp;Sawhney, and Dr.&nbsp;Eramo&nbsp;options to purchase 53,787, 34,065, and 6,275 shares of our common stock, respectively. In addition, in November 2024, our board of directors granted Ms.&nbsp;Turner an option to purchase
175,706 shares of our common stock. The terms of these awards are described under &#8220;&#8212;Outstanding Equity Awards as of December&nbsp;31, 2024&#8221; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>September 2025 Option Repricing </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, our board of directors approved the repricing of stock options previously granted to current executive officers, employees
and directors with per-share exercise prices above the initial price per share </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the public in this offering, including options held by Ms. Turner, Mr. Prensky and Dr. Eramo, which were &#8220;underwater&#8221;, meaning that the exercise price per share of these options
was greater than the current fair market value of our common stock. This Option Repricing is effective on the date of the pricing of this offering and reduce the exercise price per share of such options to the initial price per share to the public
in this offering, the fair market value of our common stock on the date of the Option Repricing. We believe that the Option Repricing is in our best interest and in the best interests of our stockholders, in order to motivate the optionholders to
continue to provide services to us and to work towards our success. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards as of December&nbsp;31, 2024 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding equity awards granted to our named executive officers that remained outstanding as
of December&nbsp;31, 2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares<BR>or Units<BR>of Stock<BR>that<BR>Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares<BR>or Units<BR>of Stock<BR>That<BR>Have&nbsp;Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather Turner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/18/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,706</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/17/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zachary Prensky<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/20/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/19/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">02/18/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/24/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,952</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/28/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/28/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,787</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/27/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roger Sawhney<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/28/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,065</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/27/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eramo, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,929</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">08/28/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/28/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,275</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">06/27/2034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The equity awards listed in the table above were granted under the 2023 Plan, the 2018 Plan, and the 2017 Plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exercise prices do not reflect the Option Repricing. If the initial price to the public in this offering is
less than the exercise price of these options, then upon the execution of the underwriting agreement related to this offering, the exercise prices of these options will be automatically repriced to an exercise price per share equal to the initial
price per share to the public in this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% of the option vests upon the first anniversary of the grant date, and the remainder vests and becomes
exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resigned as our Chief Executive Officer in connection with Ms. Turner&#8217;s appointment as Chief Executive
Officer. In connection with such resignation, Mr.&nbsp;Prensky&#8217;s outstanding option awards were treated as described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control&#8212;Zachary Prensky.&#8221;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Was terminated from the Chief Financial Officer role in May 2025. In connection with such termination,
Mr.&nbsp;Sawhney&#8217;s outstanding option award was treated as described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control&#8212;Roger Sawhney.&#8221; </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IPO Option Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September
2025, our board of directors approved the grant of options under our 2025 Plan to Ms. Turner and Dr. Eramo, effective upon the pricing of this offering, to purchase a number of shares of common stock such that their beneficial ownership of our total
outstanding shares of capital stock as of the pricing date of this offering, on a fully diluted basis after giving effect to this offering, will be equal to approximately 4.5% and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
0.75%, respectively. These options will have an exercise price equal to the initial public offering price. The shares underlying these options will vest as to 25% on the one-year anniversary of
the grant date, with the remainder vesting in 36 equal monthly installments thereafter, subject to the named executive officer continuing to have a service relationship with us through each applicable vesting date. Our board of directors also
approved an additional option grant under our 2025 Plan to Mr. Prensky in his capacity as a non-employee director, effective upon the pricing of this offering, to purchase a number of shares that will be equal to approximately 0.10% of our total
outstanding shares of capital stock as of such date after giving effect to this offering. Shares subject to this option will vest in three annual installments such that such option is fully vested on the third anniversary of the grant date, subject
to Mr. Prensky continuing to have a service relationship with us through each applicable vesting date. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to employment agreements with each of our named executive officers. The employment agreements set forth the named executive
officer&#8217;s base salary, eligibility for employee benefits, and severance benefits upon a qualifying termination of employment or change in control of our Company and, other than Ms.&nbsp;Turner, generally provide for an initial term commencing
on the effective date of the applicable agreement and ending on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the effective date. After the initial <FONT STYLE="white-space:nowrap">one-year</FONT> term, the employment agreement
will automatically renew for successive <FONT STYLE="white-space:nowrap">one-year</FONT> terms. Either we or the executive may elect not to renew the employment agreement after the initial <FONT STYLE="white-space:nowrap">one-year</FONT> term by
providing the other party written notice of <FONT STYLE="white-space:nowrap">non-renewal</FONT> not less than ninety (90)&nbsp;days prior to the expiration of the then-existing employment period. Each of our named executive officers has executed our
standard confidential information, inventions assignment, and arbitration agreement. The key terms of the employment agreements with our named executive officers, including potential payments upon termination or change in control, are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Heather Turner </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2024, we entered into an executive employment agreement with Heather Turner, our Chief Executive Officer and a member of our board of directors, who commenced employment on November&nbsp;18, 2024, or the Turner Employment Agreement. The
Turner Employment Agreement provides for an annual base salary of $550,000 per year. Pursuant to the Turner Employment Agreement, Ms.&nbsp;Turner is eligible to receive an annual performance cash bonus with a target bonus opportunity equal to 50% of
her base salary, as adjusted from time to time, based on the achievement of corporate and individual objectives and milestones established by our board of directors. Additionally, pursuant to the Turner Employment Agreement, Ms.&nbsp;Turner received
an option to purchase 175,706 shares of our common stock, at an exercise price of $41.84 per share. 25% of the option vests and becomes exercisable upon the first anniversary of the date Ms.&nbsp;Turner commenced employment with us, and the
remainder vests and becomes exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments thereafter, subject to Ms.&nbsp;Turner continuing to have a service relationship (as defined in the 2023
Plan) with us through each such date. In September 2025, our board of directors approved an increase in Ms. Turner&#8217;s annual base salary to $625,000, effective as of October 1, 2025, and an increase in her cash bonus target from 50% of her base
salary to 55% of her annual base salary. Ms.&nbsp;Turner is also entitled to certain severance benefits, the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Zachary Prensky </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we
entered into an executive employment agreement with Zachary Prensky, our former Chief Executive Officer and a member of our board of directors, which was amended in June 2024, or the Prensky Employment Agreement. The Prensky Employment Agreement
provided for an annual base salary of $500,000 per year, as adjusted from time to time. Pursuant to the Prensky Employment Agreement, Mr.&nbsp;Prensky was eligible to receive an annual performance cash bonus with a target bonus opportunity equal to
40% of his base salary, as adjusted from time to time, based on the achievement of corporate and individual objectives and milestones established by our board of directors. Additionally, the Prensky Employment Agreement provided for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the grant of an option to purchase (i)&nbsp;17,929 shares of our common stock, at an exercise price of $41.84 per share, whereby 25% of the option vests and becomes exercisable upon the first
anniversary of the effective date of the Prensky Employment Agreement, and the remainder vests and becomes exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments thereafter and (ii)
53,787 shares of our common stock, at an exercise price of $41.84 per share, whereby 25% of the option vests and becomes exercisable upon the first anniversary of the effective date of the amendment to the Prensky Employment Agreement, and the
remainder vests and becomes exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments thereafter, in each case, subject to Mr.&nbsp;Prensky continuing to have a service relationship (as
defined in the 2023 Plan) with us through each such date. Mr.&nbsp;Prensky was also entitled to certain severance benefits, pursuant to the Prensky Employment Agreement. In November 2024, we entered into a separation agreement with Mr.&nbsp;Prensky,
the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Roger Sawhney
</I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2024, we entered into an executive employment agreement with Roger Sawhney, our former Chief Financial Officer, who
commenced employment on June&nbsp;21, 2024, or the Sawhney Employment Agreement. The Sawhney Employment Agreement provided for an annual base salary of $410,000 per year. Pursuant to the Sawhney Employment Agreement, Mr.&nbsp;Sawhney was eligible to
receive an annual performance cash bonus with a target bonus opportunity equal to 40% of his base salary, as adjusted from time to time, based on the achievement of corporate and individual objectives and milestones established by our board of
directors. Additionally, the Sawhney Employment Agreement provided for the grant of an option to purchase 34,065 shares of our common stock, at an exercise price of $41.84 per share, whereby 25% of the option would have vested and become exercisable
upon the first anniversary of the effective date of the Sawhney Employment Agreement, with the remainder vesting and becoming exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments
thereafter, subject to Mr.&nbsp;Sawhney continuing to have a service relationship (as defined in the 2023 Plan) with us through each such date. Mr.&nbsp;Sawhney was also entitled to certain severance benefits, the terms of which are described below
under &#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221; In May 2025, we entered into a separation agreement with Mr.&nbsp;Sawhney, the terms of which are described below under &#8220;&#8212;Potential Payments Upon
Termination or Change in Control.&#8221; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anna Eramo, M.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we entered into an executive employment agreement with Anna Eramo, M.D., our Chief Medical Officer, or the Eramo Employment
Agreement. The Eramo Employment Agreement provides for an annual base salary of $375,000 per year, as adjusted from time to time. Dr.&nbsp;Eramo&#8217;s base salary was initially increased to $393,750 for 2025 and subsequently increased again in
connection with the amendment and restatement of the Eramo Employment Agreement, as described below. Pursuant to the Eramo Employment Agreement, Dr.&nbsp;Eramo is eligible to receive an annual performance cash bonus with a target bonus opportunity
equal to 40% of her base salary, as adjusted from time to time, based on the achievement of corporate and individual objectives and milestones established by our board of directors. Additionally, the Eramo Employment Agreement provided for the grant
of an option to purchase 26,893 shares of our common stock, at an exercise price of $41.84 per share. 25% of the option vested and became exercisable upon the first anniversary of the effective date of the Eramo Employment Agreement, and the
remainder vests and becomes exercisable in thirty-six (36)&nbsp;substantially equal monthly installments thereafter, subject to Dr.&nbsp;Eramo continuing to have a service relationship with us through each such date. In addition, contingent and
effective upon the effectiveness of the underwriting agreement related to the Company&#8217;s initial public offering, Dr. Eramo is eligible to receive an option to purchase a number of shares of our common stock such that her aggregate beneficial
ownership of the common stock as of the closing of the initial public offering would equal 0.75% of the fully diluted total number of shares of common stock outstanding as of the closing of this offering, rounded down to the nearest whole share. 25%
of such option shall vest and became exercisable upon the first anniversary of the pricing of this offering, and the remainder vests and becomes exercisable in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly
installments thereafter, subject to Dr.&nbsp;Eramo continuing to have a service relationship with us through each such date. Dr.&nbsp;Eramo is also entitled to certain severance benefits, the terms of which are described below under
&#8220;&#8212;Potential Payments Upon Termination or Change in Control.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Eramo Employment Agreement was amended and restated in September 2025 to, among
other changes, provide for an annual base salary of $475,000 and the grant of an option under our 2025 Plan, contingent and effective upon the pricing of this offering, as described above, and under &#8220;IPO Option Grants.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments Upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which a named executive officer&#8217;s service terminates, each of our named executive officers is entitled to
receive amounts earned during his or her term of service, including unpaid salary and unused vacation. In the event of certain termination scenarios, each named executive officer will be entitled to receive the additional benefits summarized below
pursuant to his or her employment agreement, subject to the timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a separation agreement and general release of claims (among other preconditions). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Heather Turner </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate
Ms.&nbsp;Turner&#8217;s employment without cause or she resigns for good reason (each of &#8220;cause&#8221; and &#8220;good reason&#8221; as defined in the Turner Employment Agreement) during a time period other than the three (3)&nbsp;months prior
to or twelve (12)&nbsp;months following a change in control (as defined in the Turner Employment Agreement), Ms.&nbsp;Turner will be entitled to receive the following benefits pursuant to the Turner Employment Agreement: (i)&nbsp;a severance payment
equal to twelve (12)&nbsp;months of her then-current annual base salary, and (ii)&nbsp;if Ms.&nbsp;Turner is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse Ms.&nbsp;Turner for the monthly COBRA premium
paid by her for herself and her spouse/dependents until the earliest of (A)&nbsp;twelve (12) months following the termination date; (B)&nbsp;the expiration of Ms.&nbsp;Turner&#8217;s eligibility for the continuation coverage under COBRA; or
(C)&nbsp;the date when Ms.&nbsp;Turner becomes eligible for substantially equivalent health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, in the alternative, we terminate Ms.&nbsp;Turner&#8217;s employment without cause or she resigns for good reason during the three
(3)&nbsp;months prior to or twelve (12)&nbsp;months following a change in control, Ms.&nbsp;Turner will be entitled to receive the following benefits in lieu of the regular severance benefits described above: (i)&nbsp;a lump sum cash payment equal
to eighteen (18)&nbsp;months of her then-current base salary, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(ii)&nbsp;one-and-a-half</FONT></FONT></FONT> (1.5) times the annual bonus for the year
in which the termination occurs, (iii) accelerated vesting of any unvested equity that Ms.&nbsp;Turner holds, and (iv)&nbsp;if Ms.&nbsp;Turner is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse
Ms.&nbsp;Turner for the monthly COBRA premium paid by her for herself and her spouse/dependents until the earliest of (A)&nbsp;eighteen (18) months following the termination date; (B)&nbsp;the expiration of Ms.&nbsp;Turner&#8217;s eligibility for
the continuation coverage under COBRA; or (C)&nbsp;the date when Ms.&nbsp;Turner becomes eligible for substantially equivalent health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of Ms.&nbsp;Turner&#8217;s employment by reason of death or disability (as defined in the Turner Employment Agreement),
Ms.&nbsp;Turner (or her estate) will be entitled to receive the following benefits pursuant to the Turner Employment Agreement: (i)&nbsp;a pro rata portion of the annual bonus for the fiscal year in which the termination occurs, to the extent earned
based on actual performance, and (ii)&nbsp;if Ms.&nbsp;Turner is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse Ms.&nbsp;Turner for the monthly COBRA premium paid by her (or in the event of her death,
her surviving spouse and/or dependents) for herself and her spouse/dependents, until the earliest of: (A)&nbsp;the last day of the month that is <FONT STYLE="white-space:nowrap">twenty-six</FONT> (26)&nbsp;weeks after the date of such termination;
(B)&nbsp;in the event of her disability, the date she becomes eligible to receive healthcare coverage from a subsequent employer, or (C)&nbsp;the date she is no longer eligible to receive COBRA continuation coverage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Zachary Prensky </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024,
we entered into a transition, consulting, and separation agreement with Mr.&nbsp;Prensky, or the Prensky Separation Agreement, pursuant to which he ceased serving as Chief Executive Officer and served as Advisor to our Chief Executive Officer
through December&nbsp;31, 2024, his employment termination date. Pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Prensky Separation Agreement, Mr.&nbsp;Prensky is receiving the following benefits: (i)&nbsp;eighteen (18) months of base salary, (ii)&nbsp;an amount equal to his 2024 target bonus, and
(iii)&nbsp;up to eighteen (18)&nbsp;months of COBRA premiums. The Prensky Separation Agreement also states that Mr.&nbsp;Prensky will provide consulting services following his termination of employment and while actively serving as a consultant,
will receive continued vesting of his outstanding and unvested options for the duration of the consulting period (as defined in the Prensky Separation Agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roger Sawhney </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we had
terminated Mr. Sawhney&#8217;s employment without cause or if he had resigned for good reason (each of &#8220;cause&#8221; and &#8220;good reason&#8221; as defined in the Sawhney Employment Agreement) during a time period other than the three (3)
months prior to or twelve (12) months following a change in control (as defined in the Sawhney Employment Agreement), Mr. Sawhney would have been entitled to receive the following benefits pursuant to the Sawhney Employment Agreement: (i) a
severance payment equal to nine (9) months of his then-current annual base salary, and (ii) if Mr. Sawhney had been eligible for and elected group health plan continuation coverage under COBRA, we would have reimbursed Mr. Sawhney for the monthly
COBRA premium paid by him for himself and his spouse/dependents until the earliest of (A) nine (9) months following the termination date; (B) the expiration of Mr. Sawhney&#8217;s eligibility for the continuation coverage under COBRA; or
(C)&nbsp;the date when Mr.&nbsp;Sawhney became eligible for substantially equivalent health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, in the alternative, we had terminated Mr.&nbsp;Sawhney&#8217;s employment without cause or he resigned for good reason during the three
(3)&nbsp;months prior to or twelve (12)&nbsp;months following a change in control, Mr.&nbsp;Sawhney would have been entitled to receive the following benefits in lieu of the regular severance benefits described above: (i)&nbsp;a lump sum cash
payment equal to one year of his then-current base salary, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(ii)&nbsp;one-and-a-half</FONT></FONT></FONT> (1.5) times the annual bonus for the year in
which the termination had occurred, (iii)&nbsp;accelerated vesting of any unvested equity that Mr.&nbsp;Sawhney had then held, and (iv)&nbsp;if Mr.&nbsp;Sawhney had been eligible for and elected group health plan continuation coverage under COBRA,
we would have reimbursed Mr.&nbsp;Sawhney for the monthly COBRA premium paid by him for himself and his spouse/dependents until the earliest of (A)&nbsp;twelve (12) months following the termination date; (B)&nbsp;the expiration of
Mr.&nbsp;Sawhney&#8217;s eligibility for the continuation coverage under COBRA; or (C)&nbsp;the date when Mr.&nbsp;Sawhney became eligible for substantially equivalent health insurance coverage in connection with new employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of Mr.&nbsp;Sawhney&#8217;s employment by reason of death or disability (as defined in the Sawhney Employment Agreement),
Mr.&nbsp;Sawhney (or his estate) would have been entitled to receive the following benefits pursuant to the Sawhney Employment Agreement: (i)&nbsp;a pro rata portion of the annual bonus for the fiscal year in which the termination occurred, to the
extent earned based on actual performance, and (ii)&nbsp;if Mr.&nbsp;Sawhney had been eligible for and elected group health plan continuation coverage under COBRA, we would have reimbursed Mr.&nbsp;Sawhney for the monthly COBRA premium paid by him
(or in the event of his death, his surviving spouse and/or dependents) for himself and his spouse/dependents, until the earliest of: (A)&nbsp;the last day of the month that is <FONT STYLE="white-space:nowrap">twenty-six</FONT> (26)&nbsp;weeks after
the date of such termination; (B)&nbsp;in the event of his disability, the date he became eligible to receive healthcare coverage from a subsequent employer, or (C)&nbsp;the date he was no longer eligible to receive COBRA continuation coverage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2025, we entered into a separation agreement with Mr.&nbsp;Sawhney, or the Sawhney Separation Agreement, pursuant to which his
employment with us terminated effective May&nbsp;7, 2025. Pursuant to the Sawhney Separation Agreement, Mr.&nbsp;Sawhney is receiving the following benefits: (i)&nbsp;the equivalent of nine (9)&nbsp;months of base salary, (ii)&nbsp;up to nine
(9)&nbsp;months of COBRA premiums, (iii)&nbsp;acceleration of his then-outstanding and unvested stock option under the 2023 Plan, such that 25% of the shares subject to the option will be treated as vested and exercisable as of May&nbsp;7, 2025, and
(iv)&nbsp;retention of our company-issued laptop computer provided to him during his employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anna Eramo, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Eramo Employment Agreement as it was in effect as of December 31, 2024, Dr.&nbsp;Eramo would have been entitled to
receive the following benefits in connection with specified terminations of her employment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we terminate Dr.&nbsp;Eramo&#8217;s employment without cause or she resigns for good reason (each of
&#8220;cause&#8221; and &#8220;good reason&#8221; as defined in the Eramo Employment Agreement), then Dr.&nbsp;Eramo will be entitled to receive the following benefits pursuant to the Eramo Employment Agreement: (i)&nbsp;a severance payment equal to
eighteen (18)&nbsp;months of her then-current base salary, (ii)&nbsp;a pro rata portion of the annual bonus for the fiscal year in which the termination occurs, to the extent Dr. Eramo would have otherwise earned such bonus based on actual
performance, and (iii)&nbsp;if Dr.&nbsp;Eramo is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse Dr.&nbsp;Eramo for eighteen (18)&nbsp;months of the monthly COBRA premium paid by her for herself and her
spouse/dependents, and (iv)&nbsp;an additional six (6)&nbsp;monthly installments of the option to purchase 26,893 shares of our common stock that Dr.&nbsp;Eramo received in August 2023 will automatically vest. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If, in the alternative, we terminate Dr.&nbsp;Eramo&#8217;s employment without cause or she resigns for good
reason in connection with a change in control (as defined in the Eramo Employment Agreement), Dr.&nbsp;Eramo will be entitled to receive the following benefits in lieu of the regular severance benefits set forth above: (i)&nbsp;a lump sum cash
payment equal to one year of her then-current base salary, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plus&nbsp;one-and-a-half</FONT></FONT></FONT> (1.5) times the annual bonus opportunity for
the year in which the termination occurs and (ii)&nbsp;if Dr.&nbsp;Eramo is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse Dr.&nbsp;Eramo for twelve&nbsp;(12)&nbsp;months of the monthly COBRA premium
paid by her for herself and her spouse/dependents. These severance arrangements were modified in the Eramo Employment Agreement, as amended and restated in September 2025, as described below. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Upon termination of Dr.&nbsp;Eramo&#8217;s employment by reason of death or disability (as defined in the Eramo
Employment Agreement), Dr.&nbsp;Eramo (or her estate) will be entitled to receive the following benefits pursuant to the Eramo Employment Agreement: (i)&nbsp;a pro rata portion of the annual bonus for the fiscal year in which the termination occurs,
to the extent Dr. Eramo would have otherwise earned such bonus based on actual performance, (ii)&nbsp;if Dr.&nbsp;Eramo is eligible for and elects group health plan continuation coverage under COBRA, we will reimburse Dr.&nbsp;Eramo for the monthly
COBRA premium paid by her (or in the event of her death, her surviving spouse and/or dependents) for herself and her spouse/dependents, until the earliest of: (A)&nbsp;the last day of the month that is
<FONT STYLE="white-space:nowrap">twenty-six</FONT> (26)&nbsp;weeks after the date of such termination, (B)&nbsp;in the event of Dr.&nbsp;Eramo&#8217;s disability, the date Dr.&nbsp;Eramo becomes eligible to receive healthcare coverage from a
subsequent employer, or (C)&nbsp;the date Dr.&nbsp;Eramo is no longer eligible to receive COBRA continuation coverage, and (iii)&nbsp;25% of the option to purchase 26,893 shares of our common stock that Dr.&nbsp;Eramo received in August 2023 will
automatically vest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Eramo Employment Agreement, as amended and restated in September 2025, provides for severance
benefits substantially similar to those described above with some modifications, including, among others, (i) the addition of a change in control period (the three (3) months prior to or twelve (12) months following a change in control) during which
the change in control severance benefits described above would be provided, (ii) the elimination of severance benefits in the event that we elect not to renew the term of the agreement, and (iii) upon a change in control termination, the accelerated
vesting of all outstanding equity awards. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Compensation and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our named executive officers is eligible to participate in our employee benefit plans, including our medical, dental, vision, life, and
long-term disability plans, in each case on the same basis as all of our other employees. We pay at least a portion of the premiums for medical, dental, vision, and life insurance for all of our employees, including our named executive officers. We
generally do not provide perquisites or personal benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to our named executive officers, except in limited circumstances. In addition, we provide the opportunity to participate in a 401(k) plan to our employees, including each of our named executive
officers, as discussed in the section below entitled &#8220;&#8212;401(k) Plan.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in a defined contribution retirement plan that provides eligible U.S. employees with
an opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">tax-advantaged</FONT> basis. Eligible employees may defer eligible compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or
<FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, up to the statutorily prescribed annual limits on contributions under the Code. Individual contributions are allocated to each participant&#8217;s individual account and are then
invested in selected investment alternatives according to the participants&#8217; directions. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with the 401(k) plan&#8217;s related trust intended to be tax exempt
under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan (except for Roth contributions) and earnings on those contributions are not taxable to the employees
until distributed from the 401(k) plan. We may elect, at our discretion, to make matching employee contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal features of our equity plans are summarized below. These summaries are qualified in their entirety by reference to the actual
text of the plans, which are filed as exhibits to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Equity Incentive Plan
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our 2025 Plan in August 2025 and our stockholders approved our 2025 Plan in September 2025. Our
2025 Plan is a successor to and continuation of our 2023 Plan (referred to in the 2025 Plan as LB Pharmaceuticals Inc 2023 Stock Incentive Plan) and became effective on the execution of the underwriting agreement related to this offering. Once our
2025 Plan became effective, no further grants will be made under our 2023 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. Our 2025 Plan provides for
the grant of incentive stock options, or ISOs, to employees, including employees of any parent or subsidiary, and for the grant of <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, or NSOs, stock appreciation rights, restricted
stock awards, restricted stock unit awards, performance awards, and other forms of stock awards to employees, directors, and consultants, including employees and consultants of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Initially, the maximum number of shares of our common stock that may be issued under our 2025 Plan after it becomes
effective will be 2,907,335 shares, which is the sum of: (i) 2,412,000 new shares, plus (ii) 38,519 shares available for issuance under the 2017 Plan, 2018 Plan and 2023 Plan as of the date of this prospectus, plus (iii) up to 456,816 returning
shares as such shares become available from time to time. In addition, the number of shares of our common stock reserved for issuance under our 2025 Plan will automatically increase on January&nbsp;1 of each calendar year, starting on
January&nbsp;1, 2026 (assuming the 2025 Plan becomes effective in 2025) through January&nbsp;1, 2035, in an amount equal to 5% of the total number of shares of our capital stock on a fully diluted basis on the last day of the calendar month before
the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of shares of our common stock that may be issued on the exercise of incentive stock options under our 2025 Plan is 8,722,005.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2025, our board of directors approved the grant of stock options to (i) current executive officers and employees, effective
upon the pricing of this offering, to purchase a number of shares of common stock such that their beneficial ownership of our total outstanding shares of capital stock as of the pricing date of this offering, on a fully diluted basis after giving
effect to this offering, will be equal to approximately 7.10% and 0.50%, respectively, and (ii) each of our non-employee directors, effective upon the pricing of this offering, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase a number of shares that will be equal to 0.10% of our total outstanding shares of capital stock as of the pricing of this offering after giving effect to this offering. These options
will have an exercise price equal to the initial public price per share of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to stock awards granted
under our 2025 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares available for issuance under our 2025 Plan. Additionally, shares become available
for future grant under our 2025 Plan if they were issued under stock awards under our 2025 Plan if we repurchase them or they are forfeited. This includes shares used to pay the exercise price of a stock award or to satisfy the tax withholding
obligations related to a stock award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors, or a duly authorized committee of our board of
directors, will administer our 2025 Plan. Our board of directors may also delegate to one or more persons or bodies the authority to do one or more of the following (i)&nbsp;designate recipients (other than officers) of specified stock awards
provided that no person or body may be delegated authority to grant a stock award to themself; (ii)&nbsp;determine the number of shares subject to such stock award; and (iii)&nbsp;determine the terms of such stock awards. Under our 2025 Plan, our
board of directors has the authority to determine and amend the terms of awards and underlying agreements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recipients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise, purchase or strike price of stock awards, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares subject to each stock award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the vesting schedule applicable to the awards, together with any vesting acceleration; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of consideration, if any, payable on exercise or settlement of the award. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2025 Plan, the board of directors also generally has the authority to effect, with the consent of any adversely affected
participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reduction of the exercise, purchase, or strike price of any outstanding award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cancellation of any outstanding award and the grant in substitution therefore of other awards, cash, or other
consideration; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other action that is treated as a repricing under generally accepted accounting principles.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The
plan administrator determines the exercise price for stock options, within the terms and conditions of the 2025 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock
on the date of grant. Options granted under the 2025 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax Limitations on ISOs</I>. The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs
that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to
any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (i)&nbsp;the option exercise price is at least 110% of the fair market value
of the stock subject to the option on the date of grant; and (ii)&nbsp;the option is not exercisable after the expiration of five years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards</I>. Restricted stock units are granted under restricted stock unit award agreements adopted by the plan
administrator. Restricted stock units may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit may be settled by cash, delivery
of stock, a combination of cash and stock as deemed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend equivalents may be credited in respect of
shares covered by a restricted stock unit. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator.
A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law.
The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of our
common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted under stock appreciation grant agreements adopted by the plan
administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. A stock appreciation
right granted under the 2025 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. The 2025 Plan permits the grant of performance-based stock and cash awards. The plan administrator may structure
awards so that the shares of our stock, cash, or other property will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. The
performance criteria that will be used to establish such performance goals may be based on any measure of performance selected by the plan administrator. The performance goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in
the award agreement at the time the award is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of
performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude
the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles;
(6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture;
(8)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under our bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and
(11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, we may establish or provide for other adjustment items in the award agreement at
the time the award is granted or in such other document setting forth the performance goals at the time the performance goals are established. We also retain the discretion to reduce or eliminate the compensation or economic benefit due upon
attainment of the goals. The performance goals may differ from participant to participant and from award to award. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Stock
Awards</I>. The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>. The
aggregate value of all compensation granted or paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any fiscal year following the year in which the underwriting agreement for this offering is executed, including
stock awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in total value (or in the case of the chair of the board, $1,000,000 in total value), or in the event such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the board of directors during such fiscal year, $1,000,000 in total value (in each case, calculating the value of any such stock awards based on the grant date
fair value of such stock awards for financial reporting purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event there is a specified
type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under the 2025 Plan,
(ii)&nbsp;the class and maximum number of shares by which the share reserve may increase automatically each year, (iii)&nbsp;the class and maximum number of shares that may be issued on the exercise of incentive stock options, and (iv)&nbsp;the
class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. The following applies to stock awards under the 2025 Plan in the event of a corporate transaction, unless
otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the plan administrator at the time of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined in the 2025 Plan), any stock awards outstanding under the 2025 Plan may be assumed,
continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the
surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to
the effective time of the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the transaction (contingent upon the
effectiveness of the transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards
will lapse (contingent upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise provided by an award agreement or by the administrator, the award
will accelerate at 100% of target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then with respect to any such stock awards that are held by persons other than
current participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and
may continue to be exercised notwithstanding the transaction. The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all
participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event a stock award will terminate if not exercised prior to the effective time of a transaction, the plan
administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant
would have received upon the exercise of the stock award over (ii)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our 2025 Plan, a corporate transaction is defined to include: (i)&nbsp;a sale of all or substantially all of our assets; (ii)&nbsp;the
sale or disposition of more than 50% of our outstanding securities; (iii)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction; and (iv)&nbsp;the consummation of a merger or consolidation where we do survive the
transaction but the shares of our common stock outstanding before such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement between us and
the award holder. Under the 2025 Plan, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change in control is defined to include (1)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (2)&nbsp;a merger,
consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity); (3) a
sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders; and (4)&nbsp;an unapproved change in the majority
of the board of directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. In the event of a change in control, as defined under our 2025 Plan, awards
granted under our 2025 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback</I>. All awards granted under the 2025 Plan will be subject to recoupment in accordance with any clawback policy that we are
required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act or other
applicable law. In addition, our board of directors may impose such other clawback, recovery or recoupment provisions in a stock award agreement as our board of directors determines necessary or appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. A participant may not transfer stock awards under our 2025 Plan other than by will, the laws of descent and
distribution, or as otherwise provided under our 2025 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors has the
authority to amend, suspend, or terminate our 2025 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the
approval of our stockholders. No incentive stock options may be granted after the tenth anniversary of the date our board of directors adopted our 2025 Plan. No stock awards may be granted under our 2025 Plan while it is suspended or after it is
terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2023 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted, and our stockholders approved, the 2023 Plan in August 2023. The 2023 Plan was amended in December 2024. The
2023 Plan terminated on the date the 2025 Plan became effective, and thereafter no further stock awards will be granted under the 2023 Plan. However, any outstanding stock awards granted under the 2023 Plan will remain outstanding, subject to the
terms of our 2023 Plan and award agreements, until such outstanding options are exercised or until any stock awards terminate or expire by their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2023 Plan allows for the grant of ISOs to our employees, including employees of any parent or subsidiary, and for
the grant of nonstatutory stock options and restricted stock awards to our employees, officers, directors, and consultants, including employees and consultants of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.&nbsp;Subject to certain capitalization adjustments, the aggregate number of shares of our common stock that could be
issued pursuant to stock awards under the 2023 Plan could not exceed 464,553&nbsp;shares. The maximum number of shares of our common stock that could be issued pursuant to the exercise of ISOs under our 2023 Plan was 464,553 shares. The shares we
have issued under the 2023 Plan have been authorized but unissued shares or shares we reacquired. The shares of common stock underlying any awards that are (i)&nbsp;expired or unexercisable without being exercised in full, (ii)&nbsp;surrendered
pursuant to an option exchange program (as defined in the 2023 Plan), (iii) forfeited to or repurchased by us due to a failure to vest, or (iv)&nbsp;that are withheld upon exercise of an award or settlement of an award to cover the tax withholding,
could again become available for issuance under the 2023 Plan, or collectively, 2023 Lapsed Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I>&nbsp;The 2023 Plan is administered by our board of directors or
a committee appointed by it, or the 2023 Plan Administrator. The 2023 Plan Administrator has full power to, among other things, (i)&nbsp;determine the fair market value of our common stock, (ii)&nbsp;select the individuals to whom awards may be
granted, (iii)&nbsp;determine the number of shares covered by awards, (iv)&nbsp;approve forms of award agreements for use under the 2023 Plan, (v)&nbsp;determine the specific terms and conditions of each award, (vi)&nbsp;amend the terms and
conditions of any award, (vii)&nbsp;to determine whether and under what circumstances an option may be settled in cash instead of common stock, (viii)&nbsp;institute and determine the terms of an option exchange program under which
(A)&nbsp;outstanding awards are exchanged for other awards or cash, (B)&nbsp;outstanding awards are transferred to a third party institution, or (C)&nbsp;the exercise price of outstanding awards is reduced or increased, (ix)&nbsp;approve addenda or
to grant awards to, or to modify the terms of, any outstanding award agreement or any agreement related to any award, optioned stock, or restricted stock held by participants who are foreign nationals or employed outside of the United States to
accommodate differences in local law, tax policy or custom, and (x)&nbsp;construe and interpret the terms of the 2023 Plan and awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I>&nbsp;The exercise price per share of all stock options generally must equal at least 100% of the fair market value per
share of our common stock on the date of grant. The term of a stock option may not exceed ten years. An ISO granted to a participant who owns more than 10% of the total combined voting power of all classes of our stock on the date of grant, or any
subsidiary corporations, may not have a term in excess of five years and must have an exercise price of at least 110% of the fair market value per share of our common stock on the date of grant. The 2023 Plan Administrator will determine the methods
of payment of the exercise price of an option, which may include cash, check, promissory note, other shares, consideration received under a cashless exercise program, net exercise, other consideration and methods of payment, or any combination
thereof acceptable to the 2023 Plan Administrator. After a participant&#8217;s termination of service, the participant generally may exercise his or her stock options, to the extent vested as of such date of termination, during a period of three
(3)&nbsp;months after termination of service. If a termination of service is due to death or disability, the option generally will remain exercisable, to the extent vested as of such date of termination, for a period of twelve (12)&nbsp;months
following the date&nbsp;of such termination of service. However, in no event may an option be exercised later than the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. Restricted stock awards are grants of shares of our common stock that are subject to various restrictions, including
restrictions on transferability, and forfeitures provisions. Shares of restricted stock will vest, and the restrictions on such shares will lapse, in accordance with terms and conditions established by the 2023 Plan Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event of certain changes in our capitalization, the 2023 Plan Administrator will adjust the number
and class of shares of stock that may be delivered under the 2023 Plan and/or the number, class, and price of shares of common stock covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions. </I>The 2023 Plan provides that in the event of a corporate transaction (as defined in the 2023 Plan), each
outstanding award will be treated as the 2023 Plan Administrator determines without participant&#8217;s consent. Such determination may provide for one or more of the following including, without limitation, that (i)&nbsp;awards will be continued by
us if we are the surviving entity, (ii)&nbsp;awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind
of shares and prices, (iii)&nbsp;the participant&#8217;s awards will terminate upon or immediately prior to the consummation of such&nbsp;corporate transaction for no consideration, or (iv)&nbsp;the termination of an award in exchange for a payment
in an amount equal to the excess of (1)&nbsp;the fair market value of the shares of our common stock subject to such awards as of the closing date of such corporate transaction over or (2)&nbsp;the exercise price or purchase price paid or to be paid
for the shares subject to the awards. The 2023 Plan Administrator will not be obligated to treat similarly all awards, all awards a participant holds, all awards of the same type, or all portions of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. The 2023 Plan generally does not allow for the transfer or
assignment of awards other than by will or by the laws of descent and distribution, or, at the discretion of the 2023 Plan Administrator by gift to an immediate family member or to trusts for the benefit of family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors may amend, alter, suspend, or terminate the 2023 Plan at any time and for any
reason, provided that stockholder approval is obtained where such approval is required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted, and our stockholders approved, the 2018 Plan in August 2018. The 2018 Plan terminated on the date the 2023 Plan
became effective, and thereafter no further stock awards were granted under the 2018 Plan. However, any outstanding stock awards granted under the 2018 Plan will remain outstanding, subject to the terms of our 2018 Plan and award agreements, until
such outstanding options are exercised or until any stock awards terminate or expire by their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2018
Plan allows for the grant of ISOs to our employees, including employees of any parent or subsidiary, and for the grant of nonstatutory stock options and restricted stock awards to our employees, officers, directors, and consultants, including
employees and consultants of our affiliates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.&nbsp;Subject to certain capitalization adjustments, the
aggregate number of shares of our common stock that could be issued pursuant to stock awards under the 2018 Plan could not exceed 39,328 shares. The maximum number of shares of our common stock that could be issued pursuant to the exercise of ISOs
under our 2018 Plan was 39,328 shares plus any 2018 Lapsed Awards (as defined below). The shares we have issued under the 2018 Plan have been authorized but unissued shares or shares we reacquired. The shares of common stock underlying any awards
that are (i)&nbsp;expired or unexercisable without being exercised in full, (ii)&nbsp;surrendered pursuant to an option exchange program (as defined in the 2018 Plan), (iii) forfeited to or repurchased by us due to a failure to vest, or
(iv)&nbsp;that are withheld upon exercise of an award or settlement of an award to cover the tax withholding, could again become available for issuance under the 2018 Plan, or collectively, 2018 Lapsed Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I>&nbsp;The 2018 Plan is administered by our board of directors or a committee appointed by it, or the 2018 Plan
Administrator. The 2018 Plan Administrator has full power to, among other things, (i)&nbsp;determine the fair market value of our common stock, (ii)&nbsp;select the individuals to whom awards may be granted, (iii)&nbsp;determine the number of shares
covered by awards, (iv)&nbsp;approve forms of award agreements for use under the 2018 Plan, (v)&nbsp;determine the specific terms and conditions of each award, (vi)&nbsp;amend the terms and conditions of any award, (vii)&nbsp;to determine whether
and under what circumstances an option may be settled in cash instead of common stock, (viii)&nbsp;institute and determine the terms of an option exchange program under which (A)&nbsp;outstanding awards are exchanged for other awards or cash,
(B)&nbsp;outstanding awards are transferred to a third party institution, or (C)&nbsp;the exercise price of outstanding awards is reduced or increased, (ix)&nbsp;approve addenda or to grant awards to, or to modify the terms of, any outstanding award
agreement or any agreement related to any award, optioned stock, or restricted stock held by participants who are foreign nationals or employed outside of the United States to accommodate differences in local law, tax policy or custom, and
(x)&nbsp;construe and interpret the terms of the 2018 Plan and awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I>&nbsp;The exercise price per share of all
stock options generally must equal at least 100% of the fair market value per share of our common stock on the date of grant. The term of a stock option may not exceed ten years. An ISO granted to a participant who owns more than 10% of the total
combined voting power of all classes of our stock on the date of grant, or any subsidiary corporations, may not have a term in excess of five years and must have an exercise price of at least 110% of the fair market value per share of our common
stock on the date of grant. The 2018 Plan Administrator will determine the methods of payment of the exercise price of an option, which may include cash, check, promissory note, other shares, consideration received under a cashless
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise program, net exercise, other consideration and methods of payment, or any combination thereof acceptable to the 2018 Plan Administrator. After a participant&#8217;s termination of
service, the participant generally may exercise his or her stock options, to the extent vested as of such date of termination, during a period of three (3)&nbsp;months after termination of service. If a termination of service is due to death or
disability, the option generally will remain exercisable, to the extent vested as of such date of termination, for a period of twelve (12)&nbsp;months following the date&nbsp;of such termination of service. However, in no event may an option be
exercised later than the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. Restricted stock awards are grants of shares of our common
stock that are subject to various restrictions, including restrictions on transferability, and forfeitures provisions. Shares of restricted stock will vest, and the restrictions on such shares will lapse, in accordance with terms and conditions
established by the 2018 Plan Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event of certain changes in our capitalization,
the 2018 Plan Administrator will adjust the number and class of shares of stock that may be delivered under the 2018 Plan and/or the number, class, and price of shares of common stock covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions. </I>The 2018 Plan provides that in the event of a corporate transaction (as defined in the 2018 Plan), each
outstanding award will be treated as the 2018 Plan Administrator determines without participant&#8217;s consent. Such determination may provide for one or more of the following including, without limitation, that (i)&nbsp;awards will be continued by
us if we are the surviving entity, (ii)&nbsp;awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind
of shares and prices, (iii)&nbsp;the participant&#8217;s awards will terminate upon or immediately prior to the consummation of such&nbsp;corporate transaction for no consideration, or (iv)&nbsp;the termination of an award in exchange for a payment
in an amount equal to the excess of (1)&nbsp;the fair market value of the shares of our common stock subject to such awards as of the closing date of such corporate transaction over or (2)&nbsp;the exercise price or purchase price paid or to be paid
for the shares subject to the awards. The 2018 Plan Administrator will not be obligated to treat similarly all awards, all awards a participant holds, all awards of the same type, or all portions of awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. The 2018 Plan generally does not allow for the transfer or assignment of awards other than by will or by the laws of
descent and distribution, or, at the discretion of the 2018 Plan Administrator by gift to an immediate family member or to trusts for the benefit of family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors may amend, alter, suspend, or terminate the 2018 Plan at any time and for any
reason, provided that stockholder approval is obtained where such approval is required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted, and our stockholders approved, the 2017 Plan in January 2017. The 2017 Plan was most recently amended in August
2018. The 2017 Plan terminated on the date the 2018 Plan became effective, and thereafter no further stock awards were granted under the 2017 Plan. However, any outstanding stock awards granted under the 2017 Plan will remain outstanding, subject to
the terms of our 2017 Plan and award agreements, until such outstanding options are exercised or until any stock awards terminate or expire by their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2017 Plan allows for the grant of ISOs to our employees, including employees of any parent or subsidiary, and for
the grant of nonstatutory stock options and restricted stock awards to our employees, officers, directors and consultants, including employees and consultants of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.&nbsp;Subject to certain capitalization adjustments, the aggregate number of shares of our common stock that could be
issued pursuant to stock awards under the 2017 Plan could not exceed 26,893 shares. The maximum number of shares of our common stock that could be issued pursuant to the exercise of ISOs under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our 2017 Plan was 26,893 shares plus any 2017 Lapsed Awards (as defined below). The shares we have issued under the 2017 Plan have been authorized but unissued shares or shares we reacquired. The
shares of common stock underlying any awards that are (i)&nbsp;expired or unexercisable without being exercised in full, (ii)&nbsp;surrendered pursuant to an option exchange program (as defined in the 2017 Plan), (iii) forfeited to or repurchased by
us due to a failure to vest, or (iv)&nbsp;that are withheld upon exercise of an award or settlement of an award to cover the tax withholding, could again become available for issuance under the 2017 Plan, or collectively, 2017 Lapsed Awards. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I>&nbsp;The 2017 Plan is administered by our board of directors or a committee appointed by it, or the 2017 Plan
Administrator. The 2017 Plan Administrator has full power to, among other things, (i)&nbsp;determine the fair market value of our common stock, (ii)&nbsp;select the individuals to whom awards may be granted, (iii)&nbsp;determine the number of shares
covered by awards, (iv)&nbsp;approve forms of award agreements for use under the 2017 Plan, (v)&nbsp;determine the specific terms and conditions of each award, (vi)&nbsp;amend the terms and conditions of any award, (vii)&nbsp;to determine whether
and under what circumstances an option may be settled in cash instead of common stock, (viii)&nbsp;institute and determine the terms of an option exchange program under which (A)&nbsp;outstanding awards are exchanged for other awards or cash,
(B)&nbsp;outstanding awards are transferred to a third party institution, or (C)&nbsp;the exercise price of outstanding awards is reduced or increased, (ix)&nbsp;approve addenda or to grant awards to, or to modify the terms of, any outstanding award
agreement or any agreement related to any award, optioned stock, or restricted stock held by participants who are foreign nationals or employed outside of the United States to accommodate differences in local law, tax policy or custom, and
(x)&nbsp;construe and interpret the terms of the 2017 Plan and awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I>&nbsp;The exercise price per share of all
stock options generally must equal at least 100% of the fair market value per share of our common stock on the date of grant. The term of a stock option may not exceed ten years. An ISO granted to a participant who owns more than 10% of the total
combined voting power of all classes of our stock on the date of grant, or any subsidiary corporations, may not have a term in excess of five years and must have an exercise price of at least 110% of the fair market value per share of our common
stock on the date of grant. The 2017 Plan Administrator will determine the methods of payment of the exercise price of an option, which may include cash, check, promissory note, other shares, consideration received under a cashless exercise program,
net exercise, other consideration and methods of payment, or any combination thereof acceptable to the 2017 Plan Administrator. After a participant&#8217;s termination of service, the participant generally may exercise his or her stock options, to
the extent vested as of such date of termination, during a period of three (3)&nbsp;months after termination of service. If a termination of service is due to death or disability, the option generally will remain exercisable, to the extent vested as
of such date of termination, for a period of twelve (12)&nbsp;months following the date&nbsp;of such termination of service. However, in no event may an option be exercised later than the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. Restricted stock awards are grants of shares of our common stock that are subject to various restrictions, including
restrictions on transferability, and forfeitures provisions. Shares of restricted stock will vest, and the restrictions on such shares will lapse, in accordance with terms and conditions established by the 2017 Plan Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event of certain changes in our capitalization, the 2017 Plan Administrator will adjust the number
and class of shares of stock that may be delivered under the 2017 Plan and/or the number, class, and price of shares of common stock covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions. </I>The 2017 Plan provides that in the event of a corporate transaction (as defined in the 2017 Plan), each
outstanding award will be treated as the 2017 Plan Administrator determines without participant&#8217;s consent. Such determination may provide for one or more of the following including, without limitation, that (i)&nbsp;awards will be continued by
us if we are the surviving entity, (ii)&nbsp;awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind
of shares and prices, (iii)&nbsp;the participant&#8217;s awards will terminate upon or immediately prior to the consummation of such&nbsp;corporate transaction for no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consideration, or (iv)&nbsp;the termination of an award in exchange for a payment in an amount equal to the excess of (1)&nbsp;the fair market value of the shares of our common stock subject to
such awards as of the closing date of such corporate transaction over or (2)&nbsp;the exercise price or purchase price paid or to be paid for the shares subject to the awards. The 2017 Plan Administrator will not be obligated to treat similarly all
awards, all awards a participant holds, all awards of the same type, or all portions of awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. The 2017 Plan
generally does not allow for the transfer or assignment of awards other than by will or by the laws of descent and distribution, or, at the discretion of the 2017 Plan Administrator by gift to an immediate family member or to trusts for the benefit
of family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment or Termination</I>. Our board of directors may amend, alter, suspend, or terminate the 2017 Plan at
any time and for any reason, provided that stockholder approval is obtained where such approval is required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2025 Employee Stock
Purchase Plan </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors adopted our ESPP in August 2025 and our stockholders approved our ESPP in September 2025.
The ESPP became effective upon the execution of the underwriting agreement for this offering. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for
such individuals to exert maximum efforts toward our success and that of our affiliates. Our ESPP will include two components. One component will be designed to allow eligible U.S. employees to purchase our ordinary shares in a manner that may
qualify for favorable tax treatment under Section&nbsp;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation
by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share
Reserve.</I>&nbsp;Following this offering, the ESPP authorizes the issuance of 201,000 shares of our common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common
stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2026 (assuming the ESPP becomes effective in 2025) through January&nbsp;1, 2035, by the lesser of (i) 1% of the total
number of shares of our capital stock on a fully diluted basis on the last day of the calendar month before the date of the automatic increase, and (ii) 402,000 shares; provided that before the date of any such increase, our board of directors may
determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). As of the date hereof, no shares of our common stock have been purchased under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration.</I>&nbsp;Our board of directors, or a duly authorized committee thereof, will administer our ESPP. Our board of directors
may delegate concurrent authority to administer the ESPP to our compensation and management development committee under the terms of the compensation and management development committee&#8217;s charter. The ESPP is implemented through a series of
offerings under which eligible employees are granted purchase rights to purchase shares of our common stock on specified dates during such offerings. Under the ESPP, we may specify offerings with durations of not more than 27 months and may specify
shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under
certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payroll Deductions.</I>&nbsp;Generally, all regular employees, including executive officers, employed by us or
by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to&nbsp;15% of their earnings (as defined in the ESPP) for the purchase of our common stock under the ESPP. Unless otherwise
determined by our board of directors, common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (i) 85% of the fair market value of a share of our common stock on the
first date of an offering; or (ii) 85% of the fair market value of a share of our common stock on the date of purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations</I>. Employees may have to satisfy one or more of the following service
requirements before participating in the ESPP, as determined by our board of directors, including: (i)&nbsp;customary employment with us or one of our affiliates for more than 20 hours per week and more than five months per calendar year or
(ii)&nbsp;continuous employment with us or one of our affiliates for a minimum period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market
value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are
granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure.</I>&nbsp;In the event that there occurs a change in our capital structure through such actions as a stock
split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure, or similar transaction, the board of directors will make appropriate adjustments to: (i)&nbsp;the number of shares reserved under the ESPP; (ii)&nbsp;the maximum number of shares by which the share reserve may increase
automatically each year; (iii)&nbsp;the number of shares and purchase price of all outstanding purchase rights; and (iv)&nbsp;the number of shares that are subject to purchase limits under ongoing offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I>&nbsp;In the event of certain significant corporate transactions (as defined in the ESPP), including: (i)&nbsp;a
sale of all or substantially all of our assets; (ii)&nbsp;the sale or disposition of more than 50% of our outstanding securities; (iii)&nbsp;the consummation of a merger or consolidation where we do not survive the transaction; and (iv)&nbsp;the
consummation of a merger or consolidation where we do survive the transaction but the shares of our common&nbsp;stock outstanding immediately before such transaction are converted or exchanged into other property by virtue of the transaction, any
then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to
assume, continue, or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days before such corporate transaction, and such
purchase rights will terminate immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>ESPP Amendment or Termination.</I>&nbsp;Our board of directors has the authority to amend
or terminate our ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to
our ESPP as required by applicable law or listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering limits the
liability of our current and former directors and officers for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors and officers of a corporation will not be personally liable for monetary damages
for any breach of fiduciary duties as directors or officers, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a director, unlawful payments of dividends or unlawful stock repurchases or redemptions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as an officer, derivative claims brought on behalf of the corporation by a stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or recission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will authorize us to indemnify our
directors, officers, employees, and other agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware
law and may indemnify our other employees and agents. Our amended and restated bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of
any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee, or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to
indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers, and other employees as determined by the board of directors. With certain
exceptions, these agreements provide for indemnification for related expenses including attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by any of these individuals in any action or proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and indemnification
agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#8217; and officers&#8217; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if
successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these
indemnification provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors,
executive officers, or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors, executive officers or employees for which
indemnification is sought, and we are not aware of any threatened litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades
pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some
circumstances and may terminate a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan
when they are not in possession of material nonpublic information, or MNPI subject to compliance with the terms of our insider trading policy and any applicable <FONT STYLE="white-space:nowrap">10b5-1</FONT>
guidelines.<B><I></I></B><B><I>&nbsp;</I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Practices Related to the Grant of Certain Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we grant stock options to our employees, including the named executive officers, and to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Historically, we have granted <FONT STYLE="white-space:nowrap">new-hire</FONT> option awards on or soon after a <FONT STYLE="white-space:nowrap">new-hire&#8217;s</FONT> employment start
date and refresh, promotion or retention option grants when and as determined by our board of directors. We do not maintain any written policies on the timing of awards of stock options or similar instruments with option-like features. Following the
effective date of the registration statement of which this prospectus forms a part, we expect that (i)&nbsp;the board of directors will consider whether there is any MNPI about us when determining the timing of stock option grants and will not seek
to time the award of stock options in relation to our public disclosure of MNPI and (ii)&nbsp;we will not time the public release of MNPI for the purpose of affecting the value of executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we
describe transactions since January&nbsp;1, 2022 to which we were or will be a participant, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount involved in the transaction exceeded or will exceed the lesser of (i) $120,000 and (ii) 1% of the
average of our total assets as of the end of the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our then directors, executive officers, or holders of more than 5% of our capital stock, or any member of
the immediate family of, or person sharing the household with, any of these individuals or entities, which we collectively refer to as our related parties, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C
Preferred Stock Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From August 2023 to January 2024, we issued and sold an aggregate of 50&nbsp;million shares of our
Series C preferred stock at a purchase price of $1.50 per share for aggregate gross proceeds of $75.0&nbsp;million. In addition, in August 2023, we issued an aggregate of 23,820,346 shares of our Series C preferred stock in exchange of the principal
amount of all outstanding convertible notes at a conversion price of $1.50 per share. However, prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and
have received their shares in prior offerings at prices lower than the price offered to the public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets
forth the number of shares of our Series C preferred stock purchased by our related parties. See the section titled &#8220;Principal Stockholders&#8221; for additional information. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name Of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series C<BR>Convertible<BR>Preferred<BR>Stock (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Vida
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,333,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Pontifax<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with TCG Crossover
Fund<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rebecca Luse, a member of our board of directors, is a Principal of Deep Track Capital. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rajul Jain, M.D., a member of our board of directors, is a Managing Director of Vida Ventures.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ran Nussbaum, a member of our board of directors, is a Managing Partner and the
<FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Pontifax. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chen Yu, M.D., a member of our board of directors, is a Founder and Managing Partner of TCG Crossover Fund.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2016, we entered into several Original Royalty Agreements with certain of our existing investors,
<FONT STYLE="white-space:nowrap">co-founders,</FONT> former and current directors, and former and current executive officers, including Zachary Prensky, Andrew Vaino, Ph.D., and Marc Panoff, for royalties payable, in the aggregate, of up to 5.0% of
future commercial worldwide sales of <FONT STYLE="white-space:nowrap">LB-102.</FONT> In this transaction, we received $0.2&nbsp;million in cash in exchange for the certificate holders receiving convertible notes with a face value of
$0.2&nbsp;million, shares of our common stock and the future royalties provided for in the Original Royalty Agreements. The future royalty payments provided for in the Original Royalty Agreements had an expiration date of December&nbsp;31, 2037. The
royalties were transferable upon surrender of the royalty certificate accompanied by written and notarized instructions of the transfer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided that the certificate holder could not transfer to any individual or entity (i)&nbsp;to which it was unlawful for us to make such payments or (ii)&nbsp;that owned, controlled or possessed
voting rights in the aggregate of more than 10% of our common stock. We had the option to purchase all issued and outstanding royalty certificates under the Original Royalty Agreements by way of a tender offer to all such holders, which would become
binding at such time as the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding royalty interests agreed in writing to accept such tender offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of the Series C financing, we entered into several Amended and Restated Royalty Agreements
to remove the expiration date and modify royalties payable to certificate holders in the aggregate amount of up to 2.75% of net sales of <FONT STYLE="white-space:nowrap">LB-102</FONT> through December&nbsp;31, 2035 and increasing to up to 3.25% of
net sales in 2036 and thereafter. Future sales are defined in these agreements as the gross payments received on total commercial sales of <FONT STYLE="white-space:nowrap">LB-102,</FONT> whether by us or by any licensee of <FONT
STYLE="white-space:nowrap">LB-102.</FONT> None of the proceeds from the Series C financing were allocated to the certificate holders as the investors in the Series C financing are not parties to the Original Royalty Agreements or the Amended and
Restated Royalty Agreements. Each certificate holder has the same rights and obligations as the other holders except with respect to its individual royalty amount that may come due from us if we generate any revenue from future sales of <FONT
STYLE="white-space:nowrap">LB-102.</FONT> The certificate holders may not transfer rights under the applicable Amended and Restated Royalty Agreement to any individual, entity, corporation, partnership or any other such organization without our
written consent, which shall not be unreasonably withheld. We may purchase all issued and outstanding royalty certificates under the Amended and Restated Royalty Agreements by way of a tender offer to all such holders, which will become binding at
such time as the holders of <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding royalty interests thereunder agree in writing to accept such tender offer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with
our preferred stock financings, we entered into investors&#8217; rights, right of first refusal and <FONT STYLE="white-space:nowrap">co-sale,</FONT> and voting agreements, which contain, among other things, registration rights, information rights,
voting rights, and rights of first refusal, with certain holders of our capital stock, including entities affiliated with Deep Track Capital, Vida Ventures, Pontifax and TCG Crossover Fund. These agreements will terminate upon the closing of this
offering, except for the registration rights granted under our investors&#8217; rights agreement, as more fully described in the section titled &#8220;Description of Capital Stock&#8212;Registration Rights.&#8221; See also the section titled
&#8220;Principal Stockholders&#8221; for additional information regarding beneficial ownership of our capital stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options and restricted stock awards to our executive officers and certain members of our board of directors. For more
information regarding the options granted to our executive officers and directors, see the sections titled <FONT STYLE="white-space:nowrap">&#8220;Management&#8212;Non-Employee</FONT> Director Compensation&#8221; and &#8220;Executive
Compensation.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will be in effect immediately prior to the closing of this offering will contain
provisions limiting the liability of directors and officers, and our amended and restated bylaws that will be in effect immediately prior to the closing of this offering will provide that we will indemnify each of our directors and officers to the
fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect immediately prior to the closing of this offering will also provide our board of directors with
discretion to indemnify our employees when determined appropriate by the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect to enter into indemnification
agreements with each of our directors and executive officers prior to the closing of this offering. For more information regarding these agreements, see the section titled &#8220;Executive Compensation&#8212;Limitation of Liability and
Indemnification.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Transactions with Related Persons </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have not had a formal policy regarding approval of transactions with related parties. In connection with this
offering, we intend to adopt a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration, and approval or ratification of &#8220;related-person transactions,&#8221;
which policy will become effective immediately upon the execution of the underwriting agreement related to this offering. For purposes of our policy only, a &#8220;related-person transaction&#8221; will be a transaction, arrangement or relationship
(or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are, were or will be participants involving an amount that exceeds $120,000 or, if less, 1% of the average of our total assets
for the last two competed fiscal years. Transactions involving compensation for services provided to us as an employee or director will not be covered by this policy. A related person will be any executive officer, director, nominee to become a
director or a beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and affiliates, including entities owned or controlled by such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, where a transaction has been identified as a related-person transaction, including any transaction that was not a related
person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the proposed related person transaction to
our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review, consideration, and approval or ratification. The presentation must include a description of,
among other things, all of the parties thereto, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction, and whether the transaction is on terms that are comparable to the terms available
to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer, and, to the extent feasible,
significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct that we intend to adopt prior to the closing of this offering,
our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account
the relevant available facts and circumstances including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs, and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#8217;s independence in the event the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy will require that, in determining whether to approve, ratify or reject a related person transaction, our
audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit
committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the transactions described in this section were entered into prior to the adoption of
this policy. Although we have not had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial
interest, including the transactions described above. Prior to approving such a transaction, the material facts as to a director&#8217;s or officer&#8217;s relationship or interest in the agreement or transaction were disclosed to our board of
directors. Our board of directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our capital stock as of June&nbsp;30, 2025 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership information shown in the table prior to this offering is based on 3,433,470 shares of common stock outstanding as of
June&nbsp;30, 2025, after giving effect to the Stock Split and the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership information shown in the table after this offering is based on 20,100,137 shares of common stock outstanding, after
giving effect to the Stock Split and the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering (including 382,467 additional shares
issuable upon conversion of our Series&nbsp;C convertible preferred stock due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth
on the cover page of this prospectus) and assuming the sale of 16,666,667 shares of common stock by us in this offering and no exercise by the underwriters of their option to purchase additional shares. The table below excludes any potential
purchases in this offering by the beneficial owners identified in the table below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in
accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares
of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable within 60 days of June&nbsp;30, 2025. These shares are deemed to be outstanding and beneficially owned by the
person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise
indicated, we believe based on information provided to us, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community
property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for each person or entity listed in the table
is c/o LB Pharmaceuticals Inc, One Pennsylvania Plaza, Suite 1025, New York, NY 10119. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Greater Than 5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">683,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Vida
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Pontifax<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover Fund II, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers, Directors and Director Nominees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather Turner<SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zachary Prensky<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roger Sawhney, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eramo, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Garland<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rajul Jain, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rebecca Luse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ran Nussbaum<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert R. Ruffolo, Jr., Ph.D., D.Sc. (h), D.Eng. (h), F.C.P.P.<SUP
STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">9</SUP><SUP STYLE="font-size:75%; vertical-align:top">).</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Yu, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">410,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rekha Hemrajani</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Kane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (12&nbsp;persons)<SUP
STYLE="font-size:75%; vertical-align:top">(</SUP><SUP STYLE="font-size:75%; vertical-align:top">10</SUP><SUP STYLE="font-size:75%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,531,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 683,996 shares of common stock issuable upon conversion of shares of our redeemable convertible
preferred stock held by Deep Track Biotechnology Master Fund, Ltd., or the Master Fund. Deep Track Capital, LP, or the Investment Manager, serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Deep
Track Capital GP, LLC, or the General Partner, is the General Partner of the Investment Manager. David Kroin is the Chief Investment Officer of the Investment Manager and managing member of the General Partner and may be deemed to beneficially own
such shares. The business address of the Master Fund, the Investment Manager, the General Partner and Mr.&nbsp;Kroin is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,434 shares of common stock held by Vida Ventures Management Co, LLC, (ii) 1,258 shares of
common stock issuable upon conversion of shares of our redeemable convertible preferred stock held by Vida Ventures <FONT STYLE="white-space:nowrap">III-A,</FONT> L.P. and (iii) 545,938 shares of common stock issuable upon conversion of shares of
our redeemable convertible preferred stock held by Vida Ventures III, L.P. Vida Ventures <FONT STYLE="white-space:nowrap">III-A,</FONT> L.P. and Vida Ventures III, L.P. are collectively referred to as the &#8220;Vida Funds.&#8221; Vida Ventures GP
III, L.L.C., or Vida GP, is the general partner of each of the Vida Funds. Vida Ventures Management Co., LLC is the management company of the Vida Funds. Dr.&nbsp;Jain, a member of our board of directors, is a managing member of Vida GP. Each of
Vida GP and Dr.&nbsp;Jain may be deemed to have voting and dispositive power with respect to the shares owned by the Vida Funds. Each of Vida GP and Dr.&nbsp;Jain disclaims beneficial ownership of such shares, except to the extent of their
respective pecuniary interests therein. The address for each of these entities and individuals is 10100 Santa Monica Blvd, 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Los Angeles, CA 90067. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 261,120 shares of common stock issuable upon conversion of shares of our redeemable convertible
preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii)&nbsp;149,276 shares of common stock issuable upon conversion of shares of our redeemable convertible
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P.
L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015)&nbsp;Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the
Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. The address of each of the Pontifax Entities is c/o The Pontifax Group,
14 Shenkar Street, Herzelia, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 410,397 shares of common stock issuable upon conversion of shares of our redeemable convertible
preferred stock held by TCG Crossover Fund II, L.P. TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II, L.P. and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the
sole managing member of TCG Crossover GP II, LLC and may be deemed to share voting, investment and dispositive power with respect to these securities. Dr.&nbsp;Yu disclaims beneficial ownership over the shares held by TCG Crossover Fund II, L.P.,
except to the extent of his pecuniary interest therein. The business address for TCG Crossover GP II LLC, TCG Crossover Fund II, L.P. and Dr.&nbsp;Yu is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 69,658 shares of common stock beneficially held by Mr.&nbsp;Prensky, (ii) 492 shares of common
stock issuable upon conversion of shares of our redeemable convertible preferred stock beneficially held by Mr.&nbsp;Prensky, (iii) warrants to purchase up to 246 shares of common stock beneficially held by Mr.&nbsp;Prensky, and (iv) 30,747 shares
of common stock issuable upon the exercise of options held by Mr.&nbsp;Prensky that are exercisable within 60 days of June&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of shares of common stock issuable upon the exercise of options held by Mr.&nbsp;Sawhney that are
exercisable within 60 days of June&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,585 shares of common stock and (ii) 15,276 shares of common stock issuable upon the exercise
of options held by Dr.&nbsp;Eramo that are exercisable within 60 days of June&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of shares of common stock issuable upon the exercise of options held by Mr. Garland that are
exercisable within 60 days of June 30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,365 shares of common stock and (ii)&nbsp;6,318 shares of common stock issuable upon the
exercise of options held by Dr.&nbsp;Ruffolo that are exercisable within 60 days of June&nbsp;30, 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 87,284 shares of common stock beneficially owned by our current executive officers and
directors and (ii) 1,368,481 shares of common stock issuable up on conversion of shares of our redeemable convertible preferred stock, (iii)&nbsp;warrants to purchase up to 246 shares of common stock, and (iv)&nbsp;75,167&nbsp;shares of common stock
issuable upon common stock issuable upon the exercise of options held by our current executive officers and directors within 60 days of June&nbsp;30, 2025. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and
restated bylaws, as each will become effective immediately prior to the closing of this offering, are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws, which are
filed as exhibits to the registration statement of which this prospectus is part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our authorized capital stock will consist of 500,000,000 shares of common stock, par value $0.0001 per
share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred
stock into an aggregate of 3,181,815 shares of our common stock upon the closing of this offering (including 382,467 additional shares of common stock issuable upon conversion of our Series C convertible preferred stock due to anti-dilution
adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus), there would have been 3,433,470 shares of common stock
issued and outstanding, held of record by 368 stockholders. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of common stock
is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a
majority of the voting shares are able to elect all of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive
ratably dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of our common stock will be
entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any
outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences, and Privileges </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may
designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and
nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, there were 78,072,306 shares of redeemable convertible preferred stock outstanding, held of record by 298
stockholders. Upon the closing of this offering, all of the outstanding shares of redeemable convertible preferred stock will automatically convert into 3,181,815 shares of our common stock (including 382,467 additional shares of common stock
issuable upon conversion of our Series C convertible preferred stock due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on
the cover page of this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the
estimated offering price range set forth on the cover page of this prospectus, the 73,820,346 shares of our Series C convertible preferred stock outstanding prior to the Stock Split would convert into 3,029,425 shares of our common stock including
382,467 shares of common stock issuable in respect of anti-dilution adjustments. A&nbsp;$1.00 decrease in the initial public offering price would increase the number of shares of our common stock issuable in respect of our Series C convertible
preferred stock by 19,731 shares, and a $1.00 increase in the initial public offering price would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 19,254 shares; provided, however,
that in no event would the outstanding shares of our Series C convertible preferred stock convert into more than 3,049,156 shares of our common stock upon the closing of this offering. A 1.0 million share increase in the size of this offering would
increase the number of shares of our common stock issuable in respect of our Series B convertible preferred stock by 4,261 shares, and a&nbsp;1.0 million share decrease in the size of this offering would decrease the number of shares of our common
stock issuable in respect of our Series C convertible preferred stock by 4,795 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our amended and restated certificate of
incorporation that will become effective immediately prior to the closing of this offering, our board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or
more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations, or restrictions
thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current
plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, 465,866 shares of common stock were issuable upon the exercise of outstanding stock options, at a weighted-average
exercise price of $43.51 per share. For additional information regarding terms of our equity incentive plans, see the section titled &#8220;Executive Compensation&#8212;Equity Benefit Plans.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;A Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018 and March 2019, we issued warrants to certain investors to purchase an aggregate of 913,873 shares of our common stock at an
exercise price per share of $2.30, subject to adjustment as set forth in the warrant, or the Class&nbsp;A Warrants. In August 2023, in conjunction with the Series C financing, we modified the outstanding Class&nbsp;A Warrants and reduced the
exercise price to $0.01. As of June&nbsp;30, 2025, Class&nbsp;A Warrants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to purchase up to 24,919 shares of our common stock remained unexercised. The Class&nbsp;A Warrants include a cashless exercise feature allowing the holder to receive shares underlying the
applicable Class&nbsp;A Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable Class&nbsp;A Warrant for such shares. Each Class&nbsp;A Warrant is exercisable until the
10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> anniversary from its issuance date. The Class&nbsp;A Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of our common
stock at an issuance price per share that is less than the then-effective exercise price of the Class&nbsp;A Warrants. The warrant holder is not a stockholder and has none of the rights of a stockholder until the warrant is exercised and the shares
of common stock are issued upon exercise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018 and March 2019, we issued warrants to certain investors to purchase an aggregate of 913,873 shares of our common stock at an
exercise price per share of $2.30, subject to adjustment as set forth in the warrant, or the Class&nbsp;B Warrants. In August 2023, in conjunction with the Series C financing, we modified the outstanding Class&nbsp;B Warrants and reduced the
exercise price to $0.01. As of June&nbsp;30, 2025, Class&nbsp;B Warrants to purchase up to 31,605 shares of our common stock remained unexercised. The Class&nbsp;B Warrants include a cashless exercise feature allowing the holder to receive shares
underlying the applicable Class&nbsp;B Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable Class&nbsp;B Warrant for such shares. Each Class&nbsp;B Warrant became
exercisable in May 2022 and will remain exercisable until the 10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> anniversary from its issuance date. The Class&nbsp;B Warrants include anti-dilution protection provisions, subject to certain
exceptions, relating to subsequent sales of shares of our common stock at an issuance price per share that is less than the then-effective exercise price of the Class&nbsp;B Warrants. The warrant holder is not a stockholder and has none of the
rights of a stockholder until the warrant is exercised and the shares of common stock are issued upon exercise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Warrants </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, we issued warrants to certain investors to purchase 103,915 shares
of our common stock at an exercise price per share of $3.75, subject to adjustment as set forth in the warrant, or the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants. In August 2023, in conjunction with the Series C financing, we
modified the outstanding Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants, reducing the exercise price to $0.01. As of June&nbsp;30, 2025, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants to purchase up to 2,557 shares of our
common stock remained unexercised. Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants include a cashless exercise feature allowing the holder to receive shares underlying the applicable Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrant for such shares. Each Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Warrant is exercisable until its expiration in May 2027. The Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to
subsequent sales of shares of our common stock at an issuance price per share that is less than the then-effective exercise price of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants. The warrant holder is not a stockholder and has
none of the rights of a stockholder until the warrant is exercised and the shares of common stock are issued upon exercise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Maxim Warrants
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we issued warrants to Maxim Group LLC to purchase 1,528,632 shares of our common stock at an exercise price
per share of $0.01, subject to adjustment as set forth in the warrant, or the Maxim Warrants, which are currently held by Maxim Partners LLC. As of June&nbsp;30, 2025, the Maxim Warrants to purchase up to 54,813 shares of our common stock remained
unexercised. The Maxim Warrants include a cashless exercise feature allowing the holder to receive shares underlying the Maxim Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of
the Maxim Warrant for such shares. Each Maxim Warrant is exercisable until its expiration in August 2033. The Maxim Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of our
common stock at an issuance price per share that is less than the then-effective exercise price of the Maxim Warrants. The warrant holder has certain demand and piggyback registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Series B Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we issued warrants to certain investors to purchase 100,373 shares of our common stock at an exercise price per share of $1.50,
subject to adjustment as set forth in the warrant, or the New Series B Warrants. As of June&nbsp;30, 2025, New Series B Warrants to purchase up to 3,509 shares of our common stock remained unexercised. The New Series B Warrants include a cashless
exercise feature allowing the holder to receive shares underlying the applicable New Series B Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the applicable New Series B
Warrant for such shares. Each New Series B Warrant is exercisable until its expiration in August 2028. The New Series B Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of
our common stock at an issuance price per share that is less than the then-effective exercise price of the New Series B Warrants. The warrant holder is not a stockholder and has none of the rights of a stockholder until the warrant is exercised and
the shares of common stock are issued upon exercise. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors&#8217; Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, in connection with the issuance and sale of our Series C preferred stock, we entered into an Investors&#8217; Rights Agreement,
or the IRA. The IRA grants certain rights to the holders of our outstanding redeemable convertible preferred stock, including certain registration rights with respect to the registrable securities held by them. The holders of these registrable
securities possess registration rights pursuant to the terms of the IRA and are described in additional detail below. As of the completion of this offering, after giving effect to the conversion of all outstanding shares of our redeemable
convertible preferred stock into 3,181,815&nbsp;shares of our common stock in connection with the completion of the offering (including 382,467&nbsp;additional shares of common stock issuable upon conversion of our Series C convertible preferred
stock due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus), there would have been an
aggregate of 3,181,815 shares of common stock that are entitled to these demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;registration</FONT> rights pursuant to the IRA (excluding any shares issuable upon exercise of
warrants). We will pay the registration expenses, other than the underwriting discounts and selling commissions, of the shares registered pursuant to the demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;registrations</FONT>
described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified
conditions, to limit the number of shares the holders may include. The demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights described below will expire no later than three years after the completion of this
offering, upon the closing of a deemed liquidation event, or with respect to any particular holder, at such time that such holder can sell its shares under Rule 144 of the Securities Act during any three-month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of
this offering, certain holders of shares of our common stock, including certain of those shares of our common stock that will be issued upon the conversion of our redeemable convertible preferred stock and exercise of our outstanding warrants, as
applicable, upon the closing of this offering, will be entitled to certain rights with respect to registration of such shares under the Securities Act pursuant to the terms of an investors&#8217; rights agreement by and among us and certain of our
stockholders. These shares are collectively herein referred to as registrable securities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The investors&#8217; rights agreement
provides the holders of registrable securities with demand, piggyback and <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights as described more fully below. As of June&nbsp;30, 2025, holders of an aggregate of 3,181,815&nbsp;registrable
securities were entitled to these demand, piggyback and <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights (including 382,467&nbsp;additional shares of common stock issuable upon conversion of our Series C convertible preferred stock
due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and excluding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any shares issuable upon exercise of warrants). Under the terms of the investor&#8217;s rights agreement, holders of registrable securities will have equivalent registration rights with respect
to any additional shares of our common stock acquired by these holders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the managing
underwriter, if any, has the right, subject to specified conditions, to limit the number of shares the holders may include. The demand, piggyback, and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will expire
(i)&nbsp;upon the closing of a deemed liquidation event, as such term is defined in our amended and restated certificate of incorporation as currently in effect, (ii)&nbsp;with respect to any particular holder, at such time following this offering
that such holder can sell its shares without limitation under Rule 144 of the Securities Act during any three-month period or (iii)&nbsp;the third anniversary of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any
time beginning 180 days after the effective date of the registration statement of which this prospectus is a part, the holders of the registrable securities will be entitled to certain demand registration rights. Subject to the terms of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described under &#8220;Underwriting&#8221;, the holders of at least 60% of the registrable securities then outstanding may make a written request that we register all or a portion of their shares,
subject to certain specified exceptions. Such request for registration must cover registrable securities then outstanding having an aggregate offering price in excess of $15.0&nbsp;million after deducting certain selling expenses. We are not
obligated to take any action in response to such request (i)&nbsp;during the period that is estimated to be 60 days before and 180 days after the effective date of a Company-initiated registration, (ii)&nbsp;if we have already effected one
registration pursuant to such requests for registration on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> or (iii)&nbsp;if the initiating holders propose to register securities that may be immediately registered on Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if we determine that it would be materially detrimental to us and our stockholders
for such registration statement to either become effective or remain effective, because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving us,
(ii)&nbsp;require making a premature disclosure of material information that we have a bona fide business purpose for preserving as confidential, or (iii)&nbsp;render us unable to comply with requirements under the Securities Act or Exchange Act to
effect such a demand registration, then we have the right to defer such registration, not more than once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period, for an aggregate of up to 120 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we propose to register any of our securities under the Securities Act in another offering, either for our own account or for the account of other security holders, the holders of registrable securities will be entitled to notice of the registration
and will be entitled to include their shares of common stock in the registration, subject to certain conditions and limitations, including the right of the underwriters to limit the number of shares included in such registration under specified
circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time when we are eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement, the holders of the
registrable securities then outstanding will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. Any holder of these shares can make a request that we register for offer and sale their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to certain specified exceptions. Such request for registration on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> must cover registrable securities then outstanding having an aggregate offering price in excess of $3.0&nbsp;million after deducting certain selling expenses. We are not obligated to take any action in response
to such request (i)&nbsp;during the period that is estimated to be 30 days before and 90 days after the effective date of a Company-initiated registration, or (ii)&nbsp;if we have already effected two registrations pursuant to such requests for
registration within the preceding <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if we determine that it would be materially detrimental to us and our
stockholders for such registration statement to either become effective or remain effective, because such action would (i)&nbsp;materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving us,
(ii)&nbsp;require making a premature disclosure of material information that we have a bona fide business purpose for preserving as confidential, or (iii)&nbsp;render us unable to comply with requirements under the Securities Act or Exchange Act to
effect such a demand registration, then we have the right to defer such registration, not more than once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period, for an aggregate of up to 120 days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay all expenses, including reasonable fees and expenses, not to exceed $30,000 per registration, of one counsel to
represent the selling stockholders, relating to any demand, piggyback or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration, other than underwriting discounts and commissions, stock transfer taxes, and any additional fees of counsel for
the selling stockholders, subject to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the request of a majority of holders of registrable securities to be
registered, unless holders of a majority of the registrable securities agree to forfeit their right to one demand registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
investors&#8217; rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration
statement attributable to us, and the selling stockholders are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them, subject to certain limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended and Restated Bylaws, and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL. Section&nbsp;203 generally prohibits a public Delaware corporation from engaging in a
&#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that such stockholder became an interested stockholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to such time the board of directors of the corporation approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (1)&nbsp;by persons who are directors and also officers and (2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to such time, the business combination is approved by the board of directors and authorized at
an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation and the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or by
any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation
that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any receipt by the interested stockholder of the benefit, directly or indirectly, of any loans, advances,
guarantees, pledges, or other financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an
&#8220;interested stockholder&#8221; as any entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15%
or more of the outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws that will become effective
immediately prior to the closing of this offering may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium
for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of
incorporation and amended and restated bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue, without further action by the stockholders, up to 10,000,000&nbsp;shares
of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control) that may be senior to our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66 2/3% of the voting power of all of our then-outstanding shares of the common stock entitled to vote generally at an election of
directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divide our board of directors into three classes with each class serving three-year staggard terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide advance notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chair of the board, our Chief
Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws that will become effective immediately prior to the
closing of this offering will provide that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or,
if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common
law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our
stockholders; (iii)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended
and restated certificate of incorporation or our amended and restated bylaws; (iv)&nbsp;any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and
restated bylaws (including any right, obligation, or remedy thereunder); (v) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any action asserting a claim against us
or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as
defendants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore,
Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Additionally, investors
cannot waive compliance with the federal securities laws and the rules and regulations thereunder. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other
considerations, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the
resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and
may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared
or certified any part of the documents underlying the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum
provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of
the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions
will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;Executive Compensation&#8212;Limitation of Liability and Indemnification.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our
common stock on the Nasdaq Global Market under the symbol &#8220;LBRX.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is P.O.
Box 64945, Saint Paul, MN 55164-0945. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock in the
public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below, sales
of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of common stock outstanding as of June&nbsp;30, 2025, upon the completion of this offering, an aggregate of
20,100,137 shares of common stock will be outstanding, assuming the automatic conversion of all of our outstanding shares of redeemable convertible preferred stock into an aggregate of 3,181,815 shares of common stock. Of these shares, all of the
shares of common stock sold in this offering will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by &#8220;affiliates,&#8221; as that term is defined in Rule
144 under the Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining shares of common stock outstanding after this offering will be &#8220;restricted
securities,&#8221; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration,
including the exemptions provided by under Rules 144 or 701 under the Securities Act, which rules are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and subject to the provisions of Rules 144 or 701, these restricted securities will be available for sale in the public market as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="74%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Approximate&nbsp;Number&nbsp;of&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>First Date Available for Sale into the Public
Market</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3,433,470 Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">181 days after the date of this prospectus, upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to below, subject in some cases to applicable volume, manner of sale, and other limitations
under Rule 144 and Rule 701.</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, <FONT STYLE="white-space:nowrap">non-affiliate</FONT> persons who have beneficially owned restricted shares of our common stock for
at least six months, and any affiliate of the company who owns either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by
Rule 144 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliates</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale may
sell an unlimited number of restricted securities under Rule 144 if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restricted securities have been held for at least six months, including the holding period of any prior owner
other than one of our affiliates (subject to certain exceptions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are current in our Exchange Act reporting at the time of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months preceding, a sale and
has held the restricted securities for at least one year, including the holding period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to the length of time we
have been subject to Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. <FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation, or notice filing
provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months preceding, a sale,
would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within
any three-month period only that number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 201,001 shares
immediately after the completion of this offering; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the stock exchange on which our shares are listed during
the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, persons
who are our affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the <FONT STYLE="white-space:nowrap">six-month</FONT>
holding period of Rule 144, which does not apply to sales of unrestricted securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without
compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the
resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#8220;Underwriting&#8221; and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8&nbsp;under</FONT> the Securities Act
covering the shares of common stock reserved for issuance under the 2017 Plan, the 2018 Plan, the 2023 Plan, the 2025 Plan and the ESPP. The registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8&nbsp;is</FONT> expected to be filed
and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8&nbsp;will</FONT> be available for sale in the open
market following its effective date, subject to Rule 144 volume limitations and <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> described below, if applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and Market-Standoff Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our directors, our executive officers, and the holders of substantially all of our common stock or securities convertible into, exercisable
for, or exchangeable for our common stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and/or agreements containing market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on our
ability and the ability of such security holders to offer, sell, or transfer such securities for a period of 180 days following the date of this prospectus. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering
provide that for a period of 180 days after the date of this prospectus, except with the prior written consent of Leerink Partners LLC, Piper Sandler&nbsp;&amp; Co., and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and subject to specified
exceptions, we and they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise dispose of or transfer, any
shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, directly or indirectly, any of the
economic consequences of ownership of the common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investors&#8217; rights agreement and our standard form option agreement contain market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of
this offering, certain holders of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for
ourselves. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See the section titled &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for additional
information regarding these registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal income tax
consequences relating thereto, does not address any tax consequences arising under any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, any estate, gift or other U.S. federal tax laws other than income tax laws, and does
not address the potential application of the Medicare contribution tax on net investment income, any alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Internal Revenue Code of 1986, as amended, or the
Code. This discussion is based on the Code and applicable Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the Internal Revenue Service, or the IRS, all as in effect as of
the date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested nor do we intend to
request a ruling from the IRS, or an opinion of counsel, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders that purchase our common stock pursuant to this
offering and that hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax consequences
that may be relevant to a particular holder in light of such holder&#8217;s circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special rules under the U.S. federal
income tax laws, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships, S corporations, or other pass-through entities or arrangements (and investors therein);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;specified foreign corporations&#8221; (including &#8220;controlled foreign corporations&#8221;) or
&#8220;passive foreign investment companies;&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment funds, insurance companies, or brokers or dealers in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, governmental organizations, or <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold common stock that constitutes &#8220;qualified small business stock&#8221; under
Section&nbsp;1202 of the Code, or &#8220;Section&nbsp;1244 stock&#8221; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our common stock in a transaction subject to the gain rollover provisions of the Code
(including Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock at any time (other
than as expressly provided below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock pursuant to the exercise of warrants or conversion rights under
convertible instruments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise options or otherwise as compensation for services; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction, straddle, synthetic security,
constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or an entity or
arrangement that is treated as a partnership for U.S. federal income tax purposes) holds our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of
the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to
them of holding and disposing of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS
SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS, OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our common stock that is
neither a &#8220;U.S. holder&#8221; nor a partnership (including any entity or arrangement treated as a partnership or that is disregarded from its owner) for U.S. federal income tax purposes. A U.S. holder is any beneficial owner of our common
stock that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or any entity treated as a corporation for U.S. federal income tax purposes) created or organized
in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;whose administration is subject to the primary supervision of a U.S. court, and which has one or
more &#8220;United States persons&#8221; (within the meaning of Section&nbsp;7701(a)(30) of the Code) that have the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable
Treasury Regulations to be treated as a United States person. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed under the &#8220;Dividend Policy&#8221; section of this prospectus, we have never declared or paid any cash dividends on our
common stock, and we do not intend to pay cash dividends on our common stock for the foreseeable future. However, if we make cash or other property distributions on our common stock (other than certain pro rata distributions of our stock), such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Any portion of a distribution that exceeds
our current and accumulated earnings and profits will constitute a return of capital and will first be applied against and reduce the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s tax basis in our common stock, but not below zero.
Any amount distributed in excess of tax basis will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described in the section titled &#8220;Gain on Sale or Other Taxable Disposition of Our Common
Stock&#8221; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding and Sections 1471 through
1474 of the Code, the Treasury Regulations thereunder, and other official guidance (commonly referred to as &#8220;FATCA&#8221;), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be
subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty). To receive the benefit of a reduced treaty rate, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
furnish us or our paying agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or applicable successor form) and satisfy applicable certification and other requirements. This certification must be provided to us or our paying agent before
the payment of dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the applicable withholding agent, which then will be
required to provide certification to us or our paying agent, either directly or through other intermediaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim
for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade or business in
the United States, and dividends paid on our common stock are effectively connected with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s U.S. trade or business (and are attributable to such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s permanent establishment in the United States if required by an applicable tax treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S.
federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable
withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal
income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a resident of the United States. A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income
tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax
treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be
subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s
conduct of a trade or business in the United States, and if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for 183 days or more during the taxable year of the sale or other taxable disposition (as calculated pursuant to Section&nbsp;7701(b) of the Code), and certain other requirements are met; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#8220;United States real property interest&#8221; by reason of our status as a
United States real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the sale or other taxable disposition or the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s holding period for our common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining
whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our worldwide real property interests and our other assets used or held for use in a trade or business. We believe that
we are not currently, and (although there can be no assurance in this regard) do not anticipate becoming, a USRPHC for U.S. federal income tax purposes. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable
disposition by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock will not be subject to U.S. federal income tax so long as (a)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly,
and constructively, no more than 5% of our common stock at all times within the shorter of (i)&nbsp;the five-year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period preceding the disposition or (ii)&nbsp;the holder&#8217;s holding period and (b)&nbsp;our common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on
an established securities market. There can be no assurance that our common stock will qualify as regularly traded on an established securities market. Prospective investors are encouraged to consult their own tax advisors regarding the possible
consequences to them if we are, or were to become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to
U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder were a resident of the United States. A
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected
earnings and profits for the taxable year, as adjusted for certain items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate on gain realized upon the sale or other taxable disposition of our common stock which may be offset by certain U.S.-source capital losses (even
though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating
the amount of distributions on our common stock paid to such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no
withholding was required (because the distributions were effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#8217;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable
income tax treaty) and regardless of whether such distributions constitute dividends. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the
gross proceeds of a disposition of our common stock provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing
a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or certain other
requirements are met. Backup withholding may apply if the payor has actual knowledge, or reason to know, that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a United States person that is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules,
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders are urged to consult their U.S. tax advisors regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#8217;s U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FATCA imposes a U.S. federal withholding tax of 30% on certain payments made to a &#8220;foreign financial institution&#8221; (as specially
defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities certain information regarding certain U.S. account holders of
such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax
of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity, or an
exemption applies. An intergovernmental agreement between the United States and an applicable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> country may modify these requirements. Under certain circumstances, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock. The U.S. Treasury released proposed Treasury Regulations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which, if finalized in their present form, would eliminate the U.S. federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock. In its
preamble to such proposed Treasury Regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are urged to consult with their tax advisors regarding the potential implications of FATCA on their investment in our
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON
STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL
<FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC, Piper Sandler&nbsp;&amp; Co. and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated&nbsp;are acting as representatives of
each of the underwriters named below and as joint bookrunning managers for this offering. Subject to the terms and conditions set forth in the underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each
of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of the shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and subject to other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#8217; certificates and legal opinions. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and Commissions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the initial public offering
price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195; per share. After the initial offering of the shares, the public offering price, concession or any
other term of this offering may be changed by the representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the initial public offering price,
underwriting discounts and commissions and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts
and commissions referred to above, will be approximately $4.0 million. We also have agreed to reimburse the underwriters for up to $35,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting
compensation for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Over-Allotment Option </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 2,500,000
additional shares at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to
purchase a number of additional shares proportionate to that underwriter&#8217;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar
Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and substantially all of our other existing security holders have agreed not to
sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Leerink Partners LLC, Piper
Sandler&nbsp;&amp; Co., and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated on behalf of the underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of or transfer any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file a registration statement related to the common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic
consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions apply to common stock and to securities convertible into or exchangeable or
exercisable for common stock. They also apply to common stock owned now or acquired later by the person executing the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement or for which the person executing the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement later acquires the power of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on the Nasdaq Global Market, subject to notice of issuance, under the symbol &#8220;LBRX.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the
factors to be considered in determining the initial public offering price are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after
this offering, our common stock will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do
not expect to sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization,
Short Positions and Penalty Bids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group
members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering.
&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; over-allotment option described above. The underwriters may close out any covered short position by either exercising their over-allotment option
or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to
the price at which they may purchase shares through the over-allotment option granted to them under the underwriting agreement described above. &#8220;Naked&#8221; short sales are sales in excess of such over-allotment option. The underwriters must
close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market
after pricing that could adversely affect investors who purchase in this offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the closing of this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion
of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in
the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area, or each, a Relevant State, no shares have been offered or will be offered
pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another
Relevant State and notified to the competent authority in that Relevant State, all in accordance with the EU Prospectus Regulation, except that shares may be offered to the public in that Relevant State at any time&nbsp;under the following
exemptions under the EU Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the EU Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the EU
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the EU Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the EU Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each
of the underwriters and the Company that it is a &#8220;qualified investor&#8221; within the meaning of Article&nbsp;2(e) of the EU Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in
the EU Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their
offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article&nbsp;5(1) of the EU Prospectus Regulation,
each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor
have they been acquired with a view to their offer or resale to, persons in circumstances which may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
give rise to an offer to the public other than their offer or resale in an EEA State to qualified investors, in circumstances in which the prior consent of the representatives has been obtained
to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in
relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#8220;EU Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United
Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the
publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK
Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Markets Act 2000, or
the FMSA, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of the shares shall require us or any representative to publish a prospectus pursuant to
Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares in the United Kingdom
means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#8220;UK
Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#8220;qualified investors&#8221; (as&nbsp;defined in the UK Prospectus Regulation) (i)&nbsp;who have professional experience in matters relating to investments falling within Article&nbsp;19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article&nbsp;49(2)(a) to
(d)&nbsp;of the Order (all such persons together being referred to as relevant persons) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the
FSMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document
or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult
with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts <FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT
STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to
Prospective Investors in Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth), or the Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
shares of common stock may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the shares of common stock may be issued, and no draft or definitive offering memorandum,
advertisement or other offering material relating to any shares of common stock may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all
applicable Australian laws and regulations. By submitting an application for the shares of common stock, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As any offer of shares of common stock under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By
applying for the shares of common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares of common stock, offer, transfer, assign or otherwise alienate those shares of common stock to investors in
Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result
in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an offer to the public within the meaning of the CO. No
advertisement, invitation or document relating to the common stock has been or may be issued or has been or may be in the possession of any person for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so
under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any
rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and
Exchange Act. Accordingly, none of the common stock nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident
of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at
the relevant time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of common stock may not be circulated or distributed, nor may the common stock be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended
from time to time, or SFA) pursuant to Section&nbsp;274 of the SFA; (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA,
and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contract (each term
as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any
person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities
based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification &#8212; Solely for the purposes of its obligations
pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, the company has determined, and hereby notifies all relevant persons (as defined in Section&nbsp;309A of the SFA) that the shares of common stock are &#8220;prescribed capital markets
products&#8221; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment
Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective
Investors in Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock may not be publicly offered in Switzerland and will not be listed on the SIX
Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility
in Switzerland. Neither this document nor any other offering or marketing material relating to the shares of common stock or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the company, the shares of common stock have been
or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and
the offer of shares of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the
CISA does not extend to acquirers of shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, and has not been
filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the
Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers,
investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended
from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified
investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley LLP, New York, New York. The
underwriters are being represented by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_22"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of LB Pharmaceuticals Inc as of December&nbsp;31, 2024 and 2023 and for each of the two years in
the period ended December&nbsp;31, 2024, included in this prospectus and in the Registration Statement, have been so included in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. The report on the financial statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act, with respect
to the shares of common stock being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock offered by this
prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to
the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act and we will file
reports, proxy statements, and other information with the SEC. These reports, proxy statements, and other information will be available at <I>www.sec.gov</I>.&nbsp;We also maintain a website at <I>https://lbpharma.us/</I>, at which you may access
these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and
is not part of, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc12080_24"></A>INDEX TO FINANCIAL STATEMENTS
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_2">Balance Sheets as of December&nbsp;31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_3">Statements of Operations for the Years Ended December&nbsp;31, 2024 and
2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_4">Statements of Comprehensive Loss for the Years Ended December&nbsp;
31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_5">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit
for the Years Ended December&nbsp;31, 2024 and 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_6">Statements of Cash Flows for the Years Ended December&nbsp;31, 2024 and
2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_7">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Condensed Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_50">Condensed Balance Sheets as of June 30, 2025 and December 31,
2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_51">Condensed Statements of Operations for the Six Months Ended June 30, 2025 and
 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_52">Condensed Statements of Comprehensive Loss for the Six Months Ended June 30, 2025
 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_53">Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217;
 Deficit for the Six Months Ended June 30, 2025 and 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_54">Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and
 2024</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin12080_55">Notes to Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals
Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of LB Pharmaceuticals Inc (the &#8220;Company&#8221;) as of December&nbsp;31, 2024 and
2023, the related statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders&#8217; deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2024 and 2023, and the results of its operations and its cash flows for the years then
ended<B>,</B> in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Substantial Doubt About the Company&#8217;s
Ability to Continue as a Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going
concern. As discussed in Note&nbsp;1 to the financial statements, the Company has not generated revenues, has suffered recurring losses from operations, has a net capital deficiency, and has an accumulated deficit that raise substantial doubt about
its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&nbsp;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, P.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s
auditor since 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;27,
2025, except for the effects of the reverse stock split described in Note 15, as to which the date is September 8, 2025 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_2"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share data) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,879</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,634</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217;
Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,606</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability&#8212;warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,163</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (Note 13)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Redeemable convertible preferred stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed preferred stock, $0.0001 par value, 295,467 shares authorized, 295,467 shares issued
and outstanding as of December&nbsp;31, 2024 and 2023. Liquidation preference of $443 as of December&nbsp;31, 2024 and 2023.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred stock, $0.0001 par value, 3,655,374 shares authorized, 3,655,374 shares
outstanding as of December&nbsp;31, 2024 and 2023. Liquidation preference of $8,407 as of December&nbsp;31, 2024 and 2023.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B preferred stock, $0.0001 par value, 301,119 shares authorized, 301,119 shares issued and
outstanding as of December&nbsp;31, 2024 and 2023. Liquidation preference of $903 as of December&nbsp;31, 2024 and 2023.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C preferred stock, $0.0001 par value, 75,000,000 shares authorized, 73,820,346 and
47,153,680 shares issued and outstanding as of December&nbsp;31, 2024 and 2023, respectively. Liquidation preference of $110,731 and $70,731 as of December&nbsp;31, 2024 and 2023, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 105,000,000 shares authorized, 251,655 and 249,476 shares issued
and outstanding as of December&nbsp;31, 2024 and 2023, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(94,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, redeemable convertible preferred stock and stockholders&#8217;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_3"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data)
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,830</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-operating</FONT> income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,729</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(63,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(63,102</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(176.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used in calculating net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:280pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to
financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_4"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (loss) gain on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(63,265</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:480pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial
statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_5"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data)
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series Seed</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#8217;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>247,239</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,946</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28,812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Shares issued upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of redeemable convertible Series C preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,333,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of redeemable convertible Series C preferred stock upon conversion of notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,820,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of warrants to placement agent for convertible note financing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of restricted common stock to employees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,153,680</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68,773</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,221</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation expense </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">3,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#8212;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">3,090</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT><BR></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of redeemable convertible Series C preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Shares issued upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Shares issued upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of common stock for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,820,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>251,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(104,323</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(94,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to
financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_6"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued for services rendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of deferred financing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Write-off</FONT> of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(955</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Accretion) amortization of (discounts) premiums on investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,757</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(53,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(12,094</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(28,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants and options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs of redeemable convertible Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,315</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,679</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,497</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,425</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, beginning of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21,404</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, end of year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental Disclosures of Cash Flow Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental Disclosures of <FONT STYLE="white-space:nowrap">Non-cash</FONT> Investing and
Financing Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of 2020 and 2022 Notes to redeemable convertible Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued to placement agent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants issued to redeemable convertible Series B preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to financial
statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_7"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Business Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc (the &#8220;Company&#8221; or &#8220;LB&#8221;) was incorporated under the laws of the State of Delaware in September 2015 and is
headquartered in New York, New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company developing therapies for the treatment of schizophrenia,
bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> which the Company believes has
the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United&nbsp;States. <FONT STYLE="white-space:nowrap">LB-102</FONT> is a Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> oral, small
molecule for the treatment of acute schizophrenia (defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Company&#8217;s inception, it has focused substantially all of its efforts and financial resources on organizing and staffing the Company, raising
capital, building its intellectual property portfolio, undertaking preclinical studies and clinical trials and providing general and administrative support for these activities. The Company has not generated any product revenue related to its
primary business purpose to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, regulatory approval of product candidates, uncertainty of market acceptance of products,
if approved, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and the need to obtain adequate additional financing
to fund the development of its product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of
liabilities and commitments in the normal course of business. The Company has not generated revenues and relies on the issuance of debt and equity instruments to generate working capital. The Company experienced negative operating cash flows of
$53.1&nbsp;million and net loss of $63.1&nbsp;million for the year ended December&nbsp;31, 2024 and had an accumulated deficit of $104.3&nbsp;million as of December&nbsp;31, 2024. The Company expects to incur substantial expenses for the foreseeable
future relating to research and development of <FONT STYLE="white-space:nowrap">LB-102</FONT> and to continue to generate operating losses. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><I></I><I></I><I></I><I></I>The future viability of the Company is dependent on its ability to raise additional capital to fund its operations. If the
Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue
operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prior Period Reclassifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain prior period amounts have been reclassified to conform to the current period&#8217;s presentation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure at the date of the financial statements and the reported amounts of expenses during
the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development costs and the valuation of common stock, derivative warrant and stock-based
compensation. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could
differ from the Company&#8217;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and marketable
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia. The Company has not generated revenues since inception. The Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews the Company&#8217;s performance on an aggregate basis, thus the segment&#8217;s loss is the Company&#8217;s net loss, as reported on
accompanying statements of operations, and the segment&#8217;s assets are the Company&#8217;s total assets, as reported on the accompanying balance sheets. Significant expenses provided to the CODM include research and development and general and
administrative expenses, as reported on the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CODM uses the information primarily to evaluate the
Company&#8217;s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows
the CODM to monitor the Company&#8217;s performance and make strategic adjustments as needed to support its operational and financial goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#8217;s operations and all long-lived assets are located in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company&#8217;s cash and cash
equivalents primarily consist of balances held at one financial institution and in money market funds. Cash balances may, at times, exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) amounts. Management periodically assesses the
financial condition of the banking institution and believes that any potential credit loss is minimal. As of December&nbsp;31, 2024 and 2023, the Company&#8217;s cash balance exceeded the FDIC insured limit of $250,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash primarily
consists of certificates of deposit that are held as collateral against the letter of credit that the Company is required to maintain for its operating lease agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for marketable securities held as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;available-for-sale&#8221;</FONT></FONT> in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 320, <I>Investments-Debt Securities.</I> The Company classifies
these investments as current assets and carries them at fair value. Unrealized gains and losses are recorded as a separate component of stockholders&#8217; deficit as accumulated other comprehensive income. Realized gains or losses on marketable
security transactions are reported in the statements of operations. Marketable securities are maintained at one financial institution and are governed by the Company&#8217;s investment policy, as approved by the Company&#8217;s board of directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its marketable securities with unrealized loss positions for impairment by assessing if they are related to deterioration in credit
risk and whether the entire amortized cost basis of the security will be recovered, the intent to sell, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their cost basis.
Credit-related impairment losses, not to exceed the amount that fair value is less than the amortized cost basis, are recognized through an allowance for credit losses with changes in the allowance for credit losses recorded in the statements of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No impairment losses related to marketable securities have been recognized during the years ended December&nbsp;31, 2024 and 2023. Any
unrealized losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities that are attributed to credit risk are recorded to earnings through an allowance for credit losses. Unrealized
losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities were not material as of December&nbsp;31, 2024 and 2023, and no allowance for credit losses was recorded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are
recorded at cost less accumulated depreciation. Depreciation and amortization expense is recognized using the straight-line method over the following estimated useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Useful&nbsp;Life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Lease&nbsp;term</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 years</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According
to ASC 842 <I>Leases</I>, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the use of the identified asset over the
term of the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> (&#8220;ROU&#8221;) assets
represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease
commencement date based on the present value of future lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. To the extent that the Company is unable to utilize an interest rate
implicit in the lease, the collateralized incremental borrowing rate is used based on the information available at the lease commencement date, in determining the present value of lease payments. ROU assets are based on the measurement of the lease
liability and includes any lease payments made prior to or on lease commencement and initial direct costs incurred and excludes lease incentives, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to account for lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components
together as a single lease component for all underlying assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional and accounting and other third-party fees that are directly associated with
<FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred financing costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders&#8217; equity as a reduction
of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the financings. Should the planned equity financing no longer be considered probable of being consummated, the deferred offering costs are expensed
immediately as a charge to general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2024, the Company recorded the write off of deferred offering
costs in the amount of $3.2&nbsp;million in general and administrative expenses in the accompanying statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Issuance Costs
and Debt Discounts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized debt issuance costs related to the Company&#8217;s convertible notes payable are included as a direct deduction
from the related debt liability. See Note 11 <I>Notes</I> for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt discount recorded in connection with the recognition of
the derivative liability for the embedded conversion feature is included as a direct deduction from the related debt liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These costs are amortized
into interest expense over the term of the notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the fair value method under ASC 820 <I>Fair Value Measurements and Disclosure</I> to all financial assets and liabilities and nonfinancial
assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a
liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant
unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;1 </I>&#8211;
Observable inputs, such as quoted prices for identical assets and liabilities in active markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;2 &#8211; </I>Observable
inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are
observable or can be corroborated by observable market data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;3</I> &#8211; Unobservable inputs supported by little or no
market data and requires management to develop its own assumptions based on best estimates of what market participants would use in pricing an asset or liability at the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to
the fair value measurement in its entirety. To the extent that the valuation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is based on models or inputs that are less observable or unobservable in the market, the determination of fair value may require significant judgment and involve uncertainty. Changes in fair
value measurements could have a significant impact on the results of operations in any given period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of cash equivalents, marketable
securities, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. The Company&#8217;s derivative liabilities are carried at fair value based on the fair value hierarchy. The
Company invests its excess cash in financial instruments, which are readily convertible into cash, such as money market funds, fixed-income securities, and U.S. government securities. Cash equivalents, where applicable, are classified as
Level&nbsp;1 or Level&nbsp;2, as defined by the fair value hierarchy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives
consist primarily of stock options, restricted stock grants and penny warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures all stock options and other stock-based awards to
employees, directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> based on the fair value on the date of the grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting
period of the respective award. The Company records the expense for these awards using the straight-line method over the service period. The Company recognizes adjustments to stock-based compensation expense for forfeitures as they occur. The
Company classifies stock-based compensation expenses in its statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipients&#8217; service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each stock option and other stock-based awards are estimated on the date of grant using the Black-Scholes option-pricing model. Inputs used
in the Black-Scholes option-pricing model are summarized as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Term: The expected term is calculated using the simplified method. The
simplified method calculates the expected term as the average of the vesting and contractual terms of the award. The Company elected to use the simplified method because of its limited history of stock option exercise activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Volatility: The Company used the historical stock price volatility of a peer group of publicly-traded companies to calculate the expected volatility.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk-Free Interest Rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant of the award for time
periods approximately equal to the expected term of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected Dividend Yield: The Company has never paid cash dividends and does not expect to
pay any cash dividends in the foreseeable future. Accordingly, estimated dividend yield is zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value for each restricted common stock award
and penny warrants are estimated on the date of grant based on the most recent calculation of fair value of the Company&#8217;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Warrants and Warrant Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the warrant agreement. The Company classifies warrant liabilities on the balance sheet as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance.
Changes in the fair value of the warrant liabilities are recorded in change in fair value of derivative instruments in the statements of operations. The Company values the aggregate equity value and allocates the value to the appropriate classes of
equity through the use of the Black-Scholes option pricing model. The value of the warrants is derived through this equity allocation. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See
Note 3 <I>Fair Value Measurements</I> for a description of these assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The
redeemable convertible preferred stock is recorded outside of permanent equity because upon the occurrence of certain deemed liquidation events, the majority of the holders can opt to redeem the shares at the liquidation preference and these events,
including a merger, acquisition or sale of substantially all of the assets, are considered not solely within the Company&#8217;s control. The Company has not adjusted the carrying values of the redeemable convertible preferred stock to its
redemption value because it is not considered redeemable as of December&nbsp;31, 2024 and 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs include expenditures in connection with clinical trials, employee cash and stock-based compensation, regulatory and scientific
consulting fees, contract research for preclinical studies, drug formulation, supply and handling and data collection. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as
prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The value of goods and services
received from the contract research organization (&#8220;CRO&#8221;) and other third parties are accrued each reporting period based on estimates of the level of services performed and progress in the period when invoices have not been received from
such organizations. When evaluating the adequacy of the accrued liabilities, the progress of the studies or clinical trials are analyzed, including the phase or completion of events, invoices received and contracted costs. Significant judgments and
estimates are made in determining the accrued balances at the end of any reporting period. Accruals are adjusted as actual costs become known or as additional information becomes available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative costs include expenditures that are not directly related to research and development. General and administrative costs include costs for support and administrative functions including salaries and benefits, stock-based compensation
and other personnel-related costs. Additional costs include <FONT STYLE="white-space:nowrap">non-personnel</FONT> costs such as legal and professional fees, rent, audit fees and insurance costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses external costs, such
as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company also expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income taxes have been
determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of LB&#8217;s assets and liabilities and are adjusted for
changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is
required often requires significant judgment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net loss per share, as the Company has issued shares that meet
the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and
participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their
respective rights to receive dividends as if all income for the period had been distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders
is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting loss
attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding stock options. Diluted net loss per share attributable to common stockholders is computed by
dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s outstanding redeemable convertible preferred stock contractually entitle the holders of such shares to participate in distributions but
does not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders
is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes
net loss, as well as other changes in stockholders&#8217; deficit that result from transactions and economic events other than those with stockholders. For the years ended December&nbsp;31, 2024 and 2023, the Company&#8217;s only element of other
comprehensive loss was unrealized gain/loss on marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment
Reporting (Topic 280), Improvements to Reportable Segment Disclosures</I>, which is intended to provide enhanced segment disclosures. The guidance requires disclosures about significant segment expenses and other segment items and identifying the
CODM and how they use the reported segment profitability measures to assess segment performance and allocate resources. These enhanced disclosures are required for all public entities on an interim and annual basis, even if they have only a single
reportable segment. The guidance is effective for years beginning after December&nbsp;15, 2023, and interim periods within annual periods beginning after December&nbsp;15, 2024. Early adoption is permitted. The Company adopted the guidance for the
year ended December&nbsp;31, 2024. The adoption required the Company to provide additional disclosures (<I>Segment Information</I> above), but otherwise it does not materially impact the accompanying financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax Disclosures
</I>that requires public entities to annually disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The guidance is effective for fiscal years beginning
after December&nbsp;15, 2024 and early adoption is permitted. The Company is evaluating the guidance to determine if adoption will have a material impact on the financial statements or disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> <I>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses</I>, that requires public companies to provide more detailed disclosures to provide greater transparency about the
components of specific expense categories. The guidance is effective for years beginning after December&nbsp;15, 2026, and interim periods within annual periods beginning after December&nbsp;15, 2027. Early adoption is permitted. The Company is
evaluating the guidance to determine if adoption will have a material impact on the financial statements or disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis classified under the
appropriate level of the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability - warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,218</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,449</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>31,530</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,761</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability - warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,557</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,557</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for marketable securities held as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;available-for-sale&#8221;</FONT></FONT> in accordance with ASC 320, <I>Investments-</I><I>Debt Securities</I>. The Company classifies these investments as current assets and
carries them at fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair values of the Company&#8217;s corporate debt securities are based on prices obtained from independent pricing
sources. The fair value of other marketable securities classified within Level&nbsp;2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads,
<FONT STYLE="white-space:nowrap">two-sided</FONT> markets, benchmark securities, bids, offers, and reference data including market research publications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificate of Deposit </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s certificates
of deposit are Level&nbsp;2 instruments. The fair value of such instruments is estimated based on valuations obtained from third-party pricing services that utilize industry standard valuation models, including both income-based and market-based
approaches, for which all significant inputs are observable either directly or indirectly. These inputs include interest rate curves, foreign exchange rates, and credit ratings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note Conversion Feature </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August and September 2020,
the Company entered into Convertible Promissory Note Purchase Agreements (&#8220;2020 Notes&#8221;) with a group of lenders who loaned the Company a total of $10.0&nbsp;million. In October 2022, November 2022, December 2022, and January 2023, the
Company entered into Convertible Promissory Note Purchase Agreements (&#8220;2022 Notes&#8221;) with a group of lenders who loaned the Company a total of $25.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2020 Notes and 2022 Notes include conversion features which met the definition of a derivative liability. The conversion features were bifurcated from the
host contract and a liability and corresponding discount were recorded on the date of issuance. The liability is remeasured at fair value at the end of each reporting period, with any changes recorded in the accompanying statements of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2020 Notes and 2022 Notes would automatically convert into the class of the stock issued in the
Company&#8217;s next qualified financing at a conversion price equal to 80% of the <FONT STYLE="white-space:nowrap">per-share</FONT> price of such securities issued. If the <FONT STYLE="white-space:nowrap">per-share</FONT> price of the next
qualified financing was below $2.35, the outstanding principal of the 2020 Notes and 2022 Notes would convert at the <FONT STYLE="white-space:nowrap">per-share</FONT> price paid for such securities issued (see Note 11 <I>Notes</I>). In May 2023, the
Company received a signed commitment for a qualified financing at $1.50 per share, thus the Company determined that the conversion feature had no value as of June&nbsp;30, 2023. The 2020 Notes and 2022 Notes were converted to Series C preferred
stock on August&nbsp;29, 2023. See Note 11 <I>Notes</I> for additional information related to the 2020 Notes and the 2022 Notes and the note conversion features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2023, the change in the fair value of the Level&nbsp;3 note conversion feature liability resulted in the recording of a
gain on change in fair value of derivative instruments of $16.6&nbsp;million in the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the
assumptions used in the Black-Scholes valuation model in order to determine the fair value of the note conversion feature derivative liabilities for the embedded conversion feature related to 2022 Notes issued during the year ended December&nbsp;31,
2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;26,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; financing event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; exit event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt maturity date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/30/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018 and
2019, the Company issued warrants to investors in connection with its private placement of Series A convertible preferred stock &#8220;A and B Warrants&#8221; (as defined in Note 8 <I>Redeemable Convertible Preferred Stock and Equity)</I>. Pursuant
to the terms of the A and B Warrants, the Company could be required to adjust the exercise price upon an adjustment of the price or exercise price of the Company&#8217;s existing stock or stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, the Company issued the Series B-1 Warrants (as defined below) to investors in connection with the Series B convertible preferred stock financing
(the &#8220;Series B Offering&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company issued the New Series B Warrants (as defined below) to the investors in the Series B
Offering as an inducement to consent to the Series C preferred stock financing (the &#8220;Series C Offering&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company issued warrants to
investors in connection with equity financings. The warrants are required to be measured at fair value and reported as a liability in the accompanying balance sheets. The warrants are valued at each reporting date using the Black-Scholes model with
any changes in fair value recorded in the accompanying statements of operations. The valuation of the warrants is considered Level&nbsp;3 in the fair value hierarchy as the assumptions in the valuation that are both significant to the fair value
measurement and unobservable. See Note 8 <I>Redeemable</I> <I>Convertible Preferred Stock and Equity</I> for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended
December&nbsp;31, 2024 and 2023, the Company recorded a loss on the change in the fair value of the Level&nbsp;3 warrant liability of $0.9&nbsp;million and $0.3&nbsp;million, respectively, in the accompanying statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the assumptions used in the Black-Scholes valuation model in order to determine the fair
value of the derivative liabilities for the warrant liabilities for the years ended December&nbsp;31, 2024 and 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>August&nbsp;28,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; financing event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; exit event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.58&#8201;-&#8201;2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">49.0%&#8201;-&#8201;70.0</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.01&#8201;-&#8201;$3.75</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.01&#8201;-&#8201;$1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.01&#8201;-&#8201;$1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.03</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">4.23%&#8201;-&#8201;4.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:1pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the significant unobservable inputs of volatility and discount rate were to change, this may
result in a significantly higher or lower fair value measurement at the reporting dates. The change in the derivative liabilities for the years ended December&nbsp;31, 2024 and 2023 was (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B><br><B>Conversion</B><br><B>Feature</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,228</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,454</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion feature for 2022 Notes (Jan. 2023 issuance)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of New Series B warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss due to change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,557</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,557</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss due to change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2024 and 2023, there were no transfers of instruments between Level&nbsp;1, 2 and 3
in the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are uncertainties on the fair value measurement of the instruments classified under Level&nbsp;3 due to the use of
unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Cash Equivalents, Marketable Securities and Restricted Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company invests in certain U.S. government money market funds and treasury bills classified as cash equivalents and invests in certificate of deposits that
are classified as restricted cash. The marketable securities consist of treasury bills, government securities and high investment grade corporate debt securities as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents, marketable securities and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25,334</B><BR></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B><BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,449</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US Treasury bills</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,087</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>225</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,312</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents and marketable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>38,761</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contractual maturities of the Company&#8217;s marketable securities are summarized as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After one year to five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,910</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024 and 2023, there were no
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities that have been in a continuous unrealized loss position for more than 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the cash, cash equivalents and restricted cash reported in the balance sheets that sum to
the total of the amounts shown in the statements of cash flows is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following as of December&nbsp;31, 2024 and 2023 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total property and equipment, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense totaled $0.1&nbsp;million and less than $0.1&nbsp;million for the years ended
December&nbsp;31, 2024 and 2023, respectively, and is recorded in general and administrative expense in the accompanying statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
Prepaid Expenses and Other Current Assets and Accrued Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses consisted of the following as of December&nbsp;31, 2024 and 2023 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total prepaid expenses and other current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<B></B><B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B>2,343<B></B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2024, the Company recorded the write off of deferred offering costs in the amount of
$3.2&nbsp;million in general and administrative expenses in the accompanying statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following as of December&nbsp;31, 2024 and 2023 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued CRO costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional and consulting costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued termination benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total accrued expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,217</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;26, 2024, the Company&#8217;s then-current chief executive officer (the &#8220;Former CEO&#8221;) entered
into a transition, consulting, and separation agreement (&#8220;Separation Agreement&#8221;), pursuant to which the Former CEO resigned from his role as CEO and agreed to continue employment as advisor to the CEO through December&nbsp;31, 2024.
Under the Separation Agreement, the Former CEO is entitled to termination benefits until June&nbsp;30, 2026, in the form of continuation of base salary in the same amount in effect as of December&nbsp;31, 2024; the payment of monthly premiums for
healthcare coverage; and provided that the Former CEO continues to provide consulting services to the Company as a consultant, the continued vesting of outstanding stock option awards in accordance with the applicable equity plans and stock option
agreements. During the year ended December&nbsp;31, 2024, the Company recorded $0.8&nbsp;million of termination benefits in general and administrative expense in the accompanying statements of operations. See Note 10 <I>Stock-Based Compensation</I>
for additional information on the continued vesting of outstanding stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024, the Company entered into a new lease agreement for office space in New York, New York. The Company received $1.2&nbsp;million of leasehold
improvement incentives associated with the new lease agreement. The term of this lease commenced on June&nbsp;21, 2024, which is the date the Company obtained control over the leased premises. The lease term continues through March 2032. The
Company&#8217;s real estate lease agreement includes variable payments that are passed through by the landlord, such as insurance, taxes, and common area maintenance, and payments based on the usage of the asset. Pass-through charges and payments
due to changes in usage of the asset are included within variable rent expense. Operating leases are recognized over the lease term and included in general and administrative expenses in the accompanying statements of operations. Variable lease
expenses are recognized in general and administrative expenses in the accompanying statements of operations as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s lease
agreement does not contain material residual value guarantees, restrictions, or covenants. The Company has no other operating leases recognized on the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows for the years ended December&nbsp;31, 2024 and 2023 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>72</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term lease expense includes expenses related to the Company&#8217;s 2018 operating lease agreement for
office space in New York, New York. The lease agreement was <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> and could be terminated by either party with three months&#8217; written notice. The Company
terminated the lease effective September&nbsp;30, 2024. The Company made the policy election to exclude short-term leases from recognition and measurement under ASC&nbsp;842. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made an advance payment of $0.06&nbsp;million for the first month of rent on the lease liabilities during the year ended December&nbsp;31, 2024.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental balance sheet information related to operating leases as of December&nbsp;31, 2024 and 2023 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, future minimum commitments under operating leases were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable Convertible Preferred Stock and Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Fourth Amended and Restated Certificate of Incorporation (&#8220;Fourth Amended Certificate&#8221;) designates and authorizes the Company
to issue 184.3&nbsp;million shares, consisting of: (i) 105.0&nbsp;million shares of common stock, par value $0.0001 per share; and (ii) 79.3&nbsp;million shares of preferred stock, par value $0.0001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (&#8220;Preferred Stock&#8221;) as of December&nbsp;31, 2024 and 2023 consisted of the following (in thousands, except
per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Start Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/3/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Start Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/3/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company closed the Series C Offering with four new investor groups (&#8220;Series C New Investors&#8221;)
to invest $75.0&nbsp;million of which $35.0&nbsp;million was payable upon the first closing in August 2023 and $40.0&nbsp;million payable upon the enrollment of the first patient into the Phase 2 trial of
<FONT STYLE="white-space:nowrap">LB-102.</FONT> The second closing occurred in January 2024<I></I>. The Company issued 23.3&nbsp;million and 26.7&nbsp;million shares of Series C preferred stock at the first and second closings, respectively. In
conjunction with the Series C Offering, the strike price of warrants held by Series A and Series B preferred stockholders was reduced to $0.01 per share and the Series B preferred stockholders received 100,373 newly issued warrants at a strike price
of $1.50 (&#8220;New Series B Warrants&#8221;), allowing the Series B preferred stockholders to purchase common stock in an amount equal to <FONT STYLE="white-space:nowrap">one-third</FONT> of their current Series B preferred stock. See Warrants
section below for additional information. The Company incurred issuance costs of $2.0&nbsp;million associated with the Series C preferred stock and New Series B Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Series C Offering, the 2020 Notes and 2022 Notes automatically converted to 23.8&nbsp;million shares of Series C preferred stock at a
price of $1.50 per share. See Note 11 <I>Notes</I> for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the holders of the Preferred Stock have the
following rights and preferences: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting</I></B>: The holders of the Preferred Stock shall have full voting rights and powers and shall vote
together with all other classes and series of stock of the Company. Each holder of Preferred Stock shall be entitled to the number of votes equal to the number of shares of common stock into which the preferred stock could be converted on the record
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Series C Offering, the Company&#8217;s Board of Directors shall consist of no more
than seven members, including: one director shall be designated by each of the Series C New Investors; one director shall be designated by the existing stockholders of the Company, one director shall be the CEO of the Company and one independent
director to be mutually agreed upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A and Series B Protective Provisions: </I></B>At any time when shares of Series A or Series B preferred
stock are outstanding, the Company will not, without the consent of a majority of the outstanding shares of Series A and Series B preferred stock (voting together as a single class): (i) take any action that requires the separate approval of the
Series A or Series B preferred stockholders; (ii)&nbsp;amend the Fourth Amended Certificate to adversely affect the rights of the Series A or Series B stockholders differently from the Preferred Stock; or (iii)&nbsp;increase or decrease the
authorized number of Series A or Series B preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series C Protective Provisions:</I></B> Additionally, at any time that at least 50% of
Series C preferred stock is outstanding, the Company will not without the consent of at least 60% of the Series C preferred stockholders (&#8220;Requisite Series C Holders&#8221;): (i) liquidate, dissolve or wind up the Company; (ii)&nbsp;amend,
alter, repeal or waive any provisions of the Fourth Amended Certificate of Incorporation provided that any such amendment or waiver that is adverse to any series of Preferred Stock shall require the consent of the affected series (voting separately
as a class); (iii) adversely change the rights, preferences or privileges of the Series C preferred stock; (iv)&nbsp;create any new class or series of equity interest having rights, preferences or privileges senior to or in parity with the Series C
preferred stock; (v)&nbsp;increase or decrease the authorized number of shares of Preferred or Common Stock; (vi)&nbsp;purchase or redeem any Common or Preferred Stock, other than Common Stock granted by Board approved equity compensation
arrangements; (vii)&nbsp;pay or declare any dividends or other distributions on Common or Preferred Stock; (viii)&nbsp;incur any indebtedness in excess of $1&nbsp;million (other than ordinary trade indebtedness); (ix) increase or decrease the number
of Directors on the Board; or (x)&nbsp;enter into any related party transactions other than changes in the compensation of the Company&#8217;s executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends</I></B>: The holders of Preferred Stock will not be entitled to dividends with respect to such shares, provided however that if the Board of
Directors declares any dividends, holders of Preferred Stock will first receive at least an amount equal to the sum of (i)&nbsp;any declared but unpaid dividends on the applicable series of Preferred Stock plus (ii)&nbsp;a pro rata share of any
dividends to be paid on other classes and series of the Company&#8217;s stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference</I></B>: In the event of any liquidation,
dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, the liquidation preference is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>First</I></B><B>:</B> Series C preferred stockholders would be entitled to receive the greater of: (i) $1.50 per share (adjusted for any
stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii)&nbsp;the amount that would be received if the shares of Series C preferred stock were converted to common stock (&#8220;Series C Preference
Amount&#8221;). Upon payment in full of the Series C Preference Amount, the holders of Series C preferred stock, shall not receive any additional payments from the Company. In the event the funds or assets are insufficient to pay in full the Series
C Preference Amount, as described above, then all funds or assets available for shall be paid to the holders of Series C Stock pro rata based on the full Series C Preference Amount to which they are entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Second</I></B><B>:</B> Series B preferred stockholders would be entitled to receive the greater of: (i) $3.00 per share (adjusted for any
stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii)&nbsp;the amount that would be received if the Series B Preferred were converted to Common Stock (&#8220;Series B Preference Amount&#8221;). In the
event the funds or assets are insufficient to pay in full the Series B Preference Amount, as described above, then all funds or assets available for shall be paid to the holders of Series B Stock pro rata based on the full Series C Preference Amount
to which they are entitled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Third</I></B>: Series A preferred stockholders will be entitled to receive the greater
of: (i) $2.30 per share (adjusted for any stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii)&nbsp;the amount that would be received if the Series A Preferred were converted to Common Stock
(&#8220;Series A Preference Amount&#8221;). In the event the funds or assets are insufficient to pay in full the Series A Preference Amount, as described above, then all funds or assets available for shall be paid to the holders of Series A Stock
pro rata based on the full Series A Preference Amount to which they are entitled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fourth</I></B>: Series Seed preferred stockholders
will be entitled to receive the greater of: (i) $1.50 per share (adjusted for any stock dividends, combinations or splits or similar transactions with respect to such shares), or (ii)&nbsp;the amount that would be received if the Series Seed
Preferred were converted to Common Stock (&#8220;Series Seed Preference Amount&#8221;). In the event the funds or assets are insufficient to pay in full the Series Seed Preference Amount, as described above, then all funds or assets available for
shall be paid to the holders of Series Seed Stock pro rata based on the full Series Seed Preference Amount to which they are entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">After payment of the liquidation preference to the holders of Preferred Stock, the remaining assets of the Company shall be distributed ratably
to the holders of common stock on a fully converted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Stock may be redeemed upon a Deemed Liquidation Event as defined in the
Company&#8217;s Fourth Amended Certificate of Incorporation. The Preferred Stock will be redeemed as detailed above and may be redeemed at the greater of (i)&nbsp;the original issue price per share, plus any dividends declared but unpaid thereon, or
(ii)&nbsp;such amount per share as would have been payable had all shares of such class or series of Preferred Stock been converted into common stock prior to the Deemed Liquidation Event. As of December&nbsp;31, 2024, the shares of Preferred Stock
were not redeemable and the likelihood of an occurrence of a Deemed Liquidation Event was not deemed to be probable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion</I></B>: Each share
of Preferred Stock is convertible at the option of the holder at any time after issuance into the number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as determined by dividing the original issue
price of each series of Preferred Stock by the conversion price of each series in effect at time of the conversion. The initial conversion price is the respective original issue price, subject to adjustment in accordance with the anti-dilution
provisions of the stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock will automatically be converted into one share of common stock at the then effective conversion
rate in the event of either: (i)&nbsp;the closing of a public offering at a price of at least $3.00 per share (as adjusted for stock dividends, splits or similar transactions) resulting in gross proceeds to the Company of at least
$75.0&nbsp;million; or (ii)&nbsp;an event approved by the Requisite Series C Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024 and 2023, none of the outstanding
shares of Preferred Stock had been converted into common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reissuance</B>: Shares of any Preferred Stock that are redeemed or converted will be
retired or canceled and may not be reissued by the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All issued shares of common stock are entitled to vote on a one share/one vote basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2024, the Company entered into an agreement for financial advisory services. As compensation for the services, the Company issued 1,433 shares of
common stock. The Company recorded stock-based compensation expense of $0.1&nbsp;million included in general and administrative expense on the accompanying statement of operations. The fair value of the issued shares was determined based on the fair
value of the Company&#8217;s common stock as of the date of the agreement. <I></I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, in connection with the Company&#8217;s Series A Offering in 2018 (the &#8220;Series A Offering&#8221;), the Company issued warrants to purchase
0.06&nbsp;million shares of the Company&#8217;s common stock at an exercise price of $64.14 per share. The warrants expire ten years after issuance. The warrants were issued in two tranches of which 0.03&nbsp;million were fully exercisable at
issuance (&#8220;Class&nbsp;A Warrants&#8221;) and the remaining 0.03&nbsp;million were exercisable as of May&nbsp;21, 2022 (&#8220;Class&nbsp;B Warrants&#8221;). The Class&nbsp;A Warrants and Class&nbsp;B Warrants are collectively referred to as
the &#8220;A and B Warrants&#8221;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, in connection with the Series B Offering, the Company issued the Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Warrants to purchase 2,868 shares of the Company&#8217;s common stock that were immediately exercisable at an exercise price of $104.58 per share. The warrants expire five years after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series B Offering included a Rights Offer Phase (&#8220;Rights Offer&#8221;) in which the Company offered participants in the Series A Offering to invest
in the Series B Offering. During the Rights Offer, for each Class&nbsp;A Warrant holder that invested in the Series B Offering, the Class&nbsp;A Warrant holder received the right to convert its Class&nbsp;A Warrants into the number of shares of
common stock issuable upon exercise of the Class&nbsp;A Warrants, at no cost and for an exercise price of zero ($0.00) per share. On May&nbsp;3, 2022, the Company settled the warrant liability and converted less than 0.01&nbsp;million Class&nbsp;A
Warrants to common stock. The difference in fair value based on the change in the exercise price of the warrants of less than $0.01&nbsp;million was recorded to gain (loss) on change in fair value of derivative instruments in the accompanying
statement of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the anti-dilution terms contained in the Class&nbsp;A Warrants, any Class&nbsp;A Warrant holder who chose not to
participate in the Rights Offer received a reduction in the exercise price of the Class&nbsp;A Warrants from $64.14 per share to $63.30 per share, calculated based on the amount of common stock issued upon conversion of the Class&nbsp;A Warrants in
the Rights Offer. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B Warrants issued as part of the Series A Offering remain outstanding and were not impacted by the Class&nbsp;A
Warrant conversions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, as part of the Series C Offering, the Company modified the outstanding Class&nbsp;A Warrants, Class&nbsp;B Warrants
and Class <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants reducing the exercise price to $0.01. The Company recorded a gain on the change in fair value of $0.8&nbsp;million to gain (loss) on change in fair value of derivative instruments in the
accompanying statement of operations for the year ended December&nbsp;31, 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company issued less than 0.01&nbsp;million new
warrants to the Series B preferred stockholders at a strike price of $41.83 per share (&#8220;New Series B Warrants&#8221;), allowing the Series B preferred stockholders to purchase common stock in an amount equal to 33.33% of their current Series B
Preferred holdings. The New Series B Warrants were immediately exercisable and expire five years after issuance. The New Series B Warrants were issued as an incentive for the Series B stockholders to consent to the Series C Offering. The issuance of
the New Series B Warrants was considered an inducement offer under ASC 470, <I>Debt</I> and the Company recorded financing costs based on the grant date fair value of the New Series B Warrants to other expense in the accompanying statement of
operations for the year ended December&nbsp;31, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrants outstanding as of December&nbsp;31, 2024 and 2023 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Series B Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Placement agent warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total warrants outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>117,788</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 3 <I>Fair Value Measurements</I> for warrant activity for the years ended December&nbsp;31, 2024 and 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Net Loss per Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the
computation of basic and diluted net loss per share of common stock for the years ended December&nbsp;31, 2024 and 2023 (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used in computing net loss per share, basic and diluted&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(176.15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(21.86</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included within weighted average common shares outstanding for the years ended December&nbsp;31, 2024 and 2023
are 114,095 and 75,389, respectively, common shares issuable upon the exercise of penny warrants. Per ASC 260, <I>Earnings Per Share</I>, the warrants are exercisable at any time for nominal consideration, and as such, the shares are considered
outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#8217;s potentially dilutive securities, which consist of stock options and convertible preferred stock, have been excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive impact.
Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following common stock equivalents, presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss
per share because including them would have an antidilutive effect (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Restricted stock - unvested</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Common Stock Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives
consist primarily of stock options and restricted stock grants. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2017, the Company&#8217;s Board of Directors approved the LB Pharmaceuticals Inc
2017 Stock Incentive Plan (&#8220;2017 Plan&#8221;). The 2017 Plan authorized the issuance of stock options or restricted stock up to 0.02&nbsp;million shares of the Company&#8217;s common stock. In August 2018, the Company amended the 2017 Plan,
reducing the maximum aggregate number of shares that may be issued under the 2017 Plan to 0.02&nbsp;million. No additional awards will be granted under the 2017 Plan. As of both December&nbsp;31, 2024 and 2023, there were 0.01&nbsp;million shares
outstanding under the 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2018, the Company&#8217;s Board of Directors approved the LB Pharmaceuticals Inc 2018 Stock Incentive Plan
(&#8220;2018 Plan&#8221;). The 2018 Plan authorized the issuance of stock options or restricted stock up to 0.04&nbsp;million shares of the Company&#8217;s common stock. No additional awards will be granted under the 2018 Plan. As of both
December&nbsp;31, 2024 and 2023, there were 0.03&nbsp;million shares outstanding under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company&#8217;s Board of
Directors approved the LB Pharmaceuticals Inc 2023 Stock Incentive Plan, as amended (&#8220;2023 Plan&#8221;). The 2023 Plan authorized the issuance of stock options or restricted stock up to 0.3&nbsp;million shares of the Company&#8217;s common
stock. In December 2024, the Company amended the 2023 Plan increasing the maximum aggregate number of shares that may be issued under the 2023 Plan to approximately 0.5&nbsp;million. The 2023 Plan expires in August 2033. As of December&nbsp;31, 2024
and 2023, there were 0.4&nbsp;million and 0.1&nbsp;million shares outstanding, respectively. As of December&nbsp;31, 2024, there are 0.05&nbsp;million shares available for future issuance under the 2023 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options vest based on one of
the following schedules: (i) 25% on the first anniversary of grant date with the remaining 75% to vest in 36 equal monthly installments thereafter through the fourth anniversary of the grant date; (ii) 100% vesting in 36 equal monthly installments
through the third anniversary of the grant date; or (iii) 100% vesting in 12 equal monthly installments through the first anniversary of the grant date for certain nonemployee grants. All stock options expire ten years from the grant date. The
assumptions used to determine the fair value of stock options granted to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> for the years ended December&nbsp;31, 2024 and 2023 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6.25&nbsp;-&nbsp;10.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">4.20%&nbsp;-&nbsp;4.56</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.87%&nbsp;-&nbsp;4.23</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">82.1%&nbsp;-&#8201;86.4</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">85.5%&nbsp;-&#8201;85.7</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">31.23&nbsp;-&#8201;$49.65</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">21.19&nbsp;-&#8201;$27.89</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s stock option activity and related information is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>Outstanding</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61.91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47.69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>457</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>43.50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and expected to vest as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of the stock options granted during the year ended December&nbsp;31, 2024
was $31.23. The weighted average grant date fair value of the stock options granted during the year ended December&nbsp;31, 2023 was $14.22. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation related to stock options is recorded in the accompanying statements of operations as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stock-based compensation expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,087</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company&#8217;s Former CEO entered into a Separation Agreement with the Company including
continued consulting services (see Note 6 <I>Prepaid Expenses and Accrued Expenses</I>). Pursuant to the original terms of the stock option awards, the outstanding stock options continue to vest as long as services are provided to the Company under
the Separation Agreement as a <FONT STYLE="white-space:nowrap">non-employee</FONT> consultant. In accordance with ASC 718, there was a modification of the Former CEO&#8217;s options related to a reduction in the level of required service. The
consulting services outlined in the Separation Agreement are not substantive. As a result, the Company determined the fair market value of all awards expected to vest over the duration of the Separation Agreement as of the modification date using
the Black-Scholes option-pricing model. The total amount of $1.7&nbsp;million was recognized immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, there was
$8.0&nbsp;million unrecognized stock-based compensation expense which is expected to be recognized over a weighted average period of 3.66 years. No stock options were exercised, expired or forfeited during the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no realized tax benefits for the years ended December&nbsp;31, 2024 and 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company granted 412 shares of restricted stock to employees at a price of $41.83 per share and vest ratably
over 36 months. No restricted stock was granted during the year ended December&nbsp;31, 2024. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock vests over the period of time for
which services are expected to be rendered, which ranged from immediate vesting, up to 36 months, or vests on the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the consummation of the Company&#8217;s first underwritten public
offering (&#8220;IPO&#8221;) under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s restricted stock activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant&nbsp;Date&nbsp;</B><br><B>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company agreed with its Chief Medical Officer to accelerate the
vesting of less than 0.01&nbsp;million shares of restricted stock. The Company recorded $0.1&nbsp;million of stock-based compensation expense within research and development in the accompanying statement of operations for the year ended
December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Series C Offering, the Company modified certain restricted stock awards that were previously awarded to employees
and <FONT STYLE="white-space:nowrap">non-employees</FONT> to accelerate the vesting from six months after the consummation of an IPO to immediate vesting. An aggregate amount of 0.01&nbsp;million restricted stock vested upon the closing of the
Series C Offering in August 2023. The Company recorded $0.1&nbsp;million and less than $0.01&nbsp;million of stock-based compensation with general and administrative and research and development, respectively in the accompanying statement of
operations for the year ended December&nbsp;31, 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total fair value of restricted stock that vested during the years ended December&nbsp;31,
2024 and 2023 was $0.2&nbsp;million and less than $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation related to restricted stock is recorded in
the accompanying statements of operations as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stock-based compensation expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company had unrecognized compensation expense related to such shares of
$0.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, in
connection with services provided for the issuance of the 2020 Notes, the Company issued to a placement agent, warrants to purchase the Company&#8217;s common stock at an exercise price of $0.28 per share. The number of shares underlying the
warrants was based upon 10% of the value of the 2020 Notes divided by the conversion price of the 2020 Notes upon conversion in the next round of financing or $69.72 upon maturity. As the conversion price could be based on any class of shares, and
the warrants are for common stock the Company determined that the warrants should be equity-classified as there was no obligation for the Company to raise an additional round of equity financing and no other criteria for liability classification
under ASC 718, <I>Stock Compensation, </I>were met. The warrants expire ten years after issuance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate grant date fair value of the
placement agent warrants issued in conjunction with the 2020 Notes was $0.6&nbsp;million. The stock-based compensation cost related to the warrants was treated as a debt issuance cost for the 2020 Notes (see Note 11 <I>Notes</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2022, in connection with the Series B Offering, the Company issued to the placement agent, warrants to purchase less than 0.01&nbsp;million shares of
the Company&#8217;s common stock that were immediately exercisable at an exercise price of $0.28 per share. The warrants expire ten years after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From October 2022 to January 2023, in connection with services provided for the issuance of the 2022 Notes, the Company issued to a placement agent, warrants
to purchase the Company&#8217;s common stock at an exercise price of $0.28 per share. The number of shares underlying the warrants was based upon 10% of the value of the 2022 Notes divided by the conversion price of the 2022 Notes upon conversion in
the next round of financing or $69.72&nbsp;upon maturity. As the conversion price could be based on any class of shares, and the warrants are for common stock the Company determined that the warrants should be equity-classified as there was no
obligation for the Company to raise an additional round of equity financing and no other criteria for liability classification under ASC 718, <I>Stock Compensation, </I>were met.&nbsp;The warrants expire ten years after issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate grant date fair value of the placement agent warrants issued in conjunction with the 2022 Notes was $1.5&nbsp;million. The stock-based
compensation cost related to the warrants was treated as a debt issuance cost for the 2022 Notes (see Note 11 <I>Notes)</I>. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the
Company executed a final agreement with the placement agent replacing all prior agreements. As part of this agreement, the Company issued warrants to purchase 0.05&nbsp;million of the Company&#8217;s common stock exercisable six months after the
grant date at an exercise price of $0.28 per share.&nbsp;Also, the less than 0.01&nbsp;million warrants issued as part of the Series B Stock Offering (as described above) were amended and reissued and are exercisable six months after the grant date
at an exercise price of $0.28 per share. The warrants expire ten years after issuance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the fair value of the replacement warrants was less than
the grant date fair value of the original warrants, no incremental compensation costs were recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;29, 2023, the Company entered into the Series C Offering (as described in Note 6 <I>Redeemable Convertible Preferred Stock and Equity)</I>. The
principal of all 2022 Notes and 2020 Notes outstanding at the time </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the closing, in the aggregate amount of $35.7&nbsp;million, was converted into 23.8&nbsp;million shares of Series C preferred stock at a price of $1.50 per share. The Company recorded a loss
on extinguishment of debt in the amount of $7.4&nbsp;million in the accompanying statements of operations. The Company elected to pay the accrued interest on the 2020 Notes and 2022 Notes in cash in the total amount of approximately
$2.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into the 2022 Notes with several investors who loaned the Company a total of approximately $25.7&nbsp;million as detailed below (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Issue Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Original<BR>Maturity<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;21, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/21/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;10, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/10/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;28, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/30/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;26, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/30/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total 2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate was 4% per annum. All payments of interest and principal were due and payable on the maturity date, unless
converted earlier. The principal due under the 2022 Notes would automatically convert into the class of the stock issued in the Company&#8217;s next qualified financing of at least $20.0&nbsp;million at a conversion price equal to 80% of the <FONT
STYLE="white-space:nowrap">per-share</FONT> price of such securities issued. If the <FONT STYLE="white-space:nowrap">per-share</FONT> price of the next qualified financing was below $2.35, the outstanding principal of the 2022 Notes would have
converted at the <FONT STYLE="white-space:nowrap">per-share</FONT> price paid for such securities issued. The accrued interest would either be converted into the stock issued in the qualified financing or paid to the 2022 Note investors in cash at
the Company&#8217;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Company consummated a sale of the Company prior to the conversion or repayment in full of the 2022
Notes, at the closing of such sale of the Company, in lieu of the principal and interest that would otherwise be payable on the maturity date, the Company would allow each holder of the 2022 Notes to convert the principal and interest into common
stock at a price per share of $2.50 up until the fifth day prior to the sale of the Company. In the event a holder made no such election within the <FONT STYLE="white-space:nowrap">five-day</FONT> deadline, the Company would pay such holder of the
unconverted 2022 Notes an aggregate amount equal to 1.5 times the aggregate amount of principal and interest then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At inception, the Company
concluded that the 2022 Notes contained a conversion option at a significant discount that was deemed to be an embedded derivative, which was required to be bifurcated and accounted for separately from the debt host. The derivative was bifurcated
from the host contract and a liability and corresponding discount was recorded on the date of issuances in the total amount of $0.3&nbsp;million and $7.1&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. The liability
is remeasured at fair value at the end of each reporting period, with any changes recorded in the accompanying statements of operations. For the year ended December&nbsp;31, 2023, debt issuance costs associated with the 2022 Notes totaled
$0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2022, the Company amended and restated the 2022 Notes to extend the maturity date to November&nbsp;30, 2024 for
all noteholders. In accordance with ASC <FONT STYLE="white-space:nowrap">470-50,</FONT> <I>Debt Modification and Extinguishments, </I>the Company considered this extension of maturity date as a modification. The Company amortizes the remaining debt
issuance costs and conversion feature over the remaining life of the modified debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized the following changes in the debt related to the 2022 Notes during the year ended
December&nbsp;31, 2023 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt<BR>Discount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022<BR>Notes, Net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of 2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion features for 2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion to Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,730</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,655</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Convertible Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the Company entered into the 2020 Notes with several investors who loaned the Company a total of $10.0&nbsp;million. The original maturity date for
each 2020 Note was three years after issuance. The interest rate was 4% per annum. All payments of interest and principal were due and payable on the maturity date (August and September 2023), unless converted earlier. The principal due under the
2020 Notes would automatically convert into the class of the Company&#8217;s stock issued in the Company&#8217;s next qualified financing of at least $10.0&nbsp;million at a conversion price equal to 80% of the
<FONT STYLE="white-space:nowrap">per-share</FONT> of such securities issued. If the <FONT STYLE="white-space:nowrap">per-share</FONT> price of the next qualified financing was below $2.35, the outstanding principal of the 2020 Notes would have
converted at the <FONT STYLE="white-space:nowrap">per-share</FONT> price paid for such securities issued. The accrued interest would either be converted into the stock issued in the qualified financing or paid to the 2020 Note investors in cash at
the Company&#8217;s discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the Company consummated a sale of the Company prior to the conversion or repayment in full of the 2020
Notes, at the closing of such sale of the Company, in lieu of the principal and interest that would have otherwise been payable on the maturity date, the Company would have allowed each holder of the 2020 Notes to convert the principal and interest
into common stock at a price per share of $2.50 up until the fifth day prior to the sale of the Company. In the event a holder made no such election within the <FONT STYLE="white-space:nowrap">five-day</FONT> deadline, the Company would have paid
such holder of the unconverted 2020 Notes an aggregate amount equal to 1.5 times the aggregate amount of principal and interest then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
inception, the Company concluded that the 2020 Notes contained a conversion option at a significant discount that was deemed to be an embedded derivative, which was required to be bifurcated and accounted for separately from the debt host. The
derivative was bifurcated from the host contract and a liability and corresponding discount was recorded on the date of issuances in the total amount of $0.7&nbsp;million. The liability is remeasured at fair value at the end of each reporting
period, with any changes recorded in the accompanying statements of operations. Debt issuance costs associated with the 2020 Notes totaled $1.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2022, the Company amended and restated the 2020 Notes to cause the maturity date and the conversion terms of such notes to those terms
contained in the 2022 Notes (as amended and restated). The maturity date of the 2020 Notes was extended to November&nbsp;30, 2024. In accordance with ASC <FONT STYLE="white-space:nowrap">470-50,</FONT> <I>Debt Modification and Extinguishments,
</I>the Company considered this extension of maturity date as a modification. The Company amortized the remaining debt issuance costs and conversion feature over the remaining life of the modified debt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized the following changes in the debt related to the 2020 Notes during the year ended
December&nbsp;31, 2023 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Debt</B><br><B>Discount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020<BR>Notes,<BR>Net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(548</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion to Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
provision from income taxes for the years ended December&nbsp;31, 2024 and 2023 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Current:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred tax expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax provision</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the effective tax rates of the Company and the U.S. federal statutory tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statutory tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in income taxes resulting from:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (net of federal tax benefits)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> interest and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative fair value measurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85.8</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized temporary differences of the Company that give rise to significant portions of the
Company&#8217;s deferred tax assets and liabilities as of December&nbsp;31, 2024 and 2023, are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Deferred tax assets:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gross deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,935</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,390</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>545</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Deferred tax liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciable asset basis differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain - other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deferred tax liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(545</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net deferred tax assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability
of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company&#8217;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during
the periods in which those temporary differences and carryforwards become deductible. As of December&nbsp;31, 2024 and 2023, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a
full valuation allowance has been established and no deferred tax asset is shown in the Company&#8217;s balance sheets. During the years ended December&nbsp;31, 2024 and 2023, the valuation allowance increased by $11.3&nbsp;million and
$4.0&nbsp;million, respectively, which primarily relates to the current year operating loss and capitalized research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company believes that income tax filing positions will be sustained upon examination and does not anticipate any adjustments that would result in a material adverse effect on the Company&#8217;s financial position, results of operations or cash
flows. Accordingly, the Company has not recorded any reserves, or related accruals or uncertain income tax positions as of December&nbsp;31, 2024 and 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has no accruals for interest and
penalties as of December&nbsp;31, 2024 and 2023. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Internal Revenue Code of 1986 contains certain provisions that can limit a taxpayer&#8217;s
ability to utilize net operating loss (&#8220;NOL&#8221;) and tax credit carryforwards in any given year resulting from cumulative changes in ownership interests in excess of 50&nbsp;percent over a three-year period (&#8220;ownership change&#8221;).
In the event of such a deemed ownership change, Internal Revenue Code Section&nbsp;382 (&#8220;Section&nbsp;382&#8221;) imposes an annual limitation on <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change tax attributes. As of
December&nbsp;31, 2024, the Company has not performed a formal Section&nbsp;382 study, however the Company has reviewed its temporary deductible differences in conjunction with its temporary taxable differences as a measure against its definite
lived net operating losses and anticipates any impact would be immaterial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company has federal NOL carryforwards of approximately $37.2&nbsp;million,
of which $1.5&nbsp;million is subject to the <FONT STYLE="white-space:nowrap">20-year</FONT> carryforward period and begins to expire in 2036. The remaining federal NOL carryforward of $35.7&nbsp;million has an indefinite carryforward period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has available state NOL carryforwards of approximately $41.9&nbsp;million and $49.1&nbsp;million as of December&nbsp;31, 2024 and 2023,
respectively. The state NOLs are expected to begin to expire in 2036, although not all states conform to the federal NOL carryforward period and occasionally limit the use of NOLs for a period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024 and 2023, the Company had federal research and development credits of approximately $2.7&nbsp;million and $0.8&nbsp;million,
respectively. The research and development credits, if not utilized, will begin to expire in 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation and files income
tax returns in the U.S. Federal and state jurisdictions. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open from the tax years December&nbsp;31, 2021 through December&nbsp;31, 2024. There
are currently no federal or state income tax audits in progress. The tax authorities generally have the ability to review income tax returns for periods where the statute of limitations has previously expired and can subsequently adjust the NOL
carryforward or tax credit amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has contracted with various consultants and third parties to assist in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and
development and clinical trials work for the Company&#8217;s leading drug compounds. The contracts are terminable at any time but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. <I></I>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the
Company entered into a work order with a third-party CRO to provide services with respect to the Company&#8217;s Phase 2 trial of <FONT STYLE="white-space:nowrap">LB-102.</FONT> Minimum advances will be kept by the CRO throughout the duration of the
clinical trial. As of December&nbsp;31, 2024 and 2023, the Company recorded approximately $0.4&nbsp;million and $2.2&nbsp;million, respectively, in advances to the CRO, recorded in prepaid expenses in the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other
third parties for preclinical research studies and testing and manufacturing services, which are generally cancelable upon prior written notice. Payments due upon cancellation may consist of payments for services provided or expenses incurred,
including noncancelable obligations of our service providers, up to the date of cancellation, and may also include termination penalties. As of December&nbsp;31, 2024 and 2023, the Company had no outstanding liabilities related to such items. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business,
the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business. The Company records accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss
can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized. The Company is not a party to any litigation and does not have contingency reserves established for any litigation
liabilities as of December&nbsp;31, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements
</B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Related-Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2020, the Company entered into an oral agreement with Rivopharm S.A. (&#8220;Rivopharm&#8221;), to develop an oral dose formulation of <FONT
STYLE="white-space:nowrap">LB-102</FONT> for use in future human clinical trials. Piero Poli, a former board member of the Company, is the Principal of Rivopharm. The agreement calls for a subsidiary of Rivopharm, Developharma S.A.
(&#8220;Developharma&#8221;), to complete this work for a cost to be paid in common stock of the Company totaling 15,367&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developharma
initiated the development work in 2021 and was approximately 50% complete as of December&nbsp;31, 2022. The Company recorded research and development expense of $0.2&nbsp;million for 50% of the fair value of the stock to be paid. In 2023,
Developharma completed the project. As a result of the completion, the Company issued 15,367 shares of common stock to Rivopharm and recorded additional research and development expense of $0.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of the Series C Offering, the Company entered into several amended and restated royalty participation
agreements (the &#8220;Amended and Restated Royalty Agreements&#8221;) with certain of its investors, <FONT STYLE="white-space:nowrap">co-founders,</FONT> former directors, and executive officers, none of whom are Series C New Investors. No
consideration was received as part of the Amended and Restated Royalty Agreements. Pursuant to the Amended and Restated Royalty Agreements, the Company is obligated to pay royalties to all of the holders in an aggregate amount up to 2.75% on net
sales arising from <FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide through December&nbsp;31, 2035. Thereafter, the Company is obligated to pay royalties to such holders in an aggregate amount up to 3.25% in perpetuity. Future sales are
defined in these agreements as the gross payments received on total commercial sales of <FONT STYLE="white-space:nowrap">LB-102,</FONT> whether by the Company or by any licensee of <FONT STYLE="white-space:nowrap">LB-102.</FONT> As of
December&nbsp;31, 2024, certain officers of the Company and their affiliates held 1.27% of the future royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Series C
Offering, three of the Company&#8217;s Board of Directors were replaced and the Company agreed to pay them a total of $0.2&nbsp;million as part of their departure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Subsequent Events </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated
subsequent events through September&nbsp;8, 2025, the date these financial statements were available to be issued, and has not identified any events requiring
disclosure<I></I><I></I><I></I><I></I><I></I><I></I><I></I><I></I><I></I><I></I><I></I><B></B><I></I><I></I><I></I><SUP STYLE="font-size:75%; vertical-align:top"></SUP><I></I><I></I> except for the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September, 2025, the Company effected a 1-for-27.8874 reverse stock split (the &#8220;Stock Split&#8221;) of the Company&#8217;s issued and outstanding
shares of common stock and warrants and options to purchase common stock. The Stock Split reduced the number of shares of the Company&#8217;s issued and outstanding common stock, as well as the numbers of shares reserved and available for future
issuance and underlying outstanding options to purchase common stock. No fractional shares were distributed as a result of the reverse stock split, and stockholders were entitled to a cash payment in lieu of fractional shares. The Stock Split did
not affect the par values per share or total authorized common stock. Accordingly, all shares of common stock and per share amounts for all periods presented in the financial statements have been adjusted retroactively, where applicable, to reflect
the Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_50"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>28,879</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#8217;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability&#8212;warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (Note 12)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Redeemable convertible preferred stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed preferred stock, $0.0001 par value, 295,467 shares authorized, 295,467 shares issued
and outstanding as of June&nbsp;30, 2025 and December&nbsp;31, 2024. Liquidation preference of $443 as of June&nbsp;30, 2025 and December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred stock, $0.0001 par value, 3,655,374 shares authorized, 3,655,374 outstanding as
of June&nbsp;30, 2025 and December&nbsp;31, 2024. Liquidation preference of $8,407 as of June&nbsp;30, 2025 and December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B preferred stock, $0.0001 par value, 301,119 shares authorized, 301,119 shares issued and
outstanding as of June&nbsp;30, 2025 and December&nbsp;31, 2024. Liquidation preference of $903 as of June&nbsp;30, 2025 and December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C preferred stock, $0.0001 par value, 75,000,000 shares authorized, 73,820,346 shares
issued and outstanding as of June&nbsp;30, 2025 and December&nbsp;31, 2024. Liquidation preference of $110,731 as of June&nbsp;30, 2025 and December&nbsp;31, 2024.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 105,000,000 shares authorized, 251,655 and 251,655 shares issued
and outstanding as of June&nbsp;30, 2025 and December&nbsp;31, 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#8217; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(94,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities, redeemable convertible preferred stock and stockholders&#8217;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>33,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_51"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,208</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-operating</FONT> income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(642</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(43,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,177</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used in calculating net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:320pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_52"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;2025&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (loss) gain on marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(43,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:450pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_53"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series Seed</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#8217;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,153,680</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68,773</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,221</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of redeemable convertible Series C preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,666,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Shares issued upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of common stock for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, June&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,820,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>251,162</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,888</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(85,071</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>739</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(77,443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,820,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>251,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,657</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(104,323</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(94,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance, June&nbsp;30, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>295,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>435</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,655,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>301,119</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,820,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,065</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>251,655</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(114,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(103,873</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_54"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2025&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2024&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued for services rendered</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Realized gain on sale of marketable securities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Accretion) amortization of (discounts) premium on investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on change in fair value of derivative instruments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,732</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(25,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in) investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,178</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible Series C preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of warrants and options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,746</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental Disclosures of Noncash Investing and Financing Information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements paid by lessor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin12080_55"></A>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc (the
&#8220;Company&#8221; or &#8220;LB&#8221;) was incorporated under the laws of the State of Delaware in September 2015 and is headquartered in New York, New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a clinical-stage biopharmaceutical company developing therapies for the treatment of schizophrenia, bipolar depression, and other
neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, <FONT STYLE="white-space:nowrap">LB-102,</FONT> which the Company believes has the potential to be the first
benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. <FONT STYLE="white-space:nowrap">LB-102</FONT> is a Phase <FONT STYLE="white-space:nowrap">3-ready</FONT> oral, small molecule for the treatment of acute
schizophrenia (defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Company&#8217;s inception, it has focused substantially all of its efforts and financial resources on organizing and staffing the Company, raising
capital, building its intellectual property portfolio, undertaking preclinical studies and clinical trials and providing general and administrative support for these activities. The Company has not generated any product revenue related to its
primary business purpose to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, regulatory approval of product candidates, uncertainty of market acceptance of products,
if approved, competition from substitute products and larger companies, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and the need to obtain adequate additional financing
to fund the development of its product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement
of liabilities and commitments in the normal course of business. The Company has not generated revenues and relies on the issuance of debt and equity instruments to generate working capital. The Company experienced negative operating cash flows of
$13.7&nbsp;million and net loss of $10.2&nbsp;million for the six months ended June&nbsp;30, 2025, and had an accumulated deficit of $114.5&nbsp;million as of June&nbsp;30, 2025. The Company expects to incur substantial expenses for the foreseeable
future relating to research and development of <FONT STYLE="white-space:nowrap">LB-102</FONT> and to continue to generate operating losses. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The future viability of the Company is dependent on its ability to raise additional capital to fund its operations. If the Company is unable to obtain
funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management
continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited
condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying balance sheet as of June&nbsp;30, 2025 and the statements of operations, comprehensive loss,
redeemable convertible preferred stock and stockholders&#8217; deficit and cash flows for the six months ended June&nbsp;30, 2025 and 2024 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited
annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of June&nbsp;30, 2025 and the
results of its operations and cash flows for the six months ended June&nbsp;30, 2025 and 2024. Certain information and footnote disclosures typically included in annual financial statements prepared in accordance with GAAP have been condensed or
omitted. Accordingly, these unaudited interim financial statements should be read in conjunction with the Company&#8217;s financial statements as of and for the year ended December&nbsp;31, 2024. The results for the six months ended June&nbsp;30,
2025 are not necessarily indicative of results to be expected for the year ending December&nbsp;31, 2025, any other interim periods, or any future year or period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant accounting policies and estimates used in preparation of the financial statements are described in the Company&#8217;s audited financial
statements as of and for the year ended December&nbsp;31, 2024, and the notes thereto. During the six months ended June&nbsp;30, 2025, there were no material changes to the Company&#8217;s significant accounting policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates as a
single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia. The Company has not generated revenues since inception. The Company&#8217;s chief operating decision maker
(&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;). The CODM reviews the Company&#8217;s performance on an aggregate basis, thus the segment&#8217;s loss is the Company&#8217;s net loss, as reported on accompanying condensed
statements of operations, and the segment&#8217;s assets are the Company&#8217;s total assets, as reported on the accompanying condensed balance sheets. Significant expenses provided to the CODM include research and development and general and
administrative expenses, as reported on the accompanying condensed statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CODM uses the information primarily to evaluate the
Company&#8217;s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows
the CODM to monitor the Company&#8217;s performance and make strategic adjustments as needed to support its operational and financial goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#8217;s operations and all long-lived assets are located in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements Not Yet Adopted
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax
Disclosures </I>that requires public entities to annually disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The guidance is effective for fiscal years
beginning after December&nbsp;15, 2024 and early adoption is permitted.&nbsp;The Company is evaluating the guidance to determine if adoption will have a material impact on the financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> <I>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses, </I>that requires public companies to provide more detailed disclosures to provide greater transparency about the
components of specific expense categories. The guidance is effective for years beginning after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;15, 2026, and interim periods within annual periods beginning after December&nbsp;15, 2027. Early adoption is permitted. The Company is evaluating the guidance to determine if
adoption will have a material impact on the financial statement disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis classified under the appropriate
level of the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>508</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>508</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,569</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>508</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability - warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement Using</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total marketable securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>498</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>498</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,926</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,519</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability - warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for marketable securities held as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;available-for-sale&#8221;</FONT></FONT> in accordance with ASC 320, Investments-Debt Securities. The Company classifies these investments as current assets and carries them at
fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#8217;s marketable securities classified within Level&nbsp;2 is based upon observable inputs that may include
benchmark yields, reported trades, broker/dealer quotes, issuer spreads, <FONT STYLE="white-space:nowrap">two-sided</FONT> markets, benchmark securities, bids, offers, and reference data including market research publications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificate of Deposit </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s certificates
of deposit are Level&nbsp;2 instruments. The fair value of such instruments is estimated based on valuations obtained from third-party pricing services that utilize industry standard valuation models, including both income-based and market-based
approaches, for which all significant inputs are observable either directly or indirectly. These inputs include interest rate curves, foreign exchange rates, and credit ratings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company previously issued warrants to
investors in connection with equity financings. The warrants are required to be measured at fair value and reported as a liability in the accompanying unaudited condensed balance sheets. The warrants are valued at each reporting date using the
Black-Scholes model with any changes in fair value recorded in the accompanying unaudited condensed statements of operations. The valuation of the warrants is considered under Level&nbsp;3 of the fair value hierarchy due to the need to use
assumptions in the valuation that are both significant to the fair value measurement and unobservable. See Note 8 <I>Redeemable</I> <I>Convertible Preferred Stock and Equity</I> for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2025 and 2024, the change in the fair value of the Level&nbsp;3 warrant liability resulted in the recording of a gain
(loss) on change in fair value of derivative instruments of $0.6&nbsp;million and $(1.8) million, respectively, in the accompanying unaudited condensed statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the assumptions used in the Black-Scholes valuation model in order to determine the fair value of the derivative liabilities for the warrant
liabilities as of June&nbsp;30, 2025 and December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; financing event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term &#8211; exit event (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.25&nbsp;-&nbsp;2.25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.58&nbsp;-&nbsp;2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">50.0%&nbsp;-&nbsp;68.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">49.0%&nbsp;-&nbsp;70.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.01&nbsp;-&nbsp;$1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.01&nbsp;-&nbsp;$1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.71%&nbsp;-&nbsp;4.41%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">4.23%&nbsp;-&nbsp;4.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in one or more significant unobservable inputs used in the valuation may result in a significantly higher or lower
fair value measurement at the reporting dates. The change in the derivative liabilities for the six months ended June&nbsp;30, 2025 was (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,504</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain due to change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, June&nbsp;30, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,925</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2025 and 2024, there were no transfers of instruments between
Level&nbsp;1, 2 and 3 in the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are uncertainties on the fair value measurement of the instruments classified under Level&nbsp;3
due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Cash Equivalents, Marketable Securities and Restricted Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company invests in certain U.S. government money market funds and treasury bills classified as cash equivalents and invests in certificates of deposit that
are classified as restricted cash. The marketable securities consist of government securities as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Marketable Securities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash equivalents, marketable securities and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#8212;&#8194;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>25,445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025 and December&nbsp;31, 2024, there were no marketable securities that have been in a continuous
unrealized loss position for more than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the cash, cash equivalents and restricted cash reported in the balance sheets that
sum to the total of the amounts shown in the statements of cash flows is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>June&nbsp;30,&nbsp;2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash, cash equivalents and restricted cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>23,476</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment, Net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following as of June&nbsp;30, 2025 and December&nbsp;31, 2024 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Property and equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,972</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,960</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total property and equipment, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following as of June&nbsp;30, 2025 and December&nbsp;31, 2024 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued CRO costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional and consulting costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued termination benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total accrued expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2024,
the Company entered into a new lease agreement for office space in New York, New York totaling approximately 8,900 square feet. The Company received $1.2&nbsp;million of leasehold improvement incentives associated with the new lease agreement. The
term of this lease commenced on June&nbsp;21, 2024, which is the date the Company obtained control over the leased premises. The lease term continues through March 2032. The Company&#8217;s real estate lease agreement includes variable payments that
are passed through by the landlord, such as insurance, taxes, and common area maintenance, and payments based on the usage of the asset. Pass-through charges and payments due to changes in usage of the asset are included within variable lease
expense. Operating leases are recognized over the lease term and included in general and administrative expenses in the accompanying unaudited condensed statements of operations. Variable lease expenses are recognized in general and administrative
expenses in the accompanying unaudited condensed statements of operations as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s lease agreement does not contain material
residual value guarantees, restrictions, or covenants. The Company has no other operating leases recognized on the accompanying unaudited condensed balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows for the six months ended June&nbsp;30, 2025 and 2024 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2025&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term lease expense includes expenses related to the Company&#8217;s 2018 operating lease agreement for office space in
New York City. The lease agreement was <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> and could be terminated by either party with three months&#8217; written notice. The Company terminated the lease
effective September&nbsp;30, 2024. The Company made the policy election to exclude short-term leases from recognition and measurement under ASC 842. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental balance sheet information related to operating leases as of June&nbsp;30, 2025 and December&nbsp;31, 2024 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other information related to leases for the six months ended June&nbsp;30, 2025 and 2024 was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2025&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, future minimum commitments under operating leases were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025 (remaining period)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,347</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Redeemable Convertible Preferred Stock and Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Fourth Amended and Restated Certificate of Incorporation designates and authorizes the Company to issue up to 184.3&nbsp;million shares,
consisting of: (i) 105.0&nbsp;million shares of common stock, par value $0.0001 per share; and (ii) 79.3&nbsp;million shares of preferred stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redeemable
convertible preferred stock (&#8220;Preferred Stock&#8221;) as of June&nbsp;30, 2025 and December&nbsp;31, 2024 consisted of the following (in thousands, except per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Start Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued&nbsp;and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price<BR>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/3/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Start Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/21/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/3/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/29/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company closed on the Series C preferred stock financing (the &#8220;Series C Offering&#8221;) with four
new investor groups (&#8220;Series C New Investors&#8221;) to invest $75.0&nbsp;million of which $35.0&nbsp;million was payable upon the first closing in August 2023 (&#8220;First Tranche&#8221;) in exchange for approximately 23.3&nbsp;million
shares of Series C preferred stock and $40.0&nbsp;million payable upon the enrollment of the first patient into the Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">LB-102</FONT> (&#8220;Second Tranche&#8221;). The Second Tranche closed in
January 2024 and the Company issued approximately 26.7&nbsp;million shares of Series C preferred stock at $1.50 per share for total gross proceeds of $40.0&nbsp;million. The Company incurred issuance costs of $2.0&nbsp;million and $1.7&nbsp;million
associated with the closings of the First Tranche and Second Tranche, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Series C Offering, $35.7&nbsp;million
principal of the 2020 Notes and 2022 Notes automatically converted to 23.8&nbsp;million shares of Series C preferred stock at a price of $1.50 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025 and December&nbsp;31, 2024, none of the outstanding shares of Preferred Stock had been converted into common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reissuance</B>: Shares of any Preferred Stock that are redeemed or converted will be retired or canceled and may not be reissued by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All issued shares of common stock are entitled to vote on a one share/one vote basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 3 <I>Fair Value
Measurements</I> for warrant activity for the six months ended June&nbsp;30, 2025 and 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Net Loss per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share of common stock for the six months ended June&nbsp;30, 2025 and 2024 (in
thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,177</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used in calculating net loss per share, basic and
diluted&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(28.31</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(122.67</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included within weighted average shares of common stock outstanding for the six months ended June&nbsp;30, 2025
and 2024 are 114,004 and 114,187 shares of common stock issuable upon the exercise of penny warrants, respectively. Per ASC 260, <I>Earnings Per Share</I>, the warrants are exercisable at any time for nominal consideration, and as such, the shares
are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potentially dilutive securities, which consist primarily of stock options and convertible preferred stock, have been excluded from the
computation of diluted net loss per share because including them would have had an anti-dilutive impact. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share
attributable to common stockholders is the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive shares, presented based on amounts outstanding at each period end,
have been excluded from the calculation of diluted net loss per share (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock - unvested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total potentially dilutive shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,273</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,080</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives
consist primarily of stock options and restricted stock grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, the Company&#8217;s Board of Directors approved the LB Pharmaceuticals Inc 2017 Stock
Incentive Plan (&#8220;2017 Plan&#8221;). In October 2018, the Company&#8217;s Board of Directors approved the LB Pharmaceuticals Inc 2018 Stock Incentive Plan (&#8220;2018 Plan&#8221;). No additional shares will be issued under the 2017 and 2018
Plans. As of both June&nbsp;30, 2025 and December&nbsp;31, 2024, there were 0.01&nbsp;million and 0.03&nbsp;million shares outstanding under the 2017 Plan and the 2018 Plan, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, the Company&#8217;s Board of Directors approved the LB Pharmaceuticals Inc 2023 Stock Incentive Plan (&#8220;2023 Plan&#8221;). The 2023 Plan
authorized the issuance of stock options or restricted stock up to 0.3&nbsp;million shares of the Company&#8217;s common stock. In December 2024, the Company amended the 2023 Plan increasing the maximum aggregate number of shares that may be issued
under the 2023 Plan to 0.5&nbsp;million. The 2023 Plan expires in August 2033. As of June&nbsp;30, 2025 and December&nbsp;31, 2024, there were 0.4&nbsp;million and 0.4&nbsp;million shares outstanding under the 2023 Plan, respectively. As of
June&nbsp;30, 2025, 0.03&nbsp;million shares were available for future issuance under the 2023 Plan. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock options granted in the six months ended June&nbsp;30, 2025 (awarded on February&nbsp;11, 2025) and 2024 vest based on one of the following schedules:
(i) 25% on the first anniversary of grant date with the remaining 75% to vest in 36 equal monthly installments thereafter through the fourth anniversary of the grant date; (ii) 100% vesting in 36 equal monthly installments through the third
anniversary of the grant date; or (iii) 100% vesting in 12 equal monthly installments through the first anniversary of the grant date for certain nonemployee grants. All stock options expire ten years from the grant date. The assumptions used to
determine the fair value of stock options granted were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>February&nbsp;11,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">4.20%&nbsp;-&nbsp;4.36</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">85.1%&nbsp;-&nbsp;86.3</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">41.84&nbsp;-&nbsp;$49.64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s stock option activity and related information is as follows (in thousands, except per
share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and expected to vest as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of the stock options granted during the six months ended
June&nbsp;30, 2025 was $25.94. The Company granted 0.1&nbsp;million stock options during the six months ended June&nbsp;30, 2024 at a weighted average grant date fair value of $38.21. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2025 and 2024, the Company recognized stock-based compensation expense related to stock options as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2025&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;2024&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stock-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>967</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>339</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, there was $6.5&nbsp;million unrecognized stock-based compensation expense which is expected to
be recognized over a weighted average period of 3.40 years. No stock options were exercised or expired during the six months ended June&nbsp;30, 2025 and 2024. There was 0.02&nbsp;million stock options forfeited during the six months ended
June&nbsp;30, 2024. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with a reduction in force (&#8220;RIF&#8221;) initiated in May 2025, the Company modified stock option awards
granted to the Chief Financial Officer (&#8220;Former CFO&#8221;) and Chief Scientific Officer (&#8220;Former CSO&#8221;). These modifications involve the acceleration of service-based vesting conditions and were accounted for as Type III
modifications <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(improbable-to-probable</FONT></FONT> vesting) in accordance with ASC 718. During the six months ended June&nbsp;30, 2025, the Company recognized a reduction of
$0.2&nbsp;million in stock-based compensation expense included in general and administrative expense and an increase of less than $0.1&nbsp;million included in research and development expense on the unaudited condensed statement of operations as a
result of the RIF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the modified stock options was remeasured as of May&nbsp;6, 2025 using the Black-Scholes option pricing model,
incorporating the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>May&nbsp;6,&nbsp;2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of options (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.25&nbsp;-&nbsp;0.56</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no realized tax benefits for the six months ended June&nbsp;30, 2025 or 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company did not grant any
restricted stock during the six months ended June&nbsp;30, 2025 or 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock vests over the period of time for which services are expected
to be rendered, which ranged from immediate vesting, up to 36 months, or vests on the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the consummation of the Company&#8217;s first underwritten public offering (&#8220;IPO&#8221;)
under the Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2025 and 2024, the Company recognized stock-based compensation
related to shares of restricted stock as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stock-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, the Company had unrecognized compensation expense related to such shares of $0.2&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Restructuring </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2025, the Company
commenced a RIF. This initiative affected several employees, including the Former CFO and the Former CSO. The RIF was designed to streamline operations while ensuring continuity during the transition period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the RIF, the Company entered into separation agreements with impacted employees that entitle the impacted employees to termination
benefits, with benefit terms expiring at various dates through May&nbsp;30, 2026. These benefits included the continuation of base salary, then in effect, and the payment of monthly premiums for Company-sponsored healthcare coverage. The Former CFO
and Former CSO also received accelerated vesting on outstanding stock option awards. See Note 10 <I>Stock-Based Compensation</I> for additional information on the stock option modifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to incur total restructuring charges of approximately $0.7&nbsp;million, primarily related to termination benefits, partially offset by a
reduction in stock-based compensation expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ending June&nbsp;30, 2025, the Company recognized $0.2&nbsp;million in general and
administrative expense and $0.5&nbsp;million in research and development expense in the unaudited condensed statement of operations related to termination benefits under the various separation agreements. The modification of the Former CFO&#8217;s
and Former CSO&#8217;s stock options resulted in a reduction of $0.2&nbsp;million in stock-based compensation expense included in general and administrative expense and an increase of less than $0.1&nbsp;million included in research and development
expense in the unaudited condensed statement of operations during the six months ended June&nbsp;30, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All restructuring costs associated with the
RIF were recognized in the second quarter of 2025, when the plan was communicated to affected employees and obligations were incurred. The remaining severance payments, which were accrued as of June&nbsp;30, 2025, are expected to be paid through May
2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;26, 2024, the Company&#8217;s chief executive officer (the &#8220;Former CEO&#8221;) entered into a separation and consulting
agreement (&#8220;Separation Agreement&#8221;), pursuant to which the Former CEO resigned from his role as CEO. Under the Separation Agreement, the Former CEO is entitled to termination benefits until June&nbsp;30, 2026, in the form of continuation
of base salary in the same amount in effect as of December&nbsp;31, 2024 and the payment of monthly premiums for healthcare coverage. As of December&nbsp;31, 2024, the Company recorded $0.8&nbsp;million of accrued termination benefits in the balance
sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of the beginning and ending liability balances for the six
months ended June&nbsp;30, 2025: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination benefits expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, June&nbsp;30, 2025</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has contracted with various consultants and third parties to assist in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and
development and clinical trials work for the Company&#8217;s leading drug compounds. The contracts are terminable at any time but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2023, the
Company entered into a work order with a third-party contract research organization (&#8220;CRO&#8221;) to provide services with respect to the Company&#8217;s Phase 2 clinical trial of <FONT STYLE="white-space:nowrap">LB-102.</FONT> Minimum
advances will be kept by the CRO throughout the duration of the clinical trial. As of June&nbsp;30, 2025, the Company recorded approximately $0.1&nbsp;million in advances to the CRO, recorded in prepaid expenses and other current assets in the
accompanying unaudited condensed balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into contracts in the normal course of business with contract development and
manufacturing organizations and other third parties for preclinical research studies and testing and manufacturing services, which are generally cancelable upon prior written notice. Payments due upon cancellation may consist of payments for
services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation, and may also include termination penalties. As of June&nbsp;30, 2025, the Company had no outstanding liabilities
related to such items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business. The Company records accruals for such loss contingencies when it is probable that a liability will be
incurred, and the amount of loss can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized. The Company is not a party to any litigation and does not have contingency reserves
established for any litigation liabilities as of June&nbsp;30, 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related-Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2023, contemporaneously with the closing of the Series C Offering, the Company entered into several amended and restated royalty participation
agreements (the &#8220;Amended and Restated Royalty Agreements&#8221;) with certain of its investors, <FONT STYLE="white-space:nowrap">co-founders,</FONT> former and current directors, and former and current executive officers, none of whom are
Series C New Investors. No consideration was received as part of the Amended and Restated Royalty Agreements. Pursuant to the Amended and Restated Royalty Agreements, the Company is obligated to pay royalties to all of the holders in an aggregate
amount up to 2.75% on net sales arising from <FONT STYLE="white-space:nowrap">LB-102</FONT> worldwide through December&nbsp;31, 2035. Thereafter, the Company is obligated to pay royalties to such holders in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB Pharmaceuticals Inc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an aggregate amount up to 3.25% in perpetuity. Future sales are defined in these agreements as the gross payments received on total commercial sales of
<FONT STYLE="white-space:nowrap">LB-102,</FONT> whether by the Company or by any licensee of <FONT STYLE="white-space:nowrap">LB-102.</FONT> As of June&nbsp;30, 2025, certain former and current officers of the Company and their affiliates held 1.13%
of the future royalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events through September&nbsp;8, 2025, the date these financial statements were available to be issued and has not identified
any events requiring disclosure except for the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September, 2025, the Company effected a 1-for-27.8874 reverse stock split (the &#8220;Stock
Split&#8221;) of the Company&#8217;s issued and outstanding shares of common stock and warrants and options to purchase common stock. The Stock Split reduced the number of shares of the Company&#8217;s issued and outstanding common stock, as well as
the numbers of shares reserved and available for future issuance and underlying outstanding options to purchase common stock. No fractional shares were distributed as a result of the reverse stock split, and stockholders were entitled to a cash
payment in lieu of fractional shares. The Stock Split did not affect the par values per share or total authorized common stock. Accordingly, all shares of common stock and per share amounts for all periods presented in the financial statements have
been adjusted retroactively, where applicable, to reflect the Stock Split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>16,666,667 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g65h87.jpg" ALT="LOGO" STYLE="width:2.26833in;height:0.963333in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock&nbsp; </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Leerink Partners </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Piper
Sandler </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:180pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Through and
including &#8195;&#8195;&#8195;&#8195;, 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This
delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;13.&#8195;Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
the underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the U.S. Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing
fee, and the Nasdaq listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,935,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">746,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14.&#8195;Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant,
indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended, or the
Securities Act. Our amended and restated certificate of incorporation that will become effective immediately prior to the closing of this offering permits indemnification of our directors, officers, employees and other agents to the maximum extent
permitted by the Delaware General Corporation Law, and our amended and restated bylaws that will be in effect upon the completion of this offering provide that we will indemnify our directors and executive officers and permit us to indemnify our
other officers, employees, and other agents, in each case to the maximum extent permitted by the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have entered into indemnification agreements with our directors and executive officers, whereby we have agreed to indemnify our directors and executive officers to the fullest extent permitted by law, including indemnification against expenses and
liabilities incurred in legal proceedings to which the director or executive officer was, or is threatened to be made, a party by reason of the fact that such director or executive officer is or was a director, executive officer, employee or agent
of LB Pharmaceuticals Inc, provided that such director or executive officer acted in good faith and in a manner that the director or executive officer reasonably believed to be in, or not opposed to, the best interest of LB Pharmaceuticals Inc. At
present, there is no pending litigation or proceeding involving a director or executive officer of LB Pharmaceuticals Inc regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims
for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under
the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are obligated, under certain circumstances, under the underwriting agreement to be filed as Exhibit 1.1 hereto, to indemnify
us and our officers and directors against liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15.&#8195; Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding all unregistered securities issued and options granted by us since January&nbsp;1, 2022 through the
date of this registration statement: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, we issued 15,367 shares of our common stock to Rivopharm S.A., or Rivopharm, in lieu of cash payment for work performed by a
subsidiary of Rivopharm, pursuant to an oral agreement between us and an affiliate of Rivopharm. For additional information, see &#8220;Certain Relationships and Related Party Transactions&#8212;Issuance of Common Stock.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances Pursuant to our Equity Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From January&nbsp;1, 2022 through the date of this registration statement, we have granted options under our 2023 Stock Incentive Plan to
purchase up to an aggregate of 424,904 shares (net of expirations, forfeitures and cancellations) of common stock, at a weighted-average price of $41.84 per share, in each case, to our employees, directors and consultants. From January&nbsp;1, 2022
through the date of this registration statement, no options have been granted under our 2017 Stock Incentive Plan or 2018 Stock Incentive Plan, and no shares of common stock have been issued upon the exercise of options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Warrants </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May
2022, we issued the Series B-1 Warrants to certain accredited investors to purchase 3,708 shares of our common stock at an exercise price per share of $104.58. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we issued the Maxim Warrants to Maxim Group LLC to purchase 54,813 shares of our common stock at an exercise price per share
of $0.28. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2023, we issued the New Series B Warrants to certain accredited investors to purchase 3,577 shares of our common
stock at an exercise price per share of $41.84. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, we issued 301,119 shares of our Series B preferred stock to certain individual and institutional accredited investors at a
purchase price of $3.00 per share, for aggregate consideration of approximately $0.9&nbsp;million, or the Series B Offering. Maxim Group LLC acted as placement agent for the Series B Offering and received a commission of up to 10.0% of the gross
proceeds from the Series B Offering and certain warrants which were ultimately replaced with the Maxim Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From August 2023 to
January 2024, we issued 50,000,000 shares of our Series C preferred stock to 234 individual and institutional accredited investors at a purchase price of $1.50 per share, for aggregate consideration of approximately $75.0 million. In addition, in
August 2023, we issued an aggregate of 23,820,346 shares of our Series C preferred stock in exchange of the principal amount of all outstanding convertible notes at a conversion price of $1.50 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Convertible Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
October 2022,&nbsp;November 2022, and December 2022 through January 2023, we conducted a convertible promissory notes offering in multiple closings pursuant to which we issued an aggregate principal amount of $25.7&nbsp;million of unsecured
convertible promissory notes to certain accredited investors, or the Notes Offering, bearing interest at 4.0% with a maturity on the earlier of (a)&nbsp;the first anniversary date of such note or (b)&nbsp;the sale
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Company. Maxim Group LLC acted as placement agent for the Notes Offering and received a commission of up to 10.0% of the gross proceeds from the Notes Offering and certain warrants which
were ultimately replaced with the Maxim Warrants. In addition, all of the convertible notes outstanding at the time were automatically converted into shares of our Series C preferred stock upon the closing of our Series C Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions, other than the Series B Offering and the Notes Offering, involved any underwriters, underwriting discounts
or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&nbsp;4(a)(2) of the Securities Act (and Regulation D or Regulation
S promulgated thereunder) or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule 701.
The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were
placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16.&#8195;Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits listed
below are filed as part of this registration statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex32.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation, as amended and as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex33.htm">Form of Amended and Restated Certificate of Incorporation of the Registrant, to be effective immediately prior to the closing of this offering
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex34.htm">Amended and Restated Bylaws of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.5**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex34.htm">Form of Amended and Restated Bylaws of the Registrant, to be effective immediately prior to the closing of this offering </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex41.htm">Form of Common Stock Certificate </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex42.htm">Investors&#8217; Rights Agreement, by and among the Registrant and certain of its stockholders, dated as of August&nbsp;29, 2023</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.3&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex43.htm">Form of Class&nbsp;A Warrants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.4&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex44.htm">Form of Class&nbsp;B Warrants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.5&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex45.htm">Form of Maxim Warrants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.6&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex46.htm">Form of New Series B Warrants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.7&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex47.htm">Form of Series B-1 Warrants </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex51.htm">Opinion of Cooley LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex101.htm">2017 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex102.htm">Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Award Notice under the 2017 Equity Incentive Plan</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex103.htm">2018 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex104.htm">Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Award Notice under the 2018 Equity Incentive Plan</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex105.htm">2023 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex106.htm">Amendment No. 1 to 2023 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex107.htm">Form of Option Grant Notice and Agreement, Exercise Notice, and Restricted Award Notice under the 2023 Equity Incentive Plan</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex108.htm">2025 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex109.htm">Form of Option Grant Notice and Agreement, and Exercise Notice under the 2025 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex1010.htm">Form of RSU Award Grant Notice and Agreement under the 2025 Equity Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex1011.htm">2025 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex1012.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex1013.htm">Executive Employment Agreement, dated November 1, 2024, between Heather Turner and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex1014.htm">Executive Employment Agreement, dated February 3, 2025, between Gad Soffer and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex1015.htm">Amended and Restated Executive Employment Agreement, dated September 4, 2025, between Anna&nbsp;Eramo and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex1016.htm">Amended and Restated Executive Employment Agreement, dated September 3, 2025, between Marc&nbsp;Panoff and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1018.htm">Executive Employment Agreement, dated February 3, 2025, between Richard Silva and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1019.htm">Executive Employment Agreement, dated August 25, 2023, between Zachary Prensky and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1020.htm">Amendment No 1. to Executive Employment Agreement, dated June 28, 2024, between Zachary Prensky and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1021.htm">Transition, Consulting, and Separation agreement, dated November 26, 2024, between Zachary Prensky and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1021.htm">Executive Employment Agreement, dated June 12, 2024, between Roger Sawhney and the Registrant</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22+**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1023.htm">Separation Agreement, dated May 6, 2025, between Roger Sawhney and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex1023.htm">Non-Employee Director Compensation Policy </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1025.htm">Form of Amended and Restated Royalty Participation Agreement by and between the Registrant and certain holders </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080dex1026.htm">Lease Agreement, dated May 20, 2024, between the Registrant and One Penn Plaza LLC </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001691082/000119312525186467/d12080dex211.htm">List of Subsidiaries </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex231.htm">Consent of BDO USA, P.C., Independent Registered Public Accounting Firm </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex51.htm">Consent of Cooley LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1691082/000119312525186467/d12080ds1.htm#sig">Power of Attorney (see signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex991.htm">Consent of Rekha Hemrajani to be Named as Director Nominee </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dex992.htm">Consent of William Kane to be Named as Director Nominee </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d12080dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE>  <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain schedules and exhibits to this exhibit have been omitted pursuant to Item&#8201;601(a)(5) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial statement schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements
or the notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17.&#8195;Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of New York, State of New&nbsp;York, on September&nbsp;8, 2025. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LB PHARMACEUTICALS INC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heather Turner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heather Turner</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed
by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Heather Turner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Heather Turner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September&nbsp;8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Marc Panoff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Marc Panoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Senior Vice President, Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Scott Garland</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rajul Jain, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rebecca Luse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Zachary Prensky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert R. Ruffolo, Jr., Ph.D., D.Sc. (h),</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D.Eng. (h), F.C.P.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chen Yu, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">September 8,&nbsp;2025</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heather Turner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attorney-in-Fact</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>d12080dex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB PHARMACEUTICALS INC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LB
Pharmaceuticals Inc (the &#8220;<B><I>Corporation</I></B>&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<B><I>General Corporation Law</I></B>&#8221;), does
hereby certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of the Corporation is LB Pharmaceuticals Inc. The date of filing of the original certificate
of incorporation of this corporation with the Secretary of State of the State of Delaware was September&nbsp;11, 2015. An Amended and Restated Certificate of Incorporation was filed on December&nbsp;20, 2017, a Second Amended and Restated
Certificate of Incorporation was filed on November&nbsp;16, 2018, a Third Amended and Restated Certificate of Incorporation was filed on April&nbsp;29, 2022, and a Fourth Amended and Restated Certificate of Incorporation was filed on August&nbsp;28,
2023 (as amended and restated, the &#8220;<B><I>Restated Certificate</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>That the Board of Directors of the
Corporation duly adopted resolutions approving this Certificate of Amendment to the Restated Certificate, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate
officers of the Corporation to solicit the consent of the stockholders therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIRD: </B>That the Board of Directors of the
Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law, duly adopted resolutions further amending the Restated Certificate as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is hereby inserted into Article FOURTH of the Restated Certificate immediately after the first sentence therein: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Effective at the time this Certificate of Amendment to the Restated Certificate is filed with and accepted by the Secretary of State of
the State of Delaware, every 27.88740 shares of Common Stock shall, automatically and without any action on the part of the Corporation or the respective holders thereof, be converted into one share of Common Stock, without increasing or decreasing
the par value of each share of Common Stock (the &#8220;<B><I>Reverse Split</I></B>&#8221;); provided, however, that the Corporation shall issue no fractional shares of Common Stock as a result of the Reverse Split, but shall instead pay to any
stockholder who would be entitled to receive a fractional share as a result of the actions set forth herein a sum in cash equal to the fair market value of the shares constituting such fractional share as determined by the Board of Directors of the
Corporation. The number of authorized shares of Common Stock of the Corporation shall remain as set forth in this Restated Certificate. The Reverse Split shall occur whether or not the certificates representing such shares of Common Stock are
surrendered to the Corporation or its transfer agent. The Reverse Split shall be effected on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT> basis and each certificate share number will
then be rounded down to the nearest whole share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All rights, preferences and privileges of Common Stock and each series of Preferred
Stock set forth in this Amended and Restated Certificate of Incorporation, including conversion prices and amounts per share, as applicable, shall be appropriately adjusted to give effect to the Stock Split.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 of Article Fourth is amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;4.2&#8195;<U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu
of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay a cash adjustment in respect of such fractional shares in an amount equal to the same fraction of the fair market value of a share of Common Stock as
determined in good faith by the Board of Directors at the Conversion Time (as defined below). Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of (x)&nbsp;in the event such shares are
certificated, the number of shares of Common Stock issuable upon the conversion of Preferred Stock the holder is at the time converting, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">certificate-by-certificate</FONT></FONT>
basis, with any fractional shares of Common Stock resulting from the conversion of Preferred Stock represented by a certificate not to be aggregated with any fractional shares of Common Stock resulting from the conversion of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock represented by any other certificate and held by such holder or (y)&nbsp;in the event such shares are uncertificated, the total number of shares of Preferred Stock the holder is
at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4.2 of Article Fourth is amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;4.4.2 <U>No Adjustment of Conversion Price</U>. No adjustment in the Series A Conversion Price or Series B Conversion Price shall be
made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of at least a majority of the outstanding shares of Series A Preferred and Series B Preferred,
considered together as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, agreeing that no such adjustment or partial adjustment shall be made as the result of the issuance or deemed issuance of such
Additional Shares of Common Stock. No adjustment or partial adjustment in the Series C Conversion Price shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice
from the Requisite Series C Holders agreeing that no such adjustment or partial adjustment, as specified in such notice from the Requisite Series C Holders, shall be made as the result of the issuance or deemed issuance of such Additional Shares of
Common Stock.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>This Certificate of Amendment to the Restated Certificate was approved by the holders of the
requisite number of shares of the Corporation in accordance with Section&nbsp;228 of the General Corporation Law. This Certificate of Amendment to the Restated Certificate has been duly adopted in accordance with the provisions of Sections 228 and
242 of the General Corporation Law by the stockholders of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>This Certificate of Amendment to the Restated
Certificate was duly adopted in accordance with the provisions of Sections 141 and 242 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> F<SMALL>OLLOWS</SMALL></B><SMALL></SMALL>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the undersigned has caused this Certificate of Amendment to be
signed by its duly authorized officer on September&nbsp;8, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LB PHARMACEUTICALS INC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heather Turner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d12080dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g98e95.jpg" ALT="LOGO" STYLE="width:8.66875in;height:5.80139in;">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">NUMBER pharmaceuticals SHARES INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP xxxxxx xx x SEE REVERSE FOR CERTAIN DEFINITIONS
AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF LB Pharmaceuticals Inc transferable on the books of the Corporation in person or by duly authorized attorney
upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly
authorized officers. Dated: CHIEF EXECUTIVE OFFICER SECRETARY COUNTERSIGNED AND REGISTERED: EQUINITI TRUST COMPANY, LLC TRANSFER AGENT AND REGISTRAR BY: AUTHORIZED SIGNATURE </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g12080g54n82.jpg" ALT="LOGO" STYLE="width:6.76597in;height:10.1812in;">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences
and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the
Corporation&#8217;s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM as tenants in common UNIF GIFT
MIN ACT Custodian TEN ENT as tenants by the entireties (Cust) (Minor) JT TEN as joint tenants with right of under Uniform Gifts to Minors survivorship and not as tenants Act in common (State) COM PROP as community property UNIF TRF MIN ACT Custodian
(until age ) (Cust) under Uniform Transfers (Minor) to Minors Act (State) Additional abbreviations may also be used though not in the above list. FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s) unto PLEASE INSERT SOCIAL SECURITY OR
OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) shares of the capital stock represented by within Certificate, and do hereby irrevocably constitute and appoint <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises. Dated Signature(s) Guaranteed:
NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. By THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN
ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15.</FONT>
GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d12080dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g0907100113636.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Divakar Gupta</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) <FONT
STYLE="white-space:nowrap">479-6474</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">dgupta@cooley.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Exhibit 5.1</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;8, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB
Pharmaceuticals Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Pennsylvania Plaza, Suite 1025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New
York, NY 10119 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as
counsel to LB Pharmaceuticals Inc, a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with the filing by the Company of a registration statement <FONT STYLE="white-space:nowrap">(No.&nbsp;333-289812)</FONT> on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (the &#8220;<B><I>Registration Statement</I></B>&#8221;) with the Securities and Exchange Commission (the &#8220;<B><I>Commission</I></B>&#8221;), including a related prospectus included in the
Registration Statement (the &#8220;<B><I>Prospectus</I></B>&#8221;), covering an underwritten public offering of up to 16,666,667 shares (the &#8220;<B><I>Shares</I></B>&#8221;) of its common stock, par value $0.0001 per share, including up to
2,500,000 Shares that may be sold pursuant to the exercise of an option to purchase additional Shares granted to the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
this opinion, we have (i)&nbsp;examined and relied upon (a)&nbsp;the Registration Statement and the Prospectus, (b)&nbsp;the Company&#8217;s certificate of incorporation and bylaws, each as currently in effect, (c)&nbsp;the Company&#8217;s Amended
and Restated Certificate of Incorporation and Amended and Restated Bylaws, filed as Exhibits&nbsp;3.3 and 3.5 to the Registration Statement, respectively, each of which is to be in effect in connection with the closing of the offering contemplated
by the Registration Statement and (d)&nbsp;such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below and (ii)&nbsp;assumed that
(a)&nbsp;the Shares will be sold at a price established by the Board of Directors of the Company or a duly authorized committee thereof and (b)&nbsp;the Amended and Restated Certificate of Incorporation referred to in clause (i)(c) is filed with the
Secretary of State of the State of Delaware before issuance of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed the genuineness of all signatures, the authenticity of all
documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all
documents by all persons other than the Company.&nbsp;As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws
are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, in reliance thereon and subject to the assumptions, qualifications, limitations and exceptions contained herein, we are of the
opinion that the Shares, when sold and issued against payment therefor as described in the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&#8195;55
Hudson Yards New York, NY 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: +1 (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> f: +1 (212)
<FONT STYLE="white-space:nowrap">479-6275</FONT> cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g12080g0907100113636.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page
2 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the
matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may
hereafter come to our attention or any changes in law that may hereafter occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#8220;Legal
Matters&#8221; in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consents, we do not thereby admit that we are in the category of persons whose
consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/
Divakar&nbsp;Gupta&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Divakar Gupta</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Cooley LLP&#8195;55
Hudson Yards New York, NY 10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">t: +1 (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> f: +1 (212)
<FONT STYLE="white-space:nowrap">479-6275</FONT> cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>5
<FILENAME>d12080dex108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
A<SMALL>UGUST</SMALL>&nbsp;19, 2025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
S<SMALL>EPTEMBER</SMALL>&nbsp;7, 2025 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Successor to and Continuation of Prior Plans.</B> The Plan is the successor to and continuation of the Prior Plans. As of the
Effective Date, (i)&nbsp;no additional awards may be granted under the Prior Plans; (ii)&nbsp;any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii)&nbsp;all outstanding awards granted under the
Prior Plans will remain subject to the terms of the Prior Plans (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this
Plan will be subject to the terms of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Plan Purpose.</B> The Company, by means of the Plan, seeks to secure and
retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to
benefit from increases in value of the Common Stock through the granting of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Available Awards.</B> The Plan provides
for the grant of the following Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;SARs; (iv) Restricted Stock Awards; (v)&nbsp;RSU Awards; (vi)&nbsp;Performance Awards; and (vii)&nbsp;Other Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Adoption Date; Effective Date. </B>The Plan will come into existence on the Adoption Date, but no Award may be granted prior to
the Effective Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Share Reserve. </B>Subject to adjustment in accordance with Section&nbsp;2(c) and any adjustments as necessary to implement any
Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 2,907,335 shares, which is the sum of: (i)&nbsp;2,412,000 new shares, plus (ii) 38,519 shares available for issuance
under the Prior Plans as of the Effective Date, plus (iii)&nbsp;up to 456,816 Returning Shares as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such
aggregate number of shares of Common Stock will automatically increase on January&nbsp;1 of each year for a period of ten years commencing on January&nbsp;1, 2026 and ending on (and including) January&nbsp;1, 2035, in an amount equal to five percent
(5%) of the total number of shares of Fully Diluted Capital Stock outstanding on December&nbsp;31 of the preceding year; provided, however, that the Board may act prior to January 1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of a given
year to provide that the increase for such year will be a lesser number of shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Aggregate Incentive Stock Option Limit.</B> Notwithstanding anything to the
contrary in Section&nbsp;2(a) and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is
8,722,005 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Share Reserve Operation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limit Applies to Common Stock Issued Pursuant to Awards. </B>For clarity, the Share Reserve is a limit on the number of shares
of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue
shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c)(3), NYSE Listed Company Manual Section&nbsp;303A.08, NYSE American Company Guide
Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</B> The following actions do not
result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&nbsp;the expiration or termination of any portion of an Award without the
shares covered by such portion of the Award having been issued; (2)&nbsp;the settlement of any portion of an Award in cash (<I>i.e.</I>, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be
issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&nbsp;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Reversion of Previously Issued Shares of Common Stock to Share Reserve.</B> The following shares of Common Stock previously
issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&nbsp;any shares that are forfeited back to or repurchased by
the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2)&nbsp;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&nbsp;any
shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. E<SMALL>LIGIBILITY</SMALL>
<SMALL>AND</SMALL> L<SMALL>IMITATIONS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Eligible Award Recipients.</B> Subject to the terms of the Plan,
Employees, Directors and Consultants are eligible to receive Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Specific Award Limitations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Limitations on Incentive Stock Option Recipients.</B> Incentive Stock Options may be granted only to Employees of the Company or
a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Incentive Stock Option $100,000 Limitation.</B> To the extent that the
aggregate Fair Market Value (determined at the time of grant) of the shares of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company
and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or any Incentive Stock Options otherwise do not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit
(according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</B> A Ten Percent Stockholder may not be granted
an Incentive Stock Option unless (1)&nbsp;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option and (2)&nbsp;the Option is not exercisable after the expiration of five years from the date of
grant of such Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Limitations on Nonstatutory Stock Options and SARs.</B> Nonstatutory Stock Options and SARs may not
be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company (as such term is defined in Rule 405) unless the stock underlying such Awards is treated as &#8220;service
recipient stock&#8221; under Section&nbsp;409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Aggregate Incentive Stock Option Limit.</B> The aggregate maximum number of shares of Common Stock that may be issued pursuant
to the exercise of Incentive Stock Options is the number of shares specified in Section&nbsp;2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit. </B>The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
with respect to any fiscal year following the year in which the IPO Date occurs, including Awards granted and cash fees paid by the Company to such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed (1) $750,000 in total
value (or to the extent such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director serves as the Chair of the Board, $1,000,000 in total value) or (2)&nbsp;in the event such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is
first appointed or elected to the Board during such fiscal year, $1,000,000 in total value , in each case, calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes. For
avoidance of doubt, compensation will count towards this limit for the fiscal year in which it was granted or earned, and not later when distributed, in the event it is deferred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive
Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify as an Incentive Stock Option, then such Option will be
a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs
need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Term.</B> Subject to Section&nbsp;3(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the
expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Exercise or Strike Price.</B> Subject to Section&nbsp;3(b) regarding Ten
Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or
strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in
a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Exercise Procedure and
Payment of Exercise Price for Options.</B> In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the
Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a
particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash or check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the Federal Reserve Board
that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the
Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&nbsp;at the time of exercise the Common Stock is
publicly traded, (2)&nbsp;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&nbsp;such delivery would not violate any Applicable Law or agreement
restricting the redemption of the Common Stock, (4)&nbsp;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&nbsp;such shares have been held by the Participant for any minimum period
necessary to avoid adverse accounting treatment as a result of such delivery; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> if the Option is a Nonstatutory Stock Option,
by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1)&nbsp;such shares used to pay the exercise price will not be exercisable thereafter and (2)&nbsp;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in
cash or other permitted form of payment; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of consideration that may be acceptable to the Board and
permissible under Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Exercise Procedure and Payment of Appreciation Distribution for SARs</B><B>.</B> In order
to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount
equal to the excess of (i)&nbsp;the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&nbsp;the
strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in
the SAR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Transferability.</B> Options and SARs may not be transferred to third party financial institutions for
value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will
apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and <I>provided, further</I>, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory
Stock Option as a result of such transfer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Transfer.</B> An Option or SAR will not be transferable, except
by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited
by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&nbsp;671 of the Code and applicable state
law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Domestic Relations Orders.</B> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format
acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Vesting.</B> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as
determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#8217;s
Continuous Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Termination of Continuous Service for Cause.</B> Except as explicitly
otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate
and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous
Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</B> Subject to
Section&nbsp;4(i), if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if
applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its
maximum term (as set forth in Section&nbsp;4(a)): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> three months following the date of such termination if such termination is a
termination without Cause (other than any termination due to the Participant&#8217;s Disability or death); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> 12 months
following the date of such termination if such termination is due to the Participant&#8217;s Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> 18 months following
the date of such termination if such termination is due to the Participant&#8217;s death; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> 18 months following the date of
the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&nbsp;or (ii) above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or,
if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock
subject to the terminated Award, or any consideration in respect of the terminated Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Restrictions on Exercise;
Extension of Exercisability. </B>A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other
written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination
Exercise Period: (i)&nbsp;the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law; or (ii)&nbsp;the immediate sale of any shares
of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the
exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided,
however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section&nbsp;4(a)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B><B>.</B> No Option or SAR, whether or not vested, granted to an
Employee who is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of
grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the
event of (i)&nbsp;such Participant&#8217;s death or Disability, (ii)&nbsp;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&nbsp;a Change in Control, or (iv)&nbsp;such Participant&#8217;s retirement (as such
term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment policies and guidelines). This Section&nbsp;4(j) is intended to
operate so that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Whole Shares.</B> Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Restricted Stock Awards and RSU Awards.</B> Each Restricted Stock
Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in
the Award Agreement or otherwise) to the substance of each of the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) Form of Award. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of Common
Stock subject to a Restricted Stock Award may be (A)&nbsp;held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (B)&nbsp;evidenced by a certificate, which certificate
will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock
Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: An RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of
Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue
shares of Common Stock in settlement of such Award and nothing contained in the Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any RSU Award Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the
Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii) Consideration. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A)&nbsp;cash or check, bank draft or money
order payable to the Company, (B)&nbsp;past&nbsp;services to the Company or an Affiliate, or (C)&nbsp;any other form of consideration (including future services) as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> RSU Awards: Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the
Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any
shares of Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the
issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Vesting. </B>The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award
as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the
Participant&#8217;s Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Termination of Continuous Service.</B> Except as otherwise provided in the Award
Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (1)&nbsp;the Company may receive through a forfeiture condition or a repurchase right
any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement, (2)&nbsp;any portion of his or her
RSU Award that has not vested will be forfeited upon such termination, and (3)&nbsp;the Participant will have no further right, title or interest in the Restricted Stock Award or RSU Award, the shares of Common Stock subject to or issuable pursuant
to the Restricted Stock Award or RSU Award, or any consideration in respect of the Restricted Stock Award or RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>
<B>Dividends and Dividend Equivalents. </B>Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and
specified in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> <B>Settlement of RSU Awards.</B> An RSU Award may be settled by the issuance of
shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions
that delay such delivery to a date following the vesting of the RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Performance Awards.</B> With respect to any
Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been
attained will be determined by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Other Awards.</B> Other forms of Awards valued in whole or in part by reference
to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) may be granted either alone or
in addition to Awards provided for under Section&nbsp;4 and the preceding provisions of this Section&nbsp;5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or
times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL>
C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Capitalization Adjustments</B><B>.</B> In the event of a Capitalization
Adjustment, the Board shall appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of shares of Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant
to Section&nbsp;2(a); (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;2(b); and (iii)&nbsp;the class(es) and number of securities and exercise price,
strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for
fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be
created by the adjustments referred to in the preceding provisions of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Dissolution or Liquidation.</B> Except
as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or
the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may
be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable
and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Corporate Transaction. </B>The following provisions will apply to Awards in
the event of a Corporate Transaction, except as set forth in Section&nbsp;11, and unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless
otherwise expressly provided by the Board at the time of grant of an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a
Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for
Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company
in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or
acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue or substitute the Awards held by some, but not all
Participants. The terms of any assumption, continuation or substitution will be set by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Awards Held by Current
Participants.</B> In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding
Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the
&#8220;<B><I>Current Participants</I></B>&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will<B> </B>be accelerated in full to a date prior to the
effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the
Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will
lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and that have
multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction.
With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&nbsp;and are settled in the form of a cash payment, such cash payment will be made no later than 30 days
following the occurrence of the Corporate Transaction or such later date as required to comply with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> <B>Awards Held by Persons other than Current Participants.</B> In the event of a Corporate Transaction in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or
substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase
rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in
the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such
form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1)&nbsp;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the
Board, any unvested portion of such Award), over (2)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Appointment of Stockholder Representative.</B> As a condition to the receipt of an Award under this Plan, a Participant will be
deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is
authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>
<B>No Restriction on Right to Undertake Transactions.</B> The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company, the Board or the stockholders
of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, any Change in Control, any Corporate Transaction, any merger or consolidation of the
Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into
or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. A<SMALL>DMINISTRATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan
to a Committee or Committees, as provided in subsection (c)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power,
subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to time (1)&nbsp;which of
the persons eligible under the Plan will be granted Awards; (2)&nbsp;when and how each Award will be granted; (3)&nbsp;what type or combination of types of Award will be granted; (4)&nbsp;the provisions of each Award granted (which need not be
identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5)&nbsp;the number of shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6)&nbsp;the Fair Market Value applicable to an Award; and (7)&nbsp;the terms of any
Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its
administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully
effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding the Plan and Awards granted under it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest,
notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation
of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock
or the share price of the Common Stock, including any Corporate Transaction, for reasons of administrative convenience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> To amend the Plan in any respect the Board deems necessary or advisable; provided, however<I>,</I> that stockholder approval will
be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&nbsp;the Company
requests the consent of the affected Participant, and (2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To submit any
amendment to the Plan for stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ix)</B> To approve forms of Award Agreements for use under the Plan and to amend the
terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board
discretion; <I>provided however</I>, that, a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> Generally, to exercise such powers and to perform such acts as the Board deems
necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xi)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit and
facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals or employed outside the United States
(provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(xii)</B> To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by
such action, (1)&nbsp;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&nbsp;the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A)&nbsp;a new Option, SAR, Restricted
Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of Common Stock, (B)&nbsp;cash and/or (C)&nbsp;other valuable consideration (as determined by the Board);
or (3)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Delegation to
Committee. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the
power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee),
subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee
to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at
any time, revest in the Board some or all of the powers previously delegated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> To the extent an Award is intended to qualify for the exemption from Section&nbsp;16(b) of the Exchange Act that is available under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of
the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, as determined under Rule <FONT STYLE="white-space:nowrap">16b-3(b)(3)</FONT>
of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Effect of Board</B><B>&#8217;</B><B>s Decision.</B> All determinations, interpretations and constructions made by the Board or
any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>Delegation to Other Person or Body.</B> The Board or any Committee may
delegate to one or more persons or bodies the authority to do one or more of the following to the extent permitted by Applicable Law: (i)&nbsp;designate recipients, other than Officers, of Options and SARs (and, to the extent permitted by Applicable
Law, other Awards), provided that no person or body may be delegated authority to grant an Award to themself; (ii)&nbsp;determine the number of shares subject to such Awards; and (iii)&nbsp;determine the terms of such Awards; provided, however, that
the Board or Committee action regarding such delegation will fix the terms of such delegation in accordance with Applicable Law, including without limitation Sections 152 and 157 of the Delaware General Corporation Law. Unless provided otherwise in
the Board or Committee action regarding such delegation, each Award granted pursuant to this section will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, with any modifications
necessary to incorporate or reflect the terms of such Award. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to any person or body (who is not a Director or that is not comprised solely of Directors,
respectively) the authority to determine the Fair Market Value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Withholding Authorization.</B> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding
from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate arrangements to satisfy, any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Item withholding obligations, if any, of the Company and/or an
Affiliate that arise in connection with the grant, vesting, exercise or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no
obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
<B>Satisfaction of Withholding Obligation.</B> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Item withholding obligation relating
to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the
Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to the Participant; (v)&nbsp;by allowing a Participant to effectuate a
&#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; (vi)&nbsp;allowing the Participant to enter into a &#8220;same day sale&#8221; commitment with a broker-dealer
(including, without limitation, a commitment under a previously established written trading plan that meets the requirements of <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;under</FONT> the Exchange Act); or (vii)&nbsp;by such other method
as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>No Obligation to Notify or Minimize Taxes; No Liability to Claims. </B>Except
as required by Applicable Law, the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such
holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be
liable to any holder of an Award for any adverse tax consequences </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&nbsp;agrees to not make any claim against the Company, or any of its
Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&nbsp;acknowledges that such Participant was advised to consult with his or her own personal tax, financial and
other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from
Section&nbsp;409A only if the exercise or strike price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of
compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in
the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Withholding Indemnification. </B>The Company and/or its Affiliate may withhold or account for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering statutory or other withholding rates, including minimum or maximum rates applicable in a Participant&#8217;s jurisdiction. In the event of overwithholding, the Participant may
receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock) or, if not refunded, the Participant may seek a refund from the local tax authorities. In the event of underwithholding, the Participant may
be required to pay any additional <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items directly to the applicable tax authority or to the Company and/or its Affiliate. As a condition to accepting an Award under the Plan, in the event that the
amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the
Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. Further, if the obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in
shares of Common Stock, for tax purposes, the Participant will be deemed to have been issued the full number of shares subject to the Award, notwithstanding that a number of the shares is held back solely for the purpose of paying the <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Source of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>Use of Proceeds from Sales of Common Stock.
</B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
<B>Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board,
regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the
Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the
Award Agreement or related grant documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Stockholder Rights.</B> No Participant will be deemed to be the holder of, or
to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and
(ii)&nbsp;the issuance of the Common Stock subject to such Award is reflected in the records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>No Employment
or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or
an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will (unless otherwise required under Applicable Law) and without regard to any future vesting opportunity
that a Participant may have with respect to any Award (i)&nbsp;the employment of an Employee with or without notice and with or without Cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the
Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the U.S. state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or
commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the
Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>Change in
Time Commitment.</B> In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee
of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted
by Applicable Law, to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in
lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or
extended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>Execution of Additional Documents.</B> As a condition to accepting an Award under the Plan, the Participant
agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or
other regulatory requirements, in each case at the Plan Administrator&#8217;s request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>Electronic Delivery and Participation.</B> Any reference herein or in an Award
Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared
electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any
<FONT STYLE="white-space:nowrap">on-line</FONT> electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or
electronic entry evidencing such shares) shall be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Clawback/Recovery.</B> All Awards granted
under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities
are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law.
In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired
shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntarily terminate employment upon a
&#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>Securities Law Compliance. </B>A Participant will not be issued any shares in respect of an Award unless either (i)&nbsp;the
shares are registered under the Securities Act or (ii)&nbsp;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the
Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>Transfer or Assignment of Awards; Issued Shares.</B> Except as expressly provided in the Plan or the form of Award Agreement,
Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of a Restricted Stock Award and similar awards, after the issued shares have vested,
the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and
Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>Effect on Other Employee Benefit Plans. </B>The value of any Award granted under the Plan, as determined
upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate,
except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>Deferrals.</B> To the extent permitted by Applicable Law, the Board, in its
sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections
to be made by Participants. Deferrals will be made in accordance with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>Section 409A.
</B>Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A, and,
to the extent not so exempt, in compliance with the requirements of Section&nbsp;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A, the Award Agreement evidencing such
Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby
incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant
holding an Award that constitutes &#8220;deferred compensation&#8221; under Section&nbsp;409A is a &#8220;specified employee&#8221; for purposes of Section&nbsp;409A, no distribution or payment of any amount that is due because of a
&#8220;separation from service&#8221; (as defined in Section&nbsp;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s
&#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be made in a manner that complies with Section&nbsp;409A, and any amounts so deferred will be paid in a lump sum
on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>Choice of
Law</B><B>. </B>This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result
in any application of any law other than the law of the State of Delaware. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
C<SMALL>OMPANY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary,
having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to
register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or
agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise
or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any
Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. A<SMALL>DDITIONAL</SMALL> R<SMALL>ULES</SMALL> <SMALL>FOR</SMALL> A<SMALL>WARDS</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> S<SMALL>ECTION</SMALL>&nbsp;409A. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>Application. </B>Unless the provisions of
this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Subject to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangements.</B> To the extent a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award is subject to Section&nbsp;409A due to application of a
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, the following provisions of this subsection (b)&nbsp;apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award vests in the ordinary course during the Participant&#8217;s
Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, in no event will the shares
be issued in respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award any later than the later of: (i)&nbsp;December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year that includes the applicable vesting
date; or (ii)&nbsp;the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the applicable vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If vesting of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award as of the date of grant, then the shares will be earlier issued in settlement of such <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement, but in no event later than the 60<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day that follows the date of the Participant&#8217;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations
contained in Section&nbsp;409A applicable to &#8220;specified employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such
Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> If vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award accelerates under the terms of a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award and, therefore, are not a part of the terms of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award on the date of grant, then such acceleration of vesting of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during
the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(a)(4).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a
Corporate Transaction for Employees and Consultants.</B> The provisions of this subsection (c)&nbsp;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non- Exempt Award in
connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The following provisions shall apply to any Vested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> If the Corporate Transaction is
also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Upon the Section&nbsp;409A Change in Control the settlement of the
Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Alternatively, the Company
may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&nbsp;409A Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Corporate Transaction is not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume,
continue or substitute each Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. The shares to be issued in respect of the Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the
Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may
instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares
made on the date of the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards.</B> The
following provisions shall apply to any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless otherwise determined by the Board pursuant to subsection (e)&nbsp;of this Section or as otherwise required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Unless otherwise determined by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will remain subject to the same vesting and forfeiture restrictions that were
applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be issued to the Participant by the Acquiring Entity on the same schedule
that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each
applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> If the Acquiring Entity will not assume, substitute or continue any Unvested
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in
respect of such forfeited Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&nbsp;409A, the Board may in its discretion
determine to elect to accelerate the vesting and settlement of the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award upon the Corporate Transaction, or instead </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such
discretionary election by the Board, any Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or
continue the Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards in connection with the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(3)</B>
The foregoing treatment shall apply with respect to all Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&nbsp;409A Change
in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>Treatment of <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Awards Upon a Corporate Transaction for <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</B> The following provisions of this subsection (d)&nbsp;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of
a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award in connection with a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the
Corporate Transaction is also a Section&nbsp;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Upon the Section&nbsp;409A Change in Control
the vesting and settlement of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the
<FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the
Participant upon the Section&nbsp;409A Change in Control pursuant to the preceding provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If the Corporate Transaction is
not also a Section&nbsp;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award. Unless otherwise determined by the Board, the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In
the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to
the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, then the provisions in this Section&nbsp;11(e)
shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Any exercise by the Board of discretion to accelerate the vesting of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award
shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award unless earlier issuance of the shares upon the applicable vesting dates would be in
compliance with the requirements of Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> The Company explicitly reserves the right to earlier settle any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award to the extent permitted and in compliance with the requirements of Section&nbsp;409A, including pursuant to any of the exemptions available in Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(j)(4)(ix).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent the terms of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the Change in Control or
Corporate Transaction event triggering settlement must also constitute a Section&nbsp;409A Change in Control. To the extent the terms of a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award provides that it will be settled upon a termination
of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&nbsp;409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at
the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section&nbsp;409A applicable to &#8220;specified
employees,&#8221; as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#8217;s Separation From Service, or, if earlier, the date of the
Participant&#8217;s death that occurs within such six month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> The provisions in this subsection (e)&nbsp;for delivery
of the shares in respect of the settlement of an RSU Award that is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award are intended to comply with the requirements of Section&nbsp;409A so that the delivery of the shares to the Participant in
respect of such <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award will not trigger the additional tax imposed under Section&nbsp;409A, and any ambiguities herein will be so interpreted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. S<SMALL>EVERABILITY</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all
or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be
unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a
Section to the fullest extent possible while remaining lawful and valid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the
tenth anniversary of the earlier of: (i)&nbsp;the Adoption Date; or (ii)&nbsp;the date the Plan is approved by the Company&#8217;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#8220;<B><I>Acquiring Entity</I></B>&#8221; means the surviving or acquiring corporation (or its parent company) in connection with
a Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#8220;<B><I>Adoption Date</I></B>&#8221; means the date the Plan is first approved by the Board or
Compensation Committee, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#8220;<B><I>Affiliate</I></B>&#8221; means, at the time of determination, any
&#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#8220;<B><I>Applicable Law</I></B>&#8221; means the Code and any applicable U.S.
and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities, exchange control, tax, federal, state, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule,
listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable
self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#8220;<B><I>Award</I></B>&#8221; means any right to receive Common Stock, cash or other property granted under the Plan (including
an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#8220;<B><I>Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a Participant
evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including
through electronic means, to a Participant along with the Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#8220;<B><I>Board</I></B>&#8221; means the Board of
Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final
and binding on all Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#8220;<B><I>Capital Stock</I></B>&#8221; means each and every class of common stock of the
Company, regardless of the number of votes per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <I>&#8220;</I><B><I>Capitalization Adjustment</I></B>&#8221; means any
change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the
conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#8220;<B><I>Cause</I></B>&#8221;<B><I> </I></B>has the meaning ascribed to such
term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&nbsp;such
Participant&#8217;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii)&nbsp;such Participant&#8217;s attempted commission of, or participation in, a
fraud or act of dishonesty against the Company; (iii)&nbsp;such Participant&#8217;s material violation of any contract or agreement between the Participant and the Company, the Company&#8217;s employment policies, or of any statutory or other duty
owed to the Company; (iv)&nbsp;such Participant&#8217;s unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; (v)&nbsp;such Participant&#8217;s gross misconduct; (vi)&nbsp;such Participant&#8217;s failure
or refusal to comply with a material directive from the Board, the Participant&#8217;s supervisor or, if applicable, the board of directors of any Affiliate; or (vii)&nbsp;such Participant&#8217;s breach of a fiduciary duty to the Company. The
determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#8217;s Chief
Executive Officer with respect to Participants who are not executive officers of the Company.&nbsp;Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding
Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#8220;<B><I>Change in Control</I></B>&#8221; or &#8220;<B><I>Change of Control</I></B>&#8221; means the occurrence, in a single
transaction or in a series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes
the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an
investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance
of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#8220;<I>Subject Person</I>&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a
repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting
securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving
(directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either
(A)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
transaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined
voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or
other disposition; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> individuals who, on the IPO Date, are members of the Board (the &#8220;<B><I>Incumbent
Board</I></B>&#8221;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a
majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control shall not include a sale of assets,
merger or other transaction effected exclusively for the purpose of changing the domicile of the Company and (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate
and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement,
the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also
constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#8220;<B><I>Code</I></B>&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and
guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#8220;<B><I>Committee</I></B>&#8221; means the Compensation Committee and any other committee of one or
more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>
&#8220;<B><I>Common Stock</I></B>&#8221; means the common stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#8220;<B><I>Company</I></B>&#8221; means LB
Pharmaceuticals Inc, a Delaware corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#8220;<B><I>Compensation Committee</I></B>&#8221; means the Compensation
Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#8220;<B><I>Consultant</I></B>&#8221; means any person, including an advisor, who is (i)&nbsp;engaged
by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely
as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#8220;<B><I>Continuous Service</I></B>&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether
as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; provided, however<I>,</I>
that<I> </I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases
to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by Applicable Law, the
Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive
officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for
purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by
Applicable Law. In addition, to the extent required for exemption from or compliance with Section&nbsp;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner
that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (without regard to any alternative definition thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#8220;<B><I>Corporate Transaction</I></B>&#8221; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or other disposition of at
least 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar transaction following which the
Company is not the surviving corporation; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction following which the Company is
the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the
term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&nbsp;the definition of Corporate Transaction (or any analogous term) in an
individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any
analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the
transaction or event described in clause (i), (ii), (iii), or (iv)&nbsp;also constitutes a Section&nbsp;409A Change in Control if required in order for the payment not to violate Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#8220;<B><I>determine</I></B>&#8221; or &#8220;<B><I>determined</I></B>&#8221;<B><I> </I></B>means as determined by the Board or
the Committee (or its designee) in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#8220;<B><I>Director</I></B>&#8221; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#8220;<B><I>Disability</I></B>&#8221; means, with respect to a Participant, such Participant is unable to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as
provided in Section&nbsp;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#8220;<B><I>Effective Date</I></B>&#8221; means the IPO Date, provided that this Plan is approved by the Company&#8217;s
stockholders prior to the IPO Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#8220;<B><I>Employee</I></B>&#8221; means any person employed by the Company or an
Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#8220;<B><I>Employer</I></B>&#8221; means the Company or the Affiliate of the Company that employs the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#8220;<B><I>Entity</I></B>&#8221; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#8220;<B><I>Exchange Act</I></B>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#8220;<B><I>Exchange Act Person</I></B>&#8221;<B><I> </I></B>means any natural
person, Entity or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any
employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding
securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company, or
(v)&nbsp;any natural person, Entity or &#8220;group&#8221; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more
than 50% of the combined voting power of the Company&#8217;s then outstanding securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#8220;<B><I>Fair Market
Value</I></B>&#8221; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be
the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing selling price on the last preceding date for which such quotation exists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the
Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#8220;<B><I>Fully Diluted Capital Stock</I></B>&#8221; means the number of shares of Capital Stock, determined as of the
applicable date of measurement, equal to the sum of (i)&nbsp;the number of shares of Capital Stock issued and outstanding and (ii)&nbsp;the number of shares of Capital Stock upon the exercise, conversion, or exchange of all then outstanding
warrants, options, convertible Capital Stock or indebtedness, exchangeable Capital Stock or indebtedness, or other rights exercisable for or convertible or exchangeable into, directly or indirectly, shares of Capital Stock (whether vested or
unvested), but excluding the shares reserved and available for issuance under the Company&#8217;s then-existing equity incentive plan and employee stock purchase plan, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#8220;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#8221; means any: (i)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (ii)&nbsp;federal, state, local, municipal, foreign or other government; (iii)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including
any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance
of doubt, any tax authority) or other body exercising similar powers or authority; or&nbsp;(iv)&nbsp;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#8220;<B><I>Grant Notice</I></B>&#8221; means the notice provided to a
Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment
right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B>
&#8220;<B><I>Incentive Stock Option</I></B>&#8221; means an option granted pursuant to Section&nbsp;4 of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&nbsp;422 of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#8220;<B><I>IPO Date</I></B>&#8221; means the date of the underwriting agreement between the Company and the underwriter(s)
managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#8220;<B><I>Materially Impair</I></B>&#8221;<B><I> </I></B>means any amendment to the terms of the Award that materially
adversely affects the Participant&#8217;s rights under the Award. A Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the
amendment, taken as a whole, does not materially impair the Participant&#8217;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#8217;s rights under the Award:
(i)&nbsp;imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the
Code; (iii)&nbsp;to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code; (iv)&nbsp;to clarify the
manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section&nbsp;409A; or (v)&nbsp;to comply with other Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#8221;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#8220;<B><I>Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT></I></B>&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a
business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#8220;non-employee</FONT>
director&#8221; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221;<B><I> </I></B>means any Award that is subject to, and not exempt from, Section&nbsp;409A, including as the result of (i)&nbsp;a deferral of the issuance of the shares subject to the
Award which is elected by the Participant or imposed by the Company, or (ii)&nbsp;the terms of any <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Director Award</I></B>&#8221; means a <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Severance
Arrangement</I></B>&#8221; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the
Participant&#8217;s termination of employment or separation from service (as such term is defined in Section&nbsp;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder)) (&#8220;<B><I>Separation from
Service</I></B>&#8221;) and such severance benefit does not satisfy the requirements for an exemption from application of Section&nbsp;409A provided under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> <FONT
STYLE="white-space:nowrap">1.409A-1(b)(9)</FONT> or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#8220;<B><I>Nonstatutory Stock Option</I></B>&#8221; means
any option granted pursuant to Section&nbsp;4 of the Plan that does not qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B>
&#8220;<B><I>Officer</I></B>&#8221; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#8220;<B><I>Option</I></B>&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common
Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#8220;<B><I>Option Agreement</I></B>&#8221; means a written or electronic agreement
between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions
applicable to the Option and which is provided including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#8220;<B><I>Optionholder</I></B>&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#8220;<B><I>Other Award</I></B>&#8221; means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B>
&#8220;<B><I>Other Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will
be subject to the terms and conditions of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#8220;<B><I>Own,</I></B>&#8221;<B><I>
</I></B>&#8220;<B><I>Owned,</I></B>&#8221;<B><I> </I></B>&#8220;<B><I>Owner,</I></B>&#8221;<B><I> </I></B>&#8220;<B><I>Ownership</I></B>&#8221;<B> </B>means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to
be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which
includes the power to vote or to direct the voting, with respect to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#8220;<B><I>Participant</I></B>&#8221;
means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#8220;<B><I>Performance Award</I></B>&#8221; means an Award that may vest or
may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section&nbsp;5(b) pursuant to
such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards.
Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#8220;<B><I>Performance Criteria</I></B>&#8221; means the one or more criteria that the Board will select for purposes of
establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including
earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder&#8217;s equity; return on
assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; <FONT STYLE="white-space:nowrap">pre-tax</FONT> profit; operating cash flow; sales
or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share;
share price performance; debt reduction; customer satisfaction; stockholders&#8217; equity; capital expenditures; debt levels; operating profit or net operating profit; growth of net income or operating income; billings; financing; regulatory
milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel matters; progress of internal research; progress of partnered programs; partner satisfaction; budget management; partner or collaborator
achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or completion of projects or processes; employee retention; number of users, including unique
users; strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with respect to the
marketing, distribution and sale of the Company&#8217;s products; supply chain achievements; <FONT STYLE="white-space:nowrap">co-development,</FONT> <FONT STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar
arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee whether or not listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#8220;<B><I>Performance Goals</I></B>&#8221; means, for a Performance Period, the one or more goals established by the Board for
the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to
the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document
setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to
exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments
to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of
acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect of any change in the outstanding shares of Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under the Company&#8217;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting
principles; and (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in
the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. The Board retains the discretion to reduce or eliminate the compensation or
economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the payment or
vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#8220;<B><I>Performance Period</I></B>&#8221; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#8220;<B><I>Plan</I></B>&#8221; means this LB Pharmaceuticals Inc 2025 Equity Incentive Plan, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#8220;<B><I>Plan Administrator</I></B>&#8221; means the person, persons, and/or third-party administrator designated by the
Company to administer the day to day operations of the Plan and the Company&#8217;s other equity incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B>
&#8220;<B><I>Post-Termination Exercise Period</I></B>&#8221; means the period following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in Section&nbsp;4(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#8220;<B><I>Prior Plans</I></B>&#8221; means the LB Pharmaceuticals Inc 2023 Stock Incentive Plan, the LB Pharmaceuticals Inc
2018 Stock Incentive Plan and the LB Pharmaceuticals Inc 2017 Stock Incentive Plan, each as has been amended from time to time as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(eee)</B> &#8220;<B><I>Prospectus</I></B>&#8221; means the document containing the Plan information specified in Section&nbsp;10(a) of the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(fff)</B> &#8220;<B><I>Restricted Stock Award</I></B>&#8221; or &#8220;<B><I>RSA</I></B>&#8221; means an Award of
shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ggg)</B> &#8220;<B><I>Restricted
Stock Award Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement
includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided including by electronic means, to a
Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hhh)</B> &#8220;<B><I>Returning Shares</I></B>&#8221; means shares subject to
outstanding stock awards granted under the Prior Plans and that following the Effective Date:&nbsp;(A)&nbsp;are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such
stock award having been issued;&nbsp;(B)&nbsp;are not issued because such stock award or any portion thereof is settled in cash;&nbsp;(C)&nbsp;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or
condition required for the vesting of such shares;&nbsp;(D)&nbsp;are withheld or reacquired to satisfy the exercise, strike or purchase price; or&nbsp;(E)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> &#8220;<B><I>RSU Award</I></B>&#8221; or &#8220;<B><I>RSU</I></B>&#8221;<B><I> </I></B>means an Award of restricted stock units
representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jjj)</B> &#8220;<B><I>RSU Award Agreement</I></B>&#8221;<B><I> </I></B>means a written or electronic agreement between the Company and a
holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to
the RSU Award and which is provided including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kkk)</B> &#8220;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#8221; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(lll)</B> &#8220;<B><I>Rule 405</I></B>&#8221; means Rule 405 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mmm)</B> &#8220;<B><I>SAR Agreement</I></B>&#8221; means a written or electronic agreement between the Company and a holder of a SAR
evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including
by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nnn)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#8221; means Section&nbsp;409A of the Code and the regulations
and other guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ooo)</B> &#8220;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A Change in Control</I></B>&#8221;
means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section&nbsp;409A(a)(2)(A)(v) of the Code and Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ppp)</B>
&#8220;<B><I>Securities Act</I></B>&#8221; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qqq)</B> &#8220;<B><I>Share
Reserve</I></B>&#8221; means the number of shares available for issuance under the Plan as set forth in Section&nbsp;2(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rrr)</B> &#8220;<B><I>Stock Appreciation Right</I></B>&#8221; or
&#8220;<B><I>SAR</I></B>&#8221;<B><I> </I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(sss)</B> &#8220;<B><I>Subsidiary</I></B>&#8221; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the
outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting
power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest
(whether in the form of voting or participation in profits or capital contribution) of more than 50%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ttt)</B> &#8220;<B><I><FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#8221; means any income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in
relation to a Participant&#8217;s participation in the Plan and legally applicable or deemed applicable to the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uuu)</B>
&#8220;<B><I>Ten Percent Stockholder</I></B>&#8221; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or
any Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vvv)</B> &#8220;<B><I>Trading Policy</I></B>&#8221; means the Company&#8217;s policy permitting certain individuals to
sell Company shares only during certain &#8220;window&#8221; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(www)</B> &#8220;<B><I>Unvested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xxx)</B> &#8220;<B><I>Vested <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award</I></B>&#8221; means the portion of any <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>d12080dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc (the &#8220;<B><I>Company</I></B>&#8221;), pursuant to its 2025 Equity Incentive Plan (the &#8220;<B><I>Plan</I></B>&#8221;), has
granted to you (&#8220;<B><I>Optionholder</I></B>&#8221;<B><I>)</I></B> an option to purchase the number of shares of the Common Stock set forth below (the &#8220;<B><I>Option</I></B>&#8221;). Your Option is subject to all of the terms and
conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the
Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Optionholder:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date of Grant:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Vesting Commencement Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Number of Shares of Common Stock Subject to Option:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Exercise Price (Per Share):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Total Exercise Price:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Expiration Date:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Incentive Stock Option] <U>OR</U> [Nonstatutory Stock Option]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise and Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Subject to the Optionholder&#8217;s Continuous Service through each applicable vesting date, the Option will vest as follows:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[__________________________________________________________]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optionholder Acknowledgements:</B> By your signature below or by electronic acceptance or authentication in a form
authorized by the Company, you understand and agree that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Option is governed by this Stock Option Grant Notice (this &#8220;<B><I>Grant Notice</I></B>&#8221;), and the
provisions of the Plan and the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the
&#8220;<B><I>Option Agreement</I></B>&#8221;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you)
cannot be first <I>exercisable</I> for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option.] </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other
Plan-related documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, the Notice of
Exercise and the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of
Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance
agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for
all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>O<SMALL>PTIONHOLDER</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center">Signature</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL></SMALL>: Stock Option Agreement, 2025 Equity Incentive Plan, Notice of Exercise,
Prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reflected by your Stock Option Grant Notice (&#8220;<B><I>Grant Notice</I></B>&#8221;), LB Pharmaceuticals&nbsp;Inc (the
&#8220;<B><I>Company</I></B>&#8221;) has granted you an option under its 2025<B> </B>Equity Incentive Plan (the &#8220;<B><I>Plan</I></B>&#8221;) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice
(the &#8220;<B><I>Option</I></B>&#8221;). Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable. The terms of your Option
as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general terms and conditions
applicable to your Option are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your
Option is subject to all the provisions of the Plan, including but not limited to the provisions in: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Section 6 regarding the
impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Section 9(e)
regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Section 8 regarding certain tax consequences of your Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to
the Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>V<SMALL>ESTING</SMALL>. </B>Your Option will vest as provided in your Grant Notice, subject to the provisions contained herein
and the terms of the Plan. Vesting will cease upon the termination of your Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. E<SMALL>XERCISE</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> You may generally exercise the vested portion of your Option for whole shares of Common Stock at any time during its term by
delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic
submission. Please review Sections 4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> To the extent permitted by Applicable Law, you may pay your Option exercise price
as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> cash, check, bank draft or money order; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> subject to Company and/or Committee consent at the time of exercise, pursuant to a &#8220;cashless exercise&#8221; program as
further described in Section&nbsp;4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>
subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of Common Stock as further described in Section&nbsp;4(c)(iii) of the Plan; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a
&#8220;net exercise&#8221; arrangement as further described in Section&nbsp;4(c)(iv) of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> By accepting your Option,
you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock
or other securities of the Company held by you, for a period of one hundred eighty (180)&nbsp;days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or
the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the&nbsp;&#8220;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#8221;); <I>provided, however</I>, that
nothing contained in this Section&nbsp;3(c) will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. You further agree to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this
Section&nbsp;3(c). The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section&nbsp;3(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>T<SMALL>ERM</SMALL>.</B> You may not exercise your Option before the commencement of its term or after its term expires. The term
of your Option commences on the Date of Grant and expires upon the earliest of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> immediately upon the termination
of your Continuous Service for Cause; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> three months after the termination of your Continuous Service for any reason other than
Cause, Disability or death; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> 12 months after the termination of your Continuous Service due to your Disability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> 18 months after your death if you die during your Continuous Service; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> immediately upon a Corporate Transaction if the Board has determined that the
Option will terminate in connection with a Corporate Transaction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> the Expiration Date indicated in your Grant Notice; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> the day before the 10th anniversary of the Date of Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if you die during the period provided in Section&nbsp;4(b) or 4(c) above, the term of your Option shall not expire until the
earlier of (i) 18 months after your death, (ii)&nbsp;upon any termination of the Option in connection with a Corporate Transaction, (iii)&nbsp;the Expiration Date indicated in your Grant Notice, or (iv)&nbsp;the day before the tenth anniversary of
the Date of Grant. Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in Section&nbsp;4(i) of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the
date of grant of your Option and ending on the day three months before the date of your Option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. If the Company provides for the
extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment
terminates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>W<SMALL>ITHHOLDING</SMALL> O<SMALL>BLIGATIONS</SMALL>. </B>As further provided in Section&nbsp;8 of the Plan:
(a)&nbsp;you may not exercise your Option unless the applicable tax withholding obligations are satisfied; and (b)&nbsp;at the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by
the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with
the withholding procedures established by the Company. Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of Common Stock subject to your Option, unless
and until such obligations are satisfied. In the event that the amount of the Company&#8217;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the
Company harmless from any failure by the Company to withhold the proper amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>I<SMALL>NCENTIVE</SMALL>
S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL> D<SMALL>ISPOSITION</SMALL> R<SMALL>EQUIREMENT</SMALL>.</B> If your Option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the
shares of the Common Stock issued upon exercise of your Option that occurs within two years after the date of your Option grant or within one year after such shares of Common Stock are transferred upon exercise of your Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided in Section&nbsp;4(e) of the Plan, your Option is not
transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTION</SMALL>.</B> Your Option is subject
to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any
escrow, indemnities and any contingent consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>N<SMALL>O</SMALL> L<SMALL>IABILITY</SMALL> <SMALL>FOR</SMALL>
T<SMALL>AXES</SMALL></B><SMALL><B></B></SMALL><B>.</B> As a condition to accepting the Option, you hereby (a)&nbsp;agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities
arising from the Option or other Company compensation and (b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or
knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section&nbsp;409A only if the exercise price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant
as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of
its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the
Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>S<SMALL>EVERABILITY</SMALL></B><SMALL><B></B></SMALL><B>.</B> If any part of this Option
Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.&nbsp;Any
Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible
while remaining lawful and valid </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>.</B>&nbsp;You hereby acknowledge receipt of
or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&nbsp;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Q<SMALL>UESTIONS</SMALL>. </B>If you have questions regarding these or any other terms and conditions applicable to your Option,
including a summary of the applicable federal income tax consequences please see the Prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * * * </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> III </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OTICE</SMALL> O<SMALL>F</SMALL> E<SMALL>XERCISE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">One Pennsylvania Plaza, Suite 1025</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New York, NY 10119</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Date of Exercise: _______________</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This constitutes notice to LB Pharmaceuticals Inc (the &#8220;<B><I>Company</I></B>&#8221;) that I elect to
purchase the below number of shares of Common Stock of the Company (the&nbsp;&#8220;<B><I>Shares</I></B>&#8221;) by exercising my Option for the price set forth below. Capitalized terms not explicitly defined in this Notice of Exercise but defined
in the Stock Option Grant Notice, Stock Option Agreement or 2025 Equity Incentive Plan (the&nbsp;&#8220;<B><I>Plan</I></B>&#8221;) shall have the meanings set forth in the Stock Option Grant Notice, Stock Option Agreement or Plan, as applicable. Use
of certain payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Stock Option Agreement and the Plan. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Type of Option (check one):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive &#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Nonstatutory&nbsp;&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">_______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Shares as <BR>to which Option is <BR>exercised:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">_______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certificates to be <BR>issued in name of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">_______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Total exercise price:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Cash, check, bank draft or money order delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Value of ________ Shares delivered herewith:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Regulation T Program (cashless exercise):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Value of _______ Shares pursuant to net exercise:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$______________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By this exercise, I agree (i)&nbsp;to provide such additional documents as you may require
pursuant to the terms of the Plan, (ii)&nbsp;to satisfy the tax withholding obligations, if any, relating to the exercise of this Option as set forth in the Stock Option Agreement, and (iii)&nbsp;if this exercise relates to an Incentive Stock
Option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this Option that occurs within two years after the Date of Grant or within one year after such Shares are issued upon
exercise of this Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I further agree that I will not sell, dispose of, transfer, make any short sale of, grant any option for the
purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company that I hold, for a period of 180 days following the effective date of
a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the
&#8220;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#8221;); <I>provided, however</I>, that nothing contained in this paragraph will prevent the exercise of a repurchase option, if any, in favor of the Company during the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period. I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give
further effect thereto. I further agree that in order to enforce the foregoing covenant, the Company may impose <FONT STYLE="white-space:nowrap">stop-transfer</FONT> instructions with respect to shares of Common Stock that I hold until the end of
such period. I also agree that any transferee of any shares of Common Stock (or other securities) of the Company that I hold will be bound by this paragraph.&nbsp;The underwriters of the Company&#8217;s stock are intended third party beneficiaries
of this paragraph and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> IV </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROSPECTUS</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>7
<FILENAME>d12080dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RSU A<SMALL>WARD</SMALL> G<SMALL>RANT</SMALL> N<SMALL>OTICE</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc (the &#8220;<B><I>Company</I></B>&#8221;) has awarded to you (the &#8220;<B><I>Participant</I></B>&#8221;) the number of restricted
stock units specified and on the terms set forth below in consideration of your services (the &#8220;<B><I>RSU Award</I></B>&#8221;). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company&#8217;s 2025
Equity Incentive Plan (the &#8220;<B><I>Plan</I></B>&#8221;) and the Award Agreement (the &#8220;<B><I>Agreement</I></B>&#8221;), which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein
but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Participant:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date of Grant:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Number of Restricted Stock Units:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Subject to your Continuous Service through each applicable vesting date, the RSU Award will vest as follows: [_____]</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issuance Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section&nbsp;6 of the Agreement.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participant Acknowledgements:</B> By your signature below or by electronic acceptance or authentication in a form
authorized by the Company, you understand and agree that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The RSU Award is governed by this RSU Award Grant Notice (the &#8220;<B><I>Grant Notice</I></B>&#8221;), and the
provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#8220;<B><I>RSU Award Agreement</I></B>&#8221;) may not be modified,
amended or revised except in a writing signed by you and a duly authorized officer of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You consent to receive this Grant Notice, the Agreement, the Plan, the Prospectus and any other Plan-related
documents by electronic delivery and to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or another third party designated by the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus. In
the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition
of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i)&nbsp;other equity awards previously granted to you, and (ii)&nbsp;any written employment agreement,
offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>P<SMALL>ARTICIPANT</SMALL>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>TTACHMENTS</SMALL></B><SMALL><B></B></SMALL><B>: </B>RSU Award Agreement, 2025<B> </B>Equity Incentive Plan,
Prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>WARD</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As reflected by your RSU Award Grant Notice (&#8220;<B><I>Grant Notice</I></B>&#8221;), LB Pharmaceuticals&nbsp;Inc (the
&#8220;<B><I>Company</I></B>&#8221;) has granted you a RSU Award under its 2025 Equity Incentive Plan (the &#8220;<B><I>Plan</I></B>&#8221;) for the number of restricted stock units as indicated in your Grant Notice (the &#8220;<B><I>RSU
Award</I></B>&#8221;). The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#8220;<B><I>Agreement</I></B>&#8221;) and the Grant Notice constitute your &#8220;<B><I>RSU Award Agreement</I></B>.&#8221; Defined
terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general terms applicable to your RSU Award are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>G<SMALL>OVERNING</SMALL> P<SMALL>LAN</SMALL> D<SMALL>OCUMENT</SMALL>.</B> Your RSU Award is subject to all the provisions of the
Plan, including but not limited to the provisions in: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Section 6 of the Plan regarding the impact of a Capitalization
Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Section 9(e) of the Plan regarding the
Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Section 8
of the Plan regarding certain tax consequences of your RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your RSU Award is further subject to all interpretations, amendments, rules and
regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> RSU A<SMALL>WARD</SMALL>. </B>This RSU Award represents your right to
be issued on a future date the number of shares of the Company&#8217;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your
satisfaction of the vesting conditions set forth therein (the &#8220;<B><I>Restricted Stock Units</I></B>&#8221;). Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the
Plan and the provisions of Section&nbsp;3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other
Restricted Stock Units covered by your RSU Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>V<SMALL>ESTING</SMALL>.</B><B> </B>Your Restricted Stock Units will vest,
if at all, in accordance with the vesting schedule provided in the Grant Notice, subject to the provisions contained herein and the terms of the Plan. Vesting will cease upon the termination of your Continuous Service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>D<SMALL>IVIDENDS</SMALL>.</B><B> </B>You may become entitled to receive
payments equal to any cash dividends and other distributions paid with respect to a corresponding number of shares of Common Stock to be issued in respect of the Restricted Stock Units covered by your RSU Award. Any such dividends or distributions
shall be subject to the same forfeiture restrictions as apply to the Restricted Stock Units and shall be paid at the same time that the corresponding shares are issued in respect of your vested Restricted Stock Units, provided, however that to the
extent any such dividends or distributions are paid in shares of Common Stock, then you will automatically be granted a corresponding number of additional Restricted Stock Units subject to the RSU Award (the &#8220;<B><I>Dividend
Units</I></B>&#8221;), and further provided that such Dividend Units shall be subject to the same forfeiture restrictions and restrictions on transferability, and same timing requirements for issuance of shares, as apply to the Restricted Stock
Units subject to the RSU Award with respect to which the Dividend Units relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>W<SMALL>ITHHOLDING</SMALL>
O<SMALL>BLIGATIONS</SMALL>.</B><B> </B>As further provided in Section&nbsp;8 of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to
satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the&nbsp;&#8220;<B><I>Withholding Obligation</I></B>&#8221;) in accordance with the withholding procedures established
by the Company. Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award. In the event the Withholding Obligation of the Company arises prior to the delivery
to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any
failure by the Company to withhold the proper amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> I<SMALL>SSUANCE</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> and will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the
Company shall issue to you one (1)&nbsp;share of Common Stock for each Restricted Stock Unit (subject to any adjustment under Section&nbsp;4 above, and subject to any different provisions in the Grant Notice) that vests on the applicable vesting
date(s) or on a later date as determined by the Company but in no event later than the Issuance Deadline (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>
In addition, the following provisions shall apply to the extent applicable at a vesting date when shares of Common Stock are registered under the Securities Act, unless otherwise determined by the Company. <U>If</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the applicable vest date does not occur (1)&nbsp;during an &#8220;open window period&#8221; applicable to you, as determined by the
Company in accordance with the Company&#8217;s then-effective policy on trading in Company securities, or (2)&nbsp;on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including
but not limited to under a previously established written trading plan that meets the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act and was entered into in compliance with the Company&#8217;s policies (a
&#8220;<B><I><FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement</I></B>&#8221;) or under such other policy expressly approved by the Company), <I>and</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> either (1)&nbsp;a Withholding Obligation does not apply, or (2)&nbsp;the
Company decides, prior to the applicable vest date, (A)&nbsp;not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due to you under this Award, and (B)&nbsp;not to permit you to enter into a
&#8220;same day sale&#8221; commitment with a broker-dealer (including but not limited to a commitment under a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Arrangement) and (C)&nbsp;not to permit you to pay your Withholding Obligation in cash,
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>then</U> the shares that would otherwise be issued to you on the applicable vest date will not be delivered on such applicable vest date and will
instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#8217;s Common Stock in the open public market or on such other date determined by the Company, but in no event later than the Issuance
Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#8220;<B><I>Issuance Deadline</I></B>&#8221; means (a)&nbsp;December&nbsp;31 of the calendar year in which the applicable
vest date occurs (that is, the last day of your taxable year in which the applicable vest date occurs), or (b)<U>&nbsp;if and only if</U> permitted in a manner that complies with Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4),</FONT> no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock issuable as a result of the
applicable vest date under this Award are no longer subject to a &#8220;substantial risk of forfeiture&#8221; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(d).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> To the extent the RSU Award is a <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Award, the provisions of Section&nbsp;11 of the
Plan shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>L<SMALL>OCK</SMALL><FONT STYLE="white-space:nowrap">-U</FONT><SMALL>P</SMALL>
P<SMALL>ERIOD</SMALL></B><SMALL></SMALL>. By accepting your RSU Award, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180)&nbsp;days following the effective date of a registration statement of the Company
filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the
&#8220;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I></B>&#8221;); <I>provided, however</I>, that nothing contained in this Section&nbsp;7 will prevent the exercise of a repurchase option, if any, in favor of the Company during the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period.&nbsp;You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are
necessary to give further effect thereto.&nbsp;In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period.&nbsp;You also agree that any
transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section&nbsp;7.&nbsp;The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section&nbsp;7 and will
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>
<B>T<SMALL>RANSFERABILITY</SMALL>.</B> Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTION</SMALL>.</B> Your RSU Award is
subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to
any escrow, indemnities and any contingent consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>N<SMALL>O</SMALL> L<SMALL>IABILITY</SMALL> <SMALL>FOR</SMALL>
T<SMALL>AXES</SMALL></B><SMALL><B></B></SMALL><B>.</B> As a condition to accepting the RSU Award, you hereby (a)&nbsp;agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax
liabilities arising from the RSU Award or other Company compensation and (b)&nbsp;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have
either done so or knowingly and voluntarily declined to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>
<B>S<SMALL>EVERABILITY</SMALL></B><SMALL><B></B></SMALL><B>.</B> If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion
of this Agreement or the Plan not declared to be unlawful or invalid.&nbsp;Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the
terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>
<B>O<SMALL>THER</SMALL> D<SMALL>OCUMENTS</SMALL>.</B>&nbsp;You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the
Prospectus.&nbsp;In addition, you acknowledge receipt of the Company&#8217;s Trading Policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Q<SMALL>UESTIONS</SMALL>.
</B>If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>TTACHMENT</SMALL> III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROSPECTUS</SMALL> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>8
<FILENAME>d12080dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2025 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
A<SMALL>UGUST</SMALL>&nbsp;19, 2025 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
S<SMALL>EPTEMBER</SMALL>&nbsp;7, 2025 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to
purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In addition, the Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees that do not meet the requirements of an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Plan includes two components: a
423 Component and a <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. The Company intends (but makes no undertaking or representation to maintain) the 423 Component to qualify as an Employee Stock Purchase Plan. The provisions of the 423
Component, accordingly, will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. In addition, this Plan authorizes grants of Purchase Rights under the <FONT STYLE="white-space:nowrap">Non-423</FONT>
Component that do not meet the requirements of an Employee Stock Purchase Plan. Except as otherwise provided in the Plan or determined by the Board, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will operate and be administered in
the same manner as the 423 Component. In addition, the Company may make separate Offerings which vary in terms (provided that such terms are not inconsistent with the provisions of the Plan or the requirements of an Employee Stock Purchase Plan to
the extent the Offering is made under the 423 Component), and the Company will designate which Designated Company is participating in each separate Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Company, by means of the Plan, seeks to retain the services of Eligible Employees, to secure and retain the services of new
Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
A<SMALL>DMINISTRATION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board will administer the Plan unless and until the Board delegates administration of
the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). References herein to the Board shall be deemed to refer to the Committee except where context dictates otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To designate from time to time (A)&nbsp;which Related Corporations of the Company will be eligible to participate in the Plan as
Designated 423 Companies, (B)&nbsp;which Related Corporations or Affiliates will be eligible to participate in the Plan as Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Companies, (C)&nbsp;which Affiliates or Related Corporations may be
excluded from participation in the Plan, and (D)&nbsp;which Designated Companies will participate in each separate Offering (to the extent that the Company makes separate Offerings). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to establish, amend
and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully
effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of
the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan with respect to the 423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To adopt such rules, procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit
or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside the United States. Without limiting the generality of, and consistent with, the foregoing, the Board specifically is authorized to adopt
rules, procedures, and <FONT STYLE="white-space:nowrap">sub-plans</FONT> regarding, without limitation, eligibility to participate in the Plan, the definition of eligible &#8220;earnings,&#8221; handling and making of Contributions, establishment of
bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures and handling of share issuances, any of
which may vary according to applicable requirements, and which, if applicable to a Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company, do not have to comply with the requirements of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the
administrative powers the Committee is authorized to exercise (and references in this Plan and any applicable Offering Document to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not
inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Further, to the extent not prohibited by Applicable Law, the Board or Committee may, from time to time, delegate some or all of its authority under the
Plan to one or more officers of the Company or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. The Board may retain the
authority to concurrently administer the Plan with the Committee (or its delegate) and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a
Committee (or a delegate of the Committee), the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person
and will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>
S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the provisions of
Section&nbsp;11(a) relating to Capitalization Adjustments, the maximum number of shares of Common Stock that may be issued under the Plan will not exceed 201,000 shares of Common Stock, plus the number of shares of Common Stock that are
automatically added on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January 1st of each year for a period of up to ten years, commencing on January&nbsp;1,&nbsp;2026 and ending on (and including) January&nbsp;1, 2035 in an amount equal to the lesser of
(x)&nbsp;one percent (1%) of the total number of shares of Fully Diluted Capital Stock outstanding on December 31st of the preceding calendar year, and (y)&nbsp;402,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior
to the first day of any calendar year to provide that there will be no January&nbsp;1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> increase in the share reserve for such calendar year or that the increase in the share reserve for such
calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. For the avoidance of doubt, up to the maximum number of shares of Common Stock reserved under this Section&nbsp;3(a) may
be used to satisfy purchases of Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy purchases of Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The stock purchasable under the
Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.
G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board
may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such
form and will contain such terms and conditions as the Board will deem appropriate, and with respect to the 423 Component, will comply with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have
the same rights and privileges. The terms and conditions of an Offering shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include
(through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date,
and the substance of the provisions contained in Sections 5 through 8, inclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant has more than one Purchase
Right outstanding under the Plan, unless such Participant otherwise indicates in forms delivered to the Company or a third party designated by the Company (each, a &#8220;<B><I>Company Designee</I></B>&#8221;): (i) each form will apply to all of
such Participant&#8217;s Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have identical exercise prices) will be exercised to the fullest
possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the Fair Market Value of a share of Common Stock on the
first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will terminate immediately as of that first
Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b),
to Employees of a Related Corporation or an Affiliate. Except as provided in Section&nbsp;5(b) or as required by Applicable Law, an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in
the employ of the Company, the Related Corporation or the Affiliate, as the case may be, for such continuous period preceding such Offering Date as the Board may (unless prohibited by Applicable Law) require, but in no event will the required period
of continuous employment be equal to or greater than two years. In addition, the Board may provide (unless prohibited by Applicable Law) that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date,
such Employee&#8217;s customary employment with the Company, the Related Corporation or the Affiliate is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with
Section&nbsp;423 of the Code with respect to the 423 Component. The Board may also exclude (unless prohibited by Applicable Law) from participation in the Plan or any Offering Employees who are &#8220;highly compensated employees&#8221; (within the
meaning of Section&nbsp;423(b)(4)(D) of the Code) of the Company, a Related Corporation or an Affiliate, or a subset of such highly compensated employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may provide that each person who, during the course of an Offering, first becomes an Eligible Employee will, on a date or
dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter be deemed to be a part of
that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> the date on which such Purchase Right is granted will be the &#8220;Offering Date&#8221; of such Purchase Right for all purposes,
including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> the period of the Offering with respect to such
Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Board may provide
that if such person first becomes an Eligible Employee within a specified period of time before the end of the Offering, such individual will not receive any Purchase Right under that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Employee will be eligible for the grant of any Purchase Rights under the 423 Component if, immediately after any such Purchase
Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of
Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights under the 423 Component
only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#8217;s rights to purchase stock of the Company or any
Related Corporation to accrue at a rate which, when aggregated, exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective
Offering Dates) for each calendar year in which such rights are outstanding at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Officers of the Company and any Designated Company, if they are otherwise
Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by Applicable Law) provide in an Offering that Employees who are highly compensated Employees within the
meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Notwithstanding anything in this
Section&nbsp;5 to the contrary, in the case of an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Eligible Employee (or group of Eligible Employees) may be excluded from participation in the Plan or an Offering if
the Board has determined, in its sole discretion, that participation of such Eligible Employee(s) is not advisable or practical for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Offering Date, each
Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage of earnings (as defined by the Board in each Offering) or
with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee&#8217;s earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the
Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that Offering will be
exercised and shares of Common Stock will be purchased in accordance with such Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> In connection with each Offering made
under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii)&nbsp;a maximum aggregate number of shares of Common Stock that may be
purchased by all Participants pursuant to such Offering and/or (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of
Common Stock issuable upon exercise of Purchase Rights granted under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#8217;s accumulated
Contributions) allocation of the shares of Common Stock (rounded down to the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be no less than the lesser of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the Offering Date; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the applicable Purchase Date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of making Contributions
by completing and delivering to the Company or a Company Designee, within the time specified in the Offering, an enrollment form provided by the Company or Company Designee. The enrollment form will specify the amount of Contributions not to exceed
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum amount specified by the Board. Each Participant&#8217;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general
funds of the Company except where Applicable Law requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date
(or, in the case of a payroll date that occurs after the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a
Participant may thereafter reduce (including to zero) or increase his or her Contributions. If required under Applicable Law or if specifically provided in the Offering and to the extent permitted by Section&nbsp;423 of the Code with respect to the
423 Component, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through the payment by cash, check or wire transfer prior to a Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company or a
Company Designee a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#8217;s Purchase Right in that Offering will immediately terminate and the
Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant&#8217;s Purchase Right in that Offering shall thereupon terminate. A Participant&#8217;s withdrawal from
that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Unless otherwise required by Applicable Law, Purchase Rights granted pursuant to any Offering under the Plan will terminate
immediately if the Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by Applicable Law) or (ii)&nbsp;is otherwise no longer eligible to participate. The
Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>
Unless otherwise determined by the Board, a Participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between the Company and a Designated Company or between Designated Companies
will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; however, if a Participant transfers from an Offering under the 423 Component to an Offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the Participant&#8217;s Purchase Right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a Participant
transfers from an Offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the Purchase Right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. The Board may establish different and additional rules governing transfers between separate Offerings within the 423 Component and between Offerings under the 423 Component and Offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> During a Participant&#8217;s lifetime, Purchase Rights will be
exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> Unless otherwise specified in the Offering or required by Applicable Law, the Company will have no obligation to pay interest on
Contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On each Purchase Date, each Participant&#8217;s accumulated Contributions will be applied to the purchase of shares of Common Stock,
up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Unless otherwise provided in the Offering, if any amount of accumulated
Contributions remains in a Participant&#8217;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such
remaining amount will be held in such Participant&#8217;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such next Offering, in
which case such amount will be distributed to such Participant after the final Purchase Date without interest (unless the payment of interest is otherwise required by Applicable Law). If the amount of Contributions remaining in a Participant&#8217;s
account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to
such Participant after the final Purchase Date of such Offering without interest (unless the payment of interest is otherwise required by Applicable Law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the Plan
are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the
Plan. If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and, subject to Section&nbsp;423 of the Code with respect to the 423
Component, the Purchase Date will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 27 months from
the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all Applicable Laws, as determined by the Company in its sole
discretion, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest (unless the payment of interest is otherwise required by Applicable Law). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission, agency or other Governmental Body
having jurisdiction over the Plan such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so is not practical or would cause
the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale
of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any
shares of Common Stock and/or Contributions from the Participant&#8217;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated to, permit the
Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If a Participant dies, and in the absence of a valid beneficiary designation, the
Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole
discretion, may deliver such shares of Common Stock and/or Contributions, without interest (unless the payment of interest is otherwise required by Applicable Law), to the Participant&#8217;s spouse, dependents or relatives, or if no spouse,
dependent or relative is known to the Company, then to such other person as the Company may designate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. A<SMALL>DJUSTMENTS</SMALL>
<SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and
maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii) the class(es) and maximum number of securities by which the share reserve is to increase automatically each year pursuant to Section&nbsp;3(a), (iii) the class(es)
and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The
Board will make these adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> In the event of a Corporate
Transaction, then: (i)&nbsp;any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right
to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue such Purchase
Rights or does not substitute similar rights for such Purchase Rights, then the Participants&#8217; accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days (or such
other period specified by the Board) prior to the Corporate Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.
However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Any benefits, privileges, entitlements and obligations under any outstanding Purchase
Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were granted,
(ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance
issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as necessary to obtain or
maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#8217;s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section&nbsp;423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering Document to the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of
the amount designated by a Participant in order to adjust for mistakes in the Company&#8217;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting
procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#8217;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any
ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code with respect to the 423 Component; and (v)&nbsp;establish other limitations or procedures as the Board
determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the
initial terms of each Offering and the Purchase Rights granted under each Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. T<SMALL>AX</SMALL> Q<SMALL>UALIFICATION</SMALL>;
T<SMALL>AX</SMALL> W<SMALL>ITHHOLDING</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Although the Company may endeavor to (i)&nbsp;qualify a Purchase Right for
special tax treatment under the laws of the United States or jurisdictions outside of the United States or (ii)&nbsp;avoid adverse tax treatment, the Company makes no representation to that effect and expressly disavows any covenant to maintain
special or to avoid unfavorable tax treatment, notwithstanding anything to the contrary in this Plan.&nbsp;The Company will be unconstrained in its corporate activities without regard to the potential negative tax impact on Participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each Participant will make arrangements, satisfactory to the Company and any applicable Related Corporation, to enable the Company
or the Related Corporation to fulfill any withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. Without limitation to the foregoing, in the Company&#8217;s sole discretion and subject to Applicable Law, such
withholding obligation may be satisfied in whole or in part by (i)&nbsp;withholding from the Participant&#8217;s salary or any other cash payment due to the Participant from the Company or a Related Corporation; (ii)&nbsp;withholding from the
proceeds of the sale of shares of Common Stock acquired under the Plan, either through a voluntary sale or a mandatory sale arranged by the Company; or (iii)&nbsp;any other method deemed acceptable by the Board. The Company shall not be required to
issue any shares of Common Stock under the Plan until such obligations are satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The 423 Component is exempt from the
application of Section&nbsp;409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section&nbsp;409A of the Code. The <FONT STYLE="white-space:nowrap">Non-423</FONT> Component is intended to be exempt from the
application of Section&nbsp;409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any provision in the Plan
to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section&nbsp;409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to Section&nbsp;409A, the
Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the Participant&#8217;s consent, to exempt any
outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section&nbsp;409A of the Code, but only to the extent any such amendments or action by the Committee would not violate
Section&nbsp;409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a Participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section&nbsp;409A of the Code is
not so exempt or compliant or for any action taken by the Committee with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and until the
Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section&nbsp;12(a) above, materially amended) by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of Common
Stock subject to Purchase Rights unless and until the Participant&#8217;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will in any way alter the at
will nature of a Participant&#8217;s employment or amend a Participant&#8217;s employment contract, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or
a Related Corporation or an Affiliate, or on the part of the Company, a Related Corporation or an Affiliate to continue the employment of a Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that state&#8217;s conflicts of
laws rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> If any particular provision of the Plan is found to be invalid or otherwise unenforceable, such provision will not
affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> If any provision of the Plan does not comply with Applicable Law, such provision shall be construed in such a manner as to comply
with Applicable Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. D<SMALL>EFINITIONS</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#8220;<B><I>423 Component</I></B>&#8221; means the part of the Plan, which excludes the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, pursuant to which Purchase Rights that satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#8220;<B><I>Affiliate</I></B>&#8221; means any entity, other than a Related Corporation, whether now or subsequently established,
which is at the time of determination, a &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which
&#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> &#8220;<B><I>Applicable
Law</I></B>&#8221; means shall mean the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing
rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of the New York Stock Exchange,
Nasdaq Stock Market or the Financial Industry Regulatory Authority). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> &#8220;<B><I>Board</I></B>&#8221;<I> </I>means the Board of Directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#8220;<B><I>Capital Stock</I></B>&#8221; means each and every class of common stock of the Company, regardless of
the number of votes per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#8220;<B><I>Capitalization Adjustment</I></B>&#8221; means any change that is made in, or
other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or
other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#8220;<B><I>Code</I></B>&#8221;<I> </I>means
the U.S. Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>
&#8220;<B><I>Committee</I></B>&#8221;<I> </I>means a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#8220;<B><I>Common Stock</I></B>&#8221; means, as of the IPO Date, the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> &#8220;<B><I>Company</I></B>&#8221; means LB Pharmaceuticals Inc, a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B><I>&#8220;Contributions</I></B>&#8221; means the payroll deductions and other additional payments specifically provided for in
the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the Participant has not already
had the maximum permitted amount withheld during the Offering through payroll deductions and, with respect to the 423 Component, to the extent permitted by Section&nbsp;423. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#8220;<B><I>Corporate Transaction</I></B>&#8221; means the consummation, in a single transaction or in a series of related
transactions, of any one or more of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale<B> </B>or other disposition of all or substantially all, as
determined by the Board in its sole discretion, of the consolidated assets of the Company and its subsidiaries; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> a sale or
other disposition of more than 50% of the outstanding securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> a merger, consolidation or similar transaction
following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar
transaction into other property, whether in the form of securities, cash or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#8220;<B><I>Designated 423 Company</I></B>&#8221; means any Related Corporation
selected by the Board as participating in the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#8220;<B><I>Designated Company</I></B>&#8221;<B> </B>means any
Designated <FONT STYLE="white-space:nowrap">Non-423</FONT> Company or Designated 423 Company, provided, however, that at any given time, a Related Corporation participating in the 423 Component shall not be a Related Corporation participating in the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#8220;<B><I>Designated
<FONT STYLE="white-space:nowrap">Non-423</FONT> Company</I></B>&#8221; means any Related Corporation or Affiliate selected by the Board as participating in the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> &#8220;<B><I>Director</I></B>&#8221;<I> </I>means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> &#8220;<B><I>Eligible Employee</I></B>&#8221;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#8220;<B><I>Employee</I></B>&#8221;<I> </I>means any person, including an Officer or Director, who is &#8220;employed&#8221; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation or solely with respect to the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an Affiliate. However, service solely as a Director, or payment of a fee
for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>
&#8220;<B><I>Employee Stock Purchase Plan</I></B>&#8221;<I> </I>means a plan that grants Purchase Rights intended to be options issued under an &#8220;employee stock purchase plan,&#8221; as that term is defined in Section&nbsp;423(b) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#8220;<B><I>Exchange Act</I></B>&#8221;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#8220;<B><I>Fair Market Value</I></B>&#8221; means, as of any date, the value of the
Common Stock determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any
established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the
greatest volume of trading in the Common Stock) <B><U>on the date of determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on
the date of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith in
compliance with Applicable Laws and regulations and, to the extent applicable as determined in the sole discretion of the Board, in a manner that complies with Sections 409A of the Code </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of the shares of Common
Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company&#8217;s initial public offering as specified in the final prospectus for that initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#8220;<B><I>Fully Diluted Capital Stock</I></B>&#8221; means the number of
shares of Capital Stock, determined as of the applicable date of measurement, equal to the sum of (i)&nbsp;the number of shares of Capital Stock issued and outstanding and (ii)&nbsp;the number of shares of Capital Stock upon the exercise,
conversion, or exchange of all then outstanding warrants, options, convertible capital stock or indebtedness, exchangeable Capital Stock or indebtedness, or other rights exercisable for or convertible or exchangeable into, directly or indirectly,
shares of Capital Stock (whether vested or unvested), but excluding the shares reserved and available for issuance under the Company&#8217;s then-existing equity incentive plan and employee stock purchase plan, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#8220;<B><I>Governmental</I></B><B> </B><B><I>Body</I></B>&#8221; means any: (a)&nbsp;nation, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or regulatory body, or quasi-governmental body of any nature (including any
governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal, and for the avoidance of
doubt, any tax authority) or other body exercising similar powers or authority; or (d)&nbsp;self-regulatory organization (including the New York Stock Exchange, the Nasdaq Stock Market and the Financial Industry Regulatory Authority). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#8220;<B><I>IPO Date</I></B>&#8221; means the date of the underwriting agreement between the Company and the underwriter(s)
managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B><I><FONT STYLE="white-space:nowrap">&#8220;Non-423</FONT> Component&#8221;</I></B> means the part of the Plan, which excludes
the 423 Component, pursuant to which Purchase Rights that are not intended to satisfy the requirements for an Employee Stock Purchase Plan may be granted to Eligible Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#8220;<B><I>Offering</I></B>&#8221;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#8220;<B><I>Offering Document</I></B>&#8221; approved by the Board for that Offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#8220;<B><I>Offering Date</I></B>&#8221; means a date selected by the Board for an Offering to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#8220;<B><I>Officer</I></B>&#8221;<B> </B>means<B> </B>a person who is an officer of the Company or a Related Corporation within
the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B> &#8220;<B><I>Participant</I></B>&#8221;<I> </I>means an Eligible Employee
who holds an outstanding Purchase Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#8220;<B><I>Plan</I></B>&#8221;<I> </I>means this LB Pharmaceuticals Inc 2025
Employee Stock Purchase Plan, as amended from time to time, including both the 423 Component and the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#8220;<B><I>Purchase Date</I></B>&#8221;<I> </I>means one or more dates during an Offering selected by the Board on which
Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#8220;<B><I>Purchase Period</I></B>&#8221; means a period of time specified within an Offering, generally beginning on the
Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#8220;<B><I>Purchase Right</I></B>&#8221;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#8220;<B><I>Related Corporation</I></B>&#8221;<I> </I>means any &#8220;parent
corporation&#8221; or &#8220;subsidiary corporation&#8221; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#8220;<B><I>Securities Act</I></B>&#8221;<I> </I>means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#8220;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#8221; means any income tax, social insurance,
payroll tax, fringe benefit tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items arising out of or in relation to a Participant&#8217;s participation in the Plan, including, but not limited to, the exercise of a
Purchase Right and the receipt of shares of Common Stock or the sale or other disposition of shares of Common Stock acquired under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(</B><B>kk</B><B>)</B> &#8220;<B><I>Trading Day</I></B>&#8221;<B> </B>means any day on which the exchange(s) or market(s) on which shares
of Common Stock are listed, including but not limited to the New York Stock Exchange, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>9
<FILENAME>d12080dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXECUTIVE EMPLOYMENT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</B> (this &#8220;<B>Agreement</B>&#8221;), is made as of September&nbsp;4, 2025
(the &#8220;<B>Effective Date</B>&#8221;), by and between LB Pharmaceuticals Inc, a Delaware Corporation, (the &#8220;<B>Company</B>&#8221;) and Anna Eramo, MD, an individual residing at *** (the &#8220;<B>Executive</B>&#8221;). The Company and
Executive are each a &#8220;<B>Party</B>,&#8221; and together, the &#8220;<B>Parties</B>.&#8221; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Executive are parties to that certain Executive Employment Agreement, made as of August&nbsp;25, 2023 (the
&#8220;<B>Employment Agreement</B>&#8221;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Executive now desire to enter into this Agreement, which
supersedes and replaces the Employment Agreement in its entirety and sets forth the terms and conditions of the Executive&#8217;s continuing employment with the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants, promises, and obligations contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound, acknowledge and agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Position and Duties</U></B><B>.</B><B> </B>Subject to the terms set forth herein, the Company agrees to employ the Executive as Chief
Medical Officer of the Company, and the Executive hereby accepts such employment, starting on the Effective Date (the &#8220;<B>Start Date</B>&#8221;). The Executive shall report to the Chief Executive Officer of the Company (the
&#8220;<B>CEO</B>&#8221;). The Executive shall have such duties, authority, and responsibilities commensurate with such position and such other duties and responsibilities that are specifically delegated to Executive from time to time. The Executive
will diligently and conscientiously perform Executive&#8217;s duties and will devote substantially all of the Executive&#8217;s business hours to such duties, and during such time will make the best use of the Executive&#8217;s energy, knowledge,
and training to advancing the Company&#8217;s interests. The Executive will accept no other employment or contracting work while employed by the Company, or serve as a member of the board of directors of any
<FONT STYLE="white-space:nowrap">for-profit</FONT> entity or as a member of any advisory board without the express written consent of the board of directors of the Company (the &#8220;<B>Board</B>&#8221;). Upon termination of the Executive&#8217;s
employment relationship with the Company for any reason, the Executive shall resign and relinquish any position held as an officer and/or board member of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Compensation and Benefits</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. Subject to the terms set forth herein, in consideration for all services rendered by the Executive to the Company, the
Company shall pay the Executive an annual base salary of four hundred seventy five thousand dollars ($475,000) (&#8220;<B>Annual Base Salary</B>&#8221;) in periodic installments in accordance with the Company&#8217;s regular payroll practices in
effect from time to time for executive employees, but no less frequently than semi-monthly. The Executive shall be classified as exempt from overtime and the Executive understands and acknowledges that the Executive is not entitled to overtime
compensation and that the Annual Base Salary is intended to compensate the Executive for all hours worked. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Target Bonus</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Executive will be eligible to earn a target bonus of up to forty percent (40%) of Executive&#8217;s Annual Base Salary, in all cases
subject to the discretion of the Compensation Committee of the Board of the Company determining that the applicable objectives have been achieved (the &#8220;<B>Target Bonus</B>&#8221;). Objectives will be determined annually by the Compensation
Committee in consultation with the Executive and will include both Company performance and the Executive&#8217;s personal performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Executive&#8217;s employment terminates for any reason prior to the payment date of any Target Bonus awarded, the Executive will
not have earned, and will not be paid, the awarded Target Bonus (or any portion thereof), provided that if the Company awards a Target Bonus and thereafter terminates the Executive&#8217;s employment with the Company for a reason other than for
Cause but before any such Target Bonus has been paid, the Executive will still receive the Executive&#8217;s Target Bonus payment, even if the Executive is no longer working at the Company at the time the Target Bonus is to be paid. Any Target Bonus
awarded will be paid no later than forty-five (45)&nbsp;days after it has been awarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Executive was previously granted an option to purchase up to 750,000 shares of Common Stock of the Company under the Company&#8217;s 2023
Stock Incentive Plan (the &#8220;<B>Plan</B>&#8221;), as amended (the &#8220;<B>First Option</B>&#8221;). Except as expressly provided herein, nothing in the Agreement changes, alters, forfeits, or otherwise modifies the terms of the First Option.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Contingent and effective upon the effectiveness of the underwriting agreement related to the initial public offering (the
&#8220;<B>IPO</B>&#8221;) of the Company&#8217;s Common Stock (the date of such effectiveness, the &#8220;<B>IPO Date</B>&#8221;), the Executive will receive an option (the &#8220;<B>IPO Option</B>&#8221;) under the Company&#8217;s 2025 Equity
Incentive Plan (the &#8220;<B>2025 Plan</B>&#8221;) to purchase a number of shares of Common Stock such that her beneficial ownership of the Common Stock as of the closing of the IPO, inclusive of the IPO Option, would equal 0.75% of the fully
diluted total number of shares of Common Stock outstanding as of the closing of the IPO, rounded down to the nearest whole share, subject to both (A)&nbsp;approval by the Board or the Compensation Committee of the Board and (B)&nbsp;the Executive
remaining employed by the Company through the grant date of the IPO Option. The IPO Option will have an exercise price equal to the fair market value of a share of Common Stock on the grant date. The IPO Option will vest over a four-year period,
whereby twenty-five percent (25%) of the shares initially subject to the IPO Option shall vest on the first anniversary of the IPO Date, and the balance of the shares subject to the IPO Option shall vest in
<FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments over the <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month period beginning on the last day of the month following the first
anniversary of the IPO Date and the last day of each month thereafter, in each case subject to the Executive&#8217;s Continuous Service (as defined in the 2025 Plan) through each applicable vesting date. The IPO Option shall be subject to the terms
of the 2025 Plan and a stock option agreement thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Employee Benefits</U>. During Executive&#8217;s term of employment by the Company
under this Agreement (the &#8220;<B>Employment Period</B>&#8221;), Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect from time to time (collectively, the
&#8220;<B>Employee Benefit Plans</B>&#8221;), on a basis which is no less favorable than is provided to other similarly situated senior executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole discretion, subject to the terms of such Employee Benefit Plans and applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. During the Employment Period, the Executive shall be entitled to twenty (20)&nbsp;days paid vacation per calendar
year. This vacation is in addition to Company recognized holidays and paid sick time, if any, in accordance with the Company&#8217;s practices and policies as in effect from time to time. The Company reserves the right to amend or cancel its
practices and policies at any time in its sole discretion, in accordance with applicable law. Any unused vacation may not be carried over by the Executive to any subsequent year and shall be forfeited at the end of the calendar year. The Company
will pay Executive for any accrued but unused vacation upon termination of the Executive&#8217;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Expense
Reimbursement</U>. The Company shall reimburse the Executive for all reasonable travel and other business expenses incurred by the Executive in the performance of the Executive&#8217;s duties to the Company in accordance with the Company&#8217;s
applicable expense reimbursement policies and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Withholdings</U>. All payments made subject to this Agreement will be
subject to payroll withholdings that the Company reasonably believes are required by law or elected or authorized by the Executive for state and federal income taxes, Social Security, Medicare, and other applicable payroll deductions, in accordance
with the Company&#8217;s normal payroll practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Termination of Employment</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Accrued Rights</U>. The Parties acknowledge that Executive&#8217;s
employment relationship with the Company shall be <FONT STYLE="white-space:nowrap">at-will.</FONT> Either the Company or the Executive may terminate Executive&#8217;s employment with or without Cause or Good Reason or advance notice. Upon a
termination of the Executive&#8217;s employment for any reason, the Executive (or the Executive&#8217;s estate) shall be entitled to receive (i)&nbsp;that portion of the Executive&#8217;s Annual Base Salary, then in effect, earned and unpaid as of
the termination date; (ii)&nbsp;any expenses owed and properly reimbursable to the Executive pursuant to the Company&#8217;s expense reimbursement policies; (iii)&nbsp;conversion rights, if applicable, with respect to any life insurance or
disability insurance policy provided to the Executive; and (iv)&nbsp;any vested amounts owed to the Executive under the Company&#8217;s employee benefit plans or programs and any vested options in accordance with the terms and conditions of such
employee benefit plans or programs and the Plan (collectively, the &#8220;<B>Accrued Rights</B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination by the Company for Cause or Executive</U><U>&#8217;</U><U>s Resignation
Without Good Reason</U>. Upon termination of the Executive&#8217;s employment relationship by the Company for Cause, or by the Executive&#8217;s resignation without Good Reason, the Company shall, thereafter, have no obligation to the Executive for
any unearned Annual Base Salary, Target Bonus, or any other form of compensation or benefit, except as otherwise required by law. Reimbursement of appropriately documented expenses incurred by the Executive before the termination of employment, to
the extent that the Executive would have been entitled to such reimbursement but for the termination of employment, shall be paid by the Company to the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination by the Company Without Cause or Executive</U><U>&#8217;</U><U>s Resignation for Good Reason Outside of Change in Control
Period</U>. In the event that the Company terminates the Executive&#8217;s employment without Cause or Executive resigns for Good Reason outside of the Change in Control Period (defined below), and provided that the Severance Preconditions (defined
below) are met, (A)&nbsp;the Executive shall receive eighteen (18)&nbsp;months&#8217; severance pay at the Executive&#8217;s Annual Base Salary then in effect, paid as salary continuation over the eighteen (18)&nbsp;month period immediately
following the Executive&#8217;s employment termination date pursuant to the Company&#8217;s customary payroll practices, commencing on the first payroll date following the date on which the Release becomes effective and irrevocable, provided that if
the Release Execution Period (defined below) spans two calendar years, payments shall begin no earlier than the first payroll date of the later calendar year, and provided further that, the first installment payment shall include all amounts
attributable to the period from the Executive&#8217;s employment termination date through the first payment date; (B)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion (based on the number of full days the Executive was employed in the
applicable fiscal year) of the Target Bonus, if any, Executive would have earned for the fiscal year in which Executive&#8217;s employment termination date occurs, based on actual Company performance of the full fiscal year and payable at the same
time annual bonuses are generally paid to executives for such fiscal year (but in any event no later than March&nbsp;15 of the calendar year that immediately follows the calendar year in which the Executive&#8217;s employment termination date
occurs), (C) an additional six (6)&nbsp;monthly installments of the First Option shall automatically vest, and (D)&nbsp;if the Executive is eligible for and timely and properly elects group health plan continuation coverage under the Consolidated
Omnibus Budget Reconciliation Act of 1985 (&#8220;<B>COBRA</B>&#8221;), the Company shall reimburse the Executive for monthly COBRA premiums payable to continue coverage for the Executive and the Executive&#8217;s eligible dependents until the
earliest of (x)&nbsp;eighteen (18) months following the termination date; (y)&nbsp;the expiration of the Executive&#8217;s eligibility for the continuation coverage under COBRA; or (z)&nbsp;the date when the Executive becomes eligible for
substantially equivalent health insurance coverage in connection with new employment. Such reimbursement shall be paid to the Executive no later than the end of the month immediately following the month in which the Executive timely remits each
COBRA premium payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company Without Cause or Executive&#8217;s Resignation for Good Reason in Connection
with Change in Control</U>. If at any time during the Change in Control Period, the Company terminates the Executive&#8217;s employment without Cause or the Executive resigns for Good Reason, provided the Severance Preconditions are met, the Company
will provide Executive with the following severance benefits (in lieu of, and not in addition to, the severance benefits provided in Section&nbsp;3(c)): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a lump sum severance payment, payable within sixty (60)&nbsp;days after the later of
the Change in Control and Executive&#8217;s employment termination date (provided that if the Release Execution Period spans two calendar years, payment shall not made until the beginning of the later calendar year), in an amount equal to the sum
of: (A)&nbsp;one (1) year of Executive&#8217;s Annual Base Salary then in effect; and (B) 1.5 times the Target Bonus opportunity for the year in which Executive&#8217;s employment termination date occurs; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) if the Executive is eligible for and timely and properly elects group health plan continuation coverage under COBRA, the Company shall
reimburse the Executive for monthly COBRA premiums payable to continue coverage for the Executive and the Executive&#8217;s eligible dependents until the earliest of (x)&nbsp;twelve (12) months following the termination date; (y)&nbsp;the expiration
of the Executive&#8217;s eligibility for the continuation coverage under COBRA; or (z)&nbsp;the date when the Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment. Such reimbursement
shall be paid to the Executive no later than the end of the month immediately following the month in which the Executive timely remits each COBRA premium payment; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the vesting of any outstanding unvested equity that the Executive holds shall be accelerated in full as of the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination in the Event of Executive&#8217;s Disability or Death</U>. The Executive&#8217;s employment hereunder (i)&nbsp;shall
terminate automatically upon the Executive&#8217;s death and (ii)&nbsp;may be terminated by the Company for the Executive&#8217;s Disability. Upon termination of the Executive&#8217;s employment hereunder by reason of the Executive&#8217;s
Disability or death, the Executive or the Executive&#8217;s estate (as the case may be) shall be entitled to receive: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Accrued
Rights; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to the Executive&#8217;s or, in the event of the Executive&#8217;s death, the representative of the
Executive&#8217;s estate, execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release and such Release becoming effective and irrevocable within the Release Execution Period: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion (based on the number of full days the Executive was employed in the applicable
fiscal year) of the Target Bonus, if any, Executive would have earned for the fiscal year in which Executive&#8217;s employment termination date occurs, based on actual Company performance of the full fiscal year and payable at the same time annual
bonuses are generally paid to executives for such fiscal year (but in any event no later than March&nbsp;15 of the calendar year that immediately follows the calendar year in which the Executive&#8217;s employment termination date occurs); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) twenty-five percent (25%) of the shares subject to the First Option shall automatically vest; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) if the Executive is (or in the event of the Executive&#8217;s death, the
Executive&#8217;s surviving spouse and/or dependents are) eligible for and timely and properly elects group health plan continuation coverage under COBRA, the Company shall reimburse the Executive (or in the event of the Executive&#8217;s death, the
Executive&#8217;s surviving spouse and/or dependents) for the monthly COBRA premium paid by the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) for the Executive and the
Executive&#8217;s spouse/dependents. Such reimbursement shall be paid to the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) no later than the end of the month immediately
following the month in which the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) timely remits the COBRA premium payment. The Executive (or in the event of the Executive&#8217;s
death, the Executive&#8217;s surviving spouse and/or dependents) shall be eligible to receive such reimbursement until the earliest of: (i)&nbsp;the last day of the month that is <FONT STYLE="white-space:nowrap">twenty-six</FONT> (26)&nbsp;weeks
after the termination of the Executive&#8217;s employment by reason of the Executive&#8217;s Disability or death; (ii)&nbsp;in the event of Executive&#8217;s Disability, the date Executive becomes eligible to receive healthcare coverage from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) or (iii)&nbsp;the date the Executive is (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents are) no
longer eligible to receive COBRA continuation coverage. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without
limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or
dependents) a taxable monthly payment in an amount equal to the monthly COBRA premium contemplated by the continuation benefit set forth in this Section on the last day of each month remaining in the period that the Executive would have otherwise
been eligible to receive the COBRA reimbursement benefit set forth in this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Following the termination of the
Executive&#8217;s employment by reason of the Executive&#8217;s Disability or death, except as set forth in this Section&nbsp;3, the Executive (or Executive&#8217;s estate) shall have no further rights to any compensation or any other benefits under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Effect of Termination on Post-Termination Obligations</U>. Upon termination of this Agreement for any reason, the
Executive shall continue to be bound by the post-employment obligations and covenants set forth in this Agreement and the CIIAA following Executive&#8217;s termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>No Mitigation</U>. The Executive will not be required to mitigate any of the Company&#8217;s payment obligations set forth in this
Section&nbsp;3 by making any efforts to secure other employment, and Executive&#8217;s commencement of employment with another employer will not reduce the obligations of the Company under this Section&nbsp;3, unless specifically provided for
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Resignation of Offices</U>. Promptly following any termination of the Executive&#8217;s employment with the Company for
any reason (other than by reason of the Executive&#8217;s death), the Executive shall deliver to the Company reasonably satisfactory written evidence of the Executive&#8217;s resignation from all positions that the Executive may then hold as an
employee or officer of the Company or any subsidiary of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Definitions</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. For purposes of this Agreement the term &#8220;<B>Cause</B>&#8221; shall mean any one or more of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. The Executive&#8217;s persistent unsatisfactory performance or material failure to perform the Executive&#8217;s duties or any lawful
directive of the Board or CEO after being given written notice of such deficiencies in the Executive&#8217;s performance and failure to cure them within thirty (30)&nbsp;calendar days of such written notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. The Executive&#8217;s indictment for, conviction of, plea of guilty to, or plea of nolo contendere to a felony involving the property or
operations of the Company or a crime of moral turpitude; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. The Executive&#8217;s indictment for, conviction of, plea of guilty to, or
plea of nolo contendere to embezzlement, misappropriation or fraud, whether or not related to the Executive&#8217;s employment with Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. The existence of any court order or settlement agreement prohibiting the Executive&#8217;s continued employment with the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">v. The Executive&#8217;s material breach of any material obligation in this Agreement, or any other written agreement between the Executive
and Company, or any material misconduct by the Executive that adversely affects the business of the Company or its reputation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">vi.
The Executive&#8217;s material failure to comply with the Company&#8217;s reasonable and lawful policies or rules of which the Executive is given written notice, as they may be in effect from time to time during the Executive&#8217;s employment, and
failure to cure them within thirty (30)&nbsp;calendar days of such written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. For purposes of this
Agreement, &#8220;<B>Change in Control</B>&#8221; has the meaning ascribed to such term in the Plan. Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a &#8220;change in control
event&#8221; within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)(i).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Change in Control Period.</U> For the purposes of this Agreement, &#8220;<B>Change in Control Period</B>&#8221; shall mean the period of three (3)&nbsp;months prior to or twelve (12)&nbsp;months following a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Disability</U>.<B> </B>For the purposes of this Agreement, &#8220;<B>Disability</B>&#8221; shall mean that in the good faith judgment
of the Board, despite reasonable accommodation, the Executive is unable due to a physical or mental incapacity to perform the essential functions of Executive&#8217;s most recent position for: (x)&nbsp;a period of one hundred eighty
(180)&nbsp;consecutive days or (y)&nbsp;an aggregate of six (6)&nbsp;months in any twelve (12)&nbsp;consecutive month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Good
Reason</U><B>.</B> For purposes of this Agreement, the term &#8220;<B>Good Reason</B>&#8221; shall mean any one or more of the following, in each case during the Employment Period without the Executive&#8217;s written consent: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. a material reduction of the Executive&#8217;s position, authority or responsibilities,
or the removal of the Executive from such position, authority or responsibilities, unless the Executive is provided with a new position of equal or greater organizational level, authority, responsibilities and compensation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. a material reduction in the Annual Base Salary other than a general reduction in Annual Base Salary that affects all similarly situated
executives in substantially the same proportions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. a material breach by the Company of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. a material change in the geographic location at which the Executive is required to perform services for the Company (except for office
relocations that would not increase the Executive&#8217;s one way commute by more than twenty-five (25)&nbsp;miles). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that Good Reason
shall not exist unless: (x)&nbsp;the Executive has given the Company written notice of the conduct of the Company that is alleged to constitute Good Reason within thirty (30)&nbsp;days following the occurrence of such event; (y)&nbsp;the Executive
has provided the Company at least thirty (30)&nbsp;days following the date on which such notice is provided to cure such conduct and the Company has failed to do so; and (z)&nbsp;the Executive resigns and voluntarily terminates the Executive&#8217;s
employment within thirty (30)&nbsp;days following the expiration of the Company&#8217;s opportunity to cure such conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<U>Severance Preconditions</U>. For the purposes of this Agreement, the &#8220;<B>Severance Preconditions</B>&#8221; shall mean that (i)<B></B>&nbsp;the Executive has executed and not revoked within the applicable revocation period a separation
agreement and general release in a form and substance reasonably satisfactory to the Company (the &#8220;<B>Release</B>&#8221;) and such Release becomes effective and irrevocable within sixty (60)&nbsp;days following the Executive&#8217;s employment
termination date (such <FONT STYLE="white-space:nowrap">60-day</FONT> period, the &#8220;<B>Release Execution Period</B>&#8221;); (ii) the Executive remains in compliance with the CIIAA; and (iii)&nbsp;the Executive has provided to the Company the
written resignations set forth in Section&nbsp;3(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Confidential Information and Intellectual Property
Rights</U></B><B>.</B><B> </B>As a condition of employment, the Executive agrees to execute and abide by the Confidentiality and Proprietary Rights Agreement attached as <B>Exhibit A</B> (&#8220;<B>CIIAA</B>&#8221;). The CIIAA contains provisions
that are intended by the Parties to survive and do survive any termination of this Agreement and the CIIAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U><FONT
STYLE="white-space:nowrap">Non-Disparagement</FONT></U></B>. The Executive shall not, during or after employment, make, directly or indirectly, any public or private statements, gestures, signs, signals or other verbal or nonverbal communications
that belittle, disparage or otherwise express disapproval of the Company or any of its affiliates or their respective businesses, or any of their past or present officers, directors, employees, advisors, agents, policies, procedures, practices,
decision-making, conduct, professionalism or compliance with standards, except as and to the extent required to comply with applicable federal or state law. This Agreement does not prohibit Executive from reporting possible legal violations to the
government or from making other disclosures to the government that are protected under federal or state whistleblower provisions. This Agreement does not prohibit Executive from making truthful statements or disclosures about alleged unlawful acts
in the workplace, including sexual harassment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Section 409A</U></B>. It is intended that any payment or benefit that is provided
pursuant to or in connection with this Agreement that is considered to be deferred compensation subject to Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (&#8220;<B>Code</B>&#8221;), shall be paid and provided in a manner, and at
such time and form, as complies with the applicable requirements of Section&nbsp;409A of the Code to avoid the unfavorable tax consequences provided therein for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> It is further intended that the
payments hereunder shall, to the maximum extent permissible under Section&nbsp;409A of the Code, be exempt from Section&nbsp;409A of the Code under either (i)&nbsp;the exception for involuntary separation pay to the extent that all payments are
payable within the limitations described in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9),</FONT> or (ii)&nbsp;the short-term deferral exception described in Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> to the extent that all payments are payable no later than two and a half months after the end of the first taxable year in which the right to the payment is no longer subject to a
substantial risk of forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive is a &#8220;specified employee&#8221; for purposes of Section&nbsp;409A(a)(2)(B)(i)
of the Code at such time, any payments to be made or benefits to be delivered in connection with the Executive&#8217;s &#8220;separation from service&#8221; (as defined below) that constitute deferred compensation subject to Section&nbsp;409A of the
Code shall not be made until the earlier of (i)&nbsp;the Executive&#8217;s death or (ii)&nbsp;six months plus one day after the Executive&#8217;s separation from service (&#8220;<B>409A Deferral Period</B>&#8221;) as required by Section&nbsp;409A of
the Code. Payments of any such deferred compensation otherwise due to be made in installments or periodically during the 409A Deferral Period shall be accumulated and paid in a lump sum as soon as the 409A Deferral Period ends, and the balance of
the payment shall be made as otherwise scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this Agreement, all rights to payments and benefits hereunder shall
be treated as rights to receive a series of separate payments and benefits to the fullest extent allowed by Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of this Agreement, with respect to the timing of any amounts that constitute deferred compensation subject to
Section&nbsp;409A of the Code that depends on termination of employment or separation from service, termination of employment or separation from service shall mean a &#8220;separation from service&#8221; within the meaning of Section&nbsp;409A of
the Code where it is reasonably anticipated that no further services would be performed after such date or that the level of bona fide services the Executive would perform after that date (whether as an employee or independent contractor) would
permanently decrease to a level less than or equal to twenty percent (20%) of the average level of bona fide services<B> </B>the Executive performed over the immediately preceding <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>S</U></B><B><U>ection 280G</U></B><B>. </B>If any payment or benefit Executive will or may receive from the Company or
otherwise (a &#8220;<B>Payment</B>&#8221;) would (i)&nbsp;constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by
Section&nbsp;4999 of the Code (the &#8220;<B>Excise Tax</B>&#8221;), then any such Payment shall be equal to the Reduced Amount. The &#8220;<B>Reduced Amount</B>&#8221; shall be either (x)&nbsp;the largest portion of the Payment that would result in
no portion of the Payment (after reduction) being subject to the Excise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x)&nbsp;or by clause (y)), after taking into account
all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#8217;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis,
of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to
clause (x)&nbsp;of the preceding sentence, the reduction shall occur in the manner (the &#8220;<B>Reduction Method</B>&#8221;) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same
economic benefit, the items so reduced will be reduced pro rata (the &#8220;<B>Pro Rata Reduction Method</B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any
provisions in this Section above to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes
pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the
modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on
future events (<I>e.g.</I>, being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority, Payments that are &#8220;deferred compensation&#8221; within
the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section. The Company
shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause (x)&nbsp;above and the Internal
Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x)&nbsp;above) so that no
portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;above, Executive shall have no obligation to return any portion of the Payment pursuant to
the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Indemnification</U></B>. The Company will enter into an indemnification agreement with Executive. At all
times during the Executive&#8217;s service as an officer and/or director and for at least six years thereafter, the Company shall provide that Executive is covered by the Company&#8217;s D&amp;O insurance on the same basis as other active officers
and directors (without regard to whether the Executive&#8217;s service has previously terminated). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Representations of the
Executive</U></B>. The Executive represents and warrants that: (i)&nbsp;the Executive has no legal obligations to any other party that would be breached by signing this Agreement or otherwise fulfilling Executive&#8217;s obligations hereunder,
including but not limited to any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-inducement,</FONT> confidentiality, assignment of inventions, or
other similar agreement; (ii)&nbsp;the Executive has not disclosed any third party&#8217;s confidential or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary information to the Company or its representatives or agents; (iii)&nbsp;if the Executive learns of any confidential or proprietary information that belongs to any third party, the
Executive will not disclose such information to the Company or its representatives or agents, except as allowed by law or any agreement Executive has signed with such party; and (iv)&nbsp;the Executive is not in breach of any confidentiality or <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreement that the Executive has signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B><U>Miscellaneous</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Entire Agreement</U>. This Agreement contains the entire agreement and understanding of the Executive and the Company concerning the
subject matter hereof and supersedes and replaces all prior negotiations and proposed agreements, whether oral or written, including, without limitation, the Employment Agreement. The Executive acknowledges that, by signing this Agreement, the
Executive has not relied upon any representations, promises or agreements made by the Company or its employees, officers, directors, or representatives (including any Company attorneys) that are not contained in this Agreement. This Agreement may
not be modified or amended except by an instrument in writing signed by the Parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Headings/Counterparts</U>. The
headings of the paragraphs herein are included for reference only and are not intended to affect the interpretation of the Agreement. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of
which shall constitute one and the same Agreement. Each Party agrees that faxed or electronically transmitted copies of the signature pages of this Agreement and/or any of the other instruments, agreements and documents relating to any of the
transactions contemplated hereby, whether sent to the other Party or to such other Party&#8217;s counsel, shall be deemed definitively executed and delivered, and with the same force and effect as if manually signed and delivered, for all purposes
whatsoever. Neither Party hereto shall raise the use of DocuSign, electronic mail or a facsimile machine to deliver a signature or the fact that any signature was transmitted or communicated through the use of electronic mail or a facsimile machine
as a defense to the formation of a contract and each Party forever waives any such defense. All counterparts shall be construed together and shall constitute one instrument, and the signature page from any counterpart may be attached to another
counterpart to form a complete copy of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Severability</U>. If any provision of this Agreement or the application
thereof is held invalid, such invalidation shall not affect other provisions or applications of this Agreement and to this end the provisions of this Agreement are declared to be severable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Construction/Joint Drafting</U>. The determination of the terms and conditions of this Agreement has been by mutual agreement of the
Parties. Each Party participated jointly in the drafting of this Agreement, and therefore the terms and conditions of this Agreement are not intended to be, and shall not be, construed against any Party by virtue of draftsmanship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></U> Neither the failure nor any delay on the part of either Party to exercise any
right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any other right,
remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver of any
provision of this Agreement will be binding unless made in a writing signed by the Parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment</U>. This Agreement shall be binding upon the Company and shall inure to
the benefit of the Company including any transferee of the business operation, as a going concern, in which the Executive is employed and shall be binding upon the Executive and the Executive&#8217;s heirs and personal representatives. None of the
rights or obligations of the Executive hereunder may be assigned or delegated. The Company may assign its rights and obligations under this Agreement in whole or in part to anyone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Choice of Law</U>. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the
internal laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Resolution of Disputes</U>. To aid the rapid and economical resolution of disputes that
may arise in connection with Executive&#8217;s employment with the Company, and in exchange for the mutual promises contained in this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or
equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Executive&#8217;s employment with the Company, or the termination of Executive&#8217;s
employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) or its successor, under JAMS&#8217; then applicable rules and procedures
appropriate to the relief being sought (available upon request and also currently available at the following web address: (i)&nbsp;https://www.jamsadr.com/rules-employment-arbitration/ and
<FONT STYLE="white-space:nowrap">(ii)&nbsp;https://www.jamsadr.com/rules-comprehensive-arbitration/)</FONT> at a location closest to where Executive last worked for the Company or another mutually agreeable location. <B>Executive acknowledges that
by agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge</B>. The Federal Arbitration Act, 9 U.S.C. &#167; 1 et seq., will, to the fullest extent permitted
by law, govern. the interpretation and enforcement of this arbitration agreement and any arbitration proceedings. This provision shall not be mandatory for any claim or cause of action to the extent applicable law prohibits subjecting such claim or
cause of action to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;<B>Excluded Claims</B>&#8221;), such as
<FONT STYLE="white-space:nowrap">non-individual</FONT> claims that cannot be waived under applicable law, claims or causes of action alleging sexual harassment or a nonconsensual sexual act or sexual contact, or unemployment or workers&#8217;
compensation claims brought before the applicable state governmental agency. In the event Executive or the Company intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court,
while any other claims will remain subject to mandatory arbitration. Nothing herein prevents Executive from filing and pursuing proceedings before a federal or state governmental agency, although if Executive chooses to pursue a claim following the
exhaustion of any applicable administrative remedies, that claim would be subject to this provision. In addition, with the exception of Excluded Claims arising out of 9 U.S.C. &#167; 401 et seq., all claims, disputes, or causes of action under this
section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, representative, or collective proceeding, nor joined or
consolidated with the claims </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any other person or entity. <B>Executive acknowledges that by agreeing to this arbitration procedure, both Executive and the Company waive all rights to have any dispute be brought, heard,
administered, resolved, or arbitrated on a class, representative, or collective action basis</B>. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. If a court finds, by means of a final decision, not subject to any further appeal or recourse, that the preceding sentences regarding class, representative, or collective claims or proceedings violate applicable law or are otherwise
found unenforceable as to a particular claim or request for relief, the Parties agree that any such claim(s) or request(s) for relief be severed from the arbitration and may proceed in a court of law rather than by arbitration. All other claims or
requests for relief shall be arbitrated. Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration and procedural questions which grow out of the dispute
and bear on the final disposition are matters for the arbitrator to decide, provided however, that if required by applicable law, a court and not the arbitrator may determine the enforceability of this paragraph with respect to Excluded Claims. The
arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written statement signed by the arbitrator regarding
the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all
relief that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all arbitration administrative fees in excess of the administrative fees that Executive would be required to pay if the dispute were decided in a
court of law. Each Party is responsible for its own attorneys&#8217; fees, except as may be expressly set forth in the CIIAA or as otherwise provided under applicable law. Nothing in this Agreement is intended to prevent either Executive or the
Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any
competent jurisdiction. The Executive and the Company acknowledge the Executive&#8217;s right to (1)&nbsp;report any good faith allegation of unlawful employment practices to any appropriate federal, state, or local government agency that enforces
anti-discrimination laws; (2)&nbsp;report any good faith allegation of criminal conduct to any appropriate federal, state, or local official; (3)&nbsp;participate in a proceeding with any appropriate federal, state, or local government agency that
enforces anti-discrimination laws; (4)&nbsp;make any truthful statements or disclosures required by law, regulation, or legal process; and (5)&nbsp;request or receive confidential legal advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Notices</U><U>.</U> For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in
writing and shall be deemed to have been duly given (i)&nbsp;on the date of delivery, if delivered by hand, (ii)&nbsp;on the date of transmission, if delivered by electronic mail, (iii)&nbsp;on the first business day following the date of deposit,
if delivered by guaranteed overnight delivery service, or (iv)&nbsp;on the fourth business day following the date delivered or mailed by the U.S. Postal Service, addressed as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Executive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">At the address shown in the books and records of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Company, currently: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">*** </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">LB
Pharmaceuticals Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One Penn Plaza, Suite 1025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10119 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:
Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: *** </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with copy, which shall not constitute notice, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Divakar Gupta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New
York 10001-2163 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices shall be deemed to be properly addressed, to the Company or to the Executive, if addressed to such person at such person&#8217;s
address as set forth above, or to such other address or addresses as the addressee previously may have specified by Notice given to the other parties in the manner contemplated by this Section&nbsp;11(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Survival</U>. Upon the termination of this Agreement, the respective rights and obligations of the Parties hereto shall survive such
expiration or other termination to the extent necessary to carry out the intentions of the Parties under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.
<B><U>Acknowledgement of Full Understanding</U></B><B>. </B>THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT EXECUTIVE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT EXECUTIVE HAS BEEN
REPRESENTED BY EXECUTIVE&#8217;S OWN COUNSEL OR HAS HAD AN OPPORTUNITY TO BE REPRESENTED BY AN ATTORNEY OF EXECUTIVE&#8217;S CHOICE BEFORE SIGNING THIS AGREEMENT. The Executive hereby consents to the terms set forth in this Agreement and
acknowledges and agrees that the terms set forth herein do not constitute &#8220;Good Reason,&#8221; &#8220;Cause&#8221; and/or any term with any similar meaning or import under the Employment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Remainder of page left blank intentionally; Signatures on the following page) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have duly executed and delivered this Agreement as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LB PHARMACEUTICALS INC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anna Eramo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anna Eramo</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AND PROPRIETARY RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(See attached) </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>10
<FILENAME>d12080dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXECUTIVE EMPLOYMENT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</B> (this &#8220;<B>Agreement</B>&#8221;), is made as of September&nbsp;3, 2025
(the &#8220;<B>Effective Date</B>&#8221;), by and between LB Pharmaceuticals Inc, a Delaware Corporation, (the &#8220;<B>Company</B>&#8221;) and Marc Panoff, an individual residing at *** (the &#8220;<B>Executive</B>&#8221;). The Company and
Executive are each a &#8220;<B>Party</B>,&#8221; and together, the &#8220;<B>Parties</B>.&#8221; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Executive are parties to that certain Executive Employment Agreement, made as of August&nbsp;25, 2023, as amended
by that certain Amendment No.&nbsp;1 to Executive Employment Agreement, made as of June&nbsp;28, 2024 (together, the &#8220;<B>Employment Agreement</B>&#8221;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Executive now desire to enter into this Agreement, which supersedes and replaces the Employment Agreement in its
entirety and sets forth the terms and conditions of the Executive&#8217;s continuing employment with the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants, promises, and obligations contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties intending to be legally bound, acknowledge and agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Position and Duties</U></B><B>.</B><B> </B>Subject to the terms set forth herein, the Company agrees to employ the Executive as SVP of
Finance of the Company, and the Executive hereby accepts such employment, starting on the Effective Date (the &#8220;<B>Start Date</B>&#8221;). The Executive shall report to the Chief Executive Officer of the Company. The Executive shall have such
duties, authority, and responsibilities commensurate with such position and such other duties and responsibilities that are specifically delegated to Executive from time to time. The Executive will diligently and conscientiously perform
Executive&#8217;s duties and will devote substantially all of the Executive&#8217;s business hours to such duties, and during such time will make the best use of the Executive&#8217;s energy, knowledge, and training to advancing the Company&#8217;s
interests. The Executive will accept no other employment or contracting work while employed by the Company, or serve as a member of the board of directors of any <FONT STYLE="white-space:nowrap">for-profit</FONT> entity or as a member of any
advisory board without the express written consent of the board of directors of the Company (the &#8220;<B>Board</B>&#8221;). Upon termination of the Executive&#8217;s employment relationship with the Company for any reason, the Executive shall
resign and relinquish any position held as an officer and/or board member of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Compensation and
Benefits</U></B><B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. Subject to the terms set forth herein, in consideration for all services rendered by the
Executive to the Company, the Company shall pay the Executive an annual base salary of three hundred sixty thousand dollars ($360,000) (&#8220;<B>Annual Base Salary</B>&#8221;) in periodic installments in accordance with the Company&#8217;s regular
payroll practices in effect from </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time to time for executive employees, but no less frequently than semi-monthly. The Executive shall be classified as exempt from overtime and the Executive understands and acknowledges that the
Executive is not entitled to overtime compensation and that the Annual Base Salary is intended to compensate the Executive for all hours worked. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Target Bonus</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
The Executive will be eligible to earn a target bonus of up to thirty five percent (35%) of Executive&#8217;s Annual Base Salary, in all cases subject to the discretion of the Compensation Committee of the Board of the Company determining that the
applicable objectives have been achieved (the &#8220;<B>Target Bonus</B>&#8221;). Objectives will be determined annually by the Compensation Committee in consultation with the Executive and will include both Company performance and the
Executive&#8217;s personal performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Executive&#8217;s employment terminates for any reason prior to the payment date of
any Target Bonus awarded, the Executive will not have earned, and will not be paid, the awarded Target Bonus (or any portion thereof), provided that if the Company awards a Target Bonus and thereafter terminates the Executive&#8217;s employment with
the Company for a reason other than for Cause but before any such Target Bonus has been paid, the Executive will still receive the Executive&#8217;s Target Bonus payment, even if the Executive is no longer working at the Company at the time the
Target Bonus is to be paid. Any Target Bonus awarded will be paid no later than forty-five (45)&nbsp;days after it has been awarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Equity</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Executive was previously granted an option to purchase up to 400,000 shares of Common Stock of the Company under the
Company&#8217;s 2023 Stock Incentive Plan (the &#8220;<B>Plan</B>&#8221;), as amended (the &#8220;<B>First Option</B>&#8221;). Executive was also previously granted a second option to purchase 200,000 shares of Common Stock of the Company under the
Plan, as amended (the &#8220;<B>Second Option</B>&#8221;). Except as expressly provided herein, nothing in the Agreement changes, alters, forfeits, or otherwise modifies the terms of the First Option or the Second Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Contingent and effective upon the effectiveness of the underwriting agreement related to the initial public offering (the
&#8220;<B>IPO</B>&#8221;) of the Company&#8217;s Common Stock (the date of such effectiveness, the &#8220;<B>IPO Date</B>&#8221;), the Executive will receive an option (the &#8220;<B>IPO Option</B>&#8221;) under the Company&#8217;s 2025 Equity
Incentive Plan (the &#8220;<B>2025 Plan</B>&#8221;) to purchase a number of shares of Common Stock such that his beneficial ownership of the Common Stock as of the closing of the IPO, inclusive of the IPO Option, would equal 0.50% of the fully
diluted total number of shares of Common Stock outstanding as of the closing of the IPO, rounded down to the nearest whole share, subject to both (A)&nbsp;approval by the Board or the Compensation Committee of the Board and (B)&nbsp;the Executive
remaining employed by the Company through the grant date of the IPO Option. The IPO Option will have an exercise price equal to the fair market value of a share of Common Stock on the grant date. The IPO Option will vest over a four-year period,
whereby twenty-five percent (25%) of the shares initially subject to the IPO Option shall vest on the first anniversary of the IPO Date, and the balance of the shares subject to the IPO Option shall vest in
<FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;substantially equal monthly installments over the <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning on the last day of the month following the first anniversary of the IPO Date and the last day of each month thereafter, in each case subject to the Executive&#8217;s Continuous Service
(as defined in the 2025 Plan) through each applicable vesting date. The IPO Option shall be subject to the terms of the 2025 Plan and a stock option agreement thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Employee Benefits</U>. During Executive&#8217;s term of employment by the Company under this Agreement (the &#8220;<B>Employment
Period</B>&#8221;), Executive shall be entitled to participate in all employee benefit plans, practices, and programs maintained by the Company, as in effect from time to time (collectively, the &#8220;<B>Employee Benefit Plans</B>&#8221;), on a
basis which is no less favorable than is provided to other similarly situated senior executives of the Company, to the extent consistent with applicable law and the terms of the applicable Employee Benefit Plans. The Company reserves the right to
amend or cancel any Employee Benefit Plans at any time in its sole discretion, subject to the terms of such Employee Benefit Plans and applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. During the Employment Period, the Executive shall be entitled to twenty (20)&nbsp;days paid vacation per calendar
year. This vacation is in addition to Company recognized holidays and paid sick time, if any, in accordance with the Company&#8217;s practices and policies as in effect from time to time. The Company reserves the right to amend or cancel its
practices and policies at any time in its sole discretion, in accordance with applicable law. Any unused vacation may not be carried over by the Executive to any subsequent year and shall be forfeited at the end of the calendar year. The Company
will pay Executive for any accrued but unused vacation upon termination of the Executive&#8217;s employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Expense
Reimbursement</U>. The Company shall reimburse the Executive for all reasonable travel and other business expenses incurred by the Executive in the performance of the Executive&#8217;s duties to the Company in accordance with the Company&#8217;s
applicable expense reimbursement policies and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Withholdings</U>. All payments made subject to this Agreement will be
subject to payroll withholdings that the Company reasonably believes are required by law or elected or authorized by the Executive for state and federal income taxes, Social Security, Medicare, and other applicable payroll deductions, in accordance
with the Company&#8217;s normal payroll practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Termination of Employment</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Accrued Rights</U>. The Parties acknowledge that Executive&#8217;s
employment relationship with the Company shall be <FONT STYLE="white-space:nowrap">at-will.</FONT> Either the Company or the Executive may terminate Executive&#8217;s employment with or without Cause or Good Reason or advance notice. Upon a
termination of the Executive&#8217;s employment for any reason, the Executive (or the Executive&#8217;s estate) shall be entitled to receive (i)&nbsp;that portion of the Executive&#8217;s Annual Base Salary, then in effect, earned and unpaid as of
the termination date; (ii)&nbsp;any expenses owed and properly reimbursable to the Executive pursuant to the Company&#8217;s expense reimbursement policies; (iii)&nbsp;conversion rights, if applicable, with respect to any life insurance or
disability insurance policy provided to the Executive; and (iv)&nbsp;any vested amounts owed to the Executive under the Company&#8217;s employee benefit plans or programs and any vested options in accordance with the terms and conditions of such
employee benefit plans or programs and the Plan (collectively, the &#8220;<B>Accrued Rights</B>&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination by the Company for Cause or Executive</U><U>&#8217;</U><U>s Resignation
Without Good Reason</U>. Upon termination of the Executive&#8217;s employment relationship by the Company for Cause, or by the Executive&#8217;s resignation without Good Reason, the Company shall, thereafter, have no obligation to the Executive for
any unearned Annual Base Salary, Target Bonus, or any other form of compensation or benefit, except as otherwise required by law. Reimbursement of appropriately documented expenses incurred by the Executive before the termination of employment, to
the extent that the Executive would have been entitled to such reimbursement but for the termination of employment, shall be paid by the Company to the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination by the Company Without Cause or Executive</U><U>&#8217;</U><U>s Resignation for Good Reason Outside of Change in Control
Period</U>. In the event that the Company terminates the Executive&#8217;s employment without Cause or Executive resigns for Good Reason outside of the Change in Control Period (defined below), and provided that the Severance Preconditions (defined
below) are met, (A)&nbsp;the Executive shall receive eighteen (18)&nbsp;months&#8217; severance pay at the Executive&#8217;s Annual Base Salary then in effect, paid as salary continuation over the eighteen (18)&nbsp;month period immediately
following the Executive&#8217;s employment termination date pursuant to the Company&#8217;s customary payroll practices, commencing on the first payroll date following the date on which the Release becomes effective and irrevocable, provided that if
the Release Execution Period (defined below) spans two calendar years, payments shall begin no earlier than the first payroll date of the later calendar year, and provided further that, the first installment payment shall include all amounts
attributable to the period from the Executive&#8217;s employment termination date through the first payment date; (B)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion (based on the number of full days the Executive was employed in the
applicable fiscal year) of the Target Bonus, if any, Executive would have earned for the fiscal year in which Executive&#8217;s employment termination date occurs, based on actual Company performance of the full fiscal year and payable at the same
time annual bonuses are generally paid to executives for such fiscal year (but in any event no later than March&nbsp;15 of the calendar year that immediately follows the calendar year in which the Executive&#8217;s employment termination date
occurs), (C) an additional six (6)&nbsp;monthly installments of the First Option shall automatically vest, and (D)&nbsp;if the Executive is eligible for and timely and properly elects group health plan continuation coverage under the Consolidated
Omnibus Budget Reconciliation Act of 1985 (&#8220;<B>COBRA</B>&#8221;), the Company shall reimburse the Executive for monthly COBRA premiums payable to continue coverage for the Executive and the Executive&#8217;s eligible dependents until the
earliest of (x)&nbsp;eighteen (18) months following the termination date; (y)&nbsp;the expiration of the Executive&#8217;s eligibility for the continuation coverage under COBRA; or (z)&nbsp;the date when the Executive becomes eligible for
substantially equivalent health insurance coverage in connection with new employment. Such reimbursement shall be paid to the Executive no later than the end of the month immediately following the month in which the Executive timely remits each
COBRA premium payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination by the Company Without Cause or Executive&#8217;s Resignation for Good Reason in Connection
with Change in Control</U>. If at any time during the Change in Control Period, the Company terminates the Executive&#8217;s employment without Cause or the Executive resigns for Good Reason, provided the Severance Preconditions are met, the Company
will provide Executive with the following severance benefits (in lieu of, and not in addition to, the severance benefits provided in Section&nbsp;3(c)): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a lump sum severance payment, payable within sixty (60)&nbsp;days after the later of
the Change in Control and Executive&#8217;s employment termination date (provided that if the Release Execution Period spans two calendar years, payment shall not made until the beginning of the later calendar year), in an amount equal to the sum
of: (A)&nbsp;one (1) year of Executive&#8217;s Annual Base Salary then in effect; and (B) 1.5 times the Target Bonus opportunity for the year in which Executive&#8217;s employment termination date occurs; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) if the Executive is eligible for and timely and properly elects group health plan continuation coverage under COBRA, the Company shall
reimburse the Executive for monthly COBRA premiums payable to continue coverage for the Executive and the Executive&#8217;s eligible dependents until the earliest of (x)&nbsp;twelve (12) months following the termination date; (y)&nbsp;the expiration
of the Executive&#8217;s eligibility for the continuation coverage under COBRA; or (z)&nbsp;the date when the Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment. Such reimbursement
shall be paid to the Executive no later than the end of the month immediately following the month in which the Executive timely remits each COBRA premium payment; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the vesting of any outstanding unvested equity that the Executive holds shall be accelerated in full as of the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination in the Event of Executive&#8217;s Disability or Death</U>. The Executive&#8217;s employment hereunder (i)&nbsp;shall
terminate automatically upon the Executive&#8217;s death and (ii)&nbsp;may be terminated by the Company for the Executive&#8217;s Disability. Upon termination of the Executive&#8217;s employment hereunder by reason of the Executive&#8217;s
Disability or death, the Executive or the Executive&#8217;s estate (as the case may be) shall be entitled to receive: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Accrued
Rights; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to the Executive&#8217;s or, in the event of the Executive&#8217;s death, the representative of the
Executive&#8217;s estate, execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of the Release and such Release becoming effective and irrevocable within the Release Execution Period: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion (based on the number of full days the Executive was employed in the applicable
fiscal year) of the Target Bonus, if any, Executive would have earned for the fiscal year in which Executive&#8217;s employment termination date occurs, based on actual Company performance of the full fiscal year and payable at the same time annual
bonuses are generally paid to executives for such fiscal year (but in any event no later than March&nbsp;15 of the calendar year that immediately follows the calendar year in which the Executive&#8217;s employment termination date occurs); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) twenty-five percent (25%) of the shares subject to the First Option shall automatically vest; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) if the Executive is (or in the event of the Executive&#8217;s death, the
Executive&#8217;s surviving spouse and/or dependents are) eligible for and timely and properly elects group health plan continuation coverage under COBRA, the Company shall reimburse the Executive (or in the event of the Executive&#8217;s death, the
Executive&#8217;s surviving spouse and/or dependents) for the monthly COBRA premium paid by the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) for the Executive and the
Executive&#8217;s spouse/dependents. Such reimbursement shall be paid to the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) no later than the end of the month immediately
following the month in which the Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents) timely remits the COBRA premium payment. The Executive (or in the event of the Executive&#8217;s
death, the Executive&#8217;s surviving spouse and/or dependents) shall be eligible to receive such reimbursement until the earliest of: (i)&nbsp;the last day of the month that is <FONT STYLE="white-space:nowrap">twenty-six</FONT> (26)&nbsp;weeks
after the termination of the Executive&#8217;s employment by reason of the Executive&#8217;s Disability or death; (ii)&nbsp;in the event of Executive&#8217;s Disability, the date Executive becomes eligible to receive healthcare coverage from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) or (iii)&nbsp;the date the Executive is (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or dependents are) no
longer eligible to receive COBRA continuation coverage. Notwithstanding the foregoing, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without
limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive (or in the event of the Executive&#8217;s death, the Executive&#8217;s surviving spouse and/or
dependents) a taxable monthly payment in an amount equal to the monthly COBRA premium contemplated by the continuation benefit set forth in this Section on the last day of each month remaining in the period that the Executive would have otherwise
been eligible to receive the COBRA reimbursement benefit set forth in this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Following the termination of the
Executive&#8217;s employment by reason of the Executive&#8217;s Disability or death, except as set forth in this Section&nbsp;3, the Executive (or Executive&#8217;s estate) shall have no further rights to any compensation or any other benefits under
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Effect of Termination on Post-Termination Obligations</U>. Upon termination of this Agreement for any reason, the
Executive shall continue to be bound by the post-employment obligations and covenants set forth in this Agreement and the CIIAA following Executive&#8217;s termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>No Mitigation</U>. The Executive will not be required to mitigate any of the Company&#8217;s payment obligations set forth in this
Section&nbsp;3 by making any efforts to secure other employment, and Executive&#8217;s commencement of employment with another employer will not reduce the obligations of the Company under this Section&nbsp;3, unless specifically provided for
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Resignation of Offices</U>. Promptly following any termination of the Executive&#8217;s employment with the Company for
any reason (other than by reason of the Executive&#8217;s death), the Executive shall deliver to the Company reasonably satisfactory written evidence of the Executive&#8217;s resignation from all positions that the Executive may then hold as an
employee or officer of the Company or any subsidiary of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Definitions</U></B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. For purposes of this Agreement the term &#8220;<B>Cause</B>&#8221; shall mean any one or more of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. The Executive&#8217;s persistent unsatisfactory performance or material failure to perform the Executive&#8217;s duties or any lawful
directive of the Board or Executive&#8217;s supervisors after being given written notice of such deficiencies in the Executive&#8217;s performance and failure to cure them within thirty (30)&nbsp;calendar days of such written notice; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. The Executive&#8217;s indictment for, conviction of, plea of guilty to, or plea of nolo contendere to a felony involving the property or
operations of the Company or a crime of moral turpitude; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. The Executive&#8217;s indictment for, conviction of, plea of guilty to, or
plea of nolo contendere to embezzlement, misappropriation or fraud, whether or not related to the Executive&#8217;s employment with Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. The existence of any court order or settlement agreement prohibiting the Executive&#8217;s continued employment with the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">v. The Executive&#8217;s material breach of any material obligation in this Agreement, or any other written agreement between the Executive
and Company, or any material misconduct by the Executive that adversely affects the business of the Company or its reputation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">vi.
The Executive&#8217;s material failure to comply with the Company&#8217;s reasonable and lawful policies or rules of which the Executive is given written notice, as they may be in effect from time to time during the Executive&#8217;s employment, and
failure to cure them within thirty (30)&nbsp;calendar days of such written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control.</U> For purposes of this
Agreement, &#8220;<B>Change in Control</B>&#8221; has the meaning ascribed to such term in the Plan. Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a &#8220;change in control
event&#8221; within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)(i).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Change in Control Period.</U> For the purposes of this Agreement, &#8220;<B>Change in Control Period</B>&#8221; shall mean the period of three (3)&nbsp;months prior to or twelve (12)&nbsp;months following a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Disability</U>.<B> </B>For the purposes of this Agreement, &#8220;<B>Disability</B>&#8221; shall mean that in the good faith judgment
of the Board, despite reasonable accommodation, the Executive is unable due to a physical or mental incapacity to perform the essential functions of Executive&#8217;s most recent position for: (x)&nbsp;a period of one hundred eighty
(180)&nbsp;consecutive days or (y)&nbsp;an aggregate of six (6)&nbsp;months in any twelve (12)&nbsp;consecutive month period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Good Reason</U>. For purposes of this Agreement, the term &#8220;<B>Good
Reason</B>&#8221; shall mean any one or more of the following, in each case during the Employment Period without the Executive&#8217;s written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">i. a material reduction of the Executive&#8217;s position, authority or responsibilities, or the removal of the Executive from such position,
authority or responsibilities, unless the Executive is provided with a new position of equal or greater organizational level, authority, responsibilities and compensation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">ii. a material reduction in the Annual Base Salary other than a general reduction in Annual Base Salary that affects all similarly situated
executives in substantially the same proportions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iii. a material breach by the Company of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">iv. a material change in the geographic location at which the Executive is required to perform services for the Company (except for office
relocations that would not increase the Executive&#8217;s one way commute by more than twenty-five (25)&nbsp;miles). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that Good Reason
shall not exist unless: (x)&nbsp;the Executive has given the Company written notice of the conduct of the Company that is alleged to constitute Good Reason within thirty (30)&nbsp;days following the occurrence of such event; (y)&nbsp;the Executive
has provided the Company at least thirty (30)&nbsp;days following the date on which such notice is provided to cure such conduct and the Company has failed to do so; and (z)&nbsp;the Executive resigns and voluntarily terminates the Executive&#8217;s
employment within thirty (30)&nbsp;days following the expiration of the Company&#8217;s opportunity to cure such conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<U>Severance Preconditions</U>. For the purposes of this Agreement, the &#8220;<B>Severance Preconditions</B>&#8221; shall mean that (i)<B></B>&nbsp;the Executive has executed and not revoked within the applicable revocation period a separation
agreement and general release in a form and substance reasonably satisfactory to the Company (the &#8220;<B>Release</B>&#8221;) and such Release becomes effective and irrevocable within sixty (60)&nbsp;days following the Executive&#8217;s employment
termination date (such <FONT STYLE="white-space:nowrap">60-day</FONT> period, the &#8220;<B>Release Execution Period</B>&#8221;); (ii) the Executive remains in compliance with the CIIAA; and (iii)&nbsp;the Executive has provided to the Company the
written resignations set forth in Section&nbsp;3(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Confidential Information and Intellectual Property
Rights</U></B><B>.</B><B> </B>In connection with the Executive&#8217;s employment with the Company, the Executive agrees to execute and abide by the Confidentiality and Proprietary Rights Agreement attached as <B>Exhibit A</B>
(&#8220;<B>CIIAA</B>&#8221;). The CIIAA contains provisions that are intended by the Parties to survive and do survive any termination of this Agreement and the CIIAA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U></B>. The Executive
shall not, during or after employment, make, directly or indirectly, any public or private statements, gestures, signs, signals or other verbal or nonverbal communications that belittle, disparage or otherwise express disapproval of the Company or
any of its affiliates or their respective businesses, or any of their past or present officers, directors, employees, advisors, agents, policies, procedures, practices, decision-making, conduct, professionalism or compliance with standards, except
as and to the extent required to comply with applicable federal or state law. This Agreement does not prohibit Executive from reporting possible legal violations to the government or from making other disclosures to the government that are protected
under federal or state whistleblower provisions. This Agreement does not prohibit Executive from making truthful statements or disclosures about alleged unlawful acts in the workplace, including sexual harassment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Section 409A</U></B>. It is intended that any payment or benefit that is provided pursuant to or in connection with this Agreement
that is considered to be deferred compensation subject to Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (&#8220;<B>Code</B>&#8221;), shall be paid and provided in a manner, and at such time and form, as complies with the
applicable requirements of Section&nbsp;409A of the Code to avoid the unfavorable tax consequences provided therein for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> It is further intended that the payments hereunder shall, to the maximum
extent permissible under Section&nbsp;409A of the Code, be exempt from Section&nbsp;409A of the Code under either (i)&nbsp;the exception for involuntary separation pay to the extent that all payments are payable within the limitations described in
Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(9),</FONT> or (ii)&nbsp;the short-term deferral exception described in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(4)</FONT> to the
extent that all payments are payable no later than two and a half months after the end of the first taxable year in which the right to the payment is no longer subject to a substantial risk of forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Executive is a &#8220;specified employee&#8221; for purposes of Section&nbsp;409A(a)(2)(B)(i) of the Code at such time, any
payments to be made or benefits to be delivered in connection with the Executive&#8217;s &#8220;separation from service&#8221; (as defined below) that constitute deferred compensation subject to Section&nbsp;409A of the Code shall not be made until
the earlier of (i)&nbsp;the Executive&#8217;s death or (ii)&nbsp;six months plus one day after the Executive&#8217;s separation from service (&#8220;<B>409A Deferral Period</B>&#8221;) as required by Section&nbsp;409A of the Code. Payments of any
such deferred compensation otherwise due to be made in installments or periodically during the 409A Deferral Period shall be accumulated and paid in a lump sum as soon as the 409A Deferral Period ends, and the balance of the payment shall be made as
otherwise scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this Agreement, all rights to payments and benefits hereunder shall be treated as rights to
receive a series of separate payments and benefits to the fullest extent allowed by Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of
this Agreement, with respect to the timing of any amounts that constitute deferred compensation subject to Section&nbsp;409A of the Code that depends on termination of employment or separation from service, termination of employment or separation
from service shall mean a &#8220;separation from service&#8221; within the meaning of Section&nbsp;409A of the Code where it is reasonably anticipated that no further services would be performed after such date or that the level of bona fide
services the Executive would perform after that date (whether as an employee or independent contractor) would permanently decrease to a level less than or equal to twenty percent (20%) of the average level of bona fide services<B> </B>the Executive
performed over the immediately preceding <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;month period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>S</U></B><B><U>ection 280G</U></B><B>. </B>If any payment or benefit Executive will
or may receive from the Company or otherwise (a &#8220;<B>Payment</B>&#8221;) would (i)&nbsp;constitute a &#8220;parachute payment&#8221; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the
excise tax imposed by Section&nbsp;4999 of the Code (the &#8220;<B>Excise Tax</B>&#8221;), then any such Payment shall be equal to the Reduced Amount. The &#8220;<B>Reduced Amount</B>&#8221; shall be either (x)&nbsp;the largest portion of the
Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause
(x)&nbsp;or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#8217;s receipt, on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence
and the Reduced Amount is determined pursuant to clause (x)&nbsp;of the preceding sentence, the reduction shall occur in the manner (the &#8220;<B>Reduction Method</B>&#8221;) that results in the greatest economic benefit for Executive. If more than
one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;<B>Pro Rata Reduction Method</B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any provisions in this Section above to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in
any portion of the Payment being subject to taxes pursuant to Section&nbsp;409A that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be
modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows: (A)&nbsp;as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis; (B)&nbsp;as a second priority, Payments that are contingent on future events (<I>e.g.</I>, being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent
on future events; and (C)&nbsp;as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning
of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall appoint a nationally recognized accounting or law firm to make the determinations required by
this Section. The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. If Executive receives a Payment for which the Reduced Amount was determined pursuant to clause
(x)&nbsp;above and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to
clause (x)&nbsp;above) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&nbsp;above, Executive shall have no obligation to return any
portion of the Payment pursuant to the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Indemnification</U></B>. The Company will enter into an
indemnification agreement with Executive. At all times during the Executive&#8217;s service as an officer and/or director and for at least six years thereafter, the Company shall provide that Executive is covered by the Company&#8217;s D&amp;O
insurance on the same basis as other active officers and directors (without regard to whether the Executive&#8217;s service has previously terminated). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Representations of the Executive</U></B>. The Executive represents and warrants
that: (i)&nbsp;the Executive has no legal obligations to any other party that would be breached by signing this Agreement or otherwise fulfilling Executive&#8217;s obligations hereunder, including but not limited to any <FONT
STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-inducement,</FONT> confidentiality, assignment of inventions, or other similar agreement; (ii)&nbsp;the
Executive has not disclosed any third party&#8217;s confidential or proprietary information to the Company or its representatives or agents; (iii)&nbsp;if the Executive learns of any confidential or proprietary information that belongs to any third
party, the Executive will not disclose such information to the Company or its representatives or agents, except as allowed by law or any agreement Executive has signed with such party; and (iv)&nbsp;the Executive is not in breach of any
confidentiality or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement that the Executive has signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<B><U>Miscellaneous</U></B><B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Entire Agreement</U>. This Agreement contains the entire agreement and understanding of the
Executive and the Company concerning the subject matter hereof and supersedes and replaces all prior negotiations and proposed agreements, whether oral or written, including, without limitation, the Employment Agreement. The Executive acknowledges
that, by signing this Agreement, the Executive has not relied upon any representations, promises or agreements made by the Company or its employees, officers, directors, or representatives (including any Company attorneys) that are not contained in
this Agreement. This Agreement may not be modified or amended except by an instrument in writing signed by the Parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Headings/Counterparts</U>. The headings of the paragraphs herein are included for reference only and are not intended to affect the interpretation of the Agreement. This Agreement may be executed in any number of counterparts, each of which shall
be deemed an original but all of which shall constitute one and the same Agreement. Each Party agrees that faxed or electronically transmitted copies of the signature pages of this Agreement and/or any of the other instruments, agreements and
documents relating to any of the transactions contemplated hereby, whether sent to the other Party or to such other Party&#8217;s counsel, shall be deemed definitively executed and delivered, and with the same force and effect as if manually signed
and delivered, for all purposes whatsoever. Neither Party hereto shall raise the use of DocuSign, electronic mail or a facsimile machine to deliver a signature or the fact that any signature was transmitted or communicated through the use of
electronic mail or a facsimile machine as a defense to the formation of a contract and each Party forever waives any such defense. All counterparts shall be construed together and shall constitute one instrument, and the signature page from any
counterpart may be attached to another counterpart to form a complete copy of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Severability</U>. If any provision
of this Agreement or the application thereof is held invalid, such invalidation shall not affect other provisions or applications of this Agreement and to this end the provisions of this Agreement are declared to be severable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Construction/Joint Drafting</U>. The determination of the terms and conditions of this Agreement has been by mutual agreement of the
Parties. Each Party participated jointly in the drafting of this Agreement, and therefore the terms and conditions of this Agreement are not intended to be, and shall not be, construed against any Party by virtue of draftsmanship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></U> Neither the failure nor any
delay on the part of either Party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or
further exercise of the same or of any other right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with
respect to any other occurrence. No waiver of any provision of this Agreement will be binding unless made in a writing signed by the Parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Assignment</U>. This Agreement shall be binding upon the Company and shall inure to the benefit of the Company including any transferee
of the business operation, as a going concern, in which the Executive is employed and shall be binding upon the Executive and the Executive&#8217;s heirs and personal representatives. None of the rights or obligations of the Executive hereunder may
be assigned or delegated. The Company may assign its rights and obligations under this Agreement in whole or in part to anyone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
<U>Choice of Law</U>. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the internal laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Resolution of Disputes</U>. To aid the rapid and economical resolution of disputes that may arise in connection with Executive&#8217;s
employment with the Company, and in exchange for the mutual promises contained in this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory
claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Executive&#8217;s employment with the Company, or the termination of Executive&#8217;s employment, shall be resolved, to the fullest
extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;<B>JAMS</B>&#8221;) or its successor, under JAMS&#8217; then applicable rules and procedures appropriate to the relief being sought (available
upon request and also currently available at the following web address: (i)&nbsp;https://www.jamsadr.com/rules-employment-arbitration/ and <FONT STYLE="white-space:nowrap">(ii)&nbsp;https://www.jamsadr.com/rules-comprehensive-arbitration/)</FONT> at
a location closest to where Executive last worked for the Company or another mutually agreeable location. <B>Executive acknowledges that by agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such
dispute through a trial by jury or judge</B>. The Federal Arbitration Act, 9 U.S.C. &#167; 1 et seq., will, to the fullest extent permitted by law, govern. the interpretation and enforcement of this arbitration agreement and any arbitration
proceedings. This provision shall not be mandatory for any claim or cause of action to the extent applicable law prohibits subjecting such claim or cause of action to mandatory arbitration and such applicable law is not preempted by the Federal
Arbitration Act or otherwise invalid (collectively, the &#8220;<B>Excluded Claims</B>&#8221;), such as <FONT STYLE="white-space:nowrap">non-individual</FONT> claims that cannot be waived under applicable law, claims or causes of action alleging
sexual harassment or a nonconsensual sexual act or sexual contact, or unemployment or workers&#8217; compensation claims brought before the applicable state governmental agency. In the event Executive or the Company intend to bring multiple claims,
including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. Nothing herein prevents Executive from filing and pursuing proceedings before a
federal or state governmental agency, although if Executive chooses to pursue a claim following the exhaustion of any applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrative remedies, that claim would be subject to this provision. In addition, with the exception of Excluded Claims arising out of 9 U.S.C. &#167; 401 et seq., all claims, disputes, or
causes of action under this section, whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class, representative, or collective
proceeding, nor joined or consolidated with the claims of any other person or entity. <B>Executive acknowledges that by agreeing to this arbitration procedure, both Executive and the Company waive all rights to have any dispute be brought, heard,
administered, resolved, or arbitrated on a class, representative, or collective action basis</B>. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class
proceeding. If a court finds, by means of a final decision, not subject to any further appeal or recourse, that the preceding sentences regarding class, representative, or collective claims or proceedings violate applicable law or are otherwise
found unenforceable as to a particular claim or request for relief, the Parties agree that any such claim(s) or request(s) for relief be severed from the arbitration and may proceed in a court of law rather than by arbitration. All other claims or
requests for relief shall be arbitrated. Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration and procedural questions which grow out of the dispute
and bear on the final disposition are matters for the arbitrator to decide, provided however, that if required by applicable law, a court and not the arbitrator may determine the enforceability of this paragraph with respect to Excluded Claims. The
arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written statement signed by the arbitrator regarding
the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all
relief that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all arbitration administrative fees in excess of the administrative fees that Executive would be required to pay if the dispute were decided in a
court of law. Each Party is responsible for its own attorneys&#8217; fees, except as may be expressly set forth in the CIIAA or as otherwise provided under applicable law. Nothing in this Agreement is intended to prevent either Executive or the
Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any
competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Notices</U><U>.</U> For purposes of this Agreement, notices and all other communications provided for in
this Agreement shall be in writing and shall be deemed to have been duly given (i)&nbsp;on the date of delivery, if delivered by hand, (ii)&nbsp;on the date of transmission, if delivered by electronic mail, (iii)&nbsp;on the first business day
following the date of deposit, if delivered by guaranteed overnight delivery service, or (iv)&nbsp;on the fourth business day following the date delivered or mailed by the U.S. Postal Service, addressed as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Executive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">At the address shown in the books and records of the Company, currently: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">*** </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One
Penn Plaza, Suite 1025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10119 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: *** </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with copy, which
shall not constitute notice, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Divakar Gupta </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10001-2163 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notices
shall be deemed to be properly addressed, to the Company or to the Executive, if addressed to such person at such person&#8217;s address as set forth above, or to such other address or addresses as the addressee previously may have specified by
Notice given to the other parties in the manner contemplated by this Section&nbsp;11(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Survival</U>. Upon the termination of
this Agreement, the respective rights and obligations of the Parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the Parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><U>Acknowledgement of Full Understanding</U></B><B>. </B>THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT EXECUTIVE HAS FULLY READ,
UNDERSTANDS AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES AND AGREES THAT EXECUTIVE HAS BEEN REPRESENTED BY EXECUTIVE&#8217;S OWN COUNSEL OR HAS HAD AN OPPORTUNITY TO BE REPRESENTED BY AN ATTORNEY OF EXECUTIVE&#8217;S CHOICE
BEFORE SIGNING THIS AGREEMENT. The Executive hereby consents to the terms set forth in this Agreement and acknowledges and agrees that the terms set forth herein do not constitute &#8220;Good Reason,&#8221; &#8220;Cause&#8221; and/or any term with
any similar meaning or import under the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Remainder of page left blank intentionally; Signatures on the following
page) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have duly executed and delivered this Agreement as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LB PHARMACEUTICALS INC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Panoff</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marc Panoff</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AND PROPRIETARY RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(See attached) </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>11
<FILENAME>d12080dex1023.htm
<DESCRIPTION>EX-10.23
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.23</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.23 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LB P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
P<SMALL>OLICY</SMALL> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>FFECTIVE</SMALL>:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; </U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Board of Directors (the &#8220;<B><I>Board</I></B>&#8221;) of LB Pharmaceuticals Inc (the &#8220;<B><I>Company</I></B>&#8221;) who is not
also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an &#8220;<B><I>Eligible Director</I></B>&#8221;) will receive the compensation described in this
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (this &#8220;<B><I>Policy</I></B>&#8221;) for his or her Board service upon and following the date of the underwriting agreement between the Company and the
underwriters managing the initial public offering of the Company&#8217;s common stock (the &#8220;<B><I>Common Stock</I></B>&#8221;), pursuant to which the Common Stock is priced in such initial public offering (such date, the &#8220;<B><I>Effective
Date</I></B>&#8221;). This Policy will be effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board (the &#8220;<B><I>Compensation Committee</I></B>&#8221;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Cash Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in
which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be prorated based on days served in the
applicable fiscal year, with the prorated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Annual Board Service Retainer</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Eligible Directors: $40,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chair of the Board (in addition to Eligible Director
Annual Board Service Retainer): $30,000 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Annual Committee Chair </U><U>Service Retainer</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Audit Committee: $20,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Compensation Committee: $12,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chair of the Nominating and Corporate Governance Committee: $10,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Annual Committee Member Service Retainer (other than to Committee Chairs)</U>:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee: $10,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee: $6,000 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee: $5,000 </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Equity Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equity compensation set forth below will be granted under the Company&#8217;s 2025 Equity Incentive Plan, as may be amended from time to time, or any
successor plan, (the &#8220;<B><I>Plan</I></B>&#8221;), subject to the stockholders&#8217; approval of the Plan. All equity awards granted pursuant to this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of
the Fair Market Value (as defined in the Plan) of a share of Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service or Corporate Transaction (as
defined in the Plan), in each case as provided in the Plan). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>Initial Grant. </B>On the date of the Eligible Director&#8217;s initial
election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically,
and without further action by the Board or Compensation Committee, granted a stock option award for 20,000 shares (&#8220;<B><I>Initial Grant</I></B>&#8221;). The shares subject to each Initial Grant will vest in equal annual installments over a
three-year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a
Change in Control (as defined in the Plan), subject to the Eligible Director&#8217;s Continuous Service through immediately prior to the Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> <B>Annual Grant.</B> On the date of each annual stockholder meeting held after the Effective Date, for each Eligible Director who
continues to serve as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of the Board (or who is first elected to the Board at such annual stockholder meeting), the Eligible Director will be automatically, and without further action by
the Board or Compensation Committee, granted a stock option for 10,000 shares (the &#8220;<B><I>Annual Grant</I></B>&#8221;). In addition, each Eligible Director who is first elected to the Board following the Effective Date and other than at an
annual stockholder meeting will be automatically, and without further action by the Board or Compensation Committee, granted an Annual Grant, prorated for the number of months remaining until the next annual stockholder meeting. The shares subject
to the Annual Grant will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, provided that the Annual Grant will in any case be fully vested on the date of the Company&#8217;s next annual stockholder
meeting (or the date immediately prior to the Company&#8217;s next annual stockholder meeting if the Eligible Director&#8217;s service as a director ends at such meeting due to the Eligible Director&#8217;s failure to be <FONT
STYLE="white-space:nowrap">re-elected</FONT> or the Eligible Director not standing for <FONT STYLE="white-space:nowrap">re-election),</FONT> subject to the Eligible Director&#8217;s Continuous Service through such vesting date and will vest in full
upon a Change in Control, subject to the Eligible Director&#8217;s Continuous Service through immediately prior to the Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
share amounts shall be automatically adjusted in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other
similar change in capitalization or event effecting our Common Stock, or any distribution to holders of our Common Stock other than an ordinary cash dividend, including without limitation any stock split or reverse stock split that occurs in
connection with the initial public offering of the Company&#8217;s Common Stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>C.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to an Eligible Director shall in no event exceed the
limits set forth in Section&nbsp;3(d) of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>D.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ability to Decline Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity
awards are to be granted, as the case may be. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>E.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Expenses </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will reimburse Eligible Directors for ordinary, necessary and reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> travel expenses to cover <FONT STYLE="white-space:nowrap">in-person</FONT> attendance at and participation in Board and committee meetings; provided, that
the Eligible Director timely submit to the Company appropriate documentation substantiating such expenses in accordance with the Company&#8217;s travel and expense policy, as in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>d12080dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Consent of Independent Registered Public Accounting Firm </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our
report dated June&nbsp;27, 2025, except for the effects of the reverse stock split described in Note 15, as to which the date is September&nbsp;8, 2025, relating to the financial statements of LB Pharmaceuticals Inc (the Company), which is contained
in that Prospectus. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to
the reference to us under the caption &#8220;Experts&#8221; in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, P.C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;8, 2025 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>13
<FILENAME>d12080dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT TO BE NAMED AS A DIRECTOR NOMINEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc, a Delaware corporation (the &#8220;Company&#8221;), is filing a Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection with a public offering
(the &#8220;Public Offering&#8221;) of its common stock. In connection with the Public Offering, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of the Company in the Registration
Statement, and any amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Rekha Hemrajani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Rekha Hemrajani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;8, 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>14
<FILENAME>d12080dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT TO BE NAMED AS A DIRECTOR NOMINEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LB Pharmaceuticals Inc, a Delaware corporation (the &#8220;Company&#8221;), is filing a Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (the &#8220;Registration Statement&#8221;) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection with a public offering
(the &#8220;Public Offering&#8221;) of its common stock. In connection with the Public Offering, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of the Company in the Registration
Statement, and any amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments and supplements thereto. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: William Kane</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;8, 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>15
<FILENAME>d12080dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-332">S-1</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-333">S-1/A</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-334">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="ffd:RegnFileNb" contextRef="rc" id="ixv-335">333-289812</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-336">0001691082</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-337">LB PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001691082</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-08</xbrli:startDate> <xbrli:endDate>2025-09-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001691082</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-08</xbrli:startDate> <xbrli:endDate>2025-09-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_2"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001691082</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>2</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-09-08</xbrli:startDate> <xbrli:endDate>2025-09-08</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-374">S-1</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-375">LB PHARMACEUTICALS INC</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_1" format="ixt:booleanfalse" id="ixv-376">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-377">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-378">Common Stock, par value $0.0001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-379">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-380">206,666,672.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-381">0.0001531</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-382">31,640.67</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-383">Fees Previously Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-384">Equity</ix:nonNumeric> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-385">Common Stock, par value $0.0001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-386">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-387">100,000,000.00</ix:nonFraction> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-388">15,310.00</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-389">306,666,672.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-390">46,950.67</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-391">15,310.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-392">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-393">31,640.67</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_1" id="ixv-394">(1) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. (2) Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g12080g01p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g01p65.jpg
M_]C_X  02D9)1@ ! 0$ T #0  #_[1GB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &<4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-$)BL<'P)"4S1$5SHD-C@G*S=(.$H\(G-G6D\;+_Q  ; 0$!  ,! 0$
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M47A/0FPCF'NJT%C4:V#-(B;$1C4__(N3=7HN?Z*:ZK?F-MO4^FC7NRPA]4B
MCK6Q1?53/5;\P3=8HB?]*:ZK?F%O4PF])E(H(ZUL41/^E-=5OS%=;%$]5-=5
MOS"WJ8-Z3*1 1TFZQ1,_T4UU6_,5UL479O4UU6_,+>I@WI,I$!'>MBB>JF>J
MWYBFMBB^KFNJWYA;U,&])E(H(ZUL43/]%-=5OS%=;%%]5-=5OS"WJ8-Z3*1
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M"B5.!5Z=!G95')!BWT=),\E5/Y'O-<81A'2+.&GV  10
M                        M5JW^DI<              !;:1?*S\/#&*\0
M1JM+1G)-N5T"(D-=%Z9^9>W]7)0/A,2D"85%C0842WIMO8"+Z_&BSU-H,Q#I
MKY)/#'O:RRJMM&(B*J62W!TF"A)'WW?G>'IB7PYJJFBNCHW3;E>U[YW)O?+P
M7M:CX3%:W8BMV>XIX+ WY8JP(6^>EHI?I A*H>+YS%_]I\(E8<%&NC.2&KEB
MOT4V9;+JG'L/C5IAT2MNF):'%AQ6SJ:&DQ7/5B.S552UF[. G!TA*.>KG2L!
M7*NU8:7_ (!9*5TE=X+!5R[5WM+J!"$X^5BSV(6QXDRZ>2,U9?09=+V9EL]Y
ME)1T]XJQ2LPD1L=9.%;S%NB[VNQ.,DFG8<D9&=G)I(218DU$WQVFU%1JV1,N
M@RBRT!=-%@P_/^EYJ>=[P(EI\C'I=;H[J;OZNF9![HBN2]WZ$3B3)<D/%@M)
MKQ_3KQ(S)ET5?"/T2W<FE^UQ?:30V7A(]KTA0T<U+(J-V>XI#E9=D18D.!";
M$7:Y&(B]('V5#F/=8MK=J=LEWB&G_P!N&=-HNU. @^L4REU+=OK$.L_X*23'
M-\]6^=HP43-/8JFRC/"2I",6$\(S2Z01O=;;5"*O&I/C-S3#BI?P:);@7?G]
MY]=5^&U_RL3MG]YZW(4M?HX;:>/W<_7=QN*HJ\:G0.K##?)8G;/[QJOPWR6)
MVS^\<A2P6M3PY]NO&X76W[1T%JPPW;]5B=N_O&J_#G)8G;/[QR%+$2UG\.?4
M5>-P327A<=!:L,-\EB=L_O&K##?)8G;/[QR%+!:S^'/MUXW#/C<=!:K\.<EB
M=L_O&K##G)HG;/[QR%+!:U/#G[/C4HE^-QT%JPPW;]5B=L_O&K##G)8G;/[Q
MR%+$2UJ>'/J*O&X)?C<=!:K\-\EB=L_O&J_#G)8G;/[QR%+!:U/#GVZ\;A=W
M&IT%JOPYR6)VS^\:L,-V_58G;/[QR%+!:U/#GU%7C<$5W&IT%JOPYR6)VS^\
M)N88<MG*Q.V?WCD*6(EK/X<^I?C47=^\=!:K\-\EB=L_O"[E^&[?JL3MW]XY
M"EB):U/#GVZ\:B[N-3H+5?ASDT3MG]X3<OPWPRL3MG]XY"E@M9_#GV[N%7#S
MN-QT%JOPWR:)VS^\:L,.<FB=L_O'(4L1+6IX<_77C<4N[C4Z"U88<Y+$[9_>
M-5^&^2Q.V?WCD*6(EK4\.??.SS<,[;5.@M5^'+?JT3MG]XU88<Y+$[9_>.0I
M8B6L_AS[=>-1GGFXZ"U7X<Y+$[9_>-5^&^2Q.V?WCD*6"UG\.?;KQN"7XW'0
M6K##G)8G;/[RJ;F&&^2Q.V?WCD*6(EK4\.?/.XW"[N-3H)=S##B_Y:)VS^\:
ML,.<EB=L_O'(4L1+6IX<^W=?:HN[C<=!:K\.<EB=L_O&J_#G)HG;/[QR%+$2
MUG\.?45W&HNM]KCH+5?AS@E8G;/[PFY?ASDL3MG]XY"E@M:GASZBNSS<$O;:
MIT%JPPYR6)VS^\)N88<3_*Q.V?WCD*6(EK/X<^W6VUPNO&XZ"U7X<M^K1.V?
MWA-R_#:?Y6)VS^\<A2Q$M:GAS[YW&HN[C<=!+N7X;Y+$[9_>-6&&^2Q.V?WC
MD*6(EK4\.?;KGFHNO&IT NYAAS.TK$[9_>4U88<Y*_MG]XY&CB/]_P#:VLZ
M$5>-0E^-3H#5AASDK^V?WC5AAWDK^V?WCD:.(EK,Y_NO&HNO&I/^K##O)7]L
M_O&K##O)7]L_O'(T,12UG0 BKQJ$6SDS6_ = :K\.V_5G]L_O&K##B*BK*Q-
MJ?\ 6?WDCZ^G&'R@RAZ>;5[=S!+8'I?"MG\/_<<;:8^DTZ6I,C"DY-FC A71
MJ*JK:ZJO\5,@>1/-"::,8.Z6&D  &*@
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M:\9XZ1@EK106*A$.!U*(@L5 ! 4;PW*@6JJ(I<+
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MB]J\1MK;6V%;(83^HJ5(:3166E++'6 BW !H@V  *
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M>PHME=L15*V*HA0 ")[0 ")9
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M$'GP=<(:
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MM3W'0^Y1G@^35$6RJ[;[SC]7Z:2E#65NH59IXZ3-R5+@ X'6
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M3_AXO(##N=Z=#Z5*^0&'>&G0^E3V^5M#YUD^U3O'E90^=9/M6C=JYB:2/#Y
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MR*AEY.:@S<)(LM$9%@JF3FNN8S331A\XK+TZ_)Z  8,P
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M7A./UGJ*=6$.B+?1IS2Q^;+  \YU
M                                !:KVIP_ N%@           HYR-2Z
MJB)PJJE+V1;*OO4US='C1)?!E3BP8BPWMAW1R<&9'V%73,2KTE](C5*(N:S7
MA#KL5.&UW*!,N2IQW+5<VR7=;/CX>(CN8Q],RU>;)S$I!2 ^,L)%:]5>ED7-
M4M;@XS!0JK'AU16NBQ8C5JZ0V>>MM&[,EZ0)B5$7+^D*HMLELG$A&K=T&>WF
M+..IT-)"!,+ BO1ZJ[:J)9/L/M5]T/P2MQ8$O+L?*2SD;'<Z^FMU7Z*;%V+M
M5 )$V>Q"B*BMNUR*BYHJ;#18N+*E.5>=D*;(0GPH4%L58KXBMLU6(O!PYGAI
M&*)F5H-'@R<OX1.3\1[6)%?9J6<B9KGZ2 2.U6I>RY)E9"Y<KWS3B(IHF)YJ
ME-K\W48;WS*36]L@:5VHJHQ-M]F9DIO'L]35F(%3IS&3L.#OS$AOTFN;:^WC
MS0"147H+=J[+IQW-$E<;S,*==!K$DR719;PB$L)VE=/.V[/14MPSCV)4JI!E
M9J4APX<=-*$^&JKE=/I7M9<^"X&_99JA!M7H,2N[N%5@0JA'DG0Y1D72@N1%
M6S826]V9.2*F9S5NG3<Q);L54?*QGPG^#PTNU;?L0S.G3W)M(,9Y^B75T;+-
M2' 9"T])&M1MW+FI]4<GI(<M^/JFC4TIZ8O;.T1=H\>U3E\QVBG=QM3,'-#U
M4-/HZDTOWD*W3TOB<M>/:IR^8[10E=JF?]OF.T4O&U.Z!=0PZDTD](([]Y#E
MM*[5.7S':*/'M4Y?,=HHXVIW0+J&'4FFGI#2_>0Y;2NU3AGYCM%'CVJ7_7YC
MM%'&U.Z!=0PZDTD7]I CDM]+XG+?CVJ<OF.T4>/:IR^8[11QM3N@74,.I-).
M!R!7?O(<M^/:I;]?F.T4>/:IR^8[11QM3N@74,1=2([]Y"NDGI'+25VJ<OF.
MT4+7:IR^8[11QM3N@74,.I5<GI(41W[R'+?CVJ<OF.T4>/:I;ZPF.T4<;4[H
M%U#$74FDGI#23TD.6_'M4Y?,=HH\>U3E\QVBCC:G= NH8BZDTK?M(-).%R'+
M?CVJ<OF.T4>/:IR^8[11QM3N@74,.I-)+?20:2>D<M^/:HG^?F.T4)7JHG^?
MF.T4<;4[H%U#$74FE^\5TDO]+XG+/CVJ<OF.T4KX]JG+YCM%)QM3N@74,.I-
M+;YPTDO])#EOQ[5+?K\QVBCQ[5.7S':*7C:G= NH8=2:276[D"._>0Y;2NU3
ME\QVBCQ[5.7S':*.-J=T"ZAAU(CD3]I+A7)Z7Q.6_'M4Y?,=HH2NU7E\QVBC
MC:G= NH8=1[XU$NKFI;VES$6V:WL<MPZ_5&O;_>$Q>Z717*O"=023E=+LTEN
MJHARU_3QH1TBW4JW6^X*7SL5.=M+($1$V(
M                                           MTU]%2X
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MA<FPYZM::K\YFV2G"7Z*97*BP-38
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M?^'7Z>>,\/F^P .%T@
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MC(KELBKL_@23!>D6$UZ;'(BH:IZ<\G_R;)9H3?1?8 &+(
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M#>
M           !8L-%6^9>+H!1;WR4JAKV/)J:DL,SD>0B)"CL;I(Y5MDFTBNG
MSNZ#/2"3LJ^(^ J71=-454]U[@3J%OP$ R&+<7PY-U2?%6-)P8B)%17K=,]B
MI>Z$W4"?\9TF4G-BQH:.5 ,@ F2    "K9+J82M8FI=%C)"J,TR"]6Z277@S
M[C-J1[NDUV&V+ HLK$A0YR:LD2+$5$WIBJJ*J*MN)<K@;!)8PHTY"9$EYQCX
M;XF]HJ+DKE15_DIL"+T^TBRL-E*11J)*T.=8^TTF_P 2%$15>Y6/5554]MS
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M1--'1.R67W%V2(&Y-V%5V'EP^KL6[;7X,T+BU-+AL7"   H
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M%[5XRXM:E\[Y%R&AL@  *
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MF(#VN;9$AI[%[S57K49I(PA]64E.?JA&*2(:W;="XHQ$1+(5/(=X
M
M       !9I.]!0(]Q[CN7IDRE+EI/P^:5MW-SLF?X&F-QK,PGJ^;PK!:Q$NJ
MI"B(O3>QD\'3%-\O*[,U>)!TV/:D-8]EMMOM)$FJ[AZ8@+!BSLB^&N6BJHJ=
M %F!ZE2JM3%FZ1!;!1RV>U+W139"*MQ!S&QJW!@.3>&O8K&M7)+Z6Q"50
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MJTIJ4>F9MDGA/#6 @ -;,
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M[GN'JG+8JEH\S)18<)BYJYMDVH3\6JU. N.2M7C6FUBWTZ?1#0 !J;
M
M          "FC[5 J             U;$V)9B1J4"F4J4\+J$5%>K;V1C4MF
MJ_:AYJ'C)8D>;E*Y+I(34LFD[2==%;L2WVHIY,5RU3I>)4K5,E5G&18*P70V
M_23Z*W_X\9I,67K>()VIQJA3WP)YTLB0V)L<B*Y;>_,"9FU256-#A+&8D2(S
M?&MOGH\?Q0\3,2TN)!FGP)V#%66AK$>UKTO9$55MQ[#19:3JM4J<&)X!,26]
M2.\-?$LEW)HIP*O$IC\*X;GUF8,.:DYF&^% <Q[G0V-8JJF;45N;T6VUV?2!
MN$AC5*BV1?)PX2I&CN@O1T1$5MD54M?;DB=)G'XCI<.HI(OG87A.EH*R_P"U
MQ$:4:B5&'#I,#Q7&A.E)Z,^)$1$S14>J.O?9YR(>>N4JLS=8CQ%IL;39.)$:
MZ'#8UBL1RKI::6<J[,M@$HS.)Z1+QG08L_+MBH[15JO2Z>\^$7$20:Y&E8V\
M-E(4#?EB[ZE[61;VXLR+5A18]2Q%+0Z2LU$C1&PVQ$8U5A.1&+M5;I^)E:MA
MVJK'G&)*Q(RNH^\->U=L3>VI;WW10)(D<0TR=CK!EIV!$B6TD:UR*MOZ12Z3
MKU-G)M\M*SD&)&8N;4=Q&@LPY-LK5%?)RB0;2#X4:(UJ-L_0B;;>U4/!A'#T
M_#K4BR:E9N$^6B*Z)%T6M8J:7I(ND[[0)?8F6EPK[2"J[B6%AK=MK$U$@+'1
MTFV'HH[1VMA+?9["=6Y*J(<R;K"7W7JHC4SWB'_[<,W4)(33Z1:ZDVDOR2&F
MZ]!M;Q8^W^[^!5-V*"G^E/[7\"'<US2_0.GH/6LJ/]%Q;T^GR3%KB@\UO[7\
M!KB@V^JG]K^!#J+[^@JGV]!;&C_1-^HF'7%!YJ?VOX!-V*#S4_M?P(=O[^@K
M?VKT$L:/]$WZB8=<4'FI_:_@-<4'FI_:_@0]T] X-J]!;&C_ $3?J)A3=BA<
MU/[7\!KB@\UO[7\"'KY</0+^U>@6-'^B;]1,.N*#S4_M?P&N*#S4_M?P(>7W
MKT%+^U>@6-'^B;]1,>N*#S6_M?P&N*#S6_M?P(<V\?0/M7H%C1_HF_43'KB@
M\UO[7\"FN*#S4_M?P(=1?:O0/M7H)8T?Z)OU$Q)NQ0>:G]K^ UQ0>:G]K^!#
MR>]>@7MQ] L:/]$WZB8DW8H/-3^U_ HF[%!YK?VOX$/7LG#[[#@VKT%L:/\
M1-^HF'7%!YJ?VOX%=<4'FI_:_@0[?W]!2_M7H%C1_HF_43'KB@\U/[7\!KB@
M\U/[7\"'+^U>@K]J] L:/]$WZB8=<,%/]+?G_P!W\#UTO=6@S]2EI3Q>^&L9
MZ,1V^:5O@0E]J]!D\,7\H:=HJJKO[,OM-=3TE&676"RUJD8Z.I;JK4MG<O/A
M#1R)G]%;6/N>-]W?#Z  "@
M                                    "_M!;O;?;TJ!<
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M8O5*ZQ\/77^V?\1MUL1-9&>\G:/S;*=BWN*>3E(M]6R?8M[C ZQ\/W_7,O\
MTJ5UCX>Y8O5&W6Q$UD9WR<I%OJV4[%O</)RD<VRG8M[C!:Q\/<L_XJ$W1\/<
ML_XDZ*V(FLC/>3E'YMD^Q;W!,.TCFV3[%O<8%=T?#W+/^)36/A[EB]4;=;$3
M61GO)RD<VRG8M[@F'*1S;)]BWN,%K'P]RQ>JHUCX>Y8O5+MUL1-9&=\G*1S;
M)]BWN*^3M(M]6R?8M[C ZQ\/<L_XJ-8^'K?KG_%2=%;$361G4PY2.;93L6]P
M\G:/S;*=BWN,%K'P]RS_ (J-8^'K?KB]4NW6Q$UD9U,.TCFV4[%O<?2%0:7
MB-B09&7AO:MT<R&B+_ ^]+GH-2DH4W*Q%=!B(BM7C0]GL-49IH?*,64)8?98
MK<\UX;EXL@,60
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M98]Z? \>>.L8Q=\L-(:  ,60
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MI'&_D77XNJ_#9:WZRSI*I.RW*&=)RGOD3TW=(WQZ?MNZ1QOY%UX=6>&R^?\
M:&=(\-EK?K#.DY3WQ_K'=(WQ_INZ1QOY%UX=6>&RW*&=(\-E^4,Z3E/?(GIN
MZ1OC_3=TCC?R+KPZL\-EN4,Z1X;+<H9TG*>^/S\]_2$B/]-W2.-_(NOQ=6).
MR_#,,Z0D]+<H9TG*>^/S\]W2-\?Z;ND<;^1=?BZL\-EE_P"NSI'ATMZ]G2<I
M[X_TW](WQ_INZ1QOY%WX=9PU;$9=KD<UVQ4/HF:738:ON;JKL(4YSE57;VU/
M@AL[4L>;-#IC&#LA'6&JH ,5
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M&Q$<K=ET3.QF46Z7 .2,=8ZQ;X0T^0 "*
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M-Q8206O@P-'S;I^][$,?&P=.8>H569)3,2-*1I5Z.@Z&D_?-%<T5%X<DM;@
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M4P;7);$$C'CR+V0H<9CG+HJED14.@(:68B6L>9ZR$D)O^'5Z;JZ?^E0 <;I
M
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MNA&$8:P  10
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M4GZYHS9=<DO3+"  #!D
M                                            !;O:<:EPNG&@
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M=8*7]A7+/(6XQ8?-1J(B6385" H
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M5\X$)(4)K&[&I9#Z( AJ;(?(
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M$]IY*1*>!4V6EE<CEA,1E^.Q[#Q)OG-&+T)8:0  10
M
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M5G3K2U(Z0;1P#A*;4*\)R_9N  4
M
M       +;OXD N  #@-=QIAU^(J=#EX<RDN^'$2(CEAZ>>?M3C-B &FQ<*5*
MHR$S)5JL),RT1MF(V71JL6RYWTO:6X5P4VD1IATS%@Q4B0]Z:V' 2&B-]MES
M4W0 :90L"RM,DJK+Q8GA+)]JPW79960_.1&IFO [X'B\@YN89"@5&KNF9:78
M]L!F]:.BY6JFDOG+=<R0 !ITC@YTM$HL1)I-*GHZ_P"C^FJV]N6P\;L 0EHT
M:3=,>>Z9\)AOWNZ-=9J65+YIYIOH B'$&"9V2@2+I>(L>;BS;5?$EY3_  VH
MQZ75$79L-A=@6-.2]1?4:BZ/.S:M3?%AY-:U;HB)?C5>DWVP U.LX6C32TZ/
M3YUTK.R<-(:1-"Z.;HV7*Z6/%!P&C(<LJSKG1VS;9N-$6'??G(J+FE\MGMVF
M\@#3I[!JS4O6(*S>BV?>QZ+O=]#11B6V_N?$Q%0W-XLV^,Y*BUK8T)K'(Z7T
MW,5J6\UVEDBWX.)"2 !'2X$J?C:!/LK6C$@,1D%KI?31B65,O.]J])[WX,BQ
M8=9WZ>TXE3@)#?>#]%4:J7O?VF[ #4GX-9$GZ9'B3*Z,I+++N;H9O16O2][Y
M?3^!X*!@%*55(4PZ9A18,%ZNAL271KLUO=SKK=4V&^ "RRZ2[;'.6Z)2YVJ[
ML-4@T^!$CQ4EF.5&-5V6A#XO>='.OG8@VK3M;DMV^K/P_(P9R8648U[8BV1L
M/1A7=]),[VZ3.G/MS=4&,TD)I=&M)@O$"_Z7,]D[N'D5B#FN9[)W<=(P%>L%
MKHK4;$5$TD3@4^R(EMAW<G/'[.>TE<T>1>(.:YGLG=P\B\0<US/9.[CI>R<0
MT4')3]I:2N:$P7B#FN9[)W<$P5B#FN9[)W<=+HU+%;)Q#DI^TM97,_D5B'FR
M93_Y3NXG3<\D)BG86DY>;AK#C-8B*US;*F1L=D7@*IDB'/7]5-7AI&&C93HP
MIQU@)DA4M<I<<VC<
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M[                                  !P@
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M     !1RV:JHEUXB/9"OU:)CQTK4&)+RS9=T6' 2RJY+/LJ]7CX"0UV&L3-
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M8NF[/8JJJ\2'EI6!9^5FI:!%FH3J;+3"S+&HGG:5K6V[ )&1;W7@*E-FS85
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MDU.0'T^1B.?!;#8J/NJ*F:W]O$!(:;"W3;QER;"FBG$@%0
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M                   /FL5$6UE/H
M             'SC1&PX3XCULUB*JK[#Z'CJ\FM0ITQ*;ZZ$D:&YBO;M2Z6
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MMI1(/#9+>SB0OPQ@*3HM3\81YN/.SN=HD7V[>,#<]J
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'Y%X ! ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g12080g02p65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g02p65.jpg
M_]C_X  02D9)1@ ! 0$ PP##  #_[2H$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *><
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_X4!W:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E
M:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E
M.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C$M8S P,R W
M.2XY-CDP83@W+" R,#(U+S S+S V+3$Y.C$R.C S(" @(" @(" B/@H@(" \
M<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @
M(" @(" @>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC
M;VTO97AI9B\Q+C O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O
M9G3"KB!7;W)D(&9O<B!-:6-R;W-O9G0@,S8U/"]P9&8Z4')O9'5C97(^"B @
M(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@5V]R9"!F;W(@
M36EC<F]S;V9T(#,V-3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP
M.D-R96%T941A=&4^,C R-2TP-RTR,E0Q,3HQ-SHR-RLP-3HS,#PO>&UP.D-R
M96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(U+3 W+3(R
M5#$U.C$V.C,U*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM
M<#I-971A9&%T841A=&4^,C R-2TP-RTR,E0Q-3HQ-CHS-2LP-3HS,#PO>&UP
M.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O
M8F4Z9&]C:60Z<&AO=&]S:&]P.F0T8C8R.&$S+3 T9F0M-CDT8RUA939F+6(P
M.6)E-31D.#9E,#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#HY9&$T-S9F."TQ8S1F+3<Q-#DM.&(U,"UE
M8V5A-39E-3,T,34\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HT,3$Q1$-!1"U$-#(W+31%.3DM
M038Y."TX-SDY.#DU.3-!-T,\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C5D8F4T96(R+3(Y83$M8S$T,2UA935B+3AA,V$P,F$W
M.&9F-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R-2TP-RTR,E0Q-3HQ-CHQ-2LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P(#(V+C<@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#IC,65A9#$S8BTU9#9C+34Y-# M.&1C."TX-CAB8V4Q.&9E9C,\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C4M,#<M,C)4,34Z,38Z,S4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<" R-BXW("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HY9&$T-S9F."TQ8S1F+3<Q-#DM.&(U
M,"UE8V5A-39E-3,T,34\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,#<M,C)4,34Z,38Z,S4K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-BXW("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX
M;7 N:6ED.F,Q96%D,3-B+35D-F,M-3DT,"TX9&,X+3@V.&)C93$X9F5F,SPO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^=75I9#HT,3$Q1$-!1"U$-#(W+31%.3DM038Y."TX-SDY.#DU.3-!-T,\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^=75I9#HT,3$Q1$-!1"U$-#(W+31%.3DM038Y."TX-SDY
M.#DU.3-!-T,\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/&1C.F-R96%T;W(^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D=E
M;F$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO
M9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \=&EF9CI/<FEE;G1A=&EO
M;CXQ/"]T:69F.D]R:65N=&%T:6]N/@H@(" @(" @(" \=&EF9CI84F5S;VQU
M=&EO;CXQ.34R,S<O,3 P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z65)E<V]L=71I;VX^,3DU,C,W+S$P,# \+W1I9F8Z65)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S
M;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\
M+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS
M:6]N/C8R.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF
M.E!I>&5L641I;65N<VEO;CXV,38\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $, !@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7
M%!@8%Q06%AH=)1\:&R,<%A8@+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'
M"@@*$PH*$R@:%AHH*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*/_  !$( [,#Q0,!(@ "$0$#$0'_Q  <  $  @,!
M 0$              04$!@<# @C_Q !=$  ! P,!! 4'!0X#!P(# PT!  (#
M! 41!@<2(3$305%3D1054F%QDJ$B,E2!L187(S,T-G)SD[+!T=+A-T)T""0U
M0X*BPF+P)E6S)3A$@Y3Q&$568Z-&9'73XO_$ !H! 0$! 0$! 0
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M6@TX^:?!00<9P<=J_15OBBGTO!'4'$)A&_GLZUI.J=4V1EAJ+5:]TC&X-P$
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M#V[JU[:;<JJMGIA6VYU$X $!TH?D9=V#_P!X6SQ:ZTM0AS[?3;LA]"GW"?K
M7-M4W^;4%T-7,TQL #61[V=T9)[!GF5/#8?^KLH:I?FRY\O_ $]7.W\':?\
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MHOO_ --_9_D^+X[]W^"5'-2.:+WGB(Y(B ( @4J.I %(4<TZN" D*#R4A1A
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M =2(@0!%/4B A.I2.2( HZD"( @4@H@"A,(@ X)[4 1 2.2=65"! 2$ZU"!
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MNA\HIF#Y) ^6/5S QS6BA1E8^EQZ=.N#?U&3?>^3KCMI]J8QSJ>VU#9.HEK
M/@5H6J]3U>HJAKJ@-9"S.Y&WD/[\E0'M0$=:F+PN+$]HKD9/$Y,BUD^#H.B-
M<45@LXI*FFJ9)-XG>CW<<R>L^M:CJ6XQW6]U5;"Q[(Y2,-=C(PT#^"K%(6X8
M(0F\B[LS+-.<5!]D=*LNT"@H--4]MDI:ITT<71ES=W=)\5SBFD$51%(>(8X.
M('J*^ @3'@AC;<?43S2R)7Z'2M1[0:"Z6*:AAI*IDCV@!S]W'P*U?1NJ:C3=
M5(8VB2"7'2,/JSR]?$K7 BS'PV.,'!+AEEXC)*2FWRCK#MI%DE<))[54.E'7
MNL_FJ'6&OI+U1NHJ.$P4K\;^\/E'!SC@?8M%3J68>#Q0>R78W+Q622ION='V
M-VTRU]37/9\F' 8X]9(<#]JJ]JMS\NU(Z&-P,5,"P>IW)WV+,TSK>AL=@-##
M13NJ' DR9;C>(Q[<+1:F9]3533R_C)7E[O:3DK&/%*6>66:^$:R9(QPK'%_Y
M/)$ZT7M/($3"! ;UL>_.=_ZER[4N*['OSG?^I<NU+X']1_>_@^UX#]H(B+P'
MM-.VH4-17V 14L3I'[X. /6%R;[F;M]#E]TK]$/>UC<N( 7GY5#Z;?%>[P_C
M)X8:15GCS>%CEELV?GO[F+M]"E]T_P D^YB[<?\ <Y?=/\E^A/*H?3'BGE4/
MIM\5V\RR>TY>7P]Q^>_N7NV/R.7W3_)2-,7?Z'+[I_DOT&*J'TQXIY5#Z8\4
M\RR>T?00]Q^>_N8NWT.7W3_)/N8NWT.7W3_)?H3RJ''SQXIY5#Z8\4\RR>T>
M7P]Q^>_N8N_T.7W2GW,7;EY%+[I_DOT)Y3#Z;?%/*H?3'BGF63VCR^'N/SV-
M,7;Z'+[I_DGW,7;Z'+[I_DOT)Y5#Z8\4\JA],>*>99/:/H(>X_/?W,7;C_N4
MGNG^2'3%W^AR>Z5^A/*H?3'BGE4/ICQ3S+)[1]!#W'Y[^YB[?0Y?=/\ )/N8
MNWT.7W2OT)Y5#Z8\4\JA],>*>99/:/+X>X_/?W,7;Z'+[I_DGW,7;Z'+[I_D
MOT)Y5#Z8\4\JA],>*>99/:/+X>X_/?W,7;Z'+[I_DGW,7?KHY>/_ *2OT)Y5
M#Z8\4\JA],>*>99/:/+X>X_/?W,7?'Y'+[I3[F+L!^1R^Z?Y+]">50^F/%/*
MH?3'BGF63VCR^'N/SW]S%V^AR^Z?Y)]S%V^AR^Z?Y+]">50^F/%/*H?3'BGF
M63VCR^'N/SW]S%V^AR>Z4^YB[?0Y?=/\E^A/*H?3;XIY5#Z;?%/,LGM'E\/R
M?GL:8NW51R^Z?Y)]S%WX_P"YR>Z5^A/*H?3'BGE4/ICQ3S+)[1]!#W'Y[^Y>
M[?0Y?=/\D^YB[?0Y?=/\E^A/*H?3'BGE4/IM\4\RR>T?00]Q^>QIB[<?]SE]
MT_R0:8NWT.7W3_)?H3RJ'TQXIY5#Z8\4\RR>T>7P]Q^>_N8NWT.7W3_)/N8N
MWT.7W2OT(:J$?YQXIY5#Z8\4\RR>T?00]Q^>_N8NWT.7W3_)/N8NWT.7W3_)
M?H3RJ'TQXIY5#Z8\4\RR>T>7P]Q^>_N8NWT.7W3_ "3[F+M]#E]T_P E^A/*
MH?3'BGE4/ICQ3S+)[1Y?#W'Y[^YB['_\')[I_DGW,7;Z'+[I_DOT)Y5#Z8\4
M\JA],>*>99/:/H(>X_/?W,7?Z')[I_DGW,7;C_N<GNG^2_0GE4/>-\4\JA],
M>*>99/:/+X>X_/?W,7;Z'+[I_D@TQ=_H<ONE?H3RJ'TQXIY5#CY[?%/,LGM'
ME\/<?GL:8NWT.7W3_)/N8N_T.3W3_)?H3RJ'TQXIY5#Z8\4\RR>T?00]Q^>_
MN8NV/R.7W3_)!IB[<?\ <Y/=/\E^A/*H?3'BGE4/IM\4\RR>T?00]Q^>_N7N
MWT.7W3_)/N8N_P!#E]TK]">50^F/%/*H?3;XIYED]H\OA[C\]_<Q=\X\CE]T
M_P D^YB[#_\ !R^Z?Y+]">50^F/%/*H?3'BGF63VCR^'N/SV-,7;'Y'+[I_D
MK[6=@N53=&/AII'M$8&0#ZUV;RJ'TQXJ&U<+AD2-\5E_U";DI:]C2\#!)J^Y
M^?/N8N_T.7W3_)/N8NWT*7W3_)?H3RJ'O&^*>50^F/%:\RR>TSY?#W'Y[^YB
M[?0Y?=/\D&F+M]#E]T_R7Z$\JA],>*>50^F/%/,LGM'T$/<?GL:8N^#_ +G+
M[I_D@TQ=L?D<ONG^2_0GE4/ICQ3RJ'TQXIYED]H\OA[C\]_<Q=OH<ONG^2?<
MQ=N/^YR^Z?Y+]!^50^F/%3Y5#Z8\4\RR>T>7P]Q^>QIB[_0Y?=/\D^YB[?0Y
M?=*_0?E4/ICQ4^50^F/%/,LGM'T$/<?GO[F+M]#E]T_R3[F+M]#E]TK]">50
M^FWQ3RJ'TQXIYED]H^@A[C\]_<Q=OH<ONE/N8NV?R.7W3_)?H3RJ'TQXIY5#
MZ;?%/,LGM'T$/<?GS[F+M]#D]T_R4?<Q=_H<GNG^2_0GE4/IM\4\JA],>*>9
M9/:/+X>X_/8TQ=C_ /@Y?=/\D^YB[?0Y?=/\E^A/*H?3'BGE4/IM\4\RR>T>
M7P]Q^>QIB[?0Y?=*?<Q=L?D<ONG^2_0GE4/ICQ3RJ'TV^*>99/:/+X>X_/?W
M,7;'Y'+[I_DGW,7;Z'+[I_DOT)Y5#Z8\4\JA],>*>99/:/+X>X_/?W,78#\C
MD]T_R4'3%V^AR^Z5^A?*H?3'BGE4/ICQ3S+)[1Y?#W'Y[^YB[?0Y?=/\D^YB
M[8_(Y?=/\E^A/*H?3'BGE4/ICQ3S+)[1Y?#W'Y[^YB[?0Y?=/\D^YB[<?]SD
M]TK]">50^F/%/*H?3'BGF63VCR^'N/SV=,7;Z'+[I_D@TQ=OH<ONG^2_0GE,
M/IM\4\JA],>*>99/:/+X?D_/?W,7;Z'+[I_DGW,7;Z'+[I_DOT)Y5#Z8\4\J
MA],>*>99/:/H(>X_/8TQ=OH<ONG^2?<Q=OH<ONG^2_0GE4/IM\4\JA],>*>9
M9/:/+X>X_/?W,7;C_N<ONG^2?<Q=_H<GNE?H3RJ'TV^*>50^F/%/,LGM'T$/
M<?GO[F+L?_P<ONG^2?<Q=OH<ONG^2_0GE4/ICQ3RJ'TQXIYED]H\OA[C\]_<
MQ=OH<ONG^2?<Q=OH<ONG^2_0GE4/ICQ3RJ'TQXIYED]H\OA[C\]_<Q=OH<ON
ME/N8NV/R.7W3_)?H3RJ'TQXIY5#Z8\4\RR>T>7P]Q^>_N8NWT.7W3_)!IB[_
M $.7W3_)?H3RJ'TQXIY5#Z8\4\RR>T>7P]Q^>_N8N_'_ '.7W3_)/N8NWT.7
MW3_)?H3RJ'TQXIY5#Z;?%/,LGM'E\/<?GO[F+M]#E]T_R0:8NWT.3W3_ "7Z
M$\JA],>*>50^F$\RR>T>7P]Q^>_N8NWT.7W3_)/N7N^/R.3W3_)?H3RJ'TQX
MIY5#Z8\5?,LGM'E\/<?GO[F+M]#D]T_R3[F+M]#E]T_R7Z$\JA],>*>50^F/
M%3S+)[1Y?#W'Y[^Y>[?0Y?=*?<Q=OH<ONG^2_0GE4/ICQ3RJ'TQXIYED]H\O
MA[C\]_<Q=OH<ONE/N8NWT.7W3_)?H3RJ'TV^*>50^F/%/,LGM'E\/<?GO[F+
MO]#D]T_R3[F+M]#D]T_R7Z$\JA],>*>50^F/%/,LGM'E\/<?GO[F+O\ 0Y?=
M*?<Q=L_D<ONE?H3RJ'TQXIY5#Z8\4\RR>T>7P]Q^?/N8NW51R^Z5'W,7;Z')
M[I_DOT)Y5#Z8\4\JA],>*>99/:/H(>X_/?W,7;Z'+[I_DGW,7;Z'+[I7Z$\J
MA],>*>50^F/%/,LGM'E\/<<LV6V:OH-0NEJZ=\<?1.&2".*ZRO..:.0X8X$K
MT7B\1F>:>S5'KP8EBCJF$1%P.QB7+\1]:J5;7/\ )_K54NT.QSEW"*,=JD+9
MD(.M$"$(ZU*)]J%!1 G:A!U(B!"CZTZD3M0!,J,J4 1.*>LH!UHHZE* =2(B
M (G+BH^Q 2B!$ ]J)[40!$0'@@"<@B(!U(F<% @'6G4G6G)" )]B H.* )A.
M*(4)U(B (B=2 ($1"#M10I0HRB)A"!$0<<H .2\J;\6?:O4+RI^##[4!ZCDB
M(@"(B%"(B (B* (@14!$[40!.I$0$<5*(A G6G4B (@1"@<$1$ ').2( A B
M* @)ZD10A243J0<$!'UJ>I.U!R0 (.M$0@"(@ZT*.I/8B(0(BCVH4DH."(@"
M(G6@'4G4H[5/4A B=10(4!$"#DA 4"(A2%(4*0@"=2($ ZDX($ 0!.I,)UH
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M3F\BO= $1$ 1$0!%45^I+1;[K#;:RNCBKIAF.(@Y=\,=2MU6FB6F$1%"A$1
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MKA);*UQWBV,8!=GJ((PNV*25INK.62+=-*Z,[6&S"R5]GJ?,]OAI+@QCG0=
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M+D&F?\>]0^P?N-6(14KOT-RDU1C;2?\ &*Q?H-^QRZ[?[U0V&VOK[I*8J5A
M+@PNY^H<5R+:3_C%8OT&_8Y;?MR_P^J_TV_Q722VT3.<76[1;UNO=.4=#!53
MW%HCF!+&M8YS_K:!D?6%D:<UE8]1/++37-ED''<<TL=X. *T_9;H>UNT_2W.
MZ1,N-54,/&H8'A@#B. .<< /!:QM2M\&A]4VV^6*-M(U_P E\40W6DX=U#JX
M!%CA)N"[E<Y);/L=AU'J*VZ<IHI[O.Z&*5_1M(C<_)^H%5LNO=.1UU-1FX U
M%1NB-C8W.XGD#@</K6H_[067Z:MH!P75(X]BN]"Z$LM%:Z"NFI8ZNODB9,Z:
M=H>0X@'(R,CBLJ$5#9EVDY:H\KS2Z5DVDT<M;4U+=0-W#'$UIW#C=W<G=]G6
MMZK*N"BIWSU<K(H6#)<\X 7(-2?X[6WV1_\ @LO;Y75)I[5::>1T;*R3+R#S
MQD8/JXJZ;.*OT(IZJ3-E^^CI/IS%YR<7 X)$$F[XXPM*M51%4[>XYJ>1DL3X
MGEKV'(/R).M;]:M Z<I;/'2&U4DPW?E220M<]Q[2<+F>D;/%8MMT5!3/>^"-
MDFYOG):-R3@M0TJ6OX,RVM;?D[=<[C26ND?4U\[((6#)<\X6IMVI:3=+T8N+
M\YQDT\@;XXPM-VUW-LVJ+-9J^?H+7\F:<@_.!=R/N_%64EQV9OMWD8CMS6;F
MX'B!F]RQG..?K68XEJFT^33R.VE7!T^@K*>OI65%',R:%XRU[3D%>ZX]L(NK
MG5MXM,,SIJ"%[I*<D_-;O<A[R["N>2&DJ.D);*PB(L&@B(@"(B (B( L&S?D
MI_2*SE@6;\E=^D55V9'W,]$10H1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 7*=OEZJ::TT=IHG;LM;)\K',LPX$>.%U9<5VWX^[?2_2;W0[CL
MX_277 OO.65U!FWV_9=INGL@HIZ"&><MP:ES!TF?4<+5-D-14:?U?=]*32.?
M3LD+H=X]8!R?!H79AR"XO:][_P#6 DW,;N[+O>[(M0DYJ2D245%Q:.T*OO%E
MMMYB9'=:*"KC8<M;*W> *L$7!.NQVJS6?N"TH!_P"W?L0N3VRR6O4FU?H[/0
M0T]HM[?PA@9NAY!/'V_*;X+JFTK48TSI>>K:1Y0\B.$9QEQR?L!55L:TWYET
MO'4U+3Y=6$RR.</E $-^2>OFU>B$G&#DV<913DHI'AM2T[?-3U]JH:.(>9VR
M!U4\2M:2,C/ GC@#L5B[9II=MG=2&VTX<(MSRDM'2 XQO9QSZUNJY?M%?K]S
MZZ.S04[K2YI:#$?PQ!SG&#GEZEF$I2J*=%E%*Y-68&P2KGC=>+7O%]'35#FQ
M$\< $]?)=?7,]B=59VVJ:CHV/BNC7DU39OGN=D\>(!/,+IBF;];+B_0@B(N1
MT"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#'N,+YZ*
M:.)[HWN;\ES>8*X_LSUN^T5M=:-:5CX*MLGR)*D[@'4<DXP."[0J2^Z4LE]X
MW6WQ3GMRYA\6D+I"22:D8E%MIHI-6:\TS36*L#;M0UCY(7L;%!,R0DEI ! *
MU#9+8*NKT/J$/B="VZO)@#P6\,N'6MVH=FNDJ&<34UG8V0$$%TTCN7J+B%MD
M,4<,38X6-9&T8#6C "UO&,:B9T;=R..;'-04=@;<+#?)XZ"IBF+F&H<(PX>T
MXX\?!9FV'5M!<+$;#9:N&NJZUS6N;3.$N #GJSQ^2M\ONC[#?9.DNENCF?Z0
M>YA\6D+XLNBM/66<36VVQQ2CDYSWO(]XE7J0VW]2:22U]"BK;-);MD4EO;&[
MIXJ#\(WCG>#./V*HV 7:@;I%ML?50LKXZAY,#G@/P3PP.?4NJ/8U[',> YKA
M@@]86OTFB]/TEY-UIK<V*O+B[I&ROQDG/S<X^"RIIQ<9&M&I)HYWLL_Q7U-^
MH=^]$L;7CJ:?:U0T^I92RSAF6B5VY&>!YG('//%=6M>F;1:[K4W*@HQ%6U+=
MV63I'NWAPZB2!\T<@OJ_Z<M-_B;'=Z)E0UIR,N<TCZVD%:ZJVOX,]-ZT:KJ.
M]Z/M=FF;1-M55.YA;'#3-CD>3CG@<?7GU*J_V>R7:>KR6[I-0?D]G$K<;5H;
M3EJ>Y]#;&,<06DND>_@1@_.<>I6%@L%LL$$D-HI13QR.WW#?<[)[?E$J.<=7
M%%4);)LY;LU_Q9U1^MD_?<N@[3/S U!_HY/L69;=,6BVW:JN=%1B*NJ272R]
M(\[Q))/ G YGD%87*AIKG05%%71]+2SL,<C,D;S3S&1Q4E-.2E_@L8-1:.8[
M.[RRP;(!<9"W$/$ GGEP'\5E[![3)3Z9FN=6UQJJ^8R;[A@N9NMQ\05M;]%V
M!]B;9G4'_P!FM=O"'II!Q]N]GXJZH*."WT<5+1QB*GB;NL8"3@?6K+(FG7JR
M1@TU?H<1VA__ !CM2MUB9O34=*2)6M)]1>#CE\Q;Q]Z+1G_RM_\ ^=2_U+8K
M?I6S6Z\5-UHZ(1W"H>Z228R/<7..<G!) ^<>05VDLKI*#JA'&N7+DX-JRRT6
MSC6UEN5FB,%ND.[,UTCG#JX9<3SQE96V5P?M TZYI!!@:<_]4BZSJ/3EJU)2
MLI[U2"IA8\/:TO<S!P1S:0>LK&N&CK%<*FDJ*VAZ6:D:&0N,T@W1DG'!W'F>
M:U',N&^YEXGREV+FM_(ZC]6[["N.[!OSJUI^O;^_(NSO:'L<QPRUPP1ZE3V+
M3%HL-56U-IHQ3S5CMZ=W2/=OG)/)Q..)/)<XS2BX_DZ2BW)/\&C_ .T9^84'
M^NC_ ''K(OG^!M5_H?\ R6[:BL-MU%0-H[S3"IIFO$@9ON9\H @'+2#UE?4]
MDM\]C=9Y:?>MSF=&8=]W%N<XSG/Q561**7X9'!MM_E&H['W2-V;4KH1^$#26
MCUX"K=':OM.I:*LI]8Q6ZDN$,A88ZK<8=WU;V#G.5T.S6FBLM RBMD'04K/F
MLWB['UDDJJO.A].WF=TUQMC)97<W-D>S/ND)O%MWZDUDDJ.1ZNI[-0Z\TV=#
MS1NJ9:D>4MI)>D:!OLQG!.!Q=E7.WJ.:)UCN,D;C%3N;TC@. .]G^!71[%HZ
MPV*;I;7;F0R>D7O>?^XE6MSMU)=*1]+7P-G@>,.8[^RWUDFG^"=)TU^368MH
M&F8++!4.O%$XB,#H6SL,F<<MW.5SG9O<O.^V&[UYA? 9V;W1O!#F\ .(/L72
M:'9QI2AJ144UGC;*.LRR.'@7$*SH]+6:COD]XI:)L=QG_&2A[N/#'S<X'+J"
MBG"*:5\C6;:OT.4[59&T6U2QUE4X1TVX!TCN#>OK^L+:MLU93UNS>JGHJB*H
MA=(W$D3PYIY]86Y7[3]KOT AN]&RIC'+)+2.76"#U!:+M8M-%9-E]116R'H*
M5DC2UF^YV.?6XDJPFI.*]4247%2?Y)V5:UM'W,TENN%7#0UE,PAS*AXCR"XD
M8R>/ CQ6J;3[A!KK5=LLMBD%9%&-Z22$[S0<.ZQGAQ"W32.D;'?]%6B2[6]D
M\@C=\H/<P_.(YM(SR6TZ?TK9=/Y\ST#*<D8)WG//BXDIO"$G)=QK*44GV-%V
M_C=T[:QV53?X+HFFOS>MG^FC_="^-0:?MFH*>*"\4HJ8HW[[&[[FX=V_)(5A
M301TU/%! W=BC:&,;G. !@!<G)."B=%%J39QW4G^.]N]D7_@LO;_ $=0VEM=
MV@C<]E'+A^!G&<G)]7!=#J=,VBIOL=YFHPZY1XW9ND>,8QCAG'4.I6=730U=
M.^"IC;+$\8<UPX%;65)Q?X,].TU^36[9KG3M1:8ZHWBAC ;\ICYV!P/9C*YA
MI*[PWS;@RNI6O%/(R3HR\8+F[DG'XKI#-FFDF5!F;9VB0G)_#RX\-["MH-+6
M:GO4=V@H61U\;"QLK7N  ((QNYW?\QZNM53A%.KY(XSE5^AS?;'1NH-662_S
MT[9Z!A$4P<W>:T \R.7^9;=%=M"OMXJR^P-9N;^Z1#O<LXQV^I;;6T=/74[X
M*N%DL3Q@M<%JKMF6D72F0V@;^<_E$N/#>PHIQ:2EZ%T:;:]2KV77UU]N-SEI
MK534EMC)9%/#"&=)Q Y@#/(]?4NBK&MU!2VVE934,#(8&<FM62N<VF[1N*:5
M,(B+)H(B( B(@"(B + LWY*[](K/6#9OR5WZ16EV9'W,Y$19*$1$ 1$0!$1
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M:,;(MD55YT?C\3\5'G63N?BFC&R+9%4^=7]S\4%U?W/Q5T8V1;(JKSH_N/\
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MB( .")U(@"'*<D0 (G'J1 $YA$0#DO*G^8?:O7V+S@X,/M0AZ(B?8A0G4B(
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MQM[*6WV5C_+*IP'2!IPP9[>KD56['*F"EIJNS5$#::Z0O+I [@Z08''B ?\
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M0/;VA"'TB^=]O:$#V^D$*2%YT_S#[5]A[>T+S@< PY(YH0]D7R'M[0F^WM"
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MTAC;N. W2"T<<_I*J+DZ1&TE;-H1?$$@F@CE P'M#L=F0OM0H1$0!$1 $1$
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MU54VBOODL-@J[A+63M<]T3L&+Y3^!X'TCX+JM'KUC]60V*NMLM'--$R1DCY
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!8-F_)7?I%9RP;-^2N_2*TNS)ZF<B(LE"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M"B'X(!R1.I!P0HZRB#U%"@"811CCQ0$HB! $1$ "*,J0@ ]:#"(@"#K1!ZT
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MD])WJS05D-&Z3>SO8JYN!R>>'K!92Z2MFNZ.VT%L?)<0"1*V:1^X<.R#E_/
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M=*CHY_H\ONE;"BO4)H:_T<_T>7W2FY4?1Y?=*V!$Z@T-?W)^NFD]TIN3\?\
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MU<_FJEG,4$72.,;P3(,XSCJ:>2TBFBU)JG:#>;70ZIN5OCADD<T"HD+0 [&
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M<*T[D\#7"HSC P2,^ RLO'QLG9I3MTU1N"+B]J=?=I-XN$\%VJ;59Z9_1LZ
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MU9'/IQ,"PVFELEJIZ"A9NP0M#1VD]I]96>B+FW9T7 1$0!$1 $1$ 1$0!$1
M%H^FM$SVC6UYOLE9%+'7R.D;$UA!9DGF?K6\(M*32:7J1Q3"(BR4(B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B +!LWY*[](K.6#9OR5WZ16EV9
M/4SD1%DH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$!X5E0:>/>#2[CR6%YU=W!63<OQ'UJJ76$4UR8DVF9GG5W<'XIYU=
MW!^*PE/4M:HSLS,\ZN[GXIYU=W/Q6&B:(;,S/.KNY/Q4>=7=P5B(FB&S,SSJ
M[N"GG5W<_%8?-$T0V9E^=7=Q\5/G1W<_%8:)HALS+\ZN[DJ?.KNY^*PT')-$
M-F9GG5W<'Q3SJ[N#\5AHFB&S,SSJ[N3\5'G5W<E8B)HALS+\ZN[@_%/.KNX/
MB5B#DI/)-$-F97G5W<?%/.KNX^*Q,=2)HALS,\ZNQ^(/BH\ZN[CXK$4831#9
MF9YU?W'Q*GSJ[N2L-$T0V9F>=7=R4%U<?^3\5AH$T0V9E^=7=R4\ZN[@K$'%
M$T0V9E^=7=P?BI\ZN[@_%8:)HALS,\ZNQ^(/BH\ZNQ^(/Q6)PQP1-$-F9GG5
MW<GXJ/.KNX/Q6(F>U-(C9F6+J[N#\5/G5W<'Q*P_8G:FB&S,OSJ_N/BI\ZN[
M@K#Y!$T0V9F>=7=R5'G5W<GXK$"<DT0V9E^=7=P?BGG5W<'Q*Q$31#9F9YU=
MW!^*CSJ[N#\5B(FB&S,OSJ['X@^)3SJ[N/B5B*/:FB&S,SSJ[N/BI\ZN[@K#
M0<TTB-F9GG5W'\ ?B@NKC_R2L,(FB&S,SSJ[N?BL:@KG00EHCWLG.<KXY+RI
M_F'VIJB6RQ\ZN[DJ/.KNX/Q6("@]2:(NS,OSJ_N#\4%U=W!^*Q$')-$-F9GG
M5W<_%1YU=W!^*PU(31#9F7YU=W!\4\ZN[@^*Q$ZTT0V9F>=7=P?BGG5W<'Q6
M'[$31#9F6+J[N/B5/G5W<_%8?:H31#9F9YU=W'Q3SJ[N/BL1.I-$-F9GG5W<
ME1YU=W!\5B!.>4T0V9E^=7=P?BI\ZN[@^*PE(31#9F9YU=W!^*>='=S\5A\T
M31#9F7YU=W!^*>=7=P?%8B<TT0V9F>=7=Q\4\ZN[@_%881-$-F9GG5W<'XJ/
M.KNX^*Q$[4T0V9F>=7=S\4\ZN[@K#1-$-F9GG5W<?%1YU=W'Q6)U(FB&S,OS
MJ[N/BGG5W<'Q*Q$35#9F8+H[N#\5'G5V?Q)6($31#9F9YU=W!^*>=7=S\5AY
M1-$-F9?G5W<'XJ?.KNX/Q6&G--$-F9GG5W<'XJ!=7]P?$K$1-$-F9@NKNX^*
M>=7=P?BL-$T0V9E^=7=P?BGG5W<_%8@3J31#9F9YU=W!^*>=7=R5A]J?8FB&
MS,SSJ[N?BGG5W<_%87L4IHALS+\ZN[@IYU=W'Q6(B:(;,R_.KNY^*GSH_N#\
M5A84A-$-F9?G5W<GQ3SJ[N#\5B=J)HALS+\ZN[@_%/.KNX*Q!UHFB&S,SSJ[
MN2H\ZN[CXK$1-$-F9GG5W<_%1YU=W!^*Q.I$T0V9F>=7=P?BH\ZN[@_%8B)H
MALS,%U=W!\4\ZN[@_%881-$-F65'7&HE+.CW>&<K.')55L_*/J5JN4E3X-Q=
MH(B+)HQ+E^(^M57L5K<OR?ZU5+M#L<Y=R%*=2@+9@D(@1  @3JYH.2% 3EP*
M!!A .W"A2B$(4H@0H1.7).U"!$ZDPA0@Y*,*<( "B! @"=J(@'J1,H$ 1.M$
M Y*%*( @0H@ 1$XH![$ 3J1"$=94HB =:!.?)/8H4(B?6J @Y(F.)0$84X1$
M [5"GFB (G#BB$(4Y1 @"\J;YA]J] O.G_%GVH#U0IA$ 'J1$!0H"*!\40$H
M%'4IZD 3M10@)1$^U $"(@"(.*! %"GM1" (G((A1S3M0(@"(%"$)3U(G4A0
MB <$ZD "%$0 <T[4X($(,(B!"A$4=: E$1 ,)R1 @'4@11]: E$ZE"$)0($"
M% ]2*%/:A!U<.2=2#B@Y(490<,J%* (B#UH H/)3P4( %(Y)]B!"!0%*80H3
MJXHG:@"=2($!EVS\H/L5JJJV?E'U*U7&?<Z0[!$18-&)<OR?AVK3-;786735
M=5AV[(&;K"#@[SN (^LK<[E^3_6N-;5JEUSOEFT_3Y)DD$DH!SEN\.8]6Z5Z
M,*LX9713[.-07FEU1%2:@K*N6*MC:Z+IWN< 2,C&>W>"[0N7[5;7YLHK)=:-
MI#K;(QKW-', L _=70[+6,N%JI:J-V\V6,.SZ\<?BNL^5LC&/BXLT'9]=*^K
MUS>Z:JK*B:GBC)9')(7-;Q9R!Y<RNEK@]E;=I];WJDL;NBFF&))L9Z-GR>/+
MMQV*]U#HR^62@?<K?J&KJIH<.=&X. /'UN(^"U**;[F8R==CJ]2)#33" @3;
MAW,\@['#XK7-&P:@AJ+H=12,?&^0&FW79PW+L]9Q_EX+PTKJ%VH-$2USCBH9
M"]DA!_SAG$\.7$JCV.5=34SZA\IJ)I@R=H;TCR[=^5)RSR6%%I,WLFT?$-UN
M!VR7*@-;4&A9%$6P=(=P$MBSAO+K/BMEUM3ZAGBI1IR1C") 9<NW3CCUY'JX
M+38/\=;K^JB_=A65MKK*FE9:O)JB:'>F:#T;RW/SN>%NKDE\&+X=G0ZVI=16
MB:HJ"-^.(N.!PSC^:YEH>FU!JQIO4VH*NEIA4?)IHWNW2 <EOSN7(<EM&TNQ
MR72T23LKYJ84[<EC,X?[<$=JT;99I&:Z66"Y,N]33,94G,#-[==ND'J<!Q]B
MD$E%L2O:CM:+EUIJZJP[4*N@K*B9])7'>A#Y"6ASCP S^EU+;MH-V\S:5K:A
MKMR5S3'&=[!WB#C[%AQII&U+AMFQK0=IM\K*6IM=JM,TD=952 N,;B'!F>?#
M]$JRV8TE33:5IWUTLLL\Y,CNE<7$=6./L6L:=_\ B3:E5W//24EN88HB1D'(
M<.'O^M:BJ;^"-VDOR=!K*GS38))ZB3?=34^2]Y^>X-Z_:0N/Z2U3>8M4T=9=
M*NJ=;+G*]D4<KW%C1OCD#P&,K;=LEU=':Z6STSO]XN#]P!IR1AS.KUY6%KS3
MGDNSJWNIV%E5;V-D+@TY;\G+_9Q"U"DN?4S*[X]#J(((!'(\E*H]%7=E[TY2
M5C2"7 M(SQ&"1_!<POE?>OOE5U'9YIG2O(;&TO.XSUXXA<U!MM&W-)6=FJQ*
M:684Y F+#N9]+!Q\5KFB*?4, K?NDD8\E_X'==O8&3ZSCJ6#I[3MQL%JNLUP
MN\U;-- X@.! C(:>1WC_  53L4JZFJIKH:JHEF+9<#I'EV.)[5:I.B7RK.F(
M5Q2HN-\&TVYTEHDGE?)%T36EQ<R(.W1OX.1P/_Z5;770FH(J%];3:AJI[@WY
M1B#7-:[U#Y1'9U*]-+NPIWV1U0YW3N\UJVFJ?4D5\N+[S)&Z@>[\ &NS@9/(
M9X=2QMFFIWZCTZ7U+LUD)+)#P&]@ YP,>DJ3975U-1JS5+*BHFECC>W<:]Y<
M&_*=R!Y**+28V3HZ=[47'=<5]VAVHQ4]JEG=))3L:R(/.X''(WB.(X<^2LZS
M0-]GI'59U)4FXXW^C:TM;GT>#L?!71<6QN^:1T]%H>RG4=3=J*HH+FYSJ^C<
M6N<0!O-SSY>L+3[A47RIVF7NWV>IF#Y"&MWI#N1#=:2<'A_^E10Y:#GQ9VQ0
MM)MMMN.C]-7&JGK:B[5;FAS6;IRUQ..'%V>>>74M<L&D[[J6E=<KQ>ZRCEE<
M7-A:US=W/'B YOJZD45WLNS[4=:3DN4:6K[OIW7+M/W&LDKJ60 1O>,')W2#
MUG_-VK;=7:3FU!6PU$5WJ:$1Q]'N1;V'<2<\'#M4<:?+"E:X-J1<$U39JRW7
MJEM%KOU?6UTQ^4UKWC<''G\L]BZ3J6[RZ1T13-?(Z:X,AC@8XG)>\ -)XY]J
MKAVI]R*?>_0W) N4VC1=\OE RY7345533U#1*V.-IPT'B.3@.SAA>NF;M=M-
M:N9IV]5)K()\"GF=@$DX]I//M33\,;_E'WM=NMPMU=;FT%;44S7EN\(I"T.^
M?SQ[ NG!<DVV#_[1M>>66_\ FNA:NO,=@T_5W!^"Z-H#6YQDD@#[56K2H1=-
MERG4N1V#2]^U32^=;I?*JC$_X2&.-I W7?*!X.;PX]BR;'=+GI+5D=BN]6ZN
MI:HM;!*_@020!VD_.[4T_#Y"G^4=33K48PI"YG0(@1 $0(A" I3VHA0B#D4P
M@"\J;YA]J]1ZUY4_S#VY0AZJ/:I1"A$4("40(@"!.U.* (G:A"$"($0! B(4
M#@G4B(0(B(4($3J*$ ZT0(A0B93J0$*0@1 %J>T;5'W,V3IH0'5<KQ'&T^PG
M/P6V#EQ7)=L>9]2Z?HW#>9("X@G@>)'\5O&KER8FZCP>E-I?659;_+Y=2U=/
M4D9%("['LSO\/!7.S/555=?*K7>0&W*D=NN)/%P]8/7P*WP<@N2V<MI]M51&
MSY(F$CB .9P]:3W3LS6K5'6E(0+QJZF*CI9JFH>&0Q-+W.)Q@ 9*Y'0U_7>I
MF:;M)DC:):R4[D,0YD\3G'U%:;L:NUUK[K<8;K6U-08XS\B60N#3EO(%>^F*
M6766IZB_US2;93Y921.X@D8&\.6>3NWFL38_^=-[_1/[S5VI*+7J<K;DGZ&_
MZLU-1Z:HXYJQKWNE)$;& G>(QPX#AS"Y)>M8:@K]26F;>J[;03U#6Q0MD<SI
M&;S?G#AD8(ZNM=PJJ*FJS&:F"*8QY+1(T. S[5R;:TQL>K],,C:UK!,  T8
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MM3J3GE$ "(G4@ 0>U,81" (B<>I"@\T[44_6@(4!3VH.2$'- B=2%"#UJ%*
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MR5WZ16>L"S?DKOTBJNS)ZF>B(H4(B( B(@"(B (B( B(@"(B (B( B(@"(B
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M[DU#--:[M :>\4^]OMZG 'B<<,<QU+H"X9+V^X[8ZU^T(B+!L(B( B(@"(B
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M(*WNZ;)[%6UDE3!/74+Y#EPIGM /BTJPTIL[LVG*[RV U%56#E-4N!<WJX8
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B +!LWY*[](K.6#9OR5WZ16EV9'W,Y$19*$1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MCYVUC_X4:>H2MR?K"MJ6X/H]G=+54I:Z1E"S=/8=SFKZ[VVFNUOFHJUF_!*
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M;3IV=T]$V62H(QTLQ!=C.>H#L6S+,G9J*H=J)[.M%DV$1$ 1/XJ$!(ZT1.:
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M!VH$[4^Q $1$ YH@1 $ZD4("<)VH.13M0#J7E3CY!]J]5Y4_S#[4(>J)[$*
M* I1"CK3"CGE2@(4HG4A B#L1"@)VHB =6>U2H]B( .2A2G5S0@]B(B%"(B
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MW&CIS-QB$LS6;_Z.3Q^I<HLL;]HVO7W:0.\Q6QX$#7?-D<''!&/T6]97A_M
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MZJF$1%S-A$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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D!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g12080g03a73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03a73.jpg
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M*"@H*"C_P  1" *X!V0# 2(  A$! Q$!_\0 '  !  (# 0$!
M  8'! 4( P(!_\0 6Q   0," @0&#0D%!@0$!0,%  $" P0%!A$'$B$Q$Q=!
M4571%!8B-E1A<72!D9.4L@@5,C53<Y*QTC,WH<'A(T)25G+")(*S\#ABHJ,E
M-$-UXH.$A;0FP_%%_\0 &@$!  ,! 0$               $" P0%!O_$ #01
M 0 " 0$%!@0& P$! 0$    ! A$#$A,A,5$$%!4S05)A<8&A!2(RD='P8K'!
MX?$C0O_:  P# 0 "$0,1 #\ ZI
M
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MP#C2CQC1U4M)35%++2O1DT4R)FBJFS)4W[EYA.G:(VIC@1J5F<1*4@ HN
M
M
M
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M #E=(
M
M
M                                              'G41K-3RQH]T:O
M:K4>S>W--Z>,] !#='VC^@P6^MEI*B>JGJM5'23(F;6IFN29<^>WR(3( FUI
MM.916L5C$  (2
M      (SI%P_68GPS-:J"LCI%F>U9'O:JHYB+GJ[/'EZC\T<X49@[#;+:DS9
MYG2.EFE:W51SE\7B1$3T$G!;;G9V?179C:VO4 !58
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?I*C<_\ 5]'^)*45%1%145%VHJ"U+5_5&"+1;E( "J0
M                  0;2Q=:ZUVNB=;ZF2G=),J.<Q<E5$1=F9B:,[_7U%RK
MK3>:A\T\:<)$Y^_)-BIGR[T5/2=,=FM.EO8ESSVBL:FZE8@(7I-OM5;*"DI+
M9(YE?62:K59])&IOR\:JJ)ZS7:*[M<JZONU/<ZR2IX!&Y:ZYY+FJ+EZB([-:
M=*=7/!,]HK&KNO58H,&WW>@N,TT5#5Q3R0[)&L7-6\G\@EWH%N:VY*N+LY$S
M6'6[K=G^6TQV+<L-=JO/+-UFZVKK)K<V>T_2KHE7CN?MY_\ ^G-E=L>)38NI
MJ&GGHWVM=5)YES56+FJ+MSRV9)R'1/9+9B*\<QEA'::XF;<,3A/P0[&SJ2]8
M:AFI;W#1TRSHJ3ZRZKU1')J[/7Z#;T5;1V;#MO=7W*-\/!L8VI>[9*N6:*GE
M1#*=*=F)]<\L-(U(VICTZMT%5$155<D3E-/78GLM#4I!57*GCF7+N=;/+RY;
MO28>/I&2X(N4D3VO8Z)%:YJYHJ*Y-J*172M-HB8QE-M2(B9CCA(VJCD16JBH
MO*A^D0T4=YE-]Y)\2FSJ,6V&GJ5IY;I3I*BY*B+FB+XU383?1M%YI7CA%=6L
MTBUN&6\!\PR,FB;)"]LD;TS:YJYHJ<Z*?1DU 4[C7$EXGQ#<TM%94145 B-?
MP3\D3)4:JK_S+EZ"S,)73YXP]0UJKG(^-$D_UIL=_%%.C5[-;3I%Y]6&GVBN
MI>:1Z-L#4W/$EGM<_ 5]PABFY69JJIY43<9]%64U=3-J*.>.:!VY[%S0QFEH
MC,QP:Q>LSB)XO<&D?BRPLJNQW76E27/+Z6Q%_P!6[^)M*JLIJ2E=4U4\45.B
M9K(]R(WUB:6CG!%ZSRE[@T]NQ/9;C4I3T5Q@DF7<S-6J[R9[_09E=<Z*@EIX
MJRIBADG=JQ->N2O79N]:>LF=.T3B8XD7K,9B>#,!II,462.N[$?<Z9*C/55N
MML1>;/=_$V\LC(8G22O:R-B:SG.7)$3G52)I:O."+5GE+ZW!%1R9HJ*GB(?B
M/$EHN.';Q3T-P@EG2FDR8BY*NQ=V>_T&FP'%P^C2X1+5]AHKY4X=5_9IDW;Y
M#>.SSL;=N'&(Y,IUXV]FO'AE9((K@1D-LPQ*^2[QU\#)'R.J$<NK&B(F:;>;
M+/TFRGQ/98*.*JEN5.D$N>HY'9ZV2Y+DB;=YG;2F+36O'Z+UU(FL3;@W ,:W
MUU+<:9M10SQSPKL1[%S3/F\IKZW%%DHJI:>IN5.R9JY.;K9ZJ\RY;BD4M,XB
M.*TWK$9F6Y!K[9>K;='O9;ZV&H>Q,W)&[-40Q,:U4]%A:XU%+(Z*=D>;7MWI
MM1"8TYFT4GA,HF\16;1QANP5-AJCQ9?;2E?28@<Q-=S49*]V]/0IM,*8LNE-
MB'YAQ.U%J%=J,FR1%UN1%RV*B\BG1;LDQG9M$S'.&%>U1.-J)B)Y+%!BW*XT
M=L@X:X5,5/'GDBR.RS7F3G,*V8EL]SGX&AN$$LR[F9JUR^1%RS.:*6F-J(X.
MB;UB<3/%MP8ESN5';*?AKA4Q4\6>2*]<LUYDYSPM%^M=W<]MMK8IWL3-S6KD
MY$Y\EVY#8M,;6.!M5SLYXMD#5W7$%JM,B1W"NAAD5,]15S=ESY)M,JVW&CN=
M/P]OJ8JB+/)7,=GDO,O,)I:(VIC@1>LSLYXLH %5@
M
M
M                               5]I3T<18R2&KI:A*6Z0,X-KWIFR1N
M:JC79;4R55R5.==BE?V#%V*\!8FI+%BUSJFAE<UJ+([75K%7)'L?O5$YEYN0
MG6-:?']'B*2X82E@J[?+&UJT<KF]PY$VJB.5-^_8I&Z# ^+,6XMH[SCK@*2G
MI%:K8(W-57(U=9&HC55$15WJJY_R]#2M$:>-28FN/K#CU(G;S2)B?LQ\<_\
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MH]':W=*O)Y4&IJTV;TK/"(B(^)IZ=]JEYCC,S,M/HB^O[]Z/C<(?WVR?]_\
MT#Y7#>)\/XCK*G#L<4U/4N=DYSFY(U5SR5%5-J<Z&5A["=[HL;4]TN4C*EJM
M<^:='I])6*FJB;]FQ-QI>U-J^IM1QKCXJ4K?%:;,\+,>+]]S_3__ $YK\1V2
MWQ:2K?0QTS6TE1J.DCUER<KE=GRYDFCP[<4TH.O*PM^;U3]IKIG^QU=V_>>.
M/,.7>HQ%17JQ,9--"UJ*Q7(BHYJJJ+M5$5-I%-6L7K$6Q^7'U3;2G8M,U_\
MZS]'GI0M]+:\$T]+00I#3LJVJC$55RS1ZKO-?CG]V&'/_P!#_I.-SB:TW^_8
M+IH*J"%;IV1PCXV/:U$:FLB;<\N5.4UFD>EEHM'ECI:A$;-#)%&]$7/)4B<B
MD:%H_)69S.U)K5G\]HC$8A]38-M2:/G5W!N=7K2)5K4.>N>MJZV66[+D,.QU
M,D^B&[1RN5R0/6-F?(W-CLO6JGRVW8SJ<-TMLI^"J+940L<V77:CFL5$5&*J
MKGDF[<2A,*S4.CVILU+JS5LK=9RHN2.>JHJY*O)DF7H+6U(K&+VS.U$_*/\
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MR9#%DJZV:;<\UY,^4UU]6LUM-)C$QU_XST-*8F(MG,3T_P"I* #R7I@
M
M
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M)SY>14+.!K77U*QLQ+.=*EIS,/B"*."&.&%C8XHVHUC&IDC438B(A]@&30
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MM/%>M8K&(Y  *I
M
M
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M^G8]%_Q-5B?FA^Z W.71O1H[<DTJ-\FNO\\SDM&>S_*736<:WSA88 .1T
M
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M9+Z21$"T,*JX8J47<E4[+\+2>G)VFL5U;1'5T]GM-M*LST  8-@
M
M
M
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M
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MD0_3'4OMVFT^K73IL5BL>@ "BX
M
M
M
M
M                         -'BW$M)AF@BJ*N&KJ9IY.!IZ6DA666>3)5U
M6M3Q(JYKDB$=T58VN.,Y<0NN%JCML=NJ^Q&1I)PC]=$771R[LT[G=S@3X
M  !^,>UZ9L<CDYT7,/>UB9O<C4YU7(#]!A7RX,M5DN%QERX.DIY)W9\S6J[^
M1']$URNMYT>V:YW^9)KA5Q+,]Z1HQ-5SE5FQ$1/HZH$M
M
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MGE)$86K-9Q/-M68M&8  0D
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MKY&IW$K$1%36W9YY<O.!.FHC6HUJ(B(F2(G(?H 0
M                     $'T@:1J'!=?2TM915-0Z>)94=$K41$S5,MJ^(M6
MLVG$(M:*QF4X!3O'S:.B*_\ $SK''S:.B*_\3.LTW&IT9[ZG5<0*=X^;1T17
M_B9UCCYM'1%?^)G6-QJ=#?4ZKB!3O'S:.B*_\3.L<?-HZ(K_ ,3.L;C4Z&^I
MU7$"G>/FT=$5_P")G6./FT=$5_XF=8W&IT-]3JN(%.\?-HZ(K_Q,ZQQ\VCHB
MO_$SK&XU.AOJ=5Q IWCYM'1%?^)G6./FT=$5_P")G6-QJ=#?4ZKB!3O'S:.B
M*_\ $SK''S:.B*_\3.L;C4Z&^IU7$"G>/FT=$5_XF=8X^;1T17_B9UC<:G0W
MU.JX@4[Q\VCHBO\ Q,ZQQ\VCHBO_ !,ZQN-3H;ZG5<0*=X^;1T17_B9UCCYM
M'1%?^)G6-QJ=#?4ZKB!3O'S:.B*_\3.L<?-HZ(K_ ,3.L;C4Z&^IU7$"G>/F
MT=$5_P")G6./FT=$5_XF=8W&IT-]3JN(%.\?-HZ(K_Q,ZQQ\VCHBO_$SK&XU
M.AOJ=5Q IWCYM'1%?^)G6./FT=$5_P")G6-QJ=#?4ZKB!3O'S:.B*_\ $SK'
M'S:.B*_\3.L;C4Z&^IU7$"G>/FT=$5_XF=8X^;1T17_B9UC<:G0WU.JX@4[Q
M\VCHBO\ Q,ZQQ\VCHBO_ !,ZQN-3H;ZG5<0*=X^;1T17_B9UCCYM'1%?^)G6
M-QJ=#?4ZKB!3O'S:.B*_\3.L<?-HZ(K_ ,3.L;C4Z&^IU7$"G>/FT=$5_P")
MG6./FT=$5_XF=8W&IT-]3JN(%.\?-HZ(K_Q,ZQQ\VCHBO_$SK&XU.AOJ=5Q
MIWCYM'1%?^)G6./FT=$5_P")G6-QJ=#?4ZKB!3O'S:.B*_\ $SK''S:.B*_\
M3.L;C4Z&^IU7$"HHM.=ID:JI::]-N7TF=8(W&IT3OJ=40 !VO%
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M17:S3R+#P[(EB=')OU7L7:G_ 'XLXD6K:+QF$6K-9Q( "RH
M             .E_DY=X4_GTGPL+1*N^3EWA3^?2?"PM$^>[3YMOF]K0\N
M&#4
M                                               .>?E+]\=H\T7X
MU.ACGGY2_?':/-%^-3H[-YC#M'Z)4Z #TGG@
M                                  RZ3]FOE I/V:^4%5H6B #%S
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M;SB1];;:1]8UMUD9+$K6[T16KW*KSE;<;?F],+1PC\OQ58 #O<8
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M._Z7Q7D"C>,O$'VE-['^HXR\0?:4WL?ZCPW6^!W_ $OBO(%&\9>(/M*;V/\
M4<9>(/M*;V/]1X;K? [_ *7Q7D"C>,O$'VE-['^HXR\0?:4WL?ZCPW6^!W_2
M^*\@4;QEX@^TIO8_U'&7B#[2F]C_ %'ANM\#O^E\5Y HWC+Q!]I3>Q_J.,O$
M'VE-['^H\-UO@=_TOBO(%&\9>(/M*;V/]1QEX@^TIO8_U'ANM\#O^E\5Y K;
M1UC"ZWZ^R4EP="L+8'2)J1ZJYHJ)_,LDY-;1MHVV;<W3I:M=6NU4 !DT
M          YY^4OWQVCS1?C4Z&.>?E+]\=H\T7XU.CLWF,.T?HE3H /2>>
M                                                        #+I/
MV:^4"D_9KY056A:( ,7,
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MZ"E_$O42< :.PWN>XUM135-)V-)"U%5%=FODW&\(Q8^^^\^1/Y$G
M         %<Z;/J6W^<+\*EC%<Z;/J6W^<+\*G5V+SZN?M7DV4^ #Z1X
M                                                       )WH:[
MZY?-7_$TNLI30UWUR^:O^)I=9X'XCYWT>UV#ROJ  X':             !SS
M\I?OCM'FB_&IT,<\_*7[X[1YHOQJ='9O,8=H_1*G0 >D\\
M                                            &72?LU\H%)^S7R@J
MM"T0 8N8
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MN5CVKO147)4/,R[O6+<;K6UKFHUU3,^96IR*YRKE_$Q#JCEQ<\@ )0
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M]\=H\T7XU.ACGGY2_?':/-%^-3H[-YC#M'Z)4Z #TGG@
M                                          RZ3]FOE I/V:^4%5H6
MB #%S
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M[1YHOQJ='9O,8=H_1*G0 >D\\
M                       &72?LU\H%)^S7R@JM"T0 8N8
M                                              Z$MWU?3?=-_(Y[
M.A+=]7TWW3?R.?M'H[NQ<[,@ '*]   !=RD9T>_4<GW[OR:29=RD9T>_4<GW
M[OR:!)@
M                       $8L???>?(G\B3D8L???>?(G\B3@      $:NB
M5E7B9**FKY:6/L9).X3/;K*FX]?F.X]/5/L_Z@2 $?\ F.X]/5/L_P"H^8[C
MT]4^S_J!( 1_YCN/3U3[/^H^8[CT]4^S_J!(#'N-3V'03U.KK\$Q7:N>6>1I
M_F.X]/5/L_ZF'>+17PVJJDEO,\S&QJJQJS)')S;P-K:<0T%RR;'+P<R__2DV
M+Z.<B&FSZEM_G"_"IJ;7::VY/RI(7*U%VO78U/2?>D^@J:##=OCJZQ]2[LC8
MB[F]RNQ%WJ=78O/JY^U>3960 /I'@              2C&M/%:X+1:8XV-E@
MITFJ'HU-9TC]JHJ\N299$>M[6NKZ9K_H+*U%\F9(M)ZN7&]RUN3@T3R<&TQM
M.=6M?A,_ZC_K6L8T[3\H_O[,FWR80DK8+?\ -]?*V5R1]FOGU7(J[,T8FS+,
MQ8L*K)CB2Q-G7@HY%UILMJ1HFMGY<OXGWA*W0T,;<0WE%90T[LZ>-=CJF5-R
M-\2+M5?%Y38:/ZZ6YXRN-34*BU%533*B)_B7+8GH,+3--J:3.(C[MJQ%]F+1
MQF?L^;;!A6\73YHIJ&JIG2*K(*U9U<KG)N5S-R(N7_\ HUUAP_3M=>*J^+(E
M':EU)&1+DZ236U4:B\B9I_%#!P4Q[L76AK$762I8J^1%S7^"$NN[VSX;QKP.
MW5NB.=ES:Z)GZT4B\SIVV(F<3C_>"D1>NU,<L_Z:EMOLM_LMRGLU'-;ZZ@CX
M98G3+*V6--ZYKM14_P"_%#28Z-^X7$$K_P!DRV2ZR\FW++\B'&^EF+6KGA&&
M6IB:UMZRV,%CNM1*Z*"W5;Y&M1ZM;$[-&KN7=RGQ26>Y5DLL5+05,LD*Y2-9
M$JJQ>9>8F&D&]7"CK;934=5+3Q,I(9<HG:NL]4WKEOW)O/O21?+A37NE91U+
MZ9G 1U"I"NIK2*FUSLM^Y$VF==;4MCA'%>VE2N>,\$ ?%)'*Z)['-D:NJK%3
M)47FR-IVM7O4:[YHKU:[:BI [J)Q7,C72]0/=!PG"-CD>B)_>X->Z]&2+Z#S
MH9:JS37JONM\@GI9X)&Q-BJN$=,]WT5:U%V9<_(1/:;3$;,<9B)_=,=GC,YG
MUPK>1CXI'1R-5CVJK7-<F2HJ;T4VV$+9\[XBHJ5Z?V*OUY5Y$8W:[^"9>DU#
MW.>]SWN5SG+FJJN:JO.2W#O_ ,)PA>+LNR>JRH*=>7;M>J>C\C?5M,4X<YX,
M=*L3;CRAIL57+YWQ!75J?LY),HTYF)L;_!$-QAZWVE,)UUWNM)-5.AJ6PM9'
M,L>Q43K(D3"W?NNNWGT?Y-*:L;-*UKPXQ"^G.U:;3TF7I1V>QXEAGCL*55%=
M(F+(RGG>CV3(F]$=OS_[\D4HJ"KKIUAHJ::>5-[(V*Y4\N1(=%\4C\9T3X\]
M2)'OD=R(W45-OI5#[M5/75:WJKI+FELM'#9S3*YR([-RZK41NU=^[QE=N=.U
MJYX<.?Q6V8O6+8Z\D?K+3<*.HC@JZ*HAFE7*-CXU17KXN<QJF"6FG?#41/BF
M8N3F/;DK5\:*3V\N8FCJ.2&ZNN3H+DB1U"L<U8^XSU4UMOC])[W"ULQ)B+#M
MT8U.Q[C&CJKF1T7TT7T)D17M/K:.''[?^$Z'I7GP^Z.X/I^Q,3T]#>*16Q5K
M%@<R:/)41Z=RY,]RYY;30W*D?07"II)?VD$CHW>-47(W=?=7W;'3:Z-55'UC
M$B\34<B-_@B#2(C6XTNJ,W<(B^G53/\ B7I,[R,^L?W_ &K:(V)QZ3_?](X
M#H8             "=Z&N^N7S5_Q-+K*4T-=]<OFK_B:76>!^(^=]'M=@\KZ
M@ .!V@             <\_*7[X[1YHOQJ=#'//RE^^.T>:+\:G1V;S&':/T2
MIT 'I//
M     !ETG[-?*!2?LU\H*K0M$ &+F
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MS\I?OCM'FB_&IT=F\QAVC]$J= !Z3SP
M                             9=)^S7R@4G[-?*"JT+1 !BY@
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M4U$<*N1,U:CG(F?\2]+S,3M>BMJ8F,>K!!:"X#PS38E?AZNQ%4?.LLRQ0<#
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M7XU.ACGGY2_?':/-%^-3H[-YC#M'Z)4Z #TGG@
M                                    RZ3]FOE I/V:^4%5H6B #%S
M                                                          '0
MEN^KZ;[IOY'/9T);OJ^F^Z;^1S]H]'=V+G9D  Y7H   +N4C.CWZCD^_=^32
M3+N4AV"+E1TEHDCJ:J*)ZS*NJ]R(N62 3$&O^>[9X?3_ (T'SW;/#Z?\: ;
M&O\ GNV>'T_XT-+B;$3:>&G?:JN&21']VU%1R*F7*!*CEG3S^\JX?=0_ A?]
MHQ?2564=:G8TO^+>Q?3R>DY_T[/:_2/7.8Y'-6*%45%S1?[-#N_#_-GY.3MG
ME_57P /:>6                   >E-!)4U$4%.Q9)I7(QC&[W.5<D1/2>9
M^M56N16JJ*FU%3D N*UX-Q!%HEO5LDM50VOFKXY8X51-9S41N:IM\2E=6W"%
M\N55<*6BM\DM50*B5$".1'MVJGT57-=J<AK/G&M\,J?:NZSQCJ9XI^'CFD9-
MGGPC7*CL_*8TI>N>,<?A_P"M;6K;'#DM7!]KN.$,(XJJL3Q/HJ*LHG4T%+.J
M(Z>945$5&;]F>_Q^(Q:6@J,7Z);=1V9G9-RLM7)PM,U4UUBD551R)R[51/0I
M6U55U%6]'U=1+.]$R1TCU<O\3YIJB:FE22FFDAD3<^-RM7UH5W,_JSQSG_B=
MY'+'!8]?1S80T4UEMN[> NMZJV/;2JJ:[(8\EUG)R9JF7I\I"\&]]]C\^@_Z
MC35SS2U$KI*B5\LCM[WN5RKZ5/AKE8Y',56N1<T5%R5%+UTYB)B9XRK-\S&/
M185U_?M__-Q_]5I]5?[^?_YMO_50KY99%FX59'K+GK:ZN76SY\^<<-)PW#<(
M_A=;6U]9=;/GSYR-U\?3"=Y_O*X\)Q\)I+Q\UC8YYG1U3&TDSM2*=JR]TCW9
M;$R_,P<4VV[T.#Z^CL>&:>WVB1S9J^6GKVUCW(U<VYJBYHU%V[OYD5P1B2@M
MM+?+??8JN2DNT38Y*BF<G#1JU57--;8J+GMVFQH;_AO#%!=>UQ;K6W"OIGTG
M"5;&1QQ,=O75:JJY=GD,)T[5MPC/+^\VL7K-?W5^ #M<H
M      Z7^3EWA3^?2?"PM$J+0)<Z.VX&='73MA?)5R2,145<VY-3/9XVKZBQ
MNV2T>&L_"[J/GNT^;;YO:T/+AMP:CMDM'AK/PNZAVR6CPUGX7=1@U;<&H[9+
M1X:S\+NH=LEH\-9^%W4!K['WWWGR)_(DY$\-5$53BB[30/1\;VHK7)R[B6
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MQAVC]$J= !Z3SP
M            9=)^S7R@4G[-?*"JT+1 !BY@
M                                  #H2W?5]-]TW\CGLZ$MWU?3?=-_
M(Y^T>CN[%SLR  <KT   %W*0K!5IH:ZU22U=.R61)E:BJJ[LDZR:KN4C&CSZ
MDE^_=\+0-CVN6GP*/UKUCM<M/@4?K7K-L -3VN6GP*/UKUFEQ/AV-8:=EHHD
M25TF3E:J[$RY57<3  1"T8,BBRDN4G"N^S9L:GE7>O\  H73G#'!I$KHH6-C
MC;%"B-:F2)W"'5)RSIY_>5</NH?@0[OP_P V?DY.V>7]5>@ ]IY8
M              &^P;AFJQ5<YZ&AD8R>.G?.U'?W]7+N4YE550BUHK&93$3:
M<0T()X[1WPM!7K;+_;;A<Z")9JFB@UE5K4^EJNW.R\1 RM;UOR3:DUY@)=;M
M'.*+C0T]91VULE/.Q)(W=DQ-S:J9HN2NS0UV),)WG#;('WFD2G;.JI&J3,?F
MJ99_15<MZ"-2DSB)C*9I:(S,-$>C8971+(V)ZQIO<C5R3TDFT8V*#$.,J&BK
M$5:-NM-.B?WF,3/+TKDGI)9=L1:0VK+7V^@K[;969\#3QT2)%'%R9M5NU,MZ
MJ4OJXMLQ]YPM73S&U*J0 ;,@                       '1WR?Z&EK<"R/
MK*>*=S*R1C5D:BY-U6KDGBS5?665\RVSP"F]FA7WR<N\*?SZ3X6%HGSW:?-M
M\WM:'EPU_P RVSP"F]F@^9;9X!3>S0V ,&K7_,ML\ IO9H/F6V> 4WLT-@ (
MGAR*.#%=VCA8UD;6HB-:F2)M0EA%[%WX7C_2GYH2@      CZ]_">9?[B0$?
M7OX3S+_<2          5SIL^I;?YPOPJ6,:;$^':/$=-#!7OG:R)^NW@G(BY
MY9<J*;]FU(T]6+6Y0QUZ3?3FL<W.0+KXK;%]O</:-_2.*VQ?;W#VC?TGL>(Z
M/Q>7W#54H"Z^*VQ?;W#VC?TCBML7V]P]HW](\1T?B=PU5* NOBML7V]P]HW]
M(XK;%]O</:-_2/$='XG<-52@+KXK;%]O</:-_2.*VQ?;W#VC?TCQ'1^)W#54
MH"Z^*VQ?;W#VC?TCBML7V]P]HW](\1T?B=PU5* NOBML7V]P]HW](XK;%]O<
M/:-_2/$='XG<-52@+KXK;%]O</:-_2.*VQ?;W#VC?TCQ'1^)W#54H"Z^*VQ?
M;W#VC?TCBML7V]P]HW](\1T?B=PU5* NOBML7V]P]HW](XK;%]O</:-_2/$=
M'XG<-52@+KXK;%]O</:-_2.*VQ?;W#VC?TCQ'1^)W#54H"Z^*VQ?;W#VC?TC
MBML7V]P]HW](\1T?B=PU5* NOBML7V]P]HW](XK;%]O</:-_2/$='XG<-52@
M+KXK;%]O</:-_2.*VQ?;W#VC?TCQ'1^)W#54H"Z^*VQ?;W#VC?TCBML7V]P]
MHW](\1T?B=PU5* NOBML7V]P]HW](XK;%]O</:-_2/$='XG<-52@+KXK;%]O
M</:-_2.*VQ?;W#VC?TCQ'1^)W#54H"Z^*VQ?;W#VC?TCBML7V]P]HW](\1T?
MB=PU5* NOBML7V]P]HW](XK;%]O</:-_2/$='XG<-52@+KXK;%]O</:-_2.*
MVQ?;W#VC?TCQ'1^)W#54H"Z^*VQ?;W#VC?TCBML7V]P]HW](\1T?B=PU5* N
MOBML7V]P]HW](XK;%]O</:-_2/$='XG<-52@+KXK;%]O</:-_2.*VQ?;W#VC
M?TCQ'1^)W#54H"Z^*VQ?;W#VC?TCBML7V]P]HW](\1T?B=PU4/T-=]<OFK_B
M:761G#>"K;AZO=64,E4Z5T:QJDKT5,E5%Y$3F),>5VS5KK:FU7D]'LNE;2T]
MFP #E=(             '//RE^^.T>:+\:G0QSS\I?OCM'FB_&IT=F\QAVC]
M$J= !Z3SP
M       9=)^S7R@4G[-?*"JT+1 !BY@
M                             #H2W?5]-]TW\CGLZ$MWU?3?=-_(Y^T>
MCN[%SLR  <KT   %W*1C1Y]22_?N^%I)UW*1C1Y]22_?N^%H$G     #EG3S
M^\JX?=0_ AU,<LZ>?WE7#[J'X$.[\/\ -GY.3MGE_57H /:>6
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M.,87IJ16(B?1KK\^GDOEQ?0HB4CJF1843=J:RZO\,C  -XC$893Q  2@
M                 =+_ "<N\*?SZ3X6%HE7?)R[PI_/I/A86B?/=I\VWS>U
MH>7  #!J  "+V+OPO'^E/S0E!%[%WX7C_2GYH2@      CZ]_">9?[B0$?7O
MX3S+_<2
M                        !XUE0E+ LKVN<U%VZH'L#4?/]/\ 9S>I.L?/
M]/\ 9S>I.L#;@U'S_3_9S>I.L?/]/]G-ZDZP-N#RI9V5,#98\]5W/O0]0
M   <\_*7[X[1YHOQJ=#'//RE^^.T>:+\:G1V;S&':/T2IT 'I//
M  !L(++=)X6RP6RMDB>F;7L@>K53G140PIHI(9'1S,='(U<E:Y,E3RH,IP^
M#9U]ANEOMU)7UM!/!1U2(L,SVY-?FF:9>5-HR8:P !               SK+
M:JR]7*&WVR!9ZN;/4C1R-SR157:JHFY%/.YT%3;*^HHJZ)8JJ!ZLD8JHNJJ<
MF:;!F,X3CAEB@ ( #9Q6&Z3666[Q4$[K;$[5?4(WN$7-$W^54$SA.,M8  @
M              !ETG[-?*!2?LU\H*K0M$ &+F
M         ]7P3,8CWQ2-8NYRM5$4)>0/U$S7)-JGZ]CF+D]KFKXTR"'R
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M@     <\_*7[X[1YHOQJ=#'//RE^^.T>:+\:G1V;S&':/T2IT 'I//
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M3@
M                  (O8N_"\?Z4_-"4$7L7?A>/]*?FA*      "/KW\)YE
M_N) 1]>_A/,O]Q(         !7.FSZEM_G"_"I8Q7.FSZEM_G"_"IU=B\^KG
M[5Y-E/@ ^D>
M          "=Z&N^N7S5_P 32ZRE-#7?7+YJ_P")I=9X'XCYWT>UV#ROJ  X
M':\ZF%L\#XG[G)D0J:-T4KXWIDYJY*3DCV)*75E;4-38_N7>4#2  (#?X:JL
MT?3.7=W3?YH: ]:69U/41RLWM7/R@3<'S$]LD;7L7-KDS13Z"0  #GGY2_?'
M:/-%^-3H8YY^4OWQVCS1?C4Z.S>8P[1^B5.@ ])YX          ,JHN%94TT
M-/45=1+3PIE%')(KFL_THJY)Z#&:JM<CFJJ*BYHJ<A]T\$M3.R&GB?+,]=5C
M&-5SG+S(B;S)NEIN%IE9'=*&IHY'IK-;/$K%<G.F:;1PC@GCS>==75=?,DU?
M53U,J-U4?-(KW9<V:\FU145]944T-/45=1+3P[(HGR*YK/\ 2BKDGH,8#!ED
MUM?65[F.KJNHJ7,;JM6:17JU.9,UV(?M;<*ROE9)75=14R,35:^:17JB<R*J
MF*!@RRJNXUM;.R>LK*BHF8B(V265SG-1-J9*JYH9<V([W.^%\UXN,CX?V3GU
M+U5FS+N=NS8IJ@1B#,LN"YUU.ZH=3UM3$ZHSX962N;PN>?TLEV[UW\YBM1%<
MB*N29[5YC\!*%E:4<86N[6&Q6+#LD[[?0,37=*Q6ZSFM1K=B\R:WK*U!ETUM
MKJJDGJJ:CJ9J:#;++'$YS(_]2HF2>DK6L4C$+6M-IR]+9>;G:D<ELN-91H[Z
M78\[H\_+DJ'E5W&MK*IM35UE1/4-R5)997.>F6[:JYF*"V(YHS+)JJ^KJZI*
MFKJJB>H3+*6217/3+=M5<Q65U76U"3UE5/43HB(DDLBO<B)NVJN9C 8,MG48
M@O-2Z!U3=KA*Z!=:)7U+W<&O.W-=GH);HAQ;18=Q;67._P \[FSTKXUDR61S
MGJ]J[>7^ZNTA==;*Z@BIY:ZBJ:>*H;K0OEB<Q)$V;6JJ;=Z;N<PRLUK:,)BT
MUG+;W"_W*=M32LN5;\W22.<VF69W!Y*JK]'/(UU)55%'.V>CGE@F;]&2)ZM<
MGD5#Q!,1$(S+/N=YN=T1J7.XUE8C?H]D3NDR\F:J>+*^L90OHF5=0VC>NLZ!
M)%2-R\ZMSR5=B>HQC,M]LK[BV9;?15-4D+=>588G/U$YUR39N48B#C+XGKZR
M>EAIIZNHEIH?V<3Y%<QGD15R3T":OK)Z2*EGJZB2FB_9Q/D56,\B*N2&,>K:
M:=].^=D,CH&+DZ1&JK6KS*NY"<0<67%>;I%;W4$5RK64+D5'4[9W)&J+OS;G
MD>'9]8M E%V74=A([7X#A%X/6Y]7/+,^Y;97Q6Z.OEHJEE#*[594.B<D;EV[
M$=EDNY?4IXS4T\#(W30R1MD368KVJB.3G3/>1P.+Q !*           9=)^S
M7R@4G[-?*"JT+1 !BY@                 ^XHI)GZD3'/=S-3-0/@'ZJ*B
MJBIDJ<A]11OE>C(F.>]?[K4S4#X,F*OJX:.2DBJ)64TBYOB1V37+XT]"&.Y%
M:JHY%14V*B\A^!,3ADPU]5#22TL51*RFE7-\;79-=Y4]!C  R  (>U)4STD[
M9J65\,K=SV.R5#)N%XN%Q8C*VLFF8FU&N=LS\A@'W%$^5^I$QSW<S4S48CFM
M$SC$/@RJROJZUL3:NHEF2)-5B/=GJIXO48RHK55%145-BHI^!&0 !
M               '0EN^KZ;[IOY'/9T);OJ^F^Z;^1S]H]'=V+G9D  Y7H
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MB_WI5V-3_OER(T^6JK[BZ9.$EJYI%?W"*KE<JY[,O&<D:=)U9FL8Q_N?_/\
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MY6.3QHN2GF>]PJ.RZ^IJ,LN&E=)ES9JJ_P SP.Z,XXN.>?  !*
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M]^V*_)4_]9A^Z%7PNO&.Z?@TFJI'*K8M?461J.D141=Z;5:F?)FA6;3%IO\
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MC_0F_P#(IS3?$Z#2%61OE?,YL,**]^6:]PF\[OP_S9^3D[9Y?U0( 'M/+
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M%#'4.J/[O!ZFWR]692I^JJKO7,QMH9MF)_GZ-(UL1A^  Z&(
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MGY2_?':/-%^-3H8YY^4OWQVCS1?C4Z.S>8P[1^B5.@ ])YX
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M$  +L0          #H2W?5]-]TW\CGLZ$MWU?3?=-_(Y^T>CN[%SLR  <KT
M  %W*1C1Y]22_?N^%I)UW*1C1Y]22_?N^%H$G   ^7QL>YCGL:YS%S:JIGDO
MB/H #EG3S^\JX?=0_ AU,<LZ>?WE7#[J'X$.[\/\V?DY.V>7]5>@ ]IY8
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M$J= !Z3SP
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M[,(C4M&./)+KQC1UTI)8:BUT:O>Q6-E5-9S,^5%4B( K6*\(+WM><V  2H
M         ="6[ZOIONF_D<]G0EN^KZ;[IOY'/VCT=W8N=F0 #E>@   NY2,:
M//J27[]WPM).NY2,://J27[]WPM DX     <LZ>?WE7#[J'X$.ICEG3S^\JX
M?=0_ AW?A_FS\G)VSR_JKT 'M/+                      D."<1)AJX5E
M2ZF6IX>CEI=5'ZFKKHG=;EW9;B/ BU8M&)3$S6<PD6!<1IA>\R5[J9:E'4\D
M&HC]3Z299YY*1T 16(F9,SC  "4-GAF]56'KY272@5O#T[]9$=N<BIDK5\2H
MJH3*/'5BMM=-=K!A=*6]2(Y6S2U2R10.=O<QF2<Z^0KH&=M*MYS*]=2U>$/N
M61\TKY)7*^1[E<YR[U5=ZGP :*                        .E_DY=X4_G
MTGPL+1*N^3EWA3^?2?"PM$^>[3YMOF]K0\N  &#4  $7L7?A>/\ 2GYH2@B]
MB[\+Q_I3\T)0      1]>_A/,O\ <2 CZ]_">9?[B0         "N=-GU+;_
M #A?A4L8KG39]2V_SA?A4ZNQ>?5S]J\FRGP ?2/
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M;VJRFJ(&5#(U7/4UL]G\".&VG:+5B89WK-;3$@ +J
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MC_2GYH2@B]B[\+Q_I3\T)0      1]>_A/,O]Q("/KW\)YE_N)
M*YTV?4MO\X7X5+&*YTV?4MO\X7X5.KL7GU<_:O)LI\ 'TCP
M         />@J.Q*ZGJ-77X&1LFKGEGDN>1X B8SP3$X;6ZW?L[$<MUX'4UY
MDFX+6SRR5-F>7BYCXQ)=/GF]U=PX'@>'<B\'K:VKDB)OR3F-:"L4K&)CTX)F
M\SF)]0 %U3=N)?+BJW5_ 5%[L;:RX0L1G#-J%8V7+=KMRVD0!G?3K?FO6\TY
M-A?KM47JYRUM7JI(_)$:U,FL:FQ$3Q&O +UB*QB%9F9G,@ )0
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M;AVFM5SMLE2R%579)DBKFJHO/RF->L51U-H^:[50LH:)5S<FMK.=MS_/RD6
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MG[1Z.[L7.S( !RO0   7<I&-'GU)+]^[X6DG7<I&-'GU)+]^[X6@2<
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ML7?A>/\ 2GYH2@B]B[\+Q_I3\T)0      1]>_A/,O\ <2 CZ]_">9?[B0
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M2.H@8B-G;FJYYIL54SYDRYBU=3-MG"DZ>*[2#  U9@          RZ3]FOE
MI/V:^4%5H6B #%S
M              '0EN^KZ;[IOY'/9T);OJ^F^Z;^1S]H]'=V+G9D  Y7H
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MWA3^?2?"PM$^>[3YMOF]K0\N  &#4  $7L7?A>/]*?FA*"+V+OPO'^E/S0E
M     !'U[^$\R_W$@(^O?PGF7^XD
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MY&IRKRD%!,:<1.4;<XP  NH          #+I/V:^4"D_9KY056A:( ,7,
M                                                        ="6[
MZOIONF_D<]G0EN^KZ;[IOY'/VCT=W8N=F0 #E>@   NY2,://J27[]WPM).N
MY2,://J27[]WPM DX   'C4U<%*L:5$K(N$75:KER15YLP/8Y9T\_O*N'W4/
MP(=3)M38<LZ>?WE7#[J'X$.[\/\ -GY.3MGE_57H /:>6
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MQU594S1I3.75DE<Y,]9NW)5+A.'M&C.A?8F<NS0U8UJ[40  P;
M    <\_*7[X[1YHOQJ=#'//RE^^.T>:+\:G1V;S&':/T2IT 'I//
M                                                  !ETG[-?*!2
M?LU\H*K0M$ &+F
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M(         !7.FSZEM_G"_"I8Q7.FSZEM_G"_"IU=B\^KG[5Y-E/@ ^D>
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M?OCM'FB_&IT,<\_*7[X[1YHOQJ='9O,8=H_1*G0 >D\\
M                                          &72?LU\H%)^S7R@JM"
MT0 8N8
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M5TK'W"YUE;(B-?4S/F<B;D5SE5?S,4ZHY<7/( "4
M #I?Y.7>%/Y])\+"T2KODY=X4_GTGPL+1/GNT^;;YO:T/+@ !@U  !&+'WWW
MGR)_(DY&+'WWWGR)_(DX     !'U[^$\R_W$@(^O?PGF7^XD          KG
M39]2V_SA?A4L8KG39]2V_P X7X5.KL7GU<_:O)LI\ 'TCP
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M4OWQVCS1?C4Z.S>8P[1^B5.@ ])YX
M                           ,ND_9KY0*3]FOE!5:%H@ Q<P
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M0UM53-<N;DAE<Q%7QY*?%975=:Y'5E5/4.3<LLBO5/6IC@;,9SA&U.,  +(
M>U-2SU/"=C0R2\$Q9'ZC575:F]5\1XD9  $@             G>AKOKE\U?\
M32ZRE-#7?7+YJ_XFEUG@?B/G?1[78/*^H #@=H             '//RE^^.T
M>:+\:G0QSS\I?OCM'FB_&IT=F\QAVC]$J= !Z3SP
M                                      9=)^S7R@4G[-?*"JT+1 !B
MY@
M#H2W?5]-]TW\CGLZ$MWU?3?=-_(Y^T>CN[%SLR  <KT   %W*1G1[]1R??N_
M)I)EW*1G1[]1R??N_)H$F
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MHV&3I#>U^,[JK-R2(GI1J(O\4-*9C4C:YS''Z?\ UG;$Z<XY1/#^_1'0 =+
M             3O0UWUR^:O^)I=92FAKOKE\U?\ $TNL\#\1\[Z/:[!Y7U
M<#M              YY^4OWQVCS1?C4Z&.>?E+]\=H\T7XU.CLWF,.T?HE3H
M /2>>
M   #+I/V:^4"D_9KY056A:( ,7,
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MP/#J>Z3OMNCLCMVPQ_F&U>],ZQV[88_S#:O>F=9QN!X=3W2=]MT=D=NV&/\
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M'Z)4Z #TGG@
M         RZ3]FOE I/V:^4%5H6B #%S
M                               '0EN^KZ;[IOY'/9T);OJ^F^Z;^1S]
MH]'=V+G9D  Y7H   +N4C.CWZCD^_=^323+N4C.CWZCD^_=^30),     '+.
MGG]Y5P^ZA^!#J8Y9T\_O*N'W4/P(=WX?YL_)R=L\OZJ] ![3RP
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M/I/A86B?/=I\VWS>UH>7  #!J  ",6/OOO/D3^1)R,6/OOO/D3^1)P
M          !7.FSZEM_G"_"I8Q7.FSZEM_G"_"IU=B\^KG[5Y-E/@ ^D>
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M:^DQ24:1:"EH;^Q:*%L$=13QSNA;L2-SL\T1.3=GZ2+FNE:+4B89:E9K:8D
M!HH                     )WH:[ZY?-7_$TNLI30UWUR^:O^)I=9X'XCYW
MT>UV#ROJ  X':             !SS\I?OCM'FB_&IT,<\_*7[X[1YHOQJ='9
MO,8=H_1*G0 >D\\
M             &72?LU\H%)^S7R@JM"T0 8N8
M                                    Z$MWU?3?=-_(Y[.A+=]7TWW3
M?R.?M'H[NQ<[,@ '*]   !=RD9T>_4<GW[OR:29=RD(P=>K?;K4^&LJ.#D65
M7(FHY=F2<R>(";@TO;39_#/_ &G]0[:;/X9_[3^H#= TO;39_#/_ &G]1I<3
M8EA?#3NL]8[AF/S=DUR;,N7-,E FARSIY_>5</NH?@0O6T8SC?JQW./4=NX6
M-,T]*=10VG*:*HTB5LL$C9(W10JCFKFB]PAW?A_FS\G)VSR_J@( /:>6
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MZ&.>?E+]\=H\T7XU.CLWF,.T?HE3H /2>>
M                                #+I/V:^4"D_9KY056A:( ,7,
M                                                       ="6[Z
MOIONF_D<]G0EN^KZ;[IOY'/VCT=W8N=F0 #E>@   8?S5;_ *7V+>HS !A_-
M5O\  *7V+>H?-5O\ I?8MZC, &'\U6_P"E]BWJ-+B>P)5PT\=LI:>)_"9O<U
MJ,1$RY<B3 "-6C"-'2:KZM>RI4Y')DQ/1R^DY]T[M1NDBO:U$1J10HB)R?V:
M'4YRSIY_>5</NH?@0[OP_P V?DY.V>7]5>@ ]IY8
M  $AP/AB;%EUGH*:=L,T=-).S6;FCU;EDW>F6:KOY"+6BL9E,1-IQ"/ G[,
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M8^A[?[NWJ'BE/;)X=;JYP!T?VLV/H>W^[MZAVLV/H>W^[MZAXI3VR>'6ZN<
M=']K-CZ'M_N[>H=K-CZ'M_N[>H>*4]LGAUNJJ]#7?7+YJ_XFEUF!0V:VT$RR
MT-OI:>54U5?%$UJY<V:(9YYO:M:-:^W$._L^E.C39D !SMP
M.>?E+]\=H\T7XU.ACGGY2_?':/-%^-3H[-YC#M'Z)4Z #TGG@
M                                               RZ3]FOE I/V:^
M4%5H6B #%S
M         '0EN^KZ;[IOY'/9T);OJ^F^Z;^1S]H]'=V+G9D  Y7H
M   '+.GG]Y5P^ZA^!#J8Y9T\_O*N'W4/P(=WX?YL_)R=L\OZJ] ![3RP
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MF/6,+TU(K$9]&-?I8)[Y<9J-$2EDJ9'Q(B99,5RJW^&1@ &T1B,,IX@ )0
M                   .E_DY=X4_GTGPL+1*N^3EWA3^?2?"PM$^>[3YMOF]
MK0\N  &#4
M                                                     .>?E+]\
M=H\T7XU.ACGGY2_?':/-%^-3H[-YC#M'Z)4Z #TGG@
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M:D5F</< &#K           .6=//[RKA]U#\" '=^'^;/R<G;/+^JO0 >T\L
M                                                         '2_
MR<N\*?SZ3X6%H@'SW:?-M\WM:'EP  P:@
M
M                !17RA;)=;I?[7);+;6UD;*96N=! Z1&KKKL540 UT+;-
M\PRU8S7"J>U#$G0%V]TDZAVH8DZ NWNDG4 =N]ER;J#M0Q)T!=O=).H=J&).
M@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&
M).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=
MJ&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).
MH=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=
M).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=
MO=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T
M!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q
M)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M
M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J
M#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #>R
M;J#M0Q)T!=O=).H=J&).@+M[I)U #>R;J#M0Q)T!=O=).H=J&).@+M[I)U #
;>R;J&32X2Q$D:YV&ZIMY:23J !&]E,:</__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g12080g03a75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03a75.jpg
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M$Q0Q!"$S4A4R06%Q@061(J'1P;'A(T+_V@ , P$  A$#$0 _ -Z #TG@@
M
M                   S+/W6HO3LZ2'0!S_9^ZU%Z=G20Z ,OB.\/0\%VD !
MG;@                B6EGO<W[U?^I"6D2TL][F_>K_ -2%F+U*_F$,GR3^
M'(@ /I'A@
M                               L70%WR*/T,O04ZC.7- 7?(H_0R]!3
MJ,\7^0]7]/4\'Z?[  86L                           IGY3/<2R^L/Z
M)<Q3/RF>XEE]8?T2[P_J0JS?)+GT 'J/-
M                                                       !ETGT
M:^<"D^C7S@BE"T0 4LP
M                                         ,RS]UJ+T[.DAT <_P!G
M[K47IV=)#H R^([P]#P7:0 &=N                "):6>]S?O5_P"I"6D2
MTL][F_>K_P!2%F+U*_F$,GR3^'(@ /I'A@
M      !G6JT7&[OD9:J"JK7QHBO2GB=(K4\*Y)L.3,1YR[$:]F"#=5>%,04=
M-)45=CN<%/&FL^22E>UK4\*JJ;#54M/-5U#(*6&2:9ZY,CC:KG.7P(B<(BT3
MYQ),3'=Y W-UPO?;33)47*T5U+3\&Z2PN1J>=<MAIA$Q;S@F)CN  ZX
M                                   L70%WR*/T,O04ZC.7- 7?(H_0
MR]!3J,\7^0]7]/4\'Z?[  86L                           IGY3/<2R
M^L/Z)<Q3/RF>XEE]8?T2[P_J0JS?)+GT 'J/-
M                                                           !
METGT:^<"D^C7S@BE"T0 4LP
M                                             ,RS]UJ+T[.DAT <
M_P!G[K47IV=)#H R^([P]#P7:0 &=N                "):6>]S?O5_P"I
M"6D2TL][F_>K_P!2%F+U*_F$,GR3^'(@ /I'A@
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MB\W.XTSJ1F=*Z!D+'<*NUN%>#@\!699AFTS,S,Z?37R5Y.&(C2/, !>J
M                            6+H"[Y%'Z&7H*=1G+F@+OD4?H9>@IU&>
M+_(>K^GJ>#]/]@ ,+6                           4S\IGN)9?6']$N8
MIGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M                                                     RZ3Z-?.
M!2?1KYP12A:( *68
M                                      &99^ZU%Z=G20Z .?[/W6HO
M3LZ2'0!E\1WAZ'@NT@ ,[<      !"^K[[6WFOIK?41HV"1R(CVMV)FJ)Q 3
M0$3W#%G^*I_R;\(W#%G^*I_R;\($L!$]PQ9_BJ?\F_"-PQ9_BJ?\F_"!+#%N
ME7U#;YZG4U]R;K:N>69'=PQ9_BJ?\F_"8=XAQ&VV5"UM1"ZF1O;HB-S5/R D
M5IO]!<T1L4NYS+_^E)L7\/#^!J-+/>YOWJ_]2$$B8^21K(FN<]5V(U,U4V^+
MZ>]1:-K[UPE1*?J;9')VTG"G'Q?CF68O4K^80R?)/X<T  ^D>&
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ME,]Q++ZP_HES%,_*9[B67UA_1+O#^I"K-\DN?0 >H\T
M
M     &72?1KYP*3Z-?."*4+1 !2S
M                                                   S+/W6HO3L
MZ2'0!S_9^ZU%Z=G20Z ,OB.\/0\%VD !G;@     (EACZTWO[[NFI+2)88^M
M-[^^[IJ!+0     Q[A2,KJ*6FD<YK)$U55O"9  PK9:J.VLU:2%K5XWKM<OX
MD?TL][F_>K_U(2TB6EGO<W[U?^I"S%ZE?S"&3Y)_#D0 'TCPP
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M6IY$3)"K)EM%XK7>-?VLICB:S-OTIX &A2
M        "Q= 7?(H_0R]!3J,Y<T!=\BC]#+T%.HSQ?Y#U?T]3P?I_L !A:P
M                         "F?E,]Q++ZP_HES%,_*9[B67UA_1+O#^I"K
M-\DN?0 >H\T
M                                 &72?1KYP*3Z-?."*4+1 !2S
M
M                   S+/W6HO3LZ2'0!S_9^ZU%Z=G20Z ,OB.\/0\%VD !
MG;@     (EACZTWO[[NFI+2)88^M-[^^[IJ!+0       "):6>]S?O5_ZD):
M1+2SWN;]ZO\ U(68O4K^80R?)/X<B  ^D>&
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MS[57\&?[(4W\/$]IGOJMKFT[Q]-&)+J;H_<D<D>:ZJ.X<N+,^ #2H
M                           !8N@+OD4?H9>@IU&<N: N^11^AEZ"G49X
MO\AZOZ>IX/T_V  PM8                          !3/RF>XEE]8?T2YB
MF?E,]Q++ZP_HEWA_4A5F^27/H /4>:
M                                                    #+I/HU\X
M%)]&OG!%*%H@ I9@
M                                      9EG[K47IV=)#H Y_L_=:B]
M.SI(= &7Q'>'H>"[2  SMP     $2PQ]:;W]]W34EI$L,?6F]_?=TU EH
M    !$M+/>YOWJ_]2$M(EI9[W-^]7_J0LQ>I7\PAD^2?PY$ !](\,
M
M               %BZ N^11^AEZ"G49RYH"[Y%'Z&7H*=1GB_P AZOZ>IX/T
M_P!@ ,+6                           4S\IGN)9?6']$N8IGY3/<2R^L
M/Z)=X?U(59ODESZ #U'F@
M                                           RZ3Z-?.!2?1KYP12A
M:( *68
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M)+54%7#$D,J*^2%S43M5XU0Z7 ,F?-SK<4QHTX<7*KPZ@ *%H
M               !3/RF>XEE]8?T2YBF?E,]Q++ZP_HEWA_4A5F^27/H /4>
M:
M                       #+I/HU\X%)]&OG!%*%H@ I9@
M
M         9EG[K47IV=)#H Y_L_=:B].SI(= &7Q'>'H>"[2  SMP     $2
MPQ]:;W]]W34EI$L,?6F]_?=TU EH
M
M                                   !3/RF>XEE]8?T2YBF?E,]Q++Z
MP_HEWA_4A5F^27/H /4>:
M                                           #+I/HU\X%)]&OG!%*
M%H@ I9@
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M.\G7;V(_C'2YO:=1CW6T"I=_;#O)UV]B/XQO[8=Y.NWL1_&.ES>TZC'NMH$
MP?I4L^*KY%:Z"CN$4\C7/1TS6(W)J9KP.5?V)^57QVQSI:-%E;UO&M9  02
M                          *9^4SW$LOK#^B7,4S\IGN)9?6']$N\/ZD*
MLWR2Y] !ZCS0
M                                  9=)]&OG I/HU\X(I0M$ %+,
M
M                   #,L_=:B].SI(= '/]G[K47IV=)#H R^([P]#P7:0
M&=N      B6&/K3>_ONZ:DM(EACZTWO[[NFH$M        (EI9[W-^]7_J0E
MI$M+/>YOWJ_]2%F+U*_F$,GR3^'(@ /I'A@
M                                                         L70
M%WR*/T,O04ZC.7- 7?(H_0R]!3J,\7^0]7]/4\'Z?[  86L   !> C%3<Z^G
MGDB?*F;5R^8FT"3@BG7BM^U3V4'7BM^U3V4 E8(IUXK?M4]E!UXK?M4]E )6
M"*=>*W[5/90WMGK%K*36>J+*U<G>\#.             "F?E,]Q++ZP_HES%
M,_*9[B67UA_1+O#^I"K-\DN?0 >H\T
M                                                    &72?1KYP
M*3Z-?."*4+1 !2S
M                                      S+/W6HO3LZ2'0!S_9^ZU%Z
M=G20Z ,OB.\/0\%VD !G;@     (EACZTWO[[NFI+2)88^M-[^^[IJ!+0
M    "):6>]S?O5_ZD):1+2SWN;]ZO_4A9B]2OYA#)\D_AR( #Z1X8
M                          2G"5CL%UI)Y+WB9EHF9)JLB=2NEUVY?.S1
M4X]F7D(VM%8UEVM9M.D(L"U['HTPW?:F2GM.-FU,L<:RO1M Y-5J<*JJNRXT
M(U@'!U/BBHN_5%T2AI;="L[YDAW3-J*N:Y9IQ(JE?/II,[?:5G)MK$;H:"<W
M7#.$::VU,]%C9M751QJZ*#K>]NZ.1-C<\]F?A(,64O%_.$+5FO< !)$
M                                  !8N@+OD4?H9>@IU&<N: N^11^A
MEZ"G49XO\AZOZ>IX/T_V  PM8  !HL2TOS*EJ?Y7?[*;T\ZF%L\$D3^!Z9 0
M<'W-&Z*5\;TR<U<E/@.   &QL=5U/6M1R]I)VJ_[*:X 3P&):JGJJB8]5[=.
MU=YT,L.@          %,_*9[B67UA_1+F*9^4SW$LOK#^B7>']2%6;Y)<^@
M]1YH
M                          ,ND^C7S@4GT:^<$4H6B "EF
M
M           !F6?NM1>G9TD.@#G^S]UJ+T[.DAT 9?$=X>AX+M( #.W
M 1+#'UIO?WW=-26D2PQ]:;W]]W34"6@       $2TL][F_>K_P!2$M(EI9[W
M-^]7_J0LQ>I7\PAD^2?PY$ !](\,
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MGY3/<2R^L/Z)<Q3/RF>XEE]8?T2[P_J0JS?)+GT 'J/-
M
M      !ETGT:^<"D^C7S@BE"T0 4LP
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M/45KT=WV2-JR5"4_TK^%-J<"<19B]2OYA#)\D_ARX #Z1X8
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M++ZP_HEWA_4A5F^27/H /4>:
M                                              #+I/HU\X%)]&OG
M!%*%H@ I9@
M                                9EG[K47IV=)#H Y_L_=:B].SI(=
M&7Q'>'H>"[2  SMP     $1PO]:KU]]_3)<1'"_UJO7WW],"7      5$5,E
M1%3R@ "):6>]S?O5_P"I"6D2TL][F_>K_P!2%F+U*_F$,GR3^'(@ /I'A@
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MM[;++/P[3/DR3-XTGRB8A=CII6=8\YA4@/U45%5%145.%%/PV,P
M                         +%T!=\BC]#+T%.HSES0%WR*/T,O04ZC/%_D
M/5_3U/!^G^P &%K        1:_4NX5BO:G:2]LGGXS6$ON]+U51/:B9O;VS?
M.1 .     #>X:JLG/IG+L7MF_P"YOR#T\KH)F2L^<U<R:P2-FA9(Q>U<F:!V
M'V        4S\IGN)9?6']$N8IGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M
M                  RZ3Z-?.!2?1KYP12A:( *68
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MV[N9:5KVU8P )J0                               &99^ZU%Z=G20Z
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M\.U#5WRS7"Q5[J*[TDE+4HFMJ/XT\**FQ4\J'8M$SI$N<,Q&NC7@ ZX
M        ,ND^C7S@4GT:^<$4H6B "EF
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MI9[W-^]7_J0EI$M+/>YOWJ_]2%F+U*_F$,GR3^'(@ /I'A@
M
M         L70%WR*/T,O04ZC.7- 7?(H_0R]!3J,\7^0]7]/4\'Z?[  86L
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MP3IOJE>\3QQKLK8 &IF             &72?1KYP*3Z-?."*4+1 !2S
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MDN(CA?ZU7K[[^F!+@       #3XPL[[_ (9N%JCF;"^JCU$D<F:-VHO!^!N
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MSI<6RIM'>BBJPGB>&ZS72&I9&Q[-S9$K5763+AS+9 *,F6V6>*RVF.N.-*@
M*TP          ?CD16JCLM54VY^ @\J-25Z1JJLUEU57P$GOU5N%$K&KV\O:
MIYN,BH<      E]E61;;#NO#EL\W$1B@IUJJJ.).!5VKX$XR9M:C6HUJ9(B9
M(@(?H #H  !3/RF>XEE]8?T2YBF?E,]Q++ZP_HEWA_4A5F^27/H /4>:
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M+-53NUGN5,O(B(G$B)L,$'(K$3K]7>*=-/H  ZX
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M1$R1'/Z8$O
M
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M0YV+ZH65C/DXUJ5R3([458DESSW/=6ZN6?%X"A2>#_\ UKNCF^FFP "]0
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M/H[Q<:*+<J2NJ88_[C)%1/R,2>:6HE=+/(^61W"][E55_%3S T@UF?(  <
M              9EG[K47IV=)#H Y_L_=:B].SI(= &7Q'>'H>"[2  SMP
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M< Y^T.8VQ%>\<TU%=;K-4TKHI'+&YK4151JJG AT"9<V&<-N&S1BRQEKQ0
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M:17RJY:TV[@ )(@    #+I/HU\X%)]&OG!%*%H@ I9@
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M5SKC<9ZN1C(W2NUE:S@08[6MKJ9L=*1'#/T8@ +&<
M       &99^ZU%Z=G20Z .?[/W6HO3LZ2'0!E\1WAZ'@NT@ ,[<     !$<+
M_6J]???TR7$1PO\ 6J]???TP)<        1+2SWN;]ZO_4A+2):6>]S?O5_Z
MD+,7J5_,(9/DG\.1  ?2/#
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MY519&KGDY-J^#R"V:M2N*;*+!G7SJ!+Q6=9UE6W;HNX;K\[4XLS!+8\U0
M            #+I/HU\X%)]&OG!%*%H@ I9@
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M[5E--1U<]+4L6.>![HY&+_"Y%R5/S0\2:(
M     "Q= 7?(H_0R]!3J,Y<T!=\BC]#+T%.HSQ?Y#U?T]3P?I_L !A:P
M (YB.JW2=L#5[6/:[S_]?S-]5SMIZ>25W U,_.I"I'NDD<]ZYN<N:J!\@ .
M  &WP[2[K4K,Y.UCX/.:E$S7)-JDRME-U+1LC_BX7><$,D !T        *9^
M4SW$LOK#^B7,4S\IGN)9?6']$N\/ZD*LWR2Y] !ZCS0             /J+Z
M1OG0^3]38N: 7?\ *7^=AK[LW_IG[\I;_N^&?NS?RC*COF(;M?=PZ\5\U7N"
M*D>Z+GJYY9Y?D@OF(;M?6TZ7>OFJTIT5(MT7/5SRS_DA13%->'[:K[98GB^^
MBW\:?^'NP_\ T/ZCXQ!_X<;7]Z/_ %'%1U6(KM56:&TU%?/);8518Z=5[5N6
M>7\U$V(;M-9([/+7S.MD:HK*=5[5-JK_ #51&&8T_.I.6//\:+ILM))BOY/Z
M6VSZLE=3]JZ%%1%5S9=?+SJU<T\Y^Z#L/7#"=/?;OB.!]NIMR:B)-VJY-S5S
ME3B3@\Y2=BO]UL%0Z:SU\])(Y,G;F[8[SIP+^)FW_&6(+_ D%WNM1409Y[EF
MC6*OE:U$1?Q.3AMYUB?*78RU\K3'G"VM",Z5.'<;5#4U4E>Z1$\&;'J5%@/Z
M[6#U^#_4:8]HQ#=K/35-/:Z^:F@J4RF8Q=C]BIM_!5-?25$M)4PU%-(Z*>)Z
M21O;PM<BYHJ?B3C',3:=T)O$Q7[+1^4;]>Z/U&/IR&Z^4M]#AC[L_P#Z93][
MO5QOE8VJNU7+55#6(Q'R+M1J*JHG[J>M\Q#=KZE.EXKYJM*=%2+=%SU47+/+
M\D_(Y7%,</V=G)$\7W6UI-[QF$//3?Z#RD#:UV(;M7VFFME97S34%-EN,#E[
M5F2*B9>9%5#5$L=)I&DH9+<4ZPZ7TN8PNN$K+8I+,^)CJE'-D62-'[$:W++\
MR@L38HO&)JADUZK7U"L^8S)&L9YFIL3S\)YWK$5WO<-/%=J^>JCIT5(FR+GJ
M\"?[(:DYBQ12//NEDR3>?+LO+2=WC<)?_P 7_0<?6'?_  Y73_ZG^HA4%?B*
M[5]IIK965\TU!39;E Y>U9DF29>9%R$.(KM!9)+/%7SLMDBJKZ=%[5<US7]T
M(QAGAT^^J7-C77[:+DPU9:2QZ*Z*^67#U/?KS4Y.?NL.[*S-RHN3>')N2)DG
M'M4VV-9*^7056R7>W06VL?N;G4L#-1K$6=N7:YKDJIDJ^52C[!C"_P"'Z=]/
M9[I/30.7-8TR<W/PHCD5$7S'G6XKOM=0U5'676JGIJIZ231R/UD>Y,LE7V4_
M(C.&TVUF?KJ[&6L5T^RTL 7C&UCM]LMU5AZ6[V*J8QT*HS6U8G[4[=,T1,ES
MR=^QN:Z@L>%=-UB=1,AI&5U.])(F;&,D<CFM5$XM94RR*@M./<3VFA91T%YJ
M8Z9B:K&+JO1B>!-9%R3S&AN%?5W&LDJZZIEJ*J1<W2R.5SE_$[R9F9F?+5SF
MQ$1'=T-CB[8PMF)IV6K"=ON-(Y6N@JDI'2.78GSE1VQ47/P%1Z5;I?[GB"%<
M4T4-%6Q4[6MAB38C%5515[9=NU>,\:32-BVDIDIX;[5;FU,DU]5[D3[SD5?W
M([<[C672L?5W*IFJJE_SI)7*YR_F=Q8II/GHYDR1:/+5N]'F%)L88CCMT4B0
MPM:LL\O&V-%1%R3C7:B)YRZ](%LQ!28?BPO@2R2QVQ(]6:I;*QJO1>%J9N1=
MO\2KP\!S]9;S<;)5NJ;362TD[F*Q7QKDJM547+]D-WOB8MY?K?:3W#)CO:T3
M':"EZUK,3W:2^6>OL5Q?0W:G=353$1SHW*B[%3--J*J%K?)GK(8KW>:-[D2:
M>!CXT7C1BKGE[2%37>Z5MXK7UESJ9*FI>B(LDBYJJ(F2'E05E3;ZN*JH9Y*>
MIB769)&Y6N:OD4G>DWIPRC2T4MQ0N+1YH[O]JTDLKJ^G2*@HII'=4/>F4R*C
MFMU>-<\T7R><W%+7P47RD+BVI<UG5-.R"-7?WUBC5$_'5R_$J.XX\Q/<74[J
MN\U3^IWMDC1%1J(Y%S151$1%5/*::YW2MN=Q?7U]3)/6O5%=,Y>V541$3\D1
M"OE6M,S:?IHGS*UC2L?759F-M'6(J_216OI:&22CK*K=FU29:C&N7-<UXLMN
MSR;"0:;ZFJN&-,,6G#S]:]4B/F9J.1%:YVJK4S78BY1JNWPIX2LXM(^+HJ5*
M=E]J]S1,LW:JN]I4UOW(XRXUC+BE>RJG2N1^Z)4:ZZ^MX=;AS.QCMK$V^A.2
MNDQ7ZND,(55VQBRJM&/\*HV.&+-*N2%6-<[-$R3/@=M5<VKQ&BT P04MSQI3
MTDFZTT4K(XI,\]9J.E1%_%"K*_2#BJOHG4E5>ZIT#DU7(W58KD\"JB(J_F:J
MQXANUB2H2SU\U(DZ(DNYKEK99Y9_FI'D6X9C=+G1K$[+>^3IW)Q9YHNC(:#Y
M.'U[J?4).G&0&RXBNUDCJ8[37S4K*E$25(U^?EGEG^:_F>-DO-PL=8M5:*N6
MEJ%8K%?&NU6KEFG[(3G%,\7W0C)$</V7CHQB=OHX\GBG19(Y96MI-9$W95D=
MM7/B141,_P#,>MT=?[+8[E%A?1_UKGK&JD\\50R94V+\UK=JY9KEQ)X",Z%L
M2VJ!^($O5R917JX;8Z^?+C1<^V78BHY<\ERSV> DV$ZJEP=555QO^D.*[TZQ
M*UE*RH697+FBZVKK.7/9EL\/"9[Q,6G];^:ZDQ-8_>SGIR*URM<BHJ+DJ+Q'
MX;+$EP9=L07*X11;E'55$DS6?W4<Y51/W-:;H[,D@ #@             RZ3
MZ-?.!2?1KYP12A:( *68
M                                          &99^ZU%Z=G20Z .?[/
MW6HO3LZ2'0!E\1WAZ'@NT@ ,[<     !$<+_ %JO7WW],EQ$<+_6J]???TP)
M<      'E5U$=)3OGG=JQ,3-RY9Y(!ZD2TL][F_>K_U(2BFJ(:J))::5DL:_
MQ-7,B^EGO<W[U?\ J0LQ>I7\PAD^2?PY$ !](\,
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M0Z           4S\IGN)9?6']$N8IGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M
M                     RZ3Z-?.!2?1KYP12A:( *68
M
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M)^''^)CZ5FM9HWOK6-1K4I\D1$R1.V0LQ>I7\PAD^2?PY% !](\,
M                                    SYK-<X+;'<)K=61T$F6I4OA<
MD;L^#)V62G)F(=TU9>%\3W7#-5+/9ZG<EE;JRL<U'LD3P.:NQ>/\S=U6DN_R
M4LT%)U#;DF35D?14K8GN3[R;4_ A0(SBI:=9A*,EHC2)?I^ $T
M                      %BZ N^11^AEZ"G49RYH"[Y%'Z&7H*=1GB_R'J_
MIZG@_3_8 #"U@  &CQ)59,93-7:[MG>;B-XNQ"+5=%75-3)*Z!V;E\*;$X@-
M8#-ZUUOV#OS0=:ZW[!WYH'&$#-ZUUOV#OS0=:ZW[!WYH!A&?9:7JFM;K)FQG
M;.]Q\]:ZW[!WYH;^R4:TE+_:)E*]<W>3P(!L  '0          "F?E,]Q++Z
MP_HES%,_*9[B67UA_1+O#^I"K-\DN?0 >H\T
M                                                          &7
M2?1KYP*3Z-?."*4+1 !2S
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M#@^Y6HR1[6N1[4541R<"^4^#>Q@
M L70%WR*/T,O04ZC.7- 7?(H_0R]!3J,\7^0]7]/4\'Z?[  86L
M                  IGY3/<2R^L/Z)<Q3/RF>XEE]8?T2[P_J0JS?)+GT '
MJ/-
M                         !ETGT:^<"D^C7S@BE"T0 4LP
M
M           ,RS]UJ+T[.DAT <_V?NM1>G9TD.@#+XCO#T/!=I  9VX
M")88^M-[^^[IJ2TB6&/K3>_ONZ:@2T        B6EGO<W[U?^I"6D2TL][F_
M>K_U(68O4K^80R?)/X<B  ^D>&
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MRF>XEE]8?T2YBF?E,]Q++ZP_HEWA_4A5F^27/H /4>:
M
M     #+I/HU\X%)]&OG!%*%H@ I9@
M                                                   9EG[K47IV
M=)#H Y_L_=:B].SI(= &7Q'>'H>"[2  SMP     $2PQ]:;W]]W34EI$L,?6
MF]_?=TU EH       !$M+/>YOWJ_]2$M(EI9[W-^]7_J0LQ>I7\PAD^2?PY$
M !](\,
M                            %BZ N^11^AEZ"G49RYH"[Y%'Z&7H*=1G
MB_R'J_IZG@_3_8 #"U@                          %,_*9[B67UA_1+F
M*9^4SW$LOK#^B7>']2%6;Y)<^@ ]1YH
M                                                     ,ND^C7S
M@4GT:^<$4H6B "EF
M                                      !F6?NM1>G9TD.@#G^S]UJ+
MT[.DAT 9?$=X>AX+M( #.W      1+#'UIO?WW=-26D2PQ]:;W]]W34"6@
M     'A7T=/<*.6EK863TTJ:KXWIFUR>!3W [",]@&%/%^W\T@[ ,*>+]OYI
M"3 GS;[RARZ[(SV 84\7[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[
M,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7
M[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC
M/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;
M[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^
M:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[
M,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7
M[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC
M/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;
M[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^
M:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[
M,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7
M[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC
M/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;
M[R<NNR,]@&%/%^W\T@[ ,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^
M:0DP'-OO)RZ[(SV 84\7[?S2#L PIXOV_FD),!S;[R<NNR,]@&%/%^W\T@[
M,*>+]OYI"3 <V^\G+KLC/8!A3Q?M_-(.P#"GB_;^:0DP'-OO)RZ[(SV 84\7
M[?S2#L PIXOV_FD),!S;[R<NNS26K"=AM-8VKMEIHZ6I:BHDD4:(Y$7AVF[
M(S:;><RE$1'8 !QT                           IGY3/<2R^L/Z)<Q3/
MRF>XEE]8?T2[P_J0JS?)+GT 'J/-
M                                                  !ETGT:^<"D
M^C7S@BE"T0 4LP
M                                    ,RS]UJ+T[.DAT <_V?NM1>G9
MTD.@#+XCO#T/!=I  9VX     ")88^M-[^^[IJ2TB6&/K3>_ONZ:@2T
M
M
M   IGY3/<2R^L/Z)<Q3/RF>XEE]8?T2[P_J0JS?)+GT 'J/-
M
M          !ETGT:^<"D^C7S@BE"T0 4LP
M                                                        ,RS]
MUJ+T[.DAT <_V?NM1>G9TD.@#+XCO#T/!=I  9VX     ")88^M-[^^[IJ2T
MB6&/K3>_ONZ:@2T        \*ZLIZ"DEJJV9D%/$FL^21<FM3PJI[D2TL][F
M_>K_ -2$J5XK17=&T\-9ED=GF%?&"V\^@[/,*^,%MY]#CP'J_#J;R\_K;;.P
M^SS"OC!;>?0=GF%?&"V\^AQX!\.IO)UMMG8?9YA7Q@MO/H.SS"OC!;>?0X\
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M$N8IGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M                                                        RZ3Z
M-?.!2?1KYP12A:( *68
M                                         &99^ZU%Z=G20Z .?[/W
M6HO3LZ2'0!E\1WAZ'@NT@ ,[<     !$L,?6F]_?=TU):1+#'UIO?WW=-0):
M        1+2SWN;]ZO\ U(2TB6EGO<W[U?\ J0LQ>I7\PAD^2?PY$ !](\,
M
M                     %BZ N^11^AEZ"G49RYH"[Y%'Z&7H*=1GB_R'J_I
MZG@_3_8 #"U@                          %,_*9[B67UA_1+F*9^4SW$
MLOK#^B7>']2%6;Y)<^@ ]1YH
M                                              ,ND^C7S@4GT:^<
M$4H6B "EF
M                               !F6?NM1>G9TD.@#G^S]UJ+T[.DAT
M9?$=X>AX+M( #.W      1+#'UIO?WW=-26D2PQ]:;W]]W34"6@       $2
MTL][F_>K_P!2$M(EI9[W-^]7_J0LQ>I7\PAD^2?PY$ !](\,
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MH9>@IU&<N: N^11^AEZ"G49XO\AZOZ>IX/T_V  PM8
M        !3/RF>XEE]8?T2YBF?E,]Q++ZP_HEWA_4A5F^27/H /4>:
M
M                #+I/HU\X%)]&OG!%*%H@ I9@
M
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M\IGN)9?6']$N8IGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M
M      RZ3Z-?.!2?1KYP12A:( *68
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M#;W_  #21X:FO^%[Y%>;?3N1M0W<5BDB\N2[>-.'+\2N<M8GAE9&.TQK"
ML5@                          L70%WR*/T,O04ZC.7- 7?(H_0R]!3J,
M\7^0]7]/4\'Z?[  86L                           IGY3/<2R^L/Z)<
MQ3/RF>XEE]8?T2[P_J0JS?)+GT 'J/-
M                                                     !ETGT:^
M<"D^C7S@BE"T0 4LP
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MX$3\RO)EI:W+F=-._P#Q.F.U:\<1W54 #4S@
M  L70%WR*/T,O04ZC.7- 7?(H_0R]!3J,\7^0]7]/4\'Z?[  86L
M                   IGY3/<2R^L/Z)<Q3/RF>XEE]8?T2[P_J0JS?)+GT
M'J/-
M                          !ETGT:^<"D^C7S@BE"T0 4LP
M
M            ,RS]UJ+T[.DAT <_V?NM1>G9TD.@#+XCO#T/!=I  9VX
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MJIFF2Y+PAKE:N;55%3C0_ 21     'TUSF_-<J>91NC_ .^[\SY
M                     !8N@+OD4?H9>@IU&<N: N^11^AEZ"G49XO\AZOZ
M>IX/T_V  PM8                          !3/RF>XEE]8?T2YBF?E,]Q
M++ZP_HEWA_4A5F^27/H /4>:
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M(R;(6":;W5W^WHO;=\(WNKO]O1>V[X1S*[G(R;(6":;W5W^WHO;=\(WNKO\
M;T7MN^$<RNYR,FR%@FF]U=_MZ+VW?"-[J[_;T7MN^$<RNYR,FR%@FF]U=_MZ
M+VW?"-[J[_;T7MN^$<RNYR,FR%@FF]U=_MZ+VW?"-[J[_;T7MN^$<RNYR,FR
M%@FF]U=_MZ+VW?"-[J[_ &]%[;OA',KN<C)LA8)IO=7?[>B]MWPC>ZN_V]%[
M;OA',KN<C)LA8)IO=7?[>B]MWPC>ZN_V]%[;OA',KN<C)LA8)IO=7?[>B]MW
MPC>ZN_V]%[;OA',KN<C)LA8)IO=7?[>B]MWPC>ZN_P!O1>V[X1S*[G(R;(O9
M^ZU%Z=G20Z *NH-']UIZZGF?-1JV.1KUR>[/)%S_ +I:)GS6BVFC;X2EJ1/%
M  "AK                "):6>]S?O5_ZD):1W2+;ZJZX)N]#;XEFJIX=6.-
M%1-9<TXUV$\4Z7B9W0R>=9<<@FN]9C/D.3GHOB&]9C/D.3GHOB/H.=C]T?V\
M?E7]LH4":[UF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB
M&]9C/D.3GHOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE
M7]LH4":[UF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]
M9C/D.3GHOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]
MLH4":[UF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C
M/D.3GHOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH
M4":[UF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D
M.3GHOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4"
M:[UF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3
MGHOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[
MUF,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3GH
MOB'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[UF
M,^0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3GHOB
M'.Q^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[UF,^
M0Y.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3GHOB'.
MQ^Z/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[UF,^0Y
M.>B^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3GHOB'.Q^
MZ/[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[UF,^0Y.>
MB^(;UF,^0Y.>B^(<['[H_LY5_;*% FN]9C/D.3GHOB&]9C/D.3GHOB'.Q^Z/
M[.5?VRA0)KO68SY#DYZ+XAO68SY#DYZ+XASL?NC^SE7]LH4":[UF,^0Y.>B^
M(;UF,^0Y.>B^(<['[H_LY5_;+8: N^11^AEZ"G490.A_ N)+%C>FKKM:WT](
MR*1KI%D8[)5:J)L1RJ7\>3XZT6R:UG7R>CX2LUII,  ,34
M             4S\IGN)9?6']$N8IGY3/<2R^L/Z)=X?U(59ODESZ #U'F@
M
M                     RZ3Z-?.!2?1KYP12AVZ #QWJ@
M
M
M
M                             !3/RF>XEE]8?T0"[P_J0JS?)+GT 'J/
M-
=                       !ETGT:^< $4H?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g12080g03b73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03b73.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2'\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (=\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<](6)#,V8H*3X1@T-4.BPO E)T1C@^+Q)D5DA*.4=;/R_\0 &@$!  ,! 0$
M              $#! (%!O_$ #(1 0 " 0(& 0,$ 00" P$    ! @,$$1(3
M%"$Q44$B,E(%%4)A(S-Q@:&1L20T8E/_V@ , P$  A$#$0 _ +4@
M
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M+:6$V*JKMG-J555?%7BO;Q WH!.0
M
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MJ"1BH^>.GZG^\U-W["#*S91J^OO4U34V]-V:57O=UB=JDM]''/X/HL\NL?\
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MGA\-;&Y8%9 ]J[^%Q^3CG@B;9#=I;1KRVR0O7<E?U3T[%1W#[0+EM,GRP^@
M
M
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M_P!:?S7R(1+MYI*B7:-7.B@D<W=;A4:O<:515%\H8EAHI;A!'G*MC<YJ9[^
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M$5U.RS2.L(IJK2E:D#FNPJ-5RM1?GR;3MMT7/JRPL?;\+74F7,:JXWD[4]I
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MD;OYX8540VW8ALTN'NU#>[S D-+ J]7&YWC.=C@N.[CZ@+(,3"<#)AID
M                                                     !D9  90
M9       &1D  BYY
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M$.T !QRP12XZV-C\<MYJ+@Y !QQ0119ZJ)C,\]UJ()8(ID3K8V/QRWFHN#D
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M-+&[GED34]B'<QPP  3@
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M"WJ+GS&2$NCUKBINT4]DNDB/GIV(Z%[E7+FHN%3UH38!D
M
M
M
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M;2]*6VNGHZV\4L53"Y6/8YZ(J*GSG!#M4T?-*V..^4CGN7")OIS])1F*EO\
MM$U/6ST-.M5<9U6HE;'AO->*]W:AL=EV3:V@NM(^6R3[C9$55ZUG\0%^D7*9
M3"H9/B%,1,14XX/L
M
M
M
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MCX,E^4,]H$.]#Q53:-6HGZ [E^\870Q@I=T.5_[R*WY [Z["Z0&$,@
M
M
M
M                                                     (@ # P
M!C'E4SCR@ !@  ,  ,#        (0Z7'P9K\H9[2;R$.EQ\&:_*&>T"&^AS\
M)-;\A=]=A=,I9T.?A)K?D+OKL+I@
M
M
M
M                                                  A#I<?!FORA
MGM)O(0Z7'P9K\H9[0(;Z'/PDUOR%WUV%TREG0Y^$FM^0N^NPNF
M
M
M
M
M            "$.EQ\&:_*&>TF\A#I<?!FORAGM AOH<_"36_(7?7873*6=#
MGX2:WY"[Z["Z8        #(R87!Y%\O$5OB5$7,R\D[CFUXI&]D3,1&\O0?6
MT\<R1/E8V1>Q5.9KT<F6KGS$53U<T\RRR2*LBKG)L.DKK(E3X//(YS7^]WEY
M*8L6MB]N&84US1,[-V3B##>1DWKP
M
M
M
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MC55SEJ<>\YCH6&7KK53OSQW>)WSZ"D[UB6^)W@ !TD
M
M
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MQZD-AR:?H.;C41+Y'&WH:M+;BQ0LQ3O6&0 :%@
M
M
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MY<
M
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M?-RU?28-+]&6]%.+M>8>L #T5X
M
M
M           *8P9      !YUPLMON,C9*ZB@G>U-U%>W*HAU4TI8D_\ M5)_
MAH>V /$_DI8NRU4G^&AZU-3QTT+8H(VQQ-3#6M3"(AR@#S[I9Z"ZQI'<:2*H
M9_;3CZ3J6G2MDM+]^WVV"%_YV-Y?2N3VP!A$5.1P5E'!60+%5PLFC7@K7IE#
ML #7:;16GJ6HZ^"U4[9<YWERO'S*N#86,:QJ-8B-:G)$3@9  QCGP,@#HTMI
MH:6JDJ::DACJ)%R^1K<*IVWL21CF2-1S7<%1>U#[ '3M]LH[<US:&FBIVN7*
MI&W&3DK*2"MIW05<3)87<',>F44[  \RKA6V62H;:((V/BB<Z*-$PW.%7VD6
M:+VET%\FJ[9K:*EIZR)RHF_%XJHGEXX)E7NQDT[46SC35_G?/66^-)W<WQY:
MJ^@#6]::RTGI_3E8RSOI'5D[-R-E/'E55>]<<#@Z.MEJJ'3]97UD:QK7O:]B
M+SW<NX^M#W+5LDTI;JALR4*3O:N4ZURJGHR;Y!%'!$V*!C8XVHC6M:F$1.Y$
M Y4!A%XJ9         \+6MF]W],W"W-5$DGB<UBKRWL+@KML3ND>D==SV^\(
ML#I_Q6\[@C5XX])8K6E[33VFZZYXWG0QN5J+R5V%5"E^H;U6:@O$E?7.1]3)
M^:F." 7?;<Z)414JX,=GCH?7NG1?I4'^(A1-%J^Q\N/.I]9J_P Z7TJ!>^"H
MAJ$58)62(G!=UV<'*G:0CT8.M]Q[SUV\J]<S"N7R$W-YJ!D
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M)!=*.=V[%.UR]QS&2D]MT<4.Z#X?(UC=YRHC>\^D<BHF.T[2R
M
M
M
M           --VN4$ERT'=(8&N<]L;GHB)E5PBJ09T<Z"AJM6U"5\3'S1,S$
MUZ(N%PN2PNN[O)8M,5]PAC;(^&-7;KDX+P4IY%J2IH]3)>K8U*2=LF^C&>]\
MWF4"[K:>%$PD;$3L1$,^#P_%M]!61NWK4#6HBTU*JHF%7=7CZS/X>]08_P!5
MI/HK]X%G&,:S*,:B=O ^DYJ1QL8UO7:TM]?/<8HF.@D1C>K[45,DCMYKW 9
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M.\;@ .D@
M
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M3MH>I6=XWAICN  D
M
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M$H)7]KG)ZLGG:[7^=PI_9/8T:S=M+?*N3SZ=]5/]*([Y9>Z #T%X
M  "FEZXIMV:*=.U,*;HIXFK(.NM3W8159Q,^JIQXIAQDC>LN#1E3UEMZI555
MC5?;DV).1H^B)]RMDB5??-7!O"<B-);BQ0C%.]8  :5@
M
M
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MNV>#RIDU/5[]^\O1.2(U/4;AI]BLM-,B]K$7U'GX.^HO*BG?)+T0 >@O
M       .O<(DFHIV*F=YBG8,.3**G8J$3&\;"-;/(M'>8TSC#E:I):<B-+Q'
MX)>9<=C]XD2AE2:CAD_.8BKZ#!H9X9M2?A1A[;U<X /07@
M
M
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MST1))9,*YV/,B ;(9     8[S( P@,@ 87GR,@#&."@R ,8,8\A] #"<,F0
M   $(=+CX,U^4,]I-Y"'2X^#-?E#/:!#?0Y^$FM^0N^NPNF4LZ'/PDUOR%WU
MV%TP      8[3)\JN,KW 1Q?7=9>9>_?5/62!;4W:"G3NC;[".ZUW6WF5?\
MS53UDDTR;L$;>YJ(>?H^][RHP]YF7( #T%X             T36L>Y<D?C.^
MB+Z.!L>EITEM$?>W*'G:Y@WJ6*5$SAV/:?.A9U=#/$O8N4/.I]&IF/:B.V28
M]MK3FH,(9/17@
M
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M&ZUD:2TDK%3@K5([LSUI[S'GANNPIYVI^C-2ZC)VO$I+;S7)DPU<IDR>C"\
M
M
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M'IFO'/%6)6Q.\;@ .T@
M
M                                          /&U?35M7I^KAM<CHZM
MS/$<U<+DJ^_2>LMY=ZAN"NSQ7K<Y]9;D%V+-./Q"K)BB\[S*HG\D]8?H%?\
MXG^8_DEK!>"4%?G]XGWENSKUTDD5),^GC629&JK&IVKC@6]7;U"OIH]J776*
MYT%0^DN;IXY4]]&]^?M.C&]T;D<QSFN3DJ+A22M0;/=8WF[5-=4TBODE<J\7
M*N$[$Y'G?@IU7^@IZ?\ (UQDKMWF&6<=M^T/'M5EU)=:7PFW05M1"JJF\R7A
MGYU.W_)/6'Z!7_XG^9,6Q>S:BTXZ>@N],K*%S5>QV>#793V\264Y&:^IFMMH
MB):*8(M&\JB)I/6'Z#7_ .)_F;_L9TWJBBU-X1<&U5-1,8N^V63*/5?)E2?
M5VU,VC;9W73Q6=]P\+7?]3KS\ED^JI[IX.N_ZGWGY+)]53,T(UZ,?]6*[Y0[
M["7Z^G@JZ.6"K:CH)&[KT7AE"(>C)_5FN^4.^PDO6-!47/35?24,TD%2^/\
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M         &!@ !@8!\2RQQ-5TCVL:G:Y< ?6#*)@XH:F&9,PRL>G]EV3E
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M  TK
M
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MDC$8SYH[P]$X=7*J>A22XG(^-')R5##H9[6K/PHP>)AR  ]!>
M
M
M
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M-<P(BPRHG>BG=T7-OT#XE7BQ<^G_ .#SL/T:BU?:BGTY)AL8 /17@
M
M
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MZF8N)6.<KL>7#DQ@"PV0:WH'4T.J]/07&%-URX;(W\UV$54]9L@
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M>BT
M
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M5(S=^,O*^67/K//U_BL*,_PDJE3=IHD[FHGJ.0PQ,-1.XR;X\+P $@
M         ##DRU4(SN4;J.[2-3\EV$)-7D:'K6GZNX),B\'H8==7>G%'PIS1
M].[=Z:1)8&/3DJ'*>-I6?K[2S*Y5B[JGLMY&O';CK%EM9WC< !VD
M
M
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M)R*-%?BQ[>G&&=Z@ -BT
M
M
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MKXT;MWCW'G:?_'FMC9\?TWFK8 80R>BT
M
M
M       #(,*!G(/B-[7^]<UW9P7)]@ 8<J(F7*B)WJ?$<C'YW'M5?[*Y Y .
MT                         #SKM9+9>&QMNM!2U;8URSKHD?CS93R'HKR
M.I=*UEOMU362(JL@C61R)SPB9 ZUR]R[999$K8H([=$Q=Z-6)N(F.[D:]8)M
M%7Z=\-JI+742,3*HVG9P3T$7Z[VQVF^Z9K[934L[9IF*Q%<B83**AH6R#65'
MHV[U5571/D9(Q&)N=G/[P+5?R9L?ZGM__P#69]QYU\HM*V.C\*N=NMD,&]N[
MRTS.:_,:"FWVQX7^:5/H3[S0MK>U2FU=98K;0TKXHNL217O7BN,\, 6"T?<;
M!<*>=VFTI4B8Y$D\'C1B9\N$-A0A+HNTLD>G+I.YOXN6=NZN>>$PI-R
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M:O%%-V#/7+7>/*ZEXO&[[ !>[
M
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M^0N3<Z&FN5))2UL22P2)AS%Y*A',]_T#H.X2I2K3Q5:M1'I Y'+CN7B!'2;
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M\3ISW51$]"&\65FY:J=J?FHIYVG^K47LHQ]\DR[R (#T5X
M       U35=GDGS50*YRHGC-QV&F*W"X7**G,ES"*U47&%-4U+8-[>J:-,*B
M*KV]_E/-U6EWWR49\N+?ZH:O;Z*6NJ&Q0M57+SPG)"1[31)0T;(=Y78XJJFE
M:3JTI+HC9,(C\M55)"1<H3H*5X9M\IP1&V[*<@ >BO
M
M
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MNIJ9)HIHZUS9&=6Y%QPXHOE)73F0?T8+G--9KE0RO<^.&1'1M7\E%YIZR<$
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M@>'K:C1].VI:GC-PBJ<.B*S&_2O7CS:BGG8O\.>:?$L]?HO,>VW@ ]%H
M
M
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M.P+2-3IO3DM1<6[E36.1^YVM;V9)23FIE.0
M$(=+KX,E_?L]I-Y"'2Z^#)?W[/:!#?0Y^$FM^0N^NPNF4LZ'/PDUOR%WUV%T
MP   '1O;^KM=2J+CQ%0[QXVK95BLTJ)S<J)ZRO+.U)ES:=JRU/2[$DO<.>.%
M5?4I(IHVAXE?7RR8X-:;R9M!&V+?VKP1]( #:N           ,&36]<ZLHM)
MVE]76.59'(J11HF5<[L^;D3$3,[0B9B(WEI6W?5LEHMT-LH97,JI]V17-7"H
MB.X?5/=V?ZZMMWL%#X55QQUJ,2.1LBX7*+@K3JB_5>HKQ+7US\R.\5$_-;V(
MAY3-[?16*Y'9X84]"--$TBL^6+GS%YF%YF/:]J.8Y'-7DJ+E#)639MM,KM/U
M,-%=I9)[:J[OC>,YBKY5["RE'515E+%/3O1\4K4<UR=J+Q,>3%..>[5CR1DC
MLYP8;VF2I8!0 .O74[:FDEB<B*CF]O>1U22/MMV:O%%8_"^;D2:O(T;6E&L5
M8VH8B(UZ)GSF'6TG:,D>84YH[<4?#=H9$EA8]JY1S45#[-?TA6I44'5*J[\7
M#YC8$-6*\9*Q:%M9XHW  6)
M
M
M                            !D#P=<72*SZ9KZRHIFU44<;E="[DY,+P
M*@4.I5L^K&7FQ0^"HQ^\V%7<,=J9[BXNK+*S4%BJK;)*L39VJW?W<XX*G+*=
MY$G^CY18_P!LO_\ Z_\ [P/&9TA*O<1'66-7(F%_'KQ_X3/^D)5_J2+_ !U_
MA/8_T?*)>=Z>J?)__>/]'VAS_ME_^!_[@-UV2Z\EUQ05T\M&VE6GD1F$?O9R
MF>Y#?D4TK9KH6#1%)604]6M3X0]'JJLW<83'>INC0,@
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M!>
M
M
M      +R/E[T8U7/5$:G-5[#Z[#Q]7H]VE[JV)'.>M-(C4:F55=U>0'@;2=0
MPT>C+E-;KA"RI;$Y8U:],YPI&>P765RN=]K8KY<M^%L:*WK%QQX\B&*^@O4<
M<KZFEKV0IG>=)&Y&X^<ZEOIZZHD<VVQ5,DB)E4A:JKCRX O-[KV[]-I_IH1I
MMRUG';-,QLLUSB;7NF;PC<BNW<+DKFELU%G'@=T_PW_<?=/IC4=QG;&RUW&5
M[N";T+L>G %A.CO?KG?K3=9+K4NG=',UK%7LRA+R<S1-CFDI=):393UB(E9,
M[K)4[L\D^8WM ,@                       $(=+KX,E_?L]I-Y"'2Z^#)
M?W[/:!#?0Y^$FM^0N^NPNF4LZ'/PDUOR%WUV%TP   QVD?:OD1]W<B+[U$0D
M%2-;RO7WF7''><B&'7S]$1[4YY^EO=ACZJTT[?[.?2N3T#KT$>Y1P-7L8AV#
M92-JQ"V.T  .D@       "G0O5RAM-LJ*VI<C886JYV>T[RD*](?4214=-98
M)$WY<OF1J\41.7M4[QTX[<+B]^"LRBEJ5FN-:X7C+63\<<FM5?9Q+96:W0VJ
MUT]'3-Q%$W=1$(:Z.NG$:VLO55&[>7=9"JIPQQRJ>HG1.1=J;[SP1XA5IZ[1
MQ3YD3M !F:#LX&@[9-+MU#IB5\+56MI<21JG:G'*>LWX^7M1[7-<F6JF%0ZK
M::SO#FU8M&TJN[&M4KIS4BTE2YK*2K5(WJ[ANJB\%]I:)%14\G857VOZ8?IW
M5+YX&/;2U3W2Q+C@BYSA%\F2<-D.IDU%I:'K7HM93(D<J9XKW+ZE-.HK%HYE
M5&"TUF<<MZ !D:0  >'JNA6LMZN9Q=$N]YT-=T?6^#5RPR+ADB8^<WQ[4<US
M5Y+P4C>]TSJ"Z2;J*C=[>:OD/.U59QWC-"C+'#,7A)*&3HV>K;64,4J*BNPB
M.\YWC?68M&\+XG?N  Z
M
M
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MA7AMVX9^'< 3R W+@
M
M
M                    &C[9J>2HV?75L*KO-8KEQW(BY('V Z<MM^U/.EUA
M9.R!F\V)W)>?-"RFM+E2VK3=?5U].M12LB=UD2(B[R87*<2HUCU9_)S6'NM8
M6214F_GJ'+C>;VHOK MFFBM-HB(EEH.'#^@;]QG^1>G/U+0?X#?N(G9TA*3=
M;O6>?>QQP]#[_P!(6B_4U3]- )GM=HH+2Q[+;1P4S7KER1,1N5\N#O--*V9Z
M\AUS1UD\-))3)3O1BH]47.4R;JT#(     1WMNM%VOFDDH;+3]?(^5%>B+A4
M:B+]N"1#3=H^N:?1-'3U%52S3MF?N)U>."X5>.5\@$%:1V*7ZZ-E?<Y$ML:<
M$:]<JY<^3/ UO5-BONS;4$;65CV/7QHIH7JC7(GH\A979OK^BUI23R11K331
M+QC>Y,XSP4B7I-W2EJ;I:Z.!S75$+'J]4[,JF$]0&[7'4RZIV)7*X*W=F6D?
M'*G]K<X^TC'HUHBZ\D5<<(%QZS=]FUDJ*K8A=*945KJJ.18T7RLX*1GL.ND=
MEVA4WA3MQDV8<KWJN$]H$T](O"Z!E_>-^LAHG1E>Y':A1$X>#9^<VOI)W2GC
MTG%1)(UTT[T<UJ+G@CDX^H\CHPVZ3W.O-6],,EQ"WR\$4"*[+XVU)F^G.N>O
MK4MCKE/_ *0NG[I?:5/O\;].;3ZE9>/4UO6<.YRY]BEF=?WVDCV=5E<LS59/
M U685,JKL*!7/8DYS=I%O1N<+)A<=V4+@%4>CQ0.K->K/NY93QK)GN7>3!:[
MD1 R "0(0Z77P9+^_9[2;R$.EU\&2_OV>T"JFS77%=H.]2W.UQ,DFDBZE4?R
MQE%^PE>U=)+4U7<:>!]'3;KWHURY[_F-*Z/NBK9KG5U1;;SOK3QTJRHC%5%S
MOM3L7RECZ3HZ:-I:F.>-M0CXW(Y%61W/T@3-$N]&U5[4/L^6-W6HU.2)@^@/
M U50PS43YG-1LC/RD0TNV4+Z^K; SAE>*]R&[ZODZJT/Q^4J(>)H:-'5<KNQ
MJ<#R]1CK?/%6;)6+9(AM-JM\-OIVQ1-3./&=CBIWC&.U#)Z=:Q6-H:8C;P
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MH*AM52QS,7@Y#LH>A$Q,;PT  )
M
M
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M,W%*Q>"/D7<3RHF"UO>$3O TC97H2#15J<Q7I+73HU9I,=J=B>3B;P$0
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M9U$<EING:CHW(J*O#)(MOJ6U=*R5B\')WF;1Y)F)QV\PKPV[<,_#L  W+@
M
M
M                                                          !J
M^TN[2671ESJZ=V[*D3FL=W*K5P5GV6:#GUW=)Y:F9\='$[,TG:Y>>$7T%B]L
M5&^LT!=61M5SFQK)A/(BJ0ST>]96^PU%5;+K,VG94OWV2.Y(N$3"KV<@/!TG
M:H[+MHI+="Y7QT]4K$5W/WJF[](+0+6I5ZHI97N<][$FB7DB;J-14]"&GTEQ
MI/PY-K/"(_!/"U7K<^+C=[R0-NVT"U3:<FLMJJHJJIG>WK%9Q1K47//EV(!]
M]&"YRSV*XT$KLLAD1T:+V(O/UJ3<G:09T7:"1EINE:YJI')(C&*O;CG["<T
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M4])ZK>7$Q3&W9KCOW9  &K:TMR21)51M57MX.QW'5T7<>K>ZDE<GC+EN>_\
MZ0VZHB;/#)$]/%<U47YR-ZR"2TW/N5BHY/*>=J(G#DC+'CY9\D<%N.$F)V&3
MIVNJ;5T44K%]\G'SG</0K,6C>&B._< !(
M
M
M                               #BJ(8ZB"2&=B/CD:K'-7DJ+V%9=HV
MQNZ6^OFJM.P.JZ)WC[C7(CF+GRJGJ+/+P-$UAM0T_IBH=354KYZEJ96.%,X^
M?. *K/TO?V3;JVFOWT7GU+L^DVC26R?4E_JV+54<M'2NXOFF5$7'FSGU%JK?
M<8*ZRQ72.->JDAZYJ.1,XQDT:T;8M/5MU?;ZCKZ29KUCWI&INJJ+CFB@;II2
MP4FG+)3VV@:B1Q-PJX]\O:J^=3V$/F)[9(VO8Y'-<F45%YH?0
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MMYA7AMYI/P]$! ;EP
M
M
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M$RB4>6MG6W:']XGM)-:F$(YTZW>O,7[2+ZR1T0Q:"/IF?[4X/$@ -Z\
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MHS5_Y498X9XX2&WD9/(TW<$KK>W*_C&(C5/70WTO%ZQ:%T3O&\  .D@
M
M
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M?X[;21L:QM-'AJ(U.!SP4T4&]U,;6;W/=3F<O9S,F/=J$
M   &%0Z-[MD%WMD]%5-1T,K<*BG?,+WB)V//93ZZ4E?H75^ZQZLJ*:171O1,
M;S<\%^?!:?2%]@U%8Z>OIERCVIOIGWJ]J*:1MQTC[M67W2I&*M91HJJB?E-[
M?81QL0U?[AWIUMJWM;1U;FM17?DNSC[?4;;QS\?%'F&2O^*_#/B5F4Y PU45
MJ*G)3)B:P\K4- E=;WM_+;XS3U>P^<<\G-ZQ>LUE$QO&R.M/UKK=<41V4C5=
MUR$BQN1[4<G%%3**:/J^VK3U/A$2*D;^?G/7T?<DJ*5::1?QD2(B>8P:6TXK
MSAM_PHQ3PS-);& #T6@
M
M
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M,]AN65-&#+&6G$LI;BC=D! 7.@
M
M
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MG;T^@E2.15= Y>/'D;_!(V6-LC%RUR90]3!GC-';RTX[Q>'( "]V
M
M
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MMINB8X*QWI0D6WU+:NECF8N6N0:&:Q$UV[F#;;;Y=D 'H+P
M
M
M                                     :AM7MDEUT+=*>%BODZISVHB
M9551JE;=D6N%T5?)/"XG24<_BRM1<*U4[2W[F[R*CDRG+!!6T?8FMPK'U^FI
M&Q.>F7P/7@J\>0&\4^UK2<M.DJW*-BJF=URHB^;!$VVG:?1:DMJ6BS,5\"2(
M]TZKC..Q$-2EV3ZNCFW/<QSESC*+E#;=&["[G5544VH9$IJ5%RZ)BY>[R>0#
M;NC':I:;3E=73,5K:F7$>4QE$X+[":4.I:;=36NWPT5#$D=/"U&-3S'<0
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M9/%TU<DKJ)J.5.N9P5.\]I#=CO%ZQ:%T3O&\  .T@
M
M
M                            /E5QG/(B77&VFUV*LDH[;'X=/&GC.1%W
M47N[,FX[4+I):-$W2J@=N2I$YC')S15:O(J[LWT74:ZODD#IW10-3>FEYJG/
MU@6VM-U6OTU!=-Q&NDI^NW.SEG!%-LVYTS;U-17FD2")DBQI+&BJG!<<>*DM
M6NU,H+!!;&O<Z.*#J=]>"JF,%;-LFS)=,1.O%)5.GIIIO':_&6J[*^@"SU#5
MP5U+'4TDK98)6HYKVKP5%.="'>C3>IZ[3%50U#U>E))B-57/!>."8D R
M                    0ATNO@R7]^SVDWD(=+KX,E_?L]H$-]#GX2:WY"[Z
M["Z>"EG0Y^$FM^0N^NPNF!\2QLDC<Q[45J\T(PN$34N$L;4PW>Y(2DO(C*?Q
M[TJ+VR8]9YVOC>*L^?X;_::"*AIFLB;V95>U3NHF#$?O$\Q]'H5B*QM"^(V
M 2D ,+R Z%^JO K/5U.<=5&KLKY$*K;,Z9+CM MB/17(E0UZX\BD^[:+DEOT
M/58>K'S+U2>7**13T=[;X1J>>M5N64K,97O<B_<:\'TXK69<OU9*U618FZU$
M3DG R&\@9&H                             .P^51%14QG/8?1C %<=N
M&B5L]P6\6^-W@=0[\;A?>/7*_>;;L+UNVOH4LMQE:E3 UK8%7@KVIPQ\W E&
M_P!JI[U:IZ&L8U\,J87/8O>52U':;AH;5+F,<^-T,BN@E3\MJ+P7V&W',9J<
M%O,,MXY5N./"WN3)JVS_ %73ZKL<=7$YK:E$Q-%GBQ3:<\3',36=I:8F)C>!
M3S[U;VU]$^/'CIQ:O<IZ"<3"\E.+5BT;23&\;(TMU1+:;HF]PW78<B]Q(U+.
MVH@9+&N6N1%135]7VO>:M9"WBF-_'M.#2%VZJ1:2=WB.]XJ]BGGX;3I\DXK>
M)\**3R[<$MU3R@PWRF<GI-
M
M
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MATNO@R7]^SVDWD(=+KX,E_?L]H$-]#GX2:WY"[Z["Z92SH<_"36_(7?7873
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M2,:6:>T7%<\',7#D[R1:&JCJX&2Q+E%0YTN?F5X;>81BOQ1M/EV0 :UH
M
M
M                                         8&!D(H&-U.Y!NHG+@9
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M147B?:<C3M*WK"I25*X3@C%7V&X-7@:\.6,M>*%M+1:-X9 1<@M=
M
M
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MSQ5\)';Y#)KVF[XRMB2*=S6SIPY^^/?R;\>2N2O%5?6T6C>'T "Q(
M
M
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M-N_YD/T3T;3M.E8R=;C#ONQ^+2-.:^4C(V?1&F?Y1UDC'2]7'$W><J<U3/\
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M6C>&0,C)8Z
M
M                                               ''/*R&)\LST9&
MQ%<YR\$1$(9U)MYMM!5R06NADK$9P5ZJC45?)Q-SVRU$U/L_NKJ=51RQJU53
MN5%R5AV=:,J=:7EU'3S,A9&F](]R*N$X@2A_I#RXS[AI_BC_ $AIOU&G^*=U
MG1\IMUN]>';V..(>WZ1]_P"CW2?K=W^"O\0&\;*=>.US15T[Z+P5:>1&8WL[
MV4R;XTTK9GH2+0]+600U3JGPAZ/RK=W&$QWJ;J@&0
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MG/A*@/+LEVCN5/O-\61O!S5/4;RXF^MHO&\+HF)C>  '20
M
M
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M?B[_ &ZOY.O:FJENIT>BM<D;45%[.!VL!O(R>9,[]WH1&T;&!@ A(B8
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MH^)[7-7M1<G,>G$[]X:0 $@
M
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M^5>XC.#I!M6IQ-:\0YYIS1/2!/H/#TCJ:W:IMC:VUS(]F$WVX5%8J]BGM@9
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M&1L1J)W(B8.M5,8,-<-?^4::.=EG-/\ PYP >6]$
M %Y'%/#'-$Z.5J.8Y,*B]J'*, 0_M T0M$K[A:F.= JYDC3BK?*AU-#:VEM+
MF4E>JOH^3<\VDT/8U[5:]J*U4PJ*1?K[0R;LE?:(W*Y5R^)%]:'IX-37+7E9
M_P#R\_-I[8K<W#_X2;2SQU,+)8'M?&Y,HY%RBG,07HG6-189O!ZOQZ-5XHJ9
M5OF)JM]=!<*5E122MDC<F45#)J--;!/?PTX-17-';R[0"<@9UX
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MK-J66GW8JOQX^6]CBAN%'60U;-^&1KD7TFS%J*98[+:7B_AV08SQ,E[L
M
M
M                      '3NMNI;K134=?$DM/*FZ]BJJ(J?,:DFRK1N/\
M8L7^))_$;?<JV&W4-15U3MV"!BR/7R(F?L*]LVQWF\ZVM]+;G)36V2I9&K%8
MU7/1787*X7'I E7\%>C?U+%Y?QDG\0_!9HW]2Q?XC_XC3MMVTJKT]U%JLLBQ
MULD:/EE1$7=1>SCV_>0[0;3]5TE4DZ7:HD[5:_#FK\R@6QTYIFTZ;BFCLM&V
MF9*J.>C7.7*_.JGM--4V::MBUAIJ*O:F[,WQ)F+V.0VM ,@    !%>WFPW[4
M-HHZ.P4[YHTDWYD:]K<\%3"Y5,DJ&.\"$=CFRRGI*">IU7:T=5N7<;'*N4:F
M?(N.Q"-]NNF[=IS5<<5H:D4,T?6.B:Y?$7/E\Y8[7NLK?I"U+4UKU=,Y=V.%
MGOG+A5^PJY!%>-INM%<N7RS.YN][&S/+AYP+#:,OLU+L@@NE:]RR046_ONYN
MPS.2OFSFT?RSV@P1W%SI8WOZZ;*^^1%3*+YT+$Z^MT5GV2W*@I6HD4%"Z-$3
MEC<5"%^C4U%UW(J]D#L>L#9-O^AK3:K)3W2T4K*58U2.1K,X<F>"\?.>ST:;
MY/5Z>KJ"ID5[:1V8L_DM7L].3U^D9C^0$OD>SZR&B=&5SFNU#A?_  V4\X&C
M[1J^;4^TRK:U[GL=4-@8G<C41JX]"DT:WV96*#9W*E'11PUU-"UZ3HJ[RN3"
M+GCVY4@^S>-M29E/_'/54\N\I;'7*?\ TE=/W*^T"OO1LO$U'JRIMRR+X/4Q
M9W%7AO(Y,>U2S_WE/]B3W)M(M^[^5)A?-E"X"+W"!D  "$.ESQV9+^_9[2;R
M$.EQ\&:_*&>T"'.ATF-I%<O9X [_ /V,+HY/SLV6ZZK- WV6Z44#)WR0+#NN
MY8WD7["6K=TF+[5U\$'N?3HDCT:N,=OS 6*UV_C3-[\KCT'-I*+K;)51Y1%>
MJMS\QTM;.5[J-5X*K%7V'IZ,CS:I$7DYRGG4_P#MRSQWRRK#M!1*?4$]$R9D
MT<*XWF<E4UA$X$R[>=/6:R4M ZW4J15,TCE>[?555,)WJ:UH[3]#6Z#NUQJX
M$DGBJ&QQO553'O/O/J:9.9$6GY8[8^7,Q'P\O05W6WU\2N\=8WH]J+Y.PDC5
M>N:F^T#:3J6P1[V\[=7WWD-"BM=+#(DD<>ZY.2HJG=-M<%9F)O&\PQSFF(F*
MSVEO^QW<]W)D<Q%?U2JCN[BA,J$,;'?ZP2_N7>U":$Y'D?J'^L]30_Z0 #"V
M                        ,8YF%:BHJ+R/H*!&VO-"LJ6/K;1&C9FY5T3>
M&]YC3='ZHJM-UBPSH]U,Y41\3OR?,3SV&@ZZT1'<FNK+:QD=4B*YS>6__F>C
MI]5%J\K-WA@SZ>:SS<7EN=JN=+<Z1M11RMDC7M3L4[J+DK]IV_5^F+CN.W^I
M1WXR%>U/G[2;K!>:2]43:FCDRU>"M7@J*4:G2SAG>.]5VGU$98VGM+TP 96D
M                  &,<#5]8:(M&IZ9S*RG8RH_)G8F')]_SFTGR[''),3-
M9WA$Q$QM*IVNM#W/154R9)%=2N<J15#'87[\FOV&]U-GOE/<HI'K+&]'.55R
MKDSQ1<F_;>-4+=;ZELII'+342N1R)R5_+[%(K[LGJXM[4WL\Z^U;?2NAIO4E
MMO\ 11SV^JCD5R<69PY%\J'L9*4V.]W&R5;:FV54E/(U<^*O!?.G)2;-#[9X
M)D92ZD8]DRJC4J&-3=7RKW?,ACR:6U>]>\-6/41;M9-9\O8U[5:]$<U>:*AU
M[?74U?3LGHYF2Q.3*.:IVC+LT-:O.F8JC>DI,1R<]WL4U9JUUIG7B^)4[.PD
MTZU914]9&K9XVN3OP8LNDK:>*G:55L43WKVEXEFU+#4(D=4J1O\ SNQ38V2,
MD:BL<CD7M0TB[Z9EI\R4OCL_-[4.C;KQ66Y^X]SE9VM<5TU-\4\.:/\ EQ&2
M:=KI'"+D\BU7NFKD1$562?FN[3UF\4YY-U+UO&]97Q,3&\,@ [2
M
M
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MKL]F3L<3;$Q,;PN9 !(
M
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M&VM6>[1XXYDWO67-LT:16RF8G9&GL/H-7VQQ"G3=[S+MX])G !Y[<
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MEYO/M+60<,,\<T221/:YCN**BY13DWD_.0\UO?0/G?;^<A](
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MZU'6053<T\K7^1%XG83O-L3$]X7,@ D
M
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M0PPU-*J12=6W&\F."KY<$GM()Z+=+,VW76I<BMA<]&M7L5<?Y$[IS
M                  $(=+CX,U^4,]I-Y"'2X^#-?E#/:!#?0Y^$FM^0N^NP
MNFI2SH<_"36_(7?78734#0-:+F[JG]A#K:\JEHMEM0J.W5DAW/.BM4YM6KO7
ME_F1/::]MMFZG9];HD=CK7<N],)]YCT,<6JLR3.TWE#&B($J;_31N3*+(U/2
MI<6D9N4\;4Y(U$*F;+H%FU'2X[)H_K(6VC3#$3R'MZWQ6/\ =SI/-I_V?0 ,
M#:           .PPJ@!G&5*X=(K;,ZU.J-,:;D1M:K=RIJ$SF-%RFZGEQ[27
M-I6T.S:#M+JFYS(ZH<CNIIV<7/5$[NQ.7,HSKF_U>O\ 6,URAH4;/5*UC88&
M<5POMX@:K*]\LKY)'N<]RY5SN*JIW+)=JVRU\-=;JA]/50NWF/8N%0ZU733T
ME0Z"JB?%,Q<.8]%14/6T?IFY:JOE+;+3 Z6:9V,XX-3M55[.&>8&]T6WG75-
MEWNBDV>R1N<>@W/372?O-*Y&7NVTM5'VOC5S7>M29] [%-,V+3D-'=;=#7US
MTS/,]SN+L\DPJ81#H:HZ/.C;LU[K?326Z=>2Q2.5,^9RJ!W-&;=](ZBW8ZBL
M9;:E43\74.PF5[-Y41"4*.LIJV%):.IBJ(EY/C>CD7YT*:ZRZ..I[-OU%E?#
M<8&JO!DB->U.SGCU&D676>M]!5JQ15591JQ>,4[-YJX[/&1?4!^A"8-:UCKF
MPZ0\&2^W"&GDJ'HQC%7+N*XSA.2>4@"Q=*%S+5.V\VMSZ]&JD3H43<5V.&>/
M>0!K?5UTUC>Y;E>*E\LCE7<;C"1IQPB(@'Z.T%73UU+%4T<S)H)$RQ['91R>
M13L%,-@.V>;2U5#9=0S22V9[E:QZMRL*KY>>,^TN115<%=2Q5-)*R6"1J.8]
MJY144#G          '%4PQSQ.CF8U\;N"HXBG6FS^2%[ZRSM=(Q55SH?S?,2
MW@^7IXJEV#/?#.]567#7+&UE9_#*V#\4L\[%;PW=Y4P/=*M_29OIJ=O5B(W4
M->B)A$E7@AY)])6(M$3L\"V]9F-W=CN59O)FJFY_GJ6+LBJZU4CG*JJL;>)6
MB/WR<>TLG87HZST>XY')U:<4/,_4XB(KL]#].F9FV[T08R93D>0]0
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M2
M
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MKQ,ESH
M
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M;E25*?B9FKY,\393/CO]LKHO%O$NX#&3.2UT 9X
M
M                           "\BO_ $HKJ]&V>W1O5&KUDDC47G[W&?66
M *R])SCJF@3/#J%]J >?LEV5IJZA?<KC42P4:.5C&L:F7JG/BOG.WM5V11Z7
MM#KK:JJ6:FCPDK'M3*97&<IY^XDW8!5TT.SJG;+40QNZY_!ST1>33T]L=922
M[.;PQM3 ]RL3")(B\<H!%O1ANLL=XN%N5RK#(Q'HBKR7_I"R)5?HXS10ZTF6
M:1D;5B7B]R)V*6>]T:+]+I_\1/O [0.*&>*=%6"6.1$X*K'(OL.1H&0
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M/;AFBF:CHI6/3O:Y%/)M2U?NAZ=;UM]LN4&$]1E#ET
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M)\.4&$PH3F=)9
M                                                 *T])BGFEU/0
MK%$]Z)"N=UJKVH66.K4VZDJG(ZII:>9R<$62-'+CYT HO$ESA9N1)5,8G8F4
M$ONI*Q62^%/:O-%WE0O$EEMGZNHO\!OW&?<6U_JZC_P&_<!1B&"OA?O11U#'
M=[45#L;]W_.K/^(N_P"XMK_5U'_@-^X>XMK_ %;1_P" W[@(CZ,KJI;1>/#%
MF5W7LQUN>6.S)-2<U.&FHZ>D:K:2GAA:O-(V(U%]!S@      8  C_;M\'%P
M_:;]I%O1<_VY=/W3?M)5VX123;/*]D3'/>JMPC4RO:1CT8Z6HI[W<UG@EC18
MVX5[53O F#:C ^HT#?(XF[SO!9,(G;XJE?.CG4LIMH"1R.PLL+FIY5[BT]73
MLJJ2:"5$6.1JL<GD4J/JG3%]V?ZO2KHHIEBBD22">-N6N3.<+Z.T":.D;(UF
MA'M<J(KY&HB?WD-.Z,5,Y\=^DQXJQ=5\_!31]7ZLU-M"GI:1]%)AGBMAB8N'
M.[U]7H+";'](KI32D450Q&UE1^-G\B]WHP!6N!R6S:BYU3XB1U[D7/E5<>TM
M;KJ>--%W.5SD2/J,Y\ZH03MUT)<*34<U_ME.^6EG<QSNK3*L<C43..?-/6:]
M>=HVI[UIIE@EIY$;NMC>]C%WWHWDB\/( V#TRU.T:F5J9ZK,BX\CD^\MS@A3
MH]:&J;/%47JZP+%45#$;"Q_OFMSE57U$V    (/Z7/P9_P#[#/:3@0ATN?@S
M_P#V&>T"IVS_ $7=-<WB2W61K'U$<?6KO.1J;J*B=J^5"2:7HZ:UIZJ.5T%/
MNM<BKB>/^(YNAVJ+M(K<93^8.^NPN>_@QW=@" ]>R)0Z0J87/;UV$C<U%\^2
M*],,WKAG\U$4V[:G(K:ZM8BKNK*O#/#FIJVE&_SB9W:C4^T]3].TL::L1$[[
M]WC9;\5966V95%-3Z5A;)/$QRO<N%<F>PW1CT<W+7(YJ\E0K%%/,SQ62R-;W
M(Y4+%:855L5(KE55W,Y4KUVGY<\>_F6O1Y^9'!MX>KE1Q(UVR[4;=H&RR-;(
MR:\2L5*>!%RJ+^<[N[R-=A^WM]WN2VG6,[&2RJYT-2J(U,YRC5PG_6#SVY95
M ?,;VN8CF*CFJF45.2H9R!D^>]>!]9-+VLZSI]$Z.K;E(]J56XK:9G:YZ\N'
MGP!"W2HVE]4S^2MEJ6JKV+X<K4XIGANY\R=G>0G8MEFH[YHRJU);Z-SZ:)RI
MN93>>B8RJ(O''%?0?&A['<=I6T"**97S+4U"254J_DLSE<KYD4OU8K/1V:ST
M]LHX(V4T+-Q&(W@O?GS@5)Z/^Q:HO]5#>M2TTL-KB>NY$Y=UTKDX<4YXSYN1
M<*CI8:.EBIZ:-L<,348QC>2(G(^H88X6(R%C(V)R:U,(GS(<@
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M5[ =9V!SYZ&%+C$QRX?3/1'>?"X4"[]-5054>_331RL_.8[*>HY>)^>E'?\
M7NCI>%3>*)6\-V5'.;G^]E"1-,])C4= UK+W217!J<WJB,=ZL(!<C(0@W3?2
M1TK<5C9<HY[?(Y415>F\U/1DDRRZ\TO>(V.MU\HI4=R19-Q?0["@;,#CBGBF
M;O0RLD;WM<BH<F0&#@K&J^FE:U,JK51$.?/ PN *_3Z/OBS/5M!(J*Y<+E/O
M/C^1U]_5\GI3[RP?#FIXM%JNQ5M[GM%+<Z>6XP(BO@:[BGV+R[#TH_4\GJ'G
M_M]/<HBLNB[I+<Z5E=12,IG/1)'(Y.#<\3;[CLOI9$<M#4RL7'!'JBIGT$D(
MG'D91,E5]?EM.\=EM-%BK$Q/=!UPV>7NDRZ"-L[4[6O1%]IY2Q7^T.7Q*J+=
M[<*J?<6'P<4M/%*BI+&QZ=SFY+*_J-_%XB5=M!7S29A!]!M OE$B,D>R9J<,
M2,X^K!LMNVI-542NI,=ZQHOWFZU^E;-6HO7T$.5[6IN^PUJX[,;?,G\TGD@7
M/+FAUSM+D^ZNSGE:G']MMWJ4.O;)581:KJG+V/8[VXP>]376BJDS3U<,GF<A
M%%?LQN,"+X+/'*G=R]IK\^GM06U55:>I9_:C=GV*.DT^3_3N=3GI]]%@VNRF
M45%\IE%*^4^H=0V[&*FJ8B=DC<^U#W:#:9<X5:E5"R=.U53"^HXM^G9(^V8E
MW77XY^Z)A,V3)'5OVH4,G"KII(E[TPJ&Q4&M+)6(F[6L8[\UZ*GV&:VFRT\U
M:*ZC';Q9L8.K!<:.H3,-5"_S/0["/1>2HJ>0IF)CRMB8GP^@,F,D)9!C)G(
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M  9
M                     ..>*.9BLE8U[%YM<F44XZ:CIJ9RK3T\,2KS5C$3
M)V  [.!P55+3U4:QU4$4S/S9&HY/6<X \^CL]MHI-^CH*6!_YT<36KZD._@R
M ..2-DC%;(U',7@J.3**>?'8;3'-UK+91-E_.2%N?3@]0 ?+$QP3@B=A]
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MHW45NU/8*:YV>3?II&HF,85JXY*>V
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MV=BG,RHB=[V1JG46B3>'*#XZQJ\G(9RU>TZ2^@?*+Y3(&08 &0
M         ,+S R#"=ID
M0ATN/@S7Y0SVDWD(=+CX,U^4,]H$-]#GX2:WY"[Z["Y%U7=H95\A3?H<_"36
M_(7?787'NZXM\OF.;_;*)\*N[8Y-[4T;/S(D/6V0TG7W6WIG&)6O\^%0UO:G
M/UVK:C_RVHWUJ;)H6_6_2%IDO=U1[HZ>+,;&IQ<_&<>H]72?X]+O_P#EY<QQ
M9(C^TWZ_UC:]$V&6Y7:1OBM7JH=Y$=*Y$X(GJ*1;0]JNH-9R5D-9521VR=R*
ME*DBJQJ(N4X<NQ.P\_:5KNYZYOTE?<GJD:>+%$B^*QO<AJ"]G#BG8O$\QZJ>
M=A>R*CUSHV]5M=+U<[_Q5+(C<[CDPN?5CYR4MBNPJ#2=>^ZZA=#6US5<V%G5
MY:Q,\'<>W'M($V);5*W0-WC@GWIK-4/1)XD_)SPWF^HO19KC!=K52U](JK!4
M1I(Q5[E ^+O::"\4+Z2YTD-33OYLE8CD\_$IWM\V-S:2J9+O9&.FL\TCE5C8
M_P#5^U$X=G/NY%TT0X:REBK*26FJ8VR0RM5KVNY*@'Y@(G:JXQQ0D[8MLLKM
M?79LDR.@L\+T2:?<SE.>ZGS>TEJ_]&E*C6[9;74,AT_*[?>Q??Q\?>IWEB]/
M62AT_:X;?:H&P4T2>*U &FK)0Z>M$%NM4#(*:%$1$8U$RO>N.T],(
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M?VG8/ICVO1%8Y'-7M:N0/L
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M2B]<J>]7L-B3N.&FGBJ8630/:^-Z9:Y%X*ARIS.\>.N..&JZM8K&T/H %B0
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M27%<7&E:W>=G^D3EGV>DD[OR5,Z/]6ZDVA1QHJHV=BQ8SS\9/N+9]F0,@&%
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M6L:CFKC"*5]UGH>X:<G>KU9-2(OB31JJICR^4RZ;4XK_ $UC95BRTGM'9J?
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M!\1']%!X+!\1']% /S;\#U#^CUOH4>!ZB^(K?HJ?I)X+!\1']%!X+!\1']%
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M@B@?5/625455WG+Q[3V4IX?BV?10YL(, ?$;&L3Q&HU/(F#[
M
M
M
M
M         8R?,\C(8))9%PQC5<Y>Y$XJ5IUUM<OEUOTE!I:62"F:_<9NM3?>
MJ<U\GI LQE#)4^EVCZVTO=(DO51-(Q51713(BY3R*66T=?Z;4VGZ6Z4B.:R9
MJ*K7<VN[4]('M                                #((ZVS:Y;I.Q.AI
M9%2YU3%;#C"[O9O>WT 2+E,\P5UV#ZOOM[UGX/=+E/4P+$]=QZY3.%+%
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MRM2F5-[?1$QCGR))V-;5JC4%<EHORHM4YN8ID1$1WD7 $V
M              8<YK&JYRHB)VJH&<F,D#;:MJ;J5[;5IFKD94,5>NFCQCS(
MO,V?H_7NXWS2M7476KDJIFU3F(Z1<JB;K%QZU E/)C*'!7545%1SU52[=AA:
MKW+W(A6[6FUZ^WB]24&E7/IZ='JQBM:BO?CAGR>D"S.4!4YFT+76E[A'[KU$
M[VKQZN9J+O(64T5J&GU/IZEN5-E$D:F^U?R783*>D#W0
M         O(!D9/ASD:Q7+P1$RJ^0KSM+VPW)+Q4VK3+G0I!*Z-9=UJN<J93
MAS[<@6(WC**5*K=6[1;3"RNK*RLCA=R<]$5OH)GV.[1UUA3STM>W<N,&%541
M$1Z*B\>'F D[)C*&A[6==,T99V.B;OU]1E(6X1414[5SYR!(]:[0+I!-<:6M
MJUIXU\98VHC6_,!;C(0@[8SM5JKU<&66_N5]5(J]5-NHF<(JX7'F4G!./:!D
M                          ,F,H:MM'U?3Z/T_)6S-5\SO%A8GY3BO/X0
M->ZHK9EM-1.V/GN0-:B-PG>!:_)DJQIS:SJ>P7EE/J&66I@1R-DCD:F\GES_
M )EFK/<(;K:Z6NI558:B-LK<]RID#NY,;R'S+(R*-SY'(UC4RJKV%6=I&UB[
MUVH)&V"OGI*"++&[F$W^*\?8!:G(-;V>5=17Z+M-562NEJ)8<O>O-5RILB<@
M                                    #O U3:E6NH-"7:>-51W5;G#R
M\/M*^]'6@96;06S2(CEIHGR)E,Y545/^8G/;4QS]G-TW>QK5_P")"&>C(N-:
M5>>VE7'I0#<^D];HGZ>MU?A.M94=4BHG'"M<OV'UT8:YTM@KZ-RKB%Z*U.[*
MKD[G2:_J31<?_&)]1YX'1;B?N7:7CN>*WY\_Y 3\B8!CN,@
M                'F:BO%-8;/57*N=NPP,5R]ZX["IUR]U=H]\O%U5RI!1Q
M/F7*\&,:BN1J>CUFS;?-:OO-\;8Z-ZQ4=.N[(N]P>_/:GDPAM5FJM)Z;V77.
MWTMWHIKA54DJR*US4<YZL5$3&?,!I?1M3&O_ /T7^Q2U!4G8-=Z&SZV6HN=3
M%30=4]-^1V$SA2UMOK8+A21U-%*R:"1,M>Q<HH'9
M         #BJ&K)!*Q%XN:J'*<-9.VFIY9Y.#8VJY54"H+FNT;M0Z^]TRK#%
M5N>N4SO-WO?(2CMAVC:<NVC9**VU#*RHG7@U&^\X+Q\Y&VJ+O<MIVMXZ.!J1
MQ]:YD")QW6JN,KZCV]<[%:G3U@?<J*X>&=2F9(^IW>'>GC*!MG1ELM534-QN
M-1&Z.&9S61Y_*PB\?63JA"?1^UW/=X9+)<<+-"F879XJW'%,>3'K)L0
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MXG2I$^->S*.7.?F)!Z.U_J;QI&6FJWJ]]"]L37.=E5;A41/FP!*R&0@
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M9YDVH3(WFM8Q.'[2%OK,U66FC:[FD+$X^9 .Z
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M2EHMM/70/KHX<.A1Z;R<5["0D7*
M     'B:UMBW?2URHF^^DA=NICFJ)E/653V7WYNC->Q2W-',@8Y\4R8PJ<%1
M/7@N.O(CK7&RBQZJJW5<BSTM8[&70N1$=YT5% BG;YKRWZD@H:"SS=;#$[K7
MN[,X5$QZ21NCK9)+;HM*N=JM?6NWT14QXJ*N%^=%.K8-A5BMU:RIJZFKJNK5
M'-C<YJ-5?+XI+=/%'!"R*%J-C8B-:U.2(!R
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M+0ZDDK&/CGB54B1O%.:<\DZIR/-T_:HK)9J6VTSGOBIV;C5>J;RIGR(>D@
M
M
M
M
M
M
M
M
M
M
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MGJ>:CLM'3U3MZ:.-&O7RGHY  9,(O$#(,9,Y]( &-X9 R#&3( &,^DRBYR
M"K@ #&?2,\ ,@QD9X@9!C/,SD #&3.0 ,9&0,F%7C@9X#S .)E%R1IM:VCSZ
M&FH(X*".J\)1ZKO2;N-W'D7O.YLGUY+KBCK)IJ-E,L#D:B-?O9S\R ;^!D
M#"+D#)A?.9.&L_U67]E0.NVZ42N1$J8\\L;QW,YQCB44H41-11<OZ=/:7EH4
M_F4/=N-]@'80&,X&0,@9,90#(&1D #&?0,\ ,@QO&<@ ,F,@9 1<@ 8[3)A>
M8'4FN5)"]625#&O3FBJ=F.1LC&OC<CFNY*G:4RVN)_W@W7A^6GL0M/LOQ_(*
MR8_1T]J@;2!DQD#(,(ID
M
M
M                      Q@^7HFZ[@G(^S#_>.\P%(]HZ__ %U?,?IDGUE+
M2;%T_P"[NU<,^)]Q5O:/_7F^?*Y?KJ6FV+?!U:OV -T>NZUSD3DA6>Y;9M1T
M]_GI&,I>K;4=6GBNY9QWEF)OZ*3S%'+U_6^J^5_\P%U[74OJ+1!4OQUDD2/7
M'+."NMXVSZAHM0U5,C:9((JA8^3N#47'>6$L?]6Z/Y.GL*7:K;OZMN+<\ZIZ
M9_O*!,6IMNM3U<-/I^EC?+U;5EF?E<NQQPB8[35*+;;JBFJNLGZF9G;&]'8]
MI-&S'9[9+3INAJ'TK*BKJ8&2R2R+GBY,X3TD1=(G3E%9;]3U5!"V%E2BJYJ<
MLIC[P) N^W&UTVG::JHH6SW*9N5I]_A&N$Y^GU$:5VVK54L^^SJH&*N48C7(
MF/2>ET?-%6W4<];<+LQ9FTCV(R)5PBJN]S]!*NU71UFGT3<9(Z&..6E@?+&]
MG!45&JOV >+L@VKOU/6^Y5XBBBK%15CD8JHC_)A>TE][DC8Y[G(UC4RJKR0I
M=LJGDIM>6AT:X5:AK%\RJB*6AVO722U[/KM- [=E=&D:+^TY$7U*!H&T+;<E
MMKY[?IZGBJ'Q+N.J'N56Y\F/O-'7:MKIS?"D@D\'Y[R0OW/3DT;1T]JCU-35
M&HUD=0->KY48BJKN>.7EP6#;M<T$VD\%;')X.C=W<\&=C'=R \S9YMN;<JZ.
MWZDAAIW/X-J&N5K<]RYS[2<8W(]J.:J*U4RBHN<E'M8U%JFU+5U&G=]E!(]9
M&(Y%16JJYX9+:[*+E)=-"6F>9V](D#&.7O5$0#;B/-LVK*_25CIZJV)&LDC]
MU=]%[T[E3O)#(;Z37]5:-?\ S%]K0-:TEMRJ6PW&2_QQ/D;&BTT<>4WG>7*J
M:_<]M&JZF9T]/%'309\5K6NQCRKD\G8II2DU5JGJ[CO.IJ9$D<Q%QO\ D]1:
M&JTI9I[2^W.M\/@RMW41$PJ>7/,"(]FVVN6XW.&VZBAAC25<,J&JJ<?+G).[
M7(YB.:N6JF4QVE'=5VQU@U764<2JU*>=5CRO%$SE/L+;Z-NLD^SFWU\RHZ5M
M$U7+WJC0/!VG[4Z/2#EI*1D=7<ORH]_@Q/+@ARIVR:NK)'/IMR-J+G$3'8]I
MHE[KI]0:DJ:J=RNFJ9E7/=E2W^CM&6FP66"EBHXG2*U%D<]-Y7.QY0(2TSMW
MNU+5,BOE)%/ KD1SD56O:F>/-5+"Z?O%'?;7#<+=,V6GD3@K%SA>Y?*5_P"D
M9H^BM,E%=+9 D+9U<V9K>64QA?6IWNC!>YUFK[/([>@1.O8G<Y<(OJ:@$B;4
MMH]-HJ!L3(VU-PE;O1Q*[&$SC*^A2'';6M;7F65UJHW*Q%XMIH7OW?0JG:Z3
M%KJH]3TU>L;G4KX$:C\<$7*\#S-DFTNCTC22T-RMZ30/=O=9&GC)YP/0M6V[
M4EJK4AO=$R5J+A[)&N8]/2OV$W3ZMBK] 5%_LKV/5($>UN]G<=PRU<=V2,+L
MW0&TJYQU"7!]OK,8<URI&CL>54P2EH31]%IFQ/MU-,^JI)5W_P 8Y'(J+Q[$
M0"J>NM9735TU.Z[-8WJ-Y&(U%3GC/-?(ASZ(UY>-)0U$=I:QS)517(]JKCGW
M*AOO28MU'05MF\#IHX=]LN]N)C.-S!Z?1KM5#7VVZ/K:6*9S7-1%<F>'$"4M
MEU]J]1:3@K[BC4J'N5%1J*B8PG?YS;F]IX5_N]LT?8WUE4SJ:.+'"-JKC/#D
MAI7X<M(_'5/^"[[@)37D>%J_4=%I>RSW&N>U&,3#6*N%>O<AK>G=K&G-07>"
MV6^2=:B;.XCHG(G!%5>*IW(1KTH+I*MQMUM1?Q*1]8Y$[5ROW@>+?-N&H:ZK
M<EMBBIH=Y=QK4<KE3L[3T],;;;I32K3ZFI4DIWM5.L1'->B]_'.4/KHY:1H;
MI)6W:XPI-U&&1,<O!%5>>/F]9+NO-"6C4=EE@EI8XIVIO12L3=5J@5#MSTDO
MT#D7@LR*GI+T4/"BA_83V%%;4Q8[W3,PBJDR)ZRYFK+DZTZ&KJR/W\=&Y6^=
M&+@#0]I>V2GT[626^RQPUE6Q/'D5^6,7NX??VD6OVP:QGD6:)VZQ.QC'*WVF
MFZ<H7:BU324LSU7PJ=J/7MPJ\?47'M6E+-;K8RAIZ&'J4;A<IE7=_$"%=&[=
MJOPJ*GU%2P]2Y<+-&JHJ<>:YR3];ZR"OHXJNDD9+!*U'->Q<HJ*57V\Z3IM-
M:E;/;V=725J;Z,YHU>W'SHJ_.2CT;;Q+7:5FHIG*[P1ZHS/-$5<_:![>U3:7
M3Z+2.EAA;4W"5,HQ781B=ZD0+M7US>)))+922+&U<JE-"]Z)Y\*I]])*VU,&
ML(JU['NII8T1K\<,IV9./91M0HM*VU;?<K>DD645)8T\;Y\@=RS[<;_;J[JK
MW11RQHJ(]KD<UZ>E?L+#Z?O%+?;5!7T,B/AE3*87./(0G<J30&TB[MK8[F^A
MJE1&.8Y4B1WE\9/*2WH/35/I2QI;J2>2>'?5[7/<BXRB)C@B<. 'E;2MH5!H
MJD:CT;/7R-S' C\+YU\A"=1MAUC=JA_N93(UO-&T\3W*B?,IJFU>[37;7=SD
MG?EK).K:G<B)@E#9[M T)IG3U-2[DWA6%69ZPN<JN5>_ 'AV7;?J"VUJ17RC
MCFC1<.:Y',>B?.OV%@M*:AHM2V>"X6Z1KHY&HJM1V58O:BE<-LFJ-):GIH*B
MQLD;<FN1'.ZM6(K>/>G/D>[T7[K,EVN=M<]>I=!US6KV*CFI_P R@6,3EP!A
MO(R ':@,*!3#:ZO_ '@77]M/8AO[=L:V32=JM=AIF3U44"-DD>JX:O<B(1_M
M;7&T"Z_MI["<=B^SZRQ:7HKM54Z5-75-5ZND7@WQE3@GS 1;%MIU7!5(^5T3
MFI_NW(['M)\V7ZY@UK9W3[C(:N'#9HD=GCWIY."D8=)#2]NM]#1W2AIVP3/E
M2)Z-7".\5R_8=7HN2.2\72+/BK&U?G L<G,R80R
M
M
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M<S3%H8]JM<VDB147FB[B$*=)JAJZNIM7@M--,B([/5M5V.00[G18_P!D7O\
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MRS4]0G6N5\M3/E$XKE>?V%M=-6F*QV2CMT']'3Q-CSWX3&0/3(;Z37]5*/\
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MULFZE9%1=_S*1!_H^38Q[JI_U\Q*.R.MN-?HVGGO+Y7U:N7*RMP[&$-T3R8
MAC0VQJ73>IJ.ZON"2I!O99WY:K>[RFH=)^DD;J2WU&ZO5/@W=[LSGD67P:#M
M@T4NK]/.93;J5]/X\6>WR>L#2NC!<:=UJN5#UC4J&N:]&+S5N5X^M"8K_<:6
MV6JHJJZ9L4#&\7.*:TU+J;25W<^FAK:.KC56*YC5P[CR[E3@;90TFO=HTJ4U
M=/5)1M\9SY4ZMGH1$R!']N<C[_3N:N6K,BHOSEOMH%))6[.+E%$U7/\  W.1
M$[<,4J=;K'<Z>]0,6@JE1DJ(J]4O8I=>"-LMOCBE:CF/C1KFKVICB@%+-G]9
M';-96N>J<D;&5#4<J]G%"[,,K9H6R1.1S'(BM<G:A6/:CLEN5KN4U=8875-
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M*&KI+W<755--"U8DPKV*U%](%BDY (
M
M
M                                 87M,@#@=2P.<KG0QJY>U6HIR,:U
MC41B(B)R1$/L 8[#@\%@5<K#'E?[)V !\HB(F,(B'%X+3JY56&+/;XJ'. ,(
MB-;A$PB<,'')#'(OXV-KU3O3)R@#BBBCB14B8UB+W)C)]JB.3#D147L7D?0
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M48U$:B(B=F#Z 'Q)&R5,2,:Y$7M3)\Q0119ZN-C5[<)@Y0!A#(
M
M
M
M                 &  &
M    &  & B8
?                                      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g12080g03b75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03b75.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[1CF4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*/_  !$( \ &F ,!(@ "$0$#$0'_Q  =  $  @(# 0$
M    !@<%" (#! $)_\0 61   0,# 00$!PL(!P4&!@,!  $" P0%$08'$B$Q
M"!-!410B87%TD;$5%Q@R-E16@9.RTA8C,T)2<I*A-3=38G/!T20T1(+A)29#
M56-D*#A%HL+Q=8/PL__$ !H! 0$  P$!               ! @,$!0;_Q  T
M$0$  @$" P8%! (" P$!     0(#!!$2(3$%$Q0R05%"87&!D14B,U(CH;'A
M),'14_#_V@ , P$  A$#$0 _ -J0#C+(V*)\DCD:QB*Y57DB(!YZJY45)(UE
M550Q/7DU[T13TM5'-1S5145,HJ=IH_M+O%TUCKB^7&V.J%I*9=W$;UPUK>&3
M9?H_ZK75&@:=U1)O5E([P>1%7*X1$PJ@64 JXYA%1>2HH  ^(J+R5% ^@*J)
MS7!Q;(QWQ7M7S*!R /F4SC*9 ^@XH]JKA'-5>[)R5<<P ."S1([=61F]W;R9
M.:<>0  X=;'O;O6,WN[/$#F#YO(G:A]  ^.>UOQG-3SJ&N1R>*J+Y@/H  &)
M=J6RMKO UN=(E5G'5]8F<D*Z0FIJK36SRJEM[ECJ:E[:=LC5PK,\U3U%.V[8
MZ^LV92:JEO-6EV6G6K:WS97&]D#:U%RF4Y'DNMRH[31NJKE4QTU.U419)%PB
M*I5G1HU35:AT5)37"1TM3;Y.K61SE57(N<9]1#MM%TJ-=;1K9HBSRO?21JCJ
MI8ERBKS7U(!L3154%;2QU%)*V6"1-YKV\E0[CQV6WQ6FTTE!3_HJ>)L;?,B'
ML    >:>OI*>=L,]3%'*[BUCG(BJ=ZR,1V[OMWN[)JYTAZF>+;+9&Q3RL:L$
M7BM<J)\9P&TH.NE_W:']Q/8<G/:Q,O<UJ>5< <@?&N:Y/%<B^93Z !\WD7DJ
M'QLL;G*UKVJJ<T10.0 5<<P ."S1HY$61B*O)-Y#FBY3@  543FJ(?'/:WXS
MFIYU ^@(J*F45%3R'%9&([=5[47NR!R/-65])1;OA=3%#O<M]R)D]*+E,IR*
M@VY[/;WK2X6B>S5K*=E*U6R-<]6YR[.0+?145$5%RB]J \EJ@=26NDIYGHY\
M43&.=WJB8R>I7(B954QYP/H.+7M?\1S7>9<G(  JHB95<'%LC'*J->U53N4#
MD   !\WFXSO)COR!]!\8]KTRQR.3O1<A7(WFJ)YP/H/C7M=\5S5\RGT  JHB
M<5P<&RQN54;(Q53FB*!S "JB<UP !Q;(QRJC7M54YHBG( !E,XRF>XXND8U4
M1SVHJ]Z@<@$7/(JOI%:IN6E]$MGLT_43SR]4YZ+XR(J=@%J)Q! ]AE9/7;+[
M'45D[YZB2-SG/>[><OCKS)X !QZV/.-]N>[)RY\@ "JB<U1#BKV-5$<YJ*O)
M%7F!R   !51.:X.+9&.54:]JJG/"@<@  !PZV-';O6,WN[>3)S3CR  '#K8]
M[=ZQF]W93(', ^93.,ID#Z ?$<BKA%3('T!51.:HAQ?(R-,O>UJ>5< <@?&J
MCDRU45/(?0 .+GL8F7.:U/*N R1C_B/:[S+D#D ?$5%Y*@'T'%)&*N$>W/=D
MY  #@DL:NW>L9O=V\F0.8!\1R+R5%\P'T ^(J*N$5,@?0  !\<Y&_&5$\ZGQ
MKV/^*YKO,N0.0'((J+R5%\P  ^(J+R5% ^@*J)S7!Q21CE5$>U53N4#D ,IG
M&4R !Q1[%541S<IV9.0 'BO=4ZBM%;4QXZR*%[VY[T150HWH[ZIN^I-5ZAFO
M-=)/NIAK'.X-3>7&$ OFKJZ>CBZRJFCACSC>>N$R=D<C)8VOC<CV.3*.1<HI
M76V_1MSUEIZGI+-4M@F9*CU5SU:BH2C0=IJ+%I.WV^NF26H@C1KWHN<KYP,^
M#YO)C.4P?&R,?\1S7>9<@<@?'/:U,N<B)Y5P&N:Y,M5%3R*!] /CG-;\943S
MJ!]!\8]KTRQS7)Y%R?0!U5-3#2Q=94RLBCSC>>N$.T@6V?2EQU?I-MOM%2VG
MJ$G;)O*Y6Y1$7AD"<T\\53"V6GD;)&[DYJY13L(?LFT]6Z7T116NZ3)-5Q*]
M7/1V\G%<\R7HY%Y*@'T'%)&*N$>W/=DY  #R7BH=26FMJ&*F_%"][<]Z-54]
M@'KSQQVGGJZVEH]SPJHBAWUPW?=C)0?1NU;=]4:KU#47JMDGQ$FXQSO%;XR<
MD//TLZB:&KTUU,TD:*YV=QRIGB!L6UR.:CFJBM7BBIVGTP.B)431]G=*_BM,
MS*N7GP,ZUR.3+514\B@?0#XYS6IXSD3SJ!]!\:YKOBN1?,I]    #BY[&)E[
MFM3RK@^M<UR9:Y%3R*!] .+Y&,15>]K43O7 '('%DC'IECVN3R+DY  $5%Y*
MBCD  147DJ*%5$3*K@ >:GKZ2HF=#!4Q22MYL:Y%5#NZQCFN1KVJJ)V*:M='
MJHGDVQ79LM1*]F)_%<]53XP&U !P=+&SXTC&^=40#F#XUR.3+514\A#MK]\K
M-.[/KO<K8]K*N&)%8Y?U<JB9_F!,@5)T:[O77K153676KDJ:F2J<JND=E?\
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M:R:*5LC&/DC<K5?A,*9%]QK?@].K/"I?"_ L];O+O9\YB>EO\C*+TA#UO_\
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M'97A["92:>M$EK;;9+=2NH&KE(%C3<1>_!ZK9;J.UTK::W4T5-3M7*1QMPB
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MJY.2YQW]YL W0FEVUB53;%0I4([>1Z1\47.<D@J:>*J@?!41MDA>F',<F45
MBCJ'I&V%UD;+5T52RY(SC G%%=^]_P!"':!NVL-I&T[W5AJ+A0V1DJ2OC1[D
MB:Q%^*G)%4OF;9OI":=)7V"AWT[F83U$BM=LHK52I36VEBIH$Y,B;A KUIP0
MX3M5\$C6KARM5$]1S &EEAN3]F>UVMJM1VYT[$ED;X[>QSLH]N>9;&K-OE!6
M6U]%HRBJZVYU#=QGYM4W<\UQVEPW[2MCOZHMYME-5N1,(Z1O%/K.BR:*TY9)
MF36NSTE/.WE(UGC)]81JUT=)Y:':\UEU:Z"IF;(US9/%7?5J\./E)1TJ,?E=
MI[SI[4-B$TW9DN?NBELI?#M[>Z_JTW\]^3G=;!:KM+%+<[?354D7Q'2L1RM\
MP'98/Z$H?\%OL-8-NJYV\69<\DIT7^-3:UC&L8UC$1K6IA$3L0Q==IVSU]PC
MKJVVTL]9'C<F?&BN;CEQ"H;MTT7/K31BPT&%K*55GA8OZZXXIYRI]D6V:'25
MH_)_5]+4Q>"*J1R(U55J?LJWUFSY&[QH73-XJ5J+E9J2>=5RLBMPJ^? 1J=M
MMVB5&O:ZEDI*.>"RTKE9$YZ<'NSSSWXQP-I=CZYV::>5.7@J>U3)II#3R4#*
M)+-1>",=OMBZI-U%[S+T=+!14L=-21,A@C3=9&Q,(U.Y KN*9Z5?]7+?2&ES
M%,]*O'O=,S\Y8!6>Q#:ZS1MH;:=14U0ML<JNIJAC<HG%<HB=O-#IVK:^K=JU
MRI=/:5HJAU"CT=R55>[]I4QPQE2U=B.F;+J#9#9&WFVTU7N]9A9&95/&7M+)
ML&E;'I]56S6RFI'*F%=&S"JGG",1:-)+;=F:Z=8K>N=1NB<J)PWU;A?YFLNS
M#5]1LDUA=:.]44O@\SNJE:J*U4W57#D]:FY9@[[I*PWZ3K+O:J6JEQCK'L\;
MUA6M^UO:U-KNS2V;3%NJ$H^$D\RIG@G9RX$\Z):_]QJ].ZJ__%"U;9I.PVNF
MDIZ"TTD$4C=U[6QIXR>4]MHM-OL].Z"UT<-+"Y=Y6Q-W45>\#53;54SZ9VWM
MO,U*]\#71RM54PCT3"JB*3?:5?O?2V/U5QT_#.BTE2U)J=,JY43MPGG+NOFG
MK3?HV,O%OIZQK/B]:W.#G9[';+-2OIK70P4M.]<NCC;A%7RA&M6P_:U8=(Z=
MEM5\I)*>=LF]UD4>5?P_6,+MHVAUVT.BZJSVRI98:%W6R3*Q51RXQE5Y(;*5
M6SG2555>$36&C=+O;RKNXROE0S%-IVSTMMEM]/;:6.BEX/A;&FZ[SH!6W1GK
M8:G9>R&)R*ZGE>UZ9Y*O$K#HV8]]V]<>;)L?Q*;.V>S6ZS0/@M5%!21/=O.9
M$W=15[SIMNG;/;*R2KM]MI::IDSOR1QHBKGF!&]MRHFS"_9_L%0@W1)7.B*_
MTG_(NRMI*>NI9*:LA9-!(F'QO3**AY[1:+?9Z=T%KHX:6)R[RMB;A%4*H;I=
M\:"QI_?=[4++TW9X[_L=MUMD5$2IMK6(Y4SA5;A%]9++Q9+9>6,;=:&"K:Q<
MM25F]CS'LI:>*EIXX*:-L4,;4:QC4PC43L0#4+0&J+KL9U/6VN^V^9]OE=AR
MJBM\SFKVDUV@]("CK;/-;](T]4ZLJ6=6DZ^*Z-5_91.TOF]:?M-[:U+O;J:L
M1OQ>N8CL&)MVS[2MNJ$GI+'1LF1V\CU9E47ZPB%='2T:BIM/S7/4];6ROK,=
M3#5/5RL;GXW%>&2L=H>$Z1U'YX_8;6(B(B(B(B)P,74:=L]3<FW"HMM+)7-Q
MB=T:*Y,<N(&43DAJC:D_^*FN7L]T'?Y&UQBF:<L[+JZYLMM*EP<[>6HZM-]5
M[\A65                       !CK]8[=?J%U'=J6.I@=G@],X\J=RE:R=
M'[1+YUEZFN;QSNMG3'L+; &%TMI:SZ7HUIK+11T[%^,Y$\9WG4S0
M               .$\3)X)(I$RR1JM<G>B\#F (OI/0MCTM65-59Z=T<U1\=
M7.SVY)0                                         !%+KH"PW34L-
M]JZ9SKA"J*UZ.PF4Y<"5@                              $:U?HFRZL
MDI)+U Z5U*N8U:[&..3/T=-'1TL5/ W=BB:C&IW(AW               %<W
M+8UI*Y:CJ+U64]1)53R=:]BR>(KO-@L8 ==-!%301P4\;8XHTW6L:F$1#L
M
M                                         !A=5Z9MNJ;9X!>(EEI]
MY'X1<+E#- #&Z;LE%IVSP6RUQK'20HJ,:JY7BN3)
M
M
M
M
M
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MHUH^TNE7P=ZJQS.S*&PX4
M
M
M
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MI5RL?'&'8P!Y=+-5^UI=U.'A+O:;*FO>QRUU%WUC+=WL5(8U<]7;O!5-A 0
M *A.UC7$6A=/)721.D?*_JF8[%7M-1I]I^L*BIGE@O%7N.>KD1O)$SR+ZZ7/
MR'H/2D]BF'Z(M!1UMAU"M724\ZMJ8D198T=A-U>] CET:-4Z@OM_N$5ZK9ZF
M!D.6I(G!%R;%GFI+?1T:JM)24\"KS6*-&Y]2'I"@
M
M
M
M
M   ,#^2-E]UO=+P)GAF]O]9E>9G@ ,'?=*6>^/22XT3))$_73@IRL.E[18G*
MZVT;(GJF%?S4S0 *B*BHO%%(M7: TY6U3ZB:W,ZQ[MYRM54RI*0!X[7;*.U4
MK:>WP,@A3]5J'L    "BNEQ\B*#TM/8IC^AS\G]1>DQ?=<9#I<?(B@]+3V*8
M_H<_T!J+TF+[K@C84 !0
M
M
M
M                                                        !172
MX^1%!Z6GL4Q_0Y_H#47I,7W7&0Z7'R(H/2D]BF/Z'/R?U%Z3%]UP1L*  H
M
M
M
M
M                         /)57*BI'(VIJX(G*N,.>B*=\$\-0W>@ECD;
MWL<BH!V 'BDNUOCFZJ2MIFR9QNK(F0/:#XQS7M1S'(YJ\E1<HI]   "BNES\
MAZ#TI/8IC^AS\G]1>DQ?=<9#I<_(>@]*3V*8_H<_)_47I,7W7 ;"@
M
M
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MNLO:VFFNL$E<CMWJT7M).
M
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M86JBJN<=JJ7:%
M
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MU+G.G94;KU5>:HJH;Q&CFQVI=6[6J"JD3#IJE7JGG7)O&%
M
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M/:8FDFL5K@HY)$W7.C1<JGUDA "@
M
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M:5(Y)$1))7+ESB4A0
M
M           45TN?D/0>E)[%,?T.?D_J+TF+[KC(=+CY$4'I2>Q3']#GY/ZB
M])B^ZX#84
M
M
M
M                                                %%=+CY$4'I:>
MQ3']#G^@-1>DQ?=<9#I<?(B@]+3V*8_H<_T!J+TF+[K@C84 !0
M
M
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M8U<JM V0!2&D]NT>HM9P6:GMK6TTTFXR;>7*IWX+O
M
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M7W7&0Z7/R'H/2D]BF/Z'/R?U%Z3%]UP1L*  H
M
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MV34\=)MAI*>)6NCBJU:WS(JF[YHWL:BFAVK6V.ISUZ5'C_O=IO(%@
M
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MDS=Q>L7@B%@A0
M
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M.04
M                                            #C)&R6-S)&HYCDPJ
M+R5#D *TU!LAL]QJG3TCWTJN7+FHJXR9#1^S2T:>J$J<.J:E/BN>O!%)V /-
M<:&FN5')2UL398)$PYJE9U>QBU2U;I(:F:.-RJNYE>'D+5 &'TOIV@TY;VTM
MNB1J?K/7FY?*9@    **Z7'R(H/2T]BF/Z'/R?U%Z3%]UQD.ES\AZ#TI/8IC
M^AS\G]1>DQ?=<$;"@ *
M
M
M
M                                                        **Z7
M/R'H/2D]BF/Z'/R?U%Z3%]UQD.ES\AZ#TI/8IC^AS\G]1>DQ?=<!L*
M
M
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M*G::=])6V4UFVB4\]OB; LC&R88F$1R+S0VCV=5SKCHBRU4CE=(^F9O*O:N
M)$" [;-35VE=%37"UN1E0U[6HY4SC)15IVV:VO-M=0VNF=4W%.+I8XT56IZ@
MK;,&IFF-ONHK+6U5/JB)U8YJ*U&;J-<Q_$\]YVO[1*5T=UEBDI;=,OYMKHDW
M5_D!MV"$[(];LUQI9E>YBQU,2I'.WLWL<T*MVS;:JZTWV:PZ7:K:F!^Y)-A'
M97N0#8@&J+=KVO\ 3MN<[4-'+NU#,PS2Q(F%[^1871VU_>M9R75M[F27J-U6
M8:B8R!=@
M                                    !$-;:\MNF&.C>]L];C*0M=R\
MX$O!055MHNDCOS%%#$F>_)Z;9MIJVRL2NH(WLSARM=A0B] 8?3.HK?J*A2IM
MT[7\$WV93>8OE0S 4      ,C(  93O      **Z7'R(H/2D]BF/Z'/R?U%Z
M3%]UQD.EQ\B*#TM/8IC^AS_0&HO28ONN"-A0 %
M           ,HG:<=]G[3?6!R!QZV/\ ;;ZSYUL?]HSU@W<P<.MC_M&>M!UL
M?]HSU@W<P<>L9^VWUCK&?M-]8'('Q'(O)4/H
M
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MB(Q%4#9D !0
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M5/\ ,(W6!5FR/:RS7]RJJ1*!*9T,>_E'*N>):84
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M"FU39ZCXE=&G[RX-D9*3TENKGQ6Z6AFP>6GN-'4?H*F)_F<>K*=YFVQ,3T
M%   !\<Y&M5SEPB<54QUKN\%PFGBBX.B7'/F83>M9BLSSE-X9( &:@
M
M             '8:P[6MFNKZ/5U9?=+33RTU1+US612JCHUX<,><V> &GUWC
MVL:MH66FY4M:ZF5<*DC-U'8[U+TV$;/9-":>G2N<CKA6.1\J)R:B)P0LT
M
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MC&*U$1R-3'$RQB['9X[3&]D4CG([',RAV8./NXB_5MKO$<P &UD
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MB;(Q<M<F44Y$:T1<DJJ#J'KX\?+/=Q)*=^')WE(LZ:SO&X #:H
M
M
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MB*#TM/8IC^AS_0&HO28ONN,ATN/D10>EI[%,?T.?D_J+TF+[K@C84 !0
M          .,CVQL<]ZHUK4RJKV =5=5PT5-)/4O1D;$RJJ4YJ:^UNK[FE#:
MVJM.CO%1%QO><]&NM1RWZY1VNUJKHT?N^*OQUR3G0VF(K'0M?*QJUCTR]53D
M<EK3FMP5Z>KR\E[:N\XJ3M6.L_\ IPT;H^FL<:32IUE6[BJN3XI+ #IK2*1M
M#T<>.N*O#6.0 #)F
M    'Q[4>Q6NXHJ84^@#!NTM;'.55C?E5S\8^)I6V)^I)_$9T&CPN'^L,>"O
MLQMLLM';9'/I6.1SDPJJN3) &VE*TCAK&T+$1'*  &2@
M
M
M                                  Q^H5Q8KA_@/]BFJ>G+]<=/5DM3
M:W=7*_+556Y[3;M[6O8K7HBM5,*B]IBOR<M''_LZGX_W$ UBU)JR[ZD8QET?
MUC8URW=;C![K-K_4%GH6T=!*C(&\41S,FQZZ<L__ )=3_P "!--V=/\ Z=3_
M ,"!%)Z3VD:EK]2VVDJIFN@FE1CTW,<#8(QD%AM<$K98:&!DC5RUR-XH9,*
M               HKI<_(>@]*3V*8_H<_)_47I,7W7&0Z7/R'H/2D]BF/Z'/
MR?U%Z3%]UP1L*  H             %>[4M2.HJ?W.HWXED3\YCL3N);J6[QV
M:U353U3?1/$:O:I5&D;74:JU$M?7(KH6NWG=V>Q#FSWGECKUEP:W+/+#C\UO
M^$HV9:62F@2Y5T:+,_#H\]B<>)8A\C8V-C6,3#6IA$/INQTBE>&'3@PUPTBE
M0 &;<
M
M
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M'H/2D]BF/Z'/R?U%Z3%]UQD.ES\AZ#TI/8IC^AS\G]1>DQ?=<!L*
M     #V PNK[FEJL53/O8D5JHSRJ29X8WEC>T4K-I]%<[3;LZZ7F.V4CMY&.
MQAJYRI8NC[.RS6:*%&HDKDWGKCCDKG9A:772\27.K3>1B[W%.W__ "%PG-IX
MXIG)/JX-%2<EK:BWKT^@ #J>B
M
M
M
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MB?5APS'H[ ?$<B\E0^E0
M
M
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M>T
M
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M<T]@.C'IL6+RU<V74Y<OGL(F.7( &]H
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M>UCVO3Q'([S+DZJWK;G6=W):EJ]8?0 9,0
M
M
M          !T5],E90U%,YRM;*Q6*J<TRF"!Z-V:0Z;K:R=E:^;KXW1X5,8S
MDL,Z:R;P:CGG7CU4;G^I%4"HY=B]+ON>ZZ.;O*J\6G7[S-'_ .;_ ,D()>M7
M:@U'=IGT<M0K<KN10*Y<)YD/+U>KO[*ZI]3PBT[#LGI+9>J.N;=%>Z"1'HS"
M<5+8-;-',U2FJK7X2RYI!U[=]7([=QY<FR8(  %             %%=+GY$4
M'I2>Q3']#GY/ZB])B^ZXR'2Y^0]!Z4GL4Q_0Y^3^HO28ONN"-A0 %
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MSBRYKYK<5YW  ;6H
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MRQS7)WHN3JK>M_+.[DM2U/-&SD #-@
M
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M+;V0M1JS*GCO3M4RX!VTI7'6*UZ0XKWMDM-K3SD !DP
M
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MWCY<TF!T4]73U"(L$S'YXIA3O.J)B>CEF)CJ  J
M
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M&>BQ32G';S6YR]G6Y8O?@IY:\H  =CC
M
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M=W)DPY,4[7C9V@ VM0
M
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M1$X)@^@'KL
M             /%2W6AJJN6FIZJ)\\2X<Q'<4+$3/1-XA[0 10
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M8XWFO+Y<V;!PBECE;O12,>G>U<G,Z8G=R@
M
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M.4;<$#TI V[ZLJZYR9AI<-B\Z<"QT-&BKQS;-/KRCZ0][4QW&/'IH^&.?UD
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M.131S-1T3VO1>.47)U4RTR>2=W+?%?'YXV<P ;&L
M
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M145%1%1>Q3!VW2UJM]TGN%-2QI4RNWM['Q5\AG 91>U8F(GJDUB><@ ,5
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MCEF)CJ  J
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M]*W=@HX&I^XAZV11L^(QK?,F#F#3-IGK+/:(  10
M
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M9<,7OU>+K<5<.:U*=  '6Y
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M2P,T_22P1SNF1[M[+DQ@\[1::\Y^^F/VO5KW.'05T\>>-M^7WZLV #W7G@
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M)A$3L/H!Q.@
M
M                  !%=9Z:FOLD#H)6,W.>\1M=G=9C_>(O7_T+.!Q9=!AR
MVF]HYR[<7:&?%6*4GE"+:+TY-8GU"S2,?UB(B;OG)2 =.+%7#6*4Z.;+EMFO
M-[]9  ;&L
M                                       '752I!32S.Y1M5R_4:MW^
MYW36NII(XEDEWY%9%"U>")DV9OZXL=>O_H/]BE$; H&2ZLJWO1%6-BJW/8N5
M"/?;MBE9-3L?5W%D#U3BS<WL'COVQVY6^D?/1U;:M&>,K4;A38,*B*BHO%%"
MM?MBVIJFW:A6SUDDBP3KN,8]?B.3/>; FM*1M@VRMCB1$8VOX(GG-E@D  "@
M            "BNEQ\B*#TM/8IC^AS_0&HO28ONN,ATN/D10>EI[%,?T.?Z
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M;47S3O:73CQUQQR  :&P
M
M
M
M           !X;\U7V2O:U,N6!Z(B>935&BI;Q12ODHXZF%ZJN7,RG#*FWBH
MBHJ*F44Z/ J7YM#_  (!JMX7JC^WK_XE'A>J/G%P_B4VI\"I?FT/\"#P*E^;
M0_P($:PZ,H;B[6MKGJ:>97+4(Y[W)SX]IM*=+*2G8Y',@B:Y.2HQ$5#N"@
M             **Z7'R(H/2T]BF/Z'/R?U%Z3%]UQD.ES\AZ#TI/8IC^AS\G
M]1>DQ?=<$;"@ *  "&;5JWP;3,D37;KYE1$4PNQJWXCJZ]R?&PQOD/#M@K'2
M7*"C:N=QN^B><G&SZB6BTS3-<W=<]-]3BV[S4?1Y^*>\U5K?UC9(P =KT
M<)I60Q/DD<C6-3*JO8AK[M,U;)J&[> T+U=1QOW6HB8WUS_T)AMDU9X-![D4
M$V)GIF56KQ1.XPVQW2*UE2MVN,*.IV*BQ->F=Y>_V'JZ7'7!CG49/LX\UIR6
M[NJ3;*-&):J5+A<H$\-D3+$=QW$+(")A,(F$!Y^7+;+:;V=-*12-H  :F8
M
M
M
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M;KL_>7X*](8:?'PUXIZR  X70
M
M
M
M                      ,=J&V^ZUFJJ%)%C=,S=1Z=BE'.;K+9].N[UU71
M([@O%S%1#8)51$555$1.U2 W[:=INAGEI)G25+FY:]K&HJ?S4(\FF=IEIO\
M3.HKJK:*JD8K'(]?%7/ @E9H+5%CK)/R:FDJ*.1=YKH'\./?Q,RMJT9KV=Z6
MB1]ON>,HU>"*89[]8[.9?&5:BB5>&,N:J%'KTYL]U%=[U3U.I9)8X(7H]4E7
M*KA>POB-J,8UK>2)A"O-&[4;9>NKIJ]%I*Y<)AWQ7+Y"Q$5%3*<4(0  * &&
MUC4UM'IRMJ+7CPJ-F\W*9[>(&#VI45[K[3%#I_?ZQRKUBL7"X*=T+50Z;UMU
M>HZ975.]N[TG-KE5.)*=#;6)65%3%JF1RHOZ-R-1-U?*0[5%>W6.O^MMD3EC
MDD:UO#BJ)CBN B9=(N571VI&NS&]KERG:3G9^C4V:TV.2TKL_P )&-M]DE?I
M:AG:BO6D1&.5./ P&D]HE';-!U%MJ-Y*UC%9$F."HJ8 PVRG/OCLW4SXSLJ;
M)E [#+5)7:DJ+HY%2.)%7/8JJ7\"  !5%]+CY#T'I:>Q37+1NMM0Z5IZJ*PU
M<T$<[D=(C,\53E[5-C.ES\AZ#TI/8I'NB?8[9=['?WW*A@J71U$;6+(W.$W5
M",MT<]<ZAU/?*^GOM7-/$R+>;OHO!<FP!C;58K7:7N?;:&"F<Y,.6-N%4R04
M(]KVN\ TS52HN%<FYZ\DA*]VR5.Y9:>G1?TDF53S&O+;AI,N?57X,-K?)CMC
M%$N:NL<F6\&M7N+3(CLMI/!-*Q(J>,]ZN4EQC@KPXXACHJ<&&L  -SJ836-Z
MBL=BJ:J1Z-DW%2-%7F[!0NB[7/JO5Z/GR]N_UL[EX\.Q"1[;+]X9<8K9$Y%9
M3JJN1.\E^QNPMM]A2X/:OA%4F<KS1N3UL?\ XNFF_P 5G';_ "Y>'TA8,,;8
MHFQQM1K&IA$0Y 'DNP
M
M
M
M                 !B-7+.FFKCX+GK>I=C',U]T-3Z.FI)G:HJ9HZO?7AV=
MOD-F'-1[5:Y$5JIA47M*[O6R6QW&L?41JZG<Y<JUC4QD(J6XLM%/K"A_(V66
M1F^U,KYTR;..C;+%N3,:]%3BCDRA#]*;.K/IVJ\)A9U\^,(Z1J</,3," ZCV
M86>ZUC*RG5])4M>DF8\85<Y)W3Q]5!''G.ZU&Y[SF H   5$5%14RB@ 0N^[
M-K!>*M:B>!T<CN?5KA%,CI?1EGTVJNM\"]:J8WW\5^HD8 X3PQSQ/BF8U\;D
MPYKDRBD#J]D^G*BK?.L4S%<N5:UW GX \5GM=):*)E+01-CB8F."<5\Y[0
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MRG)"SCHU^;CR<$=(:]-3AKQ3UD !P.@
M
M
M
M                                                      !172X^
M1%!Z6GL4Q_0Y_H#47I,7W7&0Z7'R(H/2T]BF/Z'/R?U%Z3%]UP1L*  KRW29
M*>W5,J\F1N7^146S>/PW6T\[T1R(CG9]6"Q]>57@FF*UV4\9N[ZR&[&*-V:N
MK<B;J^*U3ER_NRUK]WFZC]^IQT]N:T@#!ZLU)1:<MKZBLD1)%1>KC[7*=E:S
M>>&O5Z,S%8WE[[Q<(;9;YZJ=Z-;&U5-;J-E1K#5[$=E75,BY5>QIY]1ZDK[Y
M73U%3,YK'\$C15W43L+*V&6JF2*JN*O:^J5=QK<\6H>Q3%X+%:\\Y<,W[^\5
MCHM.V4<5OH(*6!,1Q,1J?4>D \:9WG>7?$;  (
M
M
M
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M?#/GLY  \=W
M
M
M
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MHU$/0 >7,[\Y=D1MR  0
M
M
M
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MU@
M
M
M
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M*\-8@ !K9@
M
M
M
M                                      "BNES\B*#TI/8IC^AS\G]1
M>DQ?=<9#I<?(B@]+3V*8_H<_T!J+TF+[K@C84HZYN==->HU>*];A/,F2[:AV
MY3RN3]5JK_(I;0C5KM>JZ1,JBO=E?(<NHYS6OO+SM?\ NMCQ^\I[M*NB6;1D
M^%3?D8D*(OF*TV(VM:K4DM8]N]'3L7CY5/?MUNW75]+;6+XD**]Z(O-5Y$PV
M-6I*#2<<[T_/5#E<Y<=G8>_7_!I-_6S=_)FV](3P 'E.P
M
M
M
M
M     .5&HJN5$1.*JH %:[3-HE+::!]):*B.6OE16Y;QZL\6PV^W&\+<DN=0
MZ?<1JMWNSB!:X(]KG4;-,V&:N5K7RIPC8J_&4H]-7ZVN<4]TI9'^"Q+E=QGB
ML3N V1!7NRG73]3TSZ6X,;'7P-XJW_Q$[RP@   HKI<?(B@]+3V*8_H<_P!
M:B])B^ZXR'2X^1-O]+3V*8_H<_T!J/TF+[K@B[]5U+J2P5DS.;6*5SLBA1]=
M65[TRK$7+O(J$KVJU3J72S]U>+Y$9_)2)::J&6?9K<J_DZ5=QJKWG/%9R:BM
M(>=FGBU58_K&Z!:@J'W_ %O(B>-OU'5_5DV/LU(V@M=-3,3"1L1,%";([=[I
MZP;/*Q>KBS*J_P!XV'/;[1MM-<4>C?I8WB;SZ@ /,=8
M
M
M
M
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MT5?.J&9,M1D[S+:SU<5>&D0  T-@
M
M
M
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M.O>6F?>5S,:C&-:W@B)A#Z <KW0
M
M
M
M
M 45TN?D10>E)[%(ET<)_!]F^LGHN%ZR-$\^ZI+>EPF=$4'I2>Q2N=BE2D.SS
M44*.P^2KBX=Z84UY9VI,M&IOP8K3\GMNTBJC4Y[R\N_)L%LOM/N1I*FB<GCR
M9D5?.4/1T3[EJ"EI&?K/3VFS]'"D%+%$B81C4:=T?X]'CQ^_-Q=FTVKQ.T '
M*]0
M
M
M
M                                     %%=+CCHFW^E)[%*@V1N>RSW
M)JY1CY&NX\N"*7!TMEQHFW^EI[%*NT% M)IEJO;ATG'S]QSZCG7ACUEY_:-M
ML.WO*S-CEO=6:OEJGL5T$$:JCL<$=G@7R5_L7M:T>F5JI&[LM4]7+GNR6 >C
MJK1-^&.D<OPZ-+3@QQ  #F=
M
M
M
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M)6^")7]:K\\-W>SD(_0-%RB*G)00)NUS0[6-3\H:/DG:I]]]W0WTAH_6H5/
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M4C9*>>Y(^-Z+E'(KTXA&_37(YJ.:N45,H?3KI_\ =X_W4]AV!0
M
M                                      !0W2+IW-N%#.B*J/C5.'D)
MQ3W&!FQV*7K$PVA:Q?WL<C-Z^TK!JJSNIGKN5#.,4G<O<5![UVL6,=1,FI_
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MP1$PA]
M
M      .,DL<29D>UB=[EP(WLD;O1N:YO>U<@<@           .I:F!)NJZZ/
MK?V-Y,^H#M           '&21D;=Z1[6-[W+@XQ312_HI6/_ '7(H'8
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MB=[EP!S!PBECE3,3VO3O:N3F !U25,$;MV2:-J]SG(AVM5')EJHJ=Z
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M+E%  X2S10IF61C$_O.P?8Y&2IF-[7IWM7('(
M
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M3OXA&R]@K5N5FHJQR86:)KU3RJ>\\EG93QVNE;0N:ZF2-J1N;R5,<SUA0
M !T5]7#0T<U55/W(8FJY[NY"@]I^T9;\QUNM#G,H4<BNE1,.<I>E^MK;M:*J
MAD>K&SL5BN3L*?VF:+MFEM ?[''OU*SL1TSN:\PB3[ WN?HE5>]SUZ]W%5R>
M#;5JZMM:0VJUN5DLR9D<B<<+R1%/;L!^0Z^D/)]66NAK9&R5=)!,]O)SV(JH
M!KNW0VI76%+SX3,C=W?5G6<=WCQ)SL,U;679*FUU\G6+3MWF/7GC/+)ZMK&M
MJ6SVR2SVU6/J9&K&]K%3$;<?]3P; =.S4=-57:I8YG7IN1HY,+CO N  !0
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M9(5IK4.H+315--9&SR4KE7>W&*Y$\I,-A$5O?>JFHJYT2X<HXW\,YS_,"^@
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M&KIW03;V525N[Q[$5% V9B=OQL?^TB*<CY'N[C=Q45N.&.X^A0
M
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MC.+4QP10)[8&2,LM"V=<RI"W>]1[PG!. "@
M
M
M
M
M
M
M
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MTEYM\=902MEA?VHO)>X]P4
M
M
M
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MM+54:JJM;/P]1:)5?1[^3E9_C)["U L
M
M
M
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MMYC=[))P!&- Z1CTA;9:2*K?5)(]';SV[N"3@
M
M                                                        !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g12080g03l46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03l46.jpg
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M\"1UTO$E58.3P^(8)SA$5&.CM$969(2%E,3_Q  ; 0$  P$! 0$
M     0(#! 4&!__$ #<1 0 " @$# @0#!P0" @,    ! @,1$@0A,1-!!5%A
M<2(R@11"D:&QP=$&(^'P,U(5-$1B\?_:  P# 0 "$0,1 #\ ]4@
M
M
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MA=R?$]'-7S0I,3'E+F !
M
M
M
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M4]2ZUU;N'1UF&M5>Y_S??CP-$C>R6-KXW->QR91S5RBIW*93$QY2^@ 0
M
M
M
M
M          "HZFU_9[(KXF2>FU:<.BA5%1J_G.Y)\5[C*-2:ZO-\WHW3^BTJ
M_P!3 JM14[UYK]W<89.HI3ZR]3I/A'4=3^+7&OSG_#7=1:YLMDWHY*CTFI;_
M %,&'*B]Z\D^\S+4.TJ\7+>CH5;;Z=>J)<R*G>[]V"C X[]1>WT?2=+\'Z?I
M^\QRGZ_X?4LLDTCI)GNDD<N5<Y<JOBI\@&#U?   D
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MKJ3N],I6_%S/Q;[C;K)>+=?*%M9:*R&KIW?3B=G"]BIS1>Y3&U9KY2[X *@
M
M
M          (?TJ?[1?</2I_M%]Q;C*-I@$/Z5/\ :+[AZ5/]HON'&3:8!#^E
M3_:+[AZ5/]HON'&3:8!#^E3_ &B^X>E3_:+[AQDVF 0_I4_VB^X>E3_:+[AQ
MDVF 0_I4_P!HON'I4_VB^X<9-I@$/Z5/]HON'I4_VB^X<9-I@$/Z5/\ :+[A
MZ5/]HON'&3:8!#^E3_:+[AZ5/]HON'&3:8!#^E3_ &B^X>E3_:+[AQDVF 0_
MI4_VB^X>E3_:+[AQDVF 0_I4_P!HON'I4_VB^X<9-I@$/Z5/]HON'I4_VB^X
M<9-I@$/Z5/\ :+[AZ5/]HON'&3:8!#^E3_:+[AZ5/]HON'&3:8!#^E3_ &B^
MX>E3_:+[AQDVF 0_I4_VB^X>E3_:+[AQDVF 0_I4_P!HON'I4_VB^X<9-I@$
M/Z5/]HON'I4_VB^X<9-I@$/Z5/\ :+[AZ5/]HON'&3:8!#^E3_:+[AZ5/]HO
MN'&3:8!#^E3_ &B^X>E3_:+[AQDVF 0_I4_VB^X>E3_:+[AQDVF 0_I4_P!H
MON/UM5-O)^47W#C)M+@ JD
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MWHI[8,MV_P"COX0:76YT<>]<;8BR)A.,D/TV^7SD\%[3LQVU.GD2\K@ ZD
M                 $C8;Y<[!7-J[/6S4E0G-T;L(Y.Q4Y*G<I' @>B-";=J
M:IZ.DU= E-+P1*R!JK&O>YO-OBF4[D-KH:NFKZ6.IHIXJBGD3>9)$Y'-<G<J
M'@PL6CM9WO2-5TMGK',B<N9*=_M12>+?Q3"]YE;%$^$[>V 9KL]VNV75'1TE
M<K;9=7<.BE=^3D7\Q_X+A?$THPF)CRD !
M
M                                       ($ &RH
M       _'.1J9<J(G>?/2Q_:,]X'V#\:J.3+514[C]
M               'ZWYR>)^'ZWYR>($Z #%8
M                 .A>KO0V6B=57*=L,2<L\5<O8B=:D3.N\K5K-YBM8W,N
M_P C/M8[2*.U])2V=&5E8G!9,YBC7Q^DOAP[RC:SU_77U9*:CWJ.W+PW&K[<
MB?G+^"</$I9Q9>J]J/IN@^!Q&K]3_#_+N7:Z5MWJW5-QJ'SS.ZW+P1.Q$Y(G
M<ATP#CF=]Y?25K%8XUC4  "P
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MFKY*ISWQS'>$Q+40 9)
M
M                     ! @ V5                     &?;=5QL]JL?;
M1?M&-Z%V?W'6%!455#64T#().B5)E=E5PB\,(O:;)MU_H\JO[:+]HS/95M!M
MVC[36TM?2U<TDT_2M6%&X1-U$XY5.P[,4VC%/'SMQY8K.3\7A%ZIT=J+0?H]
M>M6B1.?N-J*.5R;KN*HB\$5.2FW[)]3S:HTHRIK<+6T\BT\SD3&^J(BH['>B
MIYY,BVG;2V:LMD5MH**2GIDE25[Y7(KG*B*B(B)P1.)HVR&VR:5V?U-==VNA
M657UKV.3#F1HU,93MPU5\T(R[G'N_E.+47F*>&BSS14\:R3R,BC3FY[D:B>:
MG#1W"CK<^AU=/48Y]%(U^/<IYOI6WS:OJV2.6J6&G8BR8=E8Z>/.$1&]:\4\
M3NZVV<W#1%)%>K5='S1PO:CY&-6*2)57"+P5<IGAYH4]"(GC-NZ_K3,<HCL]
M&GQ-+'!&Z2:1D<;>;GKA$\RD;,=9_P (-(35MS<UM509;5/1,(Y$;O(_'5E,
M^:*9 LUZVK:Q=3-J%AI4WI&L<JK'3Q(N,X3F[BGBJ]2<JUPS,S$]M+6RQ$1,
M=]O1])<:*M<K:.LIJA4YI%*U^/<IVCSKK79E7:.MS;U:KH^H;3N;TCFL6*2+
M*X1R*BKE,X--V1:NFU3IN9*]4=<*-4CE>B8Z1%3V7>*X5%\!;%$5Y5G<%,DS
M;C:-2O#*F"151DT;E1,KAR+A#CI*ZDK-[T2J@GW.#NBD1V/'!Y.TA17&[7U;
M3:9NADN#702OSA.CSO.SW>SY\NLW39GLY?H^[5M945D56Z6%(HG,8K5:F<NR
MBY[&XX]I.3#6GF>Z,>6U_$=FC  P;@                  'ZWYR>)^'ZWY
MR>($Z #%8                                      %5$155<(AEVO-
MHZ0])0:>D1TGS9*M.*-[F=J]_N[2E\E:1N73TO29.JOPQQ_B%DUKK>BTXQT$
M>[4W%4X0M7@SO>O5X<_O,.OEYKKW6NJKE.Z61>#4Y-8G8U.I#HR2/ED=)(YS
MWN7+G.7*JO:JGR>;ES6R?9]IT/PW%T<=N]OG_P!\  ,GH@
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MNU:MM3:ZSSH]$PDD3N$D3NQR=7CR7J)TYYC20
M
M                                    $" #94
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M8WN]_84$ \R]YO.Y?;]/TV/IJ>GCC4  *MP
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M)B=2L  @
M
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M^23IP8[Q^JOP\#0&N:]J.8J.:J9147**AA@ZC'U%>6.=M<N&^&=7A^@ W9
M    =&]76DLUOEK:^5(X6>]R]2(G6HO5UI+-;I:VOE2.&-/-R]2(G6JGGW6&
MIZO4MQ6:=5CIF*J0P(O!B?BJ]:F.;-&./J]/X;\-MUEMSVK'F?[0^]9:JK-3
M5V_,JQ4D:KT,"+P:G:O:O>5X \RUIM.Y?;XL5,-(I2-1  "&@
M                                       !:-G6G5U!?XV2MS14^)9U
MZE3J;YK\,E88USW(UB*YRKA$3FJGHK0&GVZ>T_% ]J>ER_E9U_.7J\DX>_M-
M^GQ\[=_$/+^+=;^RX=5_-;M'^5C1$1$1$PB=0!':BO%+8+)6W2O=NT]+&KW=
MKEZFIWJN$3Q/3?"LG^4?K'T"U1Z;H9,5-:G25*M7BV'/!O\ B5/<B]IYN)+4
MMYJM0WVMNM>[-14R*]4ZFIU-3N1,(G@1IUTKQC2H "X
M            .2GFEIIXYJ>1\4T;D<Q[%PYJIR5%ZE/3>QO:I'J2..SWZ1D5
MY:F(Y5X-JD_!_=U]78>8#ZBD?%(R2)[F2,5'-<U<*BIR5%*6K%H'O@&0[%MJ
M+-0Q166_2M9>&-Q%,[@E2B?Z_OYFO'+-9K.I6  0
M
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M<>\UC95J&74FCJ:JJW;U7$Y8)G?6<W'M>*HJ+XY*WQQ%>59[)IDF;<;1W6\
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M1JJ00YX-3M7O4KP!YEK3:=R^ZQ8J8:12D:B  $-
M                               #L6ZCFN%=!24K-^>9Z,8G>H\HF8K&
MY7G9!ISUC=G72I9FEHU3H\IP=+U>[GXX-M([3MIALEGIJ"GXMB;[3L?/=UN\
MU)$]7#C].NGP'Q#JYZO--_;Q'V#SE\I#6/IMRBTU0R9IZ14DJE:O!TN.#?\
M"B^]>XV;:1JJ+2&E*NY/5JU&.BIHU^G*O+R3BJ]R*>,:JHEJZF:HJ9'23S/6
M21[ERKG*N55?,Z\5=]W!+B !T(
M!]0ROAE9+"]T<C'(YKVKA6JG)44]1[%]IC-44K+3>9&LO<+?9<O!*IJ?23\Y
M.M/-.O'EHYJ.JGHJN&JI)7PU$+D?'(Q<*UR<E12EJQ:"'O0&>[(=H<.L[5T%
M6K(KU3-3IXTX)(G+I&IV=J=2^*&A'+,3$ZE8 !
M
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M3\;KW,5&NSQ3"]8EHZF&!DTM/,R%^-V1S%1KL\4PO6-*\H^;@  6
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M%'?[/2W.V2I+2U#-YJ]:=J+V*B\%0D#E6
M
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MIL_RC]8^@6N/3=#)BIK$Z2J5J\6Q9X-_Q*GN3O/-YU8JZC;GD !L@
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MS50-S12.7C)&G./Q;U=W@89:?O0F&W  P2
M
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M_ >KX_K/^ Y0:1I^M^<GB2/J^/ZS_@?J4$:+G>>.4&G; !FL
M            &$;4=4K>[JM'229M]*Y4:J+PD?R5WAU)Y]I>]J^I_5%K]74<
MF*ZK:J*J+QCCY*OBO)/,PTXNJR_N0^G^!=!_^3>/M_D !Q/IUTT'K2+3%#5T
M\U"ZJZ=Z/RDB-1$QC')29_VA6+_^5*;W1_\ A,R!K&:\1J'!D^&]/DO.2T3N
M?K/^5TM^L:2AUG47JGMB14\D/1-IHW(W=X-3/!,=79UGQ8]8QVW6-QO;J-\C
M*M'HD22(BMWG(O/'<4X%?5LO/0X9B8F/,:\SXA8:'4+*;6SK\M.YS%J))^AW
ML+[6]PSCO/W4&HF775S;RVG=&Q'Q/Z)797V,=>.O!701SG6FD=-CBW/7?7']
M%QU3K&.]Z@M=R91OA;1*U5C61%5^'[W/' ZVM=5)J&\TE?3TSJ9U/&C4:YV]
ME4<KL\D[2K@F<EIWOW5Q]'AQS6:Q^6)B/U:%JG7=LU!9G13V;%Q6/<9,Y6JD
M2Y155J\^HX[1KRE?9(K5J6UI<8(41(WHJ;V$X)E%ZT3AE%*""WK7WME'PW!%
M/3B.T3N.\]OM/LN6L-:)>+;#:K91-H;9$J+N(N5=CDG#@B=?B=O3FO8*>Q):
M+_;DN%(Q-V-<IG=3DBHO9U*4($>K;?+:T]!@G'&+7:)W[[W\]^6CMVCT\=MK
MK?3V=E/1R1.B@CB>B;F45%5W#BJJN?\ K)G !6U[7\M<'2XNGWZ<:WY6O1&L
MIM-=-!) E503KE\*KA47&,IY<TZR=J=H=!0T%1#IBRLH)IT]J54:FZO;A.:I
MU=AFX+5RWK&HEED^'X,M_4M7O/GO.I^\+1HK6-5IF:9J1I54DZYDA<[''ZR+
MU+]Y8W;1+5;X9WZ>L$5+63)ATCD:U$\DYIW<#- *Y;UC429?A^#+?G:O>?/>
M>_W6?2&JG634-3=:V)]9+/&YK_;W55SG(N<X[CAH=0LIM;.ORT[G,6HDGZ'>
MPOM;W#..\KP*\[=H:STN*9M;7YHU/V6+4&HF775S;RVG=&Q'Q/Z)797V,=>.
MO!,W35#-4:SL%1'2NIDAFBCW7/WL_E$7/(HARTM1)2U,-1 [=FB>CV.QG#D7
M*+Q)C)/O[J6Z/'J.,=ZQ,1_#39]H>H[?;;W34-YM,5PI%@29BJB;[';SD7&>
M:*B)V%!UQK.3444%'34R4EN@5%;$BY5RHF$5<<$1$Y(A!7V]U]]JF5%TGZ:9
MC.C:[<:W#<JN.")UJI'%\F:;3,1X<W1_#<>"M)O&[1]9UOYQ"W:EU?'>-+VR
MTLHWQ.HTCS(K\H[=8K>6.',:BU?'=M)VRSLI'Q/HTB195?E';C%;RQPYY*B"
MDY+3OZNFO18:\=1XG<?>6CRZ_M=TM5-!J*R+6U-.GLN1^&N7&,]J9ZTXG1U'
MKJ*]Z86UR6UM/(U[71NB?AC$:O!-W'U>!1@6G->8TSK\-Z>DQ:(\3N.\]OM"
MWWK6$=QT;0V-M&^-]-T>9E?E';J*G+'>--:PCL^E;E:'T;Y75?28E1^$;O,1
MO+''EDJ *^I;>VG[%AX>GKMO?OY6K1&L9],NFA? E503KE\*KA47&,HOAS3K
M)^?:';Z"AJ(M,V5E#/.GM2JC41%[<)SQGAU&; FN6]8U$JY?A^#+?U+5[SY[
MSJ?O"V:+UE-IY*FGJ*=*V@J5S)$Y<+E4PJIG/-.:+S)F?7]NM]MJ:?2]F2AE
MJ/GRN5/97M1$YXZN.$,Z C+:(U$F3X?@R7YVCSY[SJ=?./"S5NHH)-$4=BIH
M96RLF6:>5RIAZY<O#WI[CLZ&UA'IFCN$,E&^H6JW<*U^[NX14[.\J (C):)W
M"]NCQ6I;':.TSN?OO:<T7?6Z=OC*^2!T[6L<S<:[=YIVDI0:PCI=<55_6C>Y
MDR.1(>D1%3*(G/'<4\",EHC4)R=)BR6M:T=YC4_9=+%7W*\:_GN5A;%%52*Z
M9(9G\'-X(K57KX?]<"ZUU\NBWV&"/238;L]S&.K=U)4:Q<95'HWEC/7P,<HJ
MJ>BJHZBDE?#/&N6O8N%12U)M(U*D6YZ9&JX^?T#,_=CX&N/+$1WF7!U706O>
M)QUK,1&N\S$_R\Q])3NV6K9%JBTJGM.@B21S47\]5Q\"N:^U5'JFJI)8Z5U,
MD#'-5'/WLY7/85ROK*BOJY*FMF?-/(N7/>N54X"E\LVF=>)=73=#3#3'R[VI
M$]_OY7&YZM;<M&T6GXJ*1)8>C:DF_G>5N4X)CKR:UH+3[=/:?BIWHGI<OY2=
MWYR]7@G+_P S-MC^G?6%U==:EF::C7\FBIP=+U>[GXX-L.OIZS/X[/G?C&:F
M.?V7#XWN?O(1VH[Q2V"QUMTKW;M/2QJ]W:Y>IJ=ZKA$\21/.'RC]8^G7./35
M#)FFHU22J5J\'2XX-_PHOO7N.RE>4Z>"R;4EYJM07RMNE>[>J*F17JG4U.IJ
M=R)A$\"- .M4 !(             .=*RI2B]#2>1*3I.E6%'+NJ_&-[';A"8
MLFL]1V2G6"U7FLIX%X=&DF6IX(N43R( $:%VV=6>BUSK&2DU-=:N.>I8KV3;
MZ.?-(BI[*N=GCC./ T39[LLU#IS:?%6.1&6>D?(K:KI6JLT:M5&MW4XY7*9R
MB)S[C!F.<Q[7L<K7-7**BX5%+#4:WU/4T*T<]_N3Z94W58L[O:3L5<Y5/$K:
MLSX$SMON-%<]H]TFMSF21,W(G2,Y/>UJ(Y>_BF/(D/D[_P!)E)_=YOV3-#M6
MVXUMKJDJ;;5STE2B*B2P2*QR(O-,IQ)X_AT-/N2Y^4@S/_K:+_2?7RB5_P#K
M/I>ZEA_;>9@ZZ5[[GZR=6U*W#?23TE9%Z3>3D[>SG/>+E=*^Z5:55RK:FKJ4
M1&I+/*KW(B<DRJY(BNIB1N_RE?\ ?6D/TY?VHSJ_*:_W_IC]&3]MAB]TOMVN
MSX7W2YUM8^'*Q.J)W2*S.,XRO#DGN/RZWNZ7>2*2ZW*LK9(L]&ZHF=(K/#*\
M.1%::T;;3\J+_>>F?T9OVF#Y5/\ 'Z;_ $:C[XS%KM>[I>'Q.NURK*UT6>C6
MHF=(K,\\97AR07>]W2\K$MWN597+%GH_29G2;F>>,JN,X0136OH-Z^4=6I;K
MWHJN<W>;35$DRM[=UT2X^!][:M'W#74=FOND^CN,/0;BL;(UJJU5WFN3>5$Z
MU14YIP[S KO?+K>>B];W*LKNBST?I,SI-S.,XRJXSA/<=BR:HOEB8Z.SW:LI
M(W+E8XI51JKV[O+)$4F(C1MN-PIO]G>PJJM-YEB]:W%)&-@:Y'8=)A%1.W=;
MQ5>6?(ZL7_V5Y/#_ /[##+M=:^[U2U-TK*BLJ%3'23R*]<=B9Y(<J7RZI:%M
M27.M]6+_ /=.F=T7SM[YF<<^/B3P-MN^2Y_N_5'C!]TA@!(VF^76SME;:;G6
MT39L=(E/,Z/?QG&<+QYK[R.+174S(  L   '/05E1;ZV"KHY70U,#TDCD:O%
MKD7**<  ]G[,]7P:RTQ#7LW65;/R55$GT)$[.Y>:?\E+6>.-E&LI-&ZHBJ7N
M<MNJ,15<:=;,\'(G:U>/O3K/8D$L=1!'- ]LD4C4>Q[5RCD5,HJ')>O&4P^P
M 42
M
M
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MKJ32M)J!;,UD\G14BT?2917(Q/;WO%.7>3R\#&@:[_L"U/\ _C;1_P"]D_\
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M_DJAF5;G*L<G!S5[T7*$N<:P
M
M
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MVALVU/'JW2-%<T5OI&.BJ6I]&5OSO?P5.Y4.?+77=,+. #%(
M
M
M                                                      !7M>WS
MU!INHJ6.1*F3\E!^FN>/DF5\BPF%[7;YZRU$M%"[--0HL?#DLB_.7RX)Y*8Y
M\G"FWH_"^E_:NHBL^([RHJJJJJJJJJ\550 >6^]
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M96\')[^*=RH6,XYC2P
M
M
M                        (C5EW;8]/UE>N-^-F(T7K>O!J>\\U2/=+(^2
M1RN>]5<YR\U5>LT[;;>>DJZ2T1.]F).GEQ]9>#4\DRO^(R\\[J;\K:^3[3X'
MTWI=/ZD^;?T]O\@ .9[0
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M$HFTJR11PQ8:UJ.1NXJ*JHJ8=\"L[([Y:J#9+JNCKKG14U9/Z1T4$T[6/DS
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MP[H ,D@
M
M
M        <=3-'34\L\SMV*)JO<[L1$RIR%)VNW;U?I5]/&[$U:Y(D[=WFY?=
MP\RM[<:S9OTV&<^6N*/>6*WVXR7:\5E?+G>GD5^.Q.I/),(=$ \>9WW?HM:Q
M2(K7Q   L                                     !^M:Y[D:Q%<Y5P
MB(F553DI:>:KJ8Z>FC=+-([=8QJ955-PT!H2"Q,96W%&37-4RG6V'N3M7O\
M=WZ8L4Y)[.'KNOQ]'3=N\^T('0FS;*1U^HF?G,I%^]__ (??V&JQL;&QK(VM
M8QJ81K4PB)V(?0/3QXZXXU#XGJNLR]7?EDG]/:  %W*
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MUZHB+Y.1J^12\;J0]A  Y%@
M
M
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M@ >I6L4C4/A,^>^>\Y,D[F0 %F0
M    B]2V&WZDM$UMNT"34TJ?XF.ZG-7J5.T\B[1]$5^B;RM-59FHY<NIJE$P
MDC>Q>QR=:?@>SB'U9IV@U19)[9=(M^&1,M>GSHW=3FKU*G_(O2_%&GAT$]K?
M2U=I&_36RXMSN^U%,B>S,SJ<G[NI2!.J)V@ !(     /0'R5/XG4WZ5-_P#%
M,$J_Y7/^F[[S;_DL5T4=PO\ 0O>B331Q2L:J_.1JN1?=OH4>Y;+=6,U'-0Q6
MBHE8Z9494M3\DK57@[?Y(F./'B91,1:=C2OE)?S,TW_:_P#PR<AHHMH^RNTT
M>G+TMMEI8HF31QJN$<UFZL;T145$SQ1?!<*5WY3=1%!:=.6Q7HZ9KGR.:B\=
MUK4;GS55]RD7J+9?-:[!;;]LWK;I6/E:CY%CE1)%8Y$5JLW$1>')4XKQ[E*1
M^6$N_2Q;0]F=CKXI:*EOMJ=[;GK*^9(6X5'>SE'(U4Y\,)@P5RY<JHB(BKR3
MJ/4VQ6?6DE)</X;).E"QC>@=6M1LN>.]G/%6XZW>76>9K\M,Z^7%:#'H:U,B
MPXY;F\N[\,%Z3WF$.B #4                   /UJJUR.:JHJ+E%3J/P >
MV] WQ-1Z/M5TRBR3PITN.J1/9?\ K(I/F(?)?O?36>ZV65V74TJ5$2+]5Z8<
MB=R*U%_Q&WG':-3I:  %0
M
M
M                   %.VL7'T#1U0QKL253FP-\%XK\$5/,P(TW;A<.DN5O
MH&KPAC65R=[EPGP;\3,CS.IMRO\ 9]O\$P^ETL3[V[@ ,'K@
M                       %JV=Z8=J*\ITS5] I\/G=];L9Y_=DFM9M.H99
MLU<-)R7\0MNR32"89?;E'WTL;D__ %%_#W]AJY^1L;&QK(VHUC41$:B81$[#
M]/6QXXQUU#X#K.JOU66<E_T^D  +N4
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MG/FCOM,.T #%(
M
M
M          =:YU3:*VU=4_YL$3I5_P **OX!,1-IU#SWM KO6&L+I,BY:V7H
MF^#/9_#/F5X^I'NDD>]ZY<Y5<J]JJ?)XUIY3,OTG#CC%CK2/:(@ !#0
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MK?4O^SU\1Y^__  #K?/@
M     ?CVM>QS'M1S7)A45,HJ'Z /'^V'1JZ/U5)'3L5+95YFI5ZFIGBS_"OP
M5"BGL?:UI)NKM'U-+$Q%KX/R]([KWT3YO^),I[EZCQRYJL<K7(J.1<*B\T4Z
ML=N4*R_  :                                   !ZWV!W3UGLUH&.=
MO24;WTKO)<M_5<T\D&^_)9N?^_K6]W#\G4QI[VN7]@RRQNI#?0 <RP
M
M
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MMAM%II:"G3\G Q&Y^LO6OFN5\SO 'K1&HU#\\M:;3-K>9  2J
M                                     'E+;_I9+!K-];3,W:*Z(L[,
M)P;)G\HWWJCO\1ZM*#MOTVFH=!5JQ,WJNA_[7#A.*[J+O)YMSYHA?';C*'D,
M '6@                                   TGY/5Q]!VE4D2KAE9#)3K
M_EWT^+$,V)O0]?ZKUC9*W.&PUD3G?H[R;WPR5M&XF![? !QK
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M^T=[QZ1-]H[WG$!H<OI$WVCO>/2)OM'>\X@-#E](F^T=[P<0&A/  R6
M
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MU&WA/&ZEE5/K-7>;[T5W^4PP[*3N-J@ +
M      &JK514X*G$ #W98:Q+C8[=6HN4J:>.;_,U%_$[Q3MCU7Z;LTT_+G.[
M3]#_ )'*S_27$XIC4K  (           1-P_E3O!#KG8N'\J=X(=<UCPJ  D
M
M                 $\ #%8
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M%<E]S6:SY>E  <[H          !/  Q6
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MS,[  2S
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MNGC.J=F[@ Y'6          "> !BL
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M16^ZHC89=R?[*3@[R[?("7
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MP_E3O!#KG8N'\J=X(=<UCPJ  D
M                                           $\ #%8
M
M      1^HDS8+C_=W_LJ8R;3?&[UEKT[8'_LJ8L
M               (JHJ*BX5  -TB=OQ,=VHBGT=6TR=+:J.3ZT+%_50[0
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M1?GO?U=7!.W'$X:O46N] 76F;?:F2K@E]I&3R)*R5J<T1W-%3]Q;]GGQOO\
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M:#7W6YR6#4G&X-1W12JU&N<K?G,<B=:87W*3;#,1,Q.](KFB9B)C6VL@ Q;
M                       )X &*P
M                                              Z]Q;OV^J;]:)R?
M!3$3=7MWF.:O6F#"W)NN<B]2X _
M    &O:/FZ;3="[/)FY[E5/P)@JFS:HZ2R2PJO&*9>'<J(OWY+6
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MID;F5R81RKGDG/JZR;,YV,QXI+I)]9[&^Y%_>:,99:Q6\Q"])FU=R  S7
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MGP8=[8?I6]:<J[L^]4+J5LT<:1JKVNWE179^:J]J';VX::N^HZ:T-LM&ZJ=
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M
M                 #$[K'T5TK(_J3/;[G*;89!JZ+H=1U[>V3>]Z9_$"(
M                                   7'9G5='<:JF5>$L:.3Q:O[E4T
M4QO3=9Z#>Z.=5PU'HUWZ*\%^"FR
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MO'H4PZ=R>')GGE>XWS2FDK+I6EZ&RT,<"JF'RK[4DGZ3EXKX<B=!SVO-O*P
M?CE1K5<Y41$XJJ]14?I\R2,BC<^5[6,:F5<Y<(B>)3M1;0+=;MZ*@Q75*</8
M7$;5[W=?D9E?M1W*]R*M=4+T6<I"SV6)Y=?BIT8^GM?O/:&5LL5\-&U%M$HJ
M+?AM3$K)TX=(O"-//F[R]YFEZOEPO,W27"I=(B+EK$X,;X)R(P'9CPUIX<]L
MDV\@ -5&O[((MS3E1)UOJ7>Y&M+R5?9G#T.CJ-<8617O7_,J?<B%H/*RSN\N
MW'&JP  S7          !$W#^5.\$.N=BX?RIW@AUS6/"H "0
M
M     3P ,5@
M                            ,OVAP]'J%7_:Q-=]Z?@:@4':?!B:@G1.
M;7,7R5%3[U HX                                     ;'IFN]8V2E
MG5<OW=Q_Z2<%_?YF.%VV:7#<GJ*"1>$B=)'XIS3W8]P&@
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M<B7V47O=R]V3,=0:JNE\<YM3-T=.O*"+V6>?;YD"#MQX*T^[GMDFP #9F
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M3V$[ .9H !1(
M                             %6VC0=+86RHG&&5JKX+E/Q0M)&ZEI_2
MK#718RJQ*Y$[TXI]P&-@                                    !V+=
M5R4-=!51?/B<CD[^U/,ZX W&DJ(ZNEBJ(5S'(U'-7N4Y2C[.+MO1R6R9WM-R
M^+/9UI^/FI>
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M94D7_#[7X$$7O9!2=+?ZFI5/9@@5$7L<Y41/@BE,L\:3*U(W:&N@ \EW
M
M
M                                                     <B.:J*F
M47@H &(W&G6DKZFG7^JD<SW*IURR:_I?1]0R2(F&SL;(GCR7[OB5L
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M%M-,%LEJ;RQJ5<L4K;6.=P  V9
M
M
M   "F;3*3?H:6K:G&-ZQN\%_YI\3/#9=14?I]DK*=$RYS%5OZ2<4^*&-
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M=R$EJ_4,VH;DLS\LIH\MAB^JG:O>I!'I8,7IQN?+DR7Y3V\  -V0
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M;+V\1\@ '4YP
M
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MJJ>)&6VOJ+=4I44;T9*B*B*K47@OB=8 <U952UE5)45#MZ61<N7")GW'"
M    #L6^LGH*N.II7JR5B\%[>Y>XZX V#3M[@O5)OQX9.SA)%GBU>WP)8Q&W
MUL]OJF5%+(K)6]?4J=B]QJFFM04]Y@PF(ZIJ>W$J_%.U )H
M                         .M<:ZFMU')55LK8H6)E7+]R=J]PB-CDJZF&
MCII*BID;%#&F\Y[EX(ABFM]52W^JZ.'>CM\2_DV=;U^L[O[NH_-9ZLJ-05'1
MLWH:!B^Q%GB[\YW?]Q6#T,&#A^*WERY,G+M'@ !TL0
M                    .U:Z-]PN--21?/FD1B+V97F/ V'9?;O0=+QRN3$E
M4Y9E\.3?@F?,MIQTT+*:GB@B3=CC:C&IV(B80Y#R+VY6F7?6-1H !5(
M ^)I8X(GRS/;'&Q,N<Y<(B=ZF<:DUY/63^KM+QODD>N[TZ-RYWZ"?BO_ #.?
MJ.IQ]/&[S^GO+;#@OFG55IU3JR@L$:MD=TU8J>S3L7CXN7J0HE+;[]KRK;4U
M\BTUM:OLKC#$3\QO6O>OOZB:TMH!&R)7:B=Z14N7?Z!7;R(O:]?I+W<O$T%C
M6L:C6(C6HF$1$PB(<<8,O5SRS_AK_P"O^73ZN/I^V+O;Y_X1MAL=#8Z7H:"%
M&Y^?([B]Z]ZDF >E2E:1QK&H<-K3:=V\@ +(
M
M
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MR4LVBV72N5L]373QVZ!,8WL(_'4G<G6=/4U\2]W."A@=B@;*UJN^NN<;WAV
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M]44R<$=]-B?B@&E@Z]!6T]?3I-1S-EC7K3J[E3J.P
M            ?CE1K5<Y41J<55>HH6J]H-/1H^FLN[4U')9EXQL\/K+\/$O2
MEKSJJMK16-RL^H]0T-AI>DK'YE<GY.%OSG_N3O,7U+J&MO\ 5]+5NW86K^3A
M:OLL3\5[R-K:NHKJE]15S/FF>N7/>N54X#T,6",??W<M\DV^P #9F
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MS/-U,WCA6-5^0 #L<P
M
M
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MDZH(UPB_I+U_=W%= .RM8K&H83,SWD !*
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MQH^-O3UBIAU0]./@U.I"P@'J8\5,5>-(U#AO>V2>5IW( "Z@
M
M
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MJEFB7*;J-:BIUHO/@I=0#7#@QX(XXXU#/)EOEG=YV  U9@
M
M
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MD\^?N+J>=U&3G;4>(=>*G&-@ .=J
M
M
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MVYGI])Z_@G(PSY.%>WF6F*G*4TB(B(B)A$Y(@ /-=@
M
M
M                                                        .G>+
M?%=+?+2S\GI[+NMKNI3'*ZDEH:N6FJ&[LL;L*GXFWE4UW8O3Z3TVF;FI@;[2
M(G%[/WH!F@  %@T99O6];*KYI(HH417+&N'*J\D1>KDI7R1L=WJ;-5+-2[J[
MR;KV.3@Y +EI:>T^NWT]KH)DD:UV]42O55X=W>?>G7,_AO>D7"/5%W?#*9_
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M5JXY.DZU\N7O*4?JJKE57*JJO%54_#UJ5BE>,.&T\IW( "R
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M3R5_X)YFFGQ!%'!"R*%B,B8U&M:G)$3DA]GE9+S>VY=M*\8T  HL
M
M
M
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M^8X>Q>UWFOPP:'M+OOJNRK2P/Q55:*Q,<VL^DOX>?<8N=O2X_P!^7/FO^[
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ME/&/#JQ4XQN0 ',V
M
M
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M70PQ,CZ)CD59$WUXM7/8[X'[06C-%33:,U"Z%N,R15,N4SWMQA%\BD1'"/\
ML+=^4H#:%5+4OIO2K));ZY$]N553=DX<43"87CUY.?4?_HW9[8Z!.$E4Y:E_
M>G/_ %-]Q.:YK8:NTVVRS5<%7=99HT>^+&&KR5W#ESY%;VHU3);_ !4L"IT-
M) V-$1>"*O'[E3W&F.>7&-*6[;E3@ =3$     #1-F>E/2)&7>XQ_D6+FGC<
MGSU^LO<G5WD3H'2K[Y5^DU;5;;H7>TO+I%^JGXJ;3&QL;&LC:C6-3"-1,(B=
MAR=1FU^"K?%CW^*7Z #A=(
M
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MM-,>DH^OMS/RZ<98FI\_O3O^_P"_/
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ML
M
M 7DI D\O)2!+T1( "Z
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MSX?EHME+::&.DHHT9$SWN7K55ZU.X >?,[[RZ_  "
M
M                                          7DI D\O)2!+T1( "Z
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MYS6*OEE2W:)U_9]6ODAHEE@K(V[SJ>=$1RIVHJ*J*GQ(G%>L;F$QEI:=1*W
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MGL2HGP7M0RZZ6ZIME4Z"KC5CTY+U.3M10.H
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MA=(
M
M        +R4@2>7DI EZ(D !=   (S4=HH+Y:)Z"[,1]-(G%<X5JIR<B]2H8
MK?-B=QC<Z2QW"GJX%XM9-^3?CQ3*+X\"?^4#IVJK:&CO%$Q\C:1KHZAK>*HQ
M5RCL=B+G/B1&@MKU+:;#36V^4E3(ZE8D<4T&Z[>8G)%153&$X'5CB\4Y4G?T
M<N2:3;C>/U4YE9J_9W<(HYG5-(U>+89'=)!*B<\(BJU?+BG<;'J;5JUNR"JO
MM#F&6I@2/"+QC<YZ1N1%[LNPIE6U#72:VJ*&DMM%+'3P.56(]$621[L)R3..
M7+CS-2HM&5*['%T]*B)7R0++NJO*7?Z1&^_"%LFM5M>-3M7'O=JTG<:4S8!I
MNW7-+G<;E2Q53X7,BB9*U'-;E%55PO#/(N>I]DUGO=W96P2NMK-S$D-+$UJ/
M=GYR=2+Y&9[*=:1:)K[C0WNGJ&P3.3?W6^W#(W*+EJX[>/@2VJMJ5VN^HJ2G
MT2^HBBPD;6.B:YT[U7ZJYPG+XB]<DY)FI2V.,<19:]O42P;/:.)9'RK'5Q-Z
M1ZY<[#'IE<=:D?L%TU;)].3W2MHX*FJEG=&UTS$?N,:B<D7EE57B=S;DVH9L
MVH&UTC9:M*F%)GM3".?N/RJ)V9R=_8'_ #!;_>9/P*;F,/;YKZB<WZ,HVM4%
M/9-HDJ6R)E-'B*=K(TW6M=UX3JXIDU+Y0/\ ,6/^^1_LO,WVZ_TB._L(OQ-(
M^4#_ #%C_OD?[+R\]YQJ1VC(^-A=/#5[.9J>IC;+!+42LD8Y,HYJHB*BD?M0
M;I'25MZ*FL=NDN]0W\C&L:*C$^NY.SL3K7S./9E>TT[L=N%UZ+IEIZAZM9G&
M\Y58U,]V50R+UM'=M2K<M4.J:J.1^_,V'".<G4Q,K[*=7<@K2;7M/L6O%:1'
MNO&QW0"WRJ;>KQ%BV1/S%&J82=Z+V?51?>O#M.]\HNZS/NUNM+7*E-'#Z0YJ
M<G/<JM3/@C?BI,4NVJR4M/%!366LBAB:C&,8K$1J)R1$R=+;S8Y[C26S4E'"
M]\*0)'.B)E8VK[37+W>TJ*O@(FTY(F\:^1,5].8I._FNFB=!6&BTO1LJK925
M=3/"V2>6>)'N5SDRJ(J\D3.$P8UJNE306TW>M#G,A@D9/$W.<,<F58O:G-/
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MZ+9<+M015<]8]^'29]AK7*W#>SBBKGF?ORC_ /<=H_O+OV2U;&?Z-;-X2_\
M&>5Y3&&-?-:*Q.:=_)E.WRL5-2T5JA]BBH*1B1QIR15SQ]R-3R)NFU1LWCTX
MVTR6^1S.BW'R^B)TBNQQ?O9SG/')UOE"V&H9=J6^0QN=2RQ)!*Y$SN/15QGQ
M1?@2-%M$T7_!QLU39J5+LR+"TR4351\B)U.QC=5?,TCO2NHW]F?B]MSI ?)^
MN4E-K"IH&/5::J@<N[^<Q45%]V][R)VGTWINUJNI554Z>H@BRG5O,8GXFE[(
M+_/J2IJ9Y-.VNBAIV;OI=+#N*YZ_13RRJ\>SM,^UU_3:[^_4OW1DUG_<G[(F
M/]N(^K7M4Z/L4.AKG2T]LI8T@I)'Q/;&F^U[6JJ.WN:KE./:9S\G"1R7R\1H
MOL.IFN5.]'</O4V;5G\UKS_<IOV'&+?)Q_G#=O[JG[:&5)F<5MM;Q$9*Z1.U
MW^EB7]*G_9:;=M L]FN]B5NHZI]+00/259&RI'AV%1.:+GFO Q':[_2Q+^E3
M_LM+C\H]M6MLLSH][T))9.EQRW\)N9\M_P")>8WPC:L3QYRZ=+JS9YIRU>KK
M=;9+OC*++)2M5TJJOTG.1%[N"%2V02M_VJT"P1K!%(ZHQ$JYW6]$]4:OAA/<
M6[9_K31>G](T[I:=L=WB8O2M2GWI97Y7BC\8PO>J8*ELMJUDVM4534LZ)\\T
M[E:O#=<^-_#WK@M$:BW:?U4WN:]WIL '"[@  "5MW\E3Q4BB5MW\E3Q4K;PF
M'9 !FD    Z%XN]#9Z99KA4,B;]%%XN=X)S4K:T5C=IU":UFTZAWR!U'JNV6
M)JMJ9>DJ<<((^+O/L\RDW+65XU%4NH=,TTL4:\%>W^,5.U5Y,3_K)*:<V=00
MN2IOTGI50J[RQ(J[B+WKS=]WB>?/69,\\>EC?_[3X_Y=L=-3%'+//Z1Y0<M=
MJ77,KHJ.-:6W9P["JUF/SG<W+W)[BX:9T-;;/N33M2LK$X])(GLM7\UOXKQ+
M5#%'#$V.%C8XVIAK6IA$3N0^C3#T-:V]3+/*WSG^T,\G56F.&..-?H  [G*
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M#7_2;^*>/<=G2Y/W)<^:G[T*> #M<X
M             !-::TW7W^?=I&;D#5P^=Z>RW]Z]Q$S%8W*8B9[0BZ2FGK*A
MD%+$^69ZX:QB9536M&:%AMFY675&SUO-L?-D2_BO?_YD]IG3=#8*?=I6;\[D
M_*3O3VG?N3N)HX,O43;M7PZ<>+CWD !S-@
M
M                                         !>2D"3R\E($O1$@ +H
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MJ)8)V*R6-RL>U>I4.(TK:Q8-U[+S3,X.Q'4(G;R:[\/<9J>KCO%Z[<5J\9T
M NJ                                     !],8Z1[6,:KG.7"(B955
M)K3FF+C?I$]%BW*=%PZ>3@Q/#M7N0UO3&DK?86(^)O3U>/:GD3C_ (4ZD,<F
M>M.WNTICFRF:3V>23[E5?=Z*+FVF1<.=^DO5X<_ T^EIX:2!D%-$R*%B8:QB
M81#E!P9,EKSW=5:17P  S6
M
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MC>#5_-;U>/%2U $XL-,->..-0C)DMDGE>=@ -%
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MW(?0!S-@
M
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M;V<C')_Z=T_[W;^TAN&T;^8E^_N<GW*7R3WHIBB-79G\FQR[]_9GV<0+CO\
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MSC93'/\ ^26N#_QP  R;   $K;OY*GBI%$K;OY*GBI6WA,.R #-(
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MF.2_4VGM7LWKAB/+IVNUT5J@Z&WTT<#.O=3B[Q7FOF=P YYG?EMX  0
M
M
M              +R4@2>7DI EZ(D !=   !4]JW]'M\_L/\ 4A;#CFACGB=%
M/&R2-R8<Q[45%\44FLZF)5M&XF&+?)VIH*NVZB@JH8YH7OA1T<C4<UR8?S13
M5[7IRS6F99K;:Z.EF7AOQ0M:[PS@[U)14M&CDHZ:"!'?.Z*-&Y\<'8+Y,G*T
MS'NK2G&L1+\(1VDM/.J_2762W+.J[V^M.WGV\N9. SB9CPO,1/ET:RT6VN>U
M];;J.H>QNXUTL#7JC>Q,IR.S)3PR4ZP211N@5NXL;FHK5;V8Y8.4#9I#6_2]
MBM]4E30V>@@J$7*2,@:CF^"XX>1VIK-;)ZOTJ>VT4E3E'=,^!JORG)=Y4SPP
MAWP3N34!!U>D=/5=0L]39+?)*JY5RP-RJ]_#B3@$3,>"8B?+AI*6"C@;!20Q
M00LX-CC:C6IX(AUZVT6VOE26NMU'4RHFZCYH&O7'9E4Y'>!&S3\:B-:B-1$1
M."(G4=&DLULHZCIZ2W44$_'\I% UKN//BB9.^!LTZUPH*2XTSJ>X4T-3 [BL
M<S$>WW*=6TV"TV=[GVNVTE(]R8<Z*)&N5.Q5YX),$[GP:CR'R]C9&.9(U',<
MF%:Y,HJ'T"$H#^!NF^GZ;U%;>DSG/H[>?AC!.QL;&QK(VM8QJ81K4PB(?0)F
M9GRB(B/#H+9K8M9Z6MNHO2M[?Z;H&[^]V[V,Y[SMSPQ5$+X9XV2Q/3=<Q[4<
MUR=BHO,Y 1LTZ=!;*"WJ]:"BI:57XWN@B:S>QRSA.)^72U4%UA2&YT5/5QHN
M4;-&CT1>[/([H&Y\FH\(VWV.U6ZFEIZ&W4D$$J;LC(XFHCT['<./F<]!;*&W
M[_H%%2TN_C>Z")K-['+.$X\SM@;DU#H.LUL=6>ENMU$M5O(_IE@;O[R<EWL9
MSWG? &S3H,LULCK/2V6ZB;5;ROZ9(&H_>7FN]C.>\[533PU4#X:F*.:%Z8='
M(U'-=XHIR@;-.K06ZBM[7I04=-2H_"N2&)K-[';A.)V@   "0  "5MW\E3Q4
MBB5MW\E3Q4K;PF'9 !FD
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MC9K5NN@I&R3)_6S>V[X\$\D)X'/;->WF6M<=:^  &2X
M
M
M         "\E($GEY*0)>B)  70
M                    !*V[^2IXJ11*V[^2IXJ5MX3#L@ S2
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M.3KF>J_!,)\"PTE%2T;-RDIH8&]D;$;]QV 96O:WF6D5B/  "J0
M
M
M                         %Y*0(!>B)  70
M                               !*V[^2IXJ 5MX3#L@ S2
M
M
M
M                                                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g12080g03r66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r66.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2-04&AO=&]S:&]P(#,N,  X0DE-! 0
M    (S,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H_\  $0@#Z0-@ P$B  (1 0,1 ?_$ !P  0 " P$! 0
M       &!P0%" ," ?_$ %X0  $# P$#! L-! 8&"0,#!0 ! @,$!1$&!Q(A
M$S%!40@4%B(V87&!D9*Q%1<R5%56<W23H;+!T2,W0E(S4V)RE.$D-62"PM(8
M)31#8Z*CXO&#L_ F.$2$)T5UP__$ !L! 0 # 0$! 0             ! @,$
M!08'_\0 0!$!  $# 00&!P<"!@(" P    $" Q$$$B$Q0043%%%AD152<8&A
MT? B,D)3L<'A!O$6(S,T0V(D5&."-7+2_]H # ,!  (1 Q$ /P#JD
M              *[NNV71=LN-30U5QFY>G>L<FY3/<F\G/A43"F_VD7]FFM%
M7:Y.<B2QPN;"BKC>D5,-3TJ<.<E4U3:FIW))4CP^:3&=W>7&57QJITZ:Q%W,
MU<(9W:]B(QQ=\:?O-%?[33W*US<M23MWF/PJ>E%YC8% ]BMJ9LEON&G:B3]I
M$_MFG15_A7".1/(N%\ZE_&=^WU=<TEJO;IRA^L=I&F](7".BOM5-#42,Y1J,
M@>],>5$-YIF_4&I+/#=+3(Z6CFSN.<Q6*N%PO!>)S9V5'AK0_5$]JEQ]C]^Z
MVT^5_P")2_54]1%SGGYHFN8N[')L-6[3=,:3NGN?>ZN:*JW$DW64[WIA>;BB
M>(DM@N]'?K/2W.VO=)1U+=^-SFJU53..9>*<QRUV3O[Q$^JL]JE_;%/W6Z>^
MK_\ $HFU$68N<Y_E.W/6;'A\DV !SM B.L-HVFM)2<E=[@B5/]1"U9'^=$YO
M.1_;QKR71VG(X;8]J76N561N7GC8B=\_R\R)Y3GW9AL]N6T2ZS32U$D-!&[_
M $FL?W[E<O'"97BJ_<=-FQ%<377.(AG<N;&Z.*[&=D-I5TZ,=1W5L>]CE%B;
MA$Z\;V2?Z/UQ8-71N=8Z]LTC4RZ%[59(U.O=4K:K['33[J-S:6ZW*.JW>]>]
M6.;G^[A.'G*$OEJO6S_63J1)9(;C2O:Z*6%53E&KQ14QT+U>8UIM6;OV:)WL
MYJN4QF8W.Z0:'0E[EU%I:@N53324M1*S$L4C%:J.3@O!>@W<TL<,:R32,C8G
M.YZX1/.<=5,TS-,MZ9VHS#[!IX]46"21(X[Y:GR*N$:VKC557JQDV['->U',
M5'-7BBHN44B8F.)F)?H 147F4A( ,IUH  ,*X7:W6U$6XU])2(O-R\S8\^E0
M,T&%;[O;;EGW.N%'5XX+R$S9,>A5,TF8QQ,Y #7U]\M-ND2.X72AI9%YFSU#
M&*OF52(C(V /.GGBJ8FRT\L<L3N9\;D<B^=#T   "%:MVGZ7TI=UMEZK)HJM
M&-D5K*=[TW5YN*)CH--[^FA?E&I_PDGZ%*=DU^\Z3ZG#_P 1N- ;#:?56D[?
M>7WZ:F=5-5RQ-I4<C<.5.?>3/,=M%FWU47*YXL*KE6WLTK=MVV;1%?,L;+NL
M2ITS0/8GI5"?4573UM,RHHYXYX'IEKXW(Y%\Z'-&J^QZN-NM\E38KFERDC3>
M6&2'DW.3^SQ7*^(B.QS7M9HS4L,%3,_W(J).3JH7JN&+S;Z)T*@C3V[D3U4[
MT3<JH^_&YV143,IX)9I5Q'&U7N7&>")E2 V;;!H^\76GMU!75#ZN=_)QM6FD
M:BKY50G-1&RNM\L;'X941*U'IQX.3G^\IS2VP>FL.I**[,U#+.ZFE25(EI4:
MCO%G>.>U%N<]9.&M<U8^PNL QJZX4=OBY2OJZ>EC_FFD:Q/2JF2[)!KJ"^VF
MX2+'072@JI$YVPU#'KZ$4V),Q,<3.0 Q;A<J&W1I)<*VFI&+PWIY6QIZ54@9
M0,.W76W7)%6W5])5HU<*L$S9,>A5,P3&#B &NK[Y:;=(D=PNE!2O7F;/4,8O
MH51$9&Q!Y4M3!5PMEI9XIXG<4?&]'-7SH>H #*=:'Q/-%3Q.EGE9%$U,N>]R
M-1$\:J!]@P+=>;9<W.;;;E15;F\7)!.V14\N%4SR9C'$SE^.5&M5SE1$1,JJ
M]!YTE3!5P-FI9630NSA[%RBX7'!3FSLE=87F'4/N!2U;Z>VI V1[855JR*[/
M!RHO%.',6]L-5/>KT_Q_[EWXW&LV9BUUD\_Y4VXVMAGZTV@:?T;44T%_J989
M*ABOC1D+I,HBX7F0V6D]2VW55I;<K+*^6D5RL1SXU8N4Y^"\2(;5MET.OZZ@
MJ)KM)0+2QNC1K8$DWLKG/%4P2#9OI%FBM-LM,5:ZL:V1S^5=&C%X]&,J1BWU
M><_:)FK:Q'!* ,IUH?$\T4$3I9Y&1QMXJ][D1$\ZF2[[!@6Z\VNY/<RW7*BJ
MW-^$D$[9%3RX53/)F,<3.0#*=: @ %5$YU"<>8  JHU%5RHB)Q55-1/J>PP2
MNBGO=KCE:N',?5QHJ>5%4F(F>!P;<'G3SPU$:24\L<L:\SF.1R+YT/V=_)PR
M/3&6M54R1.XC>^*NKIZ.-)*J:.%BN1B.>Y$17+P1/*>QQ?6:NO.JMHUMEN]6
M^1C+A&V.!JJD4:(]$X-SCSG:"*B\QO=LS;IB9YJ4UQ5,Q')!=2[5M*:;N\UL
MNU;/%60XWVMIWN1,IGG1,$PM5?!=+=35U&Y74U0Q)(W*U456KS<%YBJ=?;$Z
M?5NIZJ\27Z6E=/N_LFTR/1N$QS[R%H:=MJ6:QT-N;*LR4L+8DD5N-["8SCH*
MS%O8B8G[1FK;QR;  U<^HK+3U':\]XMT4^<<F^J8UV?(JY,XC/!?@V@/F-[)
M&(^-S7L7F<U<HI]$ !E.M#RJJF"DA=-5SQ01-YWR/1K4\Z@>H,*W7:W7-'+;
M:^DJT;P<M/,V3'EPJF:)C'$SD                                 /.
MHFCIZ>2:9R-BC:KG.7H1.<#GCLJ]1[TMKT_3R<&YJ:A$7IYF(OWJ>^Q'0,-T
MV6WF:K8U9;RUT<2N3X*,SNKZW$I/7=]=J/6%TNDJJZ.>=RQIU1HN&IZ$0N33
MFWNT6.QT-LI=.U7(TL38V_Z0WCCIYND]+JJZ;$44QOGBYIKB;N9X0JC9W>Y=
M':^H*R?>8E/.L-2WF[U<M<G_ .=1W!#(V:%DL:HK'M1S53I13A+7EYHM0:IK
MKI;:-]%!5.1ZPO>CE1V.^7*)TKQ.J=@6IDU%H"DCD?O5=O1*67QHB=ZOHQZ%
M(U5$U6XN3&^.*+544US3'"5/]E1X:T/U1/:I<?8_?NMM/E?^)2G.RH\-:'ZH
MGM4N/L?OW6VGRO\ Q*9S_M8]O[RM5_K^[]H4?V3O[Q$^JL]JE_;%/W6Z>^K_
M /$I0/9._O$3ZJSVJ7]L4_=;I[ZO_P 2D5?[6GV_-/\ SS[/DFP.;+GV0MZI
M+E5TS+1;G-AF?&BKOY5$<J?S>(VV@=N-VU+J^V6BHM=#%#52[CGQ[^\G#HRX
MSC2W)C.%YNTQ.)07LFJ^2IVDR4KG+R=)31M:F>";R;R^TNKL<J*.DV7T3V-1
M'U$LDKU1.==["?<B%)]DQ1/I]IDU0Y%W*FFB>U?(FZOL+J['"NCK-F%'&Q45
M]--)$]$Z%WMY/N<AO5_M8Q]<?W9S_K_7<L\Q);90S5?;4M'3OJ<;O*NC178Z
ML\YED4U!M T[IZ_16B\UW:M5+&DC7.8JLPJ\RJG,O#I.&F)F<0WG$1O2ARMB
MB<Y&KNM3.&I[$.1M=7'6&O=;MH'4]PI:>:I=!1T\K'QL8W/.O#BN.*J=:TM;
M355(E535$4U.J925CT5N/*43KGL@64==-1:6H65*Q/6-U34(NZY4X=ZU%1<>
M-3?3[45[J<S^BES$T<<(M=^Q_O\ ;K3/6P7:CJ9H6+(L+&O:JX3*HB]9B]CQ
MK.ZT>M**R35<TULKMYBQ2.WD8_=54<W/-S8\Y]R:JVKZPII&4T53'2.C<YSH
M($@8K<<>^=^I%-B7[T]/?3K^%3NHBNJFJ+DQ+FKFF,30Z<VY2/CV87Q\;W,<
MD:85JX5.^0I+L8*JHFV@U+9IY9&]HO7#WJJ?":77MV_=;??HD_$A1W8M?O$J
M?J+_ ,33FTW^E<^N3:_QI]O[PZ;U4JMTU=5:JHJ4LF%3^ZIQ_L@K:J3:?I]D
ME3.YBU:91TBJB\_C.OM6JC=+W=57")2R97_=4XZV.?O2T]];3\QH_P ?LC]S
M4_<CW_LZ8VYZPJ='Z,6HMR[M=5RI3Q2?U>455=Y41#GS0&SZ^[3&5M>Z\,8R
M*3<?)5/=(]S\9YO/SG1>V71<NM](K0T;V,KH)4G@5ZX:KD145J^5%.470ZJT
M)<W=[7VJI:O%S<HUV/&G!4)TF-F8IG%1>SF.Y)-;[-]2[/9J&JIZU]2V:3=C
MFHM]KFR="*G6O0="[%-1W>_Z3:FHJ6KBN-*[DW2SQ*SEDZ')E$X]"E#:?V[Z
MNMTD:5TM-<H$X.2:+#E3^\W'$Z(V:[0+;KNVR3T+7P54&$GIY.*LSS*B]**3
M?BYL8KC/BK;FC:^S.$&[(7:14Z;ACL5DE=#<:F/E9:ABIF)F<83QKA>/45=H
MG9)J/7-M=>*BX,I89558GU6^]\W6[R>,U6WFIDJ=J%YY5?Z-61M\B-3'M)9I
M_;=J"T62AMU+IZF=!2PLB8[DY>^1$QGG+VJ*J+,3;XR7)S<V:N$(O'<M5;(]
M8.I)*EZ\GASX=]70U$:]*(OMYT.NM-WBFO\ 8Z*Z42Y@J8TD1,_!7I1?&B\#
MCS:5J^ZZ\K:2JKK.E+)3L6-.1B?WR*N>.<E_]C1-._9LD-0Q[%@JY&-1[51<
M<%Z?&JE;]$U6HJK^]!;F(KQ3PE:P //=+D;LFOWG2?4XO^(OO81^ZNQ?1N_&
MXH3LFOWG2?4XO^(OO81^ZNQ?1N_&X[J_]K3[?FYX_P!:4^.(ML5NCM>T:]T\
M+6LC6;E&M:F$3>3)VZ<3[;*UE;M+O<D:HK62)'E.G=3"F>BSUON:7O\ 3GVP
MZFT96OKMD]NJI'*LC[6F7>-(\?D<L[+*VJ?M(LC'U,[FK5)E%D544ZAT+3.I
M-D%LAD14>EKRJ+T98J_F<K;*?WEV/ZVAOIXCK+GUWL+O^C3]<H=1[:]75&C]
M$S5EO7%?/(V"%ZHB[BKE5=A>I$4YNT=IS4.U:^5RRWA.4B1))I:I[G<ZKA&M
M3_)$.F=KNCGZUT?-;J5[(ZUCVS4[I%PW>3H7Q*BJ<GW;3VJM"7573P5=#/&N
M&U,"JK'>-')T%-)LXF/Q-+^UNQP2G76R+4&B+4EUBN#*R!KT:]:9'M?'GF7'
M5DM_L?=37^YVNIMNIJ:O6:E5'0U=3$YN^Q?X5<J<53\RF;'MOUG;7,2:MAKX
MD7BVIB155.K*84O_ &5[4K?KI)*;D74=TB;O/@5<M>G2YJ_D7O1=V)BN,^*E
M$T;43&YZ;:-=]Q&F4DI41USK%6*F1>9BXXO5/%[<'.VC='ZHVJ7&KJY[D]8V
M+^UJZMSG(KNAJ(G3Z,$N[+&9[M262%57DV4KW(GC5W^1978V11Q[+:-S$3>D
MGE<[R[V/R0SM8M6.MCC*]R=JN*.2AM<Z&U)LQJZ.KCN+G12+^SJZ1SF;K_Y5
M3KP="[$-<2ZSTPY;@BI<J%6Q3NQCE.'!_GPI/JRBIJUK&U<$4S6.1[4D:BX<
MG,J>,^XXHX(E;"QK&IS(U,(95ZCK*-FN-_>M%K9JS3*A.R VI5MKKGZ;T[.^
MFJ(T1U551N3>3*9W&]2XPJKSD)T?L9U+J^UMNM;7QT3)N^C2JWWR2(O\7B12
M%ZJD?<MHUR6K=ETUQ<UZKU;^/8=S01LA@CBC1$8QJ-:B="(F$-YGL]JG9XRI
M_J7)B>$.-;C%J[9'JB)G;DL:91[',<JPU+$7FPOLZ,G4^SG5M/K/2U-=H&<E
M([+)H<YY-Z<Z?FGB4KKLJJ2*71UMJ7HG+0U>&+XG-7*?<GH-)V)=3*K=04RJ
MO(MY-Z)T(JY0B9ZZS-<\8)CJKD1'"4'[(.LJ8MI]P9%43,8D<7>M>J)\$W]H
MTWK/:W;H:J:XMMEEI8V04L<F\K7[K4:KD1/A<W%5(QV1/[T;C]%%^$Z;V3PM
M@V;Z=8U$QVFQW#QIG\RVUL:>FJ.)5&;TQ]<G(^KM/WO9UJ9:.2K?%4,1)8:F
MF>YJ/;T*GZ'4&A;W6Z[V3/J'*UMRG@EI5=G"+(B;N]PYL\%*K[+%C4OED>B=
M\L#T5?\ >)[V,'[M/_ZV7V-(N5=;I]NKC_."(ZN]BGZW9<U:XTY=-+WM;??)
M(Y*ODT?O,D5Z;JYQQ5$7H+1V);/]2+<[!J1*B#W&55D2/EW;V[Q3X.,<_C-+
MV3/[R7_58_\ B+^V&_NKT_\ 0N_&XTJO5=1%?.?Y5ZN)N32JCLK:F>"]V%()
MI8T6GDRC'JF>^\1/^QNEDFV;PNED?([EY.+G*J\Y7?99_P"O+!]6D_$6#V-/
M[M(?K$GM,8_VOUWK5?Z\?7)2W9"U=3%M2N;(JB9C$CA[UKU1/@(2"TZ?UEM=
MMT-4^XMM=DI8VT\$3U<K7JU$1783X2]:JI&.R+_>K=/HX?P(=+;(H&TVSBPL
M8B(BTS7<.M>/YEYJV-/35'%$QF]-/UR<FZPTY?-G.I6TTM4^.=$26"IIWN:C
MTSSIY^@ZNV/:DJ-5:!M]QKE1U9WT4SOYG-7&]YTPI3_9:M3W6T\_'?+!*F?%
MO(3GL85__MJGUN7\B*ZNMT\5U<?YP8BB[B/K<I[LBJNIAVG5S(JB9C.0B[UK
MU1/@G26RQSG[.M.N>Y7.6BC555<JO YF[(_]Z-=]!%^$Z8V4_NXTY]2C]A2Y
M_MJ?KO6_YY]GR4OV553/!>[*D,TL:+ _*,>J9X^(G?8SRR3;-D=-(^1W;<O%
MSE5>@K[LL%3W=LJ93/(/7'^\3[L8OW:)]<E_(F/]K]=Y7_K1]<D"[('4^IKA
M?I;-;:6YTMHIE2-SV1.:VI>O3O(G%N>"&';^Q[U#66Z.JJ;O1T]3(S?6![7N
M5J]2NZRQ]J&VFATG7S6JUTW;]SBX2*Y<11+U+TJOD*R;M+VG:K<K+)3OCA>Y
M$:M)2X1/]]V?:6L]9U<11&/'O+FSM9JGW(AI34=^T#K1L"U,S>UZCD:JF615
MCD3.%14]BG1NVS3%WUCIBWQZ?ECBDCEY=ZR2N8BLW%Z41<\YRA=H+A3ZEFBO
M6_[HMG_;[[D<N_GCE4X'=E-_J2+ZNGX2=5.S33<CBK9G[=5/)P31T4]3=H:&
M%S4J9)DA:JNPF\KL)Q\IUAL,T3?M'QW5-0S0RK4.8L?)S.DQA%SSHF#F33_A
M[;__ /8L_P#N(=WEM7<F*(CO_A6U1$U3X?RX\V^UE3%M.NC(JB9C41G!KU1/
M@H=1;/'*[0UC<]RN5:2-555RJ\#E;L@?WHW7R,_"ATK8II*;9#330KB2.U;S
M5ZE2-3&[NTU,_7-I&_43'UR45MEVIW._7R:RZ<J9X+9$_D5Y!<.J7YPO%..,
M\$0^[7L!U+<+7'755SI:6JD9OI3R[[G)PRB.=T+Z2';$Z>.LVHV!E2B.;RRR
M=]TJC55/O.V#2[5V:F**./>K1_FU3,\(<;Z=U;JC9;JJ6@N#YWQ0NW:BBD>J
ML>U>.\W/-PXHJ'7=DN=->;52W"A?OT]1&DC%\2IS>4YQ[*VDACU%:*IB(DTL
M#FO\:(O#VEB]C/423;,HFR*JI%4RL;GJRB_F4NXNV8N\UHCJ[FQ'!06UNX55
M/M2ORLJ)T9'691J2*B<,<"=4VCM:;6Z?W;N%TCMMLDX4E-)O*U&IPRC4QP\:
M\5*\VQIG:AJ)/]K7\CL'0\#:71UE@8B(UE)&B8_NH:5U[%BBJ..[]%<9O50X
MTO=!?]G6JWTBU4E+7TZI(R6!ZHU[5YG)UHO4IV)L\OK]2:,M-UF1$FJ($61$
M_F3@OWH<[]E0QK=>4+D3BZA;GUG%R]CZN=EMHS_;_&I6[/66(KGC_<B-B]LQ
MP6* #@=(                             %8=D1J-+'L^J:6*3=J[BJ4[
M,+A=WG>OHX><L\@FT79G;==5M+472NKH4IHU8R.!S4;Q7*KQ1>):WC:C:X(G
M,1..+G;87H.EUM?JQ+LR5UMI(D5_)O5JJ]R]ZF4\BJ7A[PVB?BM9_BG$HV=Z
M$MFA;?4TMJ?-+VQ(DDDDRHKEPF$3@B<"6'1>U,U5?8G<RM6L1]ISUM:V-V*Q
MZ)K;IIV&I;5TBMD>CYG/18\X=P7RY\Q$.QKU-[C:U=;9GHE/=&I$F5X)(G%O
MYH=6U])#7T4])4L1\$S%C>U>E%3"E2T.P+3]#<(*VEN=TCG@E26-4>SO51<I
M_"6LZB-FJB[/%%RWPFCBKGLJ/#6A^J)[5+C['[]UMI\K_P 2GUM V56G6UTA
MKKG65L4L421(D+FHBIGGXHI)]&Z<IM*:?I[10R2RT\&=UTJHKERN>."G6T]1
M%OGGYK31,W=OEAS-V3O[Q$^JL]JE_;%/W6Z>^K_\2FOU[LDLVL[VESN-7713
M<FD>["YJ-PGE128Z5LD&G-/T5HHWR204K-QCI%17*F57CCRBJY3-B+?//S-B
M>MVN6/DTDVS/1\TTDLNGZ!TDCE<YRQ)E55<JI[VO9]I:U5\-;;[)1054+MZ.
M1D:(K5ZT)2##;JX9:;,=RKMO6@IM8:>BJ+5&C[M0N5T;."+*Q?A,\O,J'/\
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M4RJYXHO62;1FG*72FGZ:T4,DLM/!G==*J*Y<KGC@3=IZB+?/^Z)HF;NWR;L
M'*V
M
M
M
M
M           "\RXYP-!K/5UHT=:TK[Y4\E$YR,8QJ;SY'=36])O()6SP1RQY
MW)&HYN>I4R<X]D'I#W)T<Z[W.Y5-TNM1<F-;-,Y4;#$J/5(V-SA$X)QZ<'0]
MH_U51?0,_"@IWQ,S];BK=,1X?NR@#QK:AE)1SU,J.6.%CI';O/A$RN/0![ P
MK+<H+O;(*ZE1Z0S)O-1Z87GQQ,T
M
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ME=:*R&LI'Y1LL+MY%5.=/*3-,QOF$9B6< "J0
M
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M66-\*JK'-3&47/%%XEO'#7151.S4[XF)X  *)
M
M                                             #7:D\'KI]5E_"IL
M37:D\'KI]5E_"H&JV:^!-K^C7VJ2;H(SLU\";7]&OM4DP'-6KXNT]6W1C$QR
M=2Y6^G*$XU=IVAM[(;K;Y',97(CEIT3O$54RKDZO(1G:G#R.N;CPPCT8]/'E
MB$DNEP;7Z(T^YJJJL1T;O$K>]/.Z&IQJ+E/=/S>A_6-%%WHVS=JC,Q'Z[**W
MJRU%58GW6!JNCI9.3E1$YFJGPO3P-7:+/8]06>YVNNH:-MYDA<M!5O3=<LN.
M#%=Y<8R7/LXI(:G3=9%41MDAFD<Q[7<4<F,8*PVC:0=I>O9/2N5UOJ'+R2\<
MQJG'=5?8IW:J:[5^;U#\_BQ<T=%&MM;XQ]J/KZRI2'2&L[;5.6GLE[IJAN6J
MZ&"1J^3*=!L=GFL;W8]<VIU5=JQL';<<-5'4U#]S<5R-=O(J]"*J^+!U7LIO
MK[YIK%7)RE92OY)[G<[DYVJOF]A0>MMANJUU-<*BU1TU;1U$\DT;TEW7-1SE
M5$<BIS\>@].SJJ;\?;W9?2V:XNVZ;M'"71W=QI;YPVK_ !3/U-S;KA1W*F2H
MM]5!50+P22%Z/;Z4.)-5[,]4:6M+KE>J..&D1[8U<V9'+E>;@AO-C.U)N@(K
MC3UE'45U+5.8]K(Y$;R;D145>/6F/04JTD33FW.6T7-^]V0"BX.R2T^Y6I-9
MKK'GG5JQN1/_ #(;JCV_:-G5J2OKJ?*XS)"BHG'Q*IA.GN1R7VX6T#RI*B&K
MIHJBED;+!*U'L>Q<HYJIE%0]3%8
M
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M"N.Q\OC+WLSMWP4EHE6DD:G0K>9?.U4+'..Y&*YB6E/  !1(
M
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M%:U['<RX55XI@M4YJZ)HJV97B<QF  %4@
M
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M+@
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ME*:@ XF@
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MO$-Q9 R>2)%W6O543*IC/ Y+\Q%RF7S72]VFWK+-4[L;Y]F?[NH@4O[\%?\
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M?PR(N')Z4]&#*]I^JB*HG,+4U[21@ YUP
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MO4'RV1CDRU[53Q*?J*B\RH!^@93K&0
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M,V1'*Q."HJY3@WC@Z>:Y'-1S516JF45.DYKMJ;=6%Z:LP_0 9+
M                                                    5/JK:_IZ
MPZ@KK96V.YU%132;CY8Z=CFN7K154M@IR];0M8W76%WLN@+%1UD=I?R53-5/
MW<ORJ<,O:G.B]?,1S3RRT%KU8W66U'3]7HZPUU V#?2X5,D2,;)$J?!=C*<,
M<,\<J=!%7:7NNU2>_4<>H;!:::U.?^WEBF:KFMPO,B2+TXZ%+1+<*8A7C.0
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MU/.JIA">,<U[&O8J.:Y,HJ<RH<-5-5/&&D3$\'Z "J0
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M*3HYJJ9IG$KQ.0 %4@
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M$/7Z,NUW=-37<G,[_P!0 93.,\3%W@
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M5N@-*5C52?3UL7/\M,QOL0ZIU-NK?50SV)CA*AK)V1UX960)>;912TF\B2K
MCFO1O2J9<J9.EK97TUSMU-74<K9*:HC;+&]%YVJF4.?]M6Q:-E%!<M#6UW*1
M=Y/10\5>G0]J=:=*%11Z1U]3QI'%9M111LX(QD<J(GD1"9M6KT;5$X(JFG=+
MN<'"[K7KZ-JN=2ZF:UO3B;@>:SZZHL3NEU+$C5^$Y\^"O8_^R>L\'=@.%H]5
M:YIW;R7._-5>'?/E_,]F:^UW!E$O-X;G^9S_ ,QV*KO1UL.XP</)M.US'WJW
MZXHO4Y5S]YD1[9-;QL:SW<>N[PRYC57S\!V*OOA,7(=L@XR9MSUNU4_ZS@7'
M7 WB9#=O>N$7/;E$OB6E:5[%<\#K(=B@Y!@[('6C%59'VZ5%Z'4^,>A3*B[(
MG5K<[]+:G^6)R?\ $.QW$]9#K0'*<?9':G:W#K7:7+U[LB?\1[1]DEJ%'-Y2
MRVIS<]]A9$54]8CL=PZR'4P(_H'4]/K#2M#>J5G)I.U4?%G/)O1<.;GRH2 Y
MIB8G$K\0 $                                 <Y;9;1I&@U9/5W2_Z
MBFNU0JRMH;<]CEA1>A,_!1>HZ-*'H=06O9[M0U9)K."6)]UG;/15_)+(U8N/
M><.*8RGH\A'XD_AEKMC=KTK<]44]1;=0ZD9<Z/\ :^Y]R>UJO3&.9.=.)T24
M54:CM6O]J.FGZ,IY9);;(^:LN')+&WDMW&[E>*Y_/REZE^-,*\Y"CM+1LO'9
M*:HEN+$F6WTB,IFR)E(_@)E$Z.=?64O$J#6>E]1Z?VB/UMHRDAN#JF!(*VA>
M_=<Y,)Q;E4_E;YT\96)Q5$SXIF,TS$>'ZM9M+B9:=O&AJ^@:D4]6BPS(Q,;[
M<JWCU\'?<A>7.A3>FM-:FU;M#H=7ZSHH;936V-64="UZ.<KN/?.QGI55]!/[
M'>+U6:HNU!7V5:2V4W_9JWE$7E^/5T$Q&*8IY[Y)G-4S[&EVR:K31VDUEHH&
M272MD2EI&(U,[[D7OL=./;@W.SO2\6E--042.Y6LD7EJN=>+IIG?"<JKQ7J\
MB$#VJ:<O>HMIVD5@H9);+02,GEF16[K7;^5SQSS-0N(BG[LSWS\(*N..[]PU
MVI/!ZZ?59?PJ;$UVI/!ZZ?59?PJ!JMFO@3:_HU]JDF(SLU\";7]&OM4DP
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MG*1IA45>;*&-6FJC?&]Z%CIFQ<F*:LQ*P@ <[UP
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MYZ.DLDI?0.GJJ^:OANNK-9VZ_5]M170T%#(CF0/7AO+C'LYRZ"W*,\5><X
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MW1%7> 9&2%P#(R  R,@ ,C( #(R  R
M :W45I@O=FJJ"H3O96*B.QQ:[H5/.;($3&8Q*M5,5TS35PES/4Z>U#9:Z5K*
M.OCDC56\M UV')XG)T"/4.I*!=U:^Y,7GQ(]Z^TZ85$7G1%/-\$3TP^)CD\;
M44YNS8^[+P/06Q/^5=F/KVPYZH]HNI*65KG5O+-1>+)6(J+^9?UHK$N-KI*Q
MJ(U)XFR81>;*9P4MMMM\5'J&DF@C;&V>#BC4PF6KC\T/33FU"6SV2DM[K<DZ
MT[-SE%EQO)E<<,%;=SJZIIKEAH];.AOW+&JN3,1PF<S\UX J'WXW_([?MO\
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M;(!X=N4WQB'UT/MM1"Y,MEC5.M'(3E.8>@/CEHOZQGK(?37M<F6N14\2A+]
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MHV8:EA15;34\WT<S?SP137=HC$TY4L:KI#2VXMU6IJQY_NOR*KIY?Z*HB?\
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MSW.D<BO:CN=K%7O4]!Y71MRJBNK3SOB.;Z'IRS;NVZ-;3NFK&Z?8E  /8?-
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MW)?UIF[9M='.O/)"QZ^=$4\?HW[-V[3/?\WTG3D[=BQ<CA,?M#* ![#YL
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M[<.NW=IN1]F7L #%H
M  !5>T]JIJ&-5YE@;CTJ6H5MM5BQ<*&7H6)6^A<_F=&FG_,>5TS3G2SX3"8:
M,5%TO;L?U2)]ZFY(UL[FY73,*+_W;G-^\DIE<C%<NW1U;5BB?"/T  4=
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MAJ(IXLXWHW9PI6JW73]Z,+153/"62 "BP
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M3SN5L,\4CDXX8]%4M%43PEG-%4<8>P +*@
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M_P"NK2/;#=47O[?2.3Q*Y#W9MDK43OK33JO6DKD_(GCMG.E5_P#\2Q/)(_\
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M^731M3+I&(GC<@3A]@\VSQ/<C6RQN<O0CD4] C&
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M"H&JV:^!-K^C7VJ28C.S7P)M?T:^U23
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M%38FNU)X/73ZK+^%0-5LU\";7]&OM4DQ&=FO@3:_HU]JDF
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MX>E]'.FU$SRJWP  [GE
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M9KX$VOZ-?:I)B,[-? FU_1K[5),
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MZJ-T>Q-@ =;S@
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MU6S7P)M?T:^U23$9V:^!-K^C7VJ28
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MR)A>;CUEIE.T%MVC:CU=9*G4M-06NV6V59W=K2Y=(N,8PBKG_P"2XBW)7F
MA(     &NU)X/73ZK+^%38FNU)X/73ZK+^%0-5LU\";7]&OM4DQ&=FO@3:_H
MU]JDF
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MX'IZ:_%^W%<1AXFMTLZ2]-J9SCF  W<@
M           "&[4$G=:*-E)J:+3LKJIJ)42JB))P7O.*IS\_F(Q>]':QO%UJ
M:ZR:\=3V^9R.BBC9O-:F.A4<3[5]GL5ZM2P:GAII:%CD?FH?N-:[BB+G*87B
MI0&JJ;0^F9'OTKKNZ6ZJ;O(E/;Y5J&[W5SHGWE8G'%;CP63I;1.MK;?J2KNN
MMI:^BB=F2F6)421,<WPBT3G;8]KG:!==1TE'74]7<;&]RM?65%)R:L:B+QWD
MX9SCG53HDTF-T*1Q  52     !KM2>#UT^JR_A4V)KM2>#UT^JR_A4#5;-?
MFU_1K[5),1G9KX$VOZ-?:I)@
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MIE%1<HJ'71<IKWTSEYURS<M3BY3,>U^@ NS
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MC.S7P)M?T:^U23
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MR^DZ7H[7I(N6ZXF*=\^/R]BW0 ?0OC
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MO@3:_HU]JDF
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M2>#UT^JR_A4#5;-? FU_1K[5),1G9KX$VOZ-?:I)@
M
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M"IL37:D\'KI]5E_"H&JV:^!-K^C7VJ28C.S7P)M?T:^U23
M
M                                             *B+SH !^;K>I#]1
M$1,(F$     43J:Q[0+?M&N-[T=::&F@F=NR/29,5C>A9&N=A%\:84O8H^KM
MUUVIZUU)05-\J;;8;+.E(VEIN]?*[CESO%PX9(W[6Y/*<M[I6Z;4)[]1LO\
M9[7#:W._;R1/17-3"\W?+TX+3*3MULNFR_6E@H8+Y4W*P7>1U-VI4KO.A>B9
M1S?/U%V%MTQF%>>\ !"0     -=J3P>NGU67\*FQ-=J3P>NGU67\*@:K9KX$
MVOZ-?:I)B,[-? FU_1K[5),
M
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MX/73ZK+^%38FNU)X/73ZK+^%2!JMFO@3:_HU]JDF(SLU\";7]&OM4DP
M
M
M *+VF5NAZ75531QZ+=J/44G[2I2!J]XJ\V^Y,\?,7H4:Z]S;*]>:GJ[[:JJH
ML][J$JH;A3LWU9C.6.\29YOU(Y[TQPG#$T+#L]U%>_<2Z:$2R7A6+(R&J:N[
M(B<Z-=PX]/,75IZP6O3M M%9***CI5>LBQQIP5RXROW(5'!?9]J&N].U5BM-
M53V:T2NJ9+C.S<W\IC<;U^DN\OR[E>84?I%R6OLEM505KN3?74B/IU=P1_\
M1KA.O@B^A2\"(Z]V>V/6S(%NT<T=3!_1U5,_<E:G5G"Y3Q*5C=5M>WXIXQ,3
M]85[M.<VY[=]"T%$Y)*BE19IMWCN-RKN/5P:OI0O#.$RO,A#-!;-[#HJ2:>V
M,J*BMF3=?55;TDEW>I%PB(GD0]:+0=OI+YJ"Z,K+BZ:]1.BGC?*BLC1>EB8X
M+Y54<*=F/&?><9S/@T6K]H<\];/I_0-(Z[7[X+YFHG:]+G^)S^95\7_P9^R/
M02Z(M%4E94I67>OEY:KG3F5>AJ>),KQZ<D6A['G3$.]R-VU!'O<^Y4QIG_TR
M:;/MGUNT.M:MMKKE5=M;N_VY,C]W=SC&&ICG)IQ&43O3$UVI/!ZZ?59?PJ;$
MUVI/!ZZ?59?PJ0EJMFO@3:_HU]JDF(SLU\";7]&OM4DP
M
M                                                  .?KWM,[C]I
ME[I;@^Y7JTS/W74TD?"C<G']GG@YJY\7ZV=M;UB_1.D);C30I/6R2-@IXW)E
M%>[/%?$B(I6]KUYM TS?[(W:#24K[5>)6PQNA:Q'0N<J8SN^5,HHIWU;O8F=
MU.]*=)[9-/7V]T=HM]MN4$M2[<8KX&M8G!5XX7Q%I#"=0)0  @      UVI/
M!ZZ?59?PJ;$UVI/!ZZ?59?PJ!JMFO@3:_HU]JDF(SLU\";7]&OM4DP
M
M                                                           !
M4O9(TM94:3M;K?1SUDL-QCE6.%BN7"-=U%<[1];7G5T%C9'HV[4WN=6,JERQ
MSM]&]'P>!U J(O.F3\W&_P J>@1F///Z?),SGRQ^OS57I7:K<KW?Z.W3Z.N=
M%'4/W5J)=[=9P5<KWOB+5/Q&M3F1/0?I/)  "      #7:D\'KI]5E_"IL37
M:D\'KI]5E_"H&JV:^!-K^C7VJ28C.S7P)M?T:^U23
M
M
M -=J3P>NGU67\*FQ-=J3P>NGU67\*@:K9KX$VOZ-?:I)B,[-? FU_1K[5),
M
M
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M&JV:^!-K^C7VJ28C.S7P)M?T:^U23
M
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M)M?T:^U23
M
M                             -=J3P>NGU67\*FQ-=J3P>NGU67\*@:K
M9KX$VOZ-?:I)B,[-? FU_1K[5),
M
M                                               UVI/!ZZ?59?PJ
M;$UVI/!ZZ?59?PJ!JMFO@3:_HU]JDF(SLU\";7]&OM4DP
M
M
M/*LJ(Z2DGJ)EW8H6.D<O4B)E?8)G&\XO4%#6%VM=JKJZ^6S4TVG+-',Z*B@A
M9O+)N\ZN5%3AZ>G@2[8KK.Y:AI[M:-2;BWRT3\C,]J8Y5O%$=CH7*+]Q,1GV
M\2=WZ++-=J3P>NGU67\*FQ-=J3P>NGU67\*D#5;-? FU_1K[5),1G9KX$VOZ
M-?:I)@
M
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M=[-(FIK6^W72FD6&7AB.94_CCXKWJDQ!*4  @
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MIY6QS1TK-U\.>A%W6\?2G O&AJHZVC@JH%58IF)(Q5ZE3*$XW91G?A[  A(
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M9HZS-MUHC5&JN_+*]<OF?TN<O2IIG.9[_P!>]3&-WUAOP 52
M            %5;6]+U%9J&RWW3=VI*'5%,JLIX*F1&MJ6\55J(O.O''D7H+
M5(QK[15NUI;HJ>X.E@J*=_*T]5 N[+"[K1?1Z")Y2F.<2H7;%2:TNEGMO=I-
M;Z>LEJVP4%LH./*.7X4CE55YN")QZ?3TS;HG0V^FB>N7LB:U5\:)@K[2.RBE
MM%[AO%\O5QU#<J?*4\E<]7-B\:(JKQY^DLDMPIQXJ\9R  A(
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M(C6-<Y$1.I$Y0MRW4[J2@IZ>29\[XHVL663X3U1,97QJ3&(C$(WS.99  (2
M
M         !Y551#20/FJI8X86<7/D<C6IY54#U!\4\T51"R:GD9+$],M>Q<H
MY.M%/&>OI(*F*FGJH8ZB7^CC>]$<_P B=(&2      ^)Y8X(7RSR-CB8F\Y[
MEPB)UJI]1O;(QKXW(YCDRCD7**G6!^@
M
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MKTD8B*II]J<_9S[%Q@ JD
M
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M+7&Z.V4-+1QN7*MIX6QHJ^1$0RP
M
M
M
M               *J(BJJHB)TJ#$N\#ZFU5D$2(LDD+V-15QE51400'NE0_'
M:;[5OZCW2H?CM-]JW]3CYVPO7JN5?<B#_&1?\Q^>\7KWY(@_QD7_ #'9V:WZ
M\,]N>YV%[I4/QVF^U;^H]TJ'X[3?:M_4X]]XO7OR1!_C(O\ F'O%Z]^2(/\
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M3\_\V=W/3C)U3LYN]5?M$6>Y7!CF5D\"+,CF;B[Z*J*N.C*IDG9W>Q7.](P
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MVG;;<)HW125-.R5S'-5JM54RJ87F-F)C$X1$YC,  (2
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MDG,S..'#A\(MNSV^&TVNEH*99'0TT:1,61RN<J(G.JKSJ98)RK@ !"0
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M3*=.5\Y<0)SF<G+#SI8&4U-%!%GDXVHQN5RN$\9Z $'
M                                 541%55PB$<77.ETN?N<M_MW;N=W
MDN7;G/4/ \4C      >?;$/;'(<JSEMW>Y/>3>QUXZC"2^6QU\=9DKH%NK8^
M56EWOVB,_FQU ;$   #7WF]VVR112W:M@HXY7I$QTKMU'.7F1/&!L $5%1%1
M<HO$                  :RXW^U6VXT=!7W"GIZVL7%/#(_#I5SC@G29-TN
M-':J"6NN53'34D2;TDLBX:U/&HY9/!E Q[;74MRH8*VWSQU%+.U'QRQKEKV]
M:*9 X #755\ME)=Z6U5-=!%<:I%=!3N=A\B)G*HGF7T&Q       !KJV^6RB
MN=+;JNN@AKJK/(0/=ATF.I -B :Z@OELK[E66^BKH)ZZCPE1"QV719YMY.@#
M8@&#>KO;[)0.K;O5PT=(U4:LLKMUJ*O,F0,X'Q#*R:%DL3D?&]J.:Y.947F4
M^P
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ML
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M?H ^58U7(Y6M5R<RXXGZYK7)AS4<G4J9/T $X<P
8                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g12080g03r70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r70.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1;P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %M,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*1D?+3 M*# E*"DH_\  "P@!\ <0 0$1 /_$ !T  0 " @,! 0
M   '" $& @4)! /_Q !9$  ! P,"! (%!0D*"P@" @,  0(#! 41!@<($B$Q
M$T$B46%Q@10RD:&Q%1<V-T)S=,'1%A@C,U)48F.2LB0E)B<U4U9RDZ+A-$-$
M562"PO X@T7QA)3#_]H " $!   _ +4@          !5P8YD]OT&0
M   %5$\PBY[    !5^D(H  1>X
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M&J=$0[':W<:@W!ML]7;H)84A=RN;(O4WE%R
M                       %7'J.#Y&L^<J)[U,M>U[<L5%]RG)/J 5<'YK/
M&BXYV?VD'CQ_RV?VD,ME8[L]JKZD5#DCD7L91<@  *N#\GU,3'HQTC4<O7&4
MR?HU45.AD*N#@^1K$R]R-;ZU7!ADS)/XMS7IZVN14.:+GMCX&1DXN>C455Z(
MG=5Z'&.9DG\6]CD]CLG/FZXZ9]X:N<],&0
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M\&+E^<3["Q*+CIC*JOZSES9[=3"N[]/J,\W;M@(JKG*8P9
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M37LIQ 5%56TUEU9RJU_HLG1O55\LEIHG->U',5%143"^M#D
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M6<(J^OZBRMNKZ>X4<551RLFIY6HK7L7**?4F>N4P
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MA5R^2KU0LPSMU7*]C(
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M]!YU:^O4FK]:5E=$CE2>56Q)C*X\D+[;06E;+MY9*.1G),VG:Z1,8ZJ;B
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M[,1G1:PW/U1JJT/MUT<LE.[KCD\S8.%VIJ*+<FF9X;T;,WD7IV3)>EJ8RAD
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M^;$--'U1F?=\"S_#!MC-I6U27N[,1MQK8T1K'-ZL;GOU)Y1,
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M)T1$5$1$]7<Y-W6T@W*I=8<?[R9^TV^S76DO%"RKH)4E@?\ -<B]S[@
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M?9W*W<3&VVIM8Z@I:O3]"E3 R-K7+SHBY^)"J;";B-^;9U3_ /<AC[PNXO\
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M7K*1\6=+43;E.=%3S/;X2>DUBJA/7"M')'M=3I+&^-WBN7#VX7N3#A<=^IE
M   #")CL9 "H85,]S*)@
M      &')E.^#"MSGKU4RB85>O<SCVJ,>U3&%]8:U43&3./:IA6Y7NHY>O<R
MB8R   J&.5/_ *IE$P##DRBH85B+\[KT\_,-8C4PQ&M]R')$P8<W/FJ>X8]I
MG'M48]JC!AJ*F<KDR                                         #K
MJZQVRX2^)74%-4/_ )4D:*OTGUT=)3T4*0TD,<,2=F,;A$/V
M
M
M
M
M
M
M
M
M
M
M
M
M                               'GV,*[IV^L-7F3/D9
M
M                                     !A5QWP81V4S@ZF]ZEM%C8YU
MUKX:9$3*\ZD/ZQXC]-VMDK+2U]=,G1KFIAI!VL^(/55\18::2.CI_P"@W#OI
M+"\,NLY]3Z,='<)%DK*9?2<OFBYQ]A,B
M                                                           &
M%7!\ERNE':Z22JN-3%3T[.JR2.PF"(M3\16DK-5.AIE=<$1<*^%W3[#I*7BD
MTY++R26NKBZ]W/3]A*&C-S-,ZL:QMLN4"U3DSX#GX>;HBYSCR
M       ,*J(85V$RJ>1U=VU%:;1&K[G7T].B=5YWIDB;6/$5IFSMECMN;A,W
MHBQNZ?809K'B)U->VNAM[F4,"]/05>;'O(MJKE?M1U3W2SUM;*]?FY5QN.D=
MD]6ZB\-4H):6%Z_/E;@G'1W#+;J5S);]7/J)$PJQQHF/CDG/2>D[5I:B6FL]
M*R!B]%5$ZK[SOT3N
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M&RPQ4L+EZ.5OI$D\+6X==JB"XT-XJ$EJXE1[57S0L&Q$3.#(
M            !A5Q\3JM2WZBT[9JFYW.5(J:!JJY5\_8A4/<7B)OMYK)Z33:
M,IJ!7*UB\G\([XFFLGW-KF_*(ONPYN<Y:JX4^NT[I:^T57,2LDGY\]8ZIN<H
M6AV7W@MVO:;Y--BGN\;4YXL81WM:2PB]P         "/M^;Q+8]M+I64[^25
M42-'>\JGPSZ:AU%N)%55K5?'2O\ %5/)>^"]3&HB<K>C6].QR1J)GVD7\1.F
MJ:^[<W!\L?-44K%EB=YHN4R5QX4+J^W;B/I.=494M\-S?7U+O,[N]1D
M          &'+C_H5.WRWSO=NU%76"P>%#! ]8WR<GI*J+ZR KOJ2_ZDJW?*
MZRHJ9'+\S*K@[_26TFK-2/9\EMSV,>O\9(O*GUDWZ-X8(8WLEU+6N54PKF0O
MS])-FE=L]+Z=A1M#;8G/3'\)(G,Y<&Y,B8QJ-8UK6IT1$3L<N5 B8SUSDR
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M$3YMH+@V/JJ31JONRI#W!A+"R^7>*1$65\:<GK3&2WK>O7/1>QDU+=>ICI-
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M.U]34HOC\CD56(B]E-?X/-(3I/6ZCJF?P#F>'"J]U7/7J6L;YF0
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MW3!5/C,NV)[;;$=GT$D5N?>=7P;6KQ]05UQY57P$Y.;'K12X#?/)D
M      P[IYE4.-6L<ROL-)E4:Z%7+A?Z2F^<)%L;3;>_*T:W-2Y,KCKT)S:F
M.P5.J%?>,&WLJ='T=4N/$@<['KZX-?X+:U\E/>*5<\D;$5,^\M$WL9
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MIK[<5G1BHKH8TZ.3U*I833MAMVG[<R@L])%2TT:81K&XR=JF>N5R
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M[>6_[K:VMU+CFYY\_6>DEOC2&B@C1,(R-K<>Y#]P
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M>K)23BJTG3:>ULROM\:1LK465Z-Z(C\]RQ/#5>I;OMG0MGD5[Z;,65]6250
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M$^M2XM1UIY/]U?L4\TM9MQJVY?GW?WCT&VF7FV\L2_\ I6?8;:
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MD<<'[L:YJ4_E,1"Z4W\4]/8OZSS9W#3EUM=$_KE_O%\MDG<VVUF]D+?L0WD
M     #S[!%RG;       ,+G*87!43C.3_'=J7'_=H0KMMJVLT5JFENE'(YJ,
M=RR(G96KW/0W2-^H]1V"CNEOD:Z"H8CN_5J^:*=OG/P4HAQ.(B;IU?1%^:G8
MMKL;^+*RIZH4-\                     !T&NJ&NN6E[A26J7PJN:)6,=G
MUE -<Z*U'I*[SK=J>9CT?E)VHJHOGG)M6VF^&H=)R,@JYWU= BX6-ZHOT9+7
M[=;L:>UE!&VFJ6P5;D1%AD5$Z^PD-KT<F4[>LY(  !YG'S\PBIE>W?'3UD1;
MS;P)MW74],ZW.JO%;S\W-C!N>WNK*36^F(;G!'RM>B<\2KGE7U*=A=],V6[0
MOBK[;32HY.O\&A7+B(V8L5ETS+?M/1?(W1/:DD7-E'9R?CP8WF=L]UM;W/6%
MZH]J*N4;A"U:RL8O\(]C5=V1784YHOL,I[0  8553RS[C7=8:PL^E:!U5=ZI
ML:(BHC$5%<J^XJENGQ"W.]^-1:<YZ.B5,*],<RD0V.QWO65U2*ECFJIY7X5[
MLJB>W)9?;CALH(J))]72>/.]N5A8Y4Y/B:SN?PXU=O\ %K=*N2>E:F4@7YR$
M$1RWO25SRQU11542^U"?=L>(^>E\&BU<Q9V(B-2=$3)9S36IK7J*A;4VFKBG
M8[R1R<R? [I%SY*9  5<&%5>G0Z'5>K+1IBB?47>KCA:B*J-YDYEQ["J>ZG$
M17WA):'3/-24CNBR?E.(9M-GO>L+MRTS)JNIE<F7JBKW]I9S:GATIZ+P:[5G
M+/(B(J0(O1/>2SJC:W2VH+6M%-;(H41N&21MY5;\2KVYW#_>=.K-66=4KJ%O
MI89GF:GN(PL&I+]H^Y>)05,])+&[JU>F?8J*67VOXCJ2L6&AU4QT-0J\ORAJ
M)A?>A8>U76CNM*VIM]1'/"Y,HK'(I]R+E,A5P<4>BJJ(J9]YR1<@PJX,->CD
MRBHIE%\L=3I]2:CMFGK?)5W2J9#&Q/-R97W(5>W2XBZFJ?-0:21]/'U:L_3+
MD(&IH+UJ^ZHQJ3UM5(O5>JY+&[4\.*)X5PU<K7>DCDITS]:EE++9+?9J)E);
M*:.G@:F$1B8R:WKO;;3VL::1ESHH_'5.DS$PJ%5-S=@KWIM9ZJT*E;0-]+#$
M7+4]J$:Z=U-?='7'GM]344LC%ZL7IGX*69VNXCJ*O\*BU2U8*A>GCHB87WH6
M%M=SI+I2LJ:"=D\+TRCF.13[47*   &%7'D?C4545-&Z2HD9$QJ95SW83'Q.
MLLFIK5?99HK75QSNA7T^547'4JCQF_AA0_HS?M)BX5TSMRF?*1/L-EWGT#3Z
MYTG-2*QORR%%D@=Y\R-7IDI3H;4-RVVUXR=WB124[UCG9Y.;V4^G>&\TVH==
M?=2A<BP5#D>GK3*EW=G_ ,6]A_1T-Q        5/I/RGIHJB/DGCCE;ZGL1R
M?0:S=MOM-7659*NUP*Y>_(U&GU671EBLV5H+=3QNQCF5B*IWKT1C>GDGU%'N
M(76EZGW"G;!)+30TBHR'ERF43S-EVOXC*VA?#1:I:E13)Z/C-;Z2)\"T6DM3
MVO55L;66>H2:'"(O3JGO(JXO7SQ;8,\'YBU;$>OLPIHO!M566".ZLJGQ,NJR
MHL*O[\F%SA2U$:HJ9:J.:OFBD,<26VE3K.QP5-DIFRW6!Z)AN&J]JF.&;2&H
M=(62XT>HZ9:;GEYHVJY%Z8Z_J)K3KVZ*J(<D3'GD    !5]AP?(V-JN>J-:B
M9RJB.1LC4<Q4<U?-%Z'-%R     8=V^)73C(3_)BWN]3U^TBWA'>V+7DBO<C
M6\B*JJN$+<T^L;#6W2>V4]R@?6L:N6<W3S\SS_W,;RZZNB?UR_WB\VQ3N;;>
MT_FF_8;^      JX."R(C>951J>M5(PW(WHTWHYZ4[YTJ:W./#8F43WJ=IM[
MNEIS6=.W[GU;&5:IET+TY53]IOJ.SC"91?,RF?,     &%[_  *B<9W^FK7^
M:(T^]U+7[8KJBVM<_P "3DF;GZS>.%S<M;#=UT]=9%2@JW(V)7=48[LB%RVJ
MCD1R+E%PJ+ZRB?$]^-.K][2VNQWXL[+^90WL                     &%3
M*8\CK;Y8[?>J)]+<Z>.>%R87F3JA7#<[AO:_Q:[23E1W?P'*GU*5ON=IO>D;
MHC:J*>CJ&/Z*G3M[28-L.(>Z61L-'J)&U=&B<O.J>DB9+4:,UU8]6T:36>L9
M(['6->BI\#:.;"]>GO.29\P#"KA43UGQW*Y4EMI7U5?,V"!B95SUPA77=?B,
MIJ)LU!I-&S3Y5JSO;T1/8=;PV[LW.ZZDJ+7?ZATZ5.7QNQ\U<F[\46@ZC4^E
M_NC;F*^KH_25J>;"!-EMWJO;N2:W5\"RV^1Z<[7-ZQJG3*%@HN(W1+J17R5,
M[9E3/AI&N<D(;W[V/UQ0+9;32K%0\Z/5R)Z3L$H\).C*RQV.MO%S@='\KY5A
MYN_*B=5(RXAMQ[P_7TD%NGEIJ6B?RLPF,K_]0V;;+B1?#X5%J]C7L1>7QT;U
M1"R^F]1VK4%(E1::R.HC=A4PO5/@=QE>O3H9 5<'R7&X4]OI75-;,R"%B95S
MUPA7K=7B*H[<L]!I54J*C"M696]$]Q6"^7Z^:PNROK)I:JI>_+6(O1,^PE[:
MOA[N-[\*LU)FCHUZ\O-Z3BUVD-&V72M&RGL](R)$:F7KU<OQ-A5,+W7L81R/
MZ-5')YJ:9KW;>PZRI)&7*D:V=6JC9HT1JH51W.V"OFFWRU5H8M;0(N4Y53*)
M[4(XTWJ>^:/N:/M]1+3R1NZQN7O\"S>UW$;17%8Z/52-IJC*-\9C>B^\L':;
ME272E954$[)X9$RCFKGH?:BY /FK:Z"BIG5%5*R&)J95TBXP5^W4XB*"U-GH
MM+XJJOJSQG-Z-7V%7=0ZCO>LKLZ6NFEJ9I'91C>R>Q$)6VLX?;M?G05FH46B
MHOG<JN])R>XMAHO15FTG0-I[32M8N$S(O55^)LBM^DSR]54PYB.14=A6JF,*
MG0C+<C9O3VL(WRNA2EK555\6/HBJ5.W&V9U'HZ5\JP/J:'FZ3,7/0Z70VXNH
M-%5S'T%2[PVN]*&3JGT%JML=_P"R:BC937IZ45=A,JJ>BJDA[D722DV_NUPM
MLS?$C@YXWMZIU7N4EL^\&K+?>H*J6Y/ECCDYGQN3*.3/5"\>@-54FKM,4=VH
MWM5)6)XC?Y+_ #0V1,^9%/$??+C8="/JK3.L,RNQS)ZB,>%?6E]OVH;A#>:Y
M9X(Z=7X=Y=3:MU]_K9IU9:&Q<M7<&]W*WHQ2J6K=87[6=S=)<JB29[W^C$WL
MF?+"$A;6[#7K4[XZJ[,=16]>N7+U<GL0MKH3;VQ:.HV16NE1)4;A97=7*;<C
M<)T7Z4.2)UR%[=%.+V(]JM?AS53"HJ=%(NW)V8T]K"*25(?DM>N7)(SHBK[2
MJ&XFSNI-&RND=3.GH4^;,SK@ZC0>Y&H=%5C'454[PFN3FA?U3Z"UFV._MBU)
M%'37>1M%7JB)U3T7*31#.R>-)(7->Q>J.1>F#]47("F,^Q3Y;E<J2VT[YZZ>
M.")J95SUP0GN'Q$6&R>+!8_\/JFICFPJ-12M.M]VM3:OE>VIJUCIES_!1].A
MOO"NFHJ/5ZS04TKK;.S$CW]N_?[3Z.,WKK&A3S^3-^U28^%7\7*=OXQ/L)E4
MJSQ5[8\S/W56>'TVJC*EB=E3KZ15JF5?E$2*O9Z815]IZ-;/_BXL2?\ IFFX
M@    *N#1*W=33%%J=]CJZ^..K:O*JJ[IGU&ZTU3#4Q-DIY&2QKU1S'90_5%
MSGH9   5$7N:AK;;ZP:NI'QW2AA6547$S6(CD^)5K</AUO%IK$DL&:ZD>Y$3
ME;U:65V4T:FC=%TM)(J_*9&MDE1?)WJ.[W TK1ZQTW4VFO3T9$RQV/F.PN%^
MLI3JO:#6FCKC+)0TE5+31+EM53YPJ?2<;1NYK_3KFP/JZM8F+A8YFJO;VJ2?
MHWB>E;)'3ZAMC5;V=.U^%3UED]*ZBMNI[3%<;/4LJ*:1.KD7JB^I3N4SUR9
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M4(IW)V0T]JV.6:G@91W!R*OB,3#57VH5/W"VDU#HRH5TU.Z:DRO+-$U<'S:
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MV*3T_P"ZFTPJLK78JFIYICHXJG$Y5D:CE5<+V/1#8[\6=E]?@H;X
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MJJCE5%:OY3?V%E-[-3TFK]DH+K12,7GPLC4_)?A,H:/P9?A;</T=?M+AM\P
M   !CJBG%&X3OCW&O:PTC9]3V^6GN])'+EJX>B8<GQ//C<.R,T[K"Y6V+F2*
M*96MROY.2V'#9H/3BZ-I+S\D;/7.<[+Y$RB? G:.)L;$;&B-:GDB80YM3&>I
MD   PJ95.JI@X31-EBDBD:CF/145%3HJ%2.(O9IUODFO^G8G.I%PLL:.^;Z^
MA%6TNX=?H._QRPO5:-[T;-&[JF"^.B]46_5-E@N-MF:]DC$5S4[M7U8._1>_
ML    5.J+E>AQY?;A?8=%JG2=FU+2N@O%%%,CNG-RIS)[E*P;G\.570>-6Z5
M>ZJARYW@<J<S4[D%(^^:2N:\ORF@J(W=NK2?=K^(^>F6.AU9&Z:/M\HYNJ)[
M2S6F=46C4=''46>MAJ&N1%5K7IEN?8=WGU=?B85^/4OQ-'W!W-T]HVC>^NK(
M9*E$7E@8]%<JE2MT-\+YJV:6"A>^BMRNPUD;NJI[5-/T5H'4.M*]D=!1SO:[
MYTSFKA/;E2V.U&P]HTND-=<W)5W%O*],HF&.)K6-JM5JHBM7HJ8Z8]1%VNMC
MM*ZKJ5JGT_R.I5,*Z!$:B_ CQ_"W;UJ55MU=X2K\WEZX-TTAP^Z3L4[*B>-]
M;.S_ %J>C]!+M-2Q4L3(J:-D43$PUC&X1$]QJ>O=O+%K*E<RZ4K/'Y5Y9FM3
MF1?>52W.V O.G?&JK*CZ^A[XC;U;[T(QL6H;]I"Y<]%/44LS'=8W*J9^!9C:
M[B.I:Y8J+53$@FZ-\=%Z*OM0L-:+M0W:E;4VZJBJ(GIE%8[)]O-WZ>633-?;
MCV'1M'))<*N):AJ92!'IS*5*W0WUO>JI)*6VO=0V]7=$C<N7>]4-&T?H?4&L
M[@UMOI:B7F7#IGMRB?$M?M7L!9]-MBJ[WR5U<B([D<U.5BDWP4\=/"V*G8V.
M-O1&M3"'ZHF.WT'4ZKO$5AT_77&=51D$3G]/6B%+:'?O4MNU94UZ3/GH9'JB
M0/7HB9+);;[TZ=U=#'')-'1UZICPI']U)18Z.:->56R1N]RH1QN-L_IW6,$C
MY*=E)6.7/BQM1/I*G[C;*ZATA-)+%!+64*+TFC;GX]#7=%[@:AT77-?0U4S6
ML<G-"]RX7X%J=KN(&RZ@;%27M6T-:J85[G>BY2;J6JAJX$FI98Y8W)E'-=E%
M-5UWN'8-'44LMSK8?':U>6!'9<Y?5@J7NCOQ>M3S2TUI<ZAH,X3D=A7>]2/M
M(Z,O^LKDR.W4M1,KU]*5Z*J)\5+6[5</MIT^R*LU!RUM=T=X:HBM:I.=-30T
MT+8J:-D4;>C6L;A$^!^R)CSR  J9\\'YRP1S1JR9K9&+W:Y,HI#>YFPUAU-'
M)46MC;?7+U3PVHC7*5<U-M)JC3U^BHG4<[VODY631MRG?OE"VEOL$^F]D*F@
MJY9)9VT;G/5_DJHO0HBVDJ*JLG;2QOD>W*X:F5)>X;]QI='ZG2VW&1WW-K7I
M&]KUZ1N[(OUEXZ>1DT22Q.1T;TYFJBY14(HXG_Q75O\ OM()X/L)KNI1,HGA
MJGVG>\0>T%VN&LDN5@AEJ8ZQR<Z-3/(XVK:GAXH+2V"NU*Y*JI^=X.$Y6^\L
M#0T-/0T[8*.%D$+4PC8T1$/H1,=URID #!^4U/%-&K)V-D8O14<F45"&-S=@
M[%J6-]1:FMH*Y>W(U$:Y2JFNMM=1Z,K'I64DRQ,7I.Q.BX\\H=GMUO#J/1LS
M6-GDJ*1.BPRN5<(6PVXWJT[J^)D;YXZ.N5.L4C^Z^\E&.5LC>:-R.;W147**
M?A75]-00OFK)HX(FIE72.1$(;W"X@M/:?26&TJVXU34PG(_T44K3KS>/4^K9
M9&.JY*:F=E$BB<J=%-?TOHC46K:IK:"AJ9N?KXCFJJ?2I8G;WAIIJ;P:K4]3
MXLB+S+"U$Q\2P&G],6C3U(D-JH(8&M3NUB97XD8;Z[/UNX]=25%%<8:7P&\J
MI(Q5S]!M.S&@Y] Z;=;:JL952*_GYF-5$0D!J*GGT/GN-'!7T4U+5L22&5JL
M<U4ST4JU?^%RKGO53-;+S30T;W\\;'L7F:GJ+":,MD>B]%TE#7UC'MHX?3E5
M<)T&E=>V+4]544UIK(Y9H>[>;N;4BYS@               *N/+)CFQW0R
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M,UC?GM3S*LV_5-=1Z?J[(YSG44KE=X:JOHN)LX,?PLK_ -'7[2X;?,
MP[_H4'XG*%:/=FYHQ,,D5KT^*%B^$:N^5;7^$JY=%4O1>OET)N     5#\:F
MFBJ:=\-1&R2-Z8<U4Z*4WXB-FY=/U4M]T_ ^2W2*KY(VM_BUS]G4TS9;<VMT
M->HV2R/=;Y%1CXW+T3KW^TO9IR^45^M45?;9F312)GT79PIVB+E5Z*F#(
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MJ5UHHY4=0T3E;Z*]'+ZS9.$O0"U=>[4MPC18855(D>WHJ^LMPSS]2=$.0
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MN7"'**1LK$<U45%3.44YXZY/.W?1N-S[W[9WK]9;_AH=S;3VGV(OVJ2F
M "".+W\ H/SV2JVW.@+OKRMGI[+R*^%O,[G=RI@WQ.'#6RHF&TZ__M"\.&MD
M1<MI_P#BF@;B:"NVA:^*EO*-261O,WE=S)@MCPBX^]Y-^>_:3D      #3-X
MJ7Y9MU>H$3*N@=T^!0;0U1]SM;6^95QX4Z*>D5LF^44%/+G*/C:N?>A]0
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M[WKO'_98_P#C(=)K':'56E+*ZXWB!K*1%1%5'HY<FY\'OX?3?FE+K)Y@
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MSMU[]S(                        /RJ?XE_\ NK]AY[T/7>W'7_2N>_\
M6'H7'\U#*]RFW&.G^6E"JJJKX+1N#TX9M.]5S\K3KGWD-:"U+5Z3U-276CD>
MQ8I$5^/-OFAZ):*U'2ZHT[176B>U8ZB-'<N>K5]2GZZJ5'Z<N7?'@/Z%(]B.
MN]E+E5PE0[S]Y,'%9J?5%B^306R9U/:IFJBR,[JOO*T:7TI?-97)(Z""6:21
MW61^<)\2U>UG#S;;'X=9J5&5E6BHY(N[4)YHZ2"CIF4]+$V*!B8:QB81#]T3
M "ID^*Z6NCNE,ZGN%/'40N3"LD;DKWN=PXT5Q;)6:55M/.F7+ Y<-7W*5DU#
MIF^:.N;HZ^":GEC=TD8BX^"DE;:;_7O33XZ6\O=7T*=%1<*J)[%+6Z$W'L&L
M*5C[;5-;,K4S%(Y$<B^[)N:X<F.BF$147/*N?@:SK76]ETA;Y*B[53&JU%Y8
MFJBN7X%4-TM_[M?GS4>GW/H:+*MYF]%<GM4BK3>FKYK&YMCH89JB9Z]9'(JI
M]):?:KAWMUH;%7:GY:JK14>D*=6I[R?:&AIZ&G;!2Q,AA:F$:Q,)@^E$QW4!
M4,*F>^#IM2:9M6HJ)::\4D=3&K>5%<G5/<I6C<_AOFB=)6Z2>CXU7/@.7"HG
ML)1X==NUT5IR2:XQM;<ZA^7KGLGJ(9XJMPZBYW[]S=MG>VDI_0G:Q>DC\_\
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M]7424\3W([GC1%5%3WFE[5[(V[;^^/N=+<JFKE<WE1LC41$^@EYJ8_89
M  ,.SY%(^+VD9#N2Z9F,R0,S]!L7#+NK8=(Z>J[5?9I(7RU'BL<C<HB8+&V;
M<72]W8GR2\4O.N/1>_E7ZS9:6OI:M,TT\4O^X[)^_,N,X^DSGOT4RBY]?T
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M*Q4RY#7-BM%2:RUK31.C1]+ ]))G+ZLGH!;J2*AHHJ6F8C(8F\C43RP?2
M                      #\ZC^*=[E^P\]:#*;X-5%ZI=?_ /H>AC.K<Y[F
M53/12FW&3^&%$F?^X3 W#_\ QFT]^F(2'P7I_D5><?SMOV*2WN3H^DUGI:IM
M59&QSG-5T3EZ<K\+CJ4<T]>;KM=JZOI)N9N&O@E8B='(OF=QL%.RHWEHIHL\
MLDRNZ^W)?9O_ $,@    >9Q=&CDP[JWU*AQCA8QN&M:U%[\J8.:(OFN3(
M /SGC;+&YCDRCTY53V%"]]]*U6B-QGUD#>6FFE\>!S??DL[LCNO:M7:?I:6J
MJ6PW:")&RME<C>;'3**2I\LI_#\3QHN3&<\Z8(<X@-U[=IG3M3;;=5-ENM5&
MK&>$Y'(Q%[Y('X9-&RZIUTMUJFHM+1.29ZN3H]RKVS\"\$:(U.5,(B)T1#D
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MAN":MA]LV: L,B5*HZXU.%E5%RC<>2$HHW"JOK,@
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M41OTEM]KMA+)I=D55=4;75Z)E4>Q.5JDSPP1P1-CA8R-C>B(UN$0_1$ZJN0
M   I0_B>I74^[U;*_/+(V-R*7#VJKHZ[0%DE@Y5:E,QJX7/5$0VWS,.5$3K@
MIUQBW&.?55#0M<BNACZIGJF2;>&*@6AVOHN9,+*Y9/I)9
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MF>^MJ48S*?-9GIGX%]]'V:+3^G:&V0(B-IXFL7'FJ=SN0
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MZCM4"NKX%1)V,3Y[?7]1 FPE'41[I697P3-1KU155BICH>@K.WP.0
M    "IUSYG77ZTT=ZMM107*+Q:69N'M7S0J9N=PZW:@N2U>B6/K*>1RJD7.B
M.C-)2AW.TVB4WAU\.$Y>7*N.-%MQN)K*J:ZHHZF1BN3FDE?A&_26?V4V<H=!
M0+5U3OE-VE:B.>J)AGK1"743N
M            8=V4\\M_TQNA>D_KU+:\,2YVNH_8]WVDL@             _
M"O\ ^Q5"?U;OL4\U]<)RZSKT]4R_:7\V>7FV^M/YIOV(;F
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MS1SI_5N^Q3S:W 3EUO<4_KE^TOGLL[FVZM/YI/L0W@
M          '4ZGL%!J6U26ZZQK)2R?.:CL9(W_>Z[>YS]S:C_P#V%,)PZ[>^
M=NJ5_P#\A22M,6"@TS9J>U6B)8J*!,1L5RJJ?$[4               XRIEB
MGGOQ!*YFZ5X1'.3+T\^W0MAPON5VUE+S*JXE=^HEH
M                          !<^2'27?5-GM%2D%QK8H)53*-<Y$/ILU[M
M]YB62VU,<[&]U:[.#LDZH8<N.ZI@T>^5>B&W*5+JVVNJT7T_$1%<BFRZ>FML
MMO8MG\%:7LGA(B-.T             !^56F:69/Z"_8>;NY*<NO+DG]=^LO5
ML:O-MM:5_JT3ZD-]
M  ,+V5/8>?7$8G)NM>$5/RD^PM/PKNYMJZ?V3O\ U$O@
M                             PY,IU*0\6LLD>YRHV1Z-6!O1%]JGV\)
M&J%M^M)[;6SN;3U,2HU'+^7GI]I=%BY1?9T.KU3<FVC3]PN#U:B4T#Y<K[$/
M-_5M[GOFI+C<72R9J9G2?.]:^1<OA2<Y^W67O<]?&7JJY)I5<>[UA%SV,([O
MA,^XRBY,@           _.IRL$B)_)7[#SCW0A>FO[FOAO\ XW^27>V%55VS
MM2*BHY&=45/8A(0
M!AQY_P#$NW&[=X][?L+/<*"\VU,*_P#J'I]A,8
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MDE=W>^%%53M:.EAHX$AIHV11-^:QC<(A^P
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MAROFI?X-7*O=/(EU%[^P
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MJ'4_R%K_ )G,N<DW[':;LM@TLK=/7#[H4<RHJ3)V4DA$[^T
M                                              !4-?NNC-/7:N=6
M7*T4=54N1$626)'*N/:=G:+50V>D2EM=+#2TZ+S>'$WE3/FN#[0
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M8
M                                                PYN?8OK.GNFE
M[+=:E*BY6REJ9T3"/DC15Q[U.TIZ>.GB;% QL<3$1K6-3"(AUEVTS9KO.V:Z
M6RDJY6IRHZ6-'*B>H^Z@M]+;Z9M/0P,@A:F&L8F$0^>[V*V7AJ-NE#!5-;U:
MDS.9$4_:VVRCME/X%OIHJ>'OR1MPWZ!<K927*E=35]/'/3NZ.CD3**:+6;,:
M+JJM9W6F-B_R6=$-LT]I:SZ>C1EGH(*7IA5C;A5^)W+4QDR
4                       #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g12080g03r72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r72.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1;J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %LT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-'*!LA4C-5*AP20S0A8E)F)CX2=%5(/P.&22*$."PO'_Q  ; 0$  P$! 0$
M             0(#! 4&!__$ "\1 0$  @(" @$"!00# 0$!   ! A$#$@0Q
M!2$308$B,C1QL08S46$4(R050J'_V@ , P$  A$#$0 _ /5(
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M1YQ3XHO-.4)).S:M?L.FM%[/]2Y9M'Q>;8_-*T\O=64U"4KJ:;X+F!W,
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MR1Y6Z6"_\;Y=ZJ)Z$V4JVA\N_A ^M
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MLQS&E4K9GBJU"_V9N<G"7^IWSL0VC5-=9-5>/ITZ6/H2W9*'*2[0.S
M                         ^/VI:UHZ'TS5S*I356JVH4X-\Y,#[ 'GK"9
MYM0S+3TM3X25*.&E%UH8:W#<7'E<^MV*;4:VM7B,!FV'IX?,\,KRW7;>X]@'
M; #:2NW9'4E'5^:ZEVJSR7)JJIY3E_&O5AQWG?B!VV   .D-LVT_/-):FP.
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MWC6M=]UP^4+N+=XN--M-?H?2Z(Z0SQ./CA-4X)8;>EN]TAPL_.G8[[P.5X+
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M8>;;J86T&WU__E@.U@
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MI14(^A&<T,BS?!YYEM''9=5C5H55=-/EZ3?
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M'S6-)THUKVB^P#Z
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MSV/:8U1BWB\3AYT<2U;>I2W4_P"1ET?LBTOI?%T\7@\+.IBH+A.K/>7Z'80
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M5R+#Y;@8K=IQ2E.UG-]K.<"0
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MD;(
M^$U=LITMJO,'C<WPM:6(?.5.INW.$6P+0RE=8/%>_P#_ &.U@!UCEFP[1>6X
M^CC,-A,3W:C)2CO5KJZ_D=A9CEN&S#+:F Q4'+#5(;DHWZC< '5#V Z&;=\)
MB^+O_P __P!C)3V#:&IM..!Q#MVUK_[':8 X/36E,GTW0[EE&#A1CV\W^IS@
M '7.?[&='Y[FM;,,PPF(>(K/>DX5FE?T6./6P/0RY8/%>_\ _8[6 '5,=@6A
MHR36#Q5UQ_Y__L=D9+E>%R;+:.!P$'##TH[L4W=F\ *5Z-.O1G2K04Z<U:47
MR:.K\^V&:1S7$U,0L/6H59\]R?V?T.TP!UMI;8SI/3V*IXNAA*E;$P=U*K.Z
M3]!V1"$8048)1BN21( ^:UMHC)=9X2GA\\H5*D(.\73GNL^.6P+0R?[GBO?_
M /L=K #JE; M"\?^#Q7'_P!?_P!CD].;'=(Z>S*GC\NPE>.(IN\7.K=+_0[#
M !<%8                               '7>W&6=5-(RP6GZ4ZE;%MTZF
MZN43'L+T0M(:3I/%4G#,\3>5=M^?@CL@ 14A&I"4)J\9*S7:CSMK/16JM%ZL
MQ&=:!<>XXUO?IVWK.]^1Z* 'FW1VS'4VJM3TL_UU7C*,);SI/A=^@]'T:4*-
M*-.E%1A%6274BX Z:VM;*,QUCJ3"9E@\91I0HRBW&?F?H.WL%1>'P5&BY7E3
M@H77F1G 'F/4O1\SS,]08_'T<RPT85JKG"[=[/\ D:/@ZZF=KYQA_P#^3^AZ
MJ 'EW =&_-I8A/,<UHRI]=I-_P"QW+L]V79#HRU;!T74QK7&K.5_T/O0!Q^H
M*%?$Y'CJ&#ENXBI1E&F^QVX'6^PK0V9:5_MC%YRXO$XVI=-.[W;G;  '!ZGE
MD>,PT\JSRM0W,3%Q[G4E9N_8<X=#=)72.9XVCA\\R55ISPZ?=8TW]U+K X?4
M71WJ3QT\1I;,84,-4=XQG/DO38O1V)X+36G\;FNHL5^U8RE%[C4OLK_0X_9S
MMY>49/0RS/\ "2<L/'=563E=\>LXK:?MBQNM<%+(<CP&[AZ[2E..\Y/B!?HJ
M44]?9O4A_P N--I?_P CU@=0='O0%?2N2RQN:4^YX_$Q7V?_ "\^)V^
M
M  %=R%V]V-WUV+
M                                  B,5'[J2]!(
M
M
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MY6K_ "]CO>OZCOE:O\O8[WK^I\@!I.WUZVEZO\O8[WK^H[Y6K_+^.]Z_J?(
MCJ;?8=\O5_E['>]?U([Y6K_+^.]Z_J?( KU-OK^^5J_R_CO>OZCOE:O\OX[W
MK^I\@!U'V'?*U?Y?QWO7]2'M+U>O_GV.][+ZGR YHC*)E?6]\W5Z_P#GV-][
M+ZD=\[6'E[&>]E]3X^43&8U+[3OG:P\O8SWLOJ.^=K#R]C/>R^I\6"!]IWSM
M8>7L9[V7U'?.UAY>QGO9?4^+ 'VG?.UAY>QGO9?4=\[6'E[&>]E]3XL ?:=\
M[6'E[&>]E]25M.UAY>QGO9?4^*)7,#[7OFZP\O8WWLOJ2MI>KWQ_M_'</_5E
M]3XILR0Y%\?:'K+HN:CS?/\ !YT\XQU;%]RG#<=2;E:]^T[U/.G0]_<=0^LI
M_)GHLK?9  $)      \T=)G5^?9!JG T,IS.OA:,J+DXTY./$]+GDGI<>..7
M>SOYH#KSOG:P\O8SWLOJ.^=K#R]C/>R^I\6 /M.^=K#R]C/>R^H[YVL/+V,]
M[+ZGQ8 ^T[YVL/+V,][+ZCOG:P\O8SWLOJ?%@#[3OG:P\O8SWLOJ.^=K#R]C
M/>R^I\6 /M.^=K#R]C/>R^H[YVL/+V,][+ZGQ8 ^T[YVL/+V,][+ZCOG:P\O
M8SWLOJ?%@#[3OG:P\O8SWLOJ.^=K#R]C/>R^I\6 /M.^=K#R]C/>R^H[YVL/
M+V,][+ZGQ8 ^T[YVL/+V,][+ZCOG:P\O8SWLOJ?%@#[3OG:P\O8SWLOJ.^=K
M#R]C/>R^I\8E<LHDC['OG:P\O8SWLOJ.^=K#R]C/>R^I\AN><*!.JA]?WSM8
M>7L9[V7U)[YVL/+V,][+ZGQ^Z0T1I+['OG:P\O8SWLOJ1WSM8>7L9[V7U/C6
MK%2!]IWSM8>7L9[V7U'?.UAY>QGO9?4^+ 'VG?.UAY>QGO9?4=\[6'E[&>]E
M]3XL ?:=\[6'E[&>]E]1WSM8>7L9[V7U/BP!]IWSM8>7L9[V7U'?.UAY>QGO
M9?4^+ 'VG?.UAY>QGO9?4=\[6'E[&>]E]3XL ?:=\[6'E[&>]E]1WSM8>7L9
M[V7U/BP!]IWSM8>7L9[V7U'?.UAY>QGO9?4^+ 'VG?.UAY>QGO9?4=\[6'E[
M&>]E]3XL ?:=\[6'E[&>]E]1WSM8>7L9[V7U/BP!]IWSM8>7L9[V7U'?.UAY
M>QGO9?4^+ 'VG?.UAY>QGO9?4=\[6'E[&>]E]3XL ?:=\[6'E[&>]E]1WSM8
M>7L9[V7U/BP!]IWSM8>7L9[V7U'?.UAY>QGO9?4^+ 'VG?.UAY>QGO9?4=\[
M6'E[&>]E]3XL ?:=\[6'E[&>]E]1WSM8>7L9[V7U/BP!]IWSM8>7L9[V7U'?
M.UAY>QGO9?4^+ 'VG?.UAY>QGO9?4=\[6'E[&>]E]3XL ?:=\[6'E[&>]E]1
MWSM8>7L9[V7U/BP!W7L7U[J7-=HN4X3,,XQ=?#U:JA.$JC::/81X6V _BEDG
MKXGND         1+A%^@DB?W)>@#Q'K+:'JO"ZLS:CA\[QE*C#$2C&$:KLDG
MZ3AN^5J_R_CO>OZG':\\<\Z]JG\S@3HQQ5KZ_OE:N\O8[WK^H[Y6KE_\^QWO
M7]3X\(O,3;Z_OEZO\O8[WK^H[Y>K_+V.]Z_J?(6%B=1#Z_OEZO\ +V.]Z_J.
M^7J_R]CO>OZGR%A8:@^O[Y>K_+V.]Z_J.^7J_P O8[WK^I\A86&H/K^^7J_R
M]CO>OZCOEZO\O8[WK^I\A86&H/L.^7J_R]CO>OZCOEZN\O8[WK^I\>".J7V'
M?+U=Y>QWO7]1WR]7>7L=[U_4^/ Z_P#8^P[Y>KO+V.]Z_J.^7J[R]CO>OZGQ
MX'7_ +'U_?+U?Y>QWO7]1WR]7^7L=[U_4^0L+$ZB'U_?+U?Y>QWO7]2>^7J[
MR]CO>OZGQ]@)(/K^^7J[R]CO>OZCOEZN\O8[WK^I\@+%Y(/K^^7J[R]CO>OZ
MD]\O5WE['>]?U/CP1UAM]AWR]7>7L=[U_4=\O5_E['>]9\>1Q'24V^Q[Y>K_
M "]CO>L=\O5_E['>]9\=Q _'#;['OEZN\O8[WK^H[Y>KO+V.]Z_J?'@=8/L.
M^7J[R]CO>OZD=\O5WE['>]?U/D .L'U_?+U=Y>QWO7]2>^7J[R]CO>OZGQX'
M6&WV'?+U=Y>QWO7]2.^7J[R]CO>OZGR!!,QAM]AWR]7>7L=[UCOEZN\O8[WK
M^I\?8%ND1M]AWR]7>7L=[U_4=\O5WE['>]9\>$1TAM]AWR]7>7L=[U_4GOEZ
MO\O8[WK^I\>"MQB7V'?+U?Y>QWO7]1WRM7^7L=[U_4^/)*ZB7U_?*U?Y>QWO
M7]1WR]7^7L=[U_4^0!$D'UW?+U?Y>QWO7]2>^5J_R]CO>L^/L+#4-OL.^5J_
MR]CO>L=\K5Z_^?8[WK^I\?86&H;?7]\O5_E['>]?U'?+U?Y>QWO7]3Y"PL3J
M(?7]\O5_E['>]?U'?+U?Y>QWO7]3Y"PL-0?7]\O5_E['>]?U'?+U?Y>QWO7]
M3Y"PL-0?7]\O5_E['>]?U'?+U?Y>QWO7]3Y"PL-0?7]\O5_E['>]?U'?+U?Y
M>QWO7]3Y"Q-AJ)?7]\K5_E['>]?U"VE:O\OX[WK^I\@05'V/?+U?Y?QWO7]2
M.^5J_P OX[WK^I\@"NMCZ_OE:O\ +^.]Z_J.^5J_R_CO>OZGR '4>S>C=G>9
M9YHFKB<WQ=7%5E6W8SJ2;:7I.V#I?HI_A_6]H9W08Y>U@ /D5 %;F/%8JCA,
M/4KXFI&E1@KRG)V2*S.4TS ZGS_;IIG+,7+#82-?,*J;3=!)JYQV&Z0>0NJH
M8S+L=ADW;>FE9#L.Z0<-IO4V5:DP:Q.48NG7AUI/BO2CF+CM!(.J<_VY:<R7
M.\7EE>EB:E;#3<)N%K71Q_A"Z9M^ZXWG;DB>T-.Y@=49#MRT]G.;X7+\/AL9
M"KB)J$7)*RN=K7([0TD%;\2PF4H  L   'YXZS\:\X]KJ_U,_0X_/'67C9G'
MM=7^IF_![17#H (VL_54!((V     :  $  1<G0D@7 @ "Q9( "9$! N1<O(
M@9 !I(@(N+D%\<0 1-C28B 6L+$]32O$<2UA8=!7^8_F6L+#H*W8N38BQ7J)
MN2G8J"MP%[A,HF2F4Z:-LB(9"8O<RZI2202BM@$D K<4I!!)30$$D%=)"4+$
M("3%*/%F4AHSRQ3&&PL7E$H9V)0 " "  FPLNT@ 2N1EAR9C7(R4^3+8^T/3
M?0]_<=0>LI_)GHP\Y]#W]QU!ZRG\F>C!E[3  %0     #R3TN/'++O9W\T>M
MCR3TN/'++O9W\T!T0                  )MP%B  )1!D428$"X2L2:X8[]
MHVBY) -NL0DAK@3<%,L25B:*6,[784<>9A8EC !5(
M                          [$V ?BEDGKXGND\+; /Q2R3U\3W2
M   (G]R7H)(G]R7H _/G7GCGG7M4_F<"<]KSQRSKVJ?S9P)UR*@ )0@$@;$
MD$B"0"$@ (VA  *I   1)"))@$$@N(%B2   +1  "0  L  $:  %MH  -@ 0
M^0@7*@%Y$ !!>02""4-"4R4RH12P7!")1G4@0"*5*0 1L""0-B 2 (!()2@$
M@C:$ D 02 2D !5!U$$]1!5(  /7W13_  _K^T,[H.E^BG^']?VAG=!AG[6@
M5F[(L8JSL8<V77"U.,W4)G1W2?SK'4LAI93@85-VNXSG*'F;X'=JD:>8Y=@\
MPBEC</3K;O+?BG8X)Y&OMIU=.]'30&7X73=/.\PPRJXW$<HU%=1L=BZUT1D^
MILEKX2K@J,*C3<)PCNM,^CPE*CA</&AAX*G3AP48JR1\YM&U7A=):<Q.,Q%6
M,:[BU2BWQ;+X^1EGE_"CKJ?;S7L0S#$:9VJ?V8JLOV;NDZ4H=3X,]<9AC8X3
M+<1BI+[%.FY_Z'D[8'E>*U%M)EG4Z3>&A.52<FN%['I#:=C(X+0.=5%))_L\
ME'TV-<\M9ZVK'1VQ?3^ U;M!U/C\UPZK4=Z4H)]K9W7WM]+^38</.>8-FNTC
M,M,Y;7PN2Y>L3C<4Y;T]UMJ[\QS$MJFNLIJPK9AAYJBG>THRLR^6Y]2CT=E^
MA-/8#&4\5A\OC&M3=XROR9]4Y<#JK95M<P&LO^$Q<887,59*-^$V=H;QS9<M
MPNLEI-LJD98\4:JEQ-BF[HV\;D[72,II8 '8H   ?GCK+QLSCVNK_4S]#C\\
MM9^-F<>UU?ZF;\'M%<,$$2C>J@ *@      BY(T('  O(' $7(N6F-1M8%;B
MXZBQ%Q<J6D BXN#61"&P"4C28B+$I%DBT8FDQ%8HNHEX05S+&!I,1@4"R@;,
M::+*DBTP&KW/S#<-Q4D3W%%OQFVEN$=S-YT58HZ0_&;:3@0X&XZ2\Y7N2*]!
MI;I%C;E21C=-%+@-=HBQFE KNE+B,:)N6W2+%+QA<*1%B"EXQ>XN4N+E+QFV
M1,DHF3<SRP3*L253),[@E((N2C.P1R")!721\BCB6)*7%.V/=&Z7!7H;4W2-
MTR$CH,#5B%S,THE5'B4TE%N)>/(FR!?'%#TUT/?W'4'K*?R9Z,/.?0^_<M0^
MLI_)GHPKE[3  %0     #R3TN/'++O9W\T>MCR3TN/'++O9W\T!T0
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M]&&&7M,  52     !Y)Z7'CEEWL[^:/6QY)Z7'CEEWL[^: Z(
M     1-A$R)$R!%<"R5@EP)-,<=HV$$D'1A]*JL@ED'1BJ BY);0E,L4)N9V
M)61)6+)1CG@F4LA9 &?XT[+(60 _&;+#^0N1<M.$VD%=X;Q;\".RUD+(A,7\
MY6\*=ILA9"Y%R/PTVFR%B+C>)G#3LFPLBN\-XG\%1V6LNP617>)3N/P'8W2C
M5C(@U<PSPTM*PL@M-694R2                  #L7H_P#XHY)ZY'N@\+;
M/Q2R3U\3W2         (G]R7H)(G]R7H _/G7OCGG7M4_F< <_KWQSSKVJ?S
M.!L=<JJ 386)VA )L+#8($ K:E)#    @+$A<@3(  +:0$ $R "+D7-)BC:;
MD7((N:3%&TW!6X+S 3<BXL2D:3 0+%K$[I;H*6!?=&Z3T% 6W2=TCH* OND;
MHZ"H+;HW2>HK8FQ9(G=)F(HD+%["Q.A0AE[$-$6"J)3(L#.XBP*@IT%[DIE+
MDKB4N!M<%%P+)F=Q3M(N$.!GI)<DC@"+!((N+D:H7%P.!.@N20!H2"$2$@
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MHPPR]K0 !4      \D]+CQRR[V=_-'K8\D]+CQRR[V=_- =$
M$ )MP%C)&/ F04BN)E(2)+XXH2.HA$FN,T@( -L4*L@LRIMBJ@7(!K,=H3<7
M(L+$_C2LF2F4X@K>/8O<7* K^,VO<.10$SC-IWA<BQ-B\XX(NQ=DV%BW2"+]
MH)2)W1^,1<7+*).Z^PG\8I=CB742R@^PF<9IBL18SJF' G\:=,!*=B[B5:*7
M!"8R+(QK@6BSEY.*)E3*.\8W&QE0:NCBSX]+RL*1#+25BIBD
M   !V)L _%+)/7Q/=)X6V ?BEDGKXGND         1/[DO021/[DO0!^?.O?
M'/.O:I_,X Y_7OCEG7M4_F< =,5      !"P "Q($6%B06D0 $$R  "W4 0V
M5N:8XHV$-BY!MCBA-R 2D:3$B$KDV+QB7C!FDQ%%$O&G<RQI^8SPI^8UF UE
M1\Y94C<C3X%E2-)QHVTE1)[B;JI$]S+?B-M#N1#IF_W,JZ9%XC;0<.H=S-UT
MO,1W/S%?QIVTNYCN1N=S'<_21^,VTU2L3W,V]P=S'0VU-PJX&XZ95TQT-M-Q
M*N)MNF1W,KU&IND;AM]S'<RO0:F[8BQMRILQN!%P&O8F]C(XV*-%+@(N25L#
M*X"Z=A<I<E,I>,VO<DQW)3*7!.UP53)3*]3:0@$5J06!)2B.0#"ZQ!(()0 (
M B  !I+U[T5/P_K^T,[H.E^BI^']?VAG=!S9_P R8'&YM]^F<D<;FWWZ9XWS
M=UX>7[?Y;</\[1[2%R%^9"^Z? ]OU=RUR". X#O3242W<KP' =AD4[0W=U>D
MQP6ZWUW' <"<N2Y:W^AI=RX<BB5GS' <"+GO[-)G+[+X'+9:[T?Y(X>7W6<Q
MEO\ R5Z$>Y\!E;Y7[,>>?PML 'W#B   /SQUEXV9Q[75_J9^AQ^>6L_&S./:
MZO\ 4S?@]HKA@ =$5  2 " @@ADD%XA5E2SY$&V*$$H6)2-H!*1*B7C&Y:0(
M1N98TRU*FGVFU"DC7'"TVPQI&:-,RQ@C-"E<Z,>)7;#&GYC+&F;$*+X&W##+
MKN:R2+3"UHTZ-S:I8>_4;E+#17:;,**MUD7)>8-.G0789X4DNHV522+*!2Y+
MS&M?<X#<-G<NAW-$=C374?,64>!FW"-T;-,:B2HE]UD[HV:4<>!1HRV*20B&
M)HI*)E9%BT0UY0[#'*F;311I$RHTTITS%*!O3B8901:4TTW'S%=VYMNFBKII
M%MJZ:K@4<#;[F0Z:\XVCHU-PJXFVZ=C%*(U*K<;&M*)AE'BS:DK&&2YF66)*
MU)Q,$HFW-<&8)HYLHM&HUQ94RRCQ9C:,+!!9/@5)7(PR@NB2L2QSY1,2"$2C
M*Q(02+%=)0$ B!*([241VB>QZ:Z'W[EJ#UE/Y,]&'G/H??N6H/64_DST889>
MUH  J      >2>EQXY9=[._FCUL>2>EQXY9=[._F@.B         "; 03'F+
M$P1(NE<LN""7 DTQQ1L (N;3%5(ZB+BY:8T"MR;F,WPQ14MD7!91N=&."%5Q
M+)$QB984T:XXITHHD[AL0I(OW)><TF TW$KNFZZ2*NFO.1T0T]T6,[II=I5P
M*]1BL+%]VP9&A2P1:P0TE%A8L$3H1%%DB5$LHDR(1%%K%HQ+1A<M(E11+11D
M4$74$6F*&/=*R1GW44E%$]1KM&*2XFS**,,U9LSL2P,)EFBMC'/%"T661CBR
M\>1R<F"922N8I*S,Y5P3XG#GAI>5A!:2L18R2@            !V)L _%+)/
M7Q/=)X7V ?BCDGKD>Z         !$_N2]!)$_N2] 'Y\Z]\<LZ]JG\S@#GM>
M^.6=>U3^9P)TQ6@   (FP$(D MI ""4- 0 6D  JV:8XH3<K<BY%S68(2V0.
M9*1KC@(L2D642R@:S$42,L(71*@981X%YB*P@9H0+P@C+&"-L<#:(4S-&!,(
MFQ"".C##2OMCC3,BHFQ3IJQD4'?D7]+S%JJB3W'@;RID]SX,=D]8XYT?,4=,
MY&5-6,,H<1*CK&BZ=D5W#<E#@5[F3J(Z-3<&X;?<T0Z:(ZQ'6M7=&X;.XB.Y
MCK$=:UG KN&VZ97N1%PAJM7N9'<S9[F%3*_C/MK=R'<C;5)><CN:\X_&G[:C
MIF*=/GP-]PX&&4%Q*Y<:-N/E Q.)OSI+SF"=-+E<Y\L-+1IN)6QL2B8W$SL&
M*Q%C)ND-%.HH$R;"Q6X@F611%D8931%P0F28581(0,Q#"ZR03! Y ,M2) 7(
M%  !*7KWHJ?A_7]H9W0=+]%/\/Z_M#.Z#ES_ )DP.,S?_F4SDSBLX=JE,\+Y
M^Z\'/]O\M^#^>-!L1? A.]PN' _/._T]#2P*W%R.R%@5N+CL+ K<7'86!6XN
M.PLW]EG,9;_R5Z$<*WP9S&5.]!/S'T/^G+OROV8>1_*W0 ?>N$   _/+6?C9
MG'M=7^IGZ&GYY:S\;,X]KJ_U,VX?:*X9 ('5%0  $ @ *]1+(ZB\0J^1")?(
MA&^"J2T451EIHVQ3%HPN9Z=/S$0CP-JG#@C?#'9M-&FC9A2NA1A=F]1I<#KQ
MQF,1)MBI8>[Y&[0PRZT9:5)(VZ<!<FN./_#'##1[#-&@NPS0CP+)F-R=&'#;
MZ8U12ZC)&EP)WD5=5),SN;OX?!RS_1.X@H&/NOF_U"J^;_4CNZ?_ ,W/_AFW
M.!&Z45;S#NB__&3,F67Q^<_1;<&X%-,G>3)[.?+Q,HC=*M&2W K8F9.;+AL8
M[%)(S6,<T7E8W'3"UP*HR-%+<2RE5L5<3(0!BDC&X7,[042=H:_<PZ?F-E0)
MW!LTU>Y^8ATO,;FX0Z8[)TT94?,8*E+F<FX&&=/@RTR5TXF=.W48)1XLY*K3
M-6<.++^U,L=>FC.%S!*!O2B89Q,,\%97'SAQ9AE&QO3CQ9@G$Y\L5FHT09I1
M,4D898@F63*$HPRP(R!$1).?*+1("!D'40B>HA%4I1':2B.T3V/370^_<M0>
MLI_)GHP\Y]#[]RU!ZRG\F>C##+VM  %0     #R3TN/'++O9W\T>MCR3TN/'
M++O9W\T!T0        2B"4(A>*NBZ21%/[I)KACLVD$ WQQ_14!!%S68HVFY
M5L7*FV&"-G$E(F*,L('1C@*1A<S0I7+TZ=S9ITS?' 8H4%V&:%!=AM0I^8V*
M=&_4=./%)[)N^FI"BNPOW#S')4\/YC+^SK_\1?6,6F'_ "X=T%V%'178<S+#
M_P#Y8Q2P_F&L:CHX>5!=AAE1[$<M4HVZC6G3YE;Q3]%?N.-E3Y\"C@;\X<&8
M)PX&&6&DRM-Q(2[3/*/,QV,M"MD$BU@-!$NC&W8*02S(LGV&&,B\66E&5,LF
M8TRURTJ%[E9,B_ JV3:*R,,^;,K9BGUF=2Q,JRS*LRR01+QY%(EX\CEY"+(/
MDR$'R9Q9^EXQS*EIE3GJR  0           [%V ?BCDGKD>Z#PML _%+)/7Q
M/=(         B?W)>@DB?W)>@#\^->^.6=>U3^9P)SVO?'+.O:I_,X$Z(K0
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M>6L_&O./:ZO]3-^#VBN& %C?:H!R!,H  F""I8I<TQBHR$ C?&(61FI(Q17
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MOW+4'K*?R9Z,,,O:T  5      /)/2X\<LN]G?S1ZV/)/2X\<LN]G?S0'1
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MS[S./JKF:<DW''?JM*:-:2-RHC7FCCRB8UV0BSZRIAE!9%DRBY$HYLH1<DA
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M!A<4I*R1;J(9EG$Q@ !@L  #L78!^*.2>N1[H/"VP#\4LD]?$]T@
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MV/)/2X\<<N]G?S Z(+P*$Q=B8,R!$'<L=''DK6-E2\D5L=^&4TH@7%@:3)
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M] 'Y\Z]\<LZ]JG\S@#G]>^.6=>U3^9P!TQ6@0" D@D@OC$#*LEE;F^&**JV
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MU.!BE4YF'?7:4<^#(D3[14G<UYOBR[9BFS2*VL4NLPR,LNLQRY$9>F3%8FW
M$]1CH1%&W0CQ->"-V@N)IA-1;&;KD\(K'(4T:.$X/^1O0Y&>3IX_;(^1KM6;
M-A&*JN)RYS?T^F^/SU)%8F2$C$2F>-Y7BW*OH.//Z9E.Q$IF%L)G)AX5:7/Z
M6E(H$K\C)&%D>SXWC3CGVX/(\F80I1X\49+V(;LC!4G:_$]#'%\SYGDW.J8J
MIN]9P^+K7OQ-C'5NJYPU>?/B=$_AFWC<F>_IAQ-7GQ./JSNWQ,E>7%\35EUG
M'R9[93Z"5R(B2<666Z!*(19&=J4D=9(*; E$(DRSNEH&*IR+W*2Y'-E=ITJE
MP( *)=B; /Q2R3UZ/=)X7Z/_ .*.2^N1[H         $3^Y+T$D3^Y+T ?GS
MKWQRSKVJ?S. .?UYXY9U[5/YG =9T16@01):(""2KY&N$$,H20=&$5HBT5P(
M1>')G3C!*1>/(J61>">H$$$@R5R((ZR!EB;%(P4S+ TQ&Y3?$Y'"3LUQ.,IL
MVZ$K,Z\/N(QNJY^A(W*;X'$X>HK<SD*<_LKB9Y8NKCSU6SSN4<+]0C/AS+J7
MG,;B]3@\JXQB=/S"-/S&5R(3*Z=O_G76A1X%H\"$R&RTQ<'-SW(GUF)]99LQ
MRES-)'G9Y;8Y]9KU3/-FM59I&-:M5<S!(SU&89<C2(8V5?(LRMRRJ8F6$C!<
MLI$$KD:4O.C<I2X<SB*,N9NTIJW,IE%XY.$B\>)J4YKM,\)\.9C8WPSL9K"Q
M3?\ .3OE.KHG/E(F7!<"KE:Y#GYS!4GP?$M,66?-:5IKCQ.-Q=5=I?%5.#XG
M&5IF^&.G)GDPUY\6:-65S)7ES-5OF8<F>ZSC'-\2BXLF?&1$>;,%F6!EB8H&
M6):(9(F6*X&)<S)$UQ0GF4:)+6X$^Q@DN9AER9LR1A9GE$M21CZS8J\C7?,Y
M\X+(NC&BZ.+DFDQ* 0.>K  *CU]T4_P_K^T,[H.E^BG^']?VAG=!AE[3 ZWV
ML.U?!>AG9!UKM;?_ !. ]#/*^6_I<OV_R]7X;^KQ_?\ P^#OP1;>,*?,1EP/
MCM?6WVO73-O><;WG,6\-Y$:3IE4O.3O>=&'>0WAHZLN]YQO><Q;PWAHZLN]Y
MQO><Q;PWD-&F24OL,[;V;.^G8?Q,Z>J-;C.WMF?BY3_B9[/PF/\ [KD\3YV:
M\>?W?6@ ^L?(   'YYZR\;,X]KJ_U,_0P_//67C9G'M=7^IFG'[17"E66(9W
M8J*,B)+(1TX5#)#K,U-F")EILZ,1M4V9Z;-6#-BFS?"E;$#-%F")E@SIPJC/
M%_9!6+X"_ NT0S&^LLRC#.J,JRS*LRJ8A(ND0BT43C$5E@N1N4^TU8(V:?(O
M6F#=HO@;=)FE2=D;=)F5:2MN#+KD8*;,R9E8Z./+56MPN5?'J+1XDV,['H\7
M/IA<?,-SAR,VZ3NE=.O'S--?N9*IF:PL-+?^=E6)4UV#<7894A8:5_\ -K#W
M-=A#AV(SV(W;C29YM:S@^HBS[#:W"%!=@TUQ\W362?80;;@BCIIE;C+[;X^=
M&L2KFQW-=A*@ER16<./_  G+Y'4^F"*DS+"*29-BLG9&N.$_1YOD?(Y932S:
ML89R5C'4J[KL:U2OS-L<'C\G/EDM7J63XG&5ZUY2+XFLV:,Y7;-\9IR99$IF
M)LFY5D6LE7S*M7+6%C-+'NLC<,HL1I+%N#<,EA8C0Q-&*:,\E:YAF4RB8P21
M@:-B1@ER,<DL;YDID/F$<^<0R+D2N9"Y$KF<=_59Z;Z'W[EJ'UE/Y,]%GG3H
M??N6H?64_DST6<67M:  *I      \D]+CQRR[V=_-'K8\D]+CQRR[V=_- =$
M   C+%F)%XDP9"2B99/@:XY*Z 21R-\:A5\RK1:7,JSIPJM0020;1"00218
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M^XZA]93^1Z+.#/VO  %$@     >2>EQXY9=[._FCUL>2>EQXY9=[._F@.B
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M11FBC60(HL$0^!9"&RN]8B3XLQ3E8K:E,Y&"3);*<S'+) N)>*$461Q\G(F
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M*+E8EK'+E4P0)!CM,>F>A[^Y:A]93^3/1AYTZ'W[EJ#UE/Y,]%G+E[7@ "H
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M*.3.IB>HA$]01E?2T>F>A]^Y:@]93^3/1AYSZ'W[EJ#UE/Y,]&'-E[6@ "H
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MI#%,R]1AF89K14$I7(,T@       .Q-@'XI9)Z^)[I/"VP#\4LD]?$]T@
M     ")_<EZ"2)_<EZ /SYUYXY9U[5/YG G/:\\<LZ]JG\S@3HUM""0!,4(
M!($H@("01<DM$(*LL0T:X70QOF$2T0=6%56B77(QIEU+@;XT6+(JN):*+!8J
M7(:)%;%9%[&.7-E:E4E<B+!%4)!%B1!*,BYF)&1%H,L"Z,<"Z+Q*Q9%471>(
M0$3NBU@*OF$2T00!1E[%6A15E63+@5*A<7!5D"R+)F-,LA!<@($BI,18E("M
MB&BS*D"I1F1JY5D44*OFRQ5\V9T0 38IM 2B+%D4M N52+(PRJT$2$#"U*
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MS&Y)289%F^)1F-NTD60 52        [$V ?BEDGKXGND\+; /Q2R3U\3W2
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M6,BB3NC1MB_D2E<R;I#5AH4W1NEB+D"KB5? LV4DR!5S\Q%R&5;*[%MXC?\
M,4N1<KL'+BR+@@S[";D7 L5[ +$I$E+D(L2D"R1G<@2) ,<JM!$A HD"ZR.L
M=I0>FNA]^Y:@_CI_)GHP\Y]#[]RU!ZRG\F>C#GR]K0 !      !Y)Z7'CEEW
ML[^:/6QY)Z7'CEEWL[^: Z(          !%X%"4[$P9@8U(G>+=D+BYCWAO$
M]Z,H(CR"-,;:A( +U$  0D  D @D@OC$(;*MDOF49TX8J@(!O()1-B%S)+"%
MS+)%5S+QYF&=T1*18A=9)R9W<6BL^$3%<RSY&)G)E[6B"2$6L1$HL+$V%AI
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M1<F8&T@ GT!%PW9,QN1EEDG2SE8;YC;(,]U++OD-W5S&3?A8;$ $IV($
M         .Q-@'XI9)Z^)[I/"VP#\4LD]?$]T@        ")_<EZ"2)_<EZ
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MUQ<K<7&C:UQ<K<7&C:6ST?L \2I>ND>;FSTAT?\ CHF7KY'!\C_L_N6[E=F
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M8$<201((XD@ADR38  OJ  $-"5R()(?(QSJ8I-F,M)$6,*L@$M6((
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M=7^IGZ&GYY:S\;,X]KJ_U,UXO:*X< &T5".H O("%@"0L $ )(9**T  0D
M0@BQ8@OC="A#1>Q#1OCFKI2[)N+$6-9F+Q;+19B7 LF:XY#-&;,D),UTS)"1
MI*-F,BZ9KQD64B\R&:Y%S'O$.7!D]C2[DRCDRCD5<BO87E+@8G)D.7 JV4M$
M[S(NRMR+E=BV\Q=E;D7(V+-D7(!&P!-B4C*YBJ19(E(L99<B=(2X$@&-R2(6
M)!38BQ(         $"Y( BY(   !(N0"Y A#TUT/E_P.H/64_DST6>=.A]^X
MZ@]93^3/19S9^UH  JD     #R3TN/'++O9W\T>MCR3TN/'++O9W\T!T0
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MF^!6Y%P5N0 (&?9""24B2MR2JB4B25R*W(0D67 D)&5R2!!$F>5B0$ SV)!
M(2D! D !U%H@(!*Y$R" 2"=&T  G4  (6 B2%S)*@N0"(ZR-#TWT/OW'4'K*
M?R9Z+/.G0]_<=0^LI_(]%G+G[6@ "J0     /)/2X\<LN]G?S1ZV/)/2X\<L
MN]G?S0'1               $!>!E,<#(:\:$,QLM+K*L]#CC-  .F" 2011<
MLN15%T<N=3#K) .>U( "$@ )E0@(D$[2  A 1>Q)AE?M,<LM+1DWAO&*[%WV
ME.QIEWAO&*[[1=]H[&F7>0WD8;L78[4TS;R#D8;L7'9*SXE6+L%0
M               !V)L _%+)/7Q/=)X6V ?BEDGKXGND         1/[DO02
M1/[DO0!^?.O/'/.O:I_,X$Y[7OCEG7M4_F< CJE5L2 "4  )   ""2&5  $)
M   )1!*)@  L@     0"03*(L0T6()F5@K8BQ<@UQY$:8P6:XD6X&V.: E%2
M5UFLNQ:/,NC&N9=&D&2)=&.++Q9>"R)3*BY.QD3%S$I<^(<AV%W(QRD4<O.4
MD_.5N029CO<ELA&.>0F*+)$P7,E')GG4R!*!!SVI20 52D$(,M$)(ZB40R0"
M 1I^@( =1%A$@ I"  )2$$@1"!8FP)V() *['KWHJ?A_7]H9W0=+]%3\/Z_M
M#.Z#FS_F6@>;NE,[9UE'JI?,](GFGI5.V>Y*NITI_,[/C?ZB%]5TG*?%$[_$
MUU*[E?J(4N/,^EW&?9L[[&^:N^[\RZE979,LIW9]\;[,$;R;6\D0TT_OD'=L
M;[&^S7WNUD*3763N'=L[[&^S6WWVC??:-P[MASYGJWHVN^SR'KYGDK>^R^/$
M]9]&EWV<P]?,\SY6_P#IU_VMA=[=K@ ^=7   /SRUGXV9Q[74_J9^AI^>6L_
M&S./:ZG]3-N'VBN'7(@E<B#:*@ +RBK)2)!??T@""'65V#"#)12I  0D  0
M @   ()(9,$%6BY#1MC4*6(+6(:-\<D(3)N007["UQ<J2.P $V(N2$"Q9(%+
MDE%B0B6BO802D0BR*VB$B42"FT@0!7:1$D(DSH@ %4@L"4  !:1 0 6D  %Y
M$ (!.A( (2! ( N9)"YDF=!  C8]-=#[]RU#ZRG\F>BSSGT/OW+4'\=/Y,]&
M'-E[6@ "J0     /)/2X\<LN]G?S1ZV/)/2X\<LN]G?S0'1
M $ @,E,R=IB@9>TUXT55]95HN59VX9*52P))L;]D*I7)2)2)2*W,$K%@$86[
M62@18DSL  %4@    E  "EJ4&-EVS$S+*[3!\B "B0
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MG\S@D=,5H "R     2!!((J4 FPL5$( E 0B0"T0  D!8 E)8 $   @ !*0
M 0B&B4"V-0H0RUBK-\:JA"[ -I1*8;=B 6V%V+L@#8FX (M$%HD)%DC/*B46
M1"1)SY5,2"%UDF-2@ %4@  (,(,MB")(1)*$! (T_0!U (K:)()(L5@E  ;
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M9W).F:Y&\8KOM%WVE>QIEW@V8KOM%WVCLE:3*"X*@
M                       .Q-@'XI9)Z^)[I/"VP#\4LD]?$]T@
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M]I5652T);R2=NLSSS[0C[X &*P
M
M
M
M
A                                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g12080g03r76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r76.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_[13J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %,T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*RL1_#GIDN<^D"H*9] 1>?0"H*9]0R!4 ID"H*9"KA.8%0,_64R!4%,]2J*
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ME8V72UME;3N<K<2)A>1HUXW/K*#=R#2;*&-U+)P_G5=A>:9Z 2V@*(I5%R@
M!5P41>70"H"+D  %*9 J!D=X %,A%SW 5 5<=V2B.R!4%$7THI7(!2B+GH%(
MLWBW*K-#U]H@I*..H2LD1KN-V.% )41<@\:.99Z6&96\/:,1V/1E#V1?2 !3
M*F*U3?:;3>GZZ\5S7NIJ2/M'HQ.:IE$Y?6!E@:SH'65OUK9EN5J9,V!'JS$B
M87*&RJH%04S[2H    41?25SS[@ *<7)<(J^H<0%0412H %,^HC7?#<.JV_M
M=MJ:*DCJ7U4RQJCW8X41,@26G,%C8:UUQLU#6O9P.J(&2JW.<<347'\2^50
M*(O/H,\N@%041<]"N0 *9]0R!4&K[@ZUMVAK/%<;LR5\$DR0HD297*HJ_P"!
ME].W>"^V6DN=&CD@J6)(Q'<EQZP,B"F>>,#/("H&2B+] %0,^HIGD!4%,YZ!
M%SW 5!1%Y]"J=  "KA.A3(%0$7(  !5P !3(R!4%$=] XO5S J"F?4HSU J"
MF?4$7DH%0,A%S[0 !HU=N99J/7,&E9&5"W"9R,1R-\U%4#>5"<S :[O<NGM*
M7"ZT\*3RTT:O;&O1QA-G]956MM++<ZVD;33)*L:M15PN.\#>@4R,@5!3)5%
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M,IMZ+A?;A;);KV,SDC@1>F.2=R]"2+CORVXV^>BK-&5<E/,Q8W,<[EA4Q_5
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M>I =3OOJ&\5LZZ/TVM10Q?MS-557ZB[\+2KEH='62VPR/[*:=4DY_"1K>63
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M!(J)@^(&-BB;&Q$1K41&HG<G<?8$=;_QUTFV5S2W)(KTPLB,SE6<\]/H(FV
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M3EZKG.0,SHM<Z2LV%RGB</\ V(9E3RHZ:*CIHJ>F8D<$348QB=&HB81#T<N
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MF?XLU56-.KE7'(Z/:AAM-:6LVF:=8+%;X*.-?A<"<U^E>9FD3&0
M          *AKNK-%V/5<"1WNACG5J<+9,8>U,]$4V( 1E;-CM$VZJ2>.@EE
M<CD<C9I.-O+U8)'I::&DIV04L;(H6)AK&)A$3T(A[
M    %M<J&"Y4,]'5LXX)FJQ[?2BER ,)I/2]KTI024=EI^P@>_M')G.5,V
M                                   U_5ND+/JN&GBO=-V[('<3.>,*
M;  /.E@CI:>*"%O#%&Q&-3T(B80]                             QNH
MK)0Z@MDEONL7;4LF.)F<9&G;)0Z>M,-MM4794D6>%F<XRN5,D
M   #!ZPTK;-6VO\ )]ZB=)3YXD1KN%47VEMHS1%CT?2OAL=(D7'\.1W-[D]"
MKZ#90 1,                           %0 #3=9[;Z>UC705=[IY9)H>3
M58_ARGKY&Q6*ST5BML-!:X&04L28:QJ?Q]ID  1,
M
M!0 -:N^A[%=K_!>JZD[2X0\*L?GICH;*@
M
M              $7)3/,"H&>O(9  IGKDK^  !.8
M
M
M
M
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M<C@=PI.R9$1WLY&4VMWICUUJ);5':'TCNS63C61'=/2F )B1<@HA4
M
M
M
M
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MQPJS,C\X0Y\\%/\ 65+\U?\ BAV(@
M
M
M
M
M                                    #7-R/T#OOS1_X&QFN;D?H'??
MFC_P Y>\%/\ 65+\U?\ BAV(AQWX*?ZRI?FK_P 4.Q$
M
M
M
M
M                                         'R]R,17.7"(F54#Z](1
M<D5:BW?HJ"X2TM#1S5+HEPYV.7T&=T-N+;M3S>*I')3UB\T8_H[V ;NJX*Y,
M%J_4M)IFUK5UG$[/)K&]7*1S2;U4LE4U*BW2LIW+CC1,@3&"VMM9!<***JI7
MH^&5J.:J>@N0!KFY'Z!WWYH_\#8S7-R/T#OOS1_X <O>"G^LJ7YJ_P#%#L1#
MCOP4_P!94OS5_P"*'8B
M
M
M
M
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M"=^0$3T=
M
M
M
M
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M&F7JB-]*@?0/%*F'_>L^L>,PJJ(DK,KRZDTHYKHSR>P"+G(*@
M
M
M
M                                                         :YN
M1^@=]^:/_ V,US<C] [[\T?^ '+W@I_K*E^:O_%#L1#COP4_UE2_-7_BAV(@
M                %'NX6JN,HAI]1N#;(*B6%\-0KHW*U<(;=,F8W>P@*ZI_
MG6LQT[5WXGS>T<5<P\4S1Q?3[-PMO$S5%S@DI=QK6B9[&I^R;9;:UE?115,3
M51DC>)$=U.?U3*+CV&\6C7?B-M@I643W]DQ&\2=%/+A>TYFJ=?/X_AZ\7V7$
M4QJ(_/\ *4<^H(OJ(TDW"JG?T5O7/K13S37%[D7,5 BI_=JI[>\K'.>CPQV7
MB.,1'RD_BY] JD62:MU$[.:=L?M;@LY]3Z@1J\54R/Z4)WC1/AIF?A>[;D>*
MJF/E+_$461J=Z?60=-JVZ*Y6RW-<^U#'U.JJA$7CN$COI-QB;M7@LU3\)L5N
MGQ7:>J?UGC3J]J?O(?#JRG;UGB3]Y#G1VIN)5S53KZ4SU/!=1M7J^7Z7&XG&
MU>'#RS-C"T^*_#HYUSHF_"JH4]KT/)UYMS>M9!]HYO\ Y11N7"-E<OH1Q]-N
MTTG]%1U3L_\ #DUJ^T9_8^X31P$?O_3HI=06M.M;#]H\G:GL[>M?#]H@&%]S
MG3\W;IU]K5+R&V:@ESV5K7"^E"ZGM&?VZ8_FHS[/C]R9^$W+JVRIG_+X>7K/
M)VLK,G_JV+[%(ACTQJB7X-OB3/I+EFB=5/\ _3TS?:O_ ()J,?QT.JQ5@.=7
M1**ZVL_^_/EVN+.G25R^Q".H]OM3/^%+2,]JGM'MKJ%WPKA1Q_NJOX&=3C>-
M5'633P/*KHWY-<VA?]H[ZCS=KVT(G65?8AI;=L;ZOPKM1_1&X]F;8W547CNL
M'T,4FJQ?KH^_Z73P7*KZ;8NX%I]$WU(47<&TX^#-]1K,>V5<B+VETC]6&J>C
M=LJK/.Z-Q_94FAB_53]_T:6"Y5?386;@VIRX5DZ>U$/1-?6GO61/H0UQVV<_
M"O#<DSZ513Y3;2I[[A']D98R.-/V9X*?5]-GCUW9W+A7O;ZU0Q&L]44%?8I(
M:&H7ME<F.%<*8]=M:M$\RX19];5,9?\ 1M59;>^MGK()(V*B*U&JB\SAB=JU
M56E%.67.7?#1@YNTZ,U9Y\H:_P",5'QB;[:ES;*R6*Y4DDM1*D;)6N>JO7&"
MP1S>:(N5QW'I31^,U45/&]B22NX$ST/SU%<Q5&4OT5=,:,YPFMFJ+,KE1M?"
MOTEPV_VMWP:V%?WB-7;?7=O2:!_L0\W:%O*=&1N]C\'Z;78N/VON'YC48.?W
M?I*;;S;E_P#60?;0JEVH%^#50K^\A$JZ*OC5Y4Z+[)3Y=I&^,ZTR_0\;1B(W
MVIZP;+AIW7HZ)A;74SO@SQK^\AZ-J(G=)&+^\A"ZV"^1?["1/8Y3R=;;XS/Y
MJH^A5&U7N-J38[/"]";NV9_6;]:'TV1'=%3ZR#$AO<2_ JF_6?;+C?*=5PZJ
M;^ZI8QD\;=70V")W7*>J<4<,D(_RHO\ &F/&:I/^6?4>L;VW_P!7,O\ ::-N
MICQ4U1\)W=7PJIGY39GU#)#L.OKK&B\4D;_[28/9NX]QZ<-&3O"S[])3NV_P
MRZI<XBJ$4P[CUJ+Y\$"I_P )DJ?<F/'Y^AE=_85$-=X8?U_]L]W8GT_])$0&
M@MW*I%5<VZJQZ>)#WBW&MSD\^FG9[<&HQN'G=7#,X#$1OHENX-29K^RJF72/
M:OHP>C-=V5ZX29_V3<8FS.ZJ&)PMZ-],MI!@(=6VB7X-1CVH7":CM>?]+C^L
MU%ZW.ZJ&)L7(\LLN#&QWNWR+YM5&O[Q<LKJ9Z9;/$O[R&].GFQ-%4<%R#Q2I
MA7I+&O[R'VV1KD\U45/4I<TRE]@IGU#/J*BH**N"G%Z@/H%,^H9 J"F2J*
M
M
M
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M?3HJ=ZL0R$%MI($Q%3Q-3U-0NP<9KJG?+<4Q&Z'PV)C>C6_4?:( 953 X2H
MIP^M4'#ZU*@"B-P%3UE0!1$]8P5 %,#!4 4X?2>532PU42Q5$;9(UZM5.1[
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MM)6JOFN:OTFLX9RE]@IQ!%*BH!3B^GV 5!3(R!4%,E<@ $7(
M
M
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M1*:&"T58(].6&"@CYO:G%([TN[S.@#7-R/T#OOS1_P"!L9KFY'Z!WWYH_P#
M#A/2>G+KJ:ZOHK%$LM4C%?A'8Y(3SL'M]JK3>LUK+Y2NBI.Q5N5DSS]AJ/@J
M?K*E^:O_ ,#L-$Z@&E0               %3( 'RC$:BHB(B>P^D
M
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MG^6P@ ^F^6
M
M  #(/F5[8XW/>J(UJ*J@'/:UJN<J-;Z54M'W:WL7ADKJ5CO0Z5J?XD![@:\N
M5^NLEOLTLK:-%X6MC3SGKDQ,&W.JZ^)*GQ9%RF?SDBHX#IF"IAG3,$T<J>EC
MT=^![(N4.5F5.IM%U[5D=/3O3DB.YL<AT-H/4T&J+#'6Q+B5OF2M7JCD0#8P
M$Y@ %3( %.%/4$:B="H 8*(U$55*@ @  &N;D?H'??FC_P #8S7-R/T#OOS1
M_P" '+W@I_K*E^:O_%#L1#COP4_UE2_-7_BAV(@
M                                H %G<+G1VY(EK:B.!)7<#.-<<2^@
MNVNRB*F,*!4!
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M1&HB'.UV5& N3.GI3,-8GM/;;>CH:/Y7  /4\
M
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M9WHQB_LHJFHN17E;FF<HW<S//].24X]ZM-M:C5\:<J)A?S:GU_/9IKT5*?\
M+4TQNV-U5B*E%$Y%YHJ+G)YKMG=N?^;VX]2$TL-Z9ZF=ODWMN]&F%3/:3)^X
MI]LWFTNJ\YI6IZV*1Z[;6YI_[8GT-/!^W-R3K:U^AHTL-RDSM\I28F\>E57_
M $J3["GHF\&DL96N5/:Q2*7;>7!%_P!4O5/4P\7Z K4=_J>1/W!GAO?Z,[?N
MF!F[ND')SN7#[6*>C-V='.SF[,;[6.]Q"[]"53>MIE3]P\G:(J?DN=/8PO\
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M1$SZ$P51,'S%*R1O$QS7-]+5RA]HN<^H
M
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M@1BZ(\-N#6Q&Z$+_ )2U16>;-=*A,_UG\BVDHKI,_-5<9'>Q^3HBDVRLD/\
M2.GF_MN0R]-HJP4Z)P6Z)53O7J)QUSRQ$?!KIX.8&V'ML<<\\N>[A4R-+H[M
M41&6^HD]:90ZDI[50T[.&*EA:GJ:73(8V?!8Q$]33G.+O5>9B;E4\7-5'M]7
MOQV5L<B+_6,[1;77614188(O6[D3TB(G3D5P<9N5SOF69JF=Z':3:BJ_]350
ML_L<S+4VU-(U46>NE>G>U$P27A/0A4QO1H]-MEI]C,3PRRN]/&J&0@T%IZ''
M#0M7'3B<JFT ##Q:9L\2(C+? F/^$NH[101_!I(4_=+X >#:2!OP88T_=/1L
M3&]&-3V(?8 HC43N0JJ>P !]0P !3'H&"H I@U[6FEZ+4]M925T7&C7HYJHY
M6JWU\C8@6*IIG.%B<MS09MJ-+U/ LU-.YS&HW*3N0^)MI]-MI>SIJ:1'(Y'-
MXY7.YI[2040'377,LM*5TZN;QI(NRIXX\(G U&X3NP>V G(')DP@QZ0 &  !
M3A0IP-]"'T /A88UZL:OT'RM-#_NF?4>H \5I*=>L,?V3S=;Z1W6GB7]U"Z
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M!>K5#5T[LHYC5<F,87'0X7IUD1=CCO\ Y8K_ %?J90 'G<P
M
M                                       QFIG*VP5ZI_N7?@9,QNHV
MJ^Q5S6HKG+"Y$1._DH$,^#M&QUSO#WHBN8U$:Y4YIS4LM^8&_P KJ1(FIQRQ
M85<=5R:?9VZDM#I'6V*KIW2?"5K%Y\RMRCU%<ZEM1<(:N>9GP7.8O(";MM=
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M)L4B+A>%,<7K+U0!3'K&/_X4J "<@
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MJM:W^DBRJH\RU!5Q5</'$[/I;WM7T*:KO5UQE4LUS.]<  Y,@
M
M                                         5,@ ?/9L_JM^H=FWT)]
M2'T:]J+6-EL#D9<*R-LR_P"R:N7?4!G^S;_53ZBK6(WHB)[$-6MVO++7666Z
MMF=%1QR]DKY$QYQLM-415,#)J>1LD3TRU[5RB@>H">L            -<W(_
M0.^_-'_@;&:YN1^@=]^:/_ #E[P4_P!94OS5_P"*'8B''?@I_K*E^:O_ !0[
M$0
M
M                                                *F4PO0^(H61-
M5L;4:W.<)Z3[ %,'Q#!'"YZQ,1JO7+L=ZGH
M
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MQ)SYH!4!.8
M
M
M
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MF2,\6>N'M14[CKZEMU)3/XZ>FAB?TXF,1%P!=-]94)R
M
M
M
M
M                            #PKZIE%1S5$J*K(FJY<>A +/4U1)26&M
MG@8CY&1JJ-5,HIS#;[S>[9=JBNMS9*>65ZN<UK%X5Y^@G>Q;C6J^05[X8)49
M21J]Z/QS0P7\Z^FD54_)J\O^!H&C)N7K1K>3H^7IIR2MHM27K4$-<^]\*K&Y
M$9B/@Y&._G7TRO\ [:J?N--LT-JFVZD94.M=/V*1+AW)$S]0&U-[_5R*A  "
MH !97&U4-R:B5]+#4(G3M&(N"ENM-#;8U904L-.U?]VQ$+X ?$L3)8W,D:CV
M.3#FN3**ABZ;35GIJGQB"W4S)LYXDC3DIEP 1   -<W(_0.^_-'_ (&QFN;D
M?H'??FC_ , .7O!3_65+\U?^*'8B''?@I_K*E^:O_%#L1
M
M
M
M
M                                6]PIFUE%-32+ADK%8OL4N !H&G-M
M:"R0W"*">5Z5D:L<KNY#7JG:;3].]6SW3LW+SX7R(BDD:OKWVO3=PK(4_.11
M*YOM.<[%IS4&N9ZJLII$?AV7OE=A,KW(!OW\U^F<<[RS_JM]YNFWFF;9IV*I
M2U5C:E)517*CD=P\O411_,]J?_?T?_47W$C;3:1N>EX*UMUDB<LSD5O9KG"
M2&G>"B=Y4    &2F0*@9^H9  ( !KFY'Z!WWYH_\#8S7-R/T#OOS1_X <O>"
MG^LJ7YJ_\4.Q$.._!3_65+\U?^*'8B
M
M
M
M
M                   6-[CIIK55,KU1*56+VBKZ#FVR:SJ=(76Y16-6RT$L
MRJC9.F$S@Z%UM2OK=+7*GBSQOA<B8])#FSEDL%:VXQ7Z.)];#*C6ME=CESZ
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M3GZ,%0
M
M
M
M                                                   #%ZH@J*FP
M5T-$BK4OB5&(BX7)SFNWFKNU61+9-QK^UQHB_B=+72MBM]OGJY\]E"U7NP03
M=-X[R^NF_)M/3QTR.5&\:*JX]*J!@_Y!:T[J&I_ZJ>\E#9NQ7JRPW!M\ADB6
M1R*SC?Q93!H"[NZF[/B6.E1B\D=V:X) V;O=XOT-PK+M)))&KT;&J_!3ES1/
MX 24G>5"=X 'A72NAI)I8V<;V,5R-_K*B=#W"ID"*],;HTM3?*BCO%+#;D8B
MHV3"Y547HIH.X%9!J3<:#\C+VR98SB;WKGJ2OJO;&RZ@K75;NTI:AW-SH>2.
M]J%[I#0%GTRY9:2-9JE?]K*F53V>@"+][[=-1W*S7!S5X$A;&Y?0K3);AZNM
M=PV]HJ6EJFR5,B,XHTSEN$YDN7RST=ZH)*.X1-DB>BIS3FWUHIHENV=L5+7M
MJ))*B:-CN)L3UY?2!<;'VN>WZ05U2Q6.GE61J+_5PA(9\01,@B;'$QK&-3"-
M:F$1#[ &N;D?H'??FC_P-C-<W(_0.^_-'_@!R+X/VF;7JK7,E!>Z?QBF2G<]
M&<2ISY>@ZJTIMGI?2]Q6OLUO[&IX5;QJ]7<CF[P4_P!94OS5_P"*'8B $
M
M
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MZPH9:RS2.D@C?V:N5N.9L1"'@HIPZ(JV]S:ER?Q4F\
M
M                     -<W%8Y^C+JC/A=BJD,;9T]KK]*W^WU$<:W-[.*-
M7IE>2+T.A:J&.H@?%,WBC>U6N3U$;6S1UFT?J.IN51<F,II6N1(I7<T5?0!I
MNA[G8%T1<;9?NQ940J]8U<WSE]&%,_X/]RF?15]O>Y701OXX\]V?_P (:]==
M"VV[WB:33][IGLF<JI'(N%1?02GMSHZ+2=MDC259JF9W%(_N]B ;<B=2H1,
M           !KFY'Z!WWYH_\#8S7-R/T#OOS1_X <O>"G^LJ7YJ_\4.Q$.._
M!3_65+\U?^*'8B
M
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M-U+.ZH<]&N5%RF5]!*P
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M4_UE2_-7_BAV(AQWX*?ZRI?FK_Q0[$0
M
M
M       1,     &  *8'#GKC'L*@"B)CIR"(5 %$;SSWE43'0  4P5 %,#'K
M^HJ (XWAV^FUC1TM1:ZQ:.ZT3N.%Z=%Y]#1*RQ[O7FWK9+A5TL%$]O925#,<
M3F=#H(ICU_6!J.UVBZ?0VFH[9!)VTJJKY9L8XU53;U")@ 4Q[!PIG)4 $3!1
M4R5 !$
M                                               6EVHH[C;IZ295
M2*9JM<J=2-*C:'3M.SBJ*VHB;G.7/:B$EW6MCMUOJ*N;X$+%>OL.;*VJU%KZ
M_3^(+421(]>%C57@8U5Y9^H"0J;:K2]2[A@NDDKO0R1JJ7?\S%D^,U>?:GN(
MPNNC]5:7B\<=VS6-7F^!ZKP^TF;:75;]26-[:M5\<IG(QZK^TF.2@971FD*+
M2D,\=#)*])5156147H;*$4 "CE1.:_65->U_4U-+I.XR4*.6H[)4;PIE?H B
MK=.^U6J-0LT[9G*^")R+)P=[N_/J0Q.SL"TNX"0/^%&CFKCT\T,/I2[7O3M3
M55%/;99:B=,+))$JJWTJ6>F;Y<+;J3Q^BA62J>]>)B)E>:\P-TWXJ'5&J+90
M.<O9M:BX]JX-DW-M%)!ME1I%"QKH.SX51,+T-1WH;(FI+/<IV*Q)8&*N4QS3
MFOXFX[H7.FEVTI>SF8YTR1JU$<BJO)0/?8&K?-I2>*1V4BG5&^K*$G(1EL%2
MOATG/)(Q6]I.JMSWHB)S)-3D -<W(_0.^_-'_@;&:YN1^@=]^:/_   Y!V$U
M5:=(:UEN-]G?#2K Z-'-8KURN.Y#JC1^Z>EM6W-;?8ZR2:J1O'PNA<Q%3VJ<
MA;4:(;KS4TEJ=6^)HV)9>T1G$O+'+&3I+:W95NA=2?E1MY=6?FU9V?9</7OS
MD"9 4:5
M
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ML52G3*],+WD_- J
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M$
M
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M]-[P*@
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ME[P4_P!94OS5_P"*'8B''?@I_K*E^:O_ !0[$0
M
M
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M  $&VSP?(:&NIZE-6W6187H_A5F$7"]/A$X1MX&HF57"8RI]
M
M                          8S4R*ZPU[6HJJL+D1$3U&3*.:CD5%3**!R
M18;C?+&Z9]J2:%TOPUX%YX4R_P#+/6/QB?\ Z:G3245-\7A_Z:#Q*E^+0_\
M30#EZMU3JFNI9*>KEG?"],.:L:\R1?![@E@IKIVL3F9<F.),9Y$M^)4OQ:'_
M *:'I%!%%GLHV,SUX6H@'HG>   5< \JN-\M-*R)ZL>YJHUWH4#5-1;BV&QU
M;Z6HG<^H9\)L;<HGTE]IC6-HU&CDMU2BRMZQ.Y.(^I-NK?9ZVMNNL*V*:D<J
MJG:+CSE--T) LFY<2V'C6B;*J\;$7"-]8'0]WNM)::&2KKYFQ0,3.5[S4*+=
M;3=35M@[=\:.7"/>W#32M_KE--<;=:6/Q&J<;D1>N>1\:\T1;;3H&BK:2'AJ
MV\':/[W90"<XI&RL1\;D<QR914[T/HCS8ZZ2W#2/9U#U>ZGD6-%5<KC&20TY
MH -<W(_0.^_-'_@;&:YN1^@=]^:/_ #E[P4_UE2_-7_BAV(AQKX+U53T>XLL
MM740P1^+/3BE>C$[N]3KVDNUOK)>RI*^DGDZ\,4S7+CV(H%Z @
M
M
M                        HJX*HN0    \JFHAI872U,L<43>:OD<C6I]*
MF-_E-8_EFV__ .TSW@9<%K0W&CKV.=0U=/4M;U6&5'HGU'A=KY;+2W-RKZ6E
MY91)94:J^Q% R(+*VW6@N<?:6ZLIZIB=5AD1V/;CH7J<P          5<  8
M*\ZOL%E54N=WHJ=Z+A6.E3B1?6B<RXL^H[/>FHMJN5)5*O[,<J*[ZNH&5!3)
M87.]6ZUNA;<:R"G=*J-8DCT17+Z@,@ BY
M
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MV+FHK)^-47V(:1X*GZR9D[EI7_BAV'A%ZH@!I4(F
M
M
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MQTJB<D;*S&/:@'1D*8C;GT(?9\Q? 3V(?0
M
M             #PKJ6&MI9:>I8CX9&\+FKWH>Y97FM;;K94U;^;8F*["]X$6
M:@VHEHIW5VDJZ2EF;YW995,KZER89FNKO:&26C6UKDJJ1Z=F][DPN/3G',L6
MZGUSJ5\M5:DF\61ZM1(F<D]1E]&7^JO-Y=IW6M*RI>Y.%CGQX>U?1GZOJ K:
M-OM'ZD3QFUW>5C7\U@1R(K?5@D[2.E+;IBF=%;X_/=U>[X2D?ZBVJFHIWUND
M*QU/(BY[!7+_  4R&V&HM15%XEL^HH7+V3%<DCF87EZ^\"44!1O/F5 !0 *<
M(QZRH ICUA$YY*@ @  &N;D?H'??FC_P-C-<W(_0.^_-'_@!R]X*?ZRI?FK_
M ,4.Q$.._!3_ %E2_-7_ (H=B(
M
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MOL0^@B8[P
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M\%/]94OS5_XH=B(<=^"G^LJ7YJ_\4.Q$
M
M
M              #( !%  !     *@ 'P^)CTP]K7)W<29P5;&UB88B-3T(G(
M^@ 0 =X %.(JBY  IGU#/J J @
M
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MIH%&]Y4
M
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MJ56)%]&.J$[M[P*@
M
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M<F5%1%3Q5_7Z#L-L;47+6HG=T./?!3_65+\U?^*'8B
M
M
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MM1K6IZC()GO-'VVM.L+9#4IK.[TUQ>]V8EA1?-3ZD-W;W^L"H
M
M                                                !KFY'Z!WWYH_
M\#8S7-R/T#OOS1_X <O>"G^LJ7YJ_P#%#L1#COP4_P!94OS5_P"*'8B
M
M
M                                    ,%$0J *8&/65 #'TE.'GS7)4
M ,#'KY  4P,<ESS3UE0!#5_V6S?:F[Z3OE59JBI<KY6L^ JJN>7\3WTCLM24
M-]CO>H[I57BYQJCF.D7S45.G(E[ 1,=^0*(F.\JH %$3TC'H*@"B)ZU&"H I
M@JB8R
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M
M
M
M
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MGC=ELU+1U..'M(T7./1U V1.\J
M
M
M
M
M                       !:W2@@N=#-25;5=!*U6N1%QR4QNE=+6S2]--!
M:(GQQRNXW(YW%SQ@S@ M+E;Z:Y4<E+6Q-EAD3"M4U*AVMTS1UK:F.ED<]J\2
M->_+<^S!O  HUJ-1$1$1$Y(B%0 !KFY'Z!WWYH_\#8S7-R/T#OOS1_X <O>"
MG^LJ7YJ_\4.Q$.._!3_65+\U?^*'8B
M
M
M
M
M                                 !5&0 "  :YN1^@=]^:/_ V,US<C
M] [[\T?^ '+W@I_K*E^:O_%#L1#COP4_UE2_-7_BAV(@
M
M
M
M
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MX\\%6EG;N2DW9/2%:65.-47'<=A-[P*@
M
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M&IQKGUH;&@
M
M                            !5P:#N3N!'I58Z6GA2>OD;Q(U>C4]8&_
M9]00A.Q[OUOY2@AO=%'%!*Y$XD:J*B+WDT4\K)X62QKECT1R+ZE ]
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MDR7%]+INE2J8SDK^%5553KA#-[;[CIJ*MDMUSB93UR)EB(BIQ>E )) 10
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M<V2RW>.WV=(IGL7$SG)GA7/1 )80&/L%:^X6BDJI$1'RQH]40R
M
M
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M>6@[?Z,._$W9%R0MLC>[M+-%;)8G?DR.-RL?P\LY])-#?6!4
M         +"_T/Y2L]91\7#VT:LSZ"_-<W$J:BDT?<I:15;*D?)R=4Y@0=I#
M4+= WJZTM70QU3U<K%<CNF%7VF7VIHGW[7U5?FI'3TZ*Y_9([GS[D0^ME+9:
M;L^Y2WE(IZGEPI,[GS5<J8>"1;1NPL-@D5*=:I&<+5RW"]0.DF]"I1I4
M               !\39[-R-^$J80^Q@"#+YM]>+C57.YWRM5*:)KG11J[BSC
M/U=Q\^#TG^=;HB=.%$_BI+VJTQIRX_W*]"(O![7_ #M=O[*?]R@23K/15#JI
M875TCV+%\'AZ&L;H26;3N@Y+1&R!:A[6LBC1J<77X1MFO-54VE+,^JGR^5Z\
M,4:=5=W?00AIFW3Z[U!)<+]711TT;O/[1^%7_A0#>_!]MU13VBNJY6N9%4/:
MD:*F.F>?\26D[S&V/\GQ43*6U21.A@1&(D;LX,DG>
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M90DA.\"H
M
M                     :/N%M_2:K5E0DSJ:NC3A;(B914]:&\!0(<L6SBP
M7*&HNUT6ICB<BHQJ8SCUDP0QMAC;&Q,,:B(A]8]"E43
M        %.%/0B_0:GN/I-^K;-'11524JLD[3CX<Y]1MH4#!:)L;M/:?IK=)
M.D[H45%>C<9RN3.HF B8                       /*I@CJ8)(9FHZ*1JM
M<B]Z'J%0"'+OL_(EPEJ+'=74L<BJO Y.F?69_0.VE-IRM6X5E2M978Y.5,(A
M(B)Z5")@ @                       +.\4:W"V5-(C^!9F*SBQG!I>W&@
MI=(UE9-+7)4I.F.'@X>'FJF_JF2N (\W&T#5ZMKH)67)M-%$W",6//T]33_Y
MD:K&%OB(GJC_ /).> !HNV>AY='^/]K7^-^,\./-QPXS[S>DY
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M75TE$Z&M2E\7555.#/$;W@JJ>L"QLE"MNM=-2.?VBPQHQ78QG'>7P1,>P
M
M
M
M                           JX!J6YU;=Z#3;IM/L<^L[1$PUO$N -MR4
MR<WU.L=>44*R5;9H(DZO?%A,GG0ZYUO<$=XB]]1P<W=G'G '2G$5R1!HV^:O
MJ+/>7W2&9)XH5= CHL*KO47.T=[U-=+A4MU"R1(FM\U7Q\($K(N041>2JG/)
M5%  IDKGD  *97GR J $  'Q,JI&Y47FB*H'UDJ0/HS7-^N&O8:"KJF.I'3/
M:K$9CDG3O)W;R3U 5 1<@
M
M
M
M
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M>
M
M
M
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M23&\\J51 B8
M
M
M
M
M             "H4QZP *HF
M
M
+           ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g12080g03r84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r84.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1IL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &D\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$Q61H1$2%F$$!5-BT>$ADC&Q,C-!<08B(T+P@?_:  P# 0 "$0,1 #\ M2
M              /: !Y;$8YRM:Y%<G2E^@])K0^27E5ASDQ%54M$MT)K/K
M                  >61&OOF.1;+8]+T*?)(2ZRS8B.5%5SU=J0#ZP
M             "JB)=5L@/$5N?#<W:BH!ECVO;=BHJ;4/1\\A!67EFPU5%5/
M:A]                    8>]K&JYRHB)[5#7(Y+M6Z;3\9R$L:7B0TLBN2
MR*J'N79R<%C/=1$ _0                  #R][6)=ZHB=%U/1\T_++,P48
MBVLY% ^FX,-2R)]AD                   /+HC&JB.<B*O0BKTGI#Y9N76
M-'@/16IR;KZT/J3V@                   //*-1Z,5R9RZT0]'R/EU=/LC
MW2S6JVU@/K 0                   O0!Y;$:YZM1R*Y.E-AZ/DEY98<[&C
M*J?M$1+(FP^L                   %SRV(U]\U46RV6QE4N?-(RRRZQLY4
M7/=G)9 /J36 FI                  %]2_ &')=JIM PQ[7MNU;I\#T?-)
M05EX')JJ+K5=26]I](                   8<J-15<MD3VAKD<B*U;HO0>
M)F'RL![/>2QB5A\E 9#5456I8#]0                  /+WM8V[U1$^)Z/
MFGH"S$!T-%1%6VM4 ^E-::@8AI9C4V)8R                   'ET1K51'
M.1%5;)=>D]'RS<NL:)!<BI^S=G:TN?4                    \\HU'(U5^
MLO0AZ5+GS1)97ST*/?4Q%2P'THH"):X
M                           OKZ  ,(M[:EUF0
M
M
M
M                                 'V@
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M!D&+BX&08N+@9!BXN!D&+BX&08N+@9!BXN!D&+BX&08N+@9!BXN!D&+C. R
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MTP_PDD3=<9FF$8Q3R@ //MH
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MT:H:H?\ AE  4EL
M    -/B#$E+H')>M9ID!8M\Q%Z5MT@;@'PT>J2E8D&SE/C-C0'71'(?<@
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MA,B9/HN>QCE286RJU%]A,[&-8EF-1J)[$2P&0
M
M
M
M
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M9HC'5%XG_P"3?!2/@OB-&B1I\L(Z?'O%[ !<>;
M
M      17EKDZ[5V2M/H].CS$LG[2(]G0J^Q#>8*P/3)##<E"J=-EXLZK,Z*Z
M(Q%5'+TI\CN+"P$496,"0YNC0(V&Z8QLW"B6=#@MLKFJ?G(TZOS62*?I<[3X
M[9^&O)PH;OWGMNBZOQ):LE[^T60"-LB]%J-'P_/0:K*/EHL1Z*UK^E=1SV3K
M#-:I^4.:G9VGQ8,H[E+15Z%OT$U60S8"%\JN&JS5,<2<W3Y"+,2S8;$=$;T(
MJ*IC*_ANLU6I4>)3J?%F&0H36O5G^E;H3386 B+*#A;$D>#3ZA0YJ8SH<&&R
M)*,>J*UR)THASM;3&^*9*'3)RA9BM<F='6&B+=-JV)^LAFP'!4'!$20R?35#
MBQFK-3,-V<_V-<J$;X;I>.<)S<S*TNGO5(WU%?FW9_N1;%A+(9M]H$!X8P;B
M.GY0Y.9J,I$CPFQ,^),HOU5OTFVRQX;K%7Q+(1Z93XLS!8Q$<]O0GUB9K"P%
M>\N#%95*1#B:G>C-:J;%Z#])B%E EZ$VB,EXLQ)16(C8D-+JK5UYM['7Y4\!
MU/%%7E)JG1(#8<)B-<D1UEZ229"$Z!)2T%ZW=#AM8MMJ)8#@\EF#(V&:+-Q)
MW-6H3C/K-;_I2RV3[=9S62?#59I6,YJ:J-/BP)=S'HD1W1=5U$T60S8"-<M=
M%J59H\G#I<I$F8C(BJYK/8AN,+T*)&R;R]&J<)T"+$EEA/:[I8JW.RL+ 5\I
M=%QM@BK3,&CRL29@O^JCF)G0W)[%U^T_*)@S%G.N1GJC*Q)N)$B-BQ8S5NC-
M?0I8A$LED%@(RRL8'FL0-EJA2E;Z;+-LYB]+T3HM\3CIJ)E#JDG!I+I.8E^3
MM>*UN:JHG1=;$^YJ&; :+!E+G*10H$M4IQ\Y-_O/B.6_R-Z$2P *0_\ 2A_A
MH[^99^9,"D/?2BU9-'?S+/S KSA"3FH]-5T"5CQ6HZUV0U<GX&\]63_8)OP7
M>1,WT65_^GT7^97^Q,B7*$SX&&O5'5X_Y>N^#_\ E>KX61HD0E>/EAX>/C^E
M-?5D_P!@F_!=Y#U9/]@F_!=Y%RP<<?#)9]::_HP_M^E-/5D_V";\%WD/5D_V
M";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^
MWZ4T]63_ &";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(>K)_
ML$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_ &";\%WD7+ X^&1ZTU_1
MA_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63
M_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6FOZ,
M/[?I33U9/]@F_!=Y#U9/]@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-^"[R'JR?
M[!-^"[R+E@<?#(]::_HP_M^E-/5D_P!@F_!=Y#U9/]@F_!=Y%RP./AD>M-?T
M8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_V";\%WD/5D
M_P!@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_
MHP_M^E-/5D_V";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(>K
M)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_8)OP7>1<L#CX9'K37]
M&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6FOZ,/[?I33U9/\ 8)OP7>0]
M63_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6FO
MZ,/[?I33U9/]@F_!=Y#U9/\ 8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\A
MZLG^P3?@N\BY8''PR/6FOZ,/[?I33U9/]@F_!=Y#U9/]@F_!=Y%RP./AD>M-
M?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_V";\%WD/
M5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,CUIK
M^C#^WZ4T]63_ &";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(
M>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_ &";\%WD7+ X^&1Z
MTU_1A_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>
M0]63_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6
MFOZ,/[?I33U9/]@F_!=Y#U9/]@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-^"[R
M'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_P!@F_!=Y#U9/]@F_!=Y%RP./AD>
MM-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_V";\%W
MD/5D_P!@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(
M]::_HP_M^E-/5D_V";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+
MO(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_8)OP7>1<L#CX9'
MK37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6FOZ,/[?I33U9/\ 8)OP
M7>0]63_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR
M/6FOZ,/[?I33U9/]@F_!=Y#U9/\ 8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?
M@N\AZLG^P3?@N\BY8''PR/6FOZ,/[?I33U9/]@F_!=Y#U9/]@F_!=Y%RP./A
MD>M-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_V";\
M%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,
MCUIK^C#^WZ4T]63_ &";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L$W
MX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_ &";\%WD7+ X
M^&1ZTU_1A_;]*:>K)_L$WX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)
MOP7>0]63_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''
MPR/6FOZ,/[?I33U9/]@F_!=Y#U9/]@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-
M^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_P!@F_!=Y#U9/]@F_!=Y%RP.
M/AD>M-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@<?#(]::_HP_M^E-/5D_V"
M;\%WD/5D_P!@F_!=Y%RP./AD>M-?T8?V_2FGJR?[!-^"[R'JR?[!-^"[R+E@
M<?#(]::_HP_M^E-/5D_V";\%WD/5D_V";\%WD7+ X^&1ZTU_1A_;]*:>K)_L
M$WX+O(>K)_L$WX+O(N6!Q\,CUIK^C#^WZ4T]63_8)OP7>0]63_8)OP7>1<L#
MCX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8''PR/6FOZ,/[?I33U9/\
M8)OP7>0]63_8)OP7>1<L#CX9'K37]&']OTIIZLG^P3?@N\AZLG^P3?@N\BY8
M''PR/6FOZ,/[?I5O)?3YV'CZBOB2<PQC8RJKG0E1$^JI:%ET=MN>E2X1$3H+
M<B3LZ?+X^+SWS?YK'YG-TS8Z?+X0\/\ /C_Y\60 3LD
M
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MQ< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7
M7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q<
M!<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<
M
M
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MF9.YTIXH[1*^"@TIXH[1*^"APP%+)QAT-Z9D[G2GBCM$KX*#2GBCM$KX*'#
M4LG&'0WIF3N=*>*.T2O@H?52<J>(G5239-/EXL")%;#<U(2(ME6VI2/#]Z9_
MBU._F8?_ +D/D?A9/A'_ .L"$Z9=;EBYS$7:ES)YA?\ :9]B'H\NV0
M
M
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MTW[$/0;^Z@/.M4
M
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M+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@
M"R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+
M(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "
MR"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(  L@L@ "R"R  +(+(
M  L@L@ "R"R  +(+(  L@L@ "R"R  +(8S4V&0
M
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MG(C55%M\@+!PZI(Q$B*R<@.2'^_:(GU?M,2-5D)]SF2DW!C/3I:UR*I6O E
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M4DZHZM$(Q9 ! D
M
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M<ZULZ%=";:71J=25?ZNDX,LK_P![DFVN>9JA4R:GF3LS(P(DVVUHKF_62WQ
MKUB"FP<,X]C.KTB^9I<2,Y[>E$>U==T7:A]DU5L,1ZQ E,.862?ANM?.<J*Y
M?DO0A/\ 4J9)52"D*H2T*8AHNIKTO8^:E8=I%)C+$ITA @1%U9S6Z^\#[:9!
M;+R4"$R$V"UK$3DVK=&_ ^H  I#WTH_X:._F6?F3"I#WTH_X:._F6?F!7W W
M^$Q?^3\CHC=9$LG;L384BSK:@L#]MFYB-O["0-#$3?"\!O\ P_QDG1+TZ=6K
M^69-D3-6N,801*"6M#$3?"\ T,1-\+P$U=(R1TTVR)02UH8B;X7@&AB)OA>
M5TC(IIMD2@EK0Q$WPO -#$3?"\ KI&133;(E!+6AB)OA> :&(F^%X!72,BFF
MV1*"6M#$3?"\ T,1-\+P"ND9%--LB4$M:&(F^%X!H8B;X7@%=(R*:;9$H):T
M,1-\+P#0Q$WPO *Z1D4TVR)02UH8B;X7@&AB)OA> 5TC(IIMD2@EK0Q$WPO
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MQ$WPO -#$3?"\ KI&133;(E!+6AB)OA> :&(F^%X!72,BFFV1*"6M#$3?"\
MT,1-\+P"ND9%--LB4$M:&(F^%X!H8B;X7@%=(R*:;9$H):T,1-\+P#0Q$WPO
M *Z1D4TVR)02UH8B;X7@&AB)OA> 5TC(IIMD2@EK0Q$WPO -#$3?"\ KI&13
M3;(E!+6AB)OA> :&(F^%X!72,BFFV1*8);T,1-\+P#0Q$WRJ6_\ 0*^1D4TV
MS>Y"?\K3'_.O]B2F]!SN",-0L,47T*%%6*Y5SGO7VJ=$A@?$:X3)NK5I_P 1
M:<K3'3HA"( "%(
M
M                                              PUC6_NM1/L0R
M          !2'OI1?PT=_,L_,F%2'OI1?PT=_,L_,"/<B.5/#^#<)OI]668]
M(6,K_J-NEBPN"\3R&+:+#JE+5_HSU5J9Z66Z%>,BF2B@XSPH^H55TPDPV,K/
MV;U1+%AL$X6D,(41E+I>?Z.QRNN];K=0-^
M
M
M
M
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MM4=6B$8@ (4@
M
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M<-<W5JT_X:DG3'3HA"( "!(
M
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M+@ +BX "XN
M
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MV+8U=FZ?3XW+Q7Q70X,-&75#<SM7QG1<%3TY6XBPIE8[60FQF(JHFNZH!)>
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M:XZ]$-40 $*0
M
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M9K\!NZ,H=3R:K1:,&\YGXBW+-?@.9^(MRS7X#=T90ZGDU6BT8-YS/Q%N6:_
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M4-4[5&#6^'A&$N$(@ *R8
M
M                                   !=    ^6I2,&HR$Q)S35= CM5
MCTVHIK<,X7IN&X45E*@K#;$6[KK>YO!< @%P          N@  70
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M'@,6464R!X#%E%E,@> Q9193('@,6464R!X#%E%E,@^^ (
M
M
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MH %-8
M
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M51$:BZRSR+K4Q/FD81UZ?"S0^"A'PBR #+70
M
M
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MV>XWN/0 \\FSW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0
M\\FSW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]P
MY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN-[CT
M //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN-[CT //)L]QO
M<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN-[CT //)L]QO<.39[C>X
M] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<
M;W#DV>XWN/0 \\FSW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XW
MN/0 \\FSW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FS
MW&]PY-GN-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN
M-[CT //)L]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]PY-GN-[CT //)
ML]QO<.39[C>X] #SR;/<;W#DV>XWN/0 \\FSW&]QCDV^QC>X]@#PC$3H:B?8
M>D0R
M
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M5T"&YW2K45>XI_%?"1^'\/Y\?%8DSMWQ_CP?L "HG
M
M
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MY<^I2;6?6<L5J(B?:6TDT5)>%=/]*?V,?YK_ /JO_!?_ +/W !CKX
M
M
M                            L !BWS")93( Q9=HLOL4R ,9OL]@MM,@
M#%M>L64R /AK,JZ>I4[*L7-?&A.AHNRZ6.&R7X&G<)SL[&G)B'%;&8C41J=&
MNY(]C%OB MM%NG69 &+"RF0 UF$2QD 8L+;5,@#%A;XF0!BQE$  PB:S( !2
M'OI1?PT?_,L_,F%2'OI1?PT=_,L_,#3?1KP]2:E@2+&GY&!'B^D*F=$:BKT$
MLI@W#R__ +)E/#0J)@3*1BG"M'=(T*&UTJK\Y5Y#/U_;8M)D<Q%4\3X.@U&M
ML1LVY[FK9F9J1=AW";KA_$(Q<1T:8_Y@W',S#VZ93PT',S#VZ93PT.@!]WIF
M4>IMZ+0<_P S,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ
M93PT.@ WIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE
M/#0<S,/;IE/#0Z #>F91ZFWHM!S_ #,P]NF4\-!S,P]NF4\-#H -Z9E'J;>B
MT'/\S,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@
MWIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\ ,S#VZ93PT',S
M#VZ93PT.@ WIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/
M;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>IM
MZ+0<_P S,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT
M.@ WIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/#0<
MS,/;IE/#0Z #>F91ZFWHM!S_ #,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\
MS,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4
M>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\ ,S#VZ93PT',S#VZ9
M3PT.@ WIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/
M#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>IMZ+0<
M_P S,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ W
MIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/#0<S,/;
MIE/#0Z #>F91ZFWHM!S_ #,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;
MIE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>IMZ
M+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\ ,S#VZ93PT',S#VZ93PT.
M@ WIF4>IMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/#0<S
M,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>IMZ+0<_P S
M,/;IE/#0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>
MIMZ+0<_S,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/#0<S,/;IE/#
M0Z #>F91ZFWHM!S_ #,P]NF4\-!S,P]NF4\-#H -Z9E'J;>BT'/\S,/;IE/#
M0<S,/;IE/#0Z #>F91ZFWHM!S_,S#VZ93PT',S#VZ93PT.@ WIF4>IMZ+0:2
M5PI1)6.R/+TR5AQ6+=KDAI=%-TB6,@XU:HZO^4?%U#3#3_B  #X^@
M
M
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MDI*O?"FE2[8<5+9R? #L :?$N(Z;AR3])JD=(;5U,:FMS_L0Y6EY6L/3TVV
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M.=->WO.>(HXK7E K=-EI[_ 7^!5CG37M[SGB*.=->WO.>(HXK7E K=-EI[_
M7^!5CG37M[SGB*.=->WO.>(HXK7E K=-EI[_  %_@58YTU[>\YXBCG37M[SG
MB*.*UY0*W39:>_P%_@58YTU[>\YXBCG37M[SGB*.*UY0*W39:>_P%_@58YTU
M[>\YXBCG37M[SGB*.*UY0*W39:>_P%_@58YTU[>\YXBCG37M[SGB*.*UY0*W
M39:>_P !?X%6.=->WO.>(HYTU[>\YXBCBM>4"MTV6GO\!?X%6.=->WO.>(HY
MTU[>\YXBCBM>4"MTV6GO\!?X%6.=->WO.>(HYTU[>\YXBCBM>4"MTV6GO\!?
MX%6.=->WO.>(HYTU[>\YXBCBM>4"MTV6GO\  7^!5CG37M[SGB*.=->WO.>(
MHXK7E K=-EI[_ (I5=<55]$54J\Y=-?_ '%+"9.ZA,57"%.FYUV?'>SZSMI6
M^)^"U?#Z?-&/BDE?$0FQ\(0=* "FL
M
M
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M=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!=
M,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=
M!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,@Q=!= ,
M@Q=!= ,@Q=!= ,@Q=!= #_W'?862R2_Y#I?^S\RM;W(C'?863R37YB4K_9^9
MF_-/^J'_ +6_@_\ G_\ X[$ &"TP
M
M
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M .-<W7,_C7'Q=:9>G3_Q@  C=@
M
M
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M+K.5G0I'-^"FR=/GU?X=R_B-&N/A!VH *B<
M
M
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M+_VP2V #SC6
M
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MQGS$2([.?$<EK_(Z@QFH1S/BILW3Y=<?X=Z)&C1'QTP9 !72@
M
M
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MVJ'\.]$_1,CX:8NK !63
M
M                                                       PI7G+
MN]78RAMNMFP4LA89>DKMET_SFG_"@'=Y!*9 @X7BU!&MY>8BN8KK:[)[+DG-
MZ+D+9,,>T/#^$X,A4HD9LPR(]RHUF<FM3K$RL873HCS'A?\ Y [ZR;"+,O\
M(0HF'):>5J<M"C(S.MKLJ+J_ VVEG"_7S'A?_DXW*KCJB8BPRDE38L9TPD=C
M[.AV2R(M_P"X&MR"1'-Q7,PT=J= 5;=Q8%"O>0;_ #C%_P"!WY%@V] &0
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M$<[@;_"8O_)^1T1ZCX7_ *=/_IC3O^<0 %A$
M
M              !8F;(#_AU1_P"1"&29\@/^'5+_ 'H4OF'_ $16/AO^V"6@
M ><:P
M
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M. :'*IO*!P$Y@<C/OV*279!FARJ;R@< T.53>4#@)S Y&??L4DNR#-#E4WE
MX!H<JF\H' 3F!R,^_8I)=D&:'*IO*!P#0Y5-Y0. G,#D9]^Q22[(,T.53>4#
M@&ARJ;R@<!.8'(S[]BDEV09H<JF\H' -#E4WE X"<P.1GW[%)+L@S0Y5-Y0.
M :'*IO*!P$Y@<C/OV*279!FARJ;R@< T.53>4#@)S Y&??L4DNR#-#E4WE X
M!H<JF\H' 3F!R,^_8I)=D&:'*IO*!P#0Y5-Y0. G,#D9]^Q22[(,T.53>4#@
M&ARJ;R@<!.8'(S[]BDEV09H<JF\H' -#E4WE X"<P.1GW[%)+L@S0Y5-Y0.
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M.$EPK3(L*+,<M'BNSGN1-2'8"R;".;\9-FZ?+JC_  [T?#Z-$?-  !53
M
M
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MHL);/AN]FPXF?"S9>GS:M/\ #K1/T:X^&F+J  5TH
M
M
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M]S/[$0$P?1^_<K'^YG]BG\?_ -&K_P#O_*Q\-_V03" #S;6
M
M
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M]%S&+=$1"0 13OCIL[1Y-7AX.Y?PVB7J\T  %-8
M
M
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M: (#AT
M
M
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MYC=B=PS&[$[CT /.8W8G<,QNQ.X] #SF-V)W#,;L3N/0 \YC=B=PS&[$[CT
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MR&5/CO\ HU?_ -_Y3?#?]L$U@ \TV
M
M
M                            #@<I&!IK%\S*NAU%):! :J<GF7NY5Z3O
M@!J\-TB%1*)*4^"N<V!#1JNM;.7::;*'A!N+J7#EN6]'C0XB/9$S;ZO:AUH
MX2DX!ALP;%P_6)KTR"KU="B(RRP_L.2;DBJDHKX--KSX4H];*VRIJ^*7)H '
M#8+R=T[#LC-0XSW3D>;9F1GQ$U*FQ$.5GLCTQ FHKJ%6(DO+Q-7)N3H3[4)C
M '"Y/\GLIA5\2:B15FJ@]++%5+(U/@?'&R=1(F/'XB]8(C71DB\CR?YDC #D
M<HV$7XNI<*5AS?HRL>CLY69USR_!4O,X'@8=GHJQ.299L9K;*CO8MCL !#-/
MR/SL-ZRTU7(J4Y5NZ'"2RN-_@3)U&PIB").PJDD67>U6+"6'953V:R1P!6>%
M1H.(,I]2ILQ$=#;%F8EGLZ46ZV.UDLC<1]08^JU=\Q+,7]U&_6<FRZ]!VM/P
M%2Y'$T2N05B^EO>KU15U74ZX#F<788;6\*OHLM$;*,^IFJC;HU&KL-!)9/(D
MO@6;P^L^CGQXG*)&S-2=&JQ(H Y/)UA1V$:1$DWS/I+GQ%?G9N::.1R<Q);'
M;L0K4$<Q8JQ.1Y/;?5<D@ <3C_ $GBM8<PD596>AI9(K4NBI\3D)3(Y,1YJ&
MM9K#X\M#Z&(FNVSX$R@#YY"3@R$I"EI6&D.#";FM:GL0^@  I#WTH_X:._F6
M?F3"I#WTHOX:._F6?F!!.3NEU";HD6))R,Q'A\I;.ALNE['3^H:SNB=\(DCZ
M+CF-R?14>YB+Z0O[RIL)D;F.2[<Q4VH:4KYEJEZ(:/+_ (5-?PD-6J.KQ53]
M0UG=$[X0]0UG=$[X1:W,3W4[AF)[J=QWRNK%Q10NJEZAK.Z)WPAZAK.Z)WPB
MUN8GNIW#,3W4[ARNK$HH752]0UG=$[X0]0UG=$[X1:W,3W4[AF)[J=PY75B4
M4+JI>H:SNB=\(>H:SNB=\(M;F)[J=PS$]U.X<KJQ**%U4O4-9W1.^$/4-9W1
M.^$6MS$]U.X9B>ZG<.5U8E%"ZJ7J&L[HG?"'J&L[HG?"+6YB>ZG<,Q/=3N'*
MZL2BA=5+U#6=T3OA#U#6=T3OA%K<Q/=3N&8GNIW#E=6)10NJEZAK.Z)WPAZA
MK.Z)WPBUN8GNIW#,3W4[ARNK$HH752]0UG=$[X0]0UG=$[X1:W,3W4[AF)[J
M=PY75B44+JI>H:SNB=\(>H:SNB=\(M;F)[J=PS$]U.X<KJQ**%U4O4-9W1.^
M$/4-9W1.^$6MS$]U.X9B>ZG<.5U8E%"ZJ7J&L[HG?"'J&L[HG?"+6YB>ZG<,
MQ/=3N'*ZL2BA=5+U#6=T3OA#U#6=T3OA%K<Q/=3N&8GNIW#E=6)10NJEZAK.
MZ)WPAZAK.Z)WPBUN8GNIW#,3W4[ARNK$HH752]0UG=$[X0]0UG=$[X1:W,3W
M4[AF)[J=PY75B44+JI>H:SNB=\(>H:SNB=\(M;F)[J=PS$]U.X<KJQ**%U4O
M4-9W1.^$/4-9W1.^$6MS$]U.X9B>ZG<.5U8E%"ZJ7J&L[HG?"'J&L[HG?"+6
MYB>ZG<,Q/=3N'*ZL2BA=5+U#6=T3OA#U#6=T3OA%K<Q/=3N&8GNIW#E=6)10
MNJEZAK.Z)WPAZAK.Z)WPBUN8GNIW#,3W4[ARNK$HH752]0UG=$[X0]0UG=$[
MX1:W,3W4[AF)[J=PY75B44+JI>H:SNB=\(>H:SNB=\(M;F)[J=PS$]U.X<KJ
MQ**%U4O4-9W1.^$/4-9W1.^$6MS$]U.X9B>ZG<.5U8E%"ZJ7J&L[HG?"'J&L
M[HG?"+6YB>ZG<,Q/=3N'*ZL2BA=5+U#6=T3OA#U#6=T3OA%K<Q/=3N&8GNIW
M#E=6)10NJEZAK.Z)WPAZAK.Z)WPBUN8GNIW#,3W4[ARNK$HH752]0UG=$[X0
M]0UG=$[X1:W,3W4[AF)[J=PY75B44+JI>H:SNB=\(>H:SNB=\(M;F)[J=PS$
M]U.X<KJQ**%U4O4-9W1.^$/4-9W1.^$6MS$]U.X9B>ZG<.5U8E%"ZJ7J&L[H
MG?"'J&L[HG?"+6YB>ZG<,Q/=3N'*ZL2BA=5+U#6=T3OA#U#6=T3OA%K<Q/=3
MN&8GNIW#E=6)10NJEZAK.Z)WPAZAK.Z)WPBUN8GNIW#,3W4[ARNK$HH752]0
MUG=$[X0]0UG=$[X1:W,3W4[AF)[J=PY75B44+JI>H:SNB=\(>H:SNB=\(M;F
M)[J=PS$]U.X<KJQ**%U4O4-9W1.^$/4-9W1.^$6MS$]U.X9B>ZG<.5U8E%"Z
MJ7J&L[HG?"'J&L[HG?"+6YB>ZG<,Q/=3N'*ZL2BA=5+U#6=T3OA$IY"J/4)!
M]7F9Z4BRT.*C&LY1+*JI>Y+68GNIW'IJ6U(B?)"*?\PU3M$='E\/%)+^%AHU
M0U>+*=  ,]:
M
M
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MH?S&!#5"/^(OL !RZ
M
M
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M\9_T:O\ TF^'_P"S2GE.@! >8;
M
M
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M:O'_  _9 $Z-8,Q=
M
M
M                  &IJ6)*/3)M)6?J,O+S"HBI#>ZRZ^@VS51S45%NBZT4
M #%T]IFZ>P !=+V%P %P  OJ%P %SY*G492F2CYJ?CM@0&=+W=" ?6#X*/5Y
M&LRGI--F&1X%\W/;T7/ON !IFXHHSJLM,2?@^G([,Y&^N^PW-P %Q=+  +BX
M "XOKL   !2'OI1_PT?_ ##/S)A4A[Z4?\-'?S+/S @#!,3'[*2Y,)OJ39#/
MUI+I]7.+2Y%UKKL%P%Q0Z86H9[K\O^]:^HY7Z+7\/HO\PO\ 8F1.FX&0
M
M                        !=  "
M
M
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M>66@1YE(<6!,08:K9(BHBI]I(4.IRL:E+4)>(V-*\FL5',6Z*B)<X/'^!Z'
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M&IV^1C_/D'_A<0_$R]&SJ_B'^$DG5JW(?RL4WH 3H!YAL
M
M
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MU1C_ (;QO0 G0#&:
M
M
M                      +@ ?E'F(4"&L2-$9#AITN<MD0U\+$='C1U@PZE
M*NB^ZD1 -J#".1;6UW,@   !B^P^27JDC,3+I>!-P8D=.F&UR*[N ^P
M      ?A-S<O)PN5FXT.##Z,Y[K(9E9J!-PDBRT5D6&O0YBW10/V
M4A[Z4?\ #1_\RS\R85(>^E%_#1W\RS\P((P#E8KF#*,^G4N7EHD%7YZJ^&KE
MN6AR/XIGL7X0@U2IPX<.8<]S51C51-2G$?1BI\G-8!BOF9.7C/\ 2%1'1(37
M+:VU4)IEX$&69R<O"APH:=#8;4:G<@'Z@7%P %Q< !<7  7%P %Q< !<7  7
M%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !
M<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q< !<7  7%P %Q<  FL
M
M
M
M     \1'(QKG+J:W6I[/EJ:.6G3>9^^L)^;]ME @'$E3JV4'&KZ33IB)#DFO
M5&,1RYK43I>MC:5W(_,4^D19NGU.),3<%N<L/-5%?;9\369#5S<>S"15_:<C
M$37MN6!C18<M+OBQG(R%#;G.5>A$ C?(M-U]TA,RE=EYEL"%99>+'1;_ .W7
M[#I\28XH>'HW(5":1)CVPF:U3[=AMJ76)"K0G.I\Y"CHG3F.UI\B&\42^"*1
MBN:FZK,3M3G'*KGR[?K-SOM_("1Z!E#P]7)QDK*3>;,/_<;$3-SO@A^L[CV@
M2-7BTV;F^2F82JC\YNI/F0!.S4G'QE)S-(I\2FRZQ6*R$_79;])L<7R/K3*C
M$DW+_P"(F&,<OP6UP)OPWC>C8CGX\E2XSWQ835<MVV14VW.#R?TVBR^4.9CR
M-=B3<XJOO+K"5$3IOKN=]AC!5'PS'CQZ7!<R)&8C'*YU]2$19*4_^J\UT],7
M^R@2O"R@X==.34JZ>2'$EL[E,]+(END_&DY2<-U.=25@3N:]RV:L1,U%^9"]
M#HL"O93)B2F[^CNFGOB(BVSD15U'099L(4S#\K)3U(@K+J^)F.:BJJ:DO= )
MFQ#79&@4_P!-J4162]T;G(E]:G.S.4_#,NR7<LZKTC)=$:VZI]IQN-:A%J>1
MVGS4PJNB*YB.<OML?EDIP#2*UA]*E58;XL5T3]G9RIFHGL^($D5S&]#HL& ^
M?FT:L9J/8QJ7=FKT*J>P^"C92\.56;9+0IM841^IO*IFHJ[+G#X]D<&4W%3I
MNM34Y,S.J\I"UHB(FIOPZ"/\7SM,G:K+S%$I46F2]FHC7JOUU1>E-@%BL2XQ
MH^'(L&'5)A8;XR*YB(E[H:?2KA94U3CU_P#Y#W6*#A^K8?D:GB6 D1LK*M=G
MJ]4U9J;.DA"%2(.*L6/D\+27HTE?5=57-:G2Y5 E[*!.43$^"&3;ZJ^4D'14
MS8S6*JYVRQ].$*E1L+X"EYA:D^9D&NLD=6655V6-!E4HLM0<FLO3I1%Y*%$;
M=5UW=[5-!-(B9#I9;?\ G 29-92<-2]-@3CIY',C?NL:EW_-/8;7#.*J3B2%
M$?2IEL1T-;.AKJ<GR(QR0X'H]8PV^H567](BQ7.8U%<J9B)L-!DF8LCE065@
MN5(7[6&J;41%L!.&(\34O#LNV+59EL+/_=;TN=]B&KH&4+#U;FTEI2<1L=W[
MK8B9M_L(3QK5(%0RC3,2MK&BT^6CJSDV=.8B]"'RXTJ.')F)+1\*R,W)1H2_
M71S51+>Q4Z0+1(MS)I<&S\2I8;I\U&3]I$A)G:MFHW0!2'OI1_PT=_,L_,F%
M2'OI1_PT=_,L_,"%<F.)ZU2:!%@4VH19>#RM\UNVQUW/O%&^9CN0CG W^$Q?
M^3\CHCTGPTJ7&5IC'3#_ !9D3M>J&N/A%TG/O%&^9CN0<^\4;YF.Y#FP3[$O
M&'1'N:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<^\4;YF
M.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q1OF8[D
M'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;FN\72<^
M\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EXPZ&
MYKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[D.;
M V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<^\4
M;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q1OF
M8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;FN\7
M2<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EX
MPZ&YKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[
MD.; V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<
M^\4;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q
M1OF8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;F
MN\72<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#
M8EXPZ&YKO%TG/O%&^9CN0<^\4;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1O
MF8[D.; V)>,.AN:[Q=)S[Q1OF8[D'/O%&^9CN0YL#8EXPZ&YKO%TG/O%&^9C
MN0<^\4;YF.Y#FP-B7C#H;FN\72<^\4;YF.Y!S[Q1OF8[D.; V)>,.AN:[Q=)
MS[Q1OF8[D/NH6/\ $D.KRG+U&),0G1$:Z&]$LJ*<:?32O\5D_P#E;_<^:I$O
MPC_]8='W3,U^,/YBMK!7.A,<O2J(I[/SEO\ P\/_ &I_8_0\JVH
M
M
M
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M;9CB/IIF2^@R$_!FV-BQ'PG9S6O6Z7^P^1^92?#_ ,OL/A)GB[:6_P##PO\
M:G]C] U+(B)T(# :@
M
M
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M O\  #(,7^ O\ ,@Q?X#.U@9 0
M
M
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M"D>'_$A\1-NMY"=GPVN3H<EST?E*:Y:'_M3^Q^IYIL0
M
M
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M6]ULFOYG9Y9;)@.>NO0J'346@4RB\IZKE(<MRG[V8G2?54J=*U*4?+3T%L:
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MYIKP
M
M
M           !A5UK8(M]H&08N91;H         /S6!"5^?R;,_WK:S]  !B_
MV7%U R              >PPBZP,@    "D/?2B_AH[^99^9,*D/?2C_AH_\
MF6?F!P60S*CAO"&$GR%9BS+9ET97VAPE<EBP6$,2T[%E(94J0^(^5<JM3/9F
MK=/@5PR-9(J)C;"SZE4IN=A1TBJS-@N:C;?-"Q6!,)R>#:##I5-BQHLNQRN1
MT945UU^P#H+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9
M&+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9 &+"QD 8L+
M&0!BPL9 &+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9 &+"QD 8L+&0!BPL9 &
M+"QD $
M
M
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M:8GQ<O3*FQTZ?\-&1KCKT0U1  5DP
M
M
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MM6K3'Q@T_A],=,N$(@ *J8
M
M
M                                             6  6  "R  !86
M638+)L  ^6=ITG/9OIDM#CYO[N>E['[PH3(,-L.$U&L:ED:G0B'L  B(G0@
M'QMI4@V;6:;*04F%6_*(U,Z_VGV6  6%@ "HB]*"P "PL  L@L  L+)L  "P
M    %(>^E'_#1_\ ,L_,F%2'OI1_PT=_,L_,#F/H\XVP_A_!425JU0AR\=8Z
MNS7)KM8G>A5F0KLBV<I4PV/+N541[2JV2;(_*8YPXZIQZE%EWMB*S,:U%]A9
M')OA&%@K#D.DP)A\PUKG/SW);I4#J0
M                               6  (E@
M
M
M
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M_#^-_,+_ &)E
M
M
M
M
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M G0                     !>@ #\DC0^4S.4;G^[G)<_39K R
M             'B)$8Q4SWM;?:MK@>P88J.2Z*BHO0J&0
M       #RJV155=2=-U]AY9%8]%S7H[;9;V _0
M"]  'Y-C,<[-9$:Y=B.2Y^B=X&0                      _-T5C'6?$:U
M=BN0#] 8;T&0                    !>A0 /#WM8EWN1J;56R"'$:_6QZ.
M3X+<#V                      &'*B=*VMK R#\F161%7,B-<O_I5%/U3V
MW                       !^7*L1<U8C<_HMG)<#]0
M      POVZP,@_*)%:RV>]K;]%UL>X;D>EVJBI[%1;W ]
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M383H<MAJ@2=(D7/=+RK%:Q7]*W55U]X&V
M
M
M
M
M
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M.]BW36,IC&4O*I C2J(QW[*+=-5U7I L(WH,GB7=G0(;EZ5:B_@>P
M         !K*_5I:ATF8GYU^;"A-5?BY?8B&P<J-15541$]J^Q"#,<U.:Q]B
MV'0J.KEI\JYR1(C=;55.ER_ #HLF>4&I8IQ',24Y @0Y9(:Q&9B*BZC?91L=
M0<)P(<*%#2/48R79#7H1-JD;9#H20,>3T%%ND."YJ+]BH?AE'?ZQRK0)>-K8
MCX<*WP W=(RNU*%48,+$%-AP92,J?M&-<CFHOM^),LM'AS$&'&@N1\.(B.:Y
M/:BD09?9*##I5'BPV,:YBJQ%1+:K(=UDPCNF<"TESUNK8>;?[%4#JP
M          H"] '$93\8Q\(2,G%E($&/&CQ%:K(E[(B)TZC@%RQUW,1R4B75
M/@UWF><OLV^8K\C)-8]S8+$?J34JK[#Q*90I^C^BPJMAJ7A2F:B)G0LURIM2
MZ 2G+XI9!P3!KU58D#.@\HZ&V_3[$0C*)E@KCW/F9:D0?06NMG*U5M\%6YL\
MLM7@SV"*5%IZHDK-/SD:WV63H-AA*FR[\C45'0VWBP8D1RJFN]UM_8#L\%8E
ME,4T=L])W:J+F1(:_P"AVPWY"'T=X[FS-5EE<N99KD3V70FYO2H&0
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MC$?#5',<B*U4]J T63^8?-8.I4:)K>L%$5?LU #H
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MD)$^O]J'O!F3RE87F5F99T68FE2R1(MOJ_8B =C ;F0FMV(B?@>S#>@R
M            !HL;09R/A6I0J;=9M\*T/-Z5UZR"Z!1L;X?;,/IDH^"L=MXK
MK(JN0LB>(C4=#<U5U.14N!5G!L:O0\117T#.]/=_W;(G[M]?2='E/ANI64:3
MG8[;-<V%&<J;?:2EA3)_3\-5R9J<I,S,6-'16JV);-2_V&TQ=A6G8HDO1ZBU
MR.;^Y%9^\T"+,MU>D:I(4>!(1V1G+=[LU;YMT2Q)V3J4?(X+I<",VT1(2*Y-
MEU.:H62*C4RH0YN+,3$VL)V<R'$1$;JZ+DD-1&HB(ED34B >@
M     O0 H$;8VQS2Z)B.'(5*DNC1&YKN65J*F:OM0U&6ZMTF>PS+096-!CS+
MWH^'F*BJUOM^P[O&.#Z;BJ6:RH-<R)#7ZD:';.0Y>D9'J+)3L./,3,S-)#6Z
M0GV1J_:!PU8I4UH?ILQ%:MH497I=.ACDU'0X7Q13Y?))&EHLPQLU"AOA)#5=
M:JJK:Q+,U3Y:9I[Y&-!:Z5<SDU9;58C>8R+T5\RZ)#G9R'"5;\FEEM\$6P&J
M^CQ)/S*I/*W]FJI#:J[>E2:&GPT.DRE%I\.2I\)(<"&G1[57:OQ/O
M          $3?2"D7Q:-)3K$^I B*UZ[$7H)9/EJ4E+U&3BRDY#;$@1$LYKO
M:@$3X6KM#;DHF96+$@LCL@/8^&Y41SWK>R_$T&2*0F)R@XG9#8JPHLLK&7Z%
M=L.MC9&*-$FEB,G9MD%776'9-2;$4D&@463H5.9)4Z$C(+-NM57:H$*Y":U)
MTJ?J,M4([("N;=%?J2Z=.L^'##4K^5]\S+)G04F71578U%Z21L29)Z+6)]\W
M#BQI.(]?KMA(BM5=MC?8+P;3<*08C9%'Q(T2R/C1?WE^ '3@)T
M        0#E(>_$.527I::X<%[(:)W*I/WL.*@9/J?"Q?SA]*FG36>K^36V;
M=4ML [&!#9!ALAPTLUC4:B?!"NJ1&8=RQOB3=F04G%<KO99R]/XEC?9J.3QI
M@6EXJ5CYS/@S,/4D:%:ZIL7:!$^6FI2]9Q5)2U.BMC\FUK,YBW2ZKM)XHT!9
M6E2D!VI8<)K5^VQQN%,E](P_/-G>4C3<PW]WE;9K?C8[Y.D#(
M     4&%Z *V4Q\!V5M[L0N:L'TAZ.Y7H]MKGVY95I/.*G+1%A),(B<JL"UK
MW2W02GC')W2<3S"3,PL66FK66+!5/K?:BFNPYDHHU(GX<Y%C3$Y%AKG,2)9&
MHNT#B\M<M,+2L/3LPUROY%&/=;_5TFPQAB:GS62B5EX,=CIE[&0U8CM;;=)*
M]<H\I6Z=$DJA"Y2"]/9_I7:A'TOD8HL.;2)$G)N)"1;I#6R7^"K8#Z<@\D^6
MP@^.]+>D1LY/BB$E)K/PI\K!DI2%+2T-(<&$U&L:GL1#]P
M  !&N5JLX=@K+4W$4E,1W1$SH<6$FMGQ122CGL7X4IV*9)L"HH]',_[<5G[S
M;@0=C:C88H]!@1*--/FYR95'-5ST7,;\4]AT$.BQV9#8R9BY[XWI-O\ TZCI
M:1D>HLC.-CS,S,S:,6Z0W(B-^9(RR\)999=835@9N;F6U6V6 AO)+B20IV"*
MK G)AD.-!SGM:Y417(K;:MIKL@LJZ9Q=4)Y$_9PX3DO\7*AUM3R.4:;G8DQ!
MFYJ6:]V<L-ME1/L.UPMAV1PU36R=-AJC>ESWK]9Z[5 W0
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M/C1YN)#=G,;$1$:B@=7@F3=3\*TR6B)9[(*9R?%=8-TGR &0
M
M
M
M                      7
M
M
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M8BK[%4]W3:  ,.<UJ7<J(GQ4#(/#8T)W[L1B_8Y#W=-H #IZ
M
M
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M.Q(CXD-6)RFM&W]J7]IK8=3JT6;8]DY-<O%<B-?G+K55/HP72V5G%$A(Q/\
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M;5:VPJ-4(:09^;AMU(R*Y$[P+<PYILS2?2H*_4B0>49MUI<J_4<1UAM3F/\
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M%1R0X]\Z_P +Z@)2;T PWH,@
M
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MG,L^S=?05MEH\[(1\^569EXUK+FM5%+"9''QY[ R0ZDV-$>L1[7\NBW<U?R
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MJ)\#V
M
M                             !X5C5Z6HJ_%#*-1MT:U$OL0]    /#F
M(O[S6K\@C4;K1B(J]-CV /*I?I2Z;-IAK&HNIK47:B'L 81%1?[J95+]( 'A
M[&O:K7M1S5]CDNA^#)"4AN5T.4@-<OM2&A]0 Q;6FKH"I=+*E[F0!X1C4M]1
M-6Q#TB6,@ I\\62EHKLZ++07NVN8BJ?0 /#&(Q+-:C6IT(FI!R;;_N-[D/8
MX#+/%J<KA>%-TB-%@Q(,=%B+#Z<VRD44/*9B"1G(+YJ;]+E&K]>$]M\Y/M+)
M3$&',070HT-L2$]+.8Y+HJ$:5C([29N8?%D9F+)YVODT3.:@'S3F6.EI(O\
M0Y..LPK51K761J+8A*:BQZI4'Q%;G3$S$OFHGM5?82\S(E^T^O5_JW]D/6=E
MA+)S1\.Q4F&L6;FTZ(L9$^K]B =!A206F8>D9-^I\*$U'?:;13* #Y7R$J]^
M>Z4@*[:L-+G[LAM8W-8U&MV-U'L $Z   ,+?V&0!\T:2E8RWC2T&([:YB*?K
M#A,A):%#8Q-C6V/T &$35^)Y5C5NKF-5?L/8 \HU$Z$1/@AC-16V5J*GQ/8
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M2Y^@ ^6%(2L-RNARL%J[48A]%M5D3HZ#T ,-Z#(
M
M
M
M
M
E                                             !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g12080g03r85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g03r85.jpg
M_]C_X  02D9)1@ ! 0$"# (,  #_[1Q:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '#T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" )F VL# 2(
M A$! Q$!_\0 '  !  ,! 0$! 0            8'" 4$ P(!_\0 4A   0,"
M @4'" @$! 0$! <   $"! ,%!A$2%U63T1,6(3%14I$'%4%487&2X10B,U-7
ME*&B(S)D@0A"=+(D-F+!-#5RL3=C<W4E0T6"@[/P_\0 &P$!  ,! 0$!
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M)H\(1@CJ?#?5TI8SU*4T(0_[PBDH )%(
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MRHJ)U(JHBD%?TL]#A&?_ *EI5I:O'VO4 "LF
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M'/\ ^DAVV-1C4:U$1J)DB)Z"EZSU<OJ(0A+#AP6/3T(THQC&+^@ H+0
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M/1-)57)-!A8QEUJ?*GC)A<IS>^6$P "-V
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M68N8F)]C2?T',3$^QI/Z&G0-4J8@64N8LQ<Q,3[&D_H.8F)]C2?T-.@:I4Q
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M,K'IJT]2:,)DG !EKH
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MN+>EA5>IFV;5G>#> U,VS:L[P;P+4 O:^XMZ6%5ZF;9M6=X-X#4S;-JSO!O
MM0"]K[BWI857J9MFU9W@W@-3-LVK.\&\"U +VON+>EA5>IFV;5G>#>!8M@ME
M*S6>);HSG.I1V(QKG]:^U3W@CJ>HJ58<)X\74E*22/&6  "%(
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M_ _[J9WQ*E))3A&6$(?Y6_1SS331A&/%)@ 8S0
M                                            !\8L6A$8YD6C3HL<
MY7JUC4:BN7I5>CTJ?8         #\U?LG^Y2A/\ #U=\-U+=6L4QT2I>ZLZ1
M491J4=)RMSSZ\NQ%+[J_9/\ <I0G^']<+0K+(N-R?;*%YISY#6UJKVMJM:JY
M9=/3ETJ=2PFC'_R\CP_ZNWS+;-G0]PW@/,MLV=#W#>!XTQ=A[+_SNW[]O$<[
ML/;;M^_;Q._;5Q'RXXR='L\RVS9T/<-X#S+;-G0]PW@>/G=A[;=OW[>(YW8>
MVW;]^WB/;5Q'R<9.CV>9;9LZ'N&\!YEMFSH>X;P/'SNP]MNW[]O$<[L/;;M^
M_;Q'MJXCY.,G1[/,MLV=#W#> \RVS9T/<-X'CYW8>VW;]^WB.=V'MMV_?MXC
MVU<1\G&3H]GF6V;.A[AO >9;9LZ'N&\#Q\[L/;;M^_;Q'.[#VV[?OV\1[:N(
M^3C)T>SS+;-G0]PW@/,MLV=#W#>!X^=V'MMV_?MXCG=A[;=OW[>(]M7$?)QD
MZ/9YEMFSH>X;P'F6V;.A[AO \?.[#VV[?OV\1SNP]MNW[]O$>VKB/DXR='L\
MRVS9T/<-X#S+;-G0]PW@>/G=A[;=OW[>(YW8>VW;]^WB/;5Q'R<9.CV>9;9L
MZ'N&\!YEMFSH>X;P/'SNP]MNW[]O$<[L/;;M^_;Q'MJXCY.,G1[/,MLV=#W#
M> \RVS9T/<-X'CYW8>VW;]^WB.=V'MMV_?MXCVU<1\G&3H]GF6V;.A[AO >9
M;9LZ'N&\#Q\[L/;;M^_;Q'.[#VV[?OV\1[:N(^3C)T>SS+;-G0]PW@/,MLV=
M#W#>!X^=V'MMV_?MXCG=A[;=OW[>(]M7$?)QDZ/9YEMFSH>X;P'F6V;.A[AO
M \?.[#VV[?OV\1SNP]MNW[]O$>VKB/DXR='L\RVS9T/<-X#S+;-G0]PW@>/G
M=A[;=OW[>(YW8>VW;]^WB/;5Q'R<9.CV>9;9LZ'N&\!YEMFSH>X;P/'SNP]M
MNW[]O$<[L/;;M^_;Q'MJXCY.,G1[/,MLV=#W#> \RVS9T/<-X'CYW8>VW;]^
MWB.=V'MMV_?MXCVU<1\G&3H]GF6V;.A[AO >9;9LZ'N&\#Q\[L/;;M^_;Q'.
M[#VV[?OV\1[:N(^3C)T>SS+;-G0]PW@/,MLV=#W#>!X^=V'MMV_?MXCG=A[;
M=OW[>(]M7$?)QDZ/9YEMFSH>X;P'F6V;.A[AO \?.[#VV[?OV\1SNP]MNW[]
MO$>VKB/DXR='L\RVS9T/<-X#S+;-G0]PW@>/G=A[;=OW[>(YW8>VW;]^WB/;
M5Q'R<9.CV>9;9LZ'N&\!YEMFSH>X;P/'SNP]MNW[]O$<[L/;;M^_;Q'MJXCY
M.,G1[/,MLV=#W#> \RVS9T/<-X'CYW8>VW;]^WB>ZV7>W733\VS8\K0_FY&H
MCM'WY'D85(0XQXO8>R/^N#\^9;9LZ'N&\!YEMFSH>X;P.@#GWS9=>V&'/\RV
MS9T/<-X'NI4VTJ;64VM:QJ9(UJ9(B'Z!Y&,8_P"R$(0_T  \>@
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MQ@L< & U
M                  !\Y->G&CU:]=R,I4FJ][E]"(F:J<O"^)+?B:"^7:JC
MW4F/6FY'MT514]G]P.P#^(YJJJ(Y%5.M$7J".:N>3D7+KZ>H#^@_B.:JY(J*
MOO".:KE:CD54ZTS _H/SIMZ,G(JK[3PVZ[49\F90ITY%-T6IR3UJTE8UR_\
M2J_S)[4 Z /XCD5,T5%3M0_K51R9M5%3M0#\U?LG^Y3/?^'6?BEM=T.A;J#L
M+.F2759:K]=K^GHRS[<O0:$J_9/]RF;?(]Y1(^&,.3(%6WUI#OI]=^FQZ(G2
M[VDE.E/5C[9(<8N9YY9(<9FE$Z@5-KGB;(D[QHUSQ-D2=XTGL:^W[(KFEE;(
M*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/$V1)WC18U]OV+FE
ME;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/$V1)WC18U]OV
M+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/$V1)WC18U
M]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/$V1)WC
M18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/$V1
M)WC18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&C7/
M$V1)WC18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB3O&
MC7/$V1)WC18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>)LB
M3O&C7/$V1)WC18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4VN>
M)LB3O&C7/$V1)WC18U]OV+FEE;(*FUSQ-D2=XT:YXFR).\:+&OM^Q<TLK9!4
MVN>)LB3O&G7PGY38F(;Y0MC;?(COK(Y6O<Y%3-$SZ<O<<S>CK2PC-&7_ !![
M#U%.:/"$5A  K)@
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M$S3+/(CJ_$*,U.:6''_,'4GI:DLT(Q3( &&T@
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MJ%Q96Y;D&N^C.T7NSR^JOI_L>:ECZ'$J34NM1%:R<Z'2^CT7JN:)GDY/2ON
MG((M0QW9JEEEW-]2M1I1:O(U:56DK:J/7J;H]:JIT<-XC@X@HUG0EJLJ4':%
M:C6IJRI37T9M4#K5?LG^Y3/W^'7"'+O?B;SI-;R,V32^A-=_!=Z,U3MZ?T-
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M&;]NSKKN7_,GM$?A4T(?_KP0];##50"=0,E>
M                                              +U  07!. H-L@M
M?>+?!D7-M=]1*Z-TU1%=FWI5.M$.+B3R?7*7?[I(A?1:\2Y.:YZ5Z]6GR2]2
MYM8J(]/>6H (/3P[(MEQQ+<'\DL61;V4:*-5=)-!BHN>?]O2I$\"8>N][LN%
M7R70Z5GM]99=-[-+EGJCE^JJ=2=/I+D5$5%1>E%/XQC:;4:QJ-:G4B)D@%=.
MP7<5PO5M^E'Y=]X^GYZ2HG)\II=>77D<ZS>3JXP;O0IU?HM:W4):RFUG5ZVG
MEGFB<FBHU'>TM< 5A7P)='X;N<!KXO+R;LDYBZ2Y<GFG7T=9Y<68&Q%>9USS
MK1:]"K4:^,^K(J-Y)J9?42FGU<_:N9;( K.;AW%E?&?GI[+3*90561*5>J]&
MT69_S(U$_FR]/R/Y2P-=&WJG+<^*M)MZ6X*FDN?)Y(F75UEF@"M+Y@*?<J5_
M5E:@RI)GTYL9%<[)=%N2H_+I3/IZ4.SY/L-2K)4N,JXTHU*1+<WZM&M4JKHM
M3HTG/5<U_L3( ?FK]D_W*8UP?:;E-A3*L.WRI%+Z9533I4U<F>EU9FRJOV3_
M '*9\_PZXTHT*S\*+;IKJM>9)K)+:W^"WK7)5[>C]2?T]>-"?WPAQ15:7,E]
MO%%N;MZV1<-RHYNWK9%PW*FK409>TO:K-M5K&&64N;MZV1<-RHYNWK9%PW*F
MK<O:,O:-5FVEC#+*7-V];(N&Y4<W;ULBX;E35N7M&7M&JS;2QAEE+F[>MD7#
M<J.;MZV1<-RIJW+VC+VC59MI8PRRES=O6R+AN5'-V];(N&Y4U;E[1E[1JLVT
ML8992YNWK9%PW*CF[>MD7#<J:MR]HR]HU6;:6,,LI<W;ULBX;E1S=O6R+AN5
M-6Y>T9>T:K-M+&&64N;MZV1<-RHYNWK9%PW*FK<O:,O:-5FVEC#+*7-V];(N
M&Y4<W;ULBX;E35N7M&7M&JS;2QAEE+F[>MD7#<J.;MZV1<-RIJW+VC+VC59M
MI8PRRES=O6R+AN5'-V];(N&Y4U;E[1E[1JLVTL8992YNWK9%PW*CF[>MD7#<
MJ:MR]HR]HU6;:6,,LI<W;ULBX;E1S=O6R+AN5-6Y>T9>T:K-M+&&64N;MZV1
M<-RHYNWK9%PW*FK<O:,O:-5FVEC#+*7-V];(N&Y4<W;ULBX;E35N7M&7M&JS
M;2QAEE+F[>MD7#<J.;MZV1<-RIJW+VC+VC59MI8PRRES=O6R+AN5'-V];(N&
MY4U;E[1E[1JLVTL8992YNWK9%PW*CF[>MD7#<J:MR]HR]HU6;:6,,LI<W;UL
MBX;E1S=O6R+AN5-6Y>T9>T:K-M+&&64N;MZV1<-RIZ[1AV]K=82>:9R?QV*J
MNI*B)]9.M3467M&7M$?BLT8</:]AZ*$/^OZG4 #*70
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M
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M5\^"TI8>&Q0?-EE@0=/E/HM!E'3ZM+1:B9_H>X IQCQCQBL0APAP@  \>@
M
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M^GI248S2R\(I_3U9YJD(1BM@ &$T@
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MQ%RTF.1R9_V.9HS\/_7%["$O_'U !PZ
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M]93]?4DFH1A",/\ GW6/3230J0C&"R  ?/M0
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MN*>5I JW7):=G3_V\1KDM.SI_P"WB+*OM+BGE:0*MUR6G9T_]O$:Y+3LZ?\
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MNFE_P]EKTYH\(13, %=*
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MD07=J9M.TY_[> U,VG:<_P#;P&HT,^"UJ84B"[M3-IVG/_;P&IFT[3G_ +>
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MVG/_ &\!J-#/@M:F%(@N[4S:=IS_ -O :F;3M.?^W@-1H9\%K4PI$L;R$?\
M.,C_ $;_ />TE&IFT[3G_MX$@P7Y/X&%KE5FQ94FO5?26E_%RR1%5%7J]R$/
MJ/749Z4TLL?\Q24O35)9X1C!,P 8;1
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MW/N$5LY>A*"U4T_=D!T@<&VXA;)O5^A5Z;:%*UK3SK.?T.1S-)57LR.A:[M
MNU)U2V3*$JFUVBYU)Z.1%[%R ]E7[)_N4SY_AUPO<:U9V(*=\D4[?2F2:;K:
MB+H/7I32Z_;GU>@T'5^R?[E,A8$Q3>K1;9D:V7"K'H?3*SM!J)UJXFH4)J\W
MLE1U:D*<ONBU\B]'I/[G[%,R<_L4;8D>#> Y_8HVQ(\&\"[I=3,%>]DQ%IO/
MV*,_8IF3G]BC;$CP;P'/[%&V)'@W@-+J9@7LF(M-Y^Q1G[%,R<_L4;8D>#>
MY_8HVQ(\&\!I=3,"]DQ%IO/V*,_8IF3G]BC;$CP;P'/[%&V)'@W@-+J9@7LF
M(M-Y^Q1G[%,R<_L4;8D>#> Y_8HVQ(\&\!I=3,"]DQ%IO/V*,_8IF3G]BC;$
MCP;P'/[%&V)'@W@-+J9@7LF(M-Y^Q1G[%,R<_L4;8D>#> Y_8HVQ(\&\!I=3
M,"]DQ%IO/V*,_8IF3G]BC;$CP;P'/[%&V)'@W@-+J9@7LF(M-Y^Q1G[%,R<_
ML4;8D>#> Y_8HVQ(\&\!I=3,"]DQ%IO/V*,_8IF3G]BC;$CP;P'/[%&V)'@W
M@-+J9@7LF(M-Y^Q1G[%,R<_L4;8D>#> Y_8HVQ(\&\!I=3,"]DQ%IO/V*,_8
MIF3G]BC;$CP;P'/[%&V)'@W@-+J9@7LF(M-Y^Q1G[%,R<_L4;8D>#> Y_8HV
MQ(\&\!I=3,"]DQ%IO/V*,_8IF3G]BC;$CP;P'/[%&V)'@W@-+J9@7LF(M-Y^
MQ1G[%,R<_L4;8D>#> Y_8HVQ(\&\!I=3,"]DQ%IO/V*,_8IF3G]BC;$CP;P'
M/[%&V)'@W@-+J9@7LF(M-Y^Q09DY_8HVQ(\&\"=>1_%5YO&))$6Z3GR:"1EJ
M(CT3H<CFIT9>]3BK\.J4Y(SQC#_#J3U<L\T)807" #/6@
M
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MM.FC57P(JWQ&%2G&2$O^W=/TD9)H3<7I !E+P
M
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M8:SPU_R]:_\ 2TO]J%+UGHY?3PA&$>/%/Z>O&K&,(P=$ %!:
M
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M]>$(3?\ $M*A+2XQE  5DP
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M3ZK]D_W*9C\D_E%K88L$R!2MK)+?IU9^FZJK>MW5ED:<J_9/]RF*,-?83/\
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M@ *Z4
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M0  <O0
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M6FA*U:''EPX@ *R8
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M8MUM]&;;ZS:T:LF;'MZEZ<O^QZR*,(PCPB[APC_F  #QZ   ,@ ")D
M
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MI-&'^N,6M2A&$D(1P  B=@
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M]L_^TU.I+4AQE  1.P
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M5:.E-C,=3I5,U^JUW6F74!3<##$R1&P]'FVN0EMJ7BK62/48J\E'5&Y(]/\
M*BY+UGRQO9)%27?(EOL*QVT^32-]'@NJ.K,;E];E<U1B)V-Z2^,AD!2F((L>
MXXY96FX;G-MD5R/J5*$%SJDRKVN=E_+U>!Y[S8Y+WXBC2[%-EWR;+2I FLIJ
MK6LS3173ZFY>E%+SR&0%*W&PWVMAW%%!D:14KOGT*E1$8O\ '8UJ:2M1?YDS
M[.LDGDJMU:+<+Q*Y*11BU^31K70_HM-SD3I5K%<JIV+T%C9#(#\U?LG^Y3%&
M&O\ P\S_ %=7_<;7J_9/]RE!>0?#F&;UAN7YVH1J]Q=<*Z(QU7)ZM1>ZBYEK
MT=>6A4]TR&O3C4E]L%>@TEJVPILBE\;N(U;84V12^-W$U-4I8C_?W4K.IT_O
M[,V@TEJVPILBE\;N(U;84V12^-W$:I2Q'^_N6=3I_?V9M!I+5MA39%+XW<1J
MVPILBE\;N(U2EB/]_<LZG3^_LS:#26K;"FR*7QNXC5MA39%+XW<1JE+$?[^Y
M9U.G]_9FT&DM6V%-D4OC=Q&K;"FR*7QNXC5*6(_W]RSJ=/[^S-H-):ML*;(I
M?&[B-6V%-D4OC=Q&J4L1_O[EG4Z?W]F;0:2U;84V12^-W$:ML*;(I?&[B-4I
M8C_?W+.IT_O[*L\AW_/"_P"DJ?\ NTT$<&Q80L=BENE6J!3CUW,T%>BJJZ.>
M>72OL0[QE^KKRUZGOE7/3TXTY?;$ !53@
M
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M/+^7JZE4OBK]D_W*53_AJ_Y%F?\ W*1_N MA.H
M
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M0+FBUZ<J-2KT'H^E5:CV.3J5%3-%/H<G",.M;\,6J))3*O1C,8].Q43I0ZP
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MI&KMTF.RR7W*G:>TB7DJMTJUX)@1YU-U*NNG46FY,E:CG*J(O]LB6@
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M.@RV3X]\6;4J+27D^13IT]/J+MR4#^@                     1,@
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M$3]0/H#YT*]*NW2HU&5&]K'(J?H?0      #)  &2          !D,D  9(
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MT^G/++-.I2[$*OPU@*[OQC3Q%B.M"95IKI-H1&Y(KLLDSZ$3_P!\RT
M
M               .5B+#]MQ#"2+=HZ5J:.TFKFJ.:O:BITH1ZT>3'#-MG4Y5
M*)4JU*:Z3$K5%<U%[<O3_< ";(F0            #@XIPG:,2LI)=HRU'TLT
M948Y6N1%]&:>@\&'/)]AZP3&RX,1[I+?Y*E9ZO5GN]"  2U.@       ')Q+
MAZW8CA,B7:DZK08]*B(UZMZ<E3K3WG1B1Z<6-2CT45*5)B,:BKGDB)D@ 'U
M               4AUJ\G.'+==TN5"+4=(:]:K.4J*YK79]:( !,0  .7B*P
MP,0V_P"A76DZK'TTJ:+7JU<TZNE/> !Z[9!H6V!'AQ&JV/08E-C57/)$ZND]
>(                                    ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g12080g05h01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g05h01.jpg
M_]C_X  02D9)1@ ! 0$ IP"G  #_[1=*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %RT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( G0%I ,!(@ "$0$#$0'_Q  <  $
M @,! 0$              0<$!08# @C_Q !?$  ! P,! P0+"P<)!@0% P4
M 0(#! 41!A(A,0=!47$3%"(U5&%RD9*QLA87,C,V5G-T@<+2%2-25:&ST0@E
M-#<X0E.3P21#8G6BHR9C@O H1)3#XB?3X46#I+3C_\0 &0$!  ,! 0
M          $#! (%_\0 +!$!  (! P0!!0$  @(#      $"$0,Q,@02(3,3
M%")!46%Q0J$C4I'!T?_:  P# 0 "$0,1 #\ _5(
M
M                            #7WF\V^RTZ3W6JCIH5X.?G'%$YNM!9;S
M;[W3NGM55'4PM795S,X1?M)Q.,HS&S8 TU[U19;'*V*[7"&ED<F41^=_F0UO
MOBZ3_7E+YG?P)BEIV@[HC\NK!S]KUIIZZUT5%;[K!/52YV(VYR["*J\W0BG0
M$3$QN1,3L QKE7TULH9:ROF;!31)E\CN#4S@YWWQ=)_KRE\SOX"*S.T$VB-W
M5@Y3WQ=)_KRE\SOX'24-7!74K*FDE;+ _P""]O!>8368W@B8G9[@ A(
M
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M0]%L)\-K7+UJQI3=K_V;E7:D+5PL[$PF[BK<FG/R=U9_"C'9BT?E^F  8FH
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MZ+>HOM7]*]&N]@ &9>
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MQ$]C6I]FP==IG3ENTY1=K6R+9:JY<]R)M.ZU1$SQ+)U:1$S7>7,:=IQW;0W
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MF:.D:W$G8VOE\;]E$7U&_ *YG,YEW$8C  "$@
M
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MU9%(CE1N43..C>GG-H *-T;_ &@-0?5V_O)"\BC='?V@=0?5V?O) +R
M                                              &DO>J;39;A145Q
MJXX9ZMVRQKG(F-RKE<KPW*;M%RF4X
M
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M^!U;X[1'W;?Q%>^N?"VFN1R9:J*G2A)AVB@9;+=#21/<]D281SN*F89UP
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M>?\ ]X,@U.E]/6_35JCMUI@;#2QYV6-YLJJ^M5-L
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M5T,C)&HN,M7)]D)
M
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MC='?V@=0?5V?O)"\BC=&_P!H#4/U=G[R0"\@
M                  *XY5_CJ7R4];BQRN.5?XZE\E/6XOZ;V0KU>*O<#F08
M)W9/68T9Z0.H<X'):KL-5<KO0U%.F8XUPY=V[<OC\9UC<[*)T'TO4.*'%:Q$
MS,?EU,Y\">,A0A)TAVW)3WXJOH4]I"TBK.2KOQ5?1)[2%IGF=5[&K1X@ ,RT
M                *?UY4S1ZBJ6LED:W/!'*A<!36O\ Y2576:NDYRIUN+1]
MMU'^/+Z:D=MU&/Z1+Z:GCG<#TL0S9>W;=1_CR^FI';=1X1+Z:GCUC Q!F5?6
MJ:5.4JI>DC]I<]UM+GX3BQTJJA?_ )B;TU."MUJJX]=5%6^)4@5,H_"X7>[G
M.W]13HUQ$Y_;N\^8>Z5=1X1-Z:D=MU'A$OIJ>2<-Q''<78AQE:_)9(^6Q5+I
M'N>O;*IERY_NM.R.*Y*.\-5]97V6G:GD:_LELT^,  *G8
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MDUSFM?\ MS:)QB;.FT1\F*'R#>&%9*Q:^V0U+H^Q+(F=C&,&:43NMC8 !"0
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ME'>&J^LK[+3M#BN2?O#5?65]EIVIY&O[);=/C  "EV
M                                #CN6#^KB]>0S]XT<C_\ 5Q9?(?\
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M*BMAC=M-7"YQP3I<6G%&V*)D;$PUB(U$\2$ZDQB(SF44CS,[/H %2P
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MB9 U6M5[FX7;D_15 +ZLMWH;W0LK+54-J*9_P9&HJ(N]4Y_&BF<:^QV:@L5
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MOK*^RT[4XKDG[PU7UE?9:=J>1K^R6S3XP  I=@
M
M  "ON5GXBA\MWJ0KCGW%C\K*9@H?+=ZD*WYCU>F]<,FKRD\03@$ZQU&A7!NR
M:76/R>JNI/6;LTNL?D]5=2>LXOQE-=V'R=?)BG^SV6G2YP<UR=?)BG^SV6G3
M<"-+A";;RCQG8<F/?W[/NN.0Z3K^3'O]]GW7'.MZY-/E"V0 >0V@
M    #SGGCIX^R3/1C.&5,7\KT'A49J]?62>_Z<GH:658YE7::J<ZHB[N*=)^
M?X=.+;+L^AU345-$U%5$G8UTC5WJG,J)S+SEVGIQ>/,JKWFL[/T;5UEGK(UC
MJW4T\?Z,C=I/,J'#:AT)I2Y.=-23MH:C.6]K[,;47?T-\9JZ'DEM]?3I-2:@
MDEC7G:Q5^^9'O,0?KN?_ "G?C.J]M=K(GNMO59ECIDH[7! DJRHQN-O.<F<8
M=HH4MUOAI4D61(TQM*F,F843NMC8-9J>J?0Z>N-5"N)(87/:OC1#9GA7TL=;
M13TLR9CE8K'=2B-R=E.Z:TM05FC:Z^W*-*RNG<[?,B/1N'JF[*93<O3S&RT1
M9:&\\EJ1UU/'(K87.8YS456KLKA4547'$T==2ZHTA35ML@IEK;7,Y71[.RBM
MR[/,BKQ5.?F,33=9JQ]@CT];;:^F8]O8I)WJF]J[E7#F[N/3S&N8F8F8G\L\
M3$3C#N^1:IE=8ZNCD<KF4U3(QBN7*X1V$3]A89H=$6!-.V&*B5_9)559)'8Q
MW;MZ\Z\YOC->8FTS"^D8K$2  X=           %&Z-_M :@^KM_>2%Y%&Z._
MM Z@^KL_>2 7D                                          !7'*O
M\=2^2GK<6.5QRK_'TODIZW%_3>R%>KQE7W,02G.1Q/59#UC]H1"47I)$<%!/
M!/&1@(.8GJ(3K!"7;\E/?>J^B3VD+2*LY*=UWJOHO]4+3/,ZKV-6CQ  9EH
M               4UR@?*2IZRY2F=?\ RDJ?*-?1\Y4ZW%SB9"=0QN&=QZ3*
M<Y*;R$W!0"$D=03]A"4H$W$<24W 6GR4=X:KZROLM.U.*Y)^\-5]97V6G:GD
MZ_LELT^,  *78
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MDG[PU7UE?9:=J<5R4=X:KZROLM.U/(U_9+;I\8  4NP
M                                       I'^4O_1[#]:9^\:7<4C_*
M7_H]A^LL_>- MK2OR:M7U6/V4-H:O2OR:M7U6/V4-H
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M03SD=(W(0EV_)3WXJ_HD]I"TBK.2KOQ5?1)ZT+3/,ZKV2U:/$ !F6@
M         !36O_E)4]9<I36O_E)4]9KZ/G*G6XN;4(.8(>DRG/SA">)"*$@!
M/VD" G ($)%J\E'>&J^LK[+3M#BN2?O#5?65]EIVIY&O[);-/C  "EV
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M:M2WB6X0LDN$[FJ[>BJF\YOQF=95_G.G\H3IUQ/@BT_M?8 /&;0
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M!TD[E("!+MN2GOQ593_<I[2%IE6<E/?BJ^B3UH6F>7U7L:M'B  S+0
M          IG7_RDJ>LN8IK7_P I*KK-?1\U.MQ<XFXA><!#TF4Y@@"D"2%)
M3AD@)/\ 0( 2A:G)1WAJOK*^RT[4XODH[PU7UE?9:=H>1K^R6W3XP  I=@
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MPP.D$"?M,VR;KI3^482<ZF=94S<Z?RCFVTD;K[ !XC>
M "ON5GXBA\MWJ0K<LCE9^(H?*=ZD*W0]7IO7#)J\CFXDXYB,@T*@ )SA(A)
M3B0A*<.)U_)CW]X\WW7'(>,Z_DQ[^_9]UQ7K>N7>GRA;( /';0
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M*VN,>  '+H           HW1R?\ Q Z@^KL]N0O(HW1O]H#4'U=G[R0"\@
M     #1:T[QR=?W5-Z:+6G>.7K^ZH%7("2$Z@!/-O" ", D 1SJ3@CQA% V%
M@S^6:7RRW6_!3J*BL'?FE\LMUOP4Z@)                   KCE7^.I?)3
MUN+'*XY5_CJ;R4];C1TWLA7J\5>\5' 8'.IZK(+XPA.  YR$"$D"!T[B<$$C
MM^2KOO58_P %/:0M(JSDI7^>*KZ)/:0M,\OJO8U:/$ !F6@
M  !37*!\HZGRBY2FM??*2JZS7T?.5.MQ<X1P'[ >DS)(3G',.;<A 8"*$',2
M@R3GH(3AN"X(2M3DH[PU7UE?9:=J<5R3]X:KZROLM.U/)U_9+9I\8  4NP
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M!Z@HR0"'7\F.?R\O5]UQR'4=?R8]_OL^ZXJUO7+K3Y0MD 'D-H
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MMJR&9KW(W*)G"+PWIYS9 "C='?V@-0?5V?O)"\BC=&_V@=0?5V_O) +R
M    -%K/O'+U_P"BF]-%K3O'+U_Z*!5W%1UD\Q" .8GJ P! 3@$\8 $D8\8Z
M0-A8._%)Y9;K?@IU%1:?[\4GEENM^"G4!(                  %<<J_P =
M2^2GK<6.5ORL?'4ODIZW%_3>R%>KQE7R<X0(.L]5D,X)XD;@2@3 XDXW$($I
M3QJ020@';<E/?BJ^A3VD+3*LY*N_%5]$GM(6F>7U7L:M'B  S+0
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M9J6V1W&R57;-')G9D[&YF<*J<'(B\47F-J>%#14U! V"CA9#$W@QB81#W
M   !HM:=XY>O[JF]-%K/O'+U_=4"KD',,<1S ,9&>;( $D)P' <X#> 2!GZ?
M[\TOEENM^"G45%8._-)Y9;K?@IU 2                  !7'*O\=2^2GK<
M6.5QRK_'4ODIZW&CIO9"O5XRKX@GB,'JLB.8#FP3T@03U$<Q*+@@1S;UWA I
M/.2.UY*>_%5]"GM(6F59R4]^*KZ%/:0M,\OJO8U:/$ !F6@
M  !36O\ Y25767*4UK_Y256>DU]'SE3K<7-Y',%Z0AZ+*$[R!S;R1*$;P%0)
M G2 B;@+4Y)^\-5]97V6G:G%<D_>&J^LK[+3M3R-?V2V:?&  %+L
M       !\3?$O\E2G)JB;LCL2R>DI<<WQ,GDJ4O-\:_K ^NV)L?'2>DH[8F_
MQ9/24\P@'IVQ-_C2>DI7/+#)(Z"VHY[G8F;Q7/\ >0L$KOE>^(MWTS?:0#N[
M'/,EGHL2O^)9_>7H,[MB;_&D])36V3O11?0M]1F@>O;$W^-)Z2DMJ)E<F)9.
M/Z2GD2WBG6!;UB55LU&JJJJL3=Z]1G&!8.\M%]$WU&>
M  &AUW\D[AY+?;0I1,%UZ[^2=P\EOMH4HAZ71\)_UFUN25(7<.;>/6:E)S*.
MH<.).24";R$)3G"< E!FV7OG3^481FV;OG3I_P 1S;:2-U^  \1O
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MR4]]ZK'^$GM(6F5;R5+_ #Q5?1)[2%I'E]5[&O1X@ ,RT
M *:U_P#*2IZRY2FM?I_XCJNLU]'SE3K<7-DYY^!',#T64W8"<22"4I3G(4(3
MS$!S$)S@(2A:G)1WAJOK*^RT[4XKDG[PU7UE?9:=J>1K^R6W3XP  I=@
M           /B;XF3R5*7F^,=UET3?$R>2I2\WQCNL#XY@2F]%(W .;<5WRO
M?$6WZ9OM(6)O^PPKG:J&YM8E?3,G1BY;M9W+D";)WHHOH6^HS.=3YAC9#$V.
M-$:QJ;+43F0^@!+>*=9&"6\4ZP+>L'>6B^B;ZC/,"P=Y:+Z)OJ,\
M           -#KOY)W#R6^VA2O475KOY)W#R6^VA2J]9Z71\)_UFUN2$W9'!
M5&0AK4@)4<.! <Q',$0)SDH.8SK+WS@\HPD,RR]\Z?RCFVTNHW7X #Q&X
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M<"4(3)/ @0IV/)EW]^S[KCCLG8<F.^^KGH^ZXJUO7+K3Y0MD 'D-H
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M/1Q";B!VO)3G\L52?^2GM(6F59R5=^*KZ+[R%IGF=5[):M'B  S+0
M         IG7_P I*KK+F*:U_P#*2IZS7T?.5.MQ<X@7]A!)Z3,A!Q'6$XA
M@!/20E',$&_[!S$BU.2CO%5?65]EIVIQ7)/WAJOK*^RT[4\C7]DMFGQ@ !2[
M                ?$WQ,GDJ4O-\:XNB;XF3R5*7F^-=U@?&!O)(X\0)ZR$X
MJ21C" . W8&_G";@"]9+>*8Z02WX2=8%NV#O+1?1-]1GF#8>\M%]$WU&<
M                &AUY\D[CY+?;0I4NK7?R3N'DM]M"E#T>CX3_ *S:W(7B
M$ 4V*4\RD +SD(,DH0G!<DXPA(&;9>^E/Y1@KXC-LO?.G\HYMM*87X #Q&\
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M0"5 A.<D@<X#I 0<X$AGPDZR"6IW2=8%O6#O+1?1-]1GF!8.\M%]$WU&>
M                &AUW\D[AY+?;0I3U%UZ[^2=P\EOMH4H>ET?"?]9M;=."
M.;B3OX$&M2#I 10@0( 0E/.9EE[YT_E&$AG65?YS@1?TB+;21NOL 'B-X
M               *^Y6?B*'RW>I"MT+(Y6/B*'RG>I"N#U>F]<,FKRD(P$!H
M5" *$\9"1.("<PZR01#L.3'O]]GW7''G8<F'?W[/NN*M?URZT^4+9 !X[:
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M',$) CSCF)0A-R ;#3_?BD\LMUOP4ZBH;!WXI/++>;\%.H"0
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MS$D)6GR3]X:KZROLM.U.*Y)^\-5GPE?9:=J>3K^R6S3XP  I=@
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M)P',$\0YMP#@=AR8IB^_9]UQR&\Z_DQ[^KE>;[KBO6]<NJ<H6R #QVT
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MCF)0)6GR3]X:KZROLM.U.*Y)^\-5]97V6G:GD:_LELT^,  *78
M     #XF^)D\E2F)D_.OSTESS?$R>2I3$WQCNL#S1-RA0G/@D"!DDC@ 0D<P
M @EJ]TG6.<-^$G6!;U@[RT7T3?49Y@6#O+1?1-]1G@
M!H==_).X>2WVT*4Z2Z]=_).X>2WVT*53@>ET?"?]9M;DC@@ -:D)(3B20&"$
M0D9)$81#.LW?.GQ^D8)FV1?YS@\HYMM)&Z_  >(W@                  K
M[E9W04*_\;O4A6Z+U?:61RL_$4/EN]2%;GJ]-ZX9-7E( I*FA4(G21U#G4($
MA/-@$)N '8<F/?[[/NN.00Z_DQ3^??L^ZXJUO7+K3Y0MD 'CMH
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MH! SNX <0"(.8E.@A -AI_OQ2>66ZWX*=145@[\4GEENM^"G4!(
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M!-P';\E7?BJ^B3VD+2*LY*>_%5G_  4]I"TSR^J]C7I<0 &98
M     %-:_P#E'4^47*4UK_Y25/6:^CYRIUN+G$X;R-_ G)&<H>BS',$Q@<Y/
M,2A&-PP!UA(B<1QXA<!$YPA:G)/WAJOK*^RT[4XKDG[PU7UE?9:=J>1K^R6W
M3XP  I=@               /B;XF3R5*7E^-?UET3?$R>2I3$WQKP/@A% 3<
M YB2/L) CG',3N\X3Q@02WX2=9"<Y+/A)U@6]8.\M%]$WU&>8%@[RT7T3?49
MX                   :'7?R3N'DM]M"E2ZM>?).X>2WVT*4/1Z/A/^LVMN
M;N<8R FXUJ1"4X!""4&=^%'6@]8R!.3-LW?.G\HP4X*9ME[YT_E'-MI3&Z_
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M,86'I26:;3]"^H55D[&B;TQNYC;'S#&V*)D;-S6-1J=2'T9I\RO@ !"0
M              "C='?V@=0?5V^W(7D4;HW^T!J#ZNS]Y(!>0       !HM9
M]XY>O[JF]-%K3O')U_=4"K^D@;^8*!* A-R#A@"4(P,<0 3<$X!. Y@-A8._
M%)C],MUOP4ZBHK!WXI/++=;\%.H"0                  *WY5_CJ7R4];B
MR"N.5?XZF\E/6XT=-[(5ZO&5?=1&-Q* ]5D"$X*!SKN"!,\Q)">,)SD)2@YB
M">O@!VO)3WXJOHD]I"TRK>2GOO5?1)ZT+2/,ZKV-6CQ  9EH
M    4UR@?*.JZRY2FM?_ "DJNLU]'SE3K<7-\P3QC'.3]AZ+,9(!*(!'2 3U
M 1O0D@=/,2+4Y)^\-5]97V6G:G%<D_>&J^LK[+3M3R-?V2V:?&  %+L
M          !\3?$R>2I3$WQK\=)<\WQ,GDJ4Q-\:[K \_63Q(P2GB @DA%W#
M&X .8<. 0!S$L7NDZQSDMW.3K MVP=Y:+Z)OJ,\P+!WEHOHF^HSP
M           T.N_DG</);[:%*9+KUW\D[AY+?;0I3]IZ/1\)_P!9M;<!*CFW
MFQ0<Q Y@F\)$]1.",$\Q @S;+WSI_*,/@9ME7^<Z?RB+;20OL 'B-X
M            *_Y64_,4.?TW>I"M^LL?E9^(H/+=ZD*W7CQ/5Z;UPR:O(3G"
M$INR-QH5H', GB"#F)7K' @!U\3L.3'O[OZ/NN.07B=?R8I_/WV?=<5:WKEW
MI\H6R #QVT             <]KR]5%AT]+74<*S2L<B;*=&%\2]!55#RLW^N
M56TML[(Y%QLMD15\VP7E4P15,+HJB-LD3DPYKDRBH5QJ'D[EI:M]STA5.H*O
M>JQ-=L1KO5>#6YY^GF+M*U,8M"J\6WB6B3E$U9^HI?/_ /@1[XFK?U%+Y_\
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M$\84 A)!. ,^P8_+%)Y9;K?@IU%1:?3^>*7RRW6_!3J D
M   "M^5CXZE\E/6XL@KCE7^.I?)3UN+^F]D*]7C*O<[@HW@]9D!Q)48W 0@Y
MAU$\X0C[0@)WD)=KR4]^*KZ)/:0M,JSDJS^6*KZ+[R%IGF=5[&K1X@ ,RT
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M4_YSTW^>_P#_ &SJT=V]H16>W:LKB!A6:&J@ML,=PE26J:F'O1<HJ^8S3.N
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M/.$WD<P)$CF(',!L+!WXI/++=;\%.HJ+3_?FE\LMUOP4Z@)
M      K?E7^/I?)3UN+(*XY5_CJ7R4];B_IO9"O5XJ^7<1TCB.!ZS($\Q"A
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M]UQ7K>N76GRA;( /';0
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M]TE3UERE-:_^4E3Y1KZ/G*G6XN;3G',,\0G#>>DS"<!TCJ'!0@3@%XCGWC@
MYB=P(7<I"5J<D_>&J^LK[+3M3BN2?O#5?65]EIVIY&O[);-/C  "IV
M          ^)OB9/)4IB;XQV.DN>;XF3R5*8F^->!YX)(#>&\ .<#?P $]0(
M0!TDM^$G61U$M^$G6!;U@[RT7T3?49Y@6#O+1?1-]1G@
M  !H==_).X>2WVT*4WEUZ[^2=P\EOMH4ISGI='PG_6;6Y"+S!$"\0G#',:E(
MF]%P,] !(E B[@0 13-LO?.G\HP^!F67OG3^4<VVDC=?@ /$;P
M        5]RL_$4/EN]2%;\47!9'*Q\30^4[U(5PIZO3>N&35Y2CF !H5)(R
M$W<!XP(/K=@A-X1 ).OY,>_OV+[+CCT.PY,>_OV?=<5:_KEWI\H6R #QVT
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M4).OY,>_OV?=<<>G#<=CR8]_?L^ZXJU_7+O3Y0M@ 'CMH
M                   !R-]_K(TO]7J_98=<<YJ:UULERM]XM3(YZZA;)&RG
ME=L,>DF$55=S8P!AI_6V_P#Y&G_^PI/*M\C)_K%/^^8>]@MEQFO\E]O<4-+6
M=K=I-IX).R,5B/VT?M83?E53'B/:\6JKU#IJ:CN+8Z2H=*CT2)VVF&2(YN]<
M<=E,]&0,+E$^%I;_ )Y3>IYUQQKJ"_7ZMM[;]1TE!34-2RM8^GG65SWLRB,5
M%1,(J.7?XCL@!^<-07^3D\Y8KG=[E:JVJI*N%K8UIT;^D]>=4Z3]'GE-303K
MF:"*14YWL10*=I^7NDJ(TD@TG?WL7G1(OQGI[^D'S0U!YHOQEN-HZ5J8;30H
MGB8A/:E/X/%Z" 5%[^D'S0U!YHOQCW](/FAJ#S1?C+=[4I_!X?00=J4_@\7H
M(!47OZ0?-#4'FB_&/?T@^:&H/-%^,MWM2G\'B]!!VI3^#Q>@@%1>_I!\T-0>
M:+\9KK]RRQW*WNIXM)7YKE7BY(L<%3]+QEW=J4_@\/H(.U*?P>+T$ _,7N[F
M^;-X\S/Q$>[N;YLWCS,_$?I[M2G\'B]!!VI3^#P^@@'YB]W<WS9O'F9^(CW=
MS?-F\>9GXC]/=J4_@\7H(.U*?P>+T$ _,7N[FQ\F;QYF?B(]W<WS9O'F9^(_
M3W:E/X/%Z"#M2G\'B]! /S#[NYL?)J\>9GX@FNIL+_X9O'F9^(_3W:E/X/#Z
M"#M2G\'B]! /S5;.4.2EKH9WZ8O+FQNRJ(D>5_ZCN$Y<X$1$]R&H/-%^,MWM
M2G\'A]!!VI3^#Q>@@%1>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*?P>+T$':E/X
M/%Z" 5%[^D'S0U!YHOQCW](/FAJ#S1?C+=[4I_!XO00=J4_@\7H(!47OZ0?-
M#4'FB_&/?T@^:&H/-%^,MWM2G\'B]!!VI3^#P^@@%1>_I!\T-0>:+\8]_2#Y
MGZ@\T7XRW>U*?P>+T$':E/X/%Z" 5%[^D'S/U!YHOQCW](/FAJ#S1?C+=[4I
M_!XO00=J4_@\7H(!47OZ0?-#4'FB_&/?T@^:&H/-%^,MWM2G\'B]!!VI3^#Q
M>@@%1>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*?P>+T$':E/X/%Z" 5%[^D'S0U
M!YHOQG*ZSY3UOLD+J?2U[CV$1%[(D?CZ'>,_0_:E/X/%Z"#M2G\'B]!#JEYI
M.81,1,8E^4DU;4_-N[>9GXB/=;5?-R[>9GXC]7=J4_@\7H(.U*?P>+T$+OJM
M3]J_BJ_*/NMJ?FY=O,S\1/NMJ<?)RZ^9GXC]6]J4_@\7H(.U*?P>+T$)^JU/
MV?#5^4?=;4_-RZ^9GXA[K:E$^3=U\S/Q'ZN[4I_!X?00=J4_@\7H(1]5J?L^
M*K\H^ZVI^;EV\S/Q$^ZVI^;=U\S/Q'ZM[4I_!XO00=J4_@\7H(/JM3]GQ5?G
M'1O*2^Q5TT]1I>]2->S91&)'GCGG<=C[^D'S0U!YHOQEN]J4_@\7H(.U*?P>
M+T$*KWF\YE96L5C$*B3ET@^:&H/-%^,>_I!\T-0>:+\9;O:E/X/%Z"#M2G\'
MB]!#A*HO?T@^:&H/-%^,>_I!\S]0>:+\9;O:E/X/%Z"#M2G\'B]! *C]_2#Y
MH:@\T7XR/?T@^:&H/-%^,MWM2G\'B]!!VI3^#Q>@@%1>_I!\T-0>:+\8]_2#
MYH:@\T7XRW>U*?P>+T$':E/X/%Z" 5%[^D'S0U!YHOQCW](/F?J#S1?C+=[4
MI_!XO00=J4_@\7H(!4?OYP?-#4'FB_&1[^D'S0U!YHOQEN]J4_@\7H(.U*?P
M>+T$ J+W](/FAJ#S1?C'OZ0?-#4'FB_&6[VI3^#Q>@@[4I_!XO00"HO?T@^:
M&H/-%^,X/4NOY;M=9JJ'3-Y8QZY1')'GVC],]J4_@\/H(.U*?P>+T$.Z:EM.
M<U<VK%O$ORC[K:GYN77S,_$/=;4X^3EV\S/Q'ZN[4I_!XO00=J4_@\/H(6_5
M:G[<?%5^4?=;4_-NZ^9GXB?=;4_-R[>9GXC]6]J4_@\7H(.U*?P>+T$'U6I^
MSX:ORDFK:GA[G+MYF?B'NLJ?FY=O,S\1^K>U*?P>+T$':E/X/%Z"#ZK4_9\-
M7Y2]UM3\W+MYF?B'NMJ?FY=O,S\1^K>U*?P>+T$':E/X/%Z"#ZK4_9\-5!Z+
MY6/R#;9J:HTI?)7/E61%C2/&,(G.[Q&_]_2#YH:@\T7XRW>U*?P>+T$':E/X
M/#Z"%-K3:<RLB,1B%1>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*?P>'T$':E/X/
M%Z"'*51>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*?P>+T$':E/X/#Z" 5%[^D'S
M0U!YHOQCW](/F?J#S1?C+=[4I_!XO00=J4_@\7H(!47OZ0?-#4'FB_&/?T@^
M:&H/-%^,MWM2G\'A]!!VI3^#Q>@@%1>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*
M?P>+T$':E/X/%Z" 5%[^D'S0U!YHOQCW](/FAJ#S1?C+=[4I_!XO00=J4_@\
M7H(!47OZ0?-#4'FB_&/?T@^:&H/-%^,MWM2G\'B]!!VI3^#Q>@@%0OY<H'1N
M:FD-095,<(OQG!/U[,YRN]S-XPOB9^(_3?:E/X/%Z"#M2G\'B]! /S#[NYL?
M)J\>9GXA[NYOFS>/,S\1^GNU*?P>+T$':E/X/%Z" ?F)-=S8WZ9O'F9^(A-=
MS?-F\>9GXC]/=J4_@\7H(.U*?P>+T$ _,7N[F^;-X\S/Q$>[N;YM7CS,_$?I
M[M2G\'B]!!VI3^#P^@@'YB37<V/DU>/,S\037DJ+\F;QYF?B/T[VI3^#Q>@@
M[4I_!X?00"FK;RV14MOIX'Z1O[G1L1JJB187'_K,CW](/FAJ#S1?C+=[4I_!
MXO00=J4_@\7H(!47OZ0?,_4'FB_&3[^<'S0U!YHOQEN=J4_@\7H(.U*?P>+T
M$ J+W](/FAJ#S1?C'OZ0?-#4'FB_&6[VI3^#Q>@@[4I_!XO00"HO?T@^:&H/
M-%^,GW](/FAJ#S1?C+<[4I_!X?00=J4_@\/H(!47OZ0?,_4'FB_&/?T@^:&H
M/-%^,MWM2G\'B]!!VI3^#Q>@@%1>_I!\T-0>:+\8]_2#YH:@\T7XRW>U*?P>
M+T$':E/X/%Z" 5%[^D'S0U!YHOQD^_I!\T-0>:+\9;G:E/X/%Z"#M2G\'B]!
M *B]_2#YH:@\T7XQ[^D'S0U!YHOQEN]J4_@\7H(.U*?P>+T$ I#4?+(RZ66J
MHX=)7YCY41$<Y(L)AR+^EXC@$U;4[_\ PY=O,S\1^KNU*?P>'T$':E/X/%Z"
M%NGK6TXQ5Q:D6\R_*/NMJ?FY=O,S\035M3CY.7;S,_$?J[M2G\'B]!!VI3^#
MQ>@AW]5J?MS\-7Y1]UM3\W+MYF?B'NMJ<_)R[>9GXC]7=J4_@\7H(.U*?P>+
MT$'U6I^SXJORE[K*GYN7;S,_$1[K:G/R<NWF9^(_5W:E/X/%Z"#M2G\'B]!!
M]5J?L^*K\H^ZVI^;EV\S/Q&1;]9STU7',[3=V5&+E41&97_J/U-VI3^#Q>@@
M[4I_!X?00?5:D_E/Q55%[^D'S0U!YHOQCW](/FAJ#S1?C+=[4I_!XO00=J4_
M@\7H(9UBHO?T@^:&H/-%^,>_I!\T-0>:+\9;O:E/X/%Z"#M2G\'B]! *B]_2
M#YH:@\T7XQ[^D'S0U!YHOQEN]J4_@\7H(.U*?P>+T$ J+W](/FAJ#S1?C'OZ
M0?-#4'FB_&6[VI3^#P^@@[4I_!XO00"HO?T@^:&H/-%^,>_I!\T-0>:+\9;O
M:E/X/%Z"#M2G\'A]! *B]_2#YGZ@\T7XQ[^D'S0U!YHOQEN]J4_@\7H(.U*?
MP>+T$ J+W](/FAJ#S1?C'OZ0?-#4'FB_&6[VI3^#Q>@@[4I_!XO00"HO?T@^
M:&H/-%^,>_I!\T-0>:+\9;O:E/X/%Z"#M2G\'B]! /SYK3E26_1T[:;2M[C6
M)55>R)'OSU..4]UM3\W+MYF?B/U=VI3^#Q>@@[4I_!XO00NIKWI';#B=.MIS
M+\I)JVIQ\G+MYF?B'NMJ>'N<NWF9^(_5O:E/X/%Z"#M2G\'B]!#KZK4_;GX:
MORE[K:GYN7;S,_$1[K:G/R<NWF9^(_5W:E/X/%Z"#M2G\'B]!!]5J?L^&K\I
M>ZVI^;EV\S/Q$>ZVI^;EVQU,_$?J[M2G\'B]!!VI3^#Q>@A/U6I^SX:ORDFK
M:GYN7;S,_$;S2'*-)9;CVQ/IB\R-QP8D>>"ISN\9^D>U*?P>+T$':E/X/%Z"
M'-NHO:,2F-.L3F%1>_I!\S]0>:+\8]_2#YH:@\T7XRW>U*?P>+T$':E/X/%Z
M"%"Q47OZ0?-#4'FB_&/?T@^9^H/-%^,MWM2G\'B]!!VI3^#Q>@@%1>_I!\T-
M0>:+\8]_2#YH:@\T7XRW>U*?P>+T$':E/X/%Z" 5%[^D'S0U!YHOQGO0\MD-
M75QP)I._1J]<;3DBPG_66MVI3^#Q>@@2EIT7*01(OD(!ZQNVV-=A4RF<*2
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MRNY<;*[N<Z6TT,&G-2:;I+.U\%/=8)GU;72.D[(L<;58N7*JMPKG<,9SO L
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M-<Q<M<F47I0DYKDW57:.H5<JJN9=Z_2O.E
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M4W(FXV( YFYT53?[O%!40OIK9;JB.H1[DP^:9BHYJL7>BQ[U1>"YX'3
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MG5N%7.-ZISG0 #7V"V1V>T4]#"][VQ(O=.7*JJN5R\R<ZJ;
M
M
M
M
M
M
M
M
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M;U17VB2KMLR2P+N1R8-B55_)N_J]A\I/4A:IQ:,3AU$YC( ,ITH0D
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MH#F=(:NBU)4U\,5(^!:25T:JYZ.VMEV,G3$S$Q.)1$Q/F  $)
M
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M53&)PLB<QD !"0            !17\I_^BV;H[.SVC1VSO;2_1,]2&]_E/\
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M7RY<KNV9G2*SN6JF,\,Y_8=-J!KJ3EDM$U4OYJ6'9C5=^%5Z[OV*=36,Q/\
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M>SG9V4QDJU,>)A93/F)?8 *E@
M                                                       !0/\
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M[%L[^AJX7BO%.<[< BUIMNF*Q&P #E(
M
M
M
M
4                        _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g12080g07t84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g07t84.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[1?64&AO=&]S:&]P(#,N,  X0DE-! 0
M    %[D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@K+A\!8E-D-S=$53DM(()E1CHO%$@\)DXB?_Q  : 0$! 0$! 0$
M     0(#! 4&_\0 +!$! 0$  00!!0 " 04! 0$   $1 @,2(3$$$Q0R05$B
M87%"@9&A\%*Q!?_:  P# 0 "$0,1 #\ ^A>+X_HNY^H/\2\P;/,J+T_B[^J[
MGZ@_Q+S!ORM1?3^)Z?-^1[0:/BRJNI5P^3*IB"5]!Y.)@0FA"CJ0W1"8W*<(
MRC" I0B$$80I0B%1%"D6HA!$!"E"$$8T0I940H(PB%*$ ;H$$E*(1"",(A2
ME$("-%&%.-$H5$0$^B>5$:*",(A2 E$((ZA$*8"(00A$*<:) ((HA2(0@C"
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MNA!+9*$H* #W020HZHU02"51 1ONJRK:[56C9(-'8(1#A"73="*$X2^U&O=
MT;I >: % Y1*0W* @80EJA4-'1)"!A"28W0"8"CWU0#""6B%%"!RCNDA ^B2
M$="HL$=4 0@20D)A X0EKYH,PAIH TU2U1![H&B)1MYI:@(& E"-93* A$)0
M>Z8E  (A"4'N@<(2U1J.Z!G9$(G391$SU02$R@"0EJF- BB$ )24]0B! 0"E
M/D@:4)]$ P-D4!!GHD=T!$/HB$!'= 0B$C*8![HNC5"1GS30*(1$HZIQ (E
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M4)@(A"!=4^B4)]$ DFCHB! 1$HA$"28!0BF(C5*$PCNJA0(30A 0B!*$2@"
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M6_FY$]4-;$ZJ=#]&/JD0OH/'Q)$)H4;1"8"-)31-*$ )H"!0B/-,#="!(A-
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M]'/JA%($6YGNB.Z^@\<)-,#L@A1N$ F@)@=T0D 0F0@B$"0@E) 0FCU2G5
M0FE(3!0 "$I3E (2E.4-"$2$2AH2A.91(0"$@1)3!3#0A*0F"$PT0B$2$ A
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M1K"*E [H@=U$;(U1$H;W3@=U6GKW02AO=$!0UU3$H)".Z-.ZAU1K*"P!O=*
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M3);JX..BN7V8VC&DM#HT(D(S, U*YO%N(6VETRB&ORYRS1\#0K>V=Q3N;(5
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M581-)[QNT*&'GGW#FU-1EE381E+#\Y%!HHU7.D1$3LI^ECSSVIXX^TJ&VH/
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M:<F0>H70\<<9#&J3K:TL@XU*8;-*MG@AT[!J;7>6SPU' V)U:]>\M;EP+:+
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MGT*[]9\3S_);ZE7J.J.$C;LL6M1;5TJ[1T6_JR^+''[6552XF+R9HN9ZU/\
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MV.'/X[7V?%3V";BW;2$ZE]2(^\+:67%-A<U,C[RS8=-/A#?YK6W.%V%Q+*M
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MN'T231"J6!'VH 0B!).-40@.B03A/* FF$A2 1 0034H$*!!.B 4ALAK>Z9
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M0 1&JE!1"J:4A-13A#32=,;(4WP&_8B7RJ9/9-TQLITH/12J1!T34RJALK&
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M2T]PIF,V.AY-6G7=SV%M"-'>?^I6+;O9<SR3F ,&%RE#C7E#F75.YN*1T S
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M18G!]Z15%L7.T:YV^FZWRG=Q:X^W7G=#M!HG4;#0?*5*E#F!<I6K$6@$$E,
M0HCLFJYPX" !W20BZ<#NB DB433@(@)(G5 0$LH042BQ'9-"(1LBK+<2_P"Q
M0*MMAXECGZ)[=S@FE%OHU;F5IL%^2;Z-6YA?)ZGY/I]+\6HXD_0:WU!^*X8>
M\]=SQ&/S"O\ 4'XKAG'*3UE>GX\UYOD>R;\D56.JL=X;=Q\U!H\,SNOH/'"
MT3C1-"D6PFB2GE[IB 9T4LX[*LXB&I93U4PX=D9A*"&5 :IYQV0' (B&30J
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MC=?H7^.[.(4K=V5K_O:5:QU.KXVDFH-6^J^<\:XLQ*[NW.I-OJ @>$5G+O\
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M $=P43[C?1#M*9;\[L@GP#T7O>,AJA$H,(NB=$LR8UT"8:B(YD9E+*4LNB!
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M<(@(1*(2&B::(275.)0@!U23A "!#JF!"<(0(!+T3A'64"* G"(0$:)!22A
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M,6EV][:YY5-A&9K1N'=CY+C>,O:(<.X@K6K/A(:UC3#6L(U'FI_RU./\>L.
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M;38VXT);1&\NT6I<<K+%-!KLA)'50!=S7!VRNJ5/@QR,8:X=KF9J C(,O-)
M+OF=0JYR[<0E)/(3L2@ C=(U8;=]4T@V3*>4HS @HB$;J-R#H@'1!"21+$@@
M>2CJI-=/S2%IS 3ZI&4A)ZE35G&G"(4S1:1I<,GM*K-,M)^,#O1)B;1E"("8
MJ93JPE$YB2&P#T1KRC" $:]D:]BBY3 3T0&R)S!ODC(/IA-3*4! T3#1/OA(
MM[&5%DII) $)R C4T(4FC/L8C7U4*E<@%HMWGS 47/!^B"BE3<\%Q.7K!3-3
MQ9.4>^:%IBQ%"E([(D#HB1'J$T%+8*-8: E![IA%P=4%$%&4H8 @( ,*&NNI
M1+X6)#LH0>Y1K.Y5Q$]$0ANVJD-U%1C="E$)1H@4)J(F>JE&B)@C[DA$J,D.
M&OV=T%YS$<LQWA5<2]$TKAD>Z\#38*VA3YE(!W@@3F/53216A5N,.@'-Z*37
M$#5A1I)"@VI#O&"T=W:!1IFC5<[+>T9!]W.)/ENHN+$GU*5-A?<.RTA[QC8+
MC..>,?\ 9K,#9U[D![6YJ;X!EI/9:_ACC8<3O-HVQKT.8_EYGOS :3V6I#/V
MZ+%^+,)LZG+IW@D. @TGGIZ+'Q[$+F]P&Z?AX95(+6B1&N8=XZ+DN*^"[Z[Q
M.H^A=N:SF @-IN/3R*[SA?!WV-E4IWKQ7::A<0]NA$#OZ+7B1=>-V@XE?C5?
ME65$M%0?.;W^LO7L0P;_ &DPA^%8NU[*]1X?DI. , R#.H6V&&69K.?1MK>F
MXF26TP"5E 9:O,;I4B,PW^]9MTUIL!X<P[ [>K;V#ZYK.:UA;4=/B:" -AU*
MV],,?;##;TEE=AYA8W<=M=NJD&C.7QXYF>L]T%H-8U2)JD07G<CU64(9@YHC
MPMT^Q*C294NZLDS"L@ZI-:6N)&A[A:<U-,\FX8YG3753N:KG>,QJ5+)Y?N06
MR((T01+W<HQ"=.7-,]D\D".B T]-$,*G[JDEE(1![E1N'L@I 'NF&E NB$X*
M4%% 31E*4'S1BI)%$%&4HA#8H:$\I[H@JF#9*493.Z>51231!0&G75$P)Z0E
M!1!0"$H*EE/=5*2/1/*EE*&G\U18-4R" DP%1I,[*5%1<#"E0'@\UGEZ61UV
M$?)M_NK:K4X/\D/[JVR^=S]O?T_37XS^C5/JC\5Q3_EZGJNTQG]%J_5'XKBW
M?+5/5=NAZ<NI[-0:-2IE1!U*]D>;FD HY5(%1G=:<^)!H3C1$Z(!A1NE&B8$
M(S>26^B(D2B4@W=&4H&':J690#4RT^:(">RDUPA1(/9,-T4K<?*GM7/_ ,P6
M_P#VP_QO7/X%^EC[/Q6_]JO]?V__ &P_QN7/X'^E#[/Q7DX?F^O\;W'N-F[X
MG[5?*Q;4_$_:LD>[OT7MY/M],24I1T45&UE-S0XDJ-)S>54'=(QDF0A@ !DA
M#%M!S6#7LNT=C-+X*]N<S]5<2,IT#@DZJ[*8+H]5CEPG)+PUL,3NN=6<6F1F
M/18;-1XE53=),_O3>Z- M29X3MSPVF$5:=O5<22)<T_BMOB^*TZEKE#S[P/N
M^JY-E0M.I(GS5CG\QL9OWRLWA+=9[/+/PK$&T:\YH&<'9=30QJWK_%UGDM G
M1O5<(QH8=PI<XTW%P<>VZG+ISDMX2^7;NQ*P;LY__I*U%]?6;WDASO>[%<^:
MSG=3]Z0<';D?>I.GA.,CM*>*V;<,J4V/=G+I'A/<+46E_3;>N?F/OSMYK2&K
ME'O:>J5,ZEP/FK.G(=L=IBV-4JE!S0\]/FK'PK%J5)SCG(DCYJY*I5-1\2=N
MZD7E@$$Z^:GTIF)VS,=7BN+TZE5QSGI\U9=EC5"K3<RH\D'3W5PQ<Y[C)/WJ
M9<:0)#C]\*_2F8S]..[;<X>UY>2^3Y%8F-\04ZM![65#JT?,\UQ7.JU"<KW]
M]'%%(N>PYB3KU4G2GNDZ<=3PKBC*5W=/<^,S1\WS2Q^^IWKBUKB9 Z1U7,T:
MAI.=EG730PI,JEM0%Y/VE:^GY[E[)NMW@%W1M*U3,2#F;TG8E=-<XU;7 +'O
M<>OND+SQKRVH]TF'&=U8:CCJUY^PJ<NG.5TO"5W]"^P^U!J!SP?>V)6DXBQN
MG=YVTWDMS B6QT7-&N]PRFH[M[RK#3FB2X=U./2DNTG3GMZ&,=I"U-,O,D?0
M6DP[$V4<8NJN8@.;'N^87-&NYUQ3 +OO14J%E5QDR?-)TI/!.G'H=3%+&[IN
MJ5GN+]M&D:*[#L4PZ@YQ:YX,#YI7G#*CVT'34<#.TJME:H"8J./]Y3Z$SVQ>
M$]--[:<0IWV-W(I.)FG2W$;*7"@(M/\ ^G3_  *YWC)KJN+5'N<?<;OJN@X<
MJ1;$ 3#&;'R*[<>';Q:X<?+>50Z-%997=6E,$#7LJ:=0NZ(I'Q;=5'3LU?4N
MZE6X?G((]%CPXN$)U02XY1KY*#'$'8I%DQ;+FK.;?O9;.&;2>RU\.?L"G5IO
M%%WA=]RF2F+*CS5EQUG55,N:]OX6$#[%#,Y@9H=5)I+JL%G1:D9L;.VQFY#0
M"]ND?-"5UB]>I+7/$;^ZM7S,KCX>J3LU0DAIU4[(<9&6&9#S!N-5FVN+7#!E
M:]N@^BM6'.(B"H\TTB98>W93MWVMFMF['+Q]9LU&Q'T0HW=W5KL87D'6=E@N
MJ F0P?8H/J.CW')VQ,C.;B=:WHD,<!!^BJ:E1UP,QU)U/VK':\.;#@!ZJ5(D
M%VAA7,)-6T:E:@?"0%FMQFYHB0]H_NA:ZI4U]U#GRT^'HI9+[7MUENQBO5KN
M>YX)(^BL1E6JVLQ\C15@91FC?1-U9N4Z#[U9)/2XS:N)574FLS#3^RH6=Y4H
M/$. ^Q8;3FUA2#Y.R=L)&PN<0J50)<#'DIVV(U*=. X?^E:PO\D,J0-E.V87
MBRW7=9]7."/"Z=O-9U''*[6!I>-/[*T[:L2,NZ>VN5+QB=LK9U,<N&G1XU_L
MJBKB-:X;XG ZS[L+")#AL$4W0XB.B=L:[)/+.&(U74G,S"#_ &5BYG%U1W=8
M['QT5K'DA_A.RLF,V8XGB@'GO/\ 9;^*Z+AF3:#_ *;/P7-\2N)KNT/NM6^X
M=<6VS=_DV?@NW*>&-\MUD.>807P<IZJ=K-5\ ';U6R9@=:L06BI]E,E<;9/;
M4Y8U6@4@MR>'K@#:K^R*QZV$5J()(J?;3(6>Z-=\K7ADZJ#R2K*K'TG%I#NV
MT*I_AW6HNFS1#S(46>)-_AW5Q-,'0);JO,C5!. J]14/92 /FB(WW51<#HE(
M.BK),*5"FY[^OW++4ANAH("K%(N,PMJ<->ZBZIXH&GN+!>.4X@]#'9)RGZ3"
M;X JW/?E=DCS3)S=4\PIL<#!S#JJRC;U7AL$A54Q4+Q$;JVD9$@*5H\!VHZJ
M[AVZJ)J<PA\*RX!:9'92K@U*A#&F9Z+(=8U7VM2I#]#'NE9O)KCQQ3082S-U
M(40"!!1294!#(?IILL^]PRK2H&H0\ $#W"%-\M<IC6N9JAIRH+2W0RJ]25MS
MBZ"0HP4V. $%!*RZ8C!1!3+DLRK&'3(R&>ZMK93:U/J'\%6V PZA*X_1:FOS
M#^"G[;QP-\&_#W>@_!=MAYBA1^JW\%PMR?S\^G\%VU@?B*7U6_@NW+TY>K6R
MF J\R<^%5KBW/*\YFT&N;N=%31MZ+SGJ YAH-4\HIMYC:O,<[3E ^[Y_Z[J'
M+-9P<]QMXT@]?/HK/!V:G<0]HI?,;H M14P/X/<!UDR('SG2MXV[%!@IMH"M
M&F?OY[*EE5X^8XCNK.5CESZ/=,8U'%\7PYH:Y]-M, #W0= MY@O&EN]X;=5G
M9H,Q26!--[3G:TGL5K[RP;6GE!M+;5K%J=O+V\W+XTQZI8XA98G2YK'.<^D!
ME,$:[K*Y=6Z&5T&GN.B\4HT[W"JHJ4+BXKC-GR-+A,=-RNCPWB^X<UM*ZM*M
MJ ">94K$:SMJ L?2L\\7BZOQGI#:OP/P4S .NNJDYH>!6^<_<KG\.XHLFPP.
MM[@D[\X&/+JMY;75&[^,I5*<N$\MK@<JQYGMX>?0[?*^F1$)N;.RJ(+==5)K
MYT6H\W*$#&B>9/ED[?@ED(5<H-"$X1"!NLZ[\9X*$HT5D**2LV(P%)SV-VE(
MA1#0\[A74X\3#\VR((556[HVH)>ZG]K@-EI[SBNRI.(-2V&W_/ 6<M]1ZN'2
M\-TVUH9BX@R3)U5S6T&C25P=QQKE+N7:!XU@BOO^Y:VMQ[<M)R815J>E8_\
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MO'J6QKCRM:FZP2I;B2*<03HXJNSPJK<:LR;=25WF(VQOL.IOI F:)/A'<*C
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M3"1;U0UX!32<:"8]Y6,>V-)5;X<9E#'M9U"C4B3R7:(^#U0/$6I.N 1 A41
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ML*X2J[\^/HNTPYTT6?5:N)JC\^/HNSPX?$L^JU;O[<^/NLUZ4Z%)[D=%AN)
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MFBX^!H/H5X,W"Z]&H78:S.Z(\;AMU[+>VO$'$6'@\ZA:-9,G2?\ ^Y<[T?\
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M(RZGWO\ ):BK3-(EC_?\DEE]+*0>!\T)%T]%&4>BTGA-KH2+Y44I3#UZ6MJ
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M,B>JBUTJ-(EP38YKAH"MXNK%%#9)('1*9="1FTT).\(U28<R(D"A1) *9/5
MT'91#@1HD'22$Q8L>?C!Z*+BAWO9N@41XRZ.B&N2XKUNGQKX6_BMOPRX_!G
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M:MN<=OF/M&^%H,<N>H\ET^*4'VM%W*H%L 'PMCJM)A^)V]GC=W4H,JM-2&[
M]NY6^Q1]]?VK_@U9C#H/&!WGL5OG;W3?2W=0PIGPBE5YK)AH]X3W7"<8TVTK
ME[6TFM$-U#873VU'&[85B;RAE(Z-'_M7%<2W5Q4NG-N*@?H-@!_!=.EQ_P O
M;IPGEID*)*-U['0T!()2$$D)2E*"2 HI@H&B4I1*(<H493E%-"02E!)/0A1E
M""6B-%&4(>#,#9"2)1?!RA)*42I(4?-$JLI(E*4*-0Y0DA%TT2E*)T1#E$I2
MA P42D@% Y1*2)1=.4Y491*&G*<J*)4-222E *J'U0DC5 T)2A 3"<RHG7=/
M0(:$\NFZ4HDQ"*(+=B5-KG'H5&4FN<"8*,6&2X'6800';@%!<3OLEL/#HJSV
MQ4ZA0.]I1)[E@_DD+*DZ2PMI>30 KLT^]JHF?FZ)$O&,*[;>4*1^#5[DQ$9"
M?X+:\)>T/^C*M6E?NH^\QOYQ<Y=I!W_>H4J@;\H"6^2\CXF+'7]3("/C:F_J
MN75]/'UN,CZ7L/:'8XE=&A0J6$Y<WQ=RUQT\@NX+FNIM+8,B=%\B>S*'<2EO
M_P!AWXA?6%BYQI4PXR('X+S\;+Z?-ZT7AI)ZJW+"L:&QLHG5:E>:Q [*+-U-
MPT2IA&0\0$6WO_8I/&BC;CQ_8LWTWQKJ,.]P?8MA"U^'>XW[%L=5X.I[>OAZ
M8F,_HM7ZH_%<HP?&5%U>-?HE7ZH_%<FT^-ZWP9Y^T:0\02:/&[U2IDYO)-FK
MG+V<7FID(A3C1$*G%$>'9.4.&FBC!ZI%OM+-YI9M$LI0&]T0'9/HG$HRH8BG
M">5,!5,1 3A.$+/(XODKVO?\26W_ &P_QO7-8/\ +_=^*Z;VO?\ $EK_ -L/
M\;US.#_+_=^*Y=+\WU.C[>IX8?S?^\5ERL/#/D/[Q65.I7TGU^*P%"KS)RF&
MK&Y7G*3"NLL3JV[7L='B/SB5@N#IEA@K<U,%J.MGUYIQ3&NIG\%FY/;4L_:5
MSC;JMG2I4^67M,D F>JP+FL^ZJ@U'$:1H5CTF,M[FH:C001&BR,.P^YOJ;JU
M%[&L:[*0Z9_#S4DG%;D6T;PTFAF:0W34JPXD^I7RB(CH2L&ZMJEO4<U[FD@P
M85-*JUHSD&=E>V7RSC:X035N;@UGN8 \1KOJ5T--UM2=+K@?:5Q=2^Y3Z?+S
M@O.L!9-2M5?3S9S$K/+AI8ZO',2H.93Y=9CLK"-"N8KWO-):' ZSNL1E;FL?
MGDY=%0*E-KCE:0>ZO#ISCX)XC.I7M2WJ"FT"':ZJ^MB3V-!ANIC<K7-J,>\.
M+3([I7#@X#0Z%;[8RR[>^JT*S0 ,N^I*L&)OYKI#=3W*Q YCF%Q:953@V9 3
MMB,VXNW/=FT62S$JOP>I3 'B;EW/9:P$9=0G3J@!VAT3M@F'U0=BLNGB%1@(
MT^\K"YP=W46N!/53-:9SKUU29C[UBR@  *&9)#4I02H2A7$U9*%6#W3![IAJ
M<I2HRC,F&IRE*C*,R8)S"BP^)R0*BPZO5Q+7*<4G\[J>C5M^&_D7_59_%:7B
M@_G53T:MOPX[XE_U6?Q2?MRXW_*MW*8*KS(S*8[18D3"BTZH)T0/,B)"BU2F
M JAT22X[^!9;K^L&2-3ZE8.8L!(/O=EM.',.?B-<-ED$$^*>BSRR3:U/ZQ67
M=6JQ^^G8E46]Q4IW;CKMU*SL6L:F'5LLM <3[L]"M?3I/JU"6D:A)EFK:+E[
MS5:[717UKE]2RITST,[^J56V>:U-DB7(O+.I1HM)+=XT^U/#.HTKBM1K-R@\
MK<F=$VW5=U=Y .0G>3LL=E0O/(USOV/3_6BL;4Y<TS.8>&0KBZFZM59B(J,!
MY(&\Z;*RI=/IAT ?&3*Q752*OP4SG.L].ZL=XF01JT0F,WRK-1SVQ"M<XP&@
M;JJF0#!&JE2>"'$@Z*D2#LC8*;CE5-9V;4;*PO#SH"IBC/EU[IN,:J-9IY;8
M4J##7,#]Z$)CLYU5D!JG4MG46@F->RQ9>_8I[5;F /1(ND:*#6.(<2=DZ1$P
M4Q-2:X#>$RZ-=$-IEU1HTW6;>67+L*=3P^)T?BIX9UA-=+"HL,%_HBF(:4"/
M'Z*KKC^(7DW;A_9"WG#Y^(_N-_!:''_TIWU0MU@+OB/[C?P2?M./Y5MR)*&C
M=1:Y2!T*-G*)49359,!24 42H)A"KS)YD:B:%#,EF0U8"A0S(S)BZFA0S:)9
MDQ-6(E0S)2@L2E1S(E$2E$J.9$IAJ<Z(5<IRF&I2B5&42F&I@I2HRB4$T*$H
MS)BRIRE*B'(E,34F^X4JQ_-ZGU#^"4_%E5UC^;U/JG\%4<57_3SZ?P77X>?B
MF?5:N/J_IY]%UN'GXMGHU)^V>%\UFOW4IT*@XZI]"HVD#HFJP=$2F)JR4*$H
ME,74Y0H2EF03E-0S=T9D$I1*C*)3!-"A*,R*G*%7*>9,$T2J\R8=NF"<HE0S
M)9I3#5BJ=+G=5*5$3.Z8:L+?"W?9=9P37IT'MS/:-';KD27%NZG:W=6V,L>X
M>BSSX=TPOF8]$XEQ?E41RGM/Q;CN5QO].7%7PD"-]"5K[G$:UR,KZCSI&L*B
MGX&K'#I3C,I.,D7U*]0U XS]ZOI8I48,CGP /I%8(<7G=%4THAS"7 ZE=.V(
MGRZ3_C!6.8:#59XQ-PMF4.9X6MR^\5JF5*;'9<A4N91DGEE.R'AG6E\ZRJ@4
MZIRC75Q5]WB[X8[F>?O%:EU:B6$FFXE-]6A4:T&F= G9#PV]+&G&AK5$3](K
M7,N'T:X?3>XRZ=U3FH"C IG=2+F/@TVD9=Y2<9#PW5/B"[IT@T,; ZR?YJNK
MBE6K3=+M>V8K4NJB(@IM:Z"9"G9#PDVYKON*ARF!J#)U6?9XS=-.4B!,[E:U
MM;(XC6=DW&!+="M7C*:V5WC5Q   UGJ5@YW56YW[[*IK>9OK'=&8M=EG12<9
M/2RK$2H9D2BQ/HE*6;11E6%31*A* 418A+,E*(DF.J@"B4-2"%',C,BZE*%
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MH1"81":(PF$TCMHFIBP$%L!8%YH3ZK*I$]>ZHO0"#J-UCDUQ?(7M+)=C]O\
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M651PVK5LKFHVF_P4RX$,)G0J;(UK7U+VK&8D3Z+(9BURR&.+ 7;>%5V=CGL
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M%H*ME>6N(5&MMR2 -SY!6<I6IR;G_:&_KEIYYRL&6"QO\EB7N(N=XZKG$D]
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MZDWWPJW'QN]5(..<*ESI>_U5PC18[\J_T"V&%&*/]UJU>.'XU_H%L<+/Q/\
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MZO$L&NKN[?4;=TA2SEV4]B=EEV+K?#!#0UU03JP]UR]KC=P:+Z-1M(4@W*"
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MP<W*!M*L$&\93  <1(?VW67;87=W=2JRNUGQ;<VCH6#9TWW#@]D<X&&]MO\
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M%ML]T;[QU7&<06]8XC6%T!#JC\N4])6>/6O+E8N:QFU@ZJZHSXNB1X63H/\
M6JG<S1:7/=S8&RLX8P<XSBU;#6MFG1I&J!F@[M&_]Y=!BU'AK"KNE1NW736O
M;F.63HNEZTGAC&IH8;5NL/9<,<6-+2[+E)6IH7)?2-![7%KC)DZ+U>V=A;^'
M;<X0:Q8]A YG;5<WA/"E,V#[K$VN%)K\I+'Z](_>5SX];=M:CB65'47U,@<6
MGH%FX+9U,4OA0:XTJ9:3!$C1=K1P#"JC*@L.<7M'BSN^Y7\)6EM88RT7V< ,
M=.4RK>K,MBN9O,&-&I3:*[0 8(RQ*P;VU;9O-5U5A82&ANW^MEV'$HPLXG:T
MV&K\=4('VN'\UJN(>';2ZI<A@J$M>'>_'0_S3CU;DU7+75,\QF5^A'16VM,-
M>>;4:1&Q7576%X'9"E\)-P(8"8,K!O\ "<"NK=M2T-P2YT^(QIJM?5V>(-7<
MVQ^#O?3$D=6A*TL7\DU*A)&7-!:NU&%T</PNNZ'!H.8ZSV"S)PA^$T>>ZMF-
M/6)WA8O6_BO,37YS"ZFPL]%&WJ.+RU[CO&I7>X'PWAMW:"K;BL:>8C5\&5B8
ME@W#K!58#=?"!F;[QC-_^UN=:>L2URE7PDD/#O(*L5-#HG<4*.&W1/B%(#U,
ME09E>21,'9=>-U-6,?).BMJ 93&BIRA@D*!JERN)JYGNB=4X5;7:*4HFI:)3
MJD"D3JA*G*2C*)3&M2)0HRE*8FIG= 4,R 434^B 5'-H@.1$T*&9/,BIRA0S
M(S(J2% .1F3$U-,*L.3S=DPU,(5<HS)@L1LJP4\R8:FC=5RG*8:F@!5YD9D-
M6)*&8IYDP23*A(1F3#4QLDH!T)YM-4PU)-0#D9DPU*4Y5>8I@]TP3E$JO,C,
MF&IH!4"Y(.3%BQ1)W2S*MSHE,-4UGN@@.*XW'#\:WZSEUU5VZY'&OE1ZN7D^
M9^+EU;K>^RK_ (I/_;O_ !"^OK?Y"E]4?@OD#V5_\4'_ *#_ ,0OL&V'YO2^
MJ/P7R^+R<TP2"4TP.R<+;&&-D2>Z A 25.D?$JU.D?$L<AO[#W/N69"P[#W/
MN69HN%:C&Q/]&J>G\5H*?O.]%O<4^0?]7^*Y]CCG> M<:G+V3!XPGU*B)S@J
M1E=HQA0D F Y$%*SVT0B$:A"D]+Q\&$ 0E*"M*E(\D@1Y)!$:(&80/=2(T38
M#&JL,T,6+?['U68R.BQ;UA<#$;K/(G&OC;VD_P!=T?\ H#_$Y<[9^^NE]IK<
MF/V[>]N/\3ES%N2UXCNG1G^;T<7:V'Z"[ZW\EL:1^+;Z!:RS=%L6C:5FL<<C
M=>B^[TYXCU2[&1*)532>I4FSJMX:FYDMS<W+Y2G3:?\ SC]ZCD#AJFVF!LB=
MR9:3_P T_>H51D<!FS:;IEJKJR'?8D-$'H"I,).X^]5A[^A",SNZHR,@(T@>
M@4&T_%[R@U[P-T9G="HGE;D'5P3Y8Z50T]PJ"2=T $Z)BQ/DEIGX0?O_ ,U/
ME9Q!N#]_^:J+21JFUN4:(TGRRTQSR?*4PR/G*O+XIZJ6J(9TV*8C*=0HPE!U
M1"<Y(.3R]T9 C6I-*!ZI 0$ (FG*?VH 2@HFB4 ]$H.J4%%U*4 J("<%#3GS
M0#JHP93@A#5=4JII]Y6/]^"J':%T*X=T:;%3\8[T"S<+/Q;O0+!Q3WW>@6=A
MNE,^@7GZ<_S<Y?\ )LJ9\*N!6.SW5:%Z*ZZLS0HE\):PHOE0OE(/2+_"=$J8
MF96/7J\II)V\D3TVF$6++JJ[-7#-1I$[_:NLML!MJ57+GINTWY86GX5M;>N!
M4+#,,<[4KJ7TW5\6=1L2&#)(SKS=3G=R58T?$'#%&BVG6;<-9X2^!3 GKW6T
ML^$;2MP9:8A4NZ5-U1Y!)I#HYPWGR6UXJP]_P:U%3*?B3F@^06#C55]'V;6=
MM;'*6UYU$CWGG^*X7GRLF7]M<>6,&C@-G7^)IW%&HYWA!:P$_BM?A_!S;_'K
MNQ-T:?);G^2GJ.DZ;I\'5GC%+:I/@;5&;35=1@-[3I\>8S6.;*^B0(&N[$Y<
MN7'<:O)H*MAAE[=L=\(L[-L92T!H'77<+;^T>C;6W"> 4Z%*C5&C158T>+P[
MZ+BWX!>U+ZF*CZ)I$:C,9Z^2[GBVTS<,<,6VD4G,:X3TR@:*<M[N/D[HT-C1
MIX;PD^Z<YKZC*D<MP@F7 *[#,#HU+*\NKUS*?-I<VGS:8TD$^$G[-EK>.ZXM
ML2J8;9RRS+&OR'77???HNAQ6L+[AJQI6TA]*URNS;3D _@M;?_)N^F'@6#8=
M>,%#X3:NJZN]UKG1Z2M1@/#8-W7H73RTU*N6GS*723L"5?P-A[Z&,BK4RFIR
MW"05T+;NE4QJS+@XU&5/"8VU6K>4M\LUJ\8P6TPND*3GT7/:X DL#3J"5QU3
M*]PRN'V+I>/KBI5QFY;FTS,.W]@+D;9C@?#&Z]'1E[=M9U,NRN(E7Y0-)6-4
MIDO),+)()"ZI:C&^J4"-T09U3+-%%E(1U(4:FFQ^Y(L\03>(;HJITY(,DJ6@
M)U$JIG,/40HU,S=0=4Q$P="J)\;U?4 8TPL802XG=5-:;$C\<?0+,P_5@] L
M'$-:QGL%G8=HW[ O/Q_-RX_DSV#*K*;YJLDQKO*JS&-5/*T"7#9>BN\N/1>$
MC0J6-.G4%/0./,=&OB6PQ'#.8]O(QEUQI\FQV;-Y0'+B,!QNTLZ3:5PVJ6M!
MT:T;S/=;M^/X1:#FX92N:=9NK2X3K]I*\7+AR[MB[&3@CZ5'&;VUNLE*&90Z
MI S$QT*NH<.LP[BBT=4 -L*9+@ZEE9)#AKT[+B;W%:M[B_PESB7/J-<26@=E
MZ3Q-C5%]E5=\9S(: <H^DISX\^-F?LV-7:U:53';ZFQC#3IU8$01$K'XYQ'X
M#BKFV]$?!@QI\!ADZ]A"Y6UQQUGB-U4:YP%1VL-!ZJ>/XU3Q.BYC<\F/>:!L
MM3I7NTV.VQB^%'!+"JRBT&I;9S!CYH*Q.&[XWMLSF4>A.IGJN?NL8-]AEK;L
M+OS>B*9S- ^:!_!4X/CC,,8*+L^=H,Y6@C4RI]*]J['H=B&4\.O7BBV1)V\E
MQM3$JM'&+AX8ZNTB!1S&&[:Q_K===A=W3&%W+[@.=3<W,0!K$+E,0Q#!J%U4
MK6]"X;6<0"XZZ1Z^06.G+MF$Y1O2QM>]I52QMD6B,H$=]>BIXDN#\&MZ0I<X
M"I&?>=-US-3B@W-=KKEU1T"-& :+,K\16SK:F&BK+=1X1_-;G2Y2PG*-EC%P
MZPP2O:LHG4M=SAX8\0T_=WZJKANZJUJ=4&D^Y&1NAEV7=:^AQ%97U/D8JVM5
MIO/B#6@2!J-B.H5PXBP_"&/.$LKT2\0<S0Z0-MR4[.69AW1T.$6K*N.MSAMN
M<A\!;'VK1T\=YF+.MJ5LUKA6Y;2UVKCFB8A:VTXMSWHNZSJAJY<LAC=O1:NQ
MQ2U_I5MQ1;4%R*P>QQ&@=,@Q/=)T[[J=T=SQ;?.L>&Z-0T2+DUPUQ)ROB';]
M>RR;$MN.$\5KU:0->F!D+A+NFQW7(<3<0#$+46]V7ON0\/<0T 1!C;U5M'B<
M4L&O+;-4YM4#(<@C[5)TN7;_ -R<HZ["&T:N!6F>YIV=8SF?(#CJ=#J"H8SP
M^VA;OJMQLWQ:!\7[V;7;WCZKE++&["IA]"E?LK/JMU<6B!,GS69<X_94J#S:
M,K-=TEH/7U3Z?.7P:Y/$0?Z0KTRWE9'D3$2H<S)\6*>;KS?X*.(71N[JI4D^
M)TZB$4W.C(3HO9)<\L6L@'P?8JZ;LSH1)B$FM@R%63J'4(![I$$G5$%%E3!T
M1.B0"(,*+JLGXIRK?\F[T4C(I%5.)Y;M>BK6M%6_2CZ+=6_N-] M'6DW9]%N
MJ!\#?0+ETO=<N%\LL'52I'4JG,5.D[==L=-9"1.B&ZB4$:%9PG*($IM.B"$L
MI5-2E *C!1!1-2E$J,)@'[$-,'1$J,%, H:8.B)0&HRH: 42C*C*AHE$HRHR
MH:)T4&OEP4CLJR(.B$L*JZ"N@X4-O7JM%5M%AEVKH[+G'23JKK4U16#[)P8!
MIXNZSSX[,776XYA]WFI'#[FX:TDGX@&(TC8K;<."YH6[1B5U6(UGX0XCTW*Y
M!G%&(V@;2;7 </#\FTZA4XCQ!BEQ1)N:[7-D;,:/X+A>GRLRKL=W:XO:U1>4
M&LMZ3B2P$/$N.HE<QBEG4-]5<+-]=IB*G+)!T'6%SE*Y=0(JU#\:?'3(&QWU
M6YH<08P;-@IW+ R3$TV]SY+4Z5XW>+.NSH8G;V&&U:;N2][A(IEX!.FT+!Q^
MF<3P&U?2<7%U0.Y#/%DT<-O\NJX2G>5+IY-9V:X!ACH  67;\07UD\T:54"H
MT92<@(4G1LNSVG=&YPCA]];#:EQ4Q6I:!KR.41 .VOO#O^Y=;3N[9N%4+4TZ
M-8TJ88:Q()=I&;_17G&(8M?T*GP2O5:6/:'$-:._>/))]_B-M;-=SF<BHV
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M[)MJ'LHZ=DVQV02YB!42@=D0WLC.GS->B7,* &GHCP]D73SI!Z!E/1(QE,!
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MT1G0[HMD(D*H.1G0[HMD(D*K.C.AW1;(0#"JS(SH;%H<C,JLR,R'=%V9-I5
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M,#LC,!LCE^:>3S0+,""HP)4Q3\T\L=95U$1 1HI9=>R,JS5D?'/ME,\3VO\
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M6H5&$$.A>\GV%VD_UG>?LFJ=/V%VD_UG>?LFJ?><?Z3B\'L\2=8/S6Q+=1N
M=MEO&<<XB&?+^+_I-7K3_85:3_6=Y^R:FSV%6GZSN_V35SOR>%_;4V/(J_M
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M97?[)J?Y#+3]97?[)J?>\/Z=KP1U>D>CE"I<T@S9VR]^_(7:3_65Y^R:HO\
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M$P(E9X\J*329/NH%)G97H6M75)I,CW56:=/Z*R'.:P2\PL._O+>R87W53EM
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M,U;MH9/5![=5XAP^CR:3;VVJO=X7.;6;J=IW6SM74Z](5Z51A:[2097C^/\
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M9P"$(0"$(0"$(6@(0A (0A (0A (0A (0A (0A0"$(4 A"$ A"$ A"$ A"$
MA"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$ A"$
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M.IT7$4^JRJ;GAN:H9![*MQI%I;E.JL#:[/1IN(@D2ID#FY706QUV4="QH;H
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M&D]%&6?13P8G\*?V"/A#CH0-57+>R?A[)D$N84N84LJ,JIAFH8W3YI[J) A
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M$-X"@4)Q"@VH ,SQE&WBT5H8S*2;FE_ZD5#62B$VT_$7"JUS3M!5@9/4)HK
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M@$0A"!P(2&R$(&DA" '5$"$(0$(&Z$( #1,!"$"1"$("$0A" 0$(0@ U0A"
MA &J$(!"$(!,(0@BA"$4P@ :H0B!"$(!'0H0A $(0@$0A" A,!"$"1"$(!"$
M("$0A" 1"$(& (0 A" @2EU0A )H0@2!LA"!P$D(0)/HA"*<"4B$(1#A)"$
AG&A0A #9 V0A 1JA"$ !ND-T(2L\O3/MO=*M0A9<W__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g12080g0907100113636.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g0907100113636.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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M1SCW./I4>G?%.2.]%OKNF&V4GF2,,"GU4\D?0_A2]M"]KFBR;&N'/R?*ZO\
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M*E1G&?0XQ7!^'_&%_P""E;1=:T^9HHV+1C.'3)YQGAE)R?SJ7Q#X\N?%-O\
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.XJCU?DNA;HHHK8\@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g12080g11v99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g11v99.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_[12,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"C_P  1" +9!E4# 2(  A$! Q$!_\0 '  !  $% 0$
M          0! @,&!P4(_\0 6A   0,! P<&!PH+" $# P0#  $" P0%!A$2
M$Q0A4E.1!S%!49+1%V%C<7.AX2(R-#958K&RP=(5-3="5%9R@8*3\!8C)#-E
M=+/BHB9#P@@EE"=%@_&CT_+_Q  : 0$  P$! 0               0(#!00&
M_\0 ,Q$!  (! @((!00# 0 #      $1 @,A$C$$!1,S05%2<105,H'!(D)A
MH3138B-#D?'_V@ , P$  A$#$0 _ /JD
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M^&["HVTEBTT;HE=%'D,F=@_6F"(B^^;UG7C+4QC&:A?#*<HW  47
M
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M1N?745OSVY>&LBJ[3D;D-6'4UB:^;W+=I>@W@$=IE5'!%V  HN
M              T3E$N_7VO64\E#&CVL8C5Q5>?%>\U#^P]MX_Y#>*]QVH'0
MTNL=32PC"(C9R=?J?1U]2=3*9N46S8GPV=3Q/3![6(U?.<GL2X=_+OMGBL.W
M;+I8)I%D<U6Y>*JB)C[J)>I#L0/'&I,7_+I=G%1'DYK>RYMY;>LFQ$EM*A=:
MU ]9'SNQ:U78L5%1$9ASM7H(<UPKTV[4TC;V6U1U%%3N1S8Z=N"XHF'1&WH5
M>DZL!&KE$5!.G$O)==RR'3Y]U!"LV.5EKCCCUE+UV7):]W:ZSZ9T;))X71M5
MZJC4Q:J:\$7K/7!3BGFO4<FIV-=/-7&CL"U'1R+DN:]T:KAK<JZEP1>DTZDY
M-;P2:%9]K6S33V'2/RXX6:GZNM<A.E$Z3KH+QJY1:LZ>,N5WWN)>6W+6IY*&
MT:".SJ3#1X)7.3)PPYT1BX\R<ZJ;+<RS;V4%0YMX;2H*FC2/)CCIV(BM7%,/
M_;;T8]/2;>!.I,Q1&$1-@ ,UP                        ^8I^2J\[IGN
M2FCP5=I>X^G0;Z'2,M&^'Q::>I.')Q7DCN+;5WKTI66E"QD&:<W%%7G5/,;M
MRHW4KKU652T]F3T\,T,Z2Y4RJB8(UR=#5VC= 1J:^6>?'/-35GM/J<]N_8W*
M#36G3K:]OV=46<W%)(HXVHYR9*X8+FDZ<.D\B.X]\[,MZV*ZP+7LVFBKYWRJ
MC\7+@KG*F.,:Z_==!UD%>UGRAEV<-"N7<#\%NK:FWIHZ^MK/\U4]Y^Y,$ZDZ
M#;[-LB@LUSUH*6.!7I@[(Z2<"N6<Y<UHQC'DT>\]SZVUKZ63;$$U.VGI,<MK
MW.1RXHG,B(J='677]N=56W6T5IV+51T=JTBJK)),<E>;GU+LIT&[ F-28K^$
M<$;_ ,N=W9N3:]FR6C:E?:-/46_4LR&S)[QJ>YZ,E.AO4:[9')]?BRZ^:MIK
M9LI:N7WTLF+U_=E1+AS]!V8%NURW1V<//L&*T8;+A9;,\517(G]Y)$F#57Q:
MD^@]  REI&P                        :Y?JRZFU;*;#1M1TB/1<%-C!3
M4TXU,)PGE*N6,914N/I<FV-TSBO<=&NA0S6=8L=/4M1LC5UHGF0]H'FZ/T+3
MZ/EQ8L]/1QTYN'*[3N1>V&]M?;%W+6L^CTE?_<17.PQ7G18W)TD^T;JWJMFZ
M%79EN6K0U5;(]'1R(F0QJ>/)C3Z#HH.AVLK]G#D4EQ+[5]EQ61:ENV>ME-1&
MNCB;[I41<4UYI%YT3I-]H;HV1!9M'2STD<ZT\38D>_%57!$3'U&P C+4RDC"
M(8HH(X*=(8&HR-J8-:G,AI_)W="INY9%?16C+!-I,CG?W+E5,E6HF"XHG4IN
MH(C*8B86G&)FW(ZKDUM^)]=065;%/!8-9(KI8':WY*JN*(N0O0Y>DGWNN%;5
M;8=GV-=^OI:6SJ=G]XR5SD5[L57'%&JO3UG307[;)3LL7/+H7>OG8]330UEJ
M66ZRX\<N&%B(Y=6K7FTZ<.DZ& 4RRXIM;''AB@ %5@
M
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MY,55%X*AN9S'DX15O]>=T:_W.*)AX\F,Z<9:D1&6S73FXW  9K@
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MYY(XE54B155<G6B=>'[C?#/.(C*H:83,Q<@ *+
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MG*7H  Q:@
M
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MLM*GJ*=CD:]\$C9$8N"KKP75S#+BRFY@QX<8J);""C'->U',5%:O,J%2BX
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M.@]P%LM2<HJ48Z<8S<  ,UP
M
M
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M4YVM1KDQ7BA,S$Y1OYHB)C&=G4&KE(BIS (F"8(#R/2
M
M
M                                  0Z:S*.FJYJFGIXXYYO?N:U$5WG
M)@         $2T[.I+3IT@KX(YX4=E9#VHY,=:<R^=26!R!$1$P1$1/$
M                         $>OHJ>T*5]-60LFA?J<Q[45%_<I( &.GA93
MPLBB:C8V)@B)T&0         "''9E'':$E<RGC2K>F2Z7)3*5//SDP
M                         AR691R6@RN=!&M6Q,E)<E,K#JQY^A"8
M   "'^#*/\(K7+3QK5JW)SJM3*PU:L>?H0F
M                                            !I'*5?22[,5-36?!
MI%I5+L(V8\R8+KPP7'F3B6QQG*:A&648Q<MW!RN[]^K<H;STUBWQI(X7U**Z
M.5GN41,%PU8:];5Z>DZH,L)QYHQRC+D YM?6^]J17D;=^ZU,R>T$1'2/=K1J
M*B+S8+M)K,W)Y?>MM6UJJQ+P4Z4]JP:]6I':NK!/&6[++AXD=I%TZ& #-<
M
M
M
M
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M>'7_ $KU_P#8XD"?@-(^$_ZEVWPZ_P"E>O\ [#PZ_P"E+_7\1Q(#X#2/A/\
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MB;7SDXG2#3K[78J;<O'=:OIY&-CLNI6:5'<[D5T:ZNPI..6$[3%$QE&\2W$
M&30                       !K/*7\1[6]&WZ[3PN07\GT'IY/L/=Y2_B/
M:WHV_7:>#R"_D^@]/)]AM'=3[LI[S[.B  Q:@
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MW(X;</XUV?YW_4<=R/G^MN]CV_,OK.H.XR]_Q  #E.Z   >/?+XH6[_L9_\
MC<>P>/?+XH6[_L9_^-Q;#ZH3CSA\>/\ ?N\Y:7/]^[SEI].ZAT
M       (            &6D^$Q?M(8C+2?"8OVD^D2/M@ 'RSE     #!7_
M:GT;OH4X+4_"9?VU^D[U7_ :GT;OH4X+4_")OVU^DXG6_P"UXNE^#$"I0XKQ
M@    !T %0* # !T   !XP P"<Q4H     8:@ 0 !S*  *H=SNU^(J+T:'#$
MZ#N=VOQ%1>C0Z_5'UY>SU]$^J7I  [SW
M                                 #6>4OXC6MZ-OUVG@\@OY/H/3R?8
M>]RE_$>UO1M^NT\'D%_)]!Z=_P!AM'=3[LI[S[.B  Q:@
M                !S7EO_$U)Z1?L.E'-N6_\2TGI%^P#BH" "A5  "<X
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M&[Z%."U/PF7]M?I.)UO^W[O%TOP8@GG*@XKQJ#I 0 .8%0*(  " J4 (!T*
M"<RE2@Z% J40(  0  , 5 ITE2B  @'0 "'=+M?B*B]&APM.<[I=K\147HT.
MOU1]>7L]?1/JEZ0 .\]P
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MK(ZRF>]6-P:V5JJONTZ,3S.05?\ ]/H/3R?8;1W4^[+_ .3[.B 8@Q:@&(Q
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MX6G.=TNVO_V*B]&AU^J/KR]GKZ)SEZ0&(Q.\]P!B,0 &(Q  8C$  ,0 &(Q
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MM3.!<E0P:*W;E[:G..6N%([&I%1SUQD7G=CU'3CFO+?^)J3TB_8+DIQ8 $)
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M[QX]\OBA;O\ L9_^-Q;"9XH3C$7#X\?[]WG+2Y_OW><M/IG5
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MVGA<@OY/H/3R?8;1W4^[*>\^SH8 ,6H
M   <UY</Q+2>D7[#I1S;EO\ Q-2>D7[ .*E$*H     !  '2 !0J@0 $ 3I
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M                          #+2?"8OVD^DQ&6D^$Q?M()Y#[8 !\LY0
M   P5_P&I]&[Z%."U/PF7]M?I.]5_P !J?1N^A3@M3\)E_;7Z3B=;_M^[Q=+
M\&-"A4HAQ7C!U@KY@*!.D#K J4\X0KU@.8H @!    0 .D%2G6 0!!U@"H*
M 5* "I0$"J<YW.[?XBHO1H<+0[I=K\147HT.QU1]>7L]?1.<O2 !WGN
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MXH6[_L9_^-Q[!X]\OBA;O^QG_P"-Q;#ZH3CSA\>/]^[SEI<_W[O.6GT[J
M            $              !EI?A,7[2&(RTGPF+]I/I$C[8 !\LY0
M   P5_P&I]&[Z%."U/PB7]M?I.]5_P !J?1N^A3@M3\(E_;7Z3B=;_M>+I?@
MQ!!T%>@XKQJ!  &(0! !5"@ ! @ KT%  *E  *CH*  .@ "H0H$ J4',  0
M"IW.[7XBHO1H<+0[I=K\147HT.OU1]>7L]?1.<O2 !WGN
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M@OY/H/3O^P]WE+^(]K>C;]=IX7(+^3Z#T[_L-H[J?=E/>?9T, &+4
M                                       ##65,-'323U,C8XF)BYSE
MP1 ,P.33\M%$VJ=F++GEHFNR75&7@B?NP\W2=)L&UZ2W+,AKJ"1'PR-1=2XX
M+U+XR^6GECO,*XYXY<I>@!T'-;=Y6*.CM22BLNSIK2?%[]T3M2<$4C'"<N1E
ME&/-TH&GW'OY07JDEIXXWTU;$F+X'KKZ>[J/*O/RI4=E6M)9MGT,MI5,>&6D
M3M2:L>A%ZT)C3RF>&D<>-7;HH-,N/R@4%Z)GTJ1.I*YG/!([7S8ZN95Z>@W,
MKEC.,U*T91E%P  A(               #6>4;XKU'G3[3BG,=KY1OBO4>=/M
M.*=/B/HNJNYGW?(=>_Y,>T?DQ"#H0(N*ZCIN(<V(3F  #F'2% >8#']P7FYP
MD3QA<1CJ3K">, G,I3S%Q3H :P$UCF 8:N<#F08Z@ UXA%P0( Z5PU#KPYQT
M##%%"!!CT 8IB$@YL1SXCSA#W[A?&R@\[_J..Y'#;AX?VKH/._ZCCN1\_P!;
M=['M^9?6]0=QE[_B  '*=T   \>^7Q0MW_8S_P#&X]@\>^7Q0MW_ &,__&XM
MA]4)QYP^/'^_=YRTN?[]WG+3Z=U               0               RT
MGPF+]I/I,1EI?A,7[2"1]L  ^6<H     8*_X#4^C=]"G!:GX3+^VOTG>J_X
M#4^C=]"G!:GX1+^VOTG$ZW_:\72_!B !Q7C @*@40J$*><"J%.<  !S8@  G
M,  '0  *E  !4 4"     3   G.=TNU^(J+T:'#$.YW:_$5%Z-#K]4?7E[/7
MT3G+T@ =Y[@                                     ..\HDE!3<H*2
MWA9C0/HW-IW.QR4DR4ZO'DG8C3K[5UWIJVCL:W(&5,U0JY+5:JYM-7NN;!.=
M.!II34J:D7#D+*^SJZZUWK,LS"2V(ZV5S<C'%C%DE5/K-/H].;6<<NK>"YME
M7G=2V=9F957YIM8K%P5VI<,<GQ+P.QE]:=XV4THY[ARWES1&TMD2UC'268RJ
M3/L;T^Y>=1<Y&-5SEP:B8JIIE#>NQKT5MI68^%)J*E:JRR2(N0JHJ(J:T\?J
M*:=Q/%7)?.IBFJ\H5[+J6G=%U%13,J*G%J4\;$7%CLI#H5Q63QW0LAE5CGDI
M8D=CSXY"'$[/O+=.CMQM1279<ZC;(C4J5;[EJ]?-JYT/H&AJ8JRB@J*=<J&5
MC7L7Q*F*%]6.'&(I33GBF99P 8-@          :SRE_$:UO1M^NT\+D%_)]!
MZ>3[#W>4OXCVMZ-OUVGA<@OY/H/3R?8;1W4^[*>\^SH8 ,6H
M                                 \ZT;<LVS94CKJN.%ZIBB.Q-)Y6+
M=I:JX-<^S*ILJ*Y&.<SHU*IL%Y[CV->2K94VI'(Z5B9*9*HFK5UHO4>-;/)Y
M0P7/M&S+$8]KY_=(CE36O!#7#@B8EGEQ3$P\:Y-C4<O([49R%CG2POF<Y4UY
M2-1>?]Q9_P#3G4ODL&T('JJMBD;D_O5W<:C8]\+1L:YE3=J6RJE:UV,;'9#L
M$:J(GV*="Y);$J;KW)J*FJA=I,K,]FNG!$543UFV<3&.5^,LL)O**\(=(5,4
M5%.>VW065<"S:BT;(LC/S3+@],I7]*)^<[QDFXE[ZR]3;1BFH7T;H%5K'X*F
M/-U^<TVQ;_6S=NKK:*]M)55*XJK'HU53S8ICU&6&&43,?TTRSQJ)8.2!C+9O
M?:UL230P5,B/1M*W%%;E*OBPU><\B[=HP7*Y0K6?>.E>Y)&JUKD:CN=6JBZU
MZD/5Y.J6NMWE&JKP044E)0*JKB],,<5Q3GUJ>I;5\:RR[RU-+>FPV5%&S_)E
MBC<N/,J:\5\9O/U3'\,8^F)_EJ%/;M/6<KU!:%DP24T,JJF#D1,K%'HJX8KT
M*?1YPRYU!67NY18[>DH7TEF4J*UC7)ABF#L.?QN0[F8Z\Q<0UT8VF0 &#8
M             !K/*-\5JCSI]IQ3H.U\HWQ7J/.GVG%-9]%U5W,^[X_KW_)C
MVC\GV!.M NL>8Z;BF(Z2B8*5Z@"!$ZQ@ DZ=80=&K6.O$!UCI488\PZ0@"CK
M& 2)SZ@"H%.@ <X :]87G\P3G"!.8IT\Q7H'0$J8H5 Q!!T# ?2.<(>_<3XV
M4'G?]1QW(X;</5>R@\[_ *CCN1\_UMWL>WYE];U!W&7O^(  <IW0  #Q[Y?%
M"W?]C/\ \;CV#Q[Y?%"W?]C/_P ;BV'U0G'G#X\?[]WG+2Y_OW><M/IW4
M "    0                     ,M+\)B_:0Q&6E^$Q?M)](GD/M@ 'RSE
M    #!7_  &I]&[Z%."U/PB7]M?I.]5_P&I]&[Z%."5/PF;]M?I.)UO^W[O%
MTOP8T YPAQ7C "H H  *E.@(  ZP!4H5ZR@%1@"@ (@ZRH *"@! 50IT@ $
M%4!3H"=) JG.=SNU^(J+T:'"VG=+M?B*B]&AV.J/KR]GKZ)SEZ0 .\]P
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M[J?=E/>?9T, &+4
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M>^7Q0MW_ &,__&XMA]4)QYP^/'^_=YRTN?[]WG+3Z=U    $
M              RTGPF+]I/I,1EI/A,7[2">0^V  ?+.4     ,%?\!J?1N^
MA3@E3\(E_;7Z3O=?\!J?1N^A3@M3\)E_;7Z3B=;_ +?N\72_!B*]!1 <5XP
M(    #H  KY@4  J4Z *E!T! '6$ 36 *E G-X@  0 "J%.8  5 (=SNU^(J
M+T:'#$YSN=VOQ%1>C0Z_5'UY>SU]$^J7I  [SW
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MO1M^NT\+D%_)]!Z>3[#:.ZGW93WGV=# !BU
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M%Z-#K]4?7E[/7T3G+T@ =Y[@
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MM0
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M4T[V1*[%&J[%<6JG5XSH1Q>LM7#5U(G";V?2=3:&IH:.6.I%3?X@ !SG7
M                !9)+''_F/:WSJ7HJ*F**BIX@ !1[VL:JO<B(G2H%0613
M1RIC$]KO,I22>*-V#Y&M7J50,@,&ET^^9Q,Z*CD147%%
M   #!7_ :GT;OH4X+4_")?VU^D[U7_ :GT;OH4X+4_")OVU^DXG6_P"UXNE^
M#$@ .*\:O04*E   ZP '[P 0J4  ! @   5*!"H%.@  "I0 "I0=   8@53G
M.YW:_$5%Z-#A?2=TNW^(J+T:'7ZH^O+V>OHGU2]( '>>X
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M"_D^@]/)]A[W*7\1K6]&WZ[3PN07\GT'IY/L-H[J?=E/>?9T, &+4
M
M                         \JMO%9%#4I3U=I4D,R_F/E:B\,28B9Y%T]4
M%D$T<\3987MDC<F+7-7%%0O( 'A27OL"*1S)+6HFN;J5%F;J]9?27JL.KJ&0
M4UJ4DDKU1K6-E:JJJ_O)X9\D<4>;V@1+2M.BLR%);0JH:>-5P1TKT:BK^_S&
M.R[9LZU45;.K:>H5.=(Y$<J<!4U9<<D\ $)
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MHF(U5ZSD/)923WJOA:%Z+1;E0QJK($=K1%3)1%3]V)VDC7RG;&?!.CC$7E
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MG*HYNIYRHW2#.5&Z0D(J*B*G,H/+;T4CYR?=(,Y4;I"0!92/G)]T@SD^Z0D
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M(^<GW2#.3[I"0!92/G)]T@SD^Z0D 64CYR?=(,Y4;I"0!92/G)]T@SD^Z0D
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MY/L/>Y2_B/:WHV_7:>%R"_D^@]/)]AM'=3[LI[S[.A@ Q:@
M
M                 *F*8*:!:_)3=^T:]U5FW0*Y<7,B56M7]R*AOX+8Y3CR
ME$XQES>;8=B4-BV8RAL^!L4"-P5$36[5SKUGE7>N39=A6U5VG1,<E14(J.Q5
M<$Q5%7Z#9P.*=]^9PPU>\=RK.O!:]+7V@Z5[Z=$1D>4N3J55YL<.DV:-C8XV
ML8B(UJ(B(G0B%P(F9G:2(B'/;9Y*+#M:TYZZI?/GIEQ=@]W5AU^(Q4G)#85+
M513LDJ5=&Y')B]W.G[SHX+]KGRM7L\?)2-J,8UJ<S41"H!FN
M                                                 #D1S51R(J+J
M5%Z2 MC6:JJJV?2*J^1;W$\%9QC+G")B)YH'X&LSY/I/Y+>X?@6S/D^D_DM[
MB>".SP\H.&/) _ UF?)])_);W#\#69\GTG\EO<3P.SP\H.&/) _ UF?)])_)
M;W#\#69\GTG\EO<3P.SP\H.&/) _ MF?)])_);W#\#69\GTG\EO<3P.SP\H.
M&/) _ UF?)])_);W#\#69\GTG\EO<3P.SP\H.&/) _ UF?)])_);W#\#69\G
MTG\EO<3P.SP\H.&/) _ UF?)])_);W#\#69\GTG\EO<3P.SP\H.&/) _ UF?
M)])_);W#\#69\GTG\EO<3P.SP\H.&/) _ UF?)])_);W#\#69\GTG\EO<3P.
MSP\H.&/) _ UF?)])_);W#\#69\GTG\EO<3P.SP\H.&/) _ UF?)])_);W#\
M#69\GTG\EO<3P.SP\H.&/) _ UF?)])_);W#\#69\GTG\EO<3P.SP\H.&/)
M_ UF?)])_);W$V.-D3&LC:UC&ZD:U,$0N!,8XX\H(B(Y  +)
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M#R"_D^@]/)]A[W*7\1[6]&WZ[3P>07\GT'IY/L-H[J?=E/>?9T0 &+4
M
M
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M<<\EM3.>6+Z7C7*8BKSJ5,5)+'- UT3VO;UM7%#*>9N
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M\1[6]&WZ[3PN07\GT'IW_8;1W4^[*>\^SH8 ,6H
M
M
M
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MUO1M^NT\+D%_)]!Z>3[#:.ZGW93WGV=# !BU
M
M
M
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M<,NHW;.TO<*+2 1\NHW;.TO<,NHW;.TO<*+2 1\NHW;.TO<,NHW;.TO<*+2
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M@FK5[3N]WI:V>QJ.2U&)'6NB:LK43!$=@F*<<2^KCCC%8JZ>4Y3N]  &#8
M&EW+N3_9RVK0K])SNE_F]7J+KQ7(9;%ZK/ME:V:):9S7+&U4P7)5%3H\1N0+
M]IE=J\$53E5XN2NJM:WYK4;:[HY'*BL^;@B)L^(]BZ]R[7LFUX:JLMZ6JA9C
MC$N&"XHJ;*=9OH)G5RF*1&GC$V  S7:SRE_$:UO1M^NT\'D%_)]!Z>3[#WN4
MOXC6MZ-OUVGA<@OY/H/3O^PVCNI]V4]Y]G0P 8M0
M
M
M
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M'M;T;?KM/"Y!?R?0>G?]AM'=3[LI[S[.A@ Q:@
M
M
M
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M0
M
M
M
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M+^3Z#T\GV&T=U/NRGO/LZ( #%J
M
M
M
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MT'IY/L-H[J?=E/>?9T0 &+4
M
M
M
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MZ-OUVGA<@OY/H/3R?8;1W4^[*>\^SH8 ,6H
M
M
M
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MM/"Y!?R?0>GD^P]WE+^(UK>C;]=IX/(+^3Z#T[_L-H[J?=E/>?9T0 &+4
M
M
M
M
M                       &L\I?Q&M;T;?KM/!Y!?R?0>GD^P][E+^(UK>C
M;]=IX/(+^3Z#T\GV&T=U/NRGO/LZ( #%J
M
M
M
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M!9F8MVSLC,Q;MG O L69F/=LX#,Q;MG O L69F+=L[(S,>[9P+P+%F9BW;.
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MX#,Q;MG9+P+%F9CW;. S,6[9V2\"Q9F8MVS@,S%NV=DO L69F/=LX#,Q;MG
MO L69F+=L[(S,6[9P+P+%F9BW;.R,S'NV<"\"Q9F8MVS@,S%NV<"\"Q9F8MV
MSLC,Q;MG9+P+%F9BW;. S,6[9V2\ 69F+=LX#,Q[MG O L69F+=LX#,Q;MG
MO L69F+=LX#,Q;MG9+P+%F9BW;.R,S%NV=DO L69F+=LX#,Q;MG9+P+%F9BW
M;.R,S%NV<"\"Q9F8MVS@,S%NV=E"\"Q9F8MVSLC,Q;MG O L69F+=LX#,Q;M
MG9+P+%F9BW;. S,6[9P+P!9F8MVS@,S%NV<"\"Q9F8MVSLH,S%NV<"\"Q9F8
MMVS@,S%NV<"\"Q9F8MVS@,S%NV<"\"Q9F8MVS@,S%NV<"\"Q9F8MVS@,S%NV
M=DO L69F+=LX#,Q;MG90O L69F+=LX#,Q;MG9+P+%F9BW;. S,6[9V2\"Q9F
M8MVSLC,Q;MG O L69F+=L[*#,Q;MG O %F9BW;. S,6[9V2\"Q9F8MVSLC,Q
M;MG O L69F/=LX#,Q;MG O L69F+=L[(S,6[9P+P+%F9BW;. S,6[9V2\"Q9
MF8]VS@,S%NV<"\"Q9F8MVSLH,S%NV=DO L69F+=L[(S,6[9P+P+%F9BW;.R,
MS%NV=DO L69F+=LX#,Q;MG9+P+%F9BW;. S,6[9P+P+%F9BW;.R,S%NV<"\"
MQ9F8MVS@,S%NV<"\"Q9F8MVSLH,S%NV=DO L69F+=LX#,Q;MG9+P+%F9BW;.
M S,6[9V2\"Q9F8MVSLC,Q;MG O L69F+=LX#,Q;MG90O %F9BW;. S,6[9V2
M\"Q9F8MVSLC,Q;MG O L69F+=LX#,Q;MG90O L69F+=L[(S,6[9P+P+%F9CW
M;. S,6[9V4+P+%F9BW;.R,S%NV=DO L69F+=LX#,Q;MG O L69F+=LX#,Q;M
MG O L69F+=L[(S,6[9P+P+%F9BW;.R,S'NV<"\"Q9F8MVSLC,Q;MG O L69F
M+=L[(S,6[9V2\"Q9F8]VS@,S%NV<"\"Q9F8MVS@,S%NV<"\"Q9F8MVS@5;&Q
MJ^Y:U/,A<                            UGE+^(]K>C;]=IX7(+^3Z#T
M\GV'N\I?Q&M;T;?KM/!Y!?R?0>G?]AM'=3[LI[S[.B  Q:@
M
M
M
M
M             UGE+^(]K>C;]=IX7(+^3Z#T[_L/=Y2_B/:WHV_7:>%R"_D^
M@]/)]AM'=3[LI[S[.A@ Q:@
M
M
M
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MO9/#%W0 "JP
M
M
M
0                  #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g12080g15u24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g15u24.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_[10,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $^\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MP? C-6.B,V)R@B0T0\+3"$4E)D1D98.4I./Q_\0 &@$!  ,! 0$
M      $" P0%!O_$ #$1 0 " @$" P8%!0$! 0     !$0(A Q(R,5%2! 44
M%4%Q$S-AD:$B-&)C@4(C!O_:  P# 0 "$0,1 #\ ^J0
M                                                    _$:-"@,Q
MHT1D-O9>]R(GZG[.$PRK=9-MV_3]K@.P_B4C]-EOS6]21!C0H[,>#$9$9M,<
MBI^A\H7KK+XP->)[/2O]8'XM+A)E:):"-2/X;-S<Q#1%7(Z>U$7LN\Y+LQA!
MIM=BQX"0HTK.0F*]9>,U4<J(BKJN[EX' 5Z=J4CAFJ$6C26>S.0:BP[[M&+#
MT]B^8]6A6;K<_::;M+79=DBK)=[&P6]KKVO[>S:U=QTSAA&._)A&>4SIWUD;
M32]I8,U$EH+X22\583D>M]ZHJI_0]O*P\;%RC,;5>EY4F#>:;)V1M3&=-)**
MV+&NC+_(M\2Y>U/6<E59J9E+.LJLG/5^+-95?_%Q%BPX+TO=V(JJFKO[BOX-
MY3$)_%J(F7T4Y4:E[E1$UJ88]C_D.:[[%O*FMQ6ZE.1;-TF!.1)1*@U'1HT-
MRM5>W1H5-G7WGMT2SL6SMHX#6VI?%AQ4TR4U%5SXG9I:CGW]^KO0I^'47,K=
M=SJ'?/B,9\M[6_:MQ M!5H5&H\Q48S'1(4%$<K6KI73<4M'K,S7;459*BM??
M @.Q(4*FMBN1FA-*XGX\3T)"I56:P95^6K$.<1T!R)"B33'->YE[+OE:=9?\
M&JM7\6[I:MG:W+UND2T_"3),CM1S6/<EYZBJB)>JHB:U*&DZ%-0<&4&N0:W.
MP8\"%E(;(<5S6(B-ONN1UW<A-J5I*K7H-FJ8V=BR6>-5T:-#>J.=<KD[45-2
M">&YU)'+K<+K8]CT^(YKOL6\_14,+/K&X0:93(%3FYV2G6*KX<>(YZHMSM.E
M5U(6\9Y8]+3'+J  46                      *J(BJJW(G>"/4O\ +IOT
M3_4I,1<TC*:B9%GY1.V:E_S$ZG[A34",[%@QX41W;<UZ*I\[S'_'B?\ 4OK.
MQP3^,$?T"_N:>MS>[(XN.<^KP_1X'LWOK+GY<>.<*O\ 5W=K[4R]F623IF#$
MBYU%2$W$6ZY55$O_ %/?@O2+"9$1+D<U')^)6.'/_@6?^^M_<TLF0_\ (R_H
MV^H\R<8C&)>[$S.4PKV<PKRD"I34G"I$],.EUN>Z%I3N\WG.KLA:F0M3).F*
M>YR*Q<5['-5%:NC6B:RH+,0[11+4VB;9K-KU?=$RUVIO9^AZV#"LRUFI>NRM
M1EHO\0EHB.CY*]^/>J)H1$\RFN7%C7]/BSQY)O?@N9[FL:KGJC6HEZJO<<5-
M82*/#M'+4>6QYJ+%7%6(R]&M75I33V=Q,L]:F0M:DU)PI6<A-Q+GY:$YEZ+?
MV7H<#;*AT^AV\LQ!IDM#@-<JN<K6HBN7X^E53M*881<QDMGG-7BL:V-K9"R\
MO#?-H^+&BK=#@PT57/X(1K'VXI]I7QX4)D65F8*7O@QD5'(FG3V>8Y"W%S\,
M-GF35V:Y"]$=\G&^/[C6Z#"?APCP9;1#B2BMBI#T=J-O[/Q)CCQZ?UJT3G-_
MP]F?PLTF6G8D*%*3<Q+PW8KYEC'8C5X'>4V>@5&2A3<H](D"*W&:Y.]"J[4I
M3I"F1K)V1EEFYV9=C1L5<IDT5;U5RHB^;MN[2Q+'T=:%9Z3ISXF4=!8C5==V
MK<5SQQB+A;"<IFI>R #)H                        .5&M57*B(FE57N(
M2U:G(MRU"414_P!9O45O_)I_[O$_:I\;SRKGTSI_]1WK4Z_9?9HY[N:IMQ<7
MXE[?9LO/2DR]62TU BO1+\6'$1RW?@IXUK[4R]F623IF#$BI-14A-Q%NN551
M/ZE*?_3TJ_#":T__ *5?WM.\PY?^7H'WQO[F$<G!''R]$S;+GQ_#NEFP(B18
M,.(B7(]J.1/M*YG,*\I+U*:DX5(GIATNMSW0M*=WF\Y85/\ _(2WHF^HHFS,
M.T46U5HV6;S:]771,M=V7-[/T,^+&)NV/)E,52W[(6JD+4R3YBGJY%AKBO8Y
MJHK5_%#W7.1C5<Y41J)>JKW%,X,*S+6:@UZ6J,M%6HRT1'1\E>_'O6[0B)K1
M3O;/6JD+6),R<&6G(3<2Y^6A.9>BZKT(SXZF:\$X9W&_%#F\)%'AVCEJ/+8\
MU%C+BK$9>C6K<JW:4T]G<>I;"ULC9>7AOFT?%C15NAP8:*KG\$*XME0Z?0[>
M68@TR6AP&.57.5K417+\?M5.TGVY1'X7K/,FKLV2%>W&^3C?&U]_87_#QF8K
MR5Z\JFW7V/MQ3[2Q(\&%#BRLU!2]\&,BHY$U]AXL_A8I,M.Q(4*4FYB7ANQ7
MS,-CL1J\#QHD&&[#?%A2VAD25NBY/1H7$O[#-ITIM/IL:R=D999N=FG8T7$7
M*9-%6]5<J(OF[;NU!&&-^'BCKRKQ6I39Z!4I&#-RCTB0(K4<UR=Z$D\:QU'6
M@V=DZ>^)E'P6(CG7=]R)_0]DPFKTVBZV  A(                       #
M0Z<E6N5'3,%%30J*]-!^H4S BNQ84:&]VIKD4HRM*O\ &JA]XB?N4Z/!?_GL
M;T2^M#R>+WE/)RQQ]/U<N/M'5ETT[6U]J)>S,.3=,P8D5)F*D)N(MURJJ)_4
M]V!$2- AQ42Y'M1R)]J%9X<?_+T'[XW]["QZ=_E\KZ)OJ/9G&(QB6\3,Y3"O
MIW"O*2]3FI*%2)Z8?+K<]T+2G=YO.=59"U4A:F3?'IZN18:XKX;VJBM7\4*A
MLU#M%$M;:)MF\VQE6Z)EKNRYO9^AZV#&LR]FX=>EJC+1/XC+Q$='R5[L>]53
M0B)K13;/BQK7BRQY)O?@N9SD:U7.5$:FE57N.*F\)%'A6CEJ/+8\U%C+BK$9
M>C6K<JW:4T]G<3+/6KD+5YS)P96<A)B?&RT)S+T75>AP-LJ'3Z';JS,&F2T.
M"URJYRM:B*Y;G]JIVE,,(N8R7SRFKQ6-;&ULC9>7AOFT?%C15NAP8:*KGKH[
M+D\Y&L=;BGVFB1H$*'%E9J$E[H,9%1R)K[#D;=(C\+=GFS5V;8E[<;LQM.OO
M[#5%A0W8;XD*6T,B2UT7)Z-'Q-1,<>/3^M6B<YZGLSV%BDRT]$A0I2;F)>&[
M%?,PV.Q&KP.\ID]+U*1@S<F](D"*U'-===>B_:59:9*;3:;&LG9&66;G9M^-
M%Q%RF3TWJKE1%U)VZRPK&T=U!L[)T]\3*/A,1'.\]R)_0KGCC&-PG"<IFI>T
M #)J
M
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M15T)J^P]4#+DRR\3'",?  !18
M
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M5T1+\E$OO1+]':B?:3B+26PV4V6;!B96&UB(C]9*.>?%O'@  A(
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MI6EGZN^?D'34=$:DM)N<K6HF,O>U-:\"/PXC&T_B3.5+6 !SM@
M
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MAY6$Z[XCVZ>QW8OR5*SCEXS"T98^$2]T %%@
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MM>L[NEU"7J<C"FY.(CX$1+VK^A*+?B91%(Z,9FP &:X
M
M
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M7V!:GQ):SDQ-QT5'SDPZ*E^KL_H6"9<O?-->/M@ !FN
M
M
M                               T3LG+STNZ!-P61H+NUCVHY%_!3]R\
M&'+P&08+$9#8B-:UJ7(B(;          (G\-D_X@D]F\+.T;BI%Q$QD33HO[
M>]26                               :)V3EYZ7= FX+(T%W:Q[4<B_@
MIO &N7@PY>"R#!8C(;$1K6M2Y$1#8         !$_ALFM12>67A+-HW%2+B)
MC(FG1?V]ZDL                               T3LI+STNZ!-P61H+NU
MCVHY%_!3]R\&'+P608+$9#8B-:UJ7(B&P       TSLI G99\O-0F18+TN<Q
MZ(J*GV*;@!KEH$*6@,@R\-L.$Q+FM:ER)^!L
M                                             ##E1K5<JW(B7J51
M6L(=;G*Y/2-DZ9G,.15R1HFEU]RJEVANCY*]Y;'"<O!7+*,?%; .0P=6Q9:N
MGQ%BP<WGH#E;&A8U]RHMU_8GF.O(RQG&:E,3&47  "$@
M
M
M
M
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MO'TG3EYJO\*4Q]7JARM]L_$7"O%A0W/B6?GVL;I55:W1_O+3/$MMXJU+T?\
M5"V.6$S$=*8PRF:M6GATD?)DUP;[0\.DCY,FN#?:*(!ZOP'$Z_A)]2]_#I(^
M3)K@WVC/ATD?)DUP;[10X'P'$?"3ZOX7OX=)'R9-<&^T/#I(^3)K@WVBB /@
M.(^$GU+X\.DCY-FN#?:,>'21\F37!OM%$ ? <1\)/J7OX=)'R9-<K?:'ATD?
M)DUP;[11 'P'$?"3ZOX7OX=)#R9-<&^T/#I(^3)K@WVBB /@.(^$GU?POCPZ
M2/DR:X-]H>'20\F37*WVBAP/@.(^$GU+W\.DCY,FN#?:'ATD?)DUP;[11 'P
M'$?"3ZOX7OX=)'R9-<&^T9\.DCY,FN#?:*' ^ XCX2?5_"^/#I(^3)K@WVC'
MATD?)DUP;[11 'P'$?"3ZOX7QX=)'R9-<&^T8\.DCY,FN#?:*( ^ XCX2?5_
M"]_#I(^3)K@WVAX=)'R9-<&^T40!\!Q'PD^K^%[^'21\F37!OM&?#I(^3)K@
MWVBAP/@.(^$GU/H>5PMNFX#8TM09Z)#=V.1K;E_WF[PI3'U>J'*WVSUL"OS?
M4[_O_>X[H\ODZ,,IQKP<N7'E$S'4J_PI3'U=J'*WVQX4ICZNU#E;[9: *=>/
MI5Z<O-5_A2F/J[4.5OMCPI3'U>J'*WVRT .O'TG3EYJO\*4Q]7:ARM]LC1\,
M"2[\2-0YUCKK[E:WVRV2J<*/C$S[NWUN.;VOVK'V?CZXPO\ ZSY9RX\>JVCP
MS0O(TYRM]H>&:%Y&G.5OM'+ \OYU_KC]W-\3FZGPS0O(TYRM]H>&:%Y&G.5O
MM'+&1\Z_UQ^Y\3FZCPS0O(TYRM]H>&:%Y&G.5OM'+@?.O]<?N?$YNH\,T+R-
M.<K?:'AFA>1ISE;[1RP[A\Z_UQ^Y\3FZGPS0O(TYRM]H>&:%Y&G.5OM'+ ?.
MO]<?N?$YNI\,T+R-.<K?:'AFA>1ISE;[9RR ?.O]<?O)\3FZGPS0O(TYRM]H
M>&:%Y&G.5OM'+ ?.O]<?N?$YNI\,T+R-.<K?:'AFA>1ISE;[1RYA1\Z_UQ^Y
M\3FZGPS0O(TYRM]H>&:%Y&G.5OMG+H8'SK_7'[GQ.;J?#-"\C3G*WVAX9H7D
M:<Y6^T<LGF,W#YU_KC]T?$YNH\,T+R-.<K?;'AFA>1ISE;[1RP'SK_7'[I^)
MS=3X9H7D:<Y6^T/#-"\C3G*WVCE@@^=?ZX_<^)S=3X9H7D:<Y6^T?N#AA2/$
M1D*B3KG+V(C6^V<F=)@_\9I7\?4IIQ>]_P 3.,/P_']4X<^>4Q#TO"E,?5ZH
M<K?;'A2F/J]4.5OMEH ]GKQ]+LZ<O-5_A2F/J[4.5OMCPI3'U=J'*WVRT .O
M'TG3EYJO\*4Q]7JARM]L>%*8^KU0Y6^V6@!UX^DZ<O-5_A2F.^SU0Y6^V/"E
M,?5ZH<K?;+0!/7AZ3IR\U7^%*8^KU0Y6^V/"E,?5VH<K?;+0!'7CZ3IR\U7^
M%*8^KU0Y6^V/"E,?5VH<K?;+0 Z\?2=.7FJ_PI3'U=J'*WVQX4ICZO5#E;[9
M: '7CZ3IR\U7^%*8^KU0Y6^V/"E,?5VH<K?;+0 Z\?2=.7FJY,*<Q]7:ARM]
MLSX4ICZO5#E;[9: )Z\/2=.7FJ_PI3'U=J'*WVQX4ICZNU#E;[9: (Z\?2=.
M7FJ_PI3'U=J'*WVQX4ICZO3_ "M]LM #KQ])TY>:K_"E,?5Z?Y6^V/"E,?5Z
MH<K?;+0!/7CZ3IR\U7^%*8^KU0Y6^V/"E,?5VH<K?;+0!'7CZ3IR\U7^%*8^
MKU0Y6^V/"E,?5ZH<K?;+0 Z\/2=.7FKBD83X,U69*0GZ9-R3IN(D*$Z(UMRN
M541$^4O>J%CG$V^LW/5NT-DYR2:U8--G,M'57(ES<>&O>NIBG;$9]-1,)QO<
M2  HN                   5[AU\0XWI4_:XL(KW#KXAQO2I^UQIQ=\*<G;
M+V<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M               <[A"\4*GZ%_[5/FX^D<(7BA4_0O\ VJ?-W<  '<!@SW
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M)>\   >);;Q5J7H_ZH>V>);;Q5J7H_ZH6P[H6Q\8?'H /IWI@   !
M                   "! /J/ I\WU._[_WN.Z.%P*?-]3O^_P#>X[H^;Y_S
M,ON\WD[I  9*   %4X4/&)GH&^MQ:Q5.%'QA9Z!OK<>=[T_(_P"PY_:>QQX,
MF$36?-O. .X -8,@@8 "$@GG      $'V@ ADP  0 90&#(&+@@   =P!#H\
M'WC-*_CZE.<0Z/!]XSROX^I3?V7\['[POQ=\+C !]<]8
M                                           KW#KXAQO2I^UQ817N
M'7Q#C>E;^UQIQ=\*<G;+V<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8
M56                                <[A"\4*GZ%_P"U3YM/I+"#XH5/
MT+_VJ?-P !  N 0(    =IA#(   $"   @ &.T(9[C" 9 N #6.X  G:$"
M $ 'TC@^\4:=Z)OJ0^;CZ1P>^*-.]$WU(!T0       *HPM_YS*>A_J<*=WA
M;_SF5]#_ %.$O/JO8?[?%\+[S_NL_N+I,7Z.\SW#M.MYYW"[2.WL &#/V]H[
MA=I!!W@:#(2P@[P$ =@3S]H[4 0:0@31V=@1 D70.X7(.P($'>!W@ BZ0GF
M2(O:.X(OF 0=XN[3/=<8[ E[UAM%II'5E&^M"\RC+#>,\CZ1OK0O,\#WM^9'
MV?5^X/R<ON  \E[P  !XEMO%6I>C_JA[9XEMO%6I>C_JA?C[H6Q\8?'H /IG
MIADP   0                           /J/ I\WU._P"[][CNCA<"GS?4
M[_N_>X[H^;Y_S,ON\WD[I  9*   %4X4?&&'Z!OK<6L53A1\8F>@;ZW'G>]/
MR/\ L.?VGL<?W!!W ^:><  D9,  !K    #)@(+@,F#)@@ $%Q(   @ U@9,
M)V!  0#O !#I,'_C/*_CZE.;.DP?>,\K^/J4W]E_.Q^\+\7?"X@ ?7/6
M                                        /"MK:&'9FA1*A$9E'(Y&
M,9M.N5;OT4F(F9J$3-1<O=!3M-MC;&),U2#/2$O"G($NV8AP&KVMQE15^6O<
MCN_N+$L/7OA'9V7J#F(R*Y,6(UJ*B(]$TII\Y?+CG':N.<9/> !FN
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M;ZW'G>]/R/\ L.?VGL<>AD(80^;><! AD@#""XR2,&3" @  2!E#"&0!@!
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M=P@^*%3]"_\ :I\W'TCA!\4*GZ%_[5/FX  8 R    [@&L!   "    '<
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M&^MQ:Q5.%#QBA^@;ZW'G>]/R/^PY_:>QQX,ZS!\V\YDP@!  !"00 R@&#)@
M$ "   !GM, =P  R 0P !GN"=A@ $,]Y@RGF '1X/O&>5_'U*<V=)@^\9I7\
M?4IO[+^=A]X7XN^%Q  ^N>L
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M*=!FJ;V+Q3H2 +DJ$?-4WL7BG09JF]B\4Z$@"Y*A'S5-[%XIT&:IOHO%.A(
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MQ$Q'1UB-QKN_^?\ H6=8:@)9NSDM3L?'>Q,:([6Y42_]33.(C'Z6IA,S+W@
M8M0        KW#KXAQO2I^UQ817N'7Q#C>E3]KC3B[X4Y.V7LX+/F]H/W9/6
MIU)RV"SYO:#]V3UJ=25S[I3AVP  JL
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M)>\   >);;Q5J7H_ZH>V>);;Q5J7H_ZH6X^Z%L?&'QZ #Z=Z8
M                    #ZCP*?-]3O\ O_>X[HX7 K\WU._[_P![CNCYOG_,
MR^[S>3ND !DH   53A1\86>@;ZW%K%4X4?&)GH&^MQYWO3\C_L.?VGL<>93M
M,#2?-O. #*=@!#   &3 #U R , &0,($\X  R8[@@&4  &#)@$ !K!(&3  (
M='@^\9I;\?4ISIT>#_QGE?Q]2F_LOYV/WA?B[X7$ #ZYZP
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M_:XTXN^%.3ME[."SYO:#]V3UJ=2<M@K^;V@_=D]:G4E<^Z4X=L  *K
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MCM+\*+P00(D/"-67/8J-5K[E7_K:7H:<_<IP]H #!J
M"J,+?^<RGH?ZG"WZSN\+?^<RGH?ZG"=ZGU?L/Y&+X3WG_=9_<33V@=X3M.IP
M0*IG68\P[@DO"?8+M&D=Z@#)C[3.@#'V!%T:1]HO Q=J,_: $'8$T*!>@2=M
M]W:$[PEW89 QW:1I"&?4!A.SO,F->D=]P"\=X72/,$'V!%O3L"!.S2![UAO&
M:1](WUH7F498;QGD?2-]:%YGS_O;\R/L^L]P?DY?< !Y3W@  #Q+;>*M2]'_
M %0]L\2VWBK4O1_U0MQ]T+8^,/CT 'T[TP     0
M      ?4>!3YOJ=_W_O<=T<+@4^;ZG?]_P"]QW1\WS_F9?=YO)W2  R4   *
MIPH>,4/T#?6XM8JG"AXQ0_0-];CSO>GY'_8<_M/8X\RI@(?-/.  2  0
M  =P!D#" =X =@  SWF 9 P  ,H#%R@ #/<8 '28/O&:5_'U*<V=)@^\9Y7\
M?4IO[+^=C]X7XN^%Q  ^N>L
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MN^%.3ME[."SYO:#]V3UJ=2<M@L^;V@_=D]:G4E<^Z4X=L  *K
M                                     ,.:CFJCDO0,8UC;F(B(9 &,
M5,;&NTZS( 'X9"8QRJUJ(J]Y^P                      "J,+=_\ &97T
M/]3A4O.ZPM_YS*^A_J<*?5^P_P!OB^$]Y_W6?W+@91#"=YU. [AVWA-(3\4
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M-,RD:'#2^]SF*B)H7S&_LW#R1RXS.,^,+\>&75&EH@ ^J>H
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M6?-[0?NR>M3J3EL%GS>T'[LGK4ZDKGW2G#M@ !58
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MHT_8,)C'&<OJ91.641]'9M1&M1&I<B)<B  Q:@
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M$=C1FJJXZM<J*JW_ &ZCKY(CIF(^G\.7CF;B97& #C=0
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MM3J2N?=*<.V  %5@
M                                               "+4Y^7IDC&FYV
M*V% A-5SG.5$[$O E J_PS43.59FT?((MR1M-R_I_4L:E5"5JDC#FY&,R- B
M)>US'(J?H6RPRQ\85QSQR\)2@"O;0X5J-2*B^2A,?.1(>AZP5O1."*,<9RU!
MEE&/BL('.V/MA2[52[WT^*B1&+<Z$YR8R>>[MN.B(F)B:E,3$[@ !"0
M
M            *UM=82?K%NZ?68$6&V7EW0U<U>U<5UY90+8Y3C-PKEC&6I>5
M:FG3%5H,[)2<?-X\:&YK8FI514/ L-9.;I5F9FF5J:SE8SE7XO\ *FK]#M (
MRF(HG&)FU+P\&]J*#&F85F*ND.2CJM[5N143S]G<=9@UL&MEG3,Y.S.<U&9T
MO>G8EZJJ]QW@+Y<N645*L<>.,W  #)H
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M=D]:G4E<^Z4X=L  *K
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M4MQ1$8ZD !DT
M
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M !58
M                                   BU"G251AI#J$G+3;&K>C8\)KT
M1?L5"4 /&^"EGO(-)_\ [.'T)LI2J?)2[X$G(2DO ?\ +APH+6-=]J(ERDP$
MW**A"E*33I2!%@RLA*P8,;_B,AP6M:_[41-/:I#6RMGE556@TE57_P#9P^A[
M(%R5#S9*@T>0F&QY&E4^6CMONB099C')?H[42\]( 3-^*:H !
M
M
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M
M
M
M
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MQ=\*<G;+V<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M
M
M
M                                                    !IG96%.R
MD66F6(^#$3%<U>]"KIO Y2XE>AQH*O93KEQX=Z7W^;1]I:YS]K[64VRLJR-4
MHBX\2_)PVZ7/5+N[\4XE\,LHUBIGCC,7DYOP/V8V)GG;[)8,"$V!!;#9?BM2
MY+SA9'"?29B4DYF-"BP(,U$6&URZ;E17)IT)LJ=ZU4<EZ+>A.?7_ .C#I_\
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M>S@L^;V@_=D]:G4G+8+/F]H/W9/6IU)7/NE.';  "JP
M
M
M
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M'[LGK4ZDKGW2G#M@ !58
M
M
M
M                       K/"*LW1K44ZNP:1$JTND-\-\-C%7$^3<NAKKK
M]/=W%F%>X2;93M&J$C2J-(YW/3-ZXJHBI_+=V_::<5]6E.2NG:JYME7C3:S2
M6<GX39B;;-L@M@ON:UK',7^76M_86+8FHQ;3V]CUJ%(3$K*0I=(%\1JIC+>Y
M>U43;0\Y+28051+[/-T)<GQ&Z/T+9I\)(<LS_!9!>J7N:UJ)I_ UY,ZC<,N/
M&Y252]%364/6;-VPHT]5I&A07Q:?/OQU>QJZ+TO7L[--Y?"K<BJO<5;9*OUB
MO6UJDY$CHRA22+"2'BHGQD5NF]$O7L=W]Y3BF8N87Y(B:AJJ5&J]E<'TM1J%
M*OF)R:>K8[H4-5Q;T1%5;K^Y.T[#!O08EG;*2DC,+_CW92)H['*B7IQ*>EHE
MK+:,J-H)"HI+RLJY<2&Y<7Y*(ZY$1JHORN\M_!E6XU?LA)SDT[&F$3)Q'7(E
M[FHB*NCSEN2)C'?_ %7CF)R=2 #G;AY]?GXM,I$S.2\G%G8L)N,V!"OQG^9+
MD7U'H!4O32()5]0,(,_4:@D&?LK4*;+HQ[WS$;'Q6XK573?#1--UW;WG#QZM
M3K4U&O5>KU&2@PI6#&@R,K&CM1SEN<B.1JKV_%;V(7G,2L&8@1(,:&CH<1%:
MY.R]/P.(J6"JRT:2FFRE+;#FGL<D-[IF-<UZHMRK\9>_S&^&>$?2F.6&4QXV
M\O )/2;K.1)-DU+K-)$>_(I$3'1N.NG%OONTII\Z%HG!X,\'\"R<.)'F608E
M2>CF+&A1'JF(KK[KEN3N;W=QWA3EF)RF87XXF,8B4*MS$>4HT_,RD%T>9@P(
MD2%":EZO<C55&HB=ZJB(?/\ ;ZV%J*O9^)*U>SLY(RJO15C18+VI?<O>K4UJ
M?1I7N'5$^ <;TK?VN+<&41E$3"O+$SC,V]+!?%BMP?T-&P;T262Y;^W2OF.H
MRT;<+S>XY[!9\WM!^[)ZU.I*9S_5*^';"/EHNX7F]PRT;<+S>XD K<)I'RT;
M<+S>X9>-]'7F]Q( N"D?+1=PO-[AEHVX7F]Q( LI'RT;<+S>X9:+N%YO<2 +
M*1\M%W"\WN&7C?1UYO<2 +*1\M&W"\WN&6C;A>;W$@"RD?+1MQ_N]PRT;<+S
M>XD 7!2/EHVX7F]PRT;<+S>XD 64CY:-N%YO<,M%W"\WN) %E(^6B[A>;W#+
M1=PO-[B0!8CY:+N%YO<,M%W"\WN) %E(^6C;A>;W#+QMPO-[B0!<%(^7B[A>
M;W#+1=PO-[B0!8CY:+N%YO<,O&W"\WN) %E(^7C;A>;W#+1MQ_N]Q( N"D?+
M1MPO-[AEXWT=>;W$@"Q'RT7<+S>X9:-N%YO<2 +@1\M%W"\WN&6C;A>;W$@"
MRD?+1MQ_N]PRT;<+S>XD 64CY:+N%YO<,O%W"\WN) %E(^6B[A>;W#+1=PO-
M[B0!<%(^6B[A>;W#+1MPO-[B0!<%(^6B[A>;W#+1MQ_N]Q( LI'RT7<+S>X9
M:+N/]WN) %E(^6C;A>;W!(\7<+S>XD 7!2/EHVX7F]PRT;<+S>XD 7!2/EHN
MX7F]PRT;<+S>XD 64CI&C;A>;W#+1=PO-[B0!92/EHNX7F]PRT;<+S>XD 7!
M2/EHVX7F]PRT;<+S>XD 6(^6C?1UYO<,M&W"\WN) %P4CY:-N/\ =[AEHNX7
MF]Q( N"D?+1MPO-[AEHNX7F]Q( L1\M&W'^[W#+1=PO-[B0!92/EHNX7F]PR
MT7<+S>XD 64CY:+N%YO<,M%W"\WN) %P4CY:-]'7F]PRT7<+S>XD 7!2/EHN
MX7F]PR\7Z.O-[B0!<"/EHVX7F]PR\;Z.O-[B0!<%(^6C;A>;W#+1=PO-[B0!
M8CY:-N%YO<,M%W"\WN) %E(^6B[A>;W#+1MPO-[B0!<%(^6C;C_=[AEHNX7F
M]Q( LI'RT;<+S>X9:+N/]WN) %B/EXVX7F]PR\7<+S>XD 6(^6B[A>;W#+QO
MHZ\WN) %P(^6C;A>;W#+1=PO-[B0!<%(^6C;A>;W#+QMPO-[B0!<%(^6C;A>
M;W#+1=PO-[B0!<%(^6C;A>;W#+1MPO-[B0!92/EHNX7F]PRT;Z.O-[B0!8CY
M>-]'7F]PRT;<?[O<2 +@1\M&W"\WN&6C;A>;W$@"X*1\M&W"\WN&6B[A>;W$
M@"RD?+1MPO-[AEXWT=>;W$@"X*1\M&W"\WN&6C;A>;W$@"X*1\M%W"\WN&6B
M[A>;W$@"RD?+1MPO-[AEHNX7F]Q( LI'RT;<+S>X9:+N%YO<2 +@1\M&W"\W
MN&6C;A>;W$@"RD?+1=PO-[AEXWT=>;W$@"X*1\M&W"\WN&6C;A>;W$@"RD?+
M1MPO-[AEHNX7F]Q( N"D?+1=PO-[AEHVX7F]Q( LI'RT;<+S>X9:+N%YO<2
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MJ\A0I1(U/GXF/E,=J+I2]>UR=]_:A?2WXJW=O<5+.NPEYY'S:'+Y#'7$O?\
MRWZ!PS,7X?\ 3DBW[J-(J]D\'DM1Z)+)'G)MZMCKVXMZ(BK?>B=B'88-J%%L
M[9.4D9E+H]V4B)>BW.5$O31YRGZ[;NVE$G&RDY'E73+NR'!?CN3[433W%PX.
MIRK3]F8,S7H3X4X]RKBO:K5Q>[0I;DC*,=_57CG&<M.F !SMP        KW#
MKXAQO2I^UQ817N'7Q#C>E3]KC3B[X4Y.V7LX+/F]H/W9/6IU)RV"SYO:#]V3
MUJ=25S[I3AVP  JL
M
M
M
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MV<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M
M
M
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MIC?BJW:%[CN+#46<H-"9(U";2;BL>Y6Q+U7XO=?>B%N7*,HC?@CBQG&?!T
M.=L        %>X=?$.-Z5/VN+"*]PZ^(<;TJ?M<:<7?"G)VR]G!9\WM!^[)Z
MU.I.6P6?-[0?NR>M3J2N?=*<.V  %5@
M
M
M
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M4=8J*D.#,L>[Y+NY%O+<43UPKR3'3+K<%GS>T'[LGK4ZDY3!8YJ8/:%>Y/\
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M]H/W9/6IU)RV"SYO:#]V3UJ=25S[I3AVP  JL
M
M
M
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MV3UJ=25S[I3AVP  JL
M
M
M
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M;KW>;Y'F3N/H:PDU29NST!UGVXL@SXC?BJFE-'>B%^3BZ(4PY.N70  Q:@
M     !7N'7Q#C>E3]KBPBO<.OB'&]*G[7&G%WPIR=LO9P6?-[0?NR>M3J3EL
M%GS>T'[LGK4ZDKGW2G#M@ !58
M
M
M
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M CX\SNV<5&/,[MG%11:0"/CS.[9Q48\QNV<5%%I (^/,[MG%1CS&[9Q446D
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M)RV"SYO:#]V3UJ=25S[I3AVP  JL
M
M
M
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M@
M
M
M
M        !5N157N*LM-A+LXL:+)I2OXM'AOQ5ANA(J7IY\52TU2]%1>Q3QY"
MS-&D8KXDK3X+8CU57.=>Y555O7MO[R^$XQW*Y1,^"A)RSE5M3,-?1[+1*/IT
M1%:L-->PTNW!W1I^A69@R56F73$TURN5SG*ZY%[KU5>PZ5K4:ES41$\R&2V?
M+.45]%<..,9L !DT        "O<.OB'&]*W]KBPBO<.OB'&]*G[7&G%WPIR=
MLO9P6?-[0?NR>M3J3EL%GS>T'[LGK4ZDKGW2G#M@ !58
M
M
M
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M\G;+V<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M
M
M
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MZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M
M
M
M                                                     "O<.OB'
M&]*G[7%A%>X=?$.-Z5/VN-.+OA3D[9>S@L^;V@_=D]:G4G+8+/F]H/W9/6IU
M)7/NE.';  "JP
M
M
M
M                                     5[AU\0XWI4_:XL(KW#KXAQO
M2I^UQIQ=\*<G;+V<%GS>T'[LGK4ZDY;!9\WM!^[)ZU.I*Y]TIP[8  56
M
M
M
M
M               !ARXK574EY3G\8M3:NTM:EJ14X-.@4V*]B,<QJJZYSD1?
MD+L_J7PPZE<LNE<@.!P3VEJ%<E9V7JJMB1Y.(L-8S41$?I\R)ZCOB,L9QFI3
MCEU1<!7N'7Q#C>E3]KBPBO<.OB'&]*W]KBW%WPKR=LO9P6?-[0?NR>M3J3EL
M%GS>T'[LGK4ZDKGW2G#M@ !58
M
M
M
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MS.J%P7J+YK5"X+U) %E(]\UJA<%ZB^:U0N"]20!92/?-:H7!>HOFM4+@O4D
M64CWS6J%P7J+YK5"X+U) %E(]\UJA<%ZB^:U0N"]20!92/?-:H7!>HOFM4+@
MO4D 64CWS6J%P7J+YK5"X+U) %E(]\S_ *7!>HOFM4+@O4D 64CWS6J%P7J+
MYK_2X+U) %E(]\UJA<%ZB^:U0N"]20!92/?-:H7!>HOFM4+@O4D 64CWS7^E
MP7J+YK5"X+U) %E(]\UJA<%ZB^:U0N"]20!92/?,ZH7!>HOFM4+@O4D 64CW
MS7^EP7J+YK5"X+U) %E(]\UJA<%ZB^:U0N"]20!92/?-:H7!>HOFM4+@O4D
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MFM4+@O47S6J%P7J2 +*1[YK5"X+U%\UJA<%ZD@"RD>^:U0N"]1?-:H7!>I(
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M9/%\R>\W $)
M
M
M
C                                           ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g12080g16t96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g16t96.jpg
M_]C_X  02D9)1@ ! 0$!) $D  #_[1QD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '$<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M $18WH#*!!L3J0'IX>LM3?JXTE$8FRAI=^T<0,A^!4D.C*^AI(?1'H$AV_\
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M;:6U6AD@I*<@B5YVG+=TKGN]E.,E1<ZK5R9NMK2$HO/EGK/7TT=WM?\ E?\
MVICC]W6'^J/W"JZJ*NIJBTU51--J[N4>79>=9EJZF6%L4M1,^)GT6.>2UO4.
M"ZH79QC"-?2<\KPI.;IK+0MM!)?]&,-!;Y(G5+7#-KG999.XJK*F%U/420R9
M:\;BTY<X*_=-655*"*6HFASW\F\MS\R^+G%SBYQ+G$YDD[2MMC9.S<L\FZFN
MTM%:)99K(QP1 BWFD+*PFU .E.I.=,T 3BB(2864RV($(">I$0D9(B( B($
M1 @0#G1$0!.*PLE" $1$ 'K1$0 ;D"($)&[\T1.M  B)QV(0$X(B )[$3B@"
M#BG0L9(#*9($0#@40(A)C<LHFW,H0$S6%E $R1!L0D!,@43/J0@!.I.*Z5CM
MU%J-^9TVX?\ XF_DN2\WI7>E56ITW>[NVKG2AS44X+I;M=1>)TWHF_DG:ZB\
M3IO1-_)<OFBX?R=/ESXCFE NENUU%XG3>B;^2=KJ+Q.F]$W\D\T7#^1Y<^(Y
MI1=+=KJ+Q.F]$W\D[747B=-Z)OY)YHN'\CRY\1S2BZ6[747B=-Z)OY)VNHO$
MZ;T3?R3S1</Y'E[XCFE.==+=KJ+Q.F]$W\D[747B=-Z)OY)YHN'\CRY\1S2$
M"Z6[747B=-Z)OY)VNHO$Z;T3?R3S1</Y'ESXCFD<4"Z6[747B=-Z)OY)VNHO
M$Z;T3?R3S1</Y'ESXCFE NENUU%XG3>B;^2=KJ+Q.F]$W\D\T7#^1Y<^(YI"
M+I;M=1>)TWHF_DG:ZB\3IO1-_)/-%P_D>7/B.:472W:ZB\3IO1-_).UU%XG3
M>B;^2>:+A_(\N?$<THNENUU%XG3>B;^2=KJ+Q.F]$W\D\T7#^1Y<^(YI6%TO
MVNHO$Z;T3?R3M=1>)TWHF_DGFBX?R/+GQ'-(*!=+=KJ+Q.F]$W\D[747B=-Z
M)OY)YHN'\CRY\1S3Q1=+=KJ+Q.F]$W\D[747B=-Z)OY)YHN'\CRY\1S3P0+I
M;M=1>)TWHF_DG:ZB\3IO1-_)/-%P_D>7/B.:>.] NENUU%XG3>B;^2=KJ+Q.
MF]$W\D\T7#^1Y<^(YI1=+=KJ+Q.F]$W\D[747B=-Z)OY)YHN'\CRY\1S3P1=
M+=KJ+Q.F]$W\D[747B=-Z)OY)YHN'\CRY\1S2BZ6[747B=-Z)OY)VNHO$Z;T
M3?R3S1</Y'ESXCFG/8BZ6[747B=-Z)OY)VNHO$Z;T3?R3S1</Y'ESXCFD<47
M2W:ZB\3IO1-_).UU%XG3>B;^2>:+A_(\N?$<TIFIOI=AB@Q- R&-D;32M.3&
M@#/6?S*#_BK&RM/J04_DX;2'TY./P9X+I^/N;>H+F +I^/N;>H*MQ3=Z]COP
M[>Z=S*(BJ"S"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B("F=,??3!Y(SWWJ"Y]*G6F/OI@\D9[[U!LSS+
MTMTV,>10WG:R,<"NGX^YMZ@N8 NGX^YMZ@N'%-WKV.O#M[IW,HB*H+,(B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@*9TQ]],'DC/?>H*IUIC[Z8/)&>^]03\5Z6Z;&/(H+SM9&0NGX^YM
MZ@N8%T_'W-O4%PXIN]>QV8=O=.YE$15!9A$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1%ACVO;K,<'-YP<T!E$6&O:XD-<"1L.1W(#*(B (B( B(@"+ <"X@$9C>
M%E $1$ 1$0!$6'.:T9N( Z2@,HB( B(@"(B IG3'WTP>2,]]Z@NQ3K3'WTP>
M2,]]Z@N:]+=-C'D4%YVL@%T_'W-O4%S!N73\?<V]07#BF[U['9AV]T[F41%4
M%F$1?&LJ8Z.DFJ9SE%$PO<>@!-8/LBB OU\[#[:=KZ7M7]/D]9W+:G \W2I3
M15,=92Q5$#M:.1NLTK.4''68QFI:C[(B+ R"(B (B( B(@"(B (B("(XFQ35
M66IJV5=AN$EL;'F*ZF#9!M&W6:#FT \2H?HQQ=5#"M%16NR7*YSLD<)9@ R)
MN;B?ID[P"-BG.-K#68B@HZ".J$%L=+K5H:2'R-&T-!YB=ZU;7A2:QXKDK+)+
M%!9ZF/YQ1D'5$@W.8!L!(WK=%PT:/6:FI:53?Q#?;A:9*9T-AK:^F>W6F?3.
M:Y\1YM3/-WX*NL$XW#;MB06^U72XU-35\K% R/+4:!D=<D_)VJS<64ESKK'4
M4UEJ8Z:KER:)7Y_);GMRRW')1QN Q:*RT5V&964U92@0U!D^C4QGZ6MEO=GM
M2#CHT8DI5R)E;)YZF@@FK*5U)4/;F^!SPXL/-F-A6RB+2;0B(@"\;$MXJ+/#
M!+3VFMN3'.RE%(T.?&W+?J\>I>RM*]BO-IJQ9S$+@8R(#-] .X9J8Z\R'J*P
MM6/Z$X[O4T4%UJ>6@@9#1QT[C*'-#@\:IW9$A698JZ>XVYE35T$]!*XG]A-E
MK 9["<N=0/XN)[=;Z"NLM4&XGIY#--52..K4%Y'*!^S,C?E_NK+CUM1O*9:^
M6W+=FMEHX[IA9J2]1E$1:C8$1$!^9'%D;W-:7. )#1QZ%3^DW&AEL,5+4VZZ
MVJM%5&[]K&6M<T.VZKP<CL5Q*$7'!TN(,2U57B1\4]MCC,5'3,)R&>][@?XE
MLLG%.LC7:)M41Z>'\4NOE>&4EHN45"6%PK*F+DV./  $YE211S MJNEDMDMO
MN=3'4P0ORI9 27F/F=GS;E(UC*E<C*-:9A$18F01$0%,Z8^^B#R1GOO4%"G6
MF/OI@\D9[[U!<B>*]+=-C'D4%YVL@NGX^YMZ@N8."Z?C[FWJ"X<4W>O8[,.W
MNG<RB(J@LPO$QNUSL)W,,SSY(G9S9[5[:_,L;)HGQRM#HW@M<T[B"LHO1:9$
ME5-'CMEA^" DS;R78F_A]%?C K'LPK;Q("#J;CUE:GP1;JFG[957:S6S[$_A
MRYL]^2DT4;(8FQQM#6-&0 X!9R<:43ULPBG6K/TB(M1L/C+,]CR&PN<.<%>!
M5XULU'4RT]35Q1SQ.U7L<[:T\RDJYJQYWY7GRE_M4U"52ZOA]8/'X?YO]EGX
M?6#Q^'^;_9<[(E2:'1/P^L'C\/\ -_LGP]L'C\/\W^RYV'%.)2J%#HCX?6#Q
M^'^;_9>Q;+S#<Z45-O;R\!):'L.S,;UR_P ZOO0WWE1??R>U*D4)?V1)XL_S
MKQYL7VJ":2*6HC9)&XM<TNV@C80I"N?L0_7]S\IE'_W*[KC=H7EM2RH5>)WV
M=SC%P5:_);OPTL_C4?\ ,GPSL_C4?\RI+(Y)UJQ\ILOEE/Y];\*_)=OPTL_C
M4?\ ,GPTL_C4?\RI'J7ZZD\ILOECSZVX5^2[/AG9_&XOYEZE#<V5U,RHI(S+
M _/5>T[#D<CZPN?@-BNS1OWFT'^I_4<N2^W*%WLU.+KF6&&XG:7NU<)I+*N7
M0]SLB3Q9_G4=K<?6"AJYJ6KKX8JB%Q8]CG;6D<-RE:Y*TD=_E^\K?[5RW6QC
M;2:D>@LK/3=&SH/XR<,_XI3_ ,Q_)/C)PS_BE/\ S?[+EA97=Y?9_+-_AE\G
M4_QDX9_Q2G_F/Y+'QDX9_P 4I_YO]ERPB>7V?RQX9?)U1\9.&?\ %*?^;_92
M"WW6.XT4571,,U-*-9DC3L<.A<;KJ[15^[VQ_<?W%<MZNL+&*DC5:V2@JIDB
M[(D\6?YUYTV(Z*&5\4KPV1A+7-)W%>TJEQ!]>5_W[_:51WZ].[14HJM3DM9N
M"R)[\*+?X5O\R?"BW^%;YU62*M\XM.%?G_Z:/KR+-^%%O\*W^9/A1;_"M\ZK
M)$\WM.%?D?7D6;\*+?X5OG7HPUCIHF210/=&\!S7 [""JA5MV#ZDH/N&>P+N
MN-^E>9-225#;96CFZ,WHW%S 2TM)X'@LHBL3>4SIC[Z:?R1GOO4$\RGFF/OI
M@\D9[[U!%Z6Z;&/(H+SM9<PNGX^YMZ@N8%T_'W-O4%PXIN=>QV8=O=.YE$15
M!9A$1 $1$ 1$0!<U8\[\;SY2_P!JZ57-./._*\^4O]J$H\)86<D4$CJ0+"SN
M0&%?NAOO*B^^D]JH-7YH;[RHOOI/:@9-US]B'O@N?E,OOE= KG[$.7;^Y[_^
M)E]\JYPCURY'G<?V<.;//W9I[4W9ITJ]/+A$_!-R <%=FC?O-H/]3^HY4IZU
M=>CCO-H/]3^HY5>+;%<^S+O ?U$OV]T25<E:2._R_>5O]JZU7)6DCO\ +]Y6
M_P!JK\.];Y'M;OK9'$0=*PK<ZS/!865A 975NBK]WMC^X_N*Y175VBK]WMC^
MX_N*K\1V:YG/>/22M5+B#Z\K_OW^TJVE4M_^O*_[]_M*\AB^SCS*R\:D>>B(
MJ Y0B(@"MNP?4E!]PSV!5(K;L'U)0?<,]@5O@_KER.B[ZV;Z(BOSJ*9TQ]]$
M'DC/?>H*#EL4[TQ]],'DC/?>H*%Z6Z;&/(H+SM9&!N73\?<V]07,"Z?C[FWJ
M"X<4W>O8[,.WNG<RB(J@LPB+\R/;'&][SDUH+B>@(#](HM3XK[+O]+14E,XT
MDNL#/("W,@$[ I2LI0<=9C&2EJ"(BQ,@N:L>=^-Y\I?[5TJN:L>=^5Y\I?[4
M)1X*!$4$F.= LH-R *_-#?>5%]])[50:OO0WWE1??R>U R<+G[$7U_<]O_J9
M/?*Z!7/N(OKZY^52^^5<X1ZY'G<?V<.;-#>$V!%A7IY<SP3CM39U(@"NS1QW
MG4'7)_4<J3"NS1OWFT'^I_4<JO%MBN?9EW@/ZB7[>Z)*N2M)'?Y?O*W^U=:K
MDK21W^7[RM_M5?AWK?(]K=];(VB+/.K<ZS"RL($ XKJ_15^[VQ_<?W%<H+J[
M15^[VQ_<?W%5^([-<S1>/2B5JI;_ /7E?]^_VE6TJEQ!]>5_W[_:O(8OLX\R
MKO&I'GHB*@.4(B( K;L'U)0?<,]@52*V[!]24'W#/8%;X1ZY<CHN^MF^B(K\
MZBF=,??3!Y(SWWJ"YY*=Z8^^B#R1GOO4$7I;IL8\B@O.UD%T_'W-O4%S NGX
M^YMZ@N'%-SKV.S#M[IW//O\ <76RWF>*'EIG.;'''GEK.)R&U1V3$&(725$$
M-LHVU%%'RM2'RDM<#M 81Q(!WKVL7.H!8YQ=&2R0.( 9#GRCG9[ W+;GFHC:
M[79JJ*IC>+U;*[DG.G@J)<I9X^DG,$</DG8JV"5*L[Y-UHB8"]&2Q4=SI:*I
MJ6U,;)&Q1MS> YN>U;%IKY+A%(Z:AJ:35.6K.T#6ZDP]-!4V&W34<1AII*>-
MT49WL86C(?@%OK!M:J&23UU(S>@&XNL0  &3\LO\I4F7FUMK%5=Z&NY;5-+K
M?(U<];,9;\]B])3)II"*:;"(BP,CXRSN8\M$,CLN(&Q<W8Y=K8OO!R+<ZE^P
M[]ZZ77-6/._*\>4O]J$H\$(L+.Y02$YT0(#"O;1!.68,B AD=^VDVM&S>J*5
M^:&^\J+[^3VJ40R7=DN\7F\RH:_G6OUQ.66=3)L/^8KH)<_8A'_C]SX_.9??
M*N,(]<N1YW']G#FSST6-RSSA7IY@+.2QEEQ3- -V]7+H\G<S"%"T0R.[IM:-
MG='*FBKLT;]YM!_J?U'*LQ78KGV9=X#^HE^WNCW.R7>+S>9<I:17:V.;Z2"W
M.K><CPVKK9<E:2._R_>5O]JKL.];Y'M;MK9&T1%;G6 LK"( NI]%M0YN +(!
M#(X"'>!L^D5RQP75VBK]WMC^X_N*K\0V:YG/>?2B1=DN\7F\RJR^G6O-<X@C
M.9^P\-I5N*I<0?7E?]^_VE>0QC9QYE9;ZD>>B(J Y0$1$ 5J6.H<VS4($$IR
MA8,P-^P*JPK;L'U)0?<,]@5Q@^TER-]WULWHW:S XM+2>!WA91%?'64UIC[Z
M(/)&>^]038IUID[Z(/)&>^]05>ENFQCR*&\[60"Z?C[FWJ"Y@73\?<V]07#B
MFYU['7AV]T[GGW^V&ZVYU.RH=32AP?',UH<6.!S!R.]:M^L(O%LCAEJ715\0
MSBK(FY.8_++/+/<>+2<B-B]M5Y-55$5;4QX.JKE6U(>=>&HS?3-=GM^4_(@9
M_8*JX5>HL)41-;#0&UV2@H'2<J:6!D)DU=76U6@9Y<-RWEX>&KG<JN2IH[W0
M1TM=3-8YSH'E\4@=GM:2 ?X3F-O!>XL76N9DM601$4$A$1 %S5CSORO/E+_:
MNE5S5CSORO/E+_:A*/!1$X*"0@WHB QQ5^:&^\J+[^3VJ@_Q5^Z&^\J+[Z3V
MH&3=<_8A^O[GEXS+[Y70*Y^Q#]?W/;_ZF7WRKG"/7+D>=Q_9PYL\_AD-Z;>*
M#8L*]/+F4W;TV\R(!DKLT;]YM!_J?U'*D^"NS1QWG4'^I_4<JO%MBN?9EW@/
MZB7[>Z)*N2M)'?Y?O*W^U=:KDK21W^7[RM_M5?AWK?(]K=];(VB(K<ZPG.B(
M NKM%7[O;']Q_<5RBNK]%7[O;']Q_<57XCLUS-%X]*)4JEQ!]>5_W[_:5;2J
M7$'UY7_?O]I7D,7V<>95WC4CST1%0'*$1$ "MNP?4E!]PSV!5(K;L'U)0?<,
M]@5OA&TER-]WULWT1%?G64SIC[Z(/)&>^]04#9M]JG6F/OH@\D9[[U!=J]+=
M-C'D4%YVL@%T_'W-O4%S /4NGX^YMZ@N'%-WKV.S#M[IW,JKYJRM?4S/J[_/
M;P>6:8V:K&1O:26-VCBT9].:GV(KH+/:I:ODC,\$-9&#D7N)R S49N$&((8)
MJ^Z45FKJ9@Y62D#,WC(;PXC(D#-5EF=\R4X?F=4V*W3R&0OEIXWN,GTB2T';
MTK?7PM]1%5T%-4TW<)HVR1[,ODD9CU+\W.K;06^IJW@N;#&7D#><AN6%*NAG
MJ1LHH;)<,1LMO;<]BBFU1)V)J_+U#_S<ZE5MJV5U#!51@ALK0X K*4'%5,8S
M4LC81$6!F%S5CSOQO/E+_:NE5S3CSORO/E+_ &H2CPEA9VHH)"(B <%?FAOO
M*B^_D]JH/@K\T-]Y47WTGM0,FZY]Q%]?W/RF7WRN@ES]B'Z^N?/V3+[Y5SA'
MKER/._Z@V<.;//&Q861MZT5Z>6 .W--F:<Z#?M0E ;E=NCCO.H.N3^HY4D.E
M79HWVX-H/]3^HY5>+;%<^S+O ?U$OV]T25<E:2._R_>5O]JZU7)6DCO[OWE;
M_:J_#O6^1[6[ZV1Q8"(K<ZPB(@ XKJ[15^[VQ_<?W%<HKJ[15^[VQ_<?W%5^
M([-<S1>/2B5JI<0?7E?]^_VE6TJEQ!]=U_W[_:5Y#%]G'F5=XU(\]$14!RA
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M\?<V]07,"Z?C[FWJ"X<4W>O8Z\.WNG<RB(J@LPB(@"(B (B( B(@"(B (B(
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M7L?I$18F01$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MMTV,>107G:R"Z?C[FWJ"Y@'%=/Q]S;U!<.*;O7L=F';W3N91$50681$0!$1
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MN8,LUT_'W-O4%PXIN]>QV8=O=.YE$15!9A$1 $1$ 1%^9'MCC<^1P:QHS)/
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MA:3L_2Z$Z^,^]^ H/1N_4GQGWOP%O]&[]2@O!9&Y:_"6/"C/Q-KQ$Y^,^]^
MM_HW_J3XS[WQ@M_HW?J4$X+/.GA+'A0\3:\1.OC/O?@+?Z-WZD^,^]^ M_HW
M?J4%0)X2QX4/$VO$3KXS[WX"@]&[]2?&?>_ 4'HW_J4%YTX)X2QX4/$VO$3K
MXS[WX"@]&_\ 4GQGWOP%!Z-_ZE!0B>$L>%$^(M>(G7QGWOP%!Z-WZD^,^]^
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$5G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g12080g20l82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g20l82.jpg
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MA,3#_\0 %@$! 0$                   $"_\0 &!$! 0$! 0
M     !$!(4'_V@ , P$  A$#$0 _ -=L*V1V3:!IFNN-WK;E!-!6+3M;2O8U
MJM1C'97>8O'+E+(\6?2?G6^_.P_IGQW('L"N_P )N^ZC+U"J-\6?2?G6^_.P
M_ICQ9])^=;[\[#^F7D E4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGY
MUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?
M%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O
M( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWY
MV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3
M\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3
M'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]
M^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^
MD_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %
M4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_
MIEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6?2?G6
M^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL/Z8\6
M?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGYUOOSL
M/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?%GTGY
MUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O( JC?
M%GTGYUOOSL/Z8\6?2?G6^_.P_IEY %4;XL^D_.M]^=A_3'BSZ3\ZWWYV'],O
M( JC?%GTGYUOOSL/Z8\6?2?G6^_.P_IF^VH;7H=(WN&P6>TSWJ_2-1RT\3E1
M&;W%J<$57.5..$3DO,C%!M[K[9>*:BUYI&LLD-0ODSJCVJU,XWMQ[45R)UJB
M_$H7K)\6?2?G6^_.P_ICQ9])^=;[\[#^F3S:AK:JT;8:.XVRRRWM:B=(NCA>
MK=UJM<[?RC793@B<NLEMKJ75MLI*J2)87SPLE=&JY5BN:BX^("EO%GTGYUOO
MSL/Z8\6?2?G6^_.P_IEY )5&^+/I/SK??G8?TQXL^D_.M]^=A_3+R-'KB_+I
MC2=TO24Z5*T4*R]"K]S?PO+.%Q\@55/BSZ3\ZWWYV'],>+/I/SK??G8?TRQ]
ME^KEUQH^EOCJ)*)9GR,Z%)>DQNN5OKL)SQV$K HWQ9])^=;[\[#^F/%GTGYU
MOOSL/Z9>0"51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ
M9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.
MP_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?
MG6^_.P_ICQ9])^=;[\[#^F6#M7UJN@M*.O3:!*]4G9#T*R]%Z[/'.%[.PU6H
M=H]9;=FMEU50Z?EN$UQ2)5HHI5S&CV*[.\C%SC&.2<PJ)^+/I/SK??G8?TQX
ML^D_.M]^=A_3+DL-<^YV.WU\U.ZFDJJ>.=T+ERL:N:BJU>"<LXY(9P2J-\6?
M2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"
MJ-\6?2?G6^_.P_ICQ9])^=;[\[#^F7;63=[TD\^[O=&QS\9QG"9(%L;VCNVC
M6VXU;K6EN[TF;%NI/TN_E,YSNMP%0_Q9])^=;[\[#^F/%GTGYUOOSL/Z9>0"
M51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#
M^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=
M;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ
M9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.
MP_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?
MG6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-
M\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??G8?TR
M\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I/SK??
MG8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV'],>+/I
M/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZWWYV']
M,>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBSZ3\ZW
MWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D 51OBS
MZ3\ZWWYV'],>+/I/SK??G8?TR\@"J-\6?2?G6^_.P_ICQ9])^=;[\[#^F7D
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M.Y ]@5W^$W?=1EZE%=R![ KO\)N^ZC+U"
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M57*814SG/'TTA=+[H>Y55SCVE:,K+#?VRN5%M;'1[Z>E%=NJ[.?*PJ+E"1;
MM(7FXZ!UM1U#:FDM%W@6&WMJ<IEZM>G28[.+$543CCT :_3-PUCM&IKC?Y]H
MD&G%9*YE)0-GZ)CE1$7"HCDPWBB;RHY5X_'9_<]:^K]::?KZ:^.9)=K7*V.6
M9J(G2L<B[KE1.&<M<BXX<$*'TE/I'2%'<;1M+T;5SWV"5SH'HCDZ1,(B,7RD
M3&4RCDRBHOHXWQW/=$U-/U=T_9*GTVM8YK6-BDD5:AC<X>K7JJM3+EQV\?0!
M:P "
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MNS/$#]
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M93.#Z
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MNBKVL]9WQ"UZL]Q53*?$<ECL5JL-,ZGLENI*"%RY<RGB:Q'+VKA.*^Z;$
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MX1YW5RU$5>'I*+[GRHU4SU>J]+V&UW>JD>QM3-73HR1B+O+A,JG!RY5>U4]
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M6Y7"IN.SCAR(SW'7L?U'_FHO]"F@[GRW27=NU*VPN1LM93K3L55QA7].U/M
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M4L6D+CK_ &1UVJ=2ZENDU3;J:;O"!)$Z-K86JN7Y3+G*J*F>"\LJIO\ 9[M
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M8:(H+76]T'15&S!D[;!2M1]5*F^D;6[JH]/+XX=P1$7KY<$-OMC_ -Y;1/\
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M1381'-<KE7CP3KY87K)P$,)V(,)V(  PG8@PG8@ #"=B#"=B  ,)V(,)V(
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MM#D=;6T\:4RH]7HL6ZF[ARJJKPQQ4S@AA.Q!A.Q  &$[$&$[$  83L083L0
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MOF!=R)BN=C*]2$KV2Q20;,],Q3QOCE901-<Q[516KN\E1>1+ $
M                                                    ZX[6O]YO
M1'O=)]_*=CC$GME!45L=944-++5Q8W)WQ-<]F%RF'*F4XJH%6]T[IJKO^SM)
M[="^:>VU"53HV)ERQ[KFNPGHRB^XBE8:FVJ6&\[":32U+%4+?'04U&M.D2[K
M5C<WRT=R5%W.")QRO([6&HI],6&GN*W"GLELBKU7>[Y92QMDSV[R)G(5IMC]
MGJ[#LUL%NN37,JXJ?,C'<V*YRNW5]*;V/B)@ $
M    !%MJ5AFU-L^OMHI41U344ZK"U>&](U4>U/C5J)\9U_V8;4+)I'9A>--7
MZ"IANT*U#&0+"J],KT5-UR_TJBY1<XX)U\CM2:FNTS8KA7)6U]EME36)C$\U
M*Q[TQR\I4R!5_<J62NM6SRHJ*^-\+;A5K40,>F%6/<:U'8]*HOQ(B]9<P1$1
M$1$PB                                 #JILJN-MV7;7M3V_5C^\62
M-?%!4R,56[O2;S5RB9PYN%SZ#=[')F:C[H'5.H;$U_J)T<B+-N*UKU<K$3XW
M*USN/'@7GJ72&G]3]'ZOVBDKG1IACY6>6U.Q')QQZ,F;8[+;;#0MHK-0T]#2
MHN>C@8C45>U<<U]*A6P  0                     4GW5VGJJ[:&H[C11.
ME6UU"R3-:F52)S<.=\2HW/HRO407:'M,TWJ+8G;;!;5D?>G-IH5I$A=F%T>,
MJBXPJ+C"87/E<N9VE<U'-5KD16JF%1>2F@H-%:8M]R]4*'3]KIZU%WDFCI6-
M<U>U.'!?<"L?9=;*NS[/-/4%Q:YM7!1QMD8[FQ<9W5]S./B)0 $
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MK_2[&5;\6<?$;"CTS8J*O6NH[);*>M5<K414K&R9_P"9$R;8
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MQSAO5UD@
M              _'.1K5<Y41J)E57J0JJEVE:BU&^JJ-":.==+/3R.B2MJ:U
ME.E0K>?1M5.*>GY<<@+6!$]G6MJ;6=OJWLI)Z"XT,RT];0S^O@D[,]:+A<+P
MY*2P                                 "IH-3ZTUI?;S%HMULM=FM=0
MM)WU7Q.D?4RM]=NM3@C>7IPJ=N$WNS#6-PO]5>[+J.D@IK_99FQ5/>RJL4K7
M(NZ]F>*9PO!?1VX0)X                        #&N5?26RAFK;C4Q4M)
M"W>DFE<C6M3TJI5.E=K#]6[6(;-9HE;I[O261L\L2M=4N:N-]N>3,HJ)VX7/
M8@6^                           ,6ZW&DM-NJ*^Y3LIZ.G8LDLK^36IU
ME.6/:I<-4[7[#;K5!44FEZB*H<Q\\.ZZNW8W+TB93*-1S4QCTY[$"[0
M                      (;M.V@VK0=DEJ:V5DEP>Q>]:)'>7,[JX=3>UW_
M +X0"9 TFB+Q+J'2-GN]1$R*6MI63NC9G=:KDSA,F[
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M<$XEOE76FCJF]T9>ZQU-,E(ZQ,C;.K%W%=TD?DH[EG@O M$(
M                                                 /B>&.H@DAF:
MCXI&JQ[5Y*BIA4(S=;CIS9II#?D2*WVJEWDAIX^;W.57;C$7BJJJJOX(AOKO
M7QVNU5MPG:]T5+"^=[6)ERHUJJJ(G6O ZR:>UK:[OJJ74^T6AO5960R*ENMT
M5$KZ:C9U.XJF\_TJG5GGC 6KL.LUS1=1:LOE,M%5ZCJ6U$=(O.*%N]N9]*[R
M_$B+UEHD4T+KNV:T6M2UTUQ@[TW-_ORGZ+.]G&[Q7/K5)6
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MK6HDC\(B)R0M\K6NL5RDV_6Z]LHY%M4=F=3OJ>&ZDF^]=WMSA4 LH
M                   <-924]=324U;!%44\B8?%*U'-<G8J+P4JC5+6L[HS
M0S6-1K6VVI1$1,(B;DA;I7FH-,W2LVT:6U!3T[76JAHYX9Y>D:BM<YKT1-W.
M5]<G) 8L,                          "LMJ6CK'3:9UMJ-M"R2\U5NEW
MJF5=]6(D6ZB,SP;P3JXKE2S2+;5(9:C9MJ>&GC?+-);YFL8QJN<Y58N$1$YJ
M!Q;(/Y7Z6^#H?]*$N(ILG@EIMFNF8:B)\4T=!$U['M5KFKNIP5%Y*2L
M              !^/<UC5<]4:U$RJJN$1#]*QV\VO5U^T_2VC1]+TU/4O<MP
M<E0R%RQIC$:*Y4X.RN<?X<=8&BU?>:O:S<)=(Z/<Y-.12-]5[RB>0Y$7/11+
M_4N43CU^YQ6X[=1P6ZWTU%2,W*:FB;#$W_"UJ81/D0J&P5>TFP6FGMMHV=V>
MEHH&[K(V7)GRKY7%5ZU7BI;=GEK)K51RW.G935SXFNGA8[>;'(J>4U%ZT1>&
M0,L                   #\<JHU51,JB<$[0(KM!US;-%6ULM;O5%?4+N4E
M!#QFJ7\D1$[,XROVKA%T.R?2EVIKC=M7:NW6ZBO.ZBT[/6TD*8W8_=X)GW$Z
M\E?V2Q[2Z'6=QU1<='4%UNU0[$$E3<8\4D?'#(T1V$X<,\_E7-J:)NVMZ^Z2
MQ:MTW16JB2%7,F@K&S*Z3*8;A%7AC*Y] 5-0 $                     %
M2]TU&R+9-5-C8UC>^X%PU,)Z\M:F_P"[Q?\ *GV$*VT:5N&LM#3VBT.@;5/G
MBD19WJUN&NRO%$4F\+59$QJ\T:B ?0          Q[C_  ^J]Z=]BGF\>D-Q
M_A]5[T[[%/-X+CMIW('L"N_PF[[J,O4HKN0/8%=_A-WW49>,T\,"(L\L<:+R
MWW(F?E".0'!'64TKD;%40O<O4UZ*IS@ ?$4L<S-Z)['MY9:N4/L    !\12Q
MS,WX7LD;VM7* ?8     <=3&LM--&U417L5J9]*'( (7L?TI6:+T+262Y34\
MU3#)(]SX%56*CGJY,91%Z^PF@
M
M                      %5$15541$YJI\QO9*QKXW->QR91S5RB@?0
M
M
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MBH;4J+N6ESLP7BBXKY^+>7]);H0
M
M                        4YMJK]97"W:CMUDHTM=AH*1TM5=)7^75-Z+?
M6*%$XHG'=5?0O%.2S'8S_*S2_P#D8_L,G:K_ "TU3\&U'W;C&V,_RLTO_D8_
ML F0
M
M                                                        #'N/
M\/JO>G?8IYO'I#<?X?5>].^Q3S>"X[:=R![ KO\ ";ONHR?[3= MUNEG<V[5
M%KJ+9.M3#- Q'.1_#"IE4PJ*B*0#N0/8%=_A-WW49>H%32[);O61N@NFT;4U
M12/3$D3)$CWTZTSE?L)_I#3%KTC9(K58Z=(*6-5<N5RY[EYN<O6JX^Q.2&Z
M16M#LBM46S>IT?65E14TTM0ZI;4HU&21R*J*BHG%.&/C15.--F5VN-"EMU5K
MBZ7:SHU&]Z,@93=(B<DD>W+GI\:9+. %;3;*H)ME,>AY+M,M/')OMJNA3?QT
MBR8W<XYJJ$VOMH9=M,7"S/E=''64<E&LJ)E6H]BLWL?'DV8 TVC;$S3.F+;9
M8IW5$=%$D22N;NJ['6J&OV::.AT+I>.RT]7)5QLE?+TKV(U5WESC"$I $5TK
MHVGL%XU-7)4NJ?5RI[XDBD8B-C]=Y*=J>5UD6BV57"S254.B]9W&Q6JH>LCJ
M'O=E0R-5Y]&KE16?;Z2TP!!;/LOL5NT3<M-O[XJ8;FJOK:J5^9II%X[ZNQS1
M414_]\KG46_9?>(K='9J_7EUJ=/,8D*44=/'#(Z)."1K,F7;N.'#'#@6B (I
MLVT7!H6RU-KHJN2HI9*I]3&DC<+&CD1-S.>.,<R5@
M
M                                       &MU/:67[3MSM,DKH65U/)
M3ND:F5:CFJF43XSBTC9&:;TS;;-%,Z=E%"V%LKFX5R)UJAMP
M
M
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M1.KL++ ]B.5?*ZT\GW/*Y< +C
M                                               $;U]K*UZ)L$US
MNTS45$5(($=Y<[^IK4^U>KF9>B[W^TFE;7>5@[W[]@;-T6_O;F>K.$S\A!=J
MN@[*^TZPU3612UEU=;)4A6H?OQTJ-AW?W3>3<XSGBN57&"0[&?Y6:7_R,?V
M3(                       &NU%>J#3MEJKK=Y^@H:9J.DDW5=C*HB<$XJ
MJJJ)\94>C]HE\U1MCHZ22EJK7I^6W23TM+.U&OJ&YPDSDZLJBX3EA.O.2Z:B
M"&IB6*HBCEC5456/:CDRBY1<+V*B+\14]R_WG;5_Y?=]X\"W
M
M
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M3:7:J=TAK-V%W5ME/QQZ(S[U>U5[H;03D1<)15>5Q_\ TWEL
M
M            (MM415V:ZI1$RJVVH^[<8VQI%39;I=%145*&/@ON$R
M                    @%9I:Y2[;*#4[&Q>I4-I=1O=O^7TBO<OK>S"IQ)^
M
M
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MU_Y6+_0AL0
M          U6JKW'IVP5=TFIJFJ; C<04K-^21SG(UK6IUJJJA3>D;]JNZ;=
MZ#]J*=]LAGM4L]-;$DST,:N5$5Z=;U5JJN?1RY 7R
M
M
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MZ>FB5RQPQMC:KN:HB83/R',
M                       J.Y?[SMJ_\ON^\>6X0RJT=/-M8H]7)51)3P6U
M:%:?=7?5RN<N]GECR@)F
M
M                                              ,>X_P^J]Z=]BGF
M\>D-Q_A]5[T[[%/-X+CMIW('L"N_PF[[J,O4HKN0/8%=_A-WW49/MINT:W[/
MF6J2ZTM3/%72NCWH<?NT;C*JB\^?4!-P<-'4P5M)#54DK)J>9B21R,7*.:J9
M14^(CNEM94VH=2:DL]/2S12V29D,LCU16R*[>XMQ_P O6$2@
M      8URH::YV^IH:Z))J2IC=#+&JJB/8Y,*G#CQ13YM%MI+1;::WVV%(*.
MG8D<42*JHUJ<DX\3+
M
M
M                                     /F61D4;Y)7M9&Q%<YSEPB(G
M-54#Z!&-#ZVM>M$NK[*LKZ>@J5IEF<B(V5<(N\SCZWCUX).
M                                  :76&I;;I.PU-VO$[8J>%O!N?*E
M=U,:G6Y?_G@<FD[W'J/3=NO$$3X8JV%LS8WJBJU%ZEP!M@
M         ?CW-8QSGN1K6IE55<(B!JHYJ.:J*BIE%3K*#V]7'65UTWJ)E/1)
M9]+VY49-/*_]]</+1N&)U,RN?2B<UY%RZ,]A]B_R$'W;0-P          ,>X
M_P /JO>G?8IYO'I#<?X?5>].^Q3S>"X[:=R![ KO\)N^ZC,WN@Z&GN>I=G%!
M71I+2U-U6&5B_P!3'+&BI\BF%W('L"N_PF[[J,VVW#V;[+OAI/\ 5&!P;*KA
M5:'U95;.+_,Y]/Y519*J3_QH5556//:G'AVHY.PYMD*XVI;55PJXK8."=?\
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M7-5%14RBH!^@ (
M
M
M                                     1+7VBVZS]3Z:NNE;36B%7NJ
MJ.F=N)69W=U'NYHU,.X=>]U8): *=[G.E@H7Z[I*2-(J:"^S11,3DUK>")\B
M%Q%1[ ?XAM"_\PS_ &EN
M      %2[7= 6^NMVJ]3W:IJZ^HAMTJT-+*_]Q1JV'"N8WK<JHKLKUKRX9)1
ML9_E9I?_ ",?V&3M5_EIJGX-J/NW&-L9_E9I?_(Q_8!,@
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M]'%2.7*P,A:UBK_RHF#,:U&M1K41&HF$1.2'Z
M
M
M
M      ,:CH*.B=,M%2T].L[UDE6*-&=(]>;G83BOI4R0
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MAA@NL'0UT]3&LZJN5W$8U,HG#/%?Z4".R8
M
M
MU6J;[3:;L-7=JZ.>6"G1N8X&;\CU<Y&M:U.M5543XRGM(ZIU5>MN5"S4%-46
MB@FM<L]+;'2+Y,>\J(^1O^-5:O-.' O8J.Y?[SMJ_P#+[OO'@6X
M
M
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M['!.&$X]I<X -SNIO81<<<
M
M                                                 0FJT?5S;7:+
M5K:B!**"V+1.A7/2*Y7.7*<,8\KM)L
M
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M*:LM[7L<Q[4RJ.:[JXI\N<\, 6P
M
M
M                                       8%_O%#8;/572ZSM@HZ9BO
MD>[L[$[57DB=:J9Y36VK0]3=[5J:^7R]5-1;J&CDFMMKB3<BB>V+U[U3U[M[
M>5.SMQP M:P7:FOMEHKI0[_>M9$V:+?;AVZY,IE.HSR([(/Y7Z6^#H?]*$N
M                                             ,&^7:BL=IJKG=)V
MT]'3,6221R\D3J3M5>2)UJI\Z>N]+?[)176@W^]*N))8M]NZ[=7EE"K=L^AZ
MF]6[4MZO=ZJ)K70T4DUNM<2;D<<C8?7R*GKUWMY4[,IQQP)AL9_E9I?_ ",?
MV 3(                     '('S+&V6)\<B98]%:Y.U% J]FT^[WNKK?V%
MT?47VVTDJPOKGUC*:.1R<TCWD7>]W^Q)MGFMZ36=%6+'2U%!<:&7H*VAJ$_>
M0/X_*BX7"^A3EFDTWLVTB]V(K99J3><V-'*N7.55W6Y55<Y5SA"(;$+=<*RX
M:FUK=*5U%^T,['TM*[@YL#$5&N<G:J*GR9ZP+6          &/<?X?5>].^Q
M3S>/2&X_P^J]Z=]BGF\%QVT[D#V!7?X3=]U&9VW-)-6ZHTML^I)GQMK95KJ]
M[.<<+$7'RX>O'K1I@]R![ KO\)N^ZC+D98[8R^/O+:&!+J^/H756[^\5G#R<
M]G! *TN6QNJN%MGH:O7NIYZ:5FXZ&:='1N3J16XXIR(/:I[CJ+N>M5:2E8]U
M]T](E/)"G%SHXY4>G#KX,>U/^5#LH:VAL-JH+K67*BH*>"OK/^\3QLPZ7_F7
MK"(MIC7^FUV>4-X?=:..G@HV=+&LK4?&]K$S'NYSO93")U\,<RN]?ZI=>+;L
MNU=<K?):J#U8;)(DK][HV93=<JX3@J-5R<.1:51LVT;471;A-INVOJU=OJY8
M4W7.[5;ZU5]U"072U4%UMSZ"Y4=/543T1'02QHYBHG+@O8!3?=,ZIL\^SYMM
MHKC2U=955$3VQT\J2*D;795ZX7@F<)E>:J9NVBHAHM<[+:NLEC@I8J^7I)9'
M(UC.$7-5X(3FAV<Z0H:&IHZ;3MO93U.[TS5BWM_"HY$55XX141<<C;Z@T]:-
M14+:.^6ZFKJ9KD>UDS-[=7M3K1?< I':C0VZ7;-I^Z7BZUE!8+I;>]H+G0U7
M1-;(CG.1%D3*;JHY/1Y6>I3\UQIK1-!-:;;67_55_JJ^J8R"AI[HVH=GJD5K
MN"(B]?I]"EVSZ;LU18H[+46RDFM4;$8REDC1S&HG+"+RQVF#IS0FF--U2U5C
ML=%25*HJ=,QF7HB\T1RY5$]P*DB)A$0IJR5E/I7;_JJ*^3,I8K]303T,\SD:
MR16-1KF(Y>&<YX>CTH7*:G4>G+/J2D;37ZVTU?"U=YJ3,RK5[6KS3X@BJM9Z
M@MMUV];/Z"VU,-3+0K5.G?$Y'-:KXUPW*<,^1E4]*&=ME7]EM6Z3UY&CD@I)
MEM]Q5J9S3R9PJ_\ *N\ONJA/+5HK35J=0NMMDH:=]$Y[Z=[(D1T;G(B.5%YY
M5$1,KV$"VN5MWU9+/H&U:>N2,JIH4J+M+#_V5D.6O<YKNM4QC'#BBX"N?8C3
MSLTA>]87&FEFN%_J);@Z%B(KW1-WDCC:B\^&<?\ ,A$+)I70^HK7)J71>IJ[
M1U2]7.FACK&L2!R*N4?&JY1.O".QA2_K;106VW4M#2,2.FIHFPQM3J:U,(GR
M(1FY[-='7.XOKJ[3EOEJGNWGOZ/=WU[7(F$5?="*RM^H+QJ;N<=55-[E[[F@
M;/3Q5:,W>^8F;N),?^I,^CMR8.LJF&MV*:"NMMECKXK!-05%?%3O1[HFMCP[
M>1.2HN$PO:IV CM]'';O4^.DIVT'1K%WLD:)'N*F-W=Y8QU&ML&E+%I^GJJ>
MRVJEHX*I<SQQL\F3@J<47T*O *TNJM>Z;I=#5MW;=J*>FDI7]"UDK5=,Y6KN
ML1O/*JN,=7'.,%+WVTU5G[G#1M-<(W1SONT4RQO3"M:]TKFHJ>XJ+\9=])LU
MT91W)*^FTU;6537;S7="BHU>U&KY*?$AO[U9K=>Z:.GN]%!601R)*UDS=Y&O
M3.')Z4RH1%]M_P#*?4_^47[4*YU?_ -AW^;H/NXR]+E04MSH)Z*X4\=323-W
M9(I$RUZ=BH8=1IVT5$5LBGMU-)';',=1-<S*4ZM1$:K.S"(GR 55JF[W/4>U
MZMTC/J:HTS:**D9.Q:5[8IJQSD:JXD7EC>7@G^%>'/$1N]#8+/MHT+1V>]7"
M\UK*IW?M165JU*M5V$8W>Y(O!RJB<>*%\ZFT=I[5#HG7^T4E=)$F&22,\MJ=
MB.3CCT9/RFT7INEIZ*"FL=!%%13)44Z,A1.CD_QHO/>X)Q"I   @
M
M
M
M $2VN?RPU5\'3_Z%):<%?1T]PHIZ.NA9/2SL6.6)Z9:]J\%14[ (QL@_E?I;
MX.A_TH2XX+?14UNHH*.AA9!2P,2.*)B8:QJ<D1.PYP
M                           "+;5?Y::I^#:C[MQC;&?Y6:7_ ,C']A*Z
MZDIZ^BGI*V%D]-.Q8Y8GIEKVJF%14[#\MU#36VA@HZ"".GI8&HR.*-,-8U.2
M(@&0                     &/<:R*WV^JK:E52"FB=-(J)E=UJ*J\/<0R
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MI(;1>+=731\7LIJEDCF^ZC54#:@
M
M
M                                    !5&UW:BM@I[I9]+T\]=J&GIU
MEG<R-5CH(]W>Z1ZKPSA45$]S/8H6N"-;,Z^JNFS_ $]7W"9T]74444DLCL9>
MY6IE>!)0
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MY%54SS7AR GP "
M
M
M                     $-VKTT$.S76$L,,4<LUOF=*]K419%2-417+UKA$
M3CV$R(_M!M=3>M#WZV4#6NJZNCEAB:YVZBN<U43*]0&#L@_E?I;X.A_TH2XC
MVSRUU5DT/8K9<&M95TE''#*UKMY$<C41<+UDA
M
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M5])L0
M
M
M                         8MTN%+:K=4U]PG93TE/&LDLKUX-:G-0,H&'
M9[E2WBU4EQMTO2T=5&V6)^ZK=YJIE%PO%/C,P
M                        QKE74ULM]175\S(*2G8LDLKUPC6HF54X[+=*
M2]6JEN5MEZ:CJHTEBDW5;O-7DN%XH!F@
M        ,>X_P^J]Z=]BGF\>D-Q_A]5[T[[%/-X+CMIW('L"N_PF[[J,V'=+
M?]QT;\.P_8XU_<@>P*[_  F[[J,V'=+?]QT;\.P_8X'K?;1-HE=I;5]EL=OL
MWJI+<X7NBC9)N/65%PUN5X(W/%57DF36IK_5NGM2V:AUU8;=3V^[SI2P55OG
M<_HI%X(UZ+SYIV=:IG&#XUJB+W0^S_*9_P"R5?W;S[[H'_["?^9*7_\ 4!M]
M7ZUO$6LH=)Z.ME)6WCO7OR>:MF6.&&/>W4X)Q<N<<NU.?'')H[5FHI]4SZ<U
MA88Z*L;3]\PUE$YTE-,W.,95,M7GP5>I>7#.BU[9-+ZNVB16I]QN=DUA2TB2
MP5M*_HNDCSP:B_UXRO!,+P7CP,+3-SU5I+:G:]'WC4#-24%PIY)6R21(VHIM
MUKE17855PN[CBJYSU ;5VO\ 4NI;Y<Z+9Y9:"JHK;*M//<;C,YD3Y4YL8C>*
MX[?LRF=OL_UU47R\W+3VHK9ZDZDM[4DD@;)OQS1KC$D;NSBG#TIQYXC'<SSQ
M46FKOIZJ>V.]6ZY3)4P.X/7.$1^.M%PJ9] H*B*^=TK/4VE[9J>U6?O:LFC7
M+>D5ZJC,IPSY2?\ I7L ^=/[2M8:N]4J?2NFZ!T]OJI(9JFKJ'-@1$7#6HB<
M5>N%5>I.':?6G=IVJM50U-NL&EZ=FH;?*Z*XK5U"MI8'(JHB(J>4Y7*CN'5N
M\U.;N;$1-/:G7'%;_4_Z6')L01$U1M+5$3/J[)]K@-KL_P!?5U^H]2TMZMD=
M!?K Y6U4$;]Z-V6N5JM7L7<7MZESQ(YI?:-KK6M@BN.E=+VU&1[S9I:VI5K)
M)$5?(B1%15PF[Y2KC*JG4?FCOYC;9/>Z?[F0W7<U(B;&['A.;JC/S\@'U9=H
M;=1;+]27FKM$<=;:8ZF&MMTZ[\;I(V;RM7AQ:O+CZ4X]?WX0(;+LFLNH66=%
MFK8XHZ6VT2;K>D?G=8G#R6\%XX(-ICV!;;OA"Y?Z'&0_5]STQL9V?4MC?!35
MMWZ&B;6U#<QTR+S>J+PZTY\,(H&[O^M-HVE[4^^7W3-DDM,.ZZHAI:MZSQ-5
M43*JODKC/4BEJVFOANEJH[A2JJT]7"R>/>3"[KFHY,_$I0NV/35;9=GURK-4
M:_N]QJ)&M9!2(K*>&>17)P6-N=Y$3*XSU%Q;-U1VSS2ZIR]2Z7[IH$B  0
M
M
M
M                  *7VW:3O=\M.I;C=[WT>GK?2/GH;;2MW5ED;'G?F<O/
M#LX3CPQRXYN@B6US^6&JO@Z?_0H'YL@_E?I;X.A_TH2XB.R#^5^EO@Z'_2A+
M@                                             "F]M>D[W?;9J2N
MNM[Z'3=OHWU%%;:5NZZ:1L6=Z9R\T1^<)QX8Y*3+8S_*S2_^1C^PR=JO\M-4
M_!M1]VXQMC/\K-+_ .1C^P"9
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MTMHME+;K=$L5'31I%%&KW.W6IR3+E5?E4RP
M
M
M                                                           Q
M;M;J6[6RJM]PBZ:CJHW131[RMWFJF%3**BI\1E #$M%NI;1;*6WVZ+H:.FC2
M**-'*[=:B81,JJJOQF6
M      8MTH*:ZVVJH*^+IJ2IC=#-'E4WF.3"IE.*<%ZCYL]LI+-:Z6W6V%(*
M*F8D<4:.5VZU.29555?C,P
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M<E95KE$<J)_1P7M3&4_J4[%IPY
M
M
M                  *RVM;4Z+2-'66^T9K]2MA<]*>)JO2F;NYZ27')$3CC
MFO#DG$LT@VU*UT%+L_UK74U'!'65=OE6>=K$1\N(\)O.YKA$1 -QLZN=5>M"
MV&Y7!Z25E71QS2O1J-17*U%5<)P0D)$=D'\K]+?!T/\ I0EP
M
M             !CW'^'U7O3OL4\WCTAN/\/JO>G?8IYO!<=M.Y ]@5W^$W?=
M1EA[4]$,UM8(Z>*I6BNE'*E30U:?^%*G+...%]'H7J*\[D#V!7?X3=]U&7J!
M4=+K':59X$H[UH+U7JHTW4K:"M:R.;_B5N%QGXO<0^--:7U?J3:+;-9ZSAHK
M1';(Y(Z2W0.Z614>US?+<BX_KS\7)"WP$4A8K?J30.M]55*:2FU#!>*QU53U
M]++&DC&JKEZ-V]Q1$SZ$X=?5EZ<L>L9MM5/JK4%KBIJ*IMSZ9(X)VR)1HBY:
MQZ\-YRJBJJM14\HN0 5'1W77NF9+C:[[INHU=1OG<^EKX)8FJ^->3)&*G#'N
M=?7S.79=H>YVVT:PJ;G24UJJ-12.=%;H'(YE(S=>C4RG#/E\<<.">XEK@"@]
M-V75Z;&;WH>OTQ+3U-+2R,I:E*ECFU3G3*[=1.K".YYX^@M73=C<_9I;;#=X
MG1N=:HZ*ICRBJU>B1CDRG#*<23@"F-)56N-GMG334VDY=0TU(YS:"NHZEC&O
MC555$D1W%N,\_MQE=EHC9]7U%NU=6ZT6)EWU2BLJ(8';R4L6ZK6M1>M4WO2G
M!.9:H IK2MQUYH6QQ:<J]'RWY*)%BHJ^CJF,9+'_ $H]'<6XY>Y\J[NTV37U
M1H&]>J=\;2ZHKGNGI&QHU8Z),Y2)%PN47BBKQQE,9QQLH 4G?KGK/4>DYM/7
M79RL]UF@6G=635$2T[7JF.F1>I4]<B(N<]9SW?9K>K9I3151IZ>"IU)I=%5K
M)';L=2UW&2-%7DG4F<<,\BY0!3&K*K7.T*S.TW!I273U-5JUM=75E2QZ,C14
M56QHWB[..?Q<,Y37;:*"ML]]V4T&ETC6LHI98:1L[L-?N-A1&N7L5$PONE\$
M4U;HV/46I-,7=]8^!UCG?.V)(]Y)M[=X*N>'K?3S @6K&:RVET4&FZC3$NG;
M5+,Q]RJZFI9(JL8Y';D:-]=Q1%SZ$Y&]U7IBX3[5- W&VT2NM-JBJ(YY4<U$
MA18]UB85<K\2*66 *ZVVZ?N>H;3IV&S4CJJ2EOE-53-1S6[D36R(YW%4Y;R>
MGB:'5=EOUBVOOUA1Z?=J2W5%$VF2**1J2TCTQQ:CNW"\4_Q.Y==Q@"C]3V[7
M&JM9:-OT^GDH+5:[@QW>??+'U#6.<U7S/XHU$PU$1J*J\^TV^HK/?=/;2J[5
M.BJ6EO/?U.R&Z6E:EL,J*U$W)&JO!.")S[5X+G*6R0'5FSV:XZF34FF[_56"
M^.A2GFECB;-'.Q.2.8[@J\$XYZDX 5S>JK4]TVU;/:G4MN@M4;Y*CO6WQSI-
M)&UK,O?(Y.&7<."<D:2>KL^I=":^O5^TU:/5VR7Q6RU='%,V.:"9,^4W>X.1
M<JO#MZL(JR#2>SQ]MU+^T>I+Y5:@OK8EAAGFC;%' Q<Y1D;>"*N5X^E>TGH%
M;Z7GUQJ'6<=UNU+)IW3=-"K&6U\C)):IZY\I^$\E$Y]7).>54B^G:#4NS_6&
MJ)?V1FU!%=JQU53W"EFC21&N55W'[W%$3/RYYEX "G-+V/6#]M+=4ZAMD5/1
MUEM=3HR"=LB4B(Y%;&]>"N=Y.55J*F7&^V-Z?N=A_:[U7I'4W?M\J*JGRYKN
MDB=C==P5<9QU\2Q0!%]J%MJ[QL^O]NML*SUE32OCBC1417.7DF5X'[H^ROCV
M:V>R7B%8Y$M45'4Q*J*K5Z)&O;E.':A)P!2^D9-:[-K6[3;]+3:CMU,]_>%;
M1U#&*K'.5R-D:[BBY5>/5RXXR3/9I2ZMZ*Y7'6U2UD];-OT]MC5KF44:9\G>
M3FJY[5Y)UJI-0!3>S[2-\M>PK4=BK[>^&[54-<V&G5[%5ZR1JC.*+CBO:HO6
M@KU=M@EFL$,38+[01PS-@D>F%D8JY9O(N,X5<=6<%R "D=8UVT'7.B[A8X]&
MNM$LD'_:9YZICDD5O'HXF]KE1$RJX1%7W3:ZGMFKIMFVE])6&B?3U%514])<
MJU9&(VCC;&ULB<\JJ\4\G/!%[4+9 %-739Y6:%NVG[[LWH75#Z6-M%<J%)&L
M6LAYK(JN5$W\\?=W>I%+DC=OQM<K7-541=UW-/0I^@
M
M
M                                 !'-H]OJKKH+4-OM\2S5E312Q11H
MJ(KG*U41,KP)& (WLUMU5:= Z?M]QA6&LIJ***6-515:Y&HBIE.!)
M
M                    #'N/\/JO>G?8IYO'I#<?X?5>].^Q3S>"X[:=R![
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M&\B)NNY</2G:F;&
M8&H%N266L]0DIUNG1JE/WQGH]_J5V.. /BLOMLH[U06FIK(V7*N1[J>GXJZ1
M&)ER\.28[<&R.O%#IJXV#;]HZ>_7B6[WBX4]3-4S*W=C8J1O1&1MZFI_\HAV
M'
M
M                                  ''4314U/+/42,BAB:KWR/7#6M1
M,JJKU(B'(4MMPMVK[W:-2(^JI[7I.W4KIVMB7>GN#FQ[V'?X6([*8Z\<EZ@N
M*AJZ>OHX:NBGCJ*:9J/CEC<CFO:O)45.:'.1'9!_*_2WP=#_ *4)<
M
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MY
M
M                                  $2VN?RPU5\'3_Z%):8&H+33WVR
M5]JK5D2EK(702+&N';KDPN%X\0-!L@_E?I;X.A_TH2XU^GK33V&QT-JH5D6E
MHX6P1K(N7;K4PF5X<38
M                                             &/<?X?5>].^Q3S>
M/2&X_P /JO>G?8IYO!<=M.Y ]@5W^$W?=1EZE%=R![ KO\)N^ZC+.VB:RH=$
M:?=<J]CYY7O2&FIH_7SRKR:GR<5ZO3P10DX*DII]L=TITN$46F+4QZ;\=!4I
M(^1$ZD>Y,X7XT^(W&SK:#4WN\5VF]46U+1JBB;OO@1V]'.S_ !QKV<4X97@N
M<KQP188      032>K;A=MI>L-/U,=,VBM"4ZT[F-5'NWVY7>555%^)$ G8
M               !!ML^K*_1>A:B\VF.GDJHYHXT;4-5S,.=A>"*B_W G(
M    1^CFU&NM*^*JIJ-NF6T[5I9FK^^=-Y.\CDWN7KNI.H"0
M
M
M                                                     %?;5MIU
MKT/;)XV21U=^=&JT]"Q=YR+C._(B>M8G/CSQP[4"P0:'0-WJ+]HNR76M2-*J
MLI(YY$C14:CG)E<(JKP-\
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M:([=7KPH%E@ (
M
M
M            5YM0T[:*/1FM[S3T$#;K66Z7IZI6YD<B1;J)E>28:G!,)P+#
M(SM.HZBOV>:CI**&2>JGH)HXHHVY<]RM7"(G6H&/L@_E?I;X.A_TH2XC&RZC
MJ+?L[TY25T$E/50T,3)(I&[KF.1J914ZE).
M
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M,;W83$
M
M
M                  ^9I&0Q/EF>V.)C5<Y[EPC43FJKU(!] XJ2I@K*:*HI
M)HYZ>5J/CEC<CFO:O)45."H<H
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MK+;TV_RW.@\K/HQD"7R[7%H4IJV^Z3O=KL%2]K8[E.UJHU'>M=(Q%RQ%]/\
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MBS@V80
M
M
M          *6VWP:RO-HU)#"^"T:4M]*Z9TK7;T]P5(]Y683UK,Y1>W'6BX+
MI(EM<_EAJKX.G_T*!^;(/Y7Z6^#H?]*$N(CL@_E?I;X.A_TH2X
M
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M<.1:0 XJ6GAI*6&FIHVQ00L2..-B81K43"(B=B(<H
M
M
M                                               UVH[1!?[#<+36
M/E93UL#X)'1*B/1KDPJHJHJ9X]BFQ &NTW9X-/V"WVBC?+)3T4+8(W2JBO5K
M4PBJJ(B9^(V(
M                                      !CW'^'U7O3OL4\WCTAN/\
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M5U%56I<9V.?-(KU;C=\E%5>"(N<(6B
M
M
M
M
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M)S_<MTCNS[2E-HO2E%9*.5TS8$5TDSDPLKW+ESL=7%>"=F"1!
M
M
M
M
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M56](Z>XUM"L5/*J\E1RKG"]N/=P6:
M
M
M
M
M       ?DCVQL<^1R-8U,JYRX1$[5#7(YJ.:J.:J914XHJ%!;>J_65VTWJ)L
M-&VSZ6MRHR2:1^9KC^\:U$:B>MCRN?3CFO(N;1GL/L7^0@^[:!N
M !CW'^'U7O3OL4\WCTAN/\/JO>G?8IYO!<=M.Y ]@5W^$W?=1FTV[^RW9?\
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MPT6T72<6M=*5=CJ*J2ECJ',<LK&HY4W7H[DON$A@CZ&".-%RC&HW/;A C[
M
M
M
M
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M+ZW"[V<]J$L
M
M
M
M                             T.M]5VS1U@J+K>)FLCC14CCSY<S^IC4
MZU7^W->!SZ/O;=2:8MEY9 M.VM@;,D2NWE9GJSPR!MP
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M*L>$1KGHO)R_9CM)Z$
M
M
M
M                       %4;6= VFIMFK=4W)U175[;;+WI%/)O0T>[#C,
M;.2*JHKLKUKE,$EV,_RLTO\ Y&/[#)VJ_P M-4_!M1]VXQMC/\K-+_Y&/[ )
MD                       "CMM^@;31:,UAJ>H=45]YG1BQ354F^E*Q9F)
MN1-Y-3"X[>?+);.C/8?8O\A!]VTBG="?R>U)[W%]\PE>C/8?8O\ (0?=M W
M          Q[C_#ZKWIWV*>;QZ0W'^'U7O3OL4\W@N.VG<@>P*[_  F[[J,O
M4HKN0/8%=_A-WW49>H1\)#$DG2)&Q)/\6ZF?E/L #Y6-BR(]6-5Z<G8X_*?0
M       /ED;&*Y6,:U7<U1,9/H #\<U'-5KD16KS14/T ?C&-8U&L:C6IR1$
MPA^@ #YDC9(W=D8U[>QR9/H $3"83@A\NBC<]'N8U7MY.5.*'T
M
M
M
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M BY3*<@
M
M
M
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M>I]3OHZ;7>JH*ZSTTS9W4E'1)"M0YO+?=G@GH3^W!2U@ 1,)A.0
M
M
M
M
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M5%3^Z$T
M
M
M
M                     -+K#4UMTE8:F[7B=L5/"WR6Y\J5W4QJ=;E_^>!R
M:2O<>H]-VV\00OABK86S-C>J*K47J7!7>UW0%NK;;JO5%VJ:NOJ(;=*M#2RO
M_<4:MAPKF-ZW*J*[*]:\N&24;&?Y6:7_ ,C']@$R
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MH7U#Y73,1$1LJ[W%N>ST9ZRQ0B83"<@$
M
M
M
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MYL;ERS*91K51/2N5R7,
M
M
M                                           %0[7]>7JGI[[9-'6R
MJ=5T%,LM?='IN0TC%CW_ "'?U2*U4QV9Z^J8[(ZB:KV::;J*J:2>>2BC<^21
MRN<Y<<U5>*J!+0                                    &/<?X?5>].
M^Q3S>/2&X_P^J]Z=]BGF\%QVT[D#V!7?X3=]U&<_=%4<EPU-LXHX*N:CEJ+D
MZ)M3"N'Q*KHD1S?2G,X.Y ]@5W^$W?=1DOVN:)O.JZ[35=IZNHJ.LLU2ZI:Z
MJ1RHKO(5O!$7/%O6!'K]L;OMRM512^$:_3I(U46&K<YT4G_"Y$<G!?C]P_-$
M:GM=[V*7F#5$3+/0VK?ME:E"JL;NMW?]GSXNWD;CCE<]IGS:>VMU<3X)]7V.
MECD3==+34:K(U/\ ARU./QF:S9';H=E-;HRGK)=ZJ=T\E:YN7/GWFN1ZMSR\
MEJ8SR3GGB!'+7?IZK1K+3I/9C6SV):;HXYKE)%3,DCW?]HY%1=[///7G)!HJ
M^J@[E6W4\,SXV5ER6CD>B^MB69[E3W,I_=2U*/3>TFKLS+#=KW8*2V)"E-)6
MT$4CJN2-$W51$=AC7*G#*)PYH?NFME20[**O16H*F*:.2:1\-13YRS+D<QV%
M1/*1>:<E3W0);<M%:>J=&RZ=FH8(;0D'1HC&M:L:(GKT54X.3GO+U\RH-J3*
MVP:WV9T^D(UNE92TM13T*3RH[?\ (1B.<[@BHU%RO+@TD]5I/:;<;([3=PU#
M84M$D?>\MPBAE[\DBQA45J^1E4X*N?C-O+LW6FU5H6LM$T,5KTW!+ Z*1562
M1',W45,)C.>*YQS T7<\-HJF.^UET25^N653XKN^J5%E;Y7DHSLCPG).M.Q$
M+D*^ONAJYNTBW:OTQ54U+4.9T%T@FWD;5Q<,<D7RD1.:_P"%O8N;!"*7V0V6
M@J-J>T>[5$,<M;!<N@A<],K$U5<KE3L5<(F?1[ISST\5B[I.W,M3&PQWFU2.
MKHHTPUSFJ]4>J=OD(F?=[5(SHRW:IDVF[1J_1MQM\-1#<DBFI+BQRP3M57JB
MJK/*1S<+C'^)2Q]"Z)N=%J:NU5K"X4]PU#4PI31MIF*V"EA1<[C,\5RJ<U]/
M:JA40L.H;/;-0:B_8+2=XU/6U%8]U;<%5B1=+UQME=_2B\<8Z^M,'#L?=6>&
MO6O?UHBLD\M'!++00RMD:QR[N%5S41%54557'6Y3;:;T/KG0[Z^W:/N.GY[%
M4U+JF/U29+TT"NPBHFYP=P1.:\<=1LM!;/+OIO:!=-0W&\QW3U3I$94/<Q8Y
M.FWFKY+43",1$PB9RG "N='_ .[)K'_,5/VL+-V?Z6LS=CEMHUMU,^*MM;)J
MC>C15D>^/>5RKUKE>"]7#L-=8]F=RM^R.^Z3EK:-U9<)99(YF[W1M1ZMQGAG
MJ[">Z;M$MJT;;+/-(Q\]+0QTKGMSNJYL:-54Z\90"%=S5(^38]9ND<KMU\[4
MSU(DS^!9Y#]DFE:K1>AJ&QU\\-140/D<Z2'.ZN\]7)C*(O63 (
M                                 8]QH:6Y4,U'7P1U%+,W=DBD3+7I
MV*G6AD "G]500TO= ;/8*:*.&".AJFLCC:C6M1&/X(B<D+@*XU1I^Z5FVK1]
MZIJ1S[914M1'43HYJ)&YS'HU,9SQRG)"QP
M
M
M                                                         BNU
M7^6FJO@VH^[4Q]C/\K-+_P"1C^PW6L[3+?=)WFU4\C(YJVDEIV/?G=:KFJB*
MN.KB<.@[+-IS1UGL]5)'+/14[87OCSNN5.M,\0-\
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M#''F!LP
M$;K]:6BCUI;=+.E?+=ZYCY$9&B*D36M5V7KGAE$7'/D20
M
M
M
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MNLJI%?)/)T;TWE[/<^T[!%1ZS_WA] _Y.J_T/+<
M
M
M
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M:9O%L51"U[6KVHBIP^(XK#IRS:?C>RQVJBH&R>O[WA:Q7^ZJ)E?C-J
M                                              Q)K703W&GN$]#2
MR5].U6PU+XFK)&B\T:Y4RB+E>1E@
M
M
M
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MJ2K8E-HNIN%_J]#UM3$E6YDE1:)6I&VE5.&6,QPRN<X54Y)PP@1:P
M                                       :O5%[I=.:>N%XKU7O:CB6
M5Z-YNQR:GI5<)\8%;[>-HE=I:"EMNFWXNLBLGJ9D8CTIH%>C$547*9<Y41/0
MB^@MPZO:LN=GJ-E=VN59?;35ZKOM;35=5!#5LD?#&DC=R%$1<X8SGZ<G9>UW
M&BNU%'66NKIZRDDSN302)(QV%5%PY."X5%0#*
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MGD\DQZ3<[)M07R'56HM$ZIK/5&MM",FIZY6[KIH7(F-[THCF^GBO%<9"K3
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M4^WT877:5NUPOO=!QW.JMM3;*>:PO2F@JDW9E@29,/>W^G+U=A.Q$"KP  0
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M\\R_0YORCP\[/O/,OT.;\H%H J_P\[/O/,OT.;\H\/.S[SS+]#F_*!: *O\
M#SL^\\R_0YORCP\[/O/,OT.;\H%H J_P\[/O/,OT.;\H\/.S[SS+]#F_*!:
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M/.S[SS+]#F_*/#SL^\\R_0YOR@6@"K_#SL^\\R_0YORCP\[/O/,OT.;\H%H
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M
M
M
M
M
-              '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g12080g23m57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g23m57.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_[14(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %.L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M 0 "$0,1 #\ _5(
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MI6V%5LU49V+/LE8?*,CQ7*KL^+F6]5VKK,9TJCM91J7*SP 5+
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MRR<A&A\E AJS%QTO:F-JW>LM0JU,8QFH683,Q<@ ,&8
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M:P=T2-0++RTE-/QHR7N<FR]=!TI1E$1,Q"[&9F-P $)
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MG-FN14S:UUZA[O&)F).?*8B87.##4N:B;$,FNO
M
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M]-+.5.:2Z)%T)=FS)HV)J.P!'O,JI/)%V  P9
M !7=<L#-5"KS<VR9@-;&B*]$55O2_P#(L0%VAQ&>A,S@UN)X33XK&,=2-H5S
M1\'\U(U64FGS4!S8,5L1415O6Y;]AV5J*8^L4"<I\-[6/CL1J.=H3.B_H>H"
M=;B=36F,L_LCAN#TN&QG'3C:52TG!_:ZER\*6D[1P(<M#NN8C47-^<,]&U=@
MZO5JG3:A)U.#!G)2&C5B.UN1&Y[L54TM+)!A[W*[7>[BJ5I3,',_,5R!4K3U
M?+G2_P VQB7)^=S6[5+ 2FR*1.423E^4OOQN32^_H)8,<LYR[66.$8]CQK84
M=]=L_-TZ%$;#?&8K4<[0EZ*GZD6EV8APK'0Z%/N;%8C%8YS56Y>Z5?$=&!&4
MQ%'+%VJ.7P45!$@R,U6UB4:$_'2#=W2KP_J>C;K!]4Z_.2J2-1A2\A+0VMAP
M'*MR*FM>Y6_0FDLL&?OLKMC[K&J<+9*S=I:5/PEJ-9@3$C#;B\C#8B:TV,3Q
MZSN@##++FFY9XX\L5  #%(                       #RK4TM]9H$Y3X;V
ML?':C4<[0ERHOZ%,]HVH?:4IQ._]2^P7Z7$9Z45A*S#4RPBH5_@OL),6/B3C
MIB9@QN7NNY-56Z[SHANPCV+G+3S4C,2$Y"E8LMG1S[].?Q+M.Z!CEJY99\\]
MJO4_F=3@;.68M5)5%(M5KT*;E<5R.A(U$OO14W$]9X<M@ZM+3IZ?C4BN2\M#
MFHKHBMNO7.JKK8NTMH$>]R8>[AQ=A[!R]GH<R^<BY?-S*WQ7Q$O35FN_)-1U
MLM)RTLJK+2\&$JZ58Q&W]!O!C.4Y3<LHQC':''VJLE&K-I:34X<>&QDD[&<U
MRK>[.FC-XC-O+&MM+#EHTO,+*U"65%A1D_/,NG:NHZ\$QG,5_9$X1-_W5]9>
MP4W39Z;JE3J*3=8BPW0X<6[-#O14OT)MV'/P,&=I):KQZC KDME45RKCO3&5
M$5;\U[%N+A!E&KDQ]WB\6R<A4Z?3G0JU.LG)E7WI$:B(EVS,B>H]H KF;FV<
M16P "$@                       .9MA9R+7705A1F0^33_=?X_%XSF^UU
M,_W<'I7W%E U-3@M'5RG/*-U66CAE-RA463=3Z9 E7N1SH:77IYRM9G!U:"#
M7IZH4:M0)3*G7JEUZZMK%V%K@W-.?=Q6+*<(F(A7D[8NM5.QDU1ZK584S-18
MC7MC*ER(B+HS-3U'CNP;VDG)"'3:A:*&M.:F+R<-J7W;/D)ZRVP9QJY1V(G3
MB7D4NSU.I].EY-LK"BL@MQ6NB,1RW?F>K"A0X,-&0F-8Q-#6I<B'T#"9F>UG
M$4X^Q=DHUGZS5YV+'AQ&SL3':UJK>WSYD/"KN#>=B5>;F[/U7(84XET>&NOS
M9EV(6:#*-3*)MCR15*\G,'\Q!L?#HE%GTEW.SQXKE5%B+<E^>Y?'LTGE4*P%
MJ:-!9 DJ[*PH"+>J(Q%5<]^E8=Y; )C5RJD>[Q?,)'-AM1ZWN1,ZGT 5K
M
M
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M5K@8:Y?CZ,V_DGS;L7C>644:D5E-+M.;Q@ !@S
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M2LQ,3<7E'PI955D/.JW)>B;5Z")TXC#F3&<SE2R  4+@
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ME^;:?H.SL.%!H<C"EXR1H4."UB1$_P!UR77F.IA&$)T\YREZ  *5H
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M<+F-P &+(
M
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M-5Z0E:O*TV/%5DS,MQH5Z=RY,^O\E/4,*I9=@ (
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M1++R\T^8B-='F7X[F0_DMS(ER=&T[, QRRG*;EEC$8Q4  (2
M
M
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M ?(1):S$Q-1T5'3<RZ*B>*YJ?H8Y9<V.4RG''EF(A8H *%P
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MD9%6[9W2_H6W)0<GE(4+<:C2G4Z8_-;AVRW  I6@
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MS4?DI=/&[N6K=TEAV;E5DJ#(2[OE0X+$7SW%&?1^:['J_)Z( *5H
M
M
M                                          !\Q&-B,<QZ(YKDN5%U
MGT (%'I$G1Y=T"GPDA0G.QL1-"+XD_(G@"9LB*        1:G(0*E)1)2;:K
MH,1+G-1=*'W)2D&1E8<O*PVPX,-+FM:ER(;P+^Q0
M         $"LTB2K$NV!4(+8K&N1[;T2]%36A/ B:*MB&U&,:U%541+LYD
M       #SIJBR,U59>HS$%(DU ;BPW.SXNG1TJ>B +*
M             \Y*+(I6/C1L%&SF)B*]N;&3/IVZ3T0+HH       !YU2HLE
M4IN5F)R"D6)*NQX6-G1JWHM]WY(>BF9,P LH
M                                              >9:6KPJ'1)JH1[
ME;!;>B7W7JJW)UJA3R6QMM%ICK2,APTI*/QN1N6_$TZ;MFNXLPTYSBX899QB
MO0'CV1K<*T-GY2I041J1FK>U'7W*BJU>M%/8,)BIJ643<7  "$@
M
M
M
M
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MDX$S#OQ(T-L1M^FY4O0&JD2SI.DR4K$5%?!@,AN5-:M:B?H"F5L)8
M              4EA5^M*SO\V%VE)X5?K2L[_-A=H=2K5Z5V)H 30"E:
M                              #YB_-/]%3\O6C[X*I^*B^VI^H8OS3_
M $5/R]:/OAJGXJ+[:@>> F= @   !J"@ @  (-0  !     (-00# ,@ F@!!
MJ QYP9  ( EP V2OTB%Z:>LUFR5^D0O33U@?JV#\TWS'T?,'YIOF/H
M%/84>^5_H-]2%PE/84N^5_H-]2'2]E=_^3B^W?IH]8_=QZJBC6$!Z-X\U^((
M+@$FK0!J"( 31G'G4&;@/E,WB,W"_;<$""_8-&H"\)-031>$&@#-WC,)>$,@
M80?Q!H'K""\;= 36$"32->8>8: @3QJ/.%\X3: 3093-I,(+\]ZA*_;+=[=,
M_#0_90]0\NRW>W3/PT/V4/4/':O7EZR^B</W6/I'^@ %:T   HSX27TJB_=Q
M/6A>91GPDOI5%^[B>M#;X+OH7:'7"E4 !WF^#4
M        :@/T-\'?O:G/O4_4M<JCX._>S.?>I^I:YY[BN^R<[5ZY  :ZL
MXW"I_0('XEOLN.R.-PJ?T"!^);[+C5XWN,_15K=$JK,F#)Y1RV 90P "
M  " 9,(/, "  #)@  @  R8    !>-0" %!DP!86"G_F>=/46(5Y@I_YOI)Z
ME+#/4>SOI\73X?NX  ;JX
M                    I+"K]:5G?YL+M*2PJ_6E9W^;"[0ZE6KTKM30 F@%
M*T                                  'S%^:?Z*GY>M'WPU3\5%]M3]
M0Q?FG^BI^7K1=\-4_%1?;4#ST   !  O'YF#*7 #"&0@#0 $ POB,@(
M7 $   :1J   ( &H #!MEOI,+TT]9K-DM](A>FGK _5L'YIOF/H^8/S3?,?0
M      *>PH]\K_0;ZD+A*>PH]\KO0;ZD.E[*[_\ )Q?;OTT>L?NX^],X%V8:
M3T;R NP*+LQD#"#QH8O 1;-VLRF:_881% 2;;@!I0!?L!A#*!!J\8"#6$B:
M@&@(!M")T#->$F>X#5I 0!-8T><P"V5,F- "0($N&L(7[97O;IGX:'[*'J'E
MV6[VZ9^&A^RAZAX[5Z\O67T7A^ZQ](  5K0  "C/A)?2Z+]W$]:%YE%_"2^E
MT7[N)ZT-O@N^A=H=<*6 !WF^                 #4              ?H;
MX._>S.?>I^I:Y5/P>.]F;^]3]2UCSW%=]DYVKUR  UU8  !QN%/^@0/Q+?9<
M=D<;A4_H$#\2WV7&KQO<9^BK6Z)56 #RCEB!/&!H0#)@&0!@   $ R8" #)@
MRGC, $&TRF8$#"&3&L:20U   $ U  $,@8"! !86"C_F^=/46(5W@HT3OI)Z
ME+$/4>SOI\73X?NX  ;JX
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M913T;R#!C:MY]:C'K (%T#SC8 U:1JUA/,$Z0"9TVC4/SS !^0O"H-.D($0
M($@1.D!,P#Q )F,@AB\:% U@9U&$S:=(U#0@#6$,*NPSK"!-AE-)@PFG,!?U
ME>]NE_AH?LH>H>79;O;IGX:'[*'J'CM7KR]9?1>'[K'T@ !6M   *,^$E]*H
MOW<3UH7F49\)/Z51?NXGK0V^"[Z%VAUPI4 '>;X
M        (  /T/\ !X[V9S[U/U+6*H^#OWM3GWJ?J6N>>XKOLG.U>N0 &NK
M  .-PI_T"!^);[+SLCC<*G] @?B6^RXU>-[C/T5:W1*JPBYP#RCE@    !Z@
M-8N (9,#4 ,F @    9, -0%X R8   :3(&$Z@$" 90P !8>"G_F>=/46&5Y
M@HT3OI)ZE+#/4>SOI\73X?NX  ;JX
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M2_T>'Z*>H^RI8%)85?K2L[_-A=I26%7ZTK._S87:'4JU>E=J: $T I6@
M                              ^8OS3_ $5/R]:/O@JGXJ+[:GZAB_-/
M]%3\OVC[X*I^*B^VH'G& 9 *  ,9C)@R !@R    P9  &$UF0" #U@$S 7@
M-00 $":!> "   AME?I,+TT]9J-DM](A>FGK _5L'YIOF/H^87S;?,?0
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MRX[(XS"I_0('XEOLN-7C>XS]%6MT2JP 'E'+ +P VW!  " ($ ( -0  (
M (!J    FL (      $!E# %AX*?^9YT]1897F"G_F>=/46&>H]G?3XNGP_=
MP  W5P                                          !QD]A)LU)S46
M6F9[%BPW8KF\D]<_"=F<;7[)63EH,U4ZI(2J-3NXD1S&Y^E#/#EO\3'+FK9R
MTS:7!TZ.^;Q(+IA$O1>1B9UX3K\'-I'VDID>8R9L"7A/Q(.*BIC,SW+G78B%
M8K:3!LR(N+15<B:\G;GZBT<'E9I%7I#EH$KDTK!5&XG)HS;J3S%NIC6/9/YJ
MM.;GMAU( -=>'*VWLO,6BR?)JE&DN2T\FJ=UI\2G5 G&9QFX1,1,5+FK$V;C
MV=EHT*9J$6=6([&1T2[-F3-H385[AE[^;)_BF>W#+G/,J5"IM3FI>9GI2#&C
MR[L:&][$56K>BWI>GB0SPU*RYI8987CRPGR_T>%Z*>HV!J(U$1-"9@5K''X1
M[-U2T4M)PZ14&R3X2N5ZJE^-?BW>I>DI:IV>J5G[?467JL^DY&>]'->B77(?
MIDI/"K]:5G?YL-G0SGI4:N$=2XT@1;OGW#D(O/N)*: :]KJ1N0B\^X<A%Y]Q
M) LI&Y"+S[AR$7GW$D"RD;D(O/N,\A%Y]Q( LI'Y"+S[AR$7GW$@"RD;D(O/
MN'(1>?<20+*1N0B\^X<A%Y]Q) LI'Y"+S[AR$7GW$@"RD?D(O/N'(1>?<2 +
M*1^0B\^X<A%Y]Q( LI&Y"+S[C/(1>?<2 +*1^0B\^XQR$7GW$D"RD;D(O/N'
M(1>?<20+*1^0B\^XQR$7GW$D"RD2+ B\F_\ UG:%/S/:&]*_4\]ZI-1?;4_4
M,7YI_HJ?EZT??!5/Q47VU%IIYVTR@! ! $   !J,&3 &= 0P9 ! @N )K "
M /6     :@  " +@  -DM](A>FGK-9LE?I,+TT]8'ZDA0(JPV_Z[M!]\A%Y]
MQN@_--\Q]$VBD?D(O/N,<A%Y]Q) LI&Y"+S[C/(1>?<2 +*1^0B\^XJ/"8US
M+1O1SE<N(W.OF0N0I["CWRO]!OJ0Z7LJ?YWY.-[<C_S1ZQ^[C](3,@"^(]$\
M@QI,Z@J:PFN\(,XOSC4 DSA$S!!J (+\QA3(#:!M4)==?> "+<$'Y!#'C,Z
M$\0 )>E^@:QM"1 J!-!GS@-)\Z[D,^<(!C4IE IE-8(8T&4\9@)I O6S$&(M
MG::J1G(BR[,W_:AZ?(1>?<1+*][=+_#0_90]0\?JS^/+U?0^'C^5CZ0C<A%Y
M]PY"+S[B2"NUM(_(1>?<.0B\^XD 64C<A%Y]Q2'PC6.9-4;&>K[X<33YT+X*
M,^$E]*HOW<3UH;7!3_.A=H1^.%*@ [SH  0  @         !        $
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MPJ_6E9W^;"[0ZE6KTKM30 F@%*T
M 'S%^:?Z*GY?M%WP53\5%]M3]01?FG^BI^7[1=\%4_%1?;4#S@80R 0:!M"
M @  :E'G  &#( :@ "!-   (#  &1M !   ,&0""X  ;)7Z3"]-/6:S;*_28
M7IIZP/U9!^;;YCZ/F#\TWS'T      "GL*7?*_/_ +&^I"X2GL*/?,Y?(;ZD
M.E[*[_\ )Q?;OTT>L?NX] +]@;GT'HWD&-"&;QK 07^(:AH"7YPDO 37=I":
M+@ T7WC4$T!!YPB ( 3:$"7! DSWW#4+@FL !K":/& 34AC7YC/YA$V!!J"9
MAH"9P SZQJ%V8!=K":0B] 33G OVRO>W2_PT/V4/4/+LMWMTS\-#]E#U#QVK
MUY>LOHO#]UCZ0  K6@  %&?"2^E47[N)ZT+S*,^$E]+HOW<3UH;?!=]"[0ZX
M4J #O-\                               !^AO@[][,W]ZGZEKE4?!W[
MVIS[U/U+7//<5WV3G:O7( #75@  '&X4_P"@0/Q+?9<=D<;A3_H$#\2WV7&K
MQO<9^BK6Z)569,)H!Y1RV3   RA@   @&3     #)@( !G:8 &4,    !G28
M&H  AD#   L/!3HG/23U%AE>8*-$YZ2>I2PSU'L[Z?%T^'[N  &ZN
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M,7YI_HJ?EZT7?#5/Q47VU/U#%^:?Z*GY>M%WPU3\5%]M0//0  $ " # ,_F
M 0 !J,&4  "\!J   (# &4 36  &L( "  !M  &R5^DPO33UFLV2OTF#Z:>L
M#]6POFV^8^CY@_--\Q]       I["CWRONW&^I"X2GL*/?*_T&^I#I>RN_\
MR<7V[]-'K'[N/ZD":P-1Z-X\OT@(-"!)M&A%%RZ B 813.@"Z^_:$"9ETC4!
M=G\82:@FL:])G7<!BX :=8&3"9C)C6H!/%>-5P\PV@$\9E,QA1JO :AYS.HQ
MK :AJ&L)=K4!H0(/$90"_+*][=+_  T/V4/4/+LKWMTO\-#]E#U#QVKUY>LO
MH?#]UCZ1_H !6N   *,^$E]*HOW<3UH7F49\)+Z51?NXGK0V^"[Z%VAUPI4
M'>;X              ($     $    @       /T-\'CO:G/O4_4M<JCX._>
MS.?>I^I:YY[BN^R<[5ZY  :ZL   XW"I_0('XEOLO.R.-PI_T"!^);[+C5XW
MN,_15K=W*K#%X0'E'+9, )K  &4\0&   0&3 &08" $ VF=0& @   R!@  !
MK   ;0!DP#* 6%@I_P";Z2>HL,KO!3_S?23U%B'J/9WT^+I\/W<  -U<
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MFUA"_;*][=,_#0_90]0\NRO>W2_PT/V4/4/':O7EZR^B</W6/I'^@ %:X
MHOX27TNB_=Q/6A>A1GPDOI5%^[B>M#;X+OH7:'7"E0 =YO@     !J  (
M                    ?H;X._>S-_>I^I:Y5'P=^]F<^]3]2USSW%=]DYVK
MUR  UU8  !QN%/\ H$#\2WV7'9'&X4_Z! _$M]EYJ\;W&?HJUNB56& #RCEL
MZ@8,D# 0:@2&HR8  !#(& !J R8  &4, #*&+P !DP ,IK,:@ ,F     L+!
M1HG/23U%B%=X*-$YZ2>HL0]1[.^GQ=/A^[@ !NK@
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M9^BO6G\$JO0 'E'+ !M :@#* 8":!J ! +@ 0 ( U SM,( ,H80   @ (9,
M9, R!@ R!@!#(%A8*=$[Z2>HL,KG!9$8S+,9UV=/46#E$+?0]1[.C_SXNEP_
M=PV@U91"WT&40M]#>J5]MH-640M]!E$+?05*+;0:LHA;Z#*(6^@HMM!JRB%O
MH,HA;Z"I+;0:LHA;Z#*(6^@HMM!JRB%OH,HA;Z"BVT&K*(6^@RB%OH*+;0:L
MHA;Z#*(6^@HMM!JRB%OH,HA;Z"I+;0:LHA;Z#*(6^@I-MH-640M]!E$+?04B
MVT&K*(6^@RB%OH*DMM!JRB%OH,HA;Z"I+;0:LHA;Z&4CPE6Y'H*+;  0D*EP
MELDYJWE'EJ_$Q*7R;U8CW7,<[N--^;86T<E;^D4&KP926KL:' CQ'JR6>KL5
M^,JHF;.BKGQ2S2FLF&I%XJ;G74AM@XD&#&A9?"G7Y*R&],9$OB79DSW'Z'I2
MQ%I\!8U_*8O=7E/T>S=AZ):5DI-5-)J;8Z]L.(ZYB*MRYTQESW+L+J;=<F+=
M=XC/6RB:IAI1,78>);&LQJ%17SLM)Q)R(UR-Y)E]ZYE6_,B[#VROFVSBU2W;
MZ#*2219*!<L>,Y$<FANJ[RBO#&Y]%F4TYJ:PIUB8EHL%ME)U5B-5N='+I_[#
MI\#4G496S\Q$J<&)+\O%6+#A/145B*JK=<OG0XNNVVJ\]7IV!9.E08LI))>]
MS8#7WIM^2MVHLO!S:-;26>AS,2$D&8A_Z<5B:$<FGK12[4BL-HI5A-Y;S;J
M :R\/&M#9FEV@2%\:RS8_)_)O1,Q[()B9C>$3%]KBZK*R]A+,SD>SE+?%C.5
M%2%";G555$OS(OG_ "*CL_5)YE<BUBT=GZG4IQ7XT)KX3\6'G5<R*U?%T'Z.
MB0V1&XL1K7-V.2]#5D<M_;P>!"W#5Y8FX[5>6G<[2\NR%:?7:2R;B2$:1=>J
M<E%145+E5-:)L/;/F'#9#;BPV-8W8U+CZ*I[=ED=F[RJ_9^FUZ'"9599D=L)
M55B.1%NONOT^9"E+<T*GT/"30(%,EF0(3UO<UJ(EZGZ *2PJ_6E9W^;"[0RF
MZ5:L15KI2#"N^;9PH9Y&%S;.%#[30"A<^.1A<VSA0<C"YMG"A]@#XY&%S;.%
M!R,+FV<*'V!8^.1A<VSA0<C"YMG"A]@#XY&%S;.%!R,+FV<*'V /CD87-LX4
M'(PN;9PH?8%CXY&%S;.%!R,+FV<*'V /CD87-LX4'(PN;9PH?8%CXY&%S;.%
M!R,+FV<*'V!8^.1A<VSA0<C"YMG"A]@6/CD87-LX4'(PN;9PH?8 ^.1A<VSA
M0<C"YMG"A]@#XY&%S;.%!R,+FV<*'V!8^.1A<VSA0<C"YMG"A]@#3%@PN2?_
M *;-"_[4/S%:+-:"J(F9,JB^VI^H8OS3_14_+]H^^"J?BHOMJ!YP!@#( 0
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M #87:4EA5^M*SO\ -A=H=2K5Z5VIH 30"E:
M         #YB_-/]%3\OVC[X*I^*B^VI^H(OS3_14_+]H^^"J?BHOMJ!YR 7
M#:    )K&@ $     $!@R UCSF#( (-0  #4!@R+@   ! $  VRWTF%Z:>LU
M&R5^D0O33U@?JV#\VWS'T?,'YIOF/H      %.X4N^5_H-]2%Q%/84>^5_H-
M]2'2]E=_^3B^W?IH]8_=R!A,X7.#T;R!<  &<><"\ +@.D!=INTA-@VBX(-&
M8($U@)@UC:-8T@$SJ $TKL!#&JXSH%V<:P@0)G0SJ/G4JA+/F V  B:4 _,>
M)0'C4:\X5-AG6!?EEN]NF?AH?LH>H>797O;IGX:'[*'J'CM7KR]9?1.'[K'T
MC_0 "M:   49\)+Z71?NXGK0O,HSX27TNB_=Q/6AM\%WT+M#KA2H .\WP  $
M                             ?H;X._>U.?>I^I:Y5'P=^]J<^]3]2US
MSW%=]DYVKUR  UU8  !QN%3^@0/Q+?9<=D<;A4_H$#\2WV7FKQO<9^BK6Z)5
M69, \HY9<9,7#S@   &H&0,&3  (#.HP !DP    R#%X  R!@RA@ #)@;0,F
M  +#P4_\WTD]2EAE>8*?^;Z2>HL,]1[.^GQ=/A^[@ !NK@
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M\GQKTEMV*LW!LQ1F24%ZQ'KW42(J_*=K7IO+]7**JU.GC-]CW@ :S8
M  "DL*OUI6=_FPNTI+"K]:5G?YL+M#J5:W2NU- ": 4K0
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M5P                                     Y#"[$="P>5AS%N=BPTO\
M_P#5I3%5JEDHF#>5DI:'#^.F0F8SD@JCL?%3&[J[:?HRJ4^6JDC%DYZ&D67B
MW8[%UW*BIUHAS?:YLO\ 9</I4OTM3'&*E3J83E-PJ.VMJJ#4,'].IE/B8T[
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MM  UEX        4EA5^M*SO\V%VE)85?K2L[_-A=H=2K5Z5VIH 30"E:
M                              #YB_-/]%3\O6C[X*I^*B^VI^H8OS3_
M $5/R_:/OAJGXJ+[:@>=K U!$N #6       8,@:@ "     &TP!D :@ "
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MD<;A4[WX'XEOLO-7C>XS]%6MW<JK!DQM/*.6   9,  @"  9&HP  U@#)@
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MO$:]*[2 :.6BW?,+Q(.6C<Q_D*+;SC<*G] @?B6^R\ZKEHW,?Y'(83XCW4*
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M$C(,  9!@@9U&  ,F$ )%AX*?^;Z2>HL,KO!3_S?23U%B'J/9WT^+I\/W<
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MHE5A@>8R>4<L,&3    9&TP  "  -   R-1@#*& $ !     #493,8 R8&H
M/.$  L/!3HG/23U%AE=X*/\ F^=/46(>H]G?3XNGP_=P  W5P
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M7ZTK._S87:4EA5^M*SO\V%VAU*M7I7:F@!- *5H
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M5.?P'4Z<IEEGP9^7BP(N/?BQ&JU=+MI-WI3?BBJU(I8H *%P
M      !3N%+OE?Z#?4A<13V%+OE=Z#?4ATO97?\ Y.+[=^FCUC]W'A+OS,7H
MAD]&\>"\9P@2(-00:P":-(%^T( &LP90(-HUW(  ">,)M,*!E0@3.+PD30-H
M"A F@7F/R,@8,BY/,H32 'YCSF$T@?2:=!A+U5+T":;QG"5^V6[VZ9^&A^RA
MZAY=EN]NF?AH?LH>H>.U>O+UE]$X?NL?2  %:T   HSX27TJB_=Q/6A>91GP
MDOI=%^[B>M#;X+OH7:'7"E0 =YO@"
M_0WP=^]F<^]3]2URJ/@[][4Y]ZGZEKGGN*[[)SM7KD !KJP  #C<*G] @?B6
M^RX[(XW"G_0('XEOLO-7C>XS]%6MT2JL#4#RCELF!J":    SJ,:S)@ $ON
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M"H9 %)85?K2L[_-A=I26%7ZTK._S87:'4JU>E=J: $T I6@
M
M      !3V%+OE?Z#?4A<)3V%'OE?Z#?4ATO97?\ Y.+[=^FCUC]W'F5,>()I
M/1O(&L7C6H1,RA +LX"!)>-1E/&8 SJ,!/$ !E#YNTJ92_4!F[48U  !<-HS
M !J&8:P@OS!.@!,Z!)YP-6<QU! M^>XS^AA#-V8 FT(+S/B"5^65[VZ7^&A^
MRAZAY=E>]NF?AH?LH>H>.U>O+UE]$X?NL?2/]  *UH  !1?PDOI=%^[B>M"]
M"C/A)?2Z+]W$]:&WP7?0NT.N%*@ [S?      !         @       U
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M,B:LR%CV"JM/J]FY6/2H+8$!&HWD4N[A41,Q9J3/+,S':PPKFJ)['0@ UEX
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MS5&O<KKX<33YT-K@N^A=H=<*:" '>=
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ML[_-A=H=2K5Z5VIH 30"E:
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M0!  !G,8 V@/.  +#P4:)WTD]1897>"C_F^=/4I8AZCV=]/BZ?#]W  #=7
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M%7ZTK._S87:'4JU>E=J: $T I6@
M                                              !3V%'OE=Z#?4A<
M)3V%%/\ Y*_T&^I#I>RN_P#R<7V[]-'K'[N.SGUM,)KO,'HWD&?R"#8BC1>
MOO10AE5, -8TYP &I0EX2^X:%S@!>-8"!= T:@+MH2:AJ 3, NVCU"[.%  :
M0 ]8U   +](UA $TC691 +\LKWMTO\-#]E#U#R[*][=,_#0_90]0\=J]>7K+
MZ+P_=8^D?Z  5K0  "C/A)?2J+]W$]:%YE&?"2^ET7[N)ZT-O@N^A=H=<*5
M!WF^                 (              #]#?!W[VIS[U/U+7*H^#OWM3
MGWJ?J6N>>XKOLG.U>N0 &NK   .-PJ?T"!^);[+CLCC<*?\ 0('XEOLN-7C>
MXS]%6MT2JL( >4<L   R8,IK P/,-0  (  0! &8   !J  (9 P@  &08U$#
M)C: A(  "P\%&B=])/4I897F"G_F^DGJ+#/4>SOI\73X?NX  ;JX
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M_-A=H=2K5Z5VIH 30"E:
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MM": ,H8  (-8 &3  !  !8>"G1.>DGJ+#*\P4:)STD]189ZCV=]/BZ?#]W
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M:
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MD<;A4_H$#\2WV7&KQO<9^BK6Z)56$ 0\HY8 93,!@&0!@ R!@ ;0,ZC!G48
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MM
M                                  !51$O70>2^T=&8]6/J<FUR9E18
MS45.L]5[<9CFKK2XK&=P.TN:FHL=T],(Z([&5$O_ /8SPC&>J6.4Y1TP[>JV
MAI\C0IBJ93!B2\-JJCFO14<[4F;\BCV4N:MA)6CM55VN27AR\195JIFS(MUU
M^S%0ZFW>#^HMLK3J/9V(Z-"AQGQ(V.JI?>C;MNZ<K4*3;RDV5F9:.L&'2X<!
MR1&-;_LN6_\ V[#8THQB+QG=1J3,S64.E^#C_3*E][^C2Y#\XX$(=?=4D=37
MM2FI$7*$5/%YO,6C5,)M+I]JVT.)"C+$Y1(3HB(ER.5;KM/F,-;"9SFF6EG$
M81;Q\/\ 3Y:9H<K-/FH<&9EG.6&QRI>]%SKZD*_K6$2J5"QS*5%IKH4-R(QT
MPK5Q52_5_P#D]OX0K)AM8IDQ$1[I%$7-JO[D]2TUK[(S%@72\LR768=#1K(3
M6-QFNOSKI\_26X16&.U_LPSWRRWIU.!:FRU-L@C)::AS+HL58D1S%1<5UR)=
MT(AWI3GP<H$TRE3\6(K\F=$5&(M]U]S<Z%QFMK16<KM*;Q@ !6L
M                      Y6WE*KE4E8#+/SS9.(UU[U5;KTN7]B<8N:1,U%
MNJ*=PJUN9M#4'69H;L9D).4FHC-"(B777Z/]W43I2D6RHE/J,S.U%)YW(.;"
MAL557&5%2_1XT.$L[/5^@RE2B1;/1X\S-HY8LR]%O1%55V&QIZ<1-Q-J<\[B
MIV=/\'%N+*U1JZHBIU-+H/SS@+K$_*U2-*R\BZ++QXCEBQ4T0\R>+Q)TEV.M
M/26UQ*0Z;8D^O_[=Z7Z_'XC'7QGGE.CE'(IK"*K*GA9EI"M1%ATYKF(B.6YM
MRHV_3F-.$^E4:S%0IE0LS,PH<PCD1T.#$:N;/G[D[3"0VR=4K\&G5MT:5J27
M8DPU+DSHEUZXR;4*YPC4*C4ITC(4F:?/3\6(CG1%>KE1N?-=>NQ"_3F^55G%
M6_1-!G5J-&DIQ<RQX38G2EY./-LU*.D*!3Y2)\N# 8Q?.B'I&E/;LVH[  $)
M                #C<*?] @?B6^R\[(YZW%'F:U2H4O)K#2(V,CUQUN2Y$<
MFSQFOQ>,YZ.6./:KU8F<)B%-@ZSL!K%VF5XU]P[ :QO2O&ON/-?!Z_DESO=9
M^#DA<=;V 5B[Y4KQK[@E@:QO2O\ Y%]Q/P>OY)/=9^#DS"'7)8"L;TKQK[AV
M 5C>E>-?<1\'K^23W.?@Y'S ZWL K&]*_P#D7W#L!K&]*\:^XGX/7\DGNL_!
MR5X.M[ *QG[J5XU]P[ :QO2O&ON'P>OY)/=9^#D@=;V UC>E>-?<.P&L;97_
M ,B^X?!Z_DD]SGX.3,'6]@%8N^5*\:^X=@-8WI7C7W#X/7\DGNL_!R0.M[ *
MQO2O&ON'8!6-Z5XU]P^#U_))[G/P<D9.L[ *QO2O&ON"6!K&]+<:^X?!Z_DD
M]UGX.2&LZWL K%WRI7C7W!; UC>E>-?</@]?R2>YS\')ZC!UW8#6-Z5XU]QC
ML K&]*\:^X?!Z_DD]SGX.2,G6=@-8WI7C7W#L K&]*_^1?<1\'K^23W6?@Y(
M(IUW8#6-LK_Y%]QCL!K&]*\:^X?!Z_DD]SGX/6P4_P#-])/46&<E8:S\Y14F
M,L6$O**BIB.5?T.M/1<#AEAH1CE%2Z&A$QA$2  VUH
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M>E=B: $T I6@
M                                               !&J<C J4A'DYM
MF/ C,5CV[45+E)( \6S-F*99N%%ATJ!R38BWNSJMZ_GYB-.6+HDY7&5>/*(Z
M=:J.1]ZZ;[[SHP9<TW=HY8[$*K4N3JTHZ6J$!L:"[4IR4+!59:',<JDBJY[T
M:KUN3K.Z C/+'LE$XQ/;#1)2D"2EVP)2$V%";H:TW@&+(
M                   !4OTFF:EH<S+1(+TN;$:K5N0W #FK'V.I]E6S"4]\
M5_+.5SN4N79L3Q&J)86DOM2E>5(F6(M]V-W-^=;^LZH&7/E=VQY8JJ<U;&Q=
M+M5"8E0:]D5GR8L-;G(>79C!E0Z#.MFX:QYJ8;\E\=U]W1<=R"8SRB*O8Y,9
MFZ  8,@                                   #6^/!8MSXL-J[%<B ;
M :V1X3W8K(L-R[$<BFP  ?#8T)SE:V(QSDTHCD50/L
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M7:F@!- *5H
M
M
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MUJL:F9%1$T>(Z(HRBIE=CO$  ,4@
M                  C5&1EZC)192<A-BR\5+G,<EZ+GO]:%)6SH4O8*:6H4
M*H0;GO5SI"-<Z^Y;[D1%3:NHM>WLU/R5DZA'I".=/-1J0T:V]<[T1<WF53\]
M4Q:W#JCI^L4":JTQCX[>7<[%:M]^BY4N\1LZ$34S>RC6F.Q>M@)N!:.S\&>F
MJ3#EHKKT5JP[K[E5+TO3Q'7-1&HB-2Y$U%,2^$>TT"&V' L@L.&W,C6JJ(G^
M)<4E%?'E846(S$>Y+U;L*M3&8FY9Z>43%0W%25BU]N9>IS,&4H;8LNQZHQW(
MN6]"VSQ+9UQ+/6?F:AB<HZ&ES&[5_B$:<U-5:<XV[:4,^4M$^T'QLZRD/EKO
MD9.N)?GSW;<_475@]JE9JE-BOKTBDG%8Y&L8C%;FS[?R*_I%:ME%KBR]1CL9
M%F)98\&$U-%R.T]RFZIW>#.T$W7:+%2I(B3TI$6#%5-:I>GK12[5N<>R%6E4
M2Z\ &LV    >1:RLPZ#09NH1$OY)N9-JJJ(GK*LIL6WM=I:V@DYQC&*O*0I1
M&WJYNE$^3GU%F.GS1=TPRSJ:74#R;*S<].T.6C5:6?+3JHJ1(;DN5%152_\
M-+E_,]8PF*FF43>X4EA5^M*SO\V%VE)85?K2L[_-A;H=2O5Z5VIH 30"E:
M
M
M
M     5'7L&-1EZ]&JME*BZ5B1G*Y[-&G.N>]-><MP&>&<X=C'+",NU5MD<&T
MU!KS:U::==.SD._$:N=$S79\Z[5/2MM8RI5RT].J,G4GP)> YJNAIXE15NSZ
M[BP 3[W*[1[O&J<3A!L+#M53Y5$F%@SLJB(R+=??FS]=QQD?!M:FJPX<I6*Z
M^)(M7.U55;TTZ,8ND#'5RQBH1.GC,V\VSE'@4*C2U.E;UAP6(V]=+E1$2_J/
M2 ,)F]UD16P "
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MUI6=_FPNTI+"K]:5G?YL+M#J5:O2NU- ": 4K0
M
M
M
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MNU- ": 4K0
M
M
M
M                          TP927@N5T*##8Y<ZJUJ(JFXYC"/6XU LI-
MSLM\_P#(8JZEN5;^HG&)F:A$S46Z;&3&NOSF2C9;!G6IVFI58U=7+7-Y7\T_
M([O!/69NJ4*- J+^4FI&)R#HF]=>E_\ B69:<1%Q-L,<YF:F*=N "I8
M   %)85?K2L[_-A=I26%7ZTK._S87:'4JU>E=J: $T I6@
M
M
M
M
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MKTKQ30 F@%*T
M
M
M
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MS>?TC)&;S^E"0!<E0CY(S>?TA)1B+?C.Z20!<E0  A(
M    %)85?K2L[_-A=I26%7ZTK._S87:'4JU>E=J: $T I6@
M
M
M
M
M                  !26%7ZTK._S87:4EA5^M*SO\V%VAU*M7I7:F@!- *5
MH
M
M
M
M                                 4EA5^M*SO\ -A=I26%7ZTK._P V
M%VAU*M7I7:F@!- *5H
M
M
M
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ME</RN%1E</8[A45)<) (^5P_*X5&5P_*X5%27"0"/E</RN%1E</8[A45)<)
M(^5P]CN%1E</RN%14EPD CY7#\KA497#V.X5%27"0"/E</8[A497#V.X5%27
M"0"/E</8[A497#V.X5%27"0"/E</8[A497#\KA45)<) (^5P_*X5&5P_*X5%
M27"0"/E</RN%1E</RN%14EPD CY7#\KA497#\KA45)<) (^5P]CN%1E</8[A
M45)<) (^5P_*X5&5P_*X5%27"0"/E</8[A497#\KA45)<) (^5P_*X5&5P_*
MX5%27"0"/E</8[A497#\KA45)<) (^5P]CN%1E</8[A45)<) (^5P]CN%1E<
M/8[A45)<) (^5P_*X5&5P_*X5%27"0"/E</8[A497#\KA45)<) (^5P]CN%1
ME</RN%14EPD CY7#V.X5&5P_*X5%27"0"/E</RN%1E</RN%14EPD CY7#\KA
M497#\KA45)<) (^5P_*X5&5P]CN%14EPD CY7#\KA497#V.X5%27"0"/E</R
MN%1E</RN%14EPD CY7#\KA497#V.X5%27"0"/E</RN%1E</RN%14EPD CY7#
M\KA497#\KA45)<) (^5P_*X5&5P_*X5%27"0"/E</RN%1E</8[A45)<) (^5
MP]CN%1E</8[A45)<) -&5P_*X5,97#\KA45)<) (^5P_*X5&5P_*X5%27"0"
M/E</RN%1E</8[A45)<) (^5P_*X5&5P_*X5%27"0"/E</RN%1E</8[A45)<)
M (^5P_*X5&5P_*X5%27"0"/E</RN%3*34-51.ZX5%27#> "$@
M  19ZFR4_BY=*2\QBZ.5AH^[I0E =@Y:UED92J68G*93X$"4=&1%3DH:-151
M47/==L*WA2-NH-G7672G,=+JWD$F<]V)=B[-GC+Q!9CJ3C%=JO+3B7-X/+/.
MLS9>5I\6)RD9F,Y[D2Y+U<KOU.D ,)F9FY9Q%14(\Y(RDZUJ3LK F$;\E(L-
M'W>:\UR=+I\E%6))R,K+Q%3%5\*"UBJFR]$\1, N4T  @
M
M
M
L                                                       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g12080g24d83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g24d83.jpg
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M*"@H*"@H*"@H*"@H*/_  !$( MH#I ,!(@ "$0$#$0'_Q  <  $  @,! 0$
M            !@<$!0@# @'_Q !;$  !! $" P0%!@<-!00(!@,  0(#! 4&
M$0<2(1,Q05$4(F%Q@14R0I&AL0@C4G)SP=$6)#,T-C=B=(*2LK/A0U.BPO 7
M1%1U)34X57:4P_$8)F.3M-(G9H3_Q  ; 0$  P$! 0$              P0%
M 0(&!__$ #,1 0 " @$# @0$!00# 0     ! @,1!!(A,1-!!3)182(C,W%2
M@9&AL105T? &-$+!_]H # ,!  (1 Q$ /P#JD
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M)-'K%?KI%@ $20
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MC]Y6L$1US:+;_9'>*O\ -WG_ .K+]Z$(_!G_ ).YC^MM_P "$WXJ_P W>?\
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MY"_SSSI_.EZXGZ<  *:R
M                                'G/!%8B6.Q$R6->]KVHY%^"GH /B
M"&*O$D=>)D4:=S6-1J)\$/M>J=0 -9^Y_#>D=O\ )./[???M/1F<V_OVW-FB
M;)LG< =F9GRY$1'AX7:56]%V5VM!9BWWY)HT>GU*?M.I6I0I#2KPUXD7?DB8
MC&_4A[ ;GP[KW8#\+BWW/2WXVDZUOOVRP-5^_GS;;F2E2LEI;*5X4L*FRR\B
M<^WO[SV W+FH>$U*K/,R::M!)*SYKWQHKF^Y5/< XZ\YX(;#.2Q%'*S??E>U
M')O\3'^2\?\ ^!J__LM_89@.[F'-/"O2JUWJZO6AB<J;*K(T:NWP/VY4K785
MBN5X;$2]>25B/;]2GL!N7=,3'XRACFN3'TJM5'=Z01-9O]2'O/!%89R3Q,E9
MOORO:CD^T] -SY<TP_DO'_\ @:O_ .RW]AZP4JM=_/7K01/VVYF1HU=O@>X&
MY-0'A+2JS3LFEK0OF9\V1T:*Y/<I[@XZ'XYJ.:K7(BM5-E14Z*A^@#QJU*U1
MKDJUX8$<NZI&Q&[_ %"U4K6VM;:KPSM:NZ)(Q'(B_$]@=W/DT^8XV11M9$QK
M&-39&M39$3W&OL8##V9UFL8G'RS*NZR/K,<[ZU0V0$3,>')B)?$,4<$;8X(V
M1QM[FL:B(GP0^+56O;8C+4$4[$ZHV1B.3[3V!S;KSKUX:T?9UXHXH^_EC:C4
M^I#[<U'M5KD1S53945-T4_0!JV:=PK)NV9A\<V7??G2LQ'?7L;/E3EY=DY=M
MMMNFQ^@[,S/ER(B/#PJTZU3F]%KPP<W5W9L1N_OV%BE5L2,DL5H)9&?-<^-'
M*WW*I[@;EW0J(J*BINBF#4Q&-IV'3T\?3@G=\Z2*%K7+[U1-S. W,&GC%4KP
MS2315X62R?/>UB(YWO7Q/JS7AM0NBLPQS1.[V2-1R+\%/0#9IKJ>"Q-*7M*>
M+H5Y._GBKL:OUHAL0!,S/ER(B/#YD8R6-S)&M>QR;*UR;HJ>U#XK5H*L:LJP
M10L5=^6-B-3?W(>H..O""E5@F?+!6@CE?\Y[(T1SO>J=Y^VJE:VC4M5X9T:N
M[4D8CMO=N>P.[DT_&HC6HUJ(B(FR(G@?H!P>%RE5O1=G=K06(_R98T>GU*>%
M#$8W'.5V/Q].JY>]886L7[$,X'=SK3FH\A@7L-B[\G:7L;2LR)]*:!KU^M4,
M\")F/!,;\O.M7AJPMBK0QPQ-[F1M1J)\$/0 XZB_$S3RZET9D*$3>:RC>VK_
M *1O5$^/5/B1G@"_)0:7LXO*T;=5U.=5B6>%T:.8_JJ)NG79R.W]Z%G EC+,
M8YQSX\HYQQUQ=@U\/C:V0FO5\?4BNS;]I89"ULC]^_=R)NIG $<S,^4D1IAM
MQ>/9;]*;1JML[[]LD+4?O^=MN0WC;8O-T-/3Q=.U:GNR-A=V$3GJQF_,Y5V3
MQVV^)/@>J7Z;1:>^GFU>JLUCW0;@UIJ33>BX&6XUCO6W+9F8Y-G-5>C6KY*C
M43IYJI.0!>\WM-I]RE8I6*P  \/0
M
M
M
M
M
M
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M
M                                                          &M
MS&<Q^(CYKUEC';;I&G5Z^Y$ V1X7;M:C"LMR>.&-/%[D0K3.<0[=CFCQ425H
M_P#>/V<]?AW)]I#+=JQ<F66W-)-(OTGN55 LW+\1*4"N9C8'VGI]-WJ,_:OV
M$.RFL\S?W;Z3Z/&OT($Y?M[_ +2. #Z>]SW*Y[E<Y>JJJ[JI\@
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M>QG9>'DQ]];A=Q\FE_M*Q0?C7(YJ.:J*U4W14\3]*BP
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M2<
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M/<BVY)Y:['2,V[MG*FZ!QSU55%_!4U"J.>]%MR;.>FSE_?3.JIX*="TIH:6
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M3P\2XS"QN)QV+25,90J4TE7FD]'A;'SKYKLB;F:
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M9.]FZ_VBUL->;D\11OQILRU!'.U/8YJ+^L#,
M                                "]$W4_'N:QCG/<C6M3=55=D1"K=;
MZR=>[2ABGJVIW22IT63V)Y-^\#.UGK=6K)1PK^OS9++5^QG[?J\RN7*KE57*
MJJO557Q/P                           !/\ A%_'LC^C;]ZG/.K_ .5>
M;_KLW^8XZ&X1?Q[(_HV_>ISSJ_\ E7F_Z[-_F.-/X;\UE'F^(:D &LS@
M                   &_P!':LRFD\DEO%3;-=LDL#^L<J>3D_7WH=1Z#UIC
M=8XWMZ+^SLQHG;U7KZ\2_K3R7]?0X],_!Y>]@\E#?Q=A]>U$N[7-\4\E3Q1?
M)2KR>+7-&X[2L8.1.*=>SMH$&X8\0:>LJ/92<E?+PMWFK[]')^6SS3V=Z?:L
MY,.]+4MTV\M6MHO&Z@(+KOBII71B21Y&^EB^W_N57:27?R7KLW^TJ%:_NCXH
M<4/4TQ132^ D_P"^3*K9'M\T>J<R_P!A$]YX>EM:UX@Z:T;"KLYDXHY]MVU8
M_7F?[F)U3WKLGM*GDXA\0>(\CJ_#O".Q.*<O*N3M[;[>:.5.5/<U'*GF2G17
M O3>$F2[G%DU!E57G=-<ZQ\WFC.N_P#:5Q:\<;(HVQQ-:QC4V:UJ;(B>2(!3
M>D^ V+@M_*>MK]C4>6>O,_MGN[+?V[KS/^*[>PN"G4KT:T=:E!%7KQIRLBB8
MC&M3R1$Z(>P      !5W!U/0M6<2,7)TFCS2W-E[^29O,U?J0M$C#-++7XAR
M:GIVDB99I)4N5E9OVKFNWCD1=^BHFZ=R] (GG>)FA<C6L8O4]*VEA%<Q<;=Q
MDCY7*FZ>JB-5/<J+]1B\*YK&A^%#[6I*.1BHK<DD@J]DZ66K5>Y$:CV]Z(G5
M5\D7N+&GP%6;557/O?-Z96JR5(V<R=GRO<URKMMOOZJ)WFW H'B'F]-:T=A:
MO#R-MO5+;T4L-JI5=$ZJQ%]9TCU:FS=O!2WLGJRCCM78?3L\-IUW)LDDAD9'
MO&U&(JKS+OT[O)3?,8UF_(UK=^_9-MSZV KK/\1-"Q7K^-U0B5[-=[H7PWZ#
MW=JU%5-V>JJ.:O>GO(SP^H7*_"/7+_1;-3$W%OS8FI.U4?'6=&O*B-7JB+X)
M\?$NES&N5%<UJJG=NG<?0'/.G-9:&?PDHX*]7^4LPF/[!U&+'2/E?+RJB(CN
M3;??;KOT+6X/XW)XCAM@:.=YTR$,&SV/7=S$5RJUB^U&JU/9L3  5E,UW_XC
MJSMEY?W-.3?;I_&#3<9,;7K:_P!-ZAS:9%NGF5I:5JS1DD8ZLY55S'.6/UD:
MJKLON]Q<WB%3=-E[@*IT%!H&]J^&UIJ_DLKE:L#U;/-8LSQPL=LU4YI/515W
M[N\A.NZN0Q.LM0:)QD4K:FM+-:S#*Q/5@YG*EE?CR[K[%.BV,:Q-F-1J>2)L
M?NW4"ON,[J^%X-YV"%B1P,IMJ0QIX(Y6QM1/K0EFDJ3\=I7#494VDK4H87)[
M6L1%^XUNM]++JIV&@GM)%CJ=UERS!R;K8Y$56,WWZ)S+NO1=]B3@
M                                              _'.1K5<Y41J)NJ
MKX'Z5=K_ %8MM\F-QLG[V:NTTC5_A%\D]GW^X#RUWJU<D]]#'/5*35V>]/\
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M^7@OP59P8]Z6I;IMY:5;Q>.J  'AZ
M                                                  "+ZZU(F%H]
MC6<BWYD]1/R$_*7]7^@&HXAZJ[!LF*QTGXYR;3R-7YJ?DI[?,K(^G.5[E<Y5
M<Y5W55[U4^0                                )_P (OX]D?T;?O4YY
MU?\ RKS?]=F_S''0W"+^/9']&W[U.>=7_P J\W_79O\ ,<:?PWYK*/-\0U(
M-9G                     #56\RQDBPU8W33;[;(G1%/!*-Z^O-?F[*/\
MW;3<LACC<YS&-:YR[N5$ZJ?97G!-Y_,G<?2.T)XRQ2/RX_FQJ=&O43\3&B._
M*7JJ_$R0">M8K&JPAFTVG<@ .N,_!9>Y@\K7R.-F6*U [F:Y.Y?-%3Q1>Y4.
MM.'^KZ>L<&RY6VCLLV;9K[]8G_L7P7]>YQX2#0^J+FDL]#D::JYGS9H=]DEC
M\6K^I?!2IRN-&:NX\PL<?/.*=3X=D@P,!EZ>=Q-;)8V5)*T[>9J^*>:+Y*B]
M%,\PIB8G4M:)WW@ !QT
M                                   _'.1K5<Y41J)NJKX 8&?RL&&Q
MDMNPN_+T8S?J]W@B%&Y.]/DKTUNT_FED7=?)/)$]B&YUOGUS>45(G+Z%!NV)
M/RO-WQ^XC@                                   3_A%_'LC^C;]ZG/
M.K_Y5YO^NS?YCCH;A%_'LC^C;]ZG/.K_ .5>;_KLW^8XT_AOS64>;XAJ0 :S
M.                                6-P9UT[2V92E?E7Y'N.1)-UZ0O[
MDD3V>"^SKX'4;51R(K5147JBIXG"QT1P#UPN2I)IW)R[W*S-ZKW+UDB3Z/O;
M]WN,SG<?<>K7^:_Q,VOR[?R7" #):
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M9P9?4IOW  5TP
M                       &KU-E&X?"V+:JG:(G+&B^+U[OV_ "O^)^:]+O
MMQL#MX:R[R;>,GE\$^]2#GU(]TDCI)'*Y[E5SG+WJJ^)\@
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ML-=?4RE26K99WLD;M\4\T]J&EBSTRQ^&5+)BOC^:&$ "9$
M          '5?!?5BZGTHR.T_FR-#:"=57J]-O5?\43ZT4Y4)CPGU0NEM7UK
M$S^6C8_$6?)&*O1WP79?=OYE7EX?5QSKS"?CY?3OW\2ZX 145$5%W1?$& V
M
M         *IXH9?TO*,Q\3MX:O5^WB]?V)T^*EE9F^S&8NS<E^;"Q7(GFO@G
MQ78H.Q,^Q/)-*Y722.5[E7Q55W4#S                        /WO[CUJ
M5IK=B."M&Z69Z[-:U-U4M?2&C(,4C+5]&SWN]$[VQ>[S7V_4!&=+:$GO(RSE
MN:O67JD7<]Z>W\E/M+-Q]&MCZS8*4+(8D^BU._VKYJ9
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MK\;)UT^\  *JP
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M*_HY$MPHJ^*;-?\ \GU*4>?CZL?5]%OB7Z;Z^J]P 8C4
M                                                #2ZSO_)VF[LR
M+M(YG9,][NG[5^!NBN>+=[^(T&KYSO3[&_\ ,!7(
M  3'ASI_Y3OK=M,WJ5G)LB]SW^">Y.]?@!*.'FFDQU5,A<9^_)F^HU4_@V+^
MM?\ KQ)F                                    %(<>= I+%+J;$1?C
M&)O>B:GSD_WB)YIX^SKX*4*=T2,;(QS)&HYCDV<U4W14\E.4>+NC5TEJ-WHS
M%^2[>\E9?R?RF?#?ZE0U^!R.J/3M_)G<O#K\=4% !I*(
M  !(^'>;_<_K/%9!SN6%DR,E_1N]5WU(N_P(X#EJQ:)K/N[69K.X=T@C?#C+
M_+FB,/><[FD= D<B_P!-GJN^U%7XDD/F;5FLS6?9NUGJC<  /+H
M                                                    %*:]N>FZ
MHNJB[LB5(6_V>B_;N7-:F;7JS3O^;$Q7K[D3<Y[FD=--)*]=WO<KE7VJH'P
M  !H-2:LQF!:K;$O:VMND$75WQ\OB!OP1K1V5R^66S8R=!*E1VRU_!VWCNB]
M5\.O0DH             !D8^I+>NPU:[>:65R-:A?&&QT.*QL%.NGJ1MV5?R
ME\57WJ07A3A]UGRLS>[>*'?_ (E_5]98P
M           (UQ#TQ%JS2]K'O1J6$3M*TB_0D3?;X+W+[%)*#U6TUF+0Y:L6
MC4N&K,$M:Q+!88Z.:)RL>QR=6N1=E13S+;_"&TPF-S\.;JLVK9#U9=DZ-F1/
M^9.OO12I#Z/%DC+2+PQ,E)I::R  D>                   ="_@TY59L'E
M<6]VZUIFS,1?R7ILOVM^TN0YC_!ZR7H6O4JN=LR]7?%M_239Z?8U?K.G#!YM
M.G-/W:_%MU8X^P "HL
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MXYO[S47]9E?$J]ZV:'!MYAG  RU\
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MY/7LR*J+_1;T3[>8J4OW 5/0<+1K;;+'"U%]^W7[=P,\
M                          "D_P )?$<^/Q.78WUHI'5I%]CDYF_4K7?6
M780[C!C?E/AWF8T3=\,7I#?9R+S+]B*GQ)^-?HRUE%GKU8YAR. #Z)B@
M              '7/""UZ7PXP<F^ZLA6+^XY6_J.1CIS\'BRL_#[LU_[O;DC
M3XHUW_,4/B$;Q1/W6^%.KS'V6: #%:@
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MF8Q?<KD0Z *1T+%VNJ\<U?!ZN^IJK^HNX
M                !CY&LV[C[563JR>)T3O<Y%3]9D 1V'#$K'12OC>FSF*K
M53VH?)N=:5_1-7YRNB;)'=F:GN1[MC3'U%9W$2P9C4Z  =<
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M_P#"J?K+D*>X9?RJB_1O^XN$
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M^N,NK,U69HV?3-6>7'7<G3D9;@NMB2WS\ZI65J]>5Z;+S+ZOF>'&G*WG\/\
M 9#.XF3%V(L]6?)4;,VPY&M5Z[HYG155$[CPX@XZ;3/"[ARW([\N#RN.EO/:
MBN2)K&N1R]/!%5$^HV'&'-8[/Z/TU>PUN*Y3=J*HQ)8EW:JHYR+L'6WK\1LE
M6U!B*6I-)VL-0S$O84;<EEDCED7YK9&-^8J].FZ_8NVTU)K2U5U(FGM-85^:
MS#($LV&K8;!%7C5=FJ]ZHO5?!J)OXFEXW_QGA]_\54OO<134E2AB.,^?LZIS
M66P6/S%:O)2N5+;ZT3W1L1CXWO;TW3;=$7S]H%D:6UO\L19ROD,9+C,UADWM
MT9)$?LBM5S7->G1S7(G?L:?0?$C):SEQ]C%Z4LMPLOJ6<A):8UL,FRJK6L5$
M=(B+LBN3;JOL,;1M/2;F:JR&F,U>S5U]1(;=JS9?839&OY$1[DV7N7N5=NAL
M?P?_ .:#3?Z%_P#FO#BP0         !16KF\NI\FG_Z[E^M34&^UW'V>K,BG
MF]'?6U%-"                   $EX<OY-6TT_*1[?^!2YRB]'3=AJ?&OWV
MWF1O][I^LO0                                              X[X
MF2]MK_4#D\+LC/[KE3]1&CK>WD].WY'ID</!.JJN[I:T<F_UFLGTYP]O[]MB
M:L2K^1&^+_!L7\7QC!J*S[,RW'ZIF8M#EL'24_"S0=S?T>Q+65>Y([?ZG[FM
ML\",3,BKC\[:8GAVD;)?NY2Y3XC@OXEX_P!+D]N[G\%S7. F39OZ%FJ<WEVL
M3H_NYC17."VK:^_914K.W^ZL(F_]Y$)J\K#;Q9XGCY(]E; EMSAQJZIOVN!N
M.V_W2)+_ (54T5S"96EOZ;C+U?;O[6N]GWH2UR5MXE'-+1YAKP%3;O![>0
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MY  " <7(.:EC[&WS)',5?SDW_P"4K(N;B/6](TI9<B;K"YLB?7LOV*I3(
M                "S.$M_FK7:#EZL<DS$]B]%^Y/K*S-[HK)?)FHJLSG;1/
M7LI/S7=/L79?@!=X                                          $*
MUW:Y[4%9J](V\[O>O^B?:31SD:U7.79J)NJJ5;E+2W<A/87N>Y53V)X?84>?
MDZ<?3]4&>VJZ8H ,93                   +3Q,788RK'XMB:B^_8K&I$L
M]J&%.^1Z-^M2V$39-D[C3^'5^:RSQH\R  U%H
M      "-T-*QU-=Y34R6GNEO58JJP*Q$1B,7OWWZ[DD    1G4>DH\]J?3V5
MMVWI7P\CYXZB,3EDE5-FO<N_T>].A)@            P\S09E<3<H2RS0QVH
MG0ODA<C7M:Y-EY55%V79>\_</C:F'Q=7'8Z%L%.M&D44;>YK43_KJ98
M      #$S%7TW%7*OC+$YB>]478Y_5%151>BH=%E$ZJJ>@ZBR$&VS4E5S4]C
MNJ?8H&I                     7AHO*_*V KRN=O/&G92_G)X_%-E^)O"H
M.'&9^3<SZ-,[:M;V8N_<C_HK^KXEO@
M         +T3=>X#1ZPO>B8MT3%VEG]1/S?%?U?$KXVFH\A\H9.1[5WA9ZD?
MN3Q^)JS!Y67U<DS'B%#+?JL  K(P                  ;?2</;9RONG1F[
MU^"=/MV+&(;H*OO/:L*G1K4C3XKNOW(3(VN!7IQ;^J[@C5  %U,
M                                                    !5W%BCV6
M4JW&IZL\?(Y?Z35_8J?46B1?B106[IJ61J;R5G),GN[E^Q=_@!38
M            #]1=EW3O+IT-G4S6(;VKM[<&S)4\5\G?'[]RE3:Z:S$N$RL=
MJ/=S/FRL_+;XH!>X/&E:ANU8K-9Z/AD:CFN3Q0]@
M               $?UAD_1*7HT3OQ\Z;+M]%OC]?=]9N,A;BHU)+$Z[,8G=X
MJO@B%99"W)>MR6)EW<]>[R3P0I<S/Z=>B/,H,V3IC4>6. #%4P
M         #[@B=--'$Q-W/<C4]ZJ/(L#1]?L,)&Y4V=*Y7K]R?8ANCSK0MKU
MXH6?-C:C4^!Z'TF.G12*_1HUCIB(  >WH
M                                  #XGB9/!)#*G-'(U6.3S14V4^P!
MSYDJCZ&0L59/GPR*Q5\]E[S&)QQ4QGH^5AOQM]2RWE?^>W]J;?4I!P
M               "9</]3?)5CT&Z_P#>,KO5<O\ LG>?N7Q^OS+:1=TW3JAS
MF6'P_P!6I$D>+RDGJ?-@F<O=_17V>2@62
M     ?CWM8QSWN1K6INJKW(A^JJ(BJJHB)WJI!=49WTQSJM1W[V:OK.3Z:_L
M(<^>N&NY>+WBD;EB:DRZY.URQJJ5HU]1/RE_*4TX!@WO-[3:WE0M:;3N0 'A
MP                   WFCJOI&8:]4W;"U7K[^Y/O\ L-&3S15/L,8Z=R>O
M.[?^RG1/UEGB8^O+'V[I,->JR0@ WE\
M                                     &BUKB_E73UF)C>::-.UC_.3
MP^*;I\2D#HPI37.)^2M03L8W:";\;'Y(B]Z?!=_L CP
M      +!T1K3L$CQ^8DWB^;%8=]'V.]GM++:J.:BM5%1>J*GB<YDST'J:]5N
M08U6/MUI7<K6(OK1^U%\O8!;(                          'S(]L;'/D
M<C6-3=55=D1#RO6XJ55\\ZJD;._9-U(!G,Y/DWJQ-XZR+TC1>_VKYE?/R:X8
M[^4>3)%&9J34#KO-6IJK:W<YW<K_ /0C@!B9,ELENJRC:TVG<@ (W
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M732;S[KG'KJ-_4 !?3@
M                         $5XB8?Y3PCIXF[V*F\C=N]6_23]?P)4%3=-
MEZH!SF#?:TPRX;-RQL;M6E_&0KX<J^'P7I]1H0
M6?I#%P::PDV:RJ<L[V;M:O>QJ]S4_I+T_P"MS1\.].ID;7RA<9^\Z[O51W=(
M]/U)_P!>)CZ^U$N8O^CUG_O&NNS=NZ1WB[]G^I)CIUSI#FRQCKOW84FJLG\M
MRY*&=T<CUV[/O9RIW-5/%"P-.:YHY)&PWN6G:7IZR^HY?8OA[E*A!:MBK:&=
MCY%Z3O;HQ%W3=.X%(X'563P_*R&;M:Z?[&7JU/=XI\"P<+KS%WD:RVJTIE\)
M.K%_M?MV*UL-JK^/DTOY[2EH/F*6.:-)(GM>QW5'-7=%^)]$2P
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M3+ -^M8K&H7XC4:@ !UT
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M24+LE>7O:O1?RD\%/@/B?#GC99^C4F8O$9*^)8H ,QX
M !&=0<.\-JN=&OJ=C?E79MBOZCM_-W@[XH><6)XH<)VK\D2,U5IQB[K K561
MB>QOSV_V5<GL+<T3B^1CK\S?6<G+$B^7BI*S;X5+1CW:?*[@B8KW5AH3C7I?
M5#F5;4RX;**O*M:ZJ-17>37]R^Y=E]A9Z+NFZ=Q"==\,-+ZT8]^5H-BO*G2[
M6VCF3WKML[^TBE8?N;XG<+55^E[O[I]/Q]?0ID5TC&^2,WW3^PJ_FEQ.Z%!5
M&A^.6F\_*E+,<^!RR+R.@N+M&KO)).B)[G<JEK,<U[4<Q4<U4W147=%0./T
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M)NB[D=TMK++6X-7X?4U2BW/8&)7O6!'+!9C=&KF.1JKOLJ)U3?Q(AK/*OS?
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MG*F\<L#T<QR=W14 &4
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M %0Z3QN5R]WB!JR[B[>/;EZJ5:%.Q'RSNCCB5O,YG>BN7;9/?[%72Y#!Y5_
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MC,V)ZLV/@R&7LW:M69G(^.%ZIR\S/HJNRKR^&X)Z
M                           5GQ'TSV+WY:BS\4Y?WPQJ?-7\KW+XEF'S
M(QDL;HY&HYCD5KFJFZ*GD!SJ"3ZVTR_!V^UKHKJ$J^H[OY%_)7]1&
M   !^M17*B-155>B(GB!F8?'3Y7(0TZK=Y)%ZKX-3Q5?8A8FJ,C!I3 Q8C%N
MVM2,ZN3O:B][U]J^'^A]X.G7T9IR7(Y!J+>F1-V^._T8T^]?]"M<E=GR-Z:W
M:?S2RNW5?+V)[";#CZIW/A5Y.;HCICS+% !<98        63*[Y#X3RN^;-9
MC7XK(NW^%?L*\IP.M6X:\?SY7M8WWJNQ-N,MEM;&8K%PKLW=9%3R1J<K?O7Z
MA6O7EK3[_P"$^.>FE[_;7]54@ W&>                     +DX=YJ/4>
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M=8=;HR[?28YB*U%]SNH%G@
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MG?J*HR=MU[(VK;_G3RND7XJJD_"KU9;6^D)<T]."(^L[8P -51
M            G?"O4OR7D_DZV_:E;<B-55Z1R=R+[E[E^!! 1Y<49:32WNDQ
MY)QVBT+DU5BOD^[VD3=J\R[MV^BOBAI"0Z'S$>K--R8^\_>_6:C7.7O<GT7_
M *E_U-':@DJV)(9F\LC%V5#\^^(<2>-EF/9IVU,1>OB7D #/>       -_IO
M OOO2>RBMJHO3SD]B>SVGO'CMDMTU=K6;3J'WIC!+>>EFTU4JM7HU?\ :+^P
MG;41J(C41$3HB(?C&M8QK&(C6M39$3N1#]-[!@KAKJ%_'2*1J  $SV
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M$8FR;[KU7_1;;  @O"# 9'3V'S4&7KI!+8R]FU$G.UW-&]4Y7=%7;?;N[R=
M"I:N$S^B]2Z@?C=,PZCPV7N.R$;F3QQ35Y7_ #VN23O:JITV7H3K3T=S)X"U
M%J#!UL5Z2KXW4HYFS;Q*W;UG-1$W7KT3?PZD@ %-<(=":@PVIEGU0QJTL)5?
MCL._M&N62-\KG+)LB[HO+RMZ[=%V\#;:N;\L<;M%X^+UFXFK9R=C;Z*/1(X_
M^)"SS5TL#CZ6=R.8@A7Y1OMC9/*YZNW:Q-FM1%Z-3V)WJ!M
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M
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M<<=-87:UBL:@ ![=
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MJO>IL#%Y?-]>.B([-;C<2,,]4SW?C41K41J(B)T1$\#] *"Z
M
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M]9W_ "E596VZ_D[=M_SIY72?6JJ3\*O5FM;Z0ERSTX(CZRQ0 :JB
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M-  /+T
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M9
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M@BE;,SE>K'-<GM3P5-T7V+Y]3>5*\-2M%6JQ,A@B:C(XV)LUK439$1/!#U
M                             -?J#$UL[@[V*OMYJUR%T+T\414VW3VI
MWI[C8 "C/P;LM9Q%K/</\T[:]B)WR5]_I1J[9VWLW5')['EYE!<=:LVBM?Z<
MXB8V-RQI(VKD&L^FFRHF_P"<SF;[%:TO>E:ANTX+561LM>>-LL;V]SFN3=%3
MX >P
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M?820LE?(CF*CN97NYD3;;IXAQ>
M TVLM.4M6:;O87)\WHUIG*KF;<S%1=VN3?Q1413UTOA*VF\!2P]!\SZM2/LX
MUF?SOVW\5-H?%B5L$$DK]^6-JN7;OV1-P/L%64^-&/L8EF773&J&85R*Y;_H
M;71-:BJBN56O7HBHNY96+OU<ICJU_'S-GJ68VRQ2-[G-5-T4#)      16_J
MJ2KQ'Q>F$JL='<HR6UL<^RM5KMN7;;K]9N<?G,=D,KD\;3LMENXU8VVXD:J+
M$KV\S>JILNZ(O=N!L0:7&YN:YJ3+8J3$WJT-%L:LNRLVAL\R;JC%\=NY3=
M:?5.I<5I?'>F9FTV"-SN2-B(KI)G^#6-3JY?8ABZ!U94UII]N7Q]>S7@=*^+
ML[#41Z*U=EW1%4"1 @&=XE-QUF^VIIC462J4'NCLW*U9$B:K5V=RJYR*_;9=
MU1-NG>;677F%;HB'54,DT^-G1J0LB9O+(]SN1(T;^5S=-M_/P E0(UI35L6>
MO9#'3X^[B\K11CIJEM&\W(]%5KVJURM<B[+W+T5#VTYJ:'/Y3+P4*\CJ..E2
MNMU53DFE3Y[6)XHWHBKW;]P&_
M                                           "+ZXU/)@'X6I1KLM9
M++7F5((GN5J(WODD7;P:U-_B@$H!$==:XHZ95E!L=N[F[43WU:-*NL\KMD5$
M<K4[F[^*^2^2GCPMU5-J'!L@RT-VOGJ4,7RA';J+77G<B^LU%396JK7=WEX
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M1-=RJU.1J-3?;=5W M
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M$>UR>2HO13V:B-1$:B(B=$1         BHJKLJ=.\
M
MU^<PN/SE2.ME:S;$,<K)V(KE:K9&+NUR*BHJ*BFP 'G/!#8:UL\4<K6N1[4>
MU'(CDZHJ;^*>9Z               &'F,94S&,LX[)1=M3LL6.6/F5O,U>]-
MT5%,BM!%6KQ05XVQPQ-1C&-39&M1-D1/9L>@
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M.B0L7EIZGQZO5OAZ37\?C&I915_$3\;QAX8Q1?PK'WY';>#.R;^Q2T
M
M
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M3J;T 06G@K]_B[>U!D:ZQ8_'464<<KG(O:N>O-+(B(O3;YO7O)T
;                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g12080g26j13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g26j13.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &!!MT# 2(
M A$! Q$!_\0 '  !  (" P$               8'!0@" P0!_\0 7Q   0,#
M 0,$#08*!@@$! 4% 0 " P0%$08'$B$3,4%1%!87(E5A<8&1DY31TA4R4E16
M<@@S-E-TH:*QLL,C-T)SL\$D-6)U@I+A\#0X0\(E@X3Q&"=78Z,F1)6T\O_$
M !D! 0 # 0$                ! @,$!?_$ #41  (! @,%!@8# 0$  P$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC66]K0'9W1QP. )Y^'6L_LYU)=M2[5[!47NL=4RQF9K"6-:&@Q/.   LY?\
M_P Q])_?0?X05W)J>_C8HHIQW<+E;T^B-2U%PEHH;+6&IB =(PLQN \V2> S
MY5YWZ5OK+S\DNM-9\HXWN0$9+MWZ75CQ\RMC;3KJ_6+6$=!9ZP4E/%$R8AC
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MJ-6UI=XL>PO4-=)WLMUJ.Q80?[;<!I_F>A.T[X6U:_(H?-?1,J5$1=!B$1$
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M( [YI\BT76]#OFGR+1=>I_&_V]O].#MW]?<(B+U#SPB(@"(B (B( B(@"(B
M(B( B(@"(B (B("8[+M6PZ1OTL]; Z>AJH33SM9\X-)!R.OFYO&LQ/IW9Y42
MOGI=8U%+ 3D02T+WO9XL@#*K9%E*E>6)-IFBJ66%JY9.I]56.WZ*=I/1_9,]
M-/*):JMJ&[ID.0<-'_"WH' =.<JMD16A34%9$3FY/>379CJ:CLM5<;??"_Y$
MNE.Z"IW6EQ8<'=< .GB1Y_$H?4LCCJ)60RB6)KB&2 $;XSP.#Q&5U(I4$I.2
MYD.3:2T"(BL5"(B (B( B(@"(B (B( B(@.3 '. +@T$X)/,/&IOM$U)05UO
MLMBT_(]]GMD '*.86&:4_.<0?^\DJ#(JN";3?(LI-)I<PB(K%0B(@"(B (B(
M B(@/1;O]84O]ZW]ZW@6C]N_UA2_WK?WK>!>5_)<8^YZ'8>$@B(O,.\(B( B
M(@"(B (B( B(@*/_  G?Q.G/O5'\M4.KX_"=_$Z<^]4?RU0Z]/LWAH\ZOXC"
M(BW,0K,V\,>+[8WEKA&ZTPAKB.!(<_('I'I59JP:C:C75QBCN]HM-PHHHF1L
MIIX20PMX;[23D$CGZ.',LYIXDT:1:LTSVVT.AV W8U/!L]T9V/O=)&YDC_E=
MZ"N-PM]GTWI6P3:E%RO556P=D4]&*HQ4]/&[!X'!.3D9Q_\ >,ZOUE7ZEBI:
M66&FHK;2_B*.D9N1L\>.D_\ ?25[[=K^:.QTEKN]GMEXAHQBE?5QDOB'T<@\
M1S<%3!+CYEL4>'D2NIJ:*KV%7::VV@6NG-R8!$)GR[Y_H\OWG>CAPX+"V+4%
M;8-(45+J73]/==,UDCY*3E7AKFN!PXL<,D<2>< \3Q6)N^T&ZW73M59:F&C;
M132MD8V*/<$ ;C#& ' ;PZB>)XKKT]K>IM=G^2*Z@H;M:@\R,IZQA/)./.6.
M!R.GTGK**#L[KF,:ON?(SNI;-9+AH.74.DY*^CI(:H0U-NJ)"Y@>0.^;QX\[
M>?/FPI!KJZ66DTWHV:X:=;=H)+9&R*4U;X0PM:-YF&\,JO\ 4FLZJ\6J*TTU
M#16NTQR<KV+1L+0]_P!)Q)))79I[6]5:[1\D5U#0W:U!^^RGK6%W).Z2P@Y'
M3Z3UE,$K)LG'&[2,[5WOLS9M>(+'I-M!9G5$9GJ17&0,D#FXPUW$D\!PZU]U
M=QV,:*(X@35 S_QN4=U-K2LO5MAM<%)1VRTQ/Y1M)1Q[K7.^DX\Y*6K6M;0Z
M8FL$]'05]O=ONB%5#ON@<X'+F'/ \2?*5*@]SMS(QK>K\B0WW^HG37^\9?WR
M)KG^J;0G_P!1_$HE6:FJJK2%#IU\, I*.=T[) #ODNWL@\<8[X]"7?4U5<].
M6BS30P-I[9O\D]@.\[>.3O9./0 B@[KU9#FK/T)9H\__ ).ZW'1RM-_&%FJN
MX6JEV/Z3GK[&V[TS))HG#LE\(BDWG'CN\Y.#S_YJN;9J6JM^F;M8XHH'4UQ=
M&Z5[@=]NX<C=XXZ.D+TZ5UC6V"CJ: T])<+54G>EHZQF_&7?2'4> ] 42IMW
M?G_A,9I;O+_256B_Q3Z9U-%IC1K*:FDI-VMG%P<\1MP[==A_.1QX#BJO4OOF
MNJFNLTEHMEMH+/;9G!TT5&P@S$<V\XG)"B"TIQM<I-WL65M/_(;9[^@R?RTV
MR_\ A-&?[FA_<HE?]355[M-EM]3# R*U0NAB=&#O.!W>+LD\>]'-A-4:FJM1
M1VME7#!&+?2MI(^2!&\UO,3DGBJQ@U;W+2FG?V)8X_\ Y!-\5Z_EE5LLZ=2U
M1T<-.<E!V&*KLOE,'E-[=QCGQCS+!*T$U>Y633L7IK_5K].VK2<++/9K@);7
M$_?KZ;E7-[T# .1@*N=4:^N^H+:RW/91T-M:0[L6ABY*-Q'-GB2?)S+P:JU1
M5ZDBM;*R&"(6^F;2Q\D"-YHZ3DGCP6 5:=)16];RTZC;W/<6;ML_I&:2J(.-
M"^TQ"$CYN1S@>8M310,6Q[6LM5PI9'PQQ9YC)D<WCXM6!L.NJJWV=EHN5OH+
MQ;(W%T4-;&7&$GGW' Y"\^J=95U_HJ>WMIZ2WVJG=O1T5''N1AWTCUGB?2H4
M)64"<4;N1G=/Z@KK!H^EI]16"GNVEZV5[Z82O#7->#AQ8X9+>.><=>"N[45G
ML=RT'4Z@TD^OH::GJ6Q55NJ)"YF\< .;QX\XY_U86!T[K:JM5G=:*R@H;K:B
M_E&TU8PNY-W26$'(_P"IZRN.H]:5-VM#+324-#:K4V3E334;"T/?UN).3_WU
M!,$L5T,2PV9(-<?U2Z$_^H_B7'6XSLFT(1S#LD9_XU%+MJ:JN>G+19IH8&T]
MLW^2>P'?=O')WN./0 LE8M>5ELL+;-56ZUW2WQO+X8ZZ#E.2)SG=XCI)])3!
M))>O_P!C$FWZ&;TO_4EK']*I_P"-BXZ7=VQ;++[8SW]7:7BY4HYSN<T@'DXG
MRN45H-355%I2Z6".&!U+<)&222.!WVEI!&...CJ7#1VI*S2EZ9<K>V*20,=&
MZ.4$L>UPYC@@]1\REP=GZW(4UN]+$MVG/;9+-IG2;>>B@%56-'3-)Q(/C )\
MS@I+M>N]BH]30.N.EV7,3TD<D-5V;)$'1\< -;PX?YJI-17BIO\ >ZRZ5V[V
M14OWW!N<-Z !GH  'F4AM6O:B&ST]KO-KMUZHZ;A3]F,)?"/HM<#G'B5=FTD
M_P!WDXUO1DM57>2OV;T,-#IEMKL0KR^&?LPR[TFZ\%H#N^ZSGFX*+Z&M,]\U
M9;;?25+J2::7A.PD.C#07%PQTX!QXUW:LU=7:C92T\T5-1V^D!%/1TK-R*//
M.<=)6(L]RJK1<Z:X4$G)55.\/C=C.#[E>,6HM<RKDG*Y-KY7Z3H+U54<-@K[
MU4QS.B?5UM>]KYI <$[K!QR?.LYMC&-JUC[W=_H:7AU?TCE':[:/---)64EA
MLM%=I,EU?% 3(''G<W)(#O'Q*P^I=7UVH-04=XK(H&U-,R-C0P.W7;CB03DD
MY)/'BJ*$KI_Z7<U9HRVV[^LV\_\ RO\ "8LIM$<T:2V<.EXL%&[>SU9C4(U7
M?:C4M_JKM61Q13U&[O,B!#1NM#1C))Y@NZ_ZEJKU:;-;ZF*!D5KA,,3HP=YP
M..+LGG[T<V%90=H^7_T5<U>7G_\ 9+/P@&R=O[I79,,M+$Z$]!;@CAYP5VUL
M<C/P?Z$R-<T/NY<S>&,C=?Q'BR"L71;1JD6>EM]YL]JO+:1NY32UL1<^-O5G
M/$< O)J/7]UU!I\6BOCI13MJ!4,,4>YR8#2T,: <!H!ZL^-54964;<"SE&[E
M?B1!6=MAED@[2YH7NCECM$#F/:<%I'$$%5BL]JG4U5J-EL;5PP1B@I6TD?)
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MM40L[-M5J@JP\/DJZ: LEEP",..3D<?U!>/6&IJK5-?35=;#!%)!3,IFB$$
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MJID%YI'4SY,EF7!P> <9&"LILVT74:TO+J:.404D #ZB7G+6D\ T=).#XO\
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M?X.Y*0MSY<+SH@.SEI>3='RC]QQWBW>.">O"^<K)R7)<H_DL[VYGAGKPN"(
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MN5=51B.JK*F:,<S9)7. \Q*D&SN[T&G[I4WBM<75=+3O[!AW"0^9PW02>8
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M8I.'R[K?[8FM?#'%\Q9/X/7]83/T67_)0S6-1+4ZKO$M1(^60U<H+G')P'$
M>@84Q_!^>UFT%A>X-'8LO$G'4H3J<@ZENQ!R#5R_QE6CX\O1%7X2]66EJ>HF
M'X/.G<2O ?4"-^'8WFATN >L=Z/0%$=BKW,VF67<)&\Z1I\8Y-ZD^IY&'\'S
M3; ]I>*OBW/$=],HKL;<UFTJR.<0UH?)Q)Q_Z;UE!?\ *IZR-)>)#V/9J"KI
MK9MLJ*RK [%@NK99.', \$G_ #65VQZ6O=?K2HNENHJFXV^N9&^":E896X#
M,=[G'-GQY6'U*8G[9JHR4;KA";F"ZFC&\9AO#+0.G*M+5E+%%?)W#:3)8R]K
M3\GN+<0#'!H > WT>E5E/ X-:?O LHXE)/4A^MX7Z?V,V*PW<M;=I*DU#:<G
M+HF9><GJ^<!Y2>I5 K/U5L[K:BUU>H+7J2GU)%""^HD:_,@ '$_.=G XXR#A
M5@NCL^'"[.^_>8UKWWJQ;M,.Q?P<JHQ\#55PW\?WC1_[ H5LO_K!L'Z6S]ZF
M6F'?*^PC45OC[ZHMU0*C=ZF9:[/ZG^A0S9B0W7]@+B !5LR3Y5G#Y:B\W^"\
MOF@_)?DRNV^HFFVDW5DLKWLAY-D;7'(8WDVG ZN))\ZDFS]QDV(:RC>=YC)'
M.:#T'=9[@HIMG<U^TJ].80YI='Q!S_Z;%)]GLC&[&-9M<]H<7' )XGO&JLE_
MPA__ "3'Q9>Y4:GFS2R7:[4U>ZTZFCLC8WM#VNJ71<J2#@\#QQ_FH&BZIQ<E
M9'/!J+NR\.T[5/\ ^H\'_P#D)/>HAM)L=XM5NI)+MJF.]1OE+6Q-J72[AP>^
MP3PZE7R+*%&47=O[(TE435K?<(B+H,2Y=H?]1FC_ .]C_P .10_8PYK-IEC+
M^;?D'G,3P/UJ6[09&.V'Z0:U[2X21Y /$?T<BJRPW*6SWFAN-/QEI9FR@=>#
MG'GYER48XJ4HZW.FH\-2+]"0[7VN;M(OH?S\L#YBQI'ZE-OP?/Z.UZQED_$M
MIH][/-\V4_N7NUIH^':5/!J31]=2/DFB:RJIYG[KFN P"< X..!!Z@1E>>[=
MA[,]G-?8A6P56HKKELS879$32-T^, -R!G!)<LG452DJ2^;<K>AHH.%1U'PW
MD8V-6&:KN=7?GW&:VT%H9RLT\.-]W DM&01C .<@]6.*DDVUS3[M0]F]I]/(
M0_(K7;G9!_VOF\__ !>=8?8S?[7%17O35]J!2TUVCW&3N.&M<6EI!/,.!&">
M'!<W[$[[V7_15]L?09R*KE2!N]>,<_GQXU-3 ZDMMNT]"L,:@MG[GEVQV23E
M:+5%/<I[C;;LT&.2< /B.,AG  8QG  &,'RGV_@X.)UE<(2,QR4#]X=>'L]Y
M7S:]>K5!I^R:1LE4RMCMN'3U##EI>&EH (X$]\XG'-P"[-@A%M9JB_S<(J&A
MW<GI)R['[ ]*EMOLSO[?7<%;;JW[J555,$53-&WF:\M'F*ZE]<2YQ<><G)7Q
M=QR!$1 $1$ 1$0!$1 %NAHS\C[%^@0?X;5I>MT-&?D?8OT"#_#:O-_D?EB=W
M8?F9F$1%Y)Z)Y+K6&AH):@1ND+!P:W_/Q+!:?U&9Y>0N):U[SF.0<!]TJ4$
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M(KE0B(@"(B (B( B(@.3'N8<L<YIZP<+X22<GB5\1 %SY1^YN;[MWJSP7!$
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M_B,(B+<Q"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MYDNDVW;D4DN8BD,>^&.+/I8X*S-I&SF@L%BHKY8+A+66N=S6N,A!(#AEK@X
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M1.Y[.-6VVD=4U=DG$+1O.,;V2D#K(:20HO303551'!31/EFD<&LC8TN<XGH
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M#J"(@&!U!,#J"(@(78/RNJOO2_O4T4+L'Y757WI?WJ:($$1$ 1$0!$1 $1$
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M \S2'<W0JIU;M*U%J>C=1UU1%!1N^?!3,W&O\I))(\6<+&Z/UC>-)5$DEGJ
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MV2C:S<W&TXAQ$WCG(&<YX<Y)2I2G*XA4C&Q*]@_]8.J?NO\ \55%JG\IKO\
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MHC=,(QS,#F,./-E<[K_]%!+W-E2^!R;*17OM]FN=R8Y]NMU95L;P+H('/ ]
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M'>GI7VSQ6!]CNS[M45D=U:UO8+(F@L>>G>X>3J\ZC$N*&%F#1$4D!$1 $1$
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M,PNTRW2U.@K-?KO:F6V_.J74M2UL/(\JW#BUQ;UX:/2?$O'M,_J]V=_HL_\
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M]W-U.1NF,U3RTCJQGF6&1%"27 EMOB%Z9J^LFI(J6:KJ)*6(YCA?(2QGD;G
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M)91S4CJJ1K>9\A#3D]>"YWI4.H]17.'2==8HVLDMD\C97[S"XQN!!RTYPW.
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M&2M:UE2K*JVDK6-*E+ D[\0OI&.=7%HJ@MFB]GAUC=:&*MN54_<HHI1EK>)
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MW V7?U>V#]$8M/UN!LN_J]L'Z(Q>=_(_(O4[>Q?,R4(B+R#T@B(@"(B (B(
MB(@"(B H_P#"=_$Z<^]4?RU0ZOC\)W\3IS[U1_+5#KT^S>&CSJ_B,(B+<Q"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@+<1$7.8!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M2;9Q^5U']V3^!RN94SLX_*ZC^[)_ Y7,N2O\QZ?8_#?J$1%@=81$0!$1 0FR
M/9'JVK=(YK6[\O%QQTJ8=E4_Y^+_ )PH]6:3;454LS:PMY1Q>08\XR<]:Z>T
MT?7O_P"+_JA!)^RJ?\_%_P X717/IZJCF@[*C9RC2W>#QP4?[31]>_\ XO\
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MP07.F<)J>US0L+F\=[DW;SP/.7#S+V;<-.5E??HM16>"6NMEP@C=RU.PO#7
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MQY^)QYZS1%6$%!61,I.3NPB(K%0B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B(#>A$1>*>N$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0%'_A._B=.?
M>J/Y:H=7Q^$[^)TY]ZH_EJAUZ?9O#1YU?Q&$1%N8A$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0&]"(B\4]
M<(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@*/_  G?Q.G/O5'\M4.B+T^S>&CSJ_B,(B+<Q"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
)B (B( B(@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g12080g27v96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g27v96.jpg
M_]C_X  02D9)1@ ! 0$!) $D  #_[1RN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ')$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H_\  $0@"BP%M P$B  (1 0,1 ?_$ !P  0 " @,!
M   &!P0( 0,% O_$ %80  $# P$#!0D- @L'! (#  $  @,$!1$&$B$Q!Q-!
M49$5,S5487%SD[(4%R(D,E)3@9*AL='2%B,(-#9"56)R=)3!X4-6=8.SXO F
M-T1C)_&"PL/_Q  : 0$  @,!                 P0! @4&_\0 -1$  @(
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MVC/S7?B% [C=JVY7 5U9,)*D8^'L@<.&X#"[;U?+A>W1.N4XE,0PS#&MQGS
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MG45@EN5NV-J::&9H?&<G<&'>[<I(O#UE::V]V5U!05@I.=>T32 ':,>=X!'
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M6B-DES(IF/.RTO/$KUU6/+MX(MGIW>RLV*))^WMA\?A^U_HN/V^L'C\/VO\
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M>D)X^)J2BB3#Q7-TR31.+V N:6'J*^D1=4L%=\M/@BW^G/LE5&K<Y:?!%O\
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M\I7K+"LMP9=+;%5LC=$79:^-W%CVDM<T^8@A9JU>\V6X(B+!D(B( B(@"(B
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MB9JM9?6MHR]ZK^EA$15BP5WRT^"+?Z<^R54?WJW.6CP1;_3GV2JC!ZEZ#1_
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M1B2GF;LO8>D*,^]QI;/@J/[17,A));3H23;V'JZ/J:FJL,3JZ0RU,4DL#Y2
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MK9Z+O;?,%K"MGHN]M\P5;2GMZ]BQH[W=.Y](B+D'3"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B("N^6GP
M1;_3GV2JB&Y6[RT^![?Z<^R54:]!H_@(XF=XS"V>B[VWS!:P\%L]%WMOF"K:
M4]O7L6-'>[IW/I$1<@Z81$0!%&+C/=JO4LM!;:]E)%% V1VU"U^23Y5Z]GI[
MA3QR"YUS:MY/P2V(,V1]2W<*5V:J5NJ/01$6AL$1$ 1$0!$1 $1$ 1$0!$1
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M94-K:4 &*J!:"3TM('XJ1X=*VS13MU1[:(BC-PB(@"(B (B( B(@"(B (B(
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M-K::<G+F@G9Z 1Y5:AAJ+3O^BO*;::.S5NI:#E"MMKMMFMTXOAF827Q;/,
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M^;D?\IT>=Q*[+SH"R7F^B[7!D\E06M:^-LFS&_9X9''[U*XV-C8UD;0UC1@
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M1;JNZ71G-W.Z2&>2,;A&TG(;CH.\J?HB@E)R=LFC%15((B+4R$1$ 1$0!$1
M$1$ 1$0!$1 5WRT^"+?Z<^R541\ZMWEI\$6_TY]DJHUZ#1_ 74XF=XK.%L_%
MWMOF"UA6ST7>V^8*MI3V=>Q8T=[NG<^D1%R#IA$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$!XNH=,6G4#J=UUI&3.@<',<1OXYP?)Y%[+6M8T-8 UH
M&  , !<HLVZHQ2WA$18,A$1 $1$ 1$0!$1 $1$ 1$0!$1 5WRT^"+?Z<^R54
M6,]*MWEI\$6_TY]DJHUZ#1_ 1Q,[QF%L]%WMOF"UAZUL]%WMOF"K:4]O7L6-
M'>[IW/I$1<@Z81$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 5WRT>"+?Z<^R54>5;G+3X(M_IS[)51%>@T
M?P$<3.\5G/2MGHN]M\P6L/0MGHN]M\P5;2GLZ]BQH[W=.Y](B+D'3"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B("N^6CP1;_3GV2JCQE6YRT^"+?Z<^R5487H-'\!'$SO%8"G3>4Z]@ "
M"@P!]&[]2@O04Z59Q,*&)\ZL@AB3P_E=$Z]\^]_04'JW?J3WS[W]!;_5N_4H
M(.E<CH4?A,'E1OXG%YB=>^?>_H*#U;OU)[Y][^@H/5O_ %*"HGA,'E0\3B\Q
M.O?/O?T%O]6[]2>^A>_H*#U;OU*"IT)X3!Y4/$XO,3KWT+W]!;_5N_4@Y3[W
M]!0>K=^I04+D\$\)@\J,^)Q>8G/OGWOZ"W^K?^I/?/O?T%O]6_\ 4H-T+CJ3
MPF#RHQXG%YB=>^A>_H+?ZMWZD]\^]_04'JW?J4%0<"GA<'E1GQ&+S$Z]\^]_
M04'JW_J3WS[WGO%!ZMWZE!L;BN"GA,'E0\3B\Q.O?/O>.\4'JW?J3WS[W]!;
M_5N_4H+T(4\)@\J,>)Q>8G7OGWOZ"@]6[]2>^?>_H+?ZM_ZE!#N*Y">$P>5#
MQ.+S$Z]\^]_04'JW?J3WS[W]!0>K=^I07H*YZ$\)@\J'B<7F)S[Y][^@M_JW
M?J0<I][^@M_JW_J4$Z%SC<GA,'E0\3B\Q.O?/O?T%!ZMWZD]]"]_04'JW?J4
M%ZTZ$\)@\J'B<7F)T.4^]_04'JW?J3WS[W]!0>K=^I05<IX3!Y4/$XO,3GWS
M[W]!0>K=^I/?/O?T%O\ 5N_4H+UK@<$\)@\J'B<7F)W[Y][^@M_JW?J3WS[W
M]!;_ %;_ -2@H1/"8/*AXG%YB=>^?>_H*#U;OU(.4^]G_84'JW?J4$"Y3PF#
MRH>)Q>8G7OGWOZ"@]6[]2>^??/H+?ZMWZE!43PF#RH>)Q>8G7OGWOZ"W^K=^
MI/?/O?T%!ZM_ZE!6H"GA,'E0\3B\Q.O?/O?T%!ZMWZD]\^^?06_U;OU*"]"'
MH3PF#RH>)Q>8G7OGWOZ"@]6[]2>^A>_H*#U;OU*"]")X3!Y4/$XO,3KWS[W]
M!0>K=^I/?/O?T%O]6[]2@@X%<]2>$P>5#Q.+S$BU-JVX:BIH8:Z.F8R)VVTQ
<,(.<8Z25'1Y4.X(."EA",%452(Y2E-W)[3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g12080g42a80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g42a80.jpg
M_]C_X  02D9)1@ ! 0$!) $D  #_[1P84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &_L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%A<B)#(V4G)T@9*QL](C-#="5>'!8F/P)4,F1(.$HL+Q_\0 &@$!  (# 0
M              $% @,$!O_$ #01  (! 00(!0,%  ,!       ! A$#! 4A
M$A4Q,T)2@<$4,D%QH1,B408T0V'1(['PX?_:  P# 0 "$0,1 #\ Z(QABBFP
MY2(K\I*N1/X<.>_PKX"F[QBF[7:1RU-9(D:KFD3%U6I]R'QBZZ27>_UE3(N;
M==61IS,1<D_\\)ITXGH+K=(V44VLRDO%YE:2:3R/557.57*JJN]5/ #M.0(
M-@)'$<  0!S[0 2!S@ @   ($ 4$@9;!P   0;P0  "1P"<1N  0  @ <0 !
MP";P #Q.)[F    !GL 1-X0$@9#\P  #P$'H !(/TIYY:=R.@E=&N>>;5R/S
M0 $WPMI K[=.V*YR/JZ15R57KF]B>!2XJ&K@KZ2.II)&RPR)FUS5.9B?:/<6
MQV6WU%+69OCUT?&G-GO_ ."LOES4EIV:S.^Z7IIZ$WD0)55555VJIX 69P
M;@0-@"#G "#G"!   >( >A-XR  Z @YP"0$" $ <-X  '.!]P V!!TA   .
M "! G@  X    < 2 /O&8(' (H'$$@)N    0$ ! @ 3> @0 (   @10@3)0
M @ 3<"0@!YQ!!ZA^E/$^HJ(X8DSDD<C&ISJJY'YDMT8VSJ_$\4KVYQ4O\5W-
MGP_\\!KM)JS@Y/T-EG!SDHKU,:_8-NECMZ5E:L#H5<C5Y-RJJ*O/L(WD7.RX
M1XMIL06IR[8G+R2IS(NQ?*5Y@:T4UTQ,VAN,;G1:K]9J.5JYIT'/87B6A)VN
MU?\ 1OM;".DE9[&1L%G26/!U'B!;74K525,LB,:U'+JQY[D5?O\ "1[$MEH,
M.8LA@JFOGMDF4BLUE1R,551=J<QG"\QFZ)/97W,)7>455M?@B1M<,V:2_7-M
M%%-'"Y45VL_F3F3BI.WZ/Z2IO5)/0K_Z'+%RCEY3-R;-V:\^PU=FM5CN>.'T
M-%#(E R-V2I*[-SDRVYYF+O491>CZ*OL9*[2C):7YI[D0O5 ^UW2IHGR-E="
M[55[=RF%S\Y+I<,-KL=5%IHE='3L?M<JJY6M1,]ZF]=9\(,NG6EU/<.J-;DN
MJ,W:NO\ EZ"?$QBDG5NE2/H2DWZ*M"MX8I)I61PL<^1ZZK6M3-57P'ZUM#54
M$W)5M/+3RY9ZLC5:OI)O:K-08>QLE%=DEF57,=1O8O%5V*[<;G2*^P==X67&
M"=]:JLUG(Y4;J<>)#O7WJ,55-5)5V^QR;HTRIP3+'^&Z6U3T,MJ:Y*2J9\%%
M<KOA??X%/O'5DM=BMMN@@B>ERE:CY'*]53++;LW;S9&\0EHT]36["4=*OH0H
MW%!AVMK++4W5BPQTE/L<LCE17=&S::AJ*YVJU,U78B)Q+'QHON?P9;+&S))I
M6Z\V73FOI51:VCBXQCM;^/464%)2E+8D5S&Q7O:UN]RY(35FC.^.:CDDHLE3
M/LCOVD-I/YJ'ZZ?F6=I:J9Z>EMG4\TD:JFW4<J9[#"WM)J<80=*U,[&$'"4I
M^A#[W@N\V>!T]13MD@:F;I(5UD:GAXH1PM/11>JJXOK+9<)'5,*1:[>576R3
M/)4V\-I&K7A9+KC.OMK'+'24\S]=R;T:CE1$3PF,+PXN4;7A]296*DHRL_4B
M"'I9D%EPE6W)UJ@@N$=3FK&SJKM57)Z.',:BPX5A;C:2SW1%EB8QSD5KE;GS
M+FAFKU"CJFJ*O0Q=WDFJ4SR(4@_,LJHL^#K;>WV^N=4RS2/1&HURZL2+N15S
MS_,TN),+1V;%=!2:SI*&KD;JYK\)$ULE15_\WB%ZA)THUE7W$KO**KM(?S@L
MW$^'L*6&9_53JA'R0YQ0,<Y=NW)RKTISFKPSA>WK8I+W?5F=2KLCBBSUG;2%
M>H..G1T_[#NTE+1JJD&' L*HPQ9[U9:FLPXRJIYZ;Y44^?PO+F?G@G"MOK[!
M476Y,J*C4<YJ00NR7)$3TDN]047)^F7]A7:>EHKU("";X@M.'765]7;'U%%5
ML_\ EJG6S<GWF;AC"=LDPNEXN4=35J[->1@7:B(JIPWAWJ"CI-/;0A7>3EHI
MK\E=])()\,2PX5CO:U4*QO=DD2;]^6_G\!LL4VNP,M+:NT2ST]0BHCJ6?/6R
M^_VG[U=@H8]&\%U:R3JQRIF[E%U?EJF[=N(E;IJ+657389*QHY)YT5=I!@A/
M</X6M<&&^OF(WR]3O3..*-<E5,\D^]3]ZC"UDOECJ+AA=\\<E/GK12KORVKO
MSX>$EWJ"=,Z;*^A"NTVJ]:>I78)[@##-LO-EKY[BUR20O5J/1ZHC4R1=R;S8
M63#^$KXRII+:ZK6KA9GRSW*F?A1-WH(E>X1;33RVB-VE))IK,K(;#]Z^F6DK
M:BF<J*Z*1T:JG')50QTW'2G7,T;,CT#;EM!("( AZ"#SAX0@  "^ (.<$CH+
M8P&V+#N":J\5C%<DZZVJFQ5:BZJ)^:_>5.G$R'UM4ZG2G=4SN@3)$C615:GW
M;C1;V3MHZ-<O4VV-K])Z7J6CAC%]CDO,<-':74<M0NJLJN3+GVGE#;$MNE9>
M3;JPSQ.D;S;4V^DJACG,>CF.5KDVHJ+DJ&2ZXUJS-E=65*RM3)'K*[61.9%S
M-+N=&]![50VJ]9+26QU)7?\ ^J7_ -W%_P#J;325;I[MC6W45,F<DL#4SX-3
M6=FJ^!"NW5$SY^7?-(Z;-%Y17*KL^?,_5;A6K.D_5=2LR)JI)RCM9$YL\S-6
M$DXM/8J&/UDU)-;74N6"XVNT5%+A579H^#5?)K;$<J;NE2-X0L<UBTANI9<W
M1\D]T;\MCDV%</GE?-RLDKW2JN>NKE5V?/F?NMSKEE;(ZMJ5D:BHURRNS1%Y
MES-:NCBFE+:L_?\ )F[RFTVMCR]BP:*Z06S2E7K5.1D4SEC5[ER1JY;"15<&
M*9+N]U)4V]+:Y^LV58VJK6^3:I2DTKYI'232.D>[>YRJJK]YD-N=<R/DVUM4
MV-$R1J2NRRZ,Q.YUHTU6E,U41O5*II[:Y,E^(:S_ ./K>ZJKXJOD'1M?,QB-
M:WX2KELYLS8Z5[+4SS]>(71.HT8C55';<RM,\US7;GQ4RDK:F2-L$U5.ZGS3
M-BR*J9=!L5W<91E%[,C#ZRE&49+;F6Q@OD<389HXZI466WS-3[D]I M(=S2Z
MXGJ7L7.*%$A9]V_TYDFI<3X?P]8Y8K!RLM9.U-;71R9.RYU3<5J]SG/<YRYN
M<N:JO.:KM9/ZDIM47I7Y-EO:+04*U?KV)'H]M2W3$],W+^' O+OZ$5/^<CYQ
M]=4NV):J2-VM#&O)Q]"?[-%2U4]*]74T\L+E3)5C>K55.;8?EGM7:=7T_P#D
M^H_Q1'/]3_CT%^3]:3^:A^NW\RYL=X9J\0TU"E&^)O)-VZZY<"E$7)<TSS3<
M9R7>Y(FRX5:?_6=[37;6,IRC.#HT9V-K&$91DJIEHX<M5+@2BK*^ZUD4E2]B
M-2-B[<DVY)SJJY&@T<W^),6U\E8YL?7!RO1SER1'9JN7I()/4SU+M>IFDF<G
M&1RN5/*?DG@V*8*ZU4M-U<C+Q-''05$B[6T^*ENCU=66^*WZRJDR1-5=7@:.
MP5#JC2>]7U;*QS(5:LK&(U%R3F0KE;G7+'R:UM4K,LM7E79>3,W.C^ZTEHQ$
MVJKY%C@2-S5<C5=M7P(:G=90A)Y5I3)&Q7A2E%>E?5DNON"JNZXMFK*:IIW4
MSI$63X7PH_!D?GCVXT]9C2QT]-(V1U/*U'JU<T15>FST>DB.)KV^?$%?56JL
MG93S/1R:CG,UMG,:%KWI(DC7N21%UD<B[<^?,SLKO)Z,IO8LNIC:6T56,%M9
M/-,GSAIOLS?6<2#!MQEKL%,H[3/3QW.G3+4F1%14S7@O.5-4U,]4_7J9I)G(
MF2+(Y7+E]YY3SRT[]>"5\3]VLQRM7T&3NM;*-FWFC%7BEHYTVEP/?B"AM-54
M7RYT5&C4V,CA:NLGH(Y@*DNJVB>JL-TB94:ZHZCD1%1?#Y"#5%9552(E34S3
M(F[E'J[+RGQ35$],]7T\TD3EV9QN5J^@B-U:@U55?]9$N\)R3H\O[S+BQ(O+
M8+JG8FAIHJ]$7DD:[:J\%3TFAP327B.PMJ;!=(9'JN;Z.1$V+GMZ"O:FKJ:I
M46IJ)IE3=RCU=EY3RFJJBE55IIY857>L;U;GY!&Z.,'!/UKLR#O*<U*GIU+8
MQTK9<&NDO<-/#=,TU&L=FN>>_P#,U]=_1VFZ4_44K>HJ:BJ=K5,\LSDW+(]7
M?F%JZEU.E.ZHF6!-T:O75\FX1NCC%*NQU$KRFVZ;50M"CB9BO1Y2VZBFB974
MR-:L;W99JW-/2A^UAHO<3ABY/N\\25$^:MB8[-=V2)X2J*>HFIWZ]/+)$_Z3
M'*U?0>U-5453D=4SRS*FQ%D>KE3RAW1NL=+[6ZA7E*DJ?<E0LS1DN>$[VY=Z
MO<O_ ."&MT.=O*WQ'_*$&AK*FGC='!4S1QN^4UCU:B]*(?--4STKU=33RPN5
M,E6-ZM5?(92NS:FJ^8B-NDX9>4R\1=O[E]HD]937\#U[W/>YSW*YSES557-5
M/#JBJ)(YFZML #<2 >*#W9Q! R  ) \@0   (H   ('.   $      /$/0 @
M'. 2 @' $#G    3G  W@#G!(R Z " .(_(  )L'  D !  $W!/" !Q4  @!
M!P )'#: % ' 9#@.<$#:,LP/_-P) !TI';J+DV_$Z;<G_M-]AR7F]*[TJJU.
MB[W=V]:.E#FL)X3I;K=1=YTWFF^P=;J+O.F\TWV'+K1<OR=.KGS'-(3:=+=;
MJ+O.F\TWV#K=1=YTWFF^P:T7+\C5SYO@YI0\YSI?K=1=YTWFF^P=;J+O.F\T
MWV#6BY?D:N?,<T[%!TMUNHN\Z;S3?8.MU%WG3>:;[!K1<OR-7/F.:0=+=;J+
MO.F\TWV#K=1=YTWFF^P:T7+\C5SYCFD=!TMUNHN\Z;S3?8.MU%WG3>:;[!K1
M<OR-7/F.:1F=+=;J+O.F\TWV#K=1=YTWFF^P:T7+\C5SYCFD'2W6ZB[SIO--
M]@ZW47>=-YIOL&M%R_(U<^8YI"'2W6ZB[SIO--]@ZW47>=-YIOL&M%R_(U<^
M8YIYP=+=;J+O.F\TWV#K=1=YTWFF^P:T7+\C5SYCFE-P.ENMU%WG3>:;[!UN
MHN\Z;S3?8-:+E^1JY\QS3T@Z6ZW47>=-YIOL'6ZB[SIO--]@UHN7Y&KGS'-(
M.ENMU%WG3>:;[!UNHN\Z;S3?8-:+E^1JY\QS3S@Z6ZW47>=-YIOL'6ZB[SIO
M--]@UHN7Y&KGS'-/ '2W6ZB[SIO--]@ZW47>=-YIOL&M%R_(U<^8YIWGG Z7
MZW47>=-YIOL'6ZB[SIO--]@UHN7Y&KGS'-(.ENMU%WG3>:;[!UNHN\Z;S3?8
M-:+E^1J]\QS2#I;K=1=YTWFF^P=;J+O.F\TWV#6BY?D:N?,<T@Z6ZW47>=-Y
MIOL'6ZB[SIO--]@UHN7Y&KGS'-(.ENMU%WG3>:;[!UNHN\Z;S3?8-:+E^1JY
M\QS2$XG2W6ZB[SIO--]@ZW47>=-YIOL&M%R_(U<^8YI">4M;3%2T\%IH%@@B
MC59U158Q$S^"O,52GD.^PMOK0TZ4..VLOI3T*CG.GHNQMZ$.83IZ+L;>A"OQ
M3AZ]CMP[BZ=SZ !4%F
M                  5WIH[46_QZ^JI4>>1;FFCM1;_'KZJE1GH,/W"ZE)?=
MZP=/1=C;T(<PG3T78V]"'-BG!U['1AW%T[GT "H+,
M                                         KO33VHM_CU]52HT+<TT
M]I[?X]?54J,]!A^X127W?,'3T78V]"',)T]%V-O0AS8IP]>QT8=Q=.Y]  J"
MS
M *[TT]J+?X]?54J,MS33VHM_CU]52H\CT&'[A%)?=ZP=/1=C;T(<PG3T78V]
M"'-BG#U['1AW%T[GT "H+, &MO\ =$M5$DK8UEGD<D<,2?WO78GW$I-NB(;H
MJLV0(Q'>+M055.E^IJ1E-4.U&R4ZN74<NY'9_P#!)R91<2(R4@ #$R
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M5".5&P(J9[%UTVG+5=_/5&?='?FIU8<IU_\ /5/C'?FH9*/P0<1S@@D\ 0]
M!T%HPDG3 UK1D*.;E)DNMEG_ !''/IT3HL^8=JZ)/U'$HADAY6I[W3\:'.YT
MB<W\2[P?CZ=SS7Z@_CZ]CS@-P7,=)='FP N>T #>A;VC-\S<+1I'%KMY5^U7
M9<2H>!<FB[YJ1^-?^96XIN.I<8'^YZ/L23E:GO=/QH<CXQS7%U\5R9.ZNGS3
MF_B..P3C_&?SOOOV^?\ 4<5V'>:1[B[;6:8 %L=8"'J  '2^A629NCNW)'"C
MFZ\NW6R_]QQS.=/Z$/Z<6WZ\WZKCAQ#=+W_TT7CRDQY6I[W3\:%:8J5RX@K%
M>W5=K)FF>?\ :A:A5N+OG%6_6;ZJ'D<7W*]^S*NW\IIP$!YTY0 @ "$\P"^9
MMHG2*)'IRZ[=;+^UI T+"T=]II_'KZK2QPO]PO9FVP\Q)HE<YB+(W5=S9YGT
M >E.TKO33VHM_CU]52HT3,MS31VHM_CU]52H]G$]!A^X127W>L(AT]%V-O0A
MS#Q.GHNQMZ$.;%.'KV.C#N+IW/7+JM5<E7),\DXE8U-?;[O=[A/4X<OZ3L>D
M*OI45BO;JHN3\I$V[?)D6>1VLQ M->EH::VR3ZVLUTS7HU%E1BO1GA541-OA
M0JX.E:%A)5,S"C%CL-*Q:'J!K=9(Z9=[&:RZN>_:J9*OA4VQA66X-NEMBJV1
MNB5V;7QNWL>U5:YJ]"HJ&:8O:9+8  02   #E.O_ )ZH\:[\U.K#0OP?AY[G
M.=:*17*N:KJ;P2CFH\.E?<;AW_#T?X![C,._X>C_  $"IS6#I3W&X=_P]'^
M>XW#O^'H_P  %3FLZ)T6_,.U=$GZCC+]QN'?\/1_@-Q0T=/04L=-10LAIX\]
M6-B9(F:Y_FI(J?N<W'2)S=SEW@_'T[GFOU!_'U[#[AS@%T>;'!3T\XA%YP F
M\N31=\U(_&O_ #*;+DT7?-2/QK_S*W%=QU+G OW+]GV):<?XS^=]]^WS_J..
MP#C[&?SPOOV^?]1Q78;YI'N+MM9IP!D6QU ( G$ '3^A#^G%M^O-^HXY@.G]
M"'].+;]>;]1QP8ANE[_Z:+QY2=%6XN^<5;]9OJH6D5;B[YQ5OUF^JAY'%]RO
M?LRLM_*:<! >>.0   %A:.^TT_CU]5I7I86COM-/]H7U6ECA>_7LS;8><E
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M%6XN^<5;]9OJH>5Q?<KW[,K;?RFG 0'G3E   !/< <MUHGY+D]7EU^5G]%I
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M%V-O0AS8IP=>QT8=Q=.Y]  J"S
M                          *[TT=J+?X]?54J/9Q+<TT]J+?X]?54J/[S
MT&'[A%)?=ZPAT]%V-O0AS"=/1=C;T(<V*</7L=&'<73N?0 *@LP :W$M9+06
M*MJH'(V6./-BJF>2[MQ*570ANBJ;($9HJ+$4D<$K[Y$K7(CE;U*W=S$F)E'1
M]:D1E7T  ,3(
M   KO33VHM_CU]52HTW%N::.U%O\>OJJ5(F? ]!A^X74I;[OF>'3T78V]"',
M)T]%V-O0AS8IP=>QOP[BZ=SZ !4%F:^\2W.)D76JF@G<JKK\J_5R3AD:ZZ2+
M+AV1F(V)3)*](W=3NULLW;-OD)"?C64L-92R4]2Q)(9$U7-7BAG&25,C%QK4
MB&(+/%:;/)<Z"NK&U$*(YJOF54?MW*A+K?,ZHH8)7ID][$<J>'(TD6#[:R1J
MO?5S1-7-L,DRN8G-L)$B(B(B)DB&4Y)I*M3&$6FWL  -1L/P<VIUEU7QHW/9
MFA\ZM7W2+R*9()J10QM6J^G%Y%&K5]TB\BF2!44,;5J^Z1>11JU?TXO(ID@5
M%#&U:OZ<7D4:M5].+R&2!44,;5JOIQ>11JU?TXO(ID@5%#&U:KND7D4:M7].
M+R*9(%10QM6K[I%Y%&K5]TB\BF2!44,;5JOIQ>11JU7TXO(ID@5%#&U:OND7
MD4:M5W2+R*9(%10QM6K^G%Y%&K5?3B\BF2!44,;5JOIQ>11JU?=(O(ID@5%#
M&U:KZ<7D4:M7W2+R*9(%10QM6J^G%Y%&K5_3B\BF2!44,;5J^Z1>11JU?=(O
M(ID@5%#&U:OZ<7D4:M5W2+R*9(%10QM6K[I%Y%&K5]TB\BF2!44/F)'HQ.45
M%=X#Z ()*[TT]J+?X]?54J0MO33VHM_CU]52H]QZ##]PNI27W>L'3T78V]"'
M,.>PZ>B[&WH0YL4X>O8Z,.XNG<^@ 5!9@
M                                %=Z:>U%O\>OJJ5']Q;FFGM1;_'KZ
MJE199GH,/W"ZE)?=\SU#IZ+L;>A#F%3IZ+L;>A#FQ3AZ]CHP[BZ=SZ !4%F
M#6XCN*VNT3U+&ZTJ9-C;SO5<D)2JZ(ANBJS9 A_4]\CA9417EM16KDY:-R-:
MU<][4VDNB5SHVJ]NJ]43-N>>2F4HZ/J1&6EZ'T # R
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MAVW->9..1^VCJDN5#@^W4MZ:C*N)FIJYYJC4W(OAR)(82DU6)E&*?W  &!F
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M"Z5M%77-M9;&N1*1JHNLU-Z\=G0;["F(*3$UJ2X6]LS:=9'1IRK-55R7+-/
M;@Q<I).+,E&+I)  &!F            5WII[46_QZ^JI4:;>92W--/:BW^/7
MU5*C53T&'[A%)?=ZQQ.GHNQMZ$.83IZ+L;>A#FQ3AZ]CHP[BZ=SZ !4%F
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M3,]!A^X74I+[OF>(=/1=C;T(<PYG3T78V]"'-BG#U['1AW%T[GT "H+,
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MEDFQ=^Q?"62*NS>3S"2FLS\:)DT='"RJD26=K$1[T3)'.RVJ?L :C8
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M)?(/A,D8JIRF6YJ^TR@DW1LQDVE5&UQY@JW8OH>3JVK%61M5(*EORF+X>=/
M5%A^\UVC6ONUONMG=576K7XM5MS59EW(F:[VY[<DVY[]Z92BR:5G6NVUE%BV
MGDCO-$W5:W+^85-G0B^$E& *6YW>UMN>+H8):B29:BC8^--:G8J;$1?O-ZTK
M.+4]AJ=)NL=I]Z*,,2X9PUR=8J=6U<BU,S4W,543X/W(GES)F <\I.3JS=%*
M*H@ ""0                 "N]-':BW^/7U5*C3CL+<TT]J+?X]?54J/+PG
MH,/W"ZE)?=ZP=/1=C;T(<PYG3T78V]"'-BG!U['1AW%T[GT "H+,
M                         TEYPM:+Q<:.NN%''+44KM9CE1-O@=SH;M-B
M; ":MD42  ()                     *[TT]J+?X]?54J/(MS33VHM_CU]
M52I$/08?N$4E\WS/$YCIZ+L;>A#F':=/1=C;T(<V*</7L=&'<73N?0 *@LP
M                                                          "N
M]-/:BW^/7U5*C+<TT]J+?X]?54J-/ >@P_<+J4E]WS!T]%V-O0AS#Q.GHNQM
MZ$.;%.#KV.C#N+IW/H %068
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M+?YMW[@FD^]]PH/-N_<09-N9X3X2QY41XFUYB=>^?>^X4'FW?N'OGWON%O\
M-N_<054/.(\)8\J'B;7F)W[Y][[A0>;=^X>^?>^X4'FW?N(+_:!X2QY4/$VO
M,3KWS[WW"@\V[]P]\^]]PM_FW?N(+_:H0>$L>5#Q-KS$Z]\^]K_[%!YMW[A[
MY][[A;_-N_<07G";AX2QY4/$VO,3KWS[WW"W^;?^X>^?>^X4'FW?N(+P/5'A
M+'E0\3:\Q.??0O?<*#S;OW!-*%[[A;_-N_<01V\]4>$L>5#Q-KS$AQ-BVX8B
FIX8:Z.F8R)^NU8FJBYY9;<U4CR;1SGINA",%HQ5$:Y3<W63/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g12080g54n82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g54n82.jpg
M_]C_X0V\17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(U+C8@*%=I;F1O=W,I #(P,C4Z,#DZ,#4@,3 Z,3,Z,C@
M  .@ 0 #     ?__  "@ @ $     0   H"@ P $     0   \
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   ,@@        !(     0   $@
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M%V\P"=OJ;CZ>WV;_ ,[]Q,[.I >X8PAH!:3W!G71CMOM:]1/4,:!NQ@(<#!
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MYQ@D_P!8Q[N%,UV^J'"PA@$%D#4_O;D$YXWEOH7^TD3Z9@QX%-]O_P"ZU_\
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MIRM?UMGE^B/_ *41YM_TM?\ FG_THENL_P!+7_FG_P!*)*0$Y?;+K[?X(_\
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M,O( /Q.SQW?26BDI22222E))))*4DDDDI__7]4<UKVEKP'-.A!U!"%]CQ/\
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! !+     $  0$L     0 !.$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         !.$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!$0      !     "   "0    D      .$))300>       $
M #A"24T$&@     #CP    8              \    *     +0!% '@ : !I
M &( :0!T "  -  N #$ (  M "  3 !" "  4 !H &$ <@!M &$ (  M "
M4P!T &\ 8P!K "  0P!E '( = !I &8 :0!C &$ = !E "T ,@    $
M                     0             "@    \
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   \      4F=H=&QO;F<
M  *     !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   /      %)G:'1L;VYG   "@     -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ H !K P$B  (1 0,1 ?_=  0 !__$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M?^:?_2B6ZS_2U_YI_P#2B2D,Y,_TID:_X+_-_/2:[(W@ORF%G<"N#_G%[O\
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M4__0]522224I))))2DDDDE*22224I))))2DDDDE*22224__9.$))300A
M  !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^X
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MJ??^PZ;#Y_<53O;:-/M_:M;-C=T9V?<F&BP^V\C3+2/44&?R<E:M%AZV!:^
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MTV\NQOCYNN*FVAM?<&)_C,/2'RTWE\@*W<&1P$$>(VWM3.[JV;NI,/%14B9
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M$9K)=<9GHC;?:FXOEO\ ('Y 578F:V7G7JZ+$]T5)I]OY+.8F^<VUVONGKW
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M<7#BLC45ONO *"#_ *O/H^76_9_RQQOQ#^1V:S> F[9^2/2>X/DYL[JR;);
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M;8[>H>H,/MS>.7W?GY<%4;[QU3335^-Q=-7T(K*B&0Q4%6T7NO:3C(Z-_P!
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MPV&KIZ6BK:V&JJ4B'NM:" 3UWV-\V>I>EN_NU=C;>^+W>^^NQS7;5VQOC?\
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MM;#^/^^ZCLRERMJ#>5+_ ![9,F7QA:=I):;*3P5(#J99?=:U#M('#HJ77O\
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M+_@^X_Y<66W9GNL::K7%9.@[V[;^2(GW+LSNS:6T-V=\]";AR.8[DWGU_O\
MW1@<3LSL;/\ 7>;VU6U61Q^!R.0IU@H*F9*:2E@F=/=;H]*_+I-;@[#_ )9N
M4V%NSY0]E;/SFW>L:C-19?/=C]U=&_)'8NS-Y5GS4P^R/CG/4X[%]F;&PN-W
M]@>T]N0X+"U\='15N.QV/DBJ*I:.&1ZAO=>[Z@ Y_P W2PV3O3^7/\*-U]M;
M!Q>_J'8^\-BCXK==]M578V].X>RLGLG"=_[EW3L7XG[ R._NS\GO1=M;"S6X
M*?*T^)Q5-D8<-A3/)55<=(M7YYO=:.HT)Z#Z@Z3_ )6&Q*_M3K7%;7CJ<ON?
M;/>'0.>Z^Q^4[_WEE,)M+96U]L]X]T=+](;;I\EF:KK?#PX3<^'S1P>PH\8E
M;.:**BCEFHZ:&G]UNKX/2H^//:7P%W!F^JZGK[=_<VX<OF.Y]UX;I?='R"G^
M7V2%3W1A>KNQ-K;RVEL'=WR5C>"/+4^P,;NBCJ\335*TLM90UH\+Y"G)3W7B
M&%:CH1-L57P$V'\6:'Y([<J-K;;^)W26[>W/EKMC>\9WO1[#V3EDF[.D[&['
MV)A9PM7+M3)R[OW+/BZ+%4<^&R$64\N'II89Z-F]UHZJD'CU%W'OSX$?&S<>
MVNY:IXL1NCL7!=Q?(#%Y_96V>W>RLI)L3LQ.JLGW;W3N+![&Q.[WVCUC5C;.
MTWRN?RM)0X/&/%3()J=YF63W7NXBGETY?)W9/P-P_668[7^1-3MW;6P^U.ZN
MC=[Q]HT&\M]8#*U?>>X(-E]%]'[SV%O3KW-TNZMJ[FKL34XK#0Y# U%%"<3+
M.]8_V4E;(WNO MP'3;V'TO\ R^OB7UM(^_.M=J8#:6^]JI\::'"/@-[]I[S[
M%QN]\[V#O')==;9VUCXMZ=B[\WEV#N'?6XLUGJFA@J\[FY):C(92HG2C$]/[
MKP+'@?GT@,AVC_+1VGTW2Y9*V3-]??+/JENCOX+MC;/?G8W8G8_5?Q]VYN+K
M[/X#+;'VWB-R=Q82+IO#9S(8W<61JZ&AR.'KJ@19*H3(/ I]UON/Y=*7K/L[
M^7]LG =D==[6[ZRF]L%N?XG4'RPW;B=\]Z=Y=XK7?$6MIMU[1':>T,EV%NW>
MU5'LB1</D*6O3;\ZU25'A-5"LL](TGNO$,:$CSIT&>8HOY4FX]QYWX@;AVOB
M97WAOKH+J#(XO.[2[QQ?7V4[7^.^S=J;N^/O7.&[KR.-H]@4W9VR-I8;%38N
MAQ^X(\K5N@IW%15-+"WNO4:FKI5=H]W_ ,N/=&?RLF_L+GNS,M\O-C9'H^7(
MX;HWY$=G4/96T.OLMV[LW</66 R^T=AY_$[=J]I5T>[Y\G14$N.KH(1/D9_V
MA#4>_=> ?]G3+WW)_+&W!4;3W+VO5Y?<NX\/6[V^(-#B=A5GR0SO8G96-Z:J
M)\EV3TSOC8?3\E5OGO\ ZXV!54,U7FX<[C\_M^G:IF:H<C(3"J]UX:\T^WI^
MH][?RL]TFCQ>*W%U1EZW-;5W'_,_Q64PU5NJ;.Y7;&+W3D(]V_(?#;NQW^YB
MO&W\[438S(8NFK'GQU%(N+FQ\5$T=*??/K7</\'2M^1NY/@QLCXP](;<[?I=
M[T'QP,/4=7TGE^LML?(_)2;1?9O]TQTGD<?O;I#%UN_M@Y-:NNQ-)AIZVMHJ
MC(54ZTNJ:1Y8S[KP#$FG'I';E[Q_EW;4V'3?&;M'L#>]?M+=J=8[YW5B.YJW
MY-[PR&PE[1WGCLSU'+WMV?OY,QG.A'W%O#$TK8?'[RS.!:,Q(B0I ;'W7AJ!
MJ.A&^=U9\/<=#U#EOE=3]NT%5BMSY6GZDWCT_C/E%!N+ [MWC2T.P9\%3[Q^
M,-*,YA\COQ=S08NCQU?4QIEJF54IXI)H@8_=>6IJ!UFQNR_@EE=D[BS"[:QA
MQ-)\ENF=W;ISNX\7V/3[^PWRDW%E>DLQU'E,OF-R01]AX3?3Y#<&RX61Y(H:
M:&H2BKD2G^[IQ[KU6K^702=5]%?RXM_=E]D8+K?I'?N7K-Q4GR3ZPS.8JNN?
ME/1= 8)-Z[DRFU_DW@>F]Y;EQ=)T#UO7[YW52U]'F*C8]7C)\O4P5(BEETRG
MW[K9+"E3T)%/F?A]\;5SVV8NQ>^,QF=O=R;%V5-LMNR/E[\B-_U?;&'ZN3MO
M;FQ=G;0.;[)WINBF'5&8&?RV,PU-5XE\:C5.5333.T7NM=QH:>72,W?W'_+0
MK-[;0[ES^8Q><W+VA-T!W]2]D87;G<>>P&%AV]7[QZK^/G9'9V?VSB*S:'3V
M&&<SN<P..EW2^%I:O(+603))+1S_ &_NO=PQT8K?_9?Q+[1I]DR;^W!A=Q4^
MP_EQMSK3935--NZF&&^6FR,G6TNW-OTXQ])2-/FL1DWG5))_)B').N1UL??N
MM4/\NDU2?)WX1]0[<^9?;M%V7M3;6WNC>WYQ\S-RPQ;MR']Q>UZ7KWK"AJ:G
M=5 M!D*U?M]@3[<C>HQE/)C5CB>[":"M\?NO&II7HLG:'6O\J#9M%-BMX4^+
MPL?3&W]A=/UNV=B[L[T3*;TVG\C=R9[L;KKI#([<ZUS;97Y+[:[)W%693*T.
MT98=STK)/6M]I'2S5:O[JU7_ -7RZ5/:79'\O_O+*]+]I3U7>.\-YKM3M'%=
M<3_&S;'S.Q_8V+V9U[OS:&&[9VIOK9?QUPV-W=M_%[5[(QN'H<AAMV8^GDI\
MHJ4ZP!VE0^Z]W"O^QTO^U^G?@)T5N6@^8O:>T*3:.=R_:.W-ZX"*HD[4R-#N
M'Y"[WQ$6R=N;KVI\:</59'![A^1F?Q=0:6.MQ^U)]V,5FF9Q)'-*ONM L< ]
M!!TWO3^6-T94[*[/Z)H]WY#,;]R?=?7G6NQ]A;+^4O<NX^O*[:N;H=S]_P#7
M6Q_CK1X3>V6^-D>)W!%1U&XL-1[<VTGE-%'-$4^SC&NMG4:UZ,K45'Q>^&>P
M.M^ULIOG,=%]%8C;>R.D=D;)W!D=Z4&R*7+=X=G[8I]CKD=C9NGK=QP]@5^\
M<_38]*BNA2IQ-)5U8J_!3I.\.^JU)KZ])C<73_PD^&F\,!WK4["W'M[=&[>Q
M=U8'KG ;-QG>O;]'1=I]R4^=W5V!4=.]!;-_OW@-B[J[!Q^"R5;G<AMS;V/>
MIIHJMZJ8)-4&7W6ZL:YZ!C/;A_EL;OZ<Z@ZNQ6T^R=S[3PVY^W-]]3;6Z6ZJ
M^7&4[KZFWOUGOFOVSW-F%/4^UI.^.D=W;6WYV'48?+TV2DP]8TN6DQ[Q202O
M![]UON!)Z;,W@/Y9&UM_]9=(QTG9_5^[>E)]M=8[<R>P)/F)UCM[:.:^2F?V
MEV3@]@]J]T[&?!;,K-V]R[QKL/DZBEWEG)\CE,Y7PBI+5U?HJ/=>JV?GT-%!
MUG\&L=UCVA\O:3<>\J3HO>.V.[.V^T*Z;N/Y$)T[EMO;RQ&Y?]-&Z*_I"KWC
M_=&*;+4SY.HEBIMOI5+7.T]+$M4RN?=:JU=/GT@>RH?Y>'7F"ZG[YQ^>S776
MYN]^ANLNG.ENP^A:'M_-]U;Z^.G5]5B^[]L[?VKL_KS#[JWWE]I;3PT8J<ED
MI\+-48W&9"2FJZB):L0R>Z]W9'3GW3N/^7[\L-T]<4>Y\5V1W%N>;KK;&?VE
MOOX^;,^5%4^-Z>^1SO3XBCW5W%\<<-1T>&ZT[0@VN\];BLYEXL<\&.-75P1K
M DR>Z\ P_P!7IU@S>X?Y6^7ZF[RPF77K=>HZ[M7JW^6_W#MV/!;YQ6&Q_:NP
M-T8?JOI[HG%;=H<=1U>VLELS<W8M!'@\IM^"EI\>U1#DH*^..E2K@]U[N!!\
M^/77?.Z_@9WK1;FW1W,.^5VQ\5=F?(N+=7=.(V]\S^I=AX+9'7ACQ'R.P=3W
MAU[C-E[7['QT57UFT%;009;+/DJO#R?91S2Q.??NO#4,#SZ@;QQG\N+9M'B^
MXL1G]\;7PVT/CW\<]WTLWQCWO\G\=MF?XQP5F[J3X^;GJNO_ (XYE<#NOK'$
M4V&S*Q53XRL@H\0LGWK)121ZO=;[CCY_SZ474N"_EV;#V9F?GULK&S]<=:X(
M=C;_ */>W8B=W[$Z_P!F2=C529#L/?\ U;TQVPV)V[L2O[<J<@A?);9V[15&
MYVKBD#5+5LBS^ZT=1.GSZSX'O?\ E^T?7>QJW;4.Y9,3U=\F<C#LWKS&]2?(
MFK[<VG\E^S=O]C=DUL<_2PV;+W'!E=U;1[$W'FXS7X<XJ3%5LM3$13I$R>Z]
M1OY= OVM0_RN\!@\/C]^; [DV(M-1]O?*XKM#K'YN=?[WZ@VAW!NG,0=Y[UW
MC6];;>PF]^@>K^QMT8C(UV?P^5EPF#KIJ>?)249\1J4UCK8U'H>=J=P_ 7'=
ML]#?';8V%KJ#>W1&WY,Q\?\ !;1Z9[KI.N=F]>YW8-5L_P#OUM7?>$V5'T_7
M=7Y'9^;DQL>=DRE1AVJ*CQI/]T0?>^M=U"?(]([KK+_ 7)=Z-F>H*GO;=.\>
MWIMJ=S;GQO7D7S0W;\?:Z3Y0[,EGVUO+M':^'BR7QPVBO8VT9?OY(\]2T*T]
MTK:B*"9DF/NO4;S_ -5.D;U;V/\ RJ/AW2;5[1ZYWA5T\F^>H<MBMJ;FJ:_Y
M']_[DVC\;^G=V28'.M!'N,=E;EZ4^/6R-X0B*MK)X\)MK[JEB::60TT31>ZV
M=;8^?1DM_P"1^#69WWV3TINV;;VY>POD;U10?*_>VQL%_?C<.9[9ZPZ5;8FT
M<-V%M\;2^\CS7\";#X*FHJ#"R_?Y$1(\5-4#RN?=:[J ^0Z+IN_M'^6MWYB]
MX]NYFD[E.1G[PZDVQD=T[8ZX^:?5O9^6^0&SZ#L7K;8&TM@TFT-L[1[$S6]M
MGXZIW+B<OC]O03#'PR5 RR(A#>_=;[QCHZNW>I>B^[?C+'U'FMH=B[NZ4W7C
M:_&5>V?D!'W;1=E5,=)N>HRL59GZSNZ:@[OQ6>Q.Y*-*[#Y&KG@R%"T%)4T$
MT:Q4LB^ZK4@U\^DL/Y?_ ,4!L-^OO]'&5-')V8G=#[S;LWM9NXV[=CV\NT(^
MRO\ 3HV]SW)_?"/9RC"K5_QW4N$'\- ^Q_R?W[K>IO7H3=A?%OX_]8XG8F#V
M/UC@<'B>MMK=A[,VE1";*Y**GV_VWE\'N#M"',G+Y"ODW;D>P<_MRDKLQ7Y<
MUV0R%8CSS3O+-.TGNM5)KGJ?TQ\<>E_CW01XSI_9%-LVBAV3U_UO##!E<]E/
M#L3JFGSM#UOM>)\YE<G(F+V7C-R55'0 '7%1F. LT4$"Q^Z\23QZ0"_!_P"+
M:]R?Z>1U10?Z1/[^-VPM]P[P.Q4[<DV^=K2=NQ]3'</^BJ/MB3!$PMN4849L
ML3*:GS$R'W7M1I2O6//?!GXJ[EVCL38F7ZCQDVU>M=G;[ZZV=C*?/;NH6Q_7
MG9]3AJWL78597T.X*?)YW9F]:O;F/ER6,KYJJCJ9*"G9H]4,97W7M1R:]++<
M/Q8^/VZ<QO3.YCK'!/D>Q<?U5C=\MCYLIA*7=,/2&^:[LCJF?+X_"5^.H*G)
M[+WCDYZJFK/$*J2.3[>:26F1(5]UZI]>H'8?Q%^.?:TW955O[K#%Y^O[<JNL
MLEOK+-E=R8W-5N9Z9EJ:CJK<6#S>'S6/RVRMT;"J:R27&Y3"38[(4\K:UFU@
M,/=>!(\^H/7WPU^-G5[;0GVAUG209/9.YNQMZXG<&:W!NW=>Y\CO/MS"1[:[
M)W=O+<NZL]F<YV!N;=VW88J"IK<[49&H6CAB@B:.*&)$]U[4?7J/2?"GXMT/
MQ8JOA+2=/8"#XKUNV,SLN?IE*_<7]VAM3<&;KMQ93;]/5G,G/4F+ER^1EDBB
MBK$6F0B*'QQ(B+[KU36OGTY;D^'_ ,;-WU_=^3W#U/@LA7_)# ]9[8[MJ169
MVC??N Z=2OCZSQ=>M!EJ5,=3;2CR<ZTXH12EQ):4R6%O=>J<9X=)&O\ @=\8
M<G7]SU5?LO=-1COD)!OB/MW:#=O]R+U[NJM['&-.\<_#UY'OY-E;9W7E)L3!
M,F7Q%#09*CJ5:>FGAFDDD;W7M1QT).WOC9U/MW8N.ZY-#O'=&U\1V#MWM+&+
MV)VCV?V7G:+?&T=S87>.U\M#NS?N[]Q;J%/@=R[>HZJFHC6&AC>+3X=#NK>Z
M]4](W=7PI^..[<CN/,S[*S6VLYNOMN+OC+YWKGL?LSJS.?Z7_P#1P.HLEOS&
MYCKC=^U\CALQN7K=5Q696DD@I\S$HEK8IZ@>;W[K>H^O2 [@_EL_#GO_ &M@
M]H=S=9[A[#QF%V34=;3Y'/=Q=U_WNW=L"HSW]ZDV?V3ON@[#HMZ]H8#'[H'\
M2HJ?<.0R24%:7EIO$TDI?W7@S#@>E9D/@E\7\UOG:G96?Z\JLYO7:M!UE1MD
MZW>>^*?%[RJ^F#KZIW#V?LS%;BQVQ.TMT]?5!,V(R.X,7D:K'S!'@=##!XO=
M:U'UZ$C#_&;H?!97<.9H.L]OO6;LI^X*/<\>3^_S>-W!0]_;JP^]NX\?F,+F
MJW(8;(8[?VYL#25%;3RT[0@1&*-8X7DC;W7JGUZ#"@^!WQNPE;M#(;5PG9.Q
MJG9.P^M.L,0.O^_N^]B4M?L+IUZ__1CMO=M#M/LK$4.^Z;9])E*BDIYLU'7U
M4M!*:6>66 ",>Z\6)X]'$]^ZUU[W[KW7O?NO=>]^Z]U[W[KW7__2W^/?NO=>
M]^Z]U[W[KW7O?NO=<6U:6T!2^DZ Q(4M;TAB 2%O]; ^_=>ZJR^-GP'[AZ"[
MOV!WYDODIE^Q]S;JQ'>5'\I-G[BQ<--USELCW/O6I[HCK^@<)B*3'9/98V9V
M[(::C&X*S/2-M>JGIE>&58B/=7+ @BGV= 7AOY6'8.7^0W;.[]];DZRP'4_9
M.Y/F74[@SO7NZ>]<KV[V+L'Y9X??N$;KK<&S-^[GR70W61VDV]Z/)29S;.).
M4KJ[:U!&/!3U^76K]UO6*#UZ5^9^!_R[[/VKC-N]O=P_'N.KZ3^/N_?C]\?<
MUUUUWO3&+NH]C0]?[=SO:'=.%S&X*K'8:H@V5UU!#3;4P?W6)7)9&>IEJY8Z
M:B@A]UK4!6@/'J-FOY<'>VRMR]PYGH_MKK'(;6/=7Q)[:^+?6/:FWMT4>'Z<
MVST3O7LG?N^^B\KNG9]7-D:SK"KW9V?E:[9BTM )=M4U:<4R3XZDI%3W6PPQ
M4>6>C0[*^+?;DO0?R^V_VKOKKZN[W^8TW8^;W5D]C;>SN.ZHV%E=R=);7Z(V
M3@=O8_+5\NZ-P8?:VT=BXN3(9&K:GKLM7-4RB*FB:"GA]U4D56@P.B^YC^6A
MO6JSW7G8&"[:VOMWL7:/=OQDS.[*Z':-96X/M'XU]/[5^+M)O;I'==++D8:L
M9A.R>@:C=VR\T'E?;>3J_"$:GKLJM1[TZWJXCRZG8KX5?*K+U6.Z]WKV)T%B
M.D.K.VOE3W3U'D]H;<W[E^V-S;N[WI/D+A=BT78T.X:^BV;MW;^Q,5\B\C4Y
M2'&+D9,W68VEB1Z.D>JAF]Y]>U+QH:XZ#SH_^6OVK@?C_E?CMVG0="X+:64J
M?C3#GZKKOLCY,]HC?."ZGW'2IV+B:S$]\YW,1=>_WAV0M1%AVPE0?!D)T:J$
ML=/&??NMEQ6HK_+I2[7_ );/:U=AA!W9VCU;VOG-Z[B^-69[UK:[8&6_A':-
M%TIV!W&-S8BJP>7R^7A2@W)T=N[;6WJ.*=YDIJ_%5=8W_ B-8_=:+#R'KTH_
MCC_+U[CZ7[;Z\WQO;OO$=M8;K'OSY-;[P.6SVW<M#V7FNH^U.E^LNF^F-G;T
MW!_%)L=N/L'JS;/7=/CLKN!H8SN*FI8*N6&.MEJ7;W7BP(H!T(?8WP1RW97P
M*[$^(.X=S;3R&Y=X;S[/WAB-YU./W)2XG UN]?D7NONK 5U*<3F*#=>.SFW\
M/N%*(UE%74\WW:/)&RQ/H]^/7@W<&Z&WY._&C-]\;"ZHZ;V5OZIZ.ZOVQV;U
MYN_?$G7./P^.W:^T.GV.[^NMC]=QY+!YO9NWJ*/M#;NW)JY:S&U=(^"Q]311
MP U"R1>ZT#2I\^J]MU?RU_DU0]4=7]5;%[>ZGW<.E<GVYM3J7M#LZ;N7:GR!
MV!USN_<CY_J[>.+[UZ8W/M+=M;O[K2@K7Q65VU+$NS]VQ8S%5<BX^:D:.3W6
M]0\QT:_Y'_!S>/REQ?17779/R-[(P_6O5O7.^*+?FX.MCMK9_:O;_;>[>MQT
MTF\,U4UVU-R[*P.W!U_NW>$\U'0X^.JCS68I*BCGI5H%$ONM!J5(&>F_<7Q:
M^2]5U7\.=ST/9W5.Y?EY\/6KXJ3=&^,)O:3I_N*@W!U[FNG]XMNZEQ^6FWKM
M7<VY=FY&#+IEJ1Z]Z#/021?;U-!4SQ-[KU1W8P>FC*_&CYH8?=O6_P D]H=I
M?'/=?RHI.M^QNH^U<3OK8>^]M=$5VP^P.QZ#M+;]%UTFT<]7[WP>7ZCR^+BQ
MD=;7BKEWECGDFR/V=4E(]+[KU10BF.B_[S_E([JR?2>:V+M+N_;N)[;V_P!#
MXC9/47<N0Z\5OX7V;N3=7R6W/\BO[T[*H\JN/DZ*[_H_D//A:S:M/52_P['T
M%)4)/-7XV@J8_=6UYX8_U4Z&EOAY\G*GMC>.VFW[T;B_BKNOY@=9_+JMJ*;
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MZHPM+NO?W2_3/1'7.W>L-U;0WGMW?$V"V'L/IRFBR=7F:EI-P5U5+5M2TO\
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M[K>CU.*=)W:O\UN7?]9AL9LGXP;ZJZK<>X=B[ PV4W'O[9^V=J_Z1MVY_8V
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MTWYC.MOC+V'T7MCJG<5+\AMJ9W-4U/O;>N6Q,5/N*AW#U;A,/M3;U>^&Q/\
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M>4W[5;KVS28"KR>W=Y9*DV#456R\'_E+;QQE3#61U-'&M0L'NO:..>D1MO\
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M1Q,@$@9V-[DW]UKI+[SZJZZ[!Q&6PF[MH8;*T>;V_N3:N0F6G;'99MO;QO\
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MD@IILID5H:+&+D,C+#&CUU:N-QM/3B64M((*>..^E% ]U3J:Q"@L> H))Y/
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M*L:*G\&H-(2&J:MB4#P6"QU;&51^'.KZ^_=>KUVW7>PG#!MF[:8/'4Q,&PU
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MGL1!-+BFE-!.H9)(F1W4^Z]4CSZ5]#U1U=C*V#)8WKC8>/R%+!@J:EK:+:.
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M1'K,OH]^ZW3K/)V#)%"T\FQ-_I&D=3*6?$8N,!::L%(VLR9M5A#J?.K2%5,
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M5$@6VK5<_2WOW7NH.'W/M[<,V1@P69Q^8?$U#4F1?&U,=9!2U<=564,]*]3
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M@J^##X6O5?OZBGI1-5RRS.Q'NMZ_ETTG^5K24U%D,7A/D#NW;>/K<O59"@3
M[5I<95;,K,AFJK<N4[$Z\EI-QPTFT_D%F,W6SK6;T%/4/54%54024#23-4>_
M=>U>HZ66R?Y;^*ZZ[8Z6[+V3W-NG;6/Z?GIICLG&X*)\!NF&KV#M;9^\Z&LI
MLIGLEC*"+?6:VY)GJVJ2BERJ9.MF:*L35(9?=>U8(ITRY7^5]M2>GW!68#MK
M<>W=Y;IJ,JV?WHN"&5R&9HMRYKM/+;OQN4H:_<34-53[JB["H(*I@J2:=LXY
ME*F&,1>Z]J^6.E'T5\&]W]5X[?FTLAV[N?+8:G^.N$Z#ZUW7E<C+N#-3[KR^
M(RC=K_(+.[;R"_PZAW?O"0;7Q:XXUE93I#L_[B-X%RDT">Z\6!ICSZ!_!_RF
M)L%MK;>%I/E?VK!FMK]BYG?6'WI18.@IMQ8:BS$>?B7:V#2?.5N%AQF%CW'4
MC&"OI,G#C7TRTT,4X:5O=>U\,="A4_RX:.?I.CZAD[-PV03']U8#N&C3<'5<
M6?Z[@EV]UTW7$6*3K>LWTLJ9+,1LVX\EE%S FJ]Y3397Q()6IA[KP;-:=9NO
M?Y<C]>;%[UV;#\F.Z=X9#N&FV.N/WIO_ "V0W/N;;F2Z_P \^Y<+FLR\V>I\
M;NK)UN0\5-D):>GP[UF)@CI&8%%F'NM%JTQT&N\/Y5F;WO)N*ORORV[/QV6W
MGC\,N]'VW@3A<1NC+8G?F=WZHJ<6F[ZBJPVT9*W/R4IQ&)J\>9J2"!:NIJC$
M&/NMZ_Z/0D8S^6UMZFR7=U1F^SJC>%)W%TA6]*U-1NW9%#N#=E51UNX3N>#.
M=F[NR^?KJGM>7;]6$Q^*IJB#'K28.)*-Y)G7[D^Z]KP.DV/Y7.WZ/%;;Q>"[
M>R>WTI)!7[K&-V='3T>6WA6[HW3N+,=M;0Q]/NJGBV#W32TF?AQ>"W"C9!L-
MCJ/QM3U9D!C]U[5QQT%?;/\ +/[?W77XK"4/=%-O/ ;HH-L;"SNYMTT-;A:O
MIC86P<7MC$X+='6^UJ+*Y2',=R;BVUM^HQ>9W!)64JY-:I(I:2*D,H3W7@P_
MAZ-#4?R\.O9NK(>G(MT5M-L#%]H;D[1VUM>/#_[]W;60S/1>8ZEQ&)Q>&7,I
M#%C-K[NS#[SI4#J@SJAPB/IF7W7M>:TSTP]/?RZ,;U3VOU=VW7=P9SL'<'5.
M9W378VIW9M:AJLSNP;SV=N[:NX-W;\W#+F:NLSG=.07=$=/+NNG2B\V!H(<7
M)0,H^X'NM%J@BG7+KS^6_M/8^VNU<'D>SMR;TR7<G6???5V^MP[EQ,60K-P8
M+NB'8E)A%S=)7Y?(4F7@ZLQ^TJVGQ-/*/$T.<K%/C\DGE]Z]>U9!IT$V8_E(
M;<K\'M/%X/O[L#8$^)CBJ=XCKK&R;*P796X4W)O'+T^YMSX7 [GHZI<MMC$;
MJCQ^WFAK5_@Z8^%_\H4+$GNMZ_ET*7?G\N^H[S[UKNZ:OO'(8_'S;3Q6UH^I
ML[L#&[NZSS--B*C:F2@INPL.^X\'/OW RYO:JU344\M.ZFIE$<Z$1NGNM!J"
ME.D[M'^6A7[->MJ,3\F-_P .5+553C-S)MZF.Z?+FL_A*[,;;W/DZO<5;1;N
MZQVSM&DRFU]E;?FI88]H8'.5,:5%94)!41^ZWJ^6.E)M?^7%C-K=>?)3KF'O
M;LW.8SY YC!UN.R&ZZFNW1DNN<3MK=^0W3@L3C/XWN"MH\M48JCK8<1#6B*B
MJ#C,=1))Y)*<2-[KVK(-.'4;K[^71+UWW1A^ZZ/O#*;JS&W]YS;YP6"WYLBE
MW1C,1G\IU9E>I=QYK%Y*LW/_ 'DP^:SNW<H3(:&LI<:K(1]B6D>0^ZUJP13J
MS7W[JO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__U=_CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=?__6W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]??X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__T-_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=?__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW03]]4.;R?1G=&
M-VS0Y?)[CR'4_8M#M_&[?J'H\]D,W5[/S$&*H<)5Q,DE+EZNODCCII%(9)F5
M@01[]UL<1U2/M_X1[HZ/^'/QOQF]>F8.TMDUV].BMU?,;IOXT]19/J#MC?'6
MNVNB-T8+#[9[+VMC^W]T9CO^IZ[[[SN(S^Y,=35U+59O'T53":#(HCT-9[JY
M8%FS]G0:Y'X5]W]RTF'HNJ^C<3L'J;#9+YF[V^*_3OSDZUW%W#L#8.#S^S_C
M!AMH[)W]LB/MO;&Y.F,9V?VMB-Z9O:=(]3D<AM';E5-2C'4B2_PZEUUO4!Q/
M[/SZ.?6;+[&Z\^%WPC[_ .MNL?D[OWN'X<;=PE=5=(]EU2UOR9[*V;N'8E?U
M1VQU#NREI<[2[*S^]?/7466I*Z2:JQPGV]35-'-)"ZM-OK6"S D4/1;=C=(?
M.'I[N;JCM^'86<W[L'XTUVW^B>Q#4=D]G5?:7=M)\DJF3?\ \X>YNONJ:C -
ML_?&U9?D'V/MW+X/(Y'+X[(8S"]9U]+CZ1X*J-:GW7B5-1Z_ZA_J^?0H]:[_
M .Q=O=0? _.UGQ[^8=75_"C);>VO\@]KU/3N^Z;>^;&\/CKVETW-N;8&$R=8
MDW?NV]I=B5E'+DY<-+E*J&@JH,FD+J/3[KQI5LC/14]X=/=A93M?J7L#M?XZ
M]IU>U\YUWW%O7$X7L+X6;O\ F;5[6_TH?.?N;NC!;1SV*V%V[B*?I#M2EZKW
M7@FK(Y/XH*<2+2!U_A)AD]UNOH<_\5T=[^9!\5.[/D]VOM>IZIV-U3NEMG?$
MGOYMOP?(OK#)=E]297LO<.].HAMW9M)%1]E=<_Z-NS<WAL97&AW"_P#$5I(8
MI/) 8DD63W55( R?/HJ/3G3VX,3\K-H[OW%TSW?)]SM'X:T75>]?D=\)=X]Z
M=K8:3;'QQV=LQ<OV#\F-J]FIL_IO?^T>QZ6J?=ZMAZRDI\C35->LM3!D4DC]
MULGCD?ZJ](/,=%9NH^*G;FQ=L?"SY@X'Y;S?&'/[5^67=&YH=U[LP'=?:D>_
M.OZ_>M7CL>.SDHOE]F.S-Q8O-YS;%1A7B3#;:DFQHGP29!<2?=;J*UJ*5Z'K
M$?&7/]Q["Z@Z@V?U_N[K'8F?[6^4F([.W%M3XL;Z^%>*VA4[W^(^X,3USV-7
M=8[AW_N+,;@J<%OZ##K1;BIZWPR9>DIZ811/"SG76JT)-?YUZ0?;O6OR,[HV
MEUQ\A/D!T9V&V[=S_(W!;'W9UYG.A<W\FL;L3JGH;X_]T];TNY<C\:]A[WVN
MV0VEW-\D=PYO=V*R"5TLE!C<IMVIJ([P:(M];! J!Z?Y>DQV;THV=J]\18CX
M>?(S<7<&X_BE\7MI?!3LSKGI;?O0^W>B>WMJU/;].F>AEK]YQTGQ$PVP^S<C
MC-PYS"9?)S/)AAI=<O'4+12>Z\IP,X\^M@K ]V=?2;3S.X=S;OQVUZ#9N\\Q
MUANC<.^:>7KG#3;XVQ7_ ,$RRXJ;=W\,IZW%Y/*1LV/J())J>LB8&&20<^_=
M-TZQ_P"S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7
MWW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/
M_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^
MC1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]
M=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >
M/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ
M_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ
M]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]
M0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_ /U]
M]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_HT=C_
M /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_73'_H
MT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C_G_7
M3'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S'_'C
M_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'KW^S
M'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[KU#Z'
MKW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7WW[K
MU#Z'KW^S'_'C_G_73'_HT=C_ /U]]^Z]0^AZ]_LQ_P >/^?]=,?^C1V/_P#7
MWW[KU#Z'I;;0[$Z_[!BR$^P=];.WO#B9H:;*3;0W/A-RQ8VHJ8C/3T^0DPM=
M6I1S3P@NB2%691< CW[K75$N\]N?S%.F]E;ZK.C\KW=DZ/M'LWY1[CWCM#<&
MU<%N2@Z/ZYA^=@FQ&>Z)AV]MC-=EU>^MZ]";WS.4H*.0[DJ<E!HK:"@BJ*"&
MBFUU?M/'T'^#J?N#-?S3GZ<R6\:3<W9.4W/@NFOC1AI*3&=41[0AS6([ [H[
M63Y$]GT'7<FT]P]Q5WR%V)T=MS;-/!B8(T&/JZN;(4V#FK:P8Z'?6^STZ#[J
M6@^?V.^1>%S^XZWY*4.>[BVI\8<?OO?./ZMV_L[X[Y;K;';6[?PG<O8W9<W9
M,==N;J#OCK;:$F%JZ#%Q08F*LW)1T1;&5$63RM+0^ZV=-/+HT_3G:OS-[F^
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M *([K'_[%_?NO:F_B/7O]DW^(?\ WBM\;_\ T1W6/_V+^_=>U-_$>O?[)O\
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MCU[_ &3?XA_]XK?&_P#]$=UC_P#8O[]U[4W\1Z]_LF_Q#_[Q6^-__HCNL?\
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MNO>_=>Z][]U[K__4W^/?NO=>]^Z]U[W[KW7O?NO=(OLD@==[^)( &R]TDD\
M 8.NN2?P![]UL<1T@_C(K)\;?CVK*59>C^IU96!#*PV%@ 58&Q!!'(]^Z\>)
M^WH</?NM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13_ )RQR2?$[NI8
MT>1AMJBD*HI8B.'<.&EE<A02$BB0LQ^BJ"3P/?NK+\0Z-A[]U7KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__5
MW^/?NO=>]^Z]U[W[KW7O?NO=8:BGIZNGGI*N"*II:J&6GJ::HC2:"HIYD:.:
M":*0-'+%+&Q5E8$,"0??NO=%&H/@7\4\514N-Q?6==C,;04\5)08W'=D]K4.
M/H*.G014U%04-+OB*EHJ*EB4)%#$B1Q1J%50H 'NK:F]>I7^R-?&+_G@<U_Z
M-/MW_P"SSW[KVIO7KW^R-?&+_G@<U_Z-/MW_ .SSW[KVIO7KW^R-?&+_ )X'
M-?\ HT^W?_L\]^Z]J;UZ]_LC7QB_YX'-?^C3[=_^SSW[KVIO7KW^R-?&+_G@
M<U_Z-/MW_P"SSW[KVIO7KW^R-?&+_G@<U_Z-/MW_ .SSW[KVIO7KW^R-?&+_
M )X'-?\ HT^W?_L\]^Z]J;UZ]_LC7QB_YX'-?^C3[=_^SSW[KVIO7KW^R-?&
M+_G@<U_Z-/MW_P"SSW[KVIO7KW^R-?&+_G@<U_Z-/MW_ .SSW[KVIO7KW^R-
M?&+_ )X'-?\ HT^W?_L\]^Z]J;UZ]_LC7QB_YX'-?^C3[=_^SSW[KVIO7KW^
MR-?&+_G@<U_Z-/MW_P"SSW[KVIO7KW^R-?&+_G@<U_Z-/MW_ .SSW[KVIO7K
MW^R-?&+_ )X'-?\ HT^W?_L\]^Z]J;UZ]_LC7QB_YX'-?^C3[=_^SSW[KVIO
M7KW^R-?&+_G@<U_Z-/MW_P"SSW[KVIO7KW^R-?&+_G@<U_Z-/MW_ .SSW[KV
MIO7K!4_ [XIUR0Q9+JZ7+TL-;C\A_#LWO_LW-XJ>IQ5?392@-;B<MO.LQF0A
M@KZ.*3Q3Q21.4 92+CW[KVIO7HWGOW5>O>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_UM_CW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]#?
MX]^Z]U[W[KW7O?NO=>]^Z]UT2 "20  2238 #DDD\  >_=>Z S_9H?C1R/\
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M>H?0]>_V:#XT?]Y$=&?^C;V#_P#9![]UZA]#U[_9H/C1_P!Y$=&?^C;V#_\
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MWD1T9_Z-O8/_ -D'OW7J'T/7O]F@^-'_ 'D1T9_Z-O8/_P!D'OW7J'T/7O\
M9H/C1_WD1T9_Z-O8/_V0>_=>H?0]>_V:#XT?]Y$=&?\ HV]@_P#V0>_=>H?0
M]>_V:#XT?]Y$=&?^C;V#_P#9![]UZA]#U[_9H/C1_P!Y$=&?^C;V#_\ 9![]
MUZA]#U[_ &:#XT?]Y$=&?^C;V#_]D'OW7J'T/7O]F@^-'_>1'1G_ *-O8/\
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M7J'T/7O]F@^-'_>1'1G_ *-O8/\ ]D'OW7J'T/7O]F@^-'_>1'1G_HV]@_\
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MT9_Z-O8/_P!D'OW7J'T/77^S0_&C@?[,1T7ZF5%_XRWL#EG8(BC_ '\'+.S
M ?4D^_=>H?0]#F"" 0000""#<$'D$$<$$>_=:Z[]^Z]U[W[KW7O?NO=>]^Z]
MU__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]TP?W4VM_P \U@.22?\ </COJ3<G
M_@-]2??NO=>_NIM;_GF\!_YY\=_]3>_=>Z]_=3:W_/-X#_SSX[_ZF]^Z]U[^
MZFUO^>;P'_GGQW_U-[]U[KW]U-K?\\W@/_//CO\ ZF]^Z]U[^ZFUO^>;P'_G
MGQW_ -3>_=>Z]_=3:W_/-X#_ ,\^._\ J;W[KW7O[J;6_P">;P'_ )Y\=_\
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MGQW_ -3>_=>Z]_=3:W_/-X#_ ,\^._\ J;W[KW7O[J;6_P">;P'_ )Y\=_\
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M &6#._\ >5WRM_\ 0TZY_P#M4^_?GUZO]$=>_P!E@SO_ 'E=\K?_ $-.N?\
M[5/OWY]>K_1'7O\ 98,[_P!Y7?*W_P!#3KG_ .U3[]^?7J_T1U[_ &6#._\
M>5WRM_\ 0TZY_P#M4^_?GUZO]$=>_P!E@SO_ 'E=\K?_ $-.N?\ [5/OWY]>
MK_1'7O\ 98,[_P!Y7?*W_P!#3KG_ .U3[]^?7J_T1U[_ &6#._\ >5WRM_\
M0TZY_P#M4^_?GUZO]$=>_P!E@SO_ 'E=\K?_ $-.N?\ [5/OWY]>K_1'7O\
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M??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\
M[#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__ +Q#P_\
MZ4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P_
M_I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__
M +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*
M_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]
M>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!
MZ]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"P
MWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_
M^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z
M4;M'_P"PWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/
M_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\
M[Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S
M\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_
M $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO
M4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??
MNO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M
M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1N
MT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL_*__ +Q#
MP_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_TL_*_P#[
MQ#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[KU!Z]>_TL
M_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW[KU!Z]>_
MTL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'_P"PWW[K
MU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E&[1_^PWW
M[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P_P#Z4;M'
M_P"PWW[KU!Z]>_TL_*__ +Q#P_\ Z4;M'_[#??NO4'KU[_2S\K_^\0\/_P"E
M&[1_^PWW[KU!Z]>_TL_*_P#[Q#P__I1NT?\ [#??NO4'KU[_ $L_*_\ [Q#P
M_P#Z4;M'_P"PWW[KU!Z]=?Z6?E?=?^<0\/8N@8_[,;M#THSJ'?\ X\WG0A+6
M_-K>_=>H/7HV:DD L-)(!*WO8VY%_P V/OW6NN_?NO=>]^Z]U[W[KW7O?NO=
M?__0W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]'?X]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7__TM_CW[KW7O?NO=>]^Z]U[W[KW71( ))  !))-@ .
M223P ![]U[HO_P#LV7Q=N1_LQG1]U9D;_C*>R>'1BCJ?]S7#(ZD$?@CWZO6]
M+>G7O]FQ^+O_ 'D7T?\ ^C3V3_\ 7KWJHZWI;TZ]_LV/Q=_[R+Z/_P#1I[)_
M^O7OU1U[2WIU[_9L?B[_ -Y%]'_^C3V3_P#7KWZHZ]I;TZ]_LV/Q=_[R+Z/_
M /1I[)_^O7OU1U[2WIU[_9L?B[_WD7T?_P"C3V3_ /7KWZHZ]I;TZ]_LV/Q=
M_P"\B^C_ /T:>R?_ *]>_5'7M+>G7O\ 9L?B[_WD7T?_ .C3V3_]>O?JCKVE
MO3KW^S8_%W_O(OH__P!&GLG_ .O7OU1U[2WIU[_9L?B[_P!Y%]'_ /HT]D__
M %Z]^J.O:6].O?[-C\7?^\B^C_\ T:>R?_KU[]4=>TMZ=>_V;'XN_P#>1?1_
M_HT]D_\ UZ]^J.O:6].O?[-C\7?^\B^C_P#T:>R?_KU[]4=>TMZ=>_V;'XN_
M]Y%]'_\ HT]D_P#UZ]^J.O:6].O?[-C\7?\ O(OH_P#]&GLG_P"O7OU1U[2W
MIU[_ &;'XN_]Y%]'_P#HT]D__7KWZHZ]I;TZ]_LV/Q=_[R+Z/_\ 1I[)_P#K
MU[]4=>TMZ=>_V;'XN_\ >1?1_P#Z-/9/_P!>O?JCKVEO3KW^S8_%W_O(OH__
M -&GLG_Z]>_5'7M+>G7O]FQ^+O\ WD7T?_Z-/9/_ ->O?JCKVEO3KW^S8_%W
M_O(OH_\ ]&GLG_Z]>_5'7M+>G7O]FQ^+O_>1?1__ *-/9/\ ]>O?JCKVEO3K
MW^S8_%W_ +R+Z/\ _1I[)_\ KU[]4=>TMZ=>_P!FQ^+O_>1?1_\ Z-/9/_UZ
M]^J.O:6].O?[-C\7?^\B^C__ $:>R?\ Z]>_5'7M+>G7O]FQ^+O_ 'D7T?\
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MT]D__7KWZHZ]I;TZ]_LV/Q=_[R+Z/_\ 1I[)_P#KU[]4=>TMZ=>_V;'XN_\
M>1?1_P#Z-/9/_P!>O?JCKVEO3KW^S8_%W_O(OH__ -&GLG_Z]>_5'7M+>G7O
M]FQ^+O\ WD7T?_Z-/9/_ ->O?JCKVEO3KW^S8_%W_O(OH_\ ]&GLG_Z]>_5'
M7M+>G7O]FQ^+O_>1?1__ *-/9/\ ]>O?JCKVEO3KW^S8_%W_ +R+Z/\ _1I[
M)_\ KU[]4=>TMZ=>_P!FQ^+O_>1?1_\ Z-/9/_UZ]^J.O:6].O?[-C\7?^\B
M^C__ $:>R?\ Z]>_5'7M+>G7O]FQ^+O_ 'D7T?\ ^C3V3_\ 7KWZHZ]I;TZ]
M_LV/Q=_[R+Z/_P#1I[)_^O7OU1U[2WIU[_9L?B[_ -Y%]'_^C3V3_P#7KWZH
MZ]I;TZ]_LV/Q=_[R+Z/_ /1I[)_^O7OU1U[2WIU[_9L?B[_WD7T?_P"C3V3_
M /7KWZHZ]I;TZ]_LV/Q=_P"\B^C_ /T:>R?_ *]>_5'7M+>G7O\ 9L?B[_WD
M7T?_ .C3V3_]>O?JCKVEO3KW^S8_%W_O(OH__P!&GLG_ .O7OU1U[2WIU[_9
ML?B[_P!Y%]'_ /HT]D__ %Z]^J.O:6].O?[-C\7?^\B^C_\ T:>R?_KU[]4=
M>TMZ=>_V;'XN_P#>1?1__HT]D_\ UZ]^J.O:6].O?[-C\7?^\B^C_P#T:>R?
M_KU[]4=>TMZ=>_V;'XN_]Y%]'_\ HT]D_P#UZ]^J.O:6].O?[-C\7?\ O(OH
M_P#]&GLG_P"O7OU1U[2WIU[_ &;'XN_]Y%]'_P#HT]D__7KWZHZ]I;TZ]_LV
M/Q=_[R+Z/_\ 1I[)_P#KU[]4=>TMZ=++8_=G3G9N3K<+USVKUWOS,8VA7*9#
M%[/WGM[<F0H<:]0M(F0JZ/$9"KJ*>C:J<1B5U"%R%O?CWOK1!'$=4P_,_P"5
MO?.T_EQVI\?)=]_Q/J'=W26YMN[0ZIZCVH\796,K<_\ '7M'<V7WSVIE<UBL
M7V-CMJP;EPR28_?G7F1RV#VVU+'C<QC4R-0M2ONK  @'SZ!#;/RJ^6_0W1>P
M>K]Z=]Y;(5.:ZE_E^[@VGW-D.D]F;+;KI>YNJ>XY]_=>[Q[#[.R>8ZVV_CH:
M_I/'MB]P;IH,UG:C*YR3#24U77U>.GCUUN@))^9Z@X'^8)\_MV]"OW[1YC'T
MU!@OC=\)JC>.W:;IB+:^-P&XODAVOVAL;NKY*YG<6^L94Y'"8OIO8>P*?.4^
M%GQ_\+QE34RU69A?&Z8(=]>TK7Y9Z<\C_,,^8FUZ3XM;CW7V;M#.;.W1NS?6
M#J,+TALG;_9O<7R)PN'^0& Z[V=NO;F,S6TMC]<]KT=1M*LEI=P8GK#)XS,4
ME<S9_&K7X0"GCU_AZ]I'IULK^]]-]>]^Z]U[W[KW7O?NO=>]^Z]U_]/?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW57_>?\TGX2=0]6?(7L#;>[,)W'N'X\4,!S_7
M?7V(K*G,[DS>0[ Q_4M)1[6S-1A/X%N/;V)[2R]+A=PYS%2Y/&[8JI2F1>*;
M1#)[JP4GIQ^3_P#,0Z3^)F-V[!V;UYF*C>N:^/&>^1U?MS;]!25.W\%M':&\
M^I-F;OI:[L+(X_%[9CGP\O:3UR22F#ST6&J/0DT]%#4>Z\%J>A,;Y[?!M=CX
MWL4=O[/EVMDMX;OV'Y*?:>ZJG.XG<G7JPR[_ (=U;.I]JR[QV;B=BT=93569
MR>7H*+%XNAK:2JJ:B*GJZ:67W6M)].A#[V^47Q2^,^T]J[Y[Q[-Z^V%M7?$T
ML>T,M5PG,)N.FI,++N7*9K$TNW,?F*ZKVQ@=M0-DLGEEB_AF+QX^YJYX8")/
M?NO $\!TE,I\VOA3A-U;QV?E^X^NL;E-A[+W?V%N7(5M!74^SZ?:77VS\?V#
MOS(8OL"3#+L/<E5LG8N4@S&7HL;DJNOQN,<U-1#'$CNONMZ6].@3[ _F;?#G
M:G5.X.[=I;DVSV?L'9>/[9J=X4NV*6NH^Q:7(]5=;0]H5.#VYUMF=LT>XMQU
M^;VO6TM?!*PHZ/\ @M5'E4FEH3Y??NO:3Y]+'L;^8)\2]DX/M,X/-X_?O8'6
M'4G8';C=:XC;V3P.4W;1=:;#I.QMW[2VMN7=V!P>SLAOS;VULA3U.4PBUQR^
M'AE+UU+3B.71[KP4XKPZ'#M/Y'?'#I&LV#B>U=TX':>?[+IJFNVGMU=N9;<>
M<JL5C9<)2YW<E?C-J8/.5F#V5MJMW+CH,GGJ]*;"XZ:OIDJ:J)IX@_NM4/1<
M,5_,S^#_ /#MXY/?6\Z'JJ#9_P A.YOCI+'O[:&:QM5D=Q=$9C$X3L+?$5-2
MX*LEQO46$JL[1&KW76BGV_CA5PK6UE/+((_?NMZ3TZ]U_P PSXF=35W:>R\#
MG-O=K]U=34.+R&>Z7V4*"+<]='4[AV#AL[1X?.YBGHMF9/-;)Q_9.+RF;QU/
MD)<AB\=4Q2U4,*31,WNO!2?LZ''._)_XK[9Z6WM\BMP=B[(Q'1_7FX<UM7=G
M9M=CZJ':U#G=O[U7KC(T5!6MBM6X$.^Y%Q5-/CDJZ>NK6$=,\I(O[K5#6E,]
M(R#YP_"B6HW-3R]N['QJ;-Z\SO:6Z,AG<#G-O83![0VGM2EWUO)J_<&=V[CL
M'%NC8^S:V/)Y[;_W!S^#HM4M?14Z(Y7W6]+>G3+AOY@?P0W#CMGY/"=T;(R2
M;^[77H[:&/IML;G?<.;[3DP%+NV':E/M8[6&Y8IJG9E;%G8JJ6DCH9L"_P#$
MTF:AO4#W7M+>G3H_SI^$B83>FX3VWLUL7L7/;;VUDWBVQN6:MS^7WGN.MV?L
MQ.M<3#MA\MW!0[RW3C:G'X>LVG!FJ/*5=--'2RRM%(%]UK2?3I0XOY??$3-;
MLZZV1C.RMHU6Y.U<+MW/;,I!M[-PT<U'O&#(U&S:/<6:GV_%A-C;AWD,351X
M?$YVIQN4RM13R0TM/+,I3W[KVDYQT -9_-+^ U7M:DW;U[V-BNV\=4=D]#]<
MS1]=;,W%FJJF'R'W^>NMA[[CIVV[!-F>MVSM+6QS9O&K6T/W&/GHTD>M"T[>
MZWH/F.AC;YP_"=,3VAG9.W]B18?I^&&IWID)<)F8J:6EJMTOL6BJ]C/)M]?]
M*U'D-]H,#32[5_C,=1G)(L?$SUDL4+^ZUI/IT$$W\Q'I+_90N]/FA0=?9&NZ
MIZ/[5WSUQ7.[;<QE5N/$[ [5Q_5V=W_2-E6HQA,)25%5/73T>02GR=-%1302
MP+4@1'W6].0M>ABVY\WOA-NO [@W+ANY.NSB=I[![$[/W4V4QV1V]D-L;'ZE
MW#1[5['S>XL+N#"8O-81MI9S*44552U-/%6Z,A1RI"T-9322^ZUI/ITM^S?D
MQ\6>F)LS3]L=E]>=>S;=V?L3?^;CW6(\.^-V?V;V)3]2[#SM2*JB332[D[+J
MX<+"HO(M?/%'(J&6/5[KP4G@.@![/_F%_&'K#?U'L.=Z#>5=D>V\#T)"FP,9
M5[LR^%[<R5!VS797;^]<#C-ORU.U,+B9NK)*&+*O)/35N3J)J:,*V.KFB]UL
M*2*]8.E/YB'Q>^06R.K-S];Y793Y_?.3Z3QF[-@[IRE/MC<>PZCN_9&X=Z[=
MIJ.>KP,V*[&J&CVEEJ.BJ,'-48C+U6(KTI*YWI)4'NO%2*UX=#C\?_EA\2_E
M+!N.JZ"[,V/V-3[4PVUMRYJ7&XRNQBQ[3WO05F3V=O/'_P!X,/B#F]D;GI,;
M5_89JA^YQ55+1U,4=0TM/,D?NM$$4QT W3GS:J^VZK9^_P"3XA]D;*^)79]#
MG\OUM\I=RY+K:'"OM;";>S>Z\?V9VGUL<Q#O;I_J+?>WMN5-7@<_D5G62&HH
M/XE!BWKX4'NME:>>>EU)\_\ X+P[,Q^_)^VMM08#+[ZH>M<-!/L3?$.Z<UO?
M+;1R?8&#P>%V'+LU=]9A]Q;$PM;FL9/38Z6ER>*I)ZNEDF@BDD7W7M+>G17L
MI_-M^/LW4O1G9^Q.L<SO"N^2>>Z3VGU+U]54PVUO"//]O[U[0VO+5=FTE3MS
M(1];;*V[C^ILK5TV;G-72YZHIYJ2@61J>27W[K>@U(].C04_SW^$]'F=B[.W
M?W/TWMC?F^>M-N]I4.#3-4^8V_'M_=&S:_?^$1.P*?$4VT7R&?V9B*S+XFAG
MJ*7*Y?$4SUM+2/3@N/=:TMZ=)]OYB?PZJMV]+;3P6<JLU/W1V;O'JB"O?KK=
M6VXNN=T;+ZEK.YZS_2OC=W[:P&?Z^Q^6V5'2U6.J,E24\%;25T=9&YH5EJ$]
MU[2:5Z,/TEWY\=_D929^LZ9W3M[>D6V9\='F(DV]E<%70T>:IGK=O;AI,;N?
M"87(Y79VZJ.&27#YRDBGP^7CAE:CJ9Q%(5]UH@CCTT[L^3/Q@V-W#MWH7=>^
MMJX?M3=-;M[%XK;LV!RL]%'F]WQ9.;9NW,WNNDPE1L[:^Z-Z1X>I.%Q>3R%'
MD,N8[4<,Q9 WNO4-*TQT#FV/YC?\OC>FR]]=A;5[]ZUSFT.N:'9.3W)EJ'#9
MV1IL=V5GJS:?7U=M+&MMM<MV%2;UW;CJC$8N3;\&36MRT$E%$6JD:(>ZV58&
MA'2BZY^9_P <-\?&K._+3,UN%V)TCA]\]F[-I=VYVF@K(MP0=?\ ;NXNGL5F
M,#CL5156<R-5V'N' Q_P;#1TASLU16PT)I!7$TX]UXJ0:>?03;,_F>_"C-[<
MH]T[YW?M[J7$[E[>[@ZOZ^GWI0.1O+#]-]AP=8;A[5JAB\55OU_UL-WU45#4
MY/<JXFFQ-=(*6ND@J/V_?NO%3T*OR7^:?QQ^(O8/5FT>^I\?L;;/:6R.W=YT
M/8U9C&R&WL*.H:WK*+,XS*8[!XS+9]8JC%=CG)S9+[=<5BL=B:J:NJ(%,1?W
M6@I-:=*3,?,;X<;>W+O_ &IG.VNO<5DNK]F[FW]OBOK:&K@VIA]L[*VM2;YW
MG41;Z?$#9.9RNT-E5\.8RN,H<A4Y/'8MQ55%/'!=Q[KVD^G39M?YL_#?>N9Z
M^V[M7LG;65SG:>,Q^3V/0R;1W/B8Z],\^7BVE19O)9K:^.Q6R<OOR7!50V[1
M9R;'5FX1&&QL54KH6]U[2?3H.OC9_,<^%OR7VGUSE]M;]V?MW>/84G7F&3K;
M<-.:7<6(WMV5M_<^<V]LY*Z7%4^$W)+-/L?-XV/*8JHK,+59;$U%'3U<E2JQ
M-[K91A7'0TY7Y*]$#876':>UMR=9;CZX[0[)J.O,+O*KW#CMNX2MEQ(WN-RU
M6W*JNQ-0NZ,AAGZ^R92BA\0K(:2:6*8H@+^Z]I-2*9Z"K:W\QS^7YO:FJ*S:
MW>FP\O1TG6\?;]35P[7W5#2P=9ULOV^W]Y25%5M2"%</O:J!@VVVK5N>H5HL
M2M9(I4>Z]H;TZ7V+^9GPWRV!S6Y8.U=CT6+VWUMN_MS<8SV%R^V,IM[8/7^Y
M!L[?&5SN W)@<5GL/D-I;IDBH,ABZBFCRM)555,DE,IJJ?R^ZUI.,=-57\ZO
M@UC\_P!N;8R'>'6&.R_1>'W'GNRTR$%304&(QVS<I0X#>1PN:J\1#A=\5VSM
MS92EQ&7I,#49.KQ>:JX,=5115LT4#>ZWI;TZ;*?^8!\$:O$]?YVF[IV+-A^R
M\A48K;^13;>Y/M,3D:/>]-UI64G8TIVP!T_+1=B5:8.8;M_@@ARQ-*^F960>
MZ]I;TZ!6/^:%\:JW8/:F4PVU,AE^Y>H-V;OVONGXZ0TN*I.PY/[D_)6/XT9_
M)8;,5\--LG/187<5;19#*04&0JJC"T^1I8*]*>IGCC;W6]!J/3HZNP.]_CGV
MIE=K8/KS?.Q=VYG>FSMW=@;:Q6(2*;(Y#9VPMZ477.\<\]&]''44%)M[?F0C
MQ%0*E89%R DA"EX90GNJT/IT!2?S$/Y?\U!V9DJ7O[J^OINH\O@\%O)<909/
M*5LF3W-NW)[!V[#LK&X[ U62[1ASF^<+6X:EGVQ%F()\I1STJ.9X9$7W6]+>
MG4QOY@'P*&=ZIVVG?/5]3F.[,)L/<G6]/0TE?D*?,X+L_>&8ZZV#D\GD:'"5
M&-VA3;H[%V_6[=ICF9L>?X_3OC6"UH$!]U[2V<=)G=W\QCX8;<QCY3![G'8=
M/3=W=5]$5\NP]A;ES=##N?M;M6;I[&YW%Y@;>BPV[]EX#>6/KZ;(Y7"5&2HX
M*G'S4HD:JT0M[KVD^?4;J'^8;\6NTNP<MU;4UV"VQN[%CHW'T>0,8S77N]]V
M?($]AML3:G6'8%/AZ/%;[KGAZWK?-+3QQQ"0.J%UBDD'NO%3U+B_F*?#6;LK
M>?7T6Z:2>@V1U#A.W<CO^AVAFLILS*TV;[CWIT1#L?:U;B\%6U>Z>R8^R-C5
M6.3!4$51DZVJ=(:.&HE6=(?=>TFG1@G^0?QQ3I=/D)_>_;+]1RK!''N>#!Y&
MHJGRM1FTVQ%M9=J08:3>)WT=U2#$MM_^'_QM,M>B:E%4#$/=:H:TZ W-?S%_
MY?VVZ/8]=N'O;K[!P]B4.;R>W(\MM[<F/K(,;M;L.BZFWAD-VXZJVO%D.O:+
M9'961@PF=EW!%C$P>0E6*O-.3[]U[2?3K.?G1\;,K\L=B?#[8CX[L+LK<F1[
M?Q&\:O;E)3+@NM,GTWM7![EW)C\QDLA1TN/W+7PU6XJ3%UD&%GKY\-DY1!D$
MIY-2K[K>DT)Z6&>^:/PRVMO;?_7NY>VMA;?W+U=MO?V[-\G,XK)XW;F&P_5.
MW*;>':"Q;VK,'#LK,YGKC:E6F2SV,H,A4Y+$40>:J@BCCD9?=:TG&.D%/_,?
M_E]TVRJ;L"3O/8S[;K=XY[K^B%/M/=U7N*MWEMK9?^DG+8"BV52[1FWI5UB]
M<?[^&G,>/:.MP/\ N1IVEH_WO?NO:2/+I9UOS9^&$6_]M]48WN/JG-=C[WVE
MA=X[(P>.JXZS#;CQ^[-IY/?.QZ5-\X_&5^R\=E]\[0Q$^5P]!45R9')XM/O*
M6GG@*NWNO:3QIT@*/^8O\*'*X"J[*V'5]FT_6L?8>3Z[V=39'>D_E_T(47R'
M.T=O;GQ^VZ;;FYMUY/J6M&=Q&.BFBR6:PX-934K0K(8_=;T-Z8Z,[\?NT>N_
MD?T?U-WWL3"2TVS^X-@;7["V]29_;_\ ",W18W=&)ILK!0Y;'5E+%-3Y"A^X
M,,M@T3NA:-WC*.WNM$4)'0O_ ,&P_P#SJL;_ .<-+_UZ]^ZUU[^#8?\ YU6-
M_P#.&E_Z]>_=>Z]_!L/_ ,ZK&_\ G#2_]>O?NO=>_@V'_P"=5C?_ #AI?^O7
MOW7NO?P;#_\ .JQO_G#2_P#7KW[KW7OX-A_^=5C?_.&E_P"O7OW7NO?P;#_\
MZK&_^<-+_P!>O?NO=>_@V'_YU6-_\X:7_KU[]U[K/3T%!2.TE+14E-(RZ&>G
MIH879+ZM+-&BL5U<V^E_?NO=2_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7_]3?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5.%+_*8KHMI4
M?6]7\I=UU/7'66Q-W=7_ !HPD'5VS\;G^H=B=@=R]:]L;NH-W;KHLDD_;>9&
M-ZJQ>W,96RT^'6EQOEJ:N'(9-A6K[J^O-:=&8^9OP@G^7.1VY4Q]PY3K/'4/
M7&]^L-T8JEV9B=WQ;BP&[NR^B^UJ6NQ\V3RF-_N[G<)N;H>@C$VBKAJ:*NJ(
MWA$BPS1^ZTK4KCHOG?W\IS;_ ';V#OKM/_2S10;OWUO3MG(55+O[JRG[%V90
M==]R=;=&;$W+LB/:U)OG8[9+-8G(]"XO)8W+5M74TGCJ:B@K\97T?C2/W6P^
M*4QT8KN'X7YS<D'QWRWQ][LG^.78'QLZVWOTKLG<=-U5L/LC:\O4W8VVMAX'
M<VWI>N<TF#P&/S&/K>K-N9'"U=))%1X^?&FGGH:R@J)J1O=:#<:BM>B$]^_R
MD^Q\J_<G:&S?D!N3MK>]1U;\I\)UILS>^UMK46\=PYCOWX_9?IS%[/W'VGD<
MZFP\)M'8U3DI*K 46$VGMK&P"18,DE=%&L@]U8.,8IT..X_Y8&[.RAO[=G:_
MRGSFY^X.T-I]H;-W5O[#]/[/V=CXL%O/XV;E^.FRJ7%[)Q^X,IC*.IV%!N_(
M[@JY9*NJ_C>4JY(":3'I34M/[K6JE*#'2+WK_*+W-V5V;O+LK?WRTS>?R6\-
MO?)##U-0W4U&^X:63Y*=*Y+J',8NFS>:["SV.Q?7_6!S-36[3P>*QN+:" Q4
MV6K,O)']XVJ=>#TI0=&H^97P;J_EA2=918GMI>I,MUWC=P8F@WUANOZ;(]J;
M9;/IM]5WCTWVI@MU;$WWU1V#A&P0>F<UV8VO62.C97 Y(TU+XM]:#4\N@5WG
M_+(WGF,[VGG=E?*W,[(J>VQ\A]B[DDJNF]F;PJ:?H+Y+[CPF_P#?77^-DRV9
MIJ2/L# ]CQ9G(X3=4M/+31TF:-'D<-DA24LZ>ZWJX8_U#J!G_P"5+_%.N.UO
MCAC/D;GL;\/^Q?[R5]!\?<EU7LG<=5C,MO:MVE5;MQVYNU\C5)O;>>P:Y</E
MQ!BU.,R'^_@GCK,G74E/34L?NO:_,C/0_P /P:,'Q6JOB5'W%GSL#;_;>PMX
M],Y&?:^+J\QU+U-U9WAL7N;K/H>GDJ\C.FZ]O=>T>R8]KXG*U9CR,6WUI1/]
MQ5TK553[K6K.JF>B7=Z?RCX1%\O>P^ILO@-X[I[=P_RM[&ZSV+N'9.#I=]83
MOWY(]<;AVOE*B@[IW#NBIVSB]ITN<W/DJBAIO[LT=8D->:*ORE7CHS3M[JP?
MX0>'1E=A_P O3<,'=.V/D3W+\ALKVMVM2Y_<>0WA7X_K#;/6F'W-MJNZ%S'1
M&T]IT.&V]G<N=KS;9H-RY/,U>1AJZJIR65KG1#2T,5+20>ZUJQ0#'1?]C?R8
M-E[ ZOW1UIC=^]99M/[F]6]7==9O=_QKP>Y:[%]7=6;U?=>,V[V;55W8O\>W
MGGZ^GIZ& 9C:N1Z_GQE=0)D\;'1U\DLK^Z\7)-?/IXV)_)UVMLWLG8_8.:[L
MR/;531GI#,=IY#N?87^D3?N^-Y=!S5$NR,YM'>^6WT*?8U!30T^*I8HLKB]U
MY6@IL)2M19*GK#-62^Z]K^70F4W\M"OPN!ZCI=K?(G-XS='3G1/Q=Z7V]N/)
M];X#,T>2E^,GR)VK\@*#<V;P,6=Q0GI]\2;7&&KL;!50)2T\HJ*>=9XD]^Z]
MKXX\S_/H&]A?R7MH=8XQ*/9'<-!@<OUO6;4R7QHWM!TWAZS?/6E?L7M:D[4V
MN>S\WE]Z9*F[DQ:S8NCQ.0Q]#2[/H<C0Q-4O$F6\.2I_=>+DUZ,C6?R_,SF?
MB!WS\9L_\A<[5[V[Z[<WKW9F>\<;UML[&5FVM\;M[7Q7;-$V!ZWGGR>U)\/M
M?)X6FHZ:FK9*EJFEB#5<E1.\LLGNM:L@TX= !V'_ "[NR=W=M](UNZ=Y9OL_
M*[H^3.Z?D'\M^\8L)U_UYL+=O4N+ZOZ_V!@_B:>H*7/9?<M?M'>E=TUUU6%M
M>21*G:%77UE?'+504,WNMZO\&.CL?*;X7;+^5.ZNH=R[HW'D<%#UA-OM,Q@:
M+$8G)XCLS#[JV?D*';6 WI'D$\E7B^N.TZ? ;YQ$=V2/<&VZ1RNDN??NJAB.
M'1>Z#^6;4[9P'65-LWY%[MH-X];[3^,F"GWSNC9>'WCDM_[CZ-J/DY4=D]@=
M@05&9QDN9W7\@ZKY5[BK\K+%44XQF8C@JX/*OD@?W5M7RQ_J_P W3W2?RUL%
M0UO0]32]P;CC@Z+Z8^)_3>/ICM/ _P"_BH/BOC^Z\?C<W72QU,8H*O>L?<KM
M500J8:(XV/PW$SZ?=>U\<<3T,O0/PUP_16X]CY]=\U^\H]F?"[H7X:MC,GMO
M$8ZFS.'Z-KMWUL>^:MJ268PU^[EW8T=1C5!HZ98!XV;6UO=:+5_;7HNN'_EJ
M[Y7K2F^,6[/F9VOGOAIM[978O6VT>D\/L_:FU=^3];[TV3G^N]L]:=G]W15&
M5R7977W56T=RST^'H1AL545KT..?,U.4^UE6J]UO5FNG/4GXW_RQ</T-O;K'
ML>M[(VYG-Y=<=@4^[*G(;+Z>H.NJ?>^"Q7QY[.Z$P6 W8:W>V_,Y692A/:E?
MG&KER"TL50#24%!04DLL;>Z\7J"*=9.J_P"6C4]>)TN<M\AMQ;LJ^D\C\>*?
M"5B[ P&WI<[LGXU;G^5&8V-MC<"T>7JTFR.4PGR;:@RF1A$*U#X&*HCIH6JY
MHT]U[5QQQZ26&_E=;_V5L+*=1=5_-GLWJKJ_>6Q^N*7L:EVEU=UE+V)G.V^M
M^B]I]#T_8^T>RL]39BOZZP&[MO\ 7FWJO+8.BHY:R*IQTBXG+XJ.KG!]U[7_
M $>D]M/^43'AJ'=5!F?D )Z#L/MVIW[O[ ;0ZH_NMMK(;(W'\0=U?#W?G76
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MWE%:CV749.3#TE!5551]]0A9*R>:H,DDGNMZSC[>AAZT^ .;ZW^0'7'95/\
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M]^J.O:6].O?[-C\7?^\B^C__ $:>R?\ Z]>_5'7M+>G7O]FQ^+O_ 'D7T?\
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MT]D__7KWZHZ]I;TZ]_LV/Q=_[R+Z/_\ 1I[)_P#KU[]4=>TMZ=>_V;'XN_\
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M1XR7?<^]*2*IKZN'#"CFQ\NNO"E1P_U#_4.MEM&5T1T)*NJLI(()5@""0P#
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M"_?NO4/7O]GK^+'_ #\RI_\ 1?=G_P#V%^_=>H>O?[/7\6/^?F5/_HONS_\
M["_?NO4/7O\ 9Z_BQ_S\RI_]%]V?_P#87[]UZAZ]_L]?Q8_Y^94_^B^[/_\
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M[/\ _L+]^Z]0]>_V>OXL?\_,J?\ T7W9_P#]A?OW7J'KW^SU_%C_ )^94_\
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ME1D<H_B#9'<3?Q*4F?46]UO4>D[@?Y;7QFVT<C68>AWU2[CS>T-[==[BW?\
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M8^ZW4\:"G2H?8GQ"Z=WMV7UU-W_NJN[>VGV!-.N^-^;)VQV/F^HNX>YH\?\
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M:RERNWGKJI!6;3@DVY5183)-!2STT-!)'/0!6B=O=:)(_P!7IT%F\X_CA7;
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MMSL+)XS-;*ILCMN@;<VU.N<!V*OV:[ I'AVEB:*AGHYI:C!R2PGW7JFM ,]
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1]U[W[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g12080g56v34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g56v34.jpg
M_]C_X  02D9)1@ ! 0$!) $D  #_[1S,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '*\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"C_P  1" *+ 6T# 2(  A$! Q$!_\0 '  !  (# 0$!
M  8' 04(! (#_\0 3Q   0," @4$"PX%! ,  04  0 " P0%!A$'$B$Q01-1
M<;(5(C,U-E1A<G.1DQ06%R0R-%)3=(&AL='2"",WDK-"5<'A0V+P@B8G8X/Q
M_\0 &@$!  (# 0                ,% 0($!O_$ #41  (! @('!P0" 04!
M       ! @,1! 42(3$S4H'!%!4R-$)QH1-!4;$B89$C8G+1\.'_V@ , P$
M A$#$0 _ .B,88HIL.T@+\I:N0?RX<]_E/D5-WC%-WNSW&JK)!&3LB8=5H^X
M+XQ==)+O?ZNID)+=<LC',P'(?_>5:<+T&%PL:44VM928C$RJ2:3U&22XEQ))
M.\E81%VG*-Z#RIY0F]# "(B (@0#8AD(B( .*<41# 1$'% ,D")L0!-Z(@,
M+*(@'Y(B'=L0R.E$SX(A@9(B( G2L9;5G@@"#H6%D;$ 'D0(B&1DG!$"& -J
M(B )SH F2 (G2F2 +]8*B:G?K02/C<#GFTY+\DS2US*)OA;2!<+=,V.YR/JZ
M0["7G-[.@\5<5#5P5])'4TDC989!FUS2N9L]BGVCW%S+-;ZBEJ\W1ZX=&.;/
M?_PJS&8-26G36L[\)BFGHS>H@)))).TE$X;$X[59E>$1$,A.=.=$,#8B)]Z
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MK>4''::QFI;#]T1%H;!$1 $1$ 1$0!$1 $1$!Y+M534=NGJ*6DDK)F#-L$9
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M>8;Q,AR+*PK@[ B(@,J^/X=WRMP]=.3B#Q[J&?;9?Z J&X*_OX<?!VZ_:AU
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M2A$1>E.TKO33WHM_ISU2JCVJW--/>BW^G/5*J1NY>@R_<(I,;O6873T7<V]
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M*.Z6&3S36:.6E-5&)2YT4(<2X;-GWK;U>+JWWKMN=OL\G*<MR/(29YM;EOR
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MW6"B([5+2>X::ADI)C%)%3R%[-;(.S#B 3F'#?M6DQ=/#'B*"HI[$^XUE,&
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MR3_H.]2<F_Z#_4NUD79WE_M^?_A+VG^CBGDG_0=ZDY)_T'>I=K(G>7^WY_\
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M[A!$&MVM!V$YJ2V)]<^WL[*,:VI!()800X<';%)*&C]S2,]+['O1$49N$1$
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M4?2O09?N$4F-WK"Z>B[FWH"YAYUT]%W-O0%S9IZ.?0Z,N]7+J?2(BJ"S"(B
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M_C/"=MQ7;#2W&/\ F-!,,S=CHG<X\GD55P8GQ/HYY6QW:F-QA+=2WSAIR+N
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#3/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g12080g58d74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g58d74.jpg
M_]C_X  02D9)1@ ! 0$ QP#'  #_[18$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %><
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!!(Q!1,R48$5(C,T07&Q%%+P(V&1H=$D0L'_V@ , P$  A$#$0 _ /U2
M
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MZ]1GIQ$31AG,SNT,&%U&TM=@4R9J<2T\FV:AO<J2$%Z1$1$OT7H_R;CNJ]A
MJ3K/T1E.AM;4JDGA7WHU$5R7ZOFCN9.]AK0,ZI$K;>E5B72<F65*2B+_ ,JK
M>U6=6E3J[86QFXUKUHDK59>C2T%+XDU&>B7KHT:5;Y=IC&G,S42F=2(C=K*J
MB(JKJ0Z:@6EIE>C34*FQUBOEG8L1,1S;E^M$/#6"M?,S%?G:%.U"!4VLAJ^%
M.07HJ.U:-"KO7;L/)X/I2N3M2K\&AS;9-N657Q<6];]B:T].TRC2VFT=YTIO
MP,SL#;&>?!K\G752+,TC&OB(MV.C<:_J\'RG44JHVQM7)S-8I\^V3E8;U2'
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M92&B(EUWA*U/+M4W!J7-1%W%>IC&-4RPRF;M( *U@
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MJ7?]5VD1IX[Q/6"<\MI;4 "A<
M
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MN#*-:8FZ8]U%5;S-B9FNQX$5*_)PY56W)#:S5=R0], 53-S:R(J*  0D
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MZS7 .]FJF#N][M#;\5,;7=I) *E@
M
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M0U2EO6)3I9[O"6&V_D49XQ&,2MQF;F%D %:P
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MIJ;J4K6'DY"<PANB4'*35'@M1<>+$<]&NTW7*JJNPB-+:Y3WF]0VQ-( *5H
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MH<:"V%'6"Q8C4Z6*E]Y&>GR089\TO0  J6@
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MB]:%P\E@ND8LG9"3SF"D*8>CG/WK[Y;E7ZKCUI5E$1,Q"W&;BY  8I
M
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M&_7DX:-OY&?>[5,,.[WN)6$U:=8 *5H
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M*;FUF,5%  ,4@
M
M
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M#= R/_W)=<?D\98XS,XU]#&<MIOZM5 !K+P
M #P]!M+.UFW-2E)=Z-I,E#N7WJ7N?[W;=?M7:>SG%5LI&5-:,54Y&68(KHE+
MM#&<ET5T=R+?]19A$<LRKRF;B&G?Q"4R64R[,G?=C>4^V<0LAEL=,E=?C;+C
M <&EE)*T%DZM,5%\9V0B1$AL14Q45&(M^H[W!S%1UA:S*SL*-.RD!SV)!8J8
MRIC.2Y.1GEI1%U/1CCJS/6&K_P 7D/C4/F4+26JIE IC9Z=C7PWKBPT;I5Z[
MDON,6R%F_P"S*SWV>HU>R5,I<[9:2NI<27@PL9T*#,7*Z&NG<1EIQCO*<<YR
MVAU^#BWL:UU1GX,229+PH"IB*CE5RHM^M/J.=M[=QZ-5H-)HM/6H5*)IR=]R
M)J\M^U#S^"M$;;RU"(ER)&_,\^<FY(.'*<6:7%1T%J0U<MR7W,,YPQYYV^C&
M,LN6-_J]!92WTS6Y:?EXE-6#6I5+\UOT.U>7RG1SEOK<2<M%F)JQN2@0FJY[
MW/6Y$36I\[..;&PVU1\JN-"2'[Y4TIJ.RPM5*+/SE-LQ3UQHLY$3+W?]68R?
MA>.7&,JKJ7/+=JL;"!67V/D+29LR7EW3&3C06(CL9E[KU153YOG-3DX[)J6A
MQX2WL>V]%/$6]ID"GX,9B18U$AP(%R=:-72=M@UB1(EBZ:Z+X6(OI4KSB)QN
M/-GC<95+TP *E@                          /*81K1Q;/45KI.[/IA^2
M@7HB^^71?I\JH=S2IMS:?)I48[5FXC$<Z]$2]5\B&?867*^UECX#T7).FTOW
M>'#.JPN2^<6RL[+MB/A(],7&9K1+E+\<(RB(4SG,3,MA@SDO&B+#A16N>FM$
M.$>HRD"(K(TPQCTV*IC5>H$K9+"-9]:,Z+#2.ES\946_0]%U)N+=OH5$=:28
M6=LS4IV/MC07-1J]5Z$1I1,Q4I[R=[:NE4DG-<K9ACL5,9;EV&:.PFUJ<;,3
ME&L\Z9I,!;GQW+<NC7H1;M2H5K ?P&6K3XLO9ZH4Y6PEQH\=6JU$O31<B7G;
MVWAS-9LY$CV2JLO"IS&+EH:(J+$WHE^K1<91A&,U,(G*9BX=](VWD)BQBVAB
M-?#@-8JJQ42_&1+U37^)Y6#A)KUT*>CV;>VC1'7-CM6]RIITW7W;%VGE:S-0
MIO K 93I=T)D".UL5%TWJEZ*OF4M3L:U=G[+25;AUZ#$E41K4DV>#=<OU[-Y
ME&GC'^6$YR]W5+53=-ME2Y>,^^DU"'[R]J7M?[[;KV-VGNS(<*DVL_0[*5'$
MQ(\2::Y$39>YN@UF4572L%7>$K$5>NXISQJ(E;A.\P^H *U@
M
M
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M?])322&,:Q+F-:U/(EQ$95?]TSC=?V2 #%D
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MJL:JHUMSD55N^H]C1I)E.I<M*0DN9"9<B7%MS&N5%<UJJFI5342)RVY2,=[
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MF-<F[_JG,TU$1$1$U(1B-QL;%;C;[M))&65Q$)QQJY  8L@
M                                                     #K:C7J7
M38K8<].P8,1=356]?,6JC,9K(QX^O$:JF#V#L["MY,UVIUN+%BO152$BN5<5
M5OU7]:%F&$91,STAAGE,3$0WN5F(,U!;%EHC8D-R7HYJWHI]3'<",_,2M9K%
M!BQ7Q8$L]<EC.5<5$<J:$V&Q$9X<DTG#+FBP &#(
M
M
M
M
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M;BOW?Z@Y\O-UJ0Z]\NS//]!B5[Y=F>?Z'9!![6XK]W^H.?+S=;DZ]\NS//\
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MG>@F.J)Z,F]CMX%:[=WY39C&?8[>!6NW=^4V8MU_'*O1\$  *5H
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MYV]D+XTRW9_@T_1)^=O9"^-,MV?X--W@/C+^'\;*P =QO
M               2SPDZR#DSPV]8'[ L/XG43_#A?=0[LZ2P_B=1/\.%]U#N
MSS&?BER\NL@ ,4   &282O&.)]%OW4-;,DPE>,<3Z+?NH<WM7X'K#6XKP/*
M:P><<\ ) ;" 2@$(        $  DA  "   @&PD "$  :QL  Y,\-O6AQ.4/
MPV]:"!N]#^")/LF^@NE*B?!$GV3?073V6GX8=C'I  #-(
M                                           !2K?P1.=D[T%TI5KX
M(G.R=Z"8ZHGHR;V._@5KMW?E-F,9]COX%:[=WY39BW7\<J]'P0  I6@
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M  %2X   _.WLA?&F6[/\&GZ)/SM[(7QHENS_  :;O ?&7\/XV5@ [C>
M                         Y,\-O6<3DSPV]8'[ L/XG43_#A?=0[LZ2P_
MB=1/\.%]U#NSS&?BER\NL@ ,4   &282?&.)]%OW4-;,DPD^,<3Z+?NH<WM7
MX'K#7XKP/*$D$[#SCG(\@V  -@0D 0  "   $   ! )(!($("2  !($#8$)
MC8  !RA^&WK.)R9X3>M! W>A_!$GV3?072E0_@B3[)OH+I[+3\,.QCT@ !FD
M                                                      <8T1L*
M$^([P6I>IB[[4VRM54Z@ZRT:'*2,FY=+V-57HE^]%TZ#/#"<F.6<8MJ!GN"F
MV,[:#/9&L-3/Y-V*]S41$=I5%]!H1&6,XS4F.491<!2K7P1.=D[T%TI5KX(G
M.R=Z"(ZIGHR;V._@5KMW?E-F,9]COX%:[=WY39BW7\<J]'P0  I6@
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M\-\'#[1^  %2X   _.WLA?&F6[/\&GZ)/SM[(7QHENS_  :;O ?&7\/XV5@
M[C>           0   @             @  Y,\-O6<3DSPF]8'[ L/XG43_#
MA?=0[LZ2P_B=1/\ #A?=0[L\QGXI<O+K( #%   !DF$GQCB?1;]U#6S),)/C
M'$^BW[J'-[4^!ZPUN*\#R@)0@\XYX @    @  >D  2" !) &P"2   WA @!
M-1) 0  2@$(2%( ')GAMZT()9X:=:"!N]#^")/LF^@NE*A_ \GV3?073V6GX
M8=C'I  #-(
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MHX?:/PKY6/P/M(,K'X"]Y"P"JUU*^5C<#[2#*Q^!]I"P!92OE8_ ^TA^>_9
M.>ZT\OCMQ5R>J_R-/T8?G;V0OC3+=G^#3<X#XJ_AX]]E8 .XWP
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M=WY39C&?8[^!6NW=^4V8LU_'*O1\$  *EH
M      9#AW_GTGJB_D->,AP[?SZ3U1?R 94 @ !   () ; " !(Z@  "
M 0 !< FD -@": (U$@ %(UD[   ( _2&#GQ.IG9-]!Z0\W@Y\3J9V3?0AZ0
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MOH+I2H?P1)]DWT%T]EI^&'8QZ0  S2
M                             4JU\$3G9.]!=*5:^")SLG>@F.J)Z,F]
MCOX%:[=WY39C&?8[>!6NW=^4V8MU_'*O1\$  *5H
M            9#AV_GTGJB_D->,AP[?SZ3U1?R 94  ";0$      FT @()
M   -@0 $"           -2 !J 0 ?H_!UXG4SLF^@](>;P=>)U,[)OH/2
M    R["Y_72?T7?@:B9=A<3_ ,Z3^B[\#?[-^8CU<KMGY3+T_+/T&L;PFI4/
M3/%EQ&K>3Z0FK8$&P"\)I"1+TV #>$"A-8&S3K"3;U!+[AO6\7W!!I":$WC8
M$4)!O"C9I #>-2^0+Y @)0@)?O"2_4-?40FLE-P0:[QJ0G40$G7J&S0-5XV!
M#>+&>*U,[!IW)TUC/%:F=@T[D\?K?$R^\OHG#?!P^T?@ !4N   /SM[(7QIE
MNS_!I^B3\[>R%\:9?L_P:;O ?&7\/XV5@ [C>     !
M$       .3/#;UG$Y,\-O6!^P+#^)U$_PX7W4.[.DL/XG43_  X7W4.[/,9^
M*7+RZR  Q0   9)A*\8XGT6_=0ULR3"5XQQ/HM^ZAS>U?@>L-;BO \J0@] W
MGG'/ -A($(20    #>-8  DA )!!) A  2&P(-@0 FL  .H(3L(0 $ 32 .3
M/#;UH1<3#\-O6@@;O0_@>3[)OH+I2H?P1)]DWT%T]EI^&'8QZ0  S2
M                                !\9N:@2<%T::C0X,)NE7/<C4\X'V
M!U<"T%)F(;'P:C*O8YV(UR16JBNTZ->O0IVA,Q1=@ (          \[;FU$M
M96C1)V.C7Q-4.$KL57K^U)B)F:A$S$1<O1 \G@WM6^UU%=/195)94=BXJ/Q]
MJIKN3<>L&6,XS4D3$Q<!2K7P1.=D[T%TI5KX(G.R=Z!'4GHR;V._@5KMW?E-
MF,9]COX%:[=WY39BS7\<J]'P0  J6@
M !D.'?\ GTGJB_D->,AP[?SZ3U1?R 9402  "   +P N&P)J )M 0  +@
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MDPD^,<3Z+?NH<WM7X'JU^*\#R@ V'G'. 20    : @ $_6"  !($)O)0C8
M   :@!.LA"2" )(0DD$("!0"'*'_ #$ZT.*'*'X;>L0-WH?P1)]DWT%TI4/X
M(D^R;Z"Z>RT_##L8](  9I
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M3Z+?NH<WM6NX]8:_$^!Y1 A)!YMSP;02! 0E"   U 20@'6!*$;   0;  0
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M@F.J)Z,F]COX%:[=WY39C&?8[^!6NW=^4V8MU_'*O1\$  *5H
M                     9#AW_GTGJB_D->,AP[?SZ3U1?R 94 0 )N&P( (
M)0 !M V !L     02+P 0(     $ 2"$) @G6-A $H!< /T?@Y\3J9V3?0>D
M/-X.?$ZF=DWT(>D      !EV%S^ND_HN_ U$R["Y_7R?T7?@;_9OS$>KE=L_
M*9>GY9_K()V$J>F>+1?H'U 7 -2+I";;QH10BZ=(0*!J&L)$U:1?S&K0 A.P
MCK":M Z](27WJ$73Y!JZP$"7(%%PN ;!]8&P)$T7C9IT!%T]0 E$(34$VD;=
M.D(%U$H FL$"[1>!>$MXL9XK4SL&G<G36,\5J9V#3N3Q^M\3+[R^A\-\'#[1
M^  %2X   _.WLA?&F6[/\&GZ)/SM[(7QIENS_!IN\!\9?P_C96 #N-X
M              !          .3/#;UG$EGAMZP/V#8?Q.HG^'"^ZAW9TEA_
M$ZB?X<+[J'=GF,_%+EY=9  8H   ,DPE>,<3Z+?NH:V9)A*\8XGT6_=0YO:O
MP/5K<5X'E $!YQSPD(0!)&\G80    D@ 20!<  ) @   "0(   :0$ :M
M)M.4/PV]9Q.4/PV]8@;O0_@B3[)OH+I2H?P1)]DWT%T]EI^&'8QZ0  S2
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M   'YV]D+XT2W9_@T_1)^=O9"^-,MV?X--W@/C+^'\;*P =QO      @
M                   !R9X;>LXG)GAMZP/V!8?Q.HG^'"^ZAW9TEA_$ZB?X
M<+[J'=GF,_%+EY=9  8H   ,DPD^,D3Z+?NH:V9)A)\8XGT6_=0YO:OP/5K<
M5X'E"0@/..>$( @ !  0 (!) " "2 FT -@ ! $  !=0 (!L !-I(WD    .
M3/YC>LXG*'X;>L0-WH?P1)]DWT%TI4/X(D^R;Z"Z>RT_##L8](  9I
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M?2>J+^0UXR'#O_/I/5%_(!E2 CK)  (  0$ 2-0  ( @! @&T!L (N E-H0
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MA_!$GV3?073V6GX8=C'I  #-(
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M-L.T\LC$N3)[_(TW. KOE_#WSLM !W&^               0
M  ')GAMZSB<H?A)U@?KZP\1B6/HM[V_T<+;\U#N\HSIMYG06(EH3K'T55;I6
M4A;5Z*'=YK!Z'G4\SG7-+EY7<OIE&=-O,91G3;S/GFL'H>=1FL'H>=3'9CN^
MF49TV\QE&=-O,^>:P>AYU&:P>AYU&QN^F49TV\S)<)#D6T4145%3%;J^BAJV
M:P>AYU,HPC,:RT,1&)<F*W[J'-[5KN/6&OQ/@>60!$T#>>;<\" D"$)V$
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M!6NW=^4V8QGV._@5KMW?E-F+=?QRKT?!  "E:
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M&WK.)R9X;>L#]@6'\3J)_APONH=V=)8?Q.HG^'"^ZAW9YC/Q2Y>760 &*
M#),)/C'$^BW[J&MF282?&.)]%OW4.;VK\#UAK<5X'E-@0 \XYX -H!-H"  @
M)(0 !L !   )( "X;  )3:0"0(V   20@V@"2  0Y0_#;UG$Y0_#;UB!N]#^
M!Y/LF^@NE*A_!$GV3?073V6GX8=C'I  #-(
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M6_@B<[)WH)CJB>C)O8[^!6NW=^4V8QGV._@5KMW?E-F+=?QRKT?!  "E:
M                             &0X=_Y])ZHOY#7C(<._\^D]47\@&5
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M7   'YV]D+XT2W9_@T_1)^=O9"^-,OV?X--W@/C+^'\;*P =QO
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M=D[T$QU1/1DWL=_ K7;N_*;,8S['?P*UV[ORFS%NOXY5Z/@@ !2M
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MT;P 3;L%]PV*1LO"&\V,\5J9V#3N3IK&>*U,[!IW)X_6^)E]Y?1.&^#A]H_
M "I<   ?G;V0OC3+=G^#3]$GYV]D+XTRW9_@TW> ^,OX?QLK !W&\     &P
M                        Y,\-O6<3DSPTZP/V!8?Q.HG^'"^ZAW9TEA_$
MZB?X<+[J'=GF,_%+EY=9  8H   ,DPE>,<3Z+?NH:V9)A)\8XGT6_=0YO:GP
M/5K<5X'E-@ /..> *2!         )0;P(0  20$0  $\H ( 2 ("  $  '*'
MX;>M#B<H?AMZT$#=Z'\$2?9-]!=*5#^")/LF^@NGLM/PP[&/2  &:0
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MHOY#5D;,]-G=_4R3#BD1(]*RJHNB)=<EW0%%LON V A( FTC>!(07#>!!*!
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MN[\ILQC7L=_ K7;K^4V4LU_'*O1\$  *EH
M      9#AW_GTGJB_D->,AP[?SZ3U1?R 94       "$)  $$D=8 D(-@$(2
M  &P  @ 0 !L&T !> " @D @  _1^#KQ.IG9-]!Z0\W@Z\3J9V3?0>D
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MT%TI4/X(D^R;Z"Z>RT_##L8](  9I
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M]$X;X.'VC\  *EP  !^=O9"^-,OV?X-/T2?G;V0OC3+=G^#3=X#XR_A_&RL
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M1.=D[T$QU1/1DWL=_ K7;N_*;,8S['?P*UV[ORFS%FOXY5Z/@@ !4M
M                          #P>$NR4[:6)(NDHD%B0,?&RBKMQ=R>0]X
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M=]8363U - N \H!!KO)0CJ4)1J)1-I"$KY @&T: JA)L4=8VC8!&PFZ\*3L
MC4 FB_RA%WA"-.PE$&C0/K!3>+&>*U,[!IW)TUC/%:F=@T[D\?K?$R^\OHG#
M?!P^T?@ !4N   /SM[(7QHENS_!I^B3\[>R%\:9;L_P:;O ?&7\/XV5@ [C>
M              (               #DSPV]9Q.3/#;U@?L"P_B=1/\ #A?=
M0[LZ2P_B=1/\.%]U#NSS&?BER\NL@ ,4   &282?&.)]%OW4-;,DPD^,<3Z+
M?NH<WM7X'K#6XKP/* :B;M!YQST$D @-H" D        % WDH! )0@ @&T
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MZE41<TLF:W=R8IA"MU7X^>RM$DXLK+2JKE)K>B)IN6[1KW[#UED+26NJ57;
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M 5\M&X#O-ZR,O%X#O-ZQ1:R"OEHO =YO61EXO =YO6*+605\M&X#O-ZQEHW
M=YO6*+6 5\M%X#O-ZQEXO =YO6*+6 5\M&X#O-ZQEHW =YO6*+6 5\M%X#O-
MZQEHO =YO6*+6 5\M%X#O-ZR,O%X#O-ZQ1:R"OEHW =YO6,O%N_D.\WK%%K
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M%?+1> [FGK(RT;@.\WK%%K(*^7B\!WF]9&7C<!W-/6*+605\M%X#O-ZQEXO
M=YO6*+6 5\M%X#O-ZQEHW =S3UBBU@%?+1N [S>L9>+P'<T]8HM8!7RT7@.\
MWK&6C<!WF]8HM8,NPN79])W]%WX&DY:-P'<T]9F>%9SGSLICL5BXJZ_J-_LV
M/Z\>KE]LS_Y<O1X+9I":@FM1J/2O%&H; B#R* 'D":AM"34.H($ 7@!- 0*$
M\@35>$T($I^I"$T; +KTN )I3R#7>+M@TH@!-6D)HO":0FK2 743L(":P%Y.
MPC>+KT"$;R4"!0&I1H5!?Y GU ;Q8SQ6IG8-.Y//V/BQ$LQ34;!<J)!;IT:3
MN,M%X#O-ZSR&M']3+[R^A\-/]'#[1^%@%?+1> [S>L9:+P'>;UE5+K6 5TC1
M> [S>L9:+P'>;UBBU@_.WLA?&F6[/\&GZ!RT;@.\WK/SW[(![G6GEU>Q6KD]
M2]33<X"/ZR_AY]]EP 0[C?                            0 #DSPV]9Q
M.3/"3K _8%A_$ZB?X<+[J'=GG;$QHJ60HJ)!<J9I"TZ.BAW.6C<!WF]9YG./
M>ER\IWE9!7RT7@.\WK(2-&X#O-ZS&F-K(*^6B\!WF]8RT;@.\WK%%K!DF$GQ
MCB?1;]U#4\M%X#O-ZS*L(KG.M#$5S5:N*W0OT4.;VK']#UAK\3/N/+7  \VY
MX% V  !O (2A 1  &\   !(()($$@$B @  (/2 )(  $D; @$H3#\-O603#\
M-+MX@;O0_@B3[)OH+IU5%C14I,HB07*F2;IT;NLNY:+P'<T]9[/3CW8=?&=H
M6 5\M%X#O-ZQEHW =YO69TFU@%?+Q> [S>L9:-P'<T]8HM8!7RT7@.\WK&6C
M<!W-/6*+6 5\M&X#N:>L9:+P'>;UBBU@%?+Q> [S>L9:+P'>;UBBU@%=(T7@
M.\WK&6C<!W-/6*+6 5\M&X#O-ZQEHW =YO6*+6 5\M%X#O-ZQEHO =YO6*+6
M 5\M&X#O-ZQEHO =S3UBBU@%?+Q;_P"0[S>L9>+P'>;UBBU@%?+1> [FGK&6
MC<!WF]8HM8!72-%X#O-ZR,O%X#O-ZQ1:R"OEHO =YO6,M%X#N:>L46L KY:+
MP'>;UGUA.<YM[F*U=RBBW, $)#%K76;=.81(LA3ZA$I\.<9EHZHZY'NU^3I+
MS-I/$X1+(0*\LO.-J#J=-P,9&QF*K;T6[0JHJ;BS2RY95ZF-PR:TU1J,A9>?
ML_&GG3+9>>9"2/C7WM=#<^[7O7S'KZ30)>QN$BBRE)C1'2T[!?E6.<BZ49$6
M_1]%#X.P84J+ @PXUHE?>_*1W.=?CNTHB^%N6X[^Q5A)V0K\.L5>JNJ#X+59
M O55N145-_SE+\L\>6:E5CCE>\-(,TMO8BOUJOQYVF5Q\I+O1N+"1%T7-1%_
M[)M15^LTLJU69=*4Z8CL2]T-MZ(:V&4XSLORQC*-V-NP<VG8MS[6XJ^553\Q
MZ7!W81]"K46IU"KLJ$ZYF*BIK1--^U3-'TFMU.FR58F*[-,2>CY/%;%<B,U>
M7RGL,'M$G*#A$C2-3JTS,1&P5="8][E:]%OO72NM-',VL[Y9B_\ 37PJXV;(
M #3;0=);&C/KU!F*?"BI!=%:J(]6WW7M5/Q.[!,34W")B]GFL'UG(EE[/0Z=
M&CMCN:Y5QVMQ4TKNO4\W:[!K$J-:=5:%4G4V<B7Y16MOQE6^]="IO4TD&4:F
M43S(G")BGB\']A85EW1YF/,+-U"/X<9R7;5O_=Y[0 QRRG*;E..,8Q4!2K7P
M1.=D[T%TI5KX(G.R=Z!'4GHR;V._@5KMW?E-F,9]COX%:[=WY39BW7\<J]'P
M0  I6@                                             9W:["),T&
MLQ9&%0IN;:Q$NBPT6Y;T1>BN\T0^3Y>#$=C1(,-SMZM13+&8B=XMCE$S&TL^
M@3JX2+*U"4G9&-3=-S5C)MT:=*)O/'T*B6]H$E&I<@L#,G7KE5<BXJ77*J7.
MW(:]:.C)4Z),R,M$64?%3WL2#[Q46_R7&10:?A(I<G&I$%SIB7BWMRSKWJB+
MH\)6WE^GE<3$5ZJLXJ=U+ G CP\)52RT7+.9#BMB1$U*[&U^93]!7Z;MIX'!
M58F)9B4CS-0>V)49E46(J;->WZRE3J;;!F$1TQ,S"K1[]5ZXJMN31JNOO,=2
MM3*9B>B=.\,8B8>[FJC)OBQ)!L[!ASKVJC68Z8R+<NF[68+;R@U:S=7@U>O1
MDJ\CEE5K(BZ$2^^ZY578>TPCV)J\>T,&T%FXJ)-PT1%AK?I6]>N_6>=JUG[>
MVS6!*UIL.!*PW)>JMQ>M?!2\STHC'>]OJQU+G:FS6;GX-3H<G.2K49!BLO:U
M-ERJGX'9'7V>IC*/1I60A+>V W%O^M5_$[ UIJ]E\=-P $)
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M^@NE*A_ \GV3?073V6GX8=C'I  #-(
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M=Z"Z4JU\$3G9.]!,=43T9-['?P*UV[ORFS&,^QW\"M=N[\ILQ;K^.5>CX(
M4K0
M                    ,MPN_P!=)_1=^!J1EN%W^ODKNB[\#?[,^8CU<KMG
MY3+T_+P%VA1LUA=H1-)Z9XHWBXDA0DUH-GE%P"#8$T"Y!J DA-"Z2=A%V@)$
MU ;=8TA %'5K&P)-@07ZPB /J&P:QINT -@ 14 :@FM=Y.S60FB\ -I%^LD(
M%0)O%XV+N WBQGBM3.P:=R=-8OQ5IG8-.Y/'ZWQ,OO+Z)PWP</M'X  5+@
M#\[>R%\:);L_P:?HD_.WLA?&F6[/\&F[P'QE_#^-E8 .XW@
M                .3/#;UG$Y,\-.L#]@6'\3J)_APONH=V=)8?Q.HG^'"^Z
MAW9YC/Q2Y>760 &*   #),)/C'$^BW[J&MF282?&2)]%OW4.;VK\#U:W%>!Y
M1  ><<\ 0( V! $  GT$)M !  )(0 "2  !.T@D"$"!-H     .H "4( 7'*
M'X;>LXG*'X;>L0-WH?P1)]DWT%TI4/X(D^R;Z"Z>RT_##L8](  9I
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M
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M-O6<3DSPV]8'[ L/XG43_#A?=0[LZ2P_B=1/\.%]U#NSS&?BER\NL@ ,4
M&282?&.)]%OW4-;,DPD^,<3Z+?NH<WM7X'JUN*\#RH(V@\XYX20  U  2""2
M ( )!"2$U  $"  -H   D A    D""2$  Y0_#;UG$Y,\-O6(&[T/X(D^R;Z
M"Z4J'\$2?9-]!=/9:?AAV,>D  ,T@
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ME'6$EVH7[PA%VCR 3OTA B:/* @U@:0J7J 32HZ]8&T!=HT@;Q<$I3;I("$
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M_=0YO:OP/6&MQ7@>4 "'G'/"2   &P H  ! $ ; FT  @&L $ V "2 $ ;
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M3O03'5$]&3>QW\"M=N[\ILQC/L=_ K7;N_*;,6Z_CE7H^"  %*T
M
M        #+L+G]?)_1=^!J)EV%S^ND_HK^!O]F_,1ZN5VS\IEZ?EG^T)K&T)
MM/3/%&\! NH)$""_81KZR4)&C2$)\I"4(21M" $](_ZC6-007+O&P! D5/J
M3<HNT:](#R"]-RC\0$%UY":-@O)V $T[P$\PU]02;+P@">76 3RZP-8\BZ -
MXL7XJTOL&G<G36,\5:9V#3N3Q^M\3+[R^A<-\'#[1^  %2\   _.WLA?&B6[
M/\&GZ)/SM[(7QIENS_!IN\!\9?P_C96 #N-X"       !
M       EGA)UD')GAMZP/V!8?Q.HG^'"^ZAW9TEA_$ZB?X<+[J'=GF,_%+EY
M=9  8H   ,DPD^,<3Z+?NH:V9)A)\8XGT6_=0YO:OP/6&MQ7@>4V#: AYQST
MD!   0 -A)  E"  " !-H  D"$ 'H   !L"$D  "4 ;"  !RA^&WK0XG*'X;
M>L0-WH?P1)]DWT%TI4/X(D^R;Z"Z>RT_##L8](  9I
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M[ORFS%NOXY5Z/@@ !2M
M                                     RW"[_7R7T7?@:D9;A=_KI/Z
M+OP-_LSYB/5RNV?E,O3\O ;?(+P$1+CTSQ0-.U$"@ $VB\A+@)&Q23C=<$IV
MBZ]0@ A"=H0($)V$#2 E&C83MN WZ=(0:D"#6$4 EPN"( DU"\$)K"#3M.5V
M@CJ723JOTA,(WDD)KTC6$-XL9XK4SL&G<G36,\5J9V#3N3Q^M\3+[R^B<-\'
M#[1^  %2X   _.WLA?&B6[/\&GZ)/SO[(7QHENS_  :;O ?&7\/XV5  [C>
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M(.V]KE7^(1N2#VN5?XA&Y(.?'S+AU(.V]KE7^(1N2#VN5?XA&Y(.?'S+AU*
M[;VN5?XA&Y(/:Y5_B$;D@Y\?,N'4@[;VN5?XA&Y(/:Y5_B$;D@Y\?,N'4@[;
MVN5?XA&Y(/:Y5_B$;D@Y\?,N'4@[;VN5?XA&Y(/:Y5_B$;D@Y\?,N'4@[;VN
M5?XA&Y(/:Y5_B$;D@Y\?,N'4@[;VN5?XA&Y(/:Y5_B$;D@Y\?,N'4@[9+.5?
MXA&Y(/:Y5_B$;D@Y\?,N'4G)GAMZSM/:Y5_B$;DAR99RKXR?^!&U[D'/CYEP
M_55A_$ZB?X<+[J'=G36-8Z#9.CPHJ8L1DI#:YJ[%Q4.XQDWIS/-9^*7,RZRD
M$8S=Z<QC)O3F8H2",9-Z<QC)O3F!)DF$GQCB?1;]U#6L9N].9DN$C3:.)<NC
M%;]U#F]J_ ]8:W%>!Y3:3L(!YQSP  20"4 C8"2  " "2 "!) !(FX@( !/6
M1L    "000  VD@<H?AMZSB<H?AMZQ W>B?!$GV3?072C1')_")/2G\IOH+N
M,F].9[/3\,.QCTA((QDWIS&,W>G,R2D$8S=Z<QC-WIS D$8R;TYC&;O3F!((
MQF[TYC&3>G,"01C-WIS&,F].8$@C&3>G,8S=Z<P)!&,F].8QF[TY@2",9-Z#
M&;O3F!((QF[TYC&3>G,"01C)O3F,9-Z<P)!&,F].8QDWIS D$8R;TYC&3>G,
M"01C)O3F,9-Z<P)!&,F].9*+?J    9'A%22=A%I#;0HQ:7DW8F61,FKO>7W
MWZ-QJ52GY:FRCYJ=BM@P&78SW+<B7K=Z5/$VHJEB;32B2]5G)>(C;\1R1+E:
MJ[E14W(6Z5Q-J]3>*9E-S-!;86KRKW2KXV>*LK#AJU7)X=RHB:DT^<W>R38[
M;.R*3>-ETA^^QM=_E,MHM P=4Z<28=/0IAS?!1\5;D^K&TFQRD>%,R\.-+N1
MT)Z7M5-2H9:TW%0QTHK>7U,@PH81JE1*_$H]-@PX2M1O_D1':%O:B^2[7OV&
MOG0VDLO1*W#>ZKRD.(MVF)>K5YII*].<8F\HMGG$S'NRQ"T]#K$[9N:K-4M2
MR<R5UTM"C95NER)K1ZW>%N-'P/V6I<C0*?5X,!,_CP&JZ(J)>E[45;M'E/.U
MO! D:4>MFZHYL!VG(Q'NQ%]/D.RP8LM=1:M!HE;A(ZEPX2MAQ&L3%3%2Y+G8
MJ*NPV,\N;"L9_P#Q3ACRY;PU8ZBU5$;:"D19!\>) :]47'AK<J7*B_@=N#5B
M:FX;$Q>SPMD\'D&SU5;/,J4U,*U%3$B*MWI+6%GQ)G_H.^XX]@?">DX$]+N@
M3<-L6"[0K7:E,N>9RYI8\D1%0SW KE$P=MR/\R]^+UWJ>+I4E;.BS]5GDH[9
MB8FL97QHNER)ION6[RJ;G3:?*TR627D8+8,%-*-;J++FHYJM<EZ*ERH9][4S
M-=6/=W$1?1@&!B>K3+2SS($HUT"-,?\ E.X?OEO]*GZ *--I$C38D9\C+,@N
MBKC/5O\ V7]J7C'4SC.;AEIX<D5(Y+VJF_09+:#!!28JU&HK-1\J]T2.J;+U
M55_$UHI5KX(G.R=Z",,\L9VE.6,91NR#V/$NQ8-7:M_O8JHGV39,TA?.YF0^
MQW\"M=N[\ILQGKS//+#1B.2%?,X7SN8S2%\[F6 57*RH5\SA?.YC-(7SN98
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M>I[!XGSC_,_\8N#:/:'0?BKO]K_6/:'0?BKO]K_6/:NCY3_/4]@\3YQ_F?\
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M^ZAKQDF$KQCB?1;]U#F]JS_0]6OQ,>X\H #S;GA)"$[ !   ($  :P2 (0
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M?^RGO; SUN(]?:RTD!K)#$=>J,5/?;-IGJX\WO7#'3RK:FF@ UEX
M4JU\$3G9.]!=*5:^")SLG>@F.J)Z,F]COX%:[=WY39C&?8[^!6NW=^4V8MU_
M'*O1\$  *5H
M                                           541+U6Y  /-+;:A_Q
MMM*;.,?-JN*B,]\E]U^M.H]*3,3'5$3$] '75ZM2-"DEFJG';!@WXJ*JZUT^
MHB@5J2KTCGE.B92!C8N-=M_:BIJRXNG9 '65RO4VAP$BU.;A0&JMR(YR(J_5
M]0B+Z)F:=F#RU(M]9VJS+8$K4(65<MS6O5&W\SU*:=0G&<>J(F)Z  (2
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MU?@>K6XKP/*D$@\VYZ"4!!(;  @  (!* B\( &\$[P(0E" !) Z@  "@ $
M!-0 ;1L)( )J.4/PV]9Q.3/#;UB!N]#^")/LF^@NE*A_!$GV3?073V6GX8=C
M'I  #-(                                     ZZT%&E*[2XLA4&*^
M7BW8R(JIJ5%35Y40\?[D=E_BC_\ :_\ ]CVM7J,"E4V/.S;L6#!;C.]!Y2A8
M0)6IV>JE9B0'P)24QE:CDTO1$<J<\7SEF$YQ'N]&&7)>ZK[D=E_BC_\ :_\
M]CW-.DX5/DH4K+)BPH28K4OOT&,R^&J9SQ(LS2E2FN=<D1K%ONZ[[MBFUP8K
M(T)L2$[&8Y+T7>3J1G'C1ISA/A<P"M4XSY>0CQ83<:(QMZ)O*EBR# +,6;M3
M;25BU5:ZR CHBLQ')IU(NQ/*>YL/8>MT*N,G:C663<!&.:L-$72J[=1;EIQC
M_P#6ZK'4G+Z-& !4M        "E6_@B<[)WH+I2K7P1.=D[T$QU1/1DWL=_
MK7;N_*;,8S['?P:UV[ORFS%NOXY5Z/@@ !2M
M
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M';S<++S<:?L[3IJ92Z-&EV/?UJU%4LUM\8F.BO2VRF)=F #77@
M                  #Q=5P:V?J=0CSDU+O=&C.5SE2(]+U5?(IZ&SU$DZ!3
M6R5/8K(#;U1%55UJJ[3LP93GE,5,L8QB)N(?G^1_^OC>TB_<>:3A1L?-VNDI
M67E)ID!(3G*Y'JJ(Z^Z[9Y#UR2$JDSG"0&9?I[2R9Y:LW$Q]&,:=1,3]7YWM
MI8>T%!LO$BS=8;&DH=S<BURW:EV7>0]+@(I%2@4YM4B3N/3WL<C9>]="WZ[C
M7YB!"F82PX[$>Q=:*)>7A2T)(<!B,AI_U0RG7F<>66,:41E</ V8PB/K5LIJ
MB+3W0FPG.:D2_3[V_6GU'AL)<I-V6PAP;20X+HDH]S5<K4W(FCS*;G"DI:%,
M.CPX+&Q7:W)K4YS,O"F8:PX\-KV+L4C'4C'*XC9,X3,5,OSO:BMQL)=IZ;+4
MB5BI!A78RN34J7JJZ+]Y^AI"724DH$NW5"8C$^I#YR5-DY+^DEV0OHELQSSC
M*(B(VA.&'+<SU  5K                 R3"5XQQ/HM^ZAK9DF$KQCB?1;]
MU#F]J_ ]6MQ7@>4N)(V \XYX-@U  20BZQU 20  " (  "  20  &H"2+B=A
M!  $H!%Q) )#:-@V "26>&WK.)R9X;>L0-WH?P1)]DWT%TI4/X(D^R;Z"Z>R
MT_##L8](  9I                                     'C,,$&+&L#4
MFP$57)DU5$W)$;?YC)ZW:>G3]A*'9RB-7/(Z0X4=C6W>_N:WZ[U53]#S$"',
MP'P8[&OA/2YS7)>BH>9IU@+.T^II/2T@QL=K\=JJYRHU;[[T15N+]/4QQBI5
M9X3E.S/L),2FT'!I(T%V)GJW.;"1-**J/55N_P#EYS5+(PHL"SDA#F$5(K8:
M(Z_6>7PD4^A4Y66CK4H^:6$J0VPVZM5^J]$_ZGLJ+/0ZG2Y><@M5D.,W&1JZ
MT(SF\(,8K*5TK5)L=TA';*W9=6^\OWED\3D[5^VFIKE(?\*R'_CIB_\ ?WGS
M?I;2O&+63-,ZI5F<)5)RZ4]L&"R*_'<QLPB-1;D30B+Y$/8V#E;=PJ\UUIG,
M6GXCK[HV-[[9HO/.K!PI7_SH?<3_ -#T5@X=N6UYJVDBL=(8CKT1B)IV?]4-
MG.9F)NFOC$1.UM* !J-D.$:+#@L5\:(R&Q-;G+<B',PS"4EKZC!J$28>LG2)
M95<Q$]ZK[FKM1.O:9Z>'/-6PSRY8MM\"/"F(>/+Q8<5G28Y')S0B8F8$LS&F
M8T.$W?$<C4\YX+ ?%>ZPD%\5[GJCG7JY;UUJ>$BS/MVMI54J]5?)4>0=<B8Z
MM14577:KMR&<:7O3%]&,ZFT3YMY@1X4=B/@1616+_P!F.1R>8^AFF#>B3%-K
M$S%IE;@U&AN2YK,JKG-6_P J=>TTLKSQC&:AGC-Q<A2K7P1.=D[T%TI5OX(G
M.R=Z"(ZIGHR;V.W@5KMW?E-F,9]COX%:[=WY39BW7\<J]'P0  I6@
M
M                         #Q$]@^EINV;+0NFGI&:M^3Q=&I4UW^4]N 9
M3E,]41C$='4VHHL.OT:/3XL183(J7*Y$ONU^LK6+LU!LO15IT&,Z,Q7*[&5+
METHB?@=^".::HY8NWAZ-@ZD:9:Z9KL.8BNBQ7NB)#74BN557TGTMO@\I=JHR
M3,972\XEW_*Q$TI==IW[#V@,N\RN[1R8U5,LHV!RGRM1AS52GHL\K%O1CFW)
M]=ZJ:C!AL@PF0X;4:QB(U$38B'($99Y9=9,<(QZ  ,60
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ME?(QN.HR,;CJ6 +*5LC&XZDY&-QE+ %E*^1C<93ZPFN:VY[E<N\Y@64  A(
M                    %*M?!$YV3O072E6_@B<[)WH)CJB>C)O8[^#6NW=^
M4V8QGV._@5KMW?E-F+-?QRKT?!  "I:
M
M
M                                 !XG"';IEE$A08<J^9FHJ7L:B7IM
MUZ2<<9RFH1,QC%R]L# L&EK:]5L)4K+56.YL.)E5? N2Y+H;U3SH:QA M*VR
M]GH\[<CHZHK83530KKENO^NXSRTIQRC%ACJ1E$Y/2@P*1AV^KE*?7Y><R<-]
MZL@I=I1%5-'(TW!E7JC6Z(YU9EU@SL)ZL=>EV,ER:=?E4G+2Y8NS'4YIJGL
M#,,(>$>-2)V/2:/)NC3Z(B8ZMO:EZ7[_ "H8883G-0RRRC&+EIX,;P#VAJE9
MJ5595)ET9(<-JM1430MYLA.>')ERR89<\7  #!D
M                                                   %*M?!$YV3
MO072E6_@B<[)WH)CJB>C)_8[^!6NW=^4V4QGV._@5KMW?E-F+=?QRKT?!  "
ME:
M
M
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MYS3#1BL  %*T
M                 ,;PAX2*BBS<C0).-#675<K,KC)<ERWW*BIO3D9X83G-
M0QRSC&+EL@/$X(*I.5>Q\&:J,=\:.KG(KGN5RZUWGDJS7K26EMG/T2@S+)"%
M(N5JO1[F.=<J_.2_5N)C3F<ICR8SJ143YMC!F.#2TU7C5^>L_7'0XT:52](S
M5556Y=JJY33C'+&<9J66.7-%A2K7P1.=D[T%TI5KX(G.R=Z"(ZIGHR;V._@5
MKMW?E-F,9]CMX%:[=WY39BS7\<J]'P0  J6@
M
M
M                                       %R7WW(  (Q4OON2\D !<
M "(B:D
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MG2\"+W5+(%P;JV=+P(O=49TO B]U2R!<&ZOG*\"+W5&<KP(O=4L 7!NK9RO
MB]U1G2\"+W5+(%P;JV=+P(O=4^T)^4;>K7-\BI<<P  !"0
M       *5:^")SLG>@NE*M_!$YV3O03'5$]&3>QV\"M=N[\ILQC/L=_ K7;N
M_*;,6Z_CE7H^"  %*T
M
M
M
M                                               "E6O@B<[)WH+I
M2K7P1.=D[T$QU1/1DWL=_ K7;N_*;,8S['?P*UV[ORFS%NOXY5Z/@@ !2M
M
M
M
M
M                     R^T>%"8EZY'IEG:4M1C0+LHKEN34FJY=ZHAECA.
M71CEE&/5J /#X/K?0;4Q8\I'EG2D_!TOAKJNT:M/E.MMAA,B4RM/I5#IRU"<
MAWY1%6Y$NOO30OD4R[K*^5'>8U;2@>*P?6[@VI6/+1Y=96H0/#A+JUZ;M)[4
MPRQG&:EECE&47 4JU\$3G9.]!=*5:^")SLG>@1U)Z,F]COX%:[=WY39C&?8[
M^!6NW=^4V8MU_'*O1\$  *5H
M
M
M
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M$0\U5Z':&QULIRL6=D(D_+3JJYT.$Q5Q56_1H1=5Y9<S.6,_5A51$P^-"_\
M'P[3K8&AKVKC(GE5MYN!E6#&RU46T4[:6T$%T"9CWHR"]JHK45;]O4FPU4IU
MIB9J/HMTHFI%6Y%5=2&=5_"C9F'"J$BZ<=G#,>"K<C$\)+TNOQ;M9HJI>BHN
MI3R<S@\LU,S$6/&IL%T6*]7O<K&Z55;U748X<L>).7-_\O">QY=B2]6BQ$<U
MD2,KF.5JW.3WNHV+.8733D5J729&ER,*4DI:%#@0T5&M1J:--_XEO(PN&SNH
M3J91GE,F&,XXTXYQ"Z:<AG,+IIR.61A<-G=09&%PV=U##9ENXYQ"Z:<AG,+I
MIR.61A<-G=09&%PV=U!L;N.<PNFG(9S"Z:<CED87#9W4&1A<-G=0;&[CG$+I
M^89S"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFG(Y9&%PV=U!D87#9W4&Q
MNXYQ"Z:<AG,+IIR.61A<-G=09&%PV=U!L;N.<PNFG(9S"Z:<CED87#9W4&1A
M<-G=0;&[CG$+IIR&<PNFG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG$+IIR.61A<
M-G=09&%PV=U!L;N.<0NGYAG$+I^8Y9&%PV=U!D87#9W4&QNXYS"Z:<AG,+II
MR.61A<-G=09&%PV=U!L;N.<0NFG(9Q"Z:<CED87#9W4&1A<-G=0;&[CG$+II
MR&<0NFG(Y9&%PV=U!D87#9W4&QNXYQ"Z:<AG$+IIR.61A<-G=09&%PV=U!L;
MN.<PNFG(9Q"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFG(Y9&%PV=U!D87
M#9W4&QNXYS"Z:<AG,+IIR.61A<-G=09&%PV=U!L;N.<0NFG(9Q"Z:<CED87#
M9W4&1A<-G=0;&[CG$+IIR&<0NFG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG$+II
MR.61A<-G=09&%PV=U!L;N.<PNFG(9S"Z:<CED87#9W4&1A<-G=0;&[CG$+II
MR&<0NFG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG,+IIR.61A<-G=09&%PV=U!L;
MN.<0NFG(9Q"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFG(Y9&%PV=U!D87
M#9W4&QNXYS"Z:<AG$+IIR.61A<-G=09&%PV=U!L;N.<0NFG(9S"Z:<CED87#
M9W4&1A<-G=0;&[CG$+IIR&<PNFG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG,+II
MR.61A<-G=09&%PV=U!L;N.<PNFG(9S"Z:<CED87#9W4&1A<-G=0;&[CG,+II
MR&<0NFG(Y9&%PV=U!D87#9W4&QNXYQ"Z:<AG,+IIR.61A<-G=09&%PV=U!L;
MN.<PNFG(9S"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFARR,+AL[J#(PN&
MSNH-C=QSF%TTY#.8733D<LC"X;.Z@R,+AL[J#8W<<YA=-.0SB%TTY'+(PN&S
MNH,C"X;.Z@V-W'.8733D,YA=-.1RR,+AL[J#(PN&SNH-C=QSB%TTY#.(733D
M<LC"X;.Z@R,+AL[J#8W<<XA=/S#.(733D<LC"X;.Z@R,+AL[J#8W<<XA=-.0
MSF%TTY'+(PN&SNH,C"X;.Z@V-W'.(733D,XA=-.1RR,+AL[J#(PN&SNH-C=Q
MSB%TTY#.8733D<LC"X;.Z@R,+AL[J#8W<<XA=-.0SF%TTY'+(PN&SNH,C"X;
M.Z@V-W'.(733D,XA=-.1RR,+AL[J#(PN&SNH-C=QSB%T_,,XA=-.1RR,+AL[
MJ#(PN&SNH-C=QSB%TTY#.(733D<LC"X;.Z@R,+AL[J#8W<<YA=-.0SB%TTY'
M+(PN&SNH,C"X;.Z@V-W'.(73\PSB%TTY'+(PN&SNH,C"X;.Z@V-W'.8733D,
MYA=-.1RR,+AL[J#(PN&SNH-C=QSB%TTY#.8733D<LC"X;.Z@R,+AL[J#8W<<
MYA=-.0SB%T_,<LC"X;.Z@R,+AL[J#8W<<XA=-.0SF%T_,<LC"X;.Z@R,+AL[
MJ#8W<<YA=-.0SF%T_,<LC"X;.Z@R,+AL[J#8W<<XA=-.0SF%TTY'+(PN&SNH
M,C"X;.Z@V-W'.(733D,XA=-.1RR,+AL[J#(PN&SNH-C=QSB%TTY#.(733D<L
MC"X;.Z@R,+AL[J#8W<<YA=-.0SB%TTY'+(PN&SNH,C"X;.Z@V-W'.(73\PSF
M%TTY'+(PN&SNH,C"X;.Z@V-W'.8733D,YA=-.1RR,+AL[J#(PN&SNH-C=QSF
M%TTY#.(733D<LC"X;.Z@R,+AL[J#8W<<XA=-.0SB%TTY'+(PN&SNH,C"X;.Z
M@V-W'.(733D,XA=-.1RR,+AL[J#(PN&SNH-C=QSB%T_,,XA=/S'+(PN&SNH,
MC"X;.Z@V-W'.8733D,YA=/S'+(PN&SNH,C"X;.Z@V-W'.8733D,YA=-.1RR,
M+AL[J#(PN&SNH-C=QSB%TTY#.(733D<LC"X;.Z@R,+AL[J#8W<<YA=-.0SB%
MTT.61A<-G=09&%PV=U!L;N.<0NGYAG,+IIR.61A<-G=09&%PV=U!L;N.<PNF
MG(9S"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFG(Y9&%PV=U!D87#9W4&Q
MNXYQ"Z:<AG,+IIR.61A<-G=09&%PV=U!L;N.<PNFG(9Q"Z:<CED87#9W4&1A
M<-G=0;&[CG$+IIR&<0NFG(Y9&%PV=U!D87#9W4&QNXYQ"Z:<AG,+IIR.61A<
M-G=09&%PV=U!L;N.<PNFG(9Q"Z:<CED87#9W4&1A<-G=0;&[CG$+IIR&<PNF
MG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG,+IIR.61A<-G=09&%PV=U!L;N.<PNF
MG(9Q"Z?F.61A<-G=09&%PV=U!L;N.<0NFG(9Q"Z?F.61A<-G=09&%PV=U!L;
MN.<PNFG(9S"Z:<CED87#9W4&1A<-G=0;&[CG,+IIR&<0NFG(Y9&%PV=U!D87
M#9W4&QNXYQ"Z:<AG$+IIR.61A<-G=09&%PV=U!L;N.<0NFG(9S"Z:<CED87#
M9W4&1A<-G=0;&[CG,+IIR&<PNFG(Y9&%PV=U!D87#9W4&QNXYQ"Z:<AG$+I^
M8Y9&%PV=U!D87#9W4&QNXYQ"Z:<AG,+IIR.61A<-G=09&%PV=U!L;N.<0NGY
MAG,+IIR.61A<-G=09&%PV=U!L;N.<0NFG(9S"Z:<CED87#9W4&1A<-G=0;&[
MCG$+IIR&<0NFG(Y9&%PV=U!D87#9W4&QNXYS"Z:<AG,+IIR.61A<-G=09&%P
MV=U!L;N.<0NFG(9Q"Z:<CED87#9W4&1A<-G=0;&[CG$+IIR&<PNFG(Y9&%PV
M=U!D87#9W4&QNXYS"Z:<CZ,>UZ7M6]#CD87#9W4.36M:ES41$\B#82 "$@
M
M
M
M
<                                  #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g12080g59s60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g59s60.jpg
M_]C_X  02D9)1@ ! 0$!) $D  #_[1O$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &Z<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\
M$0@"BP%K P$B  (1 0,1 ?_$ !P  0 " P$! 0             &!P$$" 4#
M O_$ %(0  $# @(%! T)!0<# P4!   ! @,$!081!Q(A,4$3-E%Q%!8B,U)3
M872!D9*QLA47)%15<Y.ATB,R-7+1-T*#L\'"X59CHD-B@B4F)S3Q\/_$ !H!
M 0 " P$                !!0(#! ;_Q  S$0 " 0$$"0,#! ,! 0
M 0(1 P0%(1(5,3-"47&!P11!4B(RT1-AD:$T<K'P(__:  P# 0 "$0,1 #\
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MY55W=>+#=VR*YVNUKI%R3R9IP\AXBMFN^,Z:BQG2M:YS%C8L:ZB*O!<TW_\
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M FX )N "#( $@!   @&\$ )D.H  9@=( 3<!O,+NV@&4X[0!P "    ! 2$
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M;U(<P(=/Q][;U(5F*</?P6&'<7;R9 !4%F
M                                  4SICYTP>:,^-Y!=O G6F/G3!YH
MSXWD%]*GI;IN8]"@O.]D$.GX^]MZD.8#I^/O;>I#AQ3A[^#LP[B[>3( *@LP
M                                                           "
MF=,?.F#S1GQO(+ZB=:8^=,'FC/C>07T'I;IN8]"@O.]D$]9T_'WMO4AS =/Q
M][;U(<.*<'?P=F'<7;R9 !4%F
M                         4SICYTP>:,^)Y!2=:8^=$'FC/C>07UGI;IN
M8]"@O.]D#I^/O;>I#F Z?C[VWJ0X<4X>_@[,.XNWDR "H+, 'XGE9!#)+*Y&
MQL:KG.7@B;P#]@B_;8_L9:[Y*J?DM%R[)UVYY9Y9ZF_(DL,K)HF2Q.1S'IFB
MIQ0RE!QVF,9*6P_8 ,3(
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MYE1??R>\5(H2_LB3ZL_UGE5F*K;1U+Z>JF9%,Q<G,<[:A[Q1V/\ G=<OYV_
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MMY/T "H+,         '-./.>5X\Y?[SI8YJQWSRO/G+_ '@E'@A#&TR02
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MU'*6D5=;'-]545N=6_8O#:=;')6DCGY?O.W^\K\.^]]#VUV^YD; !;G6$ "
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M-1%_,WCS\.:RV"VK(Q\;UIH]9CUS<U=5-B^4] UO:9K8  02
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M<O0>557"[T%BK:JOIJ=]4Q,H64J.=FJ[-J+Y20@R4J9-&+C7W*NN5QI(L-+
MD%<M7+.R:>62%41S\\UV^XL:TUC*^ACGB9*QJIEE(W5=L\AFYV^"Y4O8]4US
MH]9'Y(N6U%S0VFIDB(FY-AG.:DMF9A"#B]H !J-I\9%J-=>3;&K>&:KF?C.K
M\&'UJ;()J10UM:K\"'UJ-:K\&'UJ;(%10ULZOP8?6HSJ_!A]:FR!44-;.K\&
M'UJ-:K\"'UJ;(%10UM:K\"'UJ,ZOP8?6IL@5%#6UJOP(?6HSJ_!A]:FR!44-
M;6J_ B]:C6J_ B]:FR!44-;6J_ A]:C6J_ A]:FR!44-;6J_ B]:C6J_ A]:
MFR!44-;6J_ A]:C6J_ B]:FR!44-;6J_ A]:C6J_ A]:FR!44-;6J_ A]:C6
MJ_ B]:FR!44-;6J_ A]:C6J_ A]:FR!44-;6J_ A]:C6J_!A]:FR!44-;6J_
M!A]:C6J_ A]:FR!44-;6J_ B]:C6J_ A]:FR!44,,UM1-?)'<<C(!!)3.F/G
M1!YHSXWD%)UICYTP>:,^-Y!,STMTW,>A07G>R,[CI^/O;>I#F!#I^/O;>I#A
MQ3A[^#LP[B[>3( *@LP
M                  "F=,?.F#S1GQO(*3K3'SI@\T9\;R"^@]+=-S'H4%YW
ML@=/Q][;U(<P=)T_'WMO4APXIP]_!V8=Q=O)D %068 /A<)EIZ"IF:N2QQ.>
MGH15"50?<$1M<.([A;Z>K2]Q1I,Q'HSL5JY9\"61HY(VI([6>B;5RRS4RE'1
MRJ8QEI>Q^@ 8F0
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MD?KJ.GH^]MZD.8#I^/O;>I#AQ3@[^#LP[B[>3( *@LP
M                                          "F=,?.F#S1GQO(,A.=
M,?.B#S1GQO(+Z3TMTW,>A07G>R&9T_'WMO4AR^=01][;U(<.*<'?P=F'<7;R
M9 !4%F #5NM:RW6VIK)4S;"Q7Y=.7 E*N2#=,S:!#(8[U54;:Y;TV"JE:DD=
M)JM1N2[4:N:DLH'SR4<3JN)(IU;W;$<BY+UH92AH^YA&6E['W !@9@
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M  @D    $!TJ8AGH*6GMUG=.^Z/>V=T<"=UR**NMMX9Y&48N3HB)2T54GP/
MP3B.GQ+9(ZNG:^-[5Y.6.3]YKDV+GZCWR&FG1A.JJ@ ""0    5]I5Q!4T3:
M.W6=:F2X*]E3+'3)W7(-=MV\,U0RC%R=$1*6BJE@@\/!F)*7%-DCN%&US$UE
MC?&_>QR;T4]PAIIT83354  02    "N]*.*);;-0T5J?4/JXI6U-3'3IW7(I
MGGFO RC%R=$8RDHJK+$!Y6&+[28CLT-RH%7D9,TR<F2M5-Z*>J0U3)F2=<T
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MWI&Q&:SUS5<DWKY3-VE%]&7[&*LZ_<*2GCI::*G@;JQ1-1C4Z$38A]0#2;0
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M2==6E5[-3L=$3)4U>"__ -XE@C2<'DQHJ:S,,1R,:CU179;53BID U&P
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MSXGD$VGI;IN8]"AO.]D#I^/O;>I#F Z?C[VWJ0X<4X._@Z\.XNWDR "H+,
M                               CUPP=9J[$%->*BD8M9"B[D35>O2Y.
M*H2$ EMO:0DEL  ()                     *9TQ\Z8/-&?&\@I.M,?.B#
MS1GQO(*>ENFYCT*"\[V038=/Q][;U(<P<%R.GX^]MZD.'%.'OX.S#N+MY,@
MJ"S
M   *9TQ\Z8/-&?&\@F7E)YICYT0>:,^-Y!3TMTW,>A07G>R,<#I^/O;>I#F!
M#I^/O;>I#AQ3@[^#LP[B[>3( *@LP
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M_#=^H?.?>\N\6_\ #?\ J(+P4#TEC\4/4VOR)U\Y]\\1;_PW?J'SGWOQ%O\
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$JS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g12080g65h87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g65h87.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_[12,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^WS,S"-4%KTUGI.<;2]GOORIU)/['_$SY,.GS593)K\2M@ ,ZT     !V#O
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M           !!(   (       @D          @  0       ()
M  $     ! F!R?Q:FY\1<XY/JK)>A12*BBV<5_A#SOR_^%%3/=Q<(_'G7Y2
M [<B   =@\P =AV/H]N6E,*V]V[&@_\ TXG''8=C:.]Z6$^8T/RXF#KMH:>F
MWEF#RY3ECKM__IG]S/4>7*>YEY\C/\+/.C=J:Q) 1Z+(  )""0   &2TVVLW
M:[/KEM]C-B]AKK3:_P!MVO\ U?N9L5=1DS\EV+8 !0L       (  @   ! @
MD    "      @         "          !
M""0      @ 3 Y-XK_"'G?E_\**F6SBO\(>=^7_PHJ9[N+A'X\Z_*0#L!VY
M  00 !]3.QM'>]'"?,:'Y<3CD[&T=[TL'\QH?EQ,'7;5:>FWEF#RY3W,O/D9
M_A9ZCRY3W,O/D9_A9YT;M4M9 $(]%E2  ()   ( 932_/-VWI^YFPEU&OM+>
M[=MZ?N9L)=1DS\EV+8 !0L$ 0!(     %U    @           (@D(
M  !W@=@        0        $$@  B"0!!( (        (     '8  ! $@
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M68/+E/<R[^1G^%GJ[#RY3W,N_D9_A9YT;M4M9 $'HLJ0!V!   D!!*
M  "  !(""0   %ETMFG1E&SNY;TWRIS?Q7W/P*T#FU8M&DIK,Q.L-KH%=TKE
M7=T/6UQ+>O37)OXT?XHL*Y[F"U9K.DM$3K&L) !"0  $  !")  !
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M     ""0       @3 Y/XM?")G/EE^&)42W<6OA$SGRR_"BHGN8N$?CSK\I
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MFQESSK1I.C5$ZQJ  @ !V          !V  !V         ""0 !!(  A 2
M                   !    @" 0)@<G\6OA$SGRR_"BHENXM?"+G?EE^&)4
M3W,7"/QYU^4B" +'( $   #O.QM'>]+"?,:'Y<3CD[&T=[TL)\QH?EQ,'7;0
MT]-O+,'ERGN;=_(S_"SU'ERGN9=_(S_"SSHW:IV:R(0)/19 #L 2 !  @ !9
MM,8.->$;N\CO3_\ ITW\;Q?@8+&6SO+^A0[)R2?F[?L-F4X1IP48+:,5LEW(
MHS7[?B%F.NOS*8I16R227+D2 9%P  ,%J'"0OJ<JUO%1NHK?E\?P?B45IQ;4
MDTUR:?8;7["BZOLU;Y%5H+:-=;[+LDNO]QIP7GC*K)7[8(@D@TJDH  $02 !
M!( MNA:F]*ZI[]4E)?=^XM12M#SVR->&_)TM_H:_B74Q9HTO*_'/^0 =A4[
M       $        0B0            @D         ""0  0 @D   @    !
M! $    )@<G\6OA$SGRR_"BHEOXN+;B+G/E8_@B5 ]S%PC\>=?E( "QR   .
MP  =C:.]Z.$^8T/RT<<G8VCO>EA/F-#\M&#KMH:>FWEF#RY/GC;M+MHS^YGJ
M/E<P\I;U8=LH-?8>;&[4U:@0D2>DR(1)!(2 @D   ,QI)?[;I;]D9?<7XUSI
MZNK?,6TWU.70?IY&QD9,\?Z78MD@(%"P   K>N()V%"?QE5V7F:?\"R%7US6
M2M[:CO[)R<_H6W[RS%SAS?C*H !&YG.H     1 ) S^B?=:I\B_O1>"D:(CO
ME:S[J+^]%W,>?FOQ\0 >8I=@          =X       ""   $ 2    0
M   "                        )@<I<7UMQ&S277Y2+_\ )$IQ<^,/PC9K
MG\>'X(E-V\3W,/"OX\^_*4#<E+Q0])8X0$3MXC9=X$ G;Q&WF CL9V-H[WI8
M3YC0_+B<=>DZ(T[Q8TO8X#&6EQ7NE6M[6E2FE;R:4HQ2?/SHQ=92UXCMC5?@
MM%9G5M4CL-=KC%I+_F+O_P -(?TQ:2?+UQ=_^&D8/0R?^9:?4KY>.]I^2O+B
MGMMT9RC]K/@CRW6J,1E[NO>8VK4E;SE\:FXM/9;\CY_I:T_;E]5FZ*SI\PSS
M,/>#P?I:T_;E]5C]+6G[<OJLGMDUA[P>#]*VG[<OJL?I6T_;E]5D=LFL/?V
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MM^A<OW,SYARSK>6BD:5  5N@  ""0            !     "  !    !!(
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M);TZ/LWY^S[?N(M/;$R1&LZ+MCK=6EC0H)>T@D_/V_:>D=@/.W:@(
M                    0!(     $ @ '> '8    0                !
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MT@ SK0   $ D 000    @                 !")     @
M@"0@         " !,#F+CM9RM>(=W4<=H7-*E5B^_P!CT7]L6:^[#??JBL)*
MOC+#,TEN[6;H5=E\6?4WX)K;^\:$/9Z:_=CA@RUTM(@@"]6      0  D@
M !9-*Y=4)JSN9;4I/]7)_%?=YF7)&J2VZ;SR:C:7T]I+E"J^WP?\3BU?MU65
MI 0*W9V     !:[-.-I13ZU"/W%8M:3K7%.G'XSV+8EV;;(KNZJD @K=) (
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MN[^K15:+:Z$6GTGNN>W1W-K>I1L:U'266O*F_DKF[4::?]B.S?TO;T%/TO\
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MF[1VN5LZ-W1WW4:D=^B^]/K3\4:PS7 ['5Y.6'R=Q9[_ !*T55CZ'R?T[FX
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MLU"J^CV>V:FO,]]NPQ<.&G$+7^7HW6N[R5G9P>Z4Y0;BNU4Z<.2;[WMZ3ID
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M-(Z#L;FM>5X7.6O%%59TT^A3BN:A'?F^?-OEOR[@;*!,
M
@                                       /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g12080g66z54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g66z54.jpg
M_]C_X  02D9)1@ ! 0$!#@$.  #_[18:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A0'QH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#DN,2UC,# S(#<Y+CDV.3!A.#<L(#(P
M,C4O,#,O,#8M,3DZ,3(Z,#,@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O
M,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O
M,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIT
M:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @
M(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@9F]R
M($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y-:6-R;W-O9G3"KB!7;W)D(&9O<B!-:6-R;W-O9G0@,S8U
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#(U+3 W+3(R5#$Q.C$W.C(W*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C4M,#<M,C)4,3$Z-#DZ,3DK,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(U+3 W+3(R5#$Q.C0Y.C$Y*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T
M;W-H;W Z,#$W-#1C8S(M9F,Q9BTP.#1D+6)A-#<M8V,R83 W,C8V,S,V/"]X
M;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX
M;7 N:6ED.C%D8S8Y-6$P+35C9&4M-F(T8BUB-C<W+3AF8S<S,64V8S5E,#PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C0Q,3%$0T%$+40T,C<M-$4Y.2U!-CDX+3@W.3DX.34Y
M,T$W0SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M96$S,64P-V8M-F$U-BUB.30P+3@Y8C M93-D96,X-C)A8C$T/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U
M+3 W+3(R5#$Q.C0Y.C$P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @
M,C8N-R H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F0T,S$W-3=A+3@R
M9&0M,68T82UB9CEA+64Y-SDR-#EE,C1F-SPO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-2TP-RTR,E0Q,3HT
M.3HQ.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(V+C<@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C%D8S8Y-6$P+35C9&4M-F(T8BUB-C<W+3AF8S<S,64V8S5E
M,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R-2TP-RTR,E0Q,3HT.3HQ.2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P(#(V+C<@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z9#0S,3<U
M-V$M.#)D9"TQ9C1A+6)F.6$M93DW.3(T.64R-&8W/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YU=6ED.C0Q,3%$
M0T%$+40T,C<M-$4Y.2U!-CDX+3@W.3DX.34Y,T$W0SPO<W12968Z9&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C0Q,3%$0T%$+40T,C<M-$4Y.2U!-CDX+3@W.3DX.34Y,T$W0SPO<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^1V5N83PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO
M<DUO9&4^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I
M96YT871I;VX^"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C(W,#8W,C$O
M,3 P,# \+W1I9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O
M;'5T:6]N/C(W,#8W,C$O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @
M(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N
M:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L
M;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C$V-C(\
M+V5X:68Z4&EX96Q81&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$
M:6UE;G-I;VX^.#,Q/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:
M'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H
M&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"C_P  1" .9!S(# 2(  A$! Q$!_\0 '  !  (# 0$!
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M(X:J"1Z]#6R(JK]V9(
M
M
M
M
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MH1=A9YR7B&PL\Y+Q$H"Y*A%V%GG)>(;"SSDO$2@+DJ$786><EXAL+/.2\1*
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M$78F><EXAL3/.2\1* N2H1=A9YR7B&PL\Y+Q$H#:DJ$786><EXAL3/.2\1*
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M>(;"SSDO$2@+DJ$786><EXB1%&D3$:BJJ)XUZ3Z N2J  89
M   47[IKX[#OHU']LO*'XEGHH4;[IKX[#OHU']LO*'XEGHH79^7CS58>/+D^
M@ 4K0
M
M
M
M
M        %%^Z:^-P[Z-1_;+RA^)9Z*%&^Z:^-P[Z-1_;+RA^)9Z*%^?EX\U6
M'CRY/H %"T
M
M
M
M
M             !1?NFOCL.^C4?VR\H?B6>BA1ONFOC<.^C4?VR\H?B6>BA?G
MY>/-5AX\N3Z !0M
M
M
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M6R5WB614^Y2X]'\C),$6'4<CM6A@:N2]"\FG,9ST]G&_5C'/:RKT9\ %2P
M
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MA:
M
M
M   -(Q=A:OQ)BBV.JWP)8*->4=%KKKR2?.F667W^(S&.,-Q8HP[-;9')&Y51
M\3\OV'IT+_-4^\SX);<[O9'9C?[JJM>!\2W"^6>HQ;7T<M%:51\,<"JJR.:N
M:*[F3YNPVJ6UX@J,6ROJJZ!^&9(5C=2(F3E545.G+/R<^9M8)3J3+$81"L<6
M:);)462:/#MM@IKBJIJ223RY)VJOX&WX%P[!AG#E)0Q1,CGY-KJE6/<Y'RZJ
M(YR9^54^8SX,3J93%3+,88Q-P  @D
M
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M9TNC]"T]73C.9EM:6CCGC<NIOUK8,_C/_P +-^0?K6P9_&?_ (6;\ARR"_\
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M>/-5AX\N3Z !2M
M
M
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MTV_B=KG*ZR_;S:G2?0 !RVJ
M
M               HOW37QN'?1J/[9>4/Q+/10HWW37QN'?1J/[9>4/Q+/10O
MS\O'FJP\>7)]  H6@
M
M
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M%'^]P^FW\3M<Y767[>;4Z3Z  .6U0
M
M                    %%^Z:^.P[Z-1_;+RA^)9Z*%&^Z:^-P[Z-1_;+RA^
M)9Z*%V?EX\U6'CRY/H %*T
M
M
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MEM18 ""8
M                                                   "B_=-?&X=
M]&H_MEY0_$L]%"C?=-?&X=]&H_MEY0_$L]%"_/R\>:K#QY<GT "A:
M
M
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MJDJL745<V<V?06< 8RRVC''9  12
M
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MYS/'/]]H:?!6F.T+9V<A33*Q71M7FR<JM<F7DR4Z (:F$8U,=TI:>4Y7$]\
M!YS3Q0Y<M+''GT:[D3,K6*/]TU\;AWT:C^V7E#\2ST4*)]TI/%-+A[D98Y,F
MSYZCD7+XLO:'XEGHH7Y^7CS58>/+D^@ 4+0
M
M
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M=WFEJG2Z+TC^8T]NJ;.EJ=ICM  -E8
M
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M%R5"-LB>?GXQLB>?GXR2!<E0C;)]?/QC9/KY^,D@7)4(VR)Y^?C&R?7S\9)
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M/10HWW37QN'?1J/[9>4/Q+/10OS\O'FJP\>7)]  H6@
M
M
M                            4%IAZ[5'JH^Z7Z4%IAZ[U'JH^Z!I/2
M"&UZ+.OEJ^V3^FXU0VK19U\M7VR?TW =$G-WB.D3FX[74_[^7Y>:_B'^GS_
M@&7,H.V\T_/O+4T/^"J_UZ=TJQ.8M/0_X)K_ %Z=TT.LOAYY.MU+\7CS^S6O
M=)^";)Z^3NH4*7U[I/P59/7R=U"A37Z#Y,/H>AX(  ;:Y[4?[W#Z;?Q.USBB
MC_>X?3;^)VN<KK+]O-J=)]%+8WZU7'TT[J&",[CCK5<?33NH8(^=](\W/YS]
MWG\_%( "I!N.BSK%-[,[O-+5*JT6=8IO9G=YI:IZ3JOR.;H]%\  #HM@
M
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M
M
M                                             *!TP]=ZCU4?=+^*
M"TP]=ZCU4?= TD'X?H VK19U\M7VR?TW&JH;5HLZ^6K[9/Z;@.B3F[RG2)S<
M=OJ?]_+\O-?Q#_3Y_@'E 3YSM/-GBZ"U-$'@JO\ 7IW4*K\I:>A_P57^N3NF
MAUE\//)U>I?B\?E/V:U[I/P39/7R=U"A2^O=)^";)Z^3NH4*:_0?)A]#T/!
M #;7/:C_ 'N'TV_B=KG%%'^]P^FW\3M<Y767[>;4Z3Z*6QQUJN/IIW4,$9W'
M'6JX^FG=0P1\[Z1YN7SG[O/ZGBD!^GX5(-QT6=8IO9G=YI:I56BSK%-[,[O-
M+5/2=5^1S='HW@  =%L
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M]&H_MEY0_$L]%"[/R\>:K#QY<GT "E:
M
M
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M=YI:I56BSK%-[,[O-+5/2=5^1S='HO@  =%L
M
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M\U6'CRY/H %"T
M
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M,[O-+5*JT6=8IO9G=YI:IZ3JOR.;H]%\  #HM@
M
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M&^Z:^.P[Z-1_;+RA^)9Z*%^?EX\U6'CRY/H %"T
M
M
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MI  5(-QT6=8IO9G=YI:I56BSK%-[,[O-+5/2=5^1S='HO@  =%L
M
M                   ,??;K;[-;GU=WG9!2(NJYSVJY.?Q9(BE-8NQ-H^NC
MW1TF'I+G5Y\VS-=3ZWSYMYU^]"XL0V.BQ!0)17.-9*?71ZM1<LU0^+5ANS6I
MJ-MULI(,NA6QIGVKSEN&6.._?:O/'++=Z*(PCA3%<EYIJJQTE?:;3RK7NCGK
M.941>=%1,E7F\J'1J= !C4U)SG>SAA&  "M,       !1?NFOCL.^C4?VR\H
M?B6>BA1ONFOCL.^C4?VR\H?B6>BA=GY>/-5AX\N3Z !2M
M
M
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M?BD!^@J0;AHLZQ3>S.[S2U2JM%G6*;V9W>:6J>DZK\CG+H]%\  #HM@
M
M                      !#O-=^C;555O)NEY!BOU&]+LO$470:6JV+%UQK
M):.X34,L;6Q4&M\2J(F:Y?/_ )G0!5V,<5V3!N+JBII[9/6WFIB:M0Z-ZHC6
M]"9]B%VC4W%6JU+[[I@JG'E]Q?>K316&WW*W,9.U]1(W6R5B=*.R3H^TNY.@
MJ.W:9V5MPI*5+!5-6H>C&JLGE7+/HYRW$Z#&K$Q451IS$W-V  J6@
M*+]TU\;AWT:C^V7E#\2ST4*-]TU\=AWT:C^V7E#\2ST4+\_+QYJL/'ER?0 *
M%H
M
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MZ/1O   Z+8
M                                      "I[U3UMMTFW'_[/DJ::^4K
M8(YT7FB5&_9\W1\Y;!^+ES9Y=/-F2PRV4<L=ISY%B.IN$N%K116V:&]VVJU)
M)414RCYT<GV*B_R.A$Z.<APQV_;I'PLI-L1/AN8C>4R^?Q^0F$M3.,NZ&,,=
MGU  5I@       *+]TU\=AWT:C^V7E#\2ST4*-]TU\;AWT:C^V7E#\2ST4+\
M_+QYJL/'ER?0 *%H
M
M
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MIO9G=YI:IZ3JOR.<NCT7P  .BV
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M7K#\2ST4+\_+QYJL/'ER?0 *%H
M
M
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M56BSK%-[,[O-+5/2=5^1SET>B^  !T6P
M
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MA%V1V\S<0V1V\S<1* VI*A%V1V\S<0V1V\S<1* VI*A%V1V\S<0V1V\S<1*
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M[9>4/Q+/10OS\O'FJP\>7)]  H6@
M
M
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ML4WLSN\TM4JK19UBF]F=WFEJGI.J_(YNCT7P  .BV
M
M          T'2'@2CQ'<*:MAN*VRZHWDV2-7)9$3-43ISS-^*FJ=6YZ;W,NE
M6L$-L@;)21N<C6O543/+/TE+-.[F8GN0U*JI>^#]'-/1XD2NO%]6\5])^S$]
MV>HOE7-57Q_S+2*7T@4D-BT@VB]6:O>MPKZAL4].QZ+FSH5<D\7,G,OS%T)T
M&=2YK*98TZBXB  %2P       !1?NFOCL.^C4?VR\H?B6>BA1ONFOCL.^C4?
MVR\H?B6>BA?GY>/-5AX\N3Z !0M
M
M
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MV9W>:6J55HLZQ3>S.[S2U3TO5?D<Y='HW@  =%L
M
M       /QSD8U7.5&M3G557)$*^QOA3#V,('7AMS2EFI<V.KH7:S41/$O/DN
M6?2BDG317U%!@2K=2.5CI7MB<Y.E&KGF5WB^.*S:-<-8?MD[GSW18ZB757/-
M'-S7[LU_D7Z6$[IB5.IE&^)AF=&=@PA)B#:J?$,E[ND"*L:3,?&C?%FB._:7
M[_'T%R%!XMPQ18(O^$9;+RD=7+*C)DU\U?SHBKE]ZE^)T&-;?643WLZ6ZXH
M!2M        47[IKXW#OHU']LO*'XEGHH4;[IKX[#OHU'XQEY0_$L]%"_/R\
M>:K#QY<GT "A:
M
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M\TM4])U7Y'.71Z-X  '1;
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ML/'ER?0 *%H
M
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M-[,[O-+5/2=5^1SET>B^  !T6P
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MEGHH7Y^7CS58>/+D^@ 4+0
M
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M(YRZ/1?   Z+8
M                                         :CI4OD^'\&U=71KJU#U
M2)CD_P *NSY_Y%>MPG54.AVJE9)/6U]UY.K>W+65%<B+EY57+I4L['^'UQ+A
MBKMS'HR5R:\;E3--9,\BK+)I,O&$;=!9;]AV:62C;R+)4D5FLC>9/\*HO-XT
M4V-*]G]/?:C4K:_5W,=06VKT<8@PU64E14.I[HU(ZF"3FR<JHF2I]Z*GCYE\
MIT,G04?;?TUI-Q?;KA6VY]LL]N^&U'9NUG9Y\RJB9JO-XNA"\#&M-U?>SI1W
MUW  *%P       "B_=-?&X=]&H_MEY0_$L]%"C?=-?&X=]&H_MEY0_$L]%"_
M/R\>:K#QY<GT "A:
M
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M>  !T6P
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M\2ST4*-]TU\;AWT:C^V7E#\2ST4+\_+QYJL/'ER?0 *%H
M
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MLZQ3>S.[S2U2JM%G6*;V9W>:6J>DZK\CFZ/1?   Z+8
M
M           >=33Q55/)!4QLEAD35<QZ9HY/G0I^\Z%&.KI9K%='T<,CE7DG
M9Y,1?$BISY?:7(">&IEAW(Y81EWM#T?Z-;=A69U9*_;;BJ9)-(F:1IX]7_?I
M-\ ,993E-RSCC&,5  "+(       "B_=-?&X=]&H_&,O*'XEGHH4;[IKXW#O
MHU']LO*'XEGHH7Y^7CS58>/+D^@ 4+0
M
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M*ED"H])?6>3U3"VV.:]J.8J.:Y,T5%S14*DTE=:'^J9^"G+ZU\CFUNE>!JH
M/..<>(W+15U@J/97=]AIIN>BKK!4>RN[[#:Z%Y^'S6Z/CA:8 /5NH
M %!:8NNU1ZJ/NE^E!:8>NU1ZJ/N@:2 ?@'Z;5HLZ^6K[9/Z;C53:M%?7RU?;
M)_3<!T2<W>(Z1.;E.WU/^_E^7FOXA_I\_P " #YSM/-'06IH@\%5_KT[I5:%
MJ:(/!5?ZY.Z:'67P\\G6ZE^+QY_9K/ND_!5D]?)W4*%+Z]TGX)LGKY.ZA0IK
M]!\F'T/0\  #;7/:C_>X?3;^)VN<44?[U#Z;?Q.USE=9?MYM3I/HI;''6JX^
MFG=0P2&=QOUJN/IIW4,$?.^D>;G\Y^[S^?BD !4@W'19UBF]F=WFEJE5:+.L
M4WLSN\TM4])U7Y'-T>B^  !T6P
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M.^C4?VR\H?B6>BA?GY>/-5AX\N3Z !0M
M
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MAYMS@W/15UAJ/97=]AIAN>BKK#4>RN[[#:Z%Y^'S6Z/CA:8 /5NH
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M55HLZQ3>S.[S2U3TG5?D<W1Z+X  '1;
M
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M[IKXW#OHU']LO*'XEGHH7Y^7CS58>/+D^@ 4+0
M
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M\/-JH /-N<&YZ*NL%3[*[OL-,-RT5=8:GV5W?8;70O/P^:W1\<+4 !ZMU
M      H+3#UWJ/51]TOTH'3#UWJ/51]T#2@  -JT6=?+5]LG]-QJIM6BSK[:
MOMD_IN Z).;OY'2)S<AV^I_W\OR\U_$/]/G^  (=IYH+4T0>"J_UR=TJLM31
M!X*K_7)W30ZR^'GDZW4OQ<<_LUGW2?@FR>OD[J%"E]>Z3\$V3U\G=0H4U^@^
M3#Z'H>"  &VN>U'^]P^FW\3M<XHH_P![@]-OXG:YRNLOV\VITGT4MCCK5<?3
M3NH8(SN..M5Q]-.ZA@CYWTCS<_G/W>?U/%(#]0_"I!N.BSK%-[,[O-+5*JT6
M=8IO9G=YI:IZ3JOR.;H]%\  #HM@
M
M           !1?NFOC<.^C4?VR\H?B6>BA1ONFOC<.^C4?VR\H?B6>BA=GY>
M/-5AX\N3Z !2M
M
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MO@  =%L
M                                                   *+]TU\=AW
MT:C^V7E#\2ST4*-]TU\;AWT:C^V7E#\2ST4+\_+QYJL/'ER?0 *%H
M
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M%G6*;V9W>:6J55HLZQ3>S.[S2U3TG5?D<Y='HO@  =%L
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MCE$P9>+&8E:H *5H
M          &'Q/B2VX9H&U=WGY*)SM1J(FLYR_,GC,Q$SNAB9K?+, QV'KS1
MW^U17&VO<^FESU5<U6KS+ET*0L4XML^&(V.N]6D3G_LQM36>Y/*B=.0V9NBX
MJV>!@,+8NLV)V2+:*I)7,YW1N35>B>7+IR,^)B8W21,3O@ !AE1?NFOCL.^C
M4?C&7E#\2ST4*-]TU\=AWT:C^V7E#\2ST4+\_+QYJL/'ER?0 *%H
M
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M6HBN^U?&>@
M       _'9JU43IRYCG?2)@:[4=GK+]B*Z.K*G71D4>LKM1%55Z5_!#HDKW3
MMU J/7,_!2[0RG'*(CU5:N,3C<I.A/\ ZN;;]K^\I6UEI8<<:8JY+RW:*6G:
MY4B<JY:K<D1/LS=F63H3_P"KJV_:_O*5OA.HBPIIEN$5U>D,<Z/C;([H^$J*
MB_RR+,?%G7>A/=C?<_;]0T^"M,5H6S1[/2S*Q71,5<LG*K7)V*= %!8QJ8<3
MZ9K/3VR1)F0NC:][.=$R55=V(A?I#6[L;[Z2TN_*NX -!TK8:Q!B)EL3#=<E
M(L"R<MG4/BUL]75_91<^A>TJQB)FIFEN4U%PTGW37QN'?1J/[9>4/Q+/10Y/
MTAX:Q!AUU F)*Y*M9T?R.50^75U=76_:1,NE#J6&&IY%G_24_93_  (7ZN,1
MAC$3Q4Z<S.64UP301>1JMY3@0<C5;RG AKU[KK2@1>1JMY3@0<C4[RG @KW+
M2@1>1J=Y3@0<C4[PG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1JMY3@0<C5;R
MG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1J=Y3@
M0<C4[RG @KW+2@1>1J=X3@0<C4[RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>
M1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5;RG @K
MW+2@1>1JMY3@0<C4[PG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1J=Y3@0<C5
M;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1JMY
M3@0<C5;RG @KW+2@1>1JMY3@0<C4[RG @KW+2@1>1JMY3@0<C4[RG @KW+2@
M1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5;RG"@KW+2@1>1JMY3@0<C5;RG
M@KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=X3@0<C5;RG @KW+2@1>1J=Y3@0<
MC5;RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J
M=Y3@0<C4[RG"@KW+2@1>1JMY3@0<C5;RG @KW+2@1>1JMY3@0<C4[PG @KW+
M2@1>1J=Y3A0<C4[RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1J=Y3@0<C5;R
MG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1JMY3@
M0<C5;RG @KW+2@1>1J=Y3@0<C4[RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>
M1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3A0<C5;RG @K
MW+2@1>1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5
M;RG @KW+2@1>1JMY3@0<C5;RG @KW+2@1>1JMY3@0<C5;RG @KW+5)IV\+6O
MU#N\5B65IO9(VZ6Q)9$>O(NR7++_ !%:F&0( !F,&=;;+[9%WT.FSF/!Z*N*
M[.C5R<M7%DOD^&ATER-5O*<"&8AA0]^\.7+VB3O*0$)U\14O5P1RYJE1)FOE
M^$I!YCV6GX8?.M7QY?,0>4 D@M71#X&KO:/]*&.]T+U%A]MC[KR7HG9,ZT5O
M)2HQ$GZ-7/\ PH8W3_',W \*RS(]NVQ\VKE_A>>=U8_^WF][U-/_ ,^G_P!Z
MN=@ =9Z$  '9N'.KUK]EB[B%9Z2^L\GJF?@6%AZ*I6P6S*H1$V:+FU4_Y$*Z
MTBM>W$KTD?KNY)G/ED>&ZWC_ -//_;A=*\/-K  /-.<&YZ*NL-3[*[OL---N
MT8M>Z_5"1/U';,[GRS_QL-KH/Q&'S6Z/CA:X(O(U6\IP(.1JMY3@0]97NZ=I
M0(O(U.\IPH.1J=Y3@05[EI0(O(U.\IP(.1JMY3@05[EI0(O(U6\IP(.1JMY3
M@05[EI106F'KM4>JC[I>?(U6\IP(43I<:]N,ZA)'Z[N2CY\LO$*+:9]@/P_3
M#(;5HLZ^6K[9/Z;C53:-&*.=CFUI&[5=G)DN6>7_  W =%G-QT/R-5O*<"'/
M'.=OJ>/'R_+S7\0SY?/\"  [3S1T(6IH@\%5_KT[I599VB>.5UKKN2EU$Y9,
M^;//X)H=9?#SR=7J;XN/E/V:_P"Z3\$V3U\G=0H4O3W1C)66JS<K*CTY:3+F
MR_PH46:_0?)A]$Z/X(  ;:Y[4?[W#Z;?Q.USB>C_ 'J'TV_B=G<C4[RG AR^
MLH\/-J=*]%08XZU7'TT[J&",WC-'-Q/7H]VLY'IFN73\%#"GSKI'FY_.?N\_
MGXI?A^GX"I!N.BSK%-[,[O-+5*FT9M>Z_P R1/U';.[GRS_Q-+/Y&JWE.!#T
MO54?^CG+H=&G]"4"+R-3O*<"#D:G>4X$.C7NV+2@1>1J=Y3@0<C5;RG @KW+
M2@1>1JMY3@0<C5;RG @KW+2@1>1J=Y3@0<C5;RG @KW+2@1>1JMY3@0<C5;R
MG @KW+168>L\=R_2#+91MKL];:$B37S\N?290B\C4[RG @Y&JWE.!#,[^^2-
MWHE B\C4[RG @Y&JWE.!#%>Y:HM)<U+4Z1+?18N<^/#K(U='E\%KG*G/FY,E
MZ<O&>NBRXT]OO&(H[0Z5<*T__$C<Y-;)WCU57G7Q>,M"LMFVL1E8D%0Q%S1L
ML+7HG:A^T]N6F@Y"G6&*'_DCA:UO8B%W:1L[*K8G:MHF(ZNKTCX.:N$<MG6I
M6.HCJEY/71N2Y>/FYS3K@S%%)I"PQ!)0VN&O@A>REBCD<L>HC%1<U^S,NVEH
M'4D7)TKH8(\U75CB:U,UZ5R0_)+<LE3'4R<@^HC3)DKH6JYOV+EF@QU(QW1W
M$X3._P!4Z#E%@C6=&I+JIKHWHS\>1^S(]8GI$Y&R*U=55\2^(C\C5;RG @Y&
MIWE.!"FO=;:KL0MTAV.TU5QK,3T*00-UE1*6/->?H_9-RT8UUVN>#J.MO\J2
M5DZN>CM1K/@9_!YD1$Z#4-(KZG$&++5A&&HUHG95%6J-R1&IFJ(O9_,WBZ7"
MDPU;Z?;KA%24R*V&)%9S>1$0ORWXQ&ZY58[LIGT>^+K_  8<LD]?.FN],FQ1
M)TR/5<D1/O4U#0WB>\8D2]+?)=9]/*UL;.3:SDT76S3F1,^A.DQ&*F8CJ\:4
MEP;99[M;*)FO2<FYK6*]R?MKGT\V61 T+UMSDQ'?HFT,D4<]1KSRJJ*D+DUL
MFJGCSZ.8S&G$:<\6-N=N%W%-7J^W6*\U\<=QJF1LJ)&M:DBHB(CER0MOD:K>
M4X$*1OJ*E[N*.7-R5$F:^7X2G!ZVRG##'9E7TJ9B(I[>^&\?Q.K_ .]4>^&\
M?Q.K_P"]4Q9^G#[;4_NGZM/;RXLG[X;Q_$ZO_O5-UT9W*MKJBO2MJIIT8QBM
M21ZNRYU*V-ZT6,D=4W#DI-148S/FSSYU-OH&IGETC&)F?^A;H93.<+,!%Y&J
MWE.!!R-5O*<"'IZ]W1M*!%Y&JWA.!!R-5O*<""O<M*!%Y&IWA.!!R-5O*<""
MO<M*!%Y&IWE.!!R-5O*<""O<M*!%Y&JWE.!!R-3O*<""O<M*!%Y&JWE.!!R-
M3O*<""O<M*!%Y&JWE.!!R-5O*<""O<M*!%Y&IWE.!!R-5O*<""O<M*!%Y&IW
MA.!!R-5O*<""O<M*!%Y&JWE.!!R-3O*<""O<M*!%Y&JWE.!!R-5O*<""O<M*
M!%Y&JWE.!!R-3O*<""O<M*!%Y&JWE.!!R-5O*<""O<M*!%Y&JWE.!!R-5O*<
M""O<M*!%Y&IWA.!!R-3O*<""O<M*!%Y&JWE.!!R-5O*<""O<M*!%Y&JWE.!!
MR-3O*<""O<M*!%Y&IWE.!"1$U[6(DCM=WERR%%OH &&0     ,/BO#U)B:T/
MMUP?,R!SD<JPN1'9IGY47RF8!F)J;AB8O=+%88L5+ARS06R@?,^GASU5E<BN
MYUSYU1$_ QN,<#6;%FHZZ12-G8F39H7(UZ)Y.=%3^1LX,QE,3<3O-F*IJ^#L
M"V7":O?;(I7SO3)9IW(Y^7DYD1/Y&T &)F<IN2(B-T  ,,J+]TU\;AWT:C^V
M7E#\2ST4*-]TU\=AWT:C^V7E#\2ST4+L_+QYJL/'ER?0 *5H
M
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M2Z8
M      "B_=-?'8=]&H_MEY0_$L]%"C?=-?'8=]&H_MEY0_$L]%"_/R\>:K#Q
MY<GT "A:
M
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M?= TGQ'XA^CQ #:]%G7RU?;)_3<:H;7HLZ^6K[9/Z;@.B#F[QG2)S<=OJ?\
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M&,_ICZ,3IXU.YV"41?\ P[<O:9.^I>Y1%_\ #MR]ID[ZGANM_!C\W#Z7W0@
M#Q'":(;]HE_>KEZ#/Q4T$W[1+^\W+T&?BIN=7_$8_P#>DKNC^9"R  >I=,
M
M !1?NFOCL.^C4?VR\H?B6>BA1ONFOC<.^C4?VR\H?B6>BA?GY>/-5AX\N3Z
M!0M
M
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M&UT+S\/FMT?'"U  >K=0        *!TQ==ZCU4?=+^*"TP]=ZCU4?= TD!
M-JT6=?+5]LG]-QJIM6BSKY:OMD_IN Z).;O%S'2)S=]IV^I_W\OR\U_$/]/G
M^ ( GC.T\T%J:(/!5?Z].Z57]A:>B#P57^O3NFAUE\//)UNI?B\>?V:U[I/P
M39/7R=U"A2^O=)^";+Z^3NH4*:_0?)A]#T/!  #;7/:C_>X?3;^)VN<44?[W
M#Z;?Q.USE=9?MYM3I/HI;''6JX^FG=0P1G<<=:KCZ:=U#!?<?.^D>;E\Y^[S
M^IXI  4H-QT6=8IO9G=YI:I56BSK%-[,[O-+5/2]5^1S='HO@  =%L
M  .<-(_7>[^M_P!*&MFR:1^N]W];_I0UL!X@ !8>@WK95^PO_J1EQ7[P'<?9
MI.ZI3N@WK95^Q/\ ZD9<5^\!7'V:3NJ3T_%"O5\&7R<^9 !#V3YT($0 "XM%
MG59/7O\ \BM?=)^%;+ZB3O(65HLZK)ZY_P#D5K[I/PM9?42=Y#SV'QN7SE]#
MZH\G3^2FP =5VPSF!>NV'O\ WC3_ -5I@S.8$Z[8?_\ >-/_ %6D<_#+$]TN
MP2B,0>';E[3)WE+W*(O_ (>N7M,G?4\!UOX,?FX'2^Z$  '":(AOVB7]ZN7H
M,_%303?M$O[U<O09^*FYU?\ $8_]Z2NZ/YD+( !ZETP
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M7.WP5M&])*>9B/8Y/&BDDU+1,Q[-'UF21%1>1SY_)F;:5Y14S"S&;BP $60
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M.RCC*HO>=I*^6$'&_P#(/>=I*^6$'&_\A;H';3PCZ'91QE47O.TE?+"#C?\
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M'&_\@]YVDKY80<;_ ,A;H+.VGA'T2[*.,JB]YVDKY80<;_R#WG:2OEA!QO\
MR%N@=M/"/H=G'&7/LB8^9CB+"ZXH7;)(N52767D\M57?\N?B\ALOO.TE?+"#
MC?\ D-OEP=KZ1H<4[3ER</)<CET_ 5N?\S;B66KW5$?1''3[[5%[SM)7RP@X
MW_D'O.TE?+"#C?\ D+=!'MIX1]$NRCC*HO>=I*^6$'&_\AA[EHIQC<ZIU37X
M@H9YW(B*][GYJB='^ O4#MIX1]#LXXRH#]3&)OXS;N)_Y1^IC$_\9MW$_P#*
M7^!VT\(^AV4* _4QB?\ C-NXG_E)%!HEQ?;ZN.JHK]00U$>>J]KGYIFBHO\
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MY3])*J\GE^QF[,SVFUC,9,;%3$PVX %*T
M   8S$=U2RVF:N="LR1Y? 1VKGFN72>.%<008AH%J(6+$]KM5\2NS5I+8RV=
MKT1VXVMGU9D&OQ8E;)BN2R;*J.8W6Y;7YEYD7HR^?RFP#+&<>]F,HR[@ $60
M      ,#68C;38IIK+LRN=,Q'\KKY(G3S99?,2QQG+N8G*,>]G@ 19
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M;QB-MMO=OMRTRR+5N1J2(_+5S5$Z,N?I,XXSE-0991C%RSP (L@
M          &G6C'=/7WU+;)2.@<YZL;(LB.17)XLLDZ2>.&643,1W(Y9XXU$
M^K<08C$]]AL%M6JF8LBJJ-;&BY*Y3\PK?&W^V[6V!8$UE;JJ[6Z/GR&QEL[5
M;C;C:V?5F  02 ?,K^3C>_+/515R,'A+$;<14]1*VF6GY%^IDK];/F^Q"48S
M,3E'=#$Y1$TSP (L@!\ROY.)[\L]5,\@/H&I6W&C*VP5UT2A<Q*5<ECY3/6Y
ML^G+F,[8+DEWM%/7-B6))D5=179Y9*J=/W$\M/+'OA#'4QR[I9  $$P
M                !K6),74MFJXZ1M/+5UCTSY./FR3YU^XAV_'<$MPBI+E;
MZB@?*NJQSUUFY_/T%L:.<QM1"N=7")JVX@ J6         !@;)B-MTO-PM[:
M98EI%5%>K\];GRZ,N8E&,S$S'HQ.41,1+/  BR
M-'K<>N@NU5006B:HD@>YBJR7IR7+/+5,CA_%%1=;@E-+:)Z1JM5W*/?FG-XN
MA"V='.(N85QJX3-1+9P#SJ)FT]/+-)GJ1M5[LNG)$S*ECT!C;%>J6]TSYZ))
M-1CM5==$3G[3)&9B8FI8B8F+@ !AD      # LQ&UV*W639E1R,U^6U^;HSZ
M,O\ ,ECC.5TQ.41WL\ "+(
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MH9J5=6:1$B:[_ES5>?\ D:U+44,%K96TF(:AUY3X:LU7ZJKY$S3(WEN&9JW
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MK/407&)(I73J]$1R.S35:F?,OS*2U<KPRBX[]R.GC6434MJ !I-L
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M&65L[^37-$RSZ>U>TN)K4:U&IS(B9(0UZQBH]=Z6A>4W/IN?H -5L@
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MS<Y95EH66VU4M)&F211HU?G7QKVF-68C#:]<OPSI1,Y;/IBF  U&T
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MPR0QG,1I[?K.YG")G/9](WLZ #3;0
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MTU-9$NDB2;,L:29(B:V2_-F2+57Q7.@AK*='I%*F;==,EZ<ALS$6SM1,TE
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MK)4.=K+K.56JOV&> )3E.7?+$8Q'<  BR
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M63:.*FC6"2.I<C]6.1NJJ\Z^4D826LK,*5EHFH)Z6:")6-=*BHDBN5R\V?\
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MJHC\U7HS0QG'_KF.$I83^N)]FV@ U6P
M   &CZ7NKM/[2G=<;P:9I4IIZJP0,I8)9GI4(JMC8KERU7<_,7:'F0JUO!+"
M8]ZL8>^UO=,[I2ZK.]8S\4(&,K36UF$[2ZEIWR24R-<^-$^%EEET=)*Q E9B
M;!DCXJ&:GJ&OUN0DYG*C5^?(OB8_1/"94S$_JCC$-FP[X MOLT?=0R!@<$UL
MU79(F5-%-2/IFM@U945%=JM3X29IT&>-3.*RF&SA-XP  BD
M                   K_2M\?8O7._%A\8XZR85]).\TDZ3:2HJ9[*M-3S3(
MR9RNY-BNU>=O3ET'SCV@K5J;)<J2EDJ64:HLD;$^%THO1T^)3=TIBL.;4SB;
MRY&EKP=;O:4_!3>*?XB/T4-'QO#6WW"]#64]%,V5DJ2OIU3X;4YTZ.DVK#E=
M)<;5%/-2RTC^=JQ2HJ*F7-GSE6<?^N/:UN$_^R?>F2 !KK@
M
M                           !A<36!E]@CBDJIJ=K%55Y/+X7S+F2;!9Z
M>R6]M)2:RM1<U<[I<ID02V\MG9O<CL1>UZ@ (I
M
M
M
M
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M)$5/YD8QF>Z$IF([VU ^*>:*HA9-!(R2)Z9M>Q<T5/F4^S#(
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M9YYY(OD3-,OF0M8AGA.,U*6.6U%@ (I
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MI&^=BZ[4Z$<URM7+YLT4QGISC%LXZD933.  K3
M
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MEC.E'<T/!:__ 'IMGKVEVW?P56>I?^"FLVK -#;KC3UD574O?"]'HUVKDO\
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M !2M
M
M                   \*^JCH:&HJYURB@C=([[$157\ /<&@:+[W<;W2W2^
M7:LU;>^56T\3LFLB8WI7/_YFYNNEO; V=U=2I"Y<FR+,U&K]BYDLL9QFD<<H
MF+3 >2U$*4_+K-&D&6MRFLFKEY<^@A_IVT_Q2@_\0S_<Q4LVR(,5<L0VN@L]
M3<Y:N*2CIT^&^%R29+XDYO&5K9-*U;?,=4=NH:*.&TU#D:UT[%Y5R>-<T=E^
M)+'3RRB9A'+.,=TK?!K^.<3P83L,MQJ(UE<BHR.-%RUW+T)GXBMF:3\46M:&
MMQ)8Z>.T5O/$^'-'Y>7G<OB5.E$,XZ6647!EJ1C-2ND&B:0,<RV)MJIK-1I6
M7"Z?NVN[)B)S9*OEZ4YN;[3&6O&^(K=BFW6;&%LI(W7%R-@EI'*B-7HYT55S
MY\O)TB-/*8LG4B)I9P*[HL07&VZ5:JR72I?-;ZR/7H]9$34=DBY<WWH6(1RQ
MG%G'+:  12                                 "/<JA:2WU-0F2K%&Y
MZ9]&:(!(!3%@QII&O]"M9:;1:9J775B.5KDYT_\ [GSH;S4XFK+!@=]WQ331
MQUT:9.@@7)'.541$3G7QJ69:4QN0C4B=[;@4HW2ABNA@I+M>+%3-L52]$8^/
M-'Y+\^LOB\J(7+0U45;1P55,[7AF8DC'>5%3-#&>G.'>8YQEW/8'@^MI8ZEM
M/)4PMJ')FD3I$1RIY<NGQ'S!7T=1,Z&GJZ>65O[3&2(YR?:B*0I.TD$:.X44
ME0L$=93OG3F6-LK5<GW9YGI4U,%+'KU,T4+/^:1Z-3M44/4&OU^,;'15E+2N
MKXIJBI7*-D"\IG\^:<R&P&9B8[V(F)[@ &&0
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M@67%%JO=PJJ.UU&T24R9R.:U=5.?+)%\9FI[V+AF@ 89
M                    *GQ_I<CM,U10X>IEJJVG?J3331KR,:HJHJ<RHJKF
MGS)]I+#"<YJ$<LHQBY6P# 6._+/@NEO=RU&*ZFY>7DTR1/L15_S*SDTH8JJJ
M>JO%KL5,_#]-)JO>_-7Y9Y=.M\Z>)<B6.GEE=,3J1"ZP:W;<86^MP<_$2:S*
M6.%TKV+DKFJU,U;]OB*V32CBM]"M]98:;WO))J*[-==.?+IUOYZHQTLLB=3&
M%V@QN&[Q3W^R4ESH\TAJ&:R-7I:O0J+]BYH2W5M*VI2G=4P)4*F:1+(FMEY<
MNDA4]R5^KW!&IZ^CJ9714U73S2-_:9'(CE3[413\AN-%-.L,-9323)TQLE:K
MD^[,4S:4#QJJJGI&:]5/%"S_ )I'HU/YF%K,8V.EN%)0K71S554N4;(%U\_G
M54YDZ!$3/<Q,Q'>V  &&0
M
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M]$=VJI:*"^XAVJV4:_\ !A:CE5$SZ.?F3H0GIY8U%SW(YXY7-1WL9C6;:J;
M]IHXI/?$L4<M/4*_52)JKDF?-S_LY_<?M='=K!I%P[58XE;<D>Y(Z:2G>J-B
M<JY9JBIFN2KG_P#0WK'VC],0U%OKK96_H^XT#$9#(C<TR1<VIS<Z9+GVF(H-
M&EUK<04-SQ9?4K]B>CXHF-7)<ES1%5>CG1"6.>-=_%&<,K1M*ZK!C[!]5 G_
M !EF:G3EFFMT%N%3W2-,1Z::*F9\*GL\22O<G.B.YER[>8M@IU.[&%N'?,@
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M.LF:<Y>!1EJO=XL^.+;;;;B5,2TM1SR\F[E$:G/GSHJHG1F7F5:UW"S2[I
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M*U4UU\F:]/E):L?IFD=+OBUG  TVT
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MA,YE8O*(Q,E_Q(JHF669*OT5'!&_U;^*\0 :;:
M
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M^1<^@],$8FIL5V**XTT:PN55;)"KM98W(N62KS?;]YB<9CO9C*)9\ $4@
M                              U=N+HYL<.PY2TCIG11<I/4I)DV-?\
MERRY_%XS,1,]S$S$=[:  89 #\>Y&-5SE1&HF:JOB _0:%7:6<+4=;)3+4U$
MO)NU7210JYB+]IM]HNU#=[:ROM]0R6E>F:/3FR\N>?02G#*-\PC&43NB4X&A
M7#2QA:BK9*9]142K&[5<^*%7,1<\NDR&),;TMIL='>:.#](6V>1K731R:NHB
MJB:V2IS]/1S&>SRX&WCQ9^YVBW75K6W.@I:MK>A)XFOR[4%LL]MM37);*"EI
M$=TI!$UF?8A*IIXZFGBG@>CXI&H]CDZ%14S13T(W/<S4=X ##(
M
M
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M^#5+8:FJU$3H1,B.?AQ2P\63] !4L
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M  @D
M
M
M             -<PYA.GL-[NU?1U$FI<':[X%3X+79YYIVJ;& 9F9G?+$1$;
MH  89        :Y;\*4]+BVLQ!)423U<[.38UZ<T3?(AL8!F9F>]B(B.X !A
MD                               !B\3V2FQ#9*FV5N?)3-RUD3G:OB5
M/L4^\.VO]#6:EMZ3OJ&P-U&R/3G5#(@S<U3%1=@ ,,@       (USI75EOJ*
M9DSH'2L5B2,3G;GXT,=@_#M+A>R0VVB57L8JJKW)DKE557->TS0,W-4Q478
M##(                                :V["=.F,TQ'#/)%4+%R4D34^#
M(F66:FR S$S'<Q,1/>  PR     !KV,\+Q8II*>EJJF6&GCD21[&)\9EXE-A
M!F)F)N&)BXJ7S%&R&)D<;4:QB(UK4Z$1.A#Z ,,@
A                                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g12080g75h77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g75h77.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_[1<$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %N<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF-\EY%.D*+908M\EY'^(:<O(ITQ1;*#%ODO(_P 0TY;?FDZ0I%LH,6G+R/\
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M5 5+N']T&=_*H_3*6T5+N'=T&=_*H_3*68=&7V_+#+JQ6T "I8
M
M
M
M                             5+N']T.>/*X_3*6T5+N']T&=_*X_3*6
MX=&7V_*O+JQ6T "I8
M
M
M                                                        5+N'
M]T.>/*HO3*6T5+N']T&=_*HO3*6X=&7V_*O+JQ6T "I8
M
M                                                    $>N=4MB1
M:-L;GWUZ:VU$@PUJR=BR;PW2D5+-0F!IF8S4,;4[_&R\2Z"*U=2NXO,I+PRO
MGFJI*:KC:R5K4>FBM[I_[8P2X2Y<&;"U;SHJ2*J\+M?6*""L2KGK)HFMDWM&
M-9I;?_;&7"F'%L,4K4HJ97VTI%U,;QJ,*J75=$R:1J-<[@0@5-!5UF]U$DB1
M2M99([71%).!4TU+1:%0Z[KZDML(J*3%VV( ,60
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M!G?RN/TREM%2[A_=#GCRN/TREN'1E]ORKRZ\5M  J6
M
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MH?HH5H670?$X?HH4:W*%>;. #75
M                                               !4NX=W09X\KC]
M,I;14VX?W0YW\KC],I;AT9?;\J\NK%;( *E@
M
M                     0,>KG8;A%561L:]T+=)&NV+K,<LHQB<IY0B9J+3
MP5FNZ/5IMH:?I.'NCU?[#!TE-+^Y[/Z_X4_U.GZK,!7F&Y_JJO$*6G=10-;-
M*R-51RW1%5$N6&AL:&T:>O$SISR68:F.?'$ !>S   "K9+KL!&Q)52@G5%5%
MT> #/OC/UV\XWQGZ[><X5)YE7\X_I'J5$W*/[_; =SIL_6;SFES0CE92*BHC
M-]2ZKL3OJ:%D\NFEY).D=JZ)D\",F8CVJB7128FI1,6Y^":#3J8ZW>Y&-<U=
M];?15=5MADPN1D>,5;I'L>B,1=\9\%$U&Y914S(5B; S>UVI;:(J&FBC>R.%
MC6N^%JVDW"*:3%7K)B<#XY(VQJQ=![]A)PZ3?,&J.T1MM)+MV.UKK-E)14TD
M38WPL5C=B<1^:B)D.'RQPL1K48MD0F_),1Q5N#SA/4-QM!9=!\2A^BA6B=XL
MBEE9#AT4DKD:Q&)=5*-;E"O42@8*>LIZAKG12M5&_"OJMSGM/50U.GO$B/T5
MLMC7I4S _$TL<+%?*]K&IPJH@E9/$V2)VDQ=B@?L
M                                                         *EW
M#^Z'._E4?IE+:*EW#^Z#._E47IE+<.C+[?E7EU8K: !4L
M
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MJ-:FQ$0B^%)KC;]  A(
M                         !ILX8]#EO+]7B4S5DWIJ:$::M-RJC43G5#<
ME8[OM+/-EFDGB56PT]0UTST_PHKFHB\ZH9Z>,991$L<YF,9F&;",X9F2MPV3
M&<#CCP[$%30?#+I.B1?@W2R=[ZE,V;<\5]/F3\ Y:H&5M?&S3F61VBC$T=)$
MV+P*AQ6(NKLK2Y3Q##<P5E<E?)&Q\$KU5BM5++9+[$V?4;7 JJ.@W<,<?B#D
MA6HIH]#2X5WMBKYD4OW(YUY*8RGE;MMSW-BYGHJEM53K38C1R+#4Q7NC7(JI
MJ7ZCK"J=R%R56<,Y5D"Z5,^K<C7)L7MEU^8M8IU,8QRJ%NG,SCQ"I=P_N@SO
MY5%Z93?9]QW-F&8E#%EO!5KZ9S+NDT56R\1RFX!-5R8AFZ2>!&U#YH72,5;:
M+ORET,\<9C3RGM^6&65YQ"YP8-.HY%G3]A[IS\DSI^PII;;,#!IU'),Z?L&G
M4<BSI^P46S@P(^HM^:9?Z?L/=.HY)G3]@HMF!ATY^29T_8>:=1R3.G[!1;.#
M!IU'(LZ?L/=.HY)G3]@HMF!ATY^19T_8-.?DF=/V"BV8&#3J.29T_8-.HY)G
M3]@HMG!@TZCD6=/V'NG/R3.G[!1;,#!IU'),Z?L/=.?DF=/V"BV8&'3J.29T
M_8-.?DF=/V"BV8&'3J.29T_8-.?DF=/V"BV8&'3GY)G3]AYIU'),Z?L%%LX,
M.G/R3.G[#S3J.29T_8*+9P8-.HY)G3]@TZCD6=/V"BV<&#3J.29T_8>Z<_),
MZ?L%%LP,"/J.&%G3]@TZCDF=/V"BV<&#3J.29T_8-.HY%G3]@HMG!@TZCD6=
M/V'NG4<DSI^P46S P:=1R+.G[!IU'(LZ?L%%LX,&G46_-,Z?L&G4<DSI^P46
MS@PZ<_),Z?L/-.HY)G3]@HMG!ATZCD6=/V#3GY)G3]@HMF!ATY^29T_8-.?D
MF=/V"BV8&'3GY)G3]@TY^29T_8*+9@8-.HY)G3]A[IU'),Z?L%%LP,&G4<DS
MI^P:=1R3.G[!1;.##IS\DSI^P(^HX8F=/V"BV8&'3J.29T_8-.HY)G3]@HMF
M!@TZCD6=/V#3J.29T_8*+9P8-.HY)G3]@TZCD6=/V"BV<&'3GY)G3]AYIU%_
MS3.G[!1;.#!IU'),Z?L/=.?DF=/V"BV8&#3J.29T_8-.HY)G3]@HMG!ATY^1
M9T_8>:=1R+.G[!1;.##IS\BSI^P:<_),Z?L%%LP,&G4<DSI^P]TY^29T_8*+
M9@8=.?DF=/V'FG4<BSI^P46S@PZ<_),Z?L/-.HY%G3]@HMG!ATY^29T_8>:=
M1R3.G[!1;.##IS\DSI^P:<_(LZ?L%%LQI,Z]RV(^+^]#:Z=1R+.G[#2YP=*[
M+6())&U&;WK5'77:G>*=>/\ BR[2QSG],J878AXBW0S(R%$7MG+_ /$]5(N%
M[NB>/W7(I*R^O]_8;;]IB]9"]TV%&8$D28UA^@YRN2HCLEN'20NQ'SV_,LZ?
ML.]X/'Z,N[>V3E+.#!IU'),Z?L/=.?DF=/V'8IMVS PZ=1R3.G[#S3J.19T_
M8*+9R-B?Q"?Z)^].?DF=/V$3$WU'X/GO$SX/Z_L%%N0LNU-87Z[F.\B7O&U/
M_D>JZ5+V8V_TB*2RQZGI?C.WG^(O\6OH.$8Z73_-MZ7L.TG?4=@O_),_-K_C
M[W@)QCBQRGA+E+VOJ/-7"8W.ENOY-O2"NE_4;;Z1UJ<&V5NU#K'?)'_"GH..
M:Z723M&[?UCJW/G_  3^:9;>D_Q][P&KM,<F_L$_JE7Y[QF/2D_4;TAI26^
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MTREF'1E]ORKRZL5M  J6
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M^=71_%8_HFQL_.6>FS  VEH
M                          #F-T'&<6P+!.S,$HF5DK'=NQ['.LVVVR*B
ME9UV?L[UE%AU324^%PQ354<35@<CE>Y7(B1N17K9%V+L77M+S5$5%14147:B
MG$8SN>87B&-T>*TCY:66*HCJ'LB?^3D5CD5.U5%1-G!8NT\\8X90JSQRGE+I
M\O38A/@]-+C,,4%>YJ[['$O:M6Z[-:\%N$V!^8W->Q%8Y'-X%1;H?HJE;  "
M    J7</[H<[^51>F4MHJ7</[H<[^51>F4MPZ,OM^5>75BMH %2P
M
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M]3DYM^U?"?E-NH_3_A.U<)^=9Q6F>@ZRD^+1_10Y3A.JH_BL?@-C9^<L]-F
M!M+0
M       &LQ_'L,R_2-J<8JFTT#G:*/<USKK]2*4?/G9]!(N"83FFG?A$JI:M
MEA<LL+%7MF_ UZN&R^$OG$<.HL2A2+$:2GJHD6Z,FC1Z(O'92IH<1PVLK)5H
M,D84^A=#.ZFE?!&BS/C;>UK<-T0OT:XW"G5OU6/DAE"S*] W"JM]91HQ=[G?
M>[^V6ZZT1=MS>&FR=5TE?ENAJ<.IHZ6ED:JLAC:C6L[945$1-6VYN2K+G*W'
ME  #%(  !4NX?W0YW\JB],I;14NX?W0YW\JB],I;AT9?;\J\NK%;0 *E@
M
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M3LGUG64?Q:/Z*&QL_.6>GS90 ;2T
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MVEAGTRII;V[YXG?,J.BOL?K'Y'79''C]W]W)2\N_+N'>4Q^LA>Z;"BL"6/\
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MIXX^?V"U5QQ\_L%%I (]JGCCY_8+5-O\OG]@HM(!'M4_-\_L%JGCCY_8*+2
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M^Z'._E47IE+:*EW#^Z'._E47IE+<.C+[?E7EU8K: !4L
M
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M^<K--F !M+0
M              &FS3ERCS)11TN(/G;$Q^G^1<C55>_=%U'XP7*^!X5&GX.P
M^F9QO1J*JDG,E-B-7A<D6#U3*6K5>UD>BJB)KXOJ*GR]EW.,.!K229DI*!%5
MS5AD?=Z(O#>Y;C%X]5*\IJ>2ZF*U6IH6T>"QZ:G*>&MPG+U'0MJ.R4B:J;[I
M:6E=56]_K-L5SS9QR  0D   J7</UYASOY7'Z92VBI=P_NASOY7'Z92W#HR^
MWY5Y=6*V@ 5+
M                                         KC=Q[GZ/Q_W%CE;[N/<
M_1^/^X"DPFM#Q.^>IJNH'1[FZ?\ 6^$>-_E4N7=/[E9?&-^\IK<V[M\)\;_*
MI<NZ=W*R^,;]YL;)\?#NT]O^6U.TJ4NJKK38%UIJ6R\)[U;3\K=4ZCU[YZW&
M4=>8\.6R?GV>LA>^(U])AM*ZIQ"IAIJ=JHBR2O1K45=2:U*(RCW2X<B\NSUD
M+ W=?T<UWC8O70X?B>&_K88SY_\ EZ[V;B\,X_>'0?CKEC]X,+__ &6=8_'7
M+/[P87_^RSK/D$(8?VW#ZI>K_IX]7V!%G'+<LC8X\=PQ[W*C6M2I8JJJ\&T_
M>=NY7$K<G]Z'R9E_Y=P[RB/UD/K3.O<MB/B_O0YGB6SQH:<U-W$M?:-.,,9I
M2:(MN$\X=E@E]?F&V^I#P;A-AE_Y=PW7_P!S%J_^:%[IL*(R_P#+V'7V]DQ;
M/IH7NFP[_@_1EW;VQ\I  =AN   $;$_B$_T221L3U4$_T0.(UKX1JL$11P*!
M^H_SB<7>.WF^(O\ %KZ#AX_A(FN]SN)_B+_%KZ"<>;'+E+C%VCC/4VJ$\)U7
M!&;4\)UKODC_ (4]!R3?A(=:[Y(_X4]!K;3Y-_8.J5<@ R=H3;M+(IODUGBR
MMTLA9%-\FL\64:_)5J<G-/\ A+X3\HA^GZW+X3PXK3>(AU='\6C\!RJ;%0ZJ
MC^*Q_1-C9^<L]/FS  VEH
M                         ?.\N'84RDCK<QNQ**:19XJF1'2=K*C4T%1$
MU6U\5CZ(.1QK.&5:2C?+7SPR0I.L*IV.Y]Y$1%75HZ]2IK+=+*8Y0KU,8GFD
M;FMOQ)PNT3XDT'=H]554[9>/6=,1\/J*>JHXIZ)S74[TNQ6I9+$@KRFYF6>,
M5%  (2   5+N']T.=_*HO3*6T5+N']T.=_*HO3*6X=&7V_*O+JQ6T "I8
M
M                         %;[N/<_1^/^XL@K?=Q[GZ/Q_P!P%)\!YWST
M\ Z7<W[M\(\=_*I<NZ=W*R^,;]Y3.YOW;X3X[^52Y=U"WXJ37O\ G&[/K-C9
M/CX=VGXA\MJ=I4HBV;KU!$6]N\>:N#F4]1%5-ME/7OGL-OE&WXR8=Q[^SUD+
M W=?T<UWC8O70K_**6S)AU[?GV>LA8&[K^CFN\;%ZZ'&\0^8T_YYO7^S73EW
MA\P@]/#;>S;#+WR[AWE$?K(?6>=M65<2\7]Z'R9E[Y=P[RB/UD/K/.O<MB/B
M_O0XGC/P_M+2VSI^TJ3OX!Z0B)8:T/G;SR?E]?[]PSRF+UT+X3841E[Y>PWR
MF+UD+W38=[P?HR[M[9.4@ .PW   "-B?Q"?Z))(V)_$)_H@<0E^!;'NU=>P)
MMX;#6MP/8_AIWU.WG^(R>+7T'$,^$VQV\WQ%_BU]!./-&7*7&\*G@5=:@ZK@
M/6?"3BN=8_Y(_P"%/0<FW6Y/"=:[Y(_X4]!K;3Y-_8.J5<\(\ L#)V1/.6/3
M?)C/%E<<99%-\FLOR91K\E>IR<T_X:GB+JN>N^$X_/ <5IO=:G54?Q:/Z)RO
M?.JH_BL?T4-C9^<L]-F !M+0
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MOFN=>H>^OFN=>H46D CVJOFN=>H>^?FN=>H46D C^^OFN=>H>^OFN=>H46D
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MPJ;$ QF;XRF(KA 5+N']T.>/*X_3*6T5+N']T.=_*HO3*6X=&7V_*O+JQ6T
M"I8
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M%UG%:;PZNC^*Q_10Y3CUG5T?Q:/Z*&QL_.6>FS  VEH
M                                               4SC66,$B9755+
MFJIHL&=.D55!&B.;I.U*E]2)=.\I<Q3%(['L P3$<NR92J,2=*Y^A5-15C<K
MFV1761;V\*%VE?&E6I7FMC ::CI,(I8,-<CJ-C;1N1;HJ77B)YH\CX9/@^5L
M/H:MVE/"Q4<OA<J_>;PJRYRLQY  (2   5+N']T.>/*HO3*6T5+N']T.=_*H
MO3*6X=&7V_*O+JQ6T "I8
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M]$V-GYRLT^;, #:6@
M                    .*W5<3KL/P6CBPVI2DEK*IE.ZHY-'+95\_F.%S$^
MLS+B^+MIL9FIZ# :3?&RQNLV29$<Z]]G A;>8\"HLPX:ZBQ*-7Q*NDU46RM<
MFQ4[Z&B]SS"6Y;DP:)]3%!+*DLLC7)IR6X%6VQ2_3SQQC]U6>$S/[-CN?XE4
M8OD_#:ZL_/RL727CLY4^XZ P4%)#04<5+2L2.&)-%K4X#.4S-S,PLB*B@ $)
M   *EW#^Z'._E<?IE+:*EW#^Z'._E4?IE+<.C+[?E7EU8K: !4L
M
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MM+0
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M<Q%NSO1=.DX2QZ;Y-9XLI7,F+UF&U%%#3)2Z51I=M,JHUMK<7A+1RQ4XC68
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M(2 "$A4NX?W0YX\JB],I;14VXAW09W\JC],I;AT9?;\J\NK%;( *E@
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M*QKLJ9CQC$,.EQ)F%15-)4-D=B,#W)+(Q.#1T$MQ_"+.,=2N%)POC8 "M8
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MI<ZJC^+1^ Y7O'5T?Q:/Z*&QL_.5FFR@ VE@
M                                       #FL_9<DS)@J04U0E-602)
M/!(J71'MV7XM=M9Q-5)NB8O#/@\]/24\<S%ADJ[+HJQR671[7;95.DW6<0K:
M/ ::FPZ?L:6NJ64JS6OH-=J5?.?K-^ *S(<D-/73038; ^HBG1=:N:BN2_UH
M7X341:K*+F:='EO"8\#P2DPZ%VDR!NBB\=U5?O-D:#(.)SXQE'#J^J2T\K%T
MOJ<J?<;\IRNYM9C5<  $)   *EW#^Z'._E47IE+:*EW#^Z'/'E47IE+<.C+[
M?E7EU8K: !4L
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MX3\[-1^G?#=X3\\"GF'->\9U5'\5C^B<JFI3JZ3XM']%#8V?G+/390 ;2T
M
M !ILW9=I,SX-+A]<KFL=VS7MM=KK+9=?A.!]SG,=7"S#\4S9/+A5T1\38D17
M,X41;K;5?@+7!GCJ98Q4,,L(RYHV&T4.'4,-)3-T88FZ+4)(!@S      J7<
M/[H<\>5Q>F4MHJ7</[H<[^51>F4MPZ,OM^5>77BMH %2P
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MBARB<)U='\6C\!L;/SEGILH -I:
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MVW/G;S[89>^7<-\IC]9"]TV%#X"BKC>'HW4O9$=E_P#DA>"136_/KS)U'?\
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MP0,2S6,;9"2 8I"I=P_NASOY5%Z92VBI=P_NASOY5%Z92W#HR^WY5Y=6*V@
M5+
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MCZ2EE94KW8G@5-5/8UCGZ2:+5NFIRI]QM['M&GJ93CC/%;HZF.4U#;  Z+8
M
M              *FW$.Z'._E47IE+9*EW#^Z'/'E47IE+<.C+[?E7EU8K: !
M4L
M      "I-U[5C=+?9O/WEME1[KZVQNEXMYX/"='POYB/NX_CGRD]X<+JM=-J
MA.\?FRVU<QZEEYMAZ9XJ)=]N._*U;K_RD])K/[2_YG+WTJC_ ,9M-QY;XM6^
M*3TFK_M+_F<O?2J/_&<+7^>C^>3W?L[\OCWE1O #W@"&^],L3<&[O*;Z#_4<
M6=NL)>OHO%?>I6.X/W>TWT'^HXL[=7^4*+Q7WJ>5]HNB?M^7+\1Z7!V71">
M;4N%LIXIQ79;EB6S#/Y,[UFEJE4[E?='-Y,[UFEK'I?"_@?>72V7H  =%L
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MA=+)\%J74BX5B+<02561N9H*B=LNW;U"O--IP (
M                         *FW$.Z#._E47IE+9*EW#^Z'._E47IE+<.C+
M[?E7EU8K: !4L
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MN\?H]JO&Q>NAP>4NZ/#O'L]9#O-WC]'M5XV+UT.-M_S&G_/-[#V9Z<N\/F1
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M'S&>;S4O+:RY-SSN2HO#)Z[BG+=\N/<\[DJ+PR>NXZGA'QI[?[AM;)USV=&
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M/'E<7IE+:*EW#^Z'/%OVN+TREN'1E]ORKRZL5M  J6
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M#?X%\47PF@X#?X%\47PEFAULL.;8@ W%P
M                  %2[A]_QASO?]JB],I;14NX?W0YX\JB],I;AT9?;\J\
MNK%;0 *E@                              &AS?FK#\KT23X@]RO??>X
MF)=S[;;$Q$S-0B9B.,M\"#@6)1XQ@]'B,#7-BJ8FRM1VU$5+ZS0XEGK"Z/,E
M'@K5DGJYY=Y>K&]K$Z]D1RK]?,3&,S-0;T1%NL-9CF/89@4+)<6JV4S'K9JN
M15OS(O&;,X3=%J,&PRNH\0K(.S,91BPT-*Y;L>YRVNJ+JVKMZAA&]-(RFHMV
M>'5U-B-)'544S9H)$NU[>$UE=FO!*'%6X;5XA''6K:T2M<NW9K1+&GR)!2Y:
MP"&&NJXFSUDZR:#?@M>ZW:-\W.<IF>EPFLQ2IRY@D;)*VJF94UU;.NDL+4T5
MLCEUWLUJ(FS69XX1.4QY,9SF(OS6\BHJ(J:T4&*CB;!201,<KFQQM:CEX41+
M7-9FC,>'Y;H.RL2D<C5718QC;N>NO4G,J_45Q%S4,[J+EN :O+&-0Y@P6GQ*
MF8]D4R71KTLJ&CQ[/E'A6(U5(VCJZKL-J.J9(6HK8D79>ZIW^8F,9F:1O1$6
M[ &"@JX:^CAJJ5^G!,U'L=QHIG,60          !1&[5W8M\F9Z7%[E$;M2?
M]8M\FC]+@.!78!X#U-H%G[A'RMBGB&^L2MU^_P"&Z77_ )/WD7<'^5L5\0WU
MB5NO+_?E+L_,_>='POYB.TN1XY\I/>'!ZE6PU(+(B+?8%35WN\>F>(=_N/K_
M 'Q7>*3TFK_M+_FLO?2J/_&;7<?3^]JU?FD])JO[2WYK+WTJC_QG"UOGH_GD
M]Y[/?+X]Y4<@/ B&^],L7<'[O:;Z#_\ ZW%G;J_RA1>*^]2L=PCN^IOH/]1Q
M9VZO\H47BOO4\K[1=$_;\N7XAR<&B6N>GFOOGM[H>)<5V&Y7?\8YK_LSO6:6
ML51N5=T<_DSO6:6N>F\+^!]Y=+9?A@ .BV   "M]W'Y HO'_ '%D%<;N/R!1
M^/\ N I)-IX$/=6U .CW-U3\=L([TO\ *I<.ZEW,KXQOWE/[G"I^.V$^-_E4
MN#=3M^+#D^<;]YL['\?#NTO$?E=3LIC8EE50FI%3A/&HKMECUJ<%CU[Y]#;9
M0O\ C)ARKR[/60[[=X_1]5>-B]=#@LH=T>';?S[/60[W=X_1]5>-B]=#B^(?
M,:?\\WK_ &9Z<N\/F4\10>FV]FGY>^7<.\HC]9#ZPSSW,5OT4])\GY>3^_<.
M\HC]9#ZPSRE\L5OT4])P_&_ASVEH[;T_:5+)J5;A=27/=J"UTU'SQY]/R]\O
M8:G!V1'ZR%[IL*(R_P#+^&^4Q^LA>Z;#O>#]&3?V3E( #L-L   T^<>YC$;<
MDOI-P:?.'<SB/BE]('S$G#QGJ;/O":]9XG#<#UJZSZBD[G7^3+ZI\NMLBH?4
M4G<Z_P E7U3+#JAAJ=$]GS[.MY9$1;=LI^4XTL?J5?RS]7^)?2?@]K')\UGF
M(JHFLO#"?T>Q>0_R%'HMB\,*_1['Y#_(<KQ;HQ[O0>SOQLNW^WR2>)PGHX"]
M]!>'UIN;_HZP3R1I\EGUIN;ZMSK!/)&G.\2^''=K;3TJGJOC,U_UU])CV[=I
MDJE]\2_27TF)+6O<^8SS>;>IL+CW.^Y*B\,GKN*<X2X]SSN2H_#)Z[CI^$?&
MGM_N&SLG7/9T8 /1N@     .'K==5-?]92.JZK<!6&:,7Q"+,%>R.MJ6L;*J
M(U)7(B><U28WB=_C]5]J[K N1+V[QU^7_DR/PKZ3YM3&\3_;ZK[9W67AN2U,
M]5E**2IE?+)OCTTGN55^$O"H'E9KJY_IKZ3"FHS5GQN?Z;O2IB35JX3JX\H<
M'+JD.HP#Y.;X5.638=3@'R>WZ2E&T=#9V+XGV<7C/RI4_3-7V'3;W,Q:>'0E
M6\C=!+/7O\9I<WYXHL.S+B-'+#,Y\4JM541++YS3^Z+0)M@J.9.LMPT<]V)B
M'?C":=A-0TD[6)-2P2MC^ CXT71\%]A8.4&HW"6HU$1$6R(G 4<FZ+0<%//S
M)UEK[E68(,P8'/+3,>Q()=[=IIM6R+]Y5M&EGCA<PPU,)B$[$_CLA$)>)V2M
MDL13@Y=4M">;Q;W.AP/XHOA.?L=!@?Q1?"6:'4RPYM@ #<7
M                                 5+N']T.=_*HO3*6T5+N']T&=_*H
MO3*6X=&7V_*O+JQ6T "I8'XGE;##)+(MF,:KG+WD0_9@Q"!:J@J:=JV66)S$
M7BNBH(%<0[HU<[%(9),-1F!SU2TL-5I:W*BJE[6XVJ6<U4<U%38NLHZDPC'I
MDPW++\*JF04>(.F=6NB<D3F:;GHJ.M;A0O!C=%J-38B6+=6(BJ5:<S-V] /S
M(U'L5J[%*EJKZ3=+K*BO@F_!K&X+/.Z"*HT[N54MM2VJZ*A:35NU%3A*'P;
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MSS>:$^%WRX]SSN2HO#)Z[BG-2%Q[G:6RE1>&3UW'3\(^-/;_ '#:V3KGLZ,
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M_P NX=K_ .YC]9"]D5+;2GXMR&NBE;)'F"1KV*CFKH)J5-G ;/W/LP_O7/\
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MZY_LV_TCW/LP_O7/]FWJ&YC]1O9>BSA<K'W/\P_O7-]FWJ'N?YA_>N;[-O\
M2-S'ZC>R]%G73C0%8IN?9A_>N;[-O](]S_,/[US_ &;?Z1N8_4;V7HLX73C*
MQ]S_ ##^]<WV;?Z1[G^8?WKF^S;_ $C<Q^HWLO19P*NGR%F**%[TS5.JM2]M
M[;_23-QO&L4Q.#&Z/&*GLE^'578[)%:B.5$TMMO )TXJ9B;(SXU,+% !6L
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M+7T-)+V\ F)CA)$Q/&'[ !"0  1HJ"FBKI:R.%K:F5J-?(FUR):WH0D@
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MK-)+HG@/V0D     8:NFAK*=\%3&DD+TLYJ[%,D4;8HVQQHC6-2R(G A^@
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MC8]K'R,:]WP6JY$5? 3.,Q-2B)B8N'[ !"0  "-14%+1/G?2PMB=._3D5O\
MB=QDD                         <)GNFBK,U9>IZAB/BDWQ'(O":"O6LP
M[$\/P:OTI&PSZ5/*O#'K1$\R%I3T--/40SS0,?-#?>WN2ZM\!^:O#J2KFBEJ
M::*66+X#G-15;X#9PUXQB(F%&6C,S,Q+B9&TF(9LQ*',4BI#"B)3QOE<QNC=
MVM+*G$AI*BHJILC(LLTKD;6:,4CE6^AJMK+,K\'P[$)$DK:*GFD1+:3V(JV\
M)^Y,+H9*5E,^DA6G8J*V/0313ZA&O$5P]$3HS-N0SG00X=E>"*DWQB/J(W.<
MLCG*KE5$O=55> P56#TT.;\.I8'U$<-33:4S4G?>3X6U;WX#NJNBIZR)L55"
MR6-JHJ-<ET14V!U%3.JHZET+%GC;HL?;6U.).<QQUJBN[*=*YOLK^AJ&X159
MEI8EF;201HK&L<KE:KFMV77OFKC?V-/@LU.L,4LDZ(YT<[GR/1;_  D5;%H_
M@RBWRH?V+#ISI:5=%.W39KYB-%E["85:L6'4K7-=I-<D:71?"9QKX^<?RF$Z
M,M%DB1C<;S'$YR)(M6KD:NU4NNL[$B1X;1Q5KZN.FB94OU.D:U$<OA4EE&IE
M&4W"[#&<8J0 &#,          'XG_,2?17T%-8#"V;+>(M?C"4K--;TRVM)J
MX>'F+H5$5%1=:*:?\5\$TK_@RE5>_&A?HZL81,2IU=.<YB8<//7.K(,MPU+9
M*3"I.UE:URM8_6W:J:[&UP-8Z;,=?283*]^&;SI.:CU>UK^VV*M^!$.PGPVB
MJ*5M--20/IVZFQJQ-%O@3@%#AM%01OCHZ6&!K_A(QB)?PDSK1.-4B-*8F[<'
ME:D_Z=Q/$8]]?71/E;$[?'=HFCP)>W"O :>KBPYV28*EM2Y^)22HLMY'*Y_Y
M2W;-O;4B)P<!:])14U)"^*FACCC<JJYK4LBJNTA?B[A%WK^#J6[UN[\FFO7<
MRC7B[GU8SH351Z.*S#-._',,IYT8^C[%:YL4TBLC<[1X53AV\QKZETR99K8>
MR6OA2K9H-C>YR1:]B*O66=6X50UT3(ZNDAF8Q$1J/8BV\!C9@N&LI.QF45.V
M!7(]6(Q$153A$:\1$<$SHS,SQ<GF?#8*#*4+H$?I22QOE>][G*Y;.UK=5MM,
M\D[9L[4+H9$?$M,Y45JW1=;#KZBDIZBF6GGACDA5+:#FHJ<Q@I\)H:9\;X*6
M)CHVZ+%:VVBFK4G,AA&K%<>?%E[OCP_97]'AL%;09CFJ5D>^"1SHORCD1B]M
MKLBVX#!B-96ST.6XYGJ^FDCN])7JULBZM3G)K+*CP^DCCG8RGC:R?\XB-^'X
M3\385034;*66D@?3QI9C',14;X#*->+N8_E,?<S51_.+ELBK)'BF(0LEB['[
M5R012.>V-=>Q5\"</ =L1,/PVBPYKDH:6&!'?"WMB)?PDLIU,HRRN%NGCNXU
M( #!F           <YNB=QN(^!GKM.C,-730UE.^"JC;+"^VDQR71==S+"=W
M*)8Y1O8S"OZ'*U3/!0=AS;UA=3!&^JB15[9R-3[R UB096S,R)-!C*U6M1NJ
MR(]2TH8HX(611,1D;$1K6HFI$0BKA-"L,\*TL6]3NTY&Z*6<M[W4OC:/53[C
MT<;B4K8,7RE),Y&1[SK<Y=6R,\M25><L69CLSFQP-;V.CI7,1$UW5+*G$AV=
M7A5#610QU5)#*R%+1H]B+H^#BV(?FMP;#JV=)JNAIYI4U:;XT52(U8K^>J9T
MI592V;D6%U^U;B*7=Q)J.JS%5,P?&:''855]+,S>9%8MV]Y5YU.I3!\.2B=2
M)10=C.=I+'H)HWX[&ES#ENHQ*.FH*:6"GPABM5\*-UZENMM7WF?OL<\N/+BQ
M]UECCP_9^\ATLC<.GKIW*Z6ME=+KX&[$3S'3&*E@934T4,:(C(VHU+=XRFMG
MEO93*_#'=B@ &+(          &*K^*S?07T*5E@."U-92U5;A3VPXC#5O:C^
M-JJZZ+YBTG(CFJBI=%2RH8*.CIZ-KVTL+(FO<KG(U+75>$MPU-R)B%>>GOS$
MRK_#<-;A&=X*>%-*5*-72/X7O[6Z_6IJH^Q),IUF(555+^'6R.1'+,Y'M7B1
MM_#P%J+14RUJ5:PL6I1NCOENVMQ7(DF 83)4NGDPZE=,Y=)7+$BW7C746QKQ
MSG]E4Z,\H<5F&HJ*B7+$.+RRQ4T[6K4I=6HYUVW1UMFU3#&D-+F;%EP:5SVL
MP]ZQ:+E?HNT761%6_>+%K\/I,0C2.MIXIV)K1)&HMC%28104<J24M'!$]&Z%
MV,1-7$1&M$8U7_A,Z,W=JNH7RMHZ"JAEIX:O?45T^_O=)(NE\%6Z]NS8='V#
M'B>?ZF*L61T24S'*QKW-15U\2H=3%E_"8JA)X\.I6RHNDCDB34O&A+;14[*Q
MU4V%B5#FZ+I+:U3BN,M>)XP8Z,QS5MC$D53BF,(C6*VFCT&)4S.:L:HU+:"(
MI'KXNSLBX%5U>E+(V96/D<Y=3-\<FLLBHP+"ZFI=/48?323.^$]T:*JZK&7\
M%T/8'878L/8G):*:.V^SPDQKQ$17DCW,S=^;A<S[W#^ ::BT'88YKKL=*Y(W
MNXE<BWX^$8&Z9OX8@9-$M-O>DE/$]SVQK=-BK]?"=N_!\.DHHZ22C@?31K=D
M;F(J-\'%M/W0X90T,;V4=)!"U_PD8Q$TO#QF/OHW:9>ZG>M7Z*V'*F#XO2.5
M\V'HU)&L7_"K4O?F0W^3+XCB.*XO(Y7LDEWJG<NJS$5=G.A(QS+LLF'/HL"[
M$HH9M4[59J<G,IN<&P^+"\.@HX-;8FHW2M;25$VDYZD3C-<Y_",-.8RXI@ -
M9L           XC='C;+68#'(U',=4*CFKL5+M(DF4YZ>*M;/-OF$T\,DM/"
MO ]6+Z%UG=5=#35;XG5,+)71+I,5R7T5XTYC-)&V2)T;VHYCD5JHNQ4XB_'6
MG'&,84SI1.4S*K4J$;D[ Z7M[RS.715^@QR:;M3EOLU&?+LCX\;S!2QOC;3M
MHU<D4,BNC1=%-:*IWLN"X;+21TLE% ^GC558QS$5&KWCVEP;#J5TCJ:BIXED
M9H.T&(EV\6HSG7QJ8KG_ .6,:.5QQ<+E^@A7(,^(2+(^H='(U%<]RHU--4LB
M7MP&'+#UEJ\'AQI5;1MIV+1I==!S]%NWOVOM[Y8L6'TD5"M''3QMI5NF]HWM
M=:W74?E^%T+X((74L2QP66)NC\"VRW$1[^)N_,C1F*_97F+R35.:L4BKF0RL
MC;:%E1,Z-K4_6;;AV&+%:JL9DJ@8^MD?"ZH5DDT:K\"RV2^U2Q:_!L.KY$DK
M**":1/\ $]B*O.9%PVB6B[#[$@[%3_*T$T>8F-?&*X<CW,\>/-P4D&'09RP1
MF$R:<6BY7-21ST:NK9=5_P#4/<KTB8EDS%Z)C[5"5#W-:BV5%T4MYT.VIL#P
MREDC?3T-/$^-55KF,1%15_\ Z/S/AC:>"J?@T5/2ULR?G-!$15UVOJ[Y'OHF
M*C]OR1I3$W+C\#JI,Q8WA*ON^/#HM*;@1);K;U4+#-!E#+ZX'3U"SR,EJJA^
MG(]C;)X$[VWG-^5ZN43E6/*%FEC,8_JY@ *E@          /'?!6Z72VPK5\
M=(V;$:C L7=ALR2.WRFGUL<[A6RWVEEFLJ< PFJF66HPZEDD76KEC2Z^$MTL
MXPNU>IA.7)P&*8M75>4L-D:Q*>)]1H2[VF@UR)I:ULB61;7)N PJ['*BFB?3
MQTTU.J/IH972-VIVVO9P\YWC\/HWTG8KZ6%:;9O2L313ZC%A^$8?ASW/H:."
M![DLKF,1%5.*Y9[['=F(A7&E-W,JYII:BIAH,KR:3IX:I=^<B[(VZD])[B"R
M5&/XRRL;#(D:HV))YG1[VW7K:B?^ZBR(\-HXZY]8RFB;5.2SI4:FDOUF*NP7
M#:^7?:RAIYI+6TGL15MX28UXODCW,US<%625%3@."QSU+I%6K2-)6*J*K;LX
M=2\*ZS/FVF7#JS":.F:J4$BZ<C99G(V1_$YU[\"'=NPVC=%!&M-%O<"HL;4:
MB(Q4XDX#]5U!25\215E/%.Q-B2-1;> B->(F.'JR]S-3Q]%?X=OC:#,<+)8N
MQ^Q7.;3Q2.D;&NBNQ5,<:[UD[!\5I'HLV'O1)4:NM&N<YJHO2+ H\)H***2.
MEHX(F2)9Z-8B:2<2\9J,;R_))AKZ/ TI*.*9Z+.BQI9R>"RZ]2$QK8S-,9TI
MB+1<EN7%,2Q#''-5&3+O45U_PI9/2TZX@X'AL6$X9!1P?!C36O&O"O.3BC4R
MC++AR788UCQY@ ,&8          .)W3DO24";[O7Y=.W_5U*3L%BB;+,E3CZ
M8C$Z-=*)^BB(G"NHWV(8?28A&D=;3QSL1;HCVWLI%I\O833J]8*"G8KVJQVB
MQ$NU=J%T:D;FZJW)WMY7^ O9-B]%3U<LRX,R95HUD^"]W:ZEX>+;JUFPBP_#
MH=T=[9V-8F@R2)'/5+ONMK:]>Q-1VSL(H'00PK20[U"NE&U&HF@O&G$?JIPN
MAJ:J*IGI(9*B)45DCF(KDLMTU^$SG7B9^S"-&8AQ>7J&.LS%CDLN^/?3R-?$
MU)'(B.1J*BV1;+P;3GVOFGAQ*:HDA96-G6U1+,]LD5EU(C4X.LMBFH::FFEE
MIX61R2K=[FI97>$B5& X545*SSX?323*MU<Z-%55[_&3CM$1/']D3H37!QE>
MQ]?F+*\-5*]Z2TSDD<QRMT^U=Q6778_.$83339FQW#9-^6@@8CV0[\]$1UD6
M^VZ[5._=A](ZH@G6GBWV!NC$[12[$V63B$5!2Q5,U1'!&V>9+2/1-;D[_,8^
M_P"%1Z?[9>YXW/\ ."K75=8S)"1Q32[VVM6-SM-=3.VU*NU$U(;?+BO@S)&R
MF?3PPR1*CZ>&5TB.V=MKO9>L[AF%T+*1]*VDA['>NDZ-6(K7+MNJ'XH,'P[#
MY%DHJ*"&14LKF,1%MQ7,IU\9B8I$:,Q,<5?4%(M=DNOBIG+V?3U3Y&-:MG(M
MS:Y9K'9ES&F(*KNQJ6!J-8NS355O]>I#HJ_"'103OP)E+25TKKNE5B67;>^I
M3S*>!MP'"TIM)KY5<KGO:EKJ,M6)QF?/^68Z<QE$>7\IN@ :K8
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M*BJW32RZE5/N)9SVY]W'X=]%WKN.A*<XW<IB%N$WC$R  Q9
M        "!C.*T^$T[)JI'JQST8F@EUNI^8L8II<32@:DF_K%OVM-6CJ[_\
MN0TNZ/\ (U/Y0PC8?W<M\@3_ ,9?CIQ.%]U,YS&5=G287B]-B536P4Z2(^DD
MWJ322R7NJ:M?>4V!QN1/EK,_EB^L\[(KU,8QRJ&>GE.6-R  P9@
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MY_L] !4L
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M/C<Z&-VDQ55-)J]Y;&[!GOY>K'<Q]'YC8D;$8W8A^@#!D
M         U]1A%+/BL.(R([LF)N@U475;7UF.# :""MJ:F.*SJANA(S5HJEK
M;+&T!EO9>K'=CT:_!\'I,(;,VB:YK)7Z:M5=2+WC8 $3,S-RF(B.$  (2
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MY1&,1R  8L@
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MGK+3,J5"R)4P*M4QDRRM5-!VMUU6R\Q<Q5GCNK,,MX !@S
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M.6^C>W!QZS/W>/HC?R]5S(J*B*FQ0?F/1WMN@J*RR65%O=#]&LO
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M:2G8L%#1),U)76NFDY+JNU5U:MB$SIXQ?!$9Y37%;  -=>
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M-?1R8E6(B14L$S';U&B+9%1%5;ZUX1EIXQ$IQSF9A8H -=<
M
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M\9NS'43Q4T+I:B1D43=:O>MD3ZR=Z>5F['-D!XQ[9&->QR.:Y+HJ;%0],4@
M
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MZ'P?,9Z#+DS,YU.-5BTZQ,A;!1L9=71M32O?4B)\+@N3EJ8RB-.8=0 #77@
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M9S5;
M
M                    #5YEQJ# <*DK:E%<C5:UK&[7N5R(B)]:DZAG6IHH
M)W,6-98VOT%VMNE['#;JVNJRM&[X#\2;I?4ET\Z&KQNCFQC=:FPQU?5TM(N'
M:;DIWZ*K96:N]K7S%L81,*YSF)6F"GLFNJ:C+.;L+D[.Q".BKG00LCDM*K4>
MJ:G67BXC%E_")HL8I7NP',<2(_X<M5I-35PIO:>D>ZJ^*/>77!8..YWP3!<3
MIL/JZASZR=^@D<3=)6K>W;<1,S3F7#<L4+:K%IEC8Y=%C6I=SE[R%<[JN!X=
MA>(X%4T=,QE358BLDTMDTGJJHNM?K4V6Z0Z)F?<GNK='L=:A4;I;-+2891AC
M-$YY1;>1;HV7Y<NS8S%-,ZEA<C'M2/MVJNRZ7-=AVZ]EG$*^FHZ9:U9JB1L3
M-*&R:3ELEUOQJ0LCHDFZKFYU.B+3:,:.M\'2UF;!]'-FZ+48@D;5PK"6I# N
MUKY=JN[RII-YAN81?!&]E-<77Y:S!!CO9K86.CDI)EAD:[CVWYE0W16^45WK
M=;S9!%^:='$]R<3M%I9!7GC4\%F$W'$ !@R                     &DS)
MF&# WT,4D;I9ZR9(8HV;57A7P(B*;M-FLK_-/;;JF56O3M6Q2N3PV<AS$&'2
MXWCV>$J,2KHH:.17QQPR:*:2-54OWN\6QIQ,*YSF)7."H,,?5XUN4X*^HIL2
MQ&=LRM7L270DLW3:BJNBZZ6LG,2LC87+#C\3I,&QZE;HJF^553IQILX-[3TB
M=.KX\B-2ZX.PCSO@DV968%3U#IJYU[[VV[6JBV5%7@49OSO@V5'1,Q:9Z2RH
MKFQQ-TG63AM<X>HP:@P/=:R_2X93QP1=CO54:B(KENW6O?)]X&;MC^S=%'.H
M4WK3XM)][>8RW,>?E5L=_+_+K7YRP5F6UQQ:I%P]-6DB:[_JVX]:$;!\]83C
M#*QM#OW95/$Z5:>9F@]R(E[IM*;I*J-F2:VC1BJM9B[NPWZ6BQCV[WK75LUM
MXCL<N/J*/=3IZ;'W0U5?4X>B130=JUC$T]2MUZ]3M=^'893I8Q$HC4F9A966
M\8@Q[!X,0I45(Y%<FBNU%1RM5.=#9E<;B;E3#L<A8NE!'B4B,6^SM6*J<ZJ6
M.4YX[N4Q"W";BY  8,@                    !I*S,4$&9Z/ V1NDJJB-T
MJJFR-J(JW7FM]9NRMZ-RNW6\S*Y-<>'-1B][1C7TG#Q453/N=XGCC\5Q!*FD
MJW)#&V6S&_EM'6G#M7B+HTHFOM_E5[R8M] $?$*VGPZBFJZR1(J>%JN>]=B(
M5KFJGGQ7#,OU#\.Q>OD?0L<]]%/H(BJB*NEVCKJ8LL4^'X;2X@_,.%8E24#V
MM:Y<3EWUCMNI$T&]\B-/A:=_C3IL W1\O8YB+:*DGE9.^V]I,S123Z.O6?O,
M>Z'@&7Z]:.MGE?4-2[VPLTM!._KU'&9F5M'GO*T]6L-3ACY7MPZ.F_)K%K9K
M7;I)LV:)K<*3%_QASK)05E% ^"3?)FSPJ]7IVUDOI)9-O&61IXSQ\F&_ER6>
M[-] F(8-"Q=*GQ5JK3U"+VJN3_#X=G.=(4YB&+28OE'*^(.IHX:N/$(FM;'J
M:J[XS6G$BEP0*JPL5VU6I<JSQW5F&5OV "MF
M
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M,B(ARV3, J,-K\9Q#$49V77U&GVJWT6(B(U+_5<ZD 3,S-R1%14  (2
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MJIQN,96DJL:R[#21QT^#88[?E1JI=ST5%:VW%VJ:^^=DFH B<IE,1$  (2
A                                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g12080g93g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g93g01.jpg
M_]C_X  02D9)1@ ! 0$ X0#A  #_[1J24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &G4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@#_@=3 P$B  (1 0,1 ?_$ !P
M 0 " @,!               &!P0% 0(#"/_$ %X0  $# P,! P8)" 8'!08!
M#0$  @,$!1$&$B$Q!Q-!%!4B46&1%C)24U1Q@9+2(S,U59.4H=-"<G2QLK,D
M-F)UM,'1)30W<X((%R9#X?!$162BPO%C&">DPV6#H__$ !H! 0$  P$!
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M<HM-Y;>/U92_O9_EIY;>/U92_O9_EH-RBTPK;Q^K*;][/\M/+KQ^K*;][/\
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MBTWEMX_5E+^]G^6@K;Q^K*;][/\ +0;E%IO+;Q^K*7][/\M/+;Q^K*7][/\
M+0;E%IO+;Q^K*;][/\M/+;Q^K*7][/\ +0;E%IO+;Q^K*7][/\M/+;Q^K*;]
M[/\ +0;E%IO+;Q^K*;][/\M/+;Q^K*7][/\ +0;E%IO+;Q^K*;][/\M/+;Q^
MK*7][/\ +0;E%IO+KQ^K*7][/\M/+;Q^K*7][/\ +0;E0'L=_0MW_P!\5_\
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M?!=T'A3_ )V;Z_\ JO=>%-^<F^O_ *KW0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0>%-^=F^O_ *KW7A3_ )V;ZU[H"(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M_P"^*_\ XAZGR@/8[^A;O_OBO_XAZ"?(>B(>B".V#_6K4W]>G_R0I$H[8/\
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MKW7A3?G)OK7N@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@*#Z6_\5==_P#D6[_!*IPH+I;_ ,5-=<__ "+=
M_@E03I%PW..5R@(B("(B B(@U$O^ME-_8Y/\;%MUIY?];:;^QR?XV+<("(B
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M$1$!:G5/Z#G_ *T?^8U;9:K5/Z#G_K1_YC4&T9\5<KAGQ5R@(B("(B B(@*
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M+]IKZR</S'\,N1=FB]RO=$1=+R1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$'#OKPH5V:\U>I^#@7$CDY_\ EL4V/K\5">S48JM4?[S/
M^6Q!-D1$&@TS^E-1?VX?Y3%OUH-,_I347]N'^4Q;] 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'A3_ )V;Z_\
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M>B#7:D_U=NG]EE_P%:OLV_U)M?\ 5?\ XW+9:D=_\.W7U>2R_P" K6=FY_\
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M+IYRLL+BX]Z,M<#[#A=7R'&QPDN#A^(Y6>=RQS_6@[3+H]E,*2,._*D EO@
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MFP7JGO5NBK*)Y<R09&>,'U*_6]?9C]\>_JVZZRDB)Y;U )"Y:<YP5Q+^:?\
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M?DO:/L7F_(</+F8?27J-^C;-5[L1&&7#FR,>!M.1M=G//(4_LU1Y321R8()
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MJW[=?K::;H66ZVPTT8<(V [=Q)/4GG*VJ  = BT6]M\G4Z%Y.SSC)7JF%%>
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M/1!PYX;U*,=G@XR.JCO:!J.GTOI6Y7.HG;$88'F+/]*3:=C?K)P%"O\ V?\
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MX9"U&H)Y*2V3S01.ED8WAC>I3''[9=5,LOK+TIGM<U-)<Z@6V.">&.(ATC9
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MB_&ML !T&$01RZ5U34T,T+;37M<X#XPC\"/]M94%UJ&01M=9KD2UH!($7/\
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M.\_ZFN?NB_&MJUK6C#6@#V!<H-3YWG_4MS]T7XUY072H9NW6:Y\GU1?C6[3
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MHL2$?Z?-_4;_ 'N0:B\UU16VBNI8[5<6OF@?&U^(\-):0/Z:W5 QS*=@?N!
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MYTW8?2QY_'^+NC9CGCEX;2$D@DKT7#0 ,!<KS7L01$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'#LK
MKM'K7=,(,>6FBD^.T$^O"@^DJ6+_ -X6N&EC<,?1^'KA5@84(TC_ .(FO/Z]
M%_DE):>$R8QC/1: ![%V;U"[X'J"86/U7L1$62"(B B(@(B("(B B(@(B("\
M:NG954[H9/B.()^PY_Y+V1!U8T-X'KRNR(@(B("(B B(@*!=COZ%NW^^*_\
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M$0$1$!=9?S3_ .J5V767\T_^J4$1[)1C0]#]O_)3!0_LF_U'H?M_Y*8("(B
MB(@(B("(B B(@QY*."2KCJ7QM=/&US&/(Y:#C(_@%D 81$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MB B(@(B("(B B(@(B(.I8#G(S]:Q8P/.$PP,=VT=/:5F'HL>&-[:N5[OBEH
M/O0>X;CH5RB("(B B(@(B("(B#PIOSDWUKW7A3?G)OK7N@(B("(B NLOYI_]
M4KLNLWYI_P#5*"(]DO\ J/0_:I@H;V2'.AZ CI@_\E,@@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@*!=COZ%NW^^*__B'J>J!=COZ$NW^^*_\ XAZ">HB("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M#U/5 NQW]"7;_?%?_P 0]!/41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&@TS
M^E-1?VX?Y3%OUH-,?I/47]N'^4Q;] 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M"G_.3?6O=>%-^<F^M>Z B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#0:9_2FH_[</\IBWZT&F?
MTIJ+^W#_ "F+?H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@\*;\Y-]:]UX4WYV;Z_^J]T!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$&@TS^D]1?VX?Y3%OUH-,_I347]N'^4Q;] 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'A3_G)OK7NO"F_.3?
M6O= 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1!H-,_I347]N'^4Q;]:#3/Z4U%_;A_E,6_0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1!X4WYV;Z_^J]UX4WYR;ZU[H"(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MHM9>;S16:B=5W*H$%.TXW$$Y)!(' ]A5?M[7X9#(:32^I*J*/([UE.QH=CQ
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MPRQD=#Q)GCV@(+Y1:^+RYEHQ(^%UQ;">22(S)CJ3C.,^Q5!?*2YW*DKJN_\
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MSU<3;[I:]8:BJ:B[MO;;BZ.T.<^H86[BYT;6,! YVG@C POH+3!N#M/VY]Z
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MI2CTE)K&V5D.IA=Z^GHVT=)!*]QVEK1F0 _TB&G/UE6I63BFHZB=PW-B8YY
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M.1KB#M<U@!&1UQ@K?X4>[/75;]$V)UQ+S5FA@,ADSN)[MOQL\Y]?M4A5!$1
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M026R:IOMWN=/0772-12T-02))9GQ.:&X)Y D)\ .BF;X(:6WS145-$&MC.R
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ML8^GJ(:B(R=[(?2:6@-(!P'9)PI7HRETM4TT5XTM1T;89F$-J(:?NW.;D<=
M<)!))0PQ.$GQ,>EGG(]2^6+M=]&-A[BUTVL7/9(6VFX0.DQ SP$(?(,# '&
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M41UC:=I@C:14%S20V0'JW#/;T01_LWJ^S&BU'#'I>EJ67.I;W4;IX:A^ !G
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MTY!J:QOI9II*:2-S9HYXP"Z)S7!P(S]2A-XN5)J"DMNG+/='4M=<A(RJJC
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MMZL<%BJ^\=_HD#@6XSP[CC)7M2WZIFU3<[4ZUU#(*6%LK*K<W9(3_1'.<_\
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M,?H D9ZY.!QUZ(-EV?3TE))=8'U]$^:KN-1/#&RI8]SFO>YPP <]%.QT5$:
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M%W(]JBW:+I>HU59:>BI+@ZW31U#:COVL#G# <, D>B?2ZC'&1T)S)8">Y;O
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M,&_4M;MDJ6-/=-BC!.''UM*OQ?,^MO@Q'VEZF?J[35[O!DEB\GEI1)L:WN6
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MR*-G 8QH 'U!>Z B(@(BZNR3P<80:[4=\M^GK8^OO$_D]&QS6ND+2[!<X-'
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M!@<RHHF9<.H<,1$8((5%A:4O.K:Z[R1:BT_!0T1E?'#+%.'/PT;@YX#B-I'
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M/2'(QG@$C!4[:UK1L:  !@ = /!6BEM-ZI[2=0"N%#1V-DE),:>6.9[FO8<
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M]'T-94DT\#0^%CFNG>UY8T-)PUN&OR6CP"LGLPNWG;3CC+;:>UU%-4RTD]+
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M?4"H9I22TZ;N]1?:[4%I?0U%!34S!!,9)-P.!Z(&<$D>WU@)B+9# , < #
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M\U#:*4B(.'H[G;,@GU=>N<*P2'0VH?A#032QV>MMM'"6QP^4M:SO!@_%:#D
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M1L3I15AA<XP$B0LP<[<>/3HJ7N]VT=>;Q6/N=/>:F.GHH6VZD8ZH#XI!NWL
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MJ/3-5:K?40><!MF93O</2Z^BX>HY\?4H18=!75EPT]<+A06^EK'5\EXN%0
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MNKKCY2?+O.;=L^_G;D EN.N,%<:<T=3Z.LW>WZNIYJ.T3.EM<[MS33;]S/3
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M>1QCUKYDLQOEQDI+L\ZA9(VMHZ2C@F?*W#1W9GDDP>0<2?&SU"^FF=.00?\
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MYI9(O-UOG\I=%N<'22 '9D#C =M=]85$=T):[3?KS)K/%4Z\%SHC!42$^1D
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MK/:*.QVJ.@M<+8*2(8:T$N/M))Y)Z<E4_8.S&FNM7>X=44%3!<&W.2=]8V<
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M'3/O5AWR@CNEGK:"8EL51"Z,N!Y&1A6PBCM;:DM-QFH+S55VKYZ"Y=XVGL]
MXQ-=$PECI';2TEKBW(R<X>.%9?9#\'W:2@DTI234=$7O#Z><N[R.0..]K]Q/
M(=GQ*KQF@^T>BN-NDMUZL3V6^$T='+('!S:<?%:]O=XSAK>>3PK0[.K!/IVR
M=Q<*F.JN51+)55<T?Q'S2/+W;>!QEQQP.$@E2(B B(@+6WWSB+74^9?)S7@
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MDP@;IKL\-/60 0125?DT;(&GD@%DFX-Z\!6!:O.ALS1<74XNFPEXB&8VO/0
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M-0/TJZD\IJS)4R[VU(S&YF/SFT.&<=,C/1?0! ((< 1[53>H=27(ZCKGT,5
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M#C..3_%3V12VCY:VT=J]NL=)>[K<FR4SC>(JN5TK()N[>]H!/ .=OQ>,8"O
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M[MCVDXXSA^./4IZ.B@78_16.BTBT:;N;KG%+,^6HJW%VZ64X!R'<@X#1CC@
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MJE95:U\F%2.SW1PI_C=[WD);C/7=OQXJ[;G"Z:VU448S))$YH!/L/\5\^3Z
MU;8^SIM%:9'58N-/%'7VJHG:3 \$.WQN+L  AP(!YR.N.'M'T):'N=:J-\L4
M44CH6%T<1!8P[1D-(XP/!5YV^"Z'3UECL=1-!5ONL3>\B#LAO=R_&P/BYQG/
ML4[TK!+2Z:M-/4-V314<,;QD'#@P C^"C?:U?*^PZ?II;48HYZFK92^4RLWM
MI@YKSWA&".-H'/K5I$'AU)J7X<:4T[J2DDBKZ:K<9:JFP*>JB$3P'9!\?1.T
M@?4KR'0*B-+:@U#-K&UT]WU+;KC#YQJ*'R=D$/> QAV'<#(!#2<CV*]V_%"1
M1$1 5?\ ;0^Q1Z2!U-Y::45+>[BI"_O)Y-K\,&WKQN//''U*P%">U.AI*ZT4
M'E5VBM4U/7QS4L\H!89@QX#79\-I=[E!2.EV:)U)JFBME-;-7TU=4;HV3U%2
M\!@')RX2$@< ?7A?2-%3PV:QQ0,,CX*. ,:7.+G;&-P.3R3@=?%5=1:>JK9V
M@VZIK=1TGD-35SU%#300GO)72;G%A>&XV8R<$XR K?V^'!;CHKZ)Y?/^O;KI
M;45?1W>HEU7!*Z/:WR2GD9M! R.GL'3CA33L3%L-#<Q::J^3^FS>;H'@MXXV
M[NH7.N;MJ)^L:*QV&Y4-DB\EDJ75=6QCVR[3&WNV@@@'\IG["LSLTOMRFJ+M
M:-17*AK:FBF;''54VUC9@021@8Y&,<)"K!]>.<E5;<^TBZ#4590VBR=]2T_?
MQ,DE>UIFDB>&/#?3Z?&ZX\%:( (../\ DOG/6+].6W65;W6OFV]_E$[IZ9U*
M^7NGR/W2!I#"!Z6?%07QI.]Q:BT]0W6G:6LJHFR;'=6$C)!^KV+3]H5LT\;-
M<KIJ.E?/!'1NIIN[<\.,3GM<6C:1U<QO/7A979S#:J?1EIAL%2:JVQP-9%,Y
MI:9 !\8@@$$KVUQ;WW/2URHX*BGIY)8BT33\QL.>KE:1\_T-FT;0U%LNEYT'
M<*"S5DD8I*PUCWN!(W,+V-F)' /4+Z=8><8.",Y7S;56V_UUNMMJJ.TC3,U/
M0R,,$98"2YC2UH<=OIC!/7.3@J]]&TMZI+.R/4UPIKA<M[BZ>"/8TC/HC&!C
M 2'MOD1$!$1 Q[_6N",CJN40<.;E0?4O91I#4EWENEYM;IZV4 /D%1*P' P.
M&N Z*<H@@VF^RC1^F[M%<K/:WP5D60R0U,K\9Z\.<0I;<YQ36^KG W.BB=(!
MZ\!9BQJZE\JHZB!SB!,QT9('(!!'_-!0U'9]*ZNMMDU'>K--#<K_ %1II115
M$C&EVQ[\D;P,8C/3Q5W:?LM!8;;#;[53MIZ6)H#6-R?>3R?K/*J:G[ *>""&
M&+5U^9# [?$QKP!&[!&6_)."1D>LJ?=G^CI=(4]7"^]7*["H>UX=72;S'@8P
MWWH,'MDLMUOFDQ36&D%76LJ&3"/O&QAVW/4N(]GBJYH8^UBEUK7ZE&C* U-9
M V!\9K8MC0 WD8ESGT![U]! <_\ /UK@LR"#T^OE!@:<FKZBRTDUXIHZ6X/C
M:Z:&-VYK'$#(!R?'/BMBN&\#IA<H"(B M5J9MU?9YVZ??!'<"6]V^?X@](9S
MP?#*VJZO'HG""F9J#5VI+S<74%9I*J%+.Z)PGI'%\1R< ET><C'@2%9FD8+K
M1V&""_RT<M?&2USJ-A;%MR=H P.@QX*K+M'2V;6]TB@UT+?<+B\R.I8Z,/
M!<,D,(R&@]3DJS]$RF?35'/YW%V$[3(VK# S>UQR/1 &.#C&.$G@9M]HQ7VF
MKH^\[ITT9:'9Z*EJ:S:YJ+3;M*56E;-36^FDBA=<VSQG+(B,2@!Y?N<&?)SZ
M7.%8?:7I:.]4#JY]7<(9J6)P9%25#X@_QY#2,E4?;Y-.-LUHGH]8WJIU$Z6
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M:H5KJ]:)K=:U]OU[21".C:Q])40T]07NR/2:\QCG^CCPZJS=#W&QW&P02Z7
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M.#=H?@G/V=%MNR:;5%-3PT=PMMO%O<Z29]9!4;S)(][G/( .!ESCP.!T &%
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M(:0P$%IYR/:DO8OH>*JKM/O=AT_JB"IN5KK;U<*FA-*:&FA[S\AWA=WC@>"
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MI>J"(B#J\X!RJ6HJ74VG;]>XK7=]/PQU=2^H%+45&7QC&2<$Y'RC]?J5TO\
M#G!7RY?F-M>M:UUZT_=ZVZ&:J;-41M?(V6*2-XB#2TX& YF>G0Y0?2&FWU[[
M+3.O#X'US@3(ZGY8>3M(/]7"A7;%9:NILU7>:.^72WFWTCWM@I,;7D9.YV1G
M_P"@6^[,:.OH=$6JFNQ>*QK'.(>[<YK2]Q8"?6&%H]B\]9U][IN_BM]EI*^W
MNI7&66IJ61MW\CNW!Q'HD8YZ<J4BF60R6VWZ8ND?:!65]355-,)Z%L[7$[W-
MR T<C&><^U?2('KX'C[%\^Z7TI?:+45/<X>RZRT_>RM<^I%U$S6-)&7L89"T
M$#D8"^@P#MY/7V)!4W;Y#%(=-RUMKK+M;X:IQJ*.F9(XR-+<#.SD8)!Y]2\N
MRF;3+]1O;8M%W.RU(B.:BHCD:W'J](\K?=J][N5N=9;99:^"V5%TJ'0FNFQM
M@:UN\X#@020"WD>*U^@KC?*'6\UAO&H8-04LE)Y3%+"R,&$[L$/+&CKSC.>H
M2%6/=*MM!;:RK='+**>)TFV-N7.P"< #J50?:(;3==1/K:*'5EKKI(V>43VV
MGE FRT$;N,$@8''J7T*[):1T 'VJKZ^\:DL6O+O+3VFYW6T3,8(V"6%K(W@#
M)9EP./K\<H-IV+PVZ#2LL5KI[C%MJ7&>2X,>V6>0AI+R'>P@<<<*P%H=)W:K
MO%%+/76N>V2MEVB*9[7%S< [LL)'CC[%OE4@B(BB(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(<>*(>G""F*V34VF=37=U'=+#3TE;+Y0(*RI#2#@-W8)
MR/BCV?Q5H:9DN$EHIS>13^7D$O,!] \G!'V85!WUFD)-7:G?KBV76\UC9MU)
M)$VI:WNM@_(MV$ '(=ST]+JK![$M2TU78:.S225\MPIF/+GU,$HPTO<6CO'C
MG ('7P2"=ZIH8;GIF[T-3/Y-!4TDL$DQ( C:YA:7<\< YY7S_;K7;(?*J>OU
MU;*JJJZJ".9S6GFGB>PB,8;P[T3R,=5?>LZ&2Y:0OE! ]D4M50SP,>]VUK7.
MC< 2? 9*I*IT;<:=ELABTE1&LK6TQ%1$(7,IY8I\N<XYY#F-!\<YP?$*3RKZ
M!I^[$,;8RTMV@CZL<%5[K:W:P+YY;5JZAMD$M0!3MJ(&$!I:QNSEIR2_=Z_C
M!6'3Q[(6;@-VT-./_OHH+VNV6[W*WV^KL,,5556^<3BDEE;&R4AS2TDN('HD
M;N?4B(QV<2:GDUD*2Z:^M5WIJ;<*F@IH&1O<=AVX(8WH<'@^"N7@< 85-Z%T
M;5V[4VFJJ2GM\+Z:*>HKZF&5I?432"0=W@')#06G/17(TC;T]ZM%7:Z\_6O6
M3+K:+E:J.GDIFP&.OJ SOMI<> 3X;O!2O0M9>*^VR37U]OD)?F&2B?O8YN!X
M\^.56G:HW3<O:*QFM:*ON=O-&P0,IV5&VF?N>7'\GC)=Z(\3QZEZ]C.I+1;Z
MRXV>CBNM/15-9FWTL\$SFPQ;6C&]P. 7!QQGQ2"[F?%Y&/8N5PWHN4!$1!B7
M6NI[905%=6NV4M-&Z65^TNVM:"2<#D\#P5*ZCU%V67WSE(Z^3TM16%CI)H(*
MH.;(PY;(,-P'#CGV!7A4PQU$3XIXV21/&US'C+7 \$$>(5(7VT7C4&K[K:])
M46G;)2VMS0]]300N-3D YP8W';SC/L*"9=B#:1NB&MH*6N@B-1(>\KLF6H/'
MY0Y\#P/_ $J:79\\-MK)*-G>5#(7NB9ZW@$@>_"B_9-?ZC4.DVU-92LI:B&9
M].1& &R!N/2:!Q@YQ]8*E5RJVT%MJZQ[2YM/$^4CQ(:"?^24CYY=J6B_]WU1
M&_5MPCU4;A)41T[0]T@G! 9 !@@L):WV>D5]#6USG4,#Y06R.C:7>UV!DKY]
M-_NE3<*FZ4>DM-?Z/3MN9E=&S?%%WKV]YD-R7-[LNP,GICE?0=!)WU)#*=I+
MV!_'3)""(]K]9/0Z-F?!63V^)U1 RIK(6;GP0.E:)'@8/1A<>G@JKT#WE-K*
MS,.JKM<9W3RLGHY9#Z+ UKF/+3X$.!RK*US<-:MKI*.R:/MUYM+X\.?554;0
MX\\%KG=.G@M!I>DUC6ZUH:ZY:2LUAIV-<*JJIG0322MQ@,R,N XQQCV\*06[
MU:>"/K*I?M=J*=_:#9Z&]:EJK-:'TAE#::0L+GY?DNV\XPUH'VJZL;@<=/4M
M5=-.6F[539[I:J&LD:S8U]1"U[FMR3@$C/4GWJBI^R35-MMM_NUG?JAUQMKJ
MAK*!U2]SI'O<&C )&<9P.5>"CU+HW3M--'-!8;9%+&]LC'LIF!S' Y!! SX*
M0H"(B B(@(B("(B B(@+KX\=<KLB"@>WJP5UWO$[9J&KK()*$^;&POPV*H!&
MXO (Z@C&<C@K=]@%):Z>KU1)IZU5=!:I)(##Y6'![C^4R/2). "WWJXUP&AH
MPT ?4@TNI;E76ZA[^VVZ6X3;PTQ1.8TM!!R3O<T> Z'*JZ^6J(:@O-1'V?UM
M2^OS%453*QC>^83R6@S MS@> 5U$9;X9\%\XZBBM5;JJ^?"?M$NMGK65CV1T
ME+([8(A\4^B"!GGCJI[%[Z188M/4$?D+K>UD+&LI7.#C$ .&Y!.<?65UUH^W
M1Z4NS[V)'6P4[S4",N#BS'."WG/U+QT-'31Z4MK:&X37*F$#.[JIB=\HP,..
M?$]5@Z[N-DFM=QLMYKW4S9J&:64MC<XMB;M#G< \C<./:K2*DMP[/*#4=N<-
M,7=CV]W*^>IJ7RLI7O#MK9&F0\^B? A?10Z+YRM%3H,!M-5ZOJ:\U54*FN=)
M23M\I<T$-:<,& -SNF%]&MZ#*>@1$0$1$'E41-F862,:^-PPYK@"#[,%5-K*
MFU!>M75-HTM!8:2.@I8I99JVF:]TF\O :W+78 V'ICJK3NM=#;J&:JJ=W<Q-
MW.VL+CCV  DJD=?4VG+OJ*.[U.HM16R>II8]K*.FG [O+B,[6>WH>5!8?9;<
M*NML$S+E2T5/64E5)32FC8&Q/<TX+FX4ANMQFHIZ&..BEG;43"-[V%N(A@\N
MR<^[*K#LOT';8)H+S9]27ZHI8YB[N*C?&Q[LY.6$#KCU*X/ @C.?4<)2/FIN
MD-,<D]F-ZZ9SY>,?7^?S]BN3LRTE8M-6IU58;5+;9+C'&^>&69TCAMS@'<YP
M&-QZ%4G&R:IL%9JBO[0ZF+45-(X^0LJ&=T)6\[=@X<,DC(!:?6OH#1]Z9>;/
M2R2U-')<!&TU45+.R41O/@2TD>!QZ^4@T_;#YM^ U<;TVJ-'ENY])^<CZ^D,
M_P#WRM';>SJ&+4-%5,U#/44%/4^7LIW2,.^H.?2) S@[G9Y\0I+VINLC='5;
M]3%WFYI#G-CD<PO/. "T@^M57V?W#2IU;;J>33VHK%4.>/))*^:<QR2?T8P-
MQ&<9/(QPD%^O(VEQ).T]!XE5'KRD;JEEOEONAJNNJH7SQMA%6R-T;<MYRV4
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M5414L3IJB2.*%G+I)'!K6CVDH*'[2;)9[YK:OI[9HV:^7FG:R2MF?6&*-K7
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M45NJ!2U;FD13$!P:[UX(/]R"A[QHW2HU)<+1ISL\DN<M UCJEYN4D36[P2W
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M)%V+3^76.NJ9M1.OU5)4E\TVQS&1N('HM:0 !C!P!CE3>[VZAKJ1S;G1T]9
MST^[J(FR-R/$!P//51'LCH:ZCH;M)6VAEH@J:UTU/2M+"6M(&XG:3U=N(!/
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M(B#J_''K6%46ZBJGGRNCIIG/C=&XR1!^6$C+<D?%.!Q[ L_ ]2(,&W6ZDML
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MS'D!IR#@C(YSCV!?/LAL=:2P7C75ZMSG@9,<[X9P#QP3T^M4?3]IBB@ME)'
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M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0<;1S[5RB("(B B(@(B("(B
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MT-FCM0<Z&."5LCY7.:6G)#G8&''Q"MT#  77;P?4NP0$1$!$1 1$0$1$!$1
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M9*R:48^I[R%*\(@X:<Y7*(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g12080g93g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g93g02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[23X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )-L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLC0W4W/P&"54E.%#16-U@[/B)B=$H]/Q_\0 &@$! 0 # 0$
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M#VLLI^.E5]!/P'M993\=*KZ"?@6^ *@]K+*?CK5?03\#A-,<I^.M3]!/P+@
M.J@]K'*?CK5?03\![6.4?'6J^@GX%O@'5/IIEE/QTJOH)^ ]K'*?CI5?03\"
MX #JH/:RRGXZU7T$_ X]K'*?CI5?03\"X %ZI_VLLI^.M5]!/P'M993\=*KZ
M"?@7  =5![6.4_'6J^@GX''M8Y3\=:KZ"?@7  G50>UEE/QUJOH)^ ]K+*?C
MI5?03\"WP!4'M993\=*KZ"?@/:QRGXZU7T$_ M\ ZJ#VLLI^.E5]!/P'M8Y3
M\=:KZ"?@6^ =4_[6.4_'2J^@GX#VL<I^.E5]!/P+@ 7JH/:RRGXZ5/T$_ X]
MK+*?CI5?03\"X $ZJ#VLLI^.M5]!/P./:RRGXZ57T$_ N  ZI_VLLI^.E3]!
M/P'M8Y3\=:KZ"?@7  =5![664_'6J^@GX''M8Y3\=*KZ"?@7  =5![664_'2
MJ^@GX!-,<I^.M5]!/P+? %/^UEE/QTJOH)^!S[664_'2J^@GX%O@'50>UEE/
MQTJOH)^!Q[6.4_'6J^@GX%P '50>UCE/QUJOH)^ 33+*?CI5?03\"WP#JH/:
MQRGXZU7T$_ >UEE'QTJOH)^!;X!U4":993\=*KZ"?@<>UCE/QUJOH)^!< "]
M4^FF.4_'2J^@GX#VLLI^.M5]!/P+@ 3JG_:QRGXZ57T$_ Y]K'*?CK5?03\"
MWP#JH/:QRGXZ57T$_ )ICE/QUJ?H)^!;X!U4'M8Y3\=:KZ"?@/:QRGXZU7T$
M_ M\ 4_[664_'2J^@GX#VLLI^.E5]!/P+@ 7JH/:RRGXZ57T$_ X]K'*/CI5
M?03\"X $4_[664_'2I^@GX'/M993\=*KZ"?@6^ =4_[6.4_'6J^@GX'/M993
M\=*KZ"?@6^ *@]K'*?CK5?03\![664_'2J^@GX%O@+U3Z:8Y3\=:KZ"?@<^U
MEE/QTJOH)^!;X"=4_P"UCE/QUJOH)^!RFF.4?'6J^@GX%O@'5/\ M8Y3\=*K
MZ"?@<^UCE/QUJOH)^!;X I]-,<I^.E5]!/P.4TRRGXZ57T$_ M\ ZJ#VLLH^
M.E5]!/P.NWV7(<2RZRI6Y%-<*>KDZ-\;VHB;<34[O*7&0?.OA5BWI'WFA4X
M 0          &-5V^DJU1:JEAF5.I7L1WVG934T%,SAIH8XF]S&HW[#M '#V
MM>U6O:CFKR5%3=%,6GME#3R=)!1T\;_VFQHBF6    ^9/>W>92JM"O?<E]-7
M[$+6D][=YCS_ *;9[8L4K\@IKS4+%+)5J]J>+S39.]4"QZ!!J<9R"@R2W>&V
MJ7I:??AWY=>V_8J]YM@@
M
M      !!\Y^%6+>D?>:3@@^=?"K%O2/O- G                     #B3W
MMWF*:T9L]!<:C(Y*RF;*]M8J(KM^2;(7+)[V[S%4Z$^^9+Z:OV(%6?0T=/0P
M]%21)''U[(9  0
M
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MZYU] ^C1Z=*UJ<U;Y"U@@
M
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M CYD][=YBJM"O?<E]-7[$+6D][=YE*IT*]\R7TU?L0*M< !
M
M                                  "#YU\*<7](^\TG!!\Z^%.+>D?>
M:!.$                     <2>]N\Q1VDV4V>QU>107.L;!(ZL5R-5JKNF
MR=R%X2>]N\RE"Z8X18\FKLAJ;O2-FF95JU%5J+LFR=Z!8NZSW6CO%)X3;YDF
MAWVXD14^TSC68[8J#'Z#P.UPI%!OOPHB)SVV[/,;,(
M
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MD][=YBJM"O?,E]-7[$+5D][=YE*JT)]WDGIJ_8@%K@
M
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M(RN9OQ)MUJA[9 .?=MNW+VK&VVVT(/G7PIQ;TC[S2<$'SKX4XOZ1]YIJ$X
M         X>U'L<UR;HJ;*<@",UK+1A-GN=SCCBIV.1TTG)&\;N;NQ/.5UHI
M;*G(KU79K>&.Z69SHJ9')OLQ-DW3?G^J=/JD+G-5K9<:HW.:^MJ$23A7]7=J
M;+](M[&+9#9[%1T5.QK&1QIR:FW->:A5'^J#E;09KCMPL\BS7R+W-*UJNXDW
M7N\ZFJU&S7.*[%'4]QQ]U%23-X9ID1SMFJBHO+LY*O6;75=)<9U9M&27"F?4
MVI&<+E1NZ1\W]_+]9#;Z@:LXO<<2JZ2W[UE551.BCB1&JJ*YJHB[;KVJ!--&
M(;?!@-OCM50D\*([=Z)MXW$N_P!9."M] ;+667 H8[@UT<LLCI$8[?Q45R[=
M99 1\R>]N\RGG'!:_,:6Z7]N+6^"JIEJE5[I';*B[)_:0]'2>]N\RE5:%>^Y
M+Z:OV(%CMLEVU'DNE,RY6>DCHU>B2N:Y%5&_2+2 "
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MTCJQ51LLB-54V3O ND&-;Z^DN,'34-1%41;[<<;D<GU&2
M                                                  !P][6-5SW(
MUJ=:JNR$$RS4^RV-RT])(ERKUY-IZ;=Z[_X44#,UA_W9Y%Z*OVH>2[-_5=-_
M<0N/*J34'.\>N4TE-);J%8U='0Q[K)-W-7QOY%7T>'9S34T<*8A<7<"<._#M
MN>AX.W'7WVK9JSQPRMR=!)-%+)D5ZGR"/'[HV@@;,WIE5$W<O/;K:IJ/8IG7
MQ.N'S%O^IKQV]6*/('7ZV5%O=4RL?&V9NW%R7?8V^9NPV:^8UENVXY\]69%H
MW)6.X[Y?ZZI<O6C'-:GU-0WEMT?Q:C5KGTTL[T_6DE=S^LL0'E-/6EMV*V6W
MI_1+?$SS[K]IM8Z>&)-HXF-\R':                               0?
M.OA5BWI'WFDX(/G/PIQ;TC[S0)P                     XD][=YB@-,\%
MLF3W#(:F[4[I965:M:J/5O+9.Y2_I/>W>92JM"O?,D]-7[$"K#QNPT&.V_P.
MUQ+'!OQ;*Y5Y[;=OF-H $
M                    !PY4:BJY41$[5(1ENI=CQ]70=*^JKNIL$+=U5?EV
M3ZP)PY4:BJY41$ZU4@N7ZFV/'G+3LD6NKU\5M/3*CW;^5-]R&]#G>H$FU0YE
MELKNMJ;=(]/\WVDYPW3FQXRQ'T\"S5?ZTTKE<JK]@$';2YWG\G'43OL-G=SZ
M--^D<GS-7ZR=8GIU8<=VEBI&5%9UNJ)DXWJO?N[=28HB(FR)L@ (B(FR)L@
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M:C41&HB(G8AR$$1$39.2
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MSHIKBCGM794:U5.VT:EXO=)>CIKBU']SFJ@$R!\0RLF8CXG(YJ]2H?8
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M72N5\:OF5R;JBIU?*62 8VV_9)SZ  10
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MTY%D00QT\38X6-8QO)$1-CL
M                          (/G7PJQ;TC[S2<$'SKX4XOZ1]YH$X 0
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M@ -
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MB&472Y7]:-655,D3>@D5R\7$B]2HG8A=@!HSRN=[4  8@
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M6:KD;X_->K=55=NI.OL(KXTXP*'&F25U;(^JN]2O'--)LNR[=2;)U$Z
M
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M9PL;;Y'(FZKLN[>\]8'E;U/W^^63_P"6R?:T]4GC^7)-MD<MDF5D_< !S(
M
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M/U^&9>Z]UU[AK]Z9\' V%6KS5.>ZKY"Y #7EE<KVDG  &*@
M
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MZF2SM8Y?D50,\'S'(R5C7Q/:]CDW1S5W14/H
M  =<]1#3MXIY8XF][W(U/K [#4Y7D-OQ:Q55VN\O14L";KLF[G*O4UJ=JJIJ
M[SJ!C5I1?"+K2O>G_LXI6N<OR(I1VK&;09OD.*6J*GJ8;.M;O-TS5:VH7=J(
MG-$WVYI_B+.?ECE?6=;E=2]1,B5:K';+;K?;'+Q0.JE57R-[%7=>WS)YU-WA
MNKEQBOT-CU#MD%KJ:A>&GK(57H9'=C5YKMOW[]:IR0S8V-C8UD;4:QJ(B(B<
MD0A&LM-!-@M7/+LDU,^.2%_:URO1.7R*IP:?.NS9,+C.5RX[LNO2(*1L>4:D
MQV.WU#[&RNCEIXY$?Q\+G(K47=?%7F9K=3<II/ZPPNM7;K6-SE3ZHSN=BX05
M/3ZRPMY5^/76G7M_0O7[AM*35[&I>4\E13+_ /%C5NWS[ 6(")4NHN*U*HD=
MZHD5>QT[$_F;>GR2RU&W0W:A?YJAB_S VP,:.OHY5VCJZ=Z_V9$7^9D(Y%ZE
M10.0  !ILLR>TXI:GW"^5;*>!.345?&D=M[EJ=JE5>W_ !2?IZ;#K[+;NOPG
MA1.7?LB*G^8O*QN4GVNX$;P;-++FML6LL=3Q\&R2P/\ %DA5>QS?GYIRY+S)
M(2SC+["#YS\*L6](^\TG!!\Z^%.+>D?>:!.     %&5]J7/M5KO07:HD2V6Q
MK>"G:Y6\2KV\O[OUGQIYB5NO6!WJW52/9#!6JL3D>Y%8J)WHOE4V^H>,S3Y2
M^[8C=H:2_HWAFA>]$XV[)MU[=W?VD/L&"ZCK1U-L=50T=#52+)-(UR*JK\BK
M]@59NB%PJ:S$.BJI'3+2R="V1WZR(U.?UEA&DPS'J?&+!36RE57-B:B*Y>MR
M[;;_ %&[" !P]R,8YSEV:U-U4#D$&K-5<2I*N:FGN:-EA>K'IT3UV5%V7J:=
MEJU/Q:Z7"*BH[DCZB5=F-Z-Z;_.T'$U -+?LHM%BJ*:"YUC(9JE_!&S955R\
MNY/*@&Z!PQR.:CFKNBINAR!P_P![=YBJ="O?,E]-7[$+5D][=YE*JT*]\R7T
MU?L0"UP                #6Y.JMQJ[.:JHJ4DJHJ=GB*!L@>"K1#45M$V:
M2Y5Z.5539LR[<E,U;=*J*BW.X[?\Y3NG@9Y3LK/'5GE.R/1^I61U=]O,>'8R
M]?")'<%=,FVT4:[(O/FN^RN^8GN'8W1XQ98:"AC1J-3=[N:JYRKNJJJ^52@?
M4LP]#G&1Q=(^1&4K%17KNNZN3F>FCDV8>F5QK#^*  P
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MWN&0I1HVKIVQMZ"7B\9'(O5MRY(74>5ORF6RY1S=[;0 &D
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MGD4E8++9]'.H1B6EF)8M6>%VNUM=5I[F:H<LKF>5O%OPKY4V)N +;?M).?0
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M%;I9&35\CW3U<S=U1\B]V_/9$1$^3?M)F ;;>_+;)SX  10
M                                                     "#YSRRK
M%O2/O-)P0?.?A5BWI'WF@3@  "!9;IC:LFNKJ^LGJ62JWAV8[9.M5_F3T >7
M%TYIKQJ;4X]:J^I@I*%B/GD<[B5W5R1.6W:2[*M#*1EEFDM5UJXZJ-NZ*Y=T
M=]:';GMBR+%,YFRW%X4J8:E.&H@3FY>I>Y?*85SU&S'(J-UML^/3TE3,G"LT
MK>3?J4*F^@E3'-@--&Q7+)"O1R<3M_&1J;EC$/TKQ=^*8K!15#D?5.VDF<G5
MQ;(B_83 (!51$5579$ZU4'55-5]+,UO-7,5$^90-//F&/03/BFO5O9(Q5:YK
MJAB*BIV=9]4F5V&LG;!2WB@EF<NS6,G:JKYD12J<.THH;E<K[4Y10O5\E7(^
M)W2/;NU7N\W9L1^TXU:)]9:2DQ2!\5);F*^HD5ZN17;)RZU_:0*]%5E9344#
MIJRHB@B3FKY'HU/G4U5%EV/UL_0TUYH))=]D:E0S=?-S*VU;M=YR7-;)9HVS
MML:IQ5+F;HCN:\E5/,AK=5].L;QW$GW&T<5!74J;QR),[=RHBKMU]Z(!>Z*B
MINB[H"':1W2KN^"6ZKN#E=4.1R*Y4ZT1RHGV$Q".)/>W>8JG0GWS)/35^Q"U
MI/>W>8I;1V^VRUU.1Q7"LA@D=6*J->Y$54V0"Z@:2FRNR5,[(8+E3OD>NS6H
M]-U4W8%.ZX9;=67:VX7C,[J6XW*/IIZQB[.@AW5.6W-%7A=SY+R3;K(=1Z7V
M!E-PU[:BMJW)N^IDF>CE=VKLB[?/N<:I7>GL_JA*2>M>C*=]!'"YZ]3.+BV5
M?)OL3MCD>U'-5%:J;HJ=IQ>=MV:[CCA>3CCVY7V0C$KK<M+\OMUNJJ^HKL3N
M;_!XV3.W6ED54V5.[GU[;(J*O+="2:RY;=J_)Z7!\6JW44LL23UU;&OC1,7?
M9J;<TY;*O5OQ(F_65QK?=Z>9]JLM/*BUK:ELS^'_ -GR5&[^5>+?;R&110RX
MGK76VV^5WA=154S&,J7\N)RM:J(O=U*GR(=.O/.Z/U+/ZN7_ .LL<[Z-K'I9
M9/!59/+6RU2ISJ5F7B5W?MU'7IG3IA^K4%NO[EN$%PAX*"NGYNC<G-&\_FY=
MO"6$5+JGDE+1YKB[&*CY;75,JIME]RG&U4;\S=U\Z''X6_;MV>F5[*PUY69(
M)-0PUE\OCI^-RMKI439RIRXE/OUEH_V7_P 1WXGU;*AE577>HBWZ.:LDD;OW
M*JJAL#[#3AC=<MCV-&O"ZY;(W^@U%#!K+01L9NQ*25Z<2[\^%>?,]<GD_0W_
M 'UT/H4O^E3U@>1Y<DVV1RY23*R?N  YD        :/*\4LN5T/@E^M\-7&G
MN'.W1\:][7)S3Y%(!1:!8A!6)-.MPJH4=OX/-.O!YN6R[?*6V#*96?27&5C6
MRWTEKH8J.VTT-+21)PLBB:C6M3R(AD@&*@
M                                                   0?.OA3B_I
M'WFDX(/G7PIQ;TC[S0)P@"    *BSW+<@NF428MA<42U,*<53/(GN$5$\OE7
ML["/55BU,QJ);E3UD%?T?C/AV3FGU&5>KC4:>:IW*\5E%-/:+DU$69C55&*G
MF1>]?F-O?=:K ^URLM#9JZM>FS(6,=NJ_,%3G3[)693C=-<$;P2JB)*S;W+M
MD54^LDA =%;-56G$&.KV+'453^G=&J;<.[4Y?43X(  "":RY6F*X=43,7^DU
M"+#"G]I47;Z]C"T+Q9U@Q1M36(JW"N<Z:5RKOUKR^K8U&KV)WK*\IL4=/3J^
MTTTZ23*KDVVW;OR^12VZ6)(*>*)J(B,:C41/(@5'JC*+/5WF?'DJT;<W,<W@
MX5W3DO-%VV[%*;U/TDKH;5676&\5%4E.KJA89G)P[(BN5.2)W$QU+T_N-7D-
M-D^*SI%=*=/&CVV23FO;NG[2D=O-/J?E-%ZTUE)#0TTJ<$LS';JK5Y+^MW*H
M%@Z,7],@P:CJ.A9"Z-5B<UB<MT54_D3DC>GN+Q8CC5/:X7\:LW<]^VVZJJK_
M #)($?,GO;O,I0^EV&6;(Z[(:FZTW2R,JU:U>)4Y;)W%\R>]N\Q5.A7OF2^F
MK]B!8DUOTVQNWUD55342MFB=Q-=QKR4F( 1Y/]4/3QU6K[X9DW8ZWQ_)UD+I
MF7>CIUIJ*_5\--MLD:2.\5/)SY?(33U0]1'2ZP++,JHSUOB3?;?]H@OKY0_\
M1WT5/7\?#5GJDV<;-6.K+'^OGVU]QHF4'@L[5DGJ%J6N<]Z[N<O-22:F5D^4
M:C5E1=*.6@F=31_HE5-V[(B(O6IH*VX4]9/0,@<KG)4L54X53EN3W7JHBH]9
M*Z29>%BT<*;HG;PH3.8?KXR?3'*8?J<GU\(W%<,E@I?!(;]4)3;<**O-Z)Y%
MZ_K-0ELBAN=I21SIY)ZV-)9)%W5V[N9DI?*'_B.^BIU,KX*R]V5E.Y7.;6Q*
MOBJGZR&S+5HUXY77)UGGAIQPMPYU;L_J?[ZE=62T5]I(89YG2-9T2KLBJJHG
MS'S[0>3?&.D_@J>E$Z@>9/)V2<E:IV3DM4EI?H_=<4S:"^W&[4]6V.%\7 R-
M6JO$FQ=H!JSSN=[D  ,0
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MCVO9::%KFKNBI W=%^8VH':G  $4
M
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MJT*]\R3TU?L0M63WMWF4JK0KWS)?35^Q JUP $
M
M                         (/G/PJQ;TC[S2<$'SGX4XMZ1]YH$X
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MQ@@
M                                                 !!\Z^%.+^D?
M>:3@@^=?"K%O2/O-!$X             4_K#BMZRO)[%#30H^TT\Z23*JKLO
M-O9MY%+;I8D@IHHFHB(QJ-V3R(=H J#76VYE>%IJ+%^5"]GZ?9RHKEW7ER3S
M$5PZAS_%+>VFM>/T3';>/(O-SU[U7@W/1("M!A-5>:NQQRY' R"O5R\3&=6V
M_+L3L-^ $<2>]N\Q5.A/OF2>FK]B%K2>]N\Q5.A/N\D]-7[$"K7  0
M
M                                         @^<_"G%O2/O-)P0?.OA
M5BWI'WF@3@                    !\R>]N\RGG'!<XK,9NE_IJ6P5MR:^J
M5ZR0HJHG).7)%/1[_>W>8JG0I/TN2>FK]B!8G6&7V;(+2E94V^>@?Q;=%,BH
MO4B[]2=YO0 @
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MAE;2O<C65,#G+U(DB*IWA
M
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MMMMN=/5^O=?*L+T=P.E>J+Y]W%F !
M
M                "#YU\*<6](^\TG!!\Z^%.+<__P"1]YH$X
M  -DWWV0  !LF^^R;@   !\R>]N\RE5:%>^9+Z:OV(6M)[V[S'G3 <Z7%KG?
MZ;UFN%?QU2NXZ:-SD3DG+DBA8]& T>(7_P!D5J\-\"J:+QN'HYVJUW4B]2HG
M>;P(
M                                                   0?.OA5BWI
M'WFDX(/G/PJQ;TC[S0)P                     ^9/>W>8JC0R-CY,D5[&
MN7PU>M-^Q"V)/>W>8JG0KWS)?35^Q +6:UK$V:U&IW(FQR
M
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MNBG(
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MLC:C45>L[P
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M[UWY=Y/
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M4<U=T5-T4#D   ==3/'30/FG>C(V)NYR]A\4-9!7TS9Z25LL+NIS>I0.\
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M.0
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MGMB?HW2)MQKS[_[Q=]TLEMNJM6XT4%2K>I9&(NQDT5'3T,"0T<+(8DZFL39
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MDCA9Q_WN%-_K,VVX_:;9,LM!;Z>"5?UF,1%-H$
M
M    'RKVH[A5S>+NWYGT       #ACVOWX'-=MU[+OL!R
M
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MNJ_8!=(,>VR]/;Z>5>M\;5^HR
M
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MX 0
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MG6J(.OJ  AN+V_)J?+K]47>NCFM$LF]%"U.<;>)W)?%3L5O:O43)51$W54V
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MO]5)@NL-#4-D?ZVY O12-5RJC9$7K3?JYO3J+H145$5.HX&
M                                      !I\PJZ^AQJX5%G@2>X,A<L
M$:]2OV7;M3M-P0G62ZUUGP2MJ;8]T<NZ,?*U=EC8N_$Y%[-NO<LG?AEAC<\I
MC/RJNDQ;*J['JF]WS+I:"]NXI(Z9)V(QFRKR5-E[$[R2:79Q=<CTDO%=<)N*
MYT;)F),U.OA8BHO7U[J5S8J+!I,.]><FRRKN5WDC<Y:9U<O$CMU1$X%<JKR,
MS0FYT<6FN5VAT\;:]&3R= CT<O#T:<^2^1?F(GK>=<8':=0-0\4?7NR=U/!"
MKFP</)97)VKOV<D[NL^L#J\_U!AJ+&M]CI*>UN='/4L14DD<CE1$55Y+R7?D
MG8A8WJ8O]U])M_Q'?::'U,W]:YIZ>[[0=?6CUWR.T9Y=\/R&N=714[%?#.Y.
M?).?/Y/K,C2[+;O4W74AU=4253+94/\ !HW<^%$=-R3Z*'38'._[1EW16/1J
M0/5'\2\*\G<D3JW3^:&JT>K)J"]:K5=+2)630U;Y&T^^W2*CIUX>I>OS%OPR
MSQF-Y/X:G#*BYZB3W2LN69RVVLCF<V&D8](T9LNR;HY%WZN_M+"TVN>6T]HO
M]OR=4G=10R/IZ]JHO2;-Y=2KV[E?V*W:>Y_%57"ZR1XS?8WNZ:&*J2/A5%5-
M]MF[]2*;+1ZXW-]WR^R4MSFO-BBIY>@JW*KD5ZM7DU=U3NY)WD8_'$T]3C?K
MED&&U55=ZI]3.VJ>Q'OZ]MUY&-C6172IU\R2SS5;WVZGI&OCA7J:NT//_,OS
MD2]3]FEAQ+'+K:L@N=-1UD%2Y[F22(U5WWY)OMS3;94[SC2:^09'K]DUTHEW
MI9Z+>-=^:HU86[^3FU1PN-ELOX9NDLCHLZU"DC79[&N<U>Y>%I'L*3/L^K+E
M04]_EI;732-62953C<KT5>%/(FR]G:;[2KX:ZB_W'_Z6F!H)J!8K)5WNUWBM
MIZ-9)8W1S2R(UKE1JHY-U[EV,I_;6[&8_HY6_?9_MWV^[Y9I;G=NM627-;I9
M;FO1Q2OYJQ=TY\O\78<ZEY+F#=9H[#BM>UBSTB*R&3?AWWDXG)V;HC>U3JU3
MOU+J)GV.6/%9O#8Z:5):J>G=Q-:WSIV>,GRFUJ$W]571=Z6]VWS3&+3.1TY>
MN7X7B=KCK[Z^HN%16M5\K4_5XF[M^TRM5,UR)TMAQK$Y$CN-<R))IUZVJYFZ
M<]_+O\AN/5$?U?9/2'?R(1J#4RX?G^*Y-5Q/=:)HH$F>C=T:K6-VY]^R.,N3
MG:VS#&83++\]_P").?\ -?6;X3G.)XG67&FR.2XQHQ$J:>5=T<BKMNG5U;HO
MR&QPG*FX+H35UT2<<\4TD4".Y[NV:C=_EV-_JQJMC"8-71VRYTE?5U#$9'##
M(UZ^Z3=51-^S=2O76":\>IUJ$MT,DBTM2^1(T1=^!O"J\NOJ0GX8R3].W^9_
MMN+/9;_D^/I?J_-_!+K4M66&G94,1D?7LBHN_9MVDXT%S:X9-::BBO[V272D
M>[](SFCX^2(N^Z]JJGR$ P.V:85^(4U3<KAX)6PQ;5$,M8C'-<FZ+XJ^8EOJ
M?$M54^ZUUAL,MOH5<L3*E\ROZ?;A7DG"FWSKU$83GY7.4)K.JU^L> VZ7G3I
M4H]S5[?&;^)?90_JA(G6C,<*R=>4%)6HR1>I$WY\U_PJ$7K*O! ]6];6KM\Q
MYBT=3PZ;)+S4HCJZJN+TD<O6GZWR<WK\QZ=A>V:%KVJBM<FYYJO$$FEVHEQB
MKVN;C=[F=4P5/"O#$]555;RZMM]O-PJ:M^&6>K+''[:=TMQ^%@'R]C9(W,>U
M',<BM5%ZE0^*:HAJH&3TTK)87HBM>Q=T<GD4C>;9A1X[1NC8]L]UDV;!2L\9
MSG+U*J)U)]IXF&O+/+UQGRXXVWJ8)'P6S*K4CE6FH;HY(=^>R*FRI_E1?E,.
MN8ZU^J-;40M_VR-D3U\BHSR^3N^;MF>A>(U6)84C+HBMN=?,M94M5=U8KD1$
M:OE1$3?RJI#;&K\A]41=YH_'I+;"U%<FZHC_ !.7=V+\WG/HK]O2T\D_J_:K
MV(AJMEGL.PNONC$1U0QG#"U45=W*NR?6J$O*M]4;9*N\:=5:T$;Y9J96R]&U
M-U5$<U5^I%,1#\7PG-,OLC<@NF455)55C.GIX8G(C6(O-J+R7EMMVFVTJSF\
MSOO6,Y+.V6\VV-TB2M1=U;XNVZ]6_C=GD-MIOJ=C"8';FUUUHZ.IHZ5D4T$L
MK6O:YC=E395W[%(3IDL^3YMD^7Q0O9;9:5U/$Y6JB.5%;U+V]I8RQDLO?_?E
MH=+*_4C/:6>.DO706^FJMY*A_NG=2\'7U)LG9VGJ&V0RT]NI8:F3I)XXFM>_
M]IR)LJ_.4OZD?X W/_YG)_HC+Q(Q5]K=FTN#X>M91HU:Z>5L$'$BJB.7==^7
MD12!V_3O-ZVP+=ZS*ZJ.\N9TS(FN3@1=M^%>7G[3:>JFLM9<<+HZR@A?.M%5
MLED8U-]F[.3?YW(2&W:L8G+B/K@Z\4<<C(-UIW3-23BV]SP[[[@1G#LTKLCT
M\RVV7QR.N]III:>=Z)[M41[=^O\ LF/H_77.WZ#-J+%3I47!LDJ1,7M7I7>5
M#2Z86ZIJ,;U&R26%\5+=632T_$BIQ-_2KO\ 6A@6*^W3'_4WT]79D>DJU3V/
M>Q51S&+*_=45.KJ3YP1LI<:R9F)U.07#+YZ6^-:L[:5U0Q6M3KX53;FO6G62
M?$<VNE[T/NEUJ9MKI24L[.F9VN8UR([S^+N5K%08*S Y+I=\IJKO?)J=52!:
MY5=QJGN>#B5>M38Z6W.C31/*K4DK6UT5/4/= KD5R-5LBHOFV[0O+>Y/K ;-
MGVHN,1W"?)I*.F:KDA1ONGJCE3=>OR]Q+=%LAR&\4N28O>ZWCNE JLCJNUJ*
MFR?6BK\IO_4W<M++9_>E_P#NO(%IM>J;'LZU'NM:[A@IEXW<^M>)41/G5 C'
MU#MF5870QU5PSJ=ZS2<$<$;55[_(B;>5/G)?CM1FUKTGEKW)+67NH=O!',]K
MG1INO-539.I/K*]Q3(+1FNH%3D><7>CHZ2@GWH:"HE:FVSNM4<J;;<+>PG^M
MN?<&G?AF%5T<\2U+(9IJ.3=8V<+E796]74A?X9^UD]+/S_W1JKQC);=B$E]J
MLSFCOT;.F6G=4,X.S=NVV_?VDKH<UN5VT)JKT^=8KC%2/:^:-.?$V-=W)SZ]
MTW*VN-KP"CPB>NJLHJKU>I(=V1K7*YRN7E[CB7O53-PB\4-5ZGB_T$$[%JZ:
M"998>).)B*Q^VZ?(I&$=NGEGU U(QR"XUF2/HJ#QFP\'NGJCE157K[44D^EN
M3Y%8<W=AF85C*R27B=2S=;U1K57GY/%7;Y3K]3_J/CM%I_16>[W*CM];1+(C
MVS3-:CMY'.147?GR5.HUMAK&Y[ZH&FO=F8LEJM<#HG5#>;7*J2]O5^N@7Z[+
M$AP?)+M6ZBZA4536R24M"]R4\:]4>SI>KZ*?,0?!X<[U#J;M3MR*2DME-4.3
MC3W2JB\D\W->SL)!IU_O4U0_YC_]4QM/4R_[#?\ TQ_^I0C"TKO>1XYJ)58;
MDUP6X1=&LT,R\U1$1?R*8=SRFZZ@:@76QT%Z;9K+:Y5AED1Z,?*O$K>2KO\
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M5UN[V-7FC45G/S%PVN%*.AI*3MCB1OS;(>&Y68
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M=;TH:&DB@I43;HV)LAG #5X_8+7CU(^ELM&RD@>]9',8JJBN79%7FJ]R&T
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M&'W&YZH560W](UI*1."@CW5=N:[JO+NV[RS.%.+BVY[;;G((H
M
M
2                    #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g12080g93j60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g93j60.jpg
M_]C_X  02D9)1@ ! 0$ X@#B  #_[1I84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"@H*"@H*"@H*"@H*"C_P  1" .7!IP# 2(  A$! Q$!_\0 '  !  $% 0$
M              0! P4&!P((_\0 6A   0,# 0,* P0&!P,)!@,)  $" P0%
M$082(3$'$Q0505%35)&2(E)A,G&!H2-"HK'!T0@6,V)RLN$D-#87-T-$<W2"
MPO E)G63TO$U56-DPR>4L^)%@Z3_Q  : 0$  P$! 0               0(#
M! 4&_\0 -1$!  (" 0,#!  $!@$% 0$   $" Q$A!!(Q!1-!(C)1810S<9$5
M(T*!H?"Q!B3!T>$E4O_:  P# 0 "$0,1 #\ ^J0                $[0
M
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M^I6(VM,Z;%E <LT%RBW'4]^9 ZW+'0.:J\[GMP=1:F\6K-2MHL]  A(
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M05T+EPQO:W=_')T,I,3"T3L !"0
M
M          !.T!.T
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M_1U$"*J?>B_Q/H5FYJ?<99OAKB^50 8M0
M
M                 !.T
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M&VZ22QU\*Q-1682/\,G4 1%YB-$TB9VT;DYT*NCZ6MB;6NJ%J5SE8T;C=^9
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MA=,::MNG*>2&UP)$Q[U<N_*\$_D9LF]^Z44KVP  HN
M
M                          )V@)Q4        #8         IE>XJ
M
M
M
M
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MIBE<G%&N121*
M
M
M
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MQR+C[P)0
M
M
M
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M $:O3:3\ ,V"F2H
M
M
M
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MS7QN3+7-7**A<
M
M
M
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M  #*  !D  ,H     90  ,H,H  R@R  &4    !D  ,C(  9  9090 !E
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M &/YNX>)'Z#F[AXD?H9  0.;N'B1^A3F[AXD9D ! YNX>)'Z#F[AXD?H3P!
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M !%IF522+S[V*WZ$H                    "=H"=H     4V4&A4# P1H
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MJ
M
M
M                              3M 3BH
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M!Q33G*;6T34ANT;JMJ;MO=E#I=AU=:;TB)35"-DQE6/397\P-@ 3?P
M
M
M
M   "'>+G2V>VSUUPEYJFA3:>["KC\$WJ!,!RFU\KC;IJ"DH*6UR,IZB16-EE
M7"KCM3&XVK16M*;4M9<*)()*>KHW8>UW!R95,IZ?F6FDPB+1+;  52
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MAU%. 3<8NTW:&OA:Z-WQ8WM7L,DB_7<>I6\7C<2UB8GF'KM !>$@
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MI$>SM9[N\V,
M
M
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M(!<!;Y^+Q6>Y!S\7BL]R 7 6^?B\5GN0<]%XK/<@%P'EDC'KACVN7Z+D]
M -3Y3J6[UNEY*>PP-J*E\C4?&[8PK,+G[6[CCZFV&#UKJ"/36GZBXR,YQS,-
M8SYG+V?O)KY1/AQZST/*K9[?'0VV)\5/&B(UBK3OQ^+LKV&[<G<FOWWV7^M_
M_P"')"[9^&!/TFTW'V-_#:^AIEOK^5&^TB7.AFYN!?B:U&1L14X_"CDRJ>IN
MO)7K&XWJIK;1J"-&7.D1%VMC85Z9PN4[^'8G$VO''PSK/+HH ,&H
MG:  !YD;M,5N<9/0 YK7<C]@JZR:IEEJTDE<KG8?NRI$U-R;RQZ/99-./D6/
MGED=MN3?G9[_ +CJN$&"\9+0K-(E\[IH/6=IM$S(JCFZ-C5>]C'LX8^+M[C
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M'+LKW9^IL>BM06:^VQ'6%[$BBPUT.-ES/O3CV<36;5U]$*1$_,MA !BT
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M&MN-*^->U[$W&X6W5MFN.$IZZ':7@UST10,\#S%(V1B.8YKD7M:N3T
M
M
M                                #GW+GSW]19.8153GV;>.QN'?Z'02
M#>*2BN-&^@N3620U";*QN7&T6K.IVBT;C36=%2::=HFGIJ6HHG42P-6H8Z1/
MM*U-K;3.Y=V_.#3>3)M%'RIWMFGU8^S\P[9=$N69VVXPO!4XX(&H>2NS6BH:
M^?4D=!3/7]$VJ<FTN/KN1?0Z1R<:<LMALZOL4Z53:G"R5*/1W.8SC&.S>I?<
M1$S^5(B?#;0 9-        #O 3BH
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MJV,>OZKUQ@V&&:.9NU$]KV]Z*!<
M
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MB>JA@:BRRM:B]JJ>X96RHBL<CD7M0:G\(W"X  D
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MH&G-2.I<PURN=&GZR]AO=+/'-"V2.1'M=O14[2V#J:9X^F44O%XVO 9!TK@
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M;@D;(SO:I=                       &4
M
M                               "BM1>*(OWH4E56Q/5J9<C55/O.)/U
MWK]KE3J5F[_]+_4M6LV\*VM%?+MZHBIA414[E*-V4^%N$QV(<037O*!VV6/[
M^:_U,GR56J_5.L;AJ+4%(M.Z:G6-%5NRCU<Y%W)OW)L_F6G',1N41DB>(==
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MFU/DW>XKTRI\F[W 3P0.F5/DW>XITVI\F[W 9 &/Z;4^3=[BO3*GR;O<!/!
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M(F)&(Y..%/36HW<B80UG-QIG&+4[>D[< ?N!BU!@
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MZ6AS7DI_XFUHG;TU/W'2D7*90
M
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M@ *+"=H"=H
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M3_+(=(.:ZI5%Y8=*XW_H)/\ +(=)0O,I5 !(
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M_P )F8*ZEG3,51$]/HY )(*(Y%3**BI]"H
M
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M8=/6>CF=IM8Y$D=B25';3LHO!<[T^XVDRM,3/"U8U  "JQW@)V@
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M7I^C<UR=Z*<]HFOEGJ8\PN%,CB$SVE4*@9   $@
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MYL%7A&5S6*OSI@#9@1:>Y450W,-5"]/H]"2U[7)\+D7[E J
M           ,@QFI'W..SU#K''#+7HGZ-DJX:J@9/(0X]1ZKU]57BKM,-!;.
MG4S4=(BOPU$7AOP=.TZZY26FG?>HXHZ]47G&QNRU-ZX_+ &3
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M4$NS(W&8G[G+G_[%YQVB-Z5B\3PVH %%@
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M>A/3.,G/^F4Q,>7H%$7=Q*(J9 ]
M     !C[O=J&RTG2;G5,IZ?.-M^>/X :-R4_\3:T_P"_)_E.DG&>3S55DMM_
MU7/77."*.HJ4DB<N</;CBFX[!25$57 R>GD22%Z9:Y."@7@          4\/
MBC>GQL:[[TR>P!C*NPVJKSTB@IWYX_HT3)@JWD[L%0CD91LAS\F4_B;@ .85
M_)/2N:Y*"L=$J\$?E4_>IKU7R4WB-?\ 9I::;'!57'\#N  ^>*K2FI[:BJD=
M1N[8)\)Z90M0:@U-:WHBU5:U$W[#FY_/>?1A8EI*>5%22")R+WL10.)T?*=>
MH51LZ,D1.**B(J_D9ZAY6HE5$K+>]G>YJHIN];I*RUB+SM!%E>UJ84U^MY+K
M+,Y70NFB5>Q'*J 2*#E+L-5A'2RQ.[G1J9VCU+:*Q<05T;E^N4_><]J^21R9
M?3W!7.[$<TU^MY.+]1N<L$:3HOAN1%_>!W:*>*5$6.1CL_*N2Z?.;:'55J16
MMAN$2)OW.VD_)232ZWU';]SZAZX[)HU_D!]!@XQ1\K-?&B=*HXI4[5:N#.47
M*O0N_P!\I98^"?#O Z6#5Z+75AJ=W3F,7^\BI_ S,%WM]2F8*VG<G_:(@$\'
MECVN^RY')WHIZWY           #G.F?^=W4O_91_N.C'.-,_\[NIO^RC_<='
M
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M9E*=7O\ ,R@9 $#J]_FI2G5[_-2@9 $#J]_F91U>_P U*!/! ZO?YF4=7O\
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MPZ?A.X8-)RVF-,XQQ$[.T &;0
M                        H[Z%2F-Z@>$^QNXD&OH8*R![:F-'IC.'(A/5
M%3>AY>JK$_<G!28F:\PK,1:.VT.9<DE%!6Q7MU1&Q[H*^6.-5;G9:CG)A#<:
M[2UJK4=ST"(Y?UF?"OY&L<C&.8U%E=_6<W^=QT5R)C>7][)O?=+/^'Q3&NV)
M<XN?)XB*JVR9^U\LKLICT-=J]/7FTN<Y8W-Q^O"_^2G9FMP[+55?HI[<QKD^
M-J?BATT]0RUC4\PXK^EX9YI],N+4.J;S0/8WGY)&M7>R9/XKO-GMNOF.=_[0
M@2)=WQ,RJ?O4V^X6&@N#52>%F_Y41#5+KR>T[U>MNDD8[Y7*BH=$9^ES?S*Z
MERVZ?KNFYQ6[OTQ-VN5-<N5+3-31R\Y"R*1KG<,+LOW?F=121-GXL;^!QNNT
MG=K:[;YG;V<[+XU3*?GDBT-YNEIE=F>=%^29%5!/I]+\X;;*>K7Q<=137_?P
M[BUJ(Q415X'AK$SE'.4YW:^4-R/8RNI6HU<9D1W\.)ME!JFTUN.:K(D>N[9=
ME%_,X<G2YL?F.'I8NMP9O%N?Q/$LXW>JGHL-F:OQ-<CFNX*F\NM=M<%0P=6X
ME7?]"J<"B9*H$A1V]J]I4+P4")44-/4L5LT3%1?H8"NTE32*KJ97QK]^XVE"
MBYP<^7IL>2/KA6:Q;X<UKK'<;<Y71HJM[%8[>*2_7&C=B1W.)\K^PZ1A7?::
MBD*LM-+5-=SL+<KW(B'#?T^T?5@M,,_:F.:RPUOU732(UE3\#\=RX,_25<%2
MW,,C7I]#4KAI!VTYU(]>*X:JH8*6DN5KD5-B5B)^LU<I^16.KZC!QEKN/RB,
MEZ_=#J>,[QO[3GMNU15TSFLJ$21J)A57B;+0:EHJAJ;<K8W=RY.K#UN')]LK
MUR19F)H(YV*V6-KV=SD14,!=-%:?N:+TNVP.5=VTUNPO[.#8(:B.5-ICT<B]
MJ%U.&[!W4R3'-9;1:8\.4W?D:LT^TMOEJJ5_%&\YEOYHJFC7;D?O]&LDE$^*
MI8W>FS)LN7UP?1R\2JINX9.FG69J?.X:1FM'E\H.75FG)<<Y<H-C<N-IS?XH
M9NU\K.I*)42J=#5MSPDBPN/_  X/HZ6%DJ8DAC>G<YJ*:W<M%6"Y[:5-!$CG
M)C:9\*IZ&W\9CM_-HO&:D^8:79N6BW2(C;G32PN5=[F)EN/55-XM&M+#=&HM
M+<8$5>QZ["_F:->.1:@F176RLF@?C<C\*W]V32;OR5:BMSE=2QMJHT_7B<C5
M],Y)]KILGVVU)VX[>'TC%-%(S,3VO:O:BY0N9[CY/Z3JK3CG(]]RI43MD8Y6
M^N,&QV?E@OE&UL=;#!5)VNDRCOR5/W%;=!?S28E6<'XE]&H5WG*;+RRVFI<C
M+A"^C7.]RY<GHB&ZVS5UBN:?['=*9Z_*K]E?13EOAR4^Z&<X[1\-@Q]$*EE'
ML>BN:_=WE[*(90H ("0        !13F/*SIUW0+A?H;K<89HHVHV&-^RSBB=
MP'3\IW@YQH/1J0LM-ZDN]QEE6-)70R2YC57-QW?4Z.
M                               /*M1V45$5/J>@!!J;1;ZG//T5/)GY
MHT4PU?H;3]6B[=O8U5[6*K?W&S@#G59R56J1%6FGJHG=B;2*W\TR:5J_0558
M*5:J*3I$#?M;*95OY'>CQ+&R6-[)6(]CDPK53**!\J,RJILHKE5<(F_._=V&
M?@HM1T$".IVU\4*\$AVNTW[3-OI?^534$"P1K#&R-[&*U,-7'8AU!&M1,(B(
MG=@#YWCU#JBD3"U%:B-^=F<>J$NGY1M20JB25;943L?$U/W(AWA]+ _[<,;O
MO:A#J;#:ZA/TM#3KCN8B <FIN5>Z,5.>I:61._95%_S&6I^5J/C54+\?_I_Z
MJ;C4:)L,ZKMV^-/JBJG\3$5?)C9)HU:Q9HOJU?Y@6J;E4LTB)SL51%_B;G]Q
ME*;E!T[.J(VM5KE['1N3^!KE1R2TBNS3U\J)C]=$7]R&*J.26K:BK!7Q/[D5
MBI_$#IM+J2TU*KS=PI]V/M/1O[R>RMI7XV*F%V?E>BG#JKDUU!"J<Q$R;O5)
M6MQZN($NE=44O"DK4QX:Y_<!]$(J*F44'SC&_5-O57*VZ1KP^-CU3]Q(CUEJ
M6A<C'ULR8XH^/^: ?0P.%4O*=>XG(LC8IDQ^LG'T,K3<K=2C,5%OB5?[CE_F
M!V '-*7E9H7X2>BD8OT=_H96DY2[!*F)YW0+]6.=^Y -V!KL&L[#.J;%R@1%
M3BYV/WF2CO5LF9M0W"D=]TK5_B!D 6XYHY&HZ-[7-7M12XG#CD "GW_D5
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M&TK4?LM1=V-M.!VHQR5U+6N]<@ *+"=H"=H
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MW9\#?\R&VY3O-2Y5L+H*ZHF_X&_YD&X_(RNC/^%;5GRS/W&:,)HQ4_JK:?\
MNS/W&;)_H
M     .<:8_YW-39WKS4>_P# Z.<XTS_SNZF_[*/]QT<         ,  >'PQR
M?;C8[[TR19K5039YVBIW9XYC0F@#!3Z1L4S<26V%?NRG[E,9/R<Z=D5592R1
M*OR2+_')N  YU5<E%H>BK35-8QW]Y[53_*8FKY)'<:6O;]S_ /['6RF .)3<
MEEW;E(I(G]WQ(ACIM!ZDHD<K(U7'AR97]YW]$& /G-]#JB@<GP7-NSVHKU0N
M)J+5%(J*M35L1.QS,_O0^AW(BIO1%+2TT#D5'PQNSWM0#@\/*+J*'".G:_"_
MKP_R,I1\J]U:_%32T;VHGZK515_:.L5%BME1GGJ&!V4Q]G!C:O1-AJ&XZOCC
M7YF<0-.I>5MBXZ50+Q_Z/_[F5I^5.SR.1)8YXT_PJI?J>3&QS(NRM3&O]QS?
MY&*J>26D<U4IZ^5B]FVU%_<@&PTO*%I^H7=5.9OQ\;%3]YEZ?4=HJ$3FKC2J
MJ]BRM1?WG,:CDEJXEQ!7,E3''9QO]3%U')K?X%58HVO1.UKVY_>!V^.NI9?[
M*IA>O]UZ*2$<B\%13YXJ-):GI79;1USE_P#T\K^XM)_6FA54YJXPJG>QW\4
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M/-(C(U:J+E%SE5^AT@ SM:;3N5XB(X@ !5(G: G:     8   HG$"H
M
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M+4:Y,ICO53C_ *L-?EV= 6\HJGI,=Z@>@4*H
M                      #Q(]L;5<]R-;VJX]F.OUII[W;)[?6J]*>5$1RQ
MNP[<N>(&B:;JH&\K&I)'31HQT4:(JKN7<=)B>R1J.C<CF]Z*: G)+IS*KM5R
M*O;SK<K^R;C8K7!9;9#04JO6"+*-61V57*JO\0,B
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M';*_;14XX7AP4FV&:_[$9(=" 1<@R:
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M55 1<C(CD                                         J?4 !A
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M0"]TF'Q&^HZ3#XC?4L]74WAH.KZ;PT O=)A\1OJ.DP^(WU+/5U-X:#JZF\-
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M +W28?$;ZCI,/B-]2SU?3>&@ZNIO#0"]TF'Q&^HZ3#XC?4L]7TWAH.KJ;PT
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M++=XJ:1(J1S9G;*+\/V]QVV"LIYW[$,K7NQG"'$?^1>WHJM_K5'E-RIT9/\
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M?::JJAT\ULB61RY5<<38Z.C@HH6Q4T:1Q-3#6IP0O@F;3/F2*Q'@ !5(
M
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MRH<>3#DQSJ\,K8[59/>#RBI@;2?4SA1Z!1%RI4D
M
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M%O/C36O@ !5(G%0$[0
M
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M<!Y1<J55<!$*@
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M\KQKX  0D3M 3M  #(SN  HBY".1>\&U0,@
M
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M6QS5<LD"-V6HF..53O VP'.[+RFMNU33,@L-S2&=VRV949LI]5^+@=$3@
M
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MCVHKLHQ?BW)Z(3;%76ZSX17).]6=W !@V
M
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MV[4%%7-PQZM=VHY,&F+K,67B//[=E<E;1Q+-IP!XC>CFHK5145.*'L[(G:X
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M
M             \RL22)[%W(Y%0Y'-R(V=9/TEYK4<_@BHQ,_=N.N2OYN)[U_
M515.,\G=9=]6:]K[U)5OZMI%PD3W*C41V=E&MX9^%=ZEZ3,;F)TK;7RK6\CF
MG:)46MU%-3[7#GG1LSZFS<GO)Y:]-W+K6UW2:M1\"PIE6JQ456KE%;_A_,YO
M+17#E.UY<(^EJR@IGO;&_:PC6(Y=G"<,JG;CL-DY'9JZRZRO.EZRI6:&!BN8
MF55$5KL93NSM<#6W?,3NRD:WX=E !SM7*N6^W\TEJNU%+)#<N?2F8]BXW.1>
M)@$M6HN3ZNM-UK+P^L@J9$IYHGR.<B.<U5X+]W$ZCK[3G]9K!)2,?S=2QR20
M/SC#TX'-&:$UO=UA9?KDWF:-,T[7/:Y%5NYO#.5^KM_U-\=HUJ98WB=[B&%_
MJZW6&IM8U]74RLFHU>Z/9QQ9N3\D.M\E5PFN>AK=45+E=+A[%<O%4:]6I^2'
M,8M&:_M<=9/1/@=-=7.Z6QKH\MRJYRJ[M_\ =[%.P:)LJZ?TS16YRHKXFJK\
M;_B555?S499X\[3CW\PS8 ,&JB=IJG*+J"X:>L[*JUTKJJ59$:K$:J[C:^\\
M20LD;LR,:].YR90FLZGE$QN'%[/RFZFK+G1T\]E<R.65K'.YM4PBNPJ^AVAK
M$<B.<U,XX]Q;;14S7(Y*>%%3>BHQ"^F[B6O:)\1I%:S'E\U:D_YZ$7MZ7$F[
M_$A]'NE;# CY'HUB)E7.7")]YPN_:5O<W*HEQCM[W472HW<ZCFXPCD[,Y-RY
M8H-0U5IIZ73[)',D16S)&J(J[T[5_$UOJT5AE3Z9EJ7*9KZJO=0_3VF&/G1Z
M\W-)"F57.[=]-YN_)/HINE;?))48=75&RKU^7"</S4X]8M.:VL-2^>VVO9G=
MNYQZQN<GW94Z+R?UNO);^UNH:?8H,+E?@W+^"Y+7K$5^F44F9GEUL#O!RN@
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M(G!"H')H
M
M                     .!3'J5 %.*E0         "\%P>$VEXK^1[ 'E4P
MF],GC"JJ;.Y"Z +;E<WAGT*-;M)\2*701K0LM1^],[L[MQ39<N4=O3NP7P-#
M$UEBH:M5=+3M5R]N]%,55:,I9-\#W1KW953:P4R8ZY8U>-L_9IYTYG<=,UU*
MF8HUF;_<0PCX*BFE16OFIWM7.%S^Y3LYCZZU4=6JK/"Q78QG@IPST-L7/3WF
MK&_2TM#FE/J:^4"_!)'41]RL1%,Q0\HD351MQIGQO[^PFW/1W%]&]/HQ5-2N
M=FFA54J8%1$_65N[U-\?J%\7T]7CW'YC_L.*^'J</.*_]^71+?JBUU:HD=;$
MBKV.^']YF8JF"1/T<T3O\+D4X5+;<+F%RM=]YZBK+G0.VHGS,^NUG\CT\$]-
MU<?Y5]3^)9SZEEQ3K)3C].\93CE"N4[SD%!KJZQ?#4203-3O9@V*BY0:%[<5
M3)6N^B93\C2_0YJ^(W_1TX_5>GO.IG4_MON4[RB*B\%0Q5OO-OKHOT%3'N^=
MR(I.8K7?V<C7)]%R<EJS7BT:>A6];1NL[7]P52UOSO4]N?LIC"K]Q74K-6Y2
M]VA+SA45>9_\R'O25!2U^B;(RJ@CE3H<6$>F?U$/'*6U$T'>=W_0_P#F0E:#
MS_4ZR?\ <XO\J%N?)$]K4-2<D-GKWR3T*R4<[LJB,<JMS]RG![W:Y;1>:RWU
M6]\+U:J]Z(NY4Q^!]C+O^\YIRG\G]#=J>JNU.[H]?&S:5R.^%Z;LY3\#MZ7K
M)K;5YW#IQ9ICBTN T-3/;:V.KHI>:G8N6NSQ^\Z%;>66^4\365$5-5;*85<;
M*KZ&=Y*^3ZW5ULI+U<U=5<ZW*0N^PGY?Q-\KN3[3=>CMNVQ1HOAJK/W&N7JL
M%YU:NUK9:3Y:/0<ML#]GI] YF?M<VJK@C\G^N;-3ZBOU973]&BK:C;CVVNX;
M+$W[OHIGJSD:L4K7I32U,.>"MDSCU13G-OY.*RZW>\T5OJXDZOGYI.=3>Y,-
M7L3^\9]O27_2NL<^'T!1:IL58F::ZT;L]\B-_>92"I@F3,,T;T_NO13YJK^3
M#4]"USX(.?:W?M1RX]$SDQ<C-76?#O\ VI$U/EVE0?P=+?9>)1&&)\2^KLIW
M@^7:/E(U70/1KZYRX_4GB;P]#8:'EIN;%:VLI:>5B+O<UJHO^8I;H<L>-2K.
M"WA] Y3O&4[T.1T'+1:941*NDJ(U[VIE#9[7RBZ<KFIL5B,=W2(K3"V&]/,*
MSBO'PW493O,927FW5;46GKJ5_P!$E;G]Y/1S5X*BI]YEJ?F%)B8\KF4[T!XV
M4/6Y$XH$*@HBHOU*@ 4_ 9 J"GX%41                             M
M3S1P1.DF>V.-$RKW+A$(B7FV(F^Y47W\^S^8&0!XIYHIXFR02,DC=P<QR.1?
MQ0]@                #EO*SHZ>X,K;TRZSPLBA;_L[7*C'8W;_ %.A:AKI
MK;9*VMIH'5$T$:O;$UJJKU3LPAHU-RGZ5OE(^BNO.4W/)LOAF1=G'U<FY"^/
M<3N%;:URTO26CYV:+EOBW.=8EIW+T5578WHB\#HW(Q_P!09[W=F.TE4=RT?!
M8UMU/7VUENV49S/2D^SCA]K/88:?7^D-)T*4%K>DC(OL0TZJ]OOWI^9>9M:)
MC2M8BO+HP,)HV]2W^R,N$](^DYQZ[$;VJB[/8N_Z=IFS%HQ6I[W1Z?L\]PN#
MD2*--S<95R]B(<K=RX4FTY6V.39SA%YQ%_@;'RY,>NEZ65,K!#5L?,B)Q9A?
M]#66WRQ0ZJTW>$CYJU243J;:DCPUKDRF_/U:J9-\5:S',;97FV^);;R><HD.
MK[E/20VU]*L47.*]7HN?B1$3A]3?SE')C7TC^4#4M+9\+;'_ *=BIA4V\M1V
M%[LJXZN9WB(GB%Z^.0 %%A.T!.T
M
M
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M3O1R*>TD13/:KV"FT5R@ %,H5R  53PK\=B@>P>6.VDSA4/0  #8
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M$'K%/#7W#K%/#7U';)W0G @=8IX:^XGM7+47O(F)@B=@ (2
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MWM[E=B*H<L+U_P 2+C\\'?AZ?OPVO_9T4Q_1M]3MX HS[*;\_4J<3G
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M%0 9K@
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MG145:B(N-N-K_P"1]!4^M+1,JYD1BI\RX,A!?;7)C8JH=_\ >)]_J*_?7?\
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MUA8+W4<Q:+M2UDGRQR9_@; [/;E5[=KL&QXX  D $X@"A5 A5"$;4*'HH3
MIWE4"0(4 %4  %"H !"@*@4*CL  H5 %"J  "@ %4"         (!0J  "
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MD7HJ #)<
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MS#4QS)F-[7)WH7$>BG1$Q,;A=Z RB\#RCLD['H#.X\[2]Q&QZ!1%R5)  $;
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M:G9:2G1TQ9O>Q\3/$_MSGE03_P![]&[O^MK_ )7'2ME,YV4R<VY4/^+]&_\
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M0S.W+,]VV["[N*[\?0:PT)8-6NB?>Z))9(FJQLC'*QZ)G.,IV97]YM!4:-M
MDY(](245+2]6\W'3O61KF2*CG.W<5[>'::5R_P!%M7[1T4,#GQ1RJUV$5=VT
MU-YW,KG=N5?N[R)A,2Y^[DCT>ZN;7+:T25')(L37*V-53L1G#?@WR.-D3.:A
M:UD;?A:B)N1.[[CTWM1,X[4RNX](3$:)E0("A*%0   * 5*%0!0%0 !0J  "
M  "B "I0J 0=A0J  0 "B J!0J@ %$*]@ %"O   $  H5* "H  )P,]'_9M^
MY# F>C_LV_<AGD7HJ #)<
M                                    YUR<_P#&>L?^^?\ DC.BG.N3
MC_C/67_?/_)&!T4               !3SAN5S@]%,)D@>'11O3#F-7[T(-59
MJ*H1=NGBRO;LF2*%+4K;[H1J):M5:1IW;2P/<Q>S=N_>82KTG6QJJQ*U_P""
MY.BH>51.\Y;]!AO\:4G%67+'TMUMZ\)VIQRF212Z@N,"IMR/<B=CU.DHQCLY
M:B_>A$JK925+5YR")5[]A,F'^'WI_*O*GLS'VRUBEUELJC9X7+]45#,4FI*"
M9$57HQ5^92-4Z3HI%58UYM?HU#$U&D*AN5IY4>G<NXCNZW%YB+'^9#=(*VGF
M3,<K%3Z*7LHJ?"XYE):;G2/5>;>F/UF.$-XN=$[XI9<)V2*N"?\ $9KQEI,)
MC-K[H=.1,<5/630Z76$J.1)H]I.]%,Q2:KHI$^-7,_Q'1BZ[#?Q.EXRUGY;(
M@(-+<J:H;F*>-4SCC@FM<CDRBY^XZJ7BWB5U0 7         YSIS_GEU'_W1
MO_[LZ,<YTY_SRZC_ .YM_P#W8'1@"+<YY::AFFIH5GF8F6QHN-I>X#GO*C_Q
M?HW_ +VO^5QTPXGJ:KU3?+M9JW^JU1"MNF69&\ZF'Y14QQ^IU+2UQK[I;.D7
M2W.M]2KE;S+G97&>(&:- Y7O]TL'_P 5I_\ .AOS>';^)H/*]_NE@_\ BM/_
M )T WR#^PC_PI^X]GB#^PC_PI^X]@        4<Y&M5SEPB)E5..:QY5Y*F=
M;9HV-TM2YRMZ2[9PO^!%W+V\<=AV*5G.1/9G&TBIDY$_D-M[WJ[KFJ15_P#T
MF_S-,?;OZE+]VOI>-":*I:.ZQWS4=ZIZFX(_GFL295V7+VN<JIE=Z[CK5-74
MM2]64]3#*]$RJ,>BK@Y+_P A5OSE;U5JOUB;_,V/0G)I2:1O+[A3W">I>Z)T
M6P^-&IA51<[O\)-^V>8E%>Z.--_ !DT        $[0$[0  "KCB !3:^X(N2
M/ZBH&2C79X 5 !(     *.^RI@?]#/.^RI@>PTQJ6  :J*'I!V'D$<O2\%/*
M*5QVXW#'=@K.H\D5$ ["F28G?A,<^950!$RO:$[NWN0E "O#/=V?7O'9_'=C
M!&S2@*HF[?V[T7L*$P0H50<$7*]FXJOP[UX(O$C8H!CLSO\ _6X=BXW;DQD;
M1H!7=OX[N!147&[[\KW$[2 8W]N%X?4-RO=Q&P*#M3N*_COXJ  Q],#Z=O;]
MPV '[@   %"H3&.W[TX!4PJH 5<@ !WE2@3\2/* HJ%>P)]<9^A'/PF)T(F.
M(^XJ4QNW$H@ QCM&..Y<]R]Q*0!%3_3M"?7@1LT (G>.&210J.]-^[BO9]!C
M/#?_ #&P 1,I\*Y*[NQ<]F.W(V* )C=E?O4*F%WY3MPO<-F@#AO7@B_D,<<J
MB*FY1M&@!=R=^-ZX[BN,9SV<?I]1LTI@#?\ ACBA5/JJ?AVD;-* (B[._&U^
M0^[>A*0%$*@ !Q3=N7Z@"A7&[=OR4W\?U?SR!4H"H   $,]'_9M^Y# &?C_L
MV_<AGD7HJ #)<
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M7*/<+G=*&IIW54$LCE?"YC,J]BX3*?D=U!;W(UJ(5[/S( #)<        3M
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M*A  ^XH5* 5[ "@%4*%0 ,]'_9M^Y# F>C_LV_<AGD7HJ #)<
M
M
M  8RY6ME?51/GRL<>_9SN5?J:;RJ4[(**P-8W91+I B(W=^NAT1%WJAH7*[_
M +K8/_BM/_G0I%*]W=)IO,'^[QX^5"S64457$K)XVN:J85%0O0+B"/\ PI^X
MNIO0FU8M&I&.M-NZ!&^)CW+%M9:BKG"&03M*A!$1'$$1H !8
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M_P"S;]R&!,]'_9M^Y#/(O14 &2X
M
M                                        &@<KW^Z6#_XK3_YT-_-!
MY7O]TL'_ ,5I_P#.@&]P?V$?^%/W'L\0?V$?^%/W'L
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M+::YQ.5(US'(QRM>Q<YRB]YFD!&DM&=R:VRH;%%<;G>*^EC<BI3U$T>PN/\
M"QJ_F;M#$R"%L434;&Q$:QJ=B'OZ :-@3@ 2@*ICM*($!Y&KCZ?</O7(0  4
M 'K.$RF]0[&]$WHFY,E$ -"+E45>*<%3B55<KG*Y[#R5 9RO%<+Q5>(3=C&$
M7A^91"I -1$7*)L_=VKWE57<J;USO^A0 $XYR-VRN[\%X*"A(KVYXJF],]_\
M@N%1$7"E"I&A55RN55RKV<,!5SO7BO$\@:%4[0 2 0H5 H5 3@    H5["@%
M04*@4!4 4  %3/1_V;?N0P'89^/^S;]R&>1>BH ,EP
M
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MO<:XX4N #!HH 8&, "A7 P#9@#>,8 H$*X&-X-@'W !V 8& " 8  =HP,*
M&\     P  0    '8 @%"J#  !0     8   (#8 @P 0IWE1@&U"H  # P
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M#IE1Y-_JO\ATRH\F_P!5_D!/! Z94>3?Z_Z#IE1Y-_K_ * 3P0.F5'DW^O\
MH.F5'DW^O^@$\$#IE1Y-_JO\ATRH\F_U7^0$\$#IE1Y-_JO\ATRH\F_U_P!
M)X('3*CR;_7_ $'3*CR;_5?Y 3P0.F5'DW^J_P ATRH\F_U_T G@@=,J/)O]
M?]!TRH\F_P!5_D!/! Z94>3?ZK_(=,J/)O\ 5?Y 3P0.F5'DW^J_R'3*CR;_
M %7^0$\$#IE1Y-_JO\ATRH\F_P!?] )X('3*CR;_ %7^0Z94>3?Z_P"@$\$#
MIE1Y-_K_ *#IE1Y-_JO\@)X('3*CR;_7_0=,J/)O]?\ 0">"!TRHS_N;_5?Y
M#IE1Y-_JO\@)X('3*CR;_5?Y#IE1Y-_K_H!/! Z94>3?ZK_(=,J/)O\ 5?Y
M3P0$K*CR;_5?Y#IE1Y-_JO\ (">"!TRH\F_U7^0Z94>3?Z_Z 3P0.F5'DW^J
M_P ATRH\F_U7^0$\$#IE1Y-_JO\ (=,J/)O]5_D!/! Z94>3?Z_Z#IE1Y-_J
MO\@)X('3*CR;_7_0=,J/)O\ 5?Y 3P0.F5'DW^J_R"5E1Y-_JO\ (">"!TRH
M\F_U_P!!TRH\F_U_T GF@<KW^Z6#_P"*T_\ G0V]:VH14_V.3?\ ?_(YAKRY
MZAO4U-3PZ6K4CH:R.H;)\2\YLJBX^R!UR#^PC_PI^X]FG:8U+>KA,Z&OTU4T
M,<<:*DDCG8<O#&]J&Q=,J/)O]5_D!/! Z94>3?Z_Z#IE1C_='Y^]?Y 3P1::
MHEED5KZ=T:)VJI*                   "G>41NY=WX'KO! \HQ$X(5P50H
MO#<2.#7W25]GY54N45NE=0](CDYW&["*F?W'1.4S23M56#H\,FQ50_%']5W+
MC\C<\(G9Z%=RIW&GNSQKX4BFMOG:@I.46RV]]JI**1U,N6HY&9QV;E-RY'=!
M5EBJI[G>/AJ7HB,B1/L)OSO_ !_(ZMLIG>5:F_),YIG?[1&/4[>L  R:
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M=&B\-H]P[&&!F>C1>&T=&B\-H]P[&&,]'_9M^Y"UT:+PVEY$PF"MK=RU:Z
M46
M
M               %,%=X 'G8X?3@>@                         "=H
M
M
M
M
M                                        )V@)V@
M
M
M
M
M                           G:!W@ "B\%-.Y0==TFD*=G.L=45<C55D+
M=V<=ZDUB;<0B9TW('#(.6VJ9.BUEH>VG<J8<UV_'XHAU)FK+<_33KXR55HD:
MJ[TPN4[,%K8[55K>+-A!PR?EMJGU*NH[2]],U>*N1,I]>XZ7H'5]'J^V.JJ/
M::^-4;)&],*U<?F3;':L;DKDBTZAM  ,UP
M
M
M
M
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M1SFL:KGJC6HF555PB 5!YCD9*Q'QO:]J\%:N44]
M                  80            ")@  $3
M                    !8JZVEHT:M74P0([<U99$;G[L@7P8_KJU?\ YG0_
M_/9_,F03PU#-NGECE9\S'(Y/R&I%P         MU$\5-$LM1+'%&G%[W(U$_
M%0+@+-+54]6Q7TD\4[$7"NC>CD1>[<>*JOHZ1R-JZNG@5>"2R(W/JHY$D&/Z
M[M7_ .9T/_\ ,,_F38)HJB)LL$C)8W<'L<CD7\4&A[
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MB/:WX6ILHOX9_$V"FNUNJIG0TMPI)I695S(YFN<F..4130N0+_@>7A_O3O\
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MFHZUM54SR[4^-VPN$^'"HB__ '.F&.2(BTQ"])F8W( "BP
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MJJM5J(N=W>;CR&WRLO&EIH[A,^:6EEV&R/7*JQ4W97M[2MX[J]VTTXG4PZ*
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MG;G;8IY._:<W_*J$FR:<M-C:J6JACI\]J*JKZJJEYR5F9E6M+1Q++)P !@V
M                             ^:;W4PTG+543U,C8HF5JJZ1ZX1J;SZ6
M.>W[DEL=[N]7<:NKN;9ZEZO<V.2-&HJ]V6*OYFN*\4G<J7K-HU#+7+E"TS0T
MDDRW:FF5J92.)VVYR]V$RIQ6R15?*!RG.N#*=5I4G21ZIPCC;N;E>_<TZ13\
MB>FHI6O=4W25$_5?+'A?1B*;Y8+%;K#1MI;53-@B3N555?O52U;UI'T^436;
M>7/N7>_U]IL]+2V^1T+:AZ(][-RJB([X<_@AK]NTWII=)LNEWU/+-/-3H]T2
MU;51C\?91O'*+N5/O.NZGT];]2VQ]#=(W.B5=IKF+AS%[T4U*T\D6F[=4-E5
M]?5;.=EE1*U6HO?AK4*UO6*Q")K/=,M"_H_;'];;GS:Y9S7PK],K@RO+W;%H
MKA:[_2HY)&R(UZIPRW>BKZ(AOFD= 6O2UTJ:ZW5%:^6=%1S9GL5J955W8:B]
MO>:ERR:SLDEIN%A19);DQS<M5BM1G!<[2[N!IWQ;)NOA7LF*:LUFT5+M?\JE
MOJV1JZBI&Q.<Y=V-AFUO1>]Z*A]!(B(B(B81#DO]'JROI;#4W2=FRZJ>K(U5
M,98U>/KDZT9YK1-M5\+XHF(Y<(_I'QS)<;3(YKUI>:5..Y797*??A4-THM6Z
M6;R?L:MPHD8E(L:TRJG.*[9QCF_M<?H;I>K10WNADH[G3MG@>F%:JJB_@J&@
MNY%-,K.LB5%S1JKGFTE9LI]/L9_,F+U[8K/P=L[F8:K_ $>F5#[U=I8V/Z+A
MJ.7@W/Q83[]Z'=S'6*RT%BH6T=K@2&!%SC*JJKPRJK]QD2E[=UIF%J5[8T
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M ( MN,?97@OU-U/,<;(V(V-C6-3@C4PAZ*VG<[36-1H !"0
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MW&Z@%9F9G<IB(CP  A(
M                                                         !K]
M9HS3U9<GU]5:J>6L>J.=*[.55-W?CL &]#.PQ1PQ-CA8UD;4PC6IA$/8
M
M
M                                                        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g12080g94g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g94g01.jpg
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M*"@H*"@H*"C_P  1" +% V<# 2(  A$! Q$!_\0 '  !  (# 0$!
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M
M
M                                #Z03S4\B/IY9(GIQ.8Y6KZT)MA;2
M-<;=*R*ZN=74>>2N=](Q.^B\_D7UD%!54HPJJTU<LIU9TW>+.GK?64]PHXJJ
MCE;+!*W6:Y.<%3:'KZZFN4EIG?\ ]GJ$5\>:[FO1,U]:(OJ0'GL(H.C-Q.[0
MK*K#**]FD=+,^1ZYN>Y7*OC4\ 'ICSP
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M&Q%(ZDHJ>C=-DJHUL3H7*GB7),RO](6$TPW61/IGNDH:C/45_P YBIQM7O\
M'N4C2PN,YY#33]253!I0CEIIKT(D 2W1WA5N)*^9U4]S**F1%DU=RO5<\FHO
M-Q+F;%2I&G%SEL13"#J248[2) NVX,P-A^9*.LIZ-LR(BJQT+IG(GC7)<CQ7
M8+P[B.U]U6/@X'N1>#F@5=15[SF__P"*::P^.IRBTGQ-K0I:U&2;7 I4'UJZ
M>2DJIJ>=NK+"]8WIWE1<E/D;RUFD  9
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MPG(7(KK5'5P=R?,]Z'+5W7?Y:^1N<=&SY*_\;LT3\M;\B6-Q+_\ JDZWZ_\
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M+Y.$8U$?&_++6:O%Z>;T&G.Q3>5!.]SES5I-6L  3(
M
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M-YC.^)B"_3UK&*R')&1-=QHU._X^-?2:, W(14(J*V(U92<FY/B  2(@
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MVV7L?8 ''.H
M
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M(L<T2QJK<\LTSX\O\T)Y$DKV(J<6[7), "!(
M
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M^/A862\)JJK\E:J]Y6\:*=&BI!1LUQ,4YN5T^  !66
M
M T./>1UV\POM-\:''O(Z[>87VEE'[D>Z*ZNY+L<]0?2H!!]*@/4,\\CP=04/
MU*G\VWV'+YU!0_4J?S;?8<O&FR/N='%VV7L?8 ''.H
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M0 !07
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MU,6UJ<'.5K(MH8[P>O45.*=WZ?\ I8H .>=<
M
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M5>]XBV"C]'G+"W?>?[CB\#G87%1FK+@;-!MQU@ &H7
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MO$;X"51M6"@D[@ $"8( [[<V?N)?XQ/R .^W-G[B7^,64^/8A/AW)^ "LF
M       0?2_R9@_%-]UQ3Q<.E_DS!^*;[KBGCTV*OQ_=GB,??EOL@ #I'%
M       !-=$?*F3\,_WFD*)KHCY4R?AG^\TU<-^Q/L;V+/RZ?<N0CFD3D?</
M(SWVDC(YI$Y'W#R,]]IY6EOQ[H^@SW64@ #MF@            2+1YRPMWWG
M^XXO H_1YRPMWWG^XXO YF&[Z[&U0W0 #3+P
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M_+I]RY".:1.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:
M    !(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
M
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M-WUV-JAN@ &F7@
M                             T./>1UV\POM-\:''O(Z[>87VEE'[D>Z
M*ZNY+L<]0?2H!!]*@/4,\\CP=04/U*G\VWV'+YU!0_4J?S;?8<O&FR/N='%V
MV7L?8 ''.H   ?CFHYJM7B5,E*0FL6-(K!)@2GM;%MKIU1MUX1-7@%DU]Z=_
M?OY^;+G+P!.$\@A*&45KCZCNU=14>";#:I4M\L$+9KD]<HXHFNRU>+>[)B+Q
M\_$61%&V*)D;$R:Q$:GD0] PY75C*C9W!I[OARW7:[VRY5L;WU-N<KZ?)ZHU
MJKEO5.?B0W!#=(V.J3"%&R-$9/=:A/\ L].YVJG'EKO7F:B^OUJB";=HB325
MY&!IKNT%/A*:SL;P]SNJM@IJ9J9N<NLF;LN\F7KR(YI8IJBQZ';):)'YR<)3
MTLRHNY=5BJJ>3-J>HSL$_L[15S[_ (GQ39Z_$E0F^1:R-64S?ZD:9[N]GZN?
M/8Z8:-F)]'$M59I8ZUM/(VKC? Y'H]&*K79*G'DBN]1?'^,HQ]2F7\HN7H3Z
MCI(:6@AHXV-2"*-(FLRW:J)EEZBLM JK3TV)K8Q5X"CN3DC3O(N[_0A(+;I&
MP]+A2*[5%SIF/;"CI:=9$X5)$3>Q&<:KGQ>LU6@BWU,.&JZZUL:QS7:K=4M:
MJ?T.9?2NMZ,B"3C"643NG*-BR0 4EIKI[[:*>9\4]UH(I6+DYCZAC7-7O*BK
MN(325M+7:;FRT-3!4QI8U:KX9$>B+PW%FG.22NP/AJOK)JJLLU)-43.5\DCF
M[W*O.I$[/9K=9--*4UII(J2!UE6161IDBN6;+/\ )"Z&39VY%4LJZOS+/ !2
M6@        $'TO\ )F#\4WW7%/%PZ7^3,'XIONN*>/38J_']V>(Q]^6^R  .
MD<4         $UT1\J9/PS_>:0HFNB/E3)^&?[S35PW[$^QO8L_+I]RY".:1
M.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:            !(M'G+
M"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
M                                                       !H<>\
MCKMYA?:;XT./>1UV\POM+*/W(]T5U=R78YZ@^E0"#Z5 >H9YY'@Z@H?J5/YM
MOL.7SJ"A^I4_FV^PY>--D?<Z.+MLO8^P ..=0   K+%5PQ!B3&\V&<-7#]5T
MM!"R:MJT3-RN=O1J<_$J<2IS]X^VEJ\W)LUEPSA^H=3W*[2ZKYF+DZ.).-<T
MWIGO7--^35-7>;RFC[27=KI=:6HDL]ZAB5L\+=;4D8F6JN]/'ZT&!))L;:1Z
MK%SJ::&TT4'<M#PJ9*Y5S15[W._/O:R(;*5DI6U)>37O>\>+?@P;Y8;QHTAI
ML04%_KKC1QS,974U2JJU['+EFB9KS[N^F:;RZ&.1[&N:N;7)FB]]"I-*F)(,
M3.7!%@;+4W.>J9'4NX-49"UCLU557CR5$7--V2+O+:AC;%"R-GS6-1J>1"%2
M[BG+:3IV3:CL/1J+SAJRWJH9/=K92UDS&ZC7RL1RHW//+UJIMP5)M;"QI/:1
MG]@<*?\ E^W=2AO;;04MLHHZ.WT\=/2QYZD4:9-;FJJN2>55,D!R;VL**6Q$
M;EP)A>6N6LDL5 Z=5UE7@DU57OJWB_(D;6HUJ-:B(U$R1$XD0_0&V]H22V
M&#(( [[<V?N)?XQ/R .^W-G[B7^,64^/8A/AW)^ "LF         0?2_R9@_
M%-]UQ3Q<.E_DS!^*;[KBGCTV*OQ_=GB,??EOL@ #I'%         !-=$?*F3
M\,_WFD*)KHCY4R?AG^\TU<-^Q/L;V+/RZ?<N0CFD3D?</(SWVDC(YI$Y'W#R
M,]]IY6EOQ[H^@SW64@ #MF@            2+1YRPMWWG^XXO H_1YRPMWWG
M^XXO YF&[Z[&U0W0 #3+P
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M73[ER$<TB<C[AY&>^TD9'-(G(^X>1GOM/*TM^/='T&>ZRD  =LT
M   "1:/.6%N^\_W'%X%'Z/.6%N^\_P!QQ>!S,-WUV-JAN@ &F7@
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MQO8L_+I]RY".:1.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:
M        !(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
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MKN3>B+N+% 522#@F>8HV0Q,CB:C8V-1K6IQ(B<2'H @3
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ML_+I]RY".:1.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:
M     !(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
M                     *FJ\-4.*-+.(J>ZNJ5BIZ6G?&V*9S,E5J(O$;K9
M+AGO7'_&/)+18>@I,57*^LFD=/711Q/C7+5:C$R14YS=%KJO5DLK5-:[H@&R
M7#/>N/\ C'C9+AGO7'_&/)^#&=GS,YN'(@&R7#/>N/\ C'C9+AGO7'_&/)^!
MG9\QFX<B ;)<,]ZX_P",>-DN&>]<?\8\GX&=GS&;AR(!LEPSWKC_ (QXV2X9
M[UQ_QCR?@9V?,9N'(@&R7#/>N/\ C'C9+AGO7'_&/)^!G9\QFX<B ;)<,]ZX
M_P",>1^\81MN%L:X-=:75;5J:US9$EG<]%1&HJ<?E+?-+?</0W>ZV6NEFDC?
M;)G31M:B9/54RR4S&K*_\F1E35M2-T "HM                     !H<>\
MCKMYA?:;XT./>1UV\POM+*/W(]T5U=R78YZ@^E0"#Z5 >H9YY'@Z@H?J5/YM
MOL.7SJ"A^I4_FV^PY>--D?<Z.+MLO8^P ..=0   KW%VD=UKQ$_#MEM,MPO*
M(W<^1L42*YJ.3>J[]RIWO*:>[V#'5ZM5;5XAOT=JIHX7RI0VY%S7)JKJN?GX
MN^XF^)\$V#$JN?=;=&^H5,NZ(_D2IWOE)Q^G-"&U^!,56>CJ(,*8EDJJ&2-T
M:T-R^5\E4RR:_)<O0C38A*-E;4_4HE&5W?6AH:P=89L'VR\5-L@J;C.CW/EG
M3A-Z2.1,D7<FY$XD+5*7PCC.IP!9:.Q8OL%?1PTZN:RLC1)(W9N5WDY^95\A
M=!"LI95V2I6R;(  J+0         0!WVYL_<2_QB?D =]N;/W$O\8LI\>Q"?
M#N3\ %9,         @^E_DS!^*;[KBGBX=+_ "9@_%-]UQ3QZ;%7X_NSQ&/O
MRWV0 !TCB@         FNB/E3)^&?[S2%$UT1\J9/PS_ 'FFKAOV)]C>Q9^7
M3[ER$<TB<C[AY&>^TD9'-(G(^X>1GOM/*TM^/='T&>ZRD  =LT
M  "1:/.6%N^\_P!QQ>!1^CSEA;OO/]QQ>!S,-WUV-JAN@ &F7@
M                 'F21D:(LCVL1=WRER/0    !XCECDSX-[7Y<>JN>1[
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M(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
M         !@7^X?JJQ7&X:NOW+3R3ZO];5:JY?D9Y\*^GAJJ&HIZM$6GFC='
M(BKDBM5%1?R4RMNLPSG7 >$JG2A/=+OB&[U*+%(D;=3)5UE3/<B[FM3=N0WF
MC&YW+".D6IP7<JMU31.<YD*N5<F.U==KFY\2.;QIWU06S1[C/#5?5I@J^T:T
M%0[)7N>F>2<6LU6JF:9\:$=L5LK*33G0T=77NN5=%.U]14+G\IR1ZSDW\R;T
M]'-Q&\VIY2OJL::3C9VUW.ERK-+]IQ7B*Z6ZTV2.6.RN1JU,[)&M17.<J+K)
MFBJC41%R\9:9JIL16B&\LM,MPIV7)ZHC:=7?+7-,TW>0TZ<G%W2-J:4E9LH/
M2)@9NCJCM]VLM[JDK'3)'DN3'+N5=9N7-NR5%SXT+]PK6SW+#-JK:QNK4U%+
M'+(F67RG-15W%$:2L"U>$70XB?<(KQ E2B+!61+DW6551,M9=9N[Q%Y8-O+<
M088MUT9$D*5$2.6-.)JHJHJ)XLT4NK/*@G>_J54E:;6ST-R #6-@       '
MQJJJGI(^$JYXH(^+6D>C4]:@'V!\J:HAJHDDIIHYHUXGQN1R>M#Z@  ^,M73
MQ2MBEGB9*[+58YZ(JY]Y #[                     &AQ[R.NWF%]IOC0X
M]Y'7;S"^TLH_<CW175W)=CGJ#Z5 (/I4!ZAGGD>#J"A^I4_FV^PY?.H*'ZE3
M^;;[#EXTV1]SHXNVR]C[  XYU   "H=*FE"IL=YEL%H8RFJ6(SAJZ9-=(T<U
M'?):F>>Y4WKZN<T.$\18 M%6MSNM?77B^/76?655.YVJO_ U>+R[U\A><]OH
MIY%DGHZ>21>-SXFJJ^E4/G^J;=X/I.I;V%ZJ14;6*73DW>Y!]LN$.E57^'<6
M*87ZIMW@^DZEO89I5)Q_I19%2_J !H<96.LO]NBHZ&\5%J3A=::2G3Y;V9*B
ML1<TRXTW^(PE=ZS+V:CZTN)[/58AFL=-6LEN<+%?)$QJKJHF6>;LLLTS3=GF
M;A[FL:KGJC6M3-55<D1"F,&6&CPWILGMMN23@([9GK2.UG/<NJJN5>^JDET\
M7.:WX!FBIW*U];.RE54X]5<W*GI1N7I+7364HQXE:J/)<GP,V72I@^.N6E=>
M&*Y%U5D;$]8\_O(F7IXB9P31U$,<T$C)(I&HYCV+FCD7B5%YT-!;\(6BGPI'
M8I**!]+P*1R9L3-[LM[\_P"MGOS(IH$JY_V<N5IJ7J]UKK7P,5>9G'EZ];UF
M'&+BW'@94I)I2XEF@ J+ 0!WVYL_<2_QB?D =]N;/W$O\8LI\>Q"?#N3\ %9
M,         @^E_DS!^*;[KBGBX=+_)F#\4WW7%/'IL5?C^[/$8^_+?9  '2.
M*         ":Z(^5,GX9_O-(4371'RID_#/]YIJX;]B?8WL6?ET^Y<A'-(G(
M^X>1GOM)&1S2)R/N'D9[[3RM+?CW1]!GNLI  ';-             D6CSEA;
MOO/]QQ>!1^CSEA;OO/\ <<7@<S#=]=C:H;H !IEX
M    /E64T5923TU0Q'P3,='(U>=JIDJ>I3Z@ HVGT?8ZPE65<>#+M MOJ'9_
M+5J.1.;6:YJHBIWVDIT7Z.9L.5]3>;]5,K+U4(J9M57-CUES<NLN]7+W_+WR
MR06RK2DK%4:44[E5U^"L3S:5HK[%=$2U),R3Z9R*V-$3.+4XM^2IWM^?&??2
MAHYJ\0W6FOF'ZQE)=X$:BZ[E:CM5<VN1R(JHY.SBR+- 562:?(SFHV:YE%7'
M FD3%G<]'B>[4K:")Z.SS:N_BSU6-367)5XU+FP_:J>QV6CME'GP%+&D;5=Q
MKEQJOC5<U])G@Q.HY*W S&FHNX !63      !SQ);6XXTSW6V8FK)XJ:F=*V
M")K]55:Q41K6Y\6:?*7)-^\Z'.<:.A?I<T@W"2>6*W4M*Q5188DX1S$=JMS7
MG7QKQ<2&Q0U93V:MI16UV1F8:I%P?IMBLF'JR:>WS9-GB<[6R16*Y4=ENS:J
M9YY9\W?.@CG>VPR:+-*5+;HWPU])7I&U9'Q(DK6/<K=R\:*BIS;E3\NAU<B*
MB*J)GN3/G%?6T_04-C7J1/29>KW9+'#+AJ@6MKYITAU$B=)J-5KEULF^1./=
MO.?ZJEOE-I-L;\4R.?=*BJIIWHYR*K461$1JY;DXN)-R'5IS[I4^V^Q??H_X
MJDL'EMC8Q7CQN=!  U38                  !H<>\CKMYA?:;XT./>1UV\
MPOM+*/W(]T5U=R78YZ@^E0"#Z5 >H9YY'@Z@H?J5/YMOL.7SJ"A^I4_FV^PY
M>--D?<Z.+MLO8^P ..=0   %:5>E9DM?4T^'<.7:]14[UC?/31JK%5.]DB[O
M+D64Y$<U47B5,BJM%>([%AZU5N'Z^[6^*:AJ9%;,L[=2H8Y<VO1V>2KS*G&F
M1;32:;:N5S;NE>QD;3+U_P#;[$'5/^ LXC_[:X8_\P6K_%,[20$9]K&8=[@
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M  ';-             D6CSEA;OO/]QQ>!1^CSEA;OO/]QQ>!S,-WUV-JAN@
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MIC?JHYKD7=G\K-%XT5"X89&RQ,D9\U[4<GD45-B:;]Q3VM-(]  J+0
M   0!WVYL_<2_P 8GY '?;FS]Q+_ !BRGQ[$)\.Y/P 5DP        "#Z7^3
M,'XIONN*>+ATO\F8/Q3?=<4\>FQ5^/[L\1C[\M]D  =(XH         )KHCY
M4R?AG^\TA1-=$?*F3\,_WFFKAOV)]C>Q9^73[ER$<TB<C[AY&>^TD9'-(G(^
MX>1GOM/*TM^/='T&>ZRD  =LT            "1:/.6%N^\_W'%X%'Z/.6%N
M^\_W'%X',PW?78VJ&Z  :9>                     %XE.:'_/=Y3I=>)3
MFA_SW>4[F)OZ_;]GE_\ DG]KW_1Y !W#RP           !T?:/YJHO,L]U#*
M,6T?S51>99[J&4>)EO,^G4]Q=@"F,67VZT^)+C#!<:N.)DJHUC97(B)XDS-3
M^T=Y\*UO7.[3:C@<FKW*W72=K%^@H+]H[SX5K>N=VC]H[SX5K>N=VF="ES&?
M7(OT%!?M'>?"M;USNT?M'>?"M;USNT:%+F,^N1?H*"_:.\^%:WKG=H_:.\^%
M:WKG=HT*7,9]<B_04%^T=Y\*UO7.[1^T=Y\*UO7.[1H4N8SZY%^@H+]H[SX5
MK>N=VES80FEJ,-6^:HD=)*^)%<]ZYJJ^-2JM@[I*[9.%13=C;@ URP
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ML]U#*/$RWF?3J>XNQ0^-.55T\\II3=8TY573SRFE.U3W$:4MK  )F
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M+I]RY".:1.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:
M   !(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
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MQO8L_+I]RY".:1.1]P\C/?:2,CFD3D?</(SWVGE:6_'NCZ#/=92  .V:
M        !(M'G+"W?>?[CB\"C]'G+"W?>?[CB\#F8;OKL;5#=  -,O
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M&FR/N='%VV7L?8 ''.H                ?):B%)DA6:-)EXF:R:WJ/J
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M@         %[X(Y*6SS*>TH@O?!')2V>93VFEANXNY?0VLW8 .:;0
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M!1=P "!,
M
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M^]SKQIN).%G9D5*^M&_ "*BYY+Q$20 /Q'(JJB*BJG&G> /T
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M,U[V:<Y\<88;I='UXPY=\-2U4"SUS*:IB?,Y[9FNWKGGXD7UIWC>67[?[_\
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MMOP%=HDU?U/*REJG-YV/3Y:^M'_WC9Z0D2_:2,(6!ORH('+<:A.-%:WYN?\
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M=04/U*G\VWV'+QILC[G1Q=ME['V !QSJ
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M6%-6;\E0P?2H"X&:*K:UR*E?6>IO8"YX?1YE2P*KR+# !P#M
M
M
M
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M@ -8V
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MW@;DC:/P[?8>,?\ (V[>97VH>\#<D;1^';[#8_Z_O^BC^][?LW@ -<O
M
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M/^8T5FFQ#I6Q;<%CO53;+93?+:V)SLHVJN3$1J*F;ER5555YE\A;>C##Z6/
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M[_HH_O>W[-X #7+P
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MLW@ -<O
M             ()BC[2\,_<?_J)V03%'VEX9^X__ %$[-BONP[?ME%'>GW_2
M  -<O
M                                -!C_ )&W;S*^U#W@;DC:/P[?8>,?
M\C;MYE?:A[P-R1M'X=OL-C_K^_Z*/[WM^S>  UR\
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MOL/&/^1MV\ROM0]X&Y(VC\.WV&Q_U_?]%'][V_9O  :Y>
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MV7RCB?)'2HZ*=6IGP:9YM<OBSS3/R&/B+2M'B7!M;;K3:*R2X34CNZE5J<%
MQ&_+=FBYJF6>6:)_DMY*B*BHJ9HI\8:6G@:YL$$4;7?.1C$1%\N1&-59*4E>
MQETW=M/:57^C7R.N/X]W\-AL?T@J-]5H]DE8BKW+4QS.\F]G^I"QV,9&F4;6
MM3O-3(Q;S;H+O::RWU:9P5,3HG^)%3+-/&G&8SG_ .F62S?\,@BF ZME;HDH
M)&*BHRWNA7RL:K%]T@WZ,/U?$?WJ?V2$LT.6*^X9M]QM%[IFI2,G62EF;(UR
M/1=SDR1<T3<B[TYU+"CC9'GP;&MSX]5,B4IJ.5%<2,8MY,GP*%NO_>4@\[%_
M 0LO$&C?#5_NT]RN='+)5S:NNYL[VHN34:FY%RXD0EW!1J_7U&Z_];+>>R,J
MK=K:K*Q*--*]]=V5]L>P=X/G_P 3)VDWM5!3VJVTU!1-5E-3QI'&U5551J<6
M]3*!"4Y2VLDH1CL1SWCS_O VO\31^UI:NE6*^NPG+-A>>>*OIY&RJV#Y\C$1
M4<U$Y^-%R\1+%BC5^NL;%?\ UE3>>R;JWR=6PBJ=KZ]I1EDTW14>'F4MYMU9
M/=X8^#5^;=25R;LW9KFB]_<I\]!>$ZNJM&(:BY0R4]#<Z?N6/6;EKHN>;D3O
M)FF2^4N^2BI9)4EDIH'RI_3=&BKZS().JDFHJUR*I.Z<G>QSG@;%%3HKN-SL
MV);=4N@D?PC71(F>LF[6;GDCFN3+?GS&7H^AK<:Z6YL5,HY*:VQ/617.3=N9
MJ,;GSNXE7+QE^5%-!4M1M3#%,U-Z)(Q')^9[C8V-B,C:UK$W(UJ9(AEUUK:6
MMF%1:LF]2*,TQ(MVTKX8M4/RG-2+6RYM:557_P!J9EZE7X2PC=ZC29=<58DI
M4IVIFVBCX1KUR5-5%^2JY9,3+RN+0(U6K**X$J:=W)\0 "DM   -!C_D;=O,
MK[4/>!N2-H_#M]AXQ_R-NWF5]J'O W)&T?AV^PV/^O[_ **/[WM^S>  UR\
M
M     @F*/M+PS]Q_^HG9!,4?:7AG[C_]1.S8K[L.W[911WI]_P!(  UR\
M
M                        T&/^1MV\ROM0]X&Y(VC\.WV'C'_(V[>97VH>
M\#<D;1^';[#8_P"O[_HH_O>W[-X #7+P
M                                     "JM+5?46S$MHK*-Z,J(H7*Q
MRHBY+FJ<2^4CFT7$G3(^H9V 'H,%I0G1BY),XF$5)PJR478;1<2=,CZAG8-H
MN).F1]0SL +]&I=*^"C/U>I_(VBXDZ9'U#.P;1<2=,CZAG8 -&I=*^!GZO4_
MD;1<2=,CZAG8-HN).F1]0SL &C4NE? S]7J?R-HN).F1]0SL&T7$G3(^H9V
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;  XYU0                          #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g12080g94g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g94g02.jpg
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M-%)3)%>"E<'A\#A68J+"0X.$M,/3XO$F1$9C_\0 &P$!  (# 0$
M      (#! 4& 0?_Q  V$0 " 0(!"@4#! ,! 0$!     0(#$002$Q0A,4%1
M4G&A!3(S@9$T8<$&(D*Q%='A\"/Q8O_:  P# 0 "$0,1 #\ Z5Q+?J'#MJEN
M%SEU(6;&M3:Y[N)K4XU.>\6Z3[[?)I&4L[K=19Y-BIW9.5/_ !/X57R9)XC]
MTR8DDOF+)Z:-Z]A6]RP1M1=BN3Z[O+GL\B(0(WF#P<814YJ[9I\5BI2DXQ>H
M^Y99)I%?,]TCUX7.7-5]9\ &P,$  ]
M
M
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M"1T4C>1R+DON/ SEK,,  ]/
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M +_V\S8YJO+]MXR.<Z."NQ)?XX4<LU?739*]W&Y5VN7^JJ7G^J&"<#6>*HQ
MR*IE<J-66H:KUD=R-C39EZO*I';):Z2TZ?I*6F8UD*(^2)B<#5=#K*B>U3\^
MD:LO9UD1<]QW.75Y-;-N?],B=2;K5(4XNT6KD*<%2ISJ-7:=B24^&<"X[M<\
MECABIY8^U62G8L3XG+P9LX%3U<NTH^LL%;3XG?8D8CZUM1V.U$X'*JY(OD78
MOD,O!T6)9I:IN%'5R/1&K-V+)J[-N6>U/&2' $5?%I=M[,1;K^D$>Y9-W=K/
MUMQ=JYK[/Z%L(RH9?[KI*]MY7)QK9/[;-O;N+!I\%X/P/8V5F)6Q54VQKI9V
MJ]'/7]ED?_)5/J@LF ,=T=0RT4T4$\2;5@8L$D>? NKP*GJ5#2?2/675L*;=
MQSF\FMVG_ C>@-9?UZ7<\]3L63=,N3-O#Z\C%C"4J#KN;RC(<XQJYE15B(XN
ML%1AJ_5-LJE1ZQ*BLD1,DD8O [_KCS+XGT?8=K\)4^5'344KX89)*M$R<QO:
MN>N:[$541=J\I _I#I'^M-N5N6Z]AIK>37=E_P 2P\=JJ:'ZG)<O]"@]["5:
MK.<*33LV1I4XPE435TBM=)CL%0X?IZ+"G8SZZ.H;KOC:YSE9JN1<Y%3;MU>!
M238<P!A_#.&4O6,VI--J)(]DF>I%GP,1J?6=Q;>/VE,674_3%!NV6Y=D1ZV?
M!EK)F=0:1*RRT.'TFQ+125E!NS4W-C=;)V2Y*NU-G#[26(RJ632BV[[>)Y0R
M:F54DDK?!#K*[1UC2H?;*.U,I:I6JK$W+<'N1.%6JU=JIPY+["J=(.%9,)7]
M]$LBRTSV[K!*J9*YBJJ9+XT5,OZ\98MIQAH[H+A#4VRPUL=9&JK&Z.!%<BY*
MFSM^3,CFF/%-#B:2U/H:6M@= DB/6IBU-9%U<LMJY\"^TEA\Y&K9)Y+XD:V1
M*G=M92X$UL6!L-89P@V]8BI>SYFPMGF5R*]&ZV7:M9P+PHF:_P!$/JP08 QW
M'54M%:&TD\3=9<HT@>B+LUD5JY+MY?8:G ^ENCAM4%MQ+3R_V3$B2HC;KM>U
M$R37;PYY<F>9)XL.X!QM#*^V1TJRHF;G4F<,C,^-6;/ZH8T\Y!MU;K[K89$,
MB22IVZ/:4/B^RNP]B.NM;I-U2!^37_XFJB*U?+DJ&G-_CG#DF%L15%M?)NS&
MHCXI,LM9B\"JG+PIZC0&XIO*@G>YJYJTFK6  )D
M
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M)(X6.X48W@S\:[5]9&P#,A%0BHK8C%E)R;DP "1$
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M7BFR/N;'P[;+V,@ &H-H
M
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M:9\.7_%">1)*]B*G%NUR3  @2
M
M                               !&-)W>#?/1U]Y)R,:3N\&^>CK[RRC
MZD>J(5?)+H<KTWVS0*;[9H.F9ST3R.S+;W.I?-,]QQF=F6WN=2^:9[C6>*;(
M^YL/#MLO8R  :@V@         *VTOXNNEEBAM=CHZI:BJ9K25D42R;BS-4[5
M$_;V+P\'NLD$H-1=VKD9)M63*9P9B_#N%+<M/16#$TE1*NM454E$U9)W\JKK
M\'(G_-278EK[UB' D5TP:M715VONK8)XVLED8U7-<Q47-$5>%-NW).4G ).:
M;RK:R*@TK7*TCTM4C:1(ZFQ7IEX1N2T24R[7\B+R9\>6?B,W0_8+A:;5<:^]
M1;A<+M5.JI(>.-%X$7D7-57+QH3X!S5K15KGJ@[W;  *R8( [[\V?P)?SB?D
M =]^;/X$OYQ93W]"$]W4GX *R8   -%B?%UCPPV-;U7QT[Y$S9&B*][DY=5J
M*N7CX#>E2U.C.MO>DJKO6)74U39W.58X&RNUE:B9,:J9)DG&N2\).FHM_N9"
M;DE^U$UPSCG#V)9UI[1<62U*)GN+VNC>J>)'(F?J)*<W8XM5#8M+]FI<)QI!
M*CZ=SXHG*J,D5Z[/%FW554\?C+0TI8>Q-B.:@H[!<$HK>YCTJU656([-4R14
M3:NS/9P%DJ4;JSLGQ(1J2:=UK1O:#'.';A?ULM%<F3W'6<W<V1O5JJU%5<GY
M:J[$7C)(<U:.+2VQZ;X;6R59DI7S1;HJ9:V43MN7$=*D:T%!I(]I3<TVP1&^
MZ1\+62N?1UUT9V2Q<GLBC=)J+R*K45$7Q<)DZ2;O+8\#WBX4SE;/'#J1N3A:
MY[D8BIY%=F4GHS9@B@P]-<,:2T\];5RN;'%(UTKFL39K:K<U157/:O)L)4Z:
ME%R?8\J5&GDHZ L-\MM_H4K+/61U5/GDKF<+5Y%1=J+XE-B5EHAP_9+?5W&Y
M87O[J^@J$U'4JLU=R76S;GFN>:)FFU-N:EFE<THRLBR#;5V#Y<]C7(CG-15X
M$5>$TN.+C66G"ERK+9 ^>NCBRA8QBO7754:BY)PY9Y^HI'#VBZZXJL53?+W=
M*JFN,BO6..IC<KEU>-ZN5%1%7/BX-I*%-265)V(SFT[)7.B@4[]';$=PN=#<
M[9<)Y*AE'N;X7R+K.:UV:*W/DV)EZR+Z0L48NQ/;KJV.@?08?HGJDTC45$E1
M'ZJ(KU^MMRV)ZR2H/+<;D<\LG*.B@5C]'=57 #\U5?\ 3)/<TLXJG')DXED)
M944P#$N]QIK3;*FOKY4BIJ=BO>Y>1/\ CQ(ARIBF^7+$F*J2]5S)(::JF1M(
MQ5V-C:_+)/7GFO&N9.E2=0A4JJ!UL "HM
M
M      !&-)W>#?/1U]Y)R,:3N\&^>CK[RRCZD>J(5?)+H<KTWVS0*;[9H.F9
MST3R.S+;W.I?-,]QQF=F6WN=2^:9[C6>*;(^YL/#MLO8R  :@V@
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M1%-D85GM5#9J)M):Z:.FID57)'&F2(J\*F:8CM?49*O;6  >'H
M
M                    (QI.[P;YZ.OO).1C2=W@WST=?>64?4CU1"KY)=#E
M>F^V:!3?;-!TS.>B>1V9;>YU+YIGN.,SLRV]SJ7S3/<:SQ39'W-AX=ME[&0
M#4&T    "JB(JJN2(4K>KYB_$&';MB:V71EHL5+K]BPQQHLL[6NRUG.XLU\?
MJXUG"&60E/)+J!6F+[GB*PT5LQ125S9[1%30-KJ![$S?K+VTC7<O;)R<'&65
M&]LD;7L7-KD147E0\<;*YZI7=C] !$D         " .^_-G\"7\XGY '??FS
M^!+^<64]_0A/=U)^ "LF
M
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M?B:LX3M%EE[\%X\ M_L?\PWX+QX!;_8_YBM 79J' Q](J<2R]^"\> 6_V/\
MF&_!>/ +?['_ #%: 9J' :14XEE[\%X\ M_L?\PWX+QX!;_8_P"8K0#-0X#2
M*G$Z@P7=YK[AJCN53'''+.CM9L>>JF3E39GY#=$3T4=X-J\DGYCB6&%)6DT;
M6FVX)O@  1)@
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MC$      .CM%'>#:O))^8XEA$]%'>#:O))^8XEAKY^9FZI>2/1  $2P
M
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M547)=BHBDGP9BR#$K:R%U+/07*B>D=51S_6C5>!47C1<EVDY4Y1VD%-/820
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M-5-CDX-OC&1*UQEJ]B3  B2
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M>^4#;5#3TBTM+2+*DDCLU55<Y4V)PKL\G)MBE:+N_P#W ]>MHGX *2X
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MEE  $20
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M63   !06..^VZ>>4OTH+''?;=//*;?P?U9=/R<]^HO0AU_#-& #H3CP
M"P-#?=BO]'3XD+9*FT-]V*_T=/B0MDY?Q/ZA^QW/@7T<>K_L@VF?O'F\_'[S
MGXZ!TS]X\WGX_><_%=#REN+]3V  +C$      .CM%'>#:O))^8XEA$]%'>#:
MO))^8XEAKY^9FZI>2/1  $2P               U&+K7+>L,7.VT[V,FJH'1
M,=)GJHJIQY&1A^B?;;#;:&9S724M-'"YS>!5:U$54\6PSP>W=K'EM=P #P]
M        (S<</U-5CVT7QDL3::CII87QJJZ[E=P9;,LO628 ];N>)6  /#T
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M-M9YEJV5N)("O=%ND27&]7<(9;<RC2E8QZ*V57ZVLJIR)R%A"47!V8C)25T
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MZA^QW/@7T<>K_L@VF?O'F\_'[SGXZ!TS]X\WGX_><_%=#REN+]3V  +C$
M   .CM%'>#:O))^8XEA$]%'>#:O))^8XEAKY^9FZI>2/1  $2P
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M:)2F),&:,L.HY+I73LF3_P!@RI5\G\J)FGKR+K/)V44D(7<FV  5%H
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MK8+9NF>>?8S<L_)ED2 !-K8&D]I\Q1LBC;'$QK&-3)K6IDB)R(A] 'AZ
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M; Y8\_+EG_0G-+40U=-%44LK)H)6H]DC%S:Y%X%13UPE':CQ24MC/4 $20(
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MY+;5PU3&+JN=$]'(B\FPS"L- O<.Y^DI\*%GF-..3)HS:4\N"DP ")8
M          #'HZ&EHEG6CIH8%GD6658V(W='KPN=EPJO*9
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M4TC9&VV1\>XZZ;'/36UE3U:J+ZN0NE3ADN4=Q3&I+*49;RZ0 4%X
M (QI.[P;YZ.OO).1C2=W@WST=?>64?4CU1"KY)=#E>F^V:!3?;-!TS.>B>1V
M9;>YU+YIGN.,SLRV]SJ7S3/<:SQ39'W-AX=ME[&0 #4&T   *ATJ:4*FQWF6
MP6AC*:I8C-VKIDUTC1S4=VK4SSV*FU?9QFAPGB+ %HJUN=UKZZ\7QZZSZRJI
MW.U5_P# U>#R[5\A><]OHIY%DGHZ>21>%SXFJJ^M4//]$V[F^DZ%O47JI%1M
M8I=.3=[D'WY<(>%57X=Q8IA?HFW<WTG0MZC-*I./\4614OY  $21H8\+4,>,
M)<2-DJ.SY(.QU:KDW/5V<66>>SE-S54\-732T]5&R6"5JL>QZ9HYJIDJ*>H/
M6VSQ)(K=VB"R9NACN-YCMKG:ZT#:K^Q7;P999_US\9/[;0TULH(**@A9!2P-
M1D<;>!J&2#V4Y2VL\C!1V(  B2! '??FS^!+^<3\@#OOS9_ E_.+*>_H0GNZ
MD_ !63   !06..^VZ>>4OTH+''?;=//*;?P?U9=/R<]^HO0AU_#-& #H3CP
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MYO\ PC&U,9"4JMM3W'E6?W2?]QWN4Y*.M:S^Z3_N.]RG)11A]YD8W^( !DF
M      77H%[AW/TE/A0L\K#0+W#N?I*?"A9Y@U?.S<8?TT  5EP
M   -%<<7X>MM6M+77J@@J$7)T;IDS:OCY/6:O2Y?I\/8&KJJC>L=7*K:>)Z<
M+5<NU4\:)FJ>,JC ^$,'2X1BK\8W**&X7#7=#NE5N;HVHY6HY&Y[5545<US0
MNA33CE2*IU&GDQ.A*:HAJH&3TTL<T+TUF21N1S7)RHJ<)Z%?Z'\,U6&K751_
MIFENELJ'))3K3JJM8NU'9+GEDNS@Y"P"N22=DR<6VKLP;O>+=9X$FNM=3T<2
MKDCII$;K+R)GPGA9<16>]J]+3<Z2K<Q,W-BD17(G*J<)5N(< WO%VE"6JO\
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M-]LT'3,YZ)Y'9EM[G4OFF>XXS.S+;W.I?-,]QK/%-D?<V'AVV7L9  -0;0
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MJ'['<^!?1QZO^R#:9^\>;S\?O.?CH'3/WCS>?C]YS\5T/*6XOU/8  N,0
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M +Y5'0._^X36;C&T9:WM(/+<KN.HNH'Q3L6*".-7:RL:C<^7).$^S%,D
M                    $8TG=X-\]'7WDG(QI.[P;YZ.OO+*/J1ZHA5\DNAR
MO3?;- IOMF@Z9G/1/([,MO<ZE\TSW'&9V9;>YU+YIGN-9XILC[FP\.VR]C(
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M]@ "XQ      #H[11W@VKR2?F.)81/11W@VKR2?F.)8:^?F9NJ7DCT0 !$L
M        !3NE[OGA]%9\3RXBG=+W?/#Z*SXGFR\*]?V9I?'OI'U1"  =,<0
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M]/59SG/*;>I&><QX][\[UZ4_WG3AS'CWOSO7I3_>:K#[6;W&^5&A !E&M
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M;>YU+YIGN-9XILC[FP\.VR]C( !J#:                      @#OOS9_
ME_.)^0!WWYL_@2_G%E/?T(3W=2?@ K)@   H+''?;=//*7Z4%CCOMNGGE-OX
M/ZLNGY.>_47H0Z_AFC !T)QX     !8&AONQ7^CI\2%LE3:&^[%?Z.GQ(6R<
MOXG]0_8[GP+Z./5_V0;3/WCS>?C]YS\= Z9^\>;S\?O.?BNAY2W%^I[  %QB
M      '1VBCO!M7DD_,<2PB>BCO!M7DD_,<2PU\_,S=4O)'H@ ")8
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MO&/)'J=)^F_4J=$9YS'CWOSO7I3_ 'G3AS'CWOSO7I3_ 'FHP^UG0XWRHT(
M,HUH     !/]"/?F[T63WM+[*$T(]^;O19/>TOLPZ_F-IA/3  *3*      !
M&-)W>#?/1U]Y)R,:3N\&^>CK[RRCZD>J(5?)+H<KTWVS0*;[9H.F9ST3R.S+
M;W.I?-,]QQF=F6WN=2^:9[C6>*;(^YL/#MLO8R  :@V@               !
MY+40I,D*S1I,O S636]AZ@    @#OOS9_ E_.)^0!WWYL_@2_G%E/?T(3W=2
M?@ K)@   H+''?;=//*7Z4%CCOMNGGE-OX/ZLNGY.>_47H0Z_AFC !T)QX
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M  ,DP      "Z] O<.Y^DI\*%GE8:!>X=S])3X4+/,&KYV;C#^F@ "LN
M     ! M,?<&C])3X7$](%IC[@T?I*?"XR\!]1#J:_Q7Z.IT*C !UI\^
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MF/'O?G>O2G^\MWL;29X=A?HYNHA5UT68ON=QJ:VIN%CW:H>LC]5943->3M#
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MZ;"F'J>UTCED1F;I)53)9'KPNR_ZV(AO 2E4<E8A&"B[@ $"8
M
M
M (QI.[P;YZ.OO).1C2=W@WST=?>64?4CU1"KY)=#E>F^V:!3?;-!TS.>B>1V
M9;>YU+YIGN.,SLRV]SJ7S3/<:SQ39'W-AX=ME[&0 #4&T
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M4E%798@-?ARLEN&'K76U&KNU32Q3/U4R36<Q%7+UJ; BU8DM8
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MDF2<         /AD,3'N>R-C7NX7(U$53[
M   /B*&.+/<HV,UMJZK43,^P #X;#$V19&QL21>%R-3-?6?8
M                       /B*&.+/<HV,UMJZK43,^P #X2&))5D2-FZ+LU
M]5,_:?8                         !&-)W>#?/1U]Y)R,:3N\&^>CK[RR
MCZD>J(5?)+H<KTWVS0*;[9H.F9ST3R+*@TRXBAACB;36O58U&IG$_/)/]LF>
M\C9^=+A[&=0WD;/SI</8SJ,&IB\-4\^OV,V&&Q%/RZB'[].)/!;5T+_G&_3B
M3P6U="_YR8;R-GYTN'L9U#>1L_.EP]C.HJSN#X=B>;Q?'N0_?IQ)X+:NA?\
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MQ*E@JO M8 &A-R
M
M
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M.$FHV:^_W(__ $A**<KW^Q98 ,4R0
M                             5I)]_47\-ZRRRM)/OZB_AO69&'_ )=&
M45OX]466 8%^N/Z)M%57+%NNX-UM36U<]N7#ZRB,7)J*VLMG-0BY2V(SP5IO
MIMYI7\1_^(WTV\TK^(__ !,W_&XGE[K_ &:W_,X+G[/_ $66#4X6O*7ZT,KD
M@W#6<YNIK:W N7#DAMC#G!PDXRVHV-.I&K%3@]3 *0TB:6[K9<6UMMLL5%)2
MTFJQ[I8W.57_ +6U')P*N7E0N.RW"&[6BCN%,N<-3$V5OB14SR/94Y12;WB-
M12;2W&8 "!, 'G4.D;3RN@8CY4:JL:JY(YV6Q,P#T!"-&EVQ;<UN7ZWVQE$V
M-S=P<C-17+MUDRS7-$V;?'QDW)2CDNQY%Y2N  1/0 0O2UB>NPGA=EQMC8'3
MNJ61*DS5<W)4<J[$5-NQ#V,7)V1Y*2BKLF@-'@>ZU%[PG:[E6)&E14PI(](T
MR;GFO F:F\#5G8)W5P #P] ,.\RU<%HK9;9"V>N9"]T$3ER1[T1=5%]9'-&E
MRQ+<[54R8NH&T=0V75AR9J*]N6W-N:\?'QDE&ZN>96NQ+P"K\6X\NUITGVK#
MU+'2+0U3H$>Y[%5_;OR7)<\N#Q"$'-V1Y*2BKLM  $20 (+I7QO48*H*":DI
M8:F2IE<Q6RJJ(B(F>>SU$HQ<G9'DI**NR= I1-)^-U3-,%3*GH\W46?4X@BM
MF$&7R],=3(VF9--$B+K->Y$[1$7CUERVDI4I1VD8U(RV&\!1#M,V(I8Y;E2X
M:C6RQOU'2JV1VKXED3M47@XN,MO!F):/%=AAN="CF-<JLDB<O;1O3A:O]/4J
M"=*4%=GD:D9NR-X "LL    !XUE5!14TE163QP4\:9ODE<C6M3QJH![ Q+5<
MJ.[43*NVU,=32O54;)&N;55%R7^J$"EQM<ZS2PS#-H92NM\#46KE>Q7.3)-9
MV2YY)PM;P<)*,&[_ &(N25BR "K[[CR[4.EBBPU#'2+;YGPM<YS%63)R9KDN
M>7]!&#GL$I*.TM  KC2/C6Y6S$MEP]AM('7*M>BRNF8KT8URY-V(J<BJOB3Q
MB,7)V0E)15V6.#\:BHU$<N:HFU>4_2)(    %<8^TKVC#T$D%KEAN5T1VKN3
M'9QQ[=NNY/<FWR$HP<W:)&4E%798X(CHNQ54XOPV^Y5E/#!*E0Z'4BSRR1&K
MGM\I%\=Z3+M8L8OL5GM$5PD;&UR(B/<]RJW65$1O(A)4I.3CO1XZD5'*+6!4
MN'=(6+[A?*"CKL)2TU+/,V.698)42-JKDKLU3+9XR6Z1L;T>"K9'-/&M163J
MK8*=KM76RX55>)$V>U Z4D\G>%4BU<EH*/32YB>W=C5M_P +I#::A4U)&LDC
M547;L<Y515RVY9)F2O2/C"Y6G"]KQ'AIU//;IG-69LL:JJL>F;5SSV<&2^-4
M/71DFEQ/%5BTWP+%!AV6Y07>TTEPI'9P5,396<J(J<"^-. S"JUBS:
M"M-'GWEXY\ZSWN++*TT>?>7CGSK/>XR*/DGT_***OGAU_#++ !CEX
M                                                     *TD^_J+
M^&]9996DGW]1?PWK,C#_ ,NC**W\>J++-!C[O0N?FT^)#?F@Q]WH7/S:?$A'
M#^K#JO[/,7]/4Z/^F4* #LCYL77HK[T(/.O]YOL172*RV*ON4^6YTL+I<O\
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MR3Z?E%%7SPZ_AEE@ QR\
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M-#*!Y<]L8<MJM\M/%!+04CX(OLXW0M5K/(F62&6UC6L1C6HC$3)&HFQ$Y#]
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MCY)]/RBBKYX=?PRRP 8Y>
M                     "M)/OZB_AO6665I)]_47\-ZS(P_\NC**W\>J++
M!CEX
M                                     *TT>?>7CGSK/>XLLK31Y]Y>
M.?.L][C(H^2?3\HHJ^>'7\,LL &.7@
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M5IH\^\O'/G6>]Q.CY)]/RB-7SPZ_AEE@ QR\
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MA\)%&C]=&-U_\66TKA/(O]T63AE6^Q1WTG?_ /._^_\ _ID_TD?=3=/0F_\
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MAEE@ QR\
M        %:2??U%_#>LLLK23[^HOX;UF1A_Y=&45OX]466 #'+P
M
M                        5IH\^\O'/G6>]Q996FCS[R\<^=9[W&11\D^G
MY115\\.OX998 ,<O
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MZ/J9VQ/D<C43-<W<2 &/BZ4(49.*2_\ TOPU2<ZL5)W_ /PN< &A-T
5                        ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g12080g94g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g94g03.jpg
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M*"@H*"@H_\  $0@#10.Z P$B  (1 0,1 ?_$ !P  0 " P$! 0
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MLBO7TJ>8 Z:5M1S[W  )(
M
M
M      /W%(^)Z/B>YCTWG-7)4)GA?27B&QRL1]6ZOI$7MH:IRNV>)V^GJ\1"
M04G3C-6DKEX3E!WB['6V#<56_%=LZJM[U:]F230/[N)W(OBY%XS?')6",1U&
M%\04]? YRQ9HR>-%V21JNU.?C3QHAUC3S1U%/%/"]'Q2-1[')O*BIFBG RO)
MNHEHU,[.2Y1UT=.M''%SJGUUQJJN1<WSRNE<OC<JK_N>8 ]"E;0<1NX !)
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M\2/IU:GI1R^HUL]H<7J9\TK<)3@-YBO"]SPO7-IKK"C==%6.5BZS)$3C1?\
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M1Z):N:Q4M-U,UD:0S-C365$E:BKK*F:Y[=O&<]F/)Z_71;2M9V+UJ/5-*]P
M#.80                                       3:WZ0[G14%-2QR/U(
M(FQ-V\34R3U$)!2=.,]I%XSE#98 !<H
M             =,Z$/L[H/Q)?>./1C6STF.\'RI0N:^HC<YU,]=]LK%5',7D
MSR5%\RGGT(?9W0?B2^\<0K1;BOZMQO=K)6294E;62K"JKL9-K+L_ZDV<Z(<%
MPDZM2<-<7?S.RIQ5.$):I*Q!M'F%9<28JCH)XWLIX':]7FF2M:U=K?$JKL__
M .'3M)5TJUDUNIE:DE)'&KV-38QKL]5/0W>Y,C4W/ZIP?07N^)"V-TZ[O/EO
MRORR:U.=?YN52#:"+C47>OQ17UK]>HJ)87O7GU]B>)$V$UYO*8NKJ4;?<BC!
M9/)4_%^A"=.W#Z;R>+U*1W"&$+MBJH?':X6[E'LDGE75C9XE7C7Q)F2+3MP^
MF\GB]2ET80M<EDT?4E/:XHW5O4FZM1VQ'S.;K;5Y-9<N8VY90Z.3PPZV:T:"
MJUYWU(K+L'W#<<_KFEW7+N=R=J^G_P#@K_%N%+KA:K;#=8$1C\]SFC76CDYE
MY?$NTL!,)Z3$N/5WUA)U1K:V?5J:O-JYY9>++(L;2';%O&CNN;<(F-JX:;JG
M)NW4E8W67)?2G,I195.G-*4E)/=X%GDT9Q;C%Q:W^)S/:;;5W>X0T-N@=/4R
MKDQC?7XD\99U#H1NDD*.K+I202*G<,8Z3+S["+Z+\3,PQ>IZA+9+<*B>+<8F
M1.R<F:HJY;%SSR0F&+J7'F,;@RHHK77VZA:Q$93OJ6QY+QN7-6YKYC8KU*JG
MA345O=C#1A3<+M.3W(T.)]$U[LM#+64\L%?!$BN>D.:/1$WUU5W_ #*0:TT3
MKE=*.AC>UCZF9D+7.WD5SD3-?2=2Z/J6\4>%J>FQ(JOKXU<U5=(DBJS/M<W)
MGGLV'.MGB9!I)HHHDU8X[LQK4Y$29$0IDV43GCC)WMXEJ]",,+CHOX$AQ!HD
MO-KIZ=]/-#7S3S)"V*!KD7-45<U5=B(FKOFTIM"-S?3(ZHNM)%,J9[FUCGHG
MBUMGJ+.TG8BJ<,X4FKJ%C'5+I&Q,5Z9HQ79]MEQY9%3Z,L<X@K,;T-+<+C-5
M4U6YS)(Y,LD[5514Y-J)O&&G6RFI2<TUH,LZ5"G44&GI(1BS#5PPO<UHKFQJ
M.5-:.1BYLD;RHII2]_I%P,=9K1.J)NC*AS$7Q*W-?90H@WLEJNM34WK-3**:
MI5'%%@:#/M!IOP9?9.B9ZZFCN%/03/1)ZF.1\;5WGHS5UD_[DV<YSMH,^T&F
M_!E]DF^G>Y5%GNV%+A1/U*BG?.]J\2_\/8OB5-B\YS\KI=;E*AO7]F[DU3JZ
M#E\_Z*[TIX4=AG$TC*>-?J^KSEILDV)MVL\R_P E0N31W9*? ^$(YKEE'6U;
MV.G5=_7<J-9'YL_2JFZH/JG&MEM-TDA;-''(VIB1V_'(W-%1>9>+CR0K727B
MKZRQ_9;+229TE#6PK*J+L?-KI[*;.=5*]9/*4J+\-?T+=7"@W57CJ^I---?V
M=7+^*+WC3F0Z;TU_9U<OXHO>-.=L.6N2]7VAMT6>M4RM8JI_A3/:OF3-?,;'
M1S2HMO?[(P9<KU4EN+^T.6R.P8 ^L*OM'52.K)7+Q1HG:^;53/\ ZC8O?%I
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MC>TRZ)F8<:E3]8I$QF:QIJ9I(CEVY\GB*Q*9+"4%+$O%E\HDI8;/P0 !MFL
M
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M)7*ZT:LEA\  #=-0
M
M
M
M %P8>T.P7:Q6^X.O,D2U4#)E8E.BZNLF>6>MM*?.ML <"+#Y%#["&AE]:=**
M<'8W<BI0J2:FKE<]@VG\.R]&3YAV#:?P[+T9/F+D!S,]K\7H=#-*/#ZE-]@V
MG\.R]&3YAV#:?P[+T9/F+D SVOQ>@S2CP^I3?8-I_#LO1D^8=@VG\.R]&3YB
MY ,]K\7H,TH\/J4WV#:?P[+T9/F'8-I_#LO1D^8N0#/:_%Z#-*/#ZE-]@VG\
M.R]&3YAV#:?P[+T9/F+D SVOQ>@S2CP^I3?8-I_#LO1D^8=@VG\.R]&3YBY
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ME%QT,M&2EI0 !4D
M
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MCQ2NDT6: #&9
M                                          "MZW&.)JG&=XL>'K1;
MZI+?J*Y\\RL54<U%Y>53/1XXN]MOM#;,9V6.WI7OW.FJZ>;=(G/XFKR;Z>G>
MRVD8IL2TV&]+V,):JDKZE)FPM1*2#=53)C5V[=AZK_65FD>\6.BM=GN-';**
MK;55-96P[EEJ_P"%O*N2KY\N),S9P+Q6BVOZ&OB?@]-RWCR5]SHK>^!E;5PP
M/GD2*)LCT19'*N2(U-]5S4@&-L57*#%7U$VX4N'J![&JVY5$+GK*JIM:Q534
M3+>VJ;W#F"+)0SLN;EDN]Q=D]*^MDW9Z\BMXD\67I,6!)7D9<5W:)^L:8P;A
M^JHK=14,MSO-:J[A21.1NQ-]SG+O)\%Y#Q6/'%6[$4%CQ19)+-7U+5=3.W9L
MT<V6^B.3>7T^K/5VW_Q6GV[+-VRTEJ:V'/\ PYJQ55/S.])\TW?V"84KH_[Q
M!=HT8J;^2[53_M0NHQNHVUHHY.SE?46:1G&^+8<,0TD;:66ON5;)N5+1Q+DZ
M1W&JKQ(F:;?&28K.Y_\ B=/EICFVLIK6Z2-%XG*KT5?0O\C'32;T^!>;:6@]
M]NQW7T]]HK7BVP269]<NK2SMJ&S1O=^ZJIO+O>E#<XWQ93X7I:;.GEK:^LDW
M&EI(MCI7<_$FU-NW?0C'T@6HS!,%4W9/35T4D3N-%[9#\7M>JM.F&HIDSC@M
MKYV-7B>NZ(J_R3T&11C*TK;_ "*.35XWW>9[Z+'EPI+U0V_%V'Y+.E>[<Z:H
M;4-FC5_$URIO+\?.;K&^+8,,4]*U*:6NN-;)N5+1PKDZ5W/Q)M3;MWT(YI_C
M:N 'S[TM/5121N3?1V:IL\RJ>6N>M=IPPXE0FR&TK.QJ\3W;HBK_ /7(%&,E
MBMO\@Y--QON-I08[N%+?*&VXMP_)9UKW:E-.VH;-&Y_[JJF\N]Z4)?>KS;K)
M2+57:L@I($WG2NRUEY$3?5?$A!?I ,1,"LJ$V34U9%)&[C1VU/\ <FU?:+=>
MXJ-]VHH*I8<I(VS-UD:Y4W\MXJU&RD63=W$CV L>P8QN=VIZ2BD@IZ+46.61
MW;2M=GDNKEVN]GOKODT*RT>(C=*6/6M1$1'P(B)Q;%+-(J)*6@FFVUI  ,9<
M                        Y"Q?PKO?ELWO'&H-OB_A7>_+9O>.-0>JALH\
MW/:8.ML <"+#Y%#["'))UM@#@18?(H?80YW2>Q'F;W1^TS?  XQU@
M    "(8\P%;L:24;[E55L/4J.1C:=[41=;+-5S:NW8:)-$%O1-F(<1=*;\I9
M@,BJR2LF4=.+=VB-X,PC3X595MIKA<:WJA6JJUDJ/U=7/N<D3+?-'=]%EJJ;
MG+<+377&RU4RYR=0RZC7*N_LXO,N7B+ !"J23O<G!&UK$.PCH]M.'+@^X[K5
M7"Z/3+JNL?KO;GOY<G/O^,F(!64G)W9*BHJR  ()!7F!?M.Q]_'2^PXL,KS
MOVG8^_CI?8<9(;,N7N4EK7^\"PP 8RX
M
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M9O>.-0>JALH\W/:8.ML <"+#Y%#["'))UM@#@18?(H?80YW2>Q'F;W1^TS?
M XQU@                        5Y@7[3L??QTOL.+#*\P+]IV/OXZ7V'&
M2&S+E[E):U_O L, &,N
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M@N-3-;+W<>IZNCE7-K7R*JHYN7)M\>S?7,R]6O!F/K'XHM8 &$R@
M    KS OVG8^_CI?8<6&5Y@7[3L??QTOL.,D-F7+W*2UK_>!88 ,9<
M
M                  'YCC9$Q&QL:QJ<34R0_0
M      !^9&,D8K)&M>U=]')FBGZ  1$1$1$R1
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ME])=49R5TBKJP3LV76#'33Q55/%/3R-DAE:CV/:N:.:J9HJ&0Q&0
M
M                Y"Q?PKO?ELWO'&H-OB_A7>_+9O>.-0>JALH\W/:8.ML
M<"+#Y%#["'))UM@#@18?(H?80YW2>Q'F;W1^TS?  XQU@   :#&F%*#%]LBH
M;H^H9#'*DR+ Y&NUD14XT79VRF_(7I6OE=:+#34]F<C+G<ZIE%!(O_IJ[/-W
M/LR\^9:%W)6*SMA=R-3Z&<'4[D;47&X1.7>1]3&W/TL-C9=#^&[9<Z*Y4E3<
MGRTTK)X]:9BM56KFF>3-J;#QTFA2ROBW2\W"Y5]<_;+-NJ-1SN/+-%7TJIXX
M[15:,,3V5+;<:FJP]=*E*.6FJ%S6)[NY<F6ST(F]DN9L8G+0IZ3#A2TN)<
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M]B'!W@Z;I4GS&MT56JDLN.L;VZW1K'20.IDC:KE<J(K7+OKMWU4S)1PRL_\
M7,3<L2NBT0 83*      ?F5FZ1/9GEK-5,RA,5:*;;A3 5XN4U7+7W&-D:1O
M5NYLCSD:BJC<UVY*J;5X]XOTA.FK[,KW_#%[UAEHS<9)+Q:,=6*<6V1SZ-G
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M>VR*I8K)ID=4.:N^FNY53_MR)J:E2V-V-FGLJX !0N
M
M   <A8OX5WORV;WCC4&WQ?PKO?ELWO'&H/50V4>;GM,'6V .!%A\BA]A#DDZ
MVP!P(L/D4/L(<[I/8CS-[H_:9O@ <8ZP   (?I1P]67ZPPOM#FI=;?4,K*5'
M;$<]N?:[>?THA,#4XJQ!189LD]SN3G)#%DB-:F;GN7>:GC4M!M25BLDFG<KJ
M/3(E Q(,18;NE)7MV/9&U-55Y4ULER]/G/S255XTDXDL]3):9K7AVUSI5Z]1
MW<\C>Y1-GJV)MV[R$\P-?ZG$EF=7U=JGMF<JMBBF555[,D5'[438N:^@TUET
M@;OBR3#][M51:JM[WMI))%565#45<E3-$RS1-F^G%F9KVOACI7S,6NV*6@G0
M -<SD/Q]@*AQI)1NN%960)2HY&M@<U$76RVKFB[=AHTT1TR)DF)L1(GE*? L
MP&159)63*.G%N[1&\%X3CPNRK;'<[A7]4*U56LEU]35S[G9LSS_D:C$NC6WW
M6\ON]OKJZSW*3_BRT3]7=/&J<O,NTG8(4Y)WN3@C:UB(X+P%;,+5,];'+45U
MSG3*2KJG:S\N-$Y,_3XR7 %92<G=DJ*BK(  @D%>8%^T['W\=+[#BPRO,"_:
M=C[^.E]AQDALRY>Y26M?[P+# !C+@      UF)K)38BL=5:JYTK*:H1J/=$J
M(Y,G(Y,E5%3?1.(V8)3L[H-7T$?P5A.@P?;9J&UR5,D,LJS.6=R.=K*B)Q(F
MS8A^,;81HL844%)<ZFLBIXG[IJ4[VMUG99(JYM7>S7TDC!.)WQ>)7"K8? UN
M'++28>LM-:[<UR4U.W)JO7-SE5<U55Y555,UXMM+>+74V^OCW2EJ&*R1N>6:
M>)>4]@(N[W)LK6(S@G!-HP=%4MM+9W/J%19))WHYRHF>2;$1$1,UXC48NT58
M>Q)7OKI4J*.LD7.1],Y$21>545%3/QID3T%E4DGBOI(P1:M;00G!NC.P85JT
MK*2.:IK6IDV>I<CE9RZJ(B(G/EF38 B4G)W9,8J*L@ "I((7BW1Q9\47N*Z7
M&:N941QMC1(9&M;DU55-BM5>/E)H"8R<7=$.*EH8(5-HWLU1B],1U<]=45R3
M),C))&K&BIW*9(W/),DRV\7&34",G'4'%/6")8ST?V3%U9355U;4-G@;J(^&
M35UFYYZKMB[,U7>R7:2T",G%W0:4E9GAGM%!/9OJF:EC?;MR2'<')FW41,D3
MS9)M*XFT&X;?5+)'57.*)5SW)LC51/$BJW,M4%HU)1U,B4(RUHU6&L/VW#=M
M;0V>F;! BZSMN;GNY7*NU5-J 5;;TLE*VA  $$GYE8DD3XW9ZKD5JY>,B&"-
M'=HP=7U%7:YJV26:+<G)/(UR99HNS)J;=A,02I-*R(<4W=GAOMLCO%HJ[=--
M/!%4L6-[X'(U^JN^B*J+OILWN,T^!\$VK!L%5':5G>ZI<CI))W(YVQ-B;$39
MM7TDF!.)I6\!A5[A4S3)=XAN&]&^'\/7^2[VZ*=*E=;4:^369%K;^JF6>]LV
MJI,@0I-:$'%/2R*XUP'9,7I&^YQ2,JHTU65,#M5Z)R+FBHJ<Z&@P_H;PU::U
ME5-U5<'QKK,94O:K$7E5K43/S["R0652:5DRKIQ;NT-[> !0N
M
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MPX,M,DZX6JJ6MK$;E)-U0V:5&^;>3F1,S*L,?W*[,;Q2_:R=  P&8
M     %>8%^T['W\=+[#BPRO,"_:=C[^.E]AQDALRY>Y26M?[P+# !C+@
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MQ@J[#6/;M<K[14=1'2)%-(C7*R-47+Q=L6B:F49-/)VHS-_),LIY9%SI:EH
M ,!M@
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M.FE?Q,=.JIMV\#( #$90
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M$]1EJ]W QT]N1D !KF<
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M_3G<3Y^R  .0>A
M                                   .0L7\*[WY;-[QQJ#;XOX5WORV
M;WCC4'JH;*/-SVF#K; ' BP^10^PAR2=;8 X$6'R*'V$.=TGL1YF]T?M,WP
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M@:'/VS7^3_U( 6P:C&7!"^>0S^[<;<U&,N"%\\AG]VXF&TB):F<7  ],<(
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MZKIN^(?SH.JZ;OB'\Z'-I];W2<XL#I<'QG<IS'T@D
M                             Y"Q?PKO?ELWO'&H-OB_A7>_+9O>.-0>
MJALH\W/:8.ML <"+#Y%#["'))UM@#@18?(H?80YW2>Q'F;W1^TS?  XQU@
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M?8<9(;,N7N4EK7^\"PP 8RX     !36ECA5_H,]:D,)GI8X5?Z#/6I#"2
M       6!H<_;-?Y/_4A7Y8&AS]LU_D_]2 %L&HQEP0OGD,_NW&W-1C+@A?/
M(9_=N)AM(B6IG%P /3'"         !USHA^S>Q?@K[;CD8ZYT0_9O8OP5]MQ
MS^D>[7,W,BVWR)>5IIH[BT<\O]!996FFCN+1SR_T&KT;\3'Z^C(Z9^"G]/5%
M8@ ]4>"         -Y@;A;:_QD+]*"P-PMM?XR%^GGNF.]CR]SV'Z<[B?/V0
M !R#T(              !&-)? ROYX_>-*.+QTE\#*_GC]XTHXE$
M  ^M[I.<^'UO=)S@'2S.Y3F/I\9W*<Q]()
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M>=4-%9L9XMQ->*'ZIPVZAL:S,6>IJNZ=%GVVKGDF]R(XS1NEB4;&-[G*Y9X
M-4V             5Y@7[3L??QTOL.+#*\P+]IV/OXZ7V'&2&S+E[E):U_O
ML, &,N      4UI8X5?Z#/6I#"9Z6.%7^@SUJ0PD@         %@:'/VS7^3
M_P!2%?E@:'/VS7^3_P!2 %L&HQEP0OGD,_NW&W-1C+@A?/(9_=N)AM(B6IG%
MP /3'"         !USHA^S>Q?@K[;CD8ZYT0_9O8OP5]MQS^D>[7,W,BVWR)
M>5IIH[BT<\O]!996FFCN+1SR_P!!J]&_$Q^OHR.F?@I_3U16( /5'@@
M   #>8&X6VO\9"_2@L#<+;7^,A?IY[ICO8\O<]A^G.XGS]D  <@]"
M        1C27P,K^>/WC2CB\=)? ROYX_>-*.)1          /K>Z3G/A];W
M2<X!TLSN4YCZ?&=RG,?2"0  #G6]WC$&D;2!46*U7"2BMT3WL:UKU:U&,7)7
MNRVN55WD\:)RJ8KQ%BC1)>J&=MU?<+;4*O:.<[<Y,LM9KFJJZJY+L5/BAZ+Q
MA[$^ ,?5%[L-NDN%%*][F+'&Z1%8]<U8]&[45.7Q)S&HTHWO%=_M%%68AMC+
M9;FS*R"%6*Q[WZJYNR=VV2)S)MXSH1TM)6PFB]";=\1TK:ZV&Y6VEKJ9<X*F
M)LS%7]UR9IZS+4SQTU/+/.Y&11,5[W+Q(B9JI&=%6OV.[#NF_P!3-]&:Y?RR
M/7I 5R8&Q K,];J";>_@4T7']V$W%+]MRD*6JQ)I;Q1614MQDMUJ@37U$<Y&
M1LSR:BM14UGKX_'O;QN\,6[&N!L:T]"J5]WL4KV-ED8Q[XT8Y<M9,\]5S=]4
M\1#=%5'BZXTURH\(5$5%$]S%JJI[M54R1VJU%R54WU78AOZ3%>+L 8SI[9BJ
MO=7TDJL637D61%C<N6NQRHCDRR78O)O<9O23NX1M;<:<6K*4K\SH8 '/-X
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MZ  *D@KS OVG8^_CI?8<6&5Y@7[3L??QTOL.,D-F7+W*2UK_ '@6& #&7
M   *:TL<*O\ 09ZU(83/2QPJ_P!!GK4AA)          + T.?MFO\G_J0K\L
M#0Y^V:_R?^I "V#48RX(7SR&?W;C;FHQEP0OGD,_NW$PVD1+4SBX 'ICA
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M?L@ #D'H0              ",:2^!E?SQ^\:4<7CI+X&5_/'[QI1Q*(
M    !];W2<Y\/K>Z3G .EF=RG,?3XSN4YCZ02 >2IN=!2R[E55U+#)EGJ22M
M:N7,JF+Z\M/A2AZ0SXDX7N(NC8 U_P!>6GPI0](9\1]>6GPI0](9\1A>X8D;
M &O^O+3X4H>D,^(^O+3X4H>D,^(PO<,2-@#7_7EI\*4/2&?$?7EI\*4/2&?$
M87N&)&P!K_KRT^%*'I#/B9J2XT59(K*2LIIWHF:MBE:Y43ER11A8NCU  @D
M                             Y"Q?PKO?ELWO'&H-OB_A7>_+9O>.-0>
MJALH\W/:8.ML <"+#Y%#["'))UM@#@18?(H?80YW2>Q'F;W1^TS?  XQU@
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M)R=V$E%60 !!(*\P+]IV/OXZ7V'%AE>8%^T['W\=+[#C)#9ER]RDM:_W@6&
M#&7      *:TL<*O]!GK4AA,]+'"K_09ZU(820         "P-#G[9K_ "?^
MI"ORP-#G[9K_ "?^I "V#48RX(7SR&?W;C;FHQEP0OGD,_NW$PVD1+4SBX '
MICA          ZYT0_9O8OP5]MQR,=<Z(?LWL7X*^VXY_2/=KF;F1;;Y$O*T
MTT=Q:.>7^@LLK331W%HYY?Z#5Z-^)C]?1D=,_!3^GJBL0 >J/!         &
M\P-PMM?XR%^E!8&X6VO\9"_3SW3'>QY>Y[#].=Q/G[(  Y!Z$
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M;Y$O*TTT=Q:.>7^@LLK331W%HYY?Z#5Z-^)C]?1D=,_!3^GJBL0 >J/!
M     &\P-PMM?XR%^E!8&X6VO\9"_3SW3'>QY>Y[#].=Q/G[(  Y!Z$
M          C&DO@97\\?O&E'%XZ2^!E?SQ^\:4<2B          ?6]TG.?#Z
MWNDYP#I9G<IS'T^,[E.8^D$G,/T@OM$E\FB]2E:EE?2"^T27R:+U*5J>BR;N
MH\CBUN\ES  ,QB      !;7T:^&=P\@=[QA4I;7T:^&=P\@=[QAKY5W,C-D_
M>(Z./+=_V56_@/\ 94]1Y;O^RJW\!_LJ<&&TCK5-A\CG  'MCYB
M"]='/ RV\S_;<447KHYX&6WF?[;CE=+]RN?LSO\ Z=^)E_S[HD@ /.'L@
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M,D-F7+W*2UK_ '@6& #&7      *:TL<*O\ 09ZU(83/2QPJ_P!!GK4AA)
M        + T.?MFO\G_J0K\L#0Y^V:_R?^I "V#48RX(7SR&?W;C;FHQEP0O
MGD,_NW$PVD1+4SBX 'ICA          ZYT0_9O8OP5]MQR,=<Z(?LWL7X*^V
MXY_2/=KF;F1;;Y$O*TTT=Q:.>7^@LLK331W%HYY?Z#5Z-^)C]?1D=,_!3^GJ
MBL0 >J/!         &\P-PMM?XR%^E!8&X6VO\9"_3SW3'>QY>Y[#].=Q/G[
M(  Y!Z$               C&DO@97\\?O&E'%XZ2^!E?SQ^\:4<2B
M   ?6]TG.?#ZWNDYP#I9G<IS'T^,[E.8^D$G,/T@OM$E\FB]2E:EE?2"^T27
MR:+U*5J>BR;NH\CBUN\ES  ,QB      !;7T:^&=P\@=[QA4I;7T:^&=P\@=
M[QAKY5W,C-D_>(Z./+=_V56_@/\ 94]1Y;O^RJW\!_LJ<&&TCK5-A\CG  'M
MCYB         "]='/ RV\S_;<447KHYX&6WF?[;CE=+]RN?LSO\ Z=^)E_S[
MHD@ /.'L@           #D+%_"N]^6S>\<:@V^+^%=[\MF]XXU!ZJ&RCS<]I
M@ZVP!P(L/D4/L(<DG6V .!%A\BA]A#G=)[$>9O='[3-\ #C'6   ! =,5+5_
M4UKNU!3NJ9+/7Q5KX6IFKF-SS_V\V9/C!75=/04DU56S,@IHFJZ21ZY-:G*I
M:#PNY62NK%68KQ727FPV'&%HBJ)*6T7-J53',R>QCFY/]IJ<FTQ8OQ=:<48@
MP?288J%K*Z.Y1U#GLC<W<XT[M%S1-]-JIR)M-Y:=)6%+O>H[%;H)YEK7JS62
MF:V%ZJFU79JBKFB<AZ,'W7!B8GN%IL=#36^\0/?$]O4[8W2:J]MJ.3?39GE_
M(S[.N+T&':U-:2=@ UC8    !6$VDV[2W>Z4=GPA5W*.@J7T[YH9UR56JJ;4
M1BY9Y;V9:,'+45E)1UEG@A&%<7WV[WB.DN6$*VUTSFN5:F615:U43-$RU$W]
M[?)N)1<79DQDI:4  5)!7F!?M.Q]_'2^PXL,KS OVG8^_CI?8<9(;,N7N4EK
M7^\"PP 8RX     !36ECA5_H,]:D,)GI8X5?Z#/6I#"2          6!H<_;
M-?Y/_4A7Y8&AS]LU_D_]2 %L&HQEP0OGD,_NW&W-1C+@A?/(9_=N)AM(B6IG
M%P /3'"         !USHA^S>Q?@K[;CD8ZYT0_9O8OP5]MQS^D>[7,W,BVWR
M)>5IIH[BT<\O]!996FFCN+1SR_T&KT;\3'Z^C(Z9^"G]/5%8@ ]4>"
M   -Y@;A;:_QD+]*"P-PMM?XR%^GGNF.]CR]SV'Z<[B?/V0 !R#T(
M       !&-)? ROYX_>-*.+QTE\#*_GC]XTHXE$          ^M[I.<^'UO=
M)S@'2S.Y3F/I\9W*<Q]().8?I!?:)+Y-%ZE*U+*^D%]HDODT7J4K4]%DW=1Y
M'%K=Y+F  9C$      "VOHU\,[AY [WC"I2VOHU\,[AY [WC#7RKN9&;)^\1
MT<>6[_LJM_ ?[*GJ/+=_V56_@/\ 94X,-I'6J;#Y'.  /;'S$         %Z
MZ.>!EMYG^VXHHO71SP,MO,_VW'*Z7[E<_9G?_3OQ,O\ GW1)  ></9
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M7?ZYO=TJ;W>4;JLGJ,]6)/\ E155<]JIO\R(9KQC9WO8PVD[JQ/  :QL
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MMOD2\K331W%HYY?Z"RRM--'<6CGE_H-7HWXF/U]&1TS\%/Z>J*Q !ZH\$
M      ;S W"VU_C(7Z4%@;A;:_QD+]//=,=['E[GL/TYW$^?L@ #D'H0
M          ",:2^!E?SQ^\:4<7CI+X&5_/'[QI1Q*(         !];W2<Y\/
MK>Z3G .EF=RG,?3XSN4YCZ02<P_2"^T27R:+U*5J65](+[1)?)HO4I6IZ+)N
MZCR.+6[R7,  S&(      %M?1KX9W#R!WO&%2EM?1KX9W#R!WO&&OE7<R,V3
M]XCHX\MW_95;^ _V5/4>6[_LJM_ ?[*G!AM(ZU38?(YP ![8^8@
MO71SP,MO,_VW%%%ZZ.>!EMYG^VXY72_<KG[,[_Z=^)E_S[HD@ /.'L@
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M9L 5M5?K%KINT4[,XZ=JKM5LFS8FW;L1?&7T7J2E'1H^Q6G&,M.G[@ &N9P
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M-[QQJ#U4-E'FY[3!UM@#@18?(H?80Y).ML <"+#Y%#["'.Z3V(\S>Z/VF;X
M'&.L   >"_W%+18[A<5B65*2!\^YHN6MJM5<L^+>.;+CCSKLN:KC&>X0V=BH
MYEOMK$U7_P 3G.3T[?%D=1*B*F2IFA^-RC_RV>A#+3J*&M:3'4@Y^)3METMX
M-LE"RCM-EN5+3M_PQPQIFO*JZ^:KXU-W9M,5BNUVH[?3T5T9-53-A8Y\;$:B
MN7)%7)^]M+'W*/\ RV>A#ZD4:+FC&HO,'.#\/,*,UX^1^@ 8C(
M  "O,"_:=C[^.E]AQ897F!?M.Q]_'2^PXR0V9<O<I+6O]X%A@ QEP     "F
MM+'"K_09ZU(83/2QPJ_T&>M2&$D          L#0Y^V:_P G_J0K\L#0Y^V:
M_P G_J0 M@U&,N"%\\AG]VXVYJ,9<$+YY#/[MQ,-I$2U,XN !Z8X0
M  .N=$/V;V+\%?;<<C'7.B'[-[%^"OMN.?TCW:YFYD6V^1+RM--'<6CGE_H+
M+*TTT=Q:.>7^@U>C?B8_7T9'3/P4_IZHK$ 'JCP0        !O,#<+;7^,A?
MI06!N%MK_&0OT\]TQWL>7N>P_3G<3Y^R  .0>A               (QI+X&5
M_/'[QI1Q>.DO@97\\?O&E'$H@         'UO=)SGP^M[I.< Z69W*<Q]/C.
MY3F/I!)S#](+[1)?)HO4I6I97T@OM$E\FB]2E:GHLF[J/(XM;O)<P #,8@
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M50V4>;GM,'6V .!%A\BA]A#DDZVP!P(L/D4/L(<[I/8CS-[H_:9O@ <8ZP
M              *\OFDB1M_J+-A:QU%\K*;94.C?J1QKO*F>2\>SBV\I:,7+
M45E)1UEA@A."L?17ZZU%GN5NGM%ZA366EF7/63E:N2<^66]M3,FPE%Q=F3&2
MDKH  J2"O,"_:=C[^.E]AQ897F!?M.Q]_'2^PXR0V9<O<I+6O]X%A@ QEP
M   "FM+'"K_09ZU(83/2QPJ_T&>M2&$D          L#0Y^V:_R?^I"ORP-#
MG[9K_)_ZD +8-1C+@A?/(9_=N-N:C&7!"^>0S^[<3#:1$M3.+@ >F.$
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M7W2H3*2LJG:S\N-$Y,\DY5\9+P")2<G=A1459  $$@
M
M
M        '(6+^%=[\MF]XXU!M\7\*[WY;-[QQJ#U4-E'FY[3!UM@#@18?(H?
M80Y).ML <"+#Y%#["'.Z3V(\S>Z/VF;X '&.L
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M(H?80Y).ML <"+#Y%#["'.Z3V(\S>Z/VF;X '&.L
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MJQO==W(LS9HJA[FT^QVUR*_D1>+C0M,Q5;.S,M/1=  &(R
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M@ZVP!P(L/D4/L(<DG6V .!%A\BA]A#G=)[$>9O='[3-\ #C'6
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MG=,AQ35K$;PG@JR87?++:Z9W5,J925$SU?(Y.3-=Y.8D@!#;;NR4DM"  ()
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MUC%4TT%52R4U3$R:GD:K'QO3-KF\BH0*71!A9\KE8RNB@<[66G94N2-?-O\
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M]X?R(.I*;O>'\B&8"[%D8>I*;O>'\B#J2F[WA_(AF NQ9  $$@
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MR#-*N[S7]C.:>_R98 *_Z_[C]T[CZ7?(.O\ N/W3N/I=\@S2KN\U_8SFGO\
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MBFW9/R9,0 :YG
M                         ,%=_<:C\-WJ4ANAS@D_RE_J:3*N_N-1^&[U
M*0W0YP2?Y2_U--F'<3YKW->7?1Y/V)R #6-@
M
M            %?P_;'/Y&GLM+ *_A^V.?R-/9:;.3?S_ .6:]?\ CS18  -8
MV
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M(T]EI8!7\/VQS^1I[+39R;^?_+->O_'FBP  :QL
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MB)$WU<Q<\D\:IFGG,49IU<7S+N#5/"9M%BM71Y8-3++J5N]R[<_YE/:"4_\
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M20P6^ECH:"FI($RB@B;$SF:F2>HSFI)W;9M15E8  @D
M                   %?P_;'/Y&GLM+ *_A^V.?R-/9:;.3?S_Y9KU_X\T6
M  #6-@
M                  P5W]QJ/PW>I2&Z'."3_*7^II,J[^XU'X;O4I#=#G!)
M_E+_ %--F'<3YKW->7?1Y/V)R #6-@
M   C>&L%VC#=TKJZTLFA?69[K'NF<?=9IDWBRVY<Y) "6V]+(22T(  @D
M         $;IL%VB#%DN)%9-+=),^WDDUFMS35V)Q9)L3Q$D!*;6HAI/6  0
M2                                       "OX?MCG\C3V6E@%?P_;'
M/Y&GLM-G)OY_\LUZ_P#'FBP  :QL
M                                        &"N_N-1^&[U*0W0YP2?Y
M2_U-)E7?W&H_#=ZE(;H<X)/\I?ZFFS#N)\U[FO+OH\G[$Y !K&P
M
M                           "OX?MCG\C3V6E@%?P_;'/Y&GLM-G)OY_\
MLUZ_\>:+  !K&P
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M3V6ELF_G_P LK7_CS18  -8V
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MBP  :QL
M                   &"N_N-1^&[U*0W0YP2?Y2_P!3295W]QJ/PW>I2&Z'
M."3_ "E_J:;,.XGS7N:\N^CR?L3D &L;
M
M         *_A^V.?R-/9:6 5_#]L<_D:>RTV<F_G_P LUZ_\>:+  !K&P
M
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M]L<_D:>RTV<F_G_RS7K_ ,>:+  !K&P
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M45JKJ.VJF2\AK\&Z,<"UKZB>DKY+Y''DUS5G35C5>741%SYU(!I&M,& =(U
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M8  -8V
M                  #!7?W&H_#=ZE(;H<X)/\I?ZFDRKO[C4?AN]2D-T.<$
MG^4O]339AW$^:]S7EWT>3]B<D?QQ9*B_69*.DDBCD25LF<BJB9(B\B+RD@!A
MIS=.2G'6C)6I1K0=.>IE1=C&[=]T'YG_ "CL8W;ON@_,_P"4MT&]VIE&]?8Y
M7862;G]R-8#L%3AZV5%-620R/DFW1%B553+51.-$Y#RZ5+5=[YA*:V6%D:S5
M+VME62341(T7-=OC5$3FS)>#3G5E.?62UG3I4(4J:I0U(@NB?!BX7PQU-=(8
M'W":9TLJID]$XFHB\R9^=3%I;P2_%&'(H;3#3LN$$R21YY,1S514<F?G1?,3
M\%>LEBQ^)?JUAP^!5:82Q%4:')L-5D<'UFQS60_VR*UT:2-<F:\629IYD-_H
MAPY7X7PFMONK8VU'5#Y,HWZR9*B9;?,34$NHVFM^D*FDTRHK/@.]TNF.3$DL
M<"6Q:B>1')*BNR?&]J=KSN0WFF?"MSQ98J&EL[8G30U.ZNW1^JFKJN3_ '0L
M$#K98E+<1U:LX[R!5.%[C)H@3#K6Q?624C(=77[761R*NWS&#11@VML6#;I9
M[^R-%K)Y%5(I-;^S=&UN_P NQ2Q .L=FMY/5JZ91UHP;C_ ]95LPM-15]#.Y
M%RE<U,\L\E5KE3)>950V>!='=[Z\W8JQ?/!U8CED;!"J+F]4U45<MB(B;R)G
MQ>>W@6=>3O\ ,JJ,459IGT>UV*IZ.YV5T:UM/'N+XI':NNW-516KO9HJKO\
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MCG\C3V6FSDW\_P#EFO7_ (\T6  #6-@
M                                           P5W]QJ/PW>I2&Z'."
M3_*7^II,J[^XU'X;O4I#=#G!)_E+_4TV8=Q/FO<UY=]'D_8G( -8V
M
M                              5_#]L<_D:>RTL K^'[8Y_(T]EILY-_
M/_EFO7_CS18  -8V
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MX37]&/Y1U_8E\)K^C'\H S>EPK[(==4XG]QU_8E\)K^C'\HZ_L2^$U_1C^4
M9O2X5]D.NJ<3^XZ_L2^$U_1C^4W.C6Y5=VQYU7<)MVJ'4[D5^JC<T3)$V(B(
M 8LHI0A2DXQ2T&2A4G*I%2;>DN4 'G#O
$  '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g12080g98e95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g12080g98e95.jpg
M_]C_X1?<17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(U+C8@*%=I;F1O=W,I #(P,C4Z,#DZ,#4@,3 Z,3(Z-#0
M  .@ 0 #     ?__  "@ @ $     0   S2@ P $     0   B,
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   6H@        !(     0   $@
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MDO\ G1=MW&@  [-GO]3U"=OI?9]GJ[_^G_(1:_JK36S8,AQG^<)8R7_U]/\
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M.7=5!J?8^I"9PK-'0-KZ=1[OTHFUOM]K/9_PB>G S[#6'XKZ0]Q:_<ZIP8T
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MW>';C7>NYSZR<6/:STW$1[?3'I>GO8YCO4W>_P#T?LK]/WLS&R]MGJ,)L/\
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M;W-H;W @,RXP #A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M     !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+     $  0$L
M     0 !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #CP    8
M             B,   ,T    +0!% '@ : !I &( :0!T "  -  N #$ (  M
M "  3 !" "  4 !H &$ <@!M &$ (  M "  4P!T &\ 8P!K "  0P!E '(
M= !I &8 :0!C &$ = !E "T ,0    $                          0
M           #-    B,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   B,     4F=H=&QO;F<   ,T    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (C
M     %)G:'1L;VYG   #-     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     CA"24T$#      6O@    $   "@    :P   >
M ,B@   6H@ 8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ :P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M=]G:9<6"L;S9O:2+*S5LW>S:],_ZU7L8'BBNP.:;&['._FQ'Z1[MGZ/Z;/\
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M'>&M?<7,806-+&PV/W5SO4<:RCJ-[(@5MAQ>TM>Y@T=?OAE'HV-:RK8U]O\
M-?Z9.C''(Z!!,@ZO_/0[0_[-[7;H#CL<-A:RS=ZFW:W>_:S_ *XM+H?77=6L
MN;Z)I] -D.Y)=JWA<88M:ZJT.%!.]XKF7 %VS8[9[=KB]=!]2V5,MRA00YFU
M@) <V"WV;(L]S]L;/4_X-')C@($@:JC*5C5__]#KOK959;E8PK+IK8YY8U_I
MEW@S?])NYW[KED8W3>H9#PT4"QMFVN1JQKC_ #_J[9]#TZK/6IV.L_FZ_P#"
M+:^M(8;6"QPKK:S<Y[_YO1WT+1+?8_\ K*]]6F[>GN9)<&6%H>XR7 -K]_\
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M/__3[+ZTAKK:P]PK8&![GO\ YOVN_F[?<QVQ_P#75WZM MP',DN#+"T/=KN
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MWJ5_U?\ MYB[A)3P,N$5&_JL(%G5X<XUQM:YM3FXX'NK],Q'O]7=7LW.<_\
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M &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #(
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M P,# P,# P,# P,# P,# P,# P,#_\  $0@"(P,T P$1  (1 0,1 ?_=  0
M9__$ :(    & @,!              <(!@4$"0,* @$ "P$   8# 0$!
M        !@4$ P<"" $)  H+$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'
M$R( "#$403(C%0E10A9A)#,74G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B
M1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H
M:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7
MV-G:Y.7FY^CIZO3U]O?X^?H1  (! P($! ,%! 0$!@8%;0$" Q$$(1(%,08
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M^:M_G'3[A_G+W)@*B]#W/UO4_; C(C^]'8M%"QIRWEHL;#C-\30JHM<O4+<
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M1UTP-B@01)ZV4KS[;F]OK?2QM;-'D\@+H4IYX9(VQ_/AUM-]84$TC@>IB/\
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MDR>,BP]-M:LR,%/4SSPT[95JHFA6HEA:%;V444JR75\4CA"<*8+$$A:4.HN
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M4E.E)%FX_M61X-&3I:8Q,BA%T/18JF;2L8TA3Z=/%K>T$G,6X2%BVC/'!/\
MA)Z4+9PK2E?]7Y=*63HKKL1&*2AS$NMBY*[DS,#%F_40::KITCN3SI ]I_WU
M?UJ'7_>%/^$'J_TT7F#^T]8H/CUU7#&\<> RD0<6=UWEO O(#>X=AG+M:_YO
M[V=\W(D$SJ?]HG_0/6OI8!@*?VG_ #]8:SX\=<U5%+C4I<W24$L7B,$&X\FZ
MA1]% K6K#I_J"2IO]/>UWR_5Q(60N#Q*+_DIUHVL1%*&GVG_ "](7*?#GJ'+
MH\=939>2*9]4L$C;;J80KA4E6-:[:]7I1T6S*-.H7O[61\U;I$:J4KZ]X_P.
M.FFV^W:H(-/R_P W0'[I_ED?&O.323TVVMNP53TTU*SYC86S,RC0U&@NC_9X
MK U)2RBP652"!SQR;V_N%OT("M.Y6M>V21?\)8?RZ22;'829\%:_-5/^0= S
MF?Y274D7VYVLFWJ1$7RU<=/5]F;,DK:U#(M/-]QMG?T\=(M/')]4@(;])72+
M>S6+W,W$ZOJ/$)\L1/0?[>,5_;_/I,W+MJ/[, #Y%U_P-T#V[/Y3VY,?1^79
MN]]]_<1F7[:@PG9>'R5#']V+53U--V'LJ&9M6D*&^^>70;!OQ[-;;W)MY&I=
M6L.GS+1$''"ABD_Y]ITGDY?=0?"GD^P,"/\ C2_Y>BN;E_EY_)O%4E+%F3C=
MW2QB2)H-R]-U6:$*ER%FGW'UQF-UX>HIY8R 7-"A5;L0I]B*WYWY?E9C$3&/
MZ,X7_C$JHP_WH]('V?<% $C*_P#IH\_M4D?RZ*Q+TQW=U5GFJMO]>Y+;5?%,
MU%25WQ^[;K-L3TM11O.T6+DP.9KNO\[DHDJ@):<^&=WJ'* E0/8B&Z[1N4.F
M:\61*5(N(0XSYZE$BC&#D8ST7?37=M)5;0J>%89*4^6DE2?48XXZ2.^NSNQY
M) G<^3:NKV6FQYQGRZ^/U%6FHEI!_DL.-W^N%VONRM>-)Y5D;^.3)>[JVI0?
M:FSV^P KM4=%R:V5R1QXUCU.@X"GZ8]#TGFGD<GZJ7N(I2XA_P #T5O^-4\^
MD_2Q=)9PU=7G/C_FZ^=L>RX^/H7O?<.7VA23RQ,4JJ[K'L3(UD,%.OD>HB6C
MW$B(IX)OP^S;M#I6'>4 U9^HMU#D>@EB J?(ZHNF/I[20N7M)&&F@$,[:1\]
M#''F11Z=)[ ;3CV]N#";JZBWY\>O[V87(TM)6=<]T4G<_P :>R*JCKHI8,AM
MVAWIV!N_?/3^;RV5I*B2.FJDKZ<1^-75=,A7VIGNUN(9K;<["^%NZDB6 P74
M0(R',<<<<ZJ" 2ND\2/+HL@M=PLIHKBTO;661"!X<HF@E93Q75)(\)<C"O7%
M*TSTE?D9O'M^KV3M?!]K]1=H=7=?[*RN0R&R\SOZ*3>6U($R6+CP1H]@]I[/
MGR_6F5V'4I1&22*+)>>HJY3)9 BH']DM-L6[GEVS<[>YO)E =8NQ\'566%PL
MJR"O$K0**9KUO<-PN9K=8[W;9[6&)CI\4:ER*5CE2L;QFF2&K4^735\;=];1
MWMC*?X?]R93(97H#?,M?D.M=U86;[C)_'3>=3"()MY]:5M=!61X;$QY"JAR-
M1C:-OM:J&EJZ"6!Z>J7Q/;]:7-H[<T;9&J[Y  )4;A=1U_LY0*%FH"H=LBJN
M"&7*?:G@G(V&Z=FV><,T3H>ZVD'%HF(("M6N@=M05*Z6P9/;F![N^6.?[U^)
M'RTW]C.GL%TSMO(;>[[[+V704U/1;NSW7U3+M3KC,;CP>^<FV*R=/1[:HWSN
M'I,<K"<R1SRRP+%&_LCGFV?EN+9N9^6+)KJ:ZD5[:&0Y19 'E56C&H5<^&Y?
MAD ,21T90)O&_+NG+N^W*0I#$R331+0.RDI&S)(=(.C]5=%1JS5:#H>.Q(L[
MV5LWIW,?'_-;&W=W%M'K%,'3[)WU2;BER:==X;>!V#M^HW@U!-BMP[RW#AIJ
M6CCSBXSRKC*S(TF1J?+352>R2Q:"QN]TCWR&:+:9;G49(R@'BLGB,(ZADC5J
ML8]=-:JT:T93T=W0N;BWLX]DFA?=HX0JK-K-45@E7TT=VP-17X78.U5;JN_<
M_<^Y,#N_"8^EWO@-T;;S^TL/09K^YV%VS+A=@=JY.KDQ^3ZOS&3;<%9C\+4;
M9SD#T>;W'+7'"+/2PQ1RBH>6)AS;[1;SVTS&T>*Y21BHD9]4L(%1,HT MK6C
M1Q!?$H22-(!Z"$F_75M- \LRS6<B!2T8CTQS,VD1L?$(4!JK),6\($+1M1IT
MY9/L/M?#9+:&U\%M[965QNZL;NW*4V1["QN[=KY*HKMFX([LFP]+2XS17YJI
MSN+BEHL+2I3FNFR+B!#-$T;%N&PVR:*[N)YYEEB=!2(HZTD;0&J<*%-&D).D
M)DT->E-YNFZVTUG%;6L303)(U9%D5U:)=;+I7+:E[4 !<O@:ATV;@[U[JV?@
MMB;KW3U+L;#;:WW@:'=>U-PX[*[VK6R-)E\E64>,V_4KAZAZJ@W!6>%DIJ2J
M@\U18I"'D#QAR#9MHNIKRVMMRG>XAD*.I$8H0 2W<*%1YE30<6H*'IJXWO>+
M6.TN;JPMX[65 ZO65JZC0(-)PY'PJPJQPH)J.EBM=\I-Q4&0KL9\;=O;<I/M
MJ.<MO'?^_-IR5+"1_N*-H8FK<A23Q4<BF.FK(J6LN@)"ZB/:7P^6[>1$EW^1
MVJ1^G'&],8-< YXE25Z?-US1<122VFQ1!-*D&1Y(ZFO<*5J !D5"DGY'H#<Q
MVKV%L]E7>?46W-J1KD*<8BOJM]=HSXFNKZB=1DL?0YFDS51CH*E((R84K/MY
MBI9UB95N3B/;-ON1_B>YRR]IU 1PU 'PDJ5!I7C2H\JUZ*/WUN\#%;ZRMH2&
M&FKST8GX@KZBN!PK0_(CH?,#B,3OKIJKWU2[IP]-NK*;+GWGD>M]J;FS>17:
MF-BR[)5Y?(ON7<&1S.XH<'0T,J96IJ<)38FJKF6BB=9%61R2=Y++=5LVMG-L
MLP02NBC6=.%&A0JZB0442%PO>10T!U93KN&W?4&\C%XT1=HHW)T+KIJ(=BS:
M::78H$+=H\B3 [2JWI:.MA=::KH(-S=C/200-431U,D'3O2$U!2##0_Q')U=
M7D$IHXH/MXKU4A%/(/"[6);A U&%0YCAJ?3]>X!.K  %:FIP.X9IT9-(1=0)
M0$"27A_S0B(&G))/E09\\=#_ +6J>LMP;XQV$DDW%LDYNM[2[XW[G]ZYNKZQ
MS6U>X<(M0F(?#[>I9VV^=C5>1DI,;+AJJ&GCBR*3^;_):&G=R2X7<(+228!)
M@@AMXUC42J\+4U:F(U>(!J<."25I3N=@#B+P&ETZ60L7E;4=!#^6.&FM%(/G
M6N%'2VI=T;JW]CMX1;T5X-V;-Z<@W%FNO.H>F<QLVBW?E-T5<_\ &]E;&VID
M::GR&^>P>N!4/6RUV/DF22.I26J!G\#,D:WMK)[4VF;:6Z*K+/.'**@[9)'!
M(CCEII"L 000N-73D<TTHD6:OCI%J98T*@EN*J#EF3C4>O=FG765ZYI.JZ;L
MFMR&[MS8G.=2;&ZK[?R6.K.N<VU%D<!N.F.X:78FS\MN9*Y4W3F9\K*<]BX)
MQ5XN0+-2I)(H1]17[;BU@D=JCPW,TT((E6H9#I,CJE.Q:#PW(HXPQ -19H5M
MDG)E<-$JR'M)J#G0":\2>X U4_#GIMWQO1,G'4=L;AH>HMP;;V[O!8ME;$Z[
MS^]>J:+=^Q^TMMOE>TNP\1M&@DHMQ[NWW4/25.+J:GR4*!HOO(JB3_*$B=M+
M3P].VP/<I</%^I)*L<Q22%J11,YJJ1BH<"C<=)4=M:23:@;IUB> /V!"RZE=
M:NP H6?B*X]:G- ?RV;ZAPV!R,&T]D[MRJ;;Q>WNM?CYFM_YV3 [%W+TSNW=
MLE3N:B.XMGO@$RN2S$V2F@I,]D::H-')1U:DIXJ&4F<46Z2RH;F\B7Q&:6Y6
M-=4BSHE$.E]6D* "T:D:M2\:N.D1%G'5HK9SH CB9R0C1LU30J16I) <@T(;
M@ O1@OO\U39Z@^/]!O6FCZ!DWU@-G]<]@[?V#D)\ALS;&,QM57UNX=T=Y8QY
MJ&FVUM_<=75X.'%Y.6&>:EJT1)!6RQ3>R31$87WI[0G>A"SRQ-(*.Y( 5+<Y
M+LH60NH(!!QH!'2\R.)5LO&_Q%G"QLJDE5 KJ:48 #54!O(TKJ(/7>.Z=%9N
MC;FY<M1;ZV'%VMW1O+KG KN+8^[,M293.8#$_P 0I]\;DKH9\CMW&=+?9YBI
MRVW\R5,D94*T[Q*5][?=2MO/;Q-#,;:U25M,B A6:AC088SU4))'P/D >K+:
MJTXF99$::0H*AB"5!HQR5""I9&I7U)Z8%W/!VKBLEUF,CUDVQMMX?L;;&^]_
M9A<WU7V5F\MUA7M4;*VIN3L'&428"#K[LO+T[Y"FH\;#6TM,E)'421ST[5#1
M/&W;;I(]P\.X^KD:)XXUTS1*LHH[K&3J\2(=I9BI)8J"&I5M9OJPT >,VZ*R
MNQJDFI#VAF II8YH*C .16@8XO<72.YFPD^>ZPW])CMP9S YKY XG8&6R.X<
M#BNW>LY:B3K?*Q[ASDD>=PNV<_3*:Y,3AZRG>KI*>ND2. )C%]KY(-W@\80[
MA")(T9;9I%"L89:>*NE>UF7X2[J=+% 2:R=(_P#$I2NNRE*2-JET$E1(GP58
MFJAAD*A%0&-!1>EWL#LG<>S-JXCMO8%9M%\MO6DW]V)WYMC;FS=P=W5^<S])
M+4;<ZSEV_@:<UN\NI,UV12254,4\148N&:*GT1R22.R2\L(+NXEVR]27PHC'
M%;NTBVX531I=3&B3+%@D'XR"V0!TH2YDB1+N"5*&KS *9"QR$ 45:/7_ "%
M*&IZ?LGTM)E\*^4B/8>4V_U_\?I^YLIVS!C,INVF"U=932;JV+M9MM5LE#EN
M^=E4VYFI4QLU-%CZW'RNB4[1!0K,>["*81L(%GGO1 (20AP#HD?4*K;R%-6H
M$LK $M7IY[76BFLI6.'Q/$RW'BHTG+J&*Z2*%32G3GN'<]=UEF*S8&S\AU[N
M[=>9VAUOVI@-M=E=85-!5[,Q-4:3#S8[;44=-1?W*[3Z^QHDS64J<Y) ^'4+
M"66D\DR-P6Z;A&E[=1SQ6R2RPLT4H(D(JP+Y/B0RFD:",'7D_%0';S/!(]O
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M:&HCCC351G8GIE[AKV6TN9;!!=.-=O;T#"VAERB1QFJ>*XI)<3D&1G<J"J*
M1OZSVIV;LN;.[GDQ-#M#=N.VUDL%N3??4$G7V[=X46,K4,<FS.\^M(J*LV?V
M7U5D)9(X<U@]S8NNQ\D$C/3UE#4K'*I-?W=C<K#;&5IK-I RQ3^(B$C\=O-4
M20S#)CDA=6!PR.M1T?1;9*#+.8UMMQ6,J9H/#+BOX)X@-$T1QK252#^%T.>F
MO<>9^->7HD@W7L6IZ[F_T<[.Z9W'@^A=Y](;1ZPAVC@M]P=@TLO5V$[RZUWI
MVKU;E:C<=,\.1J)<MNBK_ADCXZ"7[)(U5^V3?(F)M;P3CZB2X1KF*XDFUM$8
MCXS6\L<,RA350$A&L"1AK)J47UK:/0W,?A'Z:.W;Z>YB@BTK*):QI/')+&Q8
M48EY"4)130"C5V1\G>O$RO8>,ZXZ^V?L7;G:Z96'L:FV%25B9;M:'-QTT.4P
M?<O:38C ;FSVP,K-2)X]A;"QVS]KUY8I5QUT)\4E]OY?OA%8RWMY+-<6VGPC
M*12$K6C00ZF195J?\9N6GE7BI0Y%[[=;&2>XMPL:VUPQ\1(M0$@?!6>4A7>-
MJ ?3P")&S4.#0V*_,W;>_M@?#+X>C-G'U?9G4O6U!NKL/K_+T=(*7']<]M;A
M&V=L8V':]-3T6-_N;MU8H<!E,/! GVE#D50QK&I'L"<J3V=]S5S/X)86%S<%
M(I5)J985UNVLDGQ&S(DA/<RUK7H:;V+BTV+;B8E::&)=<9 T^&_9ITT \,#]
M-DI0(:<!T2ZEP>'[WV#14F&J:C#=A=&=4[NVGM[!83;/6>[=U;Y^(/9-)0]7
MUV1W9)OG#9*IS/9GP-JIX]LT];1S?=P[.R6!RJ.KT]1(XN>>39[UY945[*\N
M4=V9I42.^B)F 3PV&F+<0#*58:3.L\1'<H .2R%[''MT4DL36\#B'0$9VM)E
M,)5RX-9+ T0,.XQB"08+U".IIJ/&5%)DHMUS9.OI<QT9G8*->I_CZ[4&YN@:
MEMO;#P&[]K5FTFR6WZ#=FV*B2'/UTWW&W]WYL-55]5344E+#(:+(TBM&UFJ(
M4N5)\:ZRESWR,CB32QC< Q**201]J*SAB$+6921#'N4[RZK8JM+>FJW&E-0,
M995E!/C,:K(^=4::5*<FP6UVRN>Z]H=U[FH-G8OK_MW8.8W'F^M/CXM?B-I]
MY[ZI]ZYNHH3BM@)6T.^AN)7?;6::02[>Q\8H**1::0>WEGN#%%?/9QFZ:>&1
M46:YHSV\9C6NJ6ACT4\6.E)6.MP6'6WL8;>8V2[E.ULL,L;,T=OVI-(')($>
MH,7KH?BBC0O;TNI:J6ISF*WOFM_]?KD9^PZ7N:MQDOQ\^/R8X[DV]M"3J3;=
M*^*&V7I:#KM]I0,=P8)X:G'Y'=#?Q92LRM#[1@*D,ME#8S:/ , ;ZFYKH:3Q
MV.K74RZS^G)4,D7Z610]*GMC))'=S[@*B;Q2G@0 AE3P5J-)_3*?VB4;7)20
M%<KT.'P3W5'!NCJGH:IZ^Z.ARGQM['^1F"P?95)G-@8OY0[FVCF/B7W#EZ:E
M["ZRPNUL+NW(=5D[BB?$[KJIE218*:AJ*<54;2L4\ZVVJVW+?$OKPQ[C;VK-
M$4E-FCK>P*3%,SL@F[#KA%2"6=6TFG3W)\S1W%OL;6]OJL)ID5S+$;IT-NY!
MEB1%81MK[)" "H0$:JGK:H^*((K.^ 001V/L.X-O^\<>C_Z?C^G^'O&[F7X-
MD_YYY/\ M*N.I?VSX]Q_YKC_ *LQ=&\]A?HUZ][]U[K_T]_CW[KW71^G^Q'^
M]CW[KW6MGVC/7P?#/KZ?%/EQEX-O8^3&/M[=.(V-GZ:MC_F&[0:@J,7OK/13
M8+8-='4QI]MG:Y&HL5.JU,]XXF]SWMJH>;+U9 G@F0UUHTBD?NUZAHU[I!3C
M&O<X[1D] *]9UV)3'J\4*M-+B-J_5+33(W;&?1V[4^(X'5/U;N#(KMU<@C1;
MDW(VX=]5NY*??6>Q?9&[J#=5?OW,5\Z[P[+ZU3^ [^W[7T\T=?E^PL-3P8VL
MR4E'/,@G6G5Y4$"?4LAK'!HB"&-6BC*")0-$,W=%&,JEM(2ZKJ QJI'UM+HV
M^"NEY:R%@[K-(&,CDEYHA25SAFN(PJDZ0<J*B%_&#C<+'WAW+]SLW8D+Y;:'
M5>S-D4^%VKOKY*[LP&,QE-V!C-C9K)T$VU.KNH^K*!<?-OGLB:BK5DRE5,E-
M!69NN9?:!81+,VT;526[P\TDA9X[1&)\,R*"'FGF.L6]H&7L +,D*=+9[UK6
M."ZN00K56%%TAYV51K(<@I##$-+37+ T-0 \KT)>*SYA9G:U9DY.MX-A]);?
MSM3-DQM;I/:&U\54U,51-#-EI]V]I]H[:[*[:WYN*K\2M-D)JO%K42N'CH:>
M(^-3Q.6(KE8UOEFO)D 77<N[ 4PH2&%XH(D'DH5Z#!=CDDS;TL#GPKQ+=9&+
MA+9%CR<N7FD26>5V\VJE<411@&/V[VSO#Y"[9W3MW<G;?:^X:.EK<#N(]6;T
M@ZY?";ZS^W)CN':.Z-Z5VW.LMI[OWKC=@Y*),AC<=E*NMQB9"FBK&21H4"D$
M^WVNR3P3V^U6L<A5E\:/Q=4:N-,B1AIG2,R+VNR*KZ24J 3T)K11NBR"?<[R
M:)&5O!F,91V7N1Y*1(\@C:C(KLR!P&() ZF;8QE3M_8V[]R)6XY=T]IR2]:X
M>ER=4]9DO[MXVEESG;&=EIZLM2UT>;R_VF+I\DC"4U331QQZ?(JM3R+-=VMO
MH;Z>W_58@4&HG3"HID:5JY7A2A)X=&4*-&)Y2P\:;L%34T%6D8UXU-%U<:UZ
M.K_,)WKU3OZ+IS!;LS,6XMDYKJ/:^$I>QL!6O7;GZ7[GZ^6FPN\6QU!64D&/
MW-M/<>.R=+C]T8UIZIJR.!9:98ZBD\A"G(]KN5D=TFMHM%VET[&)A1)X).Y*
MD&J.I!:)J#36C55J=+^8S9W45K#<N?IV0 ./BCD7!P11D8$"1<U&0*K7JL#_
M $ ;]K\L*FBRW5VX-JF6BIINR*[?FW,7LN'#R,E$^6S%;4S29;!8JBC@"S4W
MVLLK1-^W$6 42$=ZLUB*M%<1W-"?"$;%]7'2 .UB:X-1GB:=!=-HN_&\0/#)
M *#Q"ZZ2*4+>JTI0BAU5P*CJROMC8.2^/OQUV_C-CT66DD[2;R[Y[;H(<UM?
M(=J;4Q\$E?!A]LX+)05F:V1TCC,@T;PS/.N1S*1Q556\<4J4R@';;Q-ZWN>2
M[=:6_P#9PG2XA<X+.P(62X(XBFF.I502"W0ON(&LK!%B!J_Q,*KJ4>0!J5C&
M/F<$\:=$:ZMPV<[GVOVAU!EQEMW9&DP/^DKJ)'I*FMSV&[#P^7QF(J-O;8CB
MGFJZ^G[ QN22FGQ\182SHDH0$NP%VX2Q;7/M^YQZ8T+^%-D!6B92=3XH#&02
M&/ 5%>'0?M8Y+^*\LIB7(&N/U5P0*#U# Y'1F]\X_&_#G'S=<[BW3T]NK<V?
MZOZLH>WMDX'?F]=D]G=>=J[*W)OO=&)R>*[,Q&U=][%P^9P^%[$.*JUJ<?44
M]0H=&L+^R&SD;FAEO8;>[BMTN9C!(T<<D4L,B1HP:)GCD96:+6M'!&#THO(7
MV=W*2VCR-;1I(C.Z2!T>1@RR*LB*0)-(JI\_+H1.C^U-G;II^RMX4^4J**LQ
M?QR^3%!OK!;XJ=M4F^MGXS>NQZ/"87>&.S6QIJG8O>W0V>WM3P4%7N?;]/CS
MMO-O1P9C&T9JDF]HMYVVZMCM]L4#QO?VAC:,.8W,<A9HV62DEM<K&2RPREO%
MCU-%(^DCI_:MPAN6G!B:&Z2WE+QN4KI8 >)&\=4N(2]%,L84HU!(B$]"=V5F
M-H[>W'O&"IPN*EW!-V[\=MW[OK>SMU38G8#-UE\5^HGAV?UWBXZ>2FC[AACK
MV.)=M<LE6"B,NE@2W;HKJ>WMF61O!%M<H@B0-+^K>3=\AK7P<=XX 9->C*XE
MAA>7X=1FC+>(U%JD,?:O].AQ\_,=$'^56?J^NZ;+4&QLIWE1XJBW33[??:F=
MW;3GM'=.([2HMQU?8F;VC2M20TLE3DJ/&RXRJR%!3X^EDTBA,4M47\HTY;@6
M^:-[Q+,RF(MK5/T5:$H(E<UK120X5BQ'QU"TH'-_N9+6/1!]25,RH54_JLLH
M8N8OZ1 TZEI7X "QR<GL?^5MT;LK^7P.[X^RLOD^UXNF.M\IF=R3/L?JO;>^
M\7MILIDZ#HS ;5W7FJ_:W4>Z.QZC<E+B<I5TN2FRKYB@1J?QU$KPL%[#W%W>
M[YX.SC;T7;/JY0JCQ)WB9](-RSHH>=(@A=%9 GAL=55 (47'*=I!RU]9+=L]
M\;:(.:1VXF6,,5MPC,4MVE9PK%&#^( 0:D@EI^)DN?W[EMI9S>^W-\]Q5\&4
M[%R]%M.1ZS%;NP^X^H9'@VYE.S<U@O\ +]\[FIL;D'C>*DJM-!0T\T-7)%#5
MZXSWF806<=S#:3PVL96(%Q0HRSY<0JV(T)%06'<Q!4$K0[V*6>Y2.2Z221Q)
M**,1K4Q'M$Q7XW4$@T)T@4) ;!N.OLSMFMZ_C[#S^T:?M"HVE#W#@]D?(CKZ
MDW'U+L&IKM];16NW/L+L7;4N($=?LW9'\<F3(5#_ &S_ &F/9C]["DDT@:OH
MKA;XV,%R;<2&%I+60K-(!&]$DB;5B232"HR-3?@) !U;R(UMX\@$I36%E4%%
M.H5*LM!VK7/# _%Q)=NU%HMK=;;)W'LW(Y7;^:K>L\GLW/;YV;O!JOXN5)ZT
MQ&6K-LT'6@3$P8ZMV/N#*X:J-/C:RFKI<E7%Z6D\01UE.]MUW&X7<%TBO$+A
M76-TI=CQ64.9>XD2*&%64J$6C-6H(+KZ3P;*.:!J2^"PUH28*QJ64 4RI(-%
M()8]HIYB5_+4^!76'S1ZSW_WWWIN7LNNWAD.VEW+@\57TL6%SF![ EZ_DQF:
M[ SV9BR-<O<.Q\EFMST^1P0J*6@HL0^'-$&J$BE4H>?^=-PY3W"RV79[>W%L
M+;0S ZE:+Q:K$JT'@2!4*RT9FDUZ^TD=).5]@BWNVGW.^FN/$:X$B*RZ7$OA
M:6D+U/CQDN&@U*%C"Z.X ]$/V'25^QM[]D]84^Z]V[UZVZPSFXFQ.7AR/7N8
MG[LH\_V-D>O-P[YZFW'M^3(;%ZVVAV53SRY7-10SQ8Y*A)*"G!=O0,[YDO+/
M;]P:"**_N$34I65?IRL0E6*=6I)*\1HB$@L11VQQ*MN=K>YO;2)97LHR77NB
M83ZI6C:: J2D22Y9UU !AH KU9C5XK UV\=^]*Y[I-<UL[$[#V_MG-=!;>PV
M^,+V[U!M390P&7V[VW6=J5D-94YJORN3R+S4_GAJ*>*.EI_+34:+=X^665+6
MRW6#=M%TTS,MPS1M#.[ZE:$0BFD "AH0:EJ,QX#.B-<2V<D :$(!X8#!T5:$
M/K\R2:^F!A:92F]<_A,Y%W!O'"X3=?\ >+%[QI>S=G[<ZAW/7Y7>V-S%/CJW
M8$=3\D)Z.FH<^O9F,Q-!65&,,-="?L&+SB6DC-.RFU@FA.UVDLL?@M$8G:9
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M&55(65BH36$X@QY8GH&;O]1>W-GML<TZ)/483Q/#=)%"--$Q[H &+:"WI(:
M#JT'O_XC=2?#S>&UJ;J%<W+'VID,-V+OO.9O/5&:DW#G8>PL12P?PZ>)!_#]
MNPT5?(E'21.RBGG6(O8*WN.]DYGW/FFVG;=-%;9&BC55"Z5\)CD>;U'<Q'$5
MIT*KO:+/995^B+#ZB?Q7)8G4Q85^Q:8"C &.J;]&-K.C=X?WF%=F\ FT_C;7
M^'&4."J*O&[XSFZZB@VON"3'9F&>GKHL!]HS3T!C:.OB_8DDB*K*)3!DCWF
MVY"3>)=#)8 QJ@+KJ6A&JN&K53W 'AT$95BGV=5N@7B*6K"@4E9=?Z;Z&!#:
M2*E#AAVDCB#7?'[%_'OI/JANU\C0=I=GS;^V\-V48K^O-JX_,T?3_6N[)ME;
MMWK@-O8K.U<SX:OW?35$&S-H/45!IJ7&5F<K6K*IZ2FB#F]/O>\;F-LC>VMU
MADT&DKE3/*GB(CNRCN"4,\]!4ND*!%#,37:5VS;-OFW299[@-'J)$8#&&-M!
M,4:L:)JKX<-2:*9&U$J #FY\GW#-15.^.RLIE-M9'-;GAHH&I]^;KZQZYQV8
MS^X<YCMO=:[3V3MG<.%SFQH:NGP;46-R>XL1#-GLS3U, K:F;2&-88]M#K:;
M;&LD21DFL:32E552\SR.K+(1J#.D3D1QE3H4=%BS3.!+NT[K>RR!0?$DBAU.
MS:(8HT96C6BZ4>5 9)0ZZV/1B?C+G]JR]UX*#/;JR6Y^\=Q]4=P[-ZYR.>QE
M10-U_P!UU>,H-V="=2=D[UK8L9M?<.^-UY>EKOX%%CHXHLI3P4ZU/FK0C2$6
M_P -S^Z)F@MECVB.Y@DE537Q+<$I<3Q1BKK&BE?$+$E"6*T2H!U83P0[C$LT
M\DFXO#)$CN/[)S1XH)930-(S5,6D4=5&JK@5K][*WQ78?,])X:0C$9KJ>OE[
M"V7NO?>2W%G<SVQNO<E11U?9.1W)5Y.*.C@R<>[8LIC=P8FC(S5.IEDK+3>(
M@:[?:))#NLR@O!=+X4J1A56%%!$2J!FFC0\3M^F30+BO08W*>ESMEL9%AN+1
MO%@9RS&5FIK=B0!\>M)(T)?34MY="UD>Y/BSN9MU[HJIINL:3LC:NU,#VQU9
MVD324L>X>L\GG<G@,ULKM.AVYF,!NG'56(W%44^5IX),?4Y%1!5$Q5:U$1+D
MVGF.%;6UC N6MY7>&:'CIF"AEDA+JR,&0%"0P7*BJ:3TH.\[#]1>;A=LUHMS
M$D<\4X)35 797BF5&212CD. 5K0,0'J.E/O7LGH<1=B=I?'':>XZK<'8*UM-
MC/D#OC;6:ZLV##E&VS_=^JPWQ/Z@RSTU#G.S:[$23XBKWX,5CL7M;&SU-6AG
MK:F(^T]M8[R/HMMW^[0004)M8W6:6FO4&O9UJ5B#4<6VMWF8*ITHIZW)<;3<
M//N/+VW,OBG%TZ&*-R%*Z+.%L&0@E&N?#C2%26JS,.N\-MW-]^460^._5Q[D
M&P>[</TR.RM[=L;$K.HO]%6V]JRXY<SL7'TT=;5XSO>IW/;[&'-0TM!MZ+%4
M].\"S5'DF/I)X=D=-]W VAOK1I_"CAD$_C.X.F4X!M@GQ>&2TI<D&BT7IY8[
MO?HY=G@AN4V^X$'BO+'X1B1""\0RPG9Z:-858P@%*L2W1K?DGMG$;_W7LW:5
M3L/K/<.S]O[8Z?P'4^V^W]T9K$=68RDV_MG.]:1=A]C9/KK)T53605L>)DR%
M%MNHJ LL53%+4,LC$,&=AN9K&VN[E;RX2Z>29IGA16F)9UE\*(2@@$5"M*!@
M@A<="/>+.'</"MY+:-X%\/PU=V6, *4U.8V!84RJ5S4$FO0"T=3W;N7$YOKS
M 'M&NVMMJKK,7NGJSH[:U)\?^E-OY"&L-'58O=E7AAL_ NY95,:Y7*55544L
MB$*RM=C9QM,$L5].+<7,@!2:X<W,["E04U:V_P!X0 &O#I)&)_#:VB,IB2JF
M.%1#$*&E&II'^],21T/W3WP$[^WM1T]5@=O;9Z]Q4[2BEAZ[VP^^-P9%)"T7
MGK=];ADV=UMM>NAB\B23-D,I.5Y"N6 ]DVZ<Y[+9L5FGDFD''Q7\-1]D:ZY7
M!]-*#[.EUKLU]( 8XXXD_HKJ8_:QTH#ZY8]6+];?RBL&F,Q]9V35T&8SU0)J
MW))OG.[C[(I:*672B45)M';M3USUVB0P@C1+%D$?5=B_L"7_ +G2>)(MBK+"
M,#PU6(GYEV$LG["OY='<'+<=%:X.I^/<2P_WD:5_P]6%]9?##IGK3#1XK&XS
M(U5(8$C--3MCMET-,L<"4[0TF/Z_QNU_#2LJV6*66HL!<LQN2"-PYLW:_E,K
M2*&KQ-9"<^9D+Y^8 Z.K?;;:W72BX^5%_P".@?Y>A^VWUEL#:9IIML;(VOAJ
MFD22.#(T>&H%RP$K,TIDS$L4F5GDE9CJ9YF9OR?9)/N%]=!A<7<CJ?(L=/\
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M=6$B :PDEB2(PQ]J[Z*6XMO#E!1&*@@4&HLP%!\O+_9Z36\D<4I9&U,*FN<
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MPLK$DFDM5W3<9%E A6-#*:B@DJ2-1/GX617RTUICH00)/]%9QLGZE6"BF2E
M,#R[^-/.M.EW4[(R5=%@=IU%5ELIG,;5F/,46%\&9S%'7PT?VK;8P<!$<^6J
MI&'DG9YXX(((/)(]A8(Q=1H9KE558F&"W:I%:ZF\@/(8J2: =+&@8B*(L2X.
M:9(-*:1Z_M%*9Z"3L_KW$[E\6'RF2R.)HJA)%Z^;$5--6_[F<P(L?D,WO&H-
M(8Y,4M=3?;QTL!$5%XGD5I)7!]F6WWLEO66.-6?_ $2H([5R%05XT-23EL#
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M&U?>4/W9O]SN</\ FA;_ /'Y.L<_O#_\DS8?MF_X];]:<OO+7K$OH^G\J_\
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ME>O,Y59'QF+*4<L]%3M(!41>(EPHF&Y647U4A2XL@M7T*4D11Q9<L)% K5&
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M<YB;"5535[CJ:US--+ '#W10 'LCPV^Z\QVB-6QLV+QD5TF.91+\^W4 L07
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ML/J[;E#3;CQN3WCA:R,M435\OW#P4[F%G>2)2;P;=[:7<*W>R;3M5];JL<)
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M>\M-_P \WM#CZ?[G<A^/I_NCWNC?[_E_WD?Y^M_[5?VG_-U[RTW_ #SFT/\
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MKJ!@YN??BIK7QY?]Y'^?KU?+0O[3UT9J<F_]V]F@_P"T9JO0?[80#GWL!O\
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M_P#*U2_^@]%[*_"3^ _[WTLS_%_+KW\7K?\ E:I?_0>B]^\)/X#_ +WU[/\
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M)')"@6 _'X]^\-/X#_O?7L_Q?RZ[_B];?5]W3:B0Q;^[\6HL!8,6^I8 6O\
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MOMO^ PF_T!=,&84_))@66X0GDJ 3S[AOF"GT^P::Z?I7X\?]R;CCT*=LP^Y
M\?''_5F+HU7L-=&O7O?NO=?_T=_CW[KW71^G^Q'^]CW[KW6L=W-V*_7O37\O
M=*6OSM+E=U9+Y98^@IMOU,E%4UU'@NRX]Q;C;)5AJ*>@AP>.VS254]0:I:@
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M75V_<Q1=/;>VK!EO)U?C>O*[$;Y??VZ*?)X)53)8RN>GBH(J84#-+'D*N9!
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M_6'4/RRW]BZ>A:MR_86=IL)LK==1N2>LW5F,G6U5%ENPII)H5S!PR4M/3QK
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MTAH&+[EKF&[.X,FWB)V 6-5E!BD5ZB8W D+,I"T-(ZZFTA:!!6[K^6!T=O\
MZ(ZT[6P.^>H,?TA%N'M5,[MC8V)SZ;BH(\/2=?;)VY4YS^(/7Y+(U.0S>8PE
M1+5U58\=5DJH25DD43SM&L0^XF\6.\[AMDUGNC7A2VTO(RZ#J,LCA:4  56
M"K4(*("0M>A[RSM]QMUM=Q3VBPJTH*J'+U C12Q)S4LI))H6^,@%B.K-O<>]
M"7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJK^;CNR39/0/5V?I<ED\7D!
M\FNK,-BJG#L%RG\:SF*W;C<138]I)Z2 5%?D*J* K--'3,LA\IT:O<D^V%K]
M9O>Y0F-63]W3,VK@%5D+$X)H "< GTST&.:KM;.SL)"[ M>1(-/Q%FU!56I
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M8 GW[KU#Z=,W^S1_&;^[\V[/]F)Z+_NM39RFVS4;E_TM[!_N_!N.MQ]5EJ/
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MC5-#4;F^2,].-,$W<&VI85L%*Q2=!],LBD#@%5(!MQ?W"O, *V^P!OB%J_\
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M,935M+(T9>GJZ>*:,K)&K#W7N'#K%@-D[,VID=V9?:VTML[:RN_<^FZ]\Y/
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MV:,=#]Q+/,HAF^ZJRDD<<;2%;M+MRFV6QN[F.XEFN)D4E0&(*M(RD4=%6K4
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MT&,MJ?6H&K4XC';V,26'8DCD*'8?XK<#P;E?#=9ND[[I=I(H\,&,\*#437(
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M+6US'L$U6(H%*M7Q!2-4)H'-09(#VI=)J@K%<J%;;[C=1\0FD<2:BFG)+#)
MIVOQ,1H]&C-1U3?+#MJ62MPU;#@J'-15530X^IS^PLRM3!D,/)#O7+8?<N&Q
M.4J/#NW9VR)XXMU8O&S5;UFV)J7>VUI,KC6J:&#QY:VP!)4+F$@$A9%H0WZ:
MLC$#L>05A=@NF4-:7(CDTNVEW.Y-4( >II53Y9(85^)1\8%:H1+&66H#K-\I
M.ULI3U,&(I,115LKUM#38P;?H-TYN@KMQL,YMB"CQ6-S])3;US&U\/2R9'%4
MU!4K2]G[1:2NP-5%F*.7$NT.7=MC96E9BF"3J**0O:Y+%28U=CI<L*VDU$F4
MQ,)1?]X7#*="@-PI2I!.1BO=09 !_53*'4-/331_,#L^NF@#8S:!3+M1RT5'
MCYZ+,34[[WI:C';)QF"R!R&.Q&ZI\]EL;/E>OLTYH\1OZC-3MJK_ (/NNB6F
MG=;E?;D!_4EJM:DU6OAFLA84+(%4A+F/N>V;3<+XMLY8-C=+@L 47/V'XL*!
MD ZCF)L+(*QG1(*%V@^6/84S4,T4^RYL76TV-JJ>HPE)4-CFIJFGJ=J+#1Y;
M<-;1TM!A-V[OC#8#+95*2+%[HAEVCN5,=/+39)VCRU8@."LOB*2"&.:@A\JH
M)+(G]HB:B\)%U;F10T?3HW&8T^'2:</V>? $_"32C?IO0T;I@G^5W=F%D RU
M)L^JDQ*T=7DJRKVWD-J82MIMJ5*83<N1K:S+9*7);)V%O+,546*S%?60RY'I
MS>B)2[CIZG UM+EO;R\M;1,#X;2@-4 !@[ N-2@ "DDD:@NBJ0M]!5H&69&C
MZ8;<KV,T9%-/.E!C!.34*Q[6)!,$F) 48-TZX[Y:=DO0M#+!M*BR.-%;2Y>7
M<>/GP4U)D-H2Q9;=U1NW;M!E,WE]K5^ Q%=%C-[XZD%;5[0\E)N;'IFMN5<D
ML+<G+-@'!!E,;4*Z2&J'[4T,0JN&8%X';2LU&MW,4Z@%V/<Y6'!=0)!KBA7+
M:A4D$##@5*8D76AJ&>K^6W=E+-4X]X=KT-;$U9CH(LGM7(9C(TE8D,6]T7+8
M+:64J#EMR;'V<7BW)@,74U$VX-H31;UVE/D*6"KQB/)RSM#!7!D*&APX4$?V
M?:S@421\Q2. (YP;2Y5&99"T^YWBL1I6N>()-?BX*<E1\:@DLE)8BP!7I[Q?
MRU[+W D+8ZGV\K3L\?\ "L)BZ;>.5HH-\4+9K9<VWI,=F:?'[^J<)BJ67*8!
MJ22"A[3VDTLF(FI<_1RXEV9>6;" GQ"^/Q,2@)C.F35528PS$))4%K.:@E#0
M,)0Y'N<TPJ@'V#N/=E2*'NQE",2IE2'!7J/E/E5W!,L59B:+;&1I,DE+58RD
MP<6*RJU$.ZXH-O[57:V>K\OBL5N>7(;DI)LKL:MF^QQ^\)EJ=H9(X;<<$'W%
MHN6]J%4E>166H):H^#N?6H5F2BD)<*-30#3=1^+ 3I])N-T!JC16'D!0UK@:
M34 DG,9- ^8CHDI6/MOYG=AY62!:E.OJE9(Z')?<8JKJ,?B<ICH:R?9M;4XS
M*[@J8?X+MK>&\OVL?D,I#"=G[NIY-H[LAH9):3)RVN.5+&(-I\<'(H14@T$@
M!"CN=(\LJ$^/ 1=6Q<!HQ6'=I9:5"'[.!%2IH3P!; )'8X,4@4T8O59\G.W*
M2GC,;;)K:[%RP39!\KMO<>W,'E\7M*N3'[WK\E45T[5^P\+5UU9%A\V]7%45
MW5V[EA_BT-9MVNCR:L)R]M;L:B8(P--+JS*7%8P ,2, "\84A;N&OA%)T,9=
M:_N@.T(7'J" 0#W5/X1^%B:F)Z:@4.KI&4OS"[?H94I,Q'MVC>G6HQV4JLQM
M*NVW7T==M.ODSVZ<QN?;L.=S.7PE?@-MU-/B^PL%0I6UNV:22FWIA#FMORSK
M"L;E;:V!>(N0:$:7#@AQI14;2JL&<%[:1M*RL&M)O!G JF3=[FH#J!Y9!!%,
MDL*D@J*"514J*2IKC)HMYOE!VU-05;X:EVY35D<LL$=/D\,N;KL94UT(WA2R
MU^'V;F*L;AK]K[7CDER5!B*F=MV[.GBW3M6:M:"KQB(UY>VL.HE,A3Y-I! [
M#1I%&D.] C.!X,X-O<A RR%2U_<E"8PM?F*T\Q4*<T'$*>]/U(R:%>D5#\S.
MTJFI$$./VG$E76-3PXW"8T;NSZ#?>*_C^S</AC09FGP^^\W045!+E=H55-+3
M8KMW;,D\6/J,=N/'R8Z56W*FVJM2\A(%:L="_IG3(S54M&I)"3@@O92@%Q)
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MCH2&H#B>PMT9=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1
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M9U0+')(-*TTMJ:, 1< 2*O%X+GL;,FWR&A\2RDPS/"Q#21+0FI90H8DMQ(&
M^L#N7X;A>&F=>LV"W'YN#*V6ILJ:6LH*E=P8G.PSR;PJX]E;2J<?N/=<<%%N
MS&[NQL$FW]L;AW#'!2;RHJ:3K_?T=#N"AQV2EK-;Z?+0RU!&DJ1H'B."J5*%
M#226.(EH&(O;(O [QBT,X84XJ:&M:_%A<MQ##M1F^.A@FTR*&,^NI**!(+SB
MGQ-%4P9+"YG&YO(XZ?:>2P=?4;)VIDJ'/[GHTR. @VO7SSX+$9O<$,E3LFJE
MFV-OB"JP%51UBTC=V)HM92"&4J#K# 2."J&C:P!(\<1I. +RS99U9>KNBT K
M1 :@@FJD=JD$\*94%O@-8I04(/3533';,<F(R\-/B<3AH%,=12X'.;-HL#B>
MMZI)3G<4YJ,CN#KC!];[BK]4U.%K<ST7GJL20#+==9-C3N,/J")8B6D<\"RN
M6,H^$X"RM*HP>V/<(UH?#OH\T5O!&B040>@(H%\QQ*JIXC+6[&HU0-A[R.(2
MG$^/RE/+&:0"AJ/O<%3[?HY*+!4O]]=PXG*X'9TTN2VVFW,G+%N3*X+;TS9/
M9^1:+?VPYJC#5%71JU'*6H\;#.11BQJQ\-6#/AM0K$DDHT3K6RO LJJ_3CQC
MX6'#Y4&.X@A<BA[B%RAI-"2I(Z9:66NQ]:**JJ*JMEK:L4=719&;%;BK\]DM
MTXZ?>6YJ')[?V93Q8_<NY]U8FF3/[BV]@Y8,/VABXDWKL5Z+=E)D,;*ZZHZ:
MU4  5!%5"A#H0AGRB(WZ<<D@+VCDVEX'MF20-(Q0Z2:DGY$DD:C4#!8CN95[
M9A^M#20,I?/'1Y^D^^HF_CM)NRG6"IIH5Q^_GW"W8M*%CJHJVLAQ^U>P1V/M
M;'>)9YA2XGNO#TWVE6N,WQBDU,U>%M#]C1&H)K'I\(\*"KQ^$YK05>P<ZE\2
MSD/3I"NI9>Y6&0.[5J_8&U#[!,,'3*O2;K:.;QFNQU565E%D%@RF"R^-J,1-
MDX,OFXHNO-IU=#N7L)129+<]?C/+MG;NXMS+'1;NH/+UQV-%!EDQN590K"NA
MU =:AE(-"J_JN"L60@-)98HJM"U+^P)B,D?2=E.&5JH:%2*5!/:N7_%^!6?$
M@_0G ?2W3E2YBGHV=*JHI\1'1/55^*K,-GEVI3XR/:572;&PVY-N93<U+5Y7
M:^.V5N*:3!4M;G4DS'5.7GEV9O"&MVC5T61#;1LXJJEBU 0RZR=8,C*P0@.9
M%I(5CHEX@%W:E+I73IU9 #1L 9!!H!I[003D!3V]W="Q,4H,1#=-F0I:+!//
M%*<;CL5AX*FE=3D-X;4Q>WL1UA7C(2FHI,:,INGKS;O5NZZO[VU&:W<'0>X:
MI<M0'+;"R<E/ Y&SS49=32L0>".6,PIQ-$E:9!I[M,>XQ#PW\.]C#,VZH@TM
M30!ZL*:#7RJ55&H<5:W8ZAJA:@G0)+-)_"LM0S4F9I8JK#3KE]JFABKHZ-%[
M W?M3=.W=IU4LM#DL2TT6XL[@MN3L<9,T'8774U1C9<ECH:$@#Q(W!B)U=KU
MI7]-'1G&0<Q1R2CO%;&^"R".0N*2QT,*2#%2* _B8,!P(^)E7AB> E=2B=64
MLF<6H#T\\^4JI9<9G\/F*/;>Z)\M/N]?[R[DPN8P6WC24/84G8& H(\OE\3B
M)(,5VOBZ>/=>UGH-Z8^>FJ&U;P2I# 1C*LI9-.CM1E9JF/PV.A'>KV;DVUR'
MM'#+9@)0P_'P((#5KD@@?$&&6"XE \2.DJD%GH\@U2W@:LJLXN>&-A\TF?QF
M_ILS4]A)48'%29":NH\9MWL6IW]M>@-'B\G7)2X;NG"P?P+.IB]_X^,S/,@&
M=(0I7&DQA1'W&E"6B$;G4Z*2]@Y\:$R63FC:OG23753-0U=6!6M VI<*QH)P
M-#Z9E%5#IH*NG@!DJ6BB--E]O9^EH9:VKPU=74$O7FVZVEW'OF5::L$T<,VW
M<'E=QIXZRD,O7W8D$;+C\DJ?O5C@5RK*30, ?%8%(\CRED2+(:E[8D]\?3Q"
ML #6G$&F02-(RWYJ"W$?HSC@W2)R>,J]K5QJZ>GI<''@%J*N!X9(]GXK&X7K
MT1[9V]7X_/9T9#='7^T-A[FR4N,PFX,F*K/]&9RK?:VZ(\CLK(T=8JV*5;E-
M+,7+X_C):7N8%5HDCR( \D2:8]PC47-N8[N-E*-T:!]2+2GY"BX%"<JJDT5S
M5K9CX<FJ%@0KZ6LQ^0CDI*V48J3&+54=519*IK]CP8+_ $>"CS^5HJ[$[7&0
MW%UK)UAN*KBRL]!C)*K,=0YN>+<>W7R>R*^IIE2NCQD,@U!J$$ 2:O%JH(9Z
M++XJ@H&<!+V,&"<1W:*Q4I(DJZ6P1BAJM--"00*E"AS05,+$2)JB8CI,5E'5
MXRLG18XDKJ5Z_&3T];@:G)SS5344'9F\\9FMO[!6.&HJ)8BNY=V[:V[(T#MX
MNRNMI3(<EB44(ZR(*DZ#0@A@,5\*,JTG#_?4,LN>.WWXIX<I3M&T;EEH&%1\
M/^W8$+Z_$Z+_ ,]%N:ZDZ6%!7PYJ&I2+'S9)Z^I%-F\!]A@MY55?/V'3+FLC
M6T]#CYZ# =D)V+MZE&2R5'C6IL/W1A:=,O@Y,;O?'U-/(EDC,+*2^F@JK59
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MNM!V!CXHNP>OY8MPPY7'EJ2,@F1% H*]NH  ,(U96D[E"-^G'))W6S$V-Z#
M8WZ<1ZC06\Z9H34C400N"2.XJN)1^O"=>I>F7)XN2IFCJJ3[G-4^<EH&:&.J
MH>T:K.UF]\)]]4S01-!0[4[3K>RMLXU8YH7>#;W>F I;R?8;_P 2HE>CD"@J
MU$* YH8@HC:@]7A$3G!S+M\AQKLI<-R1FNI<@^0[ZZA6H'!]8&1A;A1Y3+F;
M@LRE=3T4@KZMQ+'B\CA<_CIX\[44[[OK#MW9U7C-X[\2"CW)%N6GIWV[MW<&
MY%C@WO31R[![$CH]PTN+K)*31%&<:!45#*1I^ :G!2/*Z"?%ECBJ;<TO;$M
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MVC69.KIJK(Y5HZF"K2*<T,E#,(D:N;R\N0)MU>6UA20B]4QU0C21'('!+-K
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MB*0- Y24: A;B-&GPR&965*M&$8ZWCCJ]HS?56I>UD=0L5EE4-&=08#AW5U
M@$%L$MP#-B0#PY0) #TE1!/M=Z+,X*>6LP593XJ7'5=-DH\2L,5)72[4VO32
M;OWY2R5>$.'JVEP.V=P[@C>JP53+)U[V*DN,GQU;&JU+<AHIEI,"U135Q&MS
MX<9HVH4DFBC-) !?6%)!(A2Z6MR)8VK":4S3^B 6;A0]J.V5/Z$]5TD*IJW'
M#&5-0*QZ+"4L&5G$JYF;KV79$NT,W3X:.,3E:W<G6>)ZYW-6FG$U5]QG.C\[
M4G&U2UVP:\3QI=$@D4:*S$@?")?$UJ6^22F5!6@I'?QCQ%T7J:2K#HR%@>S/
MGITE33[5TG&:M QTFL)KTC<W03[8GR1E>CIX*&#=M+60Y1-R8''TU%MR:GW%
MG\1E<+LP5>:VIMO;.:FCSF9P^!>;+]6Y61-\;'DJ]L5==0(LA<7(C%"22A!&
MAB2U55E:2BN[K6-'DHEX@-G>!;A4?I)*CP:BI% &XZ@*#)!"Y"@]S!:M"WZT
M-8RR]+VBGCW [PRP3?QJ"KJ\9.U=M>ER-545,^'H=X;IPVX-O[8JH\;N*IW#
M1"/.9W";=D&/W=CEI]^]?R1YJ/)480NI@H01X) (HY  #%$96<532:QQR2]T
M+:K*]!B,;]*T82 X(<&F17- Q! P:CN(7#BDT/=J'29R&,JZN>FR&.>NJ:Z:
MOQ[9;!F3 [TJ9*O?V.K*K(YS$X^GBI<'VV.U-JTA>OH0\."[PV_2FHIACNP,
M7>52DJJK1R!0@4T;NC%(R %)-6A\%SVM0R;?*=+>)8R88DA)82QUU5R/BRP-
M2 *!]8^)?AN%%1IG6IC[5W"K18LR5D571UU/M22CJ\?O"7=+3C<U7D-J[8R]
M#N+=E/%2[RQNY\72O@-L;EW (*;?%%"^PNQ(Z7<M)C*]_7,%&EHI# O4%-%-
M #NI5#6,H3XDL453;L1>V):W:1!J"4Z4#GB%_$6^+"FK?$&^%':FL?HSTD"G
MIRK*?'QTM.L5<L>(0X6NV_F:6JSN-J]I5&/S%7M? 93';@WC2BKVYCML9J.3
M!X;,9Z)ZO:-=(^Q-]15&WYZ>I%$9RS53]7N#*0I#@J'8%4-&+K221(S290+R
MS*SAEZ<=5H 6[,%3D%36@(+< #VAFRA_2F!0@]0:6<[=^YQ&7HGQE#C:;-9$
MM012; QV"QNSZF#PY7#O]U6Y[J[;_6^X\JTM32Q&JS_0V<K \1R77>4)@NZ^
M/IEC?4S%1G]0L7!J&P%F:510$Z8]QC6A\.^CS56\*L4BT0 G': %/$>:!2<C
M+6['&J!JAVRN.E!J,;DD2)88-S4!ILN)<+024NWH*'<NX,?D\#L@/E-J0X#+
M5$&<SN(V_,<ELS(F'?&P9ZC!U%=2!J*0=KI4U*'M[C5JHI#28<LH,<;RC3.M
M;.]"S*C=7D0Y0^AXX&*$X7(H>XA35#26&J$CIEB:II,G/%61UF;J,A534553
MU6-;==?EJC*;4?=6ZJ;(;<VG+2X7<^>W=B:1<YG]N8$QXSLS&4\>_-BM2[MI
M*W'2.D*T:E"$5144.@+1]"$,]614)\..62KVKDV=YJMF204#,CD,"23Z5KBI
MP,$D=S(N)1^M#20,O2IIJ5*Z&.KHX7SL.=CQ<F0Q;4>(WPF?&]L,Z4.3C->\
M&VNQ:OL7;E*5BFE\&%[CP=*U'4B@WWCU/M.7*'2[:&2M#5H]/AMD8[XA$QR!
M62QD.I==FYZ=H& 95#!N(H&KJ'$5PQ8?[6910TE'21FCEC&-JZ+(U]9!D:K;
MDF'SV-W)MZKKEK\UEZG:6SZW'[DWG!'3Y;<-?CJ5]M[;W%N:-:'?U%&_7/9:
M0Y*FQV0=5@^(K( RAM2E& HJAW!2,U503XLL41U6[$7VWDQM(@3D%-)5B5)%
M&!!-2:+EN+$=J,^)1^A<=P5C*H,Q"(/!45T%-#3QG+4==0;FS>%H\+2[<W?)
MM7#;AV]N+<E!59O9^'V9DZJ7#4U5G(ILMU1F)Y-E;UCJ]J5F/K%H\9K58R2>
MT@HK%BR:V5E4A7:0 .1&0EX@%W:%;E77JZ2>188R#4BE&H""150I[>[NA;]*
M4&,J>H.5Q-/AA5>2#&4&/Q,&961QC=P[2H\)CMJ9:"<4TE31U-7N7JW ]?[N
MR(KI9*,5&X.AL_6)5XS[_KK*544-XY&ETT+-(Q7S5RQ<<:$!)FD0:0&I'N,:
ME9-%]&I-9$$>HD (*^1% #ZBI0*QK45:W8U6L#&CW%)4&HFH<A(U%E\549O"
M1OEL;28*'+T^ QL.]MS[7W;M39<L[XBMQ J(MPY_ [::08J1H>P^NIIL7+D:
M&-HA=(=!6)@K=I+:2Q\-'1Y*:@U#%')+36*V-\!((W+@8U*L:2"H%<5H-1#!
M>!'Q,J\/[>"JZ@.51#_&WE#&2?,SUL6/S&-S AW77Y*NW)MN3<VY\5F,#M9*
M3!;_ ,AV+@J:/)9K%8AZ?#]JXFGCW9M"2@WO03Q3:!\$ C$0%5*]@ 1]",K/
M5HQ$Q*1N]7LW)MKH/:."/,OB X[^!!SQ%2"!AM0RRC$H'B14E!JU8JID>JI
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M0:QHX*S%5H-1*Z6)<&H'6R_\='63>'R;E1(8TE[IP4J1TZZ*=(Y>B>G)$6!
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M8LCA :H3Q)_&H<G4B>9HL?#V769VLWUM&&6ID6-WQ^V.VJCM7;=*KUE*JTV
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M4S#.EV)90[ B.BR-(H#NB42^C N;8I=(Z%A6:)JB@(4>JB@- 06J553A2:M
MQ\.35$5;I;B7$OBJJ"0/B<1!29J/*4$U/5=;U.RJS:%;2Y2HABH,6,EN;KG%
M]>9VJ7*34])+/G.E\Q5#.XELCLC)3TZI*2^(I'?*2M#42B0."!DT24RJ- +
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M67JMQCL#+5U?N[;5334=#5Y-H*3;79R]H8*D6@QN4K13X7O3#4XQN1&)WYC
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M>/W=24E84+@Q%EE.D+J J=)32VHJRKF,(WZCHA+6C$75L7M69>EJD.H=!4,
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M:-J:"02:]M:XJ< T+'XF1:"5?UH:2!EZ4@E;(G[RAB3.PYBJIER%%KVYO/\
MO!+OG$2+]W3S2+3;<[2K.T]OT?ABFF^VP'=>$I/MIAB]Z8X/(Q0)V.=!4&A[
MDT^&W C+0B%C4@5DL)#J'B6CT"C# LH#*W$8:NH<1Y/K'V+,HH=,J])L1_;/
MAI**ODR-!/D-GU&&S%#NJ;,5JY&JI,AM'!5<.XMU4D%#G<[D\;$^VMN[@W!$
ME!OC'>3K;?\ %!F8L9E"H/<)=2:9 KZE*:10$.PTH254']66*,ZK=J7]D3$9
M(^DY&@I1B4)6AK4URHR10L1V*S8D'Z$U'TMU(P.4@-)0P5#TE'#10;?RM'5X
M1=P[:BPT6WLMD=O8'-8+-;U2IR>R\3LC/3' TU1FTGR?566FEV1O&*OVU5T6
M06LT9U.14DE@0VE]6I0S*RQT$AD7]0B,A+Q +RU*7"NG5HW#*JD@  $4J*4-
M 06RH4]O=4PM6*4&,@]-E=1/@**:*:F;"8ZBQU8\4<=(.O,?@:#;NXX<AI6>
M(9+/]4[<ZMW-4FK5:45>>^/6=JOXA1-E-A92:G@NK"9P5;7(6'GXI8LE/DLS
M3(*9TQ[E&-#^'>QAC5D\/%"%I_I0 #7YE AR*5:V8ZAJA8@.K51J)IJ"KJ:*
M')TZ[UPZ?QV.3#T^7I\$(-R;JVSNS9^QA,N'EQ=7+%G\W@L!-)48AI8>P^O9
M9L349#'1MA=(#HI,9\-NWN*ENU'1Y/BJ*QQR2 !Z&QO@)%1S<$L:,1X@U#.*
MTR595X$?$RKPQ/ 2I91GKL;#N!ZN0XXUV6=]S8_-8ZLQ-9O;)9J?<6U*/.9_
M 9C!X:;'X3L"I[)Q\$65RF%Q,E/BNV,?3Q;RVE-C]Y8^:EGJCF#2-=(^PJ0P
MC"A7*JRLU6B$1JB2."]FQ-K<A[5PPLR"6ITU?((/=6JU((&&U8+*,2@"6(B5
M2#"QE34QRP 1MEOOJO&4HE046^6R%=O#;7V5'14V8SXI<-V5E.R=OTQQ>-S5
M6E'A^[\)2OA<JN+WYC!++=PI#5;30$^<= CU)*K5HEB8ZVC74]A(1+'XEG)0
M41B" 16I _BJ2.%3A]0PK&@G7L;3,M2^4TU--!C(VR;PT8FVC6[<W'CMTT\4
M^&G+56T\%-2[GWK0/!D\95TYEVQA,UN2/[;+TXDZX[ A21<?D@RRL&D(C[Z.
M&4H>[@[52,X(Q+)'$:H:7]D2"\?3O:P4%L8TD'@> RW$?@4MAA^A,/A;H/)8
MFV[4T]0M7C<)'B<=B*A7_C6[MN8W$XW;^[:C';<KH=PYZGK,YLC;&P<_4MBL
M+FLDM5F^B,Y5/M+=<>3V?D*6J1>I^H5E*LY9C^%&+%D!8:5(61Y%&N2-:1[C
M&!<VQCNHV4H2IA=2I"J%'FP  ;MR02JJ<*QJULQ\*0-$P(6$0H<IBZN.HQ=/
MC:FBI\M$\,VWLWLUL'_=/<\.4GH<A1TTM3F^LQUEN25<E5T^->LS'3^4J(\]
M@7R>Q\E4P(E8/%*I60LI(SK635K0@$$T67Q4[%+!4O4!AF$=Y&I*M625,K0B
MOD5II/ CBA0Y-*F$D.FJ)B.DSD:.MPE=-'%3+!+#4[M6:FR.$I,5%+% AWGN
MO'Y39FRWG1OO*I5W1NO:NW92J1&'L[KF81-D,5[41NDR#4U00F0Q/']-"))/
M0?HPS2C.=OOQ7PY.DKH\3@J*$%N(I_2:JKZGOD1?E<0?B3I>8S,19B*=JB*;
M*-EF==R859\;OZJJI]W[27-9.:*CP$5#A.SY>T<%2Q5U9C<::?$=QX.%,]@6
MQN\Z"IIID4D)B(TD*%^%J&,#0^D9:K1>"Q*JS5>QD)AF\2T=6"R.42+4\3\0
MJ&^(5\L/K&:"BS+WIIE!'2:R^"J)ZBGRN&J(\C)DUPU=3U-#,=^U.8RNY=I2
MX7&Y3&9/,?8X'L/<'86&@&%H<ADA3X;NO#TDFU]R+CMY8ZEK95$4ZA3%,-(7
M4*'],*$?400M6B6)CXC*E7L'87-OKM9&0,RPFOBQ&I-#CNU$K2H)H&9AV@GM
MN%'AR:95#=3MJ[C%?%B5ED:GD$>T,MC<C@<E%01TRT256W-L9W"[LWQ2?>45
M)CJI)-M8+<&XJ<S4CO/UQV# 5DH<F:7-OX9E(%1WJ0PK6M&=62,T)(I+)'$:
M-B_L3AX^K03!PF?0@@^F 06]/@5F%0:P3#@W63<>&$]']Q33TN#RN)H*"K56
MW)7]?47VVS-U/3XBMH,A-39',=7'K'.U+T>/J*@5F6Z6SE0V SRY38V1@EBU
M;3:6HREXV8CX!*>].X$5"S>*HU,!I2_C'C0^'>1D'T\.M:@T<#^(K\)P0<E"
MAP#DP-V/JA;I*4.7_@L^4%;#144=!!NY)**IQ^[MK-BZ+;&XL=FMP8^?!X+[
MS+]>4>PL]7)F<[A\6U3E.I<O4C>NSY,CM+(U5 BEXO%$1C+$L4R"CU+J54AF
MHLID4&.-WHEZ@^DN@EU&KEB&5HRPD 'Q_P 0H%-3CBNDT+J*F%CXL1:)B LM
MR;7ARU/5U<6.IS.)MUT==BLCM0544T-<*;=>X<!EMI[0K!!EZ+.+%'N3/[>V
M[*L63C2#L;KZ:.JBR6.9+;W)B*H7.FB$$/2E*HK*[CM*YBCED%4S87P*F.3I
M1/;B0%PHU ,*$>N2"JG(/Q,J\<3PD$,.DCA<Q7X^OE@KJ>JS=+E*VJI\QCIU
MPV],EGY]Y8#[RN%32T I=M=B[L[0VY3K6RPT34N![[P%''E<8^*WUC7BF4S0
MHZ!HV",H&D]T84(U!0FKQ)$YT@M63;I&,<@DLY 0GAE92=:U!.1AB=0^6'9Q
MG%%N5&I=,RD%>@TF;I,5XLG3Y>BRR;8GP>:I<U_>^:OJ]P8.LV[AUAS&>HJ3
M&[URN]L= V%QV8SJP8WM'%0R;,W?%1[JI*>KD1]\+25C*NI?4I710*P9JA23
M&(S^HR1U:T<B[M2]LS*%O;(J=P9&I0@ZJU%!DX;4.T%L2K^E)20 ](;'1SX/
M(XRHHACWCA&R:VDK,;5YJF6.FQ=;D-M;:R5!NO?-I\6NW)99]M;7W!N".23;
M=3--USV'%/B9\=E%5R%9HY U:GQ 00IR0'8%(\'5B6:.(TE 6^L2)5DCZ2*#
M#(-(&GM]> J!W-PI\*.WPG]">JE6Z7E#/'-1)D<>\.WIZ'&,'A\$G6F,HZ#:
MFX72.@K),@^3W)UI1];;BGT+]T*K/=%9VJ%)4C)['RL3HC<$-X<@\0%O^:I)
M=>(I193*OI2/<(QJ7P[R,@JU.I=2$*0/]*,'@>)72?6K0,:'5$PZ0N?QK86D
MR56/MX<!#3[BQV:Q.>_C6W5VS_!ZBBW/G,#G=O;*CK,UL[ ;3S]2FX<EBL)+
M4Y3JS*RP;YV3+6[;JLAC45POXS(N3,2I4KI;7J!165I**[.H\-'D 2[0&SNP
MEPJ2%+*@CU.*"(5J#4::9((7(4'N(6K0L1-%6,LO3Y'D8:MJZAKXCDXZVKW9
MC'_B&#FW!5U<F5Q%!NO<."S.&VG-24&>S>Z*2&+<6:P.WY(L=OS%QIV-U_+3
M9B+(XUF2A4(Z'25"'#:0-+%%96>I54-8HY)*M;N387H:(QR=.J^JH8$UJ.%>
M(#$$#!)^)E7$B_KPD,&7IIR^)G@JIIJ.B3/?Q7(54M4*;&XK?E9G)M];=I9*
M^1*>HAH=L=JUO;.V:&-*JB=:7!]];?HXY(VQ>^\87G=CE5E =M&E12I,87PV
M-,Y>$0N31LR;=*Q!\2SD[6Y(])U(NH,<T :NH9QP<N.(PMPHJ-,RY=,1GK_P
MV&;*5*QR3[(JL+N"AW=ALE)!D<S#6;:P%?C-X;CHZ6CWC3[GI*1]NX/<V=@B
MH]^4L4G7V^8:3<5%CLA.W)#_ &A$0J!(&4HPPM'8%%)*:"?%DBC):W)%]9EH
M'DC%HY1159SIJM&U Y.!W$=P/PJ[8<?H34<*QEB-*O\ A\OW>-HZJBI=KY2C
MJ<3FMP85*&+!;@JMO[=W!M[<.>HY*[:]-M&OEEP>'RN>@EK]BU=34;&WS#5X
M'(4M:E?AUC2Q4EP055JZE#,K*IHY<4D=(R%N %O+,K,C(7*!M() 84."1P-
MP)X:3V@ME*F&8%&!Z8*)SM5'@>&FQF(IJ">JGAIL;G]D8W;]#M#>!-1/1M+4
MY'/=:;7ZKSU5KEI4-9G?CSN"J5X?XOUWE"8'F_QDUU%I2U 25D+%T\\!97F4
M4![8]RC!!\*^CRPA,!" !8P"?-0-+>7FJH>(RULQJ-4#85=?2P"GKX)Z3Q88
M19W'Y*BR.(DVR^.3&SQ;JS^/J,#LYJJLV\V R;Q[CS&)P<KU^UJN2#?^QYI\
M34U5![3(QU(5:LO:00VNM>Q2&>@;4*Q(\@"S"ME> 2JK]*B 0P*_IY!J*4H:
MG X4/<0N5-)HB5)'1OOAQ25\&5[.2HJJRJI'FPF07S9_;.6$V0SM.<I79O+X
M7$45/#MW=VZ8F6OR.2P$DFRM]))%N3'PT>1KLM3J%^:G0Q;=I4!NX?"ZX4T"
MJS$ZD3X562D]N08'+HD3=&&UHR-<5)*D@\0:DC)(& S<6*]DF)  Q8=6!^P5
MT<=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1#?GI'N9MJ])
M3[)VIM[?>],;\@,-FMK;4W1"DN+KLKC>KNT)(IHPQ<ME<=%KJ*)1#5L]4BJ*
M:?\ 3[&?)A@%SO N[F2&T:Q97=.(!FAQ_I3@-E:#\0Z)MY5V2Q:.%7D6X! ;
MU"/D?,>6#GR/5"VZ!39/I79^X-PX&DW)L?+=C_W9J>Z>R=A8W!_(#/[0CKIZ
M[<F"PVP1D:FNW'@MH[_K:C'X\H\&N&A,CUR+3?PL3+!5-UNH89C'>+!J\"*0
MM;*] $9I* *SQ@,W'+4"'5XG03;OM('=-<)D"F21:2E?.B_BTL: 5'#XA33T
MR?R@*#X>UVZNT:[Y1?Z'Z'M*; 4.]-CX3M3<<=9MROV9U]O@5F7[0[ VCNK"
M0;*V;VMLO?%31X]<W/D6R5=1.B11I! 05'N@W-*6VWIRX+IMN$ACD:%*,'DC
MHL,3HQDDADC#-X870K5)))Z(^3WV;7<2[RULMTT?B*)&'<L<M#/,CJ$CG272
MGB%R[+3308Z*)N;#](T/RQ[@VYT!68Z#J.EE[0PW7,$51O/;V9R.ZL-G\#65
M&/[JJ][Y2LR>Z=C579LV5?#2 P+GL8P3'2T]/"DP$\$N[R<L[9<;VK'<SX+2
MD^&RA"K &W$:@)((= D&?#?,@9FIT@2&Q@WZXMMK,8M5294"^)K#51R+EG8E
MD:4L8O.05"%0E>K+]P4V_9CG\IMG<%)4BA^,79='/F=F9_9,'Q8Q?6M/MFOI
M^VNO]U[2$2K!V]/O&LI)Y%J/N)I)(A)-'55"-5B/[=K*L$=Q 1JW&(A760W9
ME+@PR(_^^= 88H!6@*J0O0PNA,([B5'X6DE2"O@!=!UJRG@VJA-:\,@G/5Z?
MQD$:[@^1:1"18H^VMK11B;7Y=$70'3$:ES)ZV8A;W/U]P]S%7P-A)X_2O_VD
MW'0KVSX]R_YKC_JS%T:_V&>C7KWOW7NO_]7?X]^Z]UT?I_L1_O8]^Z]UKUUT
MF%I.B_BGDZ_:^Y-Z;G79_P I-I]>8#:.[J'96XJ7*]B=V4FVMU[VQ%=E#'BL
MSDNO=K(V2@H:IE@:1 Q_J)P3QFWCF6*.YCBMS+:/*SH9%(B@+)&P&5$K]I89
MIT"U6/Z?:Y3&S3".94"L%/>ZAV%<$J!4 ] %N+J_;U%V#N7H[,Y#;E/V1N_=
M_6'5.SOD=-OW[O>W838C;5=N/'9^BZ]ACAQD. R6$JJJCR^6IWJ:6LJ:=!+"
MM)3O![.H-QG>RM]XB20V$44LTEKX=$BJP4J9..H, R(:%030ZF#=)Y(E$\MI
M*ZK.[HB2ZJN]!J!T<*::AB,$^6D4Z)QD_BS_ *1<B^\MN4.;.V\QW9N[![!E
MVC+C-C;2V-W'CJN.)-Y978];MW/UL%74P52UN5HZ!6D=<E3242H\>F(4Q\R?
M0Q_27#I]0MHC2:ZR/) 1_9B0,H(!&E&;^%@]:U)#)L:3S"XA,@B^I+(J%51)
MZFLV@JQ#&M7"\:@K2F!GZFV9LWK';-*-^G:YQ^VMZ5OQYR/7';&R:]MOXK?&
MX(*W<.Y=[;JWI3XI,[N**KW/C):>IK\5/65='4Q14$L]/&_E]E6YW=UN-PQL
MQ)K>(7(EAD&HQK15C2,G2M$((5PJL"7 8BG1C9VT%C#''(1I5C%I=:C6W<TC
MO2K,6K5@3Y*2!GHQ^ H*;#TG3.:RN&Z^RF:[3[A^/]/OFBH=Y9F*+X\9'JGM
M'"+U+B.O-IU?^4UV4W'#)&:V:JDAJ)J(*E=3+5&[$4SM*VZQ0RS+%;VMR8R4
M4_4B:%O&:1QP5<Z0 0&J4;3T8>&OAV;31QEGFBU ,0(S'(/#T#U.*UH:?$*]
M;+L&K2^I@Q$T]B/]297**?\ %%('^P]X_FF*>G0YZS>]=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[J/42>- >.6 N6*@6(-RR@D#CZCZ>]@5/7N
MJ3MX9:7%]F]EXR;$>7%UG8.^L=D-I-M**D6NK-T8ZHK:[&2=:2U4D>2W'V'M
MW&"OK<!1U:X+M_"4BYK!3XW?6,>EJ):M8M>W[?()*2"",A]=:!" "):86)CI
M61E\2RD/@S+)9R!@$Y9=-S=(5JOB$%:>HK31YLP%2H.F=1J0K,M"WY*@H\_2
MXN09!,G]_-B:C;&Y8<P.PJ[)5.Y=I5>#Q"5&4SM-CL#V#6;^P2-@\?E<RE+B
M>V,) VTMUQX[=]#1U9<BD>%I!HTT#!TT^$ $<,U I+1B-OU&2.KV<A^IMB]J
M[+UZ2-940AJUII;XN(H*UH&U#M!:@F7].33* >D+A:BJP];CX8UC6>ACV#5T
MTM')DH((HL=#7[4V=E<1NG?RO48REH*LR;=VMNO<D,E7B9C-UOV5&]#)C<FB
MR95D20DG2WB UH3DAW5DCP2126:&(@.*7]@0XDCZ2QL8W5?Q@+ZTID*0S_FJ
M.U2IK!<8TMT(5.\HIJ?*X^1\)/18O'Q$"EEZ]QL./VKE*ZACI9CE9ZW=?6 Z
MLSDOV-/4UD=5F.C\U5G&9/\ B>R<E!4QH6H6,3C6"Q\_$-7 -<42;QE[B%(3
M<(QXD?AW<;*5BFH$B=IIZ:< TH0<H4.,U,#'2VJ)@>DODJ9,*M1D,3,N'H:"
MGSU!D\9E8<UMO^Z46#R5+NS<6V=Q8#9RUN6VIMG:FX)QF\IB\.:G+]49:=-Y
M[.DKMI5==CU4QL9"J2C4[%2"NEM>H%%=6>@=G4>&CO1+Q ;2Z"7*H_3+#PJR
M1]JBM0:C30U*D#(4') JT+?JQ5C)7I\EFHZNCS&K'M/02S;KIMP;;J<%6Y^J
MHJS(QT.Z]Q1S;?V;/34.9BSN-$6Y=PX3 2)0[JHXXNQ.OI8\I'7XP,A65HN^
MCT0JP8+4"J+W/4KI-8HI)!JA8FQO@8RDG3H*%7[>W.I:$D$]QPO&H[V5<.*3
M0]U5Z@9/"U$U34S4T$V3I<E49F<2MA,!OZKSTV_L+2QUJ/13STF"[3/<6WZ%
M),CCZ0TV%[PPE,M92/B.P,7(:BT<H4*"0K*%_$T87PV-,@%H? 8]K&LEA(=+
M"6RD&EN6+54TJ#7R#5U#..#ZP.Y1VSJ*C3,N<F*SA:?%T60R4\XBJ]N5>"W#
M2[RQFY<I%59W!U& VI-2[GW-3X[#[PH]\8FGEP>W=RYJ!,;V%C8&V3OF+';H
MH:&MGW)"-,CQQ@$A@RE"@HK!GJB$LAC)$DL49UVSGZNS+V[N@K'+I9(G;M[=
M+:@2*BBY:FH,.U)&Q(!X,VF0 GE)1.II*W'/'09J@EV57U#8K<&>Q--718:L
MK=L[.SVVMX[MI)ZO;5=@)YGP."S6>AEJ\#+/-U[O^*;#5E!D8JZOB1Q6)A(,
MJK$:@'=7C0@.&_M)$C(60 7UD1*CH76340RXE&DX)%:$A65CP(^%6;(J8)JH
M0>F; UD6WZ9;)3T&.I:6C@0TV!S^R<?M?$[-W94)YF_B,]=N7J[:_5.YZYH?
MM)!6YWX\;DJ&2497KW)+-"_,OU#<2TA)XLLA=G3ABBS/,@KJ&F/<X@"/#OHZ
M%-'((5JV(Z>C#2 U/M14/EEK5SG5 U0K,C211T5?1U%-4T6%$&6I<KC:C'2;
M2FP@QF2BW;FH*S#[2J:W(;5CVKDVCW%EZ+ O+D=FY"2'?>Q9:G!U591!(CG6
MC*P,M05(.O54:%(9P ^L5B1I*+.M;.\"S*C]+& *,C*0F:CX:4-3A<BA[CIR
MAI+"2A(Z3]8*S&39*DRT7\>QF?AWFDT&1IY-RSYR;,8RAW1NB)]K;'^SH,]N
M7<V+A@S^X]L[>D@H>P:&&+?VPI*;<5+DL8ZE"DJQM$=$J&/([ H4E$[Y*E40
MUCBEE!:V8FRO0T#1R!,0\+."-<;:J\6)J*L0JXU'XI$6@E'Z\-) RE16ILNT
M4<GAW)292>L_AN2BQ=/V#/G'WQM""]%4U=:U#M[M"L[2V]0^,R.*;;_<^%IB
MC?PS?>-&M-W15(K&R@5%3'I\-^( JT(A8UIF2QD-?U+.3"GLD%#1T/ _%74O
M#.'UC_:S*/PRKTF%H:_'U-%/2F:H%56;5K*+)8:;$3UL\]9MZHVAMG(T&Z]_
M-%09O*9W&QMMK;&XL^D5#OS%12]=]A1TN<@Q^5D5:XY%=7Q0."&U "C!W!2+
M*JI_5FBCJUNY%]8EH6>,)"C1,I4 @E:$4KPTCN;B2.Q';$J_XO/1@K].. S<
M$D=#D*"MI*3)4%%ALCII]Q5V#HA2[=S+;5PN5P]?N*FGRVSVV3EYI,+093-0
MU&6ZYR4LVR][1U6VJF@K_;4\+*7C="8R6&5#&K+K8,%.E_$6DC)&0ET@%W:%
M;A73I^&97"NC#4!Y$TH#I!%15=)[:L-435BEJA5NF_(XR/$T2SPMC:; 8^%*
M=Z6K.Z]H0[5I=D;IEK&H*R.G6MW'U;M_J_<V2,U%44LE7G^@]PU7WM,V5V%E
MI8J5R.3Q6TG49V-:C0^LR)2HK1)FE048&D>XQC0WAWL8+-2Q^&-:D"(#@=0T
MZ3P-*E%0FH(JULQJ-4#$";0U86.IP^8HZEA)%N&@KJ.NVK+B)IOX=G*7=6Z<
M5D-N[8KJH[1SVUYVBW+N+;V!FD?#SM#V'UW-48>7(8]:.AJLL3C\)!#ZAE2B
M,&<#6KYBBED UBMC?!90C].1R!@4D4^8-5IP-2"!\++\3*O#$\!*$CIUS%')
MF(IJ;(229*KK%W%34=5D8,;G1N==U8F/.[CP&Z=N[7%)B-]S]@XVC3-YC#8F
M2EQ_96.IHMY[-DH-VT530R-PN(B&0:5&DD"JZ-!THR,]6C\(GPTD<%K5B;2[
M#VSJXO)'X@HS=V:>>JHJ0P&&U?$RK02 "6+3(I'37C,B9ZZGQE=62SY*3*8Z
MFQ.1JLHO8V5FRNZ=HO14V.S.0ECH-K=K5/:^%HY:6@R$HI,+W5@H/X9DSBNP
ML4KSN21Z4,B)2/220!X0HCU)49>$0L064:I+"0^)'XEC)0-QR MX;-W@@#.H
MU*X!. Y<<&PLZ]K:9ERZ)CES;44U(%CR$<NTJV"KQM5_'9Y):G!Y3:VULW@=
MU[XAIL?EERN/BDVUM_<FY(5I-PTBS]>=@P1545!D0WXAB#ALI1P01I&&#NK)
M'4BAI+)%$=43:;ZQ)4O'TX4\2FG#"AJ,G@5!!;!QVJS885AF%=+=(JAEK-NS
M4&6H?+BEQ])MTI]O)4[*Q^,H=OY&IP6WI8<KN$9'/['VWL3<-8V'P=?EXJG.
M=.YFJDVCO!<ALS(T>014X6</&_=J+<:2$E@&8%5HLC2*-<BH1'?1J+JUT74;
MH4Z%HBI7% /4  &@R:E0I[5)JT#'PI:Q,&Z6I?$56)J(JP#'X7'/64M913UF
M=V;4[%EVCN@96HB:FP$>1S?76/ZMW;D5KY:7'-59CI;/SC,X9LGL:OD@C2#Q
M5D73W2M0@T5Q)K33Q:BRF9!I!:B7\8\*7P[Q 2H[&1JX0?,J5*FOEE-#9H*F
M%NY=4+$=(;.X.?"UF0IZFGB\L,6\@ZS;=RTD5=1/DL;NS==!D-H[.JY):&D@
ME,>Y]V;3VU,9Z6H\/9/6DKT[Y+&1K(IA*J,K&A*?B7!H40AY!DG,4,THH16P
MW !A'(4SHT3,#_2\CPJ"W:/+\3HN1_;VYIJ4+6@K6SAF409*;-RU6X4:.7!8
M+=E5D*S>&%ILAD:.MI<74T>W^R7[1V]1IDJZCQQ@PO<&&IH]P[=EQ^\\?5TL
MJ1E\&F5$-%_$R !&(!!(+1>"QTJS5DLI"8)P]HZL%*/XE: ZZGR!X@>F'UC.
M.V91K33*".HV1H),A6Q9C%15\.<EK\77/'#FL!O/(5E9N3!MC(,WA,KD(J;
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M\AC551SBXI5]18J<,&+$IH5@6HKLZ_IHTE$O(P;2[T7*I(4KQ& ZEP ".!
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MJ'%,QBSVZ]I[<9RL[1=D=9R21/D\<JN)DE"(>!*<&^6A&$DN,YCAFE\JV&X
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M;W8M%O/'T=1[1Q2F&JE0NG#H?TP C:V(5:O$L9.IU2LEDY%Q;:[1V7I4\:R
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M([ J*B;?M,N,Q&(R=1G'HL5VDO:>W\8T>*KYEI\'W=@J4TE>F,[$QZ&6[Q!
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M6NV;6XZL1:\8N$*LA;63Q0,27 <@A2!(SJ-;I'2.\0"ZM=%TCH4J2&)R=0%
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MV[,*3<V/$'8/7DL5?#6X_P!IBIMZ-7]$D'!TBB5C1U:2K*%8F*-Y1JB:MC?
MH4?I0CB84I208SG)[B"%P:CN8+AQ2:#(*],.:P\N1_B.3H<75RU=;5;@;*X8
M[>P&_LE6UG95%!25>8Q^/^ZH-N=KP=J;<Q8GKZ""2GPG>&WJ?[NB&-[#QY\C
MT,H3PXWE 4!:-J:, 1$D*30M#X+&BL09-OE.E_$L7PS-$2&D13KS44#'NXD
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M:VVY(,-O_(;VP&/3-9?$8:>#%=H8RFCWGLZ2@W?0U-/4-HP@93J B&DAE9U
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M0TF+ZYKDI:A*GSQU6Z.JZ/K3<64>D@J)UJ,]TKGZI\?7+DMB92*:-$0ZEHY
MS!JG@CDM**XI1)C*HJ0*1W\8#H8[R,@JP58"1"*C[1A?7S3033S:%C0ZHF!Z
M0.1PD&$U/%0K!@:8+BLMB,KM#*X&#9_]W-R-OK-X7,87!5]1N+9FW-FY6I3-
M9'&X*27+=2Y:>+>6R7JMJ5>2QRK4E::E7K,<JP<-KU+X:LK, LC2 &-7DHEZ
M@-K=A;E8W*1XQ'5E7]/@05(TT.H@@&JJ":D+4P,1+%6(LO3Y05;U4$F.R5#/
M5?Q Y'%U5)6XK;M=5ODMQU$&^-PX3-[?V#5IC<IG\[A*1-QY_"[;9,=O/%QQ
M]B=<R09:'(8QF'4*P=' TT((+ 46L:LK2"H56/A1O+5H')L;X-&4DZ>1J]I'
MRX"M3W$$+@DCN8)B04G@HP9>FS.T-54O+5TD$V6&=&2%12^?$[_DRU9V7C4C
MK):*FQ[T6V^RZCL[;..,E;C812X/O#"4XJ*-L=V'C297864 *S!2E*'NCTB(
MXJ35HA$YHK&LFWR'2_B6,F*2(35DR#6HPP.OB12@?4/B7"W"Y&F=<G5^$F9.
M0KNP53)4%1%7T6U=PTDL.=W/FILQ@:R@GPNWMP+G,\AQ_:FVYL?@A1XC>:_9
M[GGI*(87=5*,UAY*BH"7-T6A+*L; JSJ:JBZ6!U,NE<PM5M3P=T0+>+;-X4H
M537:'U":K C!&2:K2@.HX=<45\/0:9!K4DV*>P-T=]>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1 OGWG*#:NV.A-UY7.[LP&.VS\F=GYJ2M
MV3X_[RS5=+U[V1'C</1!J:N\E#G:^>.EKA]K6O\ 92RA:>7Z>QKR3"]S<;W;
M101222;>ZTD^"AEBJQR,J,KE1J [AT2[TP1-OE:1E"W2GMXGM?M^PGC0$T\C
MU1G6Y+.[<Z_VUMO;=?OGI_=F8R&5Z_DZDV7N?#[NZ9>/?N7KLR=V3[DJ:FOQ
M.2J\J*V.FJ4KY!!A:H.(*RFG"8Y9@2.&>]GN)TANK5%$GC.C)/\ I@+HT4!
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M;LF0;HRN-RFW]K&NS>S-L;2SM6F9R6)PIJLMU%F95WKM!\AM2MKJ%%4<@N0
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M8VEH.P#OS&TSX';FX<XM)1]@8^)]B;YCQ^Z*''5LU)[?220M&%:C08].@:Y
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MY.I$#B2//32S&1AGN5RQE^5 DK2H*&NF/<8QW>'>QKJHR"/\(T#Y%0H7AZE
MK9!%6MF.-4+&CE2?<120X_)TO\.R]!X\66SV!H]JTF23!P2[ZW9M+>.V]JU=
M:^VJ[;\\\>Y,U@=MO,=K2O!V+L&:JPU178^.C%2"\;:HFSVL7(U'PT=&<#6&
M%8DDEIXPK8WH654<V2IH&%)!C(TUIW%6 )H1\3*M=.)X25)'4V3'_P <>HC-
M*TF:G>+!9G$9%\5N/*5LNXH#O#<.WLS@-IQTN+WA7[_QD2Y?,X;#S04':F.B
MBWEM":AWA15%'-37X(4AOT1W*PJH&GL5E9ZE!&>Q'<%K-B;2Z#VKJXL4$GX>
M_@0:$YR00,-J^(J,2C]6(B4$%/T%?-,9H9M65.8I:=)(&:C[(JLE7=BTLL>,
MH:JKKX<5@>S<CV9AL<U+C\E5+38'OC"T38W++BM]8L&5]T H1VZ3\X@!$<D
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MDEN+59E#4!/FH.1UL4_'*G>DW;\EZ62,0R4W<>W()(E-Q%)%T)TTCQWNURC
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M5..R5!.F[<E4UF[7KMI[0RN,W?ON2GP&Y,WN# T;[?VSN/<*PX[LK'13=?\
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M0%6B>N 2:T(*J225ULCJAHY< 2%8SHN5 O+0K<*Z=.(ZT ./,$$T%#I# G(
M/;W9B),,H,9!Z9,KC8\ A+P8_&8O%TN6TRP8W+[&QNWL1L"H<13O)435NX.K
MMJ=:;MR/W"34ZU6>^/NY*C[FG7*==9-T@=C<S'!9I6(\UD+&0<,469Y4%*&D
M>Y1#2WAWT8):D014':(P#Y%0-)X^914;-15K9C4:H&P\H9UDDQF4I)<9FZ'[
MS"Z<WCZ?;E-DX<100[[W1M'=6T]B&LJMNY7!SSQ;CS^&V]+-/MJ::#L3K^6H
MP]5D:")KMH)(V#1&C=I+$%CX:.CR4#!LQ1O* )0#8WH654<N"I[6%)!C(I6G
M<595X$?$RK\.)X"5+ 2:^'^\9,;J:O+35]+BLEA\Y F]:NNR&Z,-4[NW1B<U
MM?9YH,7OVNWEB:2#,9?#8F2'#]FXRGAWILV>BW?0U=//1#X&1B(*2&4^& $8
M(C*[U:,(Q*([@O:.3:70>U=6&W F!_CX$$:LD:B"HPVH=S!<2"DL1$BD%/T%
M3-(\<1CR>2_C$.->GJH?X=ORJR&0[ Q;P8^2HJLW!28'M+)=I;:HY(*')54=
M-@N]<!2F@R7\.W_C4290ZJ 3VKH)J,Q@"(U- M6A$+FK**R;?(=<?B64AHTK
M$'20QJ/DU2W"M<.7'PL>VX4:6TS+E4Q^#(4L"+/,U+,F/J]M;AQTF#JVQ=?N
M*4;-VR]+G>P$CI\M#F*/R;<PF>SZ1T^Y*/R]==B)#6KCZ\)B"C$T&H5#J=0J
M%_4>JQY72?U9(XR3$U+ZQ)0NG3] U.-/PG&">T9;C7X S?$*PS4-#TA<D*G:
MM355,<L&)GQU%-DJ>.AWQ6[.H\;1[=W%3;4P%=C<QF:&NR^S]N;*S=3)B,+G
M\NM1ENG,Q.^R]W"MV76TE:%D16Y558%@Q -8PY)9=; JI"NTBC7)&E$OD N[
M71=HR=)7#6Y)6@(%<-IH :"A;*JIPK',#?I2UA(/2W^]QF8IZJEJ),=CY<(^
M<26FJX=R;5CPPZ\JH<C5TU5C\/+-GNJXNL]SY2+(U5/0-4YSIS-5"9K"-DMC
M9:>%$GAR1,K*&8/IR"CZO%% 06&F;Q4!4%J1WT8,,WAWD0)4+(DJD$@%2<9%
M"F:$#*%"0<5:$]Z:H6Z1\]!7X3(O.:4T$^.:MPU0DVTHZ&-4QZ0=@[QQ5=M+
M9M0U524M.*B+<&Z]H;>>4XZ5HNR>MIGIOXGCU5+(DT84MJ#48=]>/Z2,'D%"
M<&.&>2FH5L+\!O#?I*T;PR:Q@C'PTX=S"BYI^*2-:TQ<6YIJ7I88;.1YJ%5$
MD]3+D*C'4FXMOU55@MZ5GW.],%+N7(.F&VLM%MGL6+L+;N.CR62QV,>+"=M8
M6(;FVS)0[TH:FF=+-"83P "@E6 :,4C;0,O5XO"8E%9ZR64A^GN ]HZL%D4R
MRJ:<<:EJ&^(5-*88,,D+VS+^I'24$=)S,X*6J6FR^)JI\L^7?"9*&IH\RG8E
M5EZS?M'58K%U]!796&CVWV-7[_VU1/B:.3(>#$]VX.E;;VX?L-\8NEJ)U$,P
M4M%*H4+J%"OA!1&:D$+5XA$Y#L%J]A(?'@UV<C*&)H37Q8\L<X.HG4*5%<,6
M&,]MPH\.2DJ@].&U]P4V4HJ.G%1$DXHL3DL9F,77/7/!)D*J;9FT\]B=U=EI
M%+5*ZI4;>P&X-QQCS.L_7?8T*,F,KBW<P-&[MI-*L"I%*T D=2D7#REDCB.!
M2^L":R)U>WF#JHJ. ((-?Z*D%\^JJS>=8)Q72>LFYMO>:*7*8_1@:_&1U.6C
MCQV6;KF(8[9M6FVL'DL9ELLF3SG653UIN"M./QN3R7GS?3N9F;;&XQD-CY.&
MICU;W%"(W[T:BY7Q<N-; J*+*)5&IT2D=\@^H@T7D94ZGAU O& '&<=M=. 0
M34H4)HK&IA/Z;ZH6KTFL1N0[>-115T@QU%1#<2STN2>MVC!B:?KICE=R0/M_
M;T57F-@X_KO==2F4SV#Q+3YCIO.RKNK:;Y+95?5TB/RV_CZ7C&ISIH11ZF7M
M3N:BR&5!HCD>B7T8-M<B.[16+4,QBHC&@%>/;33EL#*A6-61:F!CXD6J%B.E
M+N+;4.=AK:B*CAF=_N<97XW(;=GR>NF_A]%O_=>)SNVMJ5 >KH*WR4^Y<Y@-
MN2_O!H.R.NY14G(X[VQ;W!@**6-.((:F:F-&5G&",Q1R2C'=87PT^&_3TT E
M!90-7"FFO])@0.(/Q,J_*> UJ.F'#Y:OH*YJ&JH\GFAFLG309;$9"DVMNZKS
MN7WC3G,U]L3"*/:O8NZ=^;8Q\=;54E(]/M_O/!TL>;PLE!O_ !<\4K\T*.GB
M(RII4E2"Z!53M'=EXDC<E0QK)M\A,,P>RD4AB*5D8H58U;((4U+9X<&9ES0=
MMPHUI292.EM&M)N"GQDT.4FS]#G$Q%3@MP4^XL)N6MS-1ONIKL)B:A,YG$I<
M9O.HWEA:!\1B<KFH8,9V]C89=J[LBH=UXZDFF1U:!I 8]#I4,I5D"B,!B-*U
M,8C8ZW2,E[)B+FV+VTC +3ID5>[4K4H:@UU8&3AM0[06Q,/TY*2 $HF&JK]N
M&DJJ2MCID^TQM515-'NS(1P1_:Y=]B[3KJ'<N]Z352R8669L!M;<NXXC+A9F
M?K?L>.3&U&/R*JV1+C4&0DU((*#S7Q'!2,YU4\2:*(TD%+^P(D5XRD!>W(*M
MVT'XCZZ5RWF/A1VX?[CS]I5NES%44]:&RV+^RH*NAAKZEX8Z/.]<T$%#L?+Q
M8.!;YO[W=/7%%UKNF1Z6.NK/-G>D=QU1Q5>*_8F1@J%1Z60B*4$J2!Q64DR+
MJ_#1)3*E"56D=_$/$31>(5Z5!M=&2@85\BN%-//N30<5/= W:=4+ ]&U^&6$
M%!D.QYZ2CJJ&BI?X+MRGQU7M7 8?^ZF0P\N1R&=VFM+C)?XOUW6T>7RK5E=L
M>45&"QM=6/E=LU+8;+Q11AGFN;7'8!G!<ZF)#LVL-0*]3VR@J-*W I(ZJ([A
M?%B))CM<84SE11<"E -)%:C&5R:E,J"=2'0PI8-[!/1QU[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW5+F%V7VJO\Q3<.Y,1B]Z]2=&X/M-JW=&9W#T
M?OK [)[NWKN7:-#0XRDZWS6R>]:?8L=-'D\JHSN]=W;95L_F/!CL?CZBH2;)
M)[J]1I^?0L?S9L+C,Y\?NOZ',UF&P^*_V8?KS(Y#<.X*I*7#[;AQ6W]XUL.X
M*N<&&H@?&5=/&\#PRQ5$-1HE1AH(,C>VDTD.]WSPJ[2?0R@*HJSZFC&@>1J"
M:U!!%01GH,\RP13V=HLRH8Q=1M5N"T#$.#Q!4T((((-"#U7A04M-U)DJ7%CK
M'*9?>^S^R^L]^[%K=F=AQ[?P^S8]_K74/5NX^X*.OR>0SF\-OR5N5-6V.QZU
MF-H884J9H3K:G]CF1FW.-I!N"K9RV\L<@DCU-)X=#,L! "HP TZFTLQ)4'&K
MHLU+;'2+?5*DJ,-#4TZJA#(":L,U(%5 S3RZ1V]-P9#'X;)T'9_>>\,?F>K=
MX;GZTWOL#M3:='L49KLSMVH6#9GR'V]B]H5<'FR6/W/0S0XN#*--B\I/1P&$
M)2U%1(%5I"DDL;[?M$317$22QR0N9-,4'QVS%Q@%""Q2CH&:M651TQ<OI -S
M?E3&QC*N--9)#1)%"G)U#M#5#4%* D]/M=N?/97%=E5&XLQNCY2]>;/R73W7
MW8NS-Z5&U-F;0^1D.X9L;3[:[DI]U8J+^-[3R>RZFBHZJ5JD4\V)H((S+*:R
MJD!82WABDL%@BCVZ^E6:2*1 \CVNFI>'0>UQ("0*5#L30:5'3K22F*;5JN43
M0C*VE5EU4I)4973@FM" !G4>@O[SV_MWLWJ?,=BT<G6.(I=][PW1L[JO$P-C
M\Y75N].LL3N%-W[#PF0G_B^&S59B!!/4X_)TJ1Q)!2(L+15;2M&9;-//MVYP
MV#"X9X8D>8Y4".5ET2,!1E#8#(:FI-:K2J+<XH;ZPN) 8B'+"/ ;O16# $U!
M89*L.%,$-4C85^-L\=3NCY*5,3.T-3W'MVIIVE+F1J:?H7IJ6G:3R$RAV@=2
M0Y+J>&)(/N$.8 5MN7U/$6C#\_J9Z]#';363<S_P\?\ 5F+HU/L-=&G7O?NO
M=?_4W^/?NO=='Z?[$?[V/?NO=:]]?E5P7QUZ#SU;!L-<#MSI7YG[ERNY-\4-
M/F<IUMG</VY2IU_V+U?@:A*A\MOW";CKG*Q1PR$P6+-#97]SA'%XV^[W"C3>
M.]W8HJ1DJ)5:$^+%*V-,;*!DD9\CPZ!?B&*SL';0+=8+AF9A5D(<:&0>9!)K
MCTX=$K[9WC_<OK [W.U]FT6W^QMLT6\D^0W6V[I=M]^]DXX4>*?=N^LW0Y#(
MYAJ&MK:B2IH:7'U:4^418T4O44E.A45[9:_6;B+,7$IF@D*?32IJMHC4Z(U(
M"U %&9EJF2:*S'HLOKE;6QFN_# B= YEC-)6&"S4-<G*Z3FF*D = !TY\>?G
M5\C*7?O:_2^R]P[0V109*OH\[34E7M#&S;MV[L[;?][^O:7I[<NY,%64G<78
M.2RNBCK,ZU70TM)F-5/41_YV0'FZ;YR;L1LMMW:[CEO&4%21(=#._ARF=%8&
MWC4598PK,R=RG@.@_;6O,VXRW-W:PS0VP9@57PU[%CUQ?3.RD3R2&BM(S*J-
M5"* GKKX^]J;OQ8J=KU^Q,(=\X3;66ZTRF"WID,/OWJ.DRVX\MN.?'[RWQCJ
MK*5>TME;SVCNS'M1UV$62;'97<&+=*<D,D,M=\VVT<K<1WK_ $3R"4,@:.8A
M M4C:@>2-T.I9*!DB<:LU(5;+?W#Q^#<VR"[5 A&M7B.HM0LH)6.1&&B1*E6
MD4Z#IH#8MMK-C&9//[*I-]TE3?MGXER00U^PM77F1/\ I.V .V=D?&7>]7B*
M2KBI,G4O#_%(],=-5*H^VB@2X 'N(?$CANVLB/\ %;WA)^J/T9/!DNXPQ%0*
MZ.)7\1)Z$OBD:H4EI2:#BG81XBAUA-*Y^P#A2@ZV28"&1R @'FJ!Z/ZK,Z,6
M_JY93?\ Q]P&<'\NAQUF]ZZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW42K-D6Q(]8^C!#_R4>%_USP/>QQZ]U35O:HADWUOJ>D?P?;[RWWC)P,?
MN=<<U!@:IMV;APM=05@/8-%BL1//3YG)X&E+9W;D[4^^MDRSXAZ^F,JV@(L[
M-7S6*,C*5JPT*P(_2+$ HDA_3E&JSNP)0C=!J9@99BIIW,/.F,D'\6/B*CN7
M$L55J.DY5T7]Y(!"R5+9*0/0YFARXPNY):Z?<^$EW)N3&9S;VRHX*'L:;?N'
MIX\SG<+A9(,=V/CX(MZ;(DH=YT-532/JQMSJ!'A\5*ZDH$;2I5I,Q>&U4CDD
M!:U8FTNP]HZL&602BGXO.M#Q%2"%^+4.YE7$@I+$5E!'2*Q61K:3(QN)9LM#
ME:G;\=?CZFO;L*IS=1O_ !5728=_XI54E'@.S<QV5MS$FEQ>:J/ML!WYA8&P
MV5&-[!Q@EF6R(CQG 4J&H0/""B-@6P"6B6)FJ\8K)MTA$L?B6,E DC=H6\V4
MTJ#5R=0QG@Y8"BN:+<J-#Z9UJ1 QM925]!BZG'5;M12?W9KL%F\6YJJFFDR-
M7)M?:4E)N[? B%?5U2K+@,#G]R0I29>%9MA=C0QUT6,K"AD1T>177N&L,IP#
M0:WJD? #$DD<1JAI>V)*&1>EZLKJA5NS%"/V#+?[RK,*',,PKI/2=SF&JDBG
MR6.JJG#9/%4]37*M%E7Z\H1CMJYM-M;=RV)RVYJ;([BZ]DZ]S]2^-PV6RZ3Y
MCJC,U+[5W:E?L_(4M2C\$J&D<BAXV(&1XIJZZV!"$++XJC7(B42\C N;8I=(
MRE/-"Q[T8JPS_""!@$$U*E#A6.8F/ARZHF!Z]BMPQ20U..K#2XW+8Y,]23I7
MG.;&H9*+9.2I,GEJ#(8K;?WN=ZXJ>L<_.F0RF/H3-E^GL[4IN#!29#8.0J*=
M/2P%65UJT3:2*:9#60$*06HLHF7M1FHE[&#!,([U%8[AG5QI)I(*CS7X3D$#
M*%#E@*F%CK0M"W7>ZMKIE%R!I:9=?W.=QV7H,IMC(3>>6E@H-Y;JP6XMK;-E
M5HD5VBS^=P.VG$].YA[&ZXD\39&A.[:XT%-38HI4AP*5JB,KO_SCCDEP<V%^
M*^&_59X"X8IZFH*UX=S @9I^)E3(Q/!^(=0MNYBIILG/CZNAKLJF3R/V>4Q-
M10[:W;7Y;-[PQ4FX<G#483%?P_;N^MP[[VW01Y/*T&*>+;_=V(@BW+MI\=OG
M'5-+/NXA4QK(KJNE:JP+H J-I%&-7C6-SH1GK+8.3;W >SD5AJ&2CLA4G.1@
MDEA7@*!BPR0O;<*/$CTS*05%D*(9ZGPE13YZNRHRLV!J]O[HCW!@MTU65J=[
M02XG$455E\M2T^V>P:S?6!HGQ5'DLFM/@^X<'"^W=Q)1;XQ]/4EB-_!,JM"%
M"A@R:60 1]S$*I+QB-CK94K)8R$3P%[-V7IUT$JH1(36FEJAOBP!4T#:ABI[
M9E&AZ3 'I"XBMDH#1WDIH'2':;4]73YG)NL<<&8K=G[%R&,W7N](/L!22Q2[
M=VIN;<\8,-I.L^SXFB.-R062H'UT!(J]05'\(>0%$XUQ+-%"<XW#;S7Q(^DZ
M/X9 )SCS/KI4ZCPI\,;OP_W'N/PMTO:6<K&,MARV-GI(JZ=]$63V+C*6@VGG
M?X32*'W.M3N/KE.NMR3RT5+59!:K.]*9V<XC-K7['R%),B(@?V4O<#3TD)+K
MJ/P467Q4 9E6D=_&/%AT7B,"J4\'CQQ_HCM-/Q972< FK0-VM6)@>D[DHEVW
M%59>A5<7B<6,Y1Y2BR\=5M*EV;1;85=Q;@V_G<+ME:_=^Q]E;)W!6#+9/&X>
M2HSG4>8J4W7M&2MV=6U]#&^A\<B-^Z1M)!6CER_:K*ST21Y%&A&<".]0&VN@
METB.6F BK(F(Q6H-1HID@@95%)U$+5H3^I'6(L.GVFK*&K7(S1J#30564QVY
M,)64=3F:K%Y"LVW3;RW)0UFV-B(N-S<>8A\&XLSMO;3QT6<IO%V#UW(D\>0H
MO;3*ZZ%/&@*L"%! 8QJ0\F5TYBCEE[HS6RO@04?IY65@Q4=M3J'&AIJ.%XU^
M(JN&'ZT.=0Z;Z["^6:Z48R\.6?[N2.+;F/[(EK9]\8&+(Y24X^.7'8/M.?LS
M;=*)<OC:3[7$]RXFG7+X4XSL+%LL]DETCX])7'Q&*@C:@SEH?"8T1C5[%SX4
MOB6,F&Y(JDM2H8UP-7Q"IQP?6/B446=1J33.N>.(R2URTL4]95I2U)VO-MW<
M4&6PV>J4KMXU,^VMKI'N+/-%C]_4N^,52-A<'G\RD&.[-Q\,NR-Z)1[SH:>J
MEM*FG654:AKUKI911 '?M7,9C8^))%'5K1B+RT+6CLHI')A48FF-+5!^+"BI
M^(,.U7;$H'@RTE )E54;2R35D=4]/E:6&@R[/C=U?P:"K&)S4^TMJ[LVWNG<
M\$]1MVLPC^?;F!S>X$:3!EINO>Q(:G$3XZOBHITT736,DKE-5*KK='1,,&Q+
M(D>),7UB5E#H77354U[QG!I6AH&!/ CX59N&89P5(/3-CZZ/ HO\/DI\9BZ"
MAS-:"T6[=GT&V:':&Y:6BC\(S*9+<G6FS^L]RY)X2*X5&Y.@-PU7V->,AU[D
MX98GG4SG]0%I6*C\#ERZDYTT2625!7MI%N40UIHOHR"GC;P:!,1 $^:A0I\J
MU9$1C2A[[9C0ZH&!"JJ:2GCIJZBR5&PQ'FS>)K\3D<:-I2867;P&XLO2S83;
M8J,]LZ+:F3J$W!DJ+"3/EMA9)HMZ[*EJMM5=91A*K-J1XV_5HK @Z]6KM4ZG
MHKZP/#5I!HN$K:786X57Z5D JP8=F01\-*9.!E:'N.DUC-)8B4)'29J&JL!4
M-A<G)4Y+#9*JKJ:J6I.,KJW.I7;:;>6Z?+LOKZF%'E,[DZ!5SNYMM[>:&GWK
M20Q]A=<FGS<.6Q[*5T3J)8P%F4 BE0%H^A/U)#4*#^G%+)4V[$V-_JA,3])C
MJA8HQ+1,?EG&IB%4?%3N=%_M!^O!1PZ]**!HLO'10ULL>Y:3.U5/_#\E4QT?
M9HW!)O7;3SS05+8_[':/9U1V-MJB'W$:^#;_ '/AJ9'ICC]]8QED3D&(N4'A
MN@-1F+3X;\16KQ>$QQQDL9"=6NSDPH%'50W<K<#AZZA\NU]0X_AF'"DJ]).J
MH):<T\M-4UC>7^ZU;B,GC:NDS]6^3W3(=J[1RU%NG?HIL3NK+97%0-@MM[DW
M!'#C>Q\;')L'L*.GW/3XK(,J20/J#*M>\%2"HHG>X*1U**#^I+%&2]JY%[8E
MK=I8^DCQF/30L>!!&<G"T+4!-.U';$H_0GI($;I^H,XTD:U4%1'25JTU/E=%
M+E3MJCJ<;A<Z=D;?SN*R&\XYJ[;%;MS+F;;^+R&X(7R6PLHS[#W_ !56$J*+
M(%AX:$J5JE2N1K-67Q&4B/#AUI(ZQD)<)2]LBLRNG2F.74*\&I7TJ =((U5(
MH>T:NZ-OT9@5(/2<W#CZ/%TU=D:&I3&82@H<W#_EF9W5LBBVQ'L[/4CC'5LE
M)!7[DZLV_P!5[GJ2]-D *G<'0&X*JX.1ZXR6F%3!(TC)&ZZIF9>"I(6UJ<BM
M%F:9!E<1;E&/]#OXZE/-$$K)&P$8!\RM-)K0\2BH>#9:V8_BMVH'VDJO5D,9
ME:..KIQ4;EQ5?09/;69PMVPL=-N[<6%S>V-M/+4[<S&W:J:/.YO;VW'>KP,\
MD78/7\D^#J<A0(G=*:)(WH:(P(=6^*J*RN^&5A6..244D -C>A9E1R]'(&#(
MXKD@@@CAW$$#@1\3*O#$\)*$CJ=D,,,Q.M/67K:ZI>LQ\-;D]L8/*IN1,WB9
M-U;BQ.Y=O;5DI</NN?=U!21Y/-X7"2P4'8='!'O78+TFYJ"NI7K'-X2U7""A
MH'9=&EM"E&>K($)*QR2 M;,3:7H:W=&%I(_$P?BR*E0:@Y(('Q:N+*I D'ZL
M-) 1U!P6;KJHX[%Y7(5^0R4DF&IJ/(S9;;O8M?+D-_T$K4F'S-8*?%8+LY>S
M]N8_P45?,*;!=W8&D-'4G&]AXX&:\T*+KECC58^XD -$*1G+**EHO"<U9162
MPD.I?$L7Q2*4U6*1R7Q0X8U;@&. VL#M.%G44.F=<N<]!39N"BFHYI/XQ2R;
M=KJ2LH\O49F05.<J:C:NW,OBMQ[R@AILV,QB:>;;NW\[N!3CMU4"2===A119
M*FH*X-K(T1=7'Z1U @J%PH#NI5*E=+4EECB[H6I?6),;.G5WC64*176*$9KD
MX!!-*U':I;#C]";(5ND'1U%3M>;[VB?^$08FG2O98VDV9C*3%[5RU1L_"Y*A
MS6^%KLULW%;-S52^(P^7SBU&7ZKR\TFS=\I6;3K\;6QK&5;@:6&LN:?QDEU#
ML"L=%D9U&MTCHEX@%W9E+E)$*=':$@C%/]J*#M!!:I50>U6:K0M^E-6,JW2_
MDJ,3482OA:<XC;N._BSUU%/53=?G8LVSJJAK<EIHL=#D=X]8XCK?<F02KFBI
MS/F^DLU5+7XYLAL+*31HB E65#37.VFA \3Q-8(&31)6E04!-([^,:)-%[&"
M51,;(<TC%?Z.DKQ]63237^*!C5=4+'I"YBCK,/5UM)D9[QJV]"T.1H\HU#5T
M5+14V[MW8VJVGL:&+(8^*DE\>X]S;7VY,T^,JO#V/UM(^+_B.-"N-EE5'C7/
MZ? BH))1"'DP:YBBFE%'%;"_ DT2=)6!C)#-_%Q!I0=S=JY'\3HOPFD\';J7
MI;8VJ3+3!E4#-M6R4"^?;]+O:KR&2W)@$W-DJ&JQ>"FHMN=@U&_<!3QY+(XW
M%&##=JXJ-=T[2DHMZ4E72,E=3&,G]&E?B,8 1M((+5:/PV.E'>KV;GZ>Y#VC
M*W2E6UUH>^OIJR17RPVH9(%%E'ZD=)01U$K*"KS#Q9;"RUM1EIFP]564=+58
M'=-3D:W?L$N.H,OAZS*_P[ =CS=B8'&O0QS5OV^$[EPE,V#S(Q^^L9#4R65U
MB!CE $?< 2&0 1FI5@*M%X3$,0M9+&0^-%KLY"HTR%_U(SWX) H3W8J":!M0
M%,]LRC0VF9:]<L'N.'+F">FKE%>V/P58T./W6TL5;%-N"HV-M/=6W<_NZA;R
M5GCAJ-O;?S&X(U%<OGZ[[(C2I3&5Q]- 8]2LG9J893AV^(Z,J'APED2,]N+Z
MP)7Q$ZU%*'R#W4' \172&!;_ 'E2WSAGSI/4/-X6".&/,X62&A@Q\<-6G\/G
MW%MBFQU'LS<SX/$Y/'UVY(Z[+=>OUUE:R3%XVORR393J#,5#[7W1'7[(KZ:>
MGM#*Q8Q2U8L2,Z7),B:F!"T$OB@!V5*)>H!<6Y2[1E;TL0(UJ: 4]132:#CE
M=)PI.83^G)6(@AIH<JF#IZK&9:D^PP- V866B&WLAL6+:5+MBNAS62>EQ^+:
MJW1UY@]@;DJ1E<QBJ*2JW#TSG)UW)MUJ_8&0G@C=>,S%7B;5.VG.H2:RXTBI
M-$E:11H1VI%?1CZ>?1>HK%/')X58W'Z7^ETZ:&I( [E"G+J*M Q\2.L+$!89
MW#G)2U]#75$C9%I<C1J*Z*E6DW#3181=Y[EQ.?VYL-B8LC(3!N'.;>VS(NL^
M#L3KB8/_ !+'LEBD\,(Z+^G0'%:J=7AHRO)Y<8HY)1ZV-^*>&_2N2/752W=_
M(BFH@A?]Z(3Y3P'XATC<74U8K?#,*G+9+)5 AK(:^E7L/*97);JVX,]F8Y<5
M@QC=J]A;@WWMJ@2MRM#CC3X3O' 4R[BVRU!OO&5$$RN0*4J**BC!!\( (VE<
MM5XEC<Z49JR;?(3!<:[.12$J%HV)JS$\134:D5)H*!F898"BW"C7'292"LL?
M519JEI\CC4;< SN/PDU11T8H-X4FYFWOC:O"XO(X_+[JCH<-OZOWIA*27%XO
M+9(TV+[6Q<,FV-S)1;VHJ:H9)(IA=HY.S0S"IJA3PR&8$)5HQ&Q#NBU>S<BX
MMR]H[*%*,LBAD[D8#&&#:A0&IH&U# )H)16.2DH!Z3SS5&UY(<[A:M<C@Z]*
M2HHJT;FQ] NB+*Q[!VG#/N?>5'(]%D\?Y)-N[4W3N&-S06;KKL>-Z-Z#)*^
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M!JW9U=D*&-3#*+E%J[,6T$496)+#2I5F[7=T&A7>D=Z@-K=:+I$<II(C"U4
M%*UP0  :D$#(4')"U:!CXL58BR]+B&9\P7@E%;1Y:CKIL.\5?@,3,9V?"C>N
MZ\'N; ;*J/%FJK,T[IG<O@]NRBDW'2>'L+KV5*J&OH2C9?"HPH8R-6&;^+PT
M9&D':%_LTDE&J)JV-\"I1^E*/XH(R'!ID#TU$,%.:CN(7#BDT)K4=)?+8Z:N
MJ#4P_>Y.MGR-$<UB*B3$[ZK:W)[[V_45N2K*#$XBGQVWNUT[0VOCUFR^+@^U
MV[W9@*5*_%C']A8UA(HBD5%"'2J!3I;NC $;  %B2T/A.:(YK+82$I)KL9,,
MS1:F+J26Q48;+#) % ^L#N446=1J73.N<.W=Q05*4<"U:9),@NT<C25E/59+
M=C5R[Y$VTMMY:DW)N>.CQ^],=N_&43X7;FY<Y'!1]D44#[&WVE'NVAH:V6UQ
M;LI9M.G3K!! 2GA][*42IC*$^)+%&2UJQ%Y9E[9W0:AF4T756M#YGXL U.&#
M4TH[8EIX,U)5!+Q5T<,=! C2R1T#14=?M[-XV)<17;8JL56_W5VUE,;G]ZT5
M17[;&!JUEPF"S6XHW;:TTLVQ.PHJC%ST56&4<ER:=]2&4Y#@C6X*QD!]0I))
M'$?U@!>6)60.O3S(-(!..(/FM, @MD4^%2WPYAFJI!Z91528!Y\;DIUPF(Q4
M&:KX1%DY.O,5MV@V?F:"A3-XH>#*[KZRVOL+<>05629ZS/=#YVJ^WJ/XCUQD
MXWA=*B8"2-=<C%1P\5F+J3I/!)7D4>5(]QC&I=%_&06E8PU21J(*G^$  C(X
ME54G@:M;L:'5 P(?\G1K(M;C\O%1@QTVX:%:7,T^6VY3_;X(T.Y\KC:_&;&6
MHR^TJ?;>6JHL[F,7A)9,EL')O'OC9,U5MVHJJ,,QN04>(G)4U4JV6J@(,G:Y
M8 QH\@"7*5L[L+.JOT\ZU#*]//C4<,T.G(H>XA<QM^K$2E1TQ7J:*KJZ>M@G
MKHZBLR6/R4%5M./+SY6HJ,,-U;E2HVWM2>"@SF4W%BX1F\]M[;86BW_CXX]^
M=>&GW##E<>[U RJT9TD $4>E &T)1G%5"G]..27NMF)L[[5 8WZ94LA8,2<T
M/;6N-1P.)([F1,2C]:"CZEZ?5,M3-]ZGW.=@STV+-72-/M?>W\?J>P,?4.9J
M.GF@IMI]C5W9.UZ1+W6GV[W9@Z==(QV^\=^XSA1H-$9 :'OCTB,CB02\0B<_
M.6PD)^.SDP[DU858-2HPU=7F*]K:A]BSJ/PRKTG)1+%_"LC0YC)9&CR$NULA
MA\S%O4Y"NJJ[*3UFT]K5])NK=%#%B,MN+*T4<NW\#G]QI'C.PL2C]>]@Q0[C
MAQ=>SXH?%1HE5EUAE\.@ %'<%$.I5!I))'%5[9Z7UB3 9$Z8(*E660E#I(.K
M-?A'<<%OPJS8E7]"<>)I/4VBK8'HXZ66HIE@6*DR.+R,#9K%)B:;;^?J]G8/
M.;>R^](I,MM&@VCG:R3 T=5N"&;(]<Y&278V^XJK;M505ZU92&+ '5D$=IJ6
M4.RLL>'+J!(PC(6Z4"\LRLZNG3B,I72>'$'.*'2""V0 >WN!,1_1FJA!Z@Y/
M%I@X\A XHL9BJ*CS%4K)3Y#K;%8+$;0R\$<RP53M5[JZSV]L+=%6*DS0_<;@
M^/NX*G[J Y#KG)M%'>.0S%&&II25'$2EF=<5&$E:1!2AI%N48TG1?QU-'3P@
M5) C ]"H !\CDHJG-<M;,:C5 U [&ME+5M%DIY(,K1Q[CQ$CYVD.$H<A1;9Q
MD.ZMU[2WGM?9Q?([9JMOSU,6?S6!VX\M1MRHEA[ Z^EJ<%4Y"@C:T@:&C6L9
MTMVG407.A'1WPX8 QQR2@"4 V5\%F5'-]1-58]XJ,BE:99649!'Q,J_#B:$E
M"PZD5M!%GY:D)'+596JR%;A<O09+$2[NK,K5YW;$.Y=SX;<F!VQ)0X;>]7OC
M"1P9?+83"-#C.RL9!#O394M'NZBJ:::J.80M32(*&4AM  5]*,C/5HQ&U422
M2KVKDVEV'M75A9U$H8#XZT((U5)%2& H&U#N95H)!26*D@(++B:B4B-RU?EH
MLO4XFE244./WI/EY=\8UTI*#[K-I18#LMNP]MT)I*;(S1TV$[PP<#8ZJ&/[$
MQQ,KT@&1VJ5#'B8]/AG)HM6B\)CJ*BLFWR'Q%UV,F&D:ATFI!H. :NH8!)PV
MI<!L+.HTG3.O2C>>FK*"DB-?710O+AYMO[AI\SM\U6'J<K5KLS;-7!FMW4QI
MLOBJZF\FV,#F-RJM+N"A$G7O8L4==#C:_P!L49'8Z!6C:E*M1@H\1QI0U5@:
M2R)%F-J7UB2AD3IXZ64 MCR.,5[1D\0?@4OAA^C.-04](*HCEVQ5?Y/DH<:,
M-CZ>IB-/N+,;?QV+QFV-T-M7!U^*S6X*6NW!L;;6Q]PU+XW!YW-K49OIS+U#
M[/WHE9M&OH*M5BL+E>Z,MK;S56)+IK8%5(61Y%&N2..D=\@%U:%+I'4I"A@8
M%7(H/4@  T%"<J%.$=JM 3X4M8F4]+0S8W+T59!-'3T53BZ7/P?;+BMP;+3"
M+LC.4]564ZTU ]9G^M).M=R5HKZBGI7J<YTYF:@93$'([ RE3&J33)$ZE265
MBN=2R:O$4@&IHLOBJ-()I'?(/#E\.]C4]*@4E2C"C '%"M-/V90H34@5:%NY
M=4+'I%U='E,#75 $M?3RPU.6IJFCK\)28NA:EQ^,3>.]L;DMG;.O6)1Q230;
MAW9M;;4K28R4Q=C]:RO029#&^UB/',BU"D$*00Q)J3HC(=\5XQ0S2BCBMAN
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M+28K-MM/ YS;^>W-CJFNVHVS<@9<%C,IN!),AL7*R2;#W]%5X6?'5H;EM]+
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MZ^"'$]K8ZG;:^XXZ#>E%!4,A=?".ARJA=5*ZTT^&=1#*O=&(V(=T4E[-C]3
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MV,Y49&6GK-M+5RB:GIH(Y8M5/)Y#@RW[2&&UEMUC/A6R:F$KI/I/ZH9!5(5
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M8$,'KJ!1"K.*.'H8XI)*+*H-E?!9@CEU) VI7'\0-05X&I! ^$K\3*OPG]:
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MHKYHZ;;O:N2[3P.->*DKY8:3;_=> HVH:R/%[^Q>J>[JA4L"JD+_ $T T-7
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M;Z"Y$:D=X8%2?1W5D3A0TEECB.,7]@=/B)TY#<*X +$'!%#_ +4$,WYJK/\
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M<OTSF)VP>X%R.R*^GK%89:L49-8+-Y"4DLFHUH0LGBCN8*0E\@\:'1>(R]*
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ML^-PZOC]M=L1=H[6HTJ<YAH#!@>\<+2KEL9)B]^XQX)GX9-&A))-*:5TFOA
M*CF@+9>'P7-(Y#63;W;PI!)92 AF6+5J>..K5.H4U&K+D@85]8RZX6<#4I69
M<\\%DV>30/-4T]348"KQ]3C:W';H&3CSNUTP&W:JBW3O"2DH-]IO_"T9PNW]
MQY=(*'LC&PML;>J8W>%#15DU9X@!7 8!@004II?4P*)4Q^&QURQ(2UJQ%Y:&
M2U=U'H9=51^'%/.M10=S8;4,(YQ*/T9@LJ@EUO3&FHXQ6-%CJ:?;F0P>9Q>Y
M\ABJC"UN*KVVOMG*X?<>YX:FNQ4>#K9YMOX3-[BA>? RM4;!W_3RXB:DK@V*
MZG)3O(8,I0-J##6X94H#J%)9(XB!(--[9,)0R=.D*0!7M!!!!(((- 03PI\(
M+?#F&8%2#TFJ5UVM?%9?[3$T5#CJ"=IZ"GWCM#';<H=M[V>"FS>(KF3(9_86
MU.N,W5R11QO]YGOC_FZHTU0N5Z\R230*''U'ZL568L<$HY8M'E6&%D>50"2-
M,>Y(-2F.^C(+*$P_IR4"A1P#*!1N(XE44_:ULQH=4# A1UN)CGII\5D,;3Q^
M"CSM%XY=J5V"QJ4F-S:;BR^/KL1A*JIS&SZ?9F9DBS^5Q."FER^P,R\.]-F2
M5FW*FKH@G24JPDCD.2I^,,:E=*D,P"N76L:/( ES'6TNPLZJ_3[Q!@49!P(X
M4\ZGAE:'N(7NC:DL54)'3.QJ<=6U,&2H9WCK:S>:9&AR-'B/)D#E*"'<>;AR
MVV]FS)2[DS&5I((L_N#;V :#'[XI0O8G7\D6?BR6)9WM=%:-Q4".A!.*'0NE
MGRB@DQQRR5:W/^(WH,)CEZ:!9#W+@EJ@_/)J%-"3\3(M!(/UX:/J7I\?1D"T
MM+X-V4>6J%AKJ.HJ:;L:7<%3N_;$DC34Z4(H-L]DU?9&UZ;]V-#3X3NO"4X4
MMB]]8\K*R#H%&K$ZC! ,6D(_G6KQ")SCC)82'A)9OAT@-4@!U;B/BKJ'RPVH
M?[6=1^&5>D_+1E)J*MI:B?)T==/M3(X7)XVH.X,E75.4VSD]K;:R%%N7>?V6
M%W-NC<F-$N"PFY=Q1PXWL3%Q2[#["CH\[28JOD4:ZJZE0K@.&!&D !P[@HE6
M1%-))(HJM;.1>6):%I$#!730AB5)%#Q.00,M@L?A5WQ*M89Z.%8S,/DO##1T
MS5@I%I(-O9/%5F'R4NUUI(<#(=LX3<VTLONY:[,[0H=K96HDVYCLGN&)\ML"
MNFEV+OF"HP%30Y16Y$J6;34DL&##775WLCJE%<N )62(Z+E0+RS99E>/IQ'P
M%+ 4H10TX8!4G( /:"W=&:Q2@H0W33E*+^"4\M-4,N*Q=/CWAC:3-Y[K[';<
MQ^U]\P9"C*?PFDRFXNM<'U?N6I8T7B%7F_C[N2H+I_%.N<E,878V\9@R]TA:
MOPK*7+QT/$A96F0=U=,>Y1"GZ=_&*MR)X=:"B4_B*@4:HX E50\.+6S?Q0,:
M.BU(K9:J"OCHDRZTF\<:CY?#9[#P5]!ALQ2;IW+MK>.!VA.9=NUNVZ^:'.YG
M#[?DEJ=L5TT78/7TM5@JRMQ\+=-(4QEO"JA[65B"RE$=&?X@XK'&\E!,H-C?
M!9E1RX#J)U4\6C#((J 02&"\",,P6ND_K0$H2O3CF<(N=ER\QP,LV1D_O;C<
MSALGM6BSM1EZS/XJ@R^X,!N/;N#K*/$;TGWECZ.#,9K"X*2'']ET$$.]=ES4
MV[**LHIFXY3"(AXP"=A5@Y72%8JK(S M'H)*(\E6M6)M+L-;.KBSQB74?#[^
MX$$5J2*D$##:L,RKB0 2Q$2 @M=%D:Z&M2!ZBKS$F0KZ2F$E3D\-ORHS%?N_
M;Q2"*LJ67&X'LZ?L?;="88*R04>#[PPM*:*M_A6_<<%G=9$*$Z0H )P&C"A&
M\AEHA$QJ5&J3;Y#K3Q+*3M;1V!"L:@GS(:I(X$X#Z@,'"SJ*-IF7+U"T.93!
MI/55%7!%4;3R6W]P8_+5>9R=/49'&UNT-L5W]YMVK2T.5BW-2+/MK 9C<<<=
M)NG'1R=?=AQ4]=#C\B66#1&8JH#$.&4@*" 0[C0E2N@TEDCB):)J7UB60O'T
M[0.$!)TU!!K4Y%!D\:Y12V''Z,P!"MTA8*2KVK4T=13T]/B),+!M:HIVH1E]
MOT%)0[5R%=AMM9;#YK>AJ,SLK;6S,[4O@]N9O-I49;J+,U$VS=YQU^T*RAKE
M6%UN5=68MK+UKI8DN S!ECHLCR*/$ECCHEZ@%W:%+I'3I)I:!U955::?4"BD
M@$$Y55^%&:I@:L4H:(@A;0M!EL2U#)!+M^:BI/'-!+35'6'\';;.X(\Q44VB
M@3-[CZK;K#<-::EZ:E:KS/3.:K!E\2V5V-EJF.-(P,4NL,'#'U$VK6ND<=*3
M>*HH"=,=\B^%+X=Y&I*I=,L="I4T']"E#6F*E"A-<5,).I=4+'I"92FJ<+49
M%H$HZ:>CI=]4LD&3QU=3Q+3PM1[NW-BLEL[KR6:IH**@F:+<>[ML;==VQ52T
M/8_6TLU ^2QH6Q.LJQAB2I,9J"#G*(0\N"3F*&67XQ6POP'$<G2.5'A8LB@,
M W$&GDQ!5?+\4B+\)I/;U&I>E_1UJYN'(@XR+(??OG$W#A3B4WS75%5NG;$&
M9R_V^-PDN.Q78?\ I(PL*93+XS%-!ANV\1 F[-L/0[RHZBA9$Z&%D/B%::=+
M5\,41RJU+5,7A,=",]9+)R;:X#VK*X612>*K'2,UU#XOB%3PH&U#)IVS+^I'
M24$=,.>V[4B?^+8*>KK#E:FGKH'QIV_O&NS-=N_!IC*"OHYLQ)283L;,=EX'
M&OC8I:]:;#=U8.F_@.=&+WWC8*B9Z"X6GA3J!I!&=2!0C5(.FK1+$QUG35["
M0^-#XEG(5#$]N03+!^(UQ1JEA2HKABP%,T6X4:'TS*#T\[7W.V27%QU&3?[M
M9]JY''Y7'[J DG>-,CM/;.:P^Z]U4,4<TM6L<^W<'G]Q0(E1%'/UWV)!&\6,
MR,C5S;>&9"L?;1P04X<'=61#Y8EDCB."1?6)(,D8=@GUA SY[2"#]J@@M_O*
MLP]8)P"%8MF4P%'-!19+'2X_&Y3'P[;JU&/S&Z=K4IH=I;JJ<7A<QMS+;@AJ
M=Q=>U'6F9KY<;A*[*1RYCJ?)SOM?=,==LG(4M9%>*=PSHX9HV+C*HYJZ LKJ
MM%E\50'D5"$O$'U%L4NT932: . R4$@T\"RX5L$$Y4I6BDYB/Z<FJ%@>F+;>
M8? H:>;&"@IJ.DR5&T!VYG=GT6&I=M;RCRNX83B,8*_</7.,Z^W+,,GFL#0"
MJS?26>J?[S[6?)[)KJNG1^XA$QU+)J8D'XE<L7CHO<:+*94[(Y&I'?QCZ>Y$
M=VBL6K>0Q=K+0 $84J,-4XR4"G+(*M;L?$CU0L0%9N?;D==!4U4=.:=E_O'2
M9'%Y2CQU)3+35'VN[L]ALIMWKZJDAJ,1*6BW+F</MZ1IC(8NQNNIG8Y#&%-;
M7!0JA-1VD$$DU%45E:0?%QB1Y12E;"^ [).GYX X+J*-GC_O1!"\1^,A<UI/
M :U7HUWP:J)Y<CW#325U1/-)7[6RN4@;>%!EZALMFL9][/N3.8>AIH:&KW+O
M*B^WK)-[[:==K=AT0I\LU-1YMLM  USB%$>U,$ &EP.PCM4TT*2:A$-5^GE_
M6M6U1:GA$1Z,-EK6\!^(L"1JKDBM2.%6P?$3LE%'H'+CJR#V ^C[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[JL;(_/+NV@[PI-ECX6[NJNBJOY(0?'0=^4
M_95*]5!72;JQW7\N]ZCK%=A-5P[8BWQDEA#',>K&1O7Z@JF+W[J^D4^+/1-X
MZ*NW9_,=Q?;&Z]B==YCKS8_R*W)M+K;<&V\)O/KW)[9W 96Z5W!NG?=#A>X:
MN@[N[ J.S:QL50Y/-8:'&8?&5#R4>,\MZ_W[K?X:?ZN'1F?YQ> CW1\:>O\
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M'MG9L?)C1_EL%-R\_L<ML=49[^=8[R2)/$61%E>56?3%&&9E\2<.0K>$&#?
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M8R7+YA<?.M)LW)HF]=BU]3CJFIQ[)WFBA*+)..\:@0P:O:1K5I*:CI#(LD@
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M(=)R.?)TU96M]I7U];E:K=D,N-R.W-L[EDR5=O2GAK,G2RX;%RTV"[ SG8F
MQJ9+*X;&R4^"[QPU,FZ-M28[>^.JJ6=01&R("ZJBA,AG2@C) [C5HUB8Z4D8
M&3;Y";>X$EFZL$HUQ.S*A)9FJ* U+#..#%@*LJT6Y4>)'IF!!7Z5<&5DJ<A1
M_8Y9<K6TT^2H(\[1;V.XXMSX(82@R-#65QI</V/5[ZP5$U!0Y&OCI<3VSB8F
MV[N1,;O6AI9'0E&B"HVI2H-#I,>G0VH@@5:(1L=3*M7LW/CVYDM'8!:"K@L*
M,K<175J!%*YPVH8!-!,.R33*!TBJ>%]N3X?<6$J/XCAJRIVS6TM4V1RLQ>*@
MQ&5V=MQ*O=6_$6?&Y&B25]M;:WANF%G":^L^QHQ <=DD6EA<++;SC3* X(HO
MFP=Z)'Q!_M98(3Z;A8'5XD93:3 T<L53&:>9S0:5!+<"/@21O^>>?&E@HZ'^
M'1T./JZ6E%)@Z)< <;514M=LRHV6VQ*FIH$CJ9<Q/5[CZRPO6F?R+T=-4UR5
M&=Z5RE3)A<PM?LBOIZF-,X?7(C-68ZJBHD$GB"M1IHDK2J-1"TCOT EBT7:,
MI4(49%=?[/%.*E2N*&N4T$TSW0$Z6K$0>DSD\9+MM1'(YP])1XZ;'?95T\NQ
ML5A:#;F93=>1QE?A]N193<^R=J;%R=6,M64F&:IS'2F6JEW1L\Y'9V1R%)&H
MCE$_EK8M6HI(6++H!#-1)'D T*7HE^@^GNM%TB,4TD;0G4#04X&J@ &M"!4A
M5/=VU:W8^)%JB9ATHDDI]QJSSK3G<I&[,3-1Y6CJ,GD))JR6GW=N';>Y-M["
MG6BKY,K2Q0;@S6"VY+)39M/%V+UY-]RE?CPR5-N<5^G[""#08JBNK29%#6..
M245CS8WPTE'Z?1UE%33Q>X4/'U(8+@UPQ"X;^W@-=0Z9LYA8LA]_D*;&5-?7
MS5.Z9LYA&V_CNQ:F6LW[@Z5LG545!#4T6WNTJ7MG;=-]SF,-3_;X3O'!THR^
M+..["Q[I*[#,8]"-( @"!6U&(4C8T!)!:$PN:)(:R;?(?"D\2Q<$,RPJQ,BI
M5JL6%-7Q"A(%0'UC+**+<*-:Z9USRQF8:>>*%52L2MR&/FI:F+,[>W!)E(MQ
M8)=L;9R-'NC<$N-Q/9B[]QM*V(PFYLRE)C^SZ"G.R=[+C=UX^CJI]2PZ06X4
M4U&EETZ6UN"BU,7ADZY(D+-:,?J[0R6SLJ[BEU8IYCS!K444@F@<,,*[4$H'
M@S:95!+TL5- *!#73Q4F.GV]GL'E\?NS-8RNP57A*G);<P&8Q^[MY03SXB/
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M*5,UAX3DL!F<+C*NDQV?3=NXMF[JVCMJLEJ-N5NUY5CS^9PV!FGEVC-)%O\
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M^X?,#%]P=;BAW-D-\4&R-MXK$CL/%S4^5V[DIJW;]-CXV)-GA1Y6CD5('#D
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M(".L&*KJJJK),?7P33U<E5ESB\H^+P_85?45G8F,CHJ7'YNKF:AP': [:P%
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MDM%)X8$4V(@ !4F( 1M4A@M7B$3-J(&J2PD(DCUV<C 4D0,3)&>_-0.XG4*
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M)X-Q_)"&2,PO%V_MM'@8(O@8="=-7@54)01P'T);^PH]PGS"0UOL!!J#:O\
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MM9-41\6W8*&5VF=6+>*#6O$D\1DD8#$_#*,+*M'[9!4JH?%7L&KK(YWR^UZ
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M:)3JMW:K(A:UF\:$C3Z7:Y) 15*FO$<=62&' AR*2** D"1-#C(:[]?J/HK
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M^FLYNBK2M[8RFUL+D:>DV7N22"O.Z-GY4[.W3'DX5H,C%9^9=J96'A.<,,J
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MI(II"@T;6!135%D:K$(0;>X'CVS*K-&:OM<KE>ZC5KQ)H2*5SQ(&.ZHDC[)
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M8J3EL#5)2QLGF:P=F+1/J8L"6 ;4' )9P"H8L?T[A0%6<!9U$<ZZB_\ NV8
M#4-(H12HI3R4\10=R')3*$LAIUD/6>VL?OKK[K3"?(+XWUG8'9>QJC>/3?6L
M79^+VON3N+K[9^7&^Z3,=9;3VWDEW _4N02KFW'BJK I._5>]H9,EMVIEV_5
MU.&"@<U;;(/UHY@6-2:*Y!9=#,=6'D4 (Y;MN[8Z)P)D67I.=HN5-8G04'S
M(#5 QP4DZEIF&3,9*$IT*>(Z&K=\3;NQ>U.T>F]V[HZXSNX]C;Y_AE;29J7;
M^?K$P'9#;2[3V[M66-=EY3L"DS%'6[KV_2O1?P[,S4.\=N#%553-32IUYEL
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MW"04S4U5L/=].V9VO4'&3UF,-(^9['7JT2J*USI<C4NACW]LCJO82X*W5O\
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M7<'7.9GP%=V)N/.AZ?"YBD:C@H^U]K-2U\]/1;CHX\A/9^:-M 41Q2AE IH
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M+DV^H -KBX7Z"PXL/?NO=>,:'3<7TWT\GB_!_/Y]^KU[KHQ1F]U!N0Q)O?4
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M[)XX9;'1QX#)4J950IJXG]UL,!0>70@;;H?E/LK^9MVG\VJWX1=YYSKCNSX
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M:NKPF#796XMI[GJ:K;U5D\= :FCQ./I8:8Y"6/1[$\-W<WO+.U7VZ6:17VF
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M=W+NS$=89S)8G<NWL-B<SL3']UTE5E.I9-W[7?<\F\)6WG@8H,BXPV.R_P#
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MJ6I7(25 @DJZU*F>HDIBDOM%N6[27D=C%MK7'@2H8K?2:QJP&I]=0:RG21I
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MF.F>-X9YBHHE(UM\<$]P+>>,:34UJ0< _E^T?Y.O2NZ(2I_U'HK6R_C?T_\
M(7X3?'CI+H3Y"U.V>F9.SNH.X.D=QXC=TN4WONS8G3_<^,[LS^7Z^W@:C [N
M?<U9D8I4I<LL+1XDI"*FDGB6:&7>X+:0Z(;5 5(!U5).?(>0QG.<^E.MQ-*6
M9Y?BR*>72\W3\.?B3UUDNN]U8K?G8?\ I"QE34T6X9:'Y UE/NWY0Y'K7L#(
M=UY%N]TIZL9WMC)[*[-S%9E9Z7&K2U*'(OB9%7$SICPS96GU<I4MI0"I-/GP
M'S/^"I\CUN28QJ,5/^QU&Z]^"7QR[*ZV^.NVIM^]S8W9>P]M;?[&V9T-E.PZ
M['4V>VC7]B'MC9&6[8ZXW=CVSO\ &L9OC5)%D::GP>7AC,N(J*F2E66F-[AK
M6&;P[> ,B')8DZCYU&* 'R_XKK2F5E+.]&/I3'3GL#X5?&KK??,>:3?.]\ML
MS;&[MFYSJS,[Q[F7,[(ZERG7W8=9G\)T7U?Z:*AVGL6DW]DW-5MJ:IK:RJ^S
MH:1I12T%+31:D2V>T%Q& LWB4*@F@!%1@D_D<#B.O!Y?$*-E:5K3/0U;[ZF^
M*6RNHME?"[=6Z=P;=Q_:O8=7_HQQN(WSNBE[;QG:.8W?OSY(8'>>T]W;>F_O
M1L[*[4WILS)Y?#9B5X*"DJ<5'2ZW]-/*AZ=!).KHM_0&Q_BEU)W9O7=/Q]WQ
MN;=_9G6^3W5T1\DL[V#V'DLUO/<^[ZS?&"[2[ W%O7'[FI\=D,[NJ7,[MQ:?
MWDI8OX+%0O3XB@$-/3Q4\1MM]G#<PS:Z^.1V<<4J/L-3BGY],3RNC)_!Y_ZO
MLZ&/N_X^_'7JG>?8'S9WYV7F-LSXK-XCM&/$=J=E;BF^+^W>]TV'M[HOK#MO
M+=:P.L..W318&/'8A)J*6$2FI:I\+5X@JH2DBA->GP2: =!+_+_Z8ZFVS\8=
MQ_'K8W96 ["ZPP><[UVUWOE:RE^VRW878&X.T>QL!WD^;V_N&NJMV;4V%3;K
MHLQMO /75D\HVKA*):>LGBB2I8S/T4%M KQ"2Y85.2 H]#2E3CAY5(R*=,L9
MFE8@E4KCS/1:,W\4_B]UKL;<.^LWV]\U\YMZ3<6R=PCN3K+M+??R&[M7&[9V
M-NSHO:VW]BUG6.Q]XYVOZE?JW=N5Q.;-'C*WTNN4JZZ.O@^_"FYL;:WLQ.$U
M.=)'Q@4-,'NK6I]1YXQU6.:5Y=%0!GR'47HCX[?%3Y-[3Z*P_P ?=][VQ/Q:
MV'\B>F?DO15?<VS>TMA;W[AJ>C.EMD;?ZHPG2E1VEB=B56=ZCSVP=@XF+>M<
MU#F<=N##4<T2:)JRKJ*=#.+=[6WE@CTMJ(89(J /,^1&0/\ 3>E>G5,JR2+(
M:XQP]3QIYU_R='2^:OQWZ-^36%V7F.R.Q\]D=F9_;_:.P<94[/[/V;M#"9[:
M_<N(Q&T]Z;&H-R5.'S$5?'NM,;3I0SXN:EW%0UM/_D%?'YIX95=E!;WJ%9(5
M5D(%06JU:C(KQK3(_9YAF1Y8C56J#Y4X4Z+SVQ\./@OL/9W8G>_='<_:V%PN
M"V[+#V'UO0=GY;-[7PF\.[^CX?A]5[@'4>VL?4;AE[I[?ZPSE'A(IQ&9JK/2
M)7T5+!5S5#2I9OIH+J6,VP:%33XFKPXU!I\^'R^?3J-*Z*0]'/R'V]#!LWX!
M_$+>G5U7M[L;.;]WG#M'>'=F_NQ\CV%W7/4[SIMY=\;-QV.WQN'L_(X-]MUN
MS]TTV*I:3*XP/'BJ[;N5HXJVG\,L:N&KN.%)?T"?#*@BM?,?/C]O#K<<DA6K
M4U</V==;\^*_P*Z0INO\3W;VEV)E-X?+K)=N?%3#=A=C=H[OW7V'\C-Z_+3K
M3;.!S.%S^Y<12/35.<@ZHZ%Q^,VS6"+'8K;U!CQ#2>*:K_?24Z<!;R'#_)TF
M=U?!3HJ'<O;O5E%VMW[V!4=O;GQ'8G8W76Y/D%2YT;9["R61V/7]<=C;;HSA
MGW[LG='5*]68.HV14I60XG +B(E@I)(!-$YO9[?%+"US<24A%: 8/;YGSI7%
M//U'2>2X<,$11KZG;U_EE?$/L#K7"SUG?/=]=1;C;(X'>G8M)\G)Z*H^2M5F
MNU/](U-M?N#=%!&N&WICZ#M6.;^&8S%PXR"@2JJ\72PQ4-54TDB%)(2R"2W7
MPP<TU T^W5GU%:T_ETZ3(*E6S]@I_@Z5V^^H?C3_ #$*G-T79.\<S)N3J6F[
MO^-V_LGU3OV7;%.L&<I<'3=W]/[E\M+D!A<SM^6@Q52^2QS4>9HGA'VF1C@D
MK(IE=]9PQKX]I)K@Q7S*U%17[?\ 8Z:AE>NAUH_'IR[7^'GQHW/MS+;_ (^U
MMZ2;?WWNC=F5Q]#C^[Z"AV)NC*]G[9V'LO<^#VO7( T4^2W?UAA=XXR#&5BU
M-%V#BH<E1Z6,M+*Q8K#)<10SQ HS<<UX4 P>%:'(ZO(SJK%30T_U?RZ"G8_Q
M6^*V:JMY=$;N[0[,RW9O??67=VS-]39KLF3=7<G86U]T?Z+,SVMNGLO=./PL
M"X+>]%B\?M7'X>6HI,1'08""&EQE'XO(_M1>Q6MI)'"D(=RIJ26XG IGAY\3
M]OEU6)Y9 7+4 (\ATN.S/A)\<>R^X^P=U;^[,WGM[?6_Z_&G.]D]?]W-UMNO
M(4V\>N-D=/9/IB6?"U,,V!VMVKL'8.&>3&PB.NJ\EC#E,744M9KE2MREL]JL
MT47ARB2C+D\1\\TQ^5?LZ\C2JY1C5:5'[?\ 9Z%/K_HKK+X]_(7Y(?*;.G9\
M^Z9^HND>C\!M?J7;6]MT;]VU\?>JIL_5;,EWUA(<QO'=.\.P=Q;@W?4P5&0H
M\?3)-@\%BHF$S4<LWLMZ>J30=%:^8OP\^(4=5W'NFF[9R&Q>U?D#N??W5NV]
MLY?M;<>5Z8V=\H/EST'N7X[56_:[IC"9>D5-];_V!EO%)%/-3PSR1&JIOM:F
M>>HG5V=NES*R/*$4+6OSP /VD=4>5D4$+7_,,]*7&?R\/CSDNGZFN;Y$]^9?
MMS8YR0[#[WIODM_!NXHI*[K;;>R-V=,;[["2F/\ =SK:KVIM_'P_P2KIZ6HQ
MLT,>2CFI\J\F09UA!'<_3S6ZB#Q,MW:M->(.KT]!3Y=5#2,FI&[J8&*5^RG1
MI=B?'/XY=7O6;WVM51[8S_66\-U]]9?!U&_(J;"];;Q[#Z,QW660I,]@ZW(1
M4>V-ITO7&'A^QH:YH::F\3508L6D]IA&OU/A#N372HS45XX^7IU8N2FHXQ_L
M]$R[)V3\4^V-OS?+GNGNKL+>V-7L/+_'?#;6R6Y*_P#T*[5[OW;_ !7X@[@K
M=H8^#!Q9C9V5RM)N2OPM7DZ',0[0EFG;./3O4!:\&++MTFXB".+_ !:NDFK<
M:GAFE*X&*4Z;!N%BJ3WTKY<./0C=2_ [IS=>U^T9\EVAW;V%5]B83?&&W9OW
M>_=%!V%N+>V)[?Z3V5T?N7+U.[\=A\=CV@K.J.NL-2XBJHH(Z6FJH),A&)II
MYBVKR"UM/IP(=0=:DU8'RX"N/7.?+''KR22O7N H?0=("/JCX%;-[BVSA^Q.
MU<[L'N?9T_0_4/8'6N([0W+M_ =BG9/7?:&<^*>1^1\6'C&/RU?M_KOKK<59
MB\O4U.*HLK'11TV46K7["C]I;^.V2=3;'_%V0$9K\C]F1P/#J\32E#J^($_Z
MOY]" WQ#^/F]MV=1[%VGN3?O6V9ZIZAZPZQZ8['VCW(,/W5B>N/CG1[RPFUM
MR=<UV16NKJU,_B>S\YAMSY)*3(T>X</D5@JU_:@EC636$-I9^-.=5RP6@S1?
M,UH<]OK3\^FUG>20JO\ 9YK\_P#4>B>]O;)_EJ_$O?N;V-4=G_*C;N1Z.ZPZ
MBQ/>])C<)\B-_="T6W\AL?=W7G4G:7RU[5VEUGN3;&-W3M[K3.9#QYG,9ZEI
MU@I:/(9N"K%'#.B*W:UEF1+F(+$1Q6H(QCSIQXEO4DFG!YO&TDQFK?.F<^7^
MQU:M2]/= ]G?&K'?%7(UM7C-I=/;+ZMPE!2X?L^>D[2ZJAZIBP68Z1[0Q6_L
M/D*7<N!W-@*C9V/S>'W"YA%344?GM- TBO2ZMOII H<,A%0?7R-?0@U!'EU6
M.0OW4H:YZ #9/5GQJ^+W9.)W-U3FMX[D[5KNE-^9K/\ <G8.^<ONS9>[=I=F
M=K;7W7OGL?L;LS)-1;$R_9&YMZ8C&>$M54_V6!I4AHJ>GQE.D2*["P6?5+.Q
M$"@^633)I]G[2<4ZK+,RC2 "W75+\5/B!NGNCMW=.2[LS\_<#8+/=G=I8+$]
MH4]!LS8^/^7'4^*Z,S&\,/AIHC0X:@[-VATY U)**NH@BRN--;"D3SLLR:2:
MW\1O#M%\&N 2:TQQ-?.F<>9ZN!+I +FO^K_!TVU/P!^+W9D&Z]H=D;RWE6;4
MZSWUCMV]C]?T7>A_N)N&6.+8NX< W;>W*>I,&)J<'/UICZJ@R"IB,]34YJJ=
M:YL?53T[WO8[8+;36JD(X-:GS!SU6)Y*NK_$#Z=##\SOC=L[N=>O-X9/L;O3
MK_=^V<EGAL7LOX^]L574'8FU\/NO$4L6[MM8_=N$Q.4I<]L;>4.*HI*W%96C
MR%*:NAI*VG\%930SJHL;>*^5XFB5711W#54Y\QJ _93JKR/$0P:JGR-*=!=L
M#^7;\6MMX;9'8F,E[*Z[VWMC9VT=L[@V/M'L_=F-VAV71=35.Z&ZQSW<;SU.
M3W?VIV#M3)[MR-6,G5Y$5&=J:A4RRU\,,$*4NK=!>BUM;<5!'F237.:FE!_(
M>?6TD;P]<CU_R?9TN-C_ ,OWK*H;HS-5F?[>PV*^/NUND=E=4[>_OR4@W!LK
MXZ9R?<W1LW;>-DQL_P#>/<>S\AD:PK*LM-+/!D)XJGR:K)2Z-I&RQPQ*7"T<
MU;3J%!VY\LY-:GY=>C:5@S,V":C KGUZC9#^5#\7)J+"QX'+=Z;#SNWME=9]
M:XC?'7O=>\MG[]HNO.M.LVZ@CV7#NS$U,64CP>]]A^.GSZJPEK*RFILA#)3Y
M&EIJJ(OZ>UGIF'\H#X?PP9O'T"]O8K"5NR^WM@;8PF+[6S])3=<[<[N&U:S>
MXV9E%5MRRYB/=.R<9F\3D<S7Y?(87)4JBBF@HV:D;W7M;=#UU3\%.F.GNX:[
MNG:^:[8K,W49#?\ N/'[1SW9FX*_K+;^^NX*NCRO<W8F%V# ]%@TWEVSN"D;
M)Y>:H2IIHLC5UD]!!1-6U?F]UXL2*=!%%_+6V#N?LWY-;^[=[!["WM@^_-_;
MXW=A.K<3N?+[9ZTZ^DWQT-L;H6KWECMM0U54DG<^.VOM_*14NXHI8(Z:/+&2
M.D2MC%6?=>U<*>72R[H_E\=4]L;GW/V!%N+L#&;IRVW*B?%[0R6]-PYGHD]R
MXSK3(]6;![YW5U ]=3X?<?8NR]JU5-21S^:G@J8L?1RS1/6T-%5TWNO!B.@\
MV!_*NZ6VCU;M/:V1[([]RW;VUI.MLEB_DI_I<W'/W5MC)]:=;YKJO!XC8^Y\
MY_&J?#;!IME;PS^/7"55+74TT6=JZFJ^XR+BM7W6RY)/IT(</\N_H?:F'HO]
M'5!NBASVT>TNK^^-@Q[G['WWGL+2=L]']+1=)=8U&YJNLR]9N?/;5_NQ2Q-F
MJ:>LFGRE4\M3+(T[ZO>J=:U'SZ$KX3_%_$?#_P".^U>EL=-@:W*P9[?^_P#>
M^6VSB*W!X#*]@=K;\W'V1O!L!C<KE<]F:+:F'S&YGQF"IJVOK:FAP-!14C3.
M(%MOK3'4:]&O]^ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_4,&!WK_
M #>=U=&;*ZJW=OVBZW^6V ^3W97>>Q-O=2KW3U;O:LV#B_X?L'L/N7<V_MK[
MFA^+&0HZA8SM_$8+,[AFH%?$F1:!E+:Z<_!7Y4Z-OMN6'_9LZK=/^D'N!<]!
M\QMX[6$,/5M#+\<GR57O(;<7;$_8R_'<Q/N5>HHY<<3)NPU$&\+0)5*W[)WU
MKR_+H9_YP>Y5VG\<^M\M_E'W,OR9ZBP^.2"+'GS9?.T^Z,1@H9<CEZW'XG;4
M39FMBOE:J>*GH/\ .OY+>)Y,]K+8W>_;A%C2-NG8U)PJE&:@4%G.D'L4$MP%
M.(!_.-X+';[&:A+->Q(H &6>JJ"[=L8+$5D8A4XGTZKBZ]K-O]FIG*3>&R=F
M]H;AWOO3JO;&W<9W1V/1;<IL=)75']VZRHZNS.7Q^"H,?V1CY,=-D*+#%))Z
MZKBBJ9U^X\80=7RS;?X+6UW+;P0Q3.Q@B+$@=X$RJ6)B-0K/6BJ2HQ6J2$QW
M D\6)97=T&F1J >782!1@06"\2W<<TH)NX^N\SM#!;GW#E.R=QYO&8WOBOV-
MN?:O9_6D?3.0^0AP^*R4.WX(\_C,S4=@5.%ZQKLO$*"H)$59-+',S2336]E\
M%]%=36\,=@B2-9B17AE\<6VHC4=)41AI0IU#BH!% !T])"\:LYN20)BI5U"&
M6@[:$'51*X/G]IZR[EZUW+US@-T9CM7LN;>]7\?>L-NT6<W)W=UO2;2^//;_
M &AO?*8B7KO;6\^Q<73;@SV_,%L3%5U-3I5K130U,31Q35,5,D .K?<(+^:W
MBVW;Q$E[<,52WE+W,,,8;Q7CB)58VD8$TU @U(4L3UXV\MO$YNKCQ##&*F1
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M-US8^BWKV!V'WMV54X^AW[DNQJ';-1V-24-+0XBIWM-L_K^AR63IFPJU-?\
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M7U(RF^MKXN;[E9:>>5:V=XHX U'2B-D]Q'))%96N[N62=))9S$$CI,,1-%,
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MA@I!()4@W_I;W[KW46?)8ZE"FIKZ*F#SFE0SU4$(>I"LQIU,DBAIPJ$Z!ZK
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M^3!XBHP%)C:P(<E4Y5:^>M\D<RS*E)#!:G\99!?7^";"_O5E/;6\@FF5S(.
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M0;];O4HVKB217!.&K_"M>@%V!WG\S?C32=D=8=,=FYZ;KVFW3&-T4FY*7KW
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MJZ1LK7X:@HL.M;D,7)79B/[>#?51II^WJNWI/XM=M=7;KZT['VWUGW-NO>V
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M-J[;W)7[,SJ;IV?6Y[!XO,5>U-S14%=BHMQ;:J<C2U$V"SL>+RE33+64K15
M@J)8P^B1P?=>Z4GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ,JG9?^DG^8UNWL7 #9%?@^K.
MYNN.O>Q:S:.-V[".O\G%C<!O+;.?W)E*ON[$;MJ.Y>P]PO0;5K:B?:DN&7:S
MFAQRU&0>IE/J=.5[0.KS??NF^O>_=>Z][]U[HK[?+_I/&=[57QOWKF<KUEVO
M4UN'I=B8CL;$2[:Q'<,.>H,A78VKZAW3)+4;<WQ-(V%R,,F.AJ4S,$F,J7DH
MDAC$K>ZW0TKY=$ ^0G:VT<Q\TNO.E\GG=]3Y#!][] ;\I(-N?(O;V1VVV:.Z
M<?C<3L^KZ3RV*I9JS)TJK+F\OA<;5SY3#X. ;AF5*81K+[JP^&O4/HS(=@8+
MYN=L]<X1_@#U9C,[\F^RNRLEU%OS+[GW7\ZNQMH5N"HFRG=VUJ4]C04^W,9O
M&NQ[3XF-<$^/HL!2@>IF+CW7C2@.>'5U?OW5.JN?YLNX*/;'QUV=E,G2X:MP
M\G>>S<5G<?N.M3&;<R^ R^V-Y467Q&X*MZFF;^%Y2E<P2^-O,0P$:N^E&D3V
MT@:YWVZBC+B7Z-RI458,'C*LHH<@Y%<>I R [S-.MO8PR.4$7CJ&U&BZ2&J#
MD8(\AGT!X=5HU<^U>R\+69.O[0HNLEV=A^G>E.K\IM/KV?=,]'AJ'(X^HVEU
MIEOX[MVAR&S\3C-T+X3EZ B*DQ\DBUDC5IBE@D!1<;?*D<>WFX\5YYY@\H0%
MB#KE72Q#DIG0WQ,!H&BH)0ZQW"._U(A \.-&523I%*(:@%1JQ5<!>/=0B7O7
M96X,O+V=5]M=+41A[%[:@PG:N=W;GMK=LT?0V4P>,GJJ>7:VSME54^XX*ON%
M,?CH),:M7X*"@HXT5C.)'-+2[AB&W+MFZFL%MJA5%>$W 8@'6\@TD058AJ59
MF)^&@ZW<0&3QQ=60*224<L0_AT&-*J:]]!BM  //KD^Q]V[FH]V97.=8=D=)
M4F].EL=VE\CL#UKOM-Y[UP4.Q=P8NIVGE.M^F,<:^OJ]Z=LY"E3)TU37TD]=
M059F,LXHZG2OA>6MN]M'%N,%X\5V8;5I8]$;&13K66<T CA!T$*0K+2@U+G7
MA2SQR--!)!XD6N4(U7&DC24C%3J>E:D$@\30]!E\D.V8MA[%[KV33[PQN>V7
MEX\;N^"3?NRL=5;BH]V9S:Z[>W)O'=^3..KL)A]]S/E:*ABGB2G;;[R&E#B%
MTE]F.P;8;Z^VB[-HRW:DI2.0A2BOJ6-!4,T>&8@U\6FKC4=(]XO$L[#<_$N%
M\'P]6IE&I6*Z2[FA4&I4 T 2M":4ZV#OCC&T6[/DM$\;PM%W)MZ)HI6=Y(FC
MZ'Z;5HI'D+2-)$1I8L22P-S[A'?S6VY?(-0;1O\ M)GZ&.W"DNY@C/CC_JU%
MT:;V&^C3KWOW7NO_U-_CW[KW71^G^Q'^]CW[KW6M'V5UO3]D]7?R\*67')--
M@J[Y;U,&4.3FQE514>X>R8]K[AQV,,,-4<C4;AP.2FHI*3P2O4)*/'XY%5O>
M0&W[@UAN'/1$E%<60*T!!*1%T)X4T, P-12F:CJ/YK&*[/+<KQ R1"XHU2"H
M<A' IQ#J2I%,CA3J7MO/;@ZXPNW=K[9I^S=L]Y93#]I=1_W'R6!GW+T#7Y&;
M;+Q2U_=5?A,70Q[U[#V)L/'5-538FFI]4JS*DD4U9$],*7$$%_+/<7#6\FSJ
MT,WB!M%R!KX0!B?#BDD(!<G%*@A2&Z5I*T"00J)$O&5T"TU15I^,@#4RJ*@4
MSPH6!'21PNX-T9/"=35'5?<_4^T\#/18';GQOK(:#$=3[0Z@WWL_<L=?W!F>
MQMB9:B>LW"-V88"KHZQ9**6HII:>I*)#3L2IFAMHY=R&X[5<RS59KH5:9YHW
M2D"Q2 T70W:5[@"&6I+=,ZYBL!MKN)$( B.$5&4UDU*<DD9KC%#2@Z5.V-X4
M(DDR4VW-S;EZ[W?\A]T93$8/H79C=([YPO<^S]O5>9W[FNR9QD*.'?77FYZ"
MOJ*F19*FOAHH&IJ!2M0&D1-<6KTT+/''?16*!FN'\>,P.P6-8L'PY5( % I8
MZG-5P7DF4.OZ;-&\Y($:^&0ZBKL^>Y"#7B:5"\> /UG6%+)V9\8]^T.W-L45
M'+W3U]V3LN-\_49NL_N-4=E;6Q%#V'@,/]U!30QK3255--+'3A,6*EHT0,)9
M6-DW%EL.8;)IY"_TDL4G:%'B>$[&)FH3QH0*]]*DTH.B^>SAN)MIN4CC.BY2
M1#4M0:U&M5J!6E5K0Z*XS4];6%.P>-CITVFJ5(N#RE1*I-Q_JB+_ .Q]XW-@
M_D/\'4B]9_=>O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6
MOKNOY*_)38^Z>V/D/3_+NMS5+LS^9EB?B;MOX2YW972,^T.T>K,UV'USUC7;
M+Z[R&-VUMWNV@[CP>W-UY#>=-EY,]DJ5!A:C[^@.(\\U/[IP*#04\N/3TW\T
M/N[LGLSK#KGKF@Z6V]3;B[@^&N\Y]^4%;OS=>R-^_&+Y(=I=F]>S;>Z_SFZM
MC;*&]MS9F#KO[_#[UP5/4;2RT-8(<?+,\9FDUUX(*$GY]/G4G\W+LON:GZPH
ML%\<J/963^2+=093HC<O:FZ*C9>P<1A^XH=_Y#$X;L6K>EK\_G=Q4F'ZWJOL
M:S;U)-A<_FJZ'#4U3%5P3.^^O%*5J>'1^/Y?O;W:7>/QGZR[([1S6S=SYC<V
MVLA7UVY=K9G&9(9/<5-V3V1@<O%0Q[=PF,VO5['Q^*PF,BP>6I9#+EXA-+/!
M RAIO=58 $TZ.Y[]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZHBEQ-/EOG!CDR$GQUQ=9L_P"4^Z\_MS:5
M5N&JIOD3#59C<'6%+64]-E8/D'BLED-L]C;>S&2WU_=ZKVE6XF./;,<D5)YQ
M'6K[IS\/Y=7N^_=-]>]^Z]U[W[KW5!IWMMO#?S8<S'M[=&]>M9LSVIMO9>^\
MY5T_0G:P[SRC=3P3[?ZLP^YMRT==O#X[=6;8K\C)-4XK'UZ[HRV<0?;T=+1U
M,TM3[J_X1CH4=SYW>^V_YDNV=L[6J>[NN=M[KWS@LUE-@[-Z.JNY=A[]BAVI
MO&GWMW-O;>%?D\GMKXZ[+WO'D<;@GW-#2XK*S9/;[8^G>I6OK%;77OP]&2G_
M );_ %-5]J5?9U7NW=TLLOS.P'S>HL;'CME09;']D83JZ7KR39R=@Q[8_P!(
M51UKDLJ(,U+029(U*^$XA:D8"1\6=]:U&E/E3JP_W[JO56O\V/:K;TZ,ZEP2
M4-%55K?*#JG)X>>NRJ8.GQ.5P6*W=F<9GY,Y(&@Q#X*NHQ4QRS1U$321B.2&
M1)&0R-[:77TF\;I-K(3]W3*P U:E9D5ET_BU T(!!H:@@BO0:YGM8[NUV^-X
MM3+>1.IK30RZF5P1P*D5%:CR((-.J]=HR4?0&2C\F/[GV]OK9O:.R:C:^-V9
M4_=8?>F-W#]]3];;?[HS#4VWXMA]7[KW-FJ::GIYA%/,RE99HZ*=)B.+D/O<
M= ]K)9RVTFLN*,A6AE:!:MXDR(I!(J!Q +@CHM5XMN%2LB,DJ_":@AO@\0XT
M(S'A^TT(/2(DRFY6V5E\:-^=84&"VYOCL+#]Q[*VGLU^H:O(?*#>LTL>R^Q:
MJFS.)$N\]F8O+-+03XUXZ:9YJ6KHHI:B6IC 5".W^KBD^CN&FDAB:"1W\8"T
MC_M(@5;]-RM&#9%&5B%"GIMS,J4$\0C5G$@ \.LS?"U".Y:U%,<"!4D4563W
MAGOXKW;EMZ9"+L^B5NG.N?D;E?CSLJ;K+M/L+>^;>AI>N^PNK.X:;*0')[;I
M\EBXTD@:ODH\A'!65TL*T\T4/M-':P^%M$=HAMWI/+:BYD\6&*-:F6.:$C#$
M'!TZE)1 :@GJ[3.HN7F_5/Z:2>"NEW8_"R/45 (SG(#-2A Z!KY(]:T796P=
M^[WH=D8U,3F]P9/ [4H-QYM,GG<YF-CXW)UF9VKE<#%D*>ES>^-IY:&*LTPB
MI$TU']W,\EX4C-]@W"3;[VQM'O&\5$5G*KI55D("NK4JL;BHS2@;2 ,DH-YM
M(KZQOCX",IJ%!-:LBDD,H(#,K9"Y!(J?*FQ#\<91-NWY+S*_D67N3;LD<FIW
M#Q/T+TTT3AI%20AHR#Z@#_7GW!N_BEKR\*<+1O\ M)GZ&>VYDW,_\/'_ %9B
MZ-+[#?1IU[W[KW7_U=_CW[KW71^G^Q'^]CW[KW6O=7T%%6_'SXU5^7V'@MXX
MO976/S%[)I-U;IR\F+VYTEO?9/;]#7==]G9>ECJ:;^\>/7<<XII\<3KE51)$
MKR1A#-Z.R[WS D5Z\4LMQ8Q%$74UQ')"1+$#0Z3I%0WEP- :] L?[B;=J@5H
MEBG?4QH(V5P48CS%:U'RQT5/?_8M=U[MZO[+&$WYLC>>]::'M _*O;.^ZC<>
MS]XY/+XO"R[V[6V;U_DZFAI,1M7$TV0%(F3H!'55K0PT]3'35)=W$=E8K?3I
MM_BPS6L1\'Z-H]+H 6\.%Y "2[$5T-A:EE++0!!=72VEO/>'5$6'B&<-J3@-
M<@0X"@8!&305 .2239V&^3_?V;[$WQTGTWN+<>V-L[AS+]@UFZ>NL7V#N7KB
M;:^SAOC&]@N^7W'3R;I[*[APM+"M5C=I1U<57',F/EF%0411A=2<N[+!8VF[
M;I&EQ(B^$$E,23!Y/#:(:4(2*!B://I*D%P-()Z"B3[WN-S<36-HRP(SAPT(
MD>WT1^(LC$N#-).*#1#4$,%)U\!+Z%[AK,GBL;L7=W7FZ-YYR;;N6P_^R]]A
MT^=HL#G=[923<6XL1V+BY\7%B]QXC&T].K-G\?DJI\C1>*MQJN(Q.Q+MZVJ.
M*62\M+^.*$2 _4Q:2ZQKI5HFK5"2?[-D&AJI)2M.C?:=PGN(8[>[LI/J#&-4
M+@A6+:F61#\0!']HC'4AU)Y$D]^UI,=#N+(;7C;IS-[SZRWM\3ML8C;JPL=\
M_'SK3=/9&PU[%V!UGOB*HJ,)OK#2/%%&,71U+08^)2M**C29/8.N0[01W#?5
M):W$-XY;_0[F5(I/"DFCIJC;B=;"K'XM/#H\1T5O!@$32Q20+II0Q1LZAU1^
M#TI\(.. KULM1&ZMP5M+,+'1<VE?GT<68<B_-K7YO[@ _P"3H=]9?>NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1?L7\3_B_A.Y:_Y%8?
MX[])XSOS*5-;6Y#N>AZPV;2]GU=?D\0NW\ED9M\0X=-QMD<C@4%#45'W'FGH
M[PNS1DJ?=;J:4KCJ/AOB)\5]NQ5T.W_CETE@X\E7X3*9 8CK+9^-:LR&V-[1
M]D[5K)Y*/$0R23[2W_$N9Q!)_P!Q62'GI/#)ZO?NO5/KUFC^)?Q<BQG9N%B^
M.O2<6)[GRM%G>V<;%UCLV.B[%S6,R4F;QF6WA3IAUBSN1QF?FER5--.'DI\G
M-+61E:F625O=>J<9Z$?9?5G6?6\<,/7?7NRMAT]-MC;FRJ6EV;M?"[8HZ39V
MT*G/5NU-JTE'A**BI:7;VVZO=.2DH:.-%IZ5Z^H,:*97O[K5>EY[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/55E)0Q>>MJJ>C@U(GFJIXJ>+6YTHGD
ME9$U.W %[D^[*C.:(I)^6>M$@<3T NX?E9\=-KT]=4Y?M[9BPXW$]B9VO;'Y
M+^,FDQ742T[]IU4RX>.O96Z]2KC.7BMYJ'6HE16(!.[?EC?[ED6+:IJL\2BH
MTU:>O@CNI_:T/AG@WD>BR;>]IMUD>7<(@JI,QHP-%MZ>.32O]C4>(.*UR!TF
M(?FQ\8ILE3XG_2IBH:ZKW'OW:=-'4XW.P1RY_J[KRA[:[ HON),6M/&FUNLL
ME3YRHF=E@-!*K1N[70*3R=S((VE_=C%!'$YH5/;-*8(C357OF!C XZAD 9Z3
M?UFV'Q1"=SC$IDDCH:COAB$\@J13LA(D)K0J<$G'0E;)^0'278\-%/LCM+9.
MXUR.UME;VI(Z'/4(J9-I]D4LE;U_GWHZB2&K@QN]*2%Y<7)(B_>HC&+4 ;%U
MYL6\;>76]VV:/3+)&:J::XC25:C!,9(#@'M\Z=+K7==MOE1[2^BD5HHY!I8'
M].8$Q/3B!( 2A/Q4-*]"_P"RKI?U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4XFQ_C[1_+"K.(^0QHL1N7Y#3
M;USO3!ZDV_F!EODIM3'[+DS)Q/>]1M.HW!@=NXG+9?;/\5HHZPP0;@R--B!D
M(6KSB&]U>IID>75L?OW5.O>_=>Z][]U[JG_>FX>D]M_-*AZJW%#\P<=CJKN+
MKWN>786.VAMN;XS3=L;ORE#M'K_N#.;RQ=//V31;/SG9[04T./JJ^+ 5&\Z8
M5)HBT,DGOW5\Z:XZ ^JS&P-M?S),YB=N571VQ.Z]U?);9>;[%K=PY.AV]F^X
M]N577V*VOM';.)I*#-PY3<>0V'UIC)JJ+(5\35DV^<O0XBEB.)BJ2WNM_A'I
MU?A[]TWU[W[KW1#OGIM?&;VVGTEL[<O6Z]M[-W1\A]IXK>FPSF/X#%D=J+L?
ML/)9C,UN8>IH8J"BVG#COXG4*]1!#44M+)"[J)/8RY,N'M+G>+J"_P#I;J.Q
M<QR:=5'\2(*H6AJ7KH&"02"!CHGWA1)'90M;^+"]PH85IVZ6):O]&E37! ZI
M2K-X,^UJGNG(;!RO9.XMRX-=K4'>?5F]5QG5&)S>S*BLHNKNMMK]?Y21\-NG
M+;9P-!]^PK(SD<-$)9:8U5,L3K+2VU+E=I2]6""-M9MY8ZS%9*&:5Y!W(KL=
M/:=,AH&TM4$-&1=,E\L)DE=-/B(W95:^&H0X)49SW 5I5:=$4PM7\D/E1V5E
MZ#I+9>XN]-XTV)V#'NO*=F8*DR,O9>W]T;GFV]6=\9&3-;FIMG8/"]<[GEJF
MP?CFFW'C8HQ4>"*(>2092IL'+FWQ2;Q=I9VI:70(F(\%T34+8!5,C-*FGQ*@
M1-73J)P F+S==VNVBVN S2*8=1E2OBQNY5KH%F"*D;!O#4?K"E=(2A*BZ?[D
MW%LS<,.T.W]N=FT<\>^LK6[KV'NK9E?LW"]X;>>JPNU:+"X79C4$NYM@YS'U
M\+/1T-76'$5=%-2Y&#29(55C==JM[J!KK;+BW8>"H21)!(UNU&<LTE=$JD?$
MRKK5@T;5H>E>U;E<*ZV]]#<*Y=S1XS&)U!"83+1.#E4)TLFF08( .2I3;^'W
M+L7)X/HO:VZ1\>N].XNM/CEDON*C;_5W8S)E:>D[-V3O0Y;,Q[6WEF=LS54S
M86JJ4JLA)+5-6O3U,OC4*@&>:VO$FO)+;ZZW@ENA35-%BL4B476@:@\0"BT4
M)J45)Y,?!M[BV5(4N!;321Q$=J. :.'J:$@DZ203W5()ZOQ^,PB&X?D:(#*8
M!VWM40>==$PA7X_]+K$LJ?V9$C 5A^"/<,<PU\#8*TK]*_#A_N3<="W;/CW'
M_FN/^K,71K?89Z->O>_=>Z__UM_CW[KW71^G^Q'^]CW[KW6NIN?&8;+_ !\^
M-E)E*VLH\A0=/_-3>VV7EV])N/8AR?7/;N*W-6)W#24\L=1'UE)1(!6@ZZ>>
MQ2:.5/VGG6VDEBWO?WC13&UW81OW:)*2PL@\ G_1:_#YCB"#D 9PC6FW1D]Y
M@N66HJG:ZD^)_0]1P/ U&.B*=YX"/>G6L%1M3[I<7B>I**@[#[6GQ:1?'RCK
M>[MN9JJQ,G4.T**.I-!!!FJ.1<--.8OX-3T\KF&FHIU*C'9KCZ3<"+G3XC71
M,<-?\9(MW4-XSFE3I/>!762!5G'11NML;RP>.)])^G*M)PB!E0Z2BYI1AVDB
MB"N IZ5OQ!_F6Y/X ]99OXU=C]25E=D\/V/BJ'9293M6;<>0VA_>[%9.OWAN
M[=55EM6(QO3V.SE+0#;%#BZTSY*DFJ/5',T0E3<T<@1\[;A%S!8[F%C:W8R:
M8= D\-@(XT"]QN&4MXS.M$8+Q%:(=HYFDY<@_<]W9L")XT0/,79=88R2MJPM
ML& $ 5B76N : E8^-FV=]=C[LW/EZ3K+RUW<%5#V=G>N.L<^@SF<J,%V#G-S
MY3>>R=K[NRT^\\/M3<.[<S,<'C:FK%;!&TE=/'5$+K$G,-S:6%O!"^X=MJ/"
M669>U=42HL<CHOALZ(H\1P-)-$4KFB/E^WEN&EG%BJ+<#7X<;$ZM,K,TR!R9
M%1W8F-&-0.Y@33JR[%4M/4;MK,ID<'V TFPNT_B9E\9U.T.&:C^,L_:_<.S_
M .+9'=N_(<5B*[?..FEQ#^:)8/)35FJ*J6D,9!CZ1F6V2-)X!XUM>J9NZMWX
M,#Z0D=6$9[L&M"N5U5Z&#AB^IXW;1-;D1X'@ZY%J2U!J&*D4^1IULNP6TM;3
M_GI[Z00+F9SS?ZM8\GZ7O[@ _P"3H==9O>NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=5F_*'^9'LOIFG./ZEVV_>>[X]C;A[EQ>&VWD:4X?M7
MJKI[?=/M;Y.X3I'=]'+7[?WIWKT5M]ILS7[3EDIJMZ:(*I+,PCD3EOV^N]V;
M7NEQ]%:F98"S@ZH9IX]=HUQ&0'CMKEJ1I, 1J/I2H,WWG*UVI ;&W-W/X1F5
M49=,T44A2Z6&75H:XMU!D>$D-I'VTK-W9LOY9?++&;MPN^>S\MG-J9O8W:?6
M5%V-AZQL%U]N_#-N397RE_EX_-WK[:>'BCQ^&SV7+)LK=]%C6,]-XG$J@!%$
MBVMYRORM+:S6>W(ERD\,QB8:I4;1)9[IMTKL:LJYN(&?!J*= :?;^9^:H+N&
M:]D-I)!+")E;1$XU1WFV;C'&BTJQ_0F"DD4H<4Z4/;O3G1'7^*W/V3W9W?B^
MM]I]G;[^7V8$V'@J]Q8J+/\ S@Z)Q'7_ 'ELO:PV_1[AR.YL;L[<^S<ENZGJ
M(J-UIE@D&1-,D,D@8VK>-[OI;;;]GV9KBZMH+%>XA&T[=<M+;2/J*A#(DB0$
M%LU'AZB0.E>Z\N;#917.X[QOHM[:YFOFJO>-5_;!+F--(8N(WCDN*@&@!#A:
M$],&:ZQ^*.2I>PMJ-WQG,7D-C8_O^3>V\&P&7;;6R\M\E?BYU3\:,UF*O=R8
M)=H2Y7!]<S8/(XFE@R,L]57YT(ZZ.%?@W/FB-["Y_<B,DS6WAQZEUR+:7D]V
MJB/5KTM+XB.2@ 6.HSTQ<;-RE,NY0-O\BO MSXLFDZ(FN[*&T+&33HU+#X;H
MH<DM( >G[(?#V?%;EKMR]2;DVSOS)==]F[$[2R/4-;DXZ!LEE_A)\91T/\..
MA\_5X[(U=-AMD[$[DFDW)O6LK8XH8ZN9(HXA.O+$?-@EMTM]U@E@CN+>6$3A
M:T7<;OZF_N5!4%I)(*16ZJ22 23I/2E^38XIWNMFD@N)8)XYC"7926V^T%O8
M6[%7*JD<]9;AF 4$BBAAJZ<^I?DK\J?BAE]F]6=DYZIWQA<-A-K]?4V\NTLI
M5)MG<NW>L=OUG>/\P/\ F"]D[LJ*,5NT.C>N9]PP[-V)2R5U-_&*B.%(XG!L
MC.Z<O\M<SPW>YV$ AF9WE*0J-2/,PM]LVR) U'N)=!GN3I/A@DDCB;66[\Q<
MO7%MM=_)XR!$C5I6<AEB/C;EN$DAB!\&(.(;8&0"3 &>T7+_ !R^5_5GR7VU
MMG+[/J*_ ;BW/U[A.VZ;KC=L5/C.PL=U=O#+9?'=?;[SNVHZBHK<%@^PJ+$-
M7XE:P054U'(K/#&X=%B7?^6-SY>GN([I0]O'.T!E2IB,R*IEC5R &:(MI?34
M!A@G!ZD/:-_V_>HH7M9"LSPB7PVIX@B=F6*1E4MI64*6CJ>Y<\00#->P[T==
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2529
M*GD^=6[=V;>J.LJ7K9>_]K=;;ZVE6[:ZYINWZO>]/48R/%[MPNWJS,?QF'K6
M?MBMHY:C++]IN'+YBF_BT=!58[&15K>Z<SIZNU]^Z;Z][]U[KWOW7NJ(\]M:
M>7^851UTF^.@D[4F[[Q.XY>K,YUIUA-O:MV+BJK;&+VS68_MNOPT^?KMWTW2
M=3N+<M+@WSQS..F@AJ*+%PP,\C>ZO7MIFE.A@[0WWO\ W'\NMH;:KMQ_%W/X
MZB[@V7@7ZPGKL5B._P#$;9VQV5LO<6!@:LC^0E%E<E)%#3-V+% =I/Y:?$QT
MQ@D1O*WNO =M<]6^>_=4Z][]U[JOO^81B<)N+9_0NU=QR;M3&;N^3&S]L12;
M%IIJG<\.2S'7O9=/B?M$IZBCK(Z(Y#2*Z2FFAJ8Z%I3&ZF_L;\CR3076]7-N
M(O$BV]W_ %#1*++%JK4$5I\(((U4J.B/?/"*;=')J[[I5&GC4J]/F!ZD$&GG
MU1'71KF-F;5EVQ0XG>.^</E-S=C;@S/6^UZK"?&/9NU.KMQ8_9^3_O)MC#4T
MU9G,M' ]-_%,>88H)<S6K,HJ:N.1I9C0^%=W(G=HK-U6)5E<-=.\JEQI=C11
MQTM4D1K3M4@ +Z2T,!4*UPK:R8P1$ ATG4HX_-:?$:Y(-0E^&?S9S7\L/%[_
M -K;PZOJ.Q=G=@;9QO96-HX.U]>5WAO!Z^.BVSFNN\5DJ2MVEM?9>9V[43S;
MHGE>*HQ^4AB7PB*-_$:<U<I1>X<MC<VVX"WNH9#$3X/;''2K+*00[R*P A J
M&0G-2*AO:=W?DRVN+:6U,J-'XBJ9JF60M@PANQ$T9F)(TN.&D8#=]W;M^3/R
M>[5[ZH]E[/QQ[BS^]MG?;[,W;4XJ'M/;F9P.,P^,DVYAM\9:NGJ\MM+:^U*2
MEW+DJ!Z;%Y^O7[>@EBA1D5?]-;<O\O;;LCW<K&UCCD_40'P65BQUM&H&F1W+
M1(U7B7N<$G.K9GW;>+S<X[:'PI7ECUQN:3AD51I5S4-$J!972D<IQ&: ]'LW
M#MFODP^]L!F]A=K[.DPGQF[:WMD?C)7T6-J,ON+<'5V-J=M8_MJKWI6XJGR&
MV(JBGR?W<F&2:LG>(1+!]RDGE8&VUPGCV<T-[;2Z]P@C%V"0JK,P<PA :/0C
M3K(45J6TD4Z$]W$ZVEVK12A4LY6\&@JY12 ^JE5KQTBIX<>/5]7QI8ON3Y'L
M9(IF;MW:[-- '6"9CT#TP6FA$A+B*4^I0?[)%N/<,\P_[C[!@C_%7_[2;CH6
M[9\>X_\ -<?]68NC6>PUT:]>]^Z]U__7W^/?NO=='Z?[$?[V/?NO=:ZVY]WU
M^V>@OB!@<9OS<G7=9V4.]]LG/[-BHI]S34N$[^@W)4;<@HLI#58K,8+=8IUH
M<I1U,3PR4<C,X9$:TZ6]JEQO7-$TEG'.EN;=]+UT5:V*AB00RLGQ(P-0PQ0G
MH%>-HM=IA$S(\HD *Y)TR D9P0># ^726R6(S5=F=R=A+M3>\?Q ??M!5]H=
M<9O?-+BMK]1=?4N(DH,\^%ZSRD$-3D\AF]QXJFRL.:II(=%*\CLBTZB"=3')
M$D4%C]3">9_ (BE6,LTTFJJZI1A0J$H8R#4@"NHU&BDC227 C<[:S]ZLU%C0
M"AI&>-6 8$4QGA@EBQ.U>HZG$U^3RG9.-Q=16C?G<O8VV>L,7-F<+D/B;4UV
M%J:W>%76SX? 9+#8S+O614J86AT92(T<-1#XFFET""6YW,2)''8,RCPX(GE;
M2PO*, @ + E0"?$;L.HJ:T%2T)9#4IN KT:5U05K!45-:"@8T&D=U0"*5P*O
M7^S\=431=>==Q]:=FYO^].$W;!O:HW%FNH\WE/C3NS&U^V=F[:WOV5DIXZ7
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M[.WCW9'M7?&%VQN+*OUG\98.W<QL'J/J.O\ C=AL'OS951V9NG<U%F-[Y_\
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M$O:QQP:87=]9D)UW+F5ZO$A!/;72%>@!"CKT]U)X:+)"])2[]X TZ: 1J%%
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M$K<#",A[W\-2 "*!3\5"*D.W!AGD::Z*>&%#)&ZZ9 T1K56I1=1!.:D^50:
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MN MS>3.BR$(X27QHRL<:B2J"0QKIFBBHJNU&RV:W.@,GLNK[0W/FMF3;;Q]
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MCV%JN8&9)&[O[1CXK<) "!T+>7F$UIN%Z)&8W%_/(:M(P!.@$()0'1,=J :
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M>Z)=0_"+KFF[1R';]5EJO([VK.R,UV%#EZK;NTGR5&,OOKK??$. CSDF&EW
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M%4OR3WIF\K@MO]FQ;HQU#+4TF_,A79>>HK'GJX7R%)24Z0:HR\9I<[1N$2
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MY(60E%BE/ZCH#2K:(^ ZM#@_N[F=[]I;$W=U)6;@VKB6V(:_KO8,.[]K]O\
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MH)VJ:>$357WJR43!Z]0RW&]P27FN.&%4!A*Q+:I36LDJM5G!-%4&HH31=-'
MCAD98["18M+2,6(D[VD:NDJK+10:9)%#6E36J]*//XSJ--U[9ZMINO-R]=;.
MP^P]X]95^TJOL&:/Y-;8?>V:S^\JO'=2T&[=OJ)>H,4N&J:#(Q&DBDIF94JC
M'4*I=/!)N9MKC<&O8Y[IIDE#B/\ Q1_#54!F*-_;G4&4ZC7\-5.'I!;":.U$
M6B((RD%OU1J):B5'P8(.,>>>JZ.PFW;W!W1U5TG)V!OS:F'[6SNW(JN#<%#)
MV:_6&9VAV"NR]GY3O;8>7KJ+<-9L#!X2:IJ8\37U\9Q\E:N0GDB31Y!Y8?2[
M7M.Y;O\ 10RRVR/\)\'QE>+Q'6VE4%1*S4&M5.H*44'- ;N;7-_N5CML=Q+&
MLP5@"@ET2)*$5KF%B"T"K7M) 1R'8C%3G?S*/@;U9\(=D=;]M=";Y[1@W)-O
M?L+.R[1Q.[ME0;RRVY\_B<EN#(]R469SM;CMT5FQ^M,7?$5.#QL551+C,O%-
M6R TZS$*<@<Y[CS?>7^V[U9VW@"&)-;1R&,(K*@@*J"@DE/>LCE6UH0E=5.C
M'F?8;78K>WNMNFN?&\6:5522,2!V5G:?4Y#-'".UH@&70P)IIKTCNJJ"2EZS
M["W?DJ"@7*8?9FS-J1]_9'!92?I'IS:_<]+AMQY[(Q]5X;'RS96FP=4U0E/7
MU:S4\V64U-#3UFJ41*=R<'<+*U21O#::1_I@P^HG> LJKXS&@+"E5%"$[79,
M57V;.;*2=M.OPH_UJ?I*)5#,1&/(&M"<%LJ&%>C";\K-F/L"BW'6=3[5V?O?
MLI>G-T[BW?V=NG*[2^.W8>-ZCQF7R.)WKM'#9""LHL=V+NO%4A@P1CJ:Y1,L
M$,#+4I-3 DLTN_K7@7<I);2W\=%2) ]S$9BH,;L""8D)K)A<5+=I#=&,[H+9
M)6A19Y-!+.2L3: :,!FC,/AR?(#..B3?+'=V6ZOBW33[%W!WYMK%P;@VYHPF
M^MRTT?8&\<;W+/E8NUI=D4=;C5HI-S4AJ)L<*O%1T,.(AGB6H+UDK+,+>6;6
M+<6MS>064DAC<ZHU/A(8*>#XA!KH- VERQ<@Z>P5 =Y@NY+&)_!EN%!EC4BM
M)&68D2>%4?VGX01ITU%:L:$V--_*LZ7A_EU#OS-=K;EQ79LGQ\Q^X*O-5>)V
MSU_M=MHT63R^]L?TJ.OMY9*7;FP=[;^H,Q1;5RV9JLF:T95$JX(Z><B,!M_<
M?=CSX=EAVV-MO^N*@!GE?60L9N/%C75+'&5:9(PFG02A+#/3R\J6<7+ OY[I
MQ=&S4&J)"ICU,ZP^$[:89'5EB=R^KQ 'J#CHKOQ)JMT=AY_KS^_6V^Q>T,F^
MYLG3X'K%\B]!OK&Q]-8RCSF%D[#W?AG3*;DJ=O\ W[4&/IL=/]UCZ2C:2N\-
M+.\L8AYG6VLH;WZ.X@MXO#!:8"L9,[%6\)&P@>FIBPHS-1*L #789+FX\);N
M*9I!(RK&[*9$$0#*LCK\12NE0"64 %J UZ.-LO/;4RNV*K?>^]@1;VK-B;Q[
M&S.U>S^GL9N7J;8^U]Y;]V/61[HZF[#HY8*J'(;<V_'6F*J>G^VJ:FGHT:.7
M(Q+)-["MW#<QW"6=E>F%9HH@\,Y2:1TCD&B:(XHS4J*U +&HC-!T?6\BM$T]
MQ&KZ'8AHP4569>Y&^0/GBH RU*] +V$N/Q_6NV6QU9F,'DY]IYOKG=F[.M]]
M#(_$W%Q];TF5RV!H-A5U%CJC 0[1W-E5FI&HJV/)-7Y*1J;'/K:17.K'7)?W
M'B(KQ"19426.EX?%(5C("0Q=11@RE=*#5(* 4+[F0)9QG5^H49"T9K "@9@*
M@$!32A!#$MA<X*O_ )9?P;Z^^<^S^RN_>^-S]DUNZI^S=LYJDQ&0QT>WLU4;
MXQVQ7;)[SRNXXIJV+LWJBOJMS44VWL;'34D&(FPYI&GE E14WN#SA>\G76W[
M)L]M;BW%NZE@VI1&9,1JE!X,X",)7JQ<2:@!@DOY4V2#?8+C=[V2X\1YXY.Y
M0K-*L="Y>I\>#O7P%H%C":<YZ(YL>@S74?;/;74N(W3N;=VQNJ,]N?)IN$9G
M8E7N+N2!MZU.Q=S;QZIR^W*C);&Z\V[O^BR-15YFFFDCP]#)1BCE,;R,H%]Z
M\6Z;9MFZ2P1QWEPB+HTR!8/T_$2.97 DE>(@!& +L&UBH'19MGC6-]?;?$9&
MM4+R:C)&3.?%T/-"5)6))0270D*A710$TZL\3;^UI]^;RZ5S_3$^3V'@^H\)
MLRJ^/M)0;UI_D!UIM_;\&*SV'[HSG:DT%;4UL==75TBXR*2G>&DHJ"F$M%34
M\?W$L>F>X6RM=UAW8+>/<LXN28S;2LQ*M L(H!0 :C4$LS4=B=(&BJK7,UF\
M -NL87PP&\1 !4.7S6IX>0 ': *E&[]W3M_<E9W#O+&;>SXR])N.F[2V5A^G
MM]9+*=A5&=P6/KNO'_V96BQU$NZEW7CL)13UN&G2KI&FI;F0/1 EU-G;3P)M
M=K),GA%/!D:>,+%I8B7_ !4DZ-!8A7!!H>%'Z:GG1S=S!#J4ZP(V)DJ*I64#
MNU 5*Y'[.BR?%3X_XSYE?,K.].]D]I;YGV-L?:_:#)N.A3';@P^Z-L;QQ.#2
MOV]L#L6B2AQ^S.X!O/=RYFKSL5/DCEZ*FEI8TDC0S^Q%S)O;\J<J0[IM^W0"
M[FDA[22K(Z,U&DB-3)!X:&-8R4T,0Q()T]!NPL#OF_SV=S<S^!$DPU!08S'(
MJ#3'**>'<!VUEP&+H"HP*]9OF?\ '#"?#_Y=;;ZMZ3WIF5V+V1@^M-O9BER\
MVV<_UYU3M&ME.*@ZS[,V?AZM][;NKZFIQTF[L3D,K2QUE755*TU+J@@(6O*F
M^R\T<KW&X[M:)]9 \KKI#K+-(,F:%V'AH "('1&*J!J;+#K>ZV(V;?8(+"9_
M"D6*)C5#%%&33P)D!ULS$>,CL-1^$&@/1@]GUE3M79'3&[*39*;9S>_>S9-V
MUN7[AI-P[UKODGNW:]7!LJ@ZZV-78QZ3;NQ=R9O&B1WJ(YZ61%HJ6&KJH:FG
M:ED([I5N+S=;9KOQ(H8- 6 K&+5'!D,L@:K2*IIBA'<Q52K!@?I))%;VDJ1!
M)'DJ?$JQD8'2%4B@4D?,4HH)!!!7VZ\1U)'NC9'6N%ZZR_5FQL:>W<1F]DYS
ML.LI_D/@<SVKN;*U&0H?C92[CQ!DI]J[>JL?41YB)Z77!1.JUB@:))$5M)N?
MTUW?RWR7-VW@LLBQ VS+"B@&Z*M\; @H:Y;*GB JD%L)H;9(A'#W@@M24%R?
M[*HX"AU8X<>JR^\<CNS>V\-A=,4>]NR\#MOM7*5.S*O!Y#&2]B[BV#EMD;XP
MN#V?NCLOKG*34V>JNHJ9MQ)EI<35UM-'DZ5QDM2TL<;>Y"V:.WM+6]W9K2V>
MXME#A@WA+(LD;,Z0RK51.=.@.%)0_I_$3T#-ZEEN;FRVT2W*PSDJ55/$=6CD
M14:6)OBMP6U,K&A%)/A ZMK^4_Q/Z=^"?6^U.Q]E=H=HXK+[KWEN+:S[UP4.
MR=[]\],8KN:OPE1W]V_\,X-_9:.DV%4U6Q]O2T.3CP..S&8HL)DS5TTGGI )
M8UY;YGW3G&^NMOO-NMV@CA1_#;Q([:=H PMH+XQ*3(!(P9?$9(VD32PHV#W>
M]BMMGAAO+6ZE^N>5QX@$;SQ),RM<O:"1@(ZQJR-X:M(D;LR94=%]H^Q,%M?I
M#?W27:>V\QA?C#O3J2AI:;#?'#=&;R6.Z.ZM[6!VK\7?BCT%O^DHJK>'RA^=
MGR^W1F)MQ;[K99'H(:.MECJA]O*6F/WLIKG>;'>-NN$?F**Z)UW2*IN)H2&N
M[RZC)"6>W62*(K90 VI1I[@.@_%=16FRWFRW]M(NQR6H!AMF+-!%(K&"UM2J
MLUU>7;GQ+EY6*/&S$U0N%7U-TWW'D.\.M:+JSNS-;ZVOE]_;AV3W[VWUK+MG
MKK<5!WYUS0;:ZKH^J<KUSTKE=N8WK;I_X>=+Q28NBRN$@WG@*;>&9JAGJ-X9
MEFITC;MM*[-N#[ELZ0W*0+);02ZY4-M*7F,PEN YEGOKCO9)#;RF"-?!<,"&
MM'L^YKO=DFU[Q++;O*4N98=,4GU,82%8?"@*"*"R@[5=/'C\:5_%0J:A5;B^
M<^&B^+_8':&Z=I;<[7[$3N;M7JOJ7XPY3;V1QN[Q@LIN#=^+V%L[LO 5FW<Y
MG-OY;<G3.S,ON3<V9I,:U+6X>J1"G@F-TL')<QYDLMMM+J2VL/HX9I[P.#'K
M5(VD>)PRJRI<21PPHS560$\1TOEYVB7EJZW+<;1+F^:]F@@LS&?$\-GD6-98
MR"P9[:.6>9@ '0@&@;H)-V_-GH_8FYZ1^N/B?U;GJ7(;?Z9[6PN^8L'M;&PR
M[,^1/4^U.M/BQV.*/%[5DG2BSO8^4J>FMRM3RZ]NT6-6GCDDIYOME,[7E#=K
MVW<;AS5<1R+)/"T6IV(DMIY);R*I?B(E%_#4?JLQ) 9=1+KCFVRM98I-KY*B
MDMV2.5)2BJICEMHUMI  GPB1_HK@ _HH%I4.%Z$OLCN#Y:]B9SY0]+=>]?;Y
MH8NJ^S,M0?&G=NQ]I[FV?L?MS"="9O T7<?Q W+OFER%-4?<]J82OR%9B<O@
M9-NZ!2MA:>MAK8-;(-NVGEBPAY<W?<+^!C<VZF[21T>2!KE&,%\D9!!$+A5D
M202_$)60J>E6Z;YS-N$F_;1M.V3K]-*_T[JK)'.+:33/9,ZZ2AEBJ8V1D.M2
MBR@@+TB1UWUO\>J_;/<W>?9>>WGW-U=UCNRJ[-I/CW61Y3>?RVZ;Z3WSM7'[
MC[6S#[IQ;[^VMV1\=-K9N"DW_M+$9J7=&9VCAX*#+Y/)8^EAB95]?N&^1W.T
M[-M\<.TW,Z"(W((CLIYXW*0J$;PWBNG4FVG>/P4GD+Q1QR,2&#86.RO9[GN^
MY23;I;HWB_3E==Y#%)&KR/(ZH\<MM'074(E\1X80DDCQJ5,3<F>W+WIW-UIM
MWMC>7]TZC<78.T,/UME.K\JL&5V7F]PX3);E^-'\SSX ;Y+96AGZ,[/V'528
M3MK;&6G?&?<QRT]3Y6_R:K]#!;;-M5_/MMJ)$C@D:59EJ) C*EWM.Y1]I%Q#
M)WV<RKK((*T'<'VFOMXO[<7<C"622-0T!($:NKM;[C9DAU:"8*HN(Q)I0U+U
MDTHK'_-9^*&"^*M=U?WAU/OG>M5O_-U>_JO+[/VG-UOLEJ/=V6I,EN+?/=U-
MMRCFPF2INNLG]Q_!<S@L)0MAHDR\E=6R&LD-3*Y[;\SS\R+N.T;G9PBR01!7
MD$LE8U(2.V+G4/%']I')(PD.@(HT#2'^:=D39A:7NWRR_4@2MIB,4964@O+=
M%30E&^"6)08P)#(0'[BF=C8>&AZN[7W3DDQ.(K:2'9NQ!\F\UM7<&:Z.Z]V?
MN>IH-W58HNK,3025<.-@S5>N/QRUM/*T.0GJ*NDII*>=I(GKR4MN.VVR:G4F
M23Z175;B5T!05F)H3I&IM)%5"JS!A0FD>KZ*ZG+*C:5'C%28@K48E4 J ":"
MH.:D"AJ##=I9';5+AMO[BKNGMN]6[K["WYUQVGO8=J;RKL#UKN].M=D0Q0;A
MZ@P6:%=XNW-QQS(-O)%45HJ8Z-32O.Z2Q BVZ.=Y9H4W-[FV@AEAC\% TJ>+
M)E9V6GZ*T_4J%H6[@ 0>C*Z9%6-S;I%))(KMK:BG0O%!_&?P\:TQ4CJO_P"6
M^XJ_K.+<&!V-N/OK&[13>$6U,EMW<N>6H[6WMM_M+$9W)]E9+9E'+2I1U^7J
MY*&7'UF5QD=+0I<X\ZJR9UD&W+%NE^T$UW#9-=>%K#*M(8WA91$)#6H45#*C
M5;\>%6H"_,-R]K$\4#77@^*$914S.DBL9/!Q0N::2PH.*99J$X.__P"5?U#L
M_P#EZP_(*K[3W)4=O?Z#NOLCN"JH:39W7.U=_;;PD65R6'Z/VWLK>V2GQ'5.
MZ=ZR9VAP]=619.?,#+T=Z94GE,!#%E[C[G=<\'8TVV,;9]9*%J9)7C=M(:X>
M2,:ITCTLZJ4":&[J@:NE$_*-M#RZ;^:[8WIMH0X"I"LB1ZBL"1N=,#2:@C,K
M:]8!7/:2W_%:HSN^<KLG<&^-N;T[<RT=9OG.X;9\M6]-NC!9?IN:LH<;G>W\
MEC/M\MO/.T])7"FDCH)4>EH8I8LD]/#4*Z'G,@ALTNX;.>&VA*QJS@51A. 2
ML ;$:DBH+#+$&,,5H7-DDGN$BDNDEED5Y  Q!=3$2!XQ6FI@#IHN0!1J5KT;
MK:.4VSD^O(=[;IZ_QV^ZC9]#V[AMH]U=7U&X^J^K:_(]EX/'5.X>N]_XVMI6
MI*O:6U<IF95RKNE)4O!CDF055(LM2X9NHYX[[Z2VOFA65H6>WF"S3 1,0LL9
M!J'=5&BFH58@Z6HH.(9 T#S30J^@.%D0E$.M:LK#^%2:&M#05%1GHO7;G\-P
M76^VJS&5N7P^1R>PL]M;<>X=D;RDR'Q.@EZBQ63FVSBNN9Z?%O@I]H[FW#BJ
MF>GHZ^&NJ,C5I)3XV0Q^7RG>UAY]PG61%>-9E=5D2EY29@',H+:@Z*0"RE0@
MHT@K2A=?2>'9JRL5E:%^Y23;@Q*645 H%+ G202Y!5*^8C?RT/@=UU\U>L.Q
MN]^[]T]H56Z\MVW-E<)C\IB8<+EZ;?\ _HW_ (;G-_;DS*25<7;>PJS.[F@R
M>W(_!CZ+%RXS[)Y*E%F!1>X'.=]RGN%ALVT6UM],MK1B&U+X7C56-%QX$H5"
MDV69]>NBFG23E78TWRVGW6]EN/%:X#KKC"L9?!TO(S9^HA+/J@JJJ@4)W 'H
M@76M-G-@[X[1ZM3<VZMU;!ZRSN7C6I;*;%K<SV]B,UV+E.O-R=@=5YS!UF3V
M-MC8?:2U!KLSCUJ8\;&]Z*-_+I1!KN#0WUGMNXF"..^N$7RD"P%8EE2*96 D
M>2&FE'TER.\BF24;49K:YO;)&E:SCJP!:(F:LK1O<0LI9$BFXNFH*I&@4.!:
M*N#VQ5;_ -^]2Y[IF7/[0V_UUL[!Y#I#"T^_:;OGIK"['_@.;VEW!N'M*OII
MJJI7,55;)+3"HAGC@CHZ=:BGH(HF>2.O&G6RLMQ@W4)=/.["X8QFWG:34KP+
M$#0:0 #0@DLVEG)H!J%5KF>UD@#0*BCPQJ\1 M"KESG/S\@*A0#4/=Z[MP&7
M@[6WKM3";JIMU4^_JOM78--TOO3)Y/=$6?KY)]D&K^1JT%+1;GIM^[>BQ>0K
M4ECJ:1H*5O-5K)1#UK;2UGB.VVES+&;8PB&0SQA4TBDE+6I*&-JJI!!J<+1^
M#$UPK+=3I&?$#ZU$1):I[?U ,ZA0GB*#)[1T 'Q$^.F+^:/RPWWT[V?V7O*7
MKWK;9G:6W(LIATH<[A-X;4STF.I5ING^RJ8X_'[#[.I=[;BGS-?DQ1Y'^\M$
M[A4>&+[@GG,^_2<I\M66Z;?M\/UUQ+"]&)5D=:FL\63+"8U$:IJ3PFH:U.GH
M.[9MQW_>[^SN;J?Z6%)HR0H*-&P4#P9<>#.'8O(P5O&3'PC5U ^8/0>)^(WS
M+@ZFZ9WGE(-B]FXWK_$9<YRHVAGNONLL578W*0[6ZIWIL3$UU=O#/[EPBXU=
MRX7(9:G3)UL^3"P!J>"-A?E;>9.9^5&W+=;5?K+=I672)%EE8$:YXY& 14:O
MA2(A**$J:,Q'7MTM/W/S##;V,S"";PXV;5'X4:D,([>2($NSBGBQ.0&8M2I"
MUZ,]L>ICVUMSX_[HH=GR[=K^P=^Y'L"LH^V(,YV#N;Y)[I2MQ^S:G9^PLKBT
MIL#L?/9'&S-55$M/- ZU$5*)ZK[J.2A<.W:^/<;W;O="1((1&##IC2U2A</(
M#5I%!P 0<%M*Z2' CAD*1V,BQZ&=RQ#U=I6^&BD84D9Q0@TJ:@KTJ]UXGK2#
M=>P^LJ?8F;ZPV;M[:W96RLALR7?Y@^2VUZ[M3-;AW-44?05)NC%,6ZOP4F(J
M*?,P5%+$8H*AOO/'+%&636TE^UM>[@;Q+B[DDBD$@C_Q5Q"JK6Y*'^U;4"A!
M-2.RH)Z>E$(G@M5C\.$(ZE2WZHUDG].H^$4.H4^WJLWM3^]/:7975/1M'OCL
M' ;:[1W1C*,XG-87_2?D^O=P[,[#IMK[3S_=VP*J7%YVLZSQ]-FIJ\8VHR-.
MH6>+*RND*QM)(.V?3;=MVY[RUI \]M&>Y6\$2))$7=;>4543$J%U!3P,0!-:
M O=S-?7^V[7'/.L<S A?#\73)'*%1KF(T)MUJ3IU  Z9&H *GK_F,_R_NL/A
MKUQU[W)T/V#VO5[LK^R=R9JLVYC=V;+_ +\[DW5N3'SY2;N?;&<SL^*W NW.
MI\=3/2R8'#K4TDF+RB251,=,LWL'<B<[;AS7?WVU[U96JVRVZ*&*2>&J(0!;
MNJAEUSDU$KD,'0A<M3HUYEY?M]FM[>YVV6Y>=KB272DD8E$C@DW"LY!*0"M8
ME# JPJM%KTA^FJ2HIM@;YW3G,-B<KF,7L+;.*K.Z,CA<S7=)=0;=[?HL5DMT
M35?6&'B6HSM5BL@K2FKJXY(\CE8TJ,?!6E)XU5;JRF]M+>*5EB:9R( RB>9H
M20@$K?"",4!!5*AV2H/2^Q9S:O-(JM)X25EI^DHD4%CH'F#FIPS4*ALCH<M_
MUFU)NN*?<-=U-M+9F^-[T?3LM?O/L?<^2VE\;.R,5TL<YGL#O'%X:N6JBP>^
M-P8O&R0X!X*JH@^Z6"&)8ZR-Z<E-DER+YH4W.26SB,](XD#W41GTJR%A35&K
M$&2H!I4DE#JZ77#H+59F@C69PA+.2L3>'4A@/)B!1<GT%"*=$]^5^[LAUT^7
MKNO,QWO@(L7EMN[BQ$&^MT53[MW@W=E5DZ+LW^X,-7BTPB[GPN(R;44>0QT%
M V(BJ(GKI)JME#BCEJU2_,:7\5DY9'4^&@T)]. 8O%H=6AF&HJQ;600@"\"#
M?KN6UB+VCW(?Q(_,EV$Q(D\&HT^(%) 8:0E06):@)H=M_P K;I&O_EQ/W[DN
MR]XX;M1_CU)GZ/.9#$[7ZVP>/VM'N3+[V@ZPJMD;UR']W=I[]W_A*FFVEF,Y
M6Y))FJ_'7P)3S64AZX]Q=W3GT;)'M\3[<+_25#/,Q?0L9F$D8U/%$P,T<:I3
M35&+#/3D/*MG_5@W\MS(ER;+3WHD $>MI!&8W.B.612(GE+ ZJ2=IZ*I\03N
M'L;,["Q>[]F]D;]I9-ZYW$8CJJAS:T78^-DZ=P.)WIAAV%N[$P2Y_<-;MR*H
M>CQD6*E;(1PTB331K3--,@CYH\"QBO);6[MX6\%6:8K^DWCLT;&)&[5#TU.7
M&DEB 2U 6M@DGN%B2XMYB5E:,1EE,D0B575)7&7*5TKI)- "<5/1X.L]T;<K
M,=/V3NK8--V-6]?=D[KWYA.Q.AL/NKK>'J_=6Z]AYRCW%TQNR@EBJZ+*XW"*
MIHLC(56HGI(=5+5Y$H[@(;A;SK(+"VO3 DUND;17#)+XR)(I6="*$%OB4< Q
M[E2H'0AM95*/<3()6CD+!H@5",5(:,CS X'SIP+4)Z C<U/A8>O]H4^ GR&W
MLJ*?-]0[BW)U1V$E3\6</@<"N8S\<N)S%'CY,528S=V0R_\ #<C_ !#[ZGJ\
MJ_VM$BULAN<6YE:]NFG57CJLR+-'2[+-I7N4FI* :ETZ2$[G.@=(IB/IX55J
M,28R8VK  -1X@85B:-6M6P!J/4S^6-\*^O/GCB^SNU_D)N+LW*1X[?O6N3CV
MG6TD6V,[F]T[1Q$U>NZ*;?5(\K;LZ>EH\U24N.P5/0018BJQQ0U'D\D2Z]PN
M;+[DQ]NVS9(+92T$RZP=:JCL!H,9_LYZJ2\A8EU>NFE#T6<K;/#S"MSN&Y/<
M8GA?2RA"TD:D@K*/[6WHP"1@ 1E:5K6A-<1A=P=+=]=O=/[>WYN?>^T^N<OO
M_=&$W6F3V!42]NYW#[BP6&S&<Z(DV349/9_4VX=SX[(38S+LXIZ+')BEAK3#
M)),GL5SS0;MLNU[K/9QPW,ZQ(R:9?T$9695N?$ >=4(#Q\6;75*@ ]%.WK-M
M^XWUA%--)$#)(&+0TGD1E5I+<1U6$D-X<@HJIH%0"QZLQI]L;3IMZU_2=7U'
M3UVQ_P#0$-D9'XRC&[WJ>Z*/9E:8-VR=W0]G-0R/2[9Q^X%-)A::.!OL5IT_
MR)::,UCQ\UQ<M9INR[F1=_6^(+NL8@+BJ>!X5<N5RYKW5/?J.@#<(@N#9F%3
M;^!I,-&\32<Z]?D-6%'E3@!W=(_?V9VAF\_W=N*7"[G9J-<5OW:>)ZMW_493
MNVIR?6>$&Q,=C_DGCZ*@.=J)Q4RK5X5:*6&>:%6%.\M+J;VJLXKJ*#:(1+'0
MUC=I8PL $K>(3:DG3PP^H$ _$ W3$\L9DO7*_#1U",3*= T_JJ,G^C3C3!(Z
M*E\>.E&^9GS/3H7L3L_>-9L3:>.WEEYLWC3A][[9SFW=]]?XROW3M?;>_<<^
M/I-B]NY7)[RBJ(MQHN0-12T+T<<<HC=HQ+OF[GE/E0;U8;?$+R1HQI.J-U>.
M4A'>,U,D"B.AB.FC,&)%14-6EH=^WZ?;KBYF\"(2 , 'CT2QKK"O0>%<'Q,2
M DL@H*A3UL3=0;-SF$ZEZPP>,BDBQ&W]A;9VSA(ZMH*FM7"[7QL6W\2N2F3(
MTWERIH<<AJI#%%Y926T*;CW!FZ7D,NY[C-(097G=VIPU.=34P:+4X%30>O4F
M6D!@M+6"/^RCC5%J:G2HTBI\S0"I\STOAA=WC_=--_R0A_WO,'VB\>U_B/\
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MF>EK*HQU[O2RRB$7'=-OW';K.3<K-+E4A9JLL0$8F!+W!6343*4HSZ:@J*H
MP%0W^ZKJSO+CZ"Y\$O*GXI2Q$3#1;J8Z 0 U"UHP8]Y*DT$[XP?'K$[>QVW-
MS5^V,Y28BDW(NV]R9?K[<\6U^P:/M7?"U%?L[K/KW:E77Y/9FU]N[7>FK1CX
MJFGBHJZHJY:PE],BL7<Q;Y)<23P)<*93'J595UQF&.@DEE< 2.[]NH@EE"A,
M8Z6[)M"V,43,H^(ZBAT'Q&J4BB2I2.-,@# 8DO2I;H__ %3MK=V?P^W\/A>R
M>^.GJ7MNIP/4'1>Y),#-N'L':/870.Y<GN'<.9[XW7B\Q-B(MJYE8IZ6/&5%
M9+$)JMCCU"^10"MRN+6&6:26PL[IK8--<)JTQO'<J%46Z,M=8P2X4&@&LUIT
M);9))8XU26:+Q:(E15U:,DDR,#32<@ GS[>DSFGV]O'<4,D^[=V472/R'[8W
M5N[&YOJ+J#.83<79>(Z[Q5-3=@4O?&VV&$RF-K]F[FJQ5S9+Q+C*>**26")J
MNKCU*(1/;0$"VB.[V-LB%9IE98FE8F/Z=NX$2(*!:ZR2 Q"J>FI#')(@U-]-
M<2D_IH06"BC>(,'M.2>'H-1'5=?971F\-B[SZVW]M.7"]8;ZQ.ULYV)M/>.
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MVY0')9+*).T]2,ID*Q7FJ1*S2I,[!B2"3!>[>,VZ[FPM@%-Q)0 X U&@%,4
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M !%;>'K(0O0:RU.W23J85"CQK21Y0ZK,RNA*>')&"Y^*765&JF:::T-0* ]
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MJ*FMS^*V;MVG&7R=+7P&JARE+4XV?%TDS3RQU--:4[BVNWECE+RV2,7.I1+
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MRE/L/+P5G676V![%S^WL-N-3-382([BR&P:['Y?/T-)1POCUAG@IZ%YQ3ZO
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MLH8V8[QIV@JI:&F%L4B/([F+5?<'*^W,\NMXS;@+1A.JDD@%P$:2O9D!C\>
M!7IR;>9(]"T83&N/#9A@T6K!2!JP:?AXG'0:[/\ G+W[G4ONM-[[3IU7%"GF
MK/AUOC"5N/FRM14M/39^*6FR=/E)\%21)%D*K#A:2F<AP)&F(4QN^3MF@/\
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M4Z+!S)<M>/!IE$8(R;60@@KJ#+)3305T,I74)!IX9Z&NB^6>[<W@L-@L7O\
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M9'_T!UU_H0[ _P"\H._/_.+I?_[57O7[YLO^F<LOVS_];NO?23_]'*;]D?\
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M_P"U3[U^^;+_ *9RR_;/_P!;NO?27'_1RF_9'_T!U[_0CV!]?]F@[[_K_P
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MC_13;W[]\V7_ $SEE^V?_K=U[Z2?_HY3?LC_ .@.N_\ 0CV!_P!Y0=]_U_X
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M=]_^<'2Q_P!Y_P!%/OW[YLO^F<LOVS_];NO?27'_ $<9?V1_] ==?Z$.P/\
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MT<IOV1_] ==?Z$.P/^\H._/_ #AZ7_\ M5<^]_OFR_Z9RR_;/_UNZ]])<?\
M1RF_9'_T!UW_ *$>P/\ O*#OO_SAZ6/_ ,RGWK]\V7_3.67[9_\ K=U[Z2X_
MZ.,W[(_^@.O?Z$>P/^\H._/_ #AZ7_\ M4^_?OFR_P"F<LOVS_\ 6[KWTEQ_
MT<IOV1_] =>_T(]@?]Y0=^?^</2X_P!ZZI][_?-E_P!,Y9?MG_ZW=>^DN/\
MHY3?LC_Z ZZ_T(=@?]Y0=^?^</2__P!JKW[]\V7_ $SEE^V?_K=U[Z2X_P"C
ME-^R/_H#KW^A#L#_ +R@[\_\X>E__M5>]?OFR_Z9RR_;/_UNZ]])<?\ 1RF_
M9'_T!UW_ *$>P/\ O*#OO_S@Z6_^U3[]^^;+_IG++]L__6[KWTD__1RF_9'_
M - =>_T(]@?]Y0=]_P#G#TM_]JGW[]\V7_3.67[9_P#K=U[Z2X_Z.,W[(_\
MH#KK_0AV /\ N:#OS_SAZ7/^\'JJWOW[YLO^F<LOVS_];NO?27'_ $<IOV1_
M] =>_P!"'8!_[F@[\_\ .'I<?[UU5[]^^;+_ *9RR_;/_P!;NO?27'_1QF_9
M'_T!U[_0AV!_WE!WY_YP]+__ &JO?OWS9?\ 3.67[9_^MW7OI+C_ *.,W[(_
M^@.N_P#0CV!_WE!WW^/^4'I;\?\ E*??OWS9?],Y9?MG_P"MW7OI+C_HXS?L
MC_Z ZQOT=V"PLORB[\3F]_L>ES_7C_F58XY][&\V7_3.67[9_P#K=U[Z2X_Z
M.,O[(_\ H#KDO2'8( !^4/?C$"Q/V/2_/^-CU4??OWS95_Y5RR_;/_UNZ]])
M<?\ 1QF_9'_T!UR_T(]@<_\ .4'?G/\ TP]+_P"\?\8IX]Z_?-E_TSEE^V?_
M *W=>^DN/^CC-^R/_H#KK_0AO_\ [R@[\_\ .+I?_P"U5[W^^;+_ *9RR_;/
M_P!;NO?27'_1RF_9'_T!U[_0AV!_WE!WY_YP]+__ &JO>OWS9?\ 3.67[9_^
MMW7OI+C_ *.,O[(_^@.N_P#0CV!_WE!WY_YP]+__ &J??OWS9?\ 3.67[9_^
MMW7OI+C_ *.,O[(_^@.O?Z$>P/\ O*#OO_S@Z6_^U3[]^^;+_IG++]L__6[K
MWTEQ_P!'*;]D?_0'77^A#L#_ +R@[\_\X>E__M5>_?OFR_Z9RR_;/_UNZ]])
M<?\ 1RF_9'_T!UW_ *$>P/\ O*#OO_SAZ6_^U3[]^^;+_IG++]L__6[KWTEQ
M_P!'*;]D?_0'77^A#L#_ +R@[\_\X>E__M5>]_OFR_Z9RR_;/_UNZ]])<?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Sep. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001691082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">LB PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_RegnFileNb', window );">Registration File Number</a></td>
<td class="text">333-289812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_RegnFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_RegnFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Sep. 08, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 206,666,672.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01531%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 31,640.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(1) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. (2) Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 100,000,000.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 15,310.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Sep. 08, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 306,666,672.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">15,310.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">46,950.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 31,640.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d12080dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d12080dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d12080dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d12080dexfilingfees.htm">d12080dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d12080dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d12080dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/ffd/2025": 7,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 27,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12080dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12080dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12080dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d12080dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001193125-25-197877-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-197877-xbrl.zip
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MI68IWH-K0K!&M^ R.B7/&'VH9M%ZXJ8*MP<//Q-GZ4/6?- @J!,;C1S;9ER
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M"T)Q Y[J();KX09#7FG;C-E40-C7-=;Z*^W;].VW!?6=]![=^A1F(\4&:_S
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MP@_H,3\CPO=KWY\+PNT%84M!T7?8*/D0^Y]?".[X./S5+@K/L@!LO]FS<N,
MY_ZD1^X<127U14^U[X=J$$N^Q4BM>U('CX=]:W-5AX5]'[J<B+EN'=X.^5)$
M:M:B<-"W(;447.UCD.K9/+_!74SX1?/L :!E')X#MB2#BOR<8R"R_]M)_3]0
M2P$"% ,4    " !=4"A;4*JQF@H+   M2@  %P              @ $
M9#$R,#@P9&5X9FEL:6YG9F5E<RYH=&U02P4&      $  0!%    /PL

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>d12080dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001691082</identifier>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001691082</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001691082</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-332">S-1</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-333">S-1/A</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-334">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:RegnFileNb contextRef="rc" id="ixv-335">333-289812</ffd:RegnFileNb>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-336">0001691082</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-337">LB PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-374">S-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-375">LB PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-376">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-377">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-378">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-379">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-380"
      unitRef="USD">206666672.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-381"
      unitRef="pure">0.0001531</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-382"
      unitRef="USD">31640.67</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="offrl_2" id="ixv-383">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-384">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-385">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_2" id="ixv-386">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-387"
      unitRef="USD">100000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeAmt
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-388"
      unitRef="USD">15310.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-389" unitRef="USD">306666672.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-390" unitRef="USD">46950.67</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-391" unitRef="USD">15310.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-392" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-393" unitRef="USD">31640.67</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-394">(1) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. (2) Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant, if any.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
